<SEC-DOCUMENT>0001193125-23-076227.txt : 20230322
<SEC-HEADER>0001193125-23-076227.hdr.sgml : 20230322
<ACCEPTANCE-DATETIME>20230322065447
ACCESSION NUMBER:		0001193125-23-076227
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		160
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230322
DATE AS OF CHANGE:		20230322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		23751233

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d400206d20f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:imtx="http://imtx.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>20-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To12_31_2022">2022</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001809196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="imtx-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_26_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-30</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:BuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CarryingAmountMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:AccountsPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:EventAxis" >imtx:ReorganizationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:IntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredTaxLiabilitiesRightOfUseAssetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:LeaseLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:RecognitionOfTaxLossesCarriedForwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredAssetRecognisedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:ShorttermDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >imtx:ForeignExchangeRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredTaxLiabilitiesDeferredExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:CollaborationAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredAssetNettingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:AccountsPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredLiabilityNettingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis" >imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:BuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanNameAxis" >imtx:TwentyTwentyIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:ShorttermDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingAmountMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:AccountsPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis_MilestonePaymentForLicensedProductMemberIMTXMilestoneAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:MilestoneAxis" >imtx:MilestonePaymentForLicensedProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis_ThereafterMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >imtx:ThereafterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:EventAxis" >imtx:ReorganizationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:IntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredTaxLiabilitiesRightOfUseAssetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:LeaseLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:RecognitionOfTaxLossesCarriedForwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredAssetRecognisedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:ShorttermDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >imtx:ForeignExchangeRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SchemeAxis" >imtx:ShareReinvestmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheOneMemberIMTXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TrancheAxis" >imtx:TrancheOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheTwoMemberIMTXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TrancheAxis" >imtx:TrancheTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheThreeMemberIMTXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TrancheAxis" >imtx:TrancheThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredTaxLiabilitiesDeferredExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:CollaborationAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredAssetNettingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:InvesteeAxis" >imtx:SvbSecuritiesLicMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AtTheMarketAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:ShorttermDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:BondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:AccountsPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >imtx:DeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >imtx:DeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >imtx:DeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >imtx:DeferredLiabilityNettingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis" >imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:BuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:ChristophHettichMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >imtx:IndefiniteTaxLossesCarryforwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >imtx:ForeignExchangeRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >imtx:CurrentlyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DK</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:CollaborationAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:BuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HaraldFstockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:ChristophHettichMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >imtx:CurrentlyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DK</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CollaborationAgreementsMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:CollaborationAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentIasSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentIasThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIfrsThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIfrsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIfrsNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentsToIllustrativeAccompanyingIfrsSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIasFourtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >ifrs-full:IFRS17Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIasOneIfrsPracticeStatementTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIasEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIasTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIfrsSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis" >imtx:AmendmentToIasOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis" >imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis" >imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:BuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:NancyValenteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ConvertedOptionsOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HarpreetSinghMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PeterChambreMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:AdamStoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:HeatherLMasonMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MichaelGAtiehMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:PaulCarterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:EliotForsterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:NancyValenteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >imtx:NonInterestBearingLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >imtx:IndefiniteTaxLossesCarryforwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwentySixYearTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >imtx:TwentySixYearTaxLossesCarryforwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:ImmaticsNvMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis" >imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_BottomOfRangeMemberifrsfullRangeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis" >imtx:ActiveEmployeesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis" >imtx:ActiveEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ManagementMembersMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis" >imtx:ManagementMembersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndTenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfTwoThousandAndTenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SchemeAxis" >imtx:ShareReinvestmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:SchemeAxis" >imtx:ShareReinvestmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:ShareReinvestmentSchemeAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:ShareReinvestmentSchemeAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:SchemeAxis" >imtx:ShareReinvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:DocumentInformationDocumentAxis" >imtx:OrdinaryShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:DocumentInformationDocumentAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis" >imtx:ForeignExchangeRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DirectorsAndExecutiveOfficersMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imtx:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AtTheMarketAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:InvesteeAxis" >imtx:SvbSecuritiesLicMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:InvesteeAxis" >imtx:SvbSecuritiesLicMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:InvesteeAxis" >imtx:SvbSecuritiesLicMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401licensegrantMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >imtx:Ima401licensegrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:CollaborationAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_PipeFinancingMemberifrsfullClassesOfOrdinarySharesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis" >imtx:PipeFinancingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_MdAndersonMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >imtx:MdAndersonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_RestrictedStockAcquisitionAgreementMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:RestrictedStockAcquisitionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >imtx:AryaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_AryaMergerMemberIMTXShareListingExpenseAxis_PipeFinancingMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >imtx:PipeFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:ShareListingExpenseAxis" >imtx:AryaMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanNameAxis" >imtx:TwentyTwentyIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis" >imtx:ServiceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >imtx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-28</xbrli:startDate> <xbrli:endDate>2021-09-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_28_2021To09_28_2021_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-28</xbrli:startDate> <xbrli:endDate>2021-09-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-14</xbrli:startDate> <xbrli:endDate>2020-09-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-31</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:PlanAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-30</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-30</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2020To06_30_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-30</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2020To06_30_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis" >imtx:GrantedOnSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-30</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_22_2023To03_22_2023_AuthorizationOfFinancialStatementsMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis" >imtx:AuthorizationOfFinancialStatementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-22</xbrli:startDate> <xbrli:endDate>2023-03-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:ImtxagreementAxis" >imtx:ImtxbMSCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-01</xbrli:startDate> <xbrli:endDate>2022-06-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-01</xbrli:startDate> <xbrli:endDate>2022-06-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-26</xbrli:startDate> <xbrli:endDate>2022-01-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:BmsAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imtx:AgreementAxis" >imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >imtx:ImmaticsUsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis" >imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis" >imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-12</xbrli:startDate> <xbrli:endDate>2022-10-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_12_2022To10_12_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis" >imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-12</xbrli:startDate> <xbrli:endDate>2022-10-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis" >imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-12</xbrli:startDate> <xbrli:endDate>2022-10-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:MatchingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >imtx:CurrentlyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrentlyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >imtx:CurrentlyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:ConvertedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CurrentlyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >imtx:CurrentlyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:PatentAndLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis" >imtx:SoftwareLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809196</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Warrants" > <xbrli:measure>imtx:Warrants</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_EUR_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To12_31_2022">20-F</ix:nonNumeric></div> </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-year-en"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission file number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2022To12_31_2022">001-39363</ix:nonNumeric></div> </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">Immatics N.V.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of Registrant as specified in its charter) </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:edgarprovcountryen">Netherlands</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Jurisdiction of incorporation or organization) </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">Paul-Ehrlich-Stra&#223;e 15</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">72076</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">T&#252;bingen</ix:nonNumeric>, Federal Republic of <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:countrynameen">Germany</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices) </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Edward A. Sturchio</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Immatics US, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2130 W. Holcombe Blvd., Suite 900</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Houston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">77030</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">281</ix:nonNumeric>)&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">810-7545</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, Telephone, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-mail</div> and/or Facsimile number and Address of Company Contact Person) </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered or to be registered, pursuant to Section&#160;12(b) of the Act. </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Symbol(s)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">Ordinary shares, nominal value &#8364;0.01 per share</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">IMTX</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">Warrants to purchase ordinary shares</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">IMTXW</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric></div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: None </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: None </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of business covered by the annual report. Ordinary shares, nominal value &#8364;0.01 per share: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">76,670,699</ix:nonFraction> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric>&#160;&#160;&#9746; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric>&#160;&#160;&#9746; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#160;&#8224; provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.10D-1(b).&#160;&#160;&#9744;</div> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:24%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">U.S.&#160;GAAP&#160;&#160;&#9744;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="P01_01_2022To12_31_2022">International Financial Reporting Standards</ix:nonNumeric> as issued</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Other&#160;&#160;&#9744;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">by the International Accounting Standards Board</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item&#160;17&#160;&#160;&#9744;&#160;&#160;&#160;&#160;Item&#160;18&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc"><span style="text-decoration:underline">TABLE OF CONTENTS </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_1">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_2">A. Directors and Senior Management</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_3">B. Advisers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_4">C. Auditors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_5">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_6">A. Offer Statistics</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_7">B. Method and Expected Timetable</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_8">ITEM 3. KEY INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_9">A. [Reserved]</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_10">B. Capitalization and Indebtedness</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_11">C. Reasons for the Offer and Use of Proceeds</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_12">D. Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_13">ITEM 4. INFORMATION ON THE COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_14">A. History and Development of the Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_15">B. Business Overview</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_16">C. Organizational Structure</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_17">D. Property, Plant and Equipment</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_18">ITEM 4A. UNRESOLVED STAFF COMMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_19">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_20">A. Operating Results</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_21">B. Liquidity and Capital Resources</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_22">C. Research and Development, Patents and Licenses, etc.</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_23">D. Trend Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_24">E. Critical Accounting Estimates</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_25">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_26">A. Directors and Senior Management</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_27">B. Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_28">C. Board Practices</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_29">D. Employees</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_30">E. Share Ownership</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_31">F. Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_32">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_33">A. Major Shareholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_34">B. Related Party Transactions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_35">C. Interests of Experts and Counsel</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_36">ITEM 8. FINANCIAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_37">A. Consolidated Statements and Other Financial Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_38">B. Significant Changes</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_39">ITEM 9. THE OFFER AND LISTING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_40">A. Offering and Listing Details</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_41">B. Plan of Distribution</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_42">C. Markets</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_43">D. Selling Shareholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_44">E. Dilution</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_45">F. Expenses of the Issue</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_46">ITEM 10. ADDITIONAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_47">A. Share Capital</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_48">B. Memorandum and Articles of Association</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_49">C. Material Contracts</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_50">D. Exchange Controls</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_51">E. Taxation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_52">F. Dividends and Paying Agents</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_53">G. Statement by Experts</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_54">H. Documents on Display</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_55">I. Subsidiary Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_56">J. Annual Report to Security Holders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_57">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_58">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_59">A. Debt Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_60">B. Warrants and Rights</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_61">C. Other Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_62">D. American Depositary Shares</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_63">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_64">A. Defaults</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_65">B. Arrears and Delinquencies</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_66">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_67">ITEM 15. CONTROLS AND PROCEDURES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_68">A. Disclosure Controls and Procedures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_69">B. Management&#8217;s Annual Report on Internal Control over Financial Reporting</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_70">C. Attestation Report of the Registered Public Accounting Firm</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_71">D. Changes in Internal Control Over Financial Reporting</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_72">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_73">ITEM 16B. CODE OF ETHICS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_74">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_75">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_76">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_77">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_78">ITEM 16G. CORPORATE GOVERNANCE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_79">ITEM 16H. MINE SAFETY DISCLOSURE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_80">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_81">ITEM 17. FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_82">ITEM 18. FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx400206_83">ITEM 19. EXHIBITS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRESENTATION OF FINANCIAL AND OTHER INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated or the context otherwise indicates, (i)&#160;references to the &#8220;company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221; refer to Immatics N.V., together with its subsidiaries, including Immatics Biotechnologies GmbH; (ii)&#160;references to &#8220;Immatics&#8221; refer solely to Immatics N.V.; and (iii)&#160;references to &#8220;Immatics OpCo&#8221; refer solely to Immatics Biotechnologies GmbH. Immatics N.V. is a Dutch public limited liability company (<span style="font-style:italic">naamloze vennootschap</span>) incorporated on March&#160;10, 2020 and the holding company of Immatics Biotechnologies GmbH, a German biopharmaceutical company incorporated in 2000 focused on the development of T cell receptor-based immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH holds all material assets and conducts all business activities and operations of Immatics N.V. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Trademarks, Service Marks </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Immatics logo , Immatics<sup style="font-size:75%; vertical-align:top">&#174;</sup>, XPRESIDENT<sup style="font-size:75%; vertical-align:top">&#174;</sup>, ACTengine<sup style="font-size:75%; vertical-align:top">&#174;</sup>, ACTallo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, ACTolog<sup style="font-size:75%; vertical-align:top">&#174;</sup>, XCEPTOR<sup style="font-size:75%; vertical-align:top">&#174;</sup>, TCER<sup style="font-size:75%; vertical-align:top">&#174;</sup>, AbsQuant<sup style="font-size:75%; vertical-align:top">&#174;</sup>, IMADetect<sup style="font-size:75%; vertical-align:top">&#174;</sup> and other trademarks or service marks of Immatics appearing in this filing (&#8220;Annual Report&#8221;) are the property of the company. Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this Annual Report are presented without the <sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>and <sup style="font-size:75%; vertical-align:top">TM</sup> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This Annual Report contains additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this Annual Report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms &#8220;dollar,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; refer to the U.S. dollar and the term &#8220;euro,&#8221; &#8220;EUR&#8221; or &#8220;&#8364;&#8221; refer to the euro, unless otherwise indicated. The exchange rate used for conversion between U.S. dollars and euros is based on the ECB euro reference exchange rate published by the European Central Bank. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are presented in euros and have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8220;IFRS&#8221;). None of the consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). We have made rounding adjustments to some of the figures included in this Annual Report. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market and Industry Data </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains forward-looking statements regarding our current expectations or forecasts of future events. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;will&#8221; and &#8220;potential,&#8221; among others. These forward-looking statements include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the commencement, timing, progress and results of our research and development programs, preclinical studies and clinical trials, including our Adoptive Cell Therapy (&#8220;ACT&#8221;) and bispecific T cell engaging receptor (&#8220;TCR Bispecific&#8221;) trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability and timing of investigational new drug application (&#8220;IND&#8221;) or clinical trial application (&#8220;CTA&#8221;), biologics license application (&#8220;BLA&#8221;), Marketing Authorization Application (&#8220;MAA&#8221;) and other regulatory submissions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;) or comparable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proposed clinical development pathway for our product candidates and the acceptability of the results of clinical trials for regulatory approval of such product candidates by the FDA, the EMA or comparable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assumptions relating to the identification of serious adverse, unexpected, undesirable or unacceptable side effects related to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of and our ability to obtain and maintain regulatory approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential advantages and differentiated profile of ACT and TCER Bispecific product candidates compared to existing therapies for the applicable indications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to successfully manufacture or have manufactured drug product for clinical trials and commercialization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our expectations regarding the size of the patient populations amenable to treatment with our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assumptions relating to the rate and degree of market acceptance of any approved product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the pricing and reimbursement of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to identify and develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitive position and the development of and projections relating to our competitors or our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise capital when needed in order to continue our research and development programs or commercialization efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to identify and successfully enter into strategic collaborations or licensing opportunities in the future, and our assumptions regarding any potential revenue that we may generate thereunder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates, and the scope of such protection; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our expectations regarding <span style="white-space:nowrap">geo-political</span> actions and conflict, war and terrorism, including the recent conflict between Russia and Ukraine and resulting sanctions, retaliatory measures, changes in the availability and price of various materials and effects on global financial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract and retain qualified key management and technical personnel; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;) and a foreign private issuer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections in this Annual Report titled &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">v </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART I </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_1"><span style="font-weight:bold">ITEM&#160;1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_2">A. Directors and Senior Management </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_3">B. Advisers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_4">C. Auditors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_5"><span style="font-weight:bold">ITEM&#160;2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">OFFER STATISTICS AND EXPECTED TIMETABLE </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_6">A. Offer Statistics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_7">B. Method and Expected Timetable </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_8"><span style="font-weight:bold">ITEM&#160;3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">KEY INFORMATION </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_9">A. [Reserved] </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_10">B. Capitalization and Indebtedness </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_11">C. Reasons for the Offer and Use of Proceeds </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_12">D. Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Factors Summary </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business faces significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. Our business, as well as our reputation, financial condition, results of operations and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material. These risks include, among others, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a history of operating losses and expect to continue to incur losses and will need additional capital to fund our operations and complete the development and commercialization of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our product candidates represent novel approaches to the treatment of diseases, and there are many uncertainties regarding the development of our product candidates. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our current product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinical trial costs may be higher than for more conventional therapeutic technologies or drug products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our product candidates may cause undesirable side effects or have other properties that may delay or prevent their development or regulatory approval or limit their commercial potential. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory review and approval processes of the FDA, the EMA and comparable regulatory authorities are lengthy, time-consuming and uncertain. If we are unable to obtain, or if there are delays in obtaining, regulatory approval for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory landscape that will govern our product candidates is still evolving. Regulations relating to more established gene therapy and cell therapy products and TCR Bispecific products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our product candidates are complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct preclinical studies and/or clinical trials of our product candidates. If they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently rely on third parties for the manufacture of our product candidates. Our dependence on these third parties may impair the clinical advancement and commercialization of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face substantial competition, which may result in others discovering, developing or commercializing products, treatment methods and/or technologies before or more successfully than we do. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Position and Need for Additional Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a history of operating losses and expect to continue to incur losses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company active in the development and discovery of potential T cell redirecting immunotherapies for the treatment of cancer. We have no products approved for commercial sale and have not generated revenue from operations. We have incurred net losses in each year since inception except for the year ended December&#160;31, 2022, as a result of our having received upfront payments from our licensing agreements which we have recorded partially as a one-time revenue under revenue recognition guidelines. As of December&#160;31, 2022, we had accumulated consolidated losses of &#8364;500.3&#160;million. We do not expect to generate any meaningful revenue from commercializing products for the foreseeable future. We expect to incur significant additional operating losses in the future as we continue and expand our research and development efforts for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know when or whether we will become profitable. To become and remain profitable, we must succeed in developing, obtaining regulatory approval for and commercializing one or more of our product candidates. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, discovering and developing additional product candidates, making regulatory submissions, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing commercialization capabilities for any approved products, manufacturing any approved products and achieving market acceptance for any approved products. We may never succeed in these activities. Even if we succeed in these activities, we may never generate revenue in an amount sufficient to achieve profitability. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with biotechnology product development and commercialization, we are unable to accurately predict whether and when we will achieve profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we achieve profitability, we may not be able to sustain profitability in subsequent periods. After we achieve profitability, if ever, we expect to continue to engage in substantial research and development activities and to incur substantial expenses to develop, manufacture and commercialize additional product candidates. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our revenues, expenses and profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to achieve or sustain profitability would depress our market value and could impair our ability to execute our business plan, raise capital, develop additional product candidates or continue our operations. A decline in the value of our company could cause our shareholders to lose all or part of their investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need additional capital to fund our operations and complete the development and commercialization of our product candidates. Our inability to obtain this capital when needed could force us to delay, limit, reduce or terminate our product development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. The development of biotechnology product candidates is capital intensive and we expect that we will continue to expend substantial resources for the foreseeable future to develop and commercialize our current and future product candidates. Our expenditures in the foreseeable future may include costs associated with conducting research and development activities, conducting preclinical studies and clinical trials, obtaining regulatory approvals, undertaking commercialization activities, establishing our sales and marketing capabilities, manufacturing and selling approved products and potentially acquiring or <span style="white-space:nowrap">in-licensing</span> new technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we had &#8364;362.2&#160;million in cash and cash equivalents and other financial assets. We believe that we have sufficient financial resources available to fund our projected operating requirements for at least the next twelve months. Because the outcome of our current and planned clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Our future funding requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical sites, enroll subjects and manufacture ACT and TCR Bispecific product candidates for our ongoing, planned and potential future clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">time and cost to conduct <span style="white-space:nowrap">IND-</span> or <span style="white-space:nowrap">CTA-enabling</span> studies for our preclinical programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">time and costs required to perform research and development to identify and characterize new product candidates from our research programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">time and cost necessary to obtain regulatory authorizations and approvals that may be required by regulatory authorities to execute clinical trials or commercialize our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to successfully commercialize our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to have clinical and commercial products successfully manufactured consistent with FDA, the EMA and comparable regulatory authorities&#8217; regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales and marketing costs associated with commercializing our products, if approved, including the cost and timing of building our marketing and sales capabilities; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">terms and timing of our current and any potential future collaborations, licensing or other arrangements that we have established or may establish; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cash requirements of any future acquisitions or the development of other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of operating as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">time and cost necessary to respond to technological, regulatory, political and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs associated with any potential business or product acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional funds may not be available when we need them or on terms that are acceptable to us. If adequate funds are not available to us on a timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our research and development efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional capital through the sale of equity or convertible debt securities, our existing shareholders&#8217; ownership interest will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our existing shareholders. If we raise additional capital through the sale of debt securities or through entering into credit or loan facilities, we may be restricted in our ability to take certain actions, such as incurring additional debt, making capital expenditures, acquiring or licensing intellectual property rights, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional capital through collaborations with third parties, we may be required to relinquish valuable rights to our intellectual property or product candidates or we may be required to grant licenses for our intellectual property or product candidates on unfavorable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are exposed to risks related to currency exchange rates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate internationally and are exposed to fluctuations in foreign exchange rates between the euro and other currencies, particularly the U.S. dollar. Our reporting currency is the euro and, as a result, financial line items are converted into euros at the applicable foreign exchange rates. As our business grows, we expect that at least some of our revenues and expenses will continue to be denominated in currencies other than the euro. Unfavorable developments in the value of the euro relative to other relevant currencies, especially the U.S. dollar, could adversely affect our business and financial condition. In the past, we have seen <span style="white-space:nowrap">USD-EUR</span> exchange rate fluctuations, that materially impacted our Statement of Profit and Loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The use of net operating loss carryforwards may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Immatics OpCo and Immatics US, Inc. (&#8220;Immatics US&#8221;) incurred significant losses in the past and therefore are entitled to use net operating loss carryforwards. For the year ended December&#160;31, 2022, we had German federal net operating loss carryforwards of &#8364;210.4&#160;million and Immatics US had U.S. federal net operating loss carryforwards of &#8364;146.8&#160;million. German federal net operating loss carryforwards and U.S. federal net operating loss carryforwards arising in taxable years ending after December&#160;31, 2017 do not expire, whereas U.S. federal net operating loss carryforwards arising before or in taxable years ending December&#160;31, 2017 will begin to expire in 2027. Limitation on tax loss carry forwards with respect to U.S. federal net operating losses is 80% of each subsequent year`s net income starting with losses generated after January&#160;1, 2018 and with respect to German federal net operating losses, 60% of each subsequent year`s net income. These have an indefinite carry forward period, but no carry back option. The operating loss carryforwards are subject to various </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations, including limitations under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) if Immatics US has a cumulative change in ownership of more than 50% within a three-year period. Further, due to our limited income, there is a high risk that our operating loss carryforwards will expire in part and cannot be used to offset future taxable income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any net operating loss carryforwards that we report on our tax returns are subject to review by the relevant tax authorities. Consequently, we are exposed to the risk that the tax authorities may not accept the reported net operating loss carryforwards in part or in their entirety. Any limitations in our ability to use net operating loss carryforwards to offset taxable income could adversely affect our financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Development of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates represent novel approaches to the treatment of diseases, and there are many uncertainties regarding the development of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human immunotherapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there are many uncertainties related to development of our product candidates. There can be no assurance as to the number of required clinical trials, the length of the trial period, the number of patients the FDA, the EMA or comparable regulatory authorities will require to be enrolled in the trials in order to establish the safety and efficacy of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA, the EMA or comparable regulatory authorities to support marketing approval. The FDA, the EMA and comparable regulatory authorities may take longer than usual to come to a decision on any BLA, MAA or similar marketing application that we submit and may ultimately determine that there is not enough data, information or experience with our product candidates to support an approval decision. Regulatory authorities may also require that we conduct additional post-marketing studies or implement risk management programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our current product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends heavily on the successful further development of our current and future product candidates and our research pipeline and regulatory approval of our current and future product candidates, all of which are subject to risks and uncertainties beyond our control. We are conducting clinical trials for IMA201, IMA203 and IMA401 and preclinical studies for our other product candidates. However, the FDA, the EMA and comparable regulatory authorities may ultimately disagree that data generated from our clinical trials are sufficient for regulatory approval. There can be no assurance that any of our product candidates will prove to be safe, effective or commercially viable treatments for cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we discontinue development of a product candidate, we will not receive the anticipated revenues from that product candidate, and we may not receive any return on our investment in that product candidate. In the future, we may discontinue other product candidates for clinical reasons if such product candidates do not prove to be safe and effective. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also find that the development of a companion diagnostic for our product candidates is more difficult or more expensive than anticipated, resulting in an inability to provide the required diagnostic testing for our clinical trials, or if approved, for the market. Moreover, because of the complexity and novelty of our companion diagnostic biomarker, there are only a limited number of providers who have the capability of supporting the development of a companion diagnostic. Should any of our clinical research organizations (&#8220;CROs&#8221;) fail to meet our development goals, it may take us significant time to find a replacement, if we are able to find a replacement at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to discontinue the development of any of our product candidates. Therefore, it is possible that none of our current product candidates will ever become commercial products. Our failure to develop and commercialize our current and future product candidates could have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that clinical trials of our product candidates will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of the clinical trial process, and other events may cause us to temporarily or permanently stop a clinical trial. Events that may prevent successful or timely commencement and completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative preclinical data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in receiving the required regulatory clearance from the appropriate regulatory authorities to commence clinical trials or amend clinical trial protocols, including any objections to our INDs or CTAs or protocol amendments from regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching, or a failure to reach, a consensus with regulatory authorities on study design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching, or a failure to reach, an agreement on acceptable terms with prospective independent clinical investigators, CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different investigators, CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in obtaining required Institutional Review Board (&#8220;IRB&#8221;) or ethics committee approval at each clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">challenges in recruiting and enrolling suitable patients that meet the study criteria to participate in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to enroll a sufficient number of patients in clinical trials to ensure adequate statistical power to detect statistically significant treatment effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities or IRBs for any reason, including safety concerns and <span style="white-space:nowrap">non-compliance</span> with regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by independent clinical investigators, CROs, other third parties or us to adhere to clinical trial requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with the FDA&#8217;s good clinical practices (&#8220;GCP&#8221;) or applicable regulatory guidelines in other jurisdictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to manufacture adequate quantities of a product candidate or other materials necessary in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;) and current Good Tissue Practices (&#8220;cGTPs&#8221;) to conduct clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lower than anticipated patient retention rates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in maintaining contact with patients after treatment, resulting in incomplete data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ambiguous or negative interim results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our independent clinical investigators, CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unforeseen safety issues, including occurrence of adverse events associated with the product candidate that are viewed to outweigh the product candidate&#8217;s potential benefits; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the clinical trial; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays and disruptions as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic or the conflict between Russia and Ukraine. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical trial. Further, there can be no assurance that submission of an IND, IND amendment or CTA will result in the FDA or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing and preclinical safety and efficacy testing requirements of both ACT and TCR Bispecifics remain emerging and evolving fields. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, as well as preclinical safety testing, will be a focus of IND reviews, which may delay the allowance of INDs by the FDA or CTA approval by comparable regulatory authorities. If we are not able to successfully complete clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we experience delays or difficulties in patient enrollment for clinical trials, our research and development efforts and the receipt of necessary regulatory approvals could be significantly delayed or prevented. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencement and successful and timely completion of clinical trials require us to enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or comparable regulatory authorities. Any delay or difficulty in patient enrollment could significantly delay or otherwise hinder our research and development efforts and delay or prevent receipt of necessary regulatory approvals. Despite diligent planning of our clinical trials and analysis of their feasibility regarding patient recruitment, we may experience difficulties, delays or inability in patient enrollment in our clinical trials for a variety of reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the severity and incidence of the disease under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility criteria for the study in question, including any misjudgment of, and resultant adjustment to, the appropriate ranges applicable to the exclusion and inclusion criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of the study population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of clinical trial sites and the proximity of prospective patients to those sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the trial and the complexity for patients and clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the nature, severity and frequency of adverse side effects associated with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the screening procedures and the rate of patients failing screening procedures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to provide appropriate screening assays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that patients&#8217; general health conditions do not allow the conduct of study/screening procedures (for example, tumor biopsy, or leukapheresis) or application of lymphodepletion regimen; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to manufacture patient products appropriately (for example, at a sufficient high dose, or with sufficiently active T cells); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efforts to facilitate timely enrollment in clinical trials and the effectiveness of recruiting publicity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patient referral practices of physicians within the same hospital as well as within other hospitals or private practices; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials for similar therapies, other new therapeutics, new combination treatments, new medicinal products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval of new indications for existing therapies or approval of new therapies in general or changes in standard of care; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved or become standard of care for the indications we are investigating; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain and maintain patient consents; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability of clinical sites to enroll patients as healthcare capacities are required to cope with natural disasters, epidemics or other health system emergencies, such as the <span style="white-space:nowrap">COVID-19</span> pandemic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not all patients suffering from a specific cancer that is in principle addressable by our product candidates are eligible for our clinical trials and therapies. First, patients must express a specific genetic marker called <span style="white-space:nowrap">HLA-A*02.</span> While this marker is found on approximately <span style="white-space:nowrap">40-50%</span> of individuals in North America and Europe, it is less frequent in other populations, such as China or Japan. If human leukocyte antigen (&#8220;HLA&#8221;) screening for a patient shows that <span style="white-space:nowrap">HLA-A*02</span> is not expressed, he or she cannot be treated with our current product candidates. Second, the prevalence of the targets addressed by IMA201, IMA203 and IMA401 differs between different tumor entities. For a given patient, a biomarker assay must be performed in order to find out whether he or she expresses one of the targets and can be treated with one of our product candidates. We cannot be certain that the anticipated and assumed target prevalence rates are confirmed in the patient populations of our clinical trials, and lower target prevalence rates may be experienced. Third, further eligibility criteria are in place to ensure that the patients can tolerate and potentially benefit from the treatment. Thus, only a few of the patients screened for our clinical trials will receive cellular or TCR Bispecifics products. Patients may therefore be hesitant to consent to our trials, and overall, many more patients will have to be screened to treat the targeted number of patients. It is uncertain how many more patients we will be required to screen. If the required number of patient screenings is much higher than anticipated, our clinical trial costs may increase. To mitigate this risk, we are testing several tumor targets in parallel in our clinical trials and have further product candidates against other <span style="white-space:nowrap">HLA-types</span> in early preclinical development. However, we cannot be certain whether this will be successful and effective in enhancing recruitment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some eligible patients may instead opt to enroll in a competitor&#8217;s trial. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Enrolling patients at the same sites as our competitors may compromise the quality and conclusiveness of our clinical data by introducing bias. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and approved immunotherapies, rather than enroll patients in any clinical trial. In addition, potential enrollees in our ACT trials with IMA201 or IMA203 may opt to participate in other clinical trials because of the length of time between the time that their tumor is analyzed, and the cellular product is manufactured and infused back into the patient. Challenges in recruiting and enrolling suitable patients to participate in clinical trials could increase costs, affect the timing and outcome of our planned clinical trials and result in delays to our current development plan for our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinical trial costs may be higher than for more conventional therapeutic technologies or drug products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are expensive and difficult to design, implement and conduct, in part because they are subject to rigorous regulatory requirements. Because our ACT product candidates are based on new cell therapy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies and manufactured on a <span style="white-space:nowrap"><span style="white-space:nowrap">patient-by-patient</span></span> basis, we expect that such candidates will require extensive research and development and have substantial manufacturing costs per dose. Our TCR Bispecific product candidates also require extensive research and development, as the applicable technology is new and experience with developing such biologics is rare in the field. Moreover, the development of a companion diagnostic will also require extensive research and development, and such companion diagnostic must be suitable to support both enrollment into larger clinical trials and routine hospital procedures after marketing approval. Any failure or delay in developing a suitable companion diagnostic will delay or make it impossible to conduct larger clinical trials for ACT product candidates and/or TCR Bispecific product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, costs to treat patients with recurrent and/or refractory cancer and to treat potential side effects that may result from our product candidates, <span style="white-space:nowrap">non-investigational</span> medicinal products, rescue or prophylactic medication applied in our clinical trials can be significant. Some clinical trial sites do not bill or obtain coverage from Medicare, Medicaid, health insurance or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and we can be required by those trial sites to pay such costs. In countries outside the United States, we expect that all costs related to the clinical trial and to the management of study patients (for example, management of adverse reactions or hospitalization) are paid by the sponsor of the clinical trial. As trial designs for development of our product candidates are complex, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products. At some point, we may combine two or more of our ACT or TCR Bispecific product candidates within one clinical trial or within a <span style="white-space:nowrap"><span style="white-space:nowrap">multi-TCR-T</span></span> or <span style="white-space:nowrap">multi-TCR</span> Bispecifics concept in order to enhance clinical efficacy results and to increase the patient population. The setup and conduct of such <span style="white-space:nowrap"><span style="white-space:nowrap">multi-TCR-T</span></span> or <span style="white-space:nowrap">multi-TCR</span> Bispecifics clinical trials is expensive and may bear unknown risks, such as regulatory, preclinical, safety and manufacturing risks. In addition, our proposed personalized product candidates involve several complex and costly manufacturing and processing steps, the costs of which will be borne by us. We are also responsible for the manufacturing costs of products for patients that do not receive the product due to any reason (for example, rapid degradation of general health status, not meeting inclusion/exclusion criteria for infusion). Depending on the number of patients that we ultimately screen and enroll in our trials, the number of trials that we may need to conduct, and the companion diagnostic we need to develop, our overall clinical trial costs may be higher than for more conventional treatments. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates may cause undesirable side effects or have other properties that may delay or prevent their development or regulatory approval or limit their commercial potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates or by similar product candidates developed by others could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the denial of regulatory approval by the FDA, the EMA or comparable regulatory authorities and potential product liability claims. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our cell therapy clinical trials, most commonly reported Grade &#8805;3 treatment-emergent adverse events (&#8220;TEAEs&#8221;) were cytopenias. In addition, we have observed dose-limiting toxicities (&#8220;DLT&#8221;). There can be no assurance that patients treated with our product candidates will not experience these and other serious adverse side effects and there can be no assurance that the FDA, the EMA or comparable regulatory authorities will not place clinical holds on our current or future clinical trials, the result of which could delay or prevent us from obtaining regulatory approval. In particular, our clinical trials enroll patients who have failed all available <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> treatments. As a result, these patients may be immunocompromised and thus are more susceptible to serious adverse side effects. In addition, certain of our protocols involve further weakening of patients&#8217; immune response (e.g., through lymphodepletion) prior to receiving our product candidates, which may further increase the severity and frequency of serious adverse side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, because our product candidates represent novel approaches to the treatment of cancer, we may be less able to predict the nature, severity and frequency of adverse events and thus less able to undertake measures </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to prevent serious adverse events and mitigate their effects. For example, infused T cells may be more active than we expect or than we previously observed. Moreover, because our ACTengine product candidates for a specific patient are manufactured using that patient&#8217;s white blood cells, each patient receives an individually manufactured ACTengine product candidate. As a result, it may be difficult to predict how a patient will respond to that individualized product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA, the EMA or comparable regulatory authorities delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. In addition, some of our product candidates are developed or intended to be used in combination with other therapies. When used in combination, the severity and frequency of undesirable side effects may be greater than the cumulative severity and frequency of such side effects when the therapies are used as monotherapies and the nature of undesirable side effects may be different than such side effects when the therapies are used as monotherapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or others identify undesirable side effects caused by our product candidates or those of our competitors, a number of potentially significant negative consequences could result, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may encounter delays or difficulties in enrolling patients for our clinical trials due to a negative perception of our product candidates&#8217; safety and tolerability profile; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we and/or regulatory authorities may temporarily or permanently put our clinical trials on hold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to obtain regulatory approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw or limit their approvals of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, such as a contraindication, boxed warnings or additional warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may require development of a Risk Evaluation and Mitigation Strategy with Elements to Assure Safe Use as a condition of approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may decide to remove our product candidates from the marketplace; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be subject to regulatory investigations and government enforcement actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for harm caused to patients, including as a result of hospital errors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining regulatory approval and market acceptance of our product candidates and could substantially increase commercialization costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage or other clinical trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive and promising results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage clinical trials or from clinical trials of the same product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Late-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. In particular, we expect there may be greater variability in results for products </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processed and administered on a <span style="white-space:nowrap"><span style="white-space:nowrap">patient-by-patient</span></span> basis, as for our cellular therapy product candidates, than for <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> products, like many other drugs. Therefore, despite positive results observed in early-stage clinical trials, our product candidates may fail to demonstrate sufficient efficacy in our pivotal or confirmatory clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preliminary interim or <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may announce or publish preliminary interim or <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data from clinical trials. Positive preliminary data may not be predictive of such trial&#8217;s subsequent or overall results. Preliminary data are subject to the risk that one or more of the outcomes may materially change as more data become available. Additionally, preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our studies of cellular therapies in patients without any indicated <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> treatment utilize an &#8220;open-label, single arm, <span style="white-space:nowrap">dose-escalation/de-escalation&#8221;</span> trial design. This trial design has the potential to create selection bias by encouraging the investigators to enrol a more favorable patient population (for example, indications better suitable for immunotherapies, fitter patients, fewer prior therapies) compared to a broader patient population. In our current Phase 1 clinical trials, investigators have significant discretion over the selection of patient participants. As the trials continue, the investigators may prioritize patients with more progressed forms of cancer and/or worse general health condition than the initial patient population, based on the safety/success or perceived safety/success of that initial population. Patients with more progressed forms of cancer or worse general health conditions may experience more and/or worse adverse events or be less responsive to treatment, and accordingly, interim or final safety and efficacy data may show an increase in frequency or severity of adverse events and/or a decline in patient response rate or change in other assessment metrics. As the trials continue or in subsequent trials, investigators may shift their approach to the patient population, which may ultimately experience more and/or worse adverse events and/or result in a decline in both interim and final efficacy data from the preliminary data, or conversely, a decrease in frequency and/or severity of adverse events or an increase in final efficacy data following a decline in the interim efficacy data, as patients with more progressed forms of cancer or worse general health condition are cycled out of the trials and replaced by patients with less advanced forms of cancer or with better general health conditions. This opportunity for investigator selection bias in our trials as a result of open-label design, which is standard in <span style="white-space:nowrap">dose-escalation/de-escalation</span> trials, may not be adequately handled and may cause a decline in or distortion of clinical trial data from our preliminary results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, positive preliminary results in any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary data could significantly harm our business prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The deviations in our proposed new products from existing products may require us to perform additional testing, which will increase the cost, and extend the time for obtaining approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ACT based therapy is based on first-generation adoptive cell therapy technology suitable for delivering for small, early-phase clinical trials. While we have implemented advancements to the process, the current methods of treatment are very labor intensive and expensive, which has limited their widespread application. We </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have developed new processes that we anticipate will enable more efficient manufacturing of ACT. We may have difficulty demonstrating that the products produced from our new processes are comparable to the existing products. The FDA, the EMA and comparable regulatory authorities may require additional clinical testing before permitting a larger clinical trial with the new processes, and the product may not demonstrate the desired activity in new clinical trials. In the manufacturing of cellular products, even small changes in manufacturing processes could alter the cell types, so our ability to predict the outcomes with newer manufacturing processes is limited. The changes that we have made to the historical manufacturing process may require additional testing, which may increase costs and timelines associated with these developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TCR Bispecific product candidates contain features that have not been previously tested in this composition in clinical trials or marketed products. The FDA, the EMA and comparable regulatory authorities may require additional <span style="white-space:nowrap">non-clinical</span> studies before permitting us to enter clinical trials with our product candidates. Regulatory authorities may also ask for additional early-stage trials or production of additional batches of TCR Bispecific product candidates before permitting larger clinical trials or registration trials. To comply with those requests would increase costs and timelines for the development of our TCR Bispecific product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Regulatory Approval of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory review and approval processes of the FDA, the EMA and comparable regulatory authorities are lengthy, time-consuming and uncertain. If we are unable to obtain, or if there are delays in obtaining, regulatory approval for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates must be approved by the FDA in the United States, by the EMA in the European Union and by comparable regulatory authorities in other jurisdictions prior to commercialization. In order to obtain regulatory approval for the commercial sale of any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective for use in each target indication and that manufacturing of the product candidate is robust and reproducible. The time required to obtain approval by the FDA, the EMA and comparable regulatory authorities is uncertain, typically takes many years following the commencement of clinical trials and depends upon numerous factors. Accordingly, there can be no assurance that any of our product candidates will receive regulatory approval in the United States, the European Union or other jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities have substantial discretion in the approval process. They may refuse to accept any application or may decide that our data are insufficient for approval and require additional clinical trials or other studies. We expect the novel nature of our product candidates to create additional challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T cell directed therapies for cancer. Therefore, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any comparable regulatory authority. If we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated, we may incur significant additional costs and the regulatory approval of our product candidates may be delayed or prevented. Furthermore, additional clinical trials or other testing could shorten any periods during which we may have the exclusive right to commercialize our product candidates and could allow our competitors to bring products to market before we do, which may prevent the successful commercialization of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the process and time required to obtain regulatory approval differ by jurisdiction. In many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services at market rates. Under certain circumstances, we may be required to report some of these relationships to the FDA, the EMA or comparable regulatory authorities, which could conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA, the EMA or comparable regulatory authorities may, therefore, question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could delay, or result in the rejection of, our marketing applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applications for regulatory approval and regulatory approval of our product candidates could be delayed or be denied for many reasons, including but not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, the EMA or comparable regulatory authorities may disagree with the number, design or implementation of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the population studied in the clinical trial may not be considered sufficiently broad or representative to assure safety in the full population for which we seek approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collected from clinical trials of our product candidates may not meet the level of statistical or clinical significance required by the FDA, the EMA or comparable regulatory authorities or may otherwise not be sufficient to support the submission of a BLA, MAA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, the EMA or comparable regulatory authorities may not accept data generated by our preclinical service providers and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, the EMA or comparable regulatory authorities may require us to conduct additional preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, the EMA or comparable regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications applicable to the manufacture of our product candidates, the facilities of third-party manufacturers with which we contract for clinical or commercial supplies may fail to maintain a compliance status acceptable to the FDA, the EMA or comparable regulatory authorities or the EMA or comparable regulatory authorities may fail to approve facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or any third-party service providers may be unable to demonstrate compliance with cGMPs and cGTPs to the satisfaction of the FDA, the EMA or comparable regulatory authorities, which could result in delays in regulatory approval or require us to withdraw or recall products and interrupt commercial supply of our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may change in a manner rendering our clinical data insufficient for approval; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">political factors surrounding the approval process, such as government shutdowns and political instability. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors, some of which are beyond our control, may result in our failing to obtain regulatory approval for any of our product candidates, which would significantly harm our business, financial condition and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory landscape that will govern our product candidates is still evolving. Regulations relating to more established gene therapy and cell therapy products and TCR Bispecific products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we are developing novel cell immunotherapy product candidates that are unique biological entities, the regulatory requirements to which we will be subject are not entirely clear and may change rapidly. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have become more stringent and comprehensive frequently and may continue to extend in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (&#8220;OTAT&#8221;), formerly known as the Office of Cellular, Tissue and Gene Therapies (&#8220;OCTGT&#8221;), within its Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials in the U.S. are also subject to review and oversight by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Similar regulatory bodies exist in Europe and other jurisdictions. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA, the EMA and comparable regulatory authorities to change the requirements for approval of any of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is already a T cell engaging bispecific molecule approved and regulatory guidelines have been issued for this class of drugs, bispecific therapeutics are still new in the field and regulators have even less experience with TCR Bispecifics. Thus, guidance for development and regulatory approval of such drugs may change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complex regulatory environments exist in the different jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No.&#160;1394/2007 on advanced therapy medicinal products (&#8220;ATMPs&#8221;) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our cell immunotherapy product candidates is new, our product candidates may face even more cumbersome and complex regulations than those emerging for other gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be revoked, suspended or otherwise withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Development of a product candidate intended for use in combination with an already approved product may present more or different challenges than development of a product candidate for use as a single agent. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluate our ACT and TCR Bispecifics product candidates in combination with other therapies, such as checkpoint inhibitor immunotherapies. The development of product candidates for use in combination with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
another product may present challenges. For example, the FDA may require us to use more complex clinical trial designs, in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that most or any positive results are attributable to the already approved product. Moreover, following product approval, the FDA may require that products used in conjunction with each other be cross-labelled. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement. Moreover, developments related to the already approved products may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the approved product&#8217;s safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when our ongoing Phase 1 clinical trials for IMA203 and/or IMA401 are completed and, assuming positive data, we expect to advance to potential registrational trials, either directly or following a Phase 2 trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the trial results are sufficiently compelling, we intend to discuss with the FDA a BLA submission for the relevant product candidate. Further, we plan to have discussions with other authorities, such as the EMA or Health Canada regarding any planned marketing authorization submissions. It cannot be guaranteed that FDA, the EMA and other regulatory authorities will agree to move to a registrational trial on the basis of data generated and may ask for additional data. Even if the FDA, the EMA or other regulatory authorities agrees with the design and implementation of the clinical trials set forth in an IND and CTA, we cannot guarantee that the regulatory authorities will not change their requirements in the future. For example, the regulatory authorities may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the regulatory authorities may only allow us to evaluate patients that have already failed autologous therapy or very late-stage patients, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our current clinical trials are being conducted outside the United States, and the FDA may not accept data from trials conducted in foreign locations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain current clinical trials of our drug candidates are being conducted or planned to be conducted partially or fully outside the United States. We may also conduct future clinical trials for our drug candidates partially or fully outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles and good clinical practice (&#8220;GCP&#8221;) requirements. Further, the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from such clinical trials, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek accelerated approval for some of our product candidates, which may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that the product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may attempt to seek approval on a per indication basis for our product candidates on the basis of a single pivotal trial or on the basis of data from one or more uncontrolled trials. While the FDA requires in most cases two adequate and well-controlled pivotal clinical trials to demonstrate the efficacy of a product candidate, a single trial with strong confirmatory evidence may be sufficient in instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and if confirmation of the result in a second trial would be practically or ethically impossible. In rare cancer indications with very limited treatment options, a large and/or controlled trial is often not feasible and thus data from smaller and even uncontrolled trials may be sufficient for regulatory approval. It is difficult for us to predict with such a novel technology exactly what will be required by the regulatory authorities in order to take our product candidates to market or the timeframes under which the relevant regulatory approvals can be obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For treatments granted accelerated approval, post-marketing confirmatory clinical trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory clinical trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. If any of our competitors were to receive full approval on the basis of a confirmatory clinical trial for an indication for which we seek accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical end and accelerated approval of our product candidate would be more difficult. Moreover, the FDA may withdraw approval of our product candidate approved under the accelerated approval pathway if, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical trial(s) required to verify the predicted clinical benefit of a product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other evidence demonstrates that a product candidate is not shown to be safe or effective under the conditions of use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we fail to conduct any required post-marketing confirmatory clinical trial with due diligence; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we disseminate false or misleading promotional materials relating to the relevant product candidate. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, the accelerated approval pathway has come under scrutiny within the FDA and by Congress. The FDA has put increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm the benefit. For example, FDA has convened its Oncologic Drugs Advisory Committee to review what the FDA has called dangling or delinquent accelerated approvals where confirmatory studies have not been completed or where results did not confirm benefit. In addition, Congress recently enacted the Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;), which included provisions related to the accelerated approval pathway and authorizes the FDA to require a post-approval study to be underway prior to approval or within a specified time period following approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may pursue orphan drug designation for certain of our product candidates, which we may not receive, and even if we receive such designation, we may be unable to maintain the associated benefits. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. In addition, if a product receives </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same biologic (meaning, a product with the same principal molecular structural features) for that indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity for the orphan indication following drug or biological product approval, provided that the criteria for orphan designation are still applicable at the time of the granting of the marketing authorization. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. However, orphan drug designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may pursue orphan drug designation for one or more of our product candidates. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for our product candidates in specific indications, we may not be the first to obtain regulatory approval of these product candidates for the orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Furthermore, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because a different biologic (with different principal molecular structural features) can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same biologic for the same condition if the FDA concludes that the later biologic is safer, more effective or makes a major contribution to patient care. Our inability to obtain orphan drug designation for any product candidates for the treatment of rare cancers and/or our inability to maintain that designation for the duration of the applicable exclusivity period, could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Breakthrough Therapy Designation, Fast Track Designation and Priority Review Designation by the FDA, or comparable designations by comparable regulatory authorities, for our product candidates may not lead to a faster development or regulatory review or approval process and do not increase the likelihood that a product candidate would receive regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have Breakthrough Therapy Designation, Fast Track Designation or Priority Review Designation or comparable designations by comparable regulatory authorities for our product candidates. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development. A Fast Track Designation may be available if a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the EMA has implemented the <span style="white-space:nowrap">so-called</span> &#8220;PRIME&#8221; (PRIority MEdicines) status in order support the development and accelerate the approval of complex innovative medicinal products addressing an unmet </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical need. The PRIME status enables early dialogue with the relevant EMA scientific committees and, possibly, some payers; and thus, reinforces the EMA&#8217;s scientific and regulatory support. It also opens accelerated assessment of the marketing authorization application (150 days instead of 210 days). The PRIME status, which is decided by the EMA, is reserved to medicines that may benefit from accelerated assessment, i.e., medicines of major interest from a public health perspective, in particular from a therapeutic innovation perspective and that target unmet medical need. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, the EMA and comparable regulatory authorities have broad discretion whether or not to grant Breakthrough Therapy Designation, Fast Track Designation and Priority Review Designation and comparable designations. Accordingly, even if we believe, after completing early clinical trials, that one of our product candidates meets the criteria for such designations, the applicable regulatory authority may disagree and instead determine not to make such designations. Even if we receive such designation for a product candidate, it may not result in a faster development process, review or approval compared to conventional procedures and does not guarantee ultimate approval by the applicable regulatory authority. Many drugs that have received such designations have failed to obtain ultimate approval. In addition, the applicable regulatory authority may decide to rescind such designations if it determines that our product candidates no longer meet the conditions for qualification, including as a result of the product candidates&#8217; failure to meet endpoints in any clinical trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are required to comply with comprehensive and ongoing regulatory requirements for any product candidates that receive regulatory approval, including conducting confirmatory clinical trials of any product candidates that receive accelerated approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidates for which we receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory authorities are required to undergo one or more confirmatory and post-marketing clinical trials. If such a product candidate fails to meet its safety and efficacy endpoints in such confirmatory and post-marketing clinical trials, the regulatory authority may withdraw its approval. There is no assurance that any such product will successfully advance through its confirmatory and post-marketing clinical trial(s). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw approval, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any product candidates for which we receive regulatory approval in a particular jurisdiction and the activities associated with their commercialization, including testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, will be subject to comprehensive regulation by the FDA, the EMA or comparable regulatory authorities. These requirements include, without limitation, submissions of safety and other post-marketing information and reports, registration and listing requirements, the FDA&#8217;s cGMP and cGTPs requirements or comparable requirements in foreign jurisdictions, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA, the EMA or comparable regulatory authorities, requirements regarding the distribution of samples to physicians, tracking and reporting of payments to physicians and other healthcare providers and recordkeeping. In the United States, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. The FDA also imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products and, if we promote our products beyond their approved indications or in a manner inconsistent with the approved labeling, we may be subject to enforcement action for <span style="white-space:nowrap">off-label</span> promotion. Violations of the U.S. Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policies of the FDA, the EMA and comparable regulatory authorities may change and additional regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or to the adoption of new requirements, or not able to maintain regulatory compliance, we may lose any regulatory approval that may have been obtained. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad, as the regulatory environment changes rapidly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Related to the Manufacturing of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates are complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are cellular products or biologics and the process of manufacturing our products is complex, highly regulated and subject to multiple risks. The manufacture of our cellular product candidates involves complex processes, including, for example, for ACTengine genetically modified autologous T cell products (IMA201, IMA203, and IMA204), harvesting and transporting blood cells from every patient for T cell isolation, engineering of the T cells to express a specific T cell receptor for a tumor target,<span style="font-style:italic"> ex vivo</span> multiplying the T cells to obtain the desired cell numbers for the dose, and finally transporting of the T cell product back to the patient for infusing the modified T cells back into the same patient. As a result of the complexities, the cost to manufacture cellular products per dose is generally higher than traditional small molecule chemical compounds or biologics, and the manufacturing process is less reliable, more variable and is more difficult to reproduce. Our manufacturing process may be susceptible to product loss or failure due to logistical issues associated with the collection of patients&#8217; blood cells, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product. Product loss or failure may also be caused by manufacturing issues associated with the variability in patient starting material especially from heavily treated cancer patients, interruptions in the manufacturing process, contamination, equipment failure, assay failures, improper installation or operation of equipment, vendor or operator error, inconsistency in cell growth, and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s starting material, or any intermediate product at any point in the process, or if any product does not meet the present specifications, the manufacturing process for that patient will need to be restarted, sometimes including <span style="white-space:nowrap">re-collection</span> of blood cells from the patient, and the resulting delay may adversely affect that patient&#8217;s outcome. It may even happen, that failed product manufacture may prevent a patient from getting a T cell product. If microbial, environmental or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. If such contaminations or other product quality issues are not discovered and if as a result thereof patients are exposed to a health risk, we may be held liable. Our insurance may not cover those cases, or the financial coverage may not be sufficient. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our ACTengine cellular product candidates are manufactured specifically for each individual patient, we will be required to maintain a chain of identity with respect to the patient&#8217;s cellular material as it moves from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our products from the market. Further, as product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials or otherwise necessitate the conduct of additional studies, including bridging clinical trials, which can be costly and time-consuming. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, our cellular product candidates are manufactured using processes developed or modified by us but based on current industry standards sufficient to serve early-stage development of our product candidates. We </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anticipate to implement further developments for registration-directed and commercial manufacturing. The final process will be closed, partially automated and viable for advanced clinical trials through product registration, and all ongoing and future company-sponsored clinical trials. Although we believe that this process is commercially viable, there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process upscaling, <span style="white-space:nowrap">scale-out,</span> process reproducibility, technology transfer, stability issues, lot consistency, and timely availability of raw materials. This includes potential risks associated with FDA not agreeing with all of the details of our validation data or our potency assay for our Phase 1 or future Phase 2 clinical trials. Furthermore, we or some of our CMOs may not be able to establish comparability of our/their products with the ACT products used in our Phase 1 or future Phase 2 clinical trials or may not be fully validated prior to starting our pivotal or registration clinical trial. As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing capabilities for our allogenic cellular therapy product candidate(s) IMA30x are still in the process of being developed. We may not successfully establish a robust production process that fulfills the requirements of the FDA, the EMA and comparable regulatory authorities. If we fail to establish such a manufacturing process, we may not be able to commence clinical trials or clinical trials may be delayed. There can be no assurance that the production process we are currently developing is viable and can be effectively scaled up or transferred to a CMO for later-phase clinical testing and commercialization. If we fail to develop a process that can be used throughout the life cycle of the product candidate, commercialization may be delayed or may not occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing of TCR Bispecifics (TCER), such as IMA401, IMA402, IMA403 and potential future product candidates, is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, issues with purity, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, inacceptable purity, product defects, loss of production batches and other supply disruptions. In such cases, our development program may experience major delays and we may have to produce a new batch of a given TCER. This will be costly and will delay our TCER development program. In particular, production of a new cGMP batch may be time-consuming, as it relies on the availability of facilities with cGMP capabilities at our CMO, and such facilities must be booked far in advance. We may also experience failure of production of the master cell bank that is used to produce our TCER molecules. For example, missing clonality of the cell line or <span style="white-space:nowrap">non-sterility</span> of the cell bank may require production of a new master cell bank which would be associated with additional costs and delays. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure to follow cGMP and cGTP or other regulatory requirements or any delay, interruption or other issues that arise in the manufacture, fill and finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination of or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TCR Bispecific product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer other quality defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical trials or other development activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are constructing our own manufacturing facility. However, we have no experience as a company in developing a large manufacturing facility. The designing and building process will be time consuming, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive, and we may not realize the benefit of this investment. The manufacture of biopharmaceutical products, especially of those cellular in nature like our ACT product candidates, is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability, patient to patient variability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, local and foreign regulations. Any problems or delays we or our CMOs experience in preparing for commercial scale manufacturing of a cell therapy or biologic product candidate or component may result in a delay in the regulatory approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our commercial manufacturers fail to deliver the required commercial quantities or supply of our product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products, and we would lose potential revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process and facilities for any products that we may develop is subject to FDA, the EMA and comparable regulatory authority approval processes, and we and our CMOs will need to meet all applicable regulatory authority requirements, including cGMP and cGTP requirements, on an ongoing basis, including requirements pertaining to quality control, quality assurance, and the maintenance of records and documentation. The FDA, the EMA and comparable regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must be approved by the FDA pursuant to inspections that will be conducted after we submit our marketing applications. Manufacturers are also subject to continuing FDA, the EMA and comparable regulatory authority inspections following marketing approval. Further, we, in cooperation with our CMOs, must supply all necessary chemistry, manufacturing, and control documentation in support of a BLA on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, or our CMOs&#8217; manufacturing facilities, may be unable to comply with our specifications, cGMP and cGTP requirements, and with other regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA, the EMA or comparable regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there can be no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA, the EMA or comparable regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third party to implement and may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Commercialization of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As a company, we have never commercialized a product. We currently have no active sales force or commercial infrastructure. We may lack the necessary expertise, personnel and resources to successfully commercialize our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no active sales force or commercial infrastructure. As a company, we have never commercialized a product for any indication. Even if we receive regulatory approval for one or more of our product candidates from the FDA, the EMA or comparable regulatory authorities, we will need to develop robust internal sales, marketing and distribution capabilities to commercialize such products, which will be expensive and time-consuming, or enter into collaborations with third parties to perform these services. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are costs and risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We must also compete with other biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, we may wish to establish collaborations with third parties to maximize the potential of our product candidates jurisdictions in which a product candidate has been approved. The biotechnology industry is characterized by intense competition. Therefore, we may not be successful in entering into such commercialization arrangements with third parties on favorable terms, or at all. In addition, we may have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell, market and distribute our products effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to develop the necessary commercial infrastructure and capabilities to successfully commercialize our product candidates or be able to establish or maintain relationships with third parties necessary to perform these services. As a result, we may not successfully commercialize any product in any jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, patient advocacy groups, third-party payors and the medical community. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain regulatory approval for any of our current or future product candidates, that product candidate may nevertheless not gain sufficient market acceptance among physicians, patients, patient advocacy groups, third-party payors and the medical community. For example, they may prefer current, well-established cancer treatments, such as chemotherapy and radiation therapy, to the exclusion of our product candidates or may prefer other novel product candidates rather than our product candidates. Efforts to educate physicians, patients, patient advocacy groups and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and may not receive a satisfactory return on our investment into the research and development of those product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance of our product candidates is heavily dependent on patients&#8217; and physicians&#8217; perceptions that our product candidates are safe and effective treatments. The perceptions of any product are influenced by perceptions of competitors&#8217; products that are in the same class or that have a similar mechanism of action. As a result, adverse public perception of our competitors&#8217; products may negatively impact the market acceptance of our product candidates. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant product revenues and may not become or remain profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market opportunities for our product candidates may be smaller than we estimate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who are in a position to receive our product candidates, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates that have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, and may prove to be incorrect. These estimates may be inaccurate or based on imprecise data. We do not have verifiable internal marketing data regarding the potential size of the commercial market for our product candidates, nor have we obtained current independent marketing surveys to verify the potential size of the commercial markets for our current product candidates or any future product candidates. Since our current product candidates and any future product candidates will represent novel approaches to treating various </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">For any product candidates developed in combination with other therapies, regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any product candidates developed for use in combination with an approved therapy, we are subject to the risk that the FDA, the EMA or comparable regulatory authorities could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA, the EMA or comparable regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any product candidates developed for us in combination with a therapy that has not been approved by the FDA, the EMA or comparable regulatory authorities, we may not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. These unapproved therapies face the same risks described with respect to our product candidates currently in development, including serious adverse effects and delays in their clinical trials. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#8217; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA, the EMA or comparable regulatory authorities do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and reimbursement may be limited or unavailable for our product candidates, which could make it difficult to sell our products profitably. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. We cannot be certain that coverage and adequate reimbursement will be available for any of our product candidates, if approved, or that reimbursement policies will not reduce the demand for any of our product candidates, if approved. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ACT product candidate may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may increase the overall cost of ACT therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may affect our ability to obtain reimbursement coverage for the combination therapy from third-party medical insurers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform legislation and other changes in the healthcare industry and in healthcare spending may adversely affect our business model. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue prospects could be affected by changes in healthcare spending and policies in the United States, the European Union and any other potential jurisdictions we may seek to commercialize our product candidates, if approved. We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader healthcare cost reduction effort, could have an adverse impact on our anticipated product revenues. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future. Any adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Relationships with Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct preclinical studies and/or clinical trials of our product candidates. If they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently, and we expect that we will continue to, rely on independent clinical investigators and CROs to conduct our clinical trials. CROs also assist us in the collection and analysis of data. As a result of our reliance </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on these third parties, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than we would otherwise have if we relied entirely upon our own staff. These third parties are not our employees and we have limited control over the amount of time and resources that they dedicate to our product candidates. In addition, communications with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have staffing difficulties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fail to comply with contractual obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience regulatory compliance issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">undergo changes in priorities or become financially distressed; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">form relationships with other entities, some of which may be our competitors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their duties under their agreements, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to clinical trial protocols or to regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, the clinical trials of our product candidates may not meet regulatory requirements. Specifically, the FDA, the EMA and comparable regulatory authorities require compliance with regulations and standards, including GCP, for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to assure that the data and results are credible and accurate and that the rights, integrity and confidentiality of study participants are protected. Although we rely, and intend to continue to rely, on third parties to conduct our clinical trials, they are not our employees, and we are responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan, protocol, legal and regulatory requirements and scientific standards. Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. If our third-party research and development partners fail to comply with applicable GCPs or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and preclinical development activities or clinical trials may be extended, delayed, suspended or terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete with many other companies for the resources of these third parties. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our product candidates. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with any third-party research and development partner terminates its relationship with us, we may not be able to enter into arrangements with alternative third-party research and development partners or to do so on commercially reasonable terms. Switching or adding additional third-party research and development partners involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third-party research and development partner commences work. As a result, delays may occur in our clinical trials, which can materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to obtain reagents and raw materials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of our product candidates by us or any of our CMOs requires access to a number of reagents and other critical raw materials from third-party suppliers. Such third parties may refuse to supply such reagents or other raw materials or alternatively refuse to supply on commercially reasonable terms. There may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also be capacity issues at such third-party suppliers that impact our ability to increase production of our product candidates. Some of the materials used in the manufacture and processing of our product candidates may only be supplied by one or a few vendors, which means that, should those vendors be unable to supply, for whatever reason, our ability to manufacture product candidates and progress product candidates through clinical trials could be severely impacted and result in additional delays. Such failure to supply could also impact other supply relationships with other third parties and potentially result in additional payments being made or required in relation to such delays. In addition, where any raw material or precursor material (including, for example, lentiviral vector, cell culture medium, chromatographic column material or other essential raw material) is currently supplied by one or a few vendors, replacing such raw material or precursor or finding alternative vendors may not be possible or may significantly impact on the timescales for manufacture and supply of our product candidates. Even where alternative materials or precursors or alternative vendors are identified, such alternative materials, precursors or vendors and their materials will need to be properly assessed and qualified and additional regulatory approvals may also need to be obtained all of which could result in significant delays to the supply of our product candidates or an inability to supply product candidates within anticipated timescales, if at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely on third parties for the manufacture of our product candidates. Our dependence on these third parties may impair the clinical advancement and commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical T cell products are currently manufactured by our employees through a collaboration with the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at UTHealth (&#8220;UTH&#8221;) McGovern Medical School in Houston, Texas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To scale our cell therapies for pivotal trials and initial commercial manufacturing, we have started the construction of a <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> GMP manufacturing facility in Houston metropolitan area, Texas. We have contractual agreements in place with GMP suppliers of lentiviral vectors, which is the most critical raw material for the manufacturing of genetically modified T cells products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing strategy for TCER includes CMOs for cell line development, process development, formulation development, cGMP manufacturing, analytics, release testing, fill and finish, packaging and storage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party providers may expose us to different risks than if we were to manufacture and supply product candidates ourselves. The facilities used by our CMOs or other third-party manufacturers to manufacture our product candidates must be approved by the EMA and comparable regulatory authorities, and the FDA requires our CMOs or other third-party manufacturers to maintain a compliance status acceptable to the FDA, pursuant to inspections that will be conducted after we submit the marketing application to the applicable regulatory authorities. Although we have auditing rights with all our manufacturing counterparties, we do not have control over a supplier&#8217;s or manufacturer&#8217;s compliance with these laws, regulations, applicable cGMP and cGTP standards and other laws and regulations, such as those related to environmental health and safety matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our CMOs or other third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA and comparable regulatory authorities, or if the quality or accuracy of the manufacturing and quality control data they obtain is compromised due to their failure to adhere to protocols or to regulatory requirements, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our CMOs or other third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If a CMO or other third-party manufacturer cannot maintain a compliance status acceptable to the FDA, or if the EMA or a comparable regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates and that obtained approvals could be revoked, which would adversely affect our business and reputation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Establishing additional or replacement CMOs could take a substantial amount of time and it may be difficult to establish replacement CMOs who meet regulatory requirements. There are a limited number of manufacturers that operate under cGMP and, for cellular products, also under cGTP regulations and that are both capable of manufacturing for us and willing to do so. In addition, there are limited CMOs specialized in the manufacturing of cellular therapy products. If we have to switch to a replacement CMO, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. If we are able to find a replacement CMO, the replacement CMO would need to be qualified and may require additional regulatory authority approval, which could result in further delay regulatory approval and commercialization of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, third-party providers may breach, terminate or decline to renew agreements they have with us because of factors beyond our control, such as their own financial difficulties or business priorities, international trade restrictions and financial costs, potentially at a time that is costly or otherwise inconvenient for us or our partners. In such cases, we would face the challenge of transferring complicated manufacturing techniques to other CMOs. We may incur significant costs and be required to devote significant time to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. A transfer of the manufacturing process for our product candidates would be time-consuming, and we or our partners may not be able to achieve such transfer. If we are unable to find an adequate replacement or another acceptable solution in time, clinical trials of our product candidates could be delayed or our commercial activities could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure of third-party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop companion diagnostics for our product candidates where appropriate. Such developments are expensive and time-consuming. The FDA, the EMA and comparable regulatory authorities may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing, seeking regulatory approval for or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third-party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may not perform their obligations as expected; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may encounter production difficulties that could constrain the supply of the companion diagnostic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may encounter difficulties in obtaining regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may not commit sufficient resources to the marketing and distribution of such product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may terminate their relationship with us. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We collaborate with third parties in the research, development and commercialization of certain of our product candidates and may enter into other collaborations in the future for our other product candidates. If our collaborators do not perform as expected or if we are unable to maintain existing or establish additional collaborations, our ability to develop and commercialize our product candidates may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may enter into collaboration agreements with third parties that have experience in product development, manufacturing and/or commercialization for other product candidates and/or research </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs. We may face significant competition in seeking appropriate partners for our product candidates, and the negotiation process may be time-consuming and complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. If we fail to establish and maintain collaborations related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we have not budgeted. This could negatively affect the development and commercialization of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have collaboration agreements and license agreements with, for example MD Anderson, Genmab and Bristol-Myers Squibb (&#8220;BMS&#8221;). These agreements provide us with important funding for our development programs and technology platforms. If our therapeutic programs and related collaborations do not result in the successful development and commercialization of products or if one of our collaborators or licensors terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments associated with such collaboration or license arrangement. For example, our collaboration agreement with GlaxoSmithKline was terminated in 2022. As a result, we will not receive any future milestone or royalty payments under these collaborations. In addition, any termination of an agreement by the relevant collaborators could affect our ability to develop further such product candidates or adversely affect how we are perceived in scientific and financial communities. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report also apply to the activities of our program collaborators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our collaboration arrangements, we depend on the performance of our collaborators. Our collaborators may fail to perform their obligations under the collaboration agreements or may not perform their obligations in a timely manner. If conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Furthermore, our collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. In addition, we cannot control the amount and timing of resources our collaborators may devote to our product candidates. They may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates. Even if our collaborators continue their contributions to the strategic collaborations, they may nevertheless determine not to actively pursue the development or commercialization of any resulting products. Additionally, if our collaborators pursue different clinical or regulatory strategies with their product candidates based on similar technology as used in our product candidates, adverse events with their product candidates could negatively affect our product candidates. Any of these developments could harm our product development efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our collaborators terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our collaborators do not prioritize and commit sufficient resources to our product candidates, we or our partners may be unable to develop or commercialize these product candidates, which would limit our ability to generate revenue and become profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts with respect to our product candidates and any future product candidates that we may develop. Additionally, although we intend to develop product candidates through our own internal research, we may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Any of these relationships may require us to incur <span style="white-space:nowrap">non-recurring</span> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic collaborations and licenses and the negotiation process is time-consuming and complex. We may also be unable to identify product candidates that we believe are an appropriate strategic fit for our company and intellectual property relating to, or necessary for, such product candidates. The <span style="white-space:nowrap">in-licensing</span> and acquisition of third-party intellectual property is a competitive area, and a number of more established companies are also pursuing strategies to <span style="white-space:nowrap">in-license</span> or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may not be successful in our efforts to establish strategic collaborations or other alternative arrangements for our product candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent or may depend in the future on patents, <span style="white-space:nowrap">know-how</span> and proprietary technology licensed from others. We may also enter into additional license agreements that are material to the development of our product candidates. Our current license agreements impose, and future agreements may impose, various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. Disputes may arise between us and our licensors and licensees regarding intellectual property subject to a license agreement, including those related to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense patent and other rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by us, our licensors, and our collaborators. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed, or will license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as it is for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize our product candidates successfully may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. If we do not adequately protect or enforce our intellectual property, competitors and other third parties may be able to erode or negate any competitive advantage we may have, which could harm our business. To protect our proprietary position, we file patent applications in the United States and abroad related to our product candidates that are important to our business. The patent application and approval process is expensive, complex and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issue from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in post-grant review procedures, oppositions, derivations, reexaminations, <span style="font-style:italic">inter partes</span> review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <span style="white-space:nowrap">non-infringing</span> manner. Alternatively, our competitors may seek to market generic versions of any approved products and may claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a <span style="white-space:nowrap">non-infringing</span> manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If third parties claim that our activities or products infringe upon their intellectual property, our operations could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the pharmaceutical industry. We may, from time to time, be notified of claims that we or our third-party suppliers are infringing upon patents, trademarks, copyrights, or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the future, pursue such infringement claims against us or any third-party proprietary technologies we have licensed. If we or our third-party suppliers were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including treble damages if the infringement is found to be willful, suspend the manufacture of certain product candidates or reengineer or rebrand our product candidates, if feasible, or we may be unable to enter certain new product markets. We could also be required to obtain a license to such patents in order to continue the development and commercialization of the infringing product or technology, however such a license may not be available on commercially reasonable terms or at all. Even if such license were available, it may require substantial payments or cross-licenses under our intellectual property rights, and it may only be available on a nonexclusive basis, in which case third parties, including our competitors, could use the same licensed intellectual property to compete with us. Any such claims could also be expensive and time-consuming to defend and divert management&#8217;s attention and resources. Our competitive position could suffer as a result. In addition, if we have declined to enter into a valid <span style="white-space:nowrap">non-disclosure</span> or assignment agreement for any reason, we may not own an invention or intellectual property rights and may not be adequately protected. Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a full <span style="white-space:nowrap"><span style="white-space:nowrap">freedom-to-operate</span></span> search or analysis for such product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. In addition, because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates and we may not be aware of such patents. Thus, we cannot guarantee that we can successfully commercialize product candidates in a way that will not infringe any third party&#8217;s intellectual property. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Where we license certain technology from a third party, the prosecution, maintenance and defense of the patent rights licensed from such third party may be controlled by the third party which may impact the scope of patent protection which will be obtained or enforced. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we license patent rights or technology from a third party, control of such third-party patent rights may vest in the licensor, particularly where the license is <span style="white-space:nowrap">non-exclusive</span> or field restricted. This may mean that we are not able to control or affect the scope of the claims of any relevant third-party patent or have control over any enforcement of such a patent. Therefore, we cannot be certain that such patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. Where a licensor brings an enforcement action, this could negatively impact our business or result in additional restrictions being imposed on the license we have and the scope of such license or result in invalidation or limitation of the scope of the licensed patent. In addition, should we wish to enforce the relevant patent rights against a third person, we may be reliant on consent from the relevant licensor or the cooperation of the licensor. The licensor may refuse to bring such action and leave us unable to restrict competitor entry into the market. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or lawsuits accusing our products of patent infringement, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors or third parties may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Further, such third parties could counterclaim that we infringe, misappropriate or otherwise violate their intellectual property or that a patent or other intellectual property right asserted against them is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. The outcome of any such proceeding is generally unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patents applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may be enjoined from manufacturing, using, and marketing our products, or may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Any required license may not be available on commercially reasonable terms or at all. Even if such license were available, it may require substantial payments or cross-licenses under our intellectual property rights, and it may only be available on a nonexclusive basis, in which case third parties, including our competitors, could use the same licensed intellectual property to compete with us. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. Some of our competitors may be better able to sustain the costs of complex patent litigation because they have substantially greater resources. If there is litigation against us, we may not be able to continue to operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should third parties file patent applications or be issued patents claiming technology we also use or claim, we may be required to participate in interference proceedings in the USPTO to determine priority of invention. We may be required to participate in interference proceedings involving our issued patents and pending </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications. We may be required to cease using the technology or to license rights from prevailing third parties as a result of an unfavorable outcome in an interference proceeding. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or one of our licensing collaborators initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <span style="white-space:nowrap">re-examination,</span><span style="font-style:italic"> inter partes</span> and post grant review, and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agreements with employees and our personnel policies generally provide that any inventions conceived by such individuals in the course of rendering services to us shall be our exclusive property or that we may obtain full rights to such inventions, at our election. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property. Ownership disputes may arise, for example, from conflicting obligations of consultants or others who are involved in developing our development candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also face the risk that present or former employees could continue to hold rights to intellectual property we use, may demand the registration of intellectual property rights in their name and demand damages or compensation pursuant to the German Employee Invention Act. In addition, under the German Employee Invention Act, certain employees retain rights to patents they invented or <span style="white-space:nowrap">co-invented</span> and disclosed to us prior to October&#160;1, 2009 if the employee inventions were not actively claimed by us after notification by the employee inventors. While we believe that all of our current and past German employee inventors have assigned to us their interest in inventions and patents they invented or <span style="white-space:nowrap">co-invented,</span> there can be no assurance that all such assignments are fully effective. Even if we lawfully own all inventions of our employee inventors who are subject to the German Act on Employees&#8217; Inventions, we are required under German law to reasonably compensate such employees for the use of the inventions. If we are required to pay increased compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse impact on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary <span style="white-space:nowrap">know-how</span> that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary <span style="white-space:nowrap">know-how,</span> information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary <span style="white-space:nowrap">know-how,</span> information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we or our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, that our employees have wrongfully used or disclosed alleged trade secrets of their former employers, or claiming ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. In addition, our employees involved in our strategic collaborations have access to certain joint confidential information or such information from the collaborator. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, from time to time we may be subject to claims that we, or our employees, consultants, or independent contractors, have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties, or that patents and applications we have filed to protect inventions of these individuals, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on an exclusive basis or on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Such liability can also occur if we publish or disclose confidential information from our collaboration without permission of the respective collaborator. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. or foreign countries&#8217; patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, or similar authorities in foreign </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents, nor can we predict changes in international patent law. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as protective or effective as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business may be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from utilizing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative technologies or therapies, or design around our patents. Our patents may be challenged, invalidated, circumvented or narrowed, or fail to provide us with any competitive advantages. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries. Filing, prosecuting, enforcing, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and certain state laws in the United States. Consequently, we may not be able to prevent third parties from utilizing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors or other third parties may use our technologies, or technology that we license, in jurisdictions where we have not obtained patent protection to develop our own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our lead product candidate or any other current or future product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Thus, it may be difficult for us to stop the infringement of our patents or the marketing of competing products in violation of our proprietary rights, generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could place our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect our competitive position on our product candidates or any future product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from our earliest U.S. <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Act&#8221;). The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. In the European Union, a maximum of five and a half years of supplementary protection can be achieved for an active ingredient or combinations of active ingredients of a medicinal product protected by a basic patent, if a valid marketing authorization exists (which must be the first authorization to place the product on the market as a medicinal product) and if the product has not already been the subject of supplementary protection. However, we may not receive an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if patents covering our product candidates or any future product candidates are obtained and even if we are successful in obtaining patent term extension, once the patent life has expired, we may be open to competition from competitive products. The launch of a similar or biosimilar version of one of our products would likely result in an immediate and substantial reduction in the demand for our product, which could have a material adverse effect on our business. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting our current product candidates or any future product candidates might expire before or shortly after we or our collaborators commercialize those candidates. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business depends on a strong and trusted brand, and any failure to maintain, protect, and enhance our trademarks, trade names and brand would have an adverse impact on our business, financial condition, results or operations and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely on trademarks and trade names to protect our business. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names or marks which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business, financial condition, results of operations, and prospects may be adversely affected. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. For example, we have filed an opposition against Immunocore Limited&#8217;s U.S. trademark application for IMMTAX and a petition to cancel Immunocore Limited&#8217;s EU trademark registration for IMMTAX and Immunocore Limited has brought counterclaims against our registered trademark IMMATICS </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and IMTX. In addition, TaurX Pharmaceutical Ltd. has also filed a trademark opposition against our EU trademark IMTX. If we are unsuccessful in this opposition or cancellation proceeding or if Immunocore Limited and/or TaurX Pharmaceutical Ltd. is successful in its counterclaims, we may be required to change our branding which could cause us to incur substantial costs and impede our ability to build and sustain name recognition for such platform. For more information on the opposition proceeding see &#8220;Business &#8212; Legal Proceedings.&#8221; Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of operations and prospects may be significantly harmed. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could significantly harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be able to detect infringement of our issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to develop products that are similar to our products or product candidates, or any future product candidates we may develop, but that are not covered by the claims of the patents that we may <span style="white-space:nowrap">in-license</span> in the future or own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our current or future collaborators or license partners, might not have been the first to make the inventions covered by the issued patents or patent application that we may <span style="white-space:nowrap">in-license</span> in the future or own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our current or future collaborators or license partners, might be found not have been the first to file patent applications covering certain of our or their inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that the pending patent applications we may <span style="white-space:nowrap">in-license</span> in the future or own will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents, for which we are not aware; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we hold rights to may be held invalid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents may not have sufficient term or geographic scope to provide meaningful protection; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may have an adverse effect on our business; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose not to file a patent in order to maintain certain trade secrets, and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business and Industry </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business could be adversely affected by health epidemics in regions where we have clinical trial sites or other business operations; epidemics could also cause significant disruptions in the operations of third-party manufacturers and CROs upon whom we rely. The <span style="white-space:nowrap">COVID-19</span> pandemic has caused us to modify our business practices including restricting employee travel, developing social distancing plans for our employees and cancelling physical participation in meetings, events and conferences. In addition to these observed impacts of the <span style="white-space:nowrap">COVID-19</span> pandemic, pandemics, epidemics or outbreaks of infectious diseases generally, including new variants of <span style="white-space:nowrap">COVID-19,</span> could also disrupt our research and development outcomes and schedules, clinical trials, supply and manufacturing of our products and regulatory submissions and interactions and could subject us to additional expenses and obligations. To the extent any pandemic, epidemic or outbreak of an infectious disease adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer and other executive officers in our senior management. Despite our efforts to retain valuable employees, members of our management, scientific and development teams could always terminate their employment with us on short notice. Even though we have employment agreements in place with all our employees including key personnel, these employment agreements provide for <span style="white-space:nowrap">at-will</span> employment, which means that any of our employees could leave us at any time, subject to notice periods and <span style="white-space:nowrap">non-competition</span> clauses. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our failure to put in place adequate succession plans for senior and key management roles or the failure of key employees to successfully transition into new roles could have an adverse effect on our business and operating results. The unexpected or abrupt departure of one or more of our key personnel and the failure to effectively transfer knowledge and effect smooth key personnel transitions may have an adverse effect on our business resulting from the loss of such person&#8217;s skills, knowledge of our business, and years of industry experience. If we cannot effectively manage leadership transitions and management changes in the future, our reputation and future business prospects could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for skilled personnel is intense, particularly in the biotechnology industry. We conduct substantially all of our operations at our facilities in T&#252;bingen, Germany, Houston, Texas and Munich, Germany. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. This competition may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. We may not be able to attract and retain these personnel on acceptable terms. This possibility is further compounded by the novel nature of our product candidates, as fewer people are trained in or are experienced with product candidates of this type. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed or may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may encounter difficulties in managing our growth and expanding our operations successfully. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we seek to advance our product candidates through clinical trials and commercialization, we are expanding our development, regulatory, manufacturing, marketing and sales capabilities and may need to further </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expand or contract with third parties to provide these capabilities. In addition, as our operations expand, we expect that we will need to manage additional relationships with various collaborators, suppliers and other third parties. Our growth will impose significant added responsibilities on members of management. Our management may have to divert a disproportionate amount of its attention away from our <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities and devote a substantial amount of time to these growth activities, including identifying, recruiting, integrating, maintaining and motivating additional employees, managing our research and development efforts effectively, including the clinical trials and the FDA&#8217;s, the EMA&#8217;s or comparable regulatory authority&#8217;s review process for our product candidates, while complying with our contractual obligations to contractors and other third parties and improving our operational, financial and management controls, reporting systems and procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage our growth effectively. To that end, we must be able to effectively manage our research and development efforts and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or could disrupt our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed or that we can find qualified replacements. Furthermore, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As a result of being a public company, we have incurred costs and expect to continue to incur additional costs, and we may not manage to comply with our internal control procedures and corporate governance structures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply with the requirements imposed on us as a public company, we have incurred, and expect to continue to incur, significant legal, insurance, accounting and other expenses that we did not incur as a private company. The increased costs may require us to reduce costs in other areas of our business. In addition, our board of directors (the &#8220;Board&#8221;), management and administrative staff are required to perform additional tasks. For example, we bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. We have invested, and intend to continue to invest, resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#8217;s time and attention from research and development activities. These laws, regulations and standards are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters, enforcement proceedings and higher costs necessitated by ongoing revisions to disclosure and governance practices, which could have a material adverse impact on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face substantial competition, which may result in others discovering, developing or commercializing products, treatment methods and/or technologies before or more successfully than we do. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Competition.&#8221; Our competitors include large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and capabilities in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic collaborations with large and established companies. Furthermore, mergers and acquisitions in the biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects or are more convenient than any products that we may develop, which would render our products obsolete or <span style="white-space:nowrap">non-competitive.</span> Our competitors also may obtain FDA, the EMA or regulatory approval in other jurisdictions for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. We anticipate that we will face increased competition in the future as additional companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business will be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical trials, receipt of regulatory approval or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our available capital resources or capital constraints we experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our receipt of approvals by the FDA, the EMA and comparable regulatory authorities, and the timing thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other actions, decisions or rules issued by regulators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efforts of our collaborators with respect to the commercialization of our products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the securing of, costs related to, and timing issues associated with, commercial product manufacturing as well as sales and marketing activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business, results of operations, financial condition and prospects may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We receive, generate and store significant and increasing volumes of sensitive information, such as employee and patient data. In addition, we actively seek access to medical information, including patient data, through research and development collaborations or otherwise. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of personal data. We and any potential collaborators may be subject to federal, state, local and foreign laws and regulations that apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (for example, Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;). Depending on the facts and circumstances, we could be subject to civil, criminal and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several foreign jurisdictions, including the European Union, its member states and Australia, among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions and place greater control with the data subject. In the United States, the California Consumer Privacy Act (&#8220;CCPA&#8221;) increased the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in the state of California. The CCPA gives California residents expanded rights to access and request deletion of their personal information, opt out of certain sales of personal information and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California residents regarding such use. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, California voters approved a new privacy law, the California Privacy Rights Act (&#8220;CPRA&#8221;), which went into effect on January&#160;1, 2023, and significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. As we expand our operations and research and development efforts, the CCPA and CPRA may impose new and burdensome privacy compliance obligations on our business, may increase our compliance costs and potential liability. Other states are considering similar laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws and regulations are complex and change frequently, at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations, which adds to the complexity of processing personal data from these jurisdictions. These laws have the potential to increase costs of compliance, risks of <span style="white-space:nowrap">non-compliance</span> and penalties for <span style="white-space:nowrap">non-compliance.</span> Regulation 2016/679, known as the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
General Data Protection Regulation (&#8220;GDPR&#8221;), as well as European Union member state implementing legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the European Union, or in certain circumstances, by companies located outside of the European Union and processing personal information of individuals located in the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to (i)&#160;obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii)&#160;the information provided to the individuals about how their personal information is used, (iii)&#160;ensuring the security and confidentiality of the personal data, (iv)&#160;the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v)&#160;extensive internal privacy governance obligations, and (vi)&#160;obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (the &#8220;EEA&#8221;), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to legal challenges and uncertainty about compliance with European Union data protection laws remains. For example, in July 2020, the Court of Justice of the European Union invalidated the <span style="white-space:nowrap">so-called</span> Privacy Shield, which provided a framework for data transferred from the European Union to the United States. To the extent that we were to rely on the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield Framework, we will not be able to do so in the future, which could increase our costs and limit our ability to process personal data from the EU. The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries. At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20&#160;million or 4% of annual global revenue. Such penalties are in addition to any civil litigation claims by data controllers, customers and data subjects. The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with new European Union data protection rules. The GDPR also contains a private right of action allowing data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty with regard to data protection regulation in the United Kingdom. As of January&#160;1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and EU, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June&#160;28, 2021, the European Commission announced a decision of &#8220;adequacy&#8221; concluding that the United Kingdom ensures an equivalent level of data protection to the GDPR, which provides some relief regarding the legality of continued personal data flows from the EEA to the United Kingdom. This adequacy determination will automatically expire in June 2025 unless the European Commission renews or extends it and may be modified or revoked in the interim. Should the European Commission modify or revoke its adequacy determination, the United Kingdom may become an &#8220;inadequate third country&#8221; under the GDPR and transfers of data from the EEA to the United Kingdom would require a &#8220;transfer mechanism,&#8221; such as the standard contractual clauses. In the future there may be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions, which could include civil, criminal and administrative penalties, private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our current and future operations are subject to applicable fraud and abuse, transparency, government price reporting, privacy and security, and other healthcare laws. If we are unable to comply, or do not fully comply, with such laws, we could face substantial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal civil and criminal false claims laws, such as the False Claims Act (&#8220;FCA&#8221;), which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged <span style="white-space:nowrap">off-label</span> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Health Care Reform Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <span style="white-space:nowrap">non-governmental</span> third-party payors, including private insurers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus requiring additional compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Because of the complex and <span style="white-space:nowrap">far-reaching</span> nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering and use of our drug candidates, if approved, to be in violation of applicable laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, agents, contractors or collaborators may engage in misconduct or other improper activities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, agents, contractors or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by these parties could include intentional failures to comply with FDA, the EMA or other applicable regulations, provide accurate information to the FDA, the EMA and comparable regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, the EMA or comparable regulatory authorities. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results and reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the UK Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a <span style="white-space:nowrap">non-U.S.</span> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of <span style="white-space:nowrap">non-U.S.</span> governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. We have provisions in our Code of Business Conduct and Ethics, an anti-corruption policy and certain controls and procedures in place that are designed to mitigate the risk of <span style="white-space:nowrap">non-compliance</span> with anti-corruption and anti-bribery laws. However, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions stemming from a failure to comply with these laws or regulations. Violations of these laws and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations could result in, among other things, significant administrative, civil and criminal fines and sanctions against us, our officers, or our employees, the closing down of our facilities, exclusion from participation in federal healthcare programs including Medicare and Medicaid, implementation of compliance programs, integrity oversight and reporting obligations, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of biohazardous materials and wastes and genetically modified organisms. Hazardous chemicals, including potentially infectious biological substances and genetically modified organisms, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#8217; compensation insurance as prescribed by Texas and German laws to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials or wastes, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those of our partners, third-party CROs or other contractors or consultants, may fail or suffer security incidents, which could result in a material disruption of our product development programs and significant monetary losses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our current or future partners, third-party CROs and other contractors and consultants have been subject to attacks by, and may be vulnerable to damage from, various methods, including cybersecurity attacks, breaches, intentional or accidental mistakes or errors, or other technological failures which can include, among other things, computer viruses, malicious codes, employee theft or misuse, unauthorized copying of our website or its content, unauthorized access attempts including third parties gaining access to systems using stolen or inferred credentials, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of keystroke loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. Further, as the <span style="white-space:nowrap">COVID-19</span> pandemic led to an increased number of people working from home, these cybersecurity risks may be heightened by an increased </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attack surface across our business. We cannot guarantee that our efforts, or the efforts of those upon whom we rely on and partner with, will be successful in preventing any such information security incidents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a failure, accident or security breach were to occur and cause interruptions in our, our partners&#8217; or our CROs&#8217; operations, it could result in a misappropriation of confidential information, including personally identifiable information and our intellectual property or financial information, a material disruption of our programs and/or significant monetary losses. For example, the loss of XPRESIDENT raw data, the XPRESIDENT database or other data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the GDPR and relevant member state law in the European Union or the CCPA, HIPAA and other relevant state and federal privacy laws in the United States. Moreover, because we maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information, any such security breach may compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information. Our current cybersecurity liability insurance, and any such insurance that we may obtain in the future, may not cover the damages we would sustain based on any breach of our computer security protocols or other cybersecurity attack. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, our reputation could be harmed and we could incur significant liabilities and the further development of our product candidates could be disrupted. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product liability lawsuits could cause us to incur substantial liabilities and to limit development and commercialization of any products that we may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical testing of our product candidates in human clinical trials and will face an even greater risk if we commercialize any products that we successfully develop. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. We may also still face risks from previous research and development activities. For example, IMA950, a multi-peptide vaccine we previously developed, is still in clinical use under the responsibility of clinical investigators outside of our clinical trials (investigator-initiated trials). While any sponsor responsibility is with the investigator, we cannot fully be sure that we will not be held liable in the future for any potential product defects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates or products that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial sites and/or study participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant costs to defend the related litigations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources to pursue our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to study participants or patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product recalls, withdrawals or labeling, marketing or promotional restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates that we may develop; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a decline in the price of our securities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. While we have obtained clinical trial insurance for our Phase 1 clinical trials and will also seek to obtain such insurance for future trials, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Litigation and other legal proceedings may adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, even if the regulatory or legal action is unfounded or not material to our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risks that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. Required coverage limits for such insurances are difficult to predict and may not be sufficient. If potential losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. Additionally, operating as a public company will make it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult to attract and retain qualified individuals to serve on our Board or the Board committees. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we engage in acquisitions and/or commercial collaborations in the future, we will incur a variety of costs and we may never realize the anticipated benefits of such acquisitions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may acquire technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. Such efforts may never result in a transaction, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any future growth through acquisition or <span style="white-space:nowrap">in-licensing</span> will depend upon the availability of suitable products, product candidates, research programs or companies for acquisition or <span style="white-space:nowrap">in-licensing</span> on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or <span style="white-space:nowrap">in-license</span> rights to promising products, product candidates, research programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources and personnel than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to successfully identify and acquire or <span style="white-space:nowrap">in-license</span> new products, product candidates, research programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, research programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or <span style="white-space:nowrap">in-licensing.</span> Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us or that we inadequately assess. In any event, we may not be able to realize the anticipated benefits of any acquisition or <span style="white-space:nowrap">in-licensing</span> for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or fails to reach its forecasted commercial potential, or that the integration of a product, product candidate, research program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, acquisitions create other uncertainties and risks, particularly when the acquisition takes the form of a merger or other business consolidation. We may encounter unexpected difficulties, or incur unexpected costs, in connection with transition activities and integration efforts, which include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">high acquisition costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need to incur substantial debt or engage in dilutive issuances of equity securities to pay for acquisitions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential disruption of our historical business and our activities under our collaboration agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strain on, and need to expand, our existing operational, technical, financial and administrative infrastructure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our lack of experience in late-stage product development and commercialization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the difficulties in assimilating employees and corporate cultures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the difficulties in hiring qualified personnel and establishing necessary development and/or commercialization capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure to retain key management and other personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the challenges in controlling additional costs and expenses in connection with and as a result of the acquisition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need to write down assets or recognize impairment charges; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the diversion of our management&#8217;s attention to integration of operations and corporate and administrative infrastructures; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to integrate or otherwise manage an acquired business successfully and in a timely manner, resulting operating inefficiencies could increase our costs more than we planned, could negatively impact the market price of our ordinary shares and could otherwise distract us from execution of our strategy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently conduct clinical trials in the United States and in Germany and we plan to market our product candidates, if approved, internationally. As a result, our business is subject to risks associated with conducting business internationally. Our future results could be harmed by a variety of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">differing regulatory requirements in <span style="white-space:nowrap">non-U.S.</span> countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">differing standards for the conduct of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States or elsewhere and shipping the product candidate to patients in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">import and export requirements and restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">economic weakness, including inflation, or political instability in foreign economies and markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign taxes, including withholding of payroll taxes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties staffing and managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">workforce uncertainty in countries where labor unrest is more common than in the United States or Germany; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">differing payor reimbursement regimes, governmental payors or patient <span style="white-space:nowrap">self-pay</span> systems, and price controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential liability under the FCPA or comparable foreign regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States or Germany; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from <span style="white-space:nowrap">geo-political</span> actions and conflict, war and terrorism, including the recent conflict between Russia and Ukraine and resulting sanctions, retaliatory measures, changes in the availability and price of various materials and effects on global financial markets, volatility and stress within the banking sector and the measures governments and financial services companies have taken in response; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from natural disasters including earthquakes, typhoons, floods and fires. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the formal change in the relationship between the United Kingdom and the European Union, referred to as &#8220;Brexit,&#8221; may continue to pose certain implications to our research, commercial and general business operations, including the approval and supply of our product candidates. The Trade and Cooperation Agreement between the United Kingdom and the European Union is comprehensive but does not cover all areas of regulation pertinent to the pharmaceutical industry, so certain complexities remain. It may be time-consuming and expensive for us to alter our internal operations in order to comply with new regulations as a result of Brexit. Altered regulations could also add time and expense to the process by which our product candidates receive regulatory approval in the United Kingdom and the European Union. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in our implementation could cause us to fail to meet our reporting obligations. In addition, any testing conducted by us, or any testing conducted by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which is likely to negatively affect our business and the market price of our ordinary shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to disclose changes made in our internal controls and procedures and assess the effectiveness of these controls annually. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;). An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of Our Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our securities has been and may continue to be volatile and may fluctuate due to factors beyond our control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of shares of our securities has been and may continue to be subject to wide fluctuations in response to many risk factors listed in this &#8220;D. Risk Factors&#8221; section, and others beyond our control, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results and timing of preclinical studies and clinical trials of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical trials of our competitors&#8217; products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">public concern relating to the commercial value or safety of any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to adequately protect our proprietary rights, including patents, trademarks and trade secrets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to raise additional capital and the terms on which we raise it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commencement or termination of any strategic collaboration or licensing arrangement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments, including actions with respect to our products or our competitors&#8217; products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated fluctuations in our financial condition and operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports by securities analysts about us or our competitors or our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions and departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the passage of legislation or other regulatory developments affecting us or our industry, including changes in the structure of healthcare payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in the valuation of companies perceived by investors to be comparable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our securities by us, our insiders or our other shareholders; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">speculation in the press or investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcement or expectation of additional financing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in market conditions for biopharmaceutical stocks; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in general market and economic conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our product candidates. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This risk is especially relevant for biotechnology companies, which have experienced significant stock price volatility in recent years. Securities litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our warrants may never be in the money and may expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for our warrants is $11.50 per ordinary share and our warrants are out of the money as of December&#160;31, 2022. Our warrants may never be in the money prior to their expiration, and as such, the warrants may expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant holders will have no rights as ordinary shareholders until they acquire our ordinary shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until warrant holders acquire our ordinary shares upon exercise of such warrants, they will have no rights with respect to our ordinary shares issuable upon exercise of such warrants, including the right to vote or respond to tender offers. Upon exercise of the warrants, holders will be entitled to exercise the rights of an ordinary shareholder only as to matters for which the record date occurs after the exercise date. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not continue to publish research, or publish inaccurate or unfavorable research, about our business, the price of our securities and our trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our securities depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our securities or publish inaccurate or unfavorable research about our business, the price of our securities would likely decline. In addition, if our operating results fail to meet the forecast of analysts, the price of our securities would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our securities could decrease, which might cause the price and trading volume of our securities to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The issuance of ordinary shares in connection with the exercise of warrants will dilute the ownership interest of the holders of our ordinary shares and may materially affect the trading price of our ordinary shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&#160;31, 2023, we had outstanding 7,187,500 warrants to purchase an equivalent number of our ordinary shares at an exercise price of $11.50 per ordinary share. To the extent that warrant holders elect to exercise their warrants, substantial amounts of our ordinary shares may be issued in the future. We cannot quantify the number of ordinary shares that will be issued in connection with the exercise, if any. However, the issuance of ordinary shares pursuant to such exercise could result in substantial dilution of the ownership interests of holders of our ordinary shares and could materially affect the trading price of our ordinary shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never paid dividends and do not expect to pay any dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend to reinvest any earnings in our business and do not anticipate declaring or paying any cash dividends until we have an established revenue stream to support continuing dividends. Further, since we are a holding company, our ability to pay dividends will be dependent upon the financial condition, liquidity and results of operations of, and our receipt of dividends, loans or other funds from, our subsidiaries. Our subsidiaries are separate and distinct legal entities and have no obligation to make funds available to us. In addition, there are various statutory, regulatory and contractual limitations and business considerations on the extent, if any, to which our subsidiaries may pay dividends, make loans or otherwise provide funds to us. Accordingly, investors in our securities cannot rely on dividend income, and any returns on an investment in our securities will likely depend entirely upon any future appreciation in the price of such securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain shareholders have representation on the Board, and have a substantial degree of influence over us, which could delay or prevent a change of corporate control or result in the entrenchment of our management and/or directors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of our principal shareholders, ARYA Sciences Holdings (&#8220;ARYA Sponsor&#8221;) and dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG, are represented on the Board. As a result, such shareholders may be able to significantly influence the outcome of matters submitted for director action, subject to obligation of the Board to act in the interest of all of our stakeholders, and for shareholder action, including the appointment of the Board and approval of significant corporate transactions, including business combinations, consolidations and mergers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the interests of our principal shareholders may differ from the interests of our other shareholders, the latter may be disadvantaged by any action that our principal shareholders may seek to pursue. The influence of such shareholders over us and our management could also have the effect of delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of our company, which could cause the market price of our securities to decline or prevent our shareholders from realizing a premium over the market price for our securities. Additionally, ARYA Sponsor is controlled by Perceptive Advisors LLC and its affiliates (&#8220;Perceptive&#8221;), which is in the business of making investments in companies and which may from time to time acquire and hold interests in businesses that compete directly or indirectly with us or that supply us with goods and services. Perceptive may also pursue acquisition opportunities that may be complementary to (or competitive with) our business, and as a result those acquisition opportunities may not be available to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are organized and existing under the laws of the Netherlands, and, as such, the rights of our shareholders and the civil liability of our directors and executive officers are governed in certain respects by the laws of the Netherlands. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized and existing under the laws of the Netherlands, and, as such, Dutch private international law governs the rights of our shareholders and the civil liability of our directors and executive officers are governed in certain respects by the laws of the Netherlands. The ability of our shareholders in certain countries other than the Netherlands to bring an action against us, our directors and executive officers may be limited under applicable law. In addition, substantially all of our assets are located outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, it may not be possible for shareholders to effect service of process within the United States upon us or our directors and executive officers or to enforce judgments against us or them in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States. In addition, it is not clear whether a Dutch court would impose civil liability on us or any of our directors and executive officers in an original action based solely upon the federal securities laws of the United States brought in a court of competent jurisdiction in the Netherlands. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Annual Report, there is no treaty in effect between the United States and the Netherlands providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. It is noted that, on the date of this Annual Report, the Hague Convention on Choice of Court Agreements of June&#160;30, 2005, has entered into force for the Netherlands, but has not entered into force for the United States. The Hague Convention of July&#160;2, 2019, on the Recognition and Enforcement of Foreign Judgments in Civil or Commercial Matters has not entered into force for either the Netherlands or the United States. Accordingly, a judgment rendered by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized and enforced by the competent Dutch courts. However, if a person has obtained a judgment rendered by a court in the United States that is enforceable under the laws of the United States and files a claim with the competent Dutch court, the Dutch court will in principle give binding effect to such judgment if (i)&#160;the jurisdiction of the foreign court was based on a ground of jurisdiction that is generally acceptable according to international standards, (ii)&#160;the judgment by the U.S. court was rendered in legal proceedings that comply with the Dutch standards of proper administration of justice including sufficient safeguards (<span style="font-style:italic">behoorlijke rechtspleging</span>), (iii)&#160;binding effect of such U.S. judgment is not contrary to Dutch public order (<span style="font-style:italic">openbare orde</span>) and (iv)&#160;the judgment by the U.S. court is not incompatible with a decision rendered between the same parties by a Dutch court, or with a previous decision rendered between the same parties by a foreign court in a dispute that concerns the same subject and is based on the same cause, provided that the previous decision qualifies for recognition in the Netherlands. Even if such a foreign U.S. judgement is given binding effect, a claim based thereon may, however, still be rejected if the foreign U.S. judgment is not or no longer formally enforceable. Dutch courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Code of Civil Procedure (<span style="font-style:italic">Wetboek van Burgerlijke Rechtsvordering</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against the company or our directors, representatives or certain experts named herein who are residents of the Netherlands or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, and certain other contractual arrangements between us and our directors, we will indemnify and hold our directors harmless against all claims and suits brought against them, subject to limited exceptions. There is doubt, however, as to whether U.S. courts would enforce such indemnity provisions in an action brought against one of our directors in the United States under U.S. securities laws. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that our shareholders might consider to be favorable and prevent or frustrate any attempt to replace or remove the Board at the time of such acquisition bid. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this respect, certain provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in the composition of the Board. These provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a provision that our directors can only be appointed on the basis of a binding nomination prepared by the Board or by one or more shareholders who individually or jointly represent at least 10% of our issued share capital, which can be overruled by a <span style="white-space:nowrap">two-thirds</span> majority of votes cast representing more than half of our issued share capital; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a provision that our directors can only be dismissed by the general meeting by a <span style="white-space:nowrap">two-thirds</span> majority of votes cast representing more than half of our issued share capital, unless the dismissal was proposed by the Board, in which latter case a simple majority of votes cast would be sufficient; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a requirement that certain matters, including an amendment of our articles of association, may only be resolved upon by our general meeting if proposed by the Board; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a provision implementing a staggered board, pursuant to which only one class of directors, will be elected at each general meeting, with the other classes continuing for the remainder of their respective terms. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in accordance with the Dutch Corporate Governance Code, or DCGC, shareholders who have the right to put an item on the agenda for our general meeting or to request the convening of a general meeting shall not exercise such rights until after they have consulted the Board. If exercising such rights may result in a change in our strategy (for example, through the dismissal of one or more of our directors), the Board must be given the opportunity to invoke a reasonable period of up to 180 days to respond to the shareholders&#8217; intentions. If invoked, the Board must use such response period for further deliberation and constructive consultation, in any event with the shareholder(s) concerned and exploring alternatives. At the end of the response time, the Board shall report on this consultation and the exploration of alternatives to our general meeting. The response period may be invoked only once for any given general meeting and shall not apply (i)&#160;in respect of a matter for which a response period or a statutory <span style="white-space:nowrap">cooling-off</span> period (as discussed below) has been previously invoked or (ii)&#160;in situations where a shareholder holds at least 75% of our issued share capital as a consequence of a successful public bid. Moreover, the Board can invoke a <span style="white-space:nowrap">cooling-off</span> period of up to 250 days when shareholders, using their right to have items added to the agenda for a general meeting or their right to request a general meeting, propose an agenda item for our general meeting to dismiss, suspend or appoint one or more directors (or to amend any provision in our articles of association dealing with those matters) or when a public offer for our company is made or announced without our support, provided, in each case, that the Board believes that such proposal or offer materially conflicts with the interests of our company and its business. During a <span style="white-space:nowrap">cooling-off</span> period, our general meeting cannot dismiss, suspend or appoint directors (or amend the provisions in our articles of association dealing with those matters) except at the proposal of the Board. During a <span style="white-space:nowrap">cooling-off</span> period, the Board must gather all relevant information necessary for a careful decision-making process and at least consult with shareholders representing 3% or more of our issued share capital at the time the <span style="white-space:nowrap">cooling-off</span> period was invoked, as well as with our Dutch works council (if we or, under certain circumstances, any of our subsidiaries would have one). Formal statements expressed by these stakeholders during such consultations must be published on our website to the extent these stakeholders have approved that publication. Ultimately one week following the last day of the <span style="white-space:nowrap">cooling-off</span> period, the Board must publish a report in respect of its policy and conduct of affairs during the <span style="white-space:nowrap">cooling-off</span> period on our website. This report must remain available for inspection by shareholders and others with meeting rights under Dutch law at our office and must be tabled for discussion at the next general meeting. Shareholders representing at least 3% of our issued share capital may request the Enterprise Chamber of the Amsterdam Court of Appeal, or the Enterprise Chamber (<span style="font-style:italic">Ondernemingskamer</span>), for early termination of the <span style="white-space:nowrap">cooling-off</span> period. The Enterprise Chamber must rule in favor of the request if the shareholders can demonstrate that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Board, in light of the circumstances at hand when the <span style="white-space:nowrap">cooling-off</span> period was invoked, could not reasonably have concluded that the relevant proposal or hostile offer constituted a material conflict with the interests of our company and its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Board cannot reasonably believe that a continuation of the <span style="white-space:nowrap">cooling-off</span> period would contribute to careful policy-making; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other defensive measures, having the same purpose, nature and scope as the <span style="white-space:nowrap">cooling-off</span> period, have been activated during the <span style="white-space:nowrap">cooling-off</span> period and have not since been terminated or suspended within a reasonable period at the relevant shareholders&#8217; request (i.e., no &#8216;stacking&#8217; of defensive measures). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such provisions could discourage a takeover attempt and impair the ability of shareholders to benefit from a change in control and realize any potential change of control premium. This may adversely affect the market price of our securities. See &#8220;Item 10. Additional Information&#8212;B. Memorandum and Articles of Association&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our shareholders may not have any <span style="white-space:nowrap">pre-emptive</span> rights in respect of future issuances of our ordinary shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of an increase in our share capital by way of an issuance of ordinary shares, holders of ordinary shares are generally entitled under Dutch law to full <span style="white-space:nowrap">pre-emptive</span> rights, unless these rights are limited or excluded either by a resolution of the general meeting or by another corporate body designated by the general meeting, or where shares are issued to our employees or a group company (i.e., certain affiliates, subsidiaries or related companies) or paid up by means of a <span style="white-space:nowrap">non-cash</span> contribution, or in case of an exercise of a previously acquired right to subscribe for shares. The same <span style="white-space:nowrap">pre-emptive</span> rights apply when rights to subscribe for shares are granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our resolution of the general meeting dated June&#160;30, 2020, the Board is irrevocably authorized for a period of five years from the date of the ARYA Merger to limit or exclude <span style="white-space:nowrap">pre-emptive</span> rights on our ordinary shares up to 100% of the number of our ordinary shares in our authorized share capital (from time to time). Accordingly, holders of our ordinary shares may not have any <span style="white-space:nowrap">pre-emptive</span> rights in connection with, and may be diluted by, an issue of new ordinary shares and it may be more difficult for a shareholder to obtain control over the general meeting. See &#8220;Item 10. Additional Information&#8212;B. Memorandum and Articles of Association.&#8221; Further, certain of our ordinary shareholders outside the Netherlands, in particular, U.S. ordinary shareholders, may not be allowed to exercise <span style="white-space:nowrap">pre-emptive</span> rights to which they are entitled, if any, unless a registration statement under the Securities Act is declared effective with respect to ordinary shares issuable upon exercise of such rights or an exemption from the registration requirements is available. <span style="white-space:nowrap">Pre-emptive</span> rights do not exist with respect to the issue of financing preferred shares and holders of financing preferred shares have no <span style="white-space:nowrap">pre-emptive</span> right to acquire newly issued ordinary shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are not obligated to and do not comply with all the best practice provisions of the DCGC. This could adversely affect the rights of our shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Dutch public company, we are subject to the DCGC. The DCGC contains both principles and best practice provisions on corporate governance that regulate relations between the Board and the general meeting and matters in respect of financial reporting, auditors, disclosure compliance and enforcement standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DCGC is based on a &#8220;comply or explain&#8221; principle. Accordingly, companies must disclose in their statutory annual reports whether they comply with the provisions of the DCGC. If a company subject to the DCGC does not comply with those provisions (for example, because of a conflicting Nasdaq requirement), that company would be required to give the reasons for such <span style="white-space:nowrap">non-compliance.</span> The DCGC applies to Dutch companies listed on a government recognized stock exchange, whether in the Netherlands or elsewhere, including Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acknowledge the importance of good corporate governance. However, we do not comply with all the provisions of the DCGC, to a large extent because such provisions conflict with or are inconsistent with the corporate governance rules of the Nasdaq and U.S. securities laws applicable to us, or because we believe such provisions do not reflect customary practices of global companies listed on Nasdaq. This may affect the rights of our shareholders and our shareholders may not have the same level of protection as a shareholder in a Dutch company that fully complies with the DCGC. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are a foreign private issuer, and, as a result, we are not subject to certain rules and obligations that are applicable to a U.S. domestic public company and are not subject to certain Nasdaq corporate governance listing standards that are applicable to a Nasdaq-listed U.S. domestic public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We report under the Exchange Act as a <span style="white-space:nowrap">non-U.S.</span> company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii)&#160;the sections of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Act requiring insiders to file public reports of their stock ownership and trading activities, and liability for insiders who profit from trades made in a short period of time; and (iii)&#160;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <span style="white-space:nowrap">10-Q</span> containing unaudited financial and other specified information, or current reports on Form <span style="white-space:nowrap">8-K</span> upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form <span style="white-space:nowrap">20-F</span> until four months after the end of each financial year, while U.S. domestic issuers are required to file their annual report on Form <span style="white-space:nowrap">10-K</span> in less time. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because we are a foreign private issuer, we have elected to comply with our home country governance requirements and certain exemptions thereunder, rather than complying with certain of the Nasdaq corporate governance listing standards that are applicable to U.S. companies listed on the Nasdaq. Furthermore, Nasdaq listing standards generally require Nasdaq-listed U.S. companies to, among other things, seek shareholder approval for the implementation of certain equity compensation plans and issuances of securities, which we are not required to follow as a foreign private issuer. Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers. See &#8220;Item 16G. Corporate Governance.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer, and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the&#160;Exchange Act&#160;applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June&#160;30, 2023, which would require us to comply with all of the periodic disclosure and current reporting requirements of the&#160;Exchange Act&#160;applicable to U.S. domestic issuers, including the application of US&#160;GAAP, as of January&#160;1, 2024. In order to maintain our current status as a foreign private issuer, either (a)&#160;a majority of our ordinary shares must be either directly or indirectly owned of record by <span style="white-space:nowrap">non-residents</span> of the United States or (b)(i) a majority of our executive officers or directors may not be United States citizens or residents, (ii)&#160;more than 50% of our assets cannot be located in the United States and (iii)&#160;our business must be administered principally outside the United States. If we lose this status, we would be required to comply with the&#160;Exchange Act&#160;reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time-consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would be more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies make our ordinary shares less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, (i)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, (ii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation. In addition, as an emerging growth company, we are required to provide only two years of audited </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial statements and two years of selected financial data in our initial registration statement, compared to three and five years, respectively, for comparable data reported by other public companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (i)&#160;the last day of the fiscal year during which the market value of our ordinary shares held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of any June&#160;30, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to an effective registration statement, (iii)&#160;the last day of the fiscal year during which we had total annual gross revenues of $1.24&#160;billion or more, (iv)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt during the previous three-year period. Even after we no longer qualify as an emerging growth company and if we are no longer an FPI, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the price of our securities may be more volatile. When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort towards ensuring compliance with them, and we cannot predict or estimate the amount or timing of such additional costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Taxation </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be or may become a PFIC, which could result in adverse U.S. federal income tax consequences to U.S. holders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any of our subsidiaries is a passive foreign investment company (a &#8220;PFIC&#8221;) for any taxable year, or portion thereof, that is included in the holding period of a beneficial owner of our ordinary shares that is a U.S. Holder, such U.S. Holder (as defined in &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;), may be subject to certain adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. It is uncertain whether we or any of our subsidiaries, including Immatics OpCo, will be treated as a PFIC for U.S. federal income tax purposes for 2022 or for the current or any subsequent tax year. If we determine that we and/or any of our subsidiaries is a PFIC for any taxable year, we intend to provide a U.S. Holder with such information necessary for the U.S. Holder to make and maintain a QEF Election (as defined in &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;) with respect to us and/or such subsidiaries, but there can be no assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders.&#8221; Prospective U.S. Holders of our ordinary shares or warrants are urged to consult their tax advisors regarding the possible application of the PFIC rules to them. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become taxable in a jurisdiction other than Germany, and this may cause us to be subject to increased and/or different taxes than we expect. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our incorporation, we have had, on a continuous basis, our place of effective management in Germany. Therefore, we believe that we are a tax resident of Germany under German national tax laws. As an entity incorporated under Dutch law, however, we also qualify as a tax resident of the Netherlands under Dutch national tax laws. However, based on our current management structure and the tax laws of the United States, Germany and the Netherlands, as well as applicable income tax treaties, and current interpretations thereof, we believe that we are tax resident solely in Germany for the purposes of the 2012 tax treaty between the Federal Republic of Germany and the Netherlands for the avoidance of double taxation with respect to taxes on income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sole tax residency in Germany for purposes of the above-mentioned tax treaty is subject to the application of the provisions on tax residency as stipulated in such treaty as amended from time to time. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting (the &#8220;MLI&#8221;), Germany and the Netherlands entered into, among other countries, should not, as of this date, affect such tax treaty&#8217;s rules regarding tax residency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable tax laws, tax treaties or interpretations thereof may change. Furthermore, whether we have our place of effective management in Germany and are as such solely tax resident in Germany is largely a question of fact and degree based on all the circumstances, rather than a question of law, which facts and degree may also change. Changes to applicable tax laws or interpretations thereof and changes to applicable facts and circumstances (e.g., a change of board members or the place where board meetings take place), or changes to applicable tax treaties, including a change to the application of the MLI, may result in us becoming (also) a tax resident of another jurisdiction (other than Germany), potentially also triggering an exit tax liability in Germany. As a consequence, our overall effective income tax rate and income tax expense could materially increase, which could have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we ever pay dividends, we may need to withhold tax on such dividends in both Germany and the Netherlands. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no plan to declare or pay any dividends on our ordinary shares in the foreseeable future. However, if we do pay dividends, we may need to withhold tax on such dividends both in Germany and the Netherlands. As an entity incorporated under Dutch law, any dividends distributed by us are subject to Dutch dividend withholding tax on the basis of Dutch domestic law. However, on the basis of the double tax treaty between Germany and the Netherlands, the Netherlands will be restricted in imposing these taxes if we continue to be a tax resident of Germany and our place of effective management is in Germany. However, Dutch dividend withholding tax is still required to be withheld from dividends if and when paid to Dutch resident holders of our ordinary shares (and <span style="white-space:nowrap">non-Dutch</span> resident holders of our ordinary shares that have a permanent establishment in the Netherlands to which their shareholding is attributable). As a result, upon a payment (or deemed payment) of dividends, we will be required to identify our shareholders in order to assess whether there are Dutch residents (or <span style="white-space:nowrap">non-Dutch</span> residents with a permanent establishment in the Netherlands to which the shares are attributable) in respect of which Dutch dividend tax has to be withheld. Such identification may not always be possible in practice. If the identity of our shareholders cannot be determined, withholding of both German and Dutch dividend tax from such dividend may occur upon a payment of dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the withholding tax restriction referred to above is based on the current choices and reservation of Germany under the MLI. If Germany changes its MLI choices and reservation, we may not be entitled to any benefits of the double tax treaty between Germany and the Netherlands, including the withholding tax restriction, as long as Germany and the Netherlands do not reach an agreement on our tax residency for purposes of the tax treaty between Germany and the Netherlands, except to the extent and in such manner as may be agreed upon by the authorities. As a result, any dividends distributed by us during the period no such agreement has been reached between Germany and the Netherlands, may be subject to dividend withholding tax both in Germany and the Netherlands. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a proposed law is currently pending before the Dutch parliament, namely the Emergency act conditional exit dividend tax (<span style="font-style:italic">Spoedwet conditionele eindafrekening dividendbelasting</span>) which would, if enacted, impose a dividend withholding (exit) tax on certain deemed distributions if we cease to be a Dutch tax resident and become a tax resident of a jurisdiction that is not a member of the EU or the EEA, when such jurisdiction does not satisfy certain conditions. In some cases, we would have a right to recover the amount of tax from our shareholders when such shareholder is not entitled to an exemption. If enacted in the form in which it is presently pending before the Dutch parliament, the proposed law will have retroactive effect to December&#160;8, 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left" id="tx400206_13"><span style="font-weight:bold">ITEM&#160;4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">INFORMATION ON THE COMPANY </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_14">A. History and Development of the Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a Dutch private limited liability company (<span style="font-style:italic">besloten vennootschap met beperkte aansprakelijkheid</span>) under the name Immatics B.V. on March&#160;10, 2020 solely for the purpose of effectuating the business combination (the &#8220;ARYA Merger&#8221;) between us, ARYA Sciences Acquisition Corp., a Cayman Islands exempted company (&#8220;ARYA&#8221;), Immatics Biotechnologies GmbH, a German limited liability company, Immatics Merger Sub 1, a Cayman Islands exempted company, and Immatics Merger Sub 2, a Cayman Islands exempted company. Upon the closing of the ARYA Merger on July&#160;1, 2020, we converted into a Dutch public limited liability company (<span style="font-style:italic">naamloze vennootschap</span>) and changed our name to Immatics N.V. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registered in the Commercial Register of the Chamber of Commerce (Kamer van Koophandel) in the Netherlands under number 77595726. We have our corporate seat in Amsterdam, the Netherlands and our registered office is at Paul-Ehrlich-Stra&#223;e 15, 72076 T&#252;bingen, Federal Republic of Germany, and our telephone number is +49 (7071) <span style="white-space:nowrap">5397-0.</span> Our executive office in the United States is located at Immatics US, Inc., 2130 W. Holcombe Boulevard, Houston, Texas, 77030 and our telephone number is +1 (346) <span style="white-space:nowrap">204-5400.</span> Our website is www.immatics.com. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto are not incorporated into this Annual Report. We file reports and other information with the SEC, including annual reports on Form <span style="white-space:nowrap">20-F</span> and reports on Form <span style="white-space:nowrap">6-K.</span> The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information we have filed electronically with the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_15">B. Business Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company dedicated to the development of T cell receptor (&#8220;TCR&#8221;)-based immunotherapies for the treatment of cancer. Our purpose is to deliver a meaningful impact on the lives of cancer patients by developing novel <span style="white-space:nowrap">TCR-based</span> immunotherapies that are designed to achieve effect beyond an incremental clinical benefit. Our focus is the development of product candidates for the treatment of patients with solid tumors, who are inadequately served by existing treatment modalities. We strive to become an industry leading, fully integrated global biopharmaceutical company engaged in developing, manufacturing and commercializing TCR immunotherapies for the benefit of cancer patients, our employees, our shareholders and our partners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By utilizing <span style="white-space:nowrap">TCR-based</span> therapeutics, we are able to direct T cells to intracellular cancer targets that are <span style="text-decoration:underline">not</span> accessible through classical antibody-based or <span style="white-space:nowrap">CAR-T</span> therapies. We believe that by identifying what we call <span style="font-style:italic">true</span> cancer targets and the <span style="font-style:italic">right</span> TCRs, we are well positioned to transform current solid tumor treatment paradigms by delivering cellular and bispecific product candidates that have the potential to substantially improve the lives of cancer patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our targeted immunotherapy product candidates through two distinct treatment modalities: <span style="white-space:nowrap">TCR-engineered</span> autologous (&#8220;ACTengine&#8221;) or allogeneic (&#8220;ACTallo&#8221;) Adoptive Cell Therapies (&#8220;ACT&#8221;) and antibody-like Bispecifics, also called T cell Engaging Receptors (&#8220;TCER&#8221;). Each modality is designed with distinct attributes and mechanisms of action to produce the desired therapeutic effect for a variety of cancer patient populations with different unmet medical needs. Our current pipeline shown below comprises several proprietary <span style="white-space:nowrap">TCR-based</span> product candidates in clinical and preclinical development. In addition to our proprietary pipeline, we are collaborating with industry-leading partners, including Bristol Myers Squibb (&#8220;BMS&#8221;), Editas Medicine and Genmab, to develop multiple additional therapeutic programs covering ACT and Bispecifics. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g11a01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1</sup> Phase 1a: Dose escalation, Phase 1b: Dose expansion; <sup style="font-size:75%; vertical-align:top">2</sup> Opdivo (nivolumab): programmed <span style="white-space:nowrap">death-1</span> <span style="white-space:nowrap">(PD-1)</span> immune checkpoint inhibitor; * Immatics proprietary ACTallo platform utilizing Editas&#8217; CRISPR gene editing technology </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, we are ideally positioned to comprehensively address the needs of solid tumor patients with our <span style="white-space:nowrap">TCR-based</span> therapeutic approaches: ACTengine <span style="white-space:nowrap">TCR-engineered</span> T cells <span style="white-space:nowrap">(&#8220;TCR-T&#8221;)</span> have already shown strong clinical activity in patients with high tumor burden. They are typically single infusion treatments administered at specialized medical centers and require a personalized autologous cell supply chain. TCERs are <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> available and supply chain efficient. We believe TCERs could enable the treatment of a broader patient group without the need for specialized medical centers, analogous to classical antibody-based biologics and could therefore present favorable commercial characteristics. Although TCERs will require multiple rounds of dosing, they are intended to be used in the outpatient setting. Further, both therapeutic approaches have different target requirements: While <span style="white-space:nowrap">TCR-T</span> approaches are well suited for targets with stringent tumor selectivity, they can also address targets with low number of copies per cell. TCER molecules require targets with higher copy numbers, but can also be used for targets with a broader expression profile. The positioning and distinct attributes of both approaches, ACTengine and TCER, are depicted below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g43a64.jpg" alt="LOGO" />
<sup style="font-size:75%; vertical-align:top"> </sup></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1</sup> Interim data update from the ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> Phase 1 trial with a 50% (6/12) confirmed ORR target dose or above with at least 1&#160;billion infused <span style="white-space:nowrap">TCR-T</span> cells across several solid tumor indications, 80% (4/5) confirmed ORR in Phase 1b patients; <sup style="font-size:75%; vertical-align:top">2</sup> Initial manufacturing may provide sufficient quantity for potential repeat dosing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our autologous ACTengine product candidates we are also building an allogeneic platform (ACTallo) based on allogeneic (i.e. third-party donor-derived) gamma delta T cells. ACTallo is advancing the cell therapy concept beyond individualized manufacturing and is being developed to generate an <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> cell therapy. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to deliver the power of T cells to cancer patients. We seek to execute the following strategy to develop <span style="white-space:nowrap">TCR-based</span> immunotherapies for the treatment of cancer, maximizing the value of our technology platforms and the broad portfolio of product candidates: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Realize the full multi-cancer opportunity of PRAME.</span> We believe PRAME (Preferentially Expressed Antigen in Melanoma) is one of the most promising and most prevalent, clinically validated solid tumor targets known to date. To leverage its full potential and maximize patient reach, we are: (1)&#160;focusing and accelerating the development of our ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> towards pivotal trials, (2)&#160;expanding the patient population that might benefit from a PRAME-targeting therapy by developing an <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> biologic TCER IMA402 with a different mechanism of action without the requirement for administration at specialized medical centers and (3)&#160;expanding beyond <span style="white-space:nowrap">HLA-A*02</span> by investigating new <span style="white-space:nowrap">target-TCR</span> pairs for PRAME epitopes binding to other HLA types. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We are currently investigating three ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> Phase 1b cohorts in parallel (IMA203 monotherapy, IMA203 in combination with a <span style="white-space:nowrap">PD-1</span> immune checkpoint inhibitor, and 2<sup style="font-size:75%; vertical-align:top">nd</sup>-generation IMA203CD8) and at present are prioritizing patient treatment with 1<sup style="font-size:75%; vertical-align:top">st</sup> and 2<sup style="font-size:75%; vertical-align:top">nd</sup>-generation IMA203 <span style="white-space:nowrap">TCR-T</span> monotherapy. In October 2022, we reported interim clinical data on IMA203 <span style="white-space:nowrap">TCR-T</span> monotherapy. The interim data reflected a confirmed objective response rate (&#8220;cORR&#8221;) of 50% (6/12) at target dose or above with at least 1&#160;billion infused <span style="white-space:nowrap">TCR-T</span> cells across Phase 1a and 1b, of which we reported an 80% cORR (4/5) in Phase 1b patients alone. All responses remained ongoing at data <span style="white-space:nowrap">cut-off</span> of September&#160;6, 2022. Confirmed responses were observed across different solid tumor types such as cutaneous melanoma, ovarian cancer, head and neck cancer, uveal melanoma, and synovial sarcoma. Data generated throughout 2023 with longer <span style="white-space:nowrap">follow-up</span> to assess durability of response is intended to identify the most promising cohort to advance towards pivotal trials and potential commercialization. The clinical data update on all three cohorts is planned for 2H 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">TCER IMA402 is our next-generation, half-life extended TCR Bispecific for which we plan to file a CTA in 2Q 2023 and start the clinical Phase 1/2 trial in 2H 2023 following approval. Our flexible trial design is aimed at advancing through dose escalation and towards clinical <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> (&#8220;PoC&#8221;) as fast as possible. As we previously reported in September, 2022, in preclinical studies, IMA402 demonstrated enhanced anti-tumor activity <span style="font-style:italic">in vivo</span> and reduced T cell engager-associated toxicities as part of an overall favorable <span style="font-style:italic">in vitro</span> safety profile. Pharmacokinetic characteristics of the half-life extended IMA402 molecule suggest the potential for a favorable dosing regimen in patients with prolonged drug exposure at therapeutic levels. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Both product candidates ACTengine IMA203 and TCER IMA402 are directed against a PRAME peptide presented by <span style="white-space:nowrap">HLA-A*02:01,</span> which is found in approximately <span style="white-space:nowrap">40-50%</span> of individuals in North America and Europe and in approximately <span style="white-space:nowrap">20-35%</span> of individuals in East Asia. To expand the number of patients who can potentially benefit from our PRAME-targeting therapies, we are also developing <span style="white-space:nowrap">TCR-therapeutics</span> against PRAME peptides presented by other <span style="white-space:nowrap">HLA-types</span> prevalent in a broad range of geographies, especially the Asia / Pacific region. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Advance our pipeline of innovative ACTengine <span style="white-space:nowrap">TCR-T</span> product candidates.</span> In addition to our most advanced <span style="white-space:nowrap">TCR-T</span> product candidate ACTengine IMA203, our pipeline is strengthened by innovative cell therapy programs in development. ACTengine IMA204 is directed against the novel tumor stroma target COL6A3 that is highly prevalent across many different solid tumor types and provides a promising and innovate therapeutic opportunity for a broad patient population as monotherapy or in combination with <span style="white-space:nowrap">TCR-T</span> cells directed against targets presented on tumor cells. IMA204 uses an affinity maturated <span style="white-space:nowrap">CD8-independent,</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
next-generation TCR that engages both CD4 and CD8 T cells without the need of CD8 <span style="white-space:nowrap">co-transduction.</span> Moreover, we continue to actively investigate multiple other next-generation enhancement and combination strategies to render ACTengine T cells even more potent to combat solid tumors and enhance tolerability and ease of use of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Advance our pipeline of next-generation, half-life extended TCR Bispecifics</span>. In addition to PRAME TCER IMA402 entering clinical development in 2023, we have a broad portfolio of clinical and preclinical TCR Bispecifics. Phase 1 clinical development commenced in May 2022 for our most advanced TCER program IMA401 targeting MAGEA4/8. IMA401 is being developed in collaboration with BMS and we seek to deliver clinical PoC for IMA401 and thus our TCER platform as fast as possible. We also continue development of several innovative preclinical TCER product candidates against so far undisclosed targets for our proprietary and/or partnered pipeline. IMA403 is in advanced preclinical stage with PoC studies ongoing. Additionally, TCER engineering and preclinical testing is ongoing for further TCER candidates, IMA40x, targeting peptides presented by <span style="white-space:nowrap">HLA-A*02:01</span> and other <span style="white-space:nowrap">HLA-types.</span> Our next-generation, half-life extended TCER format used in all our candidates is designed to safely apply high drug doses for activity in a broad range of tumors, even with low target density, and to achieve a patient-convenient dosing schedule. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Further enhance our cell therapy manufacturing capabilities. </span>Our proprietary ACTengine manufacturing process is generating <span style="white-space:nowrap">TCR-T</span> cells that have been shown to achieve a high rate of objective responses, infiltrate the patient&#8217;s tumor and function in the solid tumor microenvironment. With a manufacturing time of approximately one week and an accelerated product release time, we are aiming at shortening the <span style="white-space:nowrap"><span style="white-space:nowrap">vein-to-vein</span></span> time and to provide products to patients as fast as possible. We have implemented several manufacturing enhancements in our IMA203 Phase 1b trial (including monocyte depletion) that enhanced key features of the cell product and were focused on robustness, quality, and speed of product release. We continue to implement minor improvements to prepare for pivotal trials and potential commercialization. We are currently expanding our cell therapy manufacturing capabilities with construction of a <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> GMP manufacturing facility for registration-directed and commercial production of ACTengine <span style="white-space:nowrap">TCR-T</span> products, including IMA203. The manufacturing facility is expected to be operational in 2024.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop allogeneic <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> cell therapies. </span>We aim to increase the commercial opportunity of cell therapies by supplying products to patients more quickly and at lower cost with our <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> cell therapy approach, ACTallo. ACTallo is our proprietary allogeneic adoptive cell therapy platform based on gamma delta T cells sourced from healthy donors and designed to create hundreds of doses from one single donor leukapheresis. In June 2022, we entered into strategic collaborations with Bristol Myers Squibb and Editas Medicine with the goal to develop transformative next-generation allogeneic gamma delta <span style="white-space:nowrap"><span style="white-space:nowrap">TCR-T/CAR-T</span></span> programs with enhanced persistence, safety and potency by combining our proprietary ACTallo platform with Bristol Myers Squibb&#8217;s <span style="white-space:nowrap">next-gen</span> technologies and Editas Medicine&#8217;s CRISPR gene editing technology. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage the full potential of strategic collaborations</span>. We enter strategic collaborations with key industry partners to maintain our leadership position in the TCR therapeutics field and to strengthen our proprietary pipeline. We are presently developing several autologous and allogeneic <span style="white-space:nowrap">TCR-T</span> and bispecific product candidates in collaborations with industry-leading partners including BMS, Editas Medicine and Genmab. We intend to generate value from these strategic collaborations by developing transformative, cutting-edge therapeutics through the combination of synergistic capabilities and technologies, and we benefit through milestone payments and royalties for product candidates that our partners successfully advance into and through clinical development and towards commercial launch. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Strengthen our intellectual property portfolio.</span> We intend to continuously build and maintain our intellectual property portfolio, which, as of February&#160;1, 2023, comprised more than 115 active patent families and over 2,400 patents worldwide in the field of cancer targets, TCRs and related technologies. The protection of our intellectual property assets is a foundational element of our ability to not only strengthen our product pipeline, but also to successfully defend and strengthen our position in the field of TCR therapies. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Enhance the competitive edge of our technology platforms.</span> Our target and TCR discovery platforms XPRESIDENT and XCEPTOR are the foundation for the further strengthening our product pipeline and our position in the field of <span style="white-space:nowrap">TCR-based</span> therapies. We have developed a suite of proprietary technologies to identify what we refer to as &#8220;true targets&#8221; and &#8220;right TCRs.&#8221; True targets are (i)&#160;naturally occurring at significant levels on native tumor tissue (in contrast to being <span style="font-style:italic">in silico</span> predicted or identified from cell line cultures), and (ii)&#160;highly specific to cancer cells. Right TCRs are (i)&#160;high-affinity TCRs, and (ii)&#160;highly specific to the respective cancer target, with no or minimized cross-reactivities to healthy tissues. We leverage this unique knowledge to develop a pipeline of transformative <span style="white-space:nowrap">TCR-based</span> product candidates. Our goal is to maintain and expand our competitive edge in highly differentiated platform technologies aimed at developing additional, better and highly innovative product candidates within shorter development timelines, for <span style="white-space:nowrap">mid-</span> and long-term value generation as part of our own or partnered pipeline. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Near-Term Portfolio Milestones </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current focus is the clinical development of our lead assets from our autologous <span style="white-space:nowrap">TCR-T</span> (ACTengine) and TCR Bispecifics (TCER) pipeline, including execution of the following near-term portfolio milestones: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">ACTengine IMA203 (PRAME): </span>Phase 1 clinical data update on all three ongoing IMA203 Phase 1b cohorts, and identification of most promising cohort to advance towards pivotal trials is planned for 2H 2023 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA401 (MAGEA4/8):</span> Advance ongoing Phase 1 clinical trial and establish clinical PoC </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA402 (PRAME): </span>Submission of CTA* application planned 2Q 2023 and start of Phase 1/2 clinical trial in 2H 2023* </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Clinical Trial Application (CTA) is the European equivalent of an Investigational New Drug (IND) application </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACTengine <span style="white-space:nowrap">TCR-T</span> Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ACTengine programs are based on genetically engineering a patient&#8217;s own, autologous T cells with novel TCRs designed to recognize a specific cancer target on the tumor. The engineered T cells <span style="white-space:nowrap">(TCR-T)</span> are intended to induce a robust and specific anti-tumor attack to fight the cancer. The ACTengine mechanism of action is depicted below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g42a64.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon infusion of an ACTengine product, T cells &#8220;equipped&#8221; with the cancer target-specific TCR are designed to bind to the pHLA target on the tumor. Subsequent activation of the T cell induces release of cytotoxic granules that might ultimately lead to tumor killing. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACTengine IMA203 &#8211; <span style="white-space:nowrap">TCR-T</span> Targeting PRAME </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead autologous <span style="white-space:nowrap">TCR-T</span> program, ACTengine IMA203, is directed against an <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02:01-presented</span></span> peptide derived from PRAME, one of the most prevalent solid tumor targets known to date. PRAME is frequently expressed in solid tumors such as melanoma, uveal melanoma, uterine cancers, ovarian cancer, subtypes of sarcoma, squamous NSCLC, TNBC, head and neck cancer and others, thereby supporting our program&#8217;s potential to address a broad cancer patient population. Our PRAME peptide is present at a high copy number per tumor cell and is homogenously and specifically expressed in tumor tissue. The peptide has been identified and characterized by our proprietary mass spectrometry-based target discovery platform XPRESIDENT. Through our proprietary TCR discovery and engineering platform XCEPTOR, we have generated a highly specific TCR against this target for its use as <span style="white-space:nowrap">TCR-based</span> cell therapy approach ACTengine IMA203. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Patient journey </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starting with clinical trial enrollment, patients enter a multi-step process in our IMA203 trial which consists of three phases shown below: 1) screening of patients and initiating manufacturing of the cell product; 2) treatment of patients and observation for 12 months; 3) long-term <span style="white-space:nowrap">follow-up.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g02d03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">*</sup> <span style="white-space:nowrap">IL-2</span> dose reduction from twice daily to daily for the first 5 days and dosing duration from 14 to 10 days introduced prior to treatment of first patients on dose level 3; <sup style="font-size:75%; vertical-align:top">1</sup> Dose reduction of Fludarabine (from 40mg/m<sup style="font-size:75%; vertical-align:top">2</sup> to 30mg/m<sup style="font-size:75%; vertical-align:top">2</sup>) was introduced prior to treatment of the first patient on dose level 3 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient screening includes testing&#160;for the molecular marker <span style="white-space:nowrap">HLA-A*02:01</span> from a patient&#8217;s blood sample followed by target profiling by a qPCR-based test from a fresh biopsy. Patients are biopsied and the target expression for PRAME is assessed by our proprietary companion diagnostic device candidate, IMADetect. Only patients whose tumors present the target might benefit from subsequent treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IMADetect is a diagnostic, precision-medicine device screening tumor biopsies for PRAME cancer antigens and other cancer antigens at the same time. The assay is currently conducted in our <span style="white-space:nowrap">in-house</span> CLIA-certified and <span style="white-space:nowrap">CAP-accredited</span> laboratory at our R&amp;D facility in Houston, Texas and will be developed as companion diagnostics for our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only patients that are positive for <span style="white-space:nowrap">HLA-A*02:01</span> and PRAME proceed to leukapheresis, which is the starting point for manufacturing of the autologous engineered T cell product. During leukapheresis, a portion of the patients&#180; white blood cells is collected, and peripheral blood mononuclear cells (&#8220;PBMCs&#8221;) are isolated, frozen and then shipped to our central manufacturing site located in Houston, Texas. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary manufacturing process is designed to expand and engineer T cells within one week. This process is followed by release testing. We have recently implemented an expedited quality control release testing of one week which allows us to provide the cell products to patients faster. T cells, which are a subset of PBMCs, are activated and subsequently mixed with a lentiviral vector to transduce the T&#160;cells with the PRAME-specific TCR. The engineered T cells are then expanded in the presence of cytokines, concentrated and frozen before undergoing release testing. The resulting cell product is then stored frozen until the patient is ready to receive the treatment. T cells can be shipped frozen <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(&#8220;frozen-in-frozen-out&#8221;)</span></span></span> for both delivery of the patient&#8217;s cells to our manufacturing site and shipment of the T cell product to the clinical site. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients being refractory to previous treatments receive a preconditioning lymphodepleting regimen (30 mg/m<sup style="font-size:75%; vertical-align:top">2</sup> Fludarabine and 500 mg/m<sup style="font-size:75%; vertical-align:top">2</sup> Cyclophosphamide) for four days prior to infusion with target-specific T cells after day 6. Subsequently, patients receive a low dose Interleukin 2 <span style="white-space:nowrap">(IL-2)</span> to enhance T cell activation and expansion following infusion. They are monitored closely for safety and efficacy. Twelve months after T cell infusion or upon earlier disease progression, patients enter long-term <span style="white-space:nowrap">follow-up.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Design </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> in an ongoing Phase 1b trial including three expansion cohorts which have all been initiated during the first half of 2022 and build upon the promising early clinical results during our Phase 1a trial: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cohort A: IMA203 as a monotherapy (up to approx. 24 patients); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cohort B: IMA203 in combination with an immune checkpoint inhibitor (up to approx. 12 patients); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cohort C: IMA203CD8, a next-generation cell therapy where IMA203 engineered T cells are <span style="white-space:nowrap">co-transduced</span> with a CD8&#945;&#223; <span style="white-space:nowrap">co-receptor</span> (up to approx. 24 patients). </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each expansion cohort is designed to establish safety, evaluate the observed objective response rate, demonstrate durability and provide the trigger for registration trials. Data generated throughout 2023 with longer <span style="white-space:nowrap">follow-up</span> to assess durability of response is intended to identify the most promising cohort to advance towards pivotal trials and potential commercialization. The ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> Phase 1 design is shown below. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g41a63.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1</sup> RP2D (target dose) determined at DL4 (up to 1.2 x10<sup style="font-size:75%; vertical-align:top">9</sup> TCR-T cells/m<sup style="font-size:75%; vertical-align:top">2</sup> BSA), exploration of higher dose (DL5, up to 4.7x10<sup style="font-size:75%; vertical-align:top">9</sup> TCR-T cells/m<sup style="font-size:75%; vertical-align:top">2</sup> BSA) ongoing; <sup style="font-size:75%; vertical-align:top">2</sup> Demonstrated to be associated with durable response: Locke <span style="font-style:italic">et&#160;al.</span> 2020 Blood Advances; <sup style="font-size:75%; vertical-align:top">3</sup> Opdivo (nivolumab): programmed death-1 (PD-1) immune checkpoint inhibitor; <sup style="font-size:75%; vertical-align:top">4</sup> Treatment of n=3 patients at DL3 completed; enrollment at DL4a ongoing before continuation at DL4b and potentially DL5; <sup style="font-size:75%; vertical-align:top">5</sup> Demonstrated to be important for long-term remission: Melenhorst <span style="font-style:italic">et al</span>. 2022 Nature, Bai <span style="font-style:italic">et&#160;al</span>. 2022 Science Advances; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dose escalation for IMA203 Phase 1b expansion Cohort C testing our enhanced 2<sup style="font-size:75%; vertical-align:top">nd</sup>-generation candidate IMA203CD8 is based on a 3+3 design. Dose level (DL) 3 was completed with 3 patients without any dose-limiting toxicity (DLT). In the first patient treated at DL4, we observed very high biological activity (<span style="font-style:italic">in vivo</span> T cell expansion) accompanied with a DLT, which triggered an expansion of this dose level cohort from 3 patients to 6 patients. As a measure of caution and in accordance with the protocol, we decided to split DL4 into a DL4a (0.481-0.8x10<sup style="font-size:75%; vertical-align:top">9</sup> TCR-T cells/m<sup style="font-size:75%; vertical-align:top">2</sup> BSA) and DL4b (0.801-1.2x10<sup style="font-size:75%; vertical-align:top">9</sup> TCR-T cells/m<sup style="font-size:75%; vertical-align:top">2</sup> BSA). The enrollment in the dose escalation part therefore continues at the intermediate DL4a to understand safety better before continuation at DL4b and potentially DL5. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;10, 2022, we announced a clinical data update for the 1<sup style="font-size:75%; vertical-align:top">st</sup>-generation IMA203 <span style="white-space:nowrap">TCR-T</span> monotherapy covering: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The completed Phase 1a dose escalation part of the clinical trial, during which we treated 27 patients, including 7 patients at the provisional recommended Phase 2 dose (&#8220;RP2D&#8221;) (being dose level 4). The Phase 1a patients were heavily <span style="white-space:nowrap">pre-treated,</span> had a particularly high baseline tumor burden and an average of 4.2 prior lines of treatment, and patients treated at the RP2D had an average of 4.6 prior lines of treatment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Initial data from the first 5 patients in the ongoing Phase 1b dose expansion Cohort A (monotherapy). These Phase 1b patients were heavily <span style="white-space:nowrap">pre-treated,</span> had high to moderate baseline tumor burden and an average of 4.0 prior lines of treatment. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cutoff date for clinical data update is September&#160;6, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moving from Phase 1a to Phase 1b, we are continuing to introduce planned improvements that may influence clinical outcomes including (1)&#160;applying higher cell doses (DL4 and exploratory DL5), (2) optimizing the cell product through manufacturing enhancements, and (3)&#160;working with disease area experts to gradually reduce the fraction of very heavily <span style="white-space:nowrap">pre-treated</span> patients with extreme tumor burden who have exhausted standard of care and have undergone multiple clinical trials. In addition, the focus in Phase 1b is also shifting from initial ORR determined at <span style="white-space:nowrap">~6-week</span> scan to confirmed ORR determined at the <span style="white-space:nowrap">~12-week</span> scan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We observed a higher overall response rate (&#8220;ORR&#8221;) and confirmed ORR (&#8220;cORR&#8221;) in patients who received doses above 1&#160;billion <span style="white-space:nowrap">TCR-T</span> cells, being dose levels 4 and 5. The table below sets forth the observed overall response rates, as measured by RECIST v1.1: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase 1a</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase&#160;1a&#160;+&#160;Phase&#160;1b</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase 1b only</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">All&#160;pts&#160;(DL1-4)</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">DL4&#160;pts&#160;only<sup style="font-size:75%; vertical-align:top">1</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">DL4/DL5&#160;pts&#160;only1</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All&#160;pts&#160;(DL4/DL5)<sup style="font-size:75%; vertical-align:top">1</sup></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patients Treated</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">27</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ORR (~week 6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">48%&#160;(13/27)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">57%&#160;(4/7)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">67%&#160;(8/12)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">80%&#160;(4/5)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">cORR (~week 12)<sup style="font-size:75%; vertical-align:top">2</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">19%&#160;(5/27)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">29%&#160;(2/7)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">50%&#160;(6/12)*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">80%&#160;(4/5)*</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1 </sup>All patients received &gt;1&#160;billion total <span style="white-space:nowrap">TCR-T</span> cells; <sup style="font-size:75%; vertical-align:top">2</sup> confirmed ORR (cORR), * 1 patient with SD at <span style="white-space:nowrap">~6-week</span> scan with pending <span style="white-space:nowrap">~12-week</span> scan considered as <span style="white-space:nowrap">non-responder</span> for cORR; DL &#8211; dose level. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We observed confirmed objective responses in patients with a broad spectrum of different tumor types, including cutaneous melanoma, ovarian cancer, head and neck cancer, uveal melanoma and synovial sarcoma. The graphs below show the best overall response analysis (BOR) according to established RECIST 1.1 criteria. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g45x63.jpg" alt="LOGO" />
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* Maximum change of target lesions and RECIST 1.1 BOR response at different time points; #Synovial sarcoma patient (DL3) PD at week 6 not shown as target lesions were not evaluable; PD: Progressive disease; SD: Stable disease; PR: Partial response; cPR: Confirmed partial response; BL: Baseline </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we observed encouraging early signs of improved durability at higher doses and in Phase 1b patients. The graphs below &#8211; also known as spider plot analyses - show the change in sum of longest diameter of lesions over time. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g45x64.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"># Synovial sarcoma patient (DL3) PD at week 6 not shown 12 as target lesions were not evaluable; PD: Progressive disease; SD: Stable disease; PR: Partial response; cPR: Confirmed partial response; BL: Baseline </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that translational data obtained during the IMA203 monotherapy Phase 1a and Phase 1b Cohort A further provide clinical validation of our PRAME biomarker threshold used for patient selection. Confirmed clinical responses were observed at high and low PRAME-expression levels above this threshold, as shown in the following graph. Based on this data we believe, IMA203 has the potential to provide clinical benefit for all PRAME biomarker-positive cancer patients regardless of the PRAME expression level above this threshold. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g38a60.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The predicted high PRAME prevalence across key indications has so far been supported by prevalence rates obtained during the clinical screening of patients. Biological data including T cell engraftment, persistence and tumor infiltration were consistent with clinical outcomes, as shown in the following graphs, and support the proposed mechanism of action for IMA203. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g53n05.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Mann-Whitney U test; <sup style="font-size:75%; vertical-align:top">1</sup> T cell infiltration for 19 patients (9 <span style="white-space:nowrap">non-responder,</span> 10 responder) with <span style="white-space:nowrap">6-week</span> post infusion biopsy available (1 patient with <span style="white-space:nowrap">~5-week</span> post infusion biopsy) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most frequent treatment-emergent adverse events (&#8220;TEAEs&#8221;) were as expected for cell therapies, and we believe that our 1<sup style="font-size:75%; vertical-align:top">st</sup>-generation IMA203 TCR-T demonstrated a favorable tolerability profile. Specifically, we observed that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All 32 infused patients experienced cytopenia (Grade <span style="white-space:nowrap">1-4)</span> associated with lymphodepletion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">31 patients (97%) experienced cytokine release syndrome (&#8220;CRS&#8221;) of any grade: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">29 patients had low to moderate CRS (Grade <span style="white-space:nowrap">1-2)</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2 patients had Grade 3 CRS that occurred in Phase 1a, with both patients having recovered to Grade &#8804; 2 after three and four days, respectively; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">5 patients (16%) experienced a low to moderate (Grade <span style="white-space:nowrap">1-2)</span> immune effector cell associated neurotoxicity syndrome (ICANS); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No dose-dependent increase of CRS and ICANS was observed; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No additional dose limiting toxicities (&#8220;DLT&#8221;) were observed since the initial data release in March 2021, when we disclosed a Grade 3 atrial fibrillation at dose level 2 that was fully resolved within 48 hours; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No IMA203-related Grade 5 adverse events. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tables below show the Grade &#8805;3 TEAEs observed regardless of relatedness to study treatment: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g07k29.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1 </sup>All treatment-emergent adverse events (TEAEs) with &#8805; Grade 3 regardless of relatedness to study treatment that occurred in at least 1 patient (except for ICANS, where only Grade <span style="white-space:nowrap">1-2</span> occurred; listed for completeness due to being an adverse event of special interest) are presented. Adverse events were coded using the Medical Dictionary for Regulatory Activities. Grades were determined according to National Cancer Institute Common Terminology Criteria of Adverse Events, version 5.0. Grades for CRS and ICANS&#160;were determined according to CARTOX criteria (Neelapu<span style="font-style:italic">&#160;et al.</span>, 2018). Patients are counted only once per adverse event and severity classification. Based on interim data extracted from open clinical database <span style="white-space:nowrap"><span style="white-space:nowrap">(06-Sep-2022);</span></span> <sup style="font-size:75%; vertical-align:top">2 </sup>ICANS: Immune effector cell-associated neurotoxicity&#160;syndrome; <sup style="font-size:75%; vertical-align:top">3 </sup>DLT: Dose limiting toxicity in phase 1a at DL2 reported on March&#160;17, 2021; <sup style="font-size:75%; vertical-align:top">4 </sup>Fatal Adverse events in N=3 patients were not considered related to any study drug; <sup style="font-size:75%; vertical-align:top">5 </sup>Patient did not receive IMA203 <span style="white-space:nowrap">TCR-T</span> cells; * Two patients with disease progression after first IMA203 infusion received exploratory second IMA203 infusion. They had these &#8805; Grade 3 TEAEs only after second infusion, which are included in the table: First patient: Abdominal pain, Diarrhoea, Cytokine release syndrome, Hypokalaemia, Proteinuria; Second patient: Fracture, Muscle spasms,&#160;Neutropenia, Thrombocytopenia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the data presented on October&#160;10, 2022 highlight the clinical potential of PRAME as one of the most promising multi-tumor targets for achieving meaningful benefits for a large cancer patient population. The figure below sets forth the potential patient reach of IMA203 <span style="white-space:nowrap">TCR-T</span> in selected cancer indications with an exemplified focus on the US population only.&#160;&#160;&#160;&#160; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g36a58.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Incidences based on public estimates and Immatics internal model; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; Estimated 41% <span style="white-space:nowrap">HLA-A*02:01</span> positive population in the US; PRAME target prevalence is based on TCGA (for SCLC: <span style="white-space:nowrap">in-house)</span> RNAseq data combined with a proprietary mass spec-guided RNA expression threshold; Uveal melanoma target prevalence is based on IMADetect qPCR testing of screening biopsies from clinical trial patients (n=21). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe IMA203 <span style="white-space:nowrap">TCR-T</span> provides multiple further opportunities to benefit a broader group of patients, by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expanding beyond US population </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expanding into other indications such as kidney, esophageal, bladder, liver cancer, other sarcoma subtypes through indication-specific or indication-agonistic label expansion </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Moving into earlier lines of therapy (R/R Incidence <span style="FONT-FAMILY:'WINGDINGS 3'">&#103;</span> Incidence) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Inclusion of patients with lower PRAME-threshold </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently transitioning to an indication-specific development strategy for our IMA203 <span style="white-space:nowrap">TCR-T</span> trial based on PRAME prevalence, patient population size and observed responses. As a first step we will focus on indications with PRAME prevalence above 80%, such as cutaneous melanoma, uveal melanoma, ovarian and uterine carcinoma as well as uterine carcinosarcoma, where we believe we can quickly initiate registration trials in an effort to progress toward marketing authorization as efficiently as possible. We are also planning to expand to other indications such as head and neck cancer, where we have reported responses, lung cancer and TNBC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Cohort A, evaluating IMA203 <span style="white-space:nowrap">TCR-T</span> as monotherapy, we are currently investigating IMA203 in two additional Phase 1b dose expansion cohorts to realize the full clinical potential of IMA203 <span style="white-space:nowrap">TCR-T</span> targeting PRAME. We are currently prioritizing treatment of patients within the 1<sup style="font-size:75%; vertical-align:top">st</sup> and 2<sup style="font-size:75%; vertical-align:top">nd</sup>-generation IMA203 <span style="white-space:nowrap">TCR-T</span> monotherapy cohorts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cohort B evaluates IMA203 <span style="white-space:nowrap">TCR-T</span> in combination with nivolumab, a <span style="white-space:nowrap">PD-1</span> immune checkpoint inhibitor. Nivolumab has become the standard of care treatment for many solid cancer indications and we believe it fits well into the IMA203 treatment and observation schedule. Through this cohort, we are investigating how the combination with an immune checkpoint inhibitor could enhance the potency of our engineered IMA203 <span style="white-space:nowrap">TCR-T</span> cells by blocking the immune-inhibitory <span style="white-space:nowrap"><span style="white-space:nowrap">PD-1/PD-L1</span></span> pathway. We are currently not prioritizing treatment of patients in this last-line setting, but we are considering further investigation of a combination with nivolumab as a frontline therapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cohort C evaluates IMA203CD8, our 2<sup style="font-size:75%; vertical-align:top">nd</sup>-generation product candidate targeting PRAME, as monotherapy. In contrast to IMA203, IMA203CD8 engages not only CD8 T cells but also CD4 T cells via <span style="white-space:nowrap">co-transduction</span> with the CD8 <span style="white-space:nowrap">co-receptor</span> involved in T cell antigen recognition and T cell activation. We believe that our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IMA203CD8 product candidate has the potential to harness the potency of both CD4 and CD8 T cells. We believe this could further enhance depth and durability of anti-tumor response and clinical outcome of <span style="white-space:nowrap">TCR-T</span> in solid cancer patients. We believe we demonstrated the importance of CD4 T cells for the duration of responses in preclinical assays where IMA203CD8 showed enhanced potency and prolonged anti-tumor activity compared to IMA203 alone as shown in the figure below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g35a37.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Every 3 days IMA203CD8, IMA203 or <span style="white-space:nowrap">non-transduced</span> control T cells were rechallenged with fresh tumor cells and tumor fold growth was analyzed. CD8 T cells engineered with the IMA203 TCR or the IMA203 TCR plus CD8 construct (IMA203CD8) achieved comparable tumor cell killing. CD4 T cells were only capable of potent and more durable anti-tumor activity (including 5<sup style="font-size:75%; vertical-align:top">th</sup> addition of tumor cells) when transduced with IMA203CD8. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These findings are in line with a growing body of literature from CD19 <span style="white-space:nowrap">CAR-T</span> cells in hematological cancers that suggest a relevant role of engineered CD4 T cells in maintaining durable anti-tumor responses over a long period. Our proprietary construct incorporated into a lentiviral vector enables CD4 and CD8 T cells to be engineered with the PRAME-specific IMA203 TCR and a CD8&#945;&#223; construct. In the preclinical studies, this approach showed functional superiority over the other CD8 constructs tested in conjunction with the PRAME-specific IMA203 TCR. We have successfully developed the proprietary <span style="white-space:nowrap"><span style="white-space:nowrap">4-in-1</span></span> construct that includes both IMA203 TCR&#945; and TCR&#223; as well as CD8&#945; and CD8&#223; chains while maintaining a high transduction rate, circumventing the challenges associated with increasing the lentiviral vector payload. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> programs, we are addressing PRAME-positive cancers with a second therapeutic modality: TCR Bispecifics. Our TCER IMA402 is a next-generation, half-life extended TCR Bispecific that is expected to enter the clinic in 2023. Both approaches, ACTengine and TCER, are distinct therapeutic modalities that have the potential to provide innovative treatment options for a variety of cancer patient populations with different unmet medical needs and potentially at different stages of their disease. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACTengine IMA201 &#8211; <span style="white-space:nowrap">TCR-T</span> Targeting MAGEA4/8 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACTengine IMA201 <span style="white-space:nowrap">TCR-T</span> targets an <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02:01-presented</span></span> peptide derived from the tumor antigen MAGEA4 and/or MAGEA8 and is currently being evaluated at target dose level in a Phase 1a dose escalation cohort. XPRESIDENT quantitative information on target density (copy number per tumor cell) between peptides originating from the same source protein allows identification of the most relevant targets. By comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on the same tumor samples, we determined that the selected MAGEA4/8 peptide is presented at <span style="white-space:nowrap">&gt;5-fold</span> higher target density than a commonly targeted MAGEA4 peptide. We plan to discontinue this program after treatment of the remaining patients already enrolled in the clinical trial in order to focus on the TCR Bispecific program TCER IMA401 addressing the identical target peptide derived from MAGEA4/8 as IMA201. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACTengine IMA202 &#8211; <span style="white-space:nowrap">TCR-T</span> Targeting MAGEA1 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A preliminary interim analysis from 16 patients treated in the dose escalation cohort demonstrated a favorable tolerability profile for IMA202 as of May&#160;24, 2022. Signs of clinical and biological activity were observed, but were not reaching the threshold of objective responses as per RECIST1.1. Treatment-emergent adverse events for IMA202 were transient and manageable, with the most common of such events being expected cytopenia associated with lymphodepletion in all patients (94% &#8805; Grade 3). No dose-limiting toxicities or signs of auto-immune toxicities were observed. 11 out of 16 patients (69%) showed disease control and 5 out of 16 patients (31%) showed tumor shrinkage. Maximum change of target lesion was minus 35%. Following final evaluation, Immatics plans to present the full data set at a later timepoint. Immatics management has decided not to further progress the IMA202 program into Phase 1b dose expansion and is evaluating development options and partnering opportunities for the program and the target MAGEA1. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACTengine IMA204 &#8211; <span style="white-space:nowrap">TCR-T</span> Targeting Tumor Stroma Target COL6A3 Exon 6 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rigid stroma and the immunosuppressive microenvironment of solid tumors play a crucial role in tumor initiation, progression and metastasis by providing a defensive layer against the body&#8217;s immune system and pose a challenge for T cell accessibility. We believe that targeting the tumor stroma could provide a novel approach for the treatment of many solid tumors either as single-agent approach or as part of a next-generation <span style="white-space:nowrap"><span style="white-space:nowrap">multi-TCR-T</span></span> concept targeting both tumor and stroma simultaneously. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ACTengine program IMA204 is directed against COL6A3 exon 6, a novel, proprietary tumor stroma target identified and characterized by our XPRESIDENT technology platform. COL6A3 exon 6 is presented predominantly by tumor stromal cells and not, or to a far lesser extent, by normal tissues. It is highly prevalent in a broad range of tumor tissues, including pancreatic cancer, breast cancer, gastric cancer, sarcoma, esophageal cancer, <span style="white-space:nowrap">non-small</span> cell lung cancer, head&#160;&amp; neck squamous cell carcinoma, colorectal cancer, mesothelioma and ovarian cancer, with an estimated <span style="white-space:nowrap">40-80%</span> of such cancers expressing COL6A3 exon 6. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For IMA204, we have generated an affinity-enhanced proprietary TCR, that induces anti-tumor activity in both CD4 and CD8 T cells without the need for CD8 <span style="white-space:nowrap">co-transduction</span> in preclinical experiments. Expression of COL6A3 exon 6 in the tumor stroma and <span style="font-style:italic">in vivo</span> activity of IMA204 is shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:61%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:38%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">


<img src="g400206g92o71.jpg" alt="LOGO" />
</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">


<img src="g400206g95r13.jpg" alt="LOGO" />
</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Left panel: Expression of the stroma target COL6A3 exon 6 and a tumor target in the same ovarian cancer tissue sample using RNA in situ hybridization. Both pictures show the same image section. Red dots indicate target mRNA expression, which is tumor cell-specific in the case of the tumor target (right) and restricted predominantly to the tumor stroma cells in case of the stroma target, COL6A3 exon 6 (left). Right panel: Affinity-enhanced TCR targeting COL6A3 exon 6 appears to eradicate COL6A3 exon <span style="white-space:nowrap">6-positive</span> tumors implanted in mice, data by Jim Riley, University of Pennsylvania, control: <span style="white-space:nowrap">non-transduced</span> T cells. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Activation of both T cell types has been reported as favorable for induction and maintenance of anti-tumor responses against solid tumors. In the case of our IMA204 TCR candidate, this next-generation feature of being able to activate both CD8 as well as CD4 T cells is already engineered within the TCR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focusing our clinical resources on the three IMA203 Phase 1b cohorts as well as accelerating the clinical development for the PRAME TCER IMA402. Therefore, as announced in November 2022, we have delayed the IND submission for an ACTengine candidate IMA204. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACTallo&#8212;Our <span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-shelf</span></span> <span style="white-space:nowrap">TCR-T</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim to increase the commercial opportunity of cell therapies by supplying products to patients more quickly and at lower cost with our <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> cell therapy approach, ACTallo. ACTallo is our proprietary allogeneic adoptive cell therapy platform based on gamma delta T cells sourced from healthy donors as shown below. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g48z31.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing process is designed to create hundreds of doses from one single donor leukapheresis. Gamma delta T cells are abundant in the peripheral blood, show intrinsic anti-tumor activity, naturally infiltrate solid tumors and do not cause <span style="white-space:nowrap"><span style="white-space:nowrap">graft-vs-host</span></span> disease &#8211; characteristics that make this cell type well suited for an allogeneic approach. The ACTallo process engineers gamma delta T cells with CARs or TCRs, thus accessing cancer cell surface targets as well as intracellular proteins that are presented as peptides on the surface of the cancer cell. This aims to enable the redirection of gamma delta T cells to cancer cell targets. ACTallo products would be available for patient treatment without the requirement for personalized manufacturing. Since these T cells originate from healthy individuals, they are not reliant on the potentially encumbered immune system of the cancer patient. In June 2022, we entered into strategic collaborations with Bristol Myers Squibb and Editas Medicine to develop next-generation allogeneic gamma delta <span style="white-space:nowrap"><span style="white-space:nowrap">TCR-T/CAR-T</span></span> programs with enhanced persistence, safety and potency by combining our proprietary ACTallo platform with Bristol Myers Squibb&#8217;s <span style="white-space:nowrap">next-gen</span> technologies and Editas Medicine&#8217;s CRISPR gene editing technology. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TCR Bispecifics &#8212; TCER </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our half-life extended TCER molecules are next-generation, antibody-like <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> biologics that leverage the body&#8217;s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells&#8217; intrinsic specificity. The figure below sets forth the TCER format design and its mechanism of action.<span style="font-weight:bold"> </span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g12p13.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, <span style="white-space:nowrap">low-affinity</span> T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient&#8217;s T cells to the tumor to attack the cancer cells. With a <span style="white-space:nowrap">low-affinity</span> recruiter aiming to optimize biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER molecules are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER format consists of an <span style="white-space:nowrap">Fc-part</span> developed to confer half-life extension, stability, and manufacturability. The next-generation, half-life extended TCER format is designed to safely apply high drug doses for activity in a broad range of tumors and to achieve a favorable dosing regimen scheduling regime. TCER are <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and provide the opportunity to reach a large patient population without the need for treatment at specialized medical centers. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">TCER Format </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Improving drug safety, efficacy and dosing schedule are key considerations in the field of bispecific T cell engaging molecules, which we seek to address with our half-life extended next-generation TCR Bispecific molecule. We demonstrated in preclinical experiments that the TCER format had a higher combination of potency and specificity than six alternative TCR Bispecific format designs evaluated. The format was also successfully applied to different TCRs and different T cell recruiting antibodies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The T cell recruiter domain used for all our TCER molecules is a proprietary <span style="white-space:nowrap">low-affinity</span> T cell recruiter against the TCR/CD3 complex that demonstrated superior <span style="font-style:italic">in vivo</span> tumor control compared to three analogous TCER molecules designed with higher-affinity variants of a widely used antibody recruiter as shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt; text-indent:4%">


<img src="g400206g30f01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1</sup> Hs695T xenograft model in NOG mice, tumor volume of group means shown </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our preclinical data set forth below show a reduced recruiter-mediated cytokine release <span style="font-style:italic">in vitro</span> when the target is absent, which we believe indicates that our TCER format reduces T cell engager-associated toxicities in patients. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g98m33.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Whole blood cytokine release assay N=3 <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02-positive</span></span> donors, N=16 cytokines tested, 4 exemplary cytokines shown. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The half-life extended format confers a serum half-life of &gt;1 week in mice, which we believe suggests the opportunity for a favorable dosing regimen and prolonged drug exposure at therapeutic levels when compared to TCR Bispecifics lacking half-life extension approaches. Taken together, our next-generation, half-life extended TCER format is designed to maximize efficacy while minimizing toxicities in patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">TCER Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a broad pipeline of next-generation half-life extended TCR Bispecifics with the potential for addressing different indications and large patient populations with an innovative therapeutic option. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA401 targeting a MAGEA4/8 peptide presented by <span style="white-space:nowrap">HLA-A*02:01</span> (developed in collaboration with BMS):</span> Start of clinical trial in May 2022, dose escalation ongoing </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA402 targeting a PRAME peptide presented by <span style="white-space:nowrap">HLA-A*02:01:</span> </span>Start of clinical trial planned for 2H 2023 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA403 targeting an undisclosed peptide presented by <span style="white-space:nowrap">HLA-A*02:01:</span></span> Preclinical PoC studies ongoing </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">TCER IMA40x comprising several innovative TCER candidates targeting undisclosed peptides presented by <span style="white-space:nowrap">HLA-A*02:01</span> and other <span style="white-space:nowrap">HLA-types:</span> </span>TCER engineering and preclinical testing ongoing </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">TCER IMA401 </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IMA401 is the most advanced product candidate from our TCR Bispecifics pipeline targeting an <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02:01-presented</span></span> peptide derived from both MAGEA4 and MAGEA8. The MAGEA4/8 peptide has been identified and validated by our proprietary mass spectrometry-based target discovery platform XPRESIDENT and is presented at a <span style="white-space:nowrap">&gt;5-fold</span> higher copy number per tumor cell than a commonly targeted MAGEA4 peptide, and is highly prevalent in several solid tumor types. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical PoC data demonstrated potent and specific killing of tumor cells <span style="font-style:italic">in vitro</span> with MAGEA4/8 peptide levels similar to levels found in cancer patients. In two different tumor xenograft mouse studies, a cell line-derived melanoma tumor model and patient-derived <span style="white-space:nowrap">non-small</span> cell lung (NSCLC) adenocarcinoma tumor model, IMA401 achieved consistent tumor regression in all mice. In the patient-derived NSCLC model shown below, IMA401 treatment led to consistent tumor regression of all transplanted human tumors, with 3 out of 4 mice showing complete remissions. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g21p31.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IMA401 molecule further demonstrated pharmacokinetics of a terminal half-life of <span style="white-space:nowrap">10-11</span> days in mice and what we view as positive purity and stability characteristics with high production yields. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, we announced that we entered into a license, development and commercialization agreement for IMA401 with BMS. The agreement was associated with an upfront payment of $150&#160;million, milestone payments of up to $770&#160;million and tiered double-digit royalties. We are responsible for conducting the Phase 1a clinical trial for IMA401 and retain the options to <span style="white-space:nowrap">co-fund</span> U.S. development in exchange for enhanced U.S. royalty payments and/or to <span style="white-space:nowrap">co-promote</span> IMA401 in the U.S. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 clinical trial for IMA401 commenced in the first half of 2022 and is currently ongoing in <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02:01-positive</span></span> patients with tumors of high MAGEA4/8 prevalence, such as squamous NSCLC, small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The objectives of the clinical trial are to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) and to characterize safety and tolerability, evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401. The Phase 1 trial consists of a dose escalation (Phase 1a) cohort that will be followed by a dose expansion (Phase 1b) cohort to treat patients at the recommended dose level. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">TCER IMA402 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TCER IMA402 is directed against the same peptide derived from PRAME as used for ACTengine IMA203<span style="font-style:italic">. </span>PRAME is one of the most frequently expressed targets and highly prevalent in several solid tumor types, such as melanoma, uveal melanoma, uterine cancers, ovarian cancer, subtypes of sarcoma, squamous NSCLC, TNBC, head and neck cancer, among other indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preclinical studies, data demonstrated potent and selective cytotoxicity of IMA402 against tumor cell lines presenting PRAME target <span style="white-space:nowrap">peptide-HLA</span> at different target densities (target peptide copies per cell). While physiological PRAME levels detected in the majority of cancer tissues from patients are in the range of 100 &#8211; 1000 copies per cell, IMA402 showed tumor cell killing at PRAME peptide levels as low as 50 copies per cell, as shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g21p30.jpg" alt="LOGO" />
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">CpC: Target peptide copy numbers per tumor cell </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In vitro</span> safety assessment including toxicity screening against 20 normal tissue types, whole blood cytokine release assessment and alloreactivity evaluation confirmed the favorable safety profile for IMA402. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In vivo</span> studies in mice set forth below demonstrated a dose-dependent anti-tumor activity of IMA402 and that sufficiently high drug doses are key to achieving the desired anti-tumor effects over a prolonged period. </p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g35a35.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Melanoma cell line-derived tumors in MHC I/II <span style="white-space:nowrap">knock-out</span> NSG mice received weekly intravenous injections of IMA402 starting at study day 1 after intravenous transfusion of human PBMC. Treatment was discontinued when complete response was noted. Median values for n = 6 mice/group, 2 donors/group. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmacokinetic characteristics of the half-life extended IMA402 molecule with a terminal half-life of &gt;1 week <span style="font-style:italic">in vivo,</span> as shown below, suggest the potential for a favorable dosing regimen in patients with prolonged drug exposure at therapeutic levels. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g21p29.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">NOG mice received a single intravenous injection of IMA402 (2 mg/kg). TCER plasma concentrations at different time points were determined by ELISA detecting binding of IMA402 to the PRAME target via pHLA. The integrity of the molecule was confirmed via aV<sub style="font-size:75%; vertical-align:bottom">L</sub> or aFc detection. Terminal half-life (t<sub style="font-size:75%; vertical-align:bottom">1/2</sub>) was calculated via linear regression of time points between 24 h and 360 h (n=3 per timepoint, mean &#177; SD). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data generated in the field of T cell engaging bispecifics suggest that half-life extension and <span style="white-space:nowrap">low-affinity</span> CD3 recruiters are key strategies to improve safety and efficacy of bispecific molecules. We believe, our TCER molecules are the first <span style="white-space:nowrap">TCR-based</span> bispecifics candidates in clinical development where these strategies were applied. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our preclinical data for IMA402, we believe that our next-generation, half-life extended format using a <span style="white-space:nowrap">low-affinity</span> T cell recruiter can achieve higher doses with drug concentrations in the therapeutic relevant range over time, increased pressure on the tumor, more and deeper responses across a broad range of indications, including in tumors with lower target levels, and a more convenient treatment schedule combined with acceptable tolerability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To enable the start of the Phase 1/2 trial in 2023, we have completed the preclinical data package and manufacturing of the clinical batch in 2022. We plan to use a flexible design for the Phase 1/2 trial that provides the opportunity to shorten the clinical development timeline of IMA402: The dose escalation cohort has an adaptive design that uses flexible dose cohorts and an optimized MABEL (minimal anticipated biological effect level) approach. <span style="white-space:nowrap"><span style="white-space:nowrap">HLA-A*02:01-positive</span></span> patients with different solid tumors expressing PRAME will initially receive weekly infusions of IMA402. Pharmacokinetics data will be assessed throughout the trial and might provide an early opportunity for adjustment of the treatment interval based on the half-life extended TCER format. The Phase 2a dose expansion part of the trial is planned to include several cohorts to further evaluate IMA402 in specific indications and combination therapies. Submission of the CTA* is planned for 2Q 2023 and the start of the trial is planned for 2H 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*Clinical Trial Application (CTA) is the European equivalent of an Investigational New Drug (IND) application </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Technology Platforms </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To characterize our proprietary and partnered product candidates and to identify and develop future <span style="white-space:nowrap">TCR-based</span> product candidates, we established two proprietary target and TCR discovery platforms: XPRESIDENT and XCEPTOR. We believe that for the development of safe and effective <span style="white-space:nowrap">TCR-based</span> immunotherapeutics, two fundamental steps illustrated below are required (i)&#160;picking a true cancer target that is naturally occurring and presented at significant levels specifically on the tumor, and (ii)&#160;generating the right, potent TCR that specifically recognizes the selected target with no or minimized cross-reactivity with healthy tissues. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g21p28.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified a pool of more than 200 well-known and unknown cancer targets that have the potential for further development of proprietary and partnered assets and allow us to build a unique position in complementary T cell therapies &#8211; ACT and TCR Bispecifics- to maximize value generation. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">XPRESIDENT Discovers True Targets for Cancer Immunotherapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">XPRESIDENT integrates a high-throughput, ultra-sensitive mass spectrometry&#160;coupled with a proprietary workflow and an immunoinformatics platform. It builds on a primary tissue database of thousands of tissues. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
From these specimens, a multitude of data is being gathered, including genome, proteome and <span style="white-space:nowrap">in-depth</span> transcriptome. The core of the database is its quantitative immunopeptidome data set, which enables the selection of true cancer targets. To our knowledge, this is the largest collection of pHLA target information derived both from cancer and healthy tissues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilizing this foundation, we believe that XPRESIDENT identifies &#8220;true target&#8221; peptides for <span style="white-space:nowrap">TCR-based</span> immunotherapies that are proven to be displayed on patient tumors and that are not present, or present to a far lesser extent, on normal tissues. We utilize the natural mechanisms of the immune system, by leveraging on the TCR&#8211; pHLA interaction, to access intra- and extracellular cancer targets that are invisible to classical antibody or <span style="white-space:nowrap">CAR-T</span> therapies. By picking our targets from the full immunopeptidome, a target space increased by 300% as compared to the membrane-bound or extracellular peptidome, we developed a pool of more than 200 prioritized cancer targets across different target classes. These targets originate from well-known parent proteins, widely uncharacterized proteins and novel target spaces including <span style="white-space:nowrap">non-classical</span> neoantigens, <span style="white-space:nowrap">RNA-edited</span> or post-translationally modified epitopes, which we call &#8220;crypto targets&#8221;. Our prioritized targets, that have been filed in numerous patent applications, add value to our current pipeline and form a powerful source for future product candidates. We select cancer targets not only based on their prevalence and specificity to a given tumor indication, but also based on their presentation level per tumor cell. Target presentation at sufficient density per tumor cell is a key component required for mounting an efficient anti-tumor response, especially for TCR Bispecifics but also for ACT. To our knowledge, the absolute quantitation of the target (&#8220;AbsQuant&#8221;) on the tumor cell is a unique capability solely available through XPRESIDENT. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By investigating dozens of tissues for each cancer indication, XPRESIDENT is not limited by an individual tumor of a specific cancer type, but instead analyzes a broad cross-section of the cancer patient population. It has been designed to both select targets that are not only naturally presented by a given tumor at high target density and also to analyze the prevalence of target presentation among all analyzed tissues. Before entering clinical development, only targets relevant for a significant percentage of patients of a given cancer type are moved forward and are thoroughly characterized prior to or in parallel to TCR identification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">XPRESIDENT&#8217;s extensive pHLA database is based on more than 2,500 primary tissue samples from 40 healthy organ types and 20 major cancer indications. As shown below, following an analysis of over 500,000,000 MS/MS spectra and an initial long-list of 8,500 tumor-associated pHLA targets, we have prioritized over 200 mass spectrometry validated pHLA targets covering all target classes: 1) peptides of well-known and characterized cancer target proteins; 2) unknown or poorly characterized proteins and 3) crypto targets/neoantigens. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g400206g37a37.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">XPRESIDENT has identified and characterized cancer targets for all of our clinical and preclinical programs across our entire individual and partnered pipeline. Each of our pipeline programs is currently <span style="white-space:nowrap">targeting&#160;HLA-A*02:01,&#160;which</span> is found in <span style="white-space:nowrap">approximately&#160;40-50%&#160;of</span> individuals in North America and Europe and in approximately <span style="white-space:nowrap">20-35%</span> of individuals in East Asia, and is one of the most common HLA types worldwide. However, XPRESIDENT is not restricted to <span style="white-space:nowrap">HLA-A*02</span> and has identified a large set of cancer targets across many different HLA alleles, such as <span style="white-space:nowrap">HLA-A*01/</span> <span style="white-space:nowrap">-A*03/</span> <span style="white-space:nowrap">-A*24/</span> <span style="white-space:nowrap">-B*07/</span> <span style="white-space:nowrap">-B*44.</span> By developing <span style="white-space:nowrap">target-TCR</span> pairs beyond <span style="white-space:nowrap">HLA-A*02,</span> we seek to expand the patient population that might benefit from our product candidates as broadly as possible. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">XCEPTOR Identifies, Optimizes and Characterizes Right TCRs for <span style="white-space:nowrap">TCR-T</span> and TCR Bispecifics </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">XCEPTOR is our proprietary, TCR identification platform enabling the discovery and engineering of TCRs with high affinity and specificity. Apart from the fast, efficient and highly sensitive TCR identification and characterization, XCEPTOR also comprises a protein engineering module to optimize (e.g., chain pairing enhancement, engineering towards CD8 independency) and affinity-enhance TCRs prior to sourcing our product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g400206g21p27.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure above, XCEPTOR picks and optionally engineers the most suitable TCRs for ACT or Bispecific product candidates: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the case of ACT, XCEPTOR either picks high-affinity TCRs from the natural repertoire or modestly enhances these TCRs, aiming for single-digit micromolar affinities mirroring naturally occurring TCR affinities in viral infections. Additionally, we could pursue engineering TCRs to address alpha/beta chain pairing and/or CD8 independency. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the case of TCR Bispecifics, affinity of the target TCR is required to be much higher to achieve functional activity, thus the naturally occurring, specific TCRs need to be strongly affinity maturated using yeast display. Stable, high-affinity single-chain TCR variable fragments (scTvs) are serving as building blocks for the generation of the TCER compound. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irrespective of whether a TCR will be used for ACT or TCR Bispecific, we start the TCR discovery process with a variety of TCRs against a specific cancer target, characterize the receptors and select the TCRs with the most desirable affinity, potency, specificity, and safety characteristics. During the characterization process, we not only determine the binding motif of the TCRs and ensure functional efficacy at physiological cancer target levels, but also evaluate the TCRs&#8217; ability to avoid similar peptides that are presented on healthy tissues. We also test for potential reactivity against a broad panel of healthy tissues covering critical organs, multiple different cell types and organ-specific cell types. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The entire TCR selection and characterization process is guided by the XPRESIDENT peptide target database. The extensive information available on the HLA peptidome in <span style="text-decoration:underline">normal</span> tissues is specifically useful for determining&#160;potential <span style="white-space:nowrap">on-</span> <span style="white-space:nowrap">and&#160;off-target&#160;toxicities,</span> i.e. potential recognition by a TCR of target peptides and/or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar peptides that are presented on healthy tissues (=XPRESIDENT-guided <span style="white-space:nowrap">on-</span> and <span style="white-space:nowrap">off-target</span> toxicity screening). Also, during TCR maturation the information on similar peptides presented on healthy tissues is helpful to counter-screen for cross-reactive TCRs (=XPRESIDENT-guided similar peptide screening). TCRs recognizing healthy tissues would be a potential threat for the wellbeing of patients and therefore are <span style="white-space:nowrap">de-selected</span> early during preclinical development and allow us to focus on the most specific and promising TCRs as early as possible in the development process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing&#160;&amp;&#160;Supply </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACTengine </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical T cell products are currently manufactured by our employees through a collaboration with the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at UTHealth (&#8220;UTH&#8221;) McGovern Medical School in Houston, Texas that provides us exclusive access to three cGMP manufacturing suites and support areas for the manufacturing of our cell products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To scale our cell therapies for pivotal trials and initial commercial manufacturing, we have started the construction of a <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> 100,000 square foot research and commercial GMP manufacturing facility in the metropolitan area of Houston, Texas. The facility is intended to manufacture our IMA203 products as well as other future autologous and allogeneic cell therapy product candidates for early-stage and registration-directed clinical trials as well as for commercial supply. The facility is designed for flexibility and can be expanded in a modular fashion. The GMP manufacturing facility is expected to be operational in 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To secure our supply, we have contractual agreements in place with two GMP suppliers of lentiviral vectors, which is the most critical raw material for the manufacturing of genetically modified T cells products. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">TCER </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TCER are expressed in mammalian cells. We have established an <span style="white-space:nowrap">in-house</span> laboratory-scale production process to generate R&amp;D material suitable for compound characterization and early preclinical assessments. In the course of preclinical development, the manufacturing process is turned over to third party contract manufacturing organizations (&#8220;CMOs&#8221;) that are experienced in cGMP manufacturing of biologics and regulatory compliance. The <span style="white-space:nowrap">IND-enabling</span> studies (e.g.,<span style="font-style:italic"></span><span style="font-style:italic">&#160;in vitro</span>&#160;toxicology studies) are performed with material that we receive from CMOs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing phase at our CMOs includes cell line development, establishment of master- and working cell banks, upstream and downstream process development, formulation development, development of suitable analytical methods for testing and release, cGMP manufacturing, fill and finish, drug substance and drug product release testing, storage and stability testing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">An&#160;in-house&#160;chemistry,</span> manufacturing and control (&#8220;CMC&#8221;) team guides and manages the processes at our CMOs through the different stages. Before and during the cooperation with a CMO, we conduct audits to control compliance with the mutually agreed process descriptions and to cGMP regulations. Our CMOs themselves are subject to their&#160;own quality assurance functions and are inspected and certified by regulatory agencies, including European national agencies and the FDA. For the development of each TCER candidate, our CMOs need to scale the manufacturing process to suitable size. Drug formulation and process parameters need to be optimized and the manufacturing process qualified by applicable regulatory authorities. In addition to the currently contracted CMOs, we expect to engage with additional third-party manufacturers and suppliers to support potential pivotal trials and potential commercial supplies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Marketing&#160;and&#160;Sales </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have our own marketing, sales or distribution capabilities. We intend to maximize the commercial potential of any approved product candidates by developing a sales and marketing infrastructure or by pursuing strategic collaborations with commercialization partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immunotherapy and the companies and academic groups using <span style="white-space:nowrap">TCR-based</span> or TCR mimetic approaches against cancer are rapidly evolving. While we believe that our technology platforms, therapeutic modalities and scientific knowledge provide us with a competitive advantage, we also face significant competition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pharmaceutical and biotechnology companies are active in the field of TCR therapies, intending to target solid tumors following the success of <span style="white-space:nowrap">CAR-T</span> therapies in hematology. Companies developing other immunotherapies such <span style="white-space:nowrap">as&#160;CAR-T,</span> bispecific antibodies, or immune checkpoint inhibitors may show that their products demonstrate significant improvement in efficacy and compete with our approach and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and commercialize would compete with currently approved therapies and new therapies that may become available in the future. Our competitors fall primarily into the following groups, depending on their treatment approach: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Companies such as Adaptimmune, Gritstone, Immunocore, Adaptive Biotechnologies, pureMHC, BioNTech, and Genentech are also seeking to identify HLA targets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Companies such as Adaptimmune, <span style="white-space:nowrap">Affini-T,</span> Kite Pharma (a Gilead company), Tmunity (a Gilead company), <span style="white-space:nowrap">T-knife,</span> Juno Therapeutics (a BMS company), 2seventybio, Medigene, BioNTech, PACT Pharma, <span style="white-space:nowrap">T-scan</span> Therapeutics, ImmunoScape, Alaunos Therapeutics are investigating novel autologous <span style="white-space:nowrap">TCR-T</span> therapeutics. Their <span style="white-space:nowrap">TCR-T</span> programs are partially directed against peptide targets derived from the same proteins but not necessarily against the same peptide target as used by us. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Companies such as Immunocore, Eureka Therapeutics, Molecular Partners, <span style="white-space:nowrap">CDR-Life,</span> Regeneron and Roche are developing TCR Bispecific compounds or TCR mimetic antibodies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we may compete have significantly larger financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than us. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize the need for a global intellectual property strategy to protect our technology, future products and assets around the world. Consistent with our belief in intellectual property, our patent portfolio is a strategically important asset covering a large number of cancer antigen targets, TCRs, bispecific molecules or TCERs, antibodies, target validation, screening and therapeutic use methods, as well as antigen discovery platforms. Our intellectual property portfolio includes patents in many commercially significant jurisdictions such as Europe, the United States, Canada, China, Japan, Australia, and others. For technologies with potential for the highest commercial impact, our patent filing covers more than 50 countries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;1, 2023, our patent portfolio comprises more than 115 active patent families and over 5,800 patents and patent applications worldwide. We own over 2,400 patents worldwide, including more than 550 U.S. patents. We plan to continue expanding our U.S. patent portfolio to further strengthen the protection of our lead projects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, IP protection for our product candidates, encompassing proprietary cancer antigen targets, TCRs, TCERs and antibodies, includes the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IMA201: Four issued patents in the U.S., fifteen issued foreign patents in Australia (3), South Korea (3), Colombia (2), Morocco (2), Germany, India, Indonesia, Malaysia, New Zealand, Taiwan, South Africa and China; <span style="white-space:nowrap"><span style="white-space:nowrap">hundred-and-seventy-three</span></span> (173)&#160;pending patent applications in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Algeria, Eurasia, Egypt, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, Morocco, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa as well as 4 International applications (PCT) and 6 US provisional applications relating to IMA201 (MAGEA4/8). These patents and patent applications, if issued, are expected to expire between 2037 and 2042, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IMA203: Five issued patents in the U.S., four issued foreign patents in Germany (2), Taiwan and Algeria, <span style="white-space:nowrap"><span style="white-space:nowrap">hundred-and-fifty-eight</span></span> (158)&#160;pending patent applications in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Germany, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa as well as 5 International applications (PCT) and 8 US provisional applications relating to IMA203 (PRAME). These patents and patent applications, if issued, are expected to expire between 2038 and 2042 in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IMA204: Seven issued patents in the U.S., ninety-three (93)&#160;issued foreign patents in Germany, Japan, Hong Kong, South Korea, Mexico, New Zealand, Taiwan, Algeria, South Africa and Europe (two European patents each validated in 40 countries), <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">hundred-and-eighty-one</span></span></span> (181)&#160;pending patent applications in Argentina, Australia, Brazil, Canada, Chile, China, Columbia, Costa Rica, Germany, Algeria, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea , Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, Tunisia, the Ukraine, the U.S., Vietnam and South Africa as well as 4 International applications (PCT) and 7 US provisional applications relating to IMA204 (COL6A3 exon 6). These patents and patent applications, if issued, are expected to expire between 2031 and 2042, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IMA401: Four issued patents in the U.S., eight issued foreign patents in Australia (2), Germany, India, South Korea, Colombia, South Africa and Morocco, <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">two-hundred-and-twelve</span></span></span> (212)&#160;pending patent applications in Argentina, Australia, Brazil, Canada, Chile, China, Costa Rica, Algeria, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa as well as 4 International applications (PCT) and 6 US provisional applications relating to IMA401 (MAGEA4/8). These patents and patent applications, if issued, are expected to expire between 2037 and 2042, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. IMA401 is further protected by a patent family covering the TCER<sup style="font-size:75%; vertical-align:top"> </sup>Platform. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IMA402: Five issued patents in the U.S., two issued foreign patents in Taiwan and Algeria, ninety-five (95)&#160;pending patent applications in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Rica, Germany, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa as well as 4 International applications (PCT) and 6 US provisional applications relating to the clinical candidates for IMA402 (PRAME). These patents and patent applications, if issued, are expected to expire between 2038 and 2043, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. IMA402 is further protected by a patent family covering the TCER<sup style="font-size:75%; vertical-align:top"> </sup>Platform </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we pursue patent protection for different aspects of our ACT technology and methods, which also relate and thus confer protection to the clinical projects, IMA201 to IMA204, IMA401 and IMA402. To this end, our subsidiary, Immatics US, has filed and owns 23 patent families. These patents and patent applications are predominantly focused on ACT methods, cell populations, and other immunotherapy methodologies. If issued, these patents and patent applications are expected to expire between 2038 and 2043, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also place an emphasis on protecting our expanding brand recognition by filing and registering trademark applications throughout the world. We own 20 different trademarks, most of which are registered or have been allowed, in multiple countries and trademark product and services classes. Prominent trademarks are, for example, Immatics, XPRESIDENT, TCER, XCEPTOR, ACTallo and ACTengine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Collaborations and Other Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have forged strategic collaborations with biotech and pharmaceutical companies as well as academic research institutions. Key collaborations include (in order of occurrence with the latest collaboration first): </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Editas </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, we and Editas entered into a strategic collaboration and licensing agreement to combine our gamma delta T cell adoptive cell therapies with Editas&#8217; CRISPR gene editing technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Editas Medicine received an undisclosed upfront cash payment and is eligible to receive additional milestone payments based on development, regulatory, and commercial milestones. In addition, we will pay royalties on future net sales on any products that may result from this collaboration. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Bristol Myers Squibb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, we and Celgene Corporation, a wholly owned subsidiary of BMS, entered into a strategic collaboration and license agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, we may develop <span style="white-space:nowrap">TCR-T</span> programs against solid tumor targets discovered by our XPRESIDENT technology. We will utilize proprietary TCRs identified by our XCEPTOR TCR discovery and engineering platform. We will be responsible for the development of these programs through the lead candidate stage, at which time BMS may exercise its option to exclusively license one or more programs, thereby assuming sole responsibility for further worldwide development, manufacturing and commercialization of the <span style="white-space:nowrap">TCR-T</span> cell therapies. We retain certain early stage <span style="white-space:nowrap">co-development</span> and <span style="white-space:nowrap">co-funding</span> rights for selected <span style="white-space:nowrap">TCR-T</span> cell therapies arising from the collaboration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an upfront payment of $75&#160;million for three programs and are eligible to receive additional regulatory and sales milestones in aggregate amounts of up to $190&#160;million, and $300&#160;million, respectively, as well as tiered royalties based on net sales for each licensed product at percentages ranging from high single digits to teens, subject to customary reductions. BMS has the option to exclusively license up to two additional targets to expand the collaboration at predetermined economics. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, we expanded our 2019 collaboration agreement with BMS to include one additional TCR target discovered by Immatics. As part of this expansion, we have received an upfront payment of $20&#160;million and will be eligible for milestone payments and royalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, Immatics and BMS also entered into a new collaboration to develop allogeneic <span style="white-space:nowrap"><span style="white-space:nowrap">TCR-T/CAR-T</span></span> programs, bringing together our allogeneic gamma delta T cell therapy platform ACTallo with BMS&#8217; technologies and oncology drug development expertise. Under this collaboration, the parties will develop two programs owned by BMS and both companies have an option to develop up to four additional programs each. The programs will utilize our proprietary gamma delta T cell-derived, allogeneic ACT platform, called ACTallo, and a suite of next-generation technologies developed by BMS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of this agreement, we have received an upfront payment of $60&#160;million and are eligible for development, regulatory and commercial milestone payments of up to $700&#160;million per BMS program plus tiered royalty payments of up to low double-digit percentages on net product sales. We will be responsible for preclinical development of the initial two <span style="white-space:nowrap">BMS-owned</span> programs and will receive additional payment for certain activities that we could perform at BMS&#8217; request. BMS will assume responsibility for clinical development and commercialization activities of all <span style="white-space:nowrap">BMS-owned</span> programs thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;10, 2021, we entered into a License, Development and Commercialization Agreement with BMS relating to our TCR Bispecific candidate, IMA401. Pursuant to the agreement, we granted to BMS an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401 and certain other bispecific and multispecific molecules that bind to a MAGEA4/A8 peptide and engage and activate endogenous <span style="white-space:nowrap">T-cells</span> or other immune cells for any diagnostic, prophylactic or therapeutic uses, excluding cell therapy and cell therapy products. BMS granted us a <span style="white-space:nowrap">non-exclusive,</span> perpetual, worldwide, sublicensable, royalty-free license to certain BMS Company patents and <span style="white-space:nowrap">know-how</span> that are improvements to our platform technology that may be generated by Bristol-Myers Squibb in the performance of activities under the agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for such licenses, we received an upfront payment of $150&#160;million and will be eligible to receive milestone payments of up to $770&#160;million upon the achievement of certain development, regulatory and commercial milestones. In addition, during the royalty term, we will be eligible to receive tiered, low double-digit percentage royalties on worldwide net sales of licensed products. We have the option in certain instances to <span style="white-space:nowrap">co-fund</span> the development of the licensed products for the United States. If exercised, we will be responsible for a portion of the U.S. development expenses incurred by BMS and will be eligible to receive tiered, low double-digit percentage royalties on U.S. net sales of licensed products that are higher than those if we did not exercise its U.S. development <span style="white-space:nowrap">co-funding</span> option. The royalty percentages described above are subject to reduction in a given country under certain circumstances, including, but not limited to, the introduction of biosimilar products. In addition, we have the option to <span style="white-space:nowrap">co-promote</span> approved licensed products in the United States. Under the agreement, we will be responsible for, and will bear the cost of, the first Phase 1 clinical trial in Germany for the first licensed product and for performing certain related preclinical studies and <span style="white-space:nowrap">CMC-related</span> development activities. BMS will be responsible for, and will bear the cost of, performing all other development and commercialization activities, subject to our U.S. development <span style="white-space:nowrap">co-funding</span> option and U.S. <span style="white-space:nowrap">co-promote</span> option described above. The Agreement will expire upon expiration of the last royalty term contemplated by the agreement. A royalty term with respect to a licensed product in a given country begins upon the first commercial sale of such licensed product in such country and terminates upon certain events or at the end of certain time periods relevant to such licensed product, including, but not limited to: the expiration of regulatory exclusivity, the expiration of valid patent claims covering such licensed product, and 10 years after first commercial sale of the licensed product in a given country. The agreement has market termination provisions, including termination by BMS of the agreement in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis for convenience upon prior written notice or by BMS for safety reasons. Each party may terminate for uncured breach by the other party, or for the insolvency of the other party. During the term, we will not develop, manufacture or commercialize products which would directly compete with the licensed products, pursuant to the terms and conditions of the agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">GlaxoSmithKline (&#8220;GSK&#8221;) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration. Initially announced on February&#160;20, 2020, the terms of the agreement included a &#8364;45 Million upfront payment to Immatics and the potential for additional milestone and royalty payments in return for access to two of Immatics&#8217; <span style="white-space:nowrap">TCR-T</span> programs. As communicated to Immatics, GSK&#8217;s decision was made unrelated to the programs and the progress achieved in the collaboration to date. The termination became effective on December&#160;26, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following termination, Immatics regained the subject proprietary TCRs identified by our XCEPTOR technology, which were directed against two proprietary targets discovered by XPRESIDENT. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Genmab </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2018, we and Genmab entered into a research collaboration and license agreement to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, we are conducting joint research, funded by Genmab, and combining XPRESIDENT, XCEPTOR and TCER technology platforms with Genmab&#8217;s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. Effective January&#160;2, 2023 and for strategic reasons, Genmab provided Immatics with notice of its decision to terminate one program under the collaboration. Both we and Genmab are exclusively discovering and developing immunotherapies directed against two proprietary targets, discovered and developed by our XPRESIDENT platform. Genmab is responsible for development, manufacturing and worldwide commercialization. We retain an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an upfront fee of $54&#160;million and are eligible to receive additional development, regulatory and commercial milestone payments, totaling $550&#160;million for each licensed product resulting from the collaboration. In addition, we are eligible to receive tiered royalties on net sales for each licensed product at up to double-digit percentages. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">UTHealth </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a multi-year collaboration agreement to secure exclusive access to three UTHealth cGMP suites to manufacture various ACT products within the Griffin Research Laboratory. Under the agreement, general facility operations, maintenance, supply and reagents for cGMP manufacture, and <span style="white-space:nowrap">co-release</span> of product is provided by UTHealth. Under the agreement, we perform all manufacturing and <span style="white-space:nowrap">in-process</span> controls. The UTHealth facility is FDA registered to produce cells and tissues for clinical applications in compliance with cGMP and has received accreditation by the FACT in January 2016, which was renewed in 2019. In August 2020 UTHealth and Immatics extended the collaboration until the end of 2024 providing Immatics exclusive access to cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory. The extended collaboration ensures continued clinical batch supply for all of Immatics&#8217; ongoing and future ACT clinical trials in the United States and Europe. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">MD Anderson Cancer Center </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, we and The University of Texas M.D. Anderson Cancer Center (&#8220;MD Anderson&#8221;) announced the launch of Immatics US to develop multiple T cell and <span style="white-space:nowrap">TCR-based</span> adoptive cellular therapies. Immatics US secured over $60&#160;million in total funding &#8211; more than $40&#160;million from the parent company Immatics OpCo and a $19.7&#160;million grant from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) and entered into several agreements, including a restricted stock purchase agreement, several license agreements and a collaboration and license agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the collaboration and license agreement (the &#8220;MD Anderson Collaboration Agreement&#8221;), MD Anderson and Immatics US conduct work pursuant to agreed research plans to develop (i)&#160;IMA101 and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&#160;ACTengine IMA201, 202, 203 product candidates in certain cancer indications. Immatics US funds all activities by MD Anderson under the research plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the MD Anderson Collaboration Agreement, MD Anderson granted Immatics US a fully <span style="white-space:nowrap">paid-up,</span> royalty-free, <span style="white-space:nowrap">non-exclusive,</span> sublicensable license under certain technology, patent rights and <span style="white-space:nowrap">know-how</span> controlled by MD Anderson relating to the development and manufacturing of <span style="white-space:nowrap">T-cell</span> based therapies to perform activities under the MD Anderson Collaboration Agreement. Immatics US granted MD Anderson a fully <span style="white-space:nowrap">paid-up,</span> royalty-free, <span style="white-space:nowrap">non-exclusive,</span> sublicensable license under certain technology, patent rights and <span style="white-space:nowrap">know-how</span> controlled by Immatics US, including intellectual property created under the MD Anderson Collaboration Agreement, to perform activities under the MD Anderson Collaboration Agreement and a fully <span style="white-space:nowrap">paid-up,</span> royalty-free, <span style="white-space:nowrap">non-exclusive,</span> sublicensable license under technology, patent rights and <span style="white-space:nowrap">know-how</span> created under the MD Anderson Collaboration Agreement for research purposes during the term of the MD Anderson Collaboration Agreement. Immatics US owns all intellectual property resulting from or directly related to the work conducted under the research plans, provided such ownership does not result in any violation of law or adversely impact the University of Texas system&#8217;s tax exempt status. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MD Anderson Collaboration Agreement will continue until the completion of all research activities contemplated by applicable research plans, unless terminated earlier. MD Anderson has the right to terminate the MD Anderson Collaboration Agreement for Immatics US&#8217;s material breach following a certain cure period. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a number of collaborations that are important for our ability to manufacture, supply and offer our adoptive cell therapies and TCR Bispecifics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use several third-party contract manufacturers acting in accordance with FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) or cGMP, as applicable, practices for the manufacture of viral vectors and cell bank development. We generally apply second-supplier strategies to mitigate supply risks and to secure access to manufacturing innovation and competitive supply costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For manufacturing and supply of TCR Bispecifics, we have contracted third party manufacturers and may enter into additional CMO relationships in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state, and local level, and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, as well as import and export of biological products. Some jurisdictions also regulate the pricing of medicinal products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Licensure and Regulation of Biologics in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, biological products, including gene therapy products, are regulated under the Public Health Service Act (&#8220;PHSA&#8221;) and the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and their implementing regulations as well as other federal, state and local statutes and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of an applicant to comply with the applicable regulatory requirements at any time during the product development process, including during testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Failure to comply with regulatory requirements may result in the FDA&#8217;s refusal to allow an applicant to proceed with clinical trials, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, and civil or criminal investigations and penalties brought by the FDA or Department of Justice (&#8220;DOJ&#8221;), or other government entities, including state agencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps before the product candidate will be licensed by the FDA: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preclinical testing including laboratory tests, animal studies, and formulation studies, which must be performed in accordance with the FDA&#8217;s GLP regulations, as applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an IRB representing each clinical site before each clinical trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials to establish the safety, and efficacy of the product candidate for each proposed indication, in accordance with current GCP; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of a BLA for a biological product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA acceptance and substantive review of the BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the BLA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">securing FDA approval of the BLA to allow marketing of the new biological product. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical Studies and Investigational New Drug Application </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before an applicant begins testing a product candidate with potential therapeutic value in humans, the product candidate enters preclinical testing. Preclinical studies include studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, as applicable, including GLP regulations. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The IND and IRB Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. The FDA requires <span style="white-space:nowrap">a&#160;30-day&#160;waiting</span> period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during <span style="white-space:nowrap">this&#160;30-day&#160;period</span> the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or partial clinical hold. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following commencement of a clinical trial, the FDA may also place a clinical hold or partial clinical hold on that trial. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval or licensing. In particular, such studies must be conducted in accordance with cGCP, including review and approval by an independent ethics committee (&#8220;IEC&#8221;) and obtaining informed consent from subjects. The FDA must be able to validate the data through an onsite inspection, if deemed necessary by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IRB representing each institution participating in the clinical trial must review and approve among other things, the study protocol and informed consent information to be provided to study subjects before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials including the use of an investigational device sometimes require submission of an application for an Investigational Device Exemption (&#8220;IDE&#8221;), to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational protocol is scientifically sound. The IDE application must be approved in advance by the FDA, unless the product is deemed <span style="white-space:nowrap">a&#160;non-significant&#160;risk</span> device and eligible for more abbreviated IDE requirements. Clinical trials for a significant risk device may begin once the IDE application is approved by the FDA as well as the appropriate IRBs at the clinical trial sites, and the informed consent of the patients participating in the clinical trial is obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of the clinical trials must be submitted at least annually to the FDA. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or&#160;in vitro&#160;testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trials in Support of a BLA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness and safety criteria to be evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after licensing. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational biological product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of scientifically valid Phase 2 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications, and determine dose tolerance and optimal dosage. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to license, and, if licensed, how to appropriately label a biologic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the FDA requires in most cases two adequate and well-controlled pivotal clinical trials to demonstrate the efficacy of a product candidate, a single trial with strong confirmatory evidence may be sufficient in instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. In rare cancer indications with very limited treatment options a large and/or controlled trial are often not feasible and thus data from smaller and even uncontrolled trials may be sufficient for regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of biologics licensed under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Review and Approval of a BLA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a biological product in the United States, a biologics license application must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed biological product for its intended indication. The BLA includes all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2023 is $3,242,026 for an application requiring clinical data. The sponsor of an approved BLA is also </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to an annual program fee, which for fiscal year 2023 is $393,933. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following submission of a BLA, the FDA conducts a preliminary review of the application generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th day after the FDA&#8217;s receipt of the submission whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> substantive review. The FDA has agreed to specified performance goals in the review process of the BLAs. Under that agreement, 90% of original BLA submissions are meant to be reviewed within ten months of the <span style="white-space:nowrap">60-day</span> filing date, and 90% of original BLAs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the <span style="white-space:nowrap">60-day</span> filing date. The review process may be extended once per review cycle by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an application, the FDA will typically audit the preclinical study and clinical trial sites that generated the data in support of the BLA. Additionally, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These <span style="white-space:nowrap">pre-approval</span> inspections may cover all facilities associated with a BLA submission, including component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition of approval, the FDA may require an applicant to develop a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;). REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is a new molecular entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fast Track, Breakthrough Therapy, Priority Review and Regenerative Advanced Therapy Designations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as Fast Track designation, Breakthrough Therapy designation, Priority Review designation and Regenerative Advanced Therapy designation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the FDA may designate a product for Fast Track designation if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate a product for Priority Review if it is a product that treats a serious condition and, if licensed, would provide a significant improvement in safety or effectiveness. The FDA determines, on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for Priority Review and Accelerated Approval based on surrogate or intermediate endpoints. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Accelerated Approval Pathway </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant Accelerated Approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments, based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant Accelerated Approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has indicated that intermediate clinical endpoints generally may support Accelerated Approval where the therapeutic </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Accelerated Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, Accelerated Approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. Thus, the benefit of Accelerated Approval derives from the potential to receive approval based on surrogate endpoints sooner than possible for trials with clinical or survival endpoints, rather than deriving from any explicit shortening of the FDA approval timeline, as is the case with Priority Review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Accelerated Approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. The FDA might also require to already set-up and initiate such confirmatory studies prior to BLA submission. As a result, a product candidate licensed on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to initiate expedited proceedings to withdraw approval of the product. All promotional materials for product candidates licensed under accelerated regulations are subject to prior review by the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The FDA&#8217;s Decision on a BLA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for licensing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA licenses a new product, it may limit the licensed indications for use of the product. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After licensing, many types of changes to the licensed product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Licensing Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory licensing for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-licensing regulatory requirements as well as any post-licensing requirements that the FDA may have imposed as part of the licensing process. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and potency or efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to register their facilities with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing processes are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a license is granted, the FDA may suspend or revoke the license if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters, or holds on post-licensing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to licensed applications, or suspension or revocation of product licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. After licensing, a drug product generally may not be promoted for uses that are not licensed by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as <span style="white-space:nowrap">off-label</span> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, <span style="white-space:nowrap">non-misleading</span> communication regarding <span style="white-space:nowrap">off-label</span> information, such as distributing scientific or medical journal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a company is found to have promoted <span style="white-space:nowrap">off-label</span> uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;) and its implementing regulations as well as the Drug Supply Chain Security Act (&#8220;DSCA&#8221;), which regulate the distribution and tracing of prescription drug samples at the federal level and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Studies and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, a BLA or supplement thereto for a biological product with a new active ingredient, indication, dosage form, dosing regimen or route of administration must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by no later than the <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-Phase</span></span> 1 meeting for serious or life-threatening diseases and by no later than ninety (90)&#160;days after FDA&#8217;s receipt of the study plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after licensing of the product for use in adults, or full or partial waivers from the pediatric data requirements. Generally, the pediatric data requirements do not apply to products with orphan designation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA Reauthorization Act of 2017 established new requirements to govern certain molecularly targeted cancer indications. Any company that submits a BLA three years after the date of enactment of that statute must submit pediatric assessments with the BLA if the biologic is intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary potency to inform pediatric labeling for the product. Deferrals and waivers as described above are also available. Exemptions for pediatric assessments usually do not apply for molecularly targeted cancer indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of <span style="white-space:nowrap">non-patent</span> marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the <span style="white-space:nowrap">non-patent</span> and orphan exclusivity. This <span style="white-space:nowrap">six-month</span> exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot license another application. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Orphan Drug Designations and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a biological product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting a BLA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and licensing process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not license another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the licensing of a different product for the same rare disease or condition, nor does it block the licensing of the same product for different conditions. If a biologic designated as an orphan drug ultimately receives marketing licensing for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug exclusivity will not bar licensing of another product under certain circumstances, including if a subsequent product with the same biologic for the same condition is shown to be clinically superior to the licensed product on the basis of greater effectiveness, safety in a substantial portion of the target populations, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biosimilars and Regulatory Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2010 Patient Protection and Affordable Care Act, which was signed into law on March&#160;23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;). The BPCIA established a regulatory scheme authorizing the FDA to license biosimilars and interchangeable biosimilars. The FDA has licensed several biosimilar products for use in the United States. The FDA has issued several guidance documents outlining an approach to review and licensing of biosimilars. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, a manufacturer may apply for licensure of a biological product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously licensed biological product or &#8220;reference product.&#8221; In order for the FDA to license a biosimilar product, it must find, among other things, that the product is &#8220;highly similar&#8221; to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to license a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and, for products administered multiple times, that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished potency relative to exclusive use of the reference biologic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar or interchangeable biological product may not be submitted to the FDA until four years following the date of licensing of the reference product. The FDA may not license a biosimilar or interchangeable biological product until 12 years from the date on which the reference product was licensed. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA licenses a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for biosimilars licensed as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Patent Term Restoration and Extension </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing of a <span style="white-space:nowrap">non-provisional</span> patent application. In the United States, a patent claiming a new <span style="white-space:nowrap">FDA-approved</span> biological product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and FDA regulatory review. The restoration period granted on a patent covering a product is typically <span style="white-space:nowrap">one-half</span> the time between the effective date of an IND and the submission date of a marketing application (such as a BLA), plus the time between the submission date of a marketing application and the ultimate licensing date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s licensing date. Only one patent applicable to a licensed product is eligible for the extension, only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days after approval of the relevant marketing application. A patent that covers multiple products for which licensing is sought can only be extended in connection with one of the licenses. The USPTO reviews and licenses the application for any patent term extension or restoration in consultation with the FDA. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation of Companion Diagnostics </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of certain of our product candidates may depend, in part, on the development and commercialization of a companion diagnostic. Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and approval of a premarket approval (&#8220;PMA&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a preamendment device that was in commercial distribution before May&#160;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device or predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices with respect to intended use, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device or predicate devices, the subject device may be cleared for marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation (&#8220;QSR&#8221;), which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;<span style="font-style:italic">In Vitro</span> Companion Diagnostic Devices.&#8221; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#8217;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for <span style="white-space:nowrap">co-development</span> of an<span style="font-style:italic"> in vitro</span> companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding<span style="font-style:italic"> in vitro</span> companion diagnostic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities for compliance with its authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Healthcare Law and Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Business and Industry.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Review and Approval of Medicinal Products in the EU </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA licensing for a product, an applicant will need to obtain the necessary approvals by the comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product for each proposed indication. It also requires the submission to the relevant competent authorities of a MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Approval in the EU </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the EU. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the lead ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. The new Clinical Trials Regulation (EU) No 536/2014 applies since January 31, 2022 and overhauls the current system of approvals for clinical studies in the EU. Specifically, the new regulation, which is directly applicable in all member states, aims at simplifying and streamlining the approval of clinical studies in the EU. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single point and strictly defined deadlines for the assessment of clinical study applications. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PRIME Designation in the EU </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small and <span style="white-space:nowrap">medium-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than products from larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and a rapporteur from the Committee for Human Medicinal Products (&#8220;CHMP&#8221;) or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A <span style="white-space:nowrap">kick-off</span> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Marketing Authorization in the EU </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain a marketing authorization for a product under EU regulatory systems, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. Regulation (EC) No.&#160;1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants must demonstrate compliance with all measures included in an <span style="white-space:nowrap">EMA-approved</span> Pediatric Investigation Plan (&#8220;PIP&#8221;) covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for one or more of the measures included in the PIP. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area. Pursuant to Regulation (EC) No.&#160;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, ATMPs and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases and under PRIME designation, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of EU law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU Member States and chaired by a <span style="white-space:nowrap">non-voting</span> European Commission representative. The European Parliament also has a related &#8220;<span style="font-style:italic">droit de regard</span>.&#8221; The European Parliament&#8217;s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Commission may grant a <span style="white-space:nowrap">so-called</span> &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Commission may also grant a <span style="white-space:nowrap">so-called</span> &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i)&#160;the risk-benefit balance of the product candidate is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (iii)&#160;the product fulfills an unmet medical need and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the product candidates we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our product candidates, even if they have been granted an EU marketing authorization. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulatory Data Protection in the EU </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No.&#160;726/2004 repeats the entitlement for medicinal products authorized in accordance with the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During the additional <span style="white-space:nowrap">two-year</span> period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall <span style="white-space:nowrap">ten-year</span> period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, <span style="white-space:nowrap">non-clinical</span> tests and clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Periods of Authorization and Renewals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the <span style="white-space:nowrap">so-called</span> sunset clause). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Orphan Drug Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No.&#160;141/2000, as implemented by Regulation (EC) No.&#160;847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and, in addition, a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the <span style="white-space:nowrap">10-year</span> period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulatory Requirements After a Marketing Authorization Has Been Obtained </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and EU Member State laws. <span style="white-space:nowrap"><span style="white-space:nowrap">Direct-to-consumer</span></span> advertising of prescription medicines is prohibited across the EU. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_16">C. Organizational Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we had two subsidiaries. The following table set out for each of our principal subsidiaries, the countries of incorporation, and the percentage ownership and voting interest held by us (directly or indirectly through subsidiaries). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Company</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Jurisdiction&#160;of<br />Incorporation</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage<br />Ownership&#160;and<br />Voting Interest</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immatics Biotechnologies GmbH</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Germany</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immatics US, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Delaware,&#160;United&#160;States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_17">D. Property, Plant and Equipment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immatics OpCo has three locations in Germany: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The corporate headquarters are located at Paul-Ehrlich-Stra&#223;e 15 in 72076 T&#252;bingen. It comprises approximately 2,600 square meters of office space as well as research and laboratory space. It houses Operations, Immunology, TCR Discovery and Validation, TCR Engineering&#160;&amp; Bispecifics, Immunomonitoring, Discovery, Companion Diagnostics and CMC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our operations facility is approximately 1,050 square meters and is located at Aischbachstra&#223;e 1 in 72070 T&#252;bingen. It houses Operations, HR, IT, Finance, Translational Development, Regulatory Affairs and Clinical Development. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our third facility is approximately 1,040 square meters and is located in Machtlfinger Stra&#223;e <span style="white-space:nowrap">5-15</span> in 81379 Munich. It houses Intellectual Property, IT, Communications and Business Development. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immatics US has two locations, an administrative office, which is a direct lease, and the research and laboratory facility, which is subleased from MD Anderson: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The administrative office is a 6,690 square foot facility located at 2201 West Holcombe, Houston, TX 77030, and houses Operations, Human Resources, Finance, Clinical Operations, Regulatory, Bioinformatics and Program Management. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The research and laboratory facility is a 15,694 square foot facility located in the Life Science Plaza building at 2130 West Holcombe, Suite 1100, Houston, Texas 77030. The research and laboratory facility is comprised primarily of laboratory space, with limited office seating that houses CMC, Immunology, Biomarkers, Quality Assurance and Quality Control. Our sublease on the space will expire in August 2023. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">T cell products are manufactured at the leased UTHealth Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in an 1,850 square <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">foot&#160;state-of-the-art&#160;cGMP</span></span></span> facility exclusively used by us in Houston, Texas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our office, research and laboratory facilities are sufficient to meet our current needs. To scale our cell therapies for pivotal trials and initial commercial manufacturing, we have started the construction of a <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> 100,000 square foot research and commercial GMP manufacturing facility in the metropolitan area of Houston, Texas. The facility is intended to manufacture our IMA203 products as well as other future autologous and allogeneic cell therapy product candidates for registration-directed clinical trials as well as for commercial supply. The facility is designed for flexibility and can be expanded in a modular fashion. The GMP manufacturing facility is expected to be operational in 2024. The facility will replace the current locations used by Immatics US.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not aware of any environmental issues or other constraints that would materially impact the intended use of our facilities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_18"><span style="font-weight:bold">ITEM&#160;4A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">UNRESOLVED STAFF COMMENTS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_19"><span style="font-weight:bold">ITEM&#160;5.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">OPERATING AND FINANCIAL REVIEW AND PROSPECTS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements, including the notes thereto, included in this Annual Report. Our consolidated financial statements are presented in euros and have been prepared in accordance with IFRS as issued by the IASB. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under &#8220;Item 3. Key Information - D. Risk Factors&#8221; and elsewhere in this Annual Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020 and our cash flows for the year ended December&#160;31, 2020, see the section &#8220;Item 5. Operating and Financial Review and Prospects&#8221; in our Annual Report on Form <span style="white-space:nowrap">20-F</span> (File <span style="white-space:nowrap">No.&#160;001-39363)</span> filed with the SEC on March&#160;23, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_20">A. Operating Results </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company dedicated to the development of T cell receptor (&#8220;TCR&#8221;)-based immunotherapies for the treatment of cancer. Our purpose is to deliver a meaningful impact on the lives of cancer patients by developing novel <span style="white-space:nowrap">TCR-based</span> immunotherapies that are designed to achieve effect beyond an incremental clinical benefit. Our focus is the development of product candidates for the treatment of patients with solid tumors, who are inadequately served by existing treatment modalities. We strive to become an industry leading, fully integrated global biopharmaceutical company engaged in developing, manufacturing and commercializing TCR immunotherapies for the benefit of cancer patients, our employees, our shareholders and our partners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By utilizing <span style="white-space:nowrap">TCR-based</span> therapeutics, we are able to direct T cells to intracellular cancer targets that are <span style="text-decoration:underline">not</span> accessible through classical antibody-based or <span style="white-space:nowrap">CAR-T</span> therapies. We believe that by identifying what we call <span style="font-style:italic">true</span> cancer targets and the <span style="font-style:italic">right</span> TCRs, we are well positioned to transform current solid tumor treatment paradigms by delivering cellular and bispecific product candidates that have the potential to substantially improve the lives of cancer patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our targeted immunotherapy product candidates through two distinct treatment modalities: <span style="white-space:nowrap">TCR-engineered</span> autologous (&#8220;ACTengine&#8221;) or allogeneic (&#8220;ACTallo&#8221;) Adoptive Cell Therapies (&#8220;ACT&#8221;) and antibody-like Bispecifics, also called T cell Engaging Receptors (&#8220;TCER&#8221;). Each modality is designed with distinct attributes and mechanisms of action to produce the desired therapeutic effect for a variety of cancer patient populations with different unmet medical needs. Our current pipeline shown below comprises several proprietary <span style="white-space:nowrap">TCR-based</span> product candidates in clinical and preclinical development. In addition to our proprietary pipeline, we are collaborating with industry-leading partners, including Bristol Myers Squibb (&#8220;BMS&#8221;), Editas Medicine and Genmab, to develop multiple additional therapeutic programs covering ACT and Bispecifics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have focused on developing our technologies and executing our preclinical and clinical research programs with the aim to deliver the power of T cells to cancer patients. We do not have any products approved for sale. We have funded our operations primarily through equity financing and through upfront payments from our collaboration partners. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a team of 380 and 347 FTEs as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through December&#160;31, 2022 we have raised approximately &#8364;823.7&#160;million in total through licensing payments from our collaborators and through private and public placements of securities. We are holding Cash and cash equivalents and Other financial assets of &#8364;362.2&#160;million as of December&#160;31, 2022. We believe that we have sufficient capital resources to fund our operations through at least the next 12 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred net losses, which have been significant in recent years. Despite the net income that we generated within the year ended December&#160;31, 2022, we expect to continue to incur significant expenses and increasing net losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for and commercialize our product candidates. Our future profitability will be dependent upon the successful development, approval and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability and, unless and until we do, we will continue to need to raise additional capital. Our net losses may fluctuate significantly from year to year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Impact of the <span style="white-space:nowrap">COVID-19</span> Pandemic </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus <span style="white-space:nowrap">(&#8220;COVID-19&#8221;)</span> emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With <span style="white-space:nowrap">COVID-19</span> vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of <span style="white-space:nowrap">COVID-19</span> will not result in a negative impact of the Group&#8217;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#8217;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Russian-Ukraine Conflict and macroeconomic environment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Operating Results </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue from Collaboration Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue from the sale of pharmaceutical products. Our revenue has been solely derived from our collaboration agreements, such as with BMS and Genmab. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue from collaboration agreements consists of upfront payments as well as reimbursement of research and development expenses. Upfront payments allocated to the obligation to perform research and development services are initially recorded on our statement of financial position as deferred revenue and are subsequently recognized as revenue on a <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-cost</span></span> measurement basis, in accordance with our accounting policy as described further under &#8220;E. Critical Accounting Estimates.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, we grant exclusive licensing rights for the development and commercialization of future product candidates, developed for specified targets defined in the respective </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaboration agreement. We carry out our research activities using our proprietary technology and <span style="white-space:nowrap">know-how,</span> participate in joint steering committees, and prepare data packages. In three of our four current collaboration agreements, these commitments represent one combined performance obligation, because the research activities are mutually dependent and the collaborator is unable to derive significant benefit from our access to these targets without our research activities, which are highly specialized and cannot be performed by other organizations. For the collaboration signed with BMS in December 2021, we identified two separate performance obligations, because the license is a distinct obligation and the clinical trial services will not result in a modification of the license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collaboration agreements resulted in &#8364;399.2&#160;million of upfront cash payments through December&#160;31, 2022. As part of the agreements, we contribute our XPRESIDENT and other technologies, as well as commit to participating in joint research activities. In addition, we agree to license certain target rights and the potential product candidates developed under the collaboration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under each of our collaboration agreements, we are entitled to receive payments for certain development and commercial milestone events, in addition to royalty payments upon successful commercialization of a product. The uncertainty of achieving these milestones significantly impacts on our ability to generate revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from sales of pharmaceutical products and to become profitable depends on the successful commercialization of product candidates by us and/or by our collaboration partners. In the foreseeable future, we do not expect revenue from product sales. To the extent that existing or potential future collaborations generate revenue, our revenue may vary due to many uncertainties in the development of our product candidates and other factors. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of personnel-related costs (including share-based compensation) for the various research and development departments, intellectual property (&#8220;IP&#8221;) expenses, facility-related costs and amortization as well as direct expenses for clinical and preclinical programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core business is focused on the following initiatives with the goal of providing novel <span style="white-space:nowrap">TCR-based</span> immunotherapies to cancer patients: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Realize the full multi-cancer opportunity of PRAME by (1)&#160;focusing and accelerating the development of our ACTengine IMA203 <span style="white-space:nowrap">TCR-T</span> towards pivotal trials, (2)&#160;expanding the patient population that might benefit from a PRAME-targeting therapy by developing an <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> biologic TCER IMA402 and (3)&#160;expanding beyond <span style="white-space:nowrap">HLA-A*02</span> by investigating new <span style="white-space:nowrap">target-TCR</span> pairs for PRAME epitopes binding to other HLA types; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Advance our pipeline of innovative ACTengine <span style="white-space:nowrap">TCR-T</span> product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Advance our pipeline of next-generation, half-life extended TCR Bispecifics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enhance the commercial opportunities of cell therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Further enhance our cell therapy manufacturing capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Leverage the full potential of strategic collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Strengthen our intellectual property portfolio; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enhance the competitive edge of our technology platforms. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research and development costs are expensed as incurred due to scientific uncertainty. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially in the future as we advance existing and future proprietary product candidates into and through clinical studies and pursue regulatory approval. The process of conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming. We expect to increase our headcount to support our continued research activities and to advance the development of our product candidates. Clinical studies generally become larger and more costly to conduct as they advance into later stages and, in the future, we will be required to make estimates for expense accruals related to clinical study expenses. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any product candidates that we develop from our programs. Our research and development programs are at an early stage. We must demonstrate our products&#8217; safety and efficacy through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our products, including but not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after reviewing trial results, we or our collaborators may abandon projects previously believed to be promising; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, our collaborators, or regulators may suspend or terminate clinical trials if the participating subjects or patients are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our potential products may not achieve the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturers may not meet the necessary standards for the production of the product candidates or may not be able to supply the product candidates in a sufficient quantity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may find that our clinical trial design or conduct does not meet the applicable approval requirements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safety and efficacy results in various human clinical trials reported in scientific and medical literature may not be indicative of results we obtain in our clinical trials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is very expensive, can take many years, and the outcome is uncertain. It could take several years before we learn the results from any clinical trial using ACT or TCR Bispecifics. The data collected from our clinical trials may not be sufficient to support approval by the FDA, the EMA or comparable regulatory authorities of our ACT or TCR Bispecific product candidates for the treatment of solid tumors. The clinical trials for our products under development may not be completed on schedule and the FDA, EMA or regulatory authorities in other countries may not ultimately approve any of our product candidates for commercial sale. If we fail to adequately demonstrate the safety and effectiveness of any product candidate under development, we may not receive regulatory approval for those product candidates, which would prevent us from generating revenues or achieving profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related costs (including share-based compensation) for finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs. These costs relate to the operation of the business, unrelated to the research and development function or any individual program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to our planned increase in research and development activities as explained above, we also expect that our general and administrative expenses might increase. We might incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs. Additionally, if and when a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and expenses as a result of our preparation for commercial operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financial Result </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial result consists of both financial income and financial expenses. Financial income results primarily from foreign exchange gains. Our financial expenses consist of interest expenses related to lease liabilities, foreign exchange losses and expected credit losses. Additionally, our warrants are classified as Liabilities for warrants. The change in fair value of warrant liabilities consists of the change in fair value of these warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2022 and December&#160;31, 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated statements of operations for each year presented: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(Euros&#160;in&#160;thousands,&#160;except&#160;share<br />and per share data)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106,779</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(87,574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33,808</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating result</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,954</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(86,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,675</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,726</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial result</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,082</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,041</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Profit/(loss) before taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">42,036</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(93,335</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,522</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net profit/(loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,514</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(93,335</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net profit/(loss) per share:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue from Collaboration Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our collaboration revenue for the years indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue from collaboration agreements:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen, United States</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genmab, Denmark</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMS, United States</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK, United Kingdom</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">172,831</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,763</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue from collaboration agreements increased from &#8364;34.8&#160;million for the year ended December&#160;31, 2021 to &#8364;172.8&#160;million for the year ended December&#160;31, 2022. The increase in revenue of &#8364;138.0&#160;million mainly resulted from the collaborations with BMS. Our revenue from collaboration agreements with BMS includes the revenue related to the <span style="white-space:nowrap"><span style="white-space:nowrap">right-to-use</span></span> license for IMA401 amounting to &#8364;91.3&#160;million and &#8364;34.8&#160;million revenue recognized on a <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-cost</span></span> method. The revenue from collaboration agreements with GSK includes &#8364;33.4&#160;million, which resulted from the termination of the collaboration with GSK. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not achieve any milestones or receive any royalty payments in connection with our collaboration agreements during the presented years.</p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses for the years indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Direct external research and development expenses by program:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACT Programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,897</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCR Bispecifics Programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,318</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,679</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,552</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,114</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Sub-total&#160;direct</span> external expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(30,147</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(24,690</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indirect research and development expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (excluding share-based compensation)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,356</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,925</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,564</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,165</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility and depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,024</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,325</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other indirect expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,162</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Sub-total&#160;indirect</span> expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(76,632</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(62,884</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(106,779</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(87,574</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses for our ACT programs increased from &#8364;14.9&#160;million for the year ended December&#160;31, 2021 to &#8364;17.3&#160;million for the year ended December&#160;31, 2022. This increase mainly resulted from expanded activities in our clinical trials, which was the result in part of a growing number of patients recruited. Direct external research and development expenses for our TCR Bispecifics programs increased from &#8364;6.7&#160;million for the year ended December&#160;31, 2021 to &#8364;7.3&#160;million for the year ended December&#160;31, 2022. This increase mainly resulted from additional activities in our preclinical studies for IMA402. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses for our other programs such as technology platforms and collaboration agreements increased from &#8364;3.1&#160;million for the year ended December&#160;31, 2021 to &#8364;5.6&#160;million for the year ended December&#160;31, 2022. This increase mainly resulted from increased activities for our IMA401 collaboration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not allocate indirect research and development expenses by program, as our research and development personnel work across programs. Our IP expenses are incurred for the protection of cancer antigen targets, T cell receptors, antibodies, bispecific molecules, and antigen discovery platforms which are beneficial to the whole research and development group rather than for specific programs. Our programs use common research and development facility and laboratory equipment, and we also incur other costs such as general laboratory material or maintenance expenses that are incurred for commonly used activities within the whole research and development group. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel-related expenses increased from &#8364;25.5&#160;million for the year ended December&#160;31, 2021 to &#8364;39.4&#160;million for the year ended December&#160;31, 2022. This increase resulted from our headcount growth due to our increased research and development activities including clinical trials. Share-based compensation expenses decreased from &#8364;15.6&#160;million for the year ended December&#160;31, 2021 to &#8364;12.9&#160;million for the year ended </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&#160;31, 2022, mainly due to the fact that certain awards granted as part of the ARYA Merger have fully vested. IP expenses increased from &#8364;9.7&#160;million for the year ended December&#160;31, 2021 to &#8364;10.2&#160;million for the year ended December&#160;31, 2022 due to our ongoing expansion of our IP portfolio. Facility and depreciation expenses increased from &#8364;5.3&#160;million for the year ended December&#160;31, 2021 to &#8364;7.0&#160;million for the year ended December&#160;31, 2022. This increase resulted from the acquisition of laboratory equipment and leasehold improvements. Other indirect expenses increased from &#8364;6.8&#160;million for the year ended December&#160;31, 2021 to &#8364;7.2&#160;million for the year ended December&#160;31, 2022. This increase resulted from our expanded research and development activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses for the years indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,839</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (excluding share-based compensation)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,278</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,641</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,805</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other external general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,524</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(36,124</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(33,808</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased from &#8364;33.8&#160;million for the year ended December&#160;31, 2021 to &#8364;36.1&#160;million for the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses decreased from &#8364;10.8&#160;million for the year ended December&#160;31, 2021 to &#8364;9.6&#160;million for the year ended December&#160;31, 2022. Shared-based compensation expenses decrease over time mainly due to the fact that certain awards granted as part of the ARYA Merger have fully vested. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel related general and administrative expenses, excluding share-based compensation, increased from &#8364;8.6&#160;million for the year ended December&#160;31, 2021 to &#8364;11.3&#160;million for the year ended December&#160;31, 2022. The increase mainly resulted from an increased headcount in our finance, IT, human resources and communications functions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Professional and consulting fees decreased from &#8364;6.8&#160;million for the year ended December&#160;31, 2021 to &#8364;6.2&#160;million for the year ended December&#160;31, 2022. The decrease in professional and consulting fees resulted mainly from lower legal and consulting expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other external expenses increased from &#8364;7.5&#160;million for the year ended December&#160;31, 2021 to &#8364;9.0&#160;million for the year ended December&#160;31, 2022. The increase in other expenses mainly resulted from increased insurance payments, depreciation and facility expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in fair value of warrant liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of warrants decreased from &#8364;3.88 per warrant as of December&#160;31, 2021 to &#8364;2.35 per warrant as of December&#160;31, 2022. The result is a decrease in fair value of warrant liabilities of &#8364;10.9&#160;million and a corresponding income for the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, there were 7,187,500 warrants outstanding, which were classified as financial liabilities through profit and loss. The warrants entitle the holder to purchase one ordinary share at an exercise price of $11.50 per share. The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation in accordance with their terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Financial Income and Other Financial Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other financial income increased from &#8364;5.7&#160;million for the year ended December&#160;31, 2021 to &#8364;9.4&#160;million for the year ended December&#160;31, 2022. The increase mainly resulted from higher interest income and foreign exchange gains. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other financial expenses increased from &#8364;1.7&#160;million for the year ended December&#160;31, 2021 to &#8364;8.3&#160;million for the year ended December&#160;31, 2022. The increase mainly resulted from higher foreign exchange losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_21">B. Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sources of Liquidity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exception of the year ended December&#160;31, 2022, we have incurred losses since inception. We have a positive cash flow from operations for the year ended December&#160;31, 2022 due to upfront payments in connection with the closing of the BMS collaboration agreements. We have negative cash flows from operations for the year ended December&#160;31, 2021 and December&#160;31, 2020. For the year ended December&#160;31, 2022, we had an accumulated deficit of &#8364;500.3&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily from public offerings and private placements of our ordinary shares, upfront payments from collaborations agreements, and the net proceeds generated from the ARYA Merger and PIPE Financing that closed on July&#160;1, 2020 and our public offering in October 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents increased from &#8364;133.0&#160;million for the year ended December&#160;31, 2021 to &#8364;148.5&#160;million for the year ended December&#160;31, 2022. We received &#8364;212.4&#160;million in connection with the strategic collaboration agreements with BMS and &#8364;106.2&#160;million from a public offering of 10,905,000 ordinary shares during the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our existing Cash, cash equivalents and Other financial assets will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We may consider raising additional capital to pursue strategic investments, to take advantage of financing opportunities or for other reasons. Additionally, in 2021, we established an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> (&#8220;ATM&#8221;) offering program pursuant to which we may, from time to time, issue and sell shares that have an aggregate offering price of $100&#160;million. During the year ended December&#160;31, 2022, 2.8&#160;million shares were sold under the ATM agreement with SVB Securities LLC, resulting in a gross amount of &#8364;20.8&#160;million ($21.3 million). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to utilize the existing Cash, cash equivalents and Other financial assets on hand primarily to fund our operating activities associated with our research and development initiatives to continue or commence clinical trials and seek regulatory approval for our product candidates. We also expect to make capital expenditures in the near term related to the expansion of our laboratory spaces in T&#252;bingen, Germany and our new GMP manufacturing facility in Houston metropolitan area, Texas and expect to continue investing in laboratory and manufacturing equipment and operations to support our anticipated growth. Cash in excess of immediate requirements is invested in accordance with our investment policy with an emphasis on liquidity and capital preservation and consist primarily of cash in banks, short-term deposits and AAA rated bonds. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contractual obligations as of December&#160;31, 2022 include lease obligations for lease liabilities of &#8364;18.6&#160;million, reflecting our future minimum commitments for our office, manufacturing and laboratory spaces in T&#252;bingen, Munich and Houston, as well as other lease obligations of &#8364;4.9&#160;million, reflecting our future minimum commitments for our new office and laboratory spaces in T&#252;bingen and Munich which are not reflected on our balance sheet on which we committed in 2022 and will be effective in the year 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, &#8364;4.3&#160;million of the committed lease payments associated with lease liabilities and other lease obligations will occur in the next 12 months. The remaining lease payments of &#8364;19.2&#160;million will occur between January&#160;1, 2023 and April&#160;30, 2033. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally provide us with the option to cancel, reschedule, and adjust our requirements based on our business needs prior to the delivery of goods or performance of services. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flows </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each year presented: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net cash provided by / (used in):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8364;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(209,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,613</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,050</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#8364;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(79,866</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">See Note 2 of the Notes to the Consolidated Financial Statements of Immatics N.V. for details regarding the revision of prior year numbers as a result of a correction in presentation of net foreign exchange differences and effects of exchange rate changes on cash and cash equivalents </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We primarily derive cash from our collaboration agreements. Our cash used in operating activities is significantly influenced by our use of cash for operating expenses and working capital to support the business. Historically we experienced negative cash flows from operating activities as we have invested in the development of our technologies in our clinical and preclinical development of our product candidates. During the year ended December&#160;31, 2022, our cash flows from operating activities was positive, as we received upfront payments from our collaboration partner BMS under the BMS IMA401 collaboration agreement, the allogeneic ACT agreement and the amendment to the autologous ACT agreement amounting to &#8364;212.4&#160;million partly offset by ongoing expenses for research and development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash inflow from operating activities for the year ended December&#160;31, 2022 was &#8364;100.1&#160;million. This was comprised of a profit before tax of &#8364;42.0&#160;million, a decrease in working capital of &#8364;37.3&#160;million, &#8364;22.6&#160;million by <span style="white-space:nowrap">non-cash</span> charges from equity settled share-based compensation expenses for employees, depreciation and amortization charge of &#8364;7.0&#160;million and net foreign exchange differences and expected credit losses of &#8364;2.9&#160;million, partly offset by a <span style="white-space:nowrap">non-cash</span> income of &#8364;10.9&#160;million related to the change in fair value of the warrants and other effects of &#8364;0.8&#160;million. The decrease in working capital mainly resulted from a increase in accounts payable and other liabilities of &#8364;45.6&#160;million, partly offset by an increase in accounts receivable of &#8364;0.4&#160;million and an increase in other assets and prepayments of &#8364;7.9&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash outflow from operating activities for the year ended December&#160;31, 2021 was &#8364;84.7&#160;million. This was comprised of a net loss of &#8364;93.3&#160;million, an increase in working capital of &#8364;31.7&#160;million and net foreign exchange differences of &#8364;2.4&#160;million, partly offset by a <span style="white-space:nowrap">non-cash</span> expense of &#8364;11.0&#160;million related to the change in fair value of the warrants, a partial offset of &#8364;26.4&#160;million by <span style="white-space:nowrap">non-cash</span> charges from equity settled share-based compensation expenses for employees and depreciation and amortization charge of &#8364;5.3&#160;million. The increase in working capital mainly resulted from a decrease in accounts payable and other liabilities of &#8364;31.8&#160;million and an increase in other current assets and prepayments of &#8364;0.5&#160;million, partly offset by a decrease in accounts receivable of &#8364;0.6&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net outflow of cash from investing activities for the year ended December&#160;31, 2022 was &#8364;209.8&#160;million. This consisted primarily of cash paid in the amount of &#8364;214.1&#160;million for bond and short-term deposit </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investments, that are classified as Other financial assets and held with financial institutions to finance the company, &#8364;6.2&#160;million as payment for new equipment and intangible assets, partially offset by cash received from maturity of bonds of &#8364;12.7&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net inflow of cash from investing activities for the year ended December&#160;31, 2021 was &#8364;7.5&#160;million, primarily consisted of &#8364;24.4&#160;million proceeds from maturities of investments classified as Other financial assets and held with financial institutions to finance the company, partly offset by &#8364;11.3&#160;million payments for bond investments classified as Other financial assets and held with financial institutions to finance the company and &#8364;5.6&#160;million payments for new equipment and intangible assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, our net cash provided from financing activities amounted to &#8364;123.7&#160;million. As of December&#160;31, 2022, 2.8&#160;million shares had been sold under the ATM agreement with SVB Securities LLC. In addition, the Company closed an <span style="white-space:nowrap">SEC-registered</span> offering of 10.9&#160;million ordinary shares in October 2022. The Company collected a total net amount of &#8364;126.5&#160;million. This was partially offset by the principal portion of payments in connection with lease contracts in the amount of &#8364;2.8&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, our net cash used in financing activities was &#8364;2.6&#160;million. This was mainly driven by the principal portion of payments in connection with lease contracts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operation and Funding Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have incurred significant losses due to our substantial research and development expenses. We have an accumulated deficit of &#8364;500.3&#160;million for the year ended December&#160;31, 2022. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or commence clinical trials including GMP manufacturing of, and seek regulatory approval for, our product candidates. We believe that we have sufficient financial resources available to fund our projected operating requirements for at least the next twelve months. Because the outcome of our current and planned clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. For example, our costs will increase if we experience any delays in our current and planned clinical trials. Our future funding requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical sites, enroll patients and manufacture ACT and TCR Bispecific product candidates for our ongoing, planned and potential future clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">time and cost to conduct <span style="white-space:nowrap">IND-</span> or <span style="white-space:nowrap">CTA-enabling</span> studies for our preclinical programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">time and costs required to perform research and development to identify and characterize new product candidates from our research programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">time and cost necessary to obtain regulatory authorizations and approvals that may be required by regulatory authorities to execute clinical trials or commercialize our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">our ability to successfully commercialize our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">our ability to have clinical and commercial products successfully manufactured consistent with FDA, the EMA and comparable regulatory authorities&#8217; regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">8.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">sales and marketing costs associated with commercializing our products, if approved, including the cost and timing of building our marketing and sales capabilities; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">9.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">10.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">terms and timing of our current and any potential future collaborations, licensing or other arrangements that we have established or may establish; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">11.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">cash requirements of any future acquisitions or the development of other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">12.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">costs of operating as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">13.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">time and cost necessary to respond to technological, regulatory, political and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">14.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">costs of filing, prosecuting, defending and enforcing any patent claims and other IP rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">15.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">costs associated with any potential business or product acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until we can generate sufficient revenue to finance our cash requirements, which may never happen, we may seek additional capital through a variety of means, including through public and private equity offerings and debt financings, credit and loan facilities and additional collaborations. If we raise additional capital through the sale of equity or convertible debt securities, our existing shareholders&#8217; ownership interest will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our existing shareholders. If we raise additional capital through the sale of debt securities or through entering into credit or loan facilities, we may be restricted in our ability to take certain actions, such as incurring additional debt, making capital expenditures, acquiring or licensing IP rights, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional capital through collaborations with third parties, we may be required to relinquish valuable rights to our IP or product candidates or we may be required to grant licenses for our IP or product candidates on unfavorable terms. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development efforts or we may be required to grant rights to third parties to develop and market our product candidates that we would otherwise prefer to develop and market ourselves. For more information as to the risks associated with our future funding needs, see &#8220;Risk Factors&#8212;Risks Related to Our Financial Position.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_22">C. Research and Development, Patents and Licenses, etc. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8212;A. Operating Results.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_23">D. Trend Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;Item 5. Operating and Financial Review and Prospects&#8212;A. Operating Results.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years presented, we did not have any <span style="white-space:nowrap">off-balance</span> sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_24">E. Critical Accounting Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements of Immatics for the fiscal year ending December&#160;31, 2022 have been prepared in accordance with IFRS and the interpretations of the International Financial Reporting Standards Interpretations Committee and applicable on the balance sheet date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions, which affect the value of assets and liabilities, as well as contingent assets and liabilities, as reported on the balance sheet date, and revenues and expenses arising during the fiscal year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements for the fiscal year ended December&#160;31, 2022 in accordance with IFRS required the use of estimates and assumptions by the management that affect the value of assets and liabilities&#8212;as well as contingent assets and liabilities&#8212;as reported on the balance sheet date, and revenues and expenses arising during the fiscal year. The main areas in which assumptions, estimates and the exercising of a degree of discretion are appropriate relate to the determination of revenue recognition, research and development expenses, and share-based compensation as well as income taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances, and parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Hence, our estimates may vary from the actual values. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are more fully discussed in our consolidated financial statements included in this Annual Report, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements. We have reviewed these critical accounting policies and estimates with the Audit Committee of our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition for Collaboration Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue through collaboration and license agreements and reimbursement for research and development costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration and license agreements, we may receive upfront licensing payments, milestone payments and reimbursement of research and development expenses. Such collaboration agreements also include licenses of certain of our IP to the respective collaborators. As these agreements are comprised of several commitments, it must be assessed whether these commitments are capable of being distinct within the context of the contract. For three of our four collaboration agreements, we determined that the commitments included in each agreement represented single combined performance obligations, with a single measure of progress. The performance obligation is accounted for as a performance obligation satisfied over time on a <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-cost</span></span> basis, as our collaboration partner simultaneously receives and consumes the benefit from our performance. Upfront licensing payments and reimbursement for development expenses are initially deferred on our statement of financial position and subsequently recognized as revenue over time as costs are incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our collaboration with BMS regarding <span style="white-space:nowrap">IMA-401</span> that was signed in December 2021, we concluded that the commitments from the collaboration agreement represented two distinct performance obligations. The granted license is transferred at a point in time at the effective date of the agreement and we recognized the revenue allocated to the license at the effective date. The performance obligation related to promised clinical trial services is satisfied over time. We transfer control of these agreed services over time and therefore recognize revenue over time on a <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-cost</span></span> basis. The transaction price allocated to the commitment for clinical trial services is initially deferred on our statement of financial position and subsequently recognized as revenue as costs are incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone payments are generally included in the transaction price at the amount stipulated in the respective agreement and recognized to the extent that it is highly probable that a significant reversal in the amount of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cumulative revenue recognized will not occur. To date, no milestone payment has been included in the transaction price and recognized into revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide development and manufacturing work to our collaboration partners and recognize revenue over time using an input-based method to measure progress toward complete satisfaction of the service, because the collaboration partner simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before we can use them for recognition purposes. Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which we expect to complete our performance obligations under the arrangement which includes total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on revenue recognized. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company offers a share-based compensation plan that includes PSUs and service options including a conversion of previous share-based compensation arrangements entered into by Immatics GmbH. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expenses already recorded. Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available which can be utilized against the losses. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Due to our history of loss-making over the last several years as well as our expectation for the foreseeable future, we have not recognized any deferred tax assets on tax losses carried forward despite the net income for year ended December&#160;31, 2022. Changes in the estimation of our potential to use of tax losses carried forward can have a material effect on our net income. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Issued and Adopted Accounting Pronouncement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information on the standards applied for the first time as of January&#160;1, 2022 and 2021 please refer to our consolidated financial statements as of December&#160;31, 2022. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_25"><span style="font-weight:bold">ITEM&#160;6.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_26">A. Directors and Senior Management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&#160;31, 2023, our Executive Committee consists of nine executive officers. The Executive Committee is charged with the matters concerning the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> management of the Company determined by the Board. The Board may, whether or not by rule, determine the duties with which each executive officer will be particularly charged. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table lists the names, ages as of January&#160;31, 2023 and positions of the individuals who are serving as executive officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:46%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Harpreet Singh, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Arnd Christ</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cedrik Britten, M.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Carsten Reinhardt, M.D., Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">55</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Development Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Toni Weinschenk, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Innovation Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Rainer Kramer, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Business Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Steffen Walter, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Operations Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Edward Sturchio, J.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">General Counsel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jordan Silverstein</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Head of Strategy</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Harpreet Singh, Ph.D.</span> Harpreet Singh has served as Chief Executive Officer of Immatics OpCo since 2019, as Executive Director and Member of the Board since 2021 and as President and Chief Executive Officer of Immatics US since 2015. Prior to that, Harpreet served as Immatics&#8217; Managing Director and Chief Scientific Officer since <span style="white-space:nowrap">co-founding</span> the company in 2000. Harpreet has played a leadership role in the company&#8217;s inception, strategic business development, public listing at NASDAQ in 2020 and in raising more than $550&#160;million of venture capital, IPO and public <span style="white-space:nowrap">follow-on</span> proceeds. Harpreet holds a Ph.D. in immunology from the University of T&#252;bingen and is the inventor of numerous granted patents and patent applications and <span style="white-space:nowrap">co-author</span> of numerous scientific papers in high-impact journals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Arnd Christ</span>. Arnd.&#160;Christ has served as Chief Financial Officer of Immatics OpCo since 2020 and brings nearly two decades of experience serving as CFO of both private and public biotechnology companies. Before joining Immatics, he was CFO of several companies including InflaRx N.V., Proteros Biostructure GmbH, MediGene AG, NovImmune SA, Probiodrug AG and EleGene AG. Over the cause of his career, Arnd completed a broad range of corporate transactions including an IPO, capital raises and licensing deals. Prior to serving as a CFO, he held the position of Financial Director in various corporations related to the former Hoechst Group in Germany and the UK. Arnd holds a diploma in business economics from the University of W&#252;rzburg, Germany. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cedrik M. Britten, M.D.</span> Cedrik&#160;Britten has served as Chief Medical Officer of Immatics OpCo since 2020, assuming leadership for the management and global clinical development of our adoptive cell therapy and TCR Bispecifics pipeline from first testing in humans to registration trials, including managing regulatory affairs. Cedrik served as Vice President and Head of the Oncology Cell Therapy Research Unit of GlaxoSmithKline plc from 2015 to 2020, being responsible for building the Oncology Cell Therapy Unit and driving the strategy and establishing the <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> capabilities required to research and develop innovative cell therapies in oncology. Prior to that, Cedrik served as Vice President of Research and Development of BioNTech RNA Pharmaceuticals GmbH. Cedrik holds an M.D. from the University Medical Center of the Johannes-Gutenberg University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Carsten Reinhardt, M.D., Ph.D.</span> Carsten&#160;Reinhardt has served as Chief Development Officer of Immatics OpCo since 2020 and as Chief Medical Officer from 2009 to 2020. Carsten leads Immatics&#8217; Product Development Strategy and our TCR Bispecifics platform and pipeline as well as the Immunology and Translational Development functions. Prior to joining Immatics, Carsten served as Chief Medical Officer of Micromet Inc., where he was leading the development of the Bispecific T cell Engager (BiTE) platform and was instrumental in the company becoming public on Nasdaq and in various deals and transactions finally leading to the acquisition by Amgen. Prior to this, Carsten was International Medical Leader at <span style="white-space:nowrap">Hoffmann-La</span> Roche and Head of Clinical Development of Fresenius Biotech GmbH and held various academic medical positions and worked at the University of T&#252;bingen and Max Planck Institute, Munich to complete his curriculum in Neurology. Carsten is a Visiting Professor for Pharmaceutical Medicine at the University of Basel and has <span style="white-space:nowrap">co-authored</span> more than 40 publications in peer-reviewed journals, including <span style="font-style:italic">Nature</span>, <span style="font-style:italic">Science</span>, <span style="font-style:italic">Nature Medicine</span>, <span style="font-style:italic">Lancet</span>, <span style="font-style:italic">Journal of Clinical Oncology</span>, <span style="font-style:italic">Cancer Research</span> and <span style="font-style:italic">Journal of Experimental Medicine</span>. Carsten holds an M.D. from the University of Munich and a Ph.D. in cellular immunology from the Institute of Immunology in Munich. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Toni Weinschenk, Ph.D.</span> Toni Weinschenk <span style="white-space:nowrap">co-founded</span> Immatics Opco in 2000 and is currently Chief Innovation Officer of Immatics. From 2002 to 2020, he has served in various executive positions at Immatics, including as Chief Technology Officer, as Vice President and Head of Discovery. Toni oversees all of Immatics&#8217; target discovery, bioinformatics and companion diagnostics activities as well as intellectual property. In addition, he is part of the Operational Site Team in T&#252;bingen. Toni is the inventor of Immatics&#8217; proprietary XPRESIDENT technology platform, which is enabling the discovery and validation of innovative targets for immuno-oncology. Toni Weinschenk has earned the reputation as one of the world&#8217;s leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Targets identified by XPRESIDENT<sup style="font-size:75%; vertical-align:top">&#174;</sup> have been utilized for all of Immatics therapy candidates and for the collaboration with partners in pharma and academia. Toni is an inventor on many patents and <span style="white-space:nowrap">co-authored</span> publications in the cancer immunology field in peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Science Translational Medicine and Cell Report. Toni holds a diploma in biochemistry and a Ph.D. in immunology from the University of T&#252;bingen.<span style="font-style:italic">Rainer Kramer, Ph.D.</span> Rainer&#160;Kramer has served as Chief Business Officer of Immatics OpCo since 2012. Prior, he worked at Signature Diagnostics AG where he was member of the Management Board and Chief Business Officer. He is responsible for Immatics&#8217; business development, strategic alliances and early commercial activities. During his career, he has delivered numerous strategic partnerships and license deals encompassing technology and product deals as well as equity transactions with an aggregate value of more than $10&#160;billion. Rainer has worked in research, business and corporate functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire PLC and Signature Diagnostics AG. Further to his role at Immatics, Rainer is a <span style="white-space:nowrap">non-executive</span> director on the board of iOmx Therapeutics. Rainer holds a diploma in molecular biology from the University of Regensburg and a Ph.D. in neurobiology from the <span style="white-space:nowrap">Max-Planck-Institute,</span> Martinsried, Germany. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Steffen Walter, Ph.D</span>. Steffen Walter has served as Chief Operations Officer of Immatics OpCo since March&#160;21, 2023. From 2005 to 2022, Steffen served in various executive-level positions with Immatics, including as Chief Technology Officer, Chief Scientific Officer, as Vice President Immunology and as Director and Head of Immunology. Steffen established the Immatics US operations in Houston, Texas and contributed to its fundraising, including a $20&#160;million Cancer Prevention and Research grant by the State of Texas. Steffen leads Immatics&#8217; Cell Therapy manufacturing and process development, US Operations and Administrations, as well as the Global Quality and Human Resources team. In addition to supporting the development of the XPRESIDENT technology platform, under his initial leadership, Immatics developed its XCEPTOR platforms to support the generation of <span style="white-space:nowrap">TCR-based</span> therapeutic modalities. Steffen is an inventor on numerous patents and patent applications and has <span style="white-space:nowrap">co-authored</span> more than 30 publications in peer-reviewed journals, including <span style="font-style:italic">Nature</span> <span style="font-style:italic">Medicine</span>, <span style="font-style:italic">Cell Reports</span>, <span style="font-style:italic">Lancet</span> <span style="font-style:italic">Oncology</span>, <span style="font-style:italic">Brain</span> and <span style="font-style:italic">Blood</span>. Steffen holds a diploma in biochemistry and a Ph.D. in immunology from the University of T&#252;bingen. Effective as of March&#160;21, 2023, Dr.&#160;Walter&#8217;s title has changed to Chief Operating Officer. In addition to continuing to lead our cell therapy manufacturing, process development and quality functions, Dr.&#160;Walter will oversee global Human Resource functions, the construction of our lab, office and GMP cell therapy manufacturing facility and other U.S. facilities and operational matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of March&#160;21, 2023, the Board of Directors has appointed Edward Sturchio, General Counsel and Corporate Secretary and Jordan Silverstein, Head of Strategy, executive officers of the Company. As executive officers, they serve on the Executive Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Edward Sturchio, J.D.</span> Mr.&#160;Sturchio joined the Company in June 2020 and is responsible for all legal and compliance matters within the organization. He brings over 20 years of expertise as an accomplished executive and lawyer, with an extensive background in corporate, securities and life sciences matters. He previously served as SVP, General Counsel and Corporate Secretary of Abeona Therapeutics Inc. from July 2019 to February 2020. Prior to Abeona, he served as Global General Counsel and Corporate Secretary of Advanced Accelerator Applications S.A., a Novartis company (AAA), from February 2016 to August 2018, where he was responsible for worldwide legal, compliance and intellectual property functions across 22 sites in 13 countries. Before joining AAA, he worked in the Corporate&#160;&amp; Securities and Life Sciences departments of Greenberg Traurig LLP </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Day Pitney LLP. Mr.&#160;Sturchio has written and lectured extensively in the corporate and life sciences areas. Mr.&#160;Sturchio holds a J.D. from Seton Hall University School of Law and a B.A. in psychology from Villanova University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jordan Silverstein.</span> Mr.&#160;Silverstein joined Immatics in September 2019. He oversees the Investor Relations / Corporate Communications department of the organization. Mr.&#160;Silverstein has significant public markets experience, previously serving from September 2018 to August 2019 as Head of Corporate Strategy and Development at InflaRx, a German company publicly listed at NASDAQ and from May 2014 to August 2018, as the Global Head of Investor Relations at Advanced Accelerator Applications which he helped to take successfully public on NASDAQ, and through multiple financing rounds. The company was subsequently acquired by Novartis. Mr.&#160;Silverstein holds a Bachelors in Business Administration and Finance from Champlain College. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of nine members, comprised of one executive director and eight <span style="white-space:nowrap">non-executive</span> directors. Each of our directors holds office for the term set by our general meeting (as set forth in the table below), except in the case of his or her earlier death, resignation or dismissal. Our articles of association do not impose a mandatory retirement age. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, our Board is charged with the management of the company, which includes setting the Company&#8217;s policies and strategy, subject to the restrictions contained in our articles of association. Our executive director manages our <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business and operations and implement our strategy. Our Board is also entitled to represent the Company. Our <span style="white-space:nowrap">non-executive</span> directors focus on the supervision on the policy and functioning of the performance of the duties of all of our directors and our general state of affairs. Our directors may divide their tasks among themselves in or pursuant to internal rules. Each directors has a statutory duty to act in the corporate interest of our company and its business. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of our company also applies in the event of a proposed sale or <span style="white-space:nowrap">break-up</span> of our company, provided that the circumstances generally dictate how such duty is to be applied and how the respective interests of various groups of stakeholders should be weighed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists our current directors, as well as their ages as of January&#160;31, 2023, term served, the year of expiration of their term as directors and position: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:21%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Term&#160;Served</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year&#160;in&#160;which<br />Term Expires</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Harpreet Singh, Ph.D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">48</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Executive director and Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Peter Chambr&#233;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">67</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director and Chairman</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Michael G. Atieh</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">69</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Paul R. Carter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">62</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Eliot Forster, Ph.D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">56</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">September&#160;14,&#160;2020&#160;&#8211;&#160;Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Friedrich&#160;von&#160;Bohlen&#160;und&#160;Halbach,&#160;Ph.D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">60</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">June&#160;17, 2021 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Heather L. Mason</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">62</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Adam Stone</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">43</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">July&#160;1, 2020 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Nancy Valente</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">64</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">March&#160;22, 2022 &#8211; Present</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">Mathias Hothum, Ph.D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">55</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">&#8212;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">&#8212;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Non-executive</span> director nominee</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Harpreet Singh, Ph.D.</span> Harpreet Singh has served as Chief Executive Officer of Immatics Opco since 2019, as Executive Director and Member of the Board since 2021 and as President and Chief Executive Officer of Immatics US since 2015. Prior to that, Harpreet served as Immatics&#8217; Managing Director and Chief Scientific Officer since <span style="white-space:nowrap">co-founding</span> the company in 2000. Harpreet has played a leadership role in the company&#8217;s inception, strategic business development, public listing at NASDAQ in 2020 and in raising more than $550&#160;million of venture capital, IPO and public <span style="white-space:nowrap">follow-on</span> proceeds. Harpreet holds a Ph.D. in immunology from the University of T&#252;bingen and is the inventor of numerous granted patents and patent applications and <span style="white-space:nowrap">co-author</span> of numerous scientific papers in high-impact journals. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Peter Chambr&#233;</span>. Peter&#160;Chambr&#233; has served as Chairman of the Board of Directors of Immatics OpCo from 2012 to 2020. After Immatics IPO in 2020, Peter Chambr&#232; became Chairman of our Board of Immatics N.V.. From 2002 to its acquisition in 2006, Mr.&#160;Chambr&#233; served as Chief Executive Officer of Cambridge Antibody Technology Group plc. Prior to that, he served as Chief Operating Officer of Celera Genomics Group and as Chief Executive Officer of Bespak plc. In addition to serving on our Board, Peter&#160;Chambr&#233; serves on the board of directors of Cancer Research UK (Trustee), Our Future Health (Trustee) and has previously served as chairman of the board of directors of OneMed AB, Xellia Pharmaceuticals AS and ApaTech Ltd. and has previously served on the board of directors of UDG Healthcare plc, Touchstone Innovations plc, Spectris plc and BTG plc. Peter&#160;Chambr&#233; holds a B.Sc. in food science from the University of Reading. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Michael G. Atieh</span>. Michael G.&#160;Atieh has served as a member of Immatics supervisory board since 2020 and, after the implementation of its <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. From 2014 until his retirement in 2016, he served as Executive Vice President, Chief Financial and Business Officer of Ophthotech Inc. Prior to that, he served as Executive Chairman of Eyetech Inc., as Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals, as Group President &#8211; Global Business Unit and as Senior Vice President and Chief Financial Officer of Cegedim Inc., and in various executive-level positions over a <span style="white-space:nowrap">19-year</span> period at Merck and Co., Inc., including as Vice President &#8211; U.S. Human Health, Senior Vice President - Merck Medco Managed Care, Vice President - Public Affairs, Vice President &#8211; Government Relations, and Treasurer. In addition to serving on Immatics Board, Michael G.&#160;Atieh serves on the board of directors of Chubb Limited and has previously served on the board of directors of electroCore Inc., Oyster Point Pharma, Inc, Theravance BioPharma, Eyetech Inc. and OSI Pharmaceuticals. Michael G.&#160;Atieh holds a B.A. in accounting from Upsala College. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Paul R. Carter, FCMA.</span> Paul R.&#160;Carter has served as a member of Immatics&#8217; supervisory board since 2020 and, after the implementation of its <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. From 2014 to 2016, Paul R.&#160;Carter served as Executive Vice President, Commercial Operations of Gilead Sciences, Inc. Prior to that, he served as Senior Vice President and Head, International Commercial Operations of Gilead Sciences, Inc. and in various senior positions over a <span style="white-space:nowrap">10-year</span> period at GlaxoSmithKline plc, including as Regional Vice President, China&#160;&amp; Hong Kong, Vice President and General Manager, Pharmaceutical&#160;&amp; Consumer Health, Hong Kong&#160;&amp; South China, and General Manager, SmithKline Beecham Consumer Health, Russia&#160;&amp; CIS. In addition to serving on Immatics Board, Paul R.&#160;Carter serves on the board of directors of Evox Therapeutics Ltd, HUTCHMED (China) Ltd. and VectivBio Holding AG and as Board Observer at Echosens SA. Paul R. Carter has previously served on the board of directors of Alder Biopharmaceuticals Inc and Mallinckrodt PLC. He also serves as an advisor to Astorg Partners SAS, ZambonGroup, Indegene Inc. and GLG Institute. Paul R.&#160;Carter holds a B.A. in business studies from the University of West London. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eliot Forster, Ph.D.</span> Eliot&#160;Forster has served as a member of Immatics supervisory board since 2020 and, after the implementation of its <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. Since 2018, Eliot&#160;Forster is Chief Executive Officer of <span style="white-space:nowrap">F-star</span> Therapeutics Ltd. and is <span style="white-space:nowrap">non-executive</span> Chairman of Avacta plc. He has previously served as Chief Executive Officer of Immunocore Ltd, Creabilis SA and Solace Pharmaceuticals Inc. From 2012 to 2020, he has been founding Chairman of MedCity. He is an honorary visiting Professor of Molecular and Clinical Cancer Medicine at the University of Liverpool and an honorary international visiting Professor at the University of Pavia He is also Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board.&#160;Forster holds a B.Sc. in physiology from the University of Liverpool, an M.B.A. from Henley Business School and a Ph.D. in neurophysiology from the University of Liverpool. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Friedrich von Bohlen und Halbach, Ph.D. </span>Dr.&#160;Friedrich von Bohlen und Halbach has served on the Board of Directors of Immatics from 2006 to 2020 and <span style="white-space:nowrap">re-joined</span> as a member of Immatics supervisory board in June 2021 and, after the implementation of our <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. Friedrich von Bohlen und Halbach is <span style="white-space:nowrap">co-founder</span> and CEO of Molecular Health GmbH. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Friedrich von Bohlen und Halbach holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. In 1997 he founded LION bioscience AG whose CEO he was for seven years. In 2005, Friedrich von Bohlen und Halbach was <span style="white-space:nowrap">co-founder</span> and from 2005 until 2022 managing director dievini Hopp BioTech Holding GmbH&#160;&amp; Co. KG., the company managing the life science activities and investments of Dietmar Hopp, <span style="white-space:nowrap">co-founder</span> of SAP, and his family. He is Chairman of the Board of Apogenix AG and InnoSource Ventures AG, as well as board member of Heidelberg Pharma AG. Friedrich von Bohlen and Halbach has served on the Board of Directors of AC Immune SA, Lausanne and CureVac N.V. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Heather L. Mason.</span> Heather L. Mason has served as a member of our supervisory board since 2020 and, after the implementation of our <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. From 1990 to 2017, Heather L.&#160;Mason served in various leadership positions at Abbott Laboratories, Inc., including as Executive Vice President, Corporate Officer of Abbott Nutrition and as Senior Vice President, Corporate Officer of Abbott Diabetes Care. In addition to serving on Immatics Board, Heather L.&#160;Mason serves on the board of directors of Assertio Therapeutics, Inc., ConvaTec Group plc, Pendulum Therapeutics, Inc. and SCA Pharmaceuticals, LLC. She holds a B.S.E. from the University of Michigan, Ann Arbor and an M.B.A. from the University of Chicago. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Adam Stone</span>. Adam&#160;Stone has served as a member of Immatics&#8217; supervisory board since 2020 and, after the implementation of our <span style="white-space:nowrap">one-tier</span> board structure as of July&#160;1, 2021, currently serves as a <span style="white-space:nowrap">non-executive</span> director. Since 2012, Adam&#160;Stone has served as Chief Investment Officer of Perceptive Advisors, which he joined in 2006, and is a member of the internal investment committees of Perceptive Advisors&#8217; credit opportunities and venture funds. Prior to joining Perceptive Advisors, he was a Senior Analyst at Ursus Capital, where he focused on biotechnology and specialty pharmaceuticals. In addition to serving on Immatics&#8217; Board, Mr.&#160;Stone serves on the board of directors of Solid Biosciences Inc., Renovia Inc., LianBio, Xontogeny LLC, PROMETHERA Biosciences S.A./N.V., ARYA Sciences Acquisition Corp. IV and ARYA Sciences Acquisition Corp. V. Adam&#160;Stone holds a B.A. in molecular biology from Princeton University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nancy Valente.</span> Nancy Valente joined Immatics board of directors in March 2022. Nancy Valente has more than 20 years of experience in the pharmaceutical and biotech industry. From 2019 to 2021, Nancy Valente served as Senior Vice President and <span style="white-space:nowrap">Co-lead</span> for Global Product Development, Oncology, Hematology at Genentech-Roche. In this role, she was responsible for setting the global strategy for the department, clinical development, collaboration activities, and budget management. She played a critical role in the development of new therapies for patients with serious illnesses, including the approvals of GAZYVA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, VENCLEXTA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, POLIVY<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and HEMLIBRA<sup style="font-size:75%; vertical-align:top">&#174;</sup>. From 2003-2019, she held various positions with increasing responsibilities at Genentech and Roche, including Vice President Hematology Franchise and Senior Group Medical Director, Leader for Hematology Development. Prior to Genentech, she served in senior-level positions at Anosys, Inc. and Coulter Pharmaceutical, Inc. Nancy Valente has held an academic position at the University of California, San Francisco (UCSF) specializing in breast cancer. She received her medical degree from the University of Missouri and completed her internal medicine training at Oregon Health&#160;&amp; Science University, followed by fellowships in Hematology at Stanford University and Oncology at UCSF. She is currently a board member for Myovant and Xenor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mathias Hothum, Ph.D.</span> Pursuant to dievini&#8217;s rights under the business combination in 2020, dievini has designated Mathias Hothum, Ph.D. for election as a director at the 2023 annual general meeting of the shareholders in June 2023, as successor to Friedrich von Bohlen und Halbach, Ph.D. Dr. Hothum has been the Managing Director of dievini Hopp Biotech Holding since 2012, which manages the life science activities and investments of Dietmar Hopp and his family. He is also the Managing Director of several investment and consulting companies. Dr. Hothum holds a PhD in Pharmaceutical Economics and Medical Sociology from the University of Magdeburg, Germany. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Arrangements and Understandings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our Board were designated pursuant to agreements relating to the ARYA Merger. Specifically, each of Michael G. Atieh and Adam Stone is a designee of ARYA Sponsor and the <span style="white-space:nowrap">pre-Business</span> Combination independent directors of ARYA and each of Paul R. Carter and Dr.&#160;Friedrich von Bohlen und Halbach is a designee of dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG. Pursuant to the Investor Rights and <span style="white-space:nowrap">Lock-Up</span> Agreement, certain of our shareholder continue to have director nomination rights. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;Related Party Transactions.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board values diversity among its members. Our nominating and corporate governance committee, within the purview of its mandate, has the responsibility to take diversity into consideration as part of the overall director selection and nomination processes and to make the identification of diverse candidates a search criterion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The matrix below sets forth a summary of the diversity of our Board as of March&#160;22, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Country of Principal Executive Offices</span>: The Netherlands</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Foreign Private Issuer</span>: Yes</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Disclosure Prohibited under Home Country Law</span>: Yes</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="text-decoration:underline">Total Number of Directors</span>: 9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Part I: Gender Identity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Female</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Male</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-Binary</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Did&#160;Not&#160;Disclose</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">0</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">0</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Part II: Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Underrepresented individual in home country jurisdiction</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">LGBTQ+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Did not disclose</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The matrix below sets forth a summary of the diversity of our Board as of February&#160;1, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Country of Principal Executive Offices</span>: The Netherlands</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Foreign Private Issuer</span>: Yes</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="9"><span style="text-decoration:underline">Disclosure Prohibited under Home Country Law</span>: Yes</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="text-decoration:underline">Total Number of Directors</span>: 8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Part I: Gender Identity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Female</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Male</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-Binary</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Did&#160;Not&#160;Disclose</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">0</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">0</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Part II: Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Underrepresented individual in home country jurisdiction</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">LGBTQ+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Did not disclose</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_27">B. Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immatics OpCo became our wholly owned subsidiary upon the closing of the ARYA Merger on July&#160;1, 2020, and its senior management became our senior management. The following summarizes the compensation earned by the executive officers of Immatics OpCo for the fiscal year ended December&#160;31, 2022. This section also discusses the material elements of the executive compensation policies and decisions of Immatics OpCo and important factors relevant to an analysis of such policies and decisions. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our executive officers and is intended to place in perspective the information presented in the following tables and the corresponding narrative. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bonus scheme for the executive directors provides that the annual cash bonus payable to executive directors may not exceed 100% of the annual base gross salary and will be based upon the achievement of set financial and operating goals for the period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation of Executive Directors and other Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of compensation, including benefits in kind, accrued or paid to the executive officers of Immatics with respect to the year ended December&#160;31, 2022 is described in the table below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Harpreet&#160;Singh,&#160;Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All&#160;other&#160;executives</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Periodically-paid remuneration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,498</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,076</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Amounts paid in U.S. dollars have been converted to Euros using an average exchange rate for 2022 of 1.03867 to one U.S. dollar. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation of <span style="white-space:nowrap">Non-Executive</span> Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of compensation, including benefits in kind, accrued or paid to the <span style="white-space:nowrap">non-executive</span> directors with respect to the year ended December&#160;31, 2022 is described in the table below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(Euros in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Peter<br />Chambr&#233;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Friedrich<br />von<br />Bohlen&#160;und<br />Halbach</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Michael&#160;G.<br />Atieh</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Paul<br />Carter</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Heather&#160;L.<br />Mason</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Adam<br />Stone</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nancy<br />Valente</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Eliot<br />Forster</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board compensation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">379</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,336</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total board compensation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">258</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">246</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">232</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">229</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">217</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">217</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">220</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,715</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2020 and 2022 Stock Option and Incentive Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immatics N.V. has two share-based payment plans. In June 2020, Immatics N.V. established an initial equity incentive plan (&#8220;2020 Equity Plan&#8221;). At the annual general meeting of the shareholders held on June&#160;13, 2022, Immatics shareholders approved the Company&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). The 2022 Equity Plan allows the company to grant additional options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares</span>. Stock options and awards based on the ordinary shares of the Company may be issued under the 2020 Equity Plan for a maximum of 10,006,230 shares and under the 2022 Equity Plan for a maximum of 4,845,412 shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan Administration. </span>The Plan is administered by the Board (the &#8220;Administrator&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Certain Adjustments.</span> If there is a change in the Company&#8217;s capital structure, such as a stock dividend, stock split, reverse stock split, recapitalization, reorganization, reclassification or other similar event, the Administrator will appropriately adjust the number and kind (and the exercise or purchase price, if applicable) of ordinary shares of the Company remaining available for issuance under the Plan or subject to outstanding awards. In addition, any share limitations with respect to the Plan will be adjusted appropriately by the Administrator. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Transaction; Liquidity Event</span>. In the event of a merger, consolidation, substantial asset sale, sale of all of the shares of the Company or similar event affecting the Company in which the owners of the Company&#8217;s outstanding voting power prior to such event do not own at least a majority of the voting power of the successor or surviving entity (in each case, a &#8220;Transaction&#8221;), the parties thereto may cause the assumption or continuation of awards theretofore granted by the successor entity, or the substitution of such awards with new awards of the successor or parent entity, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties may agree. To the extent the parties to the Transaction do not provide for the assumption, continuation or substitution of awards, then upon the effective time of the Transaction, then, except as otherwise provided in the applicable award agreement, (i)&#160;all options and stock appreciation rights that are not exercisable will become fully exercisable at the time of the Transaction, (ii)&#160;awards with time-based vesting conditions or restrictions will become fully vested at the time of the Transaction, and (iii)&#160;all awards with conditions and restrictions relating to the attainment of performance goals may become vested in connection with the Transaction in the Administrator&#8217;s discretion or to the extent specified in the applicable award agreement. In the event of such a Transaction, each holder of an outstanding stock option or stock appreciation right may receive a cash payment from the Company equal to the excess of the consideration payable per share in the Transaction over the applicable exercise price per share, multiplied by the number of ordinary shares of the Company covered by the stock option or stock appreciation right (to the extent then exercisable) or be permitted to exercise their stock option or stock appreciation right (to the extent then exercisable) for a period of time prior to the termination of the Plan, as determined by the Administrator. The Company may also make or provide payment, in case or in kind, to the holders of other awards in an amount equal to the consideration payable per share in the Transaction multiplied by the number of vested ordinary shares of Company underlying such awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment; Termination. </span>The Administrator may amend or discontinue the Plan at any time. However, the Administrator cannot amend the Plan to increase the number of ordinary shares of the Company available for issuance under the Plan or to change the Plan in certain other ways without shareholder approval. The Plan cannot be amended if the amendment would materially and adversely affect any rights that an award holder has under outstanding awards, without the participant&#8217;s consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with market practice in the United States, the trading jurisdiction of our ordinary shares, and in order to further support our ability to attract and retain the right highly qualified candidates for our board of directors, we also granted share options to <span style="white-space:nowrap">non-executive</span> directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until December&#160;31, 2022, no options granted to directors and executive officers were exercised. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors and executive officers of Immatics hold the options (both vested and unvested) as of March&#160;31, 2023, assuming no changes to outstanding options: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Harpreet Singh,&#160;Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30,&#160;2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1,598,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,598,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30,&#160;2030</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">$3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">105,000 options vested as of March&#160;31, 2023, and an additional 63,000 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">168,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">264,624 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">264,624</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,783 options vested as of March&#160;31, 2023, and an additional 5,156 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">30,939</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.06</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;1, 2027</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options IV</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">121,143 options vested as of March&#160;31, 2023, and an additional 24,228 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">145,371</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.17</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">January&#160;1, 2028</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">105,000 options vested as of March&#160;31, 2023, and an additional 63,000 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">168,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">52,500 options vested as of March&#160;31, 2023, and an additional 115,500 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">168,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;09, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">135,000 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">135,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">388,000 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">388,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Arnd Christ</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;14, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;14, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;14, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">27,563 options vested as of March&#160;31, 2023, and an additional 21,437 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;14, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">27,563 options vested as of March&#160;31, 2023, and an additional 21,437 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">112,500 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Cedrik Britten, M.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options VI</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">78,608 options vested as of March&#160;31, 2023, and an additional 15,721 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">94,329</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;1, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">112,500 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Carsten Reinhardt, M.D., Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">255,000 options will vest quarterly until the options are fully vested if the performance condition shall</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be deemed satisfied in three equal tranches as follows:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">165,748 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">165,748</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,627 options vested as of March&#160;31, 2023, and an additional 3,126 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">18,753</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.06</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;1, 2027</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">90,000 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Rainer Kramer, Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">120,676 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">120,676</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">19,057 options vested as of March&#160;31, 2023, and an additional 3,811 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">22,868</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.06</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;1, 2027</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">112,500 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Toni Weinschenk, Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">255,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">68,070 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">68,070</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">6,542 options vested as of March&#160;31, 2023, and an additional 1,308 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7,850</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.06</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;1, 2027</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">112,500 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Steffen Walter, Ph.D.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Performance-based options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255,000 options will vest quarterly until the options are fully vested if the performance condition shall be deemed satisfied in three equal tranches as follows:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $1.5&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">255,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">b) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $2.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">c) One third (1/3) of the Option Shares shall satisfy the Performance Condition upon the Company&#8217;s achievement of market capitalization equal to $3.0&#160;billion prior to the Expiration Date, subject to the Optionee&#8217;s continuous Service Relationship through such date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">76,604 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">76,604</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Converted Stock options III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">7,463 options vested as of March&#160;31, 2023, and an additional 1,492 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">8,955</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1.06</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;1, 2027</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 18,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">49,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.70</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;17, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30,625 options vested as of March&#160;31, 2023, and an additional 67,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">98,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">112,500 options will vest quarterly until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;13, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Peter Chambr&#233;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Matching Stock options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">211,974 options vested fully as of July&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">211,974</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Adam Stone</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Friedrich von Bohlen und Halbach</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;17, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">10,938 options vested as of March&#160;31, 2023, and an additional 14,062 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">12.05</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;17, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Heather L. Mason</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficiary</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting date<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />options<br />outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Strike<br />price&#160;in<br />USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Michael G. Atieh</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Paul Carter</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;30, 2030</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><span style="font-weight:bold">Eliot Forster</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;14, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">15,625 options vested as of March&#160;31, 2023, and an additional 9,375 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.16</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&#160;13,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2020</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">4,688 options vested as of March&#160;31, 2023, and an additional 10,312 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;9, 2031</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">25,000 options will vest in full as of June&#160;14, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.94</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">June&#160;14, 2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Nancy Valente</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Service options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;22, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">7,500 options vested as of March&#160;31, 2023, and an additional 22,500 will vest quarterly thereafter until the options are fully vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">7.40</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;22, 2032</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_28">C. Board Practices </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director and Officer Qualifications </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not established any specific, minimum qualifications that must be met by each of our officers. However, we generally evaluate the following qualities: educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and ability to represent the best interests of our shareholders. The Nominating and Corporate Governance Committee of the Board has prepared policies regarding director qualification requirements and the process for identifying and evaluating director candidates for adoption by the Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has established three standing committees: Audit Committee, Compensation Committee and Nominating&#160;and Corporate Governance Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit Committee members include Michael G. Atieh (chair), Paul R. Carter, Nancy Valente and Heather L. Mason. Each member of the Audit Committee satisfies the &#8220;independence&#8221; requirements set forth in Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act and is financially literate and each of Michael G. Atieh and Paul R. Carter qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules. The Board has adopted Audit Committee rules, which detail the principal functions of the Audit Committee, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the independence of our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assuring the rotation of the audit partners (including the lead and concurring partners) as required by law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> all audit services and permitted <span style="white-space:nowrap">non-audit</span> services to be performed by our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations regarding the appointment or replacement of our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the compensation and oversight of the work of our independent registered public accounting firm (including resolution of disagreements between the Executive Committee and the independent auditors regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with the independent auditors and the executive officers our annual financial statements and related disclosures as well as critical accounting policies and practices used by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing all related person transactions for potential conflict of interest situations and voting with respect to all such transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">supervising the integrity of our financial reporting and the effectiveness of our internal risk management and control systems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for the receipt, retention and treatment of complaints received by the company regarding accounting, internal accounting controls or auditing matters. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation Committee members include Paul R. Carter (chair), Eliot Forster, Adam Stone and Heather L. Mason. The Board has adopted Compensation Committee rules, which detail the principal functions of the Compensation Committee, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the corporate goals and objectives relevant to the compensation of our Chief Executive Officer; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the performance of our Chief Executive Officer in light of such goals and objectives and determining and approving the compensation of the Chief Executive Officer based on such evaluation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the compensation of all other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations to the Board regarding policies and procedures for the grant of equity-based awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering our incentive-based and equity-based compensation plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retaining or obtaining the advice of outside compensation consultants, legal counsel or other advisers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management which executive compensation information should be included in our annual proxy statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and, where appropriate, making recommendations with regard to the compensation of directors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the Compensation Committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee members include Peter Chambr&#233; (chair), Eliot Forster, Friedrich von Bohlen und Halbach and Adam Stone. The Board has adopted Nominating and Corporate Governance Committee rules, which detail the principal functions of the Nominating and Corporate Governance Committee, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending criteria for Board and committee membership; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assessing the performance of individual executive directors, <span style="white-space:nowrap">non-executive</span> directors and committee members and reporting findings to the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing a plan for the succession of executive directors and <span style="white-space:nowrap">non-executive</span> directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">supervising selection criteria and appointment procedures for executive officers other than the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the Board a set of corporate governance guidelines and periodically reviewing and reassessing the adequacy of such guidelines; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management disclosure of the company&#8217;s corporate governance practices. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_29">D. Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, Immatics OpCo has a headcount of 293 employees and 210 full-time employees of whom 133 hold a doctorate degree. Of these full-time employees, 122 are employed in positions relating to research and development positions, 34 are employed in Clinical including Regulatory Affairs, and 48 are employed in Administrative Functions including Business Development and 6 in senior management positions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, Immatics US employed 148 full-time employees and 1 part-time employee, of which 27 hold doctorate degrees, 3 have the credentials of JD, and 1 has the credentials of M.D. Of these employees, 101 are employed in positions relating to research and development, 20 are employed in positions relating to Clinical, 27 are employed in administrative functions, and 1 was employed in senior management positions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never had a work stoppage, are not covered under any collective bargaining agreements nor are any of our employees represented by a labor union or works council. We believe we have good employee relations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_30">E. Share Ownership </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;A. Major Shareholders.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_31">F. Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_32"><span style="font-weight:bold">ITEM&#160;7.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_33">A. Major Shareholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to the beneficial ownership of our ordinary shares as of January&#160;31, 2023 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, known by us to beneficially own more than 5% of outstanding ordinary shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors and executive officers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares beneficially owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60 days from January&#160;31, 2023 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, we believe that the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person based on information provided to us by such person. This table is based on information supplied by our directors and officers and by Schedules 13D and Schedules 13G, if any, filed with the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of outstanding ordinary shares beneficially owned is computed based on 76,670,942 ordinary shares outstanding as of January&#160;31, 2023. Ordinary shares that a person has the right to acquire within 60 days are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated below, the business address for each beneficial owner is Immatics N.V., Paul-Ehrlich-Stra&#223;e 15, 72076 T&#252;bingen, Federal Republic of Germany. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />Ordinary&#160;Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage&#160;of<br />Ordinary&#160;Shares</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors, Executive Officers and Persons Nominated to Serve in Such Positions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">941,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnd Christ</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cedrik Britten, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Reinhardt, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">381,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toni Weinschenk, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">238,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rainer Kramer, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">291,946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steffen Walter, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204,244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Chambr&#233;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">338,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael G. Atieh</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Carter</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliot Forster, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Friedrich von Bohlen und Halbach, Ph.D..</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather L. Mason</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Stone<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Valente</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers and persons nominated to serve in such positions as a group (15 persons)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,745,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% or Greater Shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,202,356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,187,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Management Group LLP<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,957,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Indicates beneficial ownership of less than 1% of total outstanding ordinary shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Does not include any ordinary shares indirectly owned by Adam Stone as a result of his membership interest in ARYA Sciences Holdings. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">This information is based on a Schedule 13G filed with the SEC on February&#160;10, 2023 by dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG (&#8220;dievini&#8221;), <span style="white-space:nowrap"><span style="white-space:nowrap">DH-LT-Investments</span></span> GmbH <span style="white-space:nowrap"><span style="white-space:nowrap">(&#8220;DH-LT-Investments&#8221;),</span></span> <span style="white-space:nowrap">DH-Capital</span> GmbH&#160;&amp; Co. KG <span style="white-space:nowrap">(&#8220;DH-Capital&#8221;),</span> OH Beteiligungen GmbH&#160;&amp; Co. KG (&#8220;OH Beteiligungen&#8221;), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr.&#160;Friedrich von Bohlen und Halbach (&#8220;Dr.&#160;von Bohlen&#8221;), Prof. Dr.&#160;Christof Hettich (&#8220;Dr.Hettich&#8221;) and Dr.&#160;Mathias Hothum (&#8220;Dr.&#160;Hothum&#8221;), which reported shared voting and dispositive power over 17,202,356 ordinary shares. Dievini is the record holder of 14,901,384 shares, <span style="white-space:nowrap">DH-LT</span> Investments is the record holder of 726,282 shares, <span style="white-space:nowrap"><span style="white-space:nowrap">MH-LT-Investments</span></span> GmbH is the record holder of 329,521 shares, Bohlini invest GmbH is the record holder of 627,524 shares and 4H invest GmbH is the record holder of 617,645 shares, for which dievini has shared voting and dispositive power. <span style="white-space:nowrap">DH-Capital</span> and OH Beteiligungen, are collectively the holders of 100% of the limited partner interest in dievini. <span style="white-space:nowrap">DH-Capital</span> and OH Beteiligungen each hold a 50% limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons of dievini, <span style="white-space:nowrap">DH-Capital</span> and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini. The sole general partner of dievini with the authorization to represent are dievini Verwaltungs GmbH and Dr.&#160;Hothum; however, 100% of the shares of dievini Verwaltungs GmbH are held by dievini so dievini Verwaltungs GmbH is not considered to have control over dievini. The managing directors of dievini Verwaltungs GmbH are Dietmar Hopp and Dr.&#160;Hothum. Voting and dispositive decisions made within dievini Verwaltungs GmbH regarding the securities held by dievini are made by at least two managing directors acting together; however, Dietmar Hopp is entitled to represent dievini Verwaltungs GmbH solely. Therefore, in their capacity as managing directors, Dietmar Hopp and Dr.&#160;Hothum share voting and dispositive power over the shares held by dievini, and may be deemed to beneficially own such shares held by dievini; however, each of Dietmar Hopp and Dr.&#160;Hothum disclaims beneficial ownership of the shares held by dievini except to the extent of their pecuniary interests therein. The principal business address of dievini, Dietmar Hopp and Dr.&#160;Hothum is c/o dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG, Johann-Jakob-Astor Stra&#223;e 57, 69190 </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Walldorf, Germany. The principal business address of <span style="white-space:nowrap">DH-Capital</span> GmbH&#160;&amp; Co. KG and OH Beteiligungen GmbH&#160;&amp; Co. KG is Opelstra&#223;e 28, 68789 St. <span style="white-space:nowrap">Leon-Rot,</span> Germany. The principal business address of Oliver Hopp and Daniel Hopp is Johann-Jakob-Astor-Stra&#223;e 59, 69190 Walldorf, Germany. The principal business address of <span style="white-space:nowrap"><span style="white-space:nowrap">MH-LT-Investments</span></span> GmbH is <span style="white-space:nowrap">B&#252;rgermeister-Willinger-Str.</span> 3, 69190 Walldorf, Germany, the principal business address of Bohlini invest GmbH is Neuenheimer Landstr. 4, 69120 Heidelberg, Germany and the principal business address of 4H invest GmbH is Silcherstr. 6, Silcherstr. 6, Germany. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">This information is based on a Schedule 13G filed with the SEC on February&#160;14, 2023 by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker and Julian C. Baker, which reported sole voting and dispositive power over 5,187,081 ordinary shares, which is the aggregate number of ordinary shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the &#8220;Funds&#8221;). The Funds&#8217; respective general partners relinquished to Baker Bros. Advisors LP (the &#8220;Adviser&#8221;). Baker Bros. Advisors (GP) LLC (the &#8220;Adviser GP&#8221;), Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of the ordinary shares held by the Funds. The principal business address of each of the foregoing persons and entities is 860 Washington Street, 3rd Floor New York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">This information is based on a Schedule 13G filed with the SEC on February&#160;7, 2023 by Wellington Management Group LLP (&#8220;Wellington&#8221;), Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP and Wellington Group Holdings LLP, which reported shared voting and dispositive power over 5,957,794 ordinary shares. The principal business address is 280 Congress Street, Boston, MA 02210. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;1, 2023, we had approximately 57 shareholders of record of our ordinary shares. We estimate that as of February&#160;1, 2023, approximately 98.8% of our outstanding ordinary shares are held by 47 U.S. record holders. One of the U.S. shareholders of record is Cede&#160;&amp; Co., a specialist United States financial institution that processes transfers of stock certificates on behalf of the Depository Trust Company, or DTC. Cede&#160;&amp; Co. therefore is the shareholder of record for nearly all of our issued shares held by DTC participants, as our shareholders do not themselves hold direct property rights in our ordinary shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_34">B. Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of certain related party transactions we have entered into since January&#160;1, 2022 with any of our executive officers, directors or their affiliates and holders of more than 10% of any class of our voting securities in the aggregate, which we refer to as related parties, other than compensation arrangements which are described under &#8220;Item 6. Directors, Senior Management and Employees.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Nomination and Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the ARYA Merger, we granted certain registration rights to certain securityholders under the Investor Rights Agreement entered into as of the closing of the ARYA Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Investor Rights Agreements, until the fifth anniversary of the closing of the ARYA Merger, at each annual or special meeting of shareholders, (i)&#160;Perceptive Life Sciences Master Fund, Ltd, Dr.&#160;David Hung, Dr.&#160;Todd Wider and Kevin Conroy (collectively, the &#8220;ARYA Investors&#8221;) have the right, but not the obligation, to designate for election as a director two individuals to serve on our Board (one Class&#160;I director and one Class&#160;III director), and (ii)&#160;dievini Hopp BioTech holding GmbH&#160;&amp; Co. KG (&#8220;dievini&#8221;) has the right, but not the obligation, to designate for election as a director two individuals to serve on our Board (one Class&#160;I director and one Class&#160;III director), provided that the ARYA Investors&#8217; nomination rights will terminate if at any time ARYA Investors collectively own less than 5% of our then-outstanding ordinary shares and that dievini&#8217;s nomination rights will terminate if at any time dievini own less than 5% of our then-outstanding ordinary shares. Once nominated by these shareholders, our Board, is obligated to recommend such individuals for election and to include such recommendation in any proxy statement or similar document provided to our shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Investor Rights Agreement, we agreed to file, subject to customary exceptions, a Registration Statement covering all ordinary shares issued in connection with the ARYA Merger, including the private placement of ordinary shares. The Investor Rights Agreement also provides the parties with demand and &#8220;piggy-back&#8221; registration rights, subject to certain minimum requirements and customary conditions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles of association provide for certain indemnification rights for our directors and executive officers, and we entered into an indemnification agreement with each of our executive officers and directors providing for procedures for indemnification and advancements by us of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to us or, at our request, service to other entities, as officers or directors to the maximum extent permitted by Dutch law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_35">C. Interests of Experts and Counsel </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_36"><span style="font-weight:bold">ITEM&#160;8.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">FINANCIAL INFORMATION </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_37">A. Consolidated Statements and Other Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;Item 18. Financial Statements,&#8221; which contains our financial statements prepared in accordance with IFRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. For example, in September 2020, we filed an opposition and in October 2020 we commenced a cancellation proceeding against Immunocore Limited which challenges its IMMTAX trademark in various jurisdictions. In November 2020, Immunocore Limited filed counterclaims against our registered trademark IMMATICS and IMTX. Immatics received a negative opinion before the United Kingdom Intellectual Property Office in June 2022 and we have subsequently filed an appeal to the United Kingdom High Court of Justice. In addition, TaurX has filed a trademark opposition against our registered Trademark IMTX in the EU. Discovery and preliminary procedural matters remain ongoing in both matters. The results of litigation and claims cannot be predicted with certainty. As of the date of this Annual Report, we do not believe that we are party to any claim or litigation, the outcome of which would, individually or in the aggregate, be reasonably expected to have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends and Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends and have no plan to declare or pay any dividends on our ordinary shares in the foreseeable future. We currently intend to retain any earnings for future operations and expansion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we are a holding company, our ability to pay dividends will be dependent upon the financial condition, liquidity and results of operations of, and the receipt of dividends, loans or other funds from, our subsidiaries. Our subsidiaries are separate and distinct legal entities and have no obligation to make funds available to us. In addition, there are various statutory, regulatory and contractual limitations and business considerations on the extent, if any, to which our subsidiaries may pay dividends, make loans or otherwise provide funds to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, we may only pay dividends and other distributions from our reserves to the extent our shareholders&#8217; equity (<span style="font-style:italic">eigen vermogen</span>) exceeds the sum of our <span style="white-space:nowrap">paid-in</span> and <span style="white-space:nowrap">called-up</span> share capital plus the reserves we must maintain under Dutch law or our articles of association and (if it concerns a distribution of profits) after adoption of our statutory annual accounts by our general meeting from which it appears that such dividend distribution is allowed. Subject to those restrictions, any future determination to pay dividends or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributions from our reserves will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors we deem relevant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, profits will be at the disposal of the general meeting at the proposal of our Board for distribution on our ordinary shares, subject to applicable restrictions of Dutch law. Our Board is permitted, subject to certain requirements and applicable restrictions of Dutch law, to declare interim dividends without the approval of our general meeting. Dividends and other distributions shall be made payable four weeks after they have been declared unless our general meeting determines another date at the proposal of our Board. Claims to dividends and other distributions not made within five years from the date that such dividends or distributions became payable will lapse and any such amounts will be considered to have been forfeited to us (<span style="font-style:italic">verjaring</span>).<span style="font-weight:bold"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_38">B. Significant Changes </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A discussion of the significant changes in our business can be found under &#8220;Item 4. Information on the Company&#8212;A. History and Development of the Company&#8221; and &#8220;Item 4. Information on the Company&#8212;B. Business Overview.&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_39"><span style="font-weight:bold">ITEM&#160;9.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">THE OFFER AND LISTING </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_40">A. Offering and Listing Details </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;&#8212;C. Markets.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_41">B. Plan of Distribution </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_42">C. Markets </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares and warrants are listed on Nasdaq under the symbols &#8220;IMTX&#8221; and &#8220;IMTXW,&#8221; respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_43">D. Selling Shareholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_44">E. Dilution </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_45">F. Expenses of the Issue </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="tx400206_46"><span style="font-weight:bold">ITEM&#160;10.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">ADDITIONAL INFORMATION </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_47">A. Share Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_48">B. Memorandum and Articles of Association </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Exhibit 2.3 to this Annual Report for a description of our ordinary shares and articles of association. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_49">C. Material Contracts </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed in this Annual Report (including the exhibits thereto), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_50">D. Exchange Controls </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, there are no exchange controls applicable to the transfer to persons outside of the Netherlands of dividends or other distributions with respect to, or of the proceeds from the sale of, shares of a Dutch company, subject to applicable restrictions under sanctions and measures, including those concerning export control, pursuant to applicable resolutions adopted by the United Nations, regulations of the European Union, the Sanctions Act 1977 (<span style="font-style:italic">Sanctiewet 1977</span>), national emergency legislation, or other legislation, applicable anti-boycott regulations and similar rules and provided that, under certain circumstances, payments of such dividends or other distributions must be reported to the Dutch Central Bank at their request for statistical purposes. There are no special restrictions in our articles of association or Dutch law that limit the right of shareholders who are not citizens or residents of the Netherlands to hold or vote shares. The European Directive Mandatory Disclosure Rules (2011/16/EU) in relation to cross-border tax arrangements can provide for future notification requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under German law, there are no exchange controls restricting the transfer of funds between Germany and other countries or individuals subject to applicable restrictions concerning import or export control or sanctions and measures against certain persons, entities and countries subject to embargoes in accordance with German law and applicable resolutions adopted by the United Nations and the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under German foreign trade regulation, with certain exceptions, every corporation or individual residing in Germany must report to the German Central Bank on any payment received from or made to a <span style="white-space:nowrap">non-resident</span> corporation or individual if the payment exceeds &#8364;12,500 (or the equivalent in a foreign currency). Additionally, corporations and individuals residing in Germany must report to the German Central Bank on any claims of a resident against, or liabilities payable to, a <span style="white-space:nowrap">non-resident</span> corporation or individual exceeding an aggregate of &#8364;5&#160;million (or the equivalent in a foreign currency) at the end of any calendar month. Resident corporations and individuals are also required to report annually to the German Central Bank on any stakes of 10% or more they hold in the equity of <span style="white-space:nowrap">non-resident</span> corporations with total assets of more than &#8364;3&#160;million. Corporations residing in Germany with assets in excess of &#8364;3&#160;million must report annually to the German Central Bank on any stake of 10% or more in the company held by an individual or a corporation located outside Germany. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_51">E. Taxation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material U.S. Federal Income Tax Considerations for U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders (as defined below) described below of owning and disposing of our ordinary shares or warrants. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#8217;s decision to acquire ordinary shares or warrants. This discussion does not address consequences from a fundamental change (as described in the warrant terms) to a U.S. Holder of warrants. This discussion applies only to a U.S. Holder that is an initial purchaser of ordinary shares or warrants and that holds our ordinary shares or warrants as a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including state and local tax consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special rules, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mutual funds and pension plans; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates and certain former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities who use a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of tax accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding ordinary shares or warrants as part of a hedging transaction, &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive ownership transaction,&#8221; &#8220;constructive sale&#8221; or other integrated transaction for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> entities (including private foundations) or government organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulated investment companies or real estate investment trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trusts and estates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who acquired our ordinary shares or warrants pursuant to the exercise of any employee stock option or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our ordinary shares or warrants in connection with a trade or business, permanent establishment, or fixed base outside the United States; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 10% or more (by vote or value) of our outstanding ordinary shares. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares or warrants, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary shares or warrants and partners in such partnerships are encouraged to consult their tax advisors as to the particular U.S. federal income tax consequences of holding and disposing of ordinary shares or warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), administrative pronouncements, judicial decisions, final, temporary and proposed Treasury Regulations, and the income tax treaty between Germany and the United States (the &#8220;Treaty&#8221;), all as of the date hereof, changes to any of which may affect the tax consequences described herein&#8212;possibly with retroactive effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;U.S. Holder&#8221; is a person who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares and is: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) An individual who is a citizen or individual resident of the United States; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a trust if (1)&#160;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&#160;the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently released Treasury Regulations may in some circumstances prohibit a U.S. person from claiming a foreign tax credit with respect to certain <span style="white-space:nowrap">non-U.S.</span> taxes that are not creditable under applicable income tax treaties. Accordingly, U.S. investors that are not eligible for Treaty benefits should consult their tax advisers regarding the creditability or deductibility of any German taxes imposed on dividends on, or dispositions of, shares or warrants. The discussions below regarding the creditability of any German taxes do not address the foreign tax credit consequences to holders of shares or warrants that do not qualify for the benefits of the Treaty. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PERSONS CONSIDERING AN INVESTMENT IN ORDINARY SHARES OR WARRANTS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES APPLICABLE TO THEM RELATING TO THE ACQUISITION, OWNERSHIP AND DISPOSITION OF THE ORDINARY SHARES, INCLUDING THE APPLICABILITY OF U.S. FEDERAL, STATE AND LOCAL TAX LAWS. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions on Ordinary Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#8220;Passive Foreign Investment Company Rules,&#8221; distributions paid on ordinary shares, other than certain pro rata distributions of ordinary shares or rights to acquire ordinary shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in its ordinary shares. Any remaining excess will be treated as gain realized on the sale or other disposition of the ordinary shares and will be treated as described below under &#8220;Sale or Other Taxable Disposition of Ordinary Shares.&#8221; Subject to applicable limitations, amounts treated as dividend income to certain <span style="white-space:nowrap">non-corporate</span> U.S. Holders may be taxable at preferential rates applicable to &#8220;qualified dividend income&#8221; if we are a &#8220;qualified foreign corporation&#8221; and certain other requirements are met. However, the qualified dividend income treatment will not apply if we are treated as a PFIC (as defined below) with respect to the U.S. Holder or if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year. The amount of any such distribution will include any amounts withheld by us (or another applicable withholding agent), which, as described below under the heading &#8220;&#8212;Material German Tax Considerations&#8212;Taxation of Dividends,&#8221; is expected to be in respect of German income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other than cash (and other than certain pro rata distributions of ordinary shares or rights to acquire ordinary shares) will be the fair market value of such property on the date of distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For foreign tax credit limitation purposes, our dividends will generally be treated as passive category income. The rules governing foreign tax credits are complex and U.S. Holders should therefore consult their tax advisors regarding the effect of the receipt of dividends for foreign tax credit limitation purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, German income taxes withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be eligible for credit against the U.S. Holder&#8217;s federal income tax liability. German taxes withheld in excess of the rate applicable under such treaty will not be eligible for credit against a U.S. Holder&#8217;s federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders are urged to consult their tax advisors regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, a U.S. Holder may deduct foreign taxes, including any German income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale or Other Taxable Disposition of Ordinary Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#8220;Passive Foreign Investment Company Rules,&#8221; gain or loss realized on the sale or other taxable disposition of ordinary shares will be capital gain or loss, and will be long-term </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital gain or loss if the U.S. Holder held the ordinary shares for more than one year at the time of sale or other taxable disposition. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the ordinary shares disposed of and the amount realized on the disposition. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. Subject to the PFIC rules described below, long-term capital gains recognized by certain <span style="white-space:nowrap">non-corporate</span> U.S. Holders (including individuals) will generally be subject to reduced rates of U.S. federal income tax. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale or Other Taxable Disposition, Exercise or Expiration of Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#8220;Passive Foreign Investment Company Rules,&#8221; gain or loss realized on the sale or other taxable disposition of warrants (other than by way of exercise) will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder held the warrants for more than one year at the time of the sale or disposition. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the warrants disposed of and the amount realized on the disposition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a U.S. Holder will not be required to recognize income, gain or loss upon the exercise of warrants by payment of the exercise price in cash. A U.S. Holder&#8217;s tax basis in the ordinary share received upon exercise of a warrant will be equal to the sum of (1)&#160;the U.S. Holder&#8217;s tax basis in the warrant and (2)&#160;the exercise price of the warrant. It is unclear under current law whether a U.S. Holder&#8217;s holding period in the ordinary share received upon exercise will commence on the day the warrant is exercised or the day after the warrant is exercised, but in any case, it will not include the period during which the U.S. Holder held the warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we believe that it is reasonable to take the position that such exercise will not be taxable (except with respect to cash received in lieu of a fractional ordinary share), either because the exercise is not a gain realization event or because it qualifies as a <span style="white-space:nowrap">tax-free</span> recapitalization. In the former case, subject to the discussion below under &#8220;Passive Foreign Investment Company Rules,&#8221; the holding period of the ordinary shares would commence either on the day the warrant is exercised or the day after the warrant is exercised. In the latter case, the holding period of the ordinary shares would include the holding period of the exercised warrants. In either case, the U.S. Holder&#8217;s tax basis in the ordinary shares (including any fractional ordinary share) received generally would equal the U.S. Holder&#8217;s tax basis in the warrants. However, such position regarding the treatment of a cashless exercise is not binding on the Internal Revenue Service, or the IRS, and the IRS may treat a cashless exercise of a warrant as a taxable exchange. U.S. Holders are urged to consult their tax advisers as to the consequences of an exercise of a warrant on a cashless basis. The receipt of cash in lieu of a fractional ordinary share should result in a capital gain or loss equal to the difference between the cash received and the U.S. Holder&#8217;s tax basis in the ordinary shares allocable to the fractional share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a warrant expires without being exercised, a U.S. Holder will recognize a capital loss in an amount equal to such U.S. Holder&#8217;s tax basis in the warrant. This loss will be long-term capital loss if, at the time of the expiration, the U.S. Holder&#8217;s holding period in the warrant is more than one year. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each warrant provide for an adjustment to the exercise price of the warrant in certain events (including the payment of certain dividends and distributions to holders of ordinary shares). An adjustment which has the effect of preventing dilution generally is not taxable. The U.S. Holders of the warrants would, however, be treated as receiving a constructive distribution from us if, for example, the adjustment to the number of such shares or to such exercise price increases the warrant holders&#8217; proportionate interest in our assets or earnings and profits (e.g., through a decrease in the exercise price of the warrant) as a result of a distribution of cash or other property, such as other securities, to the holders of shares of our ordinary shares, or as a result of the issuance of a stock dividend to holders of shares of our ordinary shares, in each case which is taxable to the U.S. Holders of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such shares as a distribution. Such constructive distribution would be subject to tax in the same manner as if the U.S. Holders of the warrants received a cash distribution from us equal to the fair market value of such increased interest resulting from the adjustment. Generally, a U.S. Holder&#8217;s adjusted tax basis in its warrant would be increased to the extent any such constructive distribution is treated as a dividend. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Passive Foreign Investment Company Rules </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that we should be treated as a PFIC for the years ended December&#160;31, 2022 and 2021. Because the determination of our PFIC status is made annually based on the factual tests described below, however, we cannot provide any assurances regarding our PFIC status for the current or future taxable years or that the IRS will agree with our conclusion regarding our PFIC status. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a passive foreign investment company under Section&#160;1297 of the Code (a &#8220;PFIC&#8221;) in any taxable year, a U.S. Holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a <span style="white-space:nowrap">non-U.S.</span> company that does not distribute all of its earnings on a current basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">non-U.S.</span> corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules, either: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least 75% of its gross income is passive income (such as income from dividends, interest, rent, royalties and certain gains) (the &#8220;Income Test&#8221;); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for the production of passive income (the &#8220;Asset Test&#8221;). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is uncertain whether we or any of our subsidiaries, including Immatics OpCo, will be treated as a PFIC for U.S. federal income tax purposes for 2022 or for the current or any subsequent taxable year. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the Income Test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by our market capitalization value (which depends on the market price of our ordinary shares and may be volatile) and by the spending of the cash we raise in any offering, including this offering. Because PFIC status is based on our income, assets, and activities for the entire taxable year, it is not possible to determine whether we will be characterized as a PFIC for any taxable year until after the close of the relevant taxable year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns the ordinary shares (or, under proposed Treasury regulations that apply retroactively, warrants), we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the ordinary shares (or, under proposed Treasury regulations, warrants), regardless of whether we continue to meet the tests described above unless (i)&#160;we cease to be a PFIC and the U.S. Holder has made a &#8220;deemed sale&#8221; election under the PFIC rules, or (ii)&#160;the U.S. Holder makes a QEF Election (as defined below) with respect to all taxable years during such U.S. Holder&#8217;s holding period in which we are a PFIC. If the &#8220;deemed sale&#8221; election is made, a U.S. Holder will be deemed to have sold the ordinary shares (or, under proposed Treasury regulations, warrants) the U.S. Holder holds at their fair market value and any gain from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. Holder&#8217;s ordinary shares (or, under proposed Treasury regulations, warrants) with respect to which such election was made will not be treated as shares in a PFIC and the U.S. Holder will not be subject to the rules described below with respect to any &#8220;excess distribution&#8221; the U.S. Holder receives from us or any gain from an actual sale or other disposition of the ordinary shares (or, under proposed Treasury regulations, warrants). U.S. Holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if we cease to be a PFIC and such election becomes available. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each taxable year we are treated as a PFIC with respect to U.S. Holders, U.S. Holders will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; such U.S. Holder receives and any gain such U.S. Holder recognizes from a sale or other disposition (including, under certain circumstances, a pledge) of ordinary shares, unless (i)&#160;such U.S. Holder makes a QEF Election (as defined below) (which is generally not available with respect to warrants) or (ii)&#160;our ordinary shares constitute &#8220;marketable&#8221; securities, and such U.S. Holder makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election as discussed below (which is also generally not available to warrants). Distributions a U.S. Holder receives in a taxable year that are greater than 125% of the average annual distributions a U.S. Holder received during the shorter of the three preceding taxable years or the U.S. Holder&#8217;s holding period for the ordinary shares (or, under proposed Treasury regulations, warrants) will be treated as an excess distribution. Under these special tax rules: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the excess distribution or gain will be allocated ratably over a U.S. Holder&#8217;s holding period for ordinary shares (or, under proposed Treasury regulations, warrants); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount allocated to the taxable year of disposition, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount allocated to each other year will be subject to the highest tax rate in effect for that year for individuals or corporations, as appropriate, and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax liability for amounts allocated to years prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the ordinary shares or warrants cannot be treated as capital, even if a U.S. Holder holds the ordinary shares or warrants as capital assets. Under proposed Treasury regulations, if we were a PFIC during any taxable year during which a U.S. Holder held our warrants, the holding period for the ordinary shares received upon exercise of such warrants would include the holding period of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC, a U.S. Holder will generally be subject to similar rules with respect to distributions we receive from, and our dispositions of the stock of, any of our direct or indirect subsidiaries that also are PFICs, as if such distributions were indirectly received by, and/or dispositions were indirectly carried out by, such U.S. Holder. U.S. Holders should consult their tax advisors regarding the application of the PFIC rules to our subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ordinary shares. A U.S. Holder may avoid the general tax treatment for PFICs described above by electing to treat us as a &#8220;qualified electing fund&#8221; under Section&#160;1295 of the Code (a &#8220;QEF,&#8221; and such election, a &#8220;QEF Election&#8221;) for each of the taxable years during the U.S. Holder&#8217;s holding period that we are a PFIC. If a QEF Election is not in effect for the first taxable year in the U.S. Holder&#8217;s holding period in which we are a PFIC, a QEF Election generally can only be made if the U.S. Holder elects to make an applicable deemed sale or deemed dividend election on the first day of its taxable year in which the PFIC becomes a QEF pursuant to the QEF Election. The deemed gain or deemed dividend recognized with respect to such an election would be subject to the general tax treatment of PFICs discussed above. In order to comply with the requirements of a QEF Election, a U.S. Holder must receive a PFIC Annual Information Statement from us. We intend to provide the information necessary for U.S. Holders to make or maintain a QEF Election, including information necessary to determine the appropriate income inclusion amounts for purposes of the QEF Election. However, there is also no assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided. A QEF Election cannot be made with respect to the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder makes a QEF Election with respect to a PFIC, it will be taxed currently on its pro rata share of the PFIC&#8217;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is a PFIC, even if no distributions were received. Any distributions we make out of our earnings and profits that were previously included in such a U.S. Holder&#8217;s income under the QEF Election </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would not be taxable to such U.S. Holder. Such U.S. Holder&#8217;s tax basis in its ordinary shares would be increased by an amount equal to any income included under the QEF Election and decreased by any amount distributed on the ordinary shares that is not included in its income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of its ordinary shares in an amount equal to the difference between the amount realized and its adjusted tax basis in the ordinary shares, each as determined in U.S. dollars. Once made, a QEF Election remains in effect unless invalidated or terminated by the IRS or revoked by the shareholder. A QEF Election can be revoked only with the consent of the IRS. A U.S. Holder will not be currently taxed on the ordinary income and net capital gain of a PFIC with respect to which a QEF Election was made for any taxable year of the <span style="white-space:nowrap">non-U.S.</span> corporation that such corporation does not satisfy the Income Test or Asset Test. Each U.S. Holder should consult its tax advisor regarding the availability of, and procedure for making, any deemed gain, deemed dividend or QEF Election. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, U.S. Holders can avoid the interest charge on excess distributions or gain relating to the ordinary shares by making a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election with respect to the ordinary shares, provided that the ordinary shares constitute &#8220;marketable stock.&#8221; &#8220;Marketable stock&#8221; is, generally, stock that is &#8220;regularly traded&#8221; on certain U.S. stock exchanges or on a foreign stock exchange that meets certain conditions. For these purposes, the ordinary shares will be considered regularly traded during any calendar year during which they are traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Our ordinary shares are listed on Nasdaq, which is a qualified exchange for these purposes. Consequently, if our ordinary shares remain listed on Nasdaq and are regularly traded (as to which there can be no assurance), and you are a U.S. Holder of ordinary shares, we expect the <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election would be available to you if we are a classified as a PFIC. Each U.S. Holder should consult its tax advisor as to the whether a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election is available or advisable with respect to the ordinary shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election must include in ordinary income for each year an amount equal to the excess, if any, of the fair market value of the ordinary shares at the close of the taxable year over the U.S. Holder&#8217;s adjusted tax basis in the ordinary shares. An electing holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder&#8217;s adjusted basis in the ordinary shares over the fair market value of the ordinary shares at the close of the taxable year, but this deduction is allowable only to the extent of any net <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> gains for prior years. Gains from an actual sale or other disposition of the ordinary shares will be treated as ordinary income, and any losses incurred on a sale or other disposition of the shares will be treated as an ordinary loss to the extent of any net <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> gains for prior years. Once made, the election cannot be revoked without the consent of the IRS, unless the ordinary shares cease to be marketable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#8220;marketable.&#8221; As a result, even if a U.S. Holder validly makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election with respect to our ordinary shares, the U.S. Holder may continue to be subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. In addition, under current law, a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election is not available with respect to the warrants. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the IRS, each U.S. Holder who owns shares and/or warrants in a PFIC is required to file an annual report containing such information as the IRS may require. A U.S. Holder&#8217;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#8217;s U.S. federal income tax return to remain open with regard to the items required to be included in such report until three years after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#8217;s entire U.S. federal income tax return will remain open during such period. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WE STRONGLY URGE YOU TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT OF OUR PFIC STATUS ON YOUR INVESTMENT IN THE ORDINARY SHARES AS WELL AS THE APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT IN THE ORDINARY SHARES. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding on a duly executed IRS Form <span style="white-space:nowrap">W-9</span> or otherwise establishes an exemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not a separate tax. The amount of any backup withholding from a payment to a U.S. Holder may be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle the U.S. Holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information with Respect to Foreign Financial Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under regulations, certain entities) may be required to report information relating to the ordinary shares or warrants, subject to certain exceptions (including an exception for assets held in accounts maintained by certain U.S. financial institutions), by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. Such U.S. Holders who fail to timely furnish the required information may be subject to a penalty. Additionally, if a U.S. Holder does not file the required information, the statute of limitations with respect to tax returns of the U.S. Holder to which the information relates may not close until three years after such information is filed. U.S. Holders should consult their tax advisors regarding their reporting obligations with respect to their ownership and disposition of the ordinary shares or warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Dutch Tax Considerations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scope of Discussion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The section only outlines certain material Dutch tax consequences of the acquisition, holding and disposal of our common shares. This section does not purport to describe all possible tax considerations or consequences that may be relevant to a holder or prospective holder of common shares and does not purport to deal with the tax consequences applicable to all categories of investors, some of which (such as trusts or similar arrangements) may be subject to special rules. In view of its general nature, this section should be treated with corresponding caution. To the extent this summary relates to legal conclusions under current Netherlands tax law, and subject to the qualifications it contains, it represents the opinion of NautaDutilh N.V., our special Dutch counsel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion, it is assumed that we are a tax resident of Germany under German national tax laws since we intended to have, from our incorporation and on a continuous basis, our place of effective management in Germany. See <span style="font-style:italic">&#8220;Item 3: Key information&#8212;D. Risk factors&#8212;&#8220;We may become taxable in a jurisdiction other than Germany, and this may cause us to be subject to increased and/or different taxes than we expect.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, this section is based on and only addresses the tax laws of the Netherlands, published regulations thereunder and published authoritative case law, all as in effect on the date hereof, including, for the avoidance of doubt, the tax rates applicable on the date hereof, and all of which are subject to change, possibly with retroactive effect. Where this section refers to &#8220;the Netherlands&#8221; or &#8220;Dutch&#8221; it refers only to the part of the Kingdom of the Netherlands located in Europe. The applicable tax laws or interpretations thereof may change, or the relevant facts and circumstances may change, and such changes may affect the contents of this section, which will not be updated to reflect such change. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section is intended as general information only and is not Dutch tax advice or a complete description of all Dutch tax consequences relating to the acquisition, holding and disposal of the common shares. Holders or prospective holders of common shares should consult their own tax advisor regarding the Dutch tax consequences relating to the acquisition, holding and disposal of common shares in light of their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that this section does not describe the Dutch tax consequences for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a holder of common shares if such holder has a substantial interest (<span style="font-style:italic">aanmerkelijk belang</span>) or deemed substantial interest (<span style="font-style:italic">fictief aanmerkelijk belang</span>) in us under the Dutch Income Tax Act 2001 (Wet inkomstenbelasting 2001). Generally, a holder is considered to hold a substantial interest in us, if such holder alone or, in the case of an individual, together with such holder&#8217;s partner for Dutch income tax purposes, or any relatives by blood or marriage in the direct line (including foster children), directly or indirectly, holds (i)&#160;an interest of 5% or more of our total issued and outstanding capital or of 5% or more of the issued and outstanding capital of a certain class of shares; or (ii)&#160;rights (including warrants) to acquire, directly or indirectly, such interest; or (iii)&#160;certain profit sharing rights that relate to 5% or more of our annual profits or to 5% or more of our liquidation proceeds. A deemed substantial interest may arise if a substantial interest (or part thereof) in us has been disposed of, or is deemed to have been disposed of, on a <span style="white-space:nowrap">non-recognition</span> basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a holder of common shares if the common shares held by such holder qualify or qualified as a participation (<span style="font-style:italic">deelneming</span>) for purposes of the Dutch Corporate Income Tax Act 1969 (<span style="font-style:italic">Wet op de vennootschapsbelasting 1969</span>). Generally, a holder&#8217;s shareholding of 5% or more in our nominal <span style="white-space:nowrap">paid-up</span> share capital qualifies as a participation. A holder may also have a participation if (a)&#160;such holder does not have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation or (b)&#160;we are a related entity (statutorily defined term); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">holder of common shares which is or who is entitled to the dividend withholding tax exemption (<span style="font-style:italic">inhoudingsvrijstelling</span>) with respect to any income (<span style="font-style:italic">opbrengst</span>) derived from the common shares (as defined in Article 4 of the Dutch Dividend Withholding Tax Act 1965 (<span style="font-style:italic">Wet op de dividendbelasting</span>). Generally, a holder of common shares may be entitled or required to apply, subject to certain other requirements, the dividend withholding tax exemption if it is an entity and holds an interest of 5% or more in our nominal <span style="white-space:nowrap">paid-up</span> share capital; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">pension funds, investment institutions (<span style="font-style:italic">fiscale beleggingsinstellingen</span>) and tax exempt investment institutions (<span style="font-style:italic">vrijgestelde beleggingsinstellingen</span>) (each as defined in the Dutch Corporate Income Tax Act 1969) and other entities that are, in whole or in part, not subject to or exempt from Dutch corporate income tax, ,entities that have a function comparable to an investment institution or a tax exempt investment institution, as well as entities that are exempt from corporate income tax in their country of residence, such country of residence being another state of the European Union, Norway, Liechtenstein, Iceland or any other state with which the Netherlands has agreed to exchange information in line with international standards; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a holder of common shares if such holder is an individual for whom the common shares or any benefit derived from the common shares is a remuneration or deemed to be a remuneration for (employment) activities performed by such holder or certain individuals related to such holder (as defined in the Dutch Income Tax Act 2001). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend withholding tax </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends distributed by us are generally subject to Dutch dividend withholding tax at a rate of 15%. Generally, we are responsible for the withholding of such dividend withholding tax at source; the Dutch dividend withholding tax is for the account of the holder of common shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expression &#8220;dividends distributed&#8221; includes, but is not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distributions in cash or in kind, deemed and constructive distributions and repayments of <span style="white-space:nowrap">paid-in</span> capital not recognized for Dutch dividend withholding tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">liquidation proceeds, proceeds from the redemption of common shares, or proceeds from the repurchase of common shares (other than as temporary portfolio investment; <span style="font-style:italic">tijdelijke belegging</span>) by us or one of our subsidiaries or other affiliated entities, in each case to the extent such proceeds exceed the average <span style="white-space:nowrap">paid-in</span> capital of those common shares as recognized for Dutch dividend withholding tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an amount equal to the par value of the common shares issued or an increase of the par value of the common shares, to the extent that no related contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partial repayment of the <span style="white-space:nowrap">paid-in</span> capital recognized for Dutch dividend withholding tax purposes, if and to the extent that we have &#8220;net profits&#8221; (<span style="font-style:italic">zuivere winst</span>), unless (i)&#160;the general meeting of shareholders has resolved in advance to make such repayment and (ii)&#160;the par value of the common shares concerned has been reduced by an equal amount by way of an amendment to the articles of association. The term &#8220;net profits&#8221; includes anticipated profits that have yet to be realized. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate legal entities that are resident or deemed to be resident of the Netherlands for Dutch corporate income tax purposes (&#8220;Dutch Resident Entities&#8221;) generally are entitled to an exemption from, or a credit for, any Dutch dividend withholding tax against their Dutch corporate income tax liability. The credit in any given year is, however, limited to the amount of Dutch corporate income tax payable in respect of the relevant year with an indefinite carry forward of any excess amount. Individuals who are resident or deemed to be resident of the Netherlands for Dutch personal income tax purposes (&#8220;Dutch Resident Individuals&#8221;) generally are entitled to a credit for any Dutch dividend withholding tax against their Dutch personal income tax liability and to a refund of any residual Dutch dividend withholding tax. The above generally also applies to holders of common shares that are neither resident nor deemed to be resident of the Netherlands <span style="white-space:nowrap">(&#8220;Non-Resident</span> Holders&#8221;) if the common shares are attributable to a Dutch permanent establishment of such <span style="white-space:nowrap">Non-Resident</span> Holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of common shares that is resident of a country other than the Netherlands may, depending on such holder&#8217;s specific circumstances, be entitled to exemptions from, reduction of, or full or partial refund of, Dutch dividend withholding tax under Dutch domestic law, EU law, or treaties for the avoidance of double taxation in effect between the Netherlands and such other country. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividend stripping </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to Dutch domestic anti-dividend stripping rules, no credit against Dutch tax, exemption from, reduction, or refund of Dutch dividend withholding tax will be granted if the recipient of the dividends we paid is not considered the beneficial owner (<span style="font-style:italic">uiteindelijk gerechtigde</span>; as described in the Dutch Dividend Withholding Tax Act 1965) of those dividends. This legislation generally targets situations in which a shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction with another party. It is not required for these rules to apply that the recipient of the dividends is aware that a dividend stripping transaction took place. The Dutch State Secretary of Finance takes the position that the definition of beneficial ownership introduced by this legislation will also be applied in the context of a double taxation convention. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditional withholding tax on dividends (as of January&#160;1, 2024) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&#160;1, 2024, a Dutch conditional withholding tax will be imposed on dividends distributed by us to entities related (gelieerd) to us (within the meaning of the Dutch Withholding Tax Act 2021; <span style="font-style:italic">Wet bronbelasting 2021</span>), if such related entity: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">is considered to be resident (<span style="font-style:italic">gevestigd</span>) in a jurisdiction that is listed in the yearly updated Dutch Regulation on <span style="white-space:nowrap">low-taxing</span> states and <span style="white-space:nowrap">non-cooperative</span> jurisdictions for tax purposes (<span style="font-style:italic">Regeling laagbelastende staten en <span style="white-space:nowrap">niet-co&#246;peratieve</span> rechtsgebieden voor belastingdoeleinden</span>) (a &#8220;Listed Jurisdiction&#8221;); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">has a permanent establishment located in a Listed Jurisdiction to which the common shares are attributable; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">holds the common shares with the main purpose or one of the main purposes of avoiding taxation for another person or entity and there is an artificial arrangement or transaction or a series of artificial arrangements or transactions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">is not considered to be the beneficial owner of the common shares in its jurisdiction of residence because such jurisdiction treats another entity as the beneficial owner of the common shares (a hybrid mismatch); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">is not resident in any jurisdiction (also a hybrid mismatch); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">is a reverse hybrid (within the meaning of Article 2(12) of the Dutch Corporate Income Tax Act 1969), if and to the extent (x)&#160;there is a participant in the reverse hybrid which is related (<span style="font-style:italic">gelieerd</span>) to the reverse hybrid, (y)&#160;the jurisdiction of residence of such participant treats the reverse hybrid as transparent for tax purposes and (z)&#160;such participant would have been subject to the Dutch conditional withholding tax in respect of dividends distributed by us without the interposition of the reverse hybrid, </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all within the meaning of the Dutch Withholding Tax Act 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Dutch conditional withholding tax on dividends will be imposed at the highest Dutch corporate income tax rate in effect at the time of the distribution (2023: 25.8%). The Dutch conditional withholding tax on dividends will be reduced, but not below zero, by any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution. As such, based on the currently applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding tax (as described above) and the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate in effect at the time of the distribution (2023: 25.8%). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dual Tax Residency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Netherlands, and we are therefore a Dutch tax resident for Dutch domestic tax law purposes, including the Dutch Dividend Withholding Tax Act 1969. As set out in the introduction we are also treated as a German tax resident for German domestic tax law purposes, since our place of effective management is located in Germany. Based on the <span style="white-space:nowrap">so-called</span> <span style="white-space:nowrap">tie-breaker</span> provision (the <span style="white-space:nowrap">&#8220;Tie-Breaker</span> Provision&#8221;) included in Section&#160;4(3) of the 2012 Convention between the Federal Republic of Germany and the Kingdom of the Netherlands for the avoidance of double taxation with respect to taxes on income (the &#8220;double tax treaty between Germany and the Netherlands&#8221;) as in effect on the date hereof, our tax residence in either the Netherlands or Germany for the purposes of the double tax treaty between Germany and the Netherlands should be determined on our place of effective management. As long as our place of effective management is in Germany, and the <span style="white-space:nowrap">Tie-Breaker</span> Provision is not changed (for instance, by change in the reservations and choices made by Germany with respect to the application of the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting), we should exclusively be a tax resident of Germany for purposes of the double tax treaty between Germany and the Netherlands. As a consequence, the Netherlands will be restricted to impose Dutch dividend withholding tax on dividends distributed by us pursuant </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Section&#160;10(5) of the double tax treaty between Germany and the Netherlands, except for dividends distributed to Dutch Resident Entities, Dutch Resident Individuals and <span style="white-space:nowrap">Non-Resident</span> Holders if the common shares are attributable to a permanent establishment in the Netherlands of such <span style="white-space:nowrap">Non-Resident</span> Holder. See <span style="font-style:italic">&#8220;Item 3: Key information&#8212;D. Risk factors&#8212;If we ever pay dividends, we may need to withhold tax on such dividends in both Germany and the Netherlands.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxes on income and capital gains </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dutch Resident Entities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if the holder of common shares is a Dutch Resident Entity, any income derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is subject to Dutch corporate income tax at a rate of 19% with respect to taxable profits up to &#8364;200,000 and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2023). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dutch Resident Individuals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holder of common shares is a Dutch Resident Individual, any income derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is subject to Dutch personal income tax at the progressive rates (with a maximum of 49.5% in 2023), if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the common shares are attributable to an enterprise from which the holder of common shares derives a share of the profit, whether as an entrepreneur (<span style="font-style:italic">ondernemer</span>) or as a person who has a <span style="white-space:nowrap">co-entitlement</span> to the net worth (<span style="font-style:italic">medegerechtigd tot het vermogen</span>) of such enterprise without being a shareholder (as defined in the Dutch Income Tax Act 2001); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the holder of common shares is considered to perform activities with respect to the common shares that go beyond ordinary asset management (<span style="font-style:italic">normaal, actief vermogensbeheer</span>) or otherwise derives benefits from the common shares that are taxable as benefits from miscellaneous activities (<span style="font-style:italic">resultaat uit overige werkzaamheden</span>). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of savings and investments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the above-mentioned conditions (i)&#160;and (ii) do not apply to the Dutch Resident Individual, the common shares will be subject to an annual Dutch income tax under the regime for savings and investments (<span style="font-style:italic">inkomen uit sparen en beleggen</span>). Taxation only occurs insofar the Dutch Resident Individual&#8217;s net investment assets for the year exceed a statutory threshold (<span style="font-style:italic">heffingvrij vermogen</span>). The net investment assets for the year are the fair market value of the investment assets less the fair market value of the liabilities on January&#160;1 of the relevant calendar year (reference date; <span style="font-style:italic">peildatum</span>). The common shares are included as investment assets. The taxable benefit for the year (<span style="font-style:italic">voordeel uit sparen en beleggen</span>) is taxed at a flat rate of 32% (rate for 2023). Actual income or capital gains realized in respect of the common shares are as such not subject to Dutch income tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The taxable benefit for the year is calculated as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including the common shares, are allocated over the following three categories: (a)&#160;bank savings, (b)&#160;other investments, including the common shares, and (c)&#160;liabilities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The return (<span style="font-style:italic">rendement</span>) in respect of these assets and liabilities is calculated as follows (the return is at a minimum nihil): </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">a.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a deemed return on the fair market value of the actual amount of bank savings and cash on January&#160;1 of the relevant calendar year; plus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">b.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a deemed return on the fair market value of the actual amount of other investments, including the common shares, on January&#160;1 of the relevant calendar year; minus </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">c.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a deemed return on the sum of the fair market value of the actual amount of liabilities on January&#160;1 of the relevant calendar year less the statutory threshold for liabilities (<span style="font-style:italic">drempel</span>). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The return percentage (%) (<span style="font-style:italic">rendementspercentage</span>) is calculated as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">a.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by dividing the return calculated under (ii)&#160;above by the net investment assets for the year of the Dutch Resident Individual; multiplied by </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">b.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">100. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The taxable base (<span style="font-style:italic">grondslag sparen en beleggen</span>) is calculated as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">a.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the net investment assets for the year of the Dutch Resident Individual; minus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">b.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the applicable statutory threshold. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The taxable benefit for the year is equal to the taxable base calculated under (iv)&#160;above multiplied by the return percentage calculated under (iii)&#160;above. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the calendar year 2023, the deemed returns for the investment categories mentioned under (ii)&#160;(a) and (c) above have been temporarily set at 0.36% and 2.57%, respectively. The definitive percentages for these investment categories for the year 2023 will be published in the first months of 2024 and will have retroactive effect to January&#160;1, 2023. The deemed return applicable to the other investments (mentioned under (ii)(b) above), including the common shares is set at 6.17% for the calendar year 2023. Transactions in the three-month period before and after January&#160;1 of the relevant calendar year implemented to arbitrate between the deemed return percentages applicable to bank savings, other investments and liabilities will for this purpose be ignored if the holder of common shares cannot sufficiently demonstrate that such transactions are implemented for other than tax reasons. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-residents</span> of the Netherlands </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of common shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to Dutch income tax in respect of income derived or deemed to be derived from the common shares or in respect of capital gains realized on the disposal or deemed disposal of the common shares provided that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">such holder does not have an interest in an enterprise or deemed enterprise (as defined in the Dutch Income Tax Act 2001 and the Dutch Corporate Income Tax Act 1969, as applicable) which, in whole or in part, is either effectively managed in the Netherlands or carried on through a permanent establishment, a deemed permanent establishment or a permanent representative in the Netherlands and to which enterprise or part of an enterprise the common shares are attributable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the event the holder is an individual, such holder does not carry out any activities in the Netherlands with respect to the common shares that go beyond ordinary asset management and does not otherwise derive benefits from the common shares that are taxable as benefits from miscellaneous activities in the Netherlands. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gift and inheritance taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Residents of the Netherlands </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of a gift by, or on the death of, a holder of such common shares who is resident or deemed resident of the Netherlands at the time of the gift or such holder&#8217;s death. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-residents</span> of the Netherlands </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of a gift by, or on the death of, a holder of such common shares who is neither resident nor deemed to be resident of the Netherlands, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the case of a gift of common shares by an individual who at the date of the gift was neither resident nor deemed to be resident of the Netherlands, such individual dies within 180 days after the date of the gift, while being resident or deemed to be resident of the Netherlands; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the case of a gift of common shares is made under a condition precedent, the holder of such common shares is resident or is deemed to be resident of the Netherlands at the time the condition is fulfilled; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the transfer is otherwise construed as a gift or inheritance made by, or on behalf of, a person who, at the time of the gift or death, is or is deemed to be resident of the Netherlands. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Dutch gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to be resident of the Netherlands if such person has been a resident of the Netherlands at any time during the ten years preceding the date of the gift or such person&#8217;s death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch nationality will be deemed to be resident of the Netherlands if such person has been a resident of the Netherlands at any time during the twelve months preceding the date of the gift. Applicable tax treaties may override deemed residency. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Value added tax (VAT) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch VAT will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stamp Duties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch documentation taxes (commonly referred to as stamp duties) will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material German Tax Considerations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following section is a description of the material German tax considerations that become relevant when acquiring, owning and transferring Immatics&#8217; ordinary shares. It is based on the German tax law applicable as of the date of this Annual Report without prejudice to any amendments introduced at a later date and implemented with or without retroactive effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section is intended as general information only and does not purport to be a comprehensive or complete description of all potential German tax effects of the acquisition, ownership or transfer of ordinary shares and does not set forth all German tax considerations that may be relevant to a particular person&#8217;s decision to acquire ordinary shares. It does not constitute particular German tax advice and potential purchasers of Immatics&#8217; ordinary shares are urged to consult their own tax advisors regarding the tax consequences of the acquisition, ownership and transfer of ordinary shares in light of their particular circumstances with regard to the application of German tax law to their particular situations, in particular with respect to the procedure to be complied with to obtain a relief of withholding tax on dividends and on capital gains (<span style="font-style:italic">Kapitalertragsteuer</span>) and with respect to the influence of double tax treaty provisions, as well as any tax consequences arising under the laws of any state, local or other <span style="white-space:nowrap">non-German</span> jurisdiction. For German tax purposes, a shareholder may include an individual who or an entity that does not have the legal title to the ordinary shares, but to whom nevertheless the ordinary shares are attributed, based either on such individual or entity owning a beneficial interest in the ordinary shares or based on specific statutory provisions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the following is subject to change. Such changes could apply retroactively and could affect the consequences set forth below. This section does not refer to any foreign account tax compliance act (FATCA) aspects. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Immatics&#8217; Tax Residency Status </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immatics has its statutory seat in the Netherlands and its sole place of management in Germany and is therefore tax resident in Germany (for purposes of the German-Dutch tax treaty). Thus, Immatics qualifies as a corporation subject to German unlimited liability for corporate income tax purposes. However, because Immatics&#8217; tax residency depends on future facts regarding its place of management the German unlimited liability for corporate income tax purposes may change in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Withholding Tax on Dividend Payments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends distributed from Immatics to its shareholders are generally subject to German withholding tax, conditionally upon certain exemptions (for example, repayments of capital from the tax contribution account (<span style="font-style:italic">steuerliches Einlagekonto</span>)), as further described. The withholding tax rate is 25% plus a 5.5% solidarity surcharge (<span style="font-style:italic">Solidarit&#228;tszuschlag</span>) thereon totaling 26.375% of the gross dividend amount. Withholding tax is to be withheld and passed on for the account of the shareholders by a domestic branch of a domestic or foreign credit or financial services institution (<span style="font-style:italic">Kredit</span>- <span style="font-style:italic">und</span> <span style="font-style:italic">Finanzdienstleistungsinstitut</span>), by the domestic securities trading company (<span style="font-style:italic">inl&#228;ndisches</span> <span style="font-style:italic">Wertpapierhandelsunternehmen</span>) or a domestic securities trading bank (<span style="font-style:italic">inl&#228;ndische Wertpapierhandelsbank</span>) which keeps and administers the ordinary shares and disburses or credits the dividends or disburses the dividends to a foreign agent, or by the securities custodian bank (<span style="font-style:italic">Wertpapiersammelbank</span>) to which the ordinary shares were entrusted for collective custody if the dividends are distributed to a foreign agent by such securities custodian bank (which is referred to as the &#8220;Dividend Paying Agent&#8221;). In case the ordinary shares are not held in collective deposit with a Dividend Paying Agent, Immatics is responsible for withholding and remitting the tax to the competent tax office. Such withholding tax is levied and withheld irrespective of whether and to what extent the dividend distribution is taxable at the level of the shareholder and whether the shareholder is a person residing in Germany or in a foreign country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of dividends distributed to a company within the meaning of Art. 2 of the amended EU Directive 2011/96/EU of the Council of November&#160;30, 2011 (the &#8220;EU Parent Subsidiary Directive&#8221;) domiciled in another Member State of the European Union, withholding tax is effectively reduced to zero. This also applies to dividends distributed to a permanent establishment located in another Member State of the European Union of such a parent company or of a parent company tax resident in Germany if the participation in Immatics is effectively connected with this permanent establishment. The key prerequisite for the application of the EU Parent Subsidiary Directive is that the shareholder has held a direct participation in the share capital of Immatics of at least 10% for an uninterrupted period of at least one year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding tax on dividends distributed to other foreign resident shareholders is reduced in accordance with an applicable double tax treaty (to 15%, 5% or 0% depending on certain prerequisites) if Germany has concluded such double tax treaty with the country of residence of the shareholder and if the shareholder does not hold his ordinary shares either as part of the assets of a permanent establishment or a fixed place of business in Germany or as business assets for which a permanent representative has been appointed in Germany. Further, the foreign resident shareholder must be eligible for treaty purposes and no limitation of benefits provision in a double tax treaty and&#8212;both in relation to a reduction pursuant to the EU Parent Subsidiary Directive and an applicable tax treaty&#8212;no German anti-directive/treaty shopping provision of Section&#160;50d paragraph 3 of the German Income Tax Act (<span style="font-style:italic">Einkommensteuergesetz</span>) must be applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the deduction of withholding taxes will generally apply irrespective of a possible reduction pursuant to the EU Parent Subsidiary Directive or applicable double tax treaty except for the case that the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recipient of the dividends has been granted an exemption from the German Federal Central Tax Office (<span style="font-style:italic">Bundeszentralamt f&#252;r Steuern</span>) upon formal application by the recipient of the dividends (<span style="font-style:italic">Freistellung im Steuerabzugsverfahren</span>). In case of deducted withholding taxes, the reduction of the withholding tax pursuant to both the EU Parent Subsidiary Directive and an applicable double tax treaty is procedurally granted in such a manner that the difference between the total amount withheld, including the solidarity surcharge, and the tax liability determined on the basis of the EU Parent Subsidiary Directive (0%) or on the basis of the tax rate set forth in the applicable double tax treaty (15% unless further qualifications are met) is upon request refunded by the German Federal Central Tax Office (<span style="font-style:italic">Bundeszentralamt f&#252;r Steuern</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of dividends received by corporations who are not tax resident in Germany, <span style="white-space:nowrap">two-fifths</span> of the withholding tax deducted and remitted are refunded without the need to fulfill all prerequisites required for such refund under the EU Parent Subsidiary Directive or under a double tax treaty or if no double tax treaty has been concluded between the state of residence of the shareholder, however, likewise subject to the conditions of the German anti-directive/treaty shopping provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to receive a refund pursuant to a double tax treaty or the aforementioned option for foreign corporations, the shareholder has to submit a completed form for refund (available at the website of the Federal Central Tax Office (http://www.bzst.de) as well as at the German embassies and consulates) together with a withholding tax certificate (<span style="font-style:italic">Kapitalertragsteuerbescheinigung</span>) issued by the institution that deducted the respective withholding tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned reductions of (or exemptions from) withholding tax are further restricted if (i)&#160;the applicable double tax treaty provides for a tax reduction resulting in an applicable tax rate of less than 15% and (ii)&#160;the shareholder is not a corporation that directly holds at least 10% in the equity capital of Immatics and is subject to tax on its income and profits in its state of residence without being exempt. In this case, the reduction of (or exemption from) withholding tax is subject to the following three cumulative prerequisites: (i)&#160;the shareholder must qualify as beneficial owner of the shares in a company for a minimum holding period of 45 consecutive days occurring within a period of 45 days prior and 45 days after the due date of the dividends, (ii)&#160;the shareholder has to bear at least 70&#160;% of the change in value risk related to the shares in a company during the minimum holding period without being directly or indirectly hedged, and (iii)&#160;the shareholder must not be required to fully or largely compensate directly or indirectly the dividends to third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of the fulfillment of all of the three prerequisites, three-fifths of the withholding tax imposed on the dividends must not be credited against the shareholder&#8217;s (corporate) income tax liability, but may, upon application, be deducted from the shareholder&#8217;s tax base for the relevant assessment period. Furthermore, a shareholder that has received gross dividends without any deduction of withholding tax due to a tax exemption without qualifying for such a full tax credit has (i)&#160;to notify the competent local tax office accordingly, (ii)&#160;to declare according to the officially prescribed form and (iii)&#160;has to make a payment in the amount of the omitted withholding tax deduction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, these special rules on the restriction of withholding tax credit do not apply to a shareholder whose overall dividend earnings within an assessment period do not exceed &#8364;20,000 or that has been the beneficial owner of the shares in a company for at least one uninterrupted year upon receipt of the dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For individual or corporate shareholders tax resident outside Germany not holding the ordinary shares through a permanent establishment (<span style="font-style:italic">Betriebsst&#228;tte</span>) in Germany or as business assets (<span style="font-style:italic">Betriebsverm&#246;gen</span>) for which a permanent representative (<span style="font-style:italic">st&#228;ndiger</span> <span style="font-style:italic">Vertreter</span>) has been appointed in Germany, the remaining and paid withholding tax (if any) is then final (i.e., not refundable) and settles the shareholder&#8217;s limited tax liability in Germany. For individual or corporate shareholders tax resident in Germany (for example, those shareholders whose residence, domicile, registered office or place of management is located in Germany) holding their ordinary shares as business assets, as well as for shareholders tax resident outside of Germany holding their ordinary shares through a permanent establishment in Germany or as business assets for which a permanent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representative has been appointed in Germany, the withholding tax withheld (including solidarity surcharge) can be credited against the shareholder&#8217;s personal income tax or corporate income tax liability in Germany. Any withholding tax (including solidarity surcharge) in excess of such tax liability is refunded. For individual shareholders tax resident in Germany holding Immatics&#8217; ordinary shares as private assets, the withholding tax is a final tax (<span style="font-style:italic">Abgeltungsteuer</span>), subject to the exceptions described in the following section. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding Immatics&#8217; Ordinary Shares as Private Assets (Private Individuals) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For individual shareholders (individuals) resident in Germany holding Immatics&#8217; ordinary shares as private assets, dividends are subject to a flat rate tax which is satisfied by the withholding tax actually withheld (<span style="font-style:italic">Abgeltungsteuer</span>). Accordingly, dividend income will be taxed at a flat tax rate of 25% plus 5.5% solidarity surcharge thereon totaling 26.375% and church tax (<span style="font-style:italic">Kirchensteuer</span>) in case the shareholder is subject to church tax because of his personal circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<span style="font-style:italic">Sperrvermerk</span>) with the German Federal Tax Office (details related to the computation of the specific tax rate including church tax are to be discussed with the individual tax advisor of the relevant shareholder). Except for an annual lump sum savings allowance (<span style="font-style:italic">Sparer-Pauschbetrag</span>) of up to &#8364;1,000 (for individual filers) or up to &#8364;2,000 (for married couples and for partners in accordance with the registered partnership law (<span style="font-style:italic">Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</span>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their dividend income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The income tax owed for the dividend income is satisfied by the withholding tax withheld by the Dividend Paying Agent. However, if the flat tax results in a higher tax burden as opposed to the private individual shareholder&#8217;s personal income tax rate, the private individual shareholder can opt for taxation at his personal income tax rate. In that case, the final withholding tax will be credited against the income tax. The option can be exercised only for all capital income from capital investments received in the relevant assessment period uniformly and married couples as well as partners in accordance with the registered partnership law filing jointly may only jointly exercise the option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exceptions from the flat rate tax (satisfied by withholding the tax at source, <span style="font-style:italic">Abgeltungswirkung</span>) may apply&#8212;that is, only upon application&#8212;for shareholders who have a shareholding of at least 25% in Immatics and for shareholders who have a shareholding of at least 1% in Immatics and work for a company in a professional capacity. In such a case, the same rules apply as for sole proprietors holding the ordinary shares as business assets (see below &#8220;Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s Ordinary Shares as Business Assets&#8212;Sole Proprietors&#8221;). Further, the flat rate tax does not apply if and to the extent dividends reduced Immatics taxable income. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding Immatics&#8217; Ordinary Shares as Business Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a shareholder holds the Immatics&#8217; ordinary shares as business assets, the taxation of the dividend income depends on whether the respective shareholder is a corporation, a sole proprietor or a partnership. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividend income of corporate shareholders is exempt from corporate income tax, provided that the corporation holds a direct participation of at least 10% in the share capital of a company at the beginning of the calendar year in which the dividends are paid (participation exemption). The acquisition of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the beginning of such calendar year. Participations in the share capital of the company which a corporate shareholder holds through a partnership, including <span style="white-space:nowrap">co-entrepreneurships</span> (<span style="font-style:italic">Mitunternehmerschaften</span>), are attributable to such corporate shareholder only on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a pro rata basis at the ratio of the interest share of the corporate shareholder in the assets of the relevant partnership. However, 5% of the <span style="white-space:nowrap">tax-exempt</span> dividends are deemed to be <span style="white-space:nowrap">non-deductible</span> business expenses for tax purposes and therefore are effectively subject to corporate income tax (plus solidarity surcharge) and trade tax; i.e., tax exemption of 95%. Business expenses incurred in connection with the dividends received are entirely tax deductible. The participation exemption does not apply if and to the extent dividends reduced Immatics taxable income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For trade tax purposes the entire dividend income is subject to trade tax (i.e., the <span style="white-space:nowrap">tax-exempt</span> dividends must be added back when determining the trade taxable income), unless the corporation shareholder holds at least 15% of the company&#8217;s registered share capital at the beginning of the relevant tax assessment period (<span style="font-style:italic">Erhebungszeitraum</span>). In case of an indirect participation via a partnership, please refer to the section &#8220;Partnerships&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shareholding is below 10% in the share capital, dividends are taxable at the applicable corporate income tax rate of 15%, plus 5.5% solidarity surcharge thereon and trade tax (the rate of which depends on the applicably municipality levy rate determined by the municipality the corporate shareholder has its place of management and permanent establishments respectively). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special regulations apply which abolish the 95% tax exemption, if the company&#8217;s ordinary shares are held as trading portfolio assets in the meaning of Section&#160;340e of the German Commercial Code (<span style="font-style:italic">Handelsgesetzbuch</span>) by (i)&#160;a credit institution (<span style="font-style:italic">Kreditinstitut</span>), (ii) a financial service institution (<span style="font-style:italic">Finanzdienstleistungsinstitut</span>) or (iii)&#160;a financial enterprise within the meaning of the German Banking Act (<span style="font-style:italic">Kreditwesengesetz</span>), in case more than 50% of the shares of such financial enterprise are held directly or indirectly by a credit institution or a financial service institution, as well as by a life insurance company, a health insurance company or a pension fund in case the shares are attributable to the capital investments, resulting in fully taxable income. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sole Proprietors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For sole proprietors (individuals) resident in Germany holding ordinary shares as business assets, dividends are subject to the partial income rule (<span style="font-style:italic">Teileink&#252;nfteverfahren</span>). Accordingly, only (i) 60% of the dividend income will be taxed at his/her personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income are deductible for tax purposes. In addition, the dividend income is entirely subject to trade tax if the ordinary shares are held as business assets of a permanent establishment in Germany within the meaning of the German Trade Tax Act (<span style="font-style:italic">Gewerbesteuergesetz</span>), unless the shareholder holds at least 15% of the company&#8217;s registered share capital at the beginning of the relevant assessment period. The trade tax levied will be eligible for credit against the shareholder&#8217;s personal income tax liability based on the applicable municipal trade tax rate and the individual tax situation of the shareholder limited to currently 4.0 times the trade tax measurement amount (<span style="font-style:italic">Gewerbesteuer-Messbetrag</span>). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Partnerships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case ordinary shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax. In this regard, corporate income tax or personal income tax (and church tax, if applicable) as well as solidarity surcharge are levied only at the level of the partner with respect to their relevant part of the partnership&#8217;s taxable income and depending on their individual circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the partner is a corporation, the dividend income will be subject to corporate income tax plus solidarity surcharge (see &#8220;Corporations&#8221; above); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the partner is a sole proprietor, the dividend income will be subject to the partial income rule (see &#8220;Sole Proprietors&#8221; above); and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the partner is a private individual, the dividend income will be subject to the flat tax rate (see &#8220;Private Individuals&#8221; above); unless the partnership is a (operative or deemed) commercial partnership in which case the partial income rule applies). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case the partnership is a (operative or deemed) commercial partnership with its place of management in Germany, the dividend income is subject to German trade tax at the level of the partnership, unless the partnership holds at least 15% of a company&#8217;s registered share capital at the beginning of the relevant assessment period, in which case the dividend income is exempt from trade tax. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Dividend Income of Shareholders Tax Resident Outside of Germany </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For foreign individual or corporate shareholders tax resident outside of Germany not holding the ordinary shares through a permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany, the deducted withholding tax (possibly reduced by way of a tax relief under a double tax treaty or domestic tax law, such as in connection with the EU Parent Subsidiary Directive) is final (that is, not refundable) and settles the shareholder&#8217;s limited tax liability in Germany, unless the shareholder is entitled to apply for a withholding tax refund or exemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast, individual or corporate shareholders tax resident outside of Germany holding the company&#8217;s ordinary shares through a permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany are subject to the same rules as applicable (and described above) to shareholders resident in Germany holding the ordinary shares as business assets. The withholding tax withheld (including solidarity surcharge) is credited against the shareholder&#8217;s personal income tax or corporate income tax liability in Germany. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Capital Gains </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Withholding Tax on Capital Gains </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of ordinary shares are only subject to withholding tax if (i)&#160;a permanent establishment in Germany of a German or foreign credit or financial institution, (ii)&#160;a German securities trading company or (iii)&#160;a German securities trading bank stores or administrates or carries out the disposal of the ordinary shares and pays or credits the capital gains. In those cases, the institution (and not the company) is required to deduct the withholding tax at the time of payment for the account of the shareholder and has to pay the withholding tax to the competent tax authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case the ordinary shares in the company are held (i)&#160;as business assets by a sole proprietor, a partnership or a corporation and such shares are attributable to a German business or (ii)&#160;in case of a corporation being subject to unlimited corporate income tax liability in Germany, the capital gains are not subject to withholding tax. In case of the aforementioned exemption under (i)&#160;above, the withholding tax exemption is subject to the condition that the paying agent has been notified by the beneficiary (<span style="font-style:italic">Gl&#228;ubiger</span>) that the capital gains are exempt from withholding tax. The respective notification has to be filed by using the officially prescribed form. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Capital Gains Realized by Shareholders Tax Resident in Germany Holding Immatics&#8217; Ordinary Shares as Private Assets (Private Individuals) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For individual shareholders (individuals) resident in Germany holding ordinary shares as private assets, capital gains realized on the disposal of ordinary shares are subject to final withholding tax (<span style="font-style:italic">Abgeltungsteuer</span>). Accordingly, capital gains will be taxed at a flat tax rate of 25%, plus 5.5% solidarity surcharge thereon totaling 26.375% and church tax, in case the shareholder is subject to church tax because of his personal circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<span style="font-style:italic">Sperrvermerk</span>) with the German Federal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Central Tax Office (details related to the computation of the specific tax rate including church tax are to be discussed with the personal tax advisor of the relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the ordinary shares and the expenses directly and materially related to the disposal from the proceeds of the disposal. Apart from that, except for an annual lump sum savings allowance (<span style="font-style:italic">Sparer-Pauschbetrag</span>) of up to &#8364;1,000 (for individual filers) or up to &#8364;2,000 (for married couples and for partners in accordance with the registered partnership law (<span style="font-style:italic">Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</span>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their capital gain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case the flat tax results in a higher tax burden as opposed to the private individual shareholder&#8217;s personal income tax rate, the private individual shareholder can opt for taxation at his personal income tax rate. In that case, the withholding tax (including solidarity surcharge) withheld will be credited against the income tax. The option can be exercised only for all capital income from capital investments received in the relevant assessment period uniformly and married couples as well as for partners in accordance with the registered partnership law filing jointly may only jointly exercise the option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital losses arising from the disposal of the ordinary shares can only be offset against other capital gains resulting from the disposition of the ordinary shares or shares in other stock corporations during the same calendar year. Offsetting of overall losses with other income (such as business or rental income) and other capital income is not possible. Such losses are to be carried forward and to be offset against positive capital gains deriving from the disposal of ordinary shares in stock corporations in future years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The final withholding tax (<span style="font-style:italic">Abgeltungsteuer</span>) will not apply if the seller of the ordinary shares or in case of gratuitous transfer, its legal predecessor has held, directly or indirectly, at least 1% of the company&#8217;s registered share capital at any time during the five years prior to the disposal. In that case, capital gains are subject to the partial income rule (<span style="font-style:italic">Teileink&#252;nfteverfahren</span>). Accordingly, only (i) 60% of the capital gains will be taxed at his/her personal income tax rate, plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the capital gains are deductible for tax purposes. The withholding tax withheld (including solidarity surcharge) will be credited against the shareholder&#8217;s personal income tax liability in Germany. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Capital Gains Realized by Shareholders Tax Resident in Germany Holding Immatics&#8217; Ordinary Shares as Business Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a shareholder holds ordinary shares as business assets, the taxation of capital gains realized on the disposal of such shares depends on whether the respective shareholder is a corporation, a sole proprietor or a partnership: </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of ordinary shares by a corporate shareholder are generally exempt from corporate income tax and trade tax. However, 5% of the <span style="white-space:nowrap">tax-exempt</span> capital gains are deemed to be <span style="white-space:nowrap">non-deductible</span> business expenses for tax purposes and therefore are effectively subject to corporate income tax (plus solidarity surcharge) and trade tax; i.e., tax exemption of 95%. Business expenses incurred in connection with the capital gains are entirely tax deductible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital losses incurred upon the disposal of ordinary shares or other impairments of the share value are not tax deductible. A reduction of profit is also defined as any losses incurred in connection with a loan or security in the event the loan or the security is granted by a shareholder or by a related party thereto or by a third person with the right of recourse against the before mentioned persons and the shareholder holds directly or indirectly more than 25% of the company&#8217;s registered share capital. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special regulations apply, if the ordinary shares are held as trading portfolio assets by a credit institution, a financial service institution or a financial enterprise within the meaning of the German Banking Act (<span style="font-style:italic">Kreditwesengesetz</span>) as well as by a life insurance company, a health insurance company or a pension fund (see &#8220;Corporations&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sole Proprietors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the ordinary shares are held by a sole proprietor, capital gains realized on the disposal of the ordinary shares are subject to the partial income rule (<span style="font-style:italic">Teileink&#252;nfteverfahren</span>). Accordingly, only (i) 60% of the capital gains will be taxed at his /her personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income are deductible for tax purposes. In addition, 60% of the capital gains are subject to trade tax if the ordinary shares are held as business assets of a permanent establishment in Germany within the meaning of the German Trade Tax Act (<span style="font-style:italic">Gewerbesteuergesetz</span>). The trade tax levied, depending on the applicable municipal trade tax rate and the individual tax situation, is partly or entirely be credited against the shareholder&#8217;s personal income tax liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Partnerships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case the ordinary shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax as well as solidarity surcharge (and church tax) since partnerships qualify as transparent for German income tax purposes. In this regard, corporate income tax or personal income tax as well as solidarity surcharge (and church tax, if applicable) are levied only at the level of the partner with respect to their relevant part of the partnership&#8217;s taxable income and depending on their individual circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the partner is a corporation, the capital gains will be subject to corporate income tax plus solidarity surcharge (see above &#8220;Corporations&#8221;). Trade tax will be levied additionally at the level of the partner insofar as the relevant profit of the partnership is not subject to trade tax at the level of the partnership. However, with respect to both corporate income and trade tax, the 95%-exemption rule as described above applies. With regard to corporate partners, special regulations apply if they are held as trading portfolio assets by credit institutions, financial service institutions or financial enterprises within the meaning of the German Banking Act or life insurance companies, health insurance companies or pension funds, as described above. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the partner is a sole proprietor (individual), the capital gains are subject to the partial income rule (see above &#8220;Sole proprietors&#8221;). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the partnership is liable to German trade tax, 60% of the capital gains are subject to trade tax at the level of the partnership, to the extent the partners are individuals, and 5% of the capital gains are subject to trade tax, to the extent the partners are corporations. However, if a partner is a private individual the trade tax paid at the level of the is credited against the partner&#8217;s personal income tax liability at up to 4.0 times of the trade tax measurement amount (<span style="font-style:italic">Gewerbesteuer-Messbetrag</span>) depending on the applicable municipal trade tax levy rate and the personal tax situation. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Capital Gains Realized by Shareholders Tax Resident Outside of Germany </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of the ordinary shares by a shareholder tax resident outside of Germany are subject to German taxation provided that (i)&#160;the company&#8217;s ordinary shares are held as business assets of a permanent establishment or as business assets for which a permanent representative has been appointed in Germany, or (ii)&#160;the shareholder or, in case of a gratuitous transfer, its legal predecessor has held, directly or indirectly at least 1% of the company&#8217;s shares capital at any time during a five-year period prior to the disposal. In these cases, capital gains are generally subject to the same rules as described above for shareholders resident in Germany. However, except for the cases referred to in (i)&#160;above, most double tax treaties concluded by Germany provide for a full exemption from German taxation except that the company is considered a real </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estate holding entity for treaty purposes. Further, in case of <span style="white-space:nowrap">non-German</span> corporation, the participation exemption applies in full resulting in a tax exemption of 100% (i.e., no deemed <span style="white-space:nowrap"><span style="white-space:nowrap">non-tax-deductible</span></span> business expenses). </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inheritance and Gift Tax </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer of Immatics&#8217; ordinary shares to another person by way of succession or donation is subject to German inheritance and gift tax (<span style="font-style:italic">Erbschaft- und Schenkungsteuer</span>) if: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the decedent, the donor, the heir, the donee or any other beneficiary has his /her /its residence, domicile, registered office or place of management in Germany at the time of the transfer, or is a German citizen who has not stayed abroad for more than five consecutive years without having a residence in Germany; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (irrespective of the personal circumstances) the ordinary shares are held by the decedent or donor as business assets for which a permanent establishment in Germany is maintained or a permanent representative is appointed in Germany; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) (irrespective of the personal circumstances) at least 10% of the ordinary shares are held directly or indirectly by the decedent or person making the gift, himself or together with a related party in terms of Section&#160;1 paragraph 2 Foreign Tax Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special regulations apply to qualified German citizens who maintain neither a residence nor their domicile in Germany but in a low tax jurisdiction and to former German citizens, also resulting in inheritance and gift tax. The few double tax treaties on inheritance and gift tax which Germany has entered into provide that German inheritance and gift tax is levied only in case of (i)&#160;and, with certain restrictions, in case of (ii). </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Value Added Tax (VAT) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No German value added tax (<span style="font-style:italic">Umsatzsteuer</span>) will be payable by a shareholder in respect of any purchase, ownership and disposal of the ordinary shares except for a valid option to waive VAT exemption requiring a sale between entrepreneurs for VAT purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transfer Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No German capital transfer tax (<span style="font-style:italic">Kapitalverkehrsteuer</span>) or stamp duty (<span style="font-style:italic">Stempelgeb&#252;hr</span>) or similar taxes are levied when acquiring, owning or transferring the company&#8217;s ordinary shares. Net wealth tax (<span style="font-style:italic">Verm&#246;gensteuer</span>) is currently not levied in Germany. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;22, 2013, the Council of the European Union approved the resolution of the ministers of finance from eleven EU member states (including Germany) to introduce a financial transaction tax (&#8220;FTT&#8221;) within the framework of enhanced cooperation. On February&#160;14, 2013, the European Commission accepted the proposal for a Council Directive implementing enhanced cooperation in the area of FTT. The plan focuses on levying a financial tax of 0.1% (0.01% for derivates) on the purchase and sale of financial instruments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A joint statement issued by ten of the eleven participating EU Member States in October 2016 reaffirmed the intention to introduce a FTT. However, at the moment not many details are available. Thus, it is not known to what extent the elements of the European Commission&#8217;s proposal outlined in the preceding paragraph will be followed in relation to the taxation of shares. The FTT proposal remains subject to negotiation between the participating EU Member States and is subject to political discussion. It may therefore be altered prior to the implementation, the timing of which remains unclear. With the EU Council&#8217;s conclusion of <span style="white-space:nowrap">COVID-19</span> financial support the agreement on a FTT becomes more realistic as one of the measures to fund the EU&#8217;s response to the <span style="white-space:nowrap">COVID-19</span> pandemic. Additional EU Member States may decide to participate. If an <span style="white-space:nowrap">EU-wide</span> FTT (see above) fails, representatives of the IfW (Institute for the World Economy) intend to advocate the introduction of a comprehensive version of the tax in Germany after the <span style="white-space:nowrap">COVID-19</span> pandemic. Prospective holders of the ordinary shares are advised to seek their own professional advice in relation to FTT. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_52">F. Dividends and Paying Agents </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_53">G. Statement by Experts </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_54">H. Documents on Display </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form <span style="white-space:nowrap">20-F</span> and reports on Form <span style="white-space:nowrap">6-K.</span> The SEC maintains an Internet site at <span style="font-style:italic">www.sec.gov</span> that contains reports, proxy and information statements and other information we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also make available on our website, free of charge, our Annual Report and the text of our reports on Form <span style="white-space:nowrap">6-K,</span> including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Our website address is <span style="font-style:italic">www.immatics.com</span>. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this Annual Report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_55">I. Subsidiary Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_56">J. Annual Report to Security Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to provide an annual report to security holders in response to the requirements of Form <span style="white-space:nowrap">6-K,</span> we will submit the annual report to security holders in electronic format in accordance with the EDGAR Filer Manual. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_57"><span style="font-weight:bold">ITEM&#160;11.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to various risks in relation to financial instruments. Our principal financial instruments comprise cash and cash equivalents, short-term deposits, accounts receivables and bonds. The main purpose of these financial instruments is to invest the proceeds of capital contributions and upfront payments from collaboration agreements. We have various other financial instruments such as other receivables and trade accounts payables, which arise directly from its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main risks arising from our financial instruments are market risk and liquidity risk. The Board of Management reviews and agrees on policies for managing these risks as summarized below. We also monitor the market price risk arising from all financial instruments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interest rate risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to changes in interest rates relates to investments in deposits, bonds and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regarding the liabilities shown in the Consolidated Statement of Financial Position, we are currently not subject to interest rate risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Credit risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject us to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents, accounts receivables, short-term deposits and bonds. Our cash and cash equivalents, bonds and short-term deposits are denominated in Euros and US Dollars and maintained with three&#160;high-quality financial institutions in Germany and two in the United States. Our accounts receivables are denominated in Euros. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continually monitor our positions with, and the credit quality of, the financial institutions and corporation, which are counterparts to our financial instruments and we are not anticipating non-performance. The maximum default risk corresponds to the carrying amount of the financial assets shown in the statement of financial position. We monitor the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets, as well as expected cash flows from equity measures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Currency risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. Our business transactions are generally conducted in Euros and U.S. dollars. We aim to match EUR cash inflows with EUR cash outflows and U.S. dollar cash inflows with U.S.&#160;Dollar cash outflows where possible. Our objective of currency risk management is to identify, manage and control currency risk exposures within acceptable parameters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash and cash equivalents were &#8364;148.5 million as of December&#160;31, 2022. Approximately 87% of our cash and cash equivalents were held in Germany, of which approximately 49% were denominated in Euros and 51% were denominated in U.S. Dollars. The remainder of our cash and cash equivalents are held in the United States and denominated in U.S. Dollars. Additionally, we have bonds and short-term deposits classified as Other financial assets denominated in Euros in the amount of &#8364;123.3&#160;million and U.S. Dollars in the amount of &#8364;87.0&#160;million as of December&#160;31, 2022. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_58"><span style="font-weight:bold">ITEM&#160;12.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_59">A. Debt Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_60">B. Warrants and Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_61">C. Other Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_62">D. American Depositary Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable<span style="font-weight:bold">.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PART II </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_63"><span style="font-weight:bold">ITEM&#160;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_64">A. Defaults </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_65">B. Arrears and Delinquencies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_66"><span style="font-weight:bold">ITEM&#160;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;12, 2022, we issued and sold 10,905,000 ordinary shares at an offering price of $10.09 per share. The offering was made pursuant to our Registration Statement on Form <span style="white-space:nowrap">F-3</span> (No. <span style="white-space:nowrap">333-258351).</span> The managing underwriters of the offering were Jefferies LLC and SVB Securities LLC. The net proceeds from this offering to us, after deducting underwriting discount and total offering expenses, were &#8364;106.2&#160;million. We intend to use the net proceeds for general corporate purposes and there has been no material change in the use of proceeds as descried in the prospectus related to the offering. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_67"><span style="font-weight:bold">ITEM&#160;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">CONTROLS AND PROCEDURES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_68">A. Disclosure Controls and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by <span style="white-space:nowrap">Rule&#160;13a-15&#160;under</span> the Exchange Act, management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form <span style="white-space:nowrap">20-F</span> and have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time frame specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitations, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_69">B. Management&#8217;s Annual Report on Internal Control over Financial Reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in <span style="white-space:nowrap">Rules&#160;13a-15(f)</span> and <span style="white-space:nowrap">15d-15(f)</span> under the Exchange Act. This rule defines internal control over financial reporting as a process designed by, or under the supervision of, a company&#8217;s chief executive officer and chief financial officer and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS accounting standards and includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS accounting standards, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. This assessment was performed under the direction and supervision of our Chief Executive Officer and our Chief Financial Officer, and based on criteria established in<span style="font-style:italic"></span><span style="font-style:italic">&#160;Internal Control&#8212;Integrated Framework (2013</span>)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management concluded that we did maintain effective internal control over financial reporting as of December&#160;31, 2022, based on criteria described in<span style="font-style:italic"></span><span style="font-style:italic">&#160;Internal Control&#8212;Integrated Framework</span>&#160;(2013) issued by the COSO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_70">C. Attestation Report of the Registered Public Accounting Firm </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report does not include an attestation report of the company&#8217;s registered public accounting firm as we are an emerging growth company under the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx400206_71">D. Changes in Internal Control Over Financial Reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No change in our internal control over financial reporting (as defined in Rules <span style="white-space:nowrap">13a-15(f)</span> and <span style="white-space:nowrap">15d-15(f)</span> under the Exchange Act) occurred during the financial year ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_72"><span style="font-weight:bold">ITEM&#160;16A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">AUDIT COMMITTEE FINANCIAL EXPERTS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit Committee members include Michael G. Atieh (chair), Paul R. Carter, Nancy Valente and Heather L. Mason. Each member of the Audit Committee satisfies the &#8220;independence&#8221; requirements set forth in Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act and is financially literate and each of Michael G. Atieh and Paul R. Carter qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_73"><span style="font-weight:bold">ITEM&#160;16B.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">CODE OF ETHICS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. Our Code of Business Conduct and Ethics is available on our website. We intend to disclose any amendment to the code, or any waivers of its requirements, in our Annual Report on Form <span style="white-space:nowrap">20-F.</span> For the year ended December&#160;31, 2022, we did not grant any waivers of the Code of Business Conduct and Ethics. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_74"><span style="font-weight:bold">ITEM&#160;16C.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">PRINCIPAL ACCOUNTANT FEES AND SERVICES </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For&#160;the&#160;Years&#160;Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(euro&#160;in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, PricewaterhouseCoopers GmbH Wirtschaftspr&#252;fungsgesellschaft was the Company&#8217;s auditor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit fees include the audit work performed each fiscal year necessary to allow the auditor to issue an opinion on our financial statements and to issue an opinion on the local statutory financial statements. Audit fees also include services such as reviews of quarterly financial results and review of securities offering documents. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit-related fees consisted of fees billed for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements or for services that were traditionally performed by the external auditor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tax fees are fees billed for professional services for tax compliance, tax advice and tax planning. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee evaluates the qualifications, independence and performance of the independent auditor as well as <span style="white-space:nowrap">pre-approves</span> and reviews the audit and <span style="white-space:nowrap">non-audit</span> services to be performed by the independent auditor. In accordance with this policy, all services performed by and fees paid to PricewaterhouseCoopers GmbH Wirtschaftspr&#252;fungsgesellschaft were approved by the Audit Committee. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_75"><span style="font-weight:bold">ITEM&#160;16D.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_76"><span style="font-weight:bold">ITEM&#160;16E.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, no purchases of our equity securities were made by or on behalf of us or any affiliated purchaser. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_77"><span style="font-weight:bold">ITEM&#160;16F.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_78"><span style="font-weight:bold">ITEM&#160;16G.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">CORPORATE GOVERNANCE </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a &#8220;foreign private issuer,&#8221; as defined by the SEC, we are permitted to follow home country corporate governance practices, instead of certain corporate governance standards required by the Nasdaq for U.S. companies. Accordingly, we follow Dutch corporate governance rules in lieu of certain of the Nasdaq&#8217;s corporate governance requirements. The significant differences between our Dutch corporate governance rules and the Nasdaq&#8217;s corporate governance requirements are set forth below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Quorum Requirements</span>. In accordance with Dutch law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than <span style="white-space:nowrap">one-third</span> of the outstanding voting stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Solicitation of Proxies</span>. Although we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice will vary from the requirement of Nasdaq Listing Rule 5620(b). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Compensation Committee</span>. As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule 5605(d), which requires an issuer to have a compensation committee that, inter alia, consists entirely of independent directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Nominating and Corporate Governance Committee</span>. As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule 5605(e), which requires an issuer to have independent director oversight of director nominations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Director Compensation</span>. As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule 5250(b)(3), which requires an issuer to disclose information regarding third party compensation of its directors or director nominees. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Shareholder Approval</span>. We have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), provided that it nevertheless complies with Nasdaq&#8217;s Notification of Noncompliance requirement (Rule 5625) and the Voting Rights requirement (Rule 5640) and that it has an audit committee that satisfies Rule 5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). We intend to use these exemptions for as long as we continue to qualify as a foreign private issuer. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_79"><span style="font-weight:bold">ITEM&#160;16H.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MINE SAFETY DISCLOSURE </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_80"><span style="font-weight:bold">ITEM&#160;16I.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART III </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_81"><span style="font-weight:bold">ITEM&#160;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">FINANCIAL STATEMENTS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have responded to Item 18 in lieu of this item. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_82"><span style="font-weight:bold">ITEM&#160;18.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">FINANCIAL STATEMENTS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial statements are filed as part of this Annual Report beginning on page <span style="white-space:nowrap">F-1.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%;vertical-align:top" align="left" id="tx400206_83"><span style="font-weight:bold">ITEM&#160;19.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">EXHIBITS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are filed as part of this Annual Report or incorporated by reference herein: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit <br />Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File&#160;Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing&#160;Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520206488/d96389dex31.htm">Deed of Conversion of Immatics B.V. and Articles of Association of Immatics N.V. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-1</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-240260</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">July&#160;31,&#160;2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1746037/000121390018013990/f8k1018bex4-1_aryasciences.htm">Warrant Agreement between Continental Stock Transfer&#160;&amp; Trust Company and ARYA Sciences Acquisition Corp. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-38688</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">December&#160;16, 2018</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520162185/d865842dex41.htm">Amended and Restated Warrant Agreement, between Continental Stock Transfer<span style="text-decoration:underline"></span>&#160;&amp; Trust Company, Immatics B.V. and ARYA Sciences Acquisition Corp. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">June&#160;5, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312522082242/d268932dex23.htm">Description of Securities Registered Pursuant to Section<span style="text-decoration:underline"></span>&#160;12 of the Securities Exchange Act of 1934 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">20-F</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39363</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">2.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">March&#160;23, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520206488/d96389dex101.htm">Investor Rights and <span style="white-space:nowrap">Lock-up</span> Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-1</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-240260</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">July&#160;31, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.2#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520162185/d865842dex104.htm">Form of Indemnification Agreement (Executive Officers and Directors) </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">June&#160;5, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex105.htm">Collaboration<span style="text-decoration:underline"></span>&#160;&amp; License Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;14, 2015, by and between Immatics US, Inc. and The University of Texas M.D. Anderson Center </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex106.htm">License Royalty Adjustment Agreement, dated as of January<span style="text-decoration:underline"></span>&#160;5, 2016, by and between Immatics US, Inc. and The Board of Regents of The University of Texas System on behalf of the University of Texas M.D. Anderson Cancer Center </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.5&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex107.htm">Master Clinical Trial Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;1, 2016, by and between Immatics US, Inc. and The University of Texas MD Anderson Center </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16,&#160;2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.6&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex108.htm">Restricted Stock Acquisition Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;14, 2015, by and between Immatics US, Inc. and The University of Texas M.D. Anderson Cancer Center </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.7&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex109.htm"><span style="white-space:nowrap">Non-Exclusive</span> License Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;3, 2015, by and between Immatics Biotechnologies GmbH and Stichting Sanquin Bloedvoorziening </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit <br />Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File&#160;Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing&#160;Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.8&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1010.htm">Facilities/Equipment Use and Services Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;1, 2015, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.9&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1011.htm">Amendment Number 1 &#8212; Facilities/Equipment Use and Services Agreement, dated as of February<span style="text-decoration:underline"></span>&#160;1, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.10&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1012.htm">Amendment Number 2 &#8212; Facilities/Equipment Use and Services Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;10, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.11&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1013.htm">Amendment Number 3 &#8212; Facilities/Equipment Use and Services Agreement, dated as of October<span style="text-decoration:underline"></span>&#160;1, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.12&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1014.htm">Amendment Number 4 &#8212; Facilities/Equipment Use and Services Agreement, dated as of April<span style="text-decoration:underline"></span>&#160;1, 2017, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.13&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1015.htm">Amendment Number 5 &#8212; Facilities/Equipment Use and Services Agreement, dated as of July<span style="text-decoration:underline"></span>&#160;1, 2018, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.15</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">April&#160;16, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.14&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312521099162/d149615dex414.htm">Amendment Number 6 &#8212; Facilities/Equipment Use and Services Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;1, 2020, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">20-F</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39363</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">4.14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">March&#160;30,&#160;2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.15#</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312520163109/d865842dex1016.htm">2020 Stock Option and Incentive Plan and forms of award agreements thereunder </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">F-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-237702</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">10.16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">June&#160;8, 2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.16&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312522082242/d268932dex416.htm">License, Development and Commercialization Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;10, 2021, by and between Immatics Biotechnologies GmbH and Bristol-Myers Squibb Company </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">20-F</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39363</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">4.16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">March&#160;23,&#160;2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.17&#8224;*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex417.htm">Collaboration Agreement, dated as of June&#160;1, 2022, by and between Immatics US, Inc. and Celgene Switzerland LLC </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit <br />Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File&#160;Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing&#160;Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;8.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1809196/000119312521099162/d149615dex81.htm">Subsidiaries </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">20-F</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39363</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">8.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">March&#160;30,&#160;2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;12.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex121.htm">Certification of Principal Executive Officer Pursuant to Rules <span style="white-space:nowrap">13a-14(a)</span> and <span style="white-space:nowrap">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section<span style="text-decoration:underline"></span>&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;12.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex122.htm">Certification of Principal Financial Officer Pursuant to Rules <span style="white-space:nowrap">13a-14(a)</span> and <span style="white-space:nowrap">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section<span style="text-decoration:underline"></span>&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;13.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex131.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section<span style="text-decoration:underline"></span>&#160;1350, as Adopted Pursuant to Section<span style="text-decoration:underline"></span>&#160;906 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;13.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex132.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section<span style="text-decoration:underline"></span>&#160;1350, as Adopted Pursuant to Section<span style="text-decoration:underline"></span>&#160;906 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;15.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d400206dex151.htm">Consent of PricewaterhouseCoopers GmbH Wirtschaftspr&#252;fungsgesellschaft </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Indicates a management contract or any compensatory plan, contract or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been redacted in compliance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(6) and Item 601(b)(10). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" /><div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="imtx-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="index" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin400206_1">Report of Independent Registered Public Accounting Firm (PricewaterhouseCoopers GmbH Wirtschaftspr&#252;fungsgesellschaft, Stuttgart, Germany, Auditor Firm ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2022To12_31_2022">1275</ix:nonNumeric>)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><a href="#fin400206_3">Consolidated Statement of Profit/(Loss) of Immatics N.V.</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><a href="#fin400206_4">Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin400206_2">Consolidated Statement of Financial Position of Immatics N.V.</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin400206_5">Consolidated Statement of Cash Flows</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin400206_6">Consolidated Statement of Changes in Shareholders&#8217; equity (deficit) of Immatics N.V.</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin400206_7">Notes to the Consolidated Financial Statements of Immatics N.V.</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin400206_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To the<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Shareholders and Board of Directors of IMMATICS N.V. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial Statements </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated statement of financial position of IMMATICS N.V. and its subsidiaries<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>(the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, and the related consolidated statements of profit/(loss), comprehensive income/(loss), changes in shareholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December&#160;31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2022To12_31_2022">Stuttgart, Germany</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;22, 2023 </div> <ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2022To12_31_2022"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers GmbH </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&#252;fungsgesellschaft </div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 47%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">/s/ Stefanie Fink</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">/s/ ppa. Jens Rosenberger</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Wirtschaftspr&#252;ferin</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">Wirtschaftspr&#252;fer</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">(German Public Auditor)</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">(German Public Auditor)</div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2019. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin400206_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Profit/(Loss) of Immatics N.V. </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros&#160;in&#160;thousands,&#160;except share<br/> and per share data)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue from collaboration agreements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,763</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">106,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,186</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">325</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating result</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,954</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86,294</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">69,715</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of liabilities for warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,945</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share listing expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:ShareListingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,787</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financial income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,675</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,949</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financial expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherFinanceCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,279</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherFinanceCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherFinanceCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,063</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial result</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncomeCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,082</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceIncomeCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,041</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceIncomeCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">142,126</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit/(loss) before taxes</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,036</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Taxes on income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net profit/(loss)</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Attributable to:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity holders of the parent</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net profit/(loss) per share:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">1.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">4.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">1.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">4.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin400206_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V. </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net profit/(loss)</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other comprehensive income/(loss)</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">Items that may be reclassified subsequently to profit or loss</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences from foreign operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income/(loss) for the year</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,978</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,821</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">218,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Attributable to:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity holders of the parent</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">217,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin400206_2" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Financial Position of Immatics N.V. </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148,519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">377,154</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,207</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,033</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,439</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">407,820</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">174,646</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and shareholders&#8217; equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,056</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities for warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentWarrantLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentWarrantLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">106,452</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">95,148</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,204</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,435</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share premium</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">714,177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">565,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">500,299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">537,813</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,945</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total shareholders&#8217; equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,164</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities and shareholders&#8217; equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">407,820</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">174,646</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin400206_5" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Cash Flows of Immatics N.V. </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net profit/(loss)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Taxes on income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit/(loss) before tax</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,036</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjustments for:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share listing expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForShareListingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,787</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity settled share-based payment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentForEquitySettledSharebasedPayment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentForEquitySettledSharebasedPayment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentForEquitySettledSharebasedPayment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">MD Anderson compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Decrease) Increase in other liabilities resulting from share appreciation rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,036</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment related to share-based compensation awards previously classified as equity-settled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:PaymentsForShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences and expected credit losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of liabilities for warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,945</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Changes in:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Increase)/decrease in accounts receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">294</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Increase) in other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">483</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/(decrease) in deferred revenue, accounts payables and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31,784</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidRefund" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,131</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,746</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,696</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments for property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,420</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments for investments classified in Other financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">216,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,087</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturity of investments classified in Other financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments for intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from disposal of property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">209,791</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,493</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,949</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of shares to equity holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">134,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">217,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs deducted from equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:TransactionCostsDeductedFromEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,931</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:TransactionCostsDeductedFromEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">123,710</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,613</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,883</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,050</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,866</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,238</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">103,353</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes and expected credit losses on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,061</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148,519</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin400206_6" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Changes in Shareholders&#8217; equity (deficit) of Immatics N.V. </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share<br/> capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share<br/> premium</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> reserves</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total equity<br/> (deficit)<br/> attributable<br/> to<br/> shareholders<br/> of the parent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-<br/> controlling<br/> interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> share-<br/> holders&#8217;<br/> equity<br/> (deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of January&#160;1, 2020</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,164</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">190,945</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">233,194</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">770</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,855</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,020</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,835</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Comprehensive loss for the year</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,284</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,689</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">217,973</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">557</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">218,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reorganization</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseThroughReorganizationEquity" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseThroughReorganizationEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issue of share capital</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">MD Anderson Share Exchange</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Financing, net of transaction<br/> costs</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">89,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,077</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,077</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ARYA Merger, net of transaction costs</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreaseThroughARYAMerger" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreaseThroughARYAMerger" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">237,864</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreaseThroughARYAMerger" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">238,044</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreaseThroughARYAMerger" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">238,044</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SAR conversion</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:SARConversion" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:SARConversion" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total issuance of share capital</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:IncreasedecreaseThroughIssuanceOfEquity" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">298</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:IncreasedecreaseThroughIssuanceOfEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">328,331</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:IncreasedecreaseThroughIssuanceOfEquity" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">328,629</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="imtx:IncreasedecreaseThroughIssuanceOfEquity" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">508</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:IncreasedecreaseThroughIssuanceOfEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">328,121</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity-settled share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments related to share-based compensation awards previously classified as equity-settled</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">MD Anderson milestone compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreasedecreaseThroughCompensationExpense" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IncreasedecreaseThroughCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">538,695</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">444,478</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,459</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,387</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,387</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">538,695</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">444,478</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,459</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,387</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,387</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Comprehensive loss for the year</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,821</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,821</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity-settled share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share options exercised</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">565,192</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">537,813</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,945</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of January&#160;1, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">565,192</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">537,813</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,945</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net profit</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Comprehensive income for the year</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,978</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,978</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity-settled share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share options exercised</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issue of share capital &#8211; net of transaction costs</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IssueOfShareCapitalNetOfTransactionCosts" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IssueOfShareCapitalNetOfTransactionCosts" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IssueOfShareCapitalNetOfTransactionCosts" contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:IssueOfShareCapitalNetOfTransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">767</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">714,177</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">500,299</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,481</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,164</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,164</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin400206_7" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements of Immatics N.V. </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfCompositionOfGroupExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Group information </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics N.V., together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (&#8220;Immatics&#8221; or &#8220;the Group&#8221;) is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Immatics N.V., a Dutch public limited liability company, was converted on July&#160;1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became wholly-owned subsidiaries of Immatics N.V. as part of the ARYA Merger (see Note 3) on July&#160;1, 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics N.V. is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 T&#252;bingen, Germany. Prior to July&#160;1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Immatics N.V. is the ultimate parent company of the Group. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These annual consolidated financial statements of the Group for the year ended <ix:nonNumeric name="ifrs-full:DateOfEndOfReportingPeriod2013" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-year-en">December 31, 2022</ix:nonNumeric> were authorized for issue by the Board of Directors of Immatics N.V. on <ix:nonNumeric name="ifrs-full:DateOfAuthorisationForIssueOfFinancialStatements2013" contextRef="P03_22_2023To03_22_2023_AuthorizationOfFinancialStatementsMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis" format="ixt:date-monthname-day-year-en">March 22, 2023</ix:nonNumeric>. </div> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453024">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Basis of presentation </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (&#8220;IFRS IC&#8221;). The consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. For technical reasons, the information provided in these financial statements may contain rounding differences of +/- one unit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc., are fully consolidated from the date upon which control was transferred to Immatics N.V. All intra-company assets and liabilities, equity, income, expenses and cash flows relating to transactions between the Group are eliminated in full upon consolidation. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">The consolidated statement of profit or loss is prepared based on the function of expense method. The financial statements were prepared in accordance with the historical cost principle and on a going concern basis. This excludes financial liabilities for warrants, which are measured at fair value. The presentation in the consolidated statement of financial position distinguishes between current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets and liabilities. Assets are classified as current if it is expected to realise to sell or consume the asset in its normal operating cycle. Liabilities are classified as current if it is due within one year. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reporting period for Immatics N.V. and its subsidiaries corresponds with the calendar year. The reporting period 2022 began on January&#160;1, 2022 and ended on December&#160;31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;1, 2020 and as part of the ARYA Merger, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of MD Anderson in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V. See Note 3 for further details. The consolidated financial statements comprise the financial statements of Immatics N.V. and its wholly-owned subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="imtx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70454439">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Going concern </div></div></td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Group&#8217;s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude></div> </ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70454439" continuedAt="TextSelectionAppend_70454439_1"><ix:continuation id="TextSelection_70453024" continuedAt="TextSelectionAppend_70453024_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453024_1" continuedAt="TextSelectionAppend_70453024_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453024_2" continuedAt="TextSelectionAppend_70453024_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453024_3"><ix:continuation id="TextSelectionAppend_70454439_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketed any products commercially. Immatics&#8217; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics&#8217; cash and cash equivalents, bonds as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the financial statements. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. </div></div></div></ix:continuation> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="imtx:DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not result in a negative impact of the Group&#8217;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#8217;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. </div></ix:nonNumeric> <ix:nonNumeric name="imtx:DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2.3 Russian-Ukraine Conflict and macroeconomic environment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. </div> </ix:nonNumeric></ix:continuation> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="imtx:AryaMergerTransactionExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70454614">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ARYA Merger </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2020, Immatics entered into a definitive merger agreement with ARYA Sciences Acquisition Corp. (&#8220;ARYA&#8221;), a special purpose acquisition company sponsored by Perceptive Advisors. The transaction closed on July&#160;1, 2020. The merger (&#8220;ARYA Merger&#8221;) was effectuated as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The shareholders of Immatics Biotechnologies GmbH exchanged their interest for ordinary shares in the share capital of Immatics B.V. (&#8220;the Reorganization&#8221;). The Reorganization is accounted for as a recapitalization, with Immatics Biotechnologies GmbH being the accounting predecessor. The Reorganization resulted in a &#8364;<ix:nonFraction name="imtx:IncreaseDecreaseThroughReorganizationEquity" contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million decrease in share capital and an offsetting increase in share premium. Subsequent to the Reorganization, Immatics B.V. was converted into Immatics N.V., after the share exchange of Immatics shareholders. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As part of the Reorganization, the minority shareholder in Immatics US, Inc., MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) exchanged its interest in Immatics US, Inc. for ordinary shares</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-9</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_70454614" continuedAt="TextSelectionAppend_70454614_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70454614_1" continuedAt="TextSelectionAppend_70454614_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70454614_2" continuedAt="TextSelectionAppend_70454614_3"><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in the share capital of Immatics N.V. (&#8220;MD Anderson Share Exchange&#8221;). This resulted in a decrease to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#8364;<ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million, with corresponding increases to share capital and share premium. (See Note 19). </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">ARYA merged into Immatics N.V., with former ARYA shareholders receiving <ix:nonNumeric name="ifrs-full:DescriptionOfHowAcquirerObtainedControlOfAcquiree" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis">one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares</ix:nonNumeric> in ARYA. The merger of ARYA constituted a transaction by Immatics N.V., which is accounted for within the scope of IFRS 2. </div></td></tr></table></ix:continuation></div></div> </div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70454614_3"><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As part of the transaction, former shareholders of ARYA received <ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,968,750</ix:nonFraction> shares of Immatics N.V. and <ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">7,187,500</ix:nonFraction> warrants (&#8220;Immatics Warrants&#8221;) to purchase ordinary shares of Immatics N.V. In exchange, Immatics received the net assets held by ARYA, which had a fair value of &#8364;<ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">90.3</ix:nonFraction>&#160;million upon closing of the transaction on July&#160;1, 2020. The net assets included &#8364;<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">128.8</ix:nonFraction>&#160;million of cash and cash equivalents held in ARYA&#8217;s trust account and current liabilities of &#8364;<ix:nonFraction name="ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction>&#160;million as well as the fair value of the warrants in the amount of &#8364;<ix:nonFraction name="imtx:FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.6</ix:nonFraction>&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS 2, the difference between the fair value of the net assets contributed by ARYA and the fair value of equity instruments provided to former ARYA shareholders is treated as an expense, resulting in a &#8364;<ix:nonFraction name="imtx:ShareListingExpense" contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">152.8</ix:nonFraction>&#160;million share listing expense classified within the financial result (See&#160;Note 15) and an increase in equity. The 7,187,500 Immatics Warrants give the holder the right, but not the obligation, to subscribe to Immatics&#8217; shares at a fixed or determinable price for a specified period of time subject to the provision of the Warrant Agreement. Those instruments were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32. Due to an option of cashless exercise of the Immatics Warrants, which gives Immatics a choice over how the warrant is settled with a settlement alternative, that results in Immatics delivering a variable number of shares. Therefore, the Immatics Warrants are accounted for as financial liability through profit and loss. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Immatics N.V. raised an additional net &#8364;<ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="P07_01_2020To07_01_2020_PipeFinancingMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">90.1</ix:nonFraction>&#160;million in net equity proceeds through a private placement of ordinary shares with existing shareholders of Immatics, ARYA and other new investors (&#8220; Financing&#8221;). The PIPE Financing is treated as a capital contribution, which resulted in increases of &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To07_01_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To07_01_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">90.0</ix:nonFraction>&#160;million to share capital and share premium, respectively. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both the ARYA Merger and PIPE Financing closed as of July&#160;1, 2020. Upon consummation of the transactions, Immatics N.V. became a publicly traded corporation at the Nasdaq Capital Market under the ticker IMTX. The Immatics Warrants are traded under the ticker IMTXW. Immatics incurred incremental transaction costs directly attributable to the issuance of new shares to ARYA shareholders and the PIPE Financing of &#8364;<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To07_01_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.9</ix:nonFraction>&#160;million, which it netted against the equity proceeds as a reduction in share premium. Immatics also amended existing share-based compensation agreements held by employees of Immatics GmbH prior to the ARYA Merger (See Note 17), in addition to making additional cash and share-based payments to key management personnel (See Note 25). </div></ix:continuation> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453049">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Application of new and revised international financial reporting standards </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Application of new standards </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December&#160;31, 2021, except for the adoption of new standards and interpretations effective as of January&#160;1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-10</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453049" continuedAt="TextSelectionAppend_70453049_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453049_1" continuedAt="TextSelectionAppend_70453049_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453049_2" continuedAt="TextSelectionAppend_70453049_3"><ix:nonNumeric name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">New standards and interpretations applied for the first time: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis">Amendment IAS 16 &#8211; Property, Plant and Equipment (Proceeds before Intended Use)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis">Amendment IAS 37 &#8211; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#8211;Cost of Fulfilling a Contract)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis">Amendments to IFRS 3 &#8211; Business Combinations (Reference to the Conceptual Framework)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis">Amendments to IFRS 1 &#8211; First-time Adoption of International Financial Reporting Standards</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis">Amendments to IFRS 9 &#8211; Financial Instruments</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis">Amendments to Illustrative Examples accompanying IFRS 16</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis">Amendments to IAS 41 &#8211; Agriculture</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Those amendments on standards and interpretations had no effect on the consolidated financial statements of the Group. </div><div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Assessment of potential impact of future standards, amendments to existing standards and interpretations </div></div></td></tr></table><ix:nonNumeric name="imtx:DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December&#160;31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Potentially<br/> material&#160;effect&#160;expected<br/> on Immatics financial<br/> statements</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis">IFRS 17 &#8211; Insurance Contracts</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2023</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis">Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2023</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis">Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2023</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis">Amendments to IAS 12 &#8211; Income Taxes</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2023</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis">Amendment to IFRS 16 &#8211; Leases on sale and leaseback</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2024</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="ifrs-full:TitleOfNewIFRS" contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis">Amendment to IAS 1 &#8211; Presentation of Financial Statements (Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities with covenants)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired" contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis" format="ixt:date-monthname-day-year-en">January 1, 2024</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr></table> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.3</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revision of previously issued financial statements </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the preparation of the unaudited interim consolidated financial statements for the three and nine months ended September&#160;30, 2022, the Group identified an error in the presentation of &#8216;Net foreign exchange differences&#8217; and &#8216;Effects of exchange rate changes on cash and cash equivalents&#8217; in the statement of cash flows. The error resulted in a presentation of effects from exchange rate changes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency denominated cash and cash equivalents in Immatics N.V. and Immatics Biotechnologies GmbH as operating cash flow instead of presentation as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items in &#8216;Effects of exchange rate changes on cash and cash equivalents&#8217;. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude></div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453049_3" continuedAt="TextSelectionAppend_70453049_4"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453049_4" continuedAt="TextSelectionAppend_70453049_5"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453049_5" continuedAt="TextSelectionAppend_70453049_6"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453049_6"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This error had no impact on the Company&#8217;s consolidated statements of financial position, of profit/(loss), of comprehensive income/(loss) and of consolidated statements of changes in equity. The Company assessed the materiality of these errors on the previously issued consolidated financial statements and concluded that the errors were not material to any year presented.&#160;<ix:nonNumeric name="ifrs-full:DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70454640">The impact of the revision of the previously issued financial statements is as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_70454640"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,611</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,914</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,697</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,949</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,949</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,883</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,883</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">106,324</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,914</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,238</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">103,353</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2019_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">103,353</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,061</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,785</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,962</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,747</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,493</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,493</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,613</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,613</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">76,904</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,962</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,866</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,368</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_CurrentlyReportedMembersrtRestatementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also reclassed &#8364;<ix:nonFraction name="imtx:ReclassficationOfProvisionsToOtherCurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction>&#160;thousand from Provisions to Other current liabilities as of December&#160;31, 2021. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453131">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of accounting policies applied by the Group for the annual reporting period ending December&#160;31, 2022 </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the significant accounting policies applied by the Group in preparing its consolidated financial statements: </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment information </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#8217;s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group&#8217;s resources. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453131" continuedAt="TextSelectionAppend_70453131_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_1" continuedAt="TextSelectionAppend_70453131_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_2" continuedAt="TextSelectionAppend_70453131_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_3" continuedAt="TextSelectionAppend_70453131_4"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds), short-term deposits and bonds with an original maturity of three months or less.</div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453134">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Initial recognition and measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. </div><div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Short-term deposits </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics has short-term deposits with original maturities between three and twelve months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Bonds </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics holds bonds with an original maturity of more than three months, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Receivables </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has receivables from collaboration agreements. Receivables must be capitalized at the point in time at which the Group has become a contractual partner and an unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, receivables are measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group&#8217;s receivables have an expected maturity of less than 12 months. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Interest and other finance income and expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income and expenses from financial instruments are recorded using the effective interest rate (&#8220;EIR&#8221;). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Profit/(Loss). As of December&#160;31, 2022 and 2021, Immatics is not a counterparty in foreign exchange forward contracts. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Impairment of financial assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses on financial assets are recognized as financial expenses. The Group recognizes an allowance for expected credit losses (ECLs) for financial assets, see Note 16. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_70453134" continuedAt="TextSelectionAppend_70453134_1"><ix:continuation id="TextSelectionAppend_70453131_4" continuedAt="TextSelectionAppend_70453131_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_5" continuedAt="TextSelectionAppend_70453131_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_6" continuedAt="TextSelectionAppend_70453131_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_7" continuedAt="TextSelectionAppend_70453131_8"><ix:continuation id="TextSelectionAppend_70453134_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-months</div> (a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing information (credit default swap values) published by credit agencies and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL. </div> </ix:continuation> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expenses when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. <ix:nonNumeric name="imtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453145">The estimated useful lives are generally within the following ranges: </ix:nonNumeric></div> <ix:continuation id="TextSelection_70453145"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" format="ixt-sec:duryear">1</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" format="ixt-sec:duryear">1</ix:nonNumeric> &#8211; <ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" format="ixt-sec:duryear">15</ix:nonNumeric> years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Office equipment and installations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" format="ixt-sec:duryear">2</ix:nonNumeric> &#8211; <ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis" format="ixt-sec:duryear">20</ix:nonNumeric> years</td> </tr> </table></ix:continuation> </ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.5</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. </div> <ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" format="ixt-sec:duryear">5</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" format="ixt-sec:duryear">30</ix:nonNumeric>&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" format="ixt-sec:duryear">1</ix:nonNumeric> &#8211; <ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453137">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.6</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Research and development </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research costs are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2022, 2021 and 2020 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_70453137" continuedAt="TextSelectionAppend_70453137_1"><ix:continuation id="TextSelectionAppend_70453131_8" continuedAt="TextSelectionAppend_70453131_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453131_9" continuedAt="TextSelectionAppend_70453131_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_10" continuedAt="TextSelectionAppend_70453131_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_11" continuedAt="TextSelectionAppend_70453131_12"><ix:continuation id="TextSelectionAppend_70453137_1">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">laboratory costs; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">5.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">6.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. </div> </td> </tr> </table> </ix:continuation> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.7</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities: Initial recognition and measurement </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company&#8217;s financial liabilities include accounts payables, lease liabilities, warrant liabilities and other financial liabilities. Immatics recognized accounts payables and other current liabilities as other financial liabilities at amortized costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. </div> </ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453139">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.8</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted IFRS 16 (&#8220;Leases&#8221;) effective January&#160;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Group has elected not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Under IFRS 16, leases are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset with a corresponding liability on the date at which the leased asset is available for use by the Group (lease commencement date). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">fixed payments (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed payments), less any lease incentives received; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">amounts expected to be payable by the Group under residual value guarantees; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_70453139" continuedAt="TextSelectionAppend_70453139_1"><ix:continuation id="TextSelectionAppend_70453131_12" continuedAt="TextSelectionAppend_70453131_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453131_13" continuedAt="TextSelectionAppend_70453131_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_14" continuedAt="TextSelectionAppend_70453131_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_15" continuedAt="TextSelectionAppend_70453131_16"><ix:continuation id="TextSelectionAppend_70453139_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease term consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#8217;s leases, the lessee&#8217;s incremental borrowing rate (&#8220;IBR&#8221;) is used. The IBR is the rate that the individual lessee would have to pay to borrow the funds, necessary to obtain an asset of similar value to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset in a similar economic environment with similar terms, security and conditions. The Group used an IBR for each respective lease to calculate the initial lease liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the IBR, the Group: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">uses a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-up</div> approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Immatics; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">makes adjustments specific to the lease, including lease term, country, currency and security. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost comprising the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the amount of the initial measurement of lease liability; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any lease payments made at or before the commencement date less any lease incentives received; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any initial direct costs; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">restoration costs. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are generally depreciated over the shorter of the asset&#8217;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is depreciated over the underlying asset&#8217;s useful life. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments associated with short-term leases of equipment and vehicles and all leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> assets have a value of less than &#8364;5&#160;thousand. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group&#8217;s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December&#160;31, 2022 to determine whether option extensions are reasonably certain. </div></ix:continuation><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453140">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue from collaboration agreements </div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place, one with Genmab A/S, Copenhagen /Denmark (&#8220;Genmab&#8221;) and three with Bristol-Myers-Squibb (&#8220;BMS&#8221;). During the year ended December&#160;31, 2022, the Group entered into new collaboration agreements with BMS. Three of the Group&#8217;s strategic collaboration agreements are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage and the BMS IMA401 collaboration agreement is at clinical stage. The collaboration with GlaxoSmithKline Intellectual Property Development Limited (&#8220;GSK&#8221;) was terminated in October 2022 and the collaboration with Amgen Inc., Thousand Oaks/CA/USA (&#8220;Amgen&#8221;) was terminated in October 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the contract(s) with a customer; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the performance obligations in the contract; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_70453140" continuedAt="TextSelectionAppend_70453140_1"><ix:continuation id="TextSelectionAppend_70453131_16" continuedAt="TextSelectionAppend_70453131_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_17" continuedAt="TextSelectionAppend_70453131_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_18" continuedAt="TextSelectionAppend_70453131_19"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453140_1" continuedAt="TextSelectionAppend_70453140_2"><ix:continuation id="TextSelectionAppend_70453131_19" continuedAt="TextSelectionAppend_70453131_20">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">determine the transaction price; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">allocate the transaction price to the performance obligations in the contract; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">recognize revenue when (or as) the Group satisfies a performance obligation. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under the collaboration agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Identify the performance obligations in the contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> collaboration agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-targets</div> using Immatics&#8217; proprietary technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> participation on steering committees, and preparation of data packages. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group&#8217;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#8217; research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group&#8217;s XPRESIDENT technology and database of target and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> data. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical collaboration agreement (BMS IMA401 agreement) </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Immatics granted to Bristol-Myers Squibb an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401. Under the Agreement, Immatics is also responsible for, and will bear the cost of, the first Phase 1 clinical trial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The license contributed under the collaboration agreement represents a distinct performance obligation, because they are separately identifiable from other promises in the BMS IMA401 agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Determine the transaction price </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Upfront payment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Group&#8217;s strategic collaboration agreements includes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment. The Group records these payments as deferred revenue, which it allocates to the combined performance obligations for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude> </div></ix:continuation></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_70453140_2" continuedAt="TextSelectionAppend_70453140_3"><ix:continuation id="TextSelectionAppend_70453131_20" continuedAt="TextSelectionAppend_70453131_21"><div></div></ix:continuation></ix:continuation></div><ix:continuation id="TextSelectionAppend_70453140_3" continuedAt="TextSelectionAppend_70453140_4"><ix:continuation id="TextSelectionAppend_70453131_21" continuedAt="TextSelectionAppend_70453131_22"><div><div style="background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></ix:continuation></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_22" continuedAt="TextSelectionAppend_70453131_23"><ix:continuation id="TextSelectionAppend_70453140_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using direct costs and directly attributable personnel costs is considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#8217;s collaboration partners, due to the nature of the work being performed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Group&#8217;s BMS IMA401 agreement, the Group determined the underlying stand-alone selling price for each performance obligation to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price requires significant judgement regarding the estimation approach of the stand-alone selling prices for the distinct performance obligations as well as significant estimates regarding the expected cost for future services, profit margins and development timelines. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reimbursement for services </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are part of the transaction price and presented as revenue and not deducted from expenses. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development and Commercial Milestones </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales-based milestones and royalty payments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to fulfill contracts </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to obtain a contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. </div></ix:continuation><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453141">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.10</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Share-based payment </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 17. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_70453141" continuedAt="TextSelectionAppend_70453141_1"><ix:continuation id="TextSelectionAppend_70453131_23" continuedAt="TextSelectionAppend_70453131_24"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_24" continuedAt="TextSelectionAppend_70453131_25"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_25" continuedAt="TextSelectionAppend_70453131_26"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_26" continuedAt="TextSelectionAppend_70453131_27"><ix:continuation id="TextSelectionAppend_70453141_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.</div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5.11 Foreign currency </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Transactions and balances in Germany and in the USA </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements are presented in Euro, which is the parents, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Profit/(Loss) is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD.<ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453147"> The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: </ix:nonNumeric></div><ix:continuation id="TextSelection_70453147"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Euros per U.S.&#160;Dollar</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.93756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.94888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.88292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.84495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.81493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="5" scale="0" format="ixt:num-dot-decimal">0.87621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.12</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value of financial instruments </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the principal market for the asset or liability or </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 &#8212; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessing</div> categorization (based on the lowest level input that is significant to the fair value measurement as a whole), at the end of each reporting period. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453131_27" continuedAt="TextSelectionAppend_70453131_28"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_28" continuedAt="TextSelectionAppend_70453131_29"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453131_29" continuedAt="TextSelectionAppend_70453131_30"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453131_30"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.13</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Provisions </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the effect of the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects, when appropriate, the risks specific to the liability. </div> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.14</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred income tax </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (&#8220;Income Taxes&#8221;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority. </div> </ix:nonNumeric></ix:continuation> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453169">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Significant accounting judgements, estimates and assumptions </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Group&#8217;s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. In particular, material management judgments and estimation uncertainties apply to the recognition and measurement of income taxes (incl. deferred taxes), the revenue recognition from collaboration agreements and the measurement of share-based payments. Management bases its assessment of these judgments and estimation uncertainties on past experience, estimates from experts (lawyers, tax consultants, etc.) and the results of carefully weighing up different scenarios. Actual events and developments that lie beyond the control of management may deviate considerably from the expressed developments and assumptions. For this reason, the Group examines the estimates and assumptions made on an ongoing basis. Changes in estimates are recognized in profit or loss as soon as better information is available. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taxes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expenses already recorded. Deferred tax assets are recognized for unused tax losses to the extent, that it is probable that taxable profit will be available which can be utilized against the losses. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Due to the Group&#8217;s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group has not recognized any deferred tax assets on tax losses carried forward. Changes in the estimation of our potential to use tax losses carried forward can have a material effect on the Group`s net income. For more information, see Note 21. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_70453169" continuedAt="TextSelectionAppend_70453169_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453169_1" continuedAt="TextSelectionAppend_70453169_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453169_2" continuedAt="TextSelectionAppend_70453169_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453169_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition from collaboration agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the collaboration agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. For the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> collaboration agreements with Genmab and BMS, the Group assessed that these promises are not capable of being distinct within the context of the contract, which results in accounting for all goods and services promised as a single performance obligation with a single measure of progress. The performance obligation is accounted for as a performance obligation, satisfied over time using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method as the customer simultaneously receives and consumes the benefits from Immatics&#8217; performance. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the BMS IMA401 agreement, the Group assessed that these promises were two distinct performance obligations, the granted license and the conduct of clinical trial services. Since the collaboration agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation and allocated the transaction price to the performance obligations. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group used for the performance obligation related to clinical trial services, the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. The Group decided to estimate a stand-alone selling price for the performance obligation related to the license by using the residual approach, since it is a unique license and there is no available market price for the license. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-front</div> licensing payments are initially deferred on our Consolidated Statement of Financial Position and subsequently recognized as revenue as the performance obligations are fulfilled. Milestone payments are included in the transaction price at the amount stipulated in the respective agreement and recognized as revenue to the extent that it is highly probable that a&#160;significant reversal&#160;in the amount of cumulative revenue recognized will not occur. To date, no milestone has been included in the transaction price. Changes in this estimate can have a material effect on revenue recognized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics provides development and manufacturing services to customers and recognizes revenue over time using an input-based method to measure progress toward complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before the Group can use them for recognition purposes. Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which includes total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on revenue recognized. For more information, see Note 13. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management determined the value of share-based awards with the assistance of a third-party valuation specialist using certain assumptions, such as volatility, risk-free interest rate, exercise pattern and expected dividends. Changes in these estimates can have a material effect on share-based expenses recognized. For more information, see Note 17. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-21 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="imtx:DisclosureOfAccountReceivableExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accounts receivables </div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Receivables from collaboration agreements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:ReceivablesFromCollaborationAgreements" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:ReceivablesFromCollaborationAgreements" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, and 2021, <ix:nonFraction name="ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> expected credit losses were recognized. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfOtherAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453116">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div> </td> </tr> </table> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Value added tax receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Grant receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrentGrantReceivable" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrentGrantReceivable" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">950</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,838</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,408</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">On May&#160;27, 2022, Immatics US, Inc. entered into a Research collaboration and License agreement (the &#8220;Editas agreement&#8221;) with Editas Medicine, Inc. (&#8220;Editas&#8221;). The Editas agreement became effective on May&#160;27, 2022. Pursuant to the Editas agreement, the Group paid upfront a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> fee related to the Groups access to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> right to Editas CRISPR technology and intellectual property as well as for services provided by Editas. The Group will together with Editas combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. The Group determined to account for the upfront payment as prepaid research and development expenses. The prepaid expenses will be consumed over the term of the research and development activities. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include expenses for licenses and software of &#8364;<ix:nonFraction name="imtx:PrepaidExpensesOfLicensesAndSoftware" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.4</ix:nonFraction>&#160;million as of December&#160;31, 2022 and &#8364;<ix:nonFraction name="imtx:PrepaidExpensesOfLicensesAndSoftware" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million as of December&#160;31, 2021 and prepaid insurance expenses of &#8364;<ix:nonFraction name="imtx:CurrentPrepaidInsurance" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million as of December&#160;31, 2022 and &#8364;<ix:nonFraction name="imtx:CurrentPrepaidInsurance" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million as of December&#160;31, 2021. The Group accrued &#8364;<ix:nonFraction name="imtx:CurrentIncrementalCostForCollaborationAgreement" contextRef="P01_01_2022To12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million as of December&#160;31, 2022 and &#8364;<ix:nonFraction name="imtx:CurrentIncrementalCostForCollaborationAgreement" contextRef="P01_01_2021To12_31_2021_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million as of December&#160;31, 2021 of incremental cost for the successful arrangement of the BMS collaboration signed in 2019 and the Genmab collaboration agreement. Additionally, prepaid expenses include expenses for maintenance of &#8364;<ix:nonFraction name="imtx:CurrentPrepaidMaintenanceExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million as of December&#160;31, 2022 and &#8364;<ix:nonFraction name="imtx:CurrentPrepaidMaintenanceExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million as of December&#160;31, 2021. The remaining amount is mainly related to prepaid expenses for contract research organizations and prepaid rent. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other assets include receivables from lease incentive, capital gains tax and prepaid deposit expenses. </div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets consist of the following:</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentPrepayments" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,906</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentPrepayments" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:OtherNonCurrentAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">639</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:OtherNonCurrentAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_70453116" continuedAt="TextSelectionAppend_70453116_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453116_1" continuedAt="TextSelectionAppend_70453116_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453116_2" continuedAt="TextSelectionAppend_70453116_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_70453116_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion of prepayments for licensing agreements of &#8364;<ix:nonFraction name="imtx:NoncurrentPrepaymentsOfLicensingAgreement" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million, prepaid maintenance expenses of &#8364;<ix:nonFraction name="imtx:NonCurrentPrepaidMaintenanceExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million and accrued incremental cost of the BMS and Genmab collaboration agreement of &#8364;<ix:nonFraction name="ifrs-full:NoncurrentPrepayments" contextRef="PAsOn12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million as of December&#160;31, 2022. Other assets include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion for prepaid deposit expenses. </div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453119">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div> </td> </tr> </table> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Laboratory<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computer<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/> equipment<br/> and<br/> installations</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,968</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,322</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,436</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,630</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,470</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,661</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,761</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,476</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,428</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,665</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,569</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,052</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,966</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,237</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,255</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,578</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,504</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,424</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,506</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,630</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,470</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,661</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,761</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,737</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,898</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,303</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,938</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,052</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,966</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,237</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,255</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">333</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:AdditionsOtherPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DisposalsOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:CurrencyTranslationDifferences" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,279</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,636</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,567</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,482</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,458</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,262</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,736</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,456</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Groups additions within Office equipment and installations include leasehold improvements for the research and commercial GMP manufacturing facility construction in Houston, Texas of &#8364;<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million as of December&#160;31, 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_70453119" continuedAt="TextSelectionAppend_70453119_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453119_1" continuedAt="TextSelectionAppend_70453119_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453119_2" continuedAt="TextSelectionAppend_70453119_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453119_3"><ix:nonNumeric name="imtx:DisclosureOfDepreciationExpensesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,502</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,129</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,574</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,102</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patents<br/> and<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Software<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,132</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">738</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,870</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">908</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,459</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">403</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">554</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">957</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">480</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">664</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,144</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,071</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,315</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,029</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">988</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,017</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">480</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">664</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,144</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">218</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">559</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">826</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,385</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,470</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">162</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsAndGoodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,632</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="imtx:DisclosureOfAmortizationExpensesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">218</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">126</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="ifrs-full:DisclosureOfLeasesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453300">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of</div> use assets consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,033</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,982</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="imtx:DisclosureOfLeaseLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities &#8211; current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Lease liabilities &#8211; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,562</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,853</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additions to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities were &#8364;<ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively, including for the research and commercial GMP manufacturing facility in Houston, Texas of &#8364;<ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2022To12_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.2</ix:nonFraction>&#160;million as of December&#160;31, 2022. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Currency translation differences included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets were &#8364;<ix:nonFraction name="imtx:TranslationDifferenceOnRightOfUseAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="imtx:TranslationDifferenceOnRightOfUseAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. </div><ix:nonNumeric name="imtx:DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Expenses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation charges of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros&#160;in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,620</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,526</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,195</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses from leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:InterestExpenseOnLease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">613</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:InterestExpenseOnLease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:InterestExpenseOnLease" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Expenses relating to short-term leases and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets (included in administrative expenses)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total cash payments for leases were &#8364;<ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-25</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453300" continuedAt="TextSelectionAppend_70453300_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453300_1" continuedAt="TextSelectionAppend_70453300_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453300_2" continuedAt="TextSelectionAppend_70453300_3"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453300_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the Group has committed lease payments associated with lease liabilities of &#8364;<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.6</ix:nonFraction>&#160;million, of which &#8364;<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022_LaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million will occur in the next 12 months. The remaining lease payments will occur between January&#160;1, 2024 and February&#160;28, 2033.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount up to &#8364;<ix:nonFraction name="imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.6</ix:nonFraction> million until 2043 for the year ended December 31, 2022 and up to &#8364;<ix:nonFraction name="imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.4</ix:nonFraction> million until 2043 for the year ended December 31, 2021. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For commitments for future lease payments, refer to Note 24. </div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><ix:nonNumeric name="imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:AccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:AccruedLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,056</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,624</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities classified within accounts payables mainly relate to outstanding invoices totaling &#8364;<ix:nonFraction name="imtx:AccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.0</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="imtx:AccruedLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.6</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div></ix:nonNumeric><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453748">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place after the Amgen collaboration was terminated in 2021 and the GSK collaboration was terminated in 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As part of these collaboration arrangements, Immatics grants exclusive licensing rights or options thereto for the development and commercialization of future product candidates, developed for several targets defined in the respective collaboration agreements, in addition to research activities, including screening of highly specific molecules for reactivity with the specified targets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-targets</div> using Immatics&#8217; proprietary technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> participation on a joint steering committee, and preparation of data packages. For the preclinical collaboration agreements, these promises represent one combined performance obligation, whereas for the clinical stage BMS IMA401 agreement, the promises represent two distinct performance obligations. Immatics reassessed the total forecasted cost as part of the Group&#8217;s annual budget process and adjusted the total forecasted cost accordingly. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has not recognized any royalty or milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of December&#160;31, 2022, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenues are contract liabilities within the scope of IFRS 15. </div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Each of the Group&#8217;s strategic collaboration agreements included a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment, meant to subsidize research activities, recognized as deferred revenue. For all collaboration agreements these upfront </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-26</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453748" continuedAt="TextSelectionAppend_70453748_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_1" continuedAt="TextSelectionAppend_70453748_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_2" continuedAt="TextSelectionAppend_70453748_3"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payments exceeded the Group&#8217;s right to consideration for services performed under each collaboration agreement. Therefore, only deferred revenue net of contract assets is presented as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genmab Collaboration Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Genmab to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, Immatics and Genmab conduct joint research to combine Immatics&#8217; XPRESIDENT and Bispecific TCR technology platforms with Genmab&#8217;s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The two companies plan to develop immunotherapies directed against three proprietary targets. Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Genmab collaboration agreement contains a maximum of $<ix:nonFraction name="imtx:MilestonePaymentReceivable" contextRef="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis_MilestonePaymentForLicensedProductMemberIMTXMilestoneAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction>&#160;million of milestone payments for each licensed product resulting from the collaboration. In addition, Immatics is entitled to receive royalty payments. Royalty rates are based on aggregate net sales of a licensed product. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under the agreement, the royalty rates begin in the high single-digits, increasing to the low tens as a percentage of aggregate annual net sales of a licensed product. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction>&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2021To12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.9</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2020To12_31_2020_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.2</ix:nonFraction>&#160;million of revenue associated with the upfront payment and with reimbursements for research and development costs performed, for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.1</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.9</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BMS Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2019, Immatics Biotechnologies GmbH and BMS entered into a collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, Immatics may develop T Cell Receptor Engineered T Cell Therapy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TCR-T)</div> programs against solid tumor targets discovered with Immatics&#8217; XPRESIDENT technology. Programs would utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#8217; XCEPTOR TCR discovery and engineering platform. If Immatics develops programs against the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> targets, Immatics will be responsible for the development and validation of these programs through lead candidate stage, at which time BMS may exercise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-in</div> rights and assume sole responsibility for further worldwide development, manufacturing and commercialization of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> cell therapies. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Immatics would have certain early-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-funding</div> rights for selected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> cell therapies arising from the collaboration. With respect to this collaboration agreement with BMS, Immatics may be eligible to receive up to $505&#160;million for each licensed product in option exercise payments, development, regulatory and commercial milestone payments as well as tiered royalties on net sales. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under each contract, the royalty rates begin in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digits,</div> increasing to the low teen-digits as a percentage of aggregate annual net sales of a licensed product. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction>&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-27</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453748_3" continuedAt="TextSelectionAppend_70453748_4"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_4" continuedAt="TextSelectionAppend_70453748_5"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_5" continuedAt="TextSelectionAppend_70453748_6"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On June&#160;1, 2022, Immatics Biotechnologies GmbH entered into an Amendment to the Strategic Collaboration Agreement originally signed in 2019 (the &#8220;amendment&#8221;) with BMS. Pursuant to the amendment, the Group received a </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million ($</div><ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million) upfront<div style="display:inline;">&#160;</div>cash payment related to the performance obligations under the contract. Under the amendment, Immatics will undertake an additional T Cell Receptor Engineered T cell Therapy (TCR-T) program against a solid tumor target discovered with Immatics&#8217; XPRESIDENT technology. The program will utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#8217; XCEPTOR TCR discovery and engineering platform. The increased consideration reflects the stand-alone selling price at contract inception and the amendment contains performance obligations that are distinct from the original performance obligation under the contract. Therefore, the Group determined to account for the modification of the Allogeneic ACT agreement signed in 2019, triggered by the amendment as a separate contract.&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_6" continuedAt="TextSelectionAppend_70453748_7"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The Group recognized &#8364;</div><ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million, &#8364;</div><ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div><ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;</div><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BMS IMA401 Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On December&#160;10, 2021, Immatics Biotechnologies GmbH entered into a License, Development and Commercialization agreement (the &#8220;BMS IMA401 agreement&#8221;) with BMS. The BMS IMA401 agreement became effective on January&#160;26, 2022, after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on January&#160;25, 2022. Pursuant to the BMS IMA401 agreement, the Group received a</div></div>&#160;&#8364;<ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) upfront cash payment related to the performance obligations under the contract. The Group identified the transfer of a global exclusive IMA401 license including technology transfer and the contractually agreed clinical trial services including participation in Joint Steering Committee meetings as distinct performance obligations. The Group is eligible to receive up to $<ix:nonFraction name="imtx:MilestonePaymentReceivable" contextRef="PAsOn01_26_2022" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">770</ix:nonFraction>&#160;million development, regulatory and commercial milestone payments, in addition to low double-digit royalty payments on net sales of IMA401. Immatics retains the options to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-fund</div> U.S. development in exchange for enhanced U.S. royalty payments and/or to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promote</div> IMA401 in the US. In November 2021, Immatics filed a Clinical Trial Application (CTA) with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401. The clinical trial, which commenced in the second quarter of 2022, will enroll patients across various solid tumor types. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the BMS IMA401 agreement represent one performance obligation, combined performance obligations or multiple performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group concluded that BMS is a customer since the BMS IMA401agreement does contain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and BMS. The BMS IMA401 agreement clearly states deliverables to be delivered by the Group and BMS as mentioned below and creates enforceable rights and obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The manufacturing of the product for the trial is already completed. The clinical trial will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors, but there is no modification planned as part of this. With the end of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> phase, there was no further enhancement of the products planned. We therefore concluded that BMS can benefit from each performance obligation on its own and they are separately identifiable from other promises in the BMS IMA401 agreement. The Group concluded that there were two distinct performance obligations under the BMS IMA401 agreement, the granted license and the conduct of clinical trial services. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-28</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453748_7" continuedAt="TextSelectionAppend_70453748_8"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_8" continuedAt="TextSelectionAppend_70453748_9"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_9" continuedAt="TextSelectionAppend_70453748_10"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_10" continuedAt="TextSelectionAppend_70453748_11"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">At inception of the BMS IMA401 agreement, the Group determined the transaction price. We evaluated inclusion of the milestones as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The contractual agreed milestone payments with BMS relate to the license. Based on that the Group concluded that no variable consideration was considered as transaction price at contract inception. At the end of each reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group is required to allocate the determined transaction price of &#8364;<ix:nonFraction name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" contextRef="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million ($<ix:nonFraction name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" contextRef="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) to the two separate identified performance obligations of the BMS IMA401 agreement, based on the standalone selling price of each performance obligation as the upfront payment of &#8364;<ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) covers the cost of clinical trial services as well as an initial payment for the license. Since the BMS IMA401 agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation, to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price included estimates regarding forecasted cost for future services, profit margins and development timelines. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The most reasonable estimation method for the performance obligation related to clinical trial services is the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. On top of the forecast of expected costs, the Group added an appropriate profit margin based on average company profit margins for clinical trial services. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To estimate a stand-alone selling price for the performance obligation related to the IMA401 license, the Group concluded to use the residual approach due to the fact that the license is a unique license and there is no available market price for the license and hence no specific stand-alone selling price apart from the residual amount was identified. The Group concluded following transaction price allocation of the &#8364;<ix:nonFraction name="imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) upfront payment as of March&#160;31, 2022: </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.&#160;&#160;&#160;&#160;Stand-alone selling price for clinical trial services: &#8364;<ix:nonFraction name="imtx:Allocationofupfrontpaymenttowardsclinicaltrialservices" contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">42</ix:nonFraction>&#160;million </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.&#160;&#160;&#160;&#160;Stand-alone selling price for the license grant: &#8364;<ix:nonFraction name="imtx:Allocationofupfrontpaymenttowardslicensegrant" contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction>&#160;million </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group evaluated each performance obligation to determine if it can be satisfied at a point in time or over time. The control over the granted license is transferred at a point in time, after BMS obtains the rights to use the license at the effective date of the agreement. The performance obligation related to promised clinical trial services is satisfied over time. The Group transfers control of these agreed services over time and will therefore recognize revenue over time as costs are incurred using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method. At inception of the BMS IMA401 agreement, &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn03_31_2022" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">42</ix:nonFraction>&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended December&#160;31, 2022, &#8364;<ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401licensegrantMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.9</ix:nonFraction>&#160;million revenue was recognized based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method as well as &#8364;<ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction>&#160;million revenue related to the license for IMA 401. Total deferred revenue under the agreement was &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.8</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allogeneic ACT Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;1, 2022, Immatics US, Inc. entered into a License, Development and Commercialization agreement (the &#8220;Allogeneic ACT agreement&#8221;) with Bristol-Myer-Squibb Company (&#8220;BMS&#8221;). Pursuant to the Allogeneic ACT agreement, the Group received a $<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction>&#160;million upfront cash payment plus an additional payment of $<ix:nonFraction name="imtx:AdditionalPaymentRelatedToPerformanceObligationsReceived" contextRef="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;million related to the performance obligations under the contract. Applying the foreign exchange rate of June&#160;1, 2022, the received payments represent &#8364;<ix:nonFraction name="imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived" contextRef="PAsOn06_30_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.7</ix:nonFraction>&#160;million. As the contract is accounted for in the functional currency of Immatics US, Inc., </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:exclude>F-29</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453748_11" continuedAt="TextSelectionAppend_70453748_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_12" continuedAt="TextSelectionAppend_70453748_13"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_13" continuedAt="TextSelectionAppend_70453748_14"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US&#160;Dollar, the &#8364;&#160;amount is subject to currency fluctuations. The Group identified the transfer of an exclusive right and license with the right to grant sublicenses under the Immatics Licensed IP, technology transfer, contractually agreed research and development services including participation in Joint Steering Committee meetings and the delivery of research progress reports to BMS as a combined performance obligation. The Group is eligible to receive up to $<ix:nonFraction name="imtx:MilestoneRegulatoryAndRoyaltyPaymentReceived" contextRef="PAsOn06_01_2022" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million development, regulatory and commercial milestone payments, in addition to tiered royalty payments of up to low double-digit percentages on net product sales. </div><br/></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_14" continuedAt="TextSelectionAppend_70453748_15"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the Allogeneic ACT agreement represent one combined performance obligation or multiple performance obligations and the determination of whether milestone payments should be included in the transaction price.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group concluded that BMS is a customer since BMS obtains through the Allogeneic ACT agreement the output of Immatics&#8217; ordinary activities in exchange for a consideration. The Allogeneic ACT agreement clearly states the deliverables to the Group and BMS as mentioned below and creates enforceable rights and obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group granted to BMS exclusive access to licensed products and is performing research and development services. The research and development services performed by the Group will cover preclinical development of the initial two Bristol Myers Squibb-owned programs and is not distinct from the licensed IP, since the preclinical platform does not have a standalone value without further development. Based on the facts and circumstances, the collaboration agreement contains multiple promises, which aggregate to a combined performance obligation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At inception of the Allogeneic ACT agreement, the Group determined the transaction price. The Group evaluated inclusion of the milestones as well as potential cost reimbursements as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. For the contractual agreed milestone payments with BMS, the license is predominant. Based on that the Group concludes that no variable consideration is considered as transaction price at contract inception. At the end of each reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group allocated the determined total transaction price of &#8364;<ix:nonFraction name="imtx:ContractTransactionPrice" contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">66.1</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:ContractTransactionPrice" contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.8</ix:nonFraction> million) consisting of the received payments of &#8364;<ix:nonFraction name="imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived" contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.7</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived" contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction> million) as well as cost reimbursements to the single combined performance obligation of the Allogeneic ACT agreement. Based on the facts mentioned above the Group determined that the combined performance obligation related to promised research and development services is satisfied over time and therefore revenue will be recognized over time as costs for the research and development services incurred using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At inception of the Allogeneic ACT agreement, &#8364;<ix:nonFraction name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.7</ix:nonFraction>&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;<ix:nonFraction name="imtx:RevenueRecognizedDuringThePeriodPerformanceObligation" contextRef="P01_01_2022To12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.9</ix:nonFraction>&#160;million of revenue associated with the upfront payment for the year ended December&#160;31, 2022. Total deferred revenue under the agreement was &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">56.2</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amgen Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2016, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Amgen to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers. The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction>&#160;million ($<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million) upon signing of the Amgen agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:exclude>F-30</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453748_15" continuedAt="TextSelectionAppend_70453748_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_16" continuedAt="TextSelectionAppend_70453748_17"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_17" continuedAt="TextSelectionAppend_70453748_18"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The collaboration with Amgen has been discontinued in October 2021. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#8364;</div><ix:nonFraction name="imtx:ContractLiabilitiesRecognized" contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2021, no further revenue will be recognized from the collaboration thereafter.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The Group recognized &#8364;</div><ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div><ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million of revenue associated with the upfront payment during the years ended December&#160;31, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;</div><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.0</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GSK </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, Immatics entered into a collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;<ix:nonFraction name="imtx:UpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction>&#160;million for two initial programs upon signing of the GSK agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The collaboration with GSK has been discontinued in October 2022. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis_ThereafterMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">36.8</ix:nonFraction>&#160;million as of December&#160;31, 2022, no further revenue will be recognized from the collaboration thereafter. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.1</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2021To12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="P01_01_2020To12_31_2020_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction>&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.0</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">36.8</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div><ix:nonNumeric name="imtx:DisclosureOfRevenueFromCollaborationAgreementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements were realized with the following partners: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="9" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genmab, Denmark</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,929</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BMS, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amgen, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK, United Kingdom</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2022To12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,831</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2021To12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,763</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:RevenueFromCollaborationAgreements" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,253</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><ix:nonNumeric name="imtx:DisclosureOfContractLiabilitiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue related to the collaboration agreements consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">140,716</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">98,627</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost to obtain a contract </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Group incurred costs from a third party, who assists in identifying collaboration partners. The Group recognizes an asset to the extent these costs are incremental and directly related to a specific contract. The Group</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:exclude>F-31</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453748_18" continuedAt="TextSelectionAppend_70453748_19"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453748_19" continuedAt="TextSelectionAppend_70453748_20"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_20" continuedAt="TextSelectionAppend_70453748_21"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">then amortizes the asset consistently with the pattern of revenue recognition for the related contracts. Total assets, net of amortization, for these capitalized costs of obtaining a contract were &#8364;<ix:nonFraction name="ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively, which are classified in other current assets and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets. The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of &#8364;<ix:nonFraction name="ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. <br/></div></ix:continuation></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453748_21"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">, the Group is potentially liable to pay &#8364;</div><ix:nonFraction name="imtx:PotentialMilestonePaymentPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million ($</div><ix:nonFraction name="imtx:PotentialMilestonePaymentPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"> million) to a third-party upon successful completing the milestone of the first clinical lead selection in connection with Immatics&#8217; collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.</div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212; &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual for vacation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,366</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,552</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other current liabilities are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> and are due within <ix:nonNumeric name="ifrs-full:BorrowingsMaturity" contextRef="P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis">one year</ix:nonNumeric>. The carrying amounts of other current liabilities represents fair values due to their short-term nature. </div> </ix:nonNumeric><ix:nonNumeric name="imtx:ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453844"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Share listing expense and change in fair value of warrant liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 3, the ARYA Merger led to a share listing expense. Immatics issued shares with a fair value of &#8364;<ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">243.1</ix:nonFraction>&#160;million to ARYA shareholders, comprised of the fair value of Immatics shares, that were issued to ARYA shareholders of &#8364;<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.53</ix:nonFraction> per share. In exchange, Immatics received the identifiable net assets held by ARYA, which had a fair value upon closing of &#8364;<ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">90.3</ix:nonFraction>&#160;million, comprising of cash and cash equivalents held in ARYA&#8217;s trust account partly offset by current liabilities by ARYA and financial liabilities in the amount of &#8364;<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.4</ix:nonFraction>&#160;million accounted for the <ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">7,187,500</ix:nonFraction> ARYA Warrants considering a fair value of the warrants of &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.82</ix:nonFraction> per warrant (price of ARYA Warrants at Closing of the ARYA Merger). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-32</ix:exclude></div></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_70453844" continuedAt="TextSelectionAppend_70453844_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453844_1" continuedAt="TextSelectionAppend_70453844_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453844_2" continuedAt="TextSelectionAppend_70453844_3"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453844_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The excess of the fair value of the equity instruments issued over the fair value of the identified net assets contributed, represents a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expense in accordance with IFRS 2. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> expense as a result of the ARYA Merger, in the amount of &#8364;<ix:nonFraction name="imtx:AdjustmentsForShareListingExpense" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">152.8</ix:nonFraction>&#160;million, is recognized as share listing expense presented as part of the financial result within the Consolidated Statement of Profit/(Loss).<ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453845"> Details of the calculation of the share listing expense are as follows: </ix:nonNumeric></div> <ix:continuation id="TextSelection_70453845"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Euros in thousands, except share and per share data) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares/warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) ARYA Ordinary Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,968,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8364; Fair value of TopCo Shares issued to ARYA shareholders <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a * b)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">243,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Outstanding ARYA Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">7,187,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8364; Closing price of ARYA Warrants on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) Fair value of outstanding ARYA Warrants<br/> (d * e)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Cash and cash equivalents held in ARYA&#8217;s trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:RestrictedCashRecognizedAsOfTheAcquisitionDate" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Current liabilities by ARYA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ARYA&#8217;s identifiable net assets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(g-f-h)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 2 expense on the closing date</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8364;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:AdjustmentsForShareListingExpense" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,787</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the ARYA Merger, ARYA Warrants were converted into Immatics Warrants. The financial liabilities for the Immatics Warrants are accounted for at fair value through profit and loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants decreased from &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.88</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.39</ix:nonFraction>) per warrant as of December&#160;31, 2021 to &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.35</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.51</ix:nonFraction>) per warrant as of December&#160;31, 2022. The result is a decrease in fair value of warrant liabilities of &#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.9</ix:nonFraction>&#160;million ($<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.5</ix:nonFraction> million) for the year ended December&#160;31, 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants increased from &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.35</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.88</ix:nonFraction>) per warrant as of December&#160;31, 2020 to &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.88</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.39</ix:nonFraction>) per warrant as of December&#160;31, 2021. The result is an increase in fair value of warrant liabilities of &#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.0</ix:nonFraction>&#160;million ($<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction> million) for the year ended December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants decreased from &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.82</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.41</ix:nonFraction>) per share as of July&#160;1, 2020 to &#8364;<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.35</ix:nonFraction> ($<ix:nonFraction name="imtx:WarrantsIssuedPricePerWarrant" contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.88</ix:nonFraction>) per share as of December&#160;31, 2020. The result is a change in fair value of warrant liabilities of &#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.8</ix:nonFraction>&#160;million ($<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.3</ix:nonFraction> million) for the year ended December&#160;31, 2020. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income and expenses </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income and financial expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:InterestIncomeOnOtherFinancialAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:InterestIncomeOnOtherFinancialAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:InterestIncomeOnOtherFinancialAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on other financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,416</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,675</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,949</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,038</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:ForeignCurrencyLossesNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:ForeignCurrencyLossesNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:ForeignCurrencyLossesNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses on financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,279</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,726</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,063</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income mainly results from short-term deposits as well as cash balances for the year ended December&#160;31, 2022. Interest expenses mainly results from IFRS 16 and from negative interest rates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency gains and losses mainly consist of realized and unrealized gains and losses in connection with our USD holdings of cash and cash equivalents, short-term deposits as well as bonds. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Losses on financial instruments includes expected credit losses on cash and cash equivalents and Other financial assets for the year ended December&#160;31, 2022 and losses from foreign currency forward contracts for the year ended December&#160;31, 2021. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on other financial instruments includes an unrealized gain of &#8364;<ix:nonFraction name="imtx:UnrealisedGainLossFromForeignCurrencyForwardContracts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million and a realized gain of &#8364;<ix:nonFraction name="imtx:RealisedGainLossFromForeignCurrencyForwardContracts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million from foreign currency forward contracts for the year ended December&#160;31, 2020. </div></div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70454176"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17. Share-based payments</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immatics Biotechnologies GmbH previously issued share-based awards to employees under two different plans. Under the Immatics Biotechnologies GmbH Stock Appreciation Program 2010 (the &#8220;2010 Plan&#8221;), the Company issued stock appreciation rights (&#8220;SARs&#8221;), which the Group accounted for as cash-settled awards. Under the Immatics Biotechnologies 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;), the Company issued tandem awards, which allowed employees to exercise their awards as either a SAR or a stock option. In 2020, prior to the ARYA Merger, Immatics N.V. established the new equity incentive plan (&#8220;2020 Equity Plan&#8221;). As part of the ARYA Merger, the 2010 Plan and the 2016 Plan were converted and were superseded by the 2020 Equity Plan as described below. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). The 2022 Equity Plan allows the company to grant additional options. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of 2010 Plan and 2016 Plan in connection with ARYA Merger </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Payments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the employee award agreements, holders of vested awards under the 2010 Plan and 2016 Plan (including any awards scheduled to vest prior to 2021), agreed to receive a cash payment of $<ix:nonFraction name="imtx:CashPaymentAwardPerSharePayable" contextRef="PAsOn12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per award, less the applicable exercise price (&#8220;Award Cash Proceeds&#8221;). Per the terms of the employee award agreements, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-34</ix:exclude></div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70454176" continuedAt="TextSelectionAppend_70454176_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_1" continuedAt="TextSelectionAppend_70454176_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_2" continuedAt="TextSelectionAppend_70454176_3"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_3" continuedAt="TextSelectionAppend_70454176_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">active employees were required to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-invest</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imtx:PercentageOfCashProceedsToBeBeReinvested" contextRef="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_BottomOfRangeMemberifrsfullRangeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>%-<ix:nonFraction name="imtx:PercentageOfCashProceedsToBeBeReinvested" contextRef="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction>%</div> of the Award Cash Proceeds, net of taxes, with management members required to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-invest</div> <ix:nonFraction name="imtx:PercentageOfCashProceedsToBeBeReinvested" contextRef="P01_01_2022To12_31_2022_ManagementMembersMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>%. In total, employees elected to receive &#8364;<ix:nonFraction name="ifrs-full:PaymentsToAndOnBehalfOfEmployees" contextRef="P01_01_2022To12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.9</ix:nonFraction>&#160;million in net Award Cash Proceeds before taxes, which were paid during the third quarter in 2020. These proceeds mainly covered wage tax obligations by the employees. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These cash payments represent a modification of awards previously issued under the 2010 Plan and 2016 Plan. The Group recognized &#8364;<ix:nonFraction name="imtx:ExpenseFromTheModificationOfShareBasedAwards" contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndTenPlanMemberIMTXPlanAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction>&#160;million in operating expenses related to the modification of awards issued under the 2010 Plan and previously accounted for as a liability. The Group also recognized &#8364;<ix:nonFraction name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction>&#160;million as a reduction in share premium, associated with the modification from previously equity-settled tandem awards, which were settled in cash as part of the modification. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Awards </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The share-based awards, that were received by employees as part of the conversion, consisted of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Shares, Matching Stock Options and Converted Stock Options as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In accordance with the employee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-investment</div> elections, employees received <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">733,598</ix:nonFraction> shares in Immatics N.V. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Re-investment</div> Shares&#8221;), which had a fair value of &#8364;<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.5</ix:nonFraction>&#160;million based on the ARYA share price of $<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">15.15</ix:nonFraction>, as of the merger on July&#160;1, 2020. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Shares issued represented a modification of awards previously granted under the 2010 Plan and the 2016 Plan. This modification resulted in additional operating expenses of &#8364;<ix:nonFraction name="imtx:ExpenseFromTheModificationOfShareBasedAwards" contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction>&#160;million. For each ordinary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Share received, active employees and management members also received two stock options (&#8220;Matching Stock Options&#8221;) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> and vested in full on <ix:nonNumeric name="imtx:DateOfVestingOfStockOptions" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" format="ixt:date-monthname-day-year-en">July 31, 2021</ix:nonNumeric>. The award recipient must remain employed by Immatics or one of its affiliates through the vesting date, to receive the option. The awards have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">ten-year</ix:nonNumeric></div> contract life. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Matching Stock Options award agreements had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the <ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">July 1, 2020</ix:nonNumeric> grant date the Group assigned a fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.59</ix:nonFraction>. <ix:nonNumeric name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454180">Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. </ix:nonNumeric></div></div><ix:continuation id="TextSelection_70454180"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">15.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal">5.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-35</ix:exclude></div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70454176_4" continuedAt="TextSelectionAppend_70454176_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_5" continuedAt="TextSelectionAppend_70454176_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_6" continuedAt="TextSelectionAppend_70454176_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_7" continuedAt="TextSelectionAppend_70454176_8"><ix:nonNumeric name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">1,406,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">11,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">46,554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,348,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,348,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">7.50</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">1,422,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">6,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,406,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,413,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">8.50</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,430,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,422,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">9.50</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-36</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70454176_8" continuedAt="TextSelectionAppend_70454176_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_9" continuedAt="TextSelectionAppend_70454176_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_10" continuedAt="TextSelectionAppend_70454176_11"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_11" continuedAt="TextSelectionAppend_70454176_12"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January&#160;1, 2021, employees received replacement stock options (&#8220;Converted Options&#8221;) to acquire shares in Immatics N.V. The Converted Options have comparable terms as the previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V., are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period. The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V., and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the terms of the Converted Options award agreements, the awards had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the July&#160;1, 2020 grant date the Group assigned an average fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P07_01_2020To07_01_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.79</ix:nonFraction>. The incremental average fair value of the Converted Options compared to the share-based awards under the 2010 Plan and 2016 Plan was $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.83</ix:nonFraction>. <ix:nonNumeric name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454181">Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. </ix:nonNumeric></div></div><ix:continuation id="TextSelection_70454181"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Average exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal">5.6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454185"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">566,311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">12,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">525,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">392,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">5.01</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-37</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_70454185" continuedAt="TextSelectionAppend_70454185_1"><ix:continuation id="TextSelectionAppend_70454176_12" continuedAt="TextSelectionAppend_70454176_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_13" continuedAt="TextSelectionAppend_70454176_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_14" continuedAt="TextSelectionAppend_70454176_15"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_15" continuedAt="TextSelectionAppend_70454176_16"><ix:continuation id="TextSelectionAppend_70454185_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">594,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">18,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">566,311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">193,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">6.01</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">632,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">37,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">594,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">53,856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">7.01</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional grants under the 2020 and 2022 Equity Plan </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Options </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the ARYA Merger, Immatics N.V. established the 2020 Equity Plan. After closing the ARYA Merger, employees, directors and officers received 1,087,242 employee stock options under the 2020 Equity Plan with a service requirement (&#8220;Service Options&#8221;), to acquire shares of Immatics N.V. The service-based options will vest solely on a four-year time-based vesting schedule. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). The 2022 Equity Plan allows the company to grant additional options. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-38</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70454176_16" continuedAt="TextSelectionAppend_70454176_17"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_17" continuedAt="TextSelectionAppend_70454176_18"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_18" continuedAt="TextSelectionAppend_70454176_19"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_19" continuedAt="TextSelectionAppend_70454176_20"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted Service Options, which were accounted for using the respective grant date fair value. <ix:nonNumeric name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454183">Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options</ix:nonNumeric>, with a weighted average fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.93</ix:nonFraction>, $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction> and $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.35</ix:nonFraction> for Service Option granted during the year ended December&#160;31, 2022, 2021 and 2020, respectively. </div></div><ix:continuation id="TextSelection_70454183"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">85.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">82.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">78.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">6.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">6.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">6.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454186"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">3,725,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">2,619,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">182,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">16,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,129,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,438,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">8.87</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">1,910,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">1,967,708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">149,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Warrants" decimals="0" scale="0" format="ixt:num-dot-decimal">3,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,725,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">557,401</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">9.36</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-39</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_70454186" continuedAt="TextSelectionAppend_70454186_1"><ix:continuation id="TextSelectionAppend_70454176_20" continuedAt="TextSelectionAppend_70454176_21"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_21" continuedAt="TextSelectionAppend_70454176_22"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_22" continuedAt="TextSelectionAppend_70454176_23"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_23" continuedAt="TextSelectionAppend_70454176_24"><ix:continuation id="TextSelectionAppend_70454186_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,963,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">53,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,910,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">9.72</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance-Based Options (&#8220;PSUs&#8221;) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, after the closing of the ARYA Merger certain executive officers and key personnel of the Group received under the 2020 Equity Plan PSUs, vesting based both on achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $<ix:nonFraction name="imtx:MinimumMarketCapitalization" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheOneMemberIMTXTrancheAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;billion, $<ix:nonFraction name="imtx:MinimumMarketCapitalization" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheTwoMemberIMTXTrancheAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;billion and $<ix:nonFraction name="imtx:MinimumMarketCapitalization" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheThreeMemberIMTXTrancheAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;billion, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted PSUs on September&#160;28, 2021 which were accounted for by considering a fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P09_28_2021To09_28_2021_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.00</ix:nonFraction>. A Monte-Carlo simulation model has been used to measure the fair value at grant date of the PSUs. This model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#8217;s fair value at grant date. <ix:nonNumeric name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true" continuedAt="TextSelection_70454182">In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:</ix:nonNumeric> </div></div><ix:continuation id="TextSelection_70454182" continuedAt="TextSelectionAppend_70454182_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> September&#160;28,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">77.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">3.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P06_30_2020To06_30_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,644,000</ix:nonFraction> PSUs on June&#160;30, 2020, which were accounted for by considering a fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P06_30_2020To06_30_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.10</ix:nonFraction> and granted <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">255,000</ix:nonFraction> PSUs on September&#160;14, 2020, which were accounted for by considering a fair value of $<ix:nonFraction name="imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" contextRef="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">6.41</ix:nonFraction>. A Monte-Carlo simulation model has been used to measure each fair value at grant date of the PSUs. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-40</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70454176_24" continuedAt="TextSelectionAppend_70454176_25"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_25" continuedAt="TextSelectionAppend_70454176_26"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_26" continuedAt="TextSelectionAppend_70454176_27"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_27" continuedAt="TextSelectionAppend_70454176_28"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#8217;s fair value at grant date. <ix:continuation id="TextSelectionAppend_70454182_1" continuedAt="TextSelectionAppend_70454182_2">In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:</ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_70454182_2"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December<br/> 31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">14.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">78.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">6.98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,696,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,666,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">7.98</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,644,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,696,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">8.98</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,899,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">255,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,644,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">9.60</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-41</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70454176_28" continuedAt="TextSelectionAppend_70454176_29"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_29" continuedAt="TextSelectionAppend_70454176_30"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70454176_30" continuedAt="TextSelectionAppend_70454176_31"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70454176_31"><ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized total employee-related share-based compensation expenses from all plans for the years ended December&#160;31, 2022, 2021 and 2020 as set out below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,570</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,403</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,519</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear: both; max-height: 0px;"></div><ix:nonNumeric name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity (deficit) </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 1 and Note 3, Immatics N.V. was founded in 2020 with a share capital of &#8364;<ix:nonFraction name="imtx:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> after the Reorganization. On July&#160;1, 2020, upon closing of the ARYA Merger, Immatics N.V. had <ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">62,908,617</ix:nonFraction> outstanding ordinary shares with a par value of &#8364;<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction>, resulting in a share capital of &#8364;<ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn07_01_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction>&#160;thousand. In 2020, the ARYA Merger and PIPE Financing led to an increase in share premium by &#8364;<ix:nonFraction name="ifrs-full:SharePremium" contextRef="PAsOn07_01_2020_AryaMergerMemberIMTXShareListingExpenseAxis_PipeFinancingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">327.8</ix:nonFraction>&#160;million. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group issued in 2022, <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;million shares under the ATM agreement with SVB Securities LLC and collected a gross amount of &#8364;<ix:nonFraction name="imtx:GrossProceedsFromIssueOfSecurities" contextRef="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.8</ix:nonFraction>&#160;million less transaction costs of &#8364;<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, resulting in an increase in share capital of &#8364;<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction>&#160;thousand and share premium of &#8364;<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.2</ix:nonFraction>&#160;million. On October&#160;12, 2022, the Group closed a registered direct offering, of <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,905,000</ix:nonFraction> ordinary shares with a public offering price of $<ix:nonFraction name="imtx:ShareIssuedPricePerShare" contextRef="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.09</ix:nonFraction> per ordinary share and received a gross amount of &#8364;<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.4</ix:nonFraction>&#160;million less transaction costs of &#8364;<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.3</ix:nonFraction>&#160;million, resulting in an increase in share capital of &#8364;<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P10_12_2022To10_12_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">109</ix:nonFraction>&#160;thousand and share premium of &#8364;<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">106.1</ix:nonFraction>&#160;million. In addition, the Group issued shares from exercises of stock options by employees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022 and 2021, the total number of ordinary shares of Immatics N.V. outstanding is <ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">76,670,699</ix:nonFraction> and <ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">62,926,816</ix:nonFraction> with a par value of &#8364;<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis" unitRef="Unit_EUR_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other reserves are related to accumulated foreign currency translation amounts associated with the Group&#8217;s US operations. </div></div></ix:nonNumeric><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453956">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest related to those shares in Immatics US Inc. which have been provided to The University of Texas M.D. Anderson Cancer Center, Houston/Texas/USA, (&#8220;MD Anderson&#8221;) based on the restricted stock acquisition agreement described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until June&#160;30, 2020, Immatics and MD Anderson were partners in a Restricted Stock Acquisition Agreement (the &#8220;RSAA&#8221;). Under the terms of the RSAA, MD Anderson was entitled to additional restricted shares in Immatics US, Inc. based on performance of certain work orders between August&#160;14, 2018 and August&#160;14, 2020. MD Anderson performed services in connection with our clinical trials in our ACT platform. The RSAA was cancelled as part of the ARYA Merger (See Note 3). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;1, 2020 MD Anderson exchanged all of its <ix:nonFraction name="imtx:NumberOfSharesExchangedInSubsidiaries" contextRef="P07_01_2020To07_01_2020_MdAndersonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">379,420</ix:nonFraction> shares in Immatics US, Inc., that they acquired under the RSAA for <ix:nonFraction name="imtx:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P07_01_2020To07_01_2020_RestrictedStockAcquisitionAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">697,431</ix:nonFraction> shares in Immatics N.V. The shares of Immatics N.V. had a fair value at the date of the exchange of $<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.15</ix:nonFraction> per share. Immediately prior to the exchange, the carrying amount of the existing <ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.14</ix:nonFraction>% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in Immatics US Inc. was &#8364;<ix:nonFraction name="imtx:StockIssuedDuringPeriodValueNewIssues" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million. The exchange resulted in a decrease of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#8364;<ix:nonFraction name="imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million and a corresponding increase of share capital and net increase to share premium for the issuance of shares and derecognition of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. The RSAA was also cancelled as of July&#160;1, 2020. Any future services rendered by MD Anderson will be paid in cash. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-42</ix:exclude></div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453956" continuedAt="TextSelectionAppend_70453956_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453956_1" continuedAt="TextSelectionAppend_70453956_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453956_2" continuedAt="TextSelectionAppend_70453956_3"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453956_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The loss allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest amounted to &#8364;<ix:nonFraction name="imtx:LossOnNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million in 2020. In total, the Group recognized expenses in relation to MD Anderson&#8217;s performance under the RSAA of &#8364;<ix:nonFraction name="imtx:IncreasedecreaseThroughCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-4" scale="6" format="ixt:num-dot-decimal">0.04</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020. </div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><ix:nonNumeric name="imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><ix:nonNumeric name="imtx:DisclosureOfPersonnelExpenesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">42,924</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,098</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,245</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,711</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,086</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,639</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,570</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,403</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,519</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">73,205</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">60,587</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">51,403</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other employee benefit expenses include employee retirement fund contributions, health insurance, and statutory social expenses. Immatics US Inc. sponsors a defined contribution retirement plan for employees in the United States. During 2022, 2021 and 2020, total Group contributions to the defined contribution plan amounted to &#8364;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2022, 2021 and 2020, other employee benefits also include employee health insurance costs amounting to &#8364;<ix:nonFraction name="imtx:EmployeeHealthInsuranceCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="imtx:EmployeeHealthInsuranceCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="imtx:EmployeeHealthInsuranceCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million for Immatics US Inc., statutory social expenses amounting to &#8364;<ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction>&#160;million for our German operations and other miscellaneous expenses amounting to &#8364;<ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, respectively. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfIncomeTaxExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453812">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the year ended December&#160;31, 2022, the Group generated a net income due to the recognition of revenue in connection with the license component of the BMS IMA401 Collaboration agreement. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> revenue is not accounted for under German GAAP and consequently under German tax accounting. Instead, the Group recognizes revenue for the BMS agreement over the period of the clinical trial service. The deferred tax liability arising from the temporary difference related to delayed revenue recognition under German tax accounting is offset by deferred tax assets on tax losses carried forward that were previously not capitalized due to the Groups expectation of generating taxable losses in the foreseeable future. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Group&#8217;s German operations were subject to a statutory tax rate of <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">30.4</ix:nonFraction>% during 2022 and of <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">29.1</ix:nonFraction></ix:nonFraction>% <div style="null;text-indent: 0px;;display:inline;">during 2021 and 2020. The Group&#8217;s German statutory tax rate increased by <ix:nonFraction name="ifrs-full:TaxRateEffectFromChangeInTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.3</ix:nonFraction>% in comparison to the previous period due to increased trade tax rates. In the U.S., the Group was subject to a corporate income tax rate of</div> <ix:nonFraction name="imtx:CorporateIncomeTaxRate" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:CorporateIncomeTaxRate" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:CorporateIncomeTaxRate" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% <div style="display:inline;">for the year ended December 31, 2022, 2021 and 2020.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:exclude>F-43</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453812" continuedAt="TextSelectionAppend_70453812_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453812_1" continuedAt="TextSelectionAppend_70453812_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453812_2" continuedAt="TextSelectionAppend_70453812_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Immatics Biotechnologies GmbH, the Group recognized a current income tax expense of &#8364;<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022. The current income tax expense is calculated based on taxable income of Immatics Biotechnologies GmbH for the year ended December&#160;31, 2022. Since no deferred tax assets have been recognized as of December&#160;31, 2021, the Group took into account the tax losses carried forward that can be used to offset the taxable income generated in the year ended December&#160;31, 2022. In accordance with &#167;10d para 2 EStG (German income tax code),<div style="display:inline;">&#160;</div></div></div><ix:nonFraction name="imtx:PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" contextRef="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">60</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">% </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of an income of a given year can be offset with tax losses carried forward. Accordi</div></div><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">ngly, </div><ix:nonFraction name="imtx:PercentageOfPretaxIncomeSubjectToIncomeTax" contextRef="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">40</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">% </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the income before tax of Immatics Biotechnologies GmbH are subject to income tax. </div></div></div><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As the profit is considered a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> profit, no deferred tax assets exceeding the deferred tax liability <div style="letter-spacing: 0px; top: 0px;;display:inline;">on</div>&#160;temporary differences have been recognized in respect of tax losses carried forward. The current assessment regarding the usability of deferred tax assets may change, depending on the Group&#8217;s taxable income in future years, which could result in the recognition of deferred tax assets. The Group continued to generate losses for all other entities within the Group during the year ended December&#160;31, 2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> as well as for all entities during the year ended December&#160;31, 2021 and 2020. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. </div></div><ix:nonNumeric name="imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation between taxes on income reflected on the Consolidated Statement of Profit/(Loss) and the expected income tax benefit, based on the Group&#8217;s German statutory tax rate, for the years ended December&#160;31, 2022, 2021 and 2020 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit/(loss) before taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected taxes on income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effects</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Difference in tax rates</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants exempted from taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent Differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:TaxEffectOfPermanentDifferences" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:TaxEffectOfPermanentDifferences" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:TaxEffectOfPermanentDifferences" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">39,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization of previously unrecorded tax losses carried forward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-recognition&#160;of</div> deferred taxes on tax losses and temporary differences</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes on income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2022, permanent differences relate to share-based compensation expenses, to transaction costs directly attributable and incremental to capital raises and to the change in fair value of the financial liabilities for the warrants. For the year ended December&#160;31, 2021, permanent differences relate to share-based compensation expenses and to the change in fair value of the financial liabilities for the warrants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the main permanent difference relates to the share listing expense of &#8364;<ix:nonFraction name="imtx:EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">153</ix:nonFraction>&#160;million, which does not have a corresponding taxable expense. Other permanent differences include transaction costs directly attributable and incremental to capital raises, expenses for equity-settled share-based compensation, as well as the change in fair value of the financial liabilities for the warrants. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-44</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453812_3" continuedAt="TextSelectionAppend_70453812_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453812_4" continuedAt="TextSelectionAppend_70453812_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453812_5" continuedAt="TextSelectionAppend_70453812_6"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453812_6"><ix:nonNumeric name="imtx:DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and deferred tax liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">As of</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;" colspan="14"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,288</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,964</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">947</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,627</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of tax losses carried forward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recognized</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,319</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,319</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,927</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,629</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Netting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DeferredTaxAssetsOffset" contextRef="PAsOn12_31_2022_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DeferredTaxLiabilitiesOffSet" contextRef="PAsOn12_31_2022_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DeferredTaxAssetsOffset" contextRef="PAsOn12_31_2021_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DeferredTaxLiabilitiesOffSet" contextRef="PAsOn12_31_2021_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">Non-recognition</div> of deferred tax assets on temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="imtx:DeferredTaxAssetsOnTemporaryDifferences" contextRef="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="imtx:DeferredTaxAssetsOnTemporaryDifferences" contextRef="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net deferred tax assets/liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">For the years ended December&#160;31, 2022, and 2021, the Group had accumulated tax losses of &#8364;<ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="P01_01_2022To12_31_2022_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">357.2</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="P01_01_2021To12_31_2021_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">353.1</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, that may be offset against future taxable profits of the Group subject to certain limitations. For &#8364;<ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">319.4</ix:nonFraction> million and &#8364;<ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">353.1</ix:nonFraction> million of the accumulated tax losses no deferred tax asset has been recognised in the financial statements. For the year ended December 31, 2022,</div> &#8364;<ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="P01_01_2022To12_31_2022_TwentySixYearTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of total tax losses is subject to a twenty-year carry forward period. All other tax losses have an indefinite carry forward period.&#160;</div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitation on tax loss carry forwards in the US Inc. is <ix:nonFraction name="imtx:PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">80.00</ix:nonFraction>% of each subsequent year`s net income starting with losses generated after January&#160;1, 2018. These have an indefinite carry forward period, but no carry back option. Any losses generated prior to January&#160;1, 2018 still can be utilized at <ix:nonFraction name="imtx:PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" contextRef="PAsOn12_31_2017" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">100.00</ix:nonFraction>% and are subject to a twenty-year carry forward expiration period. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. For Immatics Biotechnologies GmbH, we believe that the ARYA Merger did not lead to a forfeiture of tax losses carried forward in accordance with &#167; 8c KStG. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453965">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Risk Management Objectives and Policies </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s principal financial instruments comprise cash and cash equivalents, short-term deposits, accounts receivables and bonds. The main purpose of these financial instruments is to invest the proceeds of capital contributions and upfront payments from collaboration agreements. The Group has various other financial instruments such as other receivables and trade accounts payables, which arise directly from its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The main risks arising from the Group&#8217;s financial instruments are market risk and liquidity risk. The Board of Management reviews and agrees on policies for managing these risks as summarized below. The Group also monitors the market price risk arising from all financial instruments. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exposure of the Group to changes in interest rates relates to investments in deposits, bonds and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-45</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453965" continuedAt="TextSelectionAppend_70453965_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_1" continuedAt="TextSelectionAppend_70453965_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_2" continuedAt="TextSelectionAppend_70453965_3"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453965_3" continuedAt="TextSelectionAppend_70453965_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regarding the liabilities shown in the Consolidated Statement of Financial Position, the Group is currently not subject to interest rate risks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Group to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents, accounts receivables, short-term deposits and bonds. The Group&#8217;s cash and cash equivalents, bonds and short-term deposits are denominated in Euros and US Dollars and maintained with three high-quality financial institutions in Germany and two in the United States. The Group&#8217;s accounts receivables are denominated in Euros. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The maximum default risk is &#8364;<ix:nonFraction name="ifrs-full:MaximumExposureToCreditRisk" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">363</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:MaximumExposureToCreditRisk" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. These amounts consist of &#8364;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million cash and cash equivalents, &#8364;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million accounts receivables as well as &#8364;<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">213</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction>&#160;million Other financial assets as of December&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cash and cash equivalents are held with banks, which are rated BBB+ to Aa3 by S&amp;P and Moody`s. Short-term deposits are with banks, which are rated Aa3 and A1 by the rating agency Moody`s. Bond investments are with banks, which are rated AAA and AA by Moody`s. The Group continually monitors its positions with, and the credit quality of, the financial institutions and corporation, which are counterparts to its financial instruments and does not anticipate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance.</div> The Group monitors the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from equity measures<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. The business transactions of the Group are generally conducted in Euros and U.S. dollars. The Group aims to match EUR cash inflows with EUR cash outflows and U.S. dollar cash inflows with U.S.&#160;Dollar cash outflows where possible. The objective of currency risk management is to identify, manage and control currency risk exposures within acceptable parameters. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s cash and cash equivalents were</div>&#160;&#8364;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">148.5</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million as of December 31, 2022. Approximately</div> <ix:nonFraction name="imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">87</ix:nonFraction>% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of the Group&#8217;s cash and cash equivalents were held in Germany, of which approximately</div> <ix:nonFraction name="imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">49</ix:nonFraction>% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">were denominated in Euros and</div> <ix:nonFraction name="imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">51</ix:nonFraction>% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">were denominated in U.S. Dollars. The remainder of the Group&#8217;s cash and cash equivalents were held in the United States and denominated in U.S. Dollars. Additionally, the Group held bonds and short-term deposits classified as Other financial assets denominated in Euros in the amount of</div> &#8364;<ix:nonFraction name="imtx:BondsAndShortTermDeposits" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">123.3</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million and U.S. Dollars in the amount of</div> &#8364;<ix:nonFraction name="imtx:BondsAndShortTermDeposits" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">87.0</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of December 31, 2022.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-46</ix:exclude> </div></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_70453965_4" continuedAt="TextSelectionAppend_70453965_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453965_5" continuedAt="TextSelectionAppend_70453965_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_6" continuedAt="TextSelectionAppend_70453965_7"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453965_7" continuedAt="TextSelectionAppend_70453965_8"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized significant foreign exchange income and losses in 2022, as Immatics N.V.`s and Immatics GmbH&#180;s functional currency is Euro, due to significant holdings of U.S. dollar amounts. The Group recognized significant foreign exchange income in 2021 and in 2020 significant foreign exchange losses. Cash and cash equivalents and Other financial assets balances denominated in U.S. dollars held by entities with functional currency of EUR are as follows: </div></div> <ix:nonNumeric name="imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics N.V. held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:MaximumExposedToCurrencyRisk" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,788</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:MaximumExposedToCurrencyRisk" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,410</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics GmbH held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,787</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:MaximumExposedToCurrencyRisk" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,588</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:MaximumExposedToCurrencyRisk" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,787</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2022, if the euro had weakened/strengthened by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars by considering that all other variables held constant, the Group`s profit would have been &#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;million lower/&#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction>&#160;million higher, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. </div></div> <ix:nonNumeric name="ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453968"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.9599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-47</ix:exclude> </div></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_70453965_8" continuedAt="TextSelectionAppend_70453965_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453965_9" continuedAt="TextSelectionAppend_70453965_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_10" continuedAt="TextSelectionAppend_70453965_11"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453965_11" continuedAt="TextSelectionAppend_70453965_12"><ix:continuation id="TextSelection_70453968" continuedAt="TextSelectionAppend_70453968_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">709</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">723</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.9599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,954</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">79,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2021, if the euro had weakened/strengthened by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars by considering that all other variables held constant, the Group`s loss would have been &#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million higher/&#8364;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million lower, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. </div></div> <ix:continuation id="TextSelectionAppend_70453968_1" continuedAt="TextSelectionAppend_70453968_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,915</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.2459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">620</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.2459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The wholly-owned subsidiary Immatics US, Inc. is located in the United States and has US Dollars as its functional currency. Therefore, the Group is subject to currency fluctuations that would <div style="display:inline;">a</div>ffect the other comprehensive income and equity of the Group. </div></div> <ix:continuation id="TextSelectionAppend_70453968_2" continuedAt="TextSelectionAppend_70453968_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,065</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.9599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-48</ix:exclude> </div></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_70453965_12" continuedAt="TextSelectionAppend_70453965_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453965_13" continuedAt="TextSelectionAppend_70453965_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_14" continuedAt="TextSelectionAppend_70453965_15"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453965_15" continuedAt="TextSelectionAppend_70453965_16"><ix:continuation id="TextSelectionAppend_70453968_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2021: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.1892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,858</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.2459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">1.0193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ValueAtRisk" contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group continuously monitors its risk to a shortage of funds. The Group&#8217;s objective is to maintain a balance between continuity of funding and flexibility through the use of capital raises. </div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfManagingLiquidityRisk" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, and 2021, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total funds available</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">362,205</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">145,117</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market risk and currency risk of warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s activities expose it to the financial risks of changes in price of the warrants. As the warrants are recognized at fair value through profit and loss on the consolidated statement of financial position of the Group, the Group&#8217;s exposure to market risks results from the volatility of the warrants price. The Warrants are publicly traded at the Nasdaq Stock Exchange. A reasonable increase (decrease) in the warrant price by <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>%, with all other variables held constant, would lead to a (loss) gain before tax of &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction></ix:nonFraction>&#160;million with a corresponding effect in the equity as of December&#160;31, 2022. A reasonable increase (decrease) in the warrant price by <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>%, with all other variables held constant, would lead to a (loss) gain before tax of &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction></ix:nonFraction>&#160;million with a corresponding effect in the equity as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The warrants are traded in U.S.&#160;Dollar while the functional currency of Immatics N.V. is Euro. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>%, with all other variables held constant, would lead to a gain (loss) before tax of &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million /(&#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;million) with a corresponding effect in the equity as of December&#160;31, 2022. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by <ix:nonFraction name="imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>%, with all other variables held constant, would lead to a gain (loss) before tax of &#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million /(&#8364;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction>&#160;million) with a corresponding effect in the equity as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The risks associated with our warrants result in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> financial statement effects and have no impact on the Company&#8217;s cash position, operating expenses or cash flows. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital management </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s capital management objectives are designed primarily to finance our growth strategy. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-49</ix:exclude> </div></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_70453965_16" continuedAt="TextSelectionAppend_70453965_17"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453965_17" continuedAt="TextSelectionAppend_70453965_18"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453965_18" continuedAt="TextSelectionAppend_70453965_19"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453965_19"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group reviews the total amount of cash on a regular basis. As part of this review, the Group considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year. In general, the aim is to maximize the financial resources available for further research and development projects. The Group is not subject to externally imposed capital requirements. The Group&#8217;s capital management objectives were achieved in the reporting year.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453674">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453676"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below are the carrying amounts and fair values of the Group&#8217;s financial instruments that are carried in the consolidated financial statements as of December&#160;31, 2022 and 2021, respectively.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">148,519</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,930</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,756</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,402</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,735</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,914</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,563</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">365,718</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,914</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,352</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">408,984</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,994</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">691</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">691</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,624</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">727</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,859</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,853</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">146,490</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,859</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,204</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:FinancialAssetsAndFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">196,553</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Short-term deposits&#8221; and &#8220;Bonds&#8221; are classified within Other financial assets </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-50</ix:exclude></div></div> </ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453676" continuedAt="TextSelectionAppend_70453676_1"><ix:continuation id="TextSelection_70453674" continuedAt="TextSelectionAppend_70453674_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453674_1" continuedAt="TextSelectionAppend_70453674_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453674_2" continuedAt="TextSelectionAppend_70453674_3"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453674_3" continuedAt="TextSelectionAppend_70453674_4"><ix:continuation id="TextSelectionAppend_70453676_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In all valuation categories with the exception of Bonds, the carrying amount represents a reasonable approximation of the fair value based on the short-term maturities of these instruments. Set out below are the carrying amounts and fair values of the Group&#8217;s Bonds as of December&#160;31, 2022 and 2021, respectively. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,756</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,300</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,113</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table></ix:continuation> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following methods and assumptions were used to estimate the fair values: All financial assets are categorized Level&#160;1 and therefore are valued using quoted (unadjusted) market prices. All financial liabilities are also categorized Level&#160;1. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The bonds&#8217; contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Bonds are classified as Level&#160;1 of the fair value hierarchy, as they are listed on publicly traded markets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants are comprised of the Immatics Warrants issued to investors with a cashless exercise mechanism as a current liability which the Company accounted for according to provisions of IAS 32. The Company measures the warrants at fair value by using the closing price of warrants at Nasdaq. The warrants are measured in each reporting period. Changes in the fair value are recognized in the Company&#8217;s Consolidated Statement of Profit/(Loss) as financial income or expenses, as appropriate. The warrants are classified as Level&#160;1 of the fair value hierarchy. The maturity of the liabilities for warrants is dependent on the development of the share price as well as the decisions by the Immatics Warrants holders. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Groups net result from financial instruments by measurement categories are disclosed below for the years ended December&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2022To12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2021To12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2020To12_31_2020_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2021To12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2020To12_31_2020_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2022To12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2021To12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2020To12_31_2020_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2022To12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2021To12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2020To12_31_2020_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,082</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,041</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:NetFinancialResult" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,661</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-51</ix:exclude></div></div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453674_4" continuedAt="TextSelectionAppend_70453674_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453674_5" continuedAt="TextSelectionAppend_70453674_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453674_6" continuedAt="TextSelectionAppend_70453674_7"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453674_7"><ix:nonNumeric name="imtx:DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table shows the changes of the liabilities from financing activities, classified as cash effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> effective as of December&#160;31, 2022 and 2021, respectively. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective" contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,843</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,655</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,707</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,324</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <ix:nonNumeric name="imtx:DisclosureOfContractualObligationsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2022 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,613</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,045</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligation<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,250</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,469</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,392</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,456</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,568</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2021 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,477</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractualObligationOfLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:OtherLeaseObligations" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract research organization agreements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractResearchOrganizationAgreements" contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractResearchOrganizationAgreements" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractResearchOrganizationAgreements" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractResearchOrganizationAgreements" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:ContractResearchOrganizationAgreements" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,659</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,735</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,370</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,972</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:ContractualCashObligation" contextRef="PAsOn12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,735</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligations comprise of obligations for leases classified as short-term and low value as well as obligations for leases signed but not yet started. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will expire five years after the completion of the ARYA Merger or earlier upon redemption or liquidation in accordance with their terms. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">As of December&#160;31, 2022, and 2021 the Group is potentially liable to pay &#8364;<ix:nonFraction name="imtx:UnrecordedContingentLiability" contextRef="PAsOn12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="imtx:UnrecordedContingentLiability" contextRef="PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction></ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million to a third-party upon successfully completing the milestone of the first clinical lead selection in connection with Immatics collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.&#160;</div> </div></div> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfRelatedPartyExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453322">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party disclosures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel have been defined as the members of the Executive Committee of Immatics N.V. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-52</ix:exclude></div></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_70453322" continuedAt="TextSelectionAppend_70453322_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453322_1" continuedAt="TextSelectionAppend_70453322_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_2" continuedAt="TextSelectionAppend_70453322_3"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453322_3" continuedAt="TextSelectionAppend_70453322_4"><ix:nonNumeric name="imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation of key management personnel consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationFixed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,706</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationFixed" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationFixed" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">886</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,016</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,574</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,814</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,387</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed and variable key management compensation represent short-term employee benefits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board of Directors of the Group received a fixed fee. <ix:nonNumeric name="imtx:DisclosureOfCompensationSupervisoryBoardTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453324">Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;<ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction>&#160;million in 2022: </ix:nonNumeric></div> <ix:continuation id="TextSelection_70453324" continuedAt="TextSelectionAppend_70453324_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen<br/> und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nancy<br/> Valente</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">379</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,336</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">258</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">246</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">232</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">229</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">217</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">217</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">220</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,715</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;<ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million in 2021: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen&#160;und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">348</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,751</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,223</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">179</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">167</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">157</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">154</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">163</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,114</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-53</ix:exclude></div></div></ix:continuation> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_70453324_1" continuedAt="TextSelectionAppend_70453324_2"><ix:continuation id="TextSelectionAppend_70453322_4" continuedAt="TextSelectionAppend_70453322_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_70453322_5" continuedAt="TextSelectionAppend_70453322_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_6" continuedAt="TextSelectionAppend_70453322_7"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453322_7" continuedAt="TextSelectionAppend_70453322_8"><ix:continuation id="TextSelectionAppend_70453324_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On July&#160;1, 2021, Immatics changed its structure from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-tier</div> Board to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tier</div> Board and Supervisory Board members became <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board of Directors. Total compensation for the Supervisory Board amounted to &#8364;<ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction>&#160;million in 2020: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Harald&#160;F.<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supervisory board compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationTravellingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment Exit arrangement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationPaymentExitArrangement" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,394</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,436</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,584</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">98</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">52</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="imtx:KeyManagementPersonnelCompensations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,116</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the ARYA Merger, Immatics N.V. established the 2020 Incentive Plan. Immatics N.V. granted certain service-based options out of the 2020 Incentive Plan to its management and directors and in addition, performance-based options to its management upon closing of the ARYA Merger. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Group&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). Service options granted out of the 2020 Incentive Plan, will vest based upon satisfaction of a four-year time-based vesting schedule, which provides for <ix:nonFraction name="imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" contextRef="PAsOn12_31_2020_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. Service options granted out of the 2022 Equity Plan to the Board of Directors, will vest in full after a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> service time. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-54</ix:exclude></div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453322_8" continuedAt="TextSelectionAppend_70453322_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_9" continuedAt="TextSelectionAppend_70453322_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_10" continuedAt="TextSelectionAppend_70453322_11"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453322_11" continuedAt="TextSelectionAppend_70453322_12"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance-based options will vest based both on achievement of certain market capitalization milestones and satisfaction of a four-year time-based vesting schedule, which provides for <ix:nonFraction name="imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" contextRef="PAsOn12_31_2022_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. <ix:nonNumeric name="imtx:DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_70453325">The following options were granted to Immatics&#8217; Directors: </ix:nonNumeric></div></div><ix:continuation id="TextSelection_70453325"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Type of options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant&#160;date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strike<br/> Price&#160;in<br/> USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration date</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managing Director</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">Performance-<br/> based options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,598,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">168,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">Matching Stock<br/> options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">264,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Converted options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">30,939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" format="ixt:date-monthname-day-year-en">July 1, 2027</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Converted options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">145,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis" format="ixt:date-monthname-day-year-en">January 1, 2028</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 17, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">168,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 17, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">168,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">135,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">Harpreet Singh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">December 13, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">388,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 13, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Peter Chambr&#233;</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">Peter Chambr&#233;</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">Matching Stock<br/> options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">211,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Peter Chambr&#233;</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Peter Chambr&#233;</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Adam Stone</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Adam Stone</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Adam Stone</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Heather L. Mason</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Heather L. Mason</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Heather L. Mason</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Paul Carter</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 30, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Paul Carter</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Paul Carter</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Eliot Forster</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">September 14, 2020</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">September 13, 2030</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Eliot Forster</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Eliot Forster</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 17, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 17, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">December 9, 2031</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">June 14, 2032</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfTransactionsWithRelatedParty" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Nancy Valente</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">March 22, 2022</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imtx:DateOfExpiryOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" format="ixt:date-monthname-day-year-en">March 22, 2032</ix:nonNumeric></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-55</ix:exclude></div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_70453322_12" continuedAt="TextSelectionAppend_70453322_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_13" continuedAt="TextSelectionAppend_70453322_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_70453322_14" continuedAt="TextSelectionAppend_70453322_15"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_70453322_15"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An additional aggregate of <ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">652,500</ix:nonFraction> service options to purchase ordinary shares, were granted to other Immatics&#8217; key management personnel in 2022, who are members of the Executive Committee but not Directors. Certain key management personnel were also participants in the share-based compensation plans of Immatics GmbH (2010 Plan and 2016 Plan). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the replacement awards issued in connection with the ARYA Merger (See Note 17), these key management personnel received in 2020 cash payments before taxes of &#8364;<ix:nonFraction name="imtx:PaymentOfPayrollTaxOfTheEmployees" contextRef="P01_01_2022To12_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.4</ix:nonFraction>&#160;million, <ix:nonFraction name="imtx:NumberOfConvertedStockOptionsInTheEntity" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">417,415</ix:nonFraction> converted options in Immatics N.V. and <ix:nonFraction name="imtx:NumberOfMatchingStockOptionInTheEntity" contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,076</ix:nonFraction> matching stock options in Immatics N.V. The cash payments mainly covered wage tax obligations of the employees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until December&#160;31, 2022, <ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_DirectorsAndExecutiveOfficersMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> options granted to directors and executive officers forfeited or were exercised. Refer to section &#8220;18. Share-based payments&#8221; regarding further details of the Groups share-based compensation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are <ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> outstanding balances, including commitments, other than the above mentioned with related parties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group did not enter into transactions with related entities in 2022, 2021 and 2020 other than the mentioned compensation contracts. </div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26. Earnings and Loss per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group reported basic and diluted earnings per share. Basic earnings per share are calculated by dividing the net profit or loss by the weighted-average number of ordinary shares outstanding for the reporting period. Diluted earnings per share for the year ended December&#160;31, 2022, are calculated by adjusting the weighted-average number of ordinary shares outstanding for any dilutive effects resulting from equity awards granted to the Board and employees of the Group as well as from publicly traded Immatics Warrants. The Group&#8217;s equity awards and Immatics Warrants for which the exercise price is exceeding the Groups weighted average share price for the year ended December&#160;31, 2022, are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares. The Group was loss-making during the year ended December&#160;31, 2021 and 2020, therefore all instruments are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including the outstanding equity awards and the <ix:nonFraction name="imtx:DilutiveEffectOfShareOptionsOnNumberOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,187,500</ix:nonFraction> Immatics Warrants issued in 2020 and outstanding as of December&#160;31, 2022. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:EarningsPerShareExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net profit/(loss):</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,514</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,335</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">211,841</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">4.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">4.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">67,220,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">62,912,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,001,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">68,824,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">62,912,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,001,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Events occurring after the reporting period </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated further subsequent events for recognition or disclosure through March&#160;22, 2023 and did not identify additional material subsequent events.</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-56 </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant hereby certifies that it meets all of the requirements for filing on <span style="white-space:nowrap">Form&#160;20-F</span> and that it has duly caused and authorized the undersigned to sign this report on its behalf. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Date: March&#160;22, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:76%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><span style="font-weight:bold">Immatics N.V.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harpreet Singh</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Harpreet Singh</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and Managing Director</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>2
<FILENAME>d400206dex417.htm
<DESCRIPTION>EX-4.17
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.17 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted because Immatics N.V. (the &#147;Company&#148;)
has determined that the information (i)&nbsp;is not material and (ii)&nbsp;is customarily and actually treated by the Company as private or confidential. </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and between </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMATICS US, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CELGENE SWITZERLAND LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of June&nbsp;1, 2022 </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1 DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">1.132</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ADDITIONAL DEFINITIONS. EACH OF THE FOLLOWING TERMS HAS THE MEANING DESCRIBED IN THE CORRESPONDING SECTION OF THIS AGREEMENT INDICATED BELOW:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2 COLLABORATION AND RESEARCH PROGRAMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BMS PROGRAMS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1.1 BMS RECEPTORS; BMS TARGETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1.2 CONDUCT OF RESEARCH PROGRAMS FOR THE INITIAL BMS PRODUCTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1.3 TECHNOLOGY TRANSFER FROM IMMATICS TO BMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1.4 EXISTING INVENTORY TRANSFER TO BMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1.5 UPDATES REGARDING IMMATICS PLATFORM TECHNOLOGY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">IMMATICS PROGRAMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2.1 IMMATICS TARGETS AND TCRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2.2 TECHNOLOGY TRANSFER FROM BMS TO IMMATICS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2.3 RESEARCH PLAN FOR IMMATICS PRODUCTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COMPLIANCE PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3.1 GENERAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3.2 GOVERNMENTS AND INTERNATIONAL PUBLIC ORGANIZATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3.3 NO AUTHORITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3.4 EXCLUSIONS LISTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3.5 PERSONAL DATA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3 DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DEVELOPMENT AND COMMERCIALIZATION.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1.1 GENERAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1.2 DILIGENCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1.3 PROGRESS UPDATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1.4 <FONT STYLE="white-space:nowrap">CO-DEVELOPMENT</FONT> AND <FONT STYLE="white-space:nowrap">CO-COMMERCIALIZATION</FONT> OPTION; RIGHT OF NEGOTIATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1.5 RIGHT OF PROCESS PARTICIPATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGULATORY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2.1 REGULATORY MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2.2 PHARMACOVIGILANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MANUFACTURING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3.1 BMS PRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3.2 IMMATICS PRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3.3 MANUFACTURING TECHNOLOGY TRANSFER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE 4 GOVERNANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GENERALLY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1.1 COMMITTEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1.2 ALLIANCE MANAGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JOINT STEERING COMMITTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.1 ESTABLISHMENT; MEETINGS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.2 MEMBERSHIP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.3 RESPONSIBILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.4 DECISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.5 MINUTES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE 5 EXCLUSIVITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXCLUSIVITY FOR CAR TARGETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1.1 GENERAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1.2 COMPETING PRODUCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXCEPTIONS FOR CHANGE OF CONTROL AND ACQUISITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2.1 IMMATICS COC COMPETING PRODUCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2.2 IMMATICS ACQUIRED COMPETING PRODUCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXCLUSIVITY FOR TCR TARGETS UNDER 2019 COLLABORATION AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE 6 FINANCIAL TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UPFRONT PAYMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RESEARCH PROGRAM COSTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2.1 GENERAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELIGIBLE RESEARCH COSTS REPORT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PAYMENT OF INVOICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CERTAIN DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ROYALTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COLLABORATION PRODUCT ROYALTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROYALTY TERM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REDUCTIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROYALTY OFFSET FOR THIRD PARTY PAYMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMPULSORY LICENSES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PAYMENT OF ROYALTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">MILESTONES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REGULATORY MILESTONES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INVOICE AND PAYMENT OF REGULATORY MILESTONE PAYMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SALES MILESTONES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INVOICE AND PAYMENT OF SALES MILESTONE PAYMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">PAYMENTS FOR IMMATICS <FONT STYLE="white-space:nowrap">IN-LICENSE</FONT>
AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OPTION FEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INITIAL REIMBURSABLE GENE EDITING TECHNOLOGY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NEW REIMBURSABLE <FONT STYLE="white-space:nowrap">IN-LICENSED</FONT> TECHNOLOGY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ADDITIONAL PAYMENT TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENCY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TAXES; WITHHOLDING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LATE PAYMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">RECORDS RETENTION; REVIEW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RECORDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REVIEW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RECORDS FINAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">IMMATICS THIRD PARTY AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">6.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADDITIONAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7 LICENSES; INTELLECTUAL PROPERTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LICENSES AND GRANTS TO BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LICENSES AND GRANTS TO IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SUBLICENSING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RIGHTS RETAINED BY THE PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXISTING IMMATICS <FONT STYLE="white-space:nowrap">IN-LICENSE</FONT>
AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NO IMPLIED LICENSES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INSOLVENCY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OWNERSHIP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8.1 DISCLOSURE AND INVENTORSHIP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8.2 OWNERSHIP OF IMMATICS LICENSED IP, BMS CONTRIBUTED COLLABORATION TECHNOLOGY
AND BMS LICENSED IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8.3 JOINT IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8.4 SOLE INVENTIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8.5 FURTHER ACTIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PATENT LIAISONS AND INTELLECTUAL PROPERTY COMMITTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.9.1 PATENT LIAISONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.9.2 INTELLECTUAL PROPERTY COMMITTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PROSECUTION AND MAINTENANCE OF IMMATICS PATENTS AND JOINT PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10.1 IMMATICS PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10.2 IMMATICS-OWNED BMS PRODUCT SPECIFIC PATENTS AND JOINT PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10.3 COOPERATION IN PROSECUTION AND MAINTENANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10.4 COSTS OF PROSECUTION AND MAINTENANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ENFORCEMENT OF IMMATICS PATENTS AND JOINT PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.1 NOTICE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.2 ENFORCEMENT OF INFRINGEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.3 JOINDER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.4 CONSULTATION; COOPERATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.5 SETTLEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.6 COSTS AND RECOVERIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11.7 BIOSIMILAR APPLICATIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PATENT TERM EXTENSIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PATENT LINKAGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMMON INTEREST AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LICENSE FILING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFENSE OF CLAIMS BROUGHT BY THIRD PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.16.1 BMS PRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.16.2 IMMATICS PRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMS LICENSED PATENTS AND BMS LICENSED
<FONT STYLE="white-space:nowrap">KNOW-HOW</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[RESERVED]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">7.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAME PATENTS LICENSED UNDER A 2019 AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 8 CONFIDENTIALITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NONDISCLOSURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMS PROGRAM SPECIFIC CONFIDENTIAL INFORMATION; OTHER BMS IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IMMATICS PROGRAM SPECIFIC CONFIDENTIAL INFORMATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JOINT CONFIDENTIAL INFORMATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXCEPTIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5.1 GENERAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AUTHORIZED DISCLOSURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6.1 DISCLOSURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6.2 TERMS OF DISCLOSURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6.3 BMS PROGRAM SPECIFIC IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6.4 IMMATICS PROGRAM SPECIFIC IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TERMS OF THIS AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECURITIES FILINGS; DISCLOSURE UNDER APPLICABLE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PUBLICITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9.1 PRESS RELEASE; PUBLIC STATEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9.2 ADDITIONAL RESTRICTIONS ON DISCLOSURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9.3 PREVIOUSLY ISSUED PUBLIC STATEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PERMITTED PUBLICATIONS OF [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10.1 PUBLICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10.2 <FONT STYLE="white-space:nowrap">RE-PUBLICATION;</FONT> <FONT
STYLE="white-space:nowrap">RE-PRESENTATION</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USE OF NAMES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">8.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CLINICAL TRIALS REGISTRY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 9 REPRESENTATIONS AND WARRANTIES; COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES OF IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COVENANTS OF IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.1 MAINTENANCE OF EXCLUSIVELY LICENSED ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.2 IMMATICS <FONT STYLE="white-space:nowrap">IN-LICENSE</FONT>
AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.3 BMS CONTINUING RIGHTS UNDER IMMATICS
<FONT STYLE="white-space:nowrap">IN-LICENSE</FONT> AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.4 LISTING OF ADDITIONAL IMMATICS PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.5 NO CONFLICTING GRANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.6 NO OTHER USES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES OF BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4.1 AS OF THE EFFECTIVE DATE,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COVENANTS OF BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5.1 NO CONFLICTING GRANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5.2 LISTING OF ADDITIONAL BMS PATENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5.3 IMMATICS <FONT STYLE="white-space:nowrap">IN-LICENSE</FONT>
AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5.4 CERTAIN RIGHTS OF THIRD PARTIES UNDER IMMATICS
<FONT STYLE="white-space:nowrap">IN-LICENSE</FONT> AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUTUAL COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">9.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DISCLAIMER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 10 INDEMNIFICATION; INSURANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INDEMNIFICATION BY BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">INDEMNIFICATION BY IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><FONT STYLE="white-space:nowrap">CO-DEVELOPED</FONT> PRODUCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">PROCEDURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">INSURANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">LIMITATION OF LIABILITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 11 TERM AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">TERM; EXPIRATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.1.1 TERM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.1.2 EFFECT OF PRODUCT EXPIRATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">TERMINATION FOR BREACH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.2.1 MATERIAL BREACH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.2.2 DISAGREEMENT AS TO MATERIAL BREACH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">VOLUNTARY TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.3.1 TERMINATION BY BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.3.2 TERMINATION BY IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">TERMINATION FOR BANKRUPTCY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">TERMINATION OF 2019 AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">EFFECTS OF EXPIRATION AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.6.1 GENERALLY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.6.2 BMS PRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">CERTAIN ADDITIONAL REMEDIES IN LIEU OF TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.7.1 ADDITIONAL REMEDIES OF BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.7.2 ADDITIONAL REMEDIES OF IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">SURVIVING PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.8.1 ACCRUED RIGHTS; REMEDIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.8.2 SURVIVAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">11.8.3 TERMINATION IN PART</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">MILESTONE PAYMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">11.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><FONT STYLE="white-space:nowrap">CO-DEVELOPED</FONT> PRODUCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="7" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 12 MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEVERABILITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NOTICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORCE MAJEURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASSIGNMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4.1 GENERALLY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4.2 BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4.3 IMMATICS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4.4 ALL OTHER ASSIGNMENTS NULL AND VOID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WAIVERS AND MODIFICATIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WAIVER OF JURY TRIAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHOICE OF LAW; DISPUTE RESOLUTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7.1 CHOICE OF LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7.2 EXCLUSIVE DISPUTE RESOLUTION MECHANISM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7.3 JURISDICTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RELATIONSHIP OF THE PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">THIRD PARTY BENEFICIARIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ENTIRE AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COUNTERPARTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EQUITABLE RELIEF; CUMULATIVE REMEDIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTERPRETATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.1 GENERALLY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.2 DEFINITIONS; INTERPRETATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.3 SUBSEQUENT EVENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.4 HEADINGS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.5 PRIOR DRAFTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13.6 INDEPENDENT SIGNIFICANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FURTHER ASSURANCES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXTENSION TO AFFILIATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IMMATICS GMBH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Page</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LIST OF SCHEDULES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;1.58</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1.60</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Initial Feeder-Free Manufacturing Process Criteria</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1.77</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Immatics Licensed Patents</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1.80</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Initial Immatics Platform Patents</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;2.1.2(a)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Initial Research Plan for First BMS Product</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;2.1.2(h)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certain Permitted Immatics Subcontractors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 2.1.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certain Materials for Technology Transfer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 2.2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Party Gatekeeper Process</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 3.1.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certain Terms of <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;3.1.4(c)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement Resolution Procedure</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 3.3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manufacturing Cost</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 6.5.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Payments under Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 9.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Immatics Disclosure Schedules</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 9.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BMS Disclosure Schedules</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 9.5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certain Terms of Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">x </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <B>COLLABORATION AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is entered into and made effective as of June&nbsp;1, 2022 (the &#147;<B>Effective
Date</B>&#148;) by and between Immatics US, Inc., a Delaware corporation having an address at 2201 W. Holcombe Boulevard, Suite 205, Houston, Texas 77030 (&#147;<B>Immatics</B>&#148;) and Celgene Switzerland LLC, a Delaware limited liability company
(&#147;<B>BMS</B>&#148;), and, solely for purposes of Section&nbsp;12.16, Immatics Biotechnologies GmbH, a limited liability company organized under the laws of Germany having an address at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany
(&#147;<B>Immatics GmbH</B>&#148;). BMS and Immatics are each referred to herein by name or as a &#147;<B>Party</B>&#148; or, collectively, as the &#147;<B>Parties</B>&#148;.<B> </B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Immatics Biotechnologies GmbH, an Affiliate of Immatics, and BMS, entered into that certain Master Collaboration Agreement, dated as of August&nbsp;20, 2019 (the &#147;<B>2019 Collaboration Agreement</B>&#148;), pursuant to which, among other
things, Immatics has conducted (and is continuing to conduct) research programs with respect to certain Selected Targets (as defined in the 2019 Collaboration Agreement) to, among other things, generate Collaboration TCRs (as defined in the 2019
Collaboration Agreement) directed to such Selected Targets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to the 2019 Collaboration Agreement, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis (as defined in the 2019 Collaboration Agreement), BMS has the right to exercise its <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right (as defined
in the 2019 Collaboration Agreement) to enter into a License Agreement (as defined in the 2019 Collaboration Agreement) with respect to such Program, including with respect to the Collaboration TCRs under such Program (each such License Agreement
that is entered into, a &#147;<B>2019 License Agreement</B>&#148;, and each of the License Agreements together with the 2019 Collaboration Agreement, collectively, the &#147;<B>2019 Agreements</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, BMS and Immatics desire to enter into this Agreement in order to, among other things, collaborate on the development of
gamma-delta <FONT STYLE="white-space:nowrap">T-cell</FONT> based allogeneic cell therapy products containing certain <FONT STYLE="white-space:nowrap">BMS-nominated</FONT> TCRs (from the 2019 Agreements) or CARs, to be commercialized by BMS, and for
Immatics to grant certain licenses under its intellectual property in connection therewith, as more particularly described in this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, BMS and Immatics also desire to enter into this Agreement in order for, among other things, Immatics to develop gamma-delta <FONT
STYLE="white-space:nowrap">T-cell</FONT> based allogeneic cell therapy products containing certain Immatics-nominated TCRs, to be commercialized by Immatics, and for BMS to grant certain licenses under its intellectual property in connection
therewith and for BMS to have certain <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> rights for such products, as more particularly described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless specifically set forth
to the contrary herein, the following terms shall have the respective meanings set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 &#147;<B>2019 Collaboration
TCR</B>&#148; means a &#147;Licensed TCR&#148; as defined in the applicable 2019 License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>2019 Collaboration
Target</B>&#148; means a &#147;Licensed Target&#148; as defined in the applicable 2019 License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Accounting
Standards</B>&#148; means either U.S. generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) or International Financial Reporting Standards (&#147;<B>IFRS</B>&#148;), as designated and used by the applicable Party in preparing its
financial statements from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Affiliate</B>&#148; means any Person which, directly or indirectly through one or
more intermediaries, controls, is controlled by or is under common control with a Party, for so long as such Person controls, is controlled by or is under common control with a Party, and regardless of whether such Affiliate is or becomes an
Affiliate on or after the Effective Date. For purposes of this definition, the term &#147;control&#148; (including, with correlative meanings, the terms &#147;controlled by&#148; and &#147;under common control with&#148;) as used with respect to a
Person means (a)&nbsp;direct or indirect ownership of fifty percent (50%) or more of the voting securities or other voting interest of any Person (including attribution from related parties), or (b)&nbsp;the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract, as a general partner, as a manager, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 &#147;<B>Allogeneic</B>&#148; means, with respect to a Cell Therapy Product, that the <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>Annual BMS Product Net Sales</B>&#148; means, on a BMS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis, the total Net Sales by BMS, its Affiliates and Sublicensees in the Territory of such BMS Product for use in the Field in a particular
Calendar Year, calculated in accordance with Accounting Standards consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Annual Immatics Product Net
Sales</B>&#148; means, on an Immatics <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product basis, the total Net Sales by Immatics, its Affiliates and Sublicensees in the Territory of such
Immatics Product for use in the Field in a particular Calendar Year, calculated in accordance with Accounting Standards consistently applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Annual Product Net Sales</B>&#148; means Annual BMS Product Net Sales or Annual Immatics Product Net Sales, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B>Applicable Law</B>&#148; or &#147;<B>Applicable Laws</B>&#148; means all applicable laws, statutes, rules, regulations, orders,
judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city or other political subdivision, including, to the extent applicable, GCP, GLP and GMP, as well as all applicable data
protection and privacy laws, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rules and regulations, including, to the extent applicable, the United States Department
of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;) and the Health Information Technology for Economic and Clinical Health Act and the EU General Data Protection
Regulation (2016/679). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 &#147;<B>Biosimilar Application</B>&#148; means an application or submission filed with a Regulatory
Authority for marketing authorization of a Biosimilar Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#147;<B>Biosimilar Product</B>&#148; means, with respect to a given
Collaboration Product in a given country, <U>[**]</U> (b) for which [Regulatory Approval is obtained <U>[**]</U>] (c) that is [approved for use in such country (or region) <U>[**]</U>, and (d)&nbsp;that is [sold in the same country as such
Collaboration Product <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 &#147;<B>BMS CAR</B>&#148; means each CAR that is designated by BMS to be included as a &#147;BMS
CAR&#148; hereunder pursuant to Section&nbsp;2.1.1(a), Section&nbsp;2.1.1(b) or Section&nbsp;2.1.1(d), as applicable, as such CAR may be further improved, optimized or modified in the course of conducting Development activities hereunder; provided
that such improved, optimized or modified CAR is still Directed to the applicable BMS Target (and no other Targets). For the avoidance of doubt, <U>[**]</U>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13 &#147;<B>BMS CAR Product</B>&#148; means any Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy
Product that (a)&nbsp;is <U>[**]</U>. For clarity, <U>[**]</U>. For the avoidance of doubt, a <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>BMS Contributed
Collaboration Technology</B>&#148; means (a)&nbsp;any <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by BMS (or its Affiliate) that <U>[**]</U> for use by Immatics in the performance of the Research Programs pursuant to this Agreement
for the Development of the Initial BMS Products, as such <FONT STYLE="white-space:nowrap">Know-How</FONT> is <U>[**]</U>, (b) any additional <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by BMS (or its Affiliate) that <U>[**]</U>, and
(c)&nbsp;any Patents that are Controlled by BMS (or its Affiliate) that specifically claim the <FONT STYLE="white-space:nowrap">Know-How</FONT> in the foregoing clauses (a)&nbsp;or (b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>BMS Licensed IP</B>&#148; means, with respect to a given Immatics TCR (and Immatics Products transduced with such Immatics TCR),
the BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and BMS Licensed Patents for such Immatics TCR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>BMS
Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means, with respect to a given Immatics TCR (and Immatics Products transduced with such Immatics TCR), (a) the <FONT STYLE="white-space:nowrap">Know-How</FONT> from the BMS
Potential Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> that <U>[**]</U> and (b) <U>[**]</U>; provided that, in each case, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>BMS Licensed Patent</B>&#148; means, with respect to a given Immatics TCR (and Immatics Products transduced with such Immatics
TCR), (a) the Patents from the BMS Potential Licensed Patents that <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>BMS Potential Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means, with respect to a given Immatics TCR (and Immatics Products transduced with such Immatics TCR), the <FONT STYLE="white-space:nowrap">Know-How</FONT> within the BMS Contributed Collaboration
Technology that <U>[**]</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>BMS Potential Licensed Patent</B>&#148; means, with
respect to a given Immatics TCR (and Immatics Products transduced with such Immatics TCR), the Patents within the BMS Contributed Collaboration Technology that (a) <U>[**]</U>, (b) <U>[**]</U>, (c) <U>[**]</U>, and (d) <U>[**]</U>. In all cases, BMS
Potential Licensed Patents exclude <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>BMS Potential Licensed Technology</B>&#148; means, with respect to a given
Immatics TCR (and Immatics Products transduced with such Immatics TCR), the BMS Potential Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and BMS Potential Licensed Patents for such Immatics TCR and Immatics Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>BMS Product</B>&#148; means a BMS TCR Product or a BMS CAR Product, as applicable. As used herein, (a)&nbsp;the &#147;<B>Initial
BMS Products</B>&#148; means (i)&nbsp;any BMS Product transduced with the First BMS Receptor designated by BMS pursuant to Section&nbsp;2.1.1(a) (or any Substitute Receptor for such First BMS Receptor designated pursuant to Section&nbsp;2.1.1(b) or
any applicable Additional Receptor with respect to such First BMS Receptor designated pursuant to Section&nbsp;2.1.1(d)) (the &#147;<B>First BMS Product</B>&#148;), and (ii)&nbsp;any BMS Product transduced with the Second BMS Receptor designated by
BMS pursuant to Section&nbsp;2.1.1(a) (or any Substitute Receptor for such Second BMS Receptor designated pursuant to Section&nbsp;2.1.1(b) or any applicable Additional Receptor with respect to such Second BMS Receptor designated pursuant to
Section&nbsp;2.1.1(d)) (the &#147;<B>Second BMS Product</B>&#148;) and (b)&nbsp;the &#147;<B>Additional BMS Products</B>&#148; means any BMS Product<B> </B>transduced with<B> </B>any other BMS Receptor designated by BMS pursuant to
Section&nbsp;2.1.1(a) (i.e., the third BMS Receptor, fourth BMS Receptor, fifth BMS Receptor or sixth BMS Receptor, as applicable, in each case, including any applicable Additional Receptor with respect thereto designated pursuant to
Section&nbsp;2.1.1(d)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>BMS Product Specific Invention</B>&#148; means any Invention: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22.1 <U>[**]</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22.2
<U>[**]</U>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22.3 <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>BMS Receptor</B>&#148; means a BMS TCR or BMS CAR, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>BMS</B> <B>Royalty Term</B>&#148; means, on a BMS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the period of time commencing on the
First Commercial Sale of such BMS Product in such country of sale and expiring upon [the latest of (a)&nbsp;the date on which there is no Valid Claim of a Patent <U>[**]</U> (b)&nbsp;the last to expire Regulatory Exclusivity period for such BMS
Product in such country, and (c)&nbsp;the ten (10)&nbsp;year anniversary of the date of First Commercial Sale of such BMS Product in such country of sale]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>BMS Sole Invention</B>&#148; means (a)&nbsp;any and all Inventions that are created, conceived, discovered, generated, invented,
made or reduced to practice, in each case, solely by or on behalf of BMS or its Affiliates, (b)&nbsp;any and all Inventions that are improvements, modifications or enhancements to <U>[**]</U>, (c) all BMS Product Specific Inventions, and
(d)&nbsp;all Research Program Deliverables, but excluding, (x)&nbsp;in the case of clauses (a)&nbsp;and (d), any Immatics Platform Inventions and (y)&nbsp;in the case of <U>[**]</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26 &#147;<B>BMS Sole Patent</B>&#148; means any Patents that claim any
BMS Sole Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27 &#147;<B>BMS Special Learnings Technology</B>&#148; means any BMS Potential Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> within the BMS Potential Licensed Technology that <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28 &#147;<B>BMS
Target</B>&#148; means the Target recognized or bound by a given BMS Receptor, as such Target is identified by BMS pursuant to Section&nbsp;2.1.1(a) or Section&nbsp;2.1.1(b), as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29 &#147;<B>BMS TCR</B>&#148; means each TCR that is designated by BMS to be included as a &#147;BMS TCR&#148; hereunder pursuant to
Section&nbsp;2.1.1(a), Section&nbsp;2.1.1(b) or Section&nbsp;2.1.1(d), as applicable, as such <U>[**]</U>. For the avoidance of doubt, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30 &#147;<B>BMS TCR Product</B>&#148; means any Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy
Product that (a)&nbsp;is transduced with<B> </B>a given BMS TCR <U>[**]</U> with respect to such BMS TCR and (b)&nbsp;<U>[**]</U>. For clarity, <U>[**]</U>. For the avoidance of doubt, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31 &#147;<B>BPCIA</B>&#148; means Biologics Price Competition and Innovation Act of 2009, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32 &#147;<B>Business Day</B>&#148; means any day that is not a Saturday, Sunday or other day on which banking institutions are required or
authorized by Applicable Law to be closed in New York City, New York, U.S. or Tuebingen, Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33 &#147;<B>Calendar
Quarter</B>&#148; means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls, and thereafter each successive period of three (3)&nbsp;consecutive calendar months ending on
the last day of March, June, September, or December, respectively; provided that the final Calendar Quarter shall end on the last day of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34 &#147;<B>Calendar Year</B>&#148; means the period beginning on the Effective Date and ending on December&nbsp;31 of the calendar year in
which the Effective Date falls, and thereafter each successive period of twelve (12)&nbsp;consecutive calendar months beginning on January&nbsp;1 and ending on December 31; provided that the final Calendar Year shall end on the last day of the Term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35 &#147;<B>CAR</B>&#148; means a chimeric antigen receptor (including any protein, polypeptide, receptor, ligand or other molecule)
that includes a transmembrane domain and an endodomain and that is designed to bind to any molecule(s) on or in a pathogenic agent, a cell surface, within a cell, or directly associated with a cell (for example, any antigens(s) or ligand(s)
displayed on a cell surface, within a cell or directly associated with a cell). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36 &#147;<B>CAR Product</B>&#148; means a therapy or
product that contains or comprises a transduced CAR as an active targeting component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37 &#147;<B>Cell Therapy Product</B>&#148; means
a human therapy or product in which the specificity of an immune system cell is genetically modified to enable the respective cell&#146;s recognition of a desired target antigen or peptide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38 &#147;<B>Change of Control</B>&#148; with respect to the ultimate
parent entity of a Party (an &#147;<B>Acquired Party</B>&#148;) shall be deemed to have occurred upon any of the following occurring after the Effective Date: (a)&nbsp;any Person or group of Persons that is not an Affiliate of such Acquired Party
becomes the beneficial owner (directly or indirectly) of fifty percent (50%) or more of the voting shares of the Acquired Party; (b)&nbsp;such Acquired Party consolidates with or merges into or with another Person that is not an Affiliate of such
Acquired Party pursuant to a transaction in which fifty percent (50%) or more of the voting shares of the acquiring or resulting entity outstanding immediately after such consolidation or merger is not held by the holders of the outstanding voting
shares of such Acquired Party immediately preceding such consolidation or merger; or (c)&nbsp;the Acquired Party sells or transfers to another Person that is not an Affiliate of such Acquired Party all or substantially all of its assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39 &#147;<B>Clinical Proof of Concept</B>&#148; means the demonstration of (a)&nbsp;safety and (b)&nbsp;either&nbsp;(i) a beneficial
activity on a recognized surrogate marker of the activity of a disease or medical condition or (ii)&nbsp;an effect on a physiologically relevant clinical measure of a disease or medical condition that <U>[**]</U> in a representative patient
population <U>[**]</U> for the disease or medical condition.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40 &#147;<B>Clinical Trial</B>&#148; means a human clinical trial,
including any Phase 1 Clinical Trial, Phase 2 Clinical Trial or Registration-Enabling Clinical Trial, any study incorporating more than one of these phases, or any human clinical trial commenced after Regulatory Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41 &#147;<B>Collaboration CAR</B>&#148; means a BMS CAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42 &#147;<B>Collaboration Product</B>&#148; means a BMS Product or Immatics Product, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43 &#147;<B>Collaboration Receptor</B>&#148; means a Collaboration CAR or Collaboration TCR, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.44 &#147;<B>Collaboration TCR</B>&#148; means a BMS TCR or Immatics TCR, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.45 &#147;<B>Combination Element</B>&#148; means any element of a Collaboration Product <U>[**]</U> that <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.46 &#147;<B>Commercialization</B>&#148; means any and all activities directed to the commercialization of a product, including commercial
manufacturing (including Manufacturing) and commercial supply of a product, marketing, detailing, promotion, market research, distributing, order processing, handling returns and recalls, booking sales, customer service, administering and
commercially selling such product, importing, exporting and transporting such product for commercial sale, and seeking of pricing and reimbursement of a product (if applicable), whether before or after Regulatory Approval has been obtained
(including making, having made, using, importing, selling and offering for sale such product), as well all regulatory compliance with respect to the foregoing. For clarity, [**]. When used as a verb, &#147;<B>Commercialize</B>&#148; means to engage
in Commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.47 &#147;<B>Commercially Reasonable Efforts</B>&#148; means<U>[**]</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.48 &#147;<B>Confidential Information</B>&#148; means, with respect to
a Party, all confidential or proprietary information and materials, including <FONT STYLE="white-space:nowrap">Know-How,</FONT> marketing plans, strategies, and customer lists, in each case, that are disclosed by or on behalf of such Party to the
other Party pursuant to this Agreement, regardless of whether any of the foregoing are marked &#147;confidential&#148; or &#147;proprietary&#148; or communicated to the other Party by or on behalf of the disclosing Party in oral, written, visual,
graphic or electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.49 &#147;<B>Control</B>&#148;, &#147;<B>Controls</B>&#148; or &#147;<B>Controlled</B>&#148; means, with
respect to any intellectual property (including Patents and <FONT STYLE="white-space:nowrap">Know-How)</FONT> or Confidential Information, the ability of a Party or its Affiliates, as applicable, (whether through ownership or license (other than a
license granted in this Agreement)) to grant to the other Party the licenses or sublicenses as provided herein, or to otherwise disclose such intellectual property or Confidential Information to the other Party, without <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.50 &#147;<B>Cover</B>&#148;, &#147;<B>Covering</B>&#148; or &#147;<B>Covered</B>&#148; means, (a)&nbsp;with reference to a given <U>[**]</U>
in a given country of sale, that (i) <U>[**]</U> has a Valid Claim that claims (x) <U>[**]</U>, (y) <U>[**]</U> or (z) <U>[**]</U>, and (ii) <U>[**]</U> or (b)&nbsp;with reference to a given <U>[**]</U> in a given country of sale, that (i)
<U>[**]</U>, and (ii) <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.51 &#147;<B>Data Package</B>&#148; means with respect to a given Immatics Product, the written data
package to be delivered by Immatics to BMS pursuant to Section&nbsp;3.1.4(a), and comprised of preclinical and clinical information related to the Immatics Product, including <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.52 &#147;<B>Development</B>&#148; means (a)&nbsp;research activities (including drug discovery, identification or synthesis) with respect to
a product, including derivatization and other modification of a product or any component thereof and (b)&nbsp;preclinical and clinical drug development activities, and other development activities, with respect to a product, including test method
development and stability testing, toxicology, formulation, process development, qualification and validation, manufacture <FONT STYLE="white-space:nowrap">scale-up,</FONT> development-stage manufacturing (including Manufacturing), quality
assurance/quality control, clinical trials (including clinical trials and other studies commenced after Regulatory Approval), statistical analysis and report writing, the preparation and submission of INDs and MAAs, regulatory affairs with respect
to the foregoing and all other activities necessary or useful or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining or expanding a Regulatory Approval. When used as a verb,
&#147;<B>Develop</B>&#148; means to engage in Development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.53 &#147;<B>Directed</B>&#148; or &#147;<B>Directed to</B>&#148; means, with
respect to (i)&nbsp;a given Target and (ii)&nbsp;a given Receptor or product, as applicable, (a)&nbsp;if such Receptor is a CAR or such product is a CAR product, as applicable, that <U>[**]</U> or (b)&nbsp;if such Receptor is a TCR or such product
is a TCR product, as applicable, that <U>[**]</U>; provided, however, that, in each case (a)&nbsp;and (b), if such <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.54
<U>[**]</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.55 &#147;<B>Dollars</B>&#148; or &#147;<B>$</B>&#148; means the legal tender of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.56 &#147;<B>EU</B>&#148; means all countries that are officially recognized as member states of the European Union at any particular time,
including the United Kingdom regardless of whether actually within the European Union. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.57 &#147;<B>Executive Officers</B>&#148; means Immatics&#146;
<U>[**]</U> and BMS&#146; <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.58 &#147;<B>Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>&#148; means the agreements set forth on <U>Schedule</U><U> 1.58</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.59 &#147;<B>Feeder-Dependent Manufacturing
Process</B>&#148;<B> </B>means, with respect to a given BMS Product, any Manufacturing process for such BMS Product other than a Feeder-Free Manufacturing Process. <I></I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.60 &#147;<B>Feeder-Free Manufacturing Process</B>&#148;<B> </B>means with respect to a given BMS Product, a Manufacturing process for such
BMS Product that satisfies the criteria set forth on <U>Schedule 1.60</U> to be &#147;feeder-free&#148;, as such <U>[**]</U>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.61 &#147;<B>Field</B>&#148; means any and all uses or purposes, including the treatment, prophylaxis or palliation of any human or animal
disease, disorder or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.62 &#147;<B>First Commercial Sale</B>&#148; means, on a Collaboration <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Collaboration</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the first sale of such Collaboration Product in such country by
the applicable Party (or its Affiliates or Sublicensees) for use or consumption by the general public (following receipt of all Regulatory Approvals that are required in order to sell such Collaboration Product in such country); <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.63 &#147;<B>Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell</FONT></B>&#148; means a <FONT STYLE="white-space:nowrap">T-Cell</FONT> that
expresses, or has ever expressed, a gamma-delta <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor dimer consisting of a gamma (<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) chain and a delta (<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>)
chain. For clarity, <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.64 &#147;<B>Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy
Product</B>&#148; means a Cell Therapy Product that contains or comprises an Allogeneic Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell</FONT> as an active component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.65 &#147;<B>Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Product</B>&#148; means a therapy or product that contains or
comprises a Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell</FONT> as an active component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.66 &#147;<B>Good Clinical
Practices</B>&#148; or &#147;<B>GCP</B>&#148; means the applicable then-current ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by
applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States, Good Clinical Practices established through FDA guidances, and, outside the United States, Guidelines for Good Clinical Practice &#150;
ICH Harmonized Tripartite Guideline (ICH E6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.67 &#147;<B>Good Laboratory Practices</B>&#148; or &#147;<B>GLP</B>&#148; means the
applicable then-current good laboratory practice standards as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States, those promulgated or endorsed by the FDA in U.S. 21
C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by the applicable Regulatory Authorities outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.68 &#147;<B>Good Manufacturing Practices</B>&#148; or
&#147;<B>GMP</B>&#148; means all applicable standards relating to manufacturing practices for fine chemicals, intermediates, bulk products or finished pharmaceutical products, as are required by applicable Regulatory Authorities or Applicable Law in
the relevant jurisdiction, including, as applicable, (a)&nbsp;all applicable requirements detailed in the FDA&#146;s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211, (b) all applicable requirements detailed in the
EMA&#146;s &#147;The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products&#148;, and (c)&nbsp;all equivalent Applicable Laws promulgated by any Governmental Authority having
jurisdiction over the manufacture of the applicable compound or pharmaceutical product, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.69 &#147;<B>Governmental
Authority</B>&#148; means any (a)&nbsp;federal, state, local, municipal, foreign or other government, (b)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau,
branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal), (c) multinational governmental organization or body, or (d)&nbsp;entity or body
exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.70 &#147;<B><FONT STYLE="white-space:nowrap">Hand-off</FONT></B>&#148; means with respect to a given Initial BMS Product: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) for <U>[**]</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) with
respect to <U>[**]</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) with respect to <U>[**]</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) in case of (a), (b), or (c), as applicable, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, with respect to <U>[**]</U>, for purposes of this Agreement, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.71 &#147;<B>HLA</B>&#148; means human leukocyte antigen, a gene complex that encodes the major histocompatibility complex
(&#147;<B>MHC</B>&#148;) antigens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.72 &#147;<B>Immatics Developed Feeder-Dependent Process</B>&#148; means the proprietary
manufacturing platform technology owned or Controlled by Immatics (or any of its Affiliates) that are methods and processes <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.73 &#147;<B>Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; means (a)&nbsp;any agreement between Immatics
(or its Affiliates, as applicable) and any Third Party pursuant to which such Third Party licenses to Immatics (or its Affiliates, as applicable) any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> that may be included in the Immatics
Licensed IP in accordance with Section&nbsp;6.5.3(b) and (b)&nbsp;the Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.74 &#147;<B>Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means the Immatics Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the Immatics Platform Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.75 &#147;<B>Immatics Licensed IP</B>&#148; means the Immatics Licensed
Patents, the Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Immatics Platform Technology and the Immatics Platform Patents, as well as Immatics&#146; (and its Affiliates&#146;) right, title and interest in and to the Joint
IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.76 &#147;<B>Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any and all <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is Controlled by Immatics or its Affiliates on the Effective Date or during the Term that is (a)&nbsp;<U>[**]</U> to research, develop, make, have made, import, use, offer to sell, sell or otherwise
exploit any BMS TCR, BMS CAR, or BMS Product, or <U>[**]</U>, or (b) <U>[**]</U>. Notwithstanding any other provision of this Agreement, if any Third Party becomes an Affiliate of Immatics after the Effective Date as a result of a Change of Control
of Immatics, Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> will exclude <U>[**]</U> that are (A) <U>[**]</U> or (B) <U>[**]</U> the &#147;<B>Excluded <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;); provided that,
for clarity, [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.77 &#147;<B>Immatics Licensed Patents</B>&#148; means any and all Patents that are Controlled by Immatics or its
Affiliates on the Effective Date or during the Term that <U>[**]</U> to research, develop, make, have made, import, use, offer to sell, sell or otherwise exploit any BMS TCR, BMS CAR, or BMS Product, or <U>[**]</U>. Immatics Licensed Patents shall
include the Patents set forth on <U>Schedule 1.77</U>. Notwithstanding any other provision of this Agreement, if any Third Party becomes an Affiliate of Immatics after the Effective Date as a result of a Change of Control of Immatics, Immatics
Licensed Patents will exclude any Patents that are (i)<U></U>&nbsp;<U>[**]</U>; provided that, for clarity, any Patents that were Controlled by Immatics (or any of its Affiliates) prior to such Change of Control (including any substitutions,
divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, registrations, confirmations, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> extensions,
supplementary protection certificates and the like of any such Patents as well as any other Patents that claim priority to any such Patents) shall continue to be within the definition of Immatics Licensed Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.78 &#147;<B>Immatics Patents</B>&#148; means the Immatics Licensed Patents and the Immatics Platform Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.79 &#147;<B>Immatics Platform Invention Patent</B>&#148; means an Immatics Sole Patent that claims solely Immatics Platform Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.80 &#147;<B>Immatics Platform Patent</B>&#148; means (a)&nbsp;those Patents set forth on <U>Schedule 1.80</U> as of the Effective Date (the
&#147;<B>Initial Immatics Platform Patents</B>&#148;), (b) subject to Section&nbsp;2.1.5, those Patents Controlled by Immatics or any of its Affiliates that claim solely Additional Immatics Platform Technology (such Patents, the &#147;<B>Additional
Immatics Platform Patents</B>&#148;), and (c)&nbsp;and the Immatics Platform Invention Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.81 &#147;<B>Immatics Platform
Technology</B>&#148; means (a)&nbsp;the proprietary platform technology owned by Immatics (or any of its Affiliates) that consists of <U>[**]</U> the &#147;<B>Initial Immatics Platform Technology</B>&#148;), (b) subject to Section&nbsp;2.1.5, any
<U>[**]</U> the &#147;<B>Additional Immatics Platform Technology</B>&#148;), and (c)&nbsp;the Immatics Platform Inventions; but, in each case of (a), (b), and (c), expressly excluding any <U>[**]</U> (the foregoing exclusions, the &#147;<B><FONT
STYLE="white-space:nowrap">Non-Platform</FONT> Technology</B>&#148;). For clarity, <U>[**]</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.82 &#147;<B>Immatics Product</B>&#148; means any Gamma-Delta <FONT
STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy Product that (a) <U>[**]</U> and (b) <U>[**]</U>. For the avoidance of doubt, <U>[**]</U>. Notwithstanding the foregoing, <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.83 &#147;<B>Immatics-Owned BMS Product Specific Patents</B>&#148; means </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.83.1 any Immatics Patent that <U>[**]</U>; and<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.83.2 any Immatics Patent that <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If requested by BMS, the IPC shall keep a list of Immatics-Owned BMS Product Specific Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.84 &#147;<B>Immatics</B> <B>Royalty Term</B>&#148; means, on an Immatics
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the period of time commencing
on the First Commercial Sale of such Immatics Product in such country of sale and expiring upon the latest of (a)&nbsp;the first date on which there is no Valid Claim of a Patent within the BMS Licensed Patents that Covers such Immatics Product in
such country of sale, (b)&nbsp;the last to expire Regulatory Exclusivity period for such Immatics Product in such country, and (c)&nbsp;the ten (10)&nbsp;year anniversary of the date of First Commercial Sale of such Immatics Product in such country
of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.85 &#147;<B>Immatics Sole Invention</B>&#148; means (a) <U>[**]</U>, and (b) <U>[**]</U> (this clause (b), the
&#147;<B>Immatics Platform Inventions</B>&#148;), but in each case ((a) and (b)), excluding <U>[**]</U>. For clarity, <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.86
&#147;<B>Immatics Sole Patent</B>&#148; means any Patents that claim any Immatics Sole Inventions, but excluding any BMS Sole Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.87 &#147;<B>Immatics Target</B>&#148; means the Target recognized or bound by a given Immatics TCR, as such Target is identified by Immatics
pursuant to Section&nbsp;2.2.1; provided that, in all cases, a given Target will only be an &#147;Immatics Target&#148; if the Target is determined to be &#147;Available&#148; pursuant to Section&nbsp;2.2.1(a) and then is subsequently added as an
&#147;Immatics Target&#148; pursuant to Section&nbsp;2.2.1(c). Notwithstanding the foregoing, <U>[**]</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.88 &#147;<B>Immatics
TCR</B>&#148; means each TCR that is designated by Immatics to be included as an &#147;Immatics TCR&#148; hereunder pursuant to Section&nbsp;2.2.1, as <U>[**]</U>; provided that <U>[**]</U>; provided further that, in all cases, <U>[**]</U>. For the
avoidance of doubt, <U>[**]</U>. Notwithstanding the foregoing, <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.89 &#147;<B>IND</B>&#148; means an investigational new
drug application (including any amendment or supplement thereto) submitted to the FDA pursuant to U.S. 21 C.F.R. Part 312, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s)
outside the U.S. for the investigation of any product in humans in any other country or group of countries (such as a Clinical Trial Application in the EU). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.90 &#147;<B>IND Acceptance</B>&#148; means, with respect to a particular BMS Product, that the IND for such BMS Product was submitted to the
FDA by BMS and accepted by the FDA (as evidenced </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by no objection by the FDA within <U>[**]</U> after the date of the IND submission (or
within <U>[**]</U> after the date of any amended IND submission by BMS if such amended submission restarted the applicable <U>[**]</U>)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.91 <B>[Reserved]</B><B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.92 &#147;<B>Indication</B>&#148; means a separate and distinct disease or medical condition in humans <U>[**]</U>. For clarity, <U>[**]</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.93 &#147;<B>Initiation</B>&#148; means, with respect to a given Clinical Trial, the administration of the first dose of Collaboration
Product to the first subject in such Clinical Trial in accordance with the protocol for such Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.94
&#147;<B>Invention</B>&#148; means all discoveries, inventions and other <FONT STYLE="white-space:nowrap">Know-How,</FONT> whether or not patentable, that are created, conceived, discovered, generated, invented, made or reduced to practice by or on
behalf of a Party (or their respective Affiliates) (whether solely by or on behalf of a Party (or its Affiliate) or jointly by or on behalf of the Parties (or their respective Affiliates)) pursuant to the conduct of activities under this Agreement
at any time during the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.95 &#147;<B>Joint IP</B>&#148; means the Joint Inventions and Joint Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.96 &#147;<B>Joint Inventions</B>&#148; means <U>[**]</U> but excluding, in each case ((a) and (b)), any BMS Sole Inventions and Immatics
Sole Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.97 &#147;<B>Joint Patents</B>&#148; means any Patents that claim any Joint Inventions, but excluding any BMS Sole
Patents or Immatics Sole Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.98 &#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all proprietary
(a)&nbsp;information, techniques, technology, practices, trade secrets, inventions, methods (including methods of use or administration or dosing), knowledge, data, results and software and algorithms, including pharmacological, toxicological and
clinical test data and results, compositions of matter, chemical structures and formulations, sequences, processes, formulae, techniques, research data, reports, standard operating procedures, batch records, manufacturing data, analytical and
quality control data, analytical methods (including applicable reference standards), assays and research tools, in each case, whether patentable or not, and (b)&nbsp;tangible manifestations thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.99 &#147;<B>Major Markets</B>&#148; means <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.100 &#147;<B>Manufacture</B>&#148; means all activities related to the manufacturing of a product or any component or ingredient thereof,
including test method development and stability testing, formulation, process development, manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> whether before or after Regulatory Approval, manufacturing any product in bulk or finished form
for Development or Commercialization (as applicable), including filling and finishing, packaging, labeling, shipping and holding, <FONT STYLE="white-space:nowrap">in-process</FONT> and finished product testing, release of a product or any component
or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of a product, and regulatory activities related to any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.101 &#147;<B>Marketing Authorization Application</B>&#148; or
&#147;<B>MAA</B>&#148; means a marketing authorization application, biologics license application (BLA) or similar application, as applicable, and all amendments and supplements thereto, submitted to the FDA, or any equivalent filing in a country or
regulatory jurisdiction other than the U.S. with the applicable Regulatory Authority, to obtain marketing approval for a product, in a country or in a group of countries, but excluding pricing or reimbursement approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.102 &#147;<B>Net Sales</B>&#148; means, in respect of a given Collaboration Product, the total gross amounts invoiced <U>[**]</U> during a
net sales measurement period for sales of such Collaboration Product in the Territory for use in the Field, <U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There shall be
no double counting in determining the foregoing deductions from gross amounts invoiced to calculate Net Sales. The calculations set forth in this definition of &#147;Net Sales&#148; shall be determined in accordance with Accounting Standards,
consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Sales or other transfers between the applicable Party and its Affiliates or Sublicensees, as well as any transfers
or dispositions of any Collaboration Products for <U>[**]</U>, in each case, shall be excluded from the computation of Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.103
&#147;<B>Parental Protein</B>&#148; means, with respect to a given BMS Target, (a)&nbsp;the parental protein(s) for such BMS Target identified by BMS pursuant to Section&nbsp;2.1.1(a) or 2.1.1(b), as applicable and (b) <U>[**]</U>. For clarity,
<U>[**]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.104 &#147;<B>Patents</B>&#148; means (a)&nbsp;all patents and patent applications in any country or supranational
jurisdiction worldwide, (b)&nbsp;any substitutions, divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, registrations, confirmations, <FONT
STYLE="white-space:nowrap">re-examinations,</FONT> extensions, supplementary protection certificates and the like of any such patents or patent applications, and (c)&nbsp;foreign counterparts of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.105 &#147;<B>Patient Sample</B>&#148; means tissue, fluid, or cells collected from a patient, or components of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.106 &#147;<B>Person</B>&#148; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust,
association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.107
&#147;<B>Personal Data</B>&#148; means any information relating to an identified or identifiable individual or otherwise as defined under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.108 &#147;<B>Phase 1 Clinical Trial</B>&#148; means (a)&nbsp;both a Phase 1a Clinical Trial and a Phase 1b Clinical Trial, or (b)&nbsp;a
single clinical trial that contains all of the elements of both a Phase 1a Clinical Trial and a Phase 1b Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.109
&#147;<B>Phase 1a Clinical Trial</B>&#148; means a human clinical trial of a product that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(a), as amended, <U>[**]</U> or a similar clinical study prescribed by the Regulatory Authorities
in a country other than the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.110 &#147;<B>Phase 1b Clinical Trial</B>&#148; means a human clinical
trial of a product, <U>[**]</U> prior to commencement of Phase&nbsp;2 Clinical Trials or Registration-Enabling Clinical Trial, and which provides <U>[**]</U>. For clarity, a Phase 1b Clinical Trial <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.111 &#147;<B>Phase 2 Clinical Trial</B>&#148; means a human clinical trial of a product that would satisfy the requirements of U.S. 21
C.F.R. Part 312.21(b), as amended, and <U>[**]</U> or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.112 &#147;<B>Prosecution and Maintenance</B>&#148; or &#147;<B>Prosecute and Maintain</B>&#148; means, with respect to a Patent, the
preparation, filing, prosecution and maintenance of such Patent, as well as <FONT STYLE="white-space:nowrap">re-examinations,</FONT> reissues and appeals with respect to such Patent, together with the initiation or defense of interferences,
oppositions, inter partes review, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> derivations, post-grant proceedings and other similar proceedings (or other defense proceedings with respect to such Patent, but excluding the defense of
challenges to such Patent as a counterclaim in an infringement proceeding) with respect to the particular Patent, and any appeals therefrom. For clarification, &#147;Prosecution and Maintenance&#148; or &#147;Prosecute and Maintain&#148; shall not
include any other enforcement actions taken with respect to a Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.113 &#147;<B>Receptor</B>&#148; means a TCR or CAR, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.114 &#147;<B>Registration-Enabling Clinical Trial</B>&#148; means [a human clinical trial of a product that would satisfy
the requirements of U.S. 21 C.F.R. Part 312.21(c), as amended, or a similar clinical study prescribed by the EMA in the EU <U>[**]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.115 &#147;<B>Regulatory Approval</B>&#148; means all approvals, licenses and authorizations of the applicable Regulatory Authority necessary
for the marketing and sale of a product for a particular Indication in a country or region <U>[**]</U> and including the approvals by the applicable Regulatory Authority of any expansion or modification of the label for such Indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.116 &#147;<B>Regulatory Authority</B>&#148; means any national or supranational Governmental Authority, including the U.S. Food and Drug
Administration (and any successor entity thereto) (the &#147;<B>FDA</B>&#148;) in the U.S., the European Medicines Agency (and any successor entity thereto) (the &#147;<B>EMA</B>&#148;) in the EU and the Ministry of Health, Labour and Welfare of
Japan, or the Pharmaceuticals and Medical Devices Agency of Japan (or any successor to either of them) as the case may be (the &#147;<B>MHLW</B>&#148;) in Japan, or any health regulatory authority in any country or region that is a counterpart to
the foregoing agencies, in each case, that holds responsibility for regulating the development and commercialization of, and the granting of Regulatory Approval for, medical product, as applicable, in such country or region. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.117 &#147;<B>Regulatory Exclusivity</B>&#148; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory
Authority with respect to a Collaboration Product in a country or jurisdiction in the Territory, other than a Patent [**], in each case, that confers exclusive rights to (i)&nbsp;BMS, its Affiliates or Sublicensees, with respect to BMS Products, or
(ii)&nbsp;Immatics, its Affiliates or Sublicensees, with respect to Immatics Products, as applicable, to market such Collaboration Product in such country or jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.118 &#147;<B>Regulatory Materials</B>&#148; means the regulatory
registrations, applications, authorizations and approvals (including approvals of MAAs, supplements and amendments, <FONT STYLE="white-space:nowrap">pre-</FONT> and post-approvals, pricing and reimbursement approvals, and labeling approvals),
Regulatory Approvals and other submissions made to or with any Regulatory Authority for research, development (including the conduct of clinical trials), manufacture, or commercialization of a product in a regulatory jurisdiction, together with all
related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each MAA, including all Drug Master Files (DMFs) (if any), INDs and supplemental biologics license applications (sBLAs)
and foreign equivalents of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.119 &#147;<B>Research Program</B>&#148; means the activities undertaken by or on
behalf of the Parties to Develop the First BMS Product and Second BMS Product as set forth in the applicable Research Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.120
&#147;<B>Research Term</B>&#148; means the period beginning on the Effective Date and ending on the <U>[**]</U> thereof, or such earlier time as <U>[**]</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.121 &#147;<B>Sublicensee</B>&#148; means, with respect to a Party, a Third Party to whom such Party has granted a sublicense, either
directly or indirectly, under any (a)&nbsp;in the case of BMS, Immatics Licensed IP licensed to BMS by Immatics pursuant to this Agreement, to Develop, Manufacture or Commercialize any BMS Products in the Field in the Territory, but excluding any
Third Party acting as a distributor and excluding Immatics and its Affiliates or (b)&nbsp;in the case of Immatics, BMS Licensed IP licensed to Immatics by BMS pursuant to this Agreement, to Develop, Manufacture or Commercialize any Immatics Products
in the Field in the Territory, but excluding any Third Party acting as a distributor and excluding BMS and its Affiliates; provided that, with respect to Immatics, a &#147;Sublicensee&#148; shall also include a Third Party to whom Immatics (or its
Affiliate) grants a license to Develop, Manufacture or Commercialize any Immatics Products in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.122 &#147;<B><FONT
STYLE="white-space:nowrap">T-Cell</FONT></B>&#148; is also known as a T lymphocyte and means any lymphoid cell that expresses a TCR on its cell surface. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.123 &#147;<B>Target</B>&#148; means either a TCR Target or a CAR Target. As used herein, (a)&nbsp;a &#147;<B>TCR Target</B>&#148; means
<U>[**]</U> and (b)&nbsp;a &#147;<B>CAR Target</B>&#148; means [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.124 &#147;<B>TCR</B>&#148; means a
<FONT STYLE="white-space:nowrap">T-Cell</FONT> receptor which [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.125 &#147;<B>Territory</B>&#148; means worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.126 &#147;<B>Third Party</B>&#148; means any Person other than Immatics or BMS that is not an Affiliate of Immatics or of BMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.127 &#147;<B>Third Party Claim</B>&#148; means any and all suits, claims, actions, proceedings or demands brought by a Third Party against a
Party (or the Immatics Indemnitees or BMS Indemnitees, as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.128 &#147;<B>Third Party Damages</B>&#148; means all losses, costs,
taxes (including penalties and interest), claims, damages, judgments, liabilities and expenses payable to a Third Party by a Party (or the Immatics Indemnitees or BMS Indemnitees, as applicable) under a Third Party Claim (including reasonable
attorneys&#146; fees and other reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of litigation in connection therewith). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.129 &#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and all of its territories and
possessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.130 &#147;<B>Valid Claim</B>&#148; means [**].<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.131 &#147;<B>Violation</B>&#148; means that a Party or any of its officers or directors or any other of such Party&#146;s personnel (or
other permitted agents of such Party performing activities hereunder including any of such Party&#146;s Affiliates, Third Party contractors and their respective officers and directors) has been: (a)&nbsp;convicted of any of the felonies identified
among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website, including 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7(a)</FONT>
(http://oig.hhs.gov/exclusions/authorities.asp); (b) identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or otherwise excluded from contracting with the federal government (see the System for
Award Management (formerly known as the Excluded Parties Listing System) at http://sam.gov/portal/public/SAM/); or (c)&nbsp;listed by any U.S. federal agency as being suspended, debarred, excluded or otherwise ineligible to participate in federal
procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs, including under 21 U.S.C. &#167; 335a (http://www.fda.gov/ora/compliance_ref/debar/) (each of (a), (b), and (c)&nbsp;collectively, the &#147;<B>Exclusions
Lists</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.132 <U>Additional Definitions</U>. Each of the following terms has the meaning described in the corresponding section
of this Agreement indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Section:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>2019 Agreements</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>2019 Collaboration Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>2019 License Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquired Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.38</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional BMS Products</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional BMS Receptor Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional BMS Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Feeder-Free Process Development Period</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.3.1(b)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Immatics Platform Patents</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.80</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Immatics Platform Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.81</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Immatics Required Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Receptor</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Alliance Manager</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;4.1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Audited Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.7.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Auditing Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.7.2</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Section:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS German Exemption Certificate</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Indemnitees</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;10.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Licensed IP Outside Date</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Nominated CAR</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Nominated CAR Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Participation Right</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Potential Licensed Technology Disclosure Report</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Product Inventory</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Program <FONT STYLE="white-space:nowrap">Non-Specific</FONT> IP</B>&#148;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Program Specific IP</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Restricted Sole Invention</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;11.6.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Restricted Sole Patent</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;11.6.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Supplemental Licensed Technology Disclosure Report</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Target Specific Information</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>BMS Third Party Payments</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.3.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>CAR Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.123</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Co-Commercialization</FONT>
Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement Outside
Date</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product Reimbursement
Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>CoC Transitioned Research Activities</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;5.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Competing Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;5.1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Cure Period</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;11.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosing Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Dispute</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;12.7.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Dual Immatics Licensed Patent</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Electronic Delivery</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;12.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Eligible Research Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Eligible Research Costs Report</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>EMA</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>EU Data Protection Laws</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded Claim</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;12.7.3(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded Immatics Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded Immatics Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded Immatics TCR</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.76</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Exclusions Lists</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.131</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Feeder-Dependent Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.70</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Feeder-Free Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.70</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Section:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>First BMS Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>First BMS Product Initial Research Plan</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>First BMS Receptor</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>First BMS Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>First Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>Schedule 1.58</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;12.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>FTE</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>GDPR</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>IFRS</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Acquired Competing Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Additional Technology List</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics CoC Competing Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Developed Feeder-Free Process</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.3.1(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Disclosure Schedule Bring Down Report</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;9.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics</B> <B>German Exemption Certificate</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics GmbH</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance
Notice</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Indemnitees</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;10.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Licensor</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;9.3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics New Additional Reimbursable
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics New BMS Product Specific Reimbursable
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics New Platform IP Notification</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Nominated TCR</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Nominated TCR Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific
Patent</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.11.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Option-Eligible Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Platform Inventions</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.85</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Product Development Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#147;Immatics Program Specific IP&#148;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Research Plan</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Selection Period</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Supplemental <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP
Acceptance Notice</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.1(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Immatics Third Party Payments</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.3.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnitee</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;10.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnitor&#148;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;10.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Indirect Tax</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(d)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Section:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Infringement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.11.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial BMS Products</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial BMS Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Direct
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Immatics Commitment Plus Permitted Overage</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Immatics FTE Commitment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Immatics Platform Patents</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.80</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Immatics Platform Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.81</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Reimbursable Gene Editing Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Technology Transfer</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Third Party
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Insolvency Event</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;11.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>IPC</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.9.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>IRC</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>JSC</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;4.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Program Assets</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;9.3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Manufacturing Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Schedule 3.3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>MHC</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.71</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>MHLW</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Milestone Event</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Milestone Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>New Additional Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT>
Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>New BMS Product Specific Reimbursable
<FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT>
Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Platform</FONT> Technology</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.81</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Officials</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Oncology Programs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;12.4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Notice</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Term</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT>
Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Partnership</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Party</B>&#148; or &#147;<B>Parties</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Patent Liaison</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.9.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Payee Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Paying Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Pharmaceutical Company Executive</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Post-Research Term Feeder-Free Process</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.3.1(b)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Receiving Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Milestone Event</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Milestone Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Rejecting Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;7.7</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Section:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Required Work Package Report</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Required Work Packages</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research Budget</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research Costs</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research FTE Cost</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research FTE Rate</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.2.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research Plan</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Research Program Deliverables</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Milestone Event</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Milestone Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.4.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Schedule 9.5.3 Breach Notice</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;9.5.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.6.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Second BMS Product</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Second BMS Receptor</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Second BMS Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>Schedule 1.58</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Regulators</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;8.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Party</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.102</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcommittee</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;4.1.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcontracting Essential Provisions</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.2(h)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Substitute Parental Proteins</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Substitute Receptor</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Substitute Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.1.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Supply Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.3.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Matters Agreement</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;3.1.4(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>TCR Target</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;1.123</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Technology Transfer Outside Date</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;2.2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Term</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;11.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Upfront Payment</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Tax Action</B>&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;6.6.2(b)(i)</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND RESEARCH PROGRAMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>BMS Programs</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1
<U>BMS Receptors; BMS Targets</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Designation of BMS Receptors and BMS Targets</U>. BMS shall have the right (but not the
obligation) from time to time to designate TCRs or CARs as BMS Receptors hereunder and to designate the associated Targets (and Parental Proteins for such Targets) to which such TCR or CAR is Directed as BMS Targets hereunder, in each case, by
providing written notice to Immatics of such designation as follows: (i)&nbsp;prior to the date that is [**] the date of the Effective Date, BMS may designate a Receptor (either a TCR or CAR) as the first BMS Receptor (either a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS TCR or BMS CAR, as applicable) hereunder (the &#147;<B>First BMS
Receptor</B>&#148;), and BMS shall simultaneously designate the Target (the &#147;<B>First BMS Targe</B>t&#148;) (and Parental Proteins for such First BMS Target) to which such Receptor is Directed as a BMS Target hereunder, (ii)&nbsp;prior to the
[**] the Effective Date (regardless of whether BMS has designated a First BMS Receptor), BMS may designate one additional Receptor (either a TCR or CAR) as the second BMS Receptor (either a BMS TCR or BMS CAR, as applicable) hereunder (the
&#147;<B>Second BMS Receptor</B>&#148;), and BMS shall simultaneously designate the Target (the &#147;<B>Second BMS Targe</B>t&#148; and together with the First BMS Target, each an &#147;<B>Initial BMS Target</B>&#148;) (and Parental Proteins for
such Second BMS Target) to which such Receptor is Directed as a BMS Target hereunder, and (iii)&nbsp;following the [**] the Effective Date and prior to the ten (10)&nbsp;year anniversary of the Effective Date (regardless of whether BMS has
designated a First BMS Receptor or Second BMS Receptor), BMS may designate up to four (4)&nbsp;additional Receptors (either TCRs or CARs, as applicable) from time to time as BMS Receptors (either a BMS TCR or BMS CAR, as applicable) hereunder (i.e.,
the third BMS Receptor, fourth BMS Receptor, fifth BMS Receptor or sixth BMS Receptor, as applicable), and BMS shall simultaneously designate the Targets (such Target for the third BMS Receptor, fourth BMS Receptor, fifth BMS Receptor or sixth BMS
Receptor, as applicable, each, an &#147;<B>Additional BMS Target</B>&#148;) (and Parental Proteins for such Target) to which such Receptors are Directed as BMS Targets hereunder. For clarity, [**]. Notwithstanding the foregoing, in all cases,
(I)&nbsp;BMS may only designate a TCR and corresponding TCR Target that is a 2019 Collaboration TCR and its corresponding 2019 Collaboration Target (as of the time of designation) as a BMS TCR and its corresponding BMS Target pursuant to this
Section&nbsp;2.1.1(a), and (II)&nbsp;BMS may only designate CARs that are (A)&nbsp;owned (solely or jointly with a Third Party) or controlled (through license or otherwise) by BMS or its Affiliate or otherwise publicly available (in each case as of
the time of designation) and (B) &#147;Available&#148; as determined pursuant to the Third Party Gatekeeper process pursuant to Section&nbsp;2.1.1(c), as BMS CARs pursuant to this Section&nbsp;2.1.1(a). If BMS designates an additional BMS Receptor
(and the corresponding BMS Target) under the foregoing clause (iii) (i.e., the third BMS Receptor, the fourth BMS Receptor, the fifth BMS Receptor or the sixth BMS Receptor, and the corresponding BMS Target) then for each such additional BMS
Receptor, BMS shall pay to Immatics an amount of [**] (each, an &#147;<B>Additional BMS Receptor Payment</B>&#148;), which amount shall be payable to Immatics within [**] after a receipt of an invoice from Immatics therefor (but subject in all cases
to Section&nbsp;2.1.1(g)). For the avoidance of doubt, no additional amounts shall be payable for the designation of the Second BMS Receptor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Substitute Receptors and Targets</U>. Without limitation of BMS&#146; rights to add BMS Receptors and BMS Targets pursuant to
Section&nbsp;2.2.1(a), if BMS believes, in its reasonable judgment, that the First BMS Product or Second BMS Product, as applicable, is [**], then BMS (through its representatives on the JSC) may notify the JSC thereof, and following discussions of
such matter by the JSC, BMS shall have the right (but not the obligation) to replace either (or both) the First BMS Receptor or Second BMS Receptor with an alternative Receptor that is Directed to a new Target (each, a &#147;<B>Substitute
Receptor</B>&#148;) (and BMS shall simultaneously designate the Target (and Parental Proteins for such Target) to which such Substitute Receptor is Directed as a BMS Target hereunder) (such Target, the &#147;<B>Substitute Target</B>&#148; and such
Parental Proteins, the &#147;<B>Substitute Parental Proteins</B>&#148;) by providing written notice thereof to Immatics at any time prior to [**] for the First BMS Product (if the First BMS Receptor is being replaced) or the Second BMS Product (if
the Second BMS Receptor is being replaced), as applicable. If BMS provides such notice, then the Substitute Receptor shall become a BMS Receptor hereunder (either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as a BMS TCR or BMS CAR, as applicable) and the Receptor that was replaced shall no
longer be a BMS Receptor hereunder. BMS shall only have the right to designate a Substitute Receptor (and the corresponding new BMS Target) once for each such Receptor (i.e., one such Substitute Receptor for the First BMS Receptor and one such
Substitute Receptor for the Second BMS Receptor) pursuant to the provisions of this Section&nbsp;2.1.1(b). Notwithstanding the foregoing, in all cases, (I)&nbsp;BMS may only designate TCRs that are 2019 Collaboration TCRs (as of the time of
designation) as BMS TCRs pursuant to this Section&nbsp;2.1.1(b), and (II)&nbsp;BMS may only designate CARs that are (A)&nbsp;owned (solely or jointly with a Third Party) or controlled (through license or otherwise) by BMS or its Affiliate or
otherwise publicly available (in each case as of the time of designation) and (B) &#147;Available&#148; as determined pursuant to the Third Party Gatekeeper process pursuant to Section&nbsp;2.1.1(c), as BMS CARs pursuant to this
Section&nbsp;2.1.1(b). For the avoidance of doubt, [**]. In the event BMS designates a Substitute Receptor pursuant to this Section&nbsp;2.1.1(b), Immatics will [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Third Party Gatekeeper</U>. In the event that BMS desires to nominate a CAR (and the associated CAR Target) as a potential BMS CAR and
BMS Target pursuant to Section&nbsp;2.1.1(a) or 2.1.1(b), as applicable (any such CAR, a &#147;<B>BMS Nominated CAR</B>&#148; and any such Target, a &#147;<B>BMS Nominated CAR Target</B>&#148;), BMS shall provide written notice of such nomination to
the Third Party Gatekeeper (as defined on <U>Schedule 2.2.1</U>) and the Third Party Gatekeeper shall determine whether BMS Nominated CAR and BMS Nominated CAR Target are &#147;Available&#148; in accordance with the procedures set forth on
<U>Schedule 2.2.1</U>. If the Third Party Gatekeeper determines that the proposed BMS Nominated CAR and BMS Nominated CAR Target are both &#147;Available&#148;, then the Third Party Gatekeeper shall notify the Parties of such BMS Nominated CAR and
BMS Nominated CAR Target and such BMS Nominated CAR shall automatically become a BMS CAR hereunder and such BMS Nominated CAR Target shall automatically become a BMS Target hereunder. If either the BMS Nominated CAR or BMS Nominated CAR Target is
not &#147;Available&#148;, then the BMS Nominated CAR shall not become a BMS CAR hereunder and the BMS Nominated CAR Target shall not become a BMS Target hereunder. The costs of the Third Party Gatekeeper shall be [**]. For the avoidance of doubt,
[**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Receptors to Existing BMS Targets</U>. Without limiting BMS&#146; rights to add or substitute BMS Receptors and
BMS Targets pursuant to Section&nbsp;2.2.1(a) or Section&nbsp;2.1.1(b), with respect to any existing BMS Target, BMS shall have the right, on a BMS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-BMS</FONT></FONT> Target
basis, at any time and in its discretion, to add additional TCRs or additional CARs, as applicable, that are Directed to such existing BMS Target to this Agreement (each, an &#147;<B>Additional Receptor</B>&#148;) by providing written notice thereof
to Immatics; provided that, [**]. If BMS provides such notice, then the Additional Receptor(s) shall become BMS Receptors hereunder (either as a BMS TCR or BMS CAR, as applicable) with respect to the applicable BMS Target. Notwithstanding the
foregoing, in all cases, (i)&nbsp;BMS may only designate TCRs that are 2019 Collaboration TCRs (as of the time of designation) as BMS TCRs pursuant to this Section&nbsp;2.1.1(d), (ii) BMS may only designate CARs that are owned (solely or jointly
with a Third Party) or controlled (through license or otherwise) by BMS or its Affiliate or otherwise publicly available (in each case as of the time of designation) as BMS CARs pursuant to this Section&nbsp;2.1.1(d); and (iii) [**]. For the
avoidance of doubt, no additional amounts shall be payable for the designation of an Additional Receptor pursuant to this Section&nbsp;2.1.1(d). In the event BMS designates an Additional Receptor pursuant to this Section&nbsp;2.1.1(d) with respect
to the First BMS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product or Second BMS Product, as applicable, then BMS may (but shall not be required
to) add activities to be conducted by Immatics for such Additional Receptors to the applicable Research Plan, provided that BMS may only add such activities to the Research Plan if the reasonable Research Costs anticipated to be incurred by Immatics
for reperforming any element of the Research Plan with the Additional Receptor for the applicable BMS Target shall be included in the overall Research Budget as reasonably agreed to by the Parties and subject to reimbursement by BMS as Eligible
Research Costs in accordance with Section&nbsp;6.2.2 and Section&nbsp;6.2.3 in accordance with the Research Budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Assistance
with Receptors and Targets</U>. At the reasonable request of BMS, Immatics may, in its sole discretion, provide reasonable assistance to BMS to help identify potential Receptors and Targets to be nominated as BMS Receptors and BMS Targets hereunder,
including providing information with respect thereto as reasonably requested by BMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>Revocation of Nomination of BMS Receptor
following Receipt of Immatics Disclosure Schedule Bring Down Report</U>. Notwithstanding the foregoing provisions of this Section&nbsp;2.1.1, if (i)&nbsp;BMS adds any additional or substitute Receptor as a BMS Receptor hereunder after the Effective
Date (either pursuant to Section&nbsp;2.1.1(a), 2.1.1(b) or 2.1.1(d), as applicable), and (ii)&nbsp;Immatics provides an Immatics Disclosure Schedule Bring Down Report to BMS pursuant to Section&nbsp;9.2 in connection with such additional or
substitute Receptor, then BMS shall have the right (in its sole discretion), by providing written notice to Immatics within [**] following BMS&#146; receipt of the Immatics Disclosure Schedule Bring Down Report, to revoke its designation of the
Receptor as a BMS Receptor hereunder, and in such case, it shall be as if BMS never designated such Receptor as a BMS Receptor hereunder [**]. If BMS does not provide such written notice to Immatics within such [**], then BMS&#146; right to revoke
its designation of the Receptor as a BMS Receptor shall lapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Antitrust or Investment Control Clearance for New Receptors</U>.
Notwithstanding anything to the contrary herein, if BMS adds any additional or substitute Receptor as a BMS Receptor hereunder after the Effective Date (either pursuant to Section&nbsp;2.1.1(a), 2.1.1(b) or 2.1.1(d), as applicable), then
(A)&nbsp;the licenses granted to BMS hereunder with respect to such BMS Receptor, as applicable, shall not be effective with respect to any country in which antitrust or investment control clearance is required for the grant of such licenses, as
determined by BMS, considering in good faith the views of Immatics, unless and until such clearance is obtained, and (B)&nbsp;no Additional BMS Receptor Payment, if any, shall be payable with respect to such BMS Receptor unless and until all
antitrust and investment control clearances in the foregoing clause (A)&nbsp;have been obtained. In furtherance of the foregoing, if BMS, considering in good faith the views of Immatics, determines that any such antitrust or investment control
clearance is required in a given country, then BMS shall notify Immatics thereof and thereafter the Parties shall cooperate in good faith, using reasonable efforts, to submit and prosecute such filings to the relevant Governmental Authorities in the
applicable country, as determined by BMS, considering in good faith the views of Immatics, to obtain the required clearances, including (i)&nbsp;responding and furnishing promptly to the relevant Governmental Authority any information reasonably
requested by them in connection with such filings, (ii)&nbsp;promptly keeping the other Party or its counsel informed of any material communication received from or given to the relevant Governmental Authority relating to such filing (and provide a
copy to the other Party if such communication is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in writing), (iii) reasonably consulting with each other in advance of any meeting or
conference with the relevant Governmental Authority, giving the other Party or its counsel the opportunity to attend and participate in such meetings and conference, and (iv)&nbsp;permitting the other Party or its counsel to review in advance, and
in good faith consider the views of the other Party or its counsel concerning (provided that such views are timely provided), any material filing or communication intended to be given to the relevant Governmental Authority in connection with such
filings; provided, that in each case, (x)&nbsp;all such materials may be redacted to remove sensitive information in the judgment of such disclosing Party, and (y)&nbsp;Immatics shall not make any submissions or communications to any Governmental
Authorities in connection with any such filings without the prior approval of BMS (such approval not to be unreasonably withheld, conditioned or delayed). Immatics and BMS, as each deems advisable and necessary, may reasonably designate any
competitively sensitive material to be provided to the other as &#147;Antitrust Counsel Only Material.&#148; Such materials and the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be
disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (Immatics or BMS as the case may be) or its legal counsel. [**]. Once all such
clearances referenced in this Section&nbsp;2.1.1(g) are obtained with respect to a given country, the applicable licenses in such country shall automatically be deemed included and effective. BMS shall be solely responsible for the filing fees
associated with any such required antitrust or investment control clearance filings. If the relevant Governmental Authorities have not granted all such clearances referenced in this Section&nbsp;2.1.1(g) within [**] after the date on which the first
filing was made to any Governmental Authority, then the applicable Receptor, and its associated Target and Parental Proteins of the Target (unless such Target or Parental Protein, as applicable, is a Target or Parental Protein of another BMS
Receptor hereunder), will cease to be a BMS Receptor and BMS Target under this Agreement; provided that, in such case, it shall be as if BMS never designated such BMS Receptor and BMS Target hereunder, and in lieu thereof, BMS shall have the right
to designate an alternative BMS Receptor and BMS Target hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Conduct of Research Programs for the Initial BMS
Products</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Generally</U>. During the Research Term, for each Initial BMS Product, the Parties shall conduct research and
development activities set forth in a research plan for such Initial BMS Product (each, a &#147;<B>Research Plan</B>&#148;) in accordance with the terms and conditions of this Agreement; provided that, for clarity, the Research Plan shall not
include any activities to be conducted by BMS after <FONT STYLE="white-space:nowrap">Hand-off</FONT> of the applicable Initial BMS Product and such BMS activities shall not be part of the Research Program. Each Research Plan shall allocate
responsibility for the research activities between the Parties, and, subject to the provisions of Section&nbsp;2.1.2(b), each Research Plan shall also include an associated budget for the research activities to be conducted by Immatics thereunder
(the &#147;<B>Research Budget</B>&#148;). The initial Research Plan to Develop the First BMS Product is attached hereto as <U>Schedule 2.1.2(a)</U> (such initial Research Plan, the &#147;<B>First BMS Product Initial Research Plan</B>&#148;);
provided that, if BMS designates the First BMS Receptor and the First BMS Target after the Effective Date, then (i)&nbsp;prior to such time as such First BMS Receptor and First BMS Target are designated, the Parties shall still conduct all
activities under the Research Plan that are capable of being conducted without the designation of the specific First BMS Receptor and First BMS Target, and (ii)&nbsp;the timelines for any specific activities in the Research Plan that require the
designation of the specific First BMS Receptor and the First BMS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Target for the performance thereof will be automatically extended by a period of time
equal to the period between the Effective Date and the date on which the First BMS Receptor and the First BMS Target are designated by BMS hereunder, provided, however, the Research Term shall not be extended. Within [**] following BMS&#146;
selection of the First BMS Receptor pursuant to Section&nbsp;2.1.1(a), the Parties shall update the First BMS Product Initial Research Plan for the inclusion of the specific First BMS Receptor and First BMS Product (including any specific additional
Development activities with respect thereto) for the JSC&#146;s review and approval. Within [**] following BMS&#146; selection of the Second BMS Receptor pursuant to Section&nbsp;2.1.1(a), the Parties shall prepare a proposed Research Plan for the
Development of the Second BMS Product for the JSC&#146;s review and approval; provided that, such proposed Research Plan shall be substantially based off the Research Plan for the First BMS Product (with respect to scope and type of activities).
Either Party may propose amendments to a Research Plan (including Research Budgets) from time to time (including to add, remove or modify activities under the Research Plan), which amendments shall be subject to the approval of the JSC (and Immatics
shall cooperate in good faith if an amendment is proposed by BMS in connection therewith). For the avoidance of doubt, there shall not be any Research Plans for any Additional BMS Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Research Budget</U>. With respect to the Research Budget, the Parties agree and acknowledge as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) <U>Overall Budget</U>. There shall be a single overall Research Budget to cover the activities under all Research Programs hereunder
(i.e., the Research Program for the First BMS Product as well as the Research Program for the Second BMS Product). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) <U>Budget for
Required Work Packages</U>. The initial Research Budget, attached hereto as part of <U>Schedule</U><U> 2.1.2(a)</U>, is an overall high level budget for the FTEs of Immatics to conduct [**] for the First BMS Product, and [**] for the Second BMS
Product, in the aggregate, (such work packages, the &#147;<B>Required Work Packages</B>&#148;) under the Research Programs (such FTEs in the initial Research Budget, the &#147;<B>Initial Immatics FTE Commitment</B>&#148;). Following such time as BMS
nominates the First BMS Receptor or Second BMS Receptor, as applicable, the Parties may update such initial high level budget to further breakdown the Initial Immatics FTE Commitment for particular activities to be conducted under the Research Plan
for the Required Work Packages for the First BMS Product or Second BMS Product, as applicable, [**]. In addition, following such time as BMS nominates the First BMS Receptor or Second BMS Receptor, as applicable, on a Required Work <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Package-by-Required</FONT></FONT> Work Package basis, prior to the start of any additional work under a Required Work Package, the Parties shall update the Research Budget to include
(A)&nbsp;the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for the specific activities for such Required Work Package to be conducted by Immatics&#146; Third Party contract research
organizations and Third Party contract manufacturers (in each case, to the extent such contractors are permitted pursuant to Section&nbsp;2.1.2(h)) that are required to conduct such Required Work Package, but excluding [**] (the &#147;<B>Initial
Third Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs</B>&#148;) and (B)&nbsp;the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT>
Costs for those other direct work package-related costs for such Required Work Package (e.g., consumables, reagents, materials, disposables, etc., but excluding costs of Third Party contractors) required to conduct such Required Work Package (the
&#147;<B>Initial Direct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) <U>New Work under Required Work Packages</U>. If BMS amends the
Research Plans to add new activities to be performed by Immatics under the Required Work Packages and the performance of such additional activities would reasonably require the aggregate FTEs of Immatics to exceed [**] of the Initial Immatics FTE
Commitment (without a commensurate reduction in other activities to be performed by Immatics under the Research Plans to offset such increase in FTEs) for all Required Work Packages in the aggregate, or, with respect to any given Required Work
Package, to exceed [**] of the Initial Third Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs [**] or to exceed [**] of the Initial Direct <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs of such Required Work Package (without a commensurate reduction in other activities to be performed by Immatics under such Required Work Package to offset such increase in Initial Third
Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs or Initial Direct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs, as applicable), then the
Research Budget shall be amended to include, as applicable, the reasonable FTEs or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs of Immatics required to conduct such additional activities above
[**] of the Initial Immatics FTE Commitment or, with respect to such Required Work Package, the Initial Third Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs or the Initial Third Party <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) <U>FTE Costs for
Optional Work Packages</U>. If Immatics [**] in each case as determined by BMS in accordance with this Agreement, then prior to the commencement of the applicable work package, the Research Budget shall be amended to include the Research FTE Costs
for the reasonable FTEs of Immatics required to conduct such work packages. If BMS amends the Research Plans to add new activities to be performed by Immatics under any optional work package and the performance of such additional activities would
increase the Research FTE Costs for such optional work package, then the Research Budget shall be amended to include the Research FTE Costs for the reasonable FTEs of Immatics required to conduct such additional activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for CROs and CMOs</U>. With
respect to [**], and with respect to [**], prior to the commencement of the applicable work package, the Research Budget for the applicable Research Plan shall be amended to include the reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for the specific activities thereunder to be conducted by Immatics&#146; Third Party contract research organizations and Third Party contract manufacturers (in each case, to the extent
such contractors are permitted pursuant to Section&nbsp;2.1.2(h)) that are required to conduct such work packages (but excluding, for clarity, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs that
are other work package-related costs (e.g., consumables, reagents, materials, disposables, etc.), which are instead handled pursuant to Section&nbsp;2.1.2(b)(vi)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for Consumables</U>. With respect
to [**] and with respect to [**], prior to the commencement of the applicable work package, the Research Budget for the applicable Research Plan shall be amended to include the reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for those other direct work package-related costs (e.g., consumables, reagents, materials, disposables, etc., but excluding costs of Third Party contractors, which are instead handled
pursuant to Section&nbsp;2.1.2(b)(v)) required by Immatics to conduct such work packages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) <U>Removal of Activities</U>. In the
event that a Research Plan is amended to remove any activities that were included in the Research Budget, then the Research Budget shall be reduced to remove the Research FTE Costs or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs, as applicable, attributable to such removed activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Research Budget is required to be amended as set forth in this
Section&nbsp;2.1.2(b), then the Parties shall prepare such Research Budget amendment and submit such amendment to the JSC for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) <U>Performance by Immatics</U>. Immatics shall conduct the activities allocated to Immatics under each Research Plan, which activities
shall be conducted in accordance with and subject to this Agreement and the applicable Research Plan (including the estimated timelines set forth therein, if any). All such activities shall be completed by Immatics prior to the end of the Research
Term; provided that, if BMS notifies Immatics that the Research Term will end prior to the [**] of the Effective Date, Immatics will not be required to complete any activities that are scheduled for completion after the early end date of the
Research Term. For the avoidance of doubt, [**]. If [**] and BMS requests in writing that Immatics performs [**] for the Second BMS Product then BMS shall pay to Immatics an amount of [**], which amount shall be payable to Immatics within [**] after
such written request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) <U>Disclosure of BMS Contributed Collaboration Technology for use in the Performance of the Research
Programs</U>. From time to time during the Research Term, BMS shall disclose to Immatics, including in response to any reasonable request from Immatics, the BMS Contributed Collaboration Technology that BMS [**] to be disclosed to Immatics in order
for Immatics to perform its activities under the Research Plan with respect to the Initial BMS Products. Except to the extent that any such BMS Contributed Collaboration Technology is included in &#147;BMS Licensed IP&#148; with respect to a given
Immatics TCR pursuant to Section&nbsp;2.2.1(c) [**], Immatics shall use the BMS Contributed Collaboration Technology solely to perform the activities for BMS with respect to the Initial BMS Products in accordance with the Research Plan and for no
other uses or purposes. At the request of BMS, the JSC shall discuss firewalls and other protections to be put in place by Immatics to ensure that [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) <U>Costs of Research Program</U>. All costs and expenses incurred in connection with the performance by the Parties of the activities
under a Research Plan shall be handled in accordance with Section&nbsp;6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) <U>Progress Reports; Deliverables</U>. Promptly
following the conclusion of a given phase under a Research Plan [**] for a given BMS Product, Immatics shall deliver to BMS in English (by providing electronic copies thereof)&nbsp;(i) all data, information, materials and compositions generated in
the performance of such Research Plan and (ii)&nbsp;all other deliverables and reports as outlined and described in such Research Plan ((i) and (ii), the &#147;<B>Research Program Deliverables</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(g) <U>Records</U>. Immatics shall maintain complete, current and accurate records of all activities, including research activities,
conducted by or on behalf of Immatics under a Research Program, and all data and other information resulting from such activities, and Immatics shall retain the same for a period of no less than [**] from their creation (or such longer period of
time as may be required by Applicable Law). Such records shall fully and properly reflect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all work done and results achieved in the performance of such activities in good
scientific manner and appropriate for regulatory and patent purposes and shall be prepared and maintained in accordance with Applicable Law, including, as applicable, GCP, GLP and GMP record keeping requirements where applicable. Upon reasonable
prior notice to Immatics, BMS shall have the right to review and copy such records as reasonably requested by BMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)
<U>Subcontracting</U>. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates or Third Party subcontractors to perform its obligations under each Research Program. To the extent that Immatics is using a
subcontractor to perform its obligations under a Research Program, (x)&nbsp;unless such subcontractor is expressly identified in the Research Plan or is set forth on <U>Schedule 2.1.2(h)</U>, Immatics shall provide reasonable prior written notice to
BMS (and in all cases at least [**]) prior to engaging such subcontractor (which notice shall identify the subcontractor and a description of the activities to be performed) in order to [**]; provided that, if Immatics [**], and (y)&nbsp;Immatics
shall ensure that any such subcontractor shall meet the qualifications typically required by Immatics for the performance of work similar in scope and complexity to the subcontracted activity and shall perform such work consistent with the terms of
this Agreement; provided, however, that Immatics shall remain fully responsible and obligated for such activities. In addition, to the extent Immatics engages a subcontractor to perform any activities under a Research Program, Immatics shall [**].
The Party engaging a subcontractor shall ensure that such subcontractor complies with all applicable provisions of this Agreement, including Sections [**] (the &#147;<B>Subcontracting Essential Provisions</B>&#148;). Each Party hereby expressly
waives any requirement that the other Party exhaust any right, power or remedy, or proceed against any subcontractor for any obligation or performance hereunder, prior to proceeding directly against such Party with respect to any failure of such
Party to perform its obligations under this Agreement through such subcontractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Technology Transfer from Immatics to BMS</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Initial Technology Transfer for a given BMS Product</U>. With respect to each BMS Product, Immatics shall (and shall cause its
Affiliates to)[ **] cooperate with BMS (and its designees) and provide reasonable assistance to BMS (and its designees) to enable BMS (and its designees) to Develop, Manufacture and Commercialize BMS Products (including any BMS Receptors therein),
as and to the extent reasonably requested by BMS in writing, including, on a BMS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis, (A)&nbsp;conducting an initial technology transfer to BMS
with respect to the Immatics Licensed IP used in connection with such BMS Products[**] including transferring to BMS the categories of materials and information as set forth on <U>Schedule 2.1.3</U>; provided that (i)&nbsp;the technology transfer
pursuant to this Section&nbsp;2.1.3(a) shall occur [**] for a given BMS Product, (ii)&nbsp;the technology transfer pursuant to this Section&nbsp;2.1.3(a) shall occur pursuant to a technology transfer plan [**], and (iii)&nbsp;with respect to the
First BMS Product and Second BMS Product, BMS shall not request such technology transfer prior to [**] or after [**]; provided further that in all cases Immatics shall complete such initial technology transfer for each Initial BMS Product prior to
[**] (this clause (A), the &#147;<B>Initial Technology Transfer</B>&#148; for a given BMS Product), (B) providing BMS (and its designees) reasonable assistance with respect to regulatory matters and materials related to BMS Receptors and BMS
Products as related to the Immatics Licensed IP [**], (C) providing BMS (and its designees) with materials [**] Controlled by Immatics (or any of its Affiliates) that are [**] the Development, Manufacture or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercialization of the BMS Products (or any BMS Receptors to the extent licensed
hereunder); provided that the transfer of materials pursuant to this Section&nbsp;2.1.3(a)(C) shall occur [**] for a given BMS Product, and (D)&nbsp;for a period of [**] following the completion of such Initial Technology Transfer for a given BMS
Product, providing BMS (and its designees) with [**] to assist with the Development, Manufacture and Commercialization of such BMS Product (including any BMS Receptors therein) and the implementation the Immatics Licensed IP, and [**]; provided
that, in all cases, BMS may request additional assistance with any regulatory matters in accordance with Section&nbsp;3.2.1(a) after the [**] period and Immatics shall reasonably comply with such requests. With respect to any of the assistance in
the foregoing clause (D)&nbsp;and assistance with any regulatory matters in accordance with Section&nbsp;3.2.1(a) for a given BMS Product (on a BMS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT>
Product basis), Immatics shall provide such assistance at its cost and expense for the [**] of assistance for a given BMS Product and BMS shall reimburse Immatics for the reasonable FTE hours of Immatics requested by BMS in excess of the [**] for
such BMS Product, which reimbursement shall be at the Research FTE Rate and made by BMS within [**] after receipt of an invoice from Immatics therefor. With respect to any of the assistance in the foregoing clauses (A)&nbsp;through (D), Immatics
shall commence such assistance promptly (and shall commence such assistance within [**]) following such request of BMS and shall complete such assistance as soon as reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Technology Transfer at the [**] of the End of the Research Program</U>. Without limiting the provisions of Section&nbsp;2.1.3(a), at
the [**] of the end of the Research Program, Immatics shall, [**], (i) promptly disclose to BMS in English (including by providing electronic copies thereof) all <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Immatics Licensed IP that
was not previously transferred to BMS pursuant to Section&nbsp;2.1.3(a), and (ii)&nbsp;at the written request of BMS, conduct a technology transfer to BMS (and its designees) with respect to such <FONT STYLE="white-space:nowrap">Know-How,</FONT>
including providing BMS (and its designees) with [**], which technology transfer shall occur pursuant to a technology transfer plan [**]. Immatics shall commence such technology transfer promptly (and in all cases within [**]) following the [**] of
the end of the Research Term and shall complete such transfer as soon as reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.4 <U>Existing Inventory Transfer to
BMS</U>. At the time of <FONT STYLE="white-space:nowrap">Hand-off</FONT> for a given Initial BMS Product, Immatics shall, at BMS&#146; request, promptly assign and transfer to BMS (or its designee) and deliver to BMS (or its designee) (at a location
to be specified by BMS to Immatics), all inventory in the form of finished goods of such Initial BMS Product (including any inventory of BMS Receptors) held by or on behalf of Immatics or its Affiliates (including any such inventory held at any
contract manufacturer or any other location) (the &#147;<B>BMS Product Inventory</B>&#148;), and, if any such BMS Product Inventory is GMP material, such BMS Product Inventory shall be transferred pursuant to and in accordance with the Supply
Agreement. Immatics represents and warrants to BMS that (a)&nbsp;the BMS Product Inventory was (and at all times up until delivery of such BMS Product Inventory hereunder shall remain) manufactured, packaged, labeled, tested, stored and handled in
accordance with all Applicable Laws (including GMP, if applicable), and specifications therefor, (b)&nbsp;the BMS Product Inventory is not adulterated or misbranded under Applicable Law and is not an article that could not, under the provisions of
the Applicable Law, be introduced into interstate commerce, and (c)&nbsp;the BMS Product Inventory is free and clear of all encumbrances (including through lien, charge, security interest, mortgage, encumbrance or otherwise). BMS shall reimburse
Immatics for the Manufacturing Cost of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such BMS Product Inventory delivered to BMS (provided that such inventory complies with
the foregoing representations and warranties), but only to the extent that any such costs are not (i)&nbsp;Eligible Research Costs reimbursed by BMS pursuant to Section&nbsp;6.2.3 or (ii)&nbsp;otherwise to be borne by Immatics pursuant to
Section&nbsp;6.2.1. Such reimbursement shall be made as follows: within [**] after delivery of the BMS Product Inventory to BMS, Immatics shall provide to BMS an invoice for the BMS Product Inventory which shall include (x)&nbsp;the quantity of BMS
Product Inventory, (y)&nbsp;the Manufacturing Cost (and calculation thereof) of such BMS Product Inventory (and accompanied by reasonable documentation of the Manufacturing Costs), and (z)&nbsp;an express reference to this Section&nbsp;2.1.4 of this
Agreement, and BMS shall pay such invoice in accordance with Section&nbsp;6.2.3, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.5 <U>Updates Regarding
Immatics Platform Technology</U>. Immatics shall promptly (and in all cases no later than the next meeting of the JSC) notify the JSC in writing of the existence of any purported new Additional Immatics Platform Technology or Additional Immatics
Platform Patents, which notice shall include a reasonably detailed description of such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents, as applicable (each, an &#147;<B>Immatics New Platform IP Notification</B>&#148;). The JSC shall
discuss and review such Immatics New Platform IP Notification, and if the JSC confirms that such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents, as applicable, should be included as Additional Immatics Platform Technology or Additional
Immatics Platform Patents, as applicable, then such <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed to be &#147;Additional Immatics Platform Technology&#148; for purposes of this Agreement or such Patents shall be deemed to be
&#147;Additional Immatics Platform Patents&#148; for purposes of this Agreement, as applicable. The JSC (or, if agreed to by the Parties, the IPC) shall keep a running list of all Additional Immatics Platform Technology or Additional Immatics
Platform Patents (the &#147;<B>Immatics Additional Technology List</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Immatics </U><U>Programs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.1 <U>Immatics Targets and TCRs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Nomination of Potential Immatics TCRs and Immatics Targets</U>. During the period from the Effective Date until the [**] of the
Effective Date (the &#147;<B>Immatics Selection Period</B>&#148;), Immatics shall have the right to nominate up to four (4)&nbsp;TCRs to potentially become Immatics TCRs hereunder and to nominate the associated TCR Targets to which such TCRs are
Directed to potentially become Immatics Targets hereunder; provided that such TCRs and TCR Targets shall only be eligible to become Immatics TCRs and Immatics Targets if such TCRs and Targets are determined to be &#147;Available&#148; in accordance
with this Section&nbsp;2.2.1 (each, an &#147;<B>Immatics Nominated TCR</B>&#148; and &#147;<B>Immatics Nominated TCR Target</B>&#148;, as applicable). In the event that, during the Immatics Selection Period, Immatics desires to nominate a TCR (and
the associated TCR Target) as a potential Immatics TCR and Immatics Target, Immatics shall provide written notice of such nomination to the Third Party Gatekeeper (as defined on <U>Schedule 2.2.1</U>) and the Third Party Gatekeeper shall determine
whether the Immatics Nominated TCR and Immatics Nominated TCR Target are &#147;Available&#148; in accordance with the procedures set forth on <U>Schedule 2.2.1</U>. If the Third Party Gatekeeper determines that the proposed Immatics Nominated TCR
and Immatics Nominated TCR Target are both &#147;Available&#148;, then the Third Party Gatekeeper shall notify the Parties of such Immatics Nominated TCR and Immatics Nominated TCR Target. If either the Immatics Nominated TCR or Immatics Nominated
TCR Target is not &#147;Available&#148;, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then the Immatics Nominated TCR shall not be eligible to become an Immatics TCR
hereunder and the Immatics Nominated TCR Target shall not be eligible to become an Immatics Target hereunder; provided that Immatics shall have the right, in its discretion, to thereafter resubmit such Immatics Nominated TCR and Immatics Nominated
TCR Target, from time to time to determine if such Immatics Nominated TCR and Immatics Nominated TCR Target have subsequently become &#147;Available&#148;. Notwithstanding the foregoing, (a)&nbsp;Immatics may only nominate a TCR pursuant to this
Section&nbsp;2.2.1 that is owned by, or exclusively licensed to, Immatics (or its Affiliate), (b) Immatics may not nominate any TCR that is Directed to a BMS Target hereunder (or to any Target derived from any Parental Protein of a BMS Target
hereunder) or any Target under any 2019 Agreement (or any Target derived from any Parental Protein under any 2019 Agreement), and (c)&nbsp;Immatics shall no longer have any rights under this Section&nbsp;2.2.1 to nominate any additional Immatics
Nominated TCRs or associated Immatics Nominated TCR Targets from and after the earliest to occur of (x)&nbsp;a Change of Control of Immatics, (y)&nbsp;termination of this Agreement with respect to all BMS Products, or (z)&nbsp;such time as the Third
Party Gatekeeper has determined that four (4)&nbsp;Immatics Nominated TCRs and associated Immatics Nominated TCR Targets were &#147;Available&#148;. The costs of the Third Party Gatekeeper shall be [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Determination of BMS Potential Licensed Technology for Potential Use with Immatics Products</U>. Immatics acknowledges that the BMS
Contributed Collaboration Technology is experimental in nature and, as of the Effective Date, may not be sufficiently protected from an intellectual property perspective [**]. In the event that BMS determines, in its reasonable discretion, that any
particular BMS Contributed Collaboration Technology owned by BMS (or its Affiliate) becomes sufficiently protected by BMS from an intellectual property perspective [**] to allow for a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to
a Third Party, during the period from the Effective Date until the earliest to occur of [**] the &#147;<B>BMS Licensed IP Outside Date</B>&#148;), then such <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents shall be deemed to be
&#147;Protected&#148; for purposes of this Agreement [**] and therefor available to be included within the BMS Potential Licensed Technology pursuant to Section&nbsp;2.2.1(c) or 2.2.1(d), as applicable (to the extent otherwise falling within the
definition of BMS Potential Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or BMS Potential Licensed Patents, as applicable); provided that, in all cases, no additional <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents shall be
eligible to be included in the BMS Potential Licensed Technology after the BMS Licensed IP Outside Date. Notwithstanding the foregoing, [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Listing, Review and Assessment of BMS Potential Licensed Technology for Use with a Given Immatics TCR; Designation of Immatics TCRs
and Immatics Targets</U>. Subject to Section&nbsp;2.2.1(b), following notification from the Third Party Gatekeeper that the proposed Immatics Nominated TCR and Immatics Nominated TCR Target are both &#147;Available&#148;, BMS shall provide Immatics
(through the IPC) with a list generally describing all then-current BMS Potential Licensed Technology that BMS [**] for the Development of a Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy Product using the
applicable Immatics Nominated TCR and Directed to the applicable Immatics Nominated TCR Target (a &#147;<B>BMS Potential Licensed Technology Disclosure Report</B>&#148;) to enable Immatics to evaluate and the Parties to discuss (through the IPC)
whether such BMS Potential Licensed Technology may be useful for the Development of a Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy Product using the applicable Immatics Nominated TCR and Directed to the
applicable Immatics Nominated TCR Target, including for the IPC to discuss [**]. The BMS Potential Licensed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Technology Disclosure Report shall also indicate if any BMS Potential License Technology
in such report is &#147;BMS Special Learnings Technology&#148;. If, and only if, Immatics, in its sole discretion, concludes that certain BMS Potential Licensed Technology set forth in the applicable BMS Potential Licensed Technology Disclosure
Report [**], and that Immatics wants to use such BMS Potential Licensed Technology, for the Development of a Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy Product using the applicable Immatics Nominated TCR
and Directed to the applicable Immatics Nominated TCR Target and provides written notice to BMS thereof (including identifying the specific applicable BMS Potential Licensed Technology from the applicable BMS Potential Licensed Technology Disclosure
Report that Immatics desires to be included as BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and BMS Licensed Patents for such Immatics Nominated TCR) (such notice, the &#147;<B>Immatics
<FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice</B>&#148;) within [**] after BMS provides the BMS Potential Licensed Technology Disclosure Report, then (i)&nbsp;such Immatics Nominated TCR will automatically become an
Immatics TCR hereunder and such Immatics Nominated TCR Target will automatically become an Immatics Target hereunder, and (ii)&nbsp;the BMS Potential Licensed Technology from the BMS Potential Licensed Technology Disclosure Report that Immatics
identifies in the Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice will be included as BMS Licensed IP with respect to such Immatics Nominated TCR and Immatics Nominated TCR Target. Notwithstanding the foregoing, in
all cases, a maximum of four (4)&nbsp;TCRs may become Immatics TCRs and a maximum of four (4)&nbsp;associated TCR Targets (one per TCR) may become Immatics Targets pursuant to this Section&nbsp;2.2.1 [**]. If Immatics does not timely provide the
Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice, then (x)&nbsp;the Immatics Nominated TCR will not become an Immatics TCR hereunder and the Immatics Nominated TCR Target will not become an Immatics Target hereunder.
Notwithstanding anything to the contrary contained herein, if any BMS Potential Licensed Technology is owned by a Third Party and Controlled by BMS or its Affiliate through a license from such Third Party, as applicable, then such BMS Potential
Licensed Technology will become BMS Licensed IP only if Immatics agrees in writing to pay (and actually pays) any and all amounts due to the Third Party under the applicable license agreement that directly result from the grant or exercise of the
license to Immatics hereunder (and, for clarity, such payments shall not be subject to Section&nbsp;6.3.4(b)) and to otherwise comply (and actually complies) with such license agreement (as provided to Immatics by BMS), including providing BMS with
any necessary reports and other information reasonably required to comply with such license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Supplements to the BMS
Potential Licensed Technology Disclosure Report</U>. If, following such time as a given Immatics Nominated TCR becomes an Immatics TCR pursuant to Section&nbsp;2.2.1(c) and while Immatics is continuing to Develop Immatics Products containing such
Immatics TCR, BMS determines (in its sole discretion) that it would like to offer to Immatics additional BMS Potential Licensed Technology to potentially be included as additional BMS Licensed IP for such Immatics TCR, then BMS shall provide
Immatics (through the IPC) with a list generally describing such additional BMS Potential Licensed Technology (a &#147;<B>BMS Supplemental Licensed Technology Disclosure Report</B>&#148;). The BMS Supplemental Licensed Technology Disclosure Report
shall also indicate if any <FONT STYLE="white-space:nowrap">Know-How</FONT> in such report is &#147;BMS Special Learnings Technology&#148;. If Immatics, in its sole discretion, concludes that it wants to include any of the additional BMS Potential
Licensed Technology from the BMS Supplemental Licensed Technology Disclosure Report as BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or BMS Licensed Patents, as applicable, for the such Immatics TCR, then Immatics shall notify BMS
thereof in writing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(which notice shall identify the specific applicable additional BMS Potential Licensed
Technology from the applicable BMS Supplemental Licensed Technology Disclosure Report that Immatics desires to be included as BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and BMS Licensed Patents for such Immatics TCR) within [**]
after receipt of the BMS Supplemental Licensed Technology Disclosure Report (such notice, the &#147;<B>Immatics Supplemental <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice</B>&#148;). If Immatics so provides an Immatics
Supplemental <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice, then the BMS Potential Licensed Technology from the BMS Supplemental Licensed Technology Disclosure Report that Immatics identifies in the Immatics Supplemental <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice will be included as BMS Licensed IP with respect to such Immatics TCR; provided that if any such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents are owned by a Third
Party and Controlled by BMS or its Affiliate through a license from such Third Party, as applicable, then such <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents will become BMS Licensed IP only if Immatics agrees in writing to pay (and
actually pays) any and all amounts due to the Third Party under the applicable license agreement that directly result from the grant or exercise of the license to Immatics hereunder (and, for clarity, such payments shall not be subject to
Section&nbsp;6.3.4(b)) and to otherwise comply (and actually complies) with such license agreement (as provided to Immatics by BMS), including providing BMS with any necessary reports and other information reasonably required to comply with such
license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right</U>. Immatics shall promptly notify the JSC of
the completion of [**], for a given Immatics TCR in accordance with the Immatics Research Plan, and upon such completion with respect to such Immatics TCR (but in all cases, within [**] thereafter), Immatics will discuss with BMS, through the JSC,
[**] and based on the data generated under the Immatics Research Plan, that any BMS Licensed IP is useful in connection with the Development or Commercialization of such Immatics TCR (or Immatics Product transduced with such Immatics TCR), and in
connection therewith, Immatics shall provide to BMS a summary of the data and other information previously generated from the Development of such Immatics TCR and Immatics Product (including a summary of the results generated under the Immatics
Research Plan). Subject to Section&nbsp;2.2.1(f), if, following such discussion, Immatics determines[**] that BMS Licensed IP is not useful in connection with either the Development or Commercialization of such Immatics TCR or Immatics Product and,
as such, Immatics determines to no longer use any of the BMS Licensed IP in connection with such Immatics TCR (and Immatics Products transduced with such Immatics TCR), then Immatics shall notify BMS in writing of such determination within [**]
after such JSC discussion (which notice shall identify the applicable Immatics TCR, Immatics Target and Immatics Products, as well as the BMS Licensed IP for such Immatics TCR) (each, an &#147;<B>Immatics
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice</B>&#148;). Subject to Section&nbsp;2.2.1(f), from and after such time as Immatics provides an Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice to BMS, (i)&nbsp;the applicable TCR
shall no longer be an Immatics TCR under this Agreement (an &#147;<B>Excluded Immatics TCR</B>&#148;), (ii) the applicable Target shall no longer be an Immatics Target under this Agreement (unless it is a Target for another Immatics TCR or Immatics
Product) (an &#147;<B>Excluded Immatics Target</B>&#148;), (iii) the applicable product shall no longer be an Immatics Product under this Agreement (such product, and any other product transduced with an Excluded Immatics TCR, an &#147;<B>Excluded
Immatics </B><B>Product</B>&#148;), including that such product shall not be subject to the royalty obligations under Section&nbsp;6.3 or the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right pursuant to Section&nbsp;3.1.4, (iv) Immatics (and
its Affiliates) shall have no further right to use, and shall not use, any BMS Licensed IP or other Confidential Information of BMS (or any of its Affiliates) (or data generated using the BMS Licensed IP) in connection with the Development,
Manufacture or Commercialization of any Excluded Immatics TCR, Excluded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics Product or Excluded Immatics Target, and (v)&nbsp;within [**] after the
delivery of the Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice, Immatics shall destroy (and shall certify to BMS the destruction of) all <FONT STYLE="white-space:nowrap">Know-How</FONT> in its (or its Affiliate&#146;s,
Sublicensee&#146;s or contractor&#146;s) possession constituting, embodying, generated or made with the use of any such BMS Licensed IP or other Confidential Information of BMS in connection with any Excluded Immatics TCR, Excluded Immatics Product
or Excluded Immatics Target. If Immatics does not timely provide an Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice with respect to a given Immatics TCR, then such Immatics TCR will continue to be an Immatics TCR under this
Agreement, and the associated Immatics Target and Immatics Products will continue to be an Immatics Target and Immatics Products hereunder. For clarity, if Immatics delivers an Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice with
respect to a given Immatics TCR, Immatics shall not have any right to replace the applicable terminated Immatics Receptor or Immatics Target with a new Immatics Receptor or new Immatics Target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>No Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right if there was Access to BMS Special Learnings Technology</U>.
Notwithstanding the foregoing provisions of Section&nbsp;2.2.1(e), if Immatics includes any BMS Special Learnings Technology as part of BMS Licensed IP hereunder (as set forth in either an Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT>
IP Acceptance Notice (pursuant to Section&nbsp;2.2.1(c)) or Immatics Supplemental <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice (pursuant to Section&nbsp;2.2.1(d)), as applicable), then the provisions of
Section&nbsp;2.2.1(e) shall no longer apply and Immatics shall not have the right to issue an Immatics <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice for any Immatics TCR (or any Immatics Products or Immatics Targets); provided, however,
that Immatics shall have the right to terminate such Immatics Product in accordance with Section&nbsp;11.3.2. Notwithstanding the foregoing, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis,
prior to BMS disclosing a particular BMS Special Learnings Technology to Immatics hereunder, the Parties (through the IPC) may agree in writing that this Section&nbsp;2.2.1(f) shall [**]. In addition, if Immatics includes any BMS Special Learnings
Technology as part of BMS Licensed IP hereunder (as set forth in either an Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice (pursuant to Section&nbsp;2.2.1(c)) or Immatics Supplemental
<FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice (pursuant to Section&nbsp;2.2.1(d)), as applicable), then, at the request of BMS, the JSC shall discuss firewalls and other reasonable protections to be put in place by
Immatics to ensure that [**]. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.2 <U>Technology Transfer from BMS to Immatics</U>.<B> </B>At the written request of Immatics,
and at Immatics&#146; expense, on an Immatics <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product basis, at any time prior to the earliest to occur of (i)&nbsp;the [**] following the
designation of the Immatics TCR (pursuant to Section&nbsp;2.2.1(c)) contained in such Immatics Product, (ii)&nbsp;a Change of Control of Immatics, and (iii)&nbsp;termination of this Agreement with respect to all BMS Products (the &#147;<B>Technology
Transfer Outside Date</B>&#148;), BMS shall provide reasonable technical assistance (including with respect to regulatory approvals and manufacturing) to Immatics to facilitate Immatics&#146; incorporation of the BMS Licensed IP into the applicable
Immatics Product, as and to the extent reasonably requested by Immatics. For the avoidance of doubt, (x)&nbsp;the technology transfer pursuant to this Section&nbsp;2.2.2 shall occur [**] for a given Immatics Product, (y)&nbsp;no additional
assistance shall be provided pursuant to this Section after the Technology Transfer Outside Date for the applicable Immatics Product, and (z)&nbsp;the assistance to be provided by BMS pursuant to this Section&nbsp;2.2.2 shall occur pursuant to a
technology transfer plan to be reasonably agreed to by the Parties through the JSC. BMS shall commence such assistance promptly (and use reasonable efforts to commence such assistance within [**]) following such request of Immatics and agreement to
the technology transfer plan, and shall complete such assistance as soon as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reasonably practicable. Immatics shall reimburse BMS for the reasonable internal
(calculated using the Research FTE Rate) and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of performing such technology transfer under this Section&nbsp;2.2.2 (which costs shall be reimbursed by
Immatics to BMS within [**] after receipt of an invoice therefor from BMS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.3 <U>Research Plan for Immatics Products</U>. Within [**]
following Immatics&#146; addition of a given TCR as an Immatics TCR pursuant to Section&nbsp;2.2.1(c), Immatics shall prepare and present to the JSC for review and discussion a research plan for the conduct of the Development activities for such
Immatics TCR (and the Immatics Products transduced with such Immatics TCR) up to [**], including [**] (each, an &#147;<B>Immatics Research Plan</B>&#148;), and Immatics shall consider any comments of BMS thereto in good faith. Immatics shall provide
an update to each Immatics Research Plan to the JSC from time to time, but in all cases no less than [**]. From time to time Immatics may amend each Immatics Research Plan[**], and will discuss any amendments to an Immatics Research Plan at the JSC
[**]. Immatics shall ensure that all <FONT STYLE="white-space:nowrap">pre-clinical</FONT> Development activities with respect to a given Immatics Product are conducted in accordance with the applicable Immatics Research Plan. On an Immatics <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product basis, Immatics shall keep BMS reasonably informed as to the progress of the Development activities under the Immatics Research Plan at each
meeting of the JSC. For the avoidance of doubt, [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Compliance Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>General</U>. To the extent that activities are conducted by or on behalf of a Party or its Affiliates pursuant to this Agreement,
including all activities under each Research Program, such Party shall ensure that such activities are conducted in compliance with all Applicable Laws (including, to the extent applicable, GCP, GLP and GMP), and good business ethics, and such Party
will promptly notify the other Party in writing after it becomes aware of any deviations from any of the foregoing. In addition, each Party hereby certifies that it has not employed or otherwise used in any capacity, and will not employ or otherwise
use in any capacity, the services of any Person that (a)&nbsp;is debarred under United States law (including 21 U.S.C. &#167; 335a) or any foreign equivalent thereof or (b)&nbsp;is the subject of an FDA debarment investigation or proceeding (or
similar proceeding by any Regulatory Authority outside the United States), in each case, in performing any portion of the activities hereunder, including any activities under each Research Program. Each Party will notify the other Party in writing
immediately if any such debarment occurs or comes to its attention, and will, with respect to any person or entity so debarred promptly remove such person or entity from performing any such activities, function or capacity related to any such
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Governments and International Public Organizations</U>. Each Party will not make any payment (and such Party shall
ensure that its Affiliates and subcontractors do not make any payment), either directly or indirectly, of money or other assets, including any compensation such Party derives from this Agreement (hereinafter collectively referred to as a
&#147;<B>Payment</B>&#148;), to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing
(hereinafter collectively referred to as &#147;<B>Officials</B>&#148;) where such Payment would constitute a violation of any Applicable Law. In addition, regardless of legality, each Party will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">not make any Payment (and will ensure that its Affiliates and subcontractors make no
payment), either directly or indirectly to Officials if such Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of such Party&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>No Authority</U>. Each Party acknowledges that no employee of the other Party or its Affiliates will have authority to give any
direction, either written or oral, relating to the making of any commitment by such Party or its agents to any Third Party in violation of terms of this or any other provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Exclusions Lists</U>. Each Party will not use (and will cause its Affiliates and subcontractors not to use) in the performance of
activities hereunder, including a Research Program, any Person (including any employee, officer, director or Third Party contractor) who is (or has been) on the Exclusions List, or who is (or has been) in Violation. Each Party certifies to the other
Party that, as of the Effective Date, such Party has screened itself, and its officers and directors (and its Affiliates or subcontractors, and their respective officers and directors) against the Exclusions Lists and that it has informed the other
Party in writing whether such Party, or any of its officers or directors (or any of its Affiliates or subcontractors or any of their respective officers and directors) has been in Violation. After the execution of this Agreement, each Party will
notify the other Party in writing immediately if any such Violation occurs or comes to its attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.5 <U>Personal Data</U>. Each
Party shall ensure that all Personal Data hereunder, if any, is processed in accordance with Applicable Laws, including the fair and lawful collection and processing of such Personal Data, the disclosure of such Personal Data to the other in
accordance with this Agreement and the transfer of such Personal Data (including any transfer from inside the EEA and/or UK or Switzerland to outside the EEA), including any applicable European law or regulation (such as the EU General Data
Protection Regulation (2016/679) (&#147;<B>GDPR</B>&#148;)) relating to the protection of Personal Data and all laws implementing and/or supplementing the GDPR (collectively, &#147;<B>EU Data Protection Laws</B>&#148;) and HIPAA. Each Party shall
promptly notify the other Party if it becomes aware that any data, including Personal Data, provided to the other Party hereunder is inaccurate or has been unlawfully obtained or processed or, where consent to process Personal Data has been
provided, consent is withdrawn, or such Party becomes aware that consent may not be reliable, or any other processing ground is no longer applicable. Each Party further covenants that any data or information that it provides to the other Party
hereunder will be anonymized, or if anonymization is not reasonably possible, then <FONT STYLE="white-space:nowrap">de-identified,</FONT> with respect to any identified or identifiable natural person, as those terms are defined or interpreted
pursuant to EU Data Protection Laws and/or HIPAA (as applicable). Each Party further represents and warrants that it has the full right to provide any such Personal Data or Protected Health Information (as such term is defined under the EU Data
Protection Laws or HIPAA, as applicable), as well as any Patient Samples, to the other Party hereunder to use as is permitted in accordance with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Development and Commercialization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.1 <U>General</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
<U>BMS Products</U>. From and after the date of the applicable <FONT STYLE="white-space:nowrap">Hand-off</FONT> (in the case of the First BMS Product and Second BMS Product) and from and after the date of designation in accordance with
Section&nbsp;2.1.1(a) (in the case of any Additional BMS Product), and subject to the terms and conditions of this Agreement and, with respect to a BMS TCR Product, the applicable terms and conditions of the applicable 2019 License Agreement (except
as otherwise set forth herein), (i) BMS will have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees or other Third Parties, at its cost, to Develop and Commercialize BMS Products
(and BMS TCRs and BMS CARs for use therein) in the Field in the Territory and (ii)&nbsp;Immatics and its Affiliates shall not have any right to, and shall not, conduct any Development or Commercialization of any BMS Products (or BMS TCRs or BMS CARs
therein) in the Field in the Territory. BMS shall, and shall require its Affiliates and Sublicensees to, create and maintain written records or lab notebooks with respect to any work conducted pursuant to this Agreement that directly uses any
Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in good faith and in accordance with its (or its applicable performing Affiliate&#146;s) customary practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Immatics Products</U>. From and after the date of designation in accordance with Section&nbsp;2.2.1(c), and subject to the terms and
conditions of this Agreement, except as expressly set forth in Section&nbsp;3.1.4, Immatics will have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees or other Third Parties, at its
cost, to Develop and Commercialize Immatics Products (and Immatics TCRs for use therein) in the Field in the Territory. Immatics shall, and shall require its Affiliates and Sublicensees to, create and maintain written records or lab notebooks with
respect to any work conducted pursuant to this Agreement that directly uses any BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in good faith and in accordance with its (or its applicable performing Affiliate&#146;s) customary
practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.2 <U>Diligence</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement (and subject further to Immatics&#146; performance and completion of the Research
Programs and technology transfers in accordance with this Agreement), BMS, itself or with or through its Affiliates, Sublicensees or other Third Parties, will use Commercially Reasonable Efforts to (a)&nbsp;Develop and seek Regulatory Approval for
at least [**] added to this Agreement in accordance with Section&nbsp;2.1.1 in [**], and (b)&nbsp;following receipt of Regulatory Approval in [**]. For the avoidance of doubt, [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions of this Agreement, Immatics, itself or with or through its Affiliates, Sublicensees or other Third
Parties, will use Commercially Reasonable Efforts to (a)&nbsp;Develop and seek Regulatory Approval for at least [**] added to this Agreement in accordance with Section&nbsp;2.2.1 in [**], and (b)&nbsp;following receipt of Regulatory Approval in
[**]. For clarity, [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.3 <U>Progress Updates</U>. On a Collaboration <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Collaboration</FONT></FONT> Product basis, each Party shall keep the other Party reasonably informed as to the progress of its and its Affiliates&#146; and Sublicensees&#146;
Development activities with respect to such Party&#146;s Collaboration Products under this Agreement by submitting to the other Party, at least [**] until such time as such Party (or its Affiliate or Sublicensee) has received Regulatory Approval for
such Collaboration Product in[**], a written report summarizing the progress of such Party&#146;s material Development activities with respect to such Collaboration Products pursuant to this Agreement since the last report, at a level of detail
reasonably sufficient for the other Party to determine such Party&#146;s compliance with its diligence obligations. Notwithstanding the foregoing, [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.4 <U><FONT STYLE="white-space:nowrap">Co-Development</FONT> and <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Option; Right
of Negotiation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Data Package</U>. Within [**] after achievement of Clinical Proof of Concept for a given Immatics Product,
Immatics shall provide to BMS a complete Data Package with respect to such Immatics Product for purposes of enabling BMS to determine whether to exercise the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right for such Immatics Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT STYLE="white-space:nowrap">Opt-In</FONT> Grant</U>. For the first [**] Immatics Products for which Clinical Proof of Concept has
been achieved (each, an &#147;<B>Immatics Option-Eligible Product</B>&#148;), Immatics hereby grants to BMS an exclusive right (the &#147;<B>BMS O</B><B><FONT STYLE="white-space:nowrap">pt-In</FONT> Right</B>&#148;), exercisable in BMS&#146; sole
discretion at any time during the period from the Effective Date until [**] after Immatics provides to BMS the complete Data Package for such Immatics Option-Eligible Product pursuant to Section&nbsp;3.1.4(a) (each &#147;<B><FONT
STYLE="white-space:nowrap">Opt-In</FONT> Term</B>&#148;), to <FONT STYLE="white-space:nowrap">co-Develop</FONT> and <FONT STYLE="white-space:nowrap">co-Commercialize</FONT> (together with Immatics) such Immatics Option-Eligible Product in the Field
in the Territory. BMS may exercise (in its sole discretion) the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right by delivering written notice of such exercise to Immatics at any time during the applicable
<FONT STYLE="white-space:nowrap">Opt-In</FONT> Term (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Notice</B>&#148;); provided that BMS shall only have the right to provide an <FONT STYLE="white-space:nowrap">Opt-In</FONT> Notice for
[one (1)&nbsp;Immatics Option-Eligible Product] hereunder. For the avoidance of doubt, BMS shall not be required to exercise the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right for any Immatics Option-Eligible Products. Immatics
acknowledges and agrees that the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right granted by Immatics to BMS as set forth herein will be granted by Immatics exclusively to BMS, and Immatics shall not (and shall ensure that its Affiliates do
not) grant any options (or other rights) to any Third Party that would conflict with or are inconsistent with the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right granted to BMS hereunder, including that Immatics shall not (and shall ensure
that its Affiliates do not) grant any rights to any Third Party to Develop, Manufacture or Commercialize a given Immatics Option-Eligible Product prior to the end of the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Term for such Immatics
Option-Eligible Product. As used herein, &#147;<B><FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product</B>&#148; shall mean the Immatics Option-Eligible Product for which BMS has exercised its BMS
<FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, which includes, for clarity, any and all other Immatics Products transduced with the same Immatics TCR as such Immatics Option-Eligible Product (e.g., all
<FONT STYLE="white-space:nowrap">back-ups).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U><FONT STYLE="white-space:nowrap">Co-Commercialization</FONT>
Agreement</U>. If BMS exercises the BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then within [**] thereafter (the &#147;<B><FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement Outside Date</B>&#148;), the Parties (or
their respective applicable local Affiliates) shall negotiate in good faith and enter into a <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> agreement (the &#147;<B><FONT
STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement</B>&#148;) to set forth the terms and conditions with respect to the <FONT STYLE="white-space:nowrap">co-Development</FONT> and
<FONT STYLE="white-space:nowrap">co-Commercialization</FONT> of the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product by the Parties in the Field in the Territory (and, for clarity, [**]). The
<FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement shall include, in addition to such other terms as the Parties may agree and as are customary in an agreement of that type, the key terms and conditions set forth on <U>Schedule
3.1.4</U>, unless otherwise agreed upon by the Parties. In the event that the Parties (or their respective applicable Affiliates) do not enter into the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement by the <FONT
STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement Outside Date, then either Party may submit any disputed terms relating to the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement to the Executive Officers, who
shall meet promptly to discuss the disputed terms, within [**] following referral of such matter, in good faith to resolve such dispute. If the Executive Officers are unable to resolve such dispute within such [**] period after it is referred to
them, then the Parties shall submit such matter for binding resolution by [**] pharmaceutical company executive (&#147;<B>Pharmaceutical Company Executive</B>&#148;) who is reasonably agreed to by the Parties, for resolution in accordance with the
procedures set forth in <U>Schedule 3.1.4(c)</U>, with a final decision to be issued within [**] after the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement Outside Date; provided that, following such determination, BMS shall
have the right, in its discretion, to decline to enter into the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement by providing written notice thereof to Immatics within [**] following issuance of such final decision, in which
case BMS shall be deemed to have revoked its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product and Immatics may continue to Develop and Commercialize the
applicable Immatics Product with no further obligations to BMS under this Section&nbsp;3.1.4; provided that if BMS revokes its <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right after such final decision by the Pharmaceutical Company Executive,
[**]. If BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right for a given Immatics Product, then Immatics, in consultation with BMS and otherwise in accordance with this Agreement, may continue to Develop such Immatics Product,
at Immatics&#146; cost, until such time as the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement is entered into; provided that Immatics shall [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U><FONT STYLE="white-space:nowrap">Opt-In</FONT> Payment</U>. If BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT>
Right for a given Immatics Product pursuant to Section&nbsp;3.1.4(b) and the Parties enter into the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement in connection therewith pursuant to Section&nbsp;3.1.4(c), then within [**]
after the effective date of the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement, BMS shall reimburse Immatics for [**] of the Immatics Product Development Costs for such Immatics Product (the &#147;<B><FONT
STYLE="white-space:nowrap">Co-Developed</FONT> Product Reimbursement Payment</B>&#148;); provided that, if BMS disputes the amount of the Immatics Product Development Costs for such Immatics Product, then such dispute shall be resolved pursuant to
Section&nbsp;6.7 (<I>mutatis mutandis</I> as if such costs were Eligible Research Costs, provided that any such audit requested pursuant to this Section&nbsp;3.1.4(d) shall not count towards the [**] limit as set forth in Section&nbsp;6.7.2). As
used herein, &#147;<B>Immatics Product Development Costs</B>&#148; shall mean, with respect to a given Immatics Product, the sum of (i)&nbsp;[**] and (ii) [**], in each case, reasonably incurred by Immatics, directly for the performance of
Development activities specifically for such Immatics Product (and [**]) during the period from and after such time as the applicable Immatics Product is added to this Agreement until such time as the Parties enter into the <FONT
STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement with respect to such Immatics Product, and in each case, that are evidenced by a product-specific development budget [**] and incurred as an expense in accordance with Immatics&#146;
Accounting Standards (consistently applied). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Tax Matters</U>. If BMS exercises its BMS <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Right, the Parties will discuss in good faith whether the arrangements between the Parties will be treated as a partnership (the &#147;<B>Partnership</B>&#148;) for tax purposes, including specifically,
German and U.S. federal and state income tax purposes. If the Parties agree to treat the arrangements as a partnership, BMS shall act as the Tax Representative for the Partnership. As soon as practicable after the exercise of the BMS <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Right, but no later than [**] thereafter, if the Parties agree to treat the arrangements as a partnership, the Parties shall enter into a separate agreement that will cover tax matters (the &#147;<B>Tax
Matters Agreement</B>&#148;), including provisions governing the preparation and filing of tax returns, review of the tax returns, the Parties&#146; rights and obligations under audit and contest, documentation retention and other terms that are
customarily covered by an agreement of this type. If the Parties agree to treat the arrangements as a partnership for U.S. federal and state income tax purposes, the Parties agree to reasonably cooperate to avoid the incurrence of any income that is
effectively connected with the conduct of a trade or business within the United States within the meaning of Section&nbsp;864 of the United States Internal Revenue Code of 1986, as amended (the &#147;<B>IRC</B>&#148;). No party shall take the
position that the arrangements between the Parties is a partnership for tax purposes without either (A)&nbsp;the written consent of the other Party or (B)&nbsp;a written tax opinion from a &#147;Big 4&#148; accounting firm indicating at a &#147;more
likely than not&#148; or stronger position that the arrangements between the Parties is a partnership with respect to a particular tax jurisdiction; any such written opinion shall be provided to a Party at such Party&#146;s request and the Parties
shall equally share the costs of obtaining such opinion. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.5 <U>Right of Process Participation</U>. Without limiting the
BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right pursuant to Section&nbsp;3.1.4(b), with respect to any Immatics Product (other than a <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product), prior to Immatics (or any of its
Affiliates) negotiating with, or responding to bona fide written offers from [**], a Third Party to grant a license or any other right to such Third Party with respect to any other Immatics Product, Immatics shall first notify BMS thereof in writing
[**] and BMS shall have the right (in its discretion), by providing written notice to Immatics within [**] of Immatics&#146; notice [**] to BMS, to discuss such proposed transaction with Immatics and, if determined by BMS, to participate in the
process for negotiating potential terms for such a potential transaction (the &#147;<B>BMS Participation Right</B>&#148;). If BMS notifies Immatics that it desires to exercise its BMS Participation Right for a given proposed transaction, then prior
to Immatics (or its Affiliate) granting any licenses or other rights to any Third Party with respect to the proposed transaction, Immatics shall ensure that BMS has been afforded the right to discuss the proposed transaction with Immatics for a
period of [**], and to thereafter participate in the process for negotiating such transaction in a similar, but not more favorable, manner to any Third Party [**]; provided that, for clarity, neither Party shall be obligated to enter into such a
transaction (with BMS or any Third Party) unless and until each Party agrees to such terms (in each Party&#146;s discretion). Immatics (and its Affiliates) shall not grant any license or other rights to a Third Party with respect to a given Immatics
Product without first complying with this Section&nbsp;3.1.5, and, for clarity, this Section&nbsp;3.1.5 shall again apply with respect to any additional license or rights to be granted to any Third Party with respect to a given Immatics Product
[**]. For the avoidance of doubt, [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Regulatory</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.1 <U>Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If BMS determines that any regulatory filings for any BMS Products are required for any activities hereunder, including INDs, MAAs and
other Regulatory Approvals (as applicable), then BMS (or its designee) shall have the sole right, in its discretion and at its cost, to seek to obtain and maintain such regulatory filings (in its or its designee&#146;s name), including with respect
to any activities under the Research Program. In addition, BMS (or its designee) shall have the sole right to communicate and otherwise interact with Regulatory Authorities with respect to the BMS Products, including with respect to any Regulatory
Materials in connection therewith. Immatics (and its Affiliates) shall have no right to, and shall not, make any regulatory filings related to any BMS Products or otherwise interact with any Regulatory Authorities with respect to the BMS Products;
provided that, as and to the extent reasonably requested by BMS in writing, Immatics shall interact with Regulatory Authorities in connection with BMS Products with respect to matters related to the Immatics Licensed IP or the Research Program
activities conducted by or on behalf of Immatics under this Agreement. At the reasonable request of BMS, and subject to the cost reimbursement provisions for the assistance provided under clause (D)&nbsp;of Section&nbsp;2.1.3(a) as set forth in such
Section, Immatics shall reasonably assist BMS in communications and filings with Regulatory Authorities with respect to the BMS Products (including in connection with the preparation of any INDs, MAAs and other Regulatory Approvals for any BMS
Products), including, as and to the extent reasonably requested by BMS in writing, Immatics shall provide assistance in connection with BMS Products with respect to matters related to the Immatics Licensed IP and the Research Program activities
conducted by or on behalf of Immatics under this Agreement. All Regulatory Materials that are solely and specifically related to any BMS Products shall be owned by, and shall be the sole property and held in the name of BMS or its designated
Affiliate, Sublicensee or designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If Immatics determines that any regulatory filings for any Immatics Products are required for
any activities hereunder, including INDs, MAAs and other Regulatory Approvals (as applicable), then Immatics (or its designee) shall have the sole right, in its discretion and its cost, to seek to obtain and maintain such regulatory filings (in its
or its designee&#146;s name). In addition, Immatics (or its designee) shall have the sole right to communicate and otherwise interact with Regulatory Authorities with respect to the Immatics Products, including with respect to any Regulatory
Materials in connection therewith. BMS (and its Affiliates) shall have no right to, and shall not, make any regulatory filings related to any Immatics Products or otherwise interact with any Regulatory Authorities with respect to the Immatics
Products; provided, however, that, at Immatics&#146; reasonable request and cost, BMS shall reasonably assist Immatics in communications and filings with Regulatory Authorities specifically with respect to the BMS Licensed IP for use with the BMS
Products. All Regulatory Materials that are solely and specifically related to any Immatics Products shall be owned by, and shall be the sole property and held in the name of Immatics or its designated Affiliate, Sublicensee or designee.
Notwithstanding the foregoing provisions of this Section&nbsp;3.2.1(b), if BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then the provisions of the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement
shall apply with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product in lieu of the provisions of this Section&nbsp;3.2.1(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.2 <U>Pharmacovigilance</U>. At the written request of either Party,
within [**] after such request, Immatics and BMS (or its designee(s)) will enter into a pharmacovigilance agreement in order to, among other things, coordinate safety matters and share safety information with respect to Collaboration Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Manufacturing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.1 <U>BMS Products</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. BMS (and its Affiliates), either itself or with or through Third Party(ies), shall have the sole right, at its cost, to
Manufacture (and shall control all aspects of the Manufacturing of) BMS Products (including the BMS Receptors contained therein) for use in the Field in the Territory; provided that Immatics shall be responsible for performing Manufacturing of the
Initial BMS Products as set forth in the Research Plans. Notwithstanding the foregoing, Immatics shall, as and to the extent requested by BMS, also Manufacture and supply to BMS [**], in each case of (i)&nbsp;and (ii), pursuant to a supply agreement
(the &#147;<B>Supply Agreement</B>&#148;), which the Parties shall negotiate in good faith and enter into within [**] after request by BMS, including the Manufacturing Cost for the applicable BMS Product, to be calculated as set forth on <U>Schedule
3.3.1</U> and such other terms as the Parties may agree and as are customary in an agreement of that type (including with respect to lead times and forecasting and ordering). In all cases, on a BMS <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis, BMS shall have the option to request an initial Manufacturing technology transfer from Immatics (and its Third Party contract manufacturers) pursuant to Section&nbsp;3.3.3(a) to
facilitate the Manufacture of such BMS Product by BMS (itself or by an Affiliate or Third Party) by providing written notice to Immatics, which notice shall specify the desired commencement date of Manufacturing technology transfer pursuant to
Section&nbsp;3.3.3(a); provided that, (i)&nbsp;the initial technology transfer pursuant to Section&nbsp;3.3.3(a) shall occur one time for a given BMS Product and (ii)&nbsp;with respect to the First BMS Product and the Second BMS Product, such
request shall occur no earlier than the [**] of the Effective Date or no later than the [**] of the Effective Date (provided further that such technology transfer for the First BMS Product and Second BMS Product shall in all cases be completed by
Immatics prior to [**] of the Effective Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Feeder-Free Manufacturing Process</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) For each Initial BMS Product, Immatics shall use Commercially Reasonable Efforts to develop a Feeder-Free Manufacturing Process in
accordance with the applicable Research Plans until <FONT STYLE="white-space:nowrap">Hand-off</FONT> has occurred with respect to both of the Initial BMS Products [**], and Immatics shall keep BMS apprised of its efforts, results and activities
(conducted and planned) with respect thereto by providing a reasonably detailed report to the JSC at each meeting of the JSC, [**] in connection therewith. For clarity, if [**], the then-current elements and processes of any Feeder-Free
Manufacturing Process [**] shall be included in the technology transfers pursuant to Section&nbsp;3.3.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) In the event that Immatics has fully developed a complete
Feeder-Free Manufacturing Process specific for Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell-Based</FONT> Allogeneic Cell Therapy Products that can be used with the BMS Products prior to [**] of the end of the Research Term, [**], then
(x)&nbsp;such Feeder-Free Manufacturing Process shall be included in the technology transfers for the BMS Products hereunder pursuant to Section&nbsp;3.3.3, and (y)&nbsp;such complete specific Feeder-Free Manufacturing Process as so developed by
Immatics prior to the [**] of the end of the Research Term, to the extent owned by, and proprietary to, Immatics and transferred to BMS (the &#147;<B>Immatics Developed Feeder-Free Process</B>&#148;) shall also be included in the definition of
Immatics Platform Technology as and to the extent set forth in such definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) In the event that Immatics has not fully developed
a complete Feeder-Free Manufacturing Process that can be used with the BMS Products as set forth in Section&nbsp;3.3.1(b)(i) prior to [**] of the end of the Research Term, as reasonably determined by BMS, then during the period from [**] of the end
of the Research Term until [**] of the Effective Date (the &#147;<B>Additional Feeder-Free Process Development Period</B>&#148;), if Immatics (or any of its Affiliates) conducts (or has conducted) any additional activities with respect to the
development of a Feeder-Free Manufacturing Process that is proprietary to Immatics and could potentially be used in connection with the BMS Products (a &#147;<B>Post-Research Term Feeder-Free Process</B>&#148;), Immatics shall keep BMS apprised of
such efforts (and the results thereof) by providing a summary report to the JSC of all material progress in the development of any Post-Research Term Feeder-Free Process, including answering questions of BMS, and providing information and data
requested by BMS, in connection therewith. In the event that, following the technology transfers pursuant to Section&nbsp;3.3.3, BMS desires to utilize any Post-Research Term Feeder-Free Process that has been further developed by or on behalf of
Immatics (or any of its Affiliates), then at the request of BMS, the Parties shall discuss in good faith and agree on the reasonable terms and conditions (including reimbursement for the direct costs incurred by Immatics for providing the technology
transfer as well as timing for the technology transfer) for Immatics to license to BMS such further developed Post-Research Term Feeder-Free Process such that BMS can fully access and utilize such further developed Post-Research Term Feeder-Free
Process with respect to the BMS Products. For the avoidance of doubt, the provisions of this Section&nbsp;3.3.1(b)(iii) shall not require Immatics to undertake any additional development activities with respect to a Post-Research Term Feeder-Free
Process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.2 <U>Immatics Products</U>. Subject to the terms of the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT>
Agreement, Immatics (and its Affiliates), either itself or with or through Third Party(ies), shall have the sole right, at its cost, to Manufacture (and shall control all aspects of the Manufacturing of) Immatics Products (including the Immatics
TCRs for use therein) for use in the Field in the Territory subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.3 <U>Manufacturing Technology
Transfer</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Initial Manufacturing Technology Transfer for a given BMS Product</U>. Without limiting the provisions of
Section&nbsp;2.1.3, at the written request of BMS in accordance with Section&nbsp;3.3.1(a), Immatics shall (and shall cause)[**], transfer from Immatics, its Affiliates and its Third Party contract manufacturers to BMS (and its designees), copies in
English (in writing and in an electronic format) of all data, information and other <FONT STYLE="white-space:nowrap">Know-How</FONT> in the Control of Immatics or its Affiliates that is (i)&nbsp;necessary or reasonably useful for the Manufacture of
the applicable BMS Products (including the BMS Receptors therein) in accordance with the current Manufacturing process then employed by or on behalf of Immatics or its Affiliates, or (ii) [**] and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shall otherwise reasonably assist BMS (and its designees) to establish, implement,
qualify and validate the processes to Manufacture the applicable BMS Products (including the BMS Receptors therein), including to enable BMS (and its designees) to replicate any Manufacturing process for products employed by or on behalf of
Immatics. Immatics shall commence such transfer promptly (and in all cases within [**]) following such request of BMS and shall complete such transfer as soon as reasonably practicable. Such transfer shall include [**] and necessary or reasonably
useful to the Manufacture of the applicable BMS Products in accordance with the current Manufacturing process then employed by or on behalf of Immatics or its Affiliates, and, if the Immatics Developed Feeder-Free Process has not been fully
developed as of the time of such technology transfer, then, if requested by BMS, such transfer shall also include the then-current elements and processes of any Feeder-Free Manufacturing Process [**]. Such transfer shall occur one time for a given
BMS Product and, if BMS determines that a technology transfer plan should be implemented to facilitate such technology transfer, then such transfer shall occur pursuant to a technology transfer plan [**]. In addition, for a period of [**] following
completion such transfer for a given BMS Product, at the reasonable request of BMS from time to time and at BMS&#146; expense (provided that such expenses are reasonable), Immatics shall make its employees and consultants (including personnel of its
Affiliates and Third Party contract manufacturers) available to BMS (and its designees) to provide reasonable consultation and technical assistance in order to ensure an orderly implementation of the manufacturing technology and operations by BMS
(and its designees) and to assist BMS (and its designees) in its Manufacture of any applicable BMS Products (including the BMS Receptors therein), and to provide assistance with any regulatory matters (including regulatory filings) with respect to
such Manufacturing; provided that, BMS may request additional assistance with any regulatory matters in accordance with Section&nbsp;3.2.1(a) after the [**] period and Immatics shall reasonably comply with such requests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Manufacturing Technology Transfer at the [**] the End of the Research Program</U>. Without limiting the provisions of
Section&nbsp;3.3.3(a), at the [**] the end of the Research Program, Immatics shall [**], (i) promptly disclose to BMS in English (including by providing electronic copies thereof) all <FONT STYLE="white-space:nowrap">Know-How</FONT> within the
Immatics Licensed IP related to the Manufacture of any BMS Product that was not previously transferred to BMS pursuant to Section&nbsp;3.3.3(a), and (ii)&nbsp;at the written request of BMS, conduct (and cause to be conducted) a technology transfer
to BMS (and its designees) with respect to such <FONT STYLE="white-space:nowrap">Know-How</FONT> [**], including providing BMS (and its designees) with reasonable access by teleconference or <FONT STYLE="white-space:nowrap">in-person</FONT> (as
requested by BMS) to Immatics personnel (and personnel of its Affiliates and Third Party contract manufacturers) to assist with the implementation of such Immatics Licensed IP and the Manufacturing process, and to answer questions related to the
same, and, if BMS determines that a technology transfer plan should be implemented to facilitate such technology transfer, then such transfer shall occur pursuant to a technology transfer plan [**]. At the request of BMS, such transfer shall also
include the then-current elements and processes of any Feeder-Free Manufacturing Process [**]. Immatics shall commence such technology transfer promptly (and in all cases within [**]) following [**] the end of the Research Term and shall complete
such transfer as soon as reasonably practicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Generally</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Committees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Establishment</U>. Pursuant to this ARTICLE 4, the Parties will establish a JSC within the timeframes set forth in Section&nbsp;4.2.1.
The JSC shall have decision-making authority with respect to the matters within its purview to the extent expressly and as more specifically provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Subcommittees</U>. From time to time, the JSC may establish subcommittees to oversee particular projects or activities, as the JSC
deems necessary or advisable (each, a &#147;<B>Subcommittee</B>&#148;); provided that the JSC may not grant any responsibilities to a Subcommittee that are beyond the scope of the responsibilities of the JSC as set forth herein. Each Subcommittee
shall consist of such number of members as the JSC determines is appropriate from time to time. Such members shall be individuals with expertise and responsibilities in the relevant areas. Such Subcommittees shall operate under the same principles
as are set forth in this Article&nbsp;4 for the committee forming such Subcommittee. Without limiting the generality of the foregoing, if BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then within [**] thereafter, the
JSC shall establish a joint development committee and a joint commercialization committee to oversee the Development and Commercialization of the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product (which committees shall also have such
other responsibilities with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product as may be more particularly described in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement), and, unless otherwise
expressly set forth in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement, such committees shall make decisions with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product by consensus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Alliance Managers</U>. Promptly after the Effective Date, each Party shall appoint an individual to act as alliance manager for such
Party (each, an &#147;<B>Alliance Manager</B>&#148;). The Alliance Managers shall be the primary point of contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder. The
Alliance Managers shall attend all meetings of the JSC and shall be responsible for assisting the JSC in performing its oversight responsibilities. The name and contact information for each Party&#146;s Alliance Manager, as well as any
replacement(s) chosen by such Party, in its sole discretion, from time to time, shall be promptly provided to the other Party in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Joint Steering Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.1 <U>Establishment; Meetings</U>. Within [**] after the Effective Date, the Parties shall establish a joint steering committee (the
&#147;<B>JSC</B>&#148;) as more fully described in this Section&nbsp;4.2. The JSC shall (a)&nbsp;have review, oversight and decision-making responsibilities for those activities performed under the Research Programs as more specifically provided in
Section&nbsp;4.2.3 and (b)&nbsp;be a forum for information sharing with respect to the Development and Commercialization of the BMS Products and Immatics Products generally, and each Party agrees to keep the JSC informed of its progress and
activities hereunder with respect to the BMS Products and Immatics Products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">at each meeting of the JSC. The first scheduled meeting of the JSC shall be held no
later than [**] after establishment of the JSC unless otherwise agreed by the Parties. After the first scheduled meeting of the JSC until the JSC is disbanded, the JSC shall meet in person or telephonically at least [**] prior to end of the Research
Term, or more or less frequently as the Parties mutually deem appropriate, on such dates and at such places and times as provided herein or as the Parties shall agree, provided that if agreed to by the Parties for a given year, the JSC shall meet at
least [**]. In any case where a matter within the JSC&#146;s authority arises, the JSC shall convene a meeting and consider such matter as soon as reasonably practicable, but in no event later than [**] after the matter is first brought to the
JSC&#146;s attention (or, if earlier, at the next regularly scheduled JSC meeting). Following the end of the Research Term, the JSC shall no longer be required to hold meetings (unless otherwise agreed to by the Parties, in which case the JSC shall
hold meetings on such frequency as agreed to by the Parties, but in all cases, no more than [**]), but the JSC shall continue to exist as a forum for (i)&nbsp;information sharing with respect to the Development and Commercialization of the BMS
Products and Immatics Products in accordance with this Agreement, and (ii)&nbsp;making decisions to be made by the JSC in accordance with this Agreement. The JSC shall disband upon the expiration or termination of this Agreement in its entirety.
Meetings that are held in person shall be at such location as the Parties may agree. The members of the JSC may also convene or be polled or consulted from time to time by means of telecommunications, video conferences, electronic mail or
correspondence, as deemed necessary or appropriate. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JSC, including all travel and living expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.2 <U>Membership</U>. The JSC shall be comprised of three (3)&nbsp;representatives (or such other number of representatives as the Parties
may mutually agree) from each of BMS and Immatics. Each representative of a Party shall have sufficient seniority and expertise to participate on the JSC as determined in such Party&#146;s reasonable judgment. Each Party may replace any or all of
its representatives on the JSC at any time upon written notice to the other Party. Each Party may, subject to the other Party&#146;s prior approval, invite <FONT STYLE="white-space:nowrap">non-member</FONT> representatives of such Party and any
Third Party to attend meetings of the JSC as <FONT STYLE="white-space:nowrap">non-voting</FONT> participants; provided that (a)&nbsp;any such representative or Third Party is bound by obligations of confidentiality,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> consistent with those set forth in ARTICLE 8 and is obligated to assign inventions to the relevant Party as necessary to effect the intent of
Section&nbsp;7.8 prior to attending such meeting, (b)&nbsp;such <FONT STYLE="white-space:nowrap">non-member</FONT> representative or Third Party shall not have any voting or decision-making authority on the JSC, and (c)&nbsp;with respect to any
Third Party, such Third Party shall be approved by the other Party in writing (such approval not to be unreasonably withheld, conditioned or delayed) prior to attendance at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.3 <U>Responsibilities</U>. The JSC shall perform the following functions, subject to the final decision-making authority as set forth in
Section&nbsp;4.2.4: (a) during the Research Term, oversee, review and monitor progress of the Research Programs, including serving as a forum for exchanging information and facilitating discussions regarding the conduct of the Research Programs;
(b)&nbsp;during the Research Term, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, create and amend any Research Plans for such Research Program; (c)&nbsp;oversee,
review and monitor the Manufacturing by Immatics of any Initial BMS Products; (d)&nbsp;act as a forum for information sharing with respect to the Development and Commercialization of BMS Products and Immatics Products; (e)&nbsp;act as a forum to
review and discuss the Immatics Research Plans (and updates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">thereto) as well as to discuss technology of BMS that BMS may potentially be willing to
make available to Immatics hereunder to address technical challenges with the Immatics Products, (f)&nbsp;discuss and attempt to resolve any disputes in any Subcommittees; and (g)&nbsp;perform such other responsibilities as may be mutually agreed by
the Parties from time to time or as otherwise expressly delegated to the JSC as set forth herein. For purposes of clarity, the JSC shall not have any authority beyond the specific matters set forth in this Section&nbsp;4.2.3 (or otherwise expressly
set forth in this Agreement), and in particular shall not have any power to (i)&nbsp;amend, modify, interpret or waive the terms of this Agreement, or to alter, diminish, expand, determine or waive compliance by a Party with a Party&#146;s
obligations under this Agreement, (ii)&nbsp;except as otherwise expressly set forth herein, make any decisions with respect to any BMS Product (other than decisions with respect to the performance of the Research Program for the Initial BMS Products
and the Manufacturing of any Initial BMS Products by Immatics) or Immatics Product (other than any <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product), or (iii)&nbsp;make decisions with respect to the preparation, filing, prosecution or
maintenance (including with respect to any patent term extensions and patent listings), enforcement or defense of intellectual property (which shall instead be handled in accordance with Article 7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.4 <U>Decisions</U>. Except as otherwise set forth in this Agreement, all decisions of the JSC shall be made by consensus, with each Party
having one (1)&nbsp;vote. If the JSC cannot agree on a matter for which the JSC has decision-making authority within [**] after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue
referred to the Executive Officers for resolution. The Parties&#146; respective Executive Officers shall meet within [**] after such matter is referred to them and shall negotiate in good faith to resolve the matter. If the Executive Officers are
unable to resolve the matter within [**], or such longer time frame the Executive Officers may otherwise agree upon, after the matter is referred to them in accordance with this Section&nbsp;4.2.4, then, except as otherwise set forth in this
Agreement, including for clarity with respect to decisions regarding the preparation, filing, prosecution or maintenance (including with respect to any patent term extensions and patent listings), enforcement or defense of intellectual property
rights as set forth in Article 7, (a) Immatics shall have the final decision making authority with respect to matters [**]; provided that, for clarity, in making such final decision, Immatics [**], (b) BMS shall have final decision making authority
with respect to matters [**], (c) BMS shall have the final decision making authority with respect to matters [**]; provided that, without Immatics&#146; consent, BMS shall not have the right to exercise its final decision-making authority to amend
the Research Plans (i)&nbsp;to require Immatics to perform material additional activities that would [**]. Any final decision made by BMS or Immatics in the course of exercising its final decision-making authority must be consistent with the terms
of this Agreement and within the scope of authority delegated to the JSC under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.5 <U>Minutes</U>. Immatics shall be
responsible for preparing and circulating minutes of each meeting of the JSC, setting forth, <I>inter alia</I>, an overview of the discussions at the meeting and a list of any actions, decisions or determinations approved by the JSC, with Immatics
responsible for minutes for the first meeting of the JSC. A draft of such minutes shall be sent by Immatics to BMS&#146; Alliance Manager within [**] after the applicable meeting. Such minutes shall be effective only after such minutes have been
approved by both Parties in writing. Definitive minutes of all JSC meetings shall be finalized no later than [**] after the meeting to which the minutes pertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Exclusivity for CAR Targets</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1.1 <U>General</U>. During the Term and subject to remaining provisions of this Section&nbsp;5.1,
Immatics shall not, and shall ensure that its Affiliates shall not, anywhere in the world: (i) [**], (A)&nbsp;[**] or (B)&nbsp;Develop, Manufacture or Commercialize any Competing Product, in each case, other than [**]; (ii) grant a license,
sublicense or other rights to any Third Party to conduct any of the activities in the foregoing clause (i), other than [**]; or (iii)&nbsp;except for the rights and licenses granted to BMS hereunder, transfer, assign, convey or otherwise sell any
Competing Product. Notwithstanding the foregoing, Immatics may, without being in violation of the foregoing provisions of this Section&nbsp;5.1.1, conduct general internal research with respect to [**]; provided that, [**]; provided that [**]. For
clarity, the restrictions contained in this Section&nbsp;5.1.1 shall not apply with respect to [**]. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1.2 <U>Competing
Product</U>. As used herein, the term &#147;<B>Competing Product</B>&#148; means, [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For clarity, if a given Competing Product is
[*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Exceptions for Change of Control and Acquisitions</U>. Notwithstanding the provisions of Section&nbsp;5.1, if
(a)&nbsp;Immatics undergoes a Change of Control with a Third Party [**] (each, an &#147;<B>Immatics CoC Competing Product</B>&#148;), or (b)&nbsp;Immatics or any of its Affiliates acquires rights to a Competing Product through the acquisition of a
Third Party [**] (an &#147;<B>Immatics Acquired Competing Product</B>&#148;), then in either such case, the following will apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2.1
<U>Immatics CoC Competing Product</U>. If Immatics undergoes a Change of Control with a Third Party who owns or has rights to an Immatics CoC Competing Product as set forth in Section&nbsp;5.2(a) above, Immatics (or its Affiliates) [**]; provided
that [**]. In addition, if Immatics [**], then [**]. For clarity, [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2.2 <U>Immatics Acquired Competing Product</U>. If Immatics or
any of its Affiliates acquires rights to an Immatics Acquired Competing Product through the acquisition of a Third Party as set forth in Section&nbsp;5.2(b) above, Immatics (or its Affiliate) [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Exclusivity for TCR Targets under 2019 Collaboration Agreement</U>. If BMS includes a given TCR Target as a BMS Target hereunder, then
[**], Immatics shall, and shall cause its Affiliates to, comply with the provisions of Article 4 of the applicable 2019 License Agreement [**] and any breach of such provisions shall also be deemed to be a breach of this Agreement. The Parties
further agree and acknowledge that [**]. Immatics and its Affiliates shall not be in breach of this Section&nbsp;5.3 or Article 4 of the applicable 2019 License Agreement, if Immatics or its Affiliates: [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL TERMS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>Upfront Payment</U>. In partial consideration for the rights granted to BMS under this Agreement to the Immatics Licensed IP that is owned by Immatics, BMS shall pay to Immatics within [**] after the Effective Date a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment of Sixty Million Dollars ($60,000,000) (the &#147;<B>Upfront
Payment</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Research Program Costs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.1 <U>General</U>. Each Party shall be responsible for any and all costs it (or its Affiliate) incurs in connection with the performance of
the Research Programs in accordance with the Research Plan; provided that BMS will reimburse Immatics for those Research Costs incurred by Immatics that are Eligible Research Costs, in accordance with the procedures set forth in the following
provisions of this Section&nbsp;6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.2 <U>Eligible Research Costs Report</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Commencing upon the first [**] immediately following the Effective Date and continuing on a [**] basis thereafter until the end of the
Research Term, as Immatics incurs Eligible Research Costs during the Research Term, Immatics will submit to BMS within [**] after the end of each [**] a report setting forth the Eligible Research Costs actually incurred by Immatics in such
just-completed [**] (each, an &#147;<B>Eligible Research Costs Report</B>&#148;) together with an invoice for such Eligible Research Costs; provided that, notwithstanding anything to the contrary contained herein, in no event shall Immatics submit
any invoices to BMS for [**]. Each such report will specify in reasonable detail all such Eligible Research Costs, and, upon BMS&#146; reasonable request, Immatics will provide to BMS other reasonable supporting documentation (including Third Party
invoices) for the Eligible Research Costs described in the applicable the Eligible Research Cost Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) With respect to the
Required Work Packages, the Parties agree and acknowledge that the Initial Immatics FTE Commitment and, when added to the Research Budget, the Initial Third Party
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs and the Initial Direct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs, are Immatics&#146;
reasonable estimate of the FTEs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs that will be required for Immatics to perform the Required Work Packages. In order to monitor the actual FTEs
used by Immatics and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs incurred by Immatics to perform the Required Work Packages, commencing upon the first [**] immediately following the Effective
Date and continuing on a [**] basis thereafter until the end of the Research Term, Immatics will submit to BMS within [**] after the end of each [**] a report setting forth the [**], as well as the [**] (each, a &#147;<B>Required Work Package
Report</B>&#148;). Immatics shall use reasonable efforts to conduct the Required Work Packages utilizing no more FTEs than the Initial Immatics FTE Commitment and incurring no
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs other than the Initial Third Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs and the
Initial Direct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs [**]. However, in the event that Immatics reasonably determines that, notwithstanding the use of such reasonable efforts, it will be
required to (x)&nbsp;use additional FTEs that [**], or (y)&nbsp;for a given Required Work Package, to incur additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs that [**] ((x) and (y), the
&#147;<B>Initial Immatics Commitment Plus Permitted Overage</B>&#148;) in order to complete the Required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Work Packages, then it shall promptly (but in all cases with respect to FTEs, and to the
extent possible with respect to the Initial Third Party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs and Initial Direct
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs, at least [**] prior to exceeding the Initial Immatics Commitment Plus Permitted Overage) notify BMS thereof in writing, including [**]. Following
the receipt of such notice, the JSC shall promptly meet to discuss such situation, and shall determine the actual number of estimated additional FTEs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT>
Costs (above the Initial Immatics FTE Commitment Plus Permitted Overage) that will be required to complete the Required Work Packages (the &#147;<B>Additional Immatics Required Costs</B>&#148;). BMS shall thereafter have the right, in its sole
discretion, to determine whether to [**]; provided that [**]. For clarity, in all cases, [**]. For clarity, [**], the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs for the specific activities
[**] shall not be handled pursuant to this Section&nbsp;6.2.2(b), and instead shall be handled separately as set forth in Section&nbsp;2.1.2(b)(v). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Immatics, in its sole discretion, may provide the Eligible Research Costs Report and the Required Work Package Report as a single report.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.3 <U>Payment of Invoices</U>. BMS will submit the undisputed portion of any Eligible Research Costs to Immatics within [**] after
receipt of Immatics&#146; invoice for such amount and all related documentation. In the event of any disagreement with respect to the calculation of such payment, BMS will pay any undisputed portion of such payment in accordance with the foregoing
timetable and will pay the remaining, disputed portion within [**] after the date on which Immatics and BMS, using good faith efforts, resolve the dispute, which dispute, at the request of either Party, may be resolved in accordance with
Section&nbsp;6.7 (provided that any such audit requested pursuant to this Section&nbsp;6.2.3 shall not count towards the [**] limit as set forth in Section&nbsp;6.7.2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.4 <U>Certain Definitions</U>. As used herein, the following defined terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>FTE</B>&#148; means one (1)&nbsp;person (or the equivalent of one (1)&nbsp;person) working full time for a twelve (12)&nbsp;month
period devoted to the conduct of specific activities under the Research Program (as set forth in the applicable Research Plan) pursuant to this Agreement (excluding, for clarity, persons employed in general and administrative, management or other <FONT
STYLE="white-space:nowrap">non-technical</FONT> capacities, as applicable) and who is employed by Immatics and assigned to perform specified Research Program work, with [**] per year being deemed to constitute one (1)&nbsp;employee performing such
work on a full-time basis. No additional payment shall be made with respect to any person who works more than [**] per year and any person who devotes less than [**] per year shall be treated as an FTE on a <I>pro rata</I> basis based upon the
actual number of hours worked divided by [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Research Costs</B>&#148; means the sum of [**], in each case, reasonably
incurred by Immatics on or after the Effective Date during the Research Term directly in connection with the performance of the Research Program activities allocated to Immatics as set forth in the applicable Research Plan, in each case, that are
incurred as an expense in accordance with Immatics&#146; Accounting Standards (consistently applied) and consistent with the applicable Research Plan, but only to the extent that such costs are within the Research Budget (and, for clarity, [**]).<B>
</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Research FTE Cost</B>&#148; means, for a given period, the
Research FTE Rate multiplied by the number of FTEs utilized by Immatics in such period for the performance of the Research Program activities allocated to Immatics as set forth in the applicable Research Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Research FTE Rate</B>&#148; means a rate of [**] per FTE (which rate represents [**]). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Eligible Research Costs</B>&#148; means the following: those Research Costs that are [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">For clarity, except with respect to [**], it is understood and agreed that there are no Eligible Research Costs for the Required Work
Packages that will be billed to, or reimbursed by, BMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Royalties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.1 <U>Collaboration Product Royalties</U>. Subject to the terms of this Section&nbsp;6.3 [**], on a [**] basis, (a)&nbsp;BMS shall pay
Immatics royalties on [**] BMS Product Net Sales of each BMS Product [**] during the applicable BMS Royalty Term for such BMS Product (provided that the [**]), and (b)&nbsp;Immatics shall pay BMS royalties on [**] Immatics Product Net Sales of each
Immatics Product [**] during the applicable Immatics Royalty Term for such Immatics Product (provided that the [**]), in each case of (a)&nbsp;and (b), equal to the following portions of [**] Product Net Sales of the applicable Collaboration Product
[**] multiplied by the applicable royalty rate set forth below for such portion of [**] Product Net Sales during the applicable BMS Royalty Term or Immatics Royalty Term, which royalties shall be paid in accordance with Section&nbsp;6.3.6. For
clarity, [**]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>[**] BMS Product Net Sales of [**]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>[**] BMS Product Net Sales of [**]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>[**] Immatics Product Net Sales of [**]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>[**] Immatics Product Net Sales of [**]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[**]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable royalty rates set forth in the applicable table above will apply only to that portion of the [**] Product Net
Sales of the applicable Collaboration Product during a given [**] that falls within the indicated range. For clarity, [**]. In addition, the Parties hereby agree and acknowledge (on behalf of themselves and their respective Affiliates),
notwithstanding anything to the contrary contained in the 2019 Agreements, no royalties shall be payable by BMS or any of its Affiliates under any of the 2019 Agreements with respect to any BMS TCR Product (and the sales of any BMS TCR Product shall
not count for purposes of calculating any royalty tiers under any 2019 Agreement), and BMS shall only be responsible for payment of royalties on a BMS TCR Product pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.2 <U>Royalty Term</U>. BMS&#146; royalty obligations to Immatics under Section&nbsp;6.3.1 shall apply [**] and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis only during the applicable BMS Royalty Term for such BMS Product in such country, and Immatics&#146; royalty obligations to BMS under
Section&nbsp;6.3.1 shall apply on an [**] and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis only during the applicable Immatics Royalty Term for such Immatics Product in such country.
Following expiration of the applicable BMS Royalty Term or Immatics Royalty Term, as applicable, for a given Collaboration Product in a given country, as applicable, no further royalties will be payable in respect of sales of such Collaboration
Product in such country and thereafter the license granted to BMS or Immatics, as applicable, hereunder with respect to such Collaboration Product in such country will automatically become fully <FONT STYLE="white-space:nowrap">paid-up,</FONT>
perpetual, irrevocable and royalty-free. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.3 <U>Reductions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Reductions for [No Valid Claim</U>. The royalty amounts payable with respect to Annual Product Net Sales shall be reduced [**] in
which there is not at least one (1)&nbsp;Valid Claim of a Patent[**] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) <U>Royalty Reduction for [</U><U>**</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Cumulative Deductions</U>. Notwithstanding anything to the contrary in this Section&nbsp;6.3.3, but subject to Section&nbsp;6.3.4 and
6.3.5, (i) in no circumstances will the aggregate royalties payable to Immatics<B> </B>in any Calendar Quarter be reduced, as a result of Section&nbsp;6.3.3(a) and Section&nbsp;6.3.3(b), [**] of the royalties otherwise payable to Immatics under
Section&nbsp;6.3.1 and (ii)&nbsp;in no circumstances will the aggregate royalties payable to BMS in any Calendar Quarter be reduced, as a result of Section&nbsp;6.3.3(a) and Section&nbsp;6.3.3(b), [**)] of the aggregate royalties otherwise payable
to BMS under Section&nbsp;6.3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.4 <U>Royalty Offset for Third Party Payments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If BMS (or any of its Affiliates or Sublicensees) obtains a right or license under intellectual property of a Third Party [**]
(&#147;<B>BMS Third Party Payments</B>&#148;). Notwithstanding the foregoing, in no event shall [**]; provided that [**]. Notwithstanding the foregoing, if [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If Immatics (or any of its Affiliates or Sublicensees) obtains a
right or license under intellectual property of a Third Party [**] (&#147;<B>Immatics</B><B> Third Party Payments</B>&#148;). Notwithstanding the foregoing, in no event [**]; provided that [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.5 <U>Compulsory Licenses</U>. If a compulsory license is [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.6 <U>Payment of Royalties</U>. Each Party shall: (a)&nbsp;within [**] following the end of each [**] in which a royalty payment payable by
such Party pursuant to Section&nbsp;6.3.1 accrues, provide to the other Party a report specifying for [**]; and (b)&nbsp;[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4
<U>Milestones</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.1 <U>Regulatory Milestones</U>. Subject to the terms of this Section&nbsp;6.4 (and subject further to Sections
6.6, 6.9 and 6.10), on a BMS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis, BMS will notify Immatics within [***] following the first achievement by BMS under this Agreement after the
Effective Date of each milestone event described below in this Section&nbsp;6.4.1 (each, a &#147;<B>Regulatory Milestone Event</B>&#148;) with respect to the first BMS Product Directed to a given BMS Target to achieve such milestone event under this
Agreement, and BMS shall thereafter pay the applicable amounts set forth below associated with the applicable milestone event in accordance with Section&nbsp;6.4.2 (each, a &#147;<B>Regulatory Milestone Payment</B>&#148;):<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Regulatory Milestone Event*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory&nbsp;Milestone&nbsp;Payment*</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filing of the first IND [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filing of the first IND [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Initiation of the first Registration-Enabling Clinical Trial [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Initiation of the first Registration-Enabling Clinical Trial [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in the U.S. [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in the U.S. [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval (whether such Regulatory Approval is issued by the EMA or another Regulatory Authority), including pricing approvals, [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[**]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval (whether such Regulatory Approval is issued by the EMA or another Regulatory Authority), including pricing approvals, [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in Japan [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in Japan [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in the U.S. issued by the FDA [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in the U.S. issued by the FDA [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval (whether such Regulatory Approval is issued by the EMA or another Regulatory Authority), including pricing approvals, [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval (whether such Regulatory Approval is issued by the EMA or another Regulatory Authority), including pricing approvals, [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in Japan [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Regulatory Approval in Japan [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*The Regulatory Milestone Payments set forth in the above chart shall be
payable only with respect to the first BMS Product Directed to a given BMS Target to achieve the applicable Regulatory Milestone Event. If a second BMS Product Directed to such BMS Target subsequently achieves a given Regulatory Milestone Event,
then the Regulatory Milestone Payment shall be [***] of the amount set forth in the foregoing chart. If any additional BMS Products Directed to such BMS Target subsequently achieves a given Regulatory Milestone Event (i.e., a third BMS Product or
any subsequent BMS Product), no Regulatory Milestone Payment shall be payable for the achievement of such Regulatory Milestone Event by such additional BMS Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the applicable BMS Product is a [***], then only the milestones under [***] shall be payable if achieved and none of the milestones under
[***] for each milestone shall be payable. Similarly, if the applicable BMS Product is a [***], then only the milestones under [***] shall be payable if achieved and none of the milestones under [***] for each milestone shall be payable. For the
second BMS Product Directed to a given BMS Target that achieves a given Regulatory Milestone Event pursuant to this Section&nbsp;6.4.1, BMS will notify Immatics within [***] following the achievement of such Regulatory Milestone Event, and BMS shall
thereafter make the applicable Regulatory Milestone Payment to Immatics in accordance with Section&nbsp;6.4.2 but only in an amount equal to [***] of the Regulatory Milestone Payment for the first BMS Product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directed to the applicable BMS Target set forth in the foregoing chart. No Regulatory
Milestone Payment shall be due hereunder for the third or any subsequent BMS Products Directed to a given BMS Target that achieve a given Regulatory Milestone Event. Each of the forgoing Regulatory Milestone Events will be payable only one time for
a given BMS Product (for the first and second BMS Products Directed to a given BMS Target to achieve such Regulatory Milestone Event) regardless of the number of times such BMS Product achieves such Regulatory Milestone Event (i.e., a maximum of
[***] Regulatory Milestone Payments may be made pursuant to this Section&nbsp;6.4.1 for a given BMS Product). For the avoidance of doubt, the maximum amount payable by BMS pursuant to this Section&nbsp;6.4.1 for a [***] is [***], assuming that each
of the milestone events in this Section&nbsp;6.4.1 were achieved for such [***] for two separate BMS Products [***], and the maximum amount payable by BMS pursuant to this Section&nbsp;6.4.1 for a [***] is [***], assuming that each of the milestone
events in this Section&nbsp;6.4.1 were achieved for such [***] for two separate BMS Products [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing provisions
of this Section&nbsp;6.4.1, on a BMS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis, the following shall apply: [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Parties hereby agree and acknowledge (on behalf of themselves and their respective Affiliates) that the Regulatory Milestone
Payments herein do not replace or supersede those Regulatory Milestone Payments (as defined in the applicable 2019 License Agreement), if any, that may be payable by BMS or any of its Affiliates under Section&nbsp;5.3.1 of the applicable 2019
License Agreement for the applicable BMS TCR Product pursuant to the terms of such 2019 License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.2 <U>Invoice and Payment
of Regulatory Milestone Payments</U>. Following receipt of notification by BMS to Immatics that BMS has achieved the applicable milestone event triggering a Regulatory Milestone Payment hereunder, Immatics shall invoice BMS for the applicable
Regulatory Milestone Payment, and BMS shall pay such Regulatory Milestone Payment within [***] after receipt of the invoice therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.3 <U>Sales Milestones</U>. Subject to the terms of this Section&nbsp;6.4 (and subject further to Sections 6.6, 6.9 and 6.10), BMS will
notify Immatics within [***] after the end of the [***] during which a given milestone event described below in this Section&nbsp;6.4.3 (each, a &#147;<B>Sales Milestone Event</B>&#148; and together with any Regulatory Milestone Event, each, a
&#147;<B>Milestone Event</B>&#148;) was first achieved by BMS under this Agreement after the Effective Date with respect to each BMS Product, and BMS shall thereafter pay the applicable amounts set forth below associated with the applicable
milestone event in accordance with Section&nbsp;6.4.4 (each, a &#147;<B>Sales Milestone Payment</B>&#148; and together with any Regulatory Milestone Payment, each, a &#147;<B>Milestone Payment</B>&#148;): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sales&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sales&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the foregoing milestones in this Section&nbsp;6.4.3 shall be payable a maximum of one (1)&nbsp;time
for a given BMS Product as set forth in the foregoing chart regardless of the number of times the applicable milestone event was achieved, and no Sales Milestone Payment shall be due hereunder for any subsequent or repeated achievement of such
milestone event by the same BMS Product. The foregoing milestones are [***]. For the avoidance of doubt, [***], assuming that each of the milestone events in this Section&nbsp;6.4.3 were achieved with respect to such BMS Product. For clarity, if no
royalty is payable on a given unit of BMS Product (e.g., following the BMS Royalty Term for such BMS Product in a given country), then the Net Sales of such unit of BMS Product shall not be included for purposes of determining whether a Sales
Milestone Event is achieved. In addition, the Parties hereby agree and acknowledge (on behalf of themselves and their respective Affiliates), notwithstanding anything to the contrary contained in the 2019 Agreements, no Sales Milestones Payments (as
defined in the 2019 Agreements) shall be payable by BMS or any of its Affiliates under the 2019 Agreements with respect to any BMS TCR Product (and the sales of any BMS TCR Product shall not count for purposes of determining whether any sales
milestones under any 2019 Agreement were achieved), and BMS shall only be responsible for payment of Sales Milestone Payments on a BMS TCR Product pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.4 <U>Invoice and Payment of Sales Milestone Payments</U>. Following receipt of notification by BMS to Immatics that BMS has achieved the
applicable milestone event triggering a Sales Milestone Payment hereunder, Immatics shall invoice BMS for the applicable Sales Milestone Payment, and BMS shall pay such <FONT STYLE="white-space:nowrap">&#147;one-time&#148;</FONT> Sales Milestone
Payment within [***] after receipt of the invoice therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Payments for Immatics
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Option Fee</U><U> for Second Existing Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement</U>. In consideration for the option to obtain a sublicense from Immatics under the Second Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement pursuant to
Section&nbsp;7.5.1, BMS shall pay to Immatics within [***] after the Effective Date a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT>
fee of [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.2 <U>Initial Reimbursable Gene Editing Technology</U>. Following the date on which BMS becomes a sublicensee under any
Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in accordance with Section&nbsp;7.5.1, BMS shall reimburse Immatics for those milestone payments and royalty payments expressly set forth on <U>Schedule</U><U> 6.5.2</U>
that arise specifically for the use of the Third Party intellectual property rights licensed to Immatics pursuant to the applicable Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (the &#147;<B>Initial Reimbursable
Gene Editing Technology</B>&#148;), but only to the extent that (a) [***] and (b) [***]; provided that, solely with respect to the payments expressly set forth on <U>Schedule 6.5.2</U> that [***], the provisions of Section&nbsp;6.3.4 shall not apply
with respect to such payments. Immatics shall invoice BMS for the applicable amount after payment thereof by Immatics, and BMS shall reimburse Immatics therefor within [***] after receipt of the invoice therefor. Notwithstanding anything to the
contrary contained herein, [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.3 <U>New Reimbursable
<FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If Immatics (or any of its Affiliates) desires to obtain a
license to use any technology (i.e., any Patents or <FONT STYLE="white-space:nowrap">Know-How)</FONT> of a Third Party that is not Controlled by Immatics (or its Affiliate) as of the Effective Date that may be necessary to [***] (the &#147;<B>New
BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology</B>&#148;), then Immatics shall promptly notify the JSC thereof and the JSC shall discuss such New BMS Product Specific Reimbursable <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> Technology, and Immatics shall take into account any reasonable concerns or suggestions expressed by BMS&#146; members of the JSC with respect thereto. Thereafter, Immatics shall have the right, but not
the obligation, to negotiate and obtain such license from such Third Party to use such New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology. If Immatics (or its Affiliate) determines to take a license
to any such New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology (such agreement, an &#147;<B>Immatics New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement</B>&#148;), Immatics shall negotiate such Immatics New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in good faith and shall keep the JSC apprised of such negotiations [***]; provided that,
with respect to any New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology that is [***], Immatics shall also keep the JSC apprised of the terms of the agreement during the course of negotiations [***],
and Immatics shall take into account any reasonable concerns or suggestions expressed by BMS&#146; members of the JSC with respect to such terms. Additionally, if Immatics (or any of its Affiliates) desires to obtain a license to use any other
technology (i.e., [***]) of a Third Party that is not Controlled by Immatics (or its Affiliate) as of the Effective Date that [***] (the &#147;<B>New Additional Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology</B>&#148;
and together with any New BMS Product-Specific Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology, the &#147;<B>New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology</B>&#148;), then Immatics may
negotiate a license to such New Additional Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology (such agreement, an &#147;<B>Immatics New Additional Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement</B>&#148; and together with any Immatics New BMS Product-Specific Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, the &#147;<B>Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>&#148;); provided that Immatics shall negotiate such Immatics New Reimbursable Additional Technology <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in good faith. In all cases, Immatics shall use reasonable efforts to
ensure that [***]. Without limiting the foregoing, Immatics shall use reasonable efforts to include in any Immatics New BMS Product Specific Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and Immatics New Additional
Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement a provision such that [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If Immatics (or its
Affiliate) enters into an Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then Immatics shall (x)&nbsp;promptly (but in all cases within [***] after entering into such license) notify BMS thereof in writing
(including providing BMS a true, correct and complete copy of the Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement) and (y)&nbsp;at the request of BMS, engage in good faith discussions with BMS in order to allow
BMS to determine whether BMS desires to include the New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology within the Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Immatics Licensed Patents, as
applicable. If BMS notifies Immatics in writing that it desires to include the New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology within the Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Immatics
Licensed Patents, as applicable, then (i)&nbsp;such New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology will be included as Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Immatics Licensed Patents,
as applicable, hereunder and shall be subject to the terms of this Agreement and (ii)&nbsp;any upfront payments, milestone payments and royalty payments payable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to a Third Party under such Immatics New Reimbursable
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (that arise specifically for the use of such New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology) that are [***] shall be reimbursable by BMS to Immatics to the
extent actually paid by Immatics to such Third Party; provided that, (A)&nbsp;the [***] and (B)&nbsp;if any such payments are [***]. Immatics shall invoice BMS for the applicable amount after payment thereof by Immatics, and BMS shall reimburse
Immatics therefor within [***] after receipt of the invoice therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If Immatics enters into an Immatics New Reimbursable <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement for any New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology, but BMS does not notify Immatics in writing that it desires to include the New Reimbursable <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> Technology within the Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Immatics Licensed Patents, as applicable, then (i)&nbsp;such New Reimbursable
<FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology shall not be included within the Immatics Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or Immatics Licensed Patents hereunder (and Immatics shall not use any such New
Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology in the conduct of the Research Programs hereunder) and (ii)&nbsp;BMS shall not be responsible for (and Immatics shall be solely responsible for) any payments under such
Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the foregoing or anything to
the contrary contained herein, BMS (or its Affiliate) shall have the right, in its discretion, to obtain a license directly from the applicable Third Party to use any New Reimbursable <FONT STYLE="white-space:nowrap">In-Licensed</FONT> Technology
for any purpose (including to Develop, Manufacture or Commercialize any BMS TCRs, BMS CARs and BMS Products), even if Immatics has entered into an Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement with respect
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Additional Payment Terms</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.1 <U>Currency</U>. All payments hereunder shall be made in U.S. Dollars by wire transfer to a bank designated in writing by the Party
receiving such payment. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with Accounting Standards and the paying Party&#146;s normal practices used to prepare its audited financial statements for
internal and external reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.2 <U>Taxes; Withholding</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Generally</U>. Except as set otherwise set forth herein, each Party will pay any and all income taxes levied on account of all
payments it receives under this Agreement except as otherwise provided in this Section&nbsp;6.6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Tax Withholding</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) Each Party shall [***] such taxes as are required to be deducted or withheld therefrom under any provision of Applicable Law. The Party
that is required to make such withholding (the &#147;<B>Paying Party</B>&#148;) will (i) [***], (ii) [***], and (iii) [***] to the other Party (the &#147;<B>Payee Party</B>&#148;) on a timely basis following that tax payment. Notwithstanding the
foregoing, the Parties acknowledge and agree that [***]. Each Party agrees to reasonably cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is in effect
to ensure that any amounts required to be withheld pursuant to this Section&nbsp;6.6.2(b) are reduced in amount to the fullest extent permitted by Applicable Law. [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) If at any time, the Immatics Licensed IP includes intellectual
property that is registered in a German public book or register, (but for the avoidance of doubt not Immatics GmbH) then Immatics shall obtain and provide BMS with a valid certificate issued by the applicable German Tax Authorities establishing
Immatics&#146; exemption from German withholding tax (the &#147;<B>Immatics</B> <B>German Exemption Certificate</B>&#148;). Intellectual property should be considered registered as soon as the application is filed (even if it is not yet granted) and
intellectual property should be considered registered in Germany if it has been filed with the German or EU office (in the case of patents, the German Patent and Trademark Office (Deutsches <FONT STYLE="white-space:nowrap">Patent-und</FONT>
Markenamt) or the European Patent and Trademark Office under the European Patent Convention). If any payment is due to Immatics hereunder with respect to such Immatics Licensed IP and, at the time such payment is to be made, Immatics is not in
possession of a valid and effective Immatics German Exemption Certificate, BMS shall inform Immatics and Immatics may elect to either have (i)&nbsp;BMS reasonably delay making such payment until such time as BMS receives such an Immatics German
Exemption Certificate or (ii)&nbsp;BMS shall withhold such amounts from such payment as determined by BMS. If BMS withholds any amount under (ii)&nbsp;above, BMS shall remit such withheld amount to the applicable German Tax Authorities and provide
Immatics with reasonable evidence of such payment. The Parties hereby consent that either Party is permitted to submit and disclose this Agreement to the German tax authorities for the purpose of applying for a certificate of exemption from German
withholding tax. For the upfront payment made by BMS to Immatics, BMS may refrain from exercising its rights under the previous section if and to the extent Immatics provides BMS with reasonable evidence that Immatics applied for exemption of such
payments under the procedure provided for in the circular issued by the German Federal Ministry of Finance on [***] and that Immatics qualifies for such exemption. Immatics shall indemnify BMS for and against any and all German taxes and related
expenses resulting from such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Tax Documentation</U>. Immatics has provided a properly completed and duly executed IRS
Form <FONT STYLE="white-space:nowrap">W-9</FONT> (or other applicable form) to BMS. BMS is classified as an entity disregarded as separate from its owner for U.S. federal income tax purposes. BMS is wholly owned by Celgene Omicron Holdings Inc,
which is classified as a C corporation for United States federal income tax purposes and is a &#147;U.S. person&#148; as defined in Section&nbsp;7701(a)(30) of the IRC. On or prior to the Effective Date, BMS shall provide to Immatics a properly
completed and duly executed IRS Form <FONT STYLE="white-space:nowrap">W-9.</FONT> Prior to the receipt of any payment under this Agreement, Immatics (and any other recipient of payments by BMS under this Agreement) shall, to the extent it is legally
permitted to, provide to BMS, at the time or times reasonably requested by BMS or as required by Applicable Law, such properly completed and duly executed documentation (for example, IRS Forms <FONT STYLE="white-space:nowrap">W-8</FONT> or <FONT
STYLE="white-space:nowrap">W-9</FONT> or foreign equivalents) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes. Within [***] after the Effective Date, BMS shall apply for (and, if
obtained, deliver to Immatics) a valid certificate issued by the applicable German Tax Authorities establishing BMS&#146; exemption from German withholding tax (the &#147;<B>BMS German Exemption Certificate</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Indirect Taxes</U>. Notwithstanding anything to the contrary in
this Agreement, with respect to any transfer, documentary, sales, use, stamp, registration, VAT, goods and services tax or other similar tax (each an &#147;<B>Indirect Tax</B>&#148;) that is imposed under Applicable Law (and subject to an invoice in
compliance with Applicable Law) with respect to the transactions, payments or the related transfer of rights or other property pursuant to the terms of this Agreement shall be borne by the Paying Party. Notwithstanding anything to the contrary
herein, if such Indirect Tax arises solely as a result of any action taken by the Paying Party or its Affiliate or Sublicensee or successor or assignee after the Effective Date, including an assignment of this Agreement as permitted under
Section&nbsp;12.4, a change in the tax residency of the Paying Party or the payments arise or are deemed to arise through a breach by the Paying Party, then Paying Party shall timely pay and be responsible for (and indemnify the Payee Party for) any
such Indirect Tax. If the Payee Party pays any such Indirect Taxes, at the Payee Party&#146;s election, the Paying Party shall, promptly reimburse the Payee Party for such Indirect Taxes including all reasonable related costs, or, credit such
amounts to the Payee Party against future payments. If the Indirect Taxes originally paid or otherwise borne by the Paying Party are in whole or in part subsequently determined not to have been chargeable, all reasonably necessary steps will be
taken by the Payee Party to obtain a refund of those undue Indirect Taxes from the applicable governmental authority and any amount of undue Indirect Taxes repaid by such authorities to the Payee Party will be transferred to the Paying Party within
[***] of receipt. The Parties shall cooperate in good faith to insure the correct Indirect Taxes are charged and corresponding tax returns are filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Foreign Derived Intangible Income</U>. Each Party shall use commercially reasonable efforts to provide, and to cause its Affiliates,
subcontractors, Sublicensees, customers and applicable Third Parties to provide, any information and documentation reasonably requested by the other Party to obtain the benefits of Section&nbsp;250 of the IRC and the applicable Treasury Regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.3 <U>Late Payments</U>. Any undisputed amount required to be paid by a Party hereunder that is not paid on the date due will accrue
interest at an annual rate of [***] ([***]%) percentage point above the prime rate as published by Citibank, N.A., New York, New York, or any successor thereto, at 12:01 a.m. on the first day of each [***] in which such undisputed payments are
overdue, (or the maximum legal interest rate allowed by Applicable Law, if less) from and after such date (or from and after the date the dispute is resolved, if later) calculated on the number of days such payment is late. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Records Retention; Review</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.1 <U>Records</U>. With respect to royalty payments to be made under Section&nbsp;6.3 of this Agreement by either Party, and also with
respect to Eligible Research Costs to be reimbursed to Immatics under Section&nbsp;6.2, such Party agrees to keep and shall procure that its Affiliates keep, for at least [***] to which they pertain, complete and accurate records of sales by, or
costs incurred by, such Party or its Affiliates (including sales by Sublicensees), as the case may be, of each Collaboration Product for which royalty payments by such Party or Eligible Research Costs to such Party are to be made, in sufficient
detail to allow the accuracy of such payments made hereunder to be confirmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.2 <U>Review</U>. Subject to the other terms of this
Section&nbsp;6.7.2, during the Term, at the request of each Party (the &#147;<B>Auditing Party</B>&#148;), which shall not be made more frequently than [***] by the Auditing Party (except for audits pursuant to Section&nbsp;6.2.3 or
Section&nbsp;3.1.4(d), which shall not count towards such [***]), upon at least [***] prior written notice from the Auditing Party, and at the expense of the Auditing Party, the other Party (the &#147;<B>Audited Party</B>&#148;) shall permit an
independent, nationally-recognized certified public accountant selected by the Auditing Party and reasonably acceptable to the Audited Party to inspect (during regular business hours) the relevant records required to be maintained by the Audited
Party under Section&nbsp;6.7.1; provided that such audit right shall not apply to records [***] to which they pertain. In every case, any such accountant must have previously entered into a confidentiality agreement with both Parties having
confidentiality obligations and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations no less restrictive than those set forth in Article 8 and limiting the disclosure and use of such information by such accountant to authorized
representatives of the Parties and the purposes germane to Section&nbsp;6.7.1. Results of any such review shall be binding on both Parties absent manifest error. Such accountant shall report to the Auditing Party only whether the particular amount
being audited was accurate, and if not, the amount of any discrepancy, and such accountant shall not report any other information to the Auditing Party. The Auditing Party shall treat the results of any such accountant&#146;s review of the Audited
Party&#146;s records as Confidential Information of the Audited Party subject to the terms of Article 8. If any review reveals a deficiency or overpayment in the calculation or payment of royalties by the Audited Party or a deficiency or overpayment
in the calculation of Eligible Research Costs to Immatics, then (a)&nbsp;the Audited Party or the Auditing Party, as applicable, shall promptly pay (or refund, as applicable) the other Party the amount of such deficiency or overpayment, as
applicable, and (b)&nbsp;in the case of a deficiency in royalties or an overpayment in Eligible Research Costs, as applicable, if such deficiency or overpayment is by more than the greater of (i) [***] or (ii) [***], the Audited Party shall, within
[***] after receipt of an invoice therefor, pay the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses incurred by the Auditing Party for such independent accountant in
connection with the review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.3 <U>Records Final</U>. Upon the expiration of [***], subject and without prejudice to the determination
of any review commenced prior to such [***] pursuant to Section&nbsp;6.7.2, the calculation of royalties and Eligible Research Costs payable with respect to such Calendar Year shall be binding and conclusive upon the Parties, and the Party with
respect to which such royalty payments or Eligible Research Costs were payable (and its Affiliates) shall be released from any liability or accountability with respect to such royalties or Eligible Research Costs for such Calendar Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Immatics Third Party Agreements</U>. Except with respect to the reimbursement of payments by BMS as expressly set forth in, and in
accordance with, Section&nbsp;6.5.2 and 6.5.3, Immatics shall be solely responsible for all costs and payments of any kind (including all upfront fees, annual payments, milestone payments and royalty payments) arising under any agreements between
Immatics (or any of its Affiliates) and a Third Party, which costs or payments arise in connection with, or as a result of, entering into this Agreement or any of the activities hereunder, including [***]. Notwithstanding anything to the contrary
contained herein, Immatics shall be solely responsible for (and BMS shall not be responsible for, and shall not be required to reimburse Immatics for) any and all amounts payable to a Third Party under any Immatics In License Agreement that
constitutes a share of sublicensee revenue (e.g., a share of any amount paid by BMS (or its Affiliate) to Immatics (or its Affiliate) pursuant to this Agreement, including a share of any upfront payments, milestone payments or royalty payments),
including any Third Party Claims and Third Party Damages in connection therewith.<B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>[***]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Additional Provisions</U>. Notwithstanding anything to the contrary herein, the terms and provisions of this Article 6 are subject to
Sections 11.7 and 11.9 of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES; INTELLECTUAL PROPERTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Licenses and Grants to BMS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.1 Subject to the terms and conditions of this Agreement, Immatics hereby grants to BMS an exclusive (even as to Immatics, except as set
forth in the last sentence of Section&nbsp;7.4) right and license, with the right to grant sublicenses (through multiple tiers) in accordance with Section&nbsp;7.3, under the Immatics Licensed IP to research, develop (including Develop), make
(including Manufacture), have made (including have Manufactured), use, offer for sale, sell, import, Commercialize and otherwise exploit BMS Products (including the BMS TCRs and BMS CARs for use in, but not separately from, BMS Products) in the
Field in the Territory. For clarity, until such time that BMS becomes a sublicensee under an Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement pursuant to Section&nbsp;7.5.1, any Patents and <FONT
STYLE="white-space:nowrap">Know-How</FONT> Controlled by Immatics under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall not be included in the Immatics Licensed IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.2 Subject to the terms and conditions of this Agreement, Immatics hereby grants to BMS a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> worldwide right and license, with the right to grant sublicenses (through multiple tiers), under
(a)&nbsp;any Immatics Sole Inventions that were created, conceived, discovered, generated, invented, made or reduced to practice by or on behalf of BMS (or its Affiliates) or jointly by or on behalf of the Parties (or their respective Affiliates)
and assigned to Immatics pursuant to Section&nbsp;7.8.4 and (b)&nbsp;any Immatics Sole Patents that claim such Immatics Sole Inventions in the foregoing clause (a), in each case, of (a)&nbsp;and (b), for any and all uses and purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Licenses and Grants to Immatics</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.1 Subject to the terms and conditions of this Agreement, BMS hereby grants to Immatics a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> right and license, with the right to grant sublicenses (through multiple tiers) in accordance with Section&nbsp;7.3, under (a)&nbsp;the BMS Contributed Collaboration Technology and the BMS Sole
Inventions set forth in Section&nbsp;1.25(b)(i) and (iii)&nbsp;and Section&nbsp;1.25(c) (and BMS Sole Patents claiming such BMS Sole Inventions) to conduct, during the Research Term, the Development activities for the Initial BMS Products under the
Research Program (in accordance with this Agreement) that are expressly delegated to Immatics as set forth in the applicable Research Plan and (b)&nbsp;on an Immatics
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product basis, the BMS Licensed IP to research, develop (including Develop), make (including Manufacture), have made (including have Manufactured),
use, offer for sale, sell, import, Commercialize and otherwise exploit the applicable Immatics Products (including the applicable Immatics TCRs for use in, but not separately from, Immatics Products) in the Field in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.2 Subject to the terms and conditions of this Agreement, BMS hereby
grants to Immatics a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> worldwide right and license, with the right to grant sublicenses (through
multiple tiers), under (a)&nbsp;BMS Sole Inventions that are improvements, modifications or enhancements specifically to particular transferred Immatics Platform Technology (but expressly excluding any
<FONT STYLE="white-space:nowrap">Non-Platform</FONT> Technology) that are conceived, discovered, generated, invented, made or reduced to practice by or on behalf of BMS (or its Affiliates) [***], (b) BMS Sole Inventions under Section&nbsp;1.25(d)
(but excluding, for clarity, [***]) that [***] (c) BMS Sole Inventions under Section&nbsp;1.25(a) (but excluding, for clarity, [***], and (d)&nbsp;any BMS Sole Patents that claim such BMS Sole Inventions in the foregoing clauses (a)&nbsp;to (c) but
solely to the extent [***]. For clarity, [***].<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Sublicensing</U>. Each Party shall have the right to grant sublicenses,
through multiple tiers of sublicensees, under the licenses granted to it in Section&nbsp;7.1.1 and Section&nbsp;7.2.1, as applicable, to its Affiliates and other Persons in connection with the Development, Manufacture or Commercialization of BMS
Products (or the BMS Receptors therein) (in the case of BMS) and Immatics Products (or the Immatics TCR therein) (in the case of Immatics); <I>provided </I>that (a)&nbsp;any such sublicenses shall be consistent with the terms and conditions of this
Agreement, and (b)&nbsp;with respect to a sublicense of the licenses granted to Immatics under Section&nbsp;7.2.1(a), [***] the Research Plan. Promptly following the execution of (a)&nbsp;any sublicense by BMS (or its Affiliate) of the licenses
granted to BMS in Section&nbsp;7.1.1, which sublicense grants Commercialization rights for a BMS Product to a Third Party in a Major Market country in the Territory (but excluding agreements with any distributors, contract sales forces or other
subcontractors, even if such agreements contain a sublicense), or (b)&nbsp;any sublicense by Immatics (or its Affiliate) of either (i)&nbsp;the licenses granted to Immatics in Section&nbsp;7.2.1(b), which sublicense grants Commercialization rights
for an Immatics Product to a Third Party in a Major Market country in the Territory (but excluding agreements with any distributors, contract sales forces or other subcontractors, even if such agreements contain a sublicense) or (ii)&nbsp;the
licenses granted to Immatics in Section&nbsp;7.2.1(a), in each case, BMS or Immatics, as applicable, shall provide the other Party with a true and complete copy of such sublicense agreement; provided that such sublicense may be redacted to the
extent not related to BMS Products or Immatics Products, as applicable, or not necessary to determine whether the sublicense is consistent with the terms and conditions of this Agreement. Each Party shall remain responsible and liable for its
Sublicensee&#146;s compliance with the applicable terms and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Rights Retained by the Parties</U>. For
clarity, each Party retains all rights under <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents Controlled by such Party not expressly granted to the other Party pursuant to this Agreement. In addition, Immatics retains the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right under the Immatics Licensed IP to perform the research activities allocated to it under a Research Program in accordance with this Agreement and the applicable Research Plan and its Manufacturing
obligations for BMS as specifically set forth in Section&nbsp;3.3.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <U>Existing Immatics
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5.1 BMS acknowledges that it has received from Immatics a copy of
each Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement pursuant to that letter dated [***]. During the Term, on an Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Agreement-by-Existing</FONT></FONT> Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement basis, BMS, in its sole discretion upon written notice to Immatics, may elect to become a sublicensee of Immatics
under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, subject to, with respect to the Second Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, Immatics obtaining the required consent
to sublicense as set forth in Section&nbsp;7.5.2. Following Immatics&#146; receipt of such notice, BMS shall thereafter become a sublicensee under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and the Patents
and <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by Immatics under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be Immatics Licensed IP licensed to BMS under Section&nbsp;7.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5.2 Immatics represents and warrants to BMS that with respect to the Second Existing Immatics
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, there are no additional consents needed from any Third Party for BMS to become a sublicensee with respect to the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> thereunder
other than the consent of [***]. With respect to the Second Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, Immatics shall use Commercially Reasonably Efforts to obtain the consent of [***], within [***] after BMS
requests that Immatics obtain such consent, in order for BMS to be able to obtain a sublicense of the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> under the Second Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement, and Immatics shall promptly notify BMS in writing once such consent has been obtained. In all cases, Immatics shall not use any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under a given Existing Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement in the performance of the Research Program unless and until (i)&nbsp;the Parties have agreed to <U>Schedule 9.5.3</U> with respect to such Existing Immatics
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and (ii)&nbsp;BMS becomes a sublicensee under the applicable Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in accordance with Section&nbsp;7.5.1.
Notwithstanding the foregoing, in the event that BMS is not a sublicensee under a given Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement by the time Immatics will be required to use the Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in the Research Program, then (i)&nbsp;Immatics shall provide written notice thereof to BMS and BMS may promptly
thereafter provide notice to Immatics in accordance with Section&nbsp;7.5.1 to become a sublicensee under such Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement or (ii)&nbsp;if BMS declines to become a sublicensee, then
the JSC shall discuss and approve alternatives to continue the Research Programs and the Research Plans shall be amended for such alternative; provided that (x)&nbsp;any alternative shall not increase the activities to be performed by Immatics under
the Research Program without an increase in the Research Budget for such activities as set forth in Section&nbsp;2.1.2(b) or, unless otherwise agreed to by Immatics, require Immatics to obtain a license to any additional Third Party intellectual
property in lieu thereof and (y)&nbsp;Immatics shall not be in breach of this Agreement for any delay in its performance under the Research Program due to (A)&nbsp;BMS&#146; election not to obtain any such sublicense or (B)&nbsp;the selection and
implementation of any such alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <U>No Implied Licenses</U>. Except as explicitly set forth in this Agreement, neither Party
shall be deemed by estoppel or implication to have granted to the other Party any license or other right to any intellectual property of such Party. For clarity, Immatics is not granting BMS any rights to practice or otherwise use any Immatics
Licensed IP other than as set forth in this Agreement, including the licenses granted in Section&nbsp;7.1, and BMS is not granting Immatics any rights to practice or otherwise use any BMS Contributed Collaboration Technology or BMS Licensed IP other
than as set forth in this Agreement, including the licenses granted in Section&nbsp;7.2. For the avoidance of doubt, nothing in this Agreement is intended to limit any licenses or rights granted to BMS under the 2019 Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <U>Insolvency</U>. If this Agreement is terminated due to the
rejection of this Agreement by or on behalf of either Party due to an Insolvency Event of such Party (the &#147;<B>Rejecting Party</B>&#148;), all licenses and rights to licenses granted under or pursuant to this Agreement by the Rejecting Party to
the other Party are and shall otherwise be deemed to be licenses of rights to &#147;intellectual property&#148; (including for purposes of Section&nbsp;365(n) of Title 11 of the United States Bankruptcy Code and other similar laws in any other
jurisdiction). The Parties agree that the other Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under any applicable insolvency statute, and that upon commencement of an
Insolvency Event by or against the Rejecting Party, the other Party shall be entitled to a complete duplicate of or complete access to (as the other Party deems appropriate), any such intellectual property and all embodiments of such intellectual
property. Such intellectual property and all embodiments thereof shall be promptly delivered to the other Party (a)&nbsp;upon any such commencement of a bankruptcy proceeding (or other Insolvency Event) upon written request therefor by the other
Party, unless the Rejecting Party elects to continue to perform all of its obligations under this Agreement or (b)&nbsp;if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the Rejecting Party,
then upon written request therefor by the other Party. The provisions of this Section&nbsp;7.7 shall be (i)&nbsp;without prejudice to any rights the other Party may have arising under any applicable insolvency statute or other Applicable Law and
(ii)&nbsp;effective only to the extent permitted by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 <U>Ownership</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.1 <U>Disclosure and Inventorship</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Disclosure</U>. Each Party will disclose to the other Party (through the IPC) all Inventions created, conceived, discovered,
generated, invented, made or reduced to practice hereunder (provided that BMS shall not be required to disclose any BMS Sole Inventions to Immatics other than those BMS Sole Inventions licensed to Immatics under Section&nbsp;7.2), whether solely or
jointly by or on behalf of such Party or its Affiliates, and such disclosure shall be made promptly and in any event reasonably prior to the filing of any patent application with respect to such Invention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Inventorship</U>. Notwithstanding the provisions of Section&nbsp;12.7.1, inventorship of
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents shall be determined by application of U.S. patent law pertaining to inventorship, and, except as provided for in Sections 7.8.2, 7.8.3, and 7.8.4, ownership of <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Patents shall be determined by inventorship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.2 <U>Ownership of Immatics Licensed IP,
BMS Contributed Collaboration Technology and BMS Licensed IP</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Immatics</U>. Subject to Section&nbsp;7.8.3 with respect to
Joint IP, as between the Parties (including their respective Affiliates), Immatics will retain all right, title and interest in and to all Immatics Licensed IP, except to the extent that any such rights are licensed or granted to BMS under this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>BMS</U>. Subject to Section&nbsp;7.8.3 with respect to Joint IP,
as between the Parties (including their respective Affiliates), BMS (or its Affiliate) will retain all right, title and interest in and to all BMS Contributed Collaboration Technology and all BMS Licensed IP, except to the extent that any such
rights are licensed or granted to Immatics under this Agreement. Notwithstanding anything to the contrary contained herein, as between the Parties, BMS shall have the sole rights (in its discretion and without consultation with, or any obligations
to, Immatics) to Prosecute and Maintain the BMS Contributed Collaboration Technology and BMS Licensed IP, to bring any enforcement action with respect to infringement or misappropriation of any BMS Contributed Collaboration Technology and any BMS
Licensed IP (including retaining all recoveries in connection therewith), and to seek and obtain patent term restoration or supplemental protection certificates or the like or their equivalents to BMS Contributed Collaboration Technology and BMS
Licensed Patents, in each case at its sole cost and expense, and Immatics shall have no rights in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.3 <U>Joint
IP</U>. Notwithstanding the provisions of Section&nbsp;7.8.2, the Parties (or their respective Affiliates) shall each own an equal, undivided interest in (a)&nbsp;any and all Joint Inventions and (b)&nbsp;any Joint Patents. Each Party shall, and
shall cause its Affiliates to, assign, and hereby assigns, to the other Party, a joint equal and undivided interest in and to such Joint IP (provided, however, that, for clarity, [***]), and at the request of a Party, the other Party will execute
such documents (including any necessary assignments) to effect such joint ownership of such Joint IP. For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Patent to practice such Joint Invention or
Joint Patent in such countries, (A)&nbsp;BMS hereby grants to Immatics a perpetual, irrevocable, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license, with the
right to grant sublicenses through multiple tiers, under BMS&#146; right, title and interest in and to all Joint Inventions and Joint Patents to use such Joint Inventions and Joint Patents subject to the terms and conditions of this Agreement, and
(B)&nbsp;Immatics hereby grants to BMS a perpetual, irrevocable, nonexclusive, worldwide, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license, with the right to grant sublicenses through multiple tiers, under Immatics&#146;
right, title and interest in and to all Joint Inventions and Joint Patents to use such Joint Inventions and Joint Patents subject to the terms and conditions of this Agreement. Each Party (or its Affiliate) shall have the right to disclose (in
accordance with Article 8) and exploit (including granting licenses to Third Parties) the Joint IP without a duty of seeking consent or accounting to the other Party; provided that, with respect to Immatics, such rights shall be subject to the
rights and licenses granted to BMS hereunder (including the obligations of Immatics as set forth in Article 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.4 <U>Sole
Inventions</U>. As between the Parties (including their respective Affiliates), (a) BMS (or its Affiliate) shall own all right, title and interest in and to the BMS Sole Inventions and BMS Sole Patents and (b)&nbsp;Immatics (or its Affiliate) shall
own all right, title and interest in and to the Immatics Sole Inventions and Immatics Sole Patents. In furtherance of the foregoing, (i)&nbsp;Immatics shall assign, and hereby assigns, to BMS, the BMS Sole Inventions and BMS Sole Patents, and all
intellectual property rights therein (provided that if such assignment is prohibited by Applicable Law, then Immatics shall grant, and hereby does grant, to BMS, a perpetual, irrevocable, exclusive, worldwide, royalty-free, fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> license, with the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">grant sublicenses through multiple tiers, under such BMS Sole Inventions and BMS Sole
Patents), and (ii)&nbsp;BMS shall assign, and hereby assigns, to Immatics, the Immatics Sole Inventions and Immatics Sole Patents, and intellectual property rights therein (provided that if such assignment is prohibited by Applicable Law, then BMS
shall grant, and hereby does grant, to Immatics, a perpetual, irrevocable, exclusive, worldwide, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license, with the right to grant sublicenses through multiple tiers, under such
Immatics Sole Inventions and Immatics Sole Patents), and at the request of a Party, the other Party will execute such documents (including any necessary assignments) to effect such ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.5 <U>Further Actions</U>. Each Party shall cause its and its Affiliates&#146; employees, consultants, sublicensees, agents and contractors
to assign to Immatics or BMS (or BMS&#146; designated Affiliate), as applicable, such Person&#146;s right, title and interest in and to any and all Joint Inventions, Joint Patents, BMS Sole Inventions, BMS Sole Patents, Immatics Sole Inventions and
Immatics Sole Patents, and intellectual property rights therein, as is necessary to effect the intent of this Section&nbsp;7.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9
<U>Patent Liaisons and Intellectual Property Committee</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.1 <U>Patent Liaisons</U>. Promptly after the Effective Date, each Party
shall appoint an individual to act as a patent liaison for such Party (each, a &#147;<B>Patent Liaison</B>&#148;). The Patent Liaisons (through the IPC) shall be the primary point of contact for the Parties regarding intellectual property-related
activities and matters contemplated by this Agreement and shall facilitate all such activities and matters hereunder. The name and contact information for each Party&#146;s Patent Liaison, as well as any replacement(s) chosen by such Party, in its
sole discretion, from time to time, shall be promptly provided to the other Party in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.2 <U>Intellectual Property
Committee</U>. Within [***] after the Effective Date, the Parties shall establish an intellectual property committee (the &#147;<B>IPC</B>&#148;) to facilitate cooperation between the Parties with respect to intellectual property matters under this
Agreement. The IPC shall serve as a forum to discuss material issues relating to the intellectual property that is the subject of this Agreement, including to coordinate the respective patent strategies of the Parties relating to the Immatics
Patents under this Agreement; provided that the rights and responsibilities (including decision making authority) delegated to each of the Parties with respect to the preparation, filing, prosecution and maintenance (including with respect to any
patent term extensions and patent listings), enforcement and defense (including with respect to retaining recoveries) of such intellectual property shall be as set forth in the remaining provisions of this Article 7 and the IPC shall not have the
right to exercise or amend such rights and responsibilities. [***]. If the IPC unanimously agrees [***]. In addition, if either Party becomes aware of any Third Party intellectual property that may be necessary to use any intellectual property
licensed under any Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then such Party shall promptly notify the Patent Liaison of the other Party for discussion of such matter at the IPC. The IPC shall not be a Subcommittee of
the JSC and, except for unanimous agreement to [***] as set forth in this Section&nbsp;7.9.2, shall have no decision making authority, but rather shall be a forum for discussion. The Patent Liaison of each Party shall serve as such Party&#146;s
representative to the IPC, which representative shall be duly authorized by each Party to carry out the activities given to them under this Agreement. The IPC shall meet either in person or telephonically on such dates and at such places and times
as the IPC shall agree. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 <U>Prosecution and Maintenance of Immatics Patents and Joint
Patents</U>. Following the Effective Date, the provisions of this Section&nbsp;7.10 shall apply with respect to the Immatics Patents and Joint Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.1 <U>Immatics Patents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>[***] First Right</U>. Subject to Section&nbsp;7.10.2, [***] shall have the first right (but not the obligation) to Prosecute and
Maintain the Immatics Patents (other than the Immatics-Owned BMS Product Specific Patents and Joint Patents) at [***] sole cost and expense and using patent counsel of [***] choosing. [***] shall keep [***] informed as to material developments with
respect to the Prosecution and Maintenance of such Patents including by providing copies of all substantive office actions, examination reports, communications or any other substantive documents to or from any patent office, including notice of all
interferences, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> inter partes reviews, derivations, post grant proceedings or oppositions. [***] shall also provide [***] with a reasonable opportunity to comment substantively on the
Prosecution and Maintenance of such Immatics Patents prior to taking material actions (including the filing of initial applications) and will in good faith consider any comments made by and actions recommended by [***] (provided, however, that [***]
does so consistent with any applicable filing deadlines); provided however, that [***] shall have the final decision making authority in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>[***] <FONT STYLE="white-space:nowrap">Back-Up</FONT> Right</U>. If [***] in any country intends to allow any Immatics Patent for
which [***] has the first right to Prosecute and Maintain pursuant to Section&nbsp;7.10.1(a) to lapse or become abandoned without having first filed a substitute, or decides not to participate in any interferences, reissues, <FONT
STYLE="white-space:nowrap">re-examinations,</FONT> inter partes reviews, derivations, post grant proceedings or oppositions with respect to any such Patent, it shall notify and consult with [***] of such decision or intention at least [***] prior to
the date upon which such Patent shall lapse or become abandoned, and, if after such consultation between the Parties, [***] still intends to allow such Immatics Patent to lapse or become abandoned, [***] shall thereupon have the right (but not the
obligation) to assume the Prosecution and Maintenance thereof at [***] expense with counsel of its choice. The foregoing shall not apply where, with reference to a specific Patent family, [***], in its reasonable determination, decides not to file a
continuing application in a particular country due to the existence of one or more pending Patents in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.2
<U>Immatics-Owned BMS Product Specific Patents and Joint Patents</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>[***] First Right</U>. Notwithstanding the provisions of
Section&nbsp;7.10.1, [***] shall have the first right (but not the obligation) to Prosecute and Maintain the Immatics-Owned BMS Product Specific Patents and Joint Patents at [***] sole cost and expense and using patent counsel of [***] choosing (or,
alternatively, [***] may in good faith direct [***] to Prosecute and Maintain one or more such Patents in one or more countries using patent counsel acceptable to [***] and shall reimburse [***] for its reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs in connection therewith). [***] shall keep [***] informed as to material developments with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prosecution and Maintenance of such Patents including by providing copies of all
substantive office actions, examination reports, communications or any other substantive documents to or from any patent office, including notice of all interferences, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> inter partes
reviews, derivations, post grant proceedings or oppositions. [***] shall also provide [***] with a reasonable opportunity to comment substantively on the Prosecution and Maintenance of such Patents prior to taking material actions (including the
filing of initial applications) and will in good faith consider any comments made by and actions recommended by [***] (provided, however, that [***] does so consistent with any applicable filing deadlines); provided however, that [***] shall have
the final decision making authority in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>[***] <FONT STYLE="white-space:nowrap">Back-Up</FONT> Right</U>. If
[***] in any country (other than [***]) intends to allow an Immatics-Owned BMS Product Specific Patent or Joint Patent, as applicable, to lapse or become abandoned without having first filed a substitute, or decides not to participate in any
interferences, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> inter partes reviews, derivations, post grant proceedings or oppositions with respect to an Immatics-Owned BMS Product Specific Patent or Joint Patent, as applicable,
it shall notify and consult with [***] of such decision or intention at least [***] prior to the date upon which such Patent shall lapse or become abandoned, and, if after such consultation between the Parties, [***] still intends to allow such
Patent to lapse or become abandoned, [***] shall thereupon have the right (but not the obligation) to assume the Prosecution and Maintenance thereof at [***] expense with counsel of its choice. The foregoing shall not apply where, with reference to
a specific Patent family, [***], in its reasonable determination, decides not to file a continuing application in a particular country due to the existence of one or more pending Patents in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.3 <U>Cooperation in Prosecution and Maintenance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Assistance</U>. The Parties shall reasonably cooperate with one another with respect to the Prosecution and Maintenance of the
Immatics Patents and Joint Patents for which either Party is responsible for Prosecution and Maintenance pursuant to this Section&nbsp;7.10. At [***] request, the Parties shall cooperate with one another to file and prosecute continuing Patents with
respect to Immatics Patents or Joint Patents, as applicable, in each case that are applicable to a BMS Target or a BMS TCR, BMS CAR or BMS Product, as applicable, if practicable to divide subject matter into different Patents primarily relating to:
(i)&nbsp;one or more BMS TCRs or BMS CARs, on the one hand, and other subject matter, on the other hand, (ii)&nbsp;one or more BMS Products, on the one hand, and other subject matter, on the other hand, or (iii)&nbsp;one or more BMS Targets, on the
one hand, and other subject matter, on the other hand, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Further Assurances</U>. If [***] determines to undertake
the Prosecution and Maintenance of an Immatics Patent or Joint Patent, as applicable, in accordance with this Section&nbsp;7.10, then [***] agrees to make its employees, agents and consultants reasonably available to [***] (and to [***] authorized
attorneys, agents or representatives) to enable [***] to undertake such Prosecution and Maintenance. In addition, [***] shall (and shall cause its Affiliates and its and their employees, agents and consultants to) provide reasonable assistance to
[***] (and to [***] authorized attorneys, agents or representatives) to enable [***] to undertake such Prosecution and Maintenance, including by executing powers of attorney and other documents for [***] to undertake such Prosecution and
Maintenance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Separation of Claims</U>. With respect to BMS Sole Patents,
Immatics Sole Patents and Joint Patents, unless otherwise agreed to by the Parties in writing, the Parties will work to Prosecute and Maintain such Patents such that (i)&nbsp;the claims within the Joint Patents claim Joint Inventions, but do not
also claim Immatics Sole Inventions or BMS Sole Inventions, (ii)&nbsp;the claims within the Immatics Sole Patents claim Immatics Sole Inventions, but do not also claim Joint Inventions or BMS Sole Inventions, (iii)&nbsp;the claims within the BMS
Sole Patents claim BMS Sole Inventions, but do not also claim Joint Inventions or Immatics Sole Inventions, and (iv)&nbsp;the claims within the Immatics Platform Patents claim solely Immatics Platform Technology. In addition, at the request of
[***], [***] shall use reasonable efforts to divide out the subject matter of any Immatics Patents (including by filing divisionals of the applicable Immatics Patent) such that (x)&nbsp;such Immatics Patent will be an Immatics-Owned BMS Product
Specific Patent or (y)&nbsp;such Immatics Patent will be an Immatics Platform Patent, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.4 <U>Costs of Prosecution and
Maintenance</U>. Except as otherwise expressly set forth in this Section&nbsp;7.10.4, each Party shall be responsible for all costs and expenses associated with its Prosecution and Maintenance activities under this Section&nbsp;7.10 with respect to
Immatics Patents, Immatics-Owned BMS Product Specific Patents and Joint Patents for which it is responsible pursuant to Section&nbsp;7.10.1 or 7.10.2, as applicable. Notwithstanding the foregoing provisions of this Section&nbsp;7.10.4, BMS will not
be responsible for any Prosecution and Maintenance costs associated with any subject matter divided out of such Patents that is not licensed to BMS (and Immatics shall reimburse BMS for any such costs incurred by BMS or any of its Affiliates for
dividing out such Patents). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 <U>Enforcement of Immatics Patents and Joint Patents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.1 <U>Notice</U>. If any Party learns of an infringement or misappropriation, or threatened infringement or misappropriation, by a Third
Party of (a)&nbsp;any Immatics Patent or Immatics <FONT STYLE="white-space:nowrap">Know-How,</FONT> which infringing or misappropriating activity involves the [***] any Competing Product or any other product that could be competitive [***] with any
BMS Product (including in connection with any Biosimilar Application referencing a BMS Product (regardless of whether such notice or copy is provided under any Applicable Laws), including under the BPCIA or the United States Patient Protection and
Affordable Care Act or their successor provisions, or any similar provisions in a country outside the United States, as applicable) or (b)&nbsp;any Joint Patent or Joint Invention ((a) and (b)&nbsp;individually or collectively, an
&#147;<B>Infringement</B>&#148;), such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such Infringement, and following such notification, the Parties shall confer. For clarity, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.2 <U>Enforcement of Infringements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>[***] First Right</U>. Subject to the remaining provisions of this Section&nbsp;7.11.2(a), [***] shall have the first right, but not
the obligation, to institute, prosecute, and control any action or proceeding (which may include settlement or otherwise seeking to secure the abatement of such Infringement) with respect to any Infringement (subject to, with respect to the Initial
Reimbursable Gene Editing Technology, the terms and conditions of the applicable Existing Immatics in License Agreements regarding enforcement of such Initial Reimbursable Gene Editing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Technology, as such terms and conditions are expressly set forth on <U>Schedule
9.5.3</U>) by counsel of its own choice, in [***] own name (or, if required, under [***] name) and under [***] direction and control, including the defense of declaratory judgment actions, as well as the defense of any challenges to the implicated
Patents as a counterclaim in such Infringement proceeding; provided that with respect to any Immatics Patent that is not an Immatics-Owned BMS Product Specific Patent (each, an &#147;<B>Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT>
Product Specific Patent</B>&#148;), [***] shall not have the right to so enforce such Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific Patent without the prior consent of [***]; provided further that if [***] desires to
enforce a given Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific Patent, but [***] does not grant such consent, then such Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific Patent shall thereafter no
longer be included in the definition of Valid Claim for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>[***]
<FONT STYLE="white-space:nowrap">Back-Up</FONT> Right</U>. If [***] determines not to institute an action or proceeding with respect to a given Infringement pursuant to Section&nbsp;7.11.2(a), it shall notify and consult with [***] of such decision,
and, subject to the remaining provisions of this Section&nbsp;7.11.2(b), [***] shall thereupon have the right (but not the obligation) to institute an action or proceeding with respect to such Infringement at [***] expense with counsel of its
choice; provided that with respect to an Infringement of an Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific Patent, [***] shall only have such right to institute an action or proceeding with respect to such Infringement of
such Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific Patent if [***] consented to [***] bringing such action or proceeding with respect to such Immatics <FONT STYLE="white-space:nowrap">Non-BMS</FONT> Product Specific
Patent pursuant to Section&nbsp;7.11.2(a) but [***] subsequently determined not to bring such action or proceeding pursuant to Section&nbsp;7.11.2(a) notwithstanding such consent from [***]. Notwithstanding the foregoing provisions of this
Section&nbsp;7.11.2(b), if [***] has reasonable grounds for believing that [***] exercise of its backup enforcement right as set forth in this Section&nbsp;7.11.2(b) could reasonably be [***], then [***] shall not be permitted to enforce such Patent
without the prior consent of [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.3 <U>Joinder</U>. In the case of any enforcement action or proceeding set forth in
Section&nbsp;7.11.2 controlled by [***] will (and will cause its Affiliates to) join any such action or proceeding as a party at [***] expense (and [***] will use commercially reasonable efforts to cause any Third Party as necessary to join such
action or proceeding as a party) if doing so is necessary for the purposes of establishing standing or is otherwise required by Applicable Law to pursue such action or proceeding or claim damages. [***] may, at its option, participate in such
enforcement action or proceeding at its own expense, but [***] shall still control such action or proceeding, except as expressly provided in Section&nbsp;7.11.2(b). In the case of any enforcement action or proceeding controlled by [***] pursuant to
Section&nbsp;7.11.2(b), [***] may, at its option, participate in such enforcement action or proceeding at its own expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.4
<U>Consultation; Cooperation</U>. The enforcing Party will keep the <FONT STYLE="white-space:nowrap">non-enforcing</FONT> Party regularly informed of the status and progress of such enforcement efforts with respect to any Immatics Patent or Joint
Patent, or Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT> or Joint Invention. The enforcing Party shall consult with the <FONT STYLE="white-space:nowrap">non-enforcing</FONT> Party and will take comments of the <FONT
STYLE="white-space:nowrap">non-enforcing</FONT> Party into good faith consideration with respect to the infringement or claim construction of any claim in any such Immatics Patent or Joint Patent or with respect to the misappropriation of any
Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT> or Joint Invention, as applicable; provided however, that the enforcing Party shall have the final decision making authority in connection therewith. The
<FONT STYLE="white-space:nowrap">non-enforcing</FONT> Party will provide the enforcing Party reasonable cooperation in such enforcement, at such enforcing Party&#146;s request and expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.5 <U>Settlement</U>. A settlement or consent judgment or other
voluntary final disposition of a suit with respect to an Infringement of any Immatics Patent or Joint Patent, or Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT> or Joint Invention, as applicable, under this Section&nbsp;7.11 may be entered
into without the consent of the Party not bringing suit; provided, however, that any such settlement, consent judgment or other disposition of any action or proceeding by the Party bringing suit under this Section&nbsp;7.11 shall not, without the
prior written consent of the Party not bringing suit, such consent not to be unreasonably withheld, conditioned or delayed, (a)&nbsp;impose any liability or obligation on the Party not bringing suit or any of its Affiliates, (b)&nbsp;conflict with
or reduce the scope of the subject matter claimed in the applicable Immatics Patent or Joint Patent, (c)&nbsp;in the case of Immatics as the party bringing the suit, include the grant of any license, covenant or other rights to any Third Party that
would conflict with or reduce the scope of the rights or licenses granted to BMS under this Agreement or the 2019 Agreements, or (d)&nbsp;in the case of Immatics as the party bringing the suit, otherwise adversely affect the rights granted to BMS
hereunder with respect to such Immatics Patents or Joint Patents, or Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT> or Joint Inventions, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.6 <U>Costs and Recoveries</U>. Except as otherwise set forth in this Section&nbsp;7.11, each Party shall bear all of its costs incurred
in connection with its activities under this Section&nbsp;7.11. Any damages or other monetary awards recovered in any action, suit or proceeding brought under this Section&nbsp;7.11 to the extent related to any Infringement of any Immatics Patents
or Joint Patents, or Immatics <FONT STYLE="white-space:nowrap">Know-How</FONT> or Joint Invention, as applicable, shall be shared as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***].<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.7
<U>Biosimilar Applications</U>. Notwithstanding the foregoing provisions of this Section&nbsp;7.11, if either Party receives a copy of a Biosimilar Application referencing a BMS Product, whether or not such notice or copy is provided under any
Applicable Laws (including under the BPCIA, the United States Patient Protection and Affordable Care Act, or their successor provisions, or any similar provisions in any jurisdiction outside the United States, as applicable), or otherwise becomes
aware that such a Biosimilar Application has been submitted to a Regulatory Authority for marketing authorization (such as in an instance described in 42 U.S.C. &#167; 262(l)(2)), the remainder of this Section&nbsp;7.11.7 shall apply. Such Party
shall promptly, but in any event within [***], notify the other Party of such Biosimilar Application. The owner of the relevant Patents shall then seek permission to view the Biosimilar Application, information regarding the process or processes
used to manufacture the product that is the subject of the Biosimilar Application, and related confidential information from the filer of the Biosimilar Application if necessary, under 42 U.S.C. &#167; 262(l)(1)(B)(iii). If either Party receives any
equivalent or similar communication or notice in the United States or any other jurisdiction, the Party receiving such communication or notice shall within [***] notify the other Party of such communication or notice to the extent permitted by
Applicable Laws. Regardless of the Party that is the &#147;reference product sponsor&#148;, as defined in 42 U.S.C. &#167; 262(l)(1)(A), for purposes of such Biosimilar Application: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) [***] shall designate, to the extent permitted by Applicable Law,
or [***], the outside counsel and <FONT STYLE="white-space:nowrap">in-house</FONT> counsel who shall receive confidential access to the Biosimilar Application, information regarding the process or processes used to manufacture the product that is
the subject of the Biosimilar Application, and any related confidential information pursuant to 42 U.S.C. &#167; 262(l)(1)(B)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
In each case, after consulting with [***] and considering [***] comments in good faith, [***] shall have the right to (i)&nbsp;list any Patents, including any Immatics Patents and Joint Patents, as required pursuant to 42 U.S.C. &#167; 262(l)(3)(A)
or 42 U.S.C. &#167; 262(l)(7), (ii) respond to any communications with respect to such lists from the filer of the Biosimilar Application, (iii)&nbsp;identify Patents on such lists that are available under a license to the filer of the Biosimilar
Application, (iv)&nbsp;negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange other than that specified in 42 U.S.C. &#167; 262(l)(1), and (v)&nbsp;as to the Patents that will
be subject to the litigation procedure as described in 42 U.S.C. &#167; 262(l)(4), decide which Patent or Patents shall be selected for litigation under 42 U.S.C. &#167; 262(l)(5)(B)(i)(II), and commence such litigation under 42 U.S.C. &#167;
262(l)(6). If Immatics is required pursuant to Applicable Law to execute any of these tasks, it shall do so in accordance with BMS&#146; instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) [***] shall have the right to bring an action for declaratory judgment pursuant to 42 U.S.C. &#167; 262(l)(9)(C) if the filer of the
Biosimilar Application fails to provide any of the information required by 42 U.S.C. &#167; 262(l)(2)(A) or otherwise fails to comply with any provision set forth in 42 U.S.C. &#167; 262. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) [***] shall have the right, after consulting with [***], to identify Patents, including any Immatics Patents and Joint Patents, or
respond to relevant communications under any equivalent or similar listing to those described in the preceding clause (b)&nbsp;in any other jurisdiction outside of the United States. If [***] is required pursuant to Applicable Law to execute any of
these tasks, it shall do so in accordance with [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) [***] shall cooperate with [***] reasonable requests in connection with the
foregoing activities to the extent required or permitted by Applicable Laws. [***] shall consult with [***] prior to identifying any Immatics Patents or Joint Patents to a Third Party as contemplated by this Section&nbsp;7.11.7. [***] shall consider
in good faith advice and suggestions with respect thereto received from [***] and notify [***] of any such lists or communications promptly after they are made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Each Party shall notify the other Party within [***] after receiving any notice of commercial marketing provided by the filer of a
Biosimilar Application pursuant to 42 U.S.C. &#167; 262(l)(8)(A). To the extent permitted by Applicable Law, [***] shall have the first right, but not the obligation, to seek an injunction against such commercial marketing as permitted pursuant to
42 U.S.C. &#167; 262(l)(8)(B) and to file an action for infringement. If required pursuant to Applicable Law, upon [***] request, [***] shall assist in seeking such injunction or filing such infringement action after consulting with [***]. Except as
otherwise provided in this Section&nbsp;7.11.7, any such action shall be subject to the terms and conditions of Sections 7.11.1 through 7.11.6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Parties recognize that procedures other than those set forth
above in this Section&nbsp;7.11.7 may apply with respect to Biosimilar Applications, either in the United States or elsewhere. If the Parties determine that certain provisions of Applicable Laws in the United States or in any other country in the
Territory apply to actions taken by the Parties with respect to Biosimilar Applications under this Section&nbsp;7.11.7 in such country, the Parties shall comply with any such Applicable Laws in such country (and any relevant and reasonable
procedures established by Parties) in exercising their rights and obligations with respect to Biosimilar Applications under this Section&nbsp;7.11.7 in a manner to effectuate the intent of this Section&nbsp;7.11.7. Notwithstanding the foregoing
provisions of this Section&nbsp;7.11.7, nothing in this Section&nbsp;7.11.7 shall grant any rights to [***] with respect to any BMS Licensed IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 <U>Patent Term Extensions</U>. [***] shall determine whether to seek, and [***]shall reasonably cooperate with [***] in [***] efforts to
seek and obtain, patent term restoration or supplemental protection certificates or the like or their equivalents in any country in the Territory, where applicable to Immatics Patents or Joint Patents, or any other Patents [***], including as may be
available to the Parties under the provisions of the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 or comparable laws outside the United States, in each case, in connection with any BMS Product; provided that, [***], such
consent not to be unreasonably withheld, conditioned or delayed (for clarity, [***]). If elections with respect to obtaining such patent term restoration or supplemental protection certificates or the like or their equivalents are to be made in
connection therewith, [***] shall have the right to make the election, and [***] agrees to abide by such election. Without limiting the foregoing, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.13 <U>Patent Linkage</U>. [***] (or its designee) shall have the sole right, but not the obligation, to list, with the applicable Regulatory
Authorities in the Territory, all applicable Patents (including any Immatics Patents or Joint Patents) for any BMS Product, including all so called &#147;Purple Book&#148; listings required under the U.S. Public Health Service Act, and all similar
listings in any other relevant countries, and [***] shall have no right to do so. For the avoidance of doubt, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.14 <U>Common
Interest Agreement</U>. At the request of either Party, the Parties shall negotiate in good faith to enter into a common interest agreement to govern their discussion of Patent matters under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.15 <U>License Filing</U>. At the request of BMS, Immatics shall, and shall cause its Affiliates to, assist in any license registration
processes with applicable Governmental Authorities that may be available for the protection of BMS&#146; interests in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.16 <U>Defense of Claims Brought by Third Parties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.16.1 <U>BMS Products</U>. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization
of a BMS TCR, BMS CAR or BMS Product by or on behalf of either Party pursuant to this Agreement infringes the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall
as soon as practicable thereafter meet to discuss in good faith regarding the best response to such notice; provided that BMS shall have the final decision-making authority </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in connection therewith. Except as set forth in Section&nbsp;10.2 (and without limiting
BMS&#146; rights under Section&nbsp;10.2), (a) BMS shall have the sole right, but not the obligation, to defend and dispose of (including through settlement or license) such claim and (b)&nbsp;any costs incurred by or on behalf of BMS (or any of its
Affiliates or Sublicensees) in connection with the defense or disposal of any such claim (including any damages, royalties or other amounts payable as a result thereof), to the extent relating to the Development, Manufacture or Commercialization of
a BMS TCR, BMS CAR or BMS Product, shall be included as BMS Third Party Payments and may be deducted from amounts payable to Immatics hereunder as set forth in Section&nbsp;6.3.4(a), and BMS shall report any such deductions to Immatics as part of
BMS&#146; royalty report under Section&nbsp;6.3.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.16.2 <U>Immatics Products</U>. If a Party becomes aware of any actual or potential
claim that the Development, Manufacture or Commercialization of an Immatics TCR or Immatics Product by or on behalf of Immatics pursuant to this Agreement infringes the intellectual property rights of any Third Party, such Party shall promptly
notify the other Party. In any such instance, the Parties shall as soon as practicable thereafter meet to discuss in good faith regarding the best response to such notice; provided that Immatics shall have the final decision-making authority in
connection therewith. Except as set forth in Section&nbsp;10.1 (and without limiting Immatics&#146; rights under Section&nbsp;10.1), Immatics shall have the sole right, but not the obligation, to defend and dispose of (including through settlement
or license) such claim. Notwithstanding the foregoing, this Section&nbsp;7.16.2 shall not apply to any <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product, and instead, the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT>
Agreement shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.17 <U>BMS Licensed Patents and BMS Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></U>.<B> </B>For
clarity (and notwithstanding the foregoing provisions of this Article 7), as between the Parties, BMS shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain the BMS Licensed Patents and BMS Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> including with respect to any patent term extensions and patent listings, and to enforce and defend (including retaining all recoveries) such BMS Licensed Patents and BMS Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> in each case, in its discretion, and Immatics shall have no rights in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.18 <B>[Reserved]</B><B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.19 <U>Same Patents Licensed under a 2019 Agreement</U>. The Parties hereby agree and acknowledge that certain of the Patents included within
the Immatics Licensed IP that are licensed to BMS hereunder may also be licensed to BMS (or its Affiliate) under a 2019 Agreement (any such Patent, a &#147;<B>Dual Immatics Licensed Patent</B>&#148;). The Parties further agree and acknowledge that
in the event of a conflict between the provisions of this Agreement and the provisions of the applicable 2019 License Agreement with respect to the enforcement (including allocation of recoveries), patent term extension or patent listing with
respect to a given Dual Immatics Licensed Patent, then (i)&nbsp;the provisions of this Agreement shall apply with respect to (x)&nbsp;an Infringement of such Dual Immatics Licensed Patent by a Competing Product (as defined herein) or any other
product that could be competitive (as reasonably determined by BMS) with any BMS CAR Product (including in connection with any Biosimilar Application referencing a BMS CAR Product) or (y)&nbsp;patent term extension or patent listing of such Dual
Immatics Licensed Patent for a BMS CAR Product, and (ii)&nbsp;the provisions of the applicable 2019 License Agreement shall apply with respect to (x)&nbsp;an Infringement (as defined in the applicable 2019 License Agreement) of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dual Immatics Licensed Patent by a Competing Product (as defined in the applicable 2019
License Agreement) or any other product that could be competitive (as reasonably determined by BMS) with any BMS TCR Product (including in connection with any Biosimilar Application referencing a BMS TCR Product), or (y)&nbsp;patent term extension
or patent listing of such Dual Immatics Licensed Patent for a BMS TCR Product, as applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1
<U>Nondisclosure</U>. Each Party agrees that a Party (the &#147;<B>Receiving Party</B>&#148;) receiving Confidential Information of the other Party (the &#147;<B>Disclosing Party</B>&#148;) pursuant to this Agreement shall (a)&nbsp;maintain in
confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of efforts,
(b)&nbsp;not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to this Article 8, and (c)&nbsp;not use such Confidential
Information for any purpose except those permitted by this Agreement, including the exercise of the rights and licenses granted to such Party hereunder (it being understood that this clause (c)&nbsp;shall not create or imply any rights or licenses
not expressly granted under this Agreement). The obligations of confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> under this Section&nbsp;8.1 shall be in full force and effect
during the Term and for a period of [***] thereafter. The Receiving Party will return all copies of or destroy (and certify such destruction in writing) the Confidential Information of the Disclosing Party disclosed or transferred to it by the other
Party pursuant to this Agreement, within [***] after the termination or expiration of this Agreement; provided, however, that a Party may retain (i)&nbsp;Confidential Information of the other Party to exercise rights and licenses which expressly
survive such termination or expiration pursuant to this Agreement, and (ii)&nbsp;one (1) copy of all other Confidential Information in archives solely for the purpose of establishing the contents thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>BMS Program Specific Confidential Information; Other BMS IP</U>. Notwithstanding anything to the contrary contained herein, the Parties
agree and acknowledge that any BMS Program Specific IP shall be deemed to be Confidential Information of BMS (without regard to Section&nbsp;8.5.1(a) or 8.5.1(e)), and BMS shall be deemed to be the Disclosing Party with respect to the BMS Program
Specific IP. BMS Program <FONT STYLE="white-space:nowrap">Non-Specific</FONT> IP shall be deemed to be the Confidential Information of Immatics. As used herein, (a)&nbsp;the term &#147;<B>BMS Program Specific IP</B>&#148; means, [***] the
&#147;<B>BMS </B><B>Target Specific Information</B>&#148;); and (b)&nbsp;the term &#147;<B>BMS Program <FONT STYLE="white-space:nowrap">Non-Specific</FONT> IP</B>&#148; means [***]. For clarity, the fact that the BMS Target Specific Information is
the Confidential Information of BMS shall not be construed as granting, conveying, or creating any license or other rights to any of Immatics&#146; other intellectual property (including Patents), except as expressly set forth herein, including in
Section&nbsp;7.1. In addition, the Parties agree and acknowledge that, in all cases, all BMS Contributed Collaboration Technology and BMS Licensed IP is the Confidential Information of BMS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Immatics Program Specific Confidential Information</U>.
Notwithstanding anything to the contrary contained herein, the Parties agree and acknowledge that any Immatics Program Specific IP shall be deemed to be Confidential Information of Immatics (without regard to Section&nbsp;8.5.1(a) or 8.5.1(e)), and
Immatics shall be deemed to be the Disclosing Party with respect to the Immatics Program Specific IP. As used herein, the term &#147;<B>Immatics Program Specific IP</B>&#148; means, [***]. Notwithstanding the foregoing, if BMS exercises its BMS <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Right, then Immatics Program Specific IP shall exclude <FONT STYLE="white-space:nowrap">Know-How</FONT> and other information specifically relating to any <FONT STYLE="white-space:nowrap">Co-Developed</FONT>
Product (or the associated Immatics TCR), and the confidentiality of such <FONT STYLE="white-space:nowrap">Know-How</FONT> and information shall be set forth in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Joint Confidential Information</U>. Subject to the provisions of Sections 8.2 and 8.3, the Parties acknowledge and agree that the Joint
Inventions shall be Confidential Information of both Parties (without regard to Section&nbsp;8.5.1(a) or 8.5.1(e)) and each Party shall be deemed to be the Disclosing Party with respect to such Joint Inventions, and each Party shall be subject to
the obligations of confidentiality and the restrictions on use and disclosure with respect to such Joint Inventions as set forth in this Article 8; provided that, for clarity, [***]. For clarity, the fact that the foregoing Joint Inventions are the
Confidential Information of both Parties shall not be construed as granting, conveying, or creating any license or other rights to any of Immatics&#146; other intellectual property (including Patents), except as expressly set forth in this
Agreement, including Section&nbsp;7.1, or to any of BMS&#146; other intellectual property (including Patents), except as expressly set forth in this Agreement, including Section&nbsp;7.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>Exceptions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5.1
<U>General</U>. The obligations in Section&nbsp;8.1 shall not apply with respect to any portion of the Confidential Information of the Disclosing Party that the Receiving Party can show by competent written proof: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use,
prior to disclosure by the Disclosing Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third
Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) is published
by a Third Party or otherwise becomes publicly available or enters the public domain (including, for clarity, as contained in a published Patent application that is permitted to be filed in accordance with this Agreement), either before or after it
is disclosed to the Receiving Party, without any breach by the Receiving Party of its obligations hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) is published by a Party
in accordance with Section&nbsp;8.10 without any breach by such Party of its obligations hereunder; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) is independently developed by
or for the Receiving Party or its Affiliates without reference to or reliance upon the Disclosing Party&#146;s Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the
Receiving Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6 <U>Authorized Disclosure</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6.1 <U>Disclosure</U>. Notwithstanding Section&nbsp;8.1, the Receiving Party may disclose Confidential Information belonging to the
Disclosing Party in the following instances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) subject to Section&nbsp;8.8, to comply with Applicable Law (including the rules and
regulations of the U.S. Securities and Exchange Commission (&#147;<B>SEC</B>&#148;) or any national securities exchange) or with judicial process (including prosecution or defense of litigation), if, in the reasonable opinion of the Receiving
Party&#146;s counsel, such disclosure is necessary for such compliance or for such judicial process (including prosecution or defense of litigation); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) to governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct Clinical Trials or to
market Collaboration Products under this Agreement, in each case, in accordance with this Agreement, but such disclosure shall only be to the extent reasonably necessary to obtain Patents or authorizations, and provided that reasonable steps are
taken to ensure confidential treatment of such Confidential Information (if available); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) to any of its officers, employees,
consultants, agents or Affiliates, or to any of its actual or potential collaborators, licensees, or sublicensees, as it deems necessary or advisable in the course of conducting activities in accordance with this Agreement in order to carry out its
responsibilities or exercise its rights under this Agreement (including in the case of either Party, (A)&nbsp;the exercise of the rights and licenses granted to such Party by the other Party hereunder, (B)&nbsp;in the case of either Party, to use
the Joint Inventions as set forth in Section&nbsp;7.8.3, (C) to such Party&#146;s subcontractors for purpose of such subcontractor performing obligations of such Party under this Agreement, and (D)&nbsp;as otherwise expressly permitted under this
Agreement); provided that each such disclosee is bound by written confidentiality obligations and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations no less restrictive than those set forth in this Article 8 to maintain the confidentiality
thereof and not to use such Confidential Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section&nbsp;8.6.1(c), the Receiving Party shall remain responsible for any
failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section&nbsp;8.6.1(c) to treat such Confidential Information as required under this Article 8; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) to such Party&#146;s (i)&nbsp;actual or potential <I>bona fide</I> acquirors or (ii)&nbsp;actual or potential <I>bona fide</I> investor
in a [***]; provided that, in each case, such disclosee is bound by written confidentiality obligations and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations substantially similar to those set forth in this Article 8 to maintain the
confidentiality thereof and not to use such Confidential Information except solely for purposes of evaluating the acquisition or investment transaction; provided, however, that (x)&nbsp;in the case of Immatics as the Receiving Party, Immatics shall
not disclose [***], in each case to the extent such information is still Confidential Information, pursuant to this Section&nbsp;8.6.1(d) to any actual or potential <I>bona fide</I> acquirors unless Immatics and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such Person are negotiating a <I>bona fide</I> transaction for the acquisition of
Immatics [***], (y) in the case of Immatics as the Receiving Party, Immatics shall not disclose [***], in each case to the extent such information is still Confidential Information, pursuant to this Section&nbsp;8.6.1(d) to any actual or potential
<I>bona fide</I> investor and (z)&nbsp;the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section&nbsp;8.6.1(d) to treat such Confidential
Information as required under this Article 8; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) disclosure, solely on a &#147;need to know basis&#148;, to its advisors (including
attorneys and accountants) in connection with activities hereunder; provided that, prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-use</FONT> no less restrictive than the obligations set forth in this Article 8 (provided, however, that in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will
not permit use of such Confidential Information for any purpose except those expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section&nbsp;8.6.1(e), the Receiving Party shall remain responsible
for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section&nbsp;8.6.1(e) to treat such Confidential Information as required under this Article 8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6.2 <U>Terms of Disclosure</U>. If and whenever any Confidential Information is disclosed in accordance with this Section&nbsp;8.6, such
disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement). Where reasonably possible
and subject to Section&nbsp;8.8, the Receiving Party shall notify the Disclosing Party of the Receiving Party&#146;s intent to make any disclosures pursuant to Section&nbsp;8.6.1(a) sufficiently prior to making such disclosure so as to allow the
Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance to the Disclosing Party with respect thereto; provided that,
in such event, the Receiving Party will use reasonable measures to ensure confidential treatment of such information and shall only disclose such Confidential Information of the Disclosing Party as is necessary for the purposes of
Section&nbsp;8.6.1(a), as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6.3 <U>BMS Program Specific IP</U>. During the Term, Immatics shall not disclose the BMS Program
Specific IP without the prior written consent of BMS, other than pursuant to Section&nbsp;8.6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6.4 <U>Immatics Program Specific
IP</U>. During the Term, BMS shall not disclose the Immatics Program Specific IP without the prior written consent of Immatics, other than pursuant to Section&nbsp;8.6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.7 <U>Terms of this Agreement</U>. The Parties agree that this Agreement and the terms hereof shall be deemed to be Confidential Information
of both Immatics and BMS, and each Party agrees not to disclose any of them without the prior written consent of the other Party, except that each Party may disclose any of them in accordance with the provisions of Section&nbsp;8.6 or 8.8, as
applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.8 <U>Securities Filings; Disclosure under Applicable Law</U>. Each
Party acknowledges and agrees that the other Party may submit this Agreement to (or file this Agreement with) the SEC or any national securities exchange in any jurisdiction (collectively, the &#147;<B>Securities Regulators</B>&#148;), or to other
Persons as may be required by Applicable Law, and if a Party does submit this Agreement to (or file this Agreement with) any Securities Regulators, or other Persons as may be required by Applicable Law, such Party agrees to consult with the other
Party with respect to the preparation and submission of a confidential treatment request for this Agreement and to mutually agree on the redactions to this Agreement to be submitted for confidential treatment request, such agreement not to be
unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, if a Party is required by Applicable Law or any Securities Regulator to make a disclosure of the terms of this Agreement in a filing or other submission as required by
Applicable Law or Securities Regulator, and (a)&nbsp;such Party has provided copies of the disclosure to the other Party reasonably in advance of such filing or other disclosure under the circumstances, (b)&nbsp;such Party has promptly notified the
other Party in writing of such requirement and any respective timing constraints, and (c)&nbsp;such Party has given the other Party a reasonable time under the circumstances from the date of notice by such Party of the required disclosure to comment
upon and request confidential treatment for such disclosure, then such Party will have the right to make such disclosure at the time and in the manner reasonably determined by its counsel to be required by Applicable Law or Securities Regulator if
the other Party has not responded within such reasonable time period. Notwithstanding the foregoing, it is hereby understood and agreed that if a Party seeks to make a disclosure as required by Applicable Law or Securities Regulator as set forth in
this Section&nbsp;8.8, and the other Party provides comments within the respective time periods or constraints specified herein or within the respective notice, the Party seeking to make such disclosure or its counsel, as the case may be, will in
good faith consider incorporating such comments, and, with respect to submitting this Agreement to (or filing this Agreement with) any Securities Regulators, or other Persons as may be required by Applicable Law, the Parties shall mutually agree on
the redactions to this Agreement to be submitted for confidential treatment request, such agreement not to be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.9 <U>Publicity</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9.1
<U>Press Release; Public Statements</U>. Subject to Sections 8.6, 8.8 and 8.10, and this Section&nbsp;8.9, each Party agrees not to (and shall cause their Affiliates not to) issue any press release or other public statement disclosing the fact that
the Parties have entered into this Agreement, the activities hereunder, or the transactions contemplated hereby, unless such press release or other public statement is approved by the other Party in writing; provided that either Party shall be
authorized to make any disclosure, without the approval of the other Party, that is required by Applicable Laws (including the U.S. Securities Act of 1933, as amended, and the U.S. Securities Exchange Act of 1934, as amended) or the rules of any
Securities Regulator, or by judicial process, subject to and in accordance with Sections 8.6 and 8.8, as applicable. Without limiting the foregoing, either Party shall have the right to issue a press release regarding the execution of this Agreement
on or promptly after the Effective Date; provided that such press release is in a form as mutually agreed to by the Parties in writing prior to the issuance thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9.2 <U>Additional Restrictions on Disclosure</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>BMS Targets, BMS Receptors and BMS Products</U>. Without limiting any other restrictions on disclosure set forth in this Article 8
with respect to any press release or other public statement proposed to be made by Immatics, if such press release or public statement discloses any information with respect to the research, development, manufacture or commercialization of any BMS
Target or any BMS TCR, BMS CAR or BMS Products, including any information related to Clinical Trials or Regulatory Approvals with respect thereto, such press release or other public statement may not be issued without BMS&#146; prior written
consent, except for such disclosures by Immatics as required by Applicable Law or Securities Regulators (solely and to the extent Immatics&#146; counsel determines such disclosure is required by Applicable Law or Securities Regulators) and in
accordance with Sections 8.6 and 8.8, as applicable, and in such case Immatics shall use reasonable efforts to afford BMS a reasonable period of time to review any such disclosure and any comments made by BMS will be considered in good faith.
Notwithstanding the foregoing, any information that has been previously publicly disclosed in accordance with this Agreement may be disclosed again in its full original form and as long as such disclosure does not exceed the scope of such prior
public disclosure. Subject to the foregoing, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Immatics TCRS and Immatics Products.</U> Without limiting any other
restrictions on disclosure set forth in this Article 8 with respect to any press release or other public statement proposed to be made by BMS, if such press release or public statement discloses any information with respect to the research,
development, manufacture or commercialization of any Immatics TCR or Immatics Products, including any information related to Clinical Trials or Regulatory Approvals with respect thereto, such press release or other public statement may not be issued
without Immatics&#146; prior written consent, except for such disclosures by BMS as required by Applicable Law or Securities Regulators (solely and to the extent BMS&#146; counsel determines such disclosure is required by Applicable Law or
Securities Regulators) and in accordance with Sections 8.6 and 8.8, as applicable, and in such case BMS shall use reasonable efforts to afford Immatics a reasonable period of time to review any such disclosure and any comments made by Immatics will
be considered in good faith. Notwithstanding the foregoing, any information that has been previously publicly disclosed in accordance with this Agreement may be disclosed again in its full original form and as long as such disclosure does not exceed
the scope of such prior public disclosure. Subject to the foregoing, [***]. Notwithstanding the foregoing, (i)&nbsp;if BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then all press release or other public statement with
respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product (or the associated Immatics TCR), shall be in accordance with the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement and (ii)&nbsp;nothing in this
Section&nbsp;8.9.2(b) shall [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9.3 <U>Previously Issued Public Statements</U>. The contents of any press release or other public
statement that has been reviewed and approved by a reviewing Party may be <FONT STYLE="white-space:nowrap">re-released</FONT> in its full original form by the publishing Party or by such reviewing Party without a requirement for <FONT
STYLE="white-space:nowrap">re-approval.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.10 <U>Permitted Publications of </U><U>[***]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10.1 <U>Publication</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>BMS Products</U>. Immatics and its Affiliates shall have no right to, and shall not, publish or publicly present any [***]. For
clarity, BMS (and its Affiliates and sublicensees) shall have the right to make publications and public presentations with respect to [***], without the prior review or consent of Immatics, but subject to the procedures set forth below if such
publication or presentation contains Confidential Information of Immatics. BMS shall provide Immatics with a copy of any proposed publication or public presentation that contains the Confidential Information of Immatics no less than [***] prior
(provided that Immatics shall use reasonable efforts to accommodate a shorter time period if required due to circumstances outside of BMS&#146; control) to its intended submission for publication or public presentation. For the avoidance of doubt,
the foregoing shall apply with respect to each such proposed publication or presentation that contains the Confidential Information of Immatics regardless of whether a prior publication or presentation was provided (e.g., if an abstract is provided
in accordance with this Section&nbsp;8.10.1(a) and BMS wishes to publish the corresponding full manuscript, the full manuscript must be provided to Immatics pursuant to this Section&nbsp;8.10.1(a)). Immatics shall respond in writing promptly and in
no event later than [***] after receipt of the proposed material (provided that Immatics shall use reasonable efforts to accommodate a shorter time period if notified by BMS and required due to circumstances outside of BMS&#146; control) with a
specific statement of concern, if any, which may include the need to seek patent protection of any Immatics&#146; intellectual property or comments regarding the description of the Immatics Licensed IP, in which case, BMS shall give good faith
consideration to any comments of Immatics and BMS agrees to delay the submission of the proposed publication for a reasonable period of time, and in no event more than [***], upon Immatics&#146; request, in order for Immatics to seek patent
protection for its Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Immatics Products</U>. BMS and its Affiliates shall have no right to, and shall not,
publish or publicly present any [***]; provided, for clarity, that the foregoing does not prohibit BMS from proposing a publication or presentation in collaboration with Immatics on an Immatics Product. For clarity, Immatics (and its Affiliates and
sublicensees) shall have the right to make publications and public presentations with respect to any Immatics Target or Immatics TCR or Immatics Product, without the prior review or consent of BMS, but subject to the procedures set forth below if
such publication or presentation contains Confidential Information of BMS. Immatics shall provide BMS with a copy of any proposed publication or public presentation that contains the Confidential Information of BMS no less than [***] prior (provided
that BMS shall use reasonable efforts to accommodate a shorter time period if required due to circumstances outside of Immatics&#146; control) to its intended submission for publication or public presentation. For the avoidance of doubt, the
foregoing shall apply with respect to each such proposed publication or presentation that contains the Confidential Information of BMS regardless of whether a prior publication or presentation was provided (e.g., if an abstract is provided in
accordance with this Section&nbsp;8.10.1(b) and Immatics wishes to publish the corresponding full manuscript, the full manuscript must be provided to BMS pursuant to this Section&nbsp;8.10.1(b)). BMS shall respond in writing promptly and in no event
later than [***] after receipt of the proposed material (provided that BMS shall use reasonable efforts to accommodate a shorter time period if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">notified by Immatics and required due to circumstances outside of Immatics&#146;
control) with a specific statement of concern, if any, which may include the need to seek patent protection of any BMS&#146; intellectual property or comments regarding the description of the BMS Licensed IP, in which case, Immatics shall give good
faith consideration to any comments of BMS and Immatics agrees to delay the submission of the proposed publication for a reasonable period of time, and in no event more than [***], upon BMS&#146; request, in order for BMS to seek patent protection
for its Confidential Information. Notwithstanding the foregoing, (i)&nbsp;if BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then all publications and presentations with respect to the
<FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product shall be in accordance with the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement and (ii)&nbsp;nothing in this Section&nbsp;8.10.1(b) shall prohibit or limit in any
way BMS (or any of its Affiliates or designees) from making any publication or other public presentation with respect to any BMS Licensed IP and the provisions of this Section&nbsp;8.10.1(b) shall not apply with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10.2 <U><FONT STYLE="white-space:nowrap">Re-Publication;</FONT> <FONT STYLE="white-space:nowrap">Re-Presentation</FONT></U>. The contents of
any publication or presentation by a Party that has been reviewed and approved by the other Party may be <FONT STYLE="white-space:nowrap">re-released</FONT> by either Party in its full original form without a requirement for <FONT
STYLE="white-space:nowrap">re-approval.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.11 <U>Use of Names</U>. Except as otherwise expressly set forth herein, no Party (or its
respective Affiliates) shall use the name, trademark, trade name or logo of the other Party or its Affiliates, or its or their respective employee(s) in any publicity, promotion, news release or other public disclosure relating to this Agreement or
its subject matter, without the prior written permission of the other Party; provided that such permission shall not be required to the extent use thereof may be required by Applicable Law or Securities Regulators, including the rules of any
securities exchange or market on which a Party&#146;s (or its Affiliate&#146;s) securities are listed or traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.12 <U>Clinical Trials
Registry</U>. For clarity, (a)&nbsp;BMS (and its Affiliates and designees) shall have the right to publish registry information and summaries of data and results from any Clinical Trials of BMS Products conducted in connection with activities under
this Agreement, on its clinical trials registry or on a government-sponsored database such as www.clinicaltrials.gov, without requiring the consent of Immatics, and (b)&nbsp;Immatics (and its Affiliates and designees) shall have the right to publish
registry information and summaries of data and results from any Clinical Trials of Immatics Products conducted in connection with activities under this Agreement, on its clinical trials registry or on a government-sponsored database such as
www.clinicaltrials.gov, without requiring the consent of BMS. The Parties shall reasonably cooperate if required or reasonably requested by either Party in order to facilitate any such publication by such Party (and its Affiliates and designees).
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES; COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Representations and Warranties of Both Parties</U>. Each Party hereby represents and warrants to the other Party, as of the Effective
Date, that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) such Party is duly organized, validly existing and in good standing under the Applicable Law of the jurisdiction of its
formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) such Party has taken all necessary corporate action on its part to
authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) this Agreement has been
duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject
to (i)&nbsp;bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors, or (ii)&nbsp;laws governing specific performance, injunctive relief and other equitable
remedies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the execution, delivery and performance of this Agreement by such Party does not breach or conflict with any agreement or
any provision thereof, or any instrument or understanding, oral or written, to which such Party (or any of its Affiliates) is a party or by which such Party (or any of its Affiliates) is bound, nor violate any Applicable Law of any Governmental
Authority having jurisdiction over such Party (or any of its Affiliates); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) except as set forth in Section&nbsp;2.1.1(g), no
government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in
effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except as may be required to conduct Clinical Trials or to seek or
obtain Regulatory Approvals or applicable Regulatory Materials; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) except as set forth in Section&nbsp;2.1.1(g), it has obtained
all necessary authorizations, consents and approvals of any Third Party that is required to be obtained by it as of the Effective Date for, or in connection with, the transaction contemplated by this Agreement, or for the performance by it of its
obligations under this Agreement, except as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Representations and Warranties of Immatics</U>. Except as set forth on <U>Schedule 9.2</U>, Immatics hereby represents and warrants to
BMS, (i)&nbsp;as of the Effective Date and (ii)&nbsp;as of the date of designation by BMS of each additional Receptor as a BMS Receptor hereunder (i.e., as an additional BMS Receptor pursuant to Section&nbsp;2.1.1(a), as a Substitute Receptor
pursuant to Section&nbsp;2.1.1(b) or as an Additional Receptor pursuant to Section&nbsp;2.1.1(d), as applicable), provided that in the case of this clause (ii), (A) any of the following representations and warranties that are made specifically with
respect to a given BMS Target, BMS TCR, BMS CAR or BMS Product shall only be made with respect to such additional BMS Receptor, Substitute Receptor or Additional Receptor, as applicable, as well as the associated BMS Targets and BMS Products and
(B)&nbsp;Immatics shall have the right to notify BMS in writing within [***] following the date of designation of the applicable BMS Receptor of any exceptions to the following representations and warranties specifically with respect to such
additional BMS Target, BMS TCR, BMS CAR or BMS Product, as applicable (each such written notice, an &#147;<B>Immatics Disclosure Schedule Bring Down Report</B>&#148;), that:<B> </B><B></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Schedule 1.77</U> and <U>Schedule 1.80</U> contain a complete
and accurate list of all Patents owned or otherwise controlled (by license or otherwise) by Immatics or any of its Affiliates that claim or cover any Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cells</FONT> (or any methods or processes in
connection therewith), any Immatics Platform Technology, or any BMS Target, BMS TCR, BMS CAR or BMS Product, in each case, including the composition or use or manufacture of any of the foregoing, and Immatics Controls all such Patents. Except for
the Immatics Licensed IP and the Initial Reimbursable Gene Editing Technology, Immatics and its Affiliates do not own or control (by license or otherwise) any Patent or <FONT STYLE="white-space:nowrap">Know-How</FONT> that is necessary or useful to
Develop, Manufacture or Commercialize any Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cells,</FONT> or any BMS Target, BMS TCR, BMS CAR or BMS Product, or to otherwise conduct the Research Program or to use or practice any Immatics Platform
Technology. All issued Patents within the Immatics Licensed IP or the Initial Reimbursable Gene Editing Technology are in full force and effect, and to Immatics&#146; knowledge, are not invalid or unenforceable, in whole or in part; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) no claim has been issued or served, or written threat of a claim or litigation made by any Person, against Immatics or its Affiliates
that alleges that any Immatics Licensed IP or Initial Reimbursable Gene Editing Technology is invalid or unenforceable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) other than
any TCRs that are included as BMS TCRs hereunder or that are Collaboration TCRs under the 2019 Collaboration Agreement or a Licensed TCR under a 2019 License Agreement, neither Immatics nor its Affiliates own or otherwise control (through license or
otherwise) any TCRs and CARs (or any products constituting, incorporating, comprising or containing any such TCR or CAR) that are Directed to any BMS Target; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Immatics has disclosed to BMS the existence of any patent opinions prepared on behalf of Immatics or its Affiliates or otherwise made
available to Immatics or its Affiliates related to Patents within the Immatics Licensed IP or the Initial Reimbursable Gene Editing Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) neither Immatics nor its Affiliates are subject to any payment obligations to Third Parties (other than (i)&nbsp;under the Existing
Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements as set forth on <U>Schedule 6.5.2</U> and (ii)&nbsp;to subcontractors) as a result of the execution or performance of this Agreement, including the research, development,
manufacture or commercialization of any BMS Target, BMS TCR, BMS CAR or BMS Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Immatics has the full right and authority to
grant all of the rights and licenses granted to BMS (or purported to be granted to BMS) hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) neither Immatics nor its
Affiliates have granted any right or license to any Third Party relating to any of the Immatics Licensed IP, any of the Initial Reimbursable Gene Editing Technology or any other Licensed Program Asset, or any BMS Target, BMS TCR, BMS CAR or BMS
Product (or any other Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell</FONT> product Directed to any BMS Target), that would conflict with or limit the scope of any of the rights or licenses granted to BMS hereunder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Immatics is the sole and exclusive owner of the Immatics Licensed
IP; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) neither Immatics nor its Affiliates have granted any mortgage, pledge, claim, security interest, lien or other charge of any
kind on the Immatics Licensed IP, the Initial Reimbursable Gene Editing Technology or other Licensed Program Asset, and (i)&nbsp;with respect to any Immatics Licensed IP and other Licensed Program Assets that are owned by Immatics (or any of its
Affiliates), such Immatics Licensed IP and the other Licensed Program Assets are free and clear of any mortgage, pledge, claim, security interest, lien or charge of any kind and (ii)&nbsp;with respect to any Immatics Licensed IP, the Initial
Reimbursable Gene Editing Technology and other Licensed Program Assets that are owned by a Third Party, to Immatics&#146; knowledge, such Immatics Licensed IP, Initial Reimbursable Gene Editing Technology and the other Licensed Program Assets are
free and clear of any mortgage, pledge, claim, security interest, lien or charge of any kind; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) neither Immatics nor its Affiliates
have received any written notice of any claim that any Patent or <FONT STYLE="white-space:nowrap">Know-How</FONT> (including any trade secret right) owned or controlled by a Third Party would be infringed or misappropriated by the conduct of the
activities under the Research Program, or the Development, Manufacture, or Commercialization of any BMS Target, BMS TCR, BMS CAR or BMS Product, or the use of any Immatics Licensed IP or any Initial Reimbursable Gene Editing Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) to Immatics&#146; and its Affiliates&#146; knowledge, (i)&nbsp;the use of the Immatics Licensed IP and the Initial Reimbursable Gene
Editing Technology, (ii)&nbsp;the conduct of the activities under the Research Program, and (iii)&nbsp;the Development, Manufacture and Commercialization of any BMS Target, BMS TCR, BMS CAR or BMS Product, as contemplated to be conducted under this
Agreement, will not violate, infringe or misappropriate any intellectual property or proprietary right of any Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) there are
no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial or legal administrative or other proceedings or governmental investigations pending or, to Immatics&#146; or its Affiliates&#146; knowledge, threatened
in writing against Immatics or its Affiliates which would reasonably be expected to adversely affect or restrict the ability of Immatics to consummate or perform the transactions contemplated under this Agreement, or which would adversely affect the
Immatics Licensed IP, the Initial Reimbursable Gene Editing Technology or other Licensed Program Assets, or Immatics&#146; Control thereof, or any BMS Target, BMS TCR, BMS CAR or BMS Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) none of the Immatics Licensed IP (and none of the inventions claimed by the Immatics Patents) and, except as set forth on <U>Schedule
9.5.3,</U> none of the Initial Reimbursable Gene Editing Technology (and none of the inventions claimed by any Patents within the Initial Reimbursable Gene Editing Technology), were conceived, reduced to practice, discovered, developed or otherwise
made in connection with any research activities funded, in whole or in part, by any grants, funds, or other money received from any governmental authority, and no governmental authority or academic institution has any right to, ownership of
(including any <FONT STYLE="white-space:nowrap">&#147;step-in&#148;</FONT> or <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights with respect to), or right to royalties for, or to impose any restriction on the assignment, transfer,
grant of licenses or other disposal of the Immatics Licensed IP or the Initial Reimbursable Gene Editing Technology, or to impose any requirement or restriction on the Exploitation of any BMS Product as contemplated herein; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) neither Immatics nor its Affiliates have issued a claim against a
Third Party alleging that a Third Party is infringing or has infringed or misappropriated any Immatics Licensed IP or any Initial Reimbursable Gene Editing Technology, and, to Immatics&#146; and its Affiliates&#146; knowledge, no issued Patents
within the Immatics Licensed IP or the Initial Reimbursable Gene Editing Technology are being infringed and no trade secrets within the Immatics Licensed IP or the Initial Reimbursable Gene Editing Technology are being misappropriated by any Third
Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) neither Immatics nor its Affiliates have entered into any agreement under which Immatics or its Affiliates (i)&nbsp;has
obtained a license or sublicense of rights from a Third Party to any BMS Target, BMS TCR, BMS CAR or BMS Product, or to any Immatics Licensed IP or any Initial Reimbursable Gene Editing Technology, except for the licenses to the Initial Reimbursable
Gene Editing Technology pursuant to the Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements set forth on <U>Schedule 1.58</U>, or (ii)&nbsp;has granted a license, sublicense, option or right to a Third Party that remains
in effect as of the Effective Date or as of the date of designation by BMS of the BMS Receptor hereunder, as applicable, to research, develop, manufacture or commercialize any BMS Target, BMS TCR, BMS CAR or BMS Product (or any other Cell Therapy
Product Directed to any BMS Target). Except as set forth in <U>Schedule 9.5.3</U>, the agreements set forth on <U>Schedule 1.58</U> do not conflict with or limit the scope of the rights or licenses granted to BMS hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) with respect to each Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, (i)&nbsp;it is in full force and
effect; (ii)&nbsp;Immatics (or its Affiliate, as applicable) is not in breach thereof; (iii)&nbsp;Immatics (or its Affiliate, as applicable) has not received any written notice from the counterparty to such Existing Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement, as applicable, of Immatics&#146; (or its Affiliate&#146;s, as applicable) breach or notice of threatened breach by Immatics (or its Affiliate, as applicable) thereof; and (iv)&nbsp;Immatics has
provided BMS with a true, correct and complete copy of each Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement pursuant to that letter dated [***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) neither Immatics nor its Affiliates have employed or otherwise used in any capacity, the services of any Person suspended, proposed for
debarment or debarred under United States law, including under 21 U.S.C. &#167; 335a, or any foreign equivalent thereof, in connection with the development of any Immatics Platform Technology or other Immatics Licensed IP or Initial Reimbursable
Gene Editing Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) Immatics (or its Affiliates, as applicable) has not entered into any agreement with a Third Party relating
to the Development, Manufacture, Commercialization or other exploitation any BMS Target, BMS TCR, BMS CAR or BMS Product (or any other Cell Therapy Product Directed to any BMS Target); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) Immatics has disclosed to BMS all material information and data,
and all material correspondences to/from any Regulatory Authority, in the possession or control of Immatics or its Affiliates, in each case related to (i)&nbsp;the Immatics Platform Technology or other Immatics Licensed IP or other Initial
Reimbursable Gene Editing Technology or (ii)&nbsp;any BMS Target, BMS TCR, BMS CAR or BMS Product (or any other Gamma-Delta <FONT STYLE="white-space:nowrap">T-Cell</FONT> product Directed to any BMS Target); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) Pursuant to Brazil Law No.&nbsp;12,529 of 2011, the resolutions issued thereunder by the Administrative Council of Economic Defence
(CADE), and Brazil Interministerial Ordinance No.&nbsp;994/2012 MJ/M, Immatics&#146; &#147;economic group&#148; did not satisfy the applicable Brazilian merger control thresholds in calendar year 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Covenants of Immatics</U>. Immatics hereby further covenants to BMS that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.1 <U>Maintenance of Exclusively Licensed Assets</U>. Commencing on the Effective Date until the end of the Term, Immatics shall not and
shall cause its Affiliates not to assign, transfer, convey, encumber (including through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey,
encumber (including through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, any Immatics Licensed IP (or any intellectual property that would otherwise be included in the Immatics Licensed IP, including the Initial
Reimbursable Gene Editing Technology), including any of its (or its Affiliate&#146;s) rights to any BMS Target, BMS Receptors or BMS Products in the Territory (collectively, the &#147;<B>Licensed Program Assets</B>&#148;), except to the extent such
assignment, transfer, conveyance, encumbrance or disposition would not conflict with, be inconsistent with or prohibit or limit in any respect any of the rights or licenses granted to BMS hereunder. During the Term, Immatics shall ensure that the
Licensed Program Assets are and remain Controlled by Immatics such that Immatics has the full rights to grant the rights and licensed thereto to BMS hereunder, except for any Licensed Program Assets that are Controlled by Immatics under an Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement for which BMS (or its Affiliate) obtains a license directly from the applicable Third Party for such Licensed Program Assets and BMS (or its Affiliate) determines (in its sole discretion), by
providing written notice to Immatics, to use such Licensed Program Assets under such BMS (or its Affiliate) license for purposes of this Agreement rather than under the Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.2 <U>Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. With respect to the Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements, (a)&nbsp;Immatics (and its Affiliates, as applicable) shall not breach, or commit any acts or permit the occurrence of any omissions that would cause the termination, of any Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement and (b)&nbsp;Immatics shall (and shall cause its Affiliates to, as applicable) satisfy all of its obligations under each Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in
all material respects and, except for any Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements for which (i)&nbsp;BMS (or its Affiliate) obtains a license directly from the applicable Third Party and (ii)&nbsp;BMS (or its
Affiliate) determines (in its sole discretion), by providing written notice to Immatics, to use the intellectual property licensed under such BMS (or its Affiliate) license for purposes of this Agreement rather than under the Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement, Immatics shall, and shall cause its Affiliates to, as applicable, maintain each Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement in full force and effect. Immatics shall,
and shall cause its Affiliates to, as applicable, enforce its rights under each Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to preserve BMS&#146; rights under this Agreement. Immatics shall not, and shall cause its
Affiliates not to, amend, modify, terminate, assign or transfer any Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics obtains BMS&#146; prior written consent (such consent not to be unreasonably
withheld, conditioned or delayed) if doing so could prohibit or limit BMS&#146; rights under this Agreement. Immatics will provide BMS with prompt written notice of any claim of a breach of which it is aware under any of the Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements or notice of termination of any Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.3 <U>BMS Continuing Rights Under Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. At the written request of BMS
on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, Immatics shall (or shall cause its Affiliates to, as applicable) use reasonable efforts to promptly negotiate and execute a written agreement, in
a form reasonably acceptable to BMS, with each Third Party that is a counterparty to the applicable Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (each such counterparty, an &#147;<B>Immatics Licensor</B>&#148;), pursuant to
which (a)&nbsp;in the event of an early termination of such Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement not otherwise resulting from the material breach of this Agreement by BMS, at the request of BMS, such Immatics
Licensor shall grant a direct license to BMS with respect to the intellectual property licensed to Immatics under such Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, on the same terms under which such Immatics Licensor grants
such license to Immatics (or its Affiliate, as applicable) under such Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement for the applicable BMS Products, (b)&nbsp;such Immatics Licensor agrees to and acknowledges the rights
granted to BMS hereunder with respect to any intellectual property licensed to Immatics (or its Affiliate, as applicable) under such Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, including the rights as set forth in this
Section&nbsp;9.3.3, and (c)&nbsp;BMS shall be a party to such written agreement and have the right to enforce such agreement directly against the counterparties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.4 <U>Listing of Additional Immatics Patents</U>. Immatics shall promptly notify BMS in writing if any Patents in the Immatics Licensed IP
that claim or cover any BMS Target, BMS TCR, BMS CAR or BMS Product, including the composition, manufacture or use of any of the foregoing, becomes known to Immatics that are not listed on <U>Schedule 1.77</U> or <U>Schedule 1.80</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.5 <U>No Conflicting Grants</U>. Immatics shall not (and shall ensure that its Affiliates do not) grant any right or license to any Third
Party relating to any of the intellectual property rights it owns or Controls (including the Immatics Licensed IP, the Initial Reimbursable Gene Editing Technology and other Licensed Program Assets), or otherwise with respect to any BMS TCR, BMS CAR
or BMS Product, which conflict with, or could otherwise limit any of the rights or licenses granted to BMS hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.6 <U>No Other
Uses</U>. Except for (a)&nbsp;the performance by Immatics of the research activities allocated to it under a Research Program in accordance with this Agreement and the applicable Research Plan, (b)&nbsp;the performance by Immatics of its
Manufacturing obligations for BMS as specifically set forth in Section&nbsp;3.3.1, and (c)&nbsp;as otherwise expressly agreed to by BMS in writing, neither Immatics nor its Affiliates shall use (and neither shall grant any Third Party the right to
use) any BMS Receptors or BMS Products for any purposes in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Representations and Warranties of BMS</U>.
Except as set forth on <U>Schedule 9.4</U>, BMS hereby represents and warrants to Immatics that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4.1 as of the Effective Date, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) BMS has the full right and authority to grant all of the rights and licenses granted to Immatics (or purported to be granted to Immatics)
hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial or legal
administrative or other proceedings or governmental investigations pending or, to BMS&#146; knowledge, threatened against BMS which would reasonably be expected to adversely affect or restrict the ability of BMS to consummate or perform the
transactions contemplated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4.2 as of the date BMS provides a given BMS Potential Licensed Technology Disclosure
Report pursuant to Section&nbsp;2.2.1(c) or BMS Supplemental Licensed Technology Disclosure Report pursuant to Section&nbsp;2.2.1(d), as applicable, to Immatics with respect to a given Immatics TCR (provided that (A)&nbsp;the following
representations and warranties shall only be made with respect to the specific BMS Potential Licensed Technology disclosed in such BMS Potential Licensed Technology Disclosure Report or BMS Supplemental Licensed Technology Disclosure Report, as
applicable, and (B)&nbsp;BMS shall have the right to notify Immatics in writing within [***] following the date BMS provides such BMS Potential Licensed Technology Disclosure Report or BMS Supplemental Licensed Technology Disclosure Report, as
applicable, of any exceptions to the following representations and warranties), that: neither BMS nor its Affiliates have received any written notice of any claim that the use of the BMS Potential Licensed Technology (identified in such BMS
Potential Licensed Technology Disclosure Report or BMS Supplemental Licensed Technology Disclosure Report, as applicable) for the Development, Manufacture or Commercialization of the applicable Immatics TCR as contemplated to be conducted under this
Agreement would infringe or misappropriate any Patent or <FONT STYLE="white-space:nowrap">Know-How</FONT> (including any trade secret right) owned or controlled by a Third Party. <B><I></I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Covenants of BMS</U>. BMS hereby further covenants to Immatics that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5.1 <U>No Conflicting Grants</U>. BMS shall not (and shall ensure that its Affiliates do not) grant any exclusive license to any Third Party
relating to the BMS Licensed IP which conflict with the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted to Immatics hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5.2 <U>Listing of Additional BMS Patents</U>. BMS shall promptly notify Immatics in writing of any Patents in the BMS Licensed IP that claim
any Immatics Target, Immatics TCR, or Immatics Product, including the composition or use of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5.3 <U>Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. Within [***] after the Effective Date, the Parties will mutually agree upon a schedule, <U>Schedule 9.5.3</U>, that will be added to this Agreement setting forth, with respect to each
Existing Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, (a)&nbsp;those rights with respect to the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> licensed thereunder that are expressly reserved to the licensor,
(b)&nbsp;any Patents that are licensed to Immatics thereunder on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis, (c)&nbsp;the terms and conditions regarding enforcement of Patents licensed thereunder, (d)&nbsp;the terms and conditions
regarding notice and cure of material breaches thereof, (e)&nbsp;whether any Patents thereunder are an exception to the representation in Section&nbsp;9.2(m), and (f)&nbsp;any other terms and conditions applicable to BMS as a sublicensee with
respect to the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> sublicensed thereunder. If BMS becomes a sublicensee under any Immatics New Reimbursable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-License</FONT> Agreement pursuant to 6.5.3(b), the
Parties will promptly update <U>Schedule 9.5.3</U> to identify the information set forth in clauses (a)&nbsp;to (f) above with respect to such Immatics New Reimbursable <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (provided that the
Parties may prepare such update prior to BMS deciding whether to take such sublicense). With respect to each Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement for which BMS is a sublicensee, BMS shall comply (and, if applicable,
shall cause its Affiliates and Sublicensees to comply) with the terms and conditions set forth on <U>Schedule 9.5.3 </U>applicable to BMS as a sublicensee in all material respects; provided that in the event that BMS (or, if applicable, its
Affiliates or Sublicensees) fails to comply with <U>Schedule 9.5.3</U> in any material respect, then (i)&nbsp;Immatics shall promptly notify BMS in writing thereof, including the specific failure to so comply (a &#147;<B>Schedule 9.5.3 Breach
Notice</B>&#148;), (ii) BMS shall have the right to remedy such failure in accordance with the terms and conditions of the applicable Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement as set forth in the foregoing clause
(d)&nbsp;of <U>Schedule 9.5.3</U> for the applicable Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, including any time periods set forth in <U>Schedule 9.5.3</U>, and (iii)&nbsp;if BMS fails to remedy such failure within the
applicable time period, then as Immatics&#146; sole and exclusive remedy, Immatics shall have the right, upon written notice to BMS within [***] following expiration of the applicable cure period, to terminate the sublicense to BMS hereunder of the
applicable impacted Immatics Licensed IP under the applicable Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, provided that, for clarity, this Agreement shall otherwise remain in full force and effect, including with respect
to any other Immatics Licensed IP that is licensed (or sublicensed) to BMS hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5.4 <U>Certain Rights of Third Parties under
Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</U>. To the extent that the rights granted to BMS hereunder (including under Section&nbsp;7.11.2(a) with respect to enforcement of certain Initial Reimbursable Gene Editing
Technology) are subject to rights or obligations granted to, or retained by, the applicable Third Parties as expressly set forth on <U>Schedule </U>9.5.3 (as may be updated from time to time in accordance with Section&nbsp;9.5.3), then Immatics
shall use reasonable efforts to allow and afford BMS the right to exercise and enjoy the rights otherwise granted to BMS hereunder, including under Section&nbsp;7.11.2(a), to the maximum extent possible under the applicable Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement, including by, to the extent not prohibited under the applicable Immatics <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, (a)&nbsp;promptly providing to BMS any relevant
information and correspondence from such Third Party related to such rights, (b)&nbsp;consulting with BMS in connection with, and affording BMS the right to review and comment on, any relevant matters, and providing BMS&#146; reasonable comments and
feedback to the applicable Third Party, and (c)&nbsp;exercising any rights or options (e.g., <FONT STYLE="white-space:nowrap">step-in</FONT> rights, consent rights, etc.) that Immatics may have under the applicable Immatics <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements as reasonably requested by BMS (including exercising <FONT STYLE="white-space:nowrap">step-in</FONT> rights, or granting or withholding consent, as applicable) in order to allow BMS to exercise
its rights hereunder, including under Section&nbsp;7.11.2(a), to the maximum extent possible, and in furtherance thereof, Immatics shall promptly notify BMS when such rights or options arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 <U>Mutual Covenants</U>. Each Party hereby covenants to the other Party that such Party and its Affiliates shall perform its activities
pursuant to this Agreement in compliance (and shall ensure compliance by any of its subcontractors) with all Applicable Laws, including, to the extent applicable, GCP, GLP and GMP. Neither Party nor their Affiliates will employ or otherwise use in
any capacity, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. &#167; 335a, or any foreign equivalent thereof, in the performance of any activities under this Agreement,
including in performing any portion of the Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 <U>Disclaimer</U>. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT),
INCLUDING WITH RESPECT TO ANY PATENTS OR <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> OR MATERIALS, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE, AND NONINFRINGEMENT
OF ANY THIRD PARTY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS. WITHOUT LIMITING THE FOREGOING, NEITHER PARTY MAKES ANY REPRESENTATION, WARRANTY OR GUARANTEE THAT THE RESEARCH PROGRAM WILL BE SUCCESSFUL, OR THAT ANY OTHER PARTICULAR RESULTS WILL
BE ACHIEVED WITH RESPECT TO THE RESEARCH PROGRAM, ANY COLLABORATION TARGET, ANY COLLABORATION RECEPTOR OR ANY COLLABORATION PRODUCT HEREUNDER. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; INSURANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Indemnification by BMS</U>. BMS shall indemnify, defend and hold harmless Immatics and its Affiliates and its and their respective
directors, officers, employees, agents, successors and assigns (collectively, the &#147;<B>Immatics Indemnitees</B>&#148;), from and against any and all Third Party Damages to the extent arising out of or relating to, directly or indirectly, any
Third Party Claim to the extent based upon: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Indemnification by Immatics</U>. Immatics shall indemnify, defend and hold harmless BMS, its Affiliates and its and their respective
directors, officers, employees, agents, successors and assigns (collectively, the &#147;<B>BMS Indemnitees</B>&#148;), from and against any and all Third Party Damages to the extent arising out of or relating to, directly or indirectly, any Third
Party Claim to the extent based upon: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U><FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product</U>. If BMS exercises its BMS
<FONT STYLE="white-space:nowrap">Opt-In</FONT> Right and the Parties enter into the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement, then the indemnification obligations of the Parties with respect to Third Party Damages to
the extent arising out of or relating to any Third Party Claim to the extent based upon the research, development (including Development), making (including Manufacture), use, offer for sale, sale, importation, Commercialization and other
exploitation of the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product in the Field in the Territory, after such time as the Parties enter into the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement, shall be as set
forth in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Procedure</U>. If a Party is seeking indemnification under
Section&nbsp;10.1 or 10.2, as applicable (the &#147;<B>Indemnitee</B>&#148;), it shall inform the other Party (the &#147;<B>Indemnitor</B>&#148;) of the claim giving rise to the obligation to indemnify pursuant to Section&nbsp;10.1 or 10.2, as
applicable, as soon as reasonably practicable after receiving notice of the claim (provided, however, any delay or failure to provide such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnitee&#146;s rights to
indemnification under Section&nbsp;10.1 or 10.2, as applicable, except to the extent that such delay or failure actually and materially prejudices the Indemnitor&#146;s ability to defend against the relevant claims). The Indemnitor shall have the
right to assume the defense of any such claim for which the Indemnitee is seeking indemnification pursuant to Section&nbsp;10.1 or 10.2, as applicable. The Indemnitee shall cooperate with the Indemnitor and the Indemnitor&#146;s insurer as the
Indemnitor may reasonably request, and at the Indemnitor&#146;s cost and expense. The Indemnitee shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the
Indemnitor. The Indemnitor shall not settle any claim without the prior written consent of the Indemnitee, not to be unreasonably withheld, conditioned or delayed; provided, however, that the Indemnitor shall not be required to obtain such consent
if the settlement (a)&nbsp;involves only the payment of money and will not result in the Indemnitee (or other Immatics Indemnitees or BMS Indemnitees, as applicable) becoming subject to injunctive or other similar type of relief or additional <FONT
STYLE="white-space:nowrap">non-monetary</FONT> obligations, (b)&nbsp;does not require an admission by the Indemnitee (or other Immatics Indemnitees or BMS Indemnitees, as applicable), and (c)&nbsp;does not adversely affect the rights or licenses
granted to the Indemnitee (or its Affiliate) under this Agreement. The Indemnitee shall not settle or compromise any such claim without the prior written consent of the Indemnitor, which it may provide in its sole discretion. If the Parties cannot
agree as to the application of Section&nbsp;10.1 or 10.2, as applicable, to any claim, pending resolution of the Dispute pursuant to Section&nbsp;12.7 the Parties may conduct separate defenses of such claims, with each Party retaining the right to
claim indemnification from the other Party in accordance with Section&nbsp;10.1 or 10.2, as applicable, upon resolution of the underlying claim. In each case, the Indemnitee shall reasonably cooperate with the Indemnitor, and shall make available to
the Indemnitor all pertinent information under the Control of the Indemnitee, which information shall be subject to Article 8. If the Indemnitor does not assume and conduct the defense of the Third Party Claim as provided above for which the
Indemnitor is required to indemnify the Indemnitee, (a)&nbsp;the Indemnitee may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Third Party Claim; provided that (i)&nbsp;the Indemnitee shall
consult with the Indemnitor and keep the Indemnitor informed in connection therewith and (ii)&nbsp;the Indemnitee shall not settle or compromise any such claim, or otherwise consent to the entry of any judgment, without the prior written consent of
the Indemnitor, which it may provide in its sole discretion, and (b)&nbsp;the Indemnitor shall remain responsible to indemnify the Indemnitee as provided in this Article 11 (Indemnification). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Insurance</U>. During the Term and for a period of [***] thereafter, each Party shall maintain, at its cost, a program of insurance or
self-insurance against liability and other risks associated with its activities and obligations under this Agreement, and its indemnification obligations hereunder, in such amounts, subject to such deductibles and on such terms as are customary for
such Party for the activities to be conducted by it under this Agreement. It is understood that such insurance shall not be construed to create a limit on either Party&#146;s liability with respect to its indemnification obligations under this
Article 10, or otherwise. Except with respect to a self-insurance program, each Party will provide the other Party with written evidence of such insurance upon the other Party&#146;s written request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>LIMITATION OF LIABILITY</U>. NEITHER IMMATICS NOR BMS, NOR ANY
OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS OR LOST
REVENUES), WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY, CONTRIBUTION OR OTHERWISE, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR
OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 10.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A)&nbsp;THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER
SECTION 10.1 OR 10.2 FOR ANY THIRD PARTY DAMAGES OR (B)&nbsp;THE LIABILITY OF ANY PARTY FOR BREACH OF ANY OF ITS OBLIGATIONS UNDER ARTICLE 8 OR THE LIABILITY OF IMMATICS FOR BREACH OF ANY OF ITS OBLIGATIONS UNDER ARTICLE 5. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND
TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>Term; Expiration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.1 <U>Term</U>. This Agreement shall become effective on the Effective Date and, except as otherwise set forth in the <FONT
STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product (if any), shall remain in effect until it expires as follows, unless earlier terminated in accordance
with this Article 11 (the &#147;<B>Term</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) on a Collaboration <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Collaboration</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, this Agreement shall expire on the date of the expiration of the
BMS Royalty Term or Immatics Royalty Term, as applicable, with respect to such Collaboration Product in such country; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) in its
entirety upon the expiration of all applicable BMS Royalty Terms and Immatics Royalty Terms under this Agreement with respect to all Collaboration Products in all countries in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.2 <U>Effect of Product Expiration</U>. After expiration of the Term with respect to a given Collaboration Product in a given country
pursuant to Section&nbsp;11.1.1(a), the licenses set forth in Section&nbsp;7.1.1, or Section&nbsp;7.2.1(b), as applicable, with respect to such Collaboration Product (and the BMS TCR, BMS CAR or Immatics TCR, as applicable, contained therein) in
such country will automatically become fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual, irrevocable and royalty-free. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>Termination for Breach</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.1 <U>Material Breach</U>. This Agreement may be terminated by a Party (a)&nbsp;on a Collaboration <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Collaboration</FONT></FONT> Product basis for the material breach by the other Party of this Agreement with respect to such Collaboration Product; provided, however, that in the event of a material breach of
this Agreement by Immatics with respect to a given Initial BMS Product, BMS shall have the right to terminate this Agreement either with respect to such Initial BMS Product or in its entirety, in BMS&#146; discretion, or (b)&nbsp;in its entirety for
the material breach by the other Party that applies to the Agreement in general (and not specific to one or more Collaboration Products), provided that, in each case ((a) or (b), as applicable), the breaching Party has not cured such breach within
[***] after the date of written notice to the breaching Party of such breach (or [***] in the case of a breach as a result of <FONT STYLE="white-space:nowrap">non-payment</FONT> of any amounts due under this Agreement) (the &#147;<B>Cure
Period</B>&#148;), which notice shall describe such breach in reasonable detail and shall state the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party&#146;s intention to terminate this Agreement with respect to such Collaboration Product
(or, solely with respect to BMS as the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party, in its entirety, as applicable). For clarity, but subject to Section&nbsp;11.2.2, the Cure Period for any allegation made as to a material breach
under this Agreement with respect to a given Collaboration Product will run from the date that written notice was first provided to the breaching Party by the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party. Any such termination of this
Agreement under this Section&nbsp;11.2.1 shall become effective at the end of the Cure Period, unless the breaching Party has cured such breach prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the
Cure Period, then such Cure Period shall be extended for an additional [***] so long as the breaching Party continues to use reasonable efforts to cure such material breach during such extension period. For the avoidance of doubt, termination of
this Agreement with respect to any particular Collaboration Product pursuant to this Section&nbsp;11.2.1 shall not terminate this Agreement with respect to any other Collaboration Product. <B><I></I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.2 <U>Disagreement as to Material Breach</U>. Notwithstanding Section&nbsp;11.2.1, if the Parties in good faith disagree as to whether
there has been a material breach of this Agreement pursuant to Section&nbsp;11.2.1, then: (a)&nbsp;the Party that disputes that there has been a material breach may contest the allegation by referring such matter, within [***] following such written
notice of alleged material breach, for resolution to the Executive Officers, who shall meet promptly to discuss the matter and determine, within [***] following referral of such matter, whether or not a material breach has occurred pursuant to
Section&nbsp;11.2.1; provided that if the Executive Officers are unable to resolve such dispute within such [***] period after it is referred to them, the matter will be resolved as provided in Section&nbsp;12.7; (b) the relevant Cure Period with
respect thereto will be tolled from the date the breaching Party notifies the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this
Agreement; (c)&nbsp;subject to Section&nbsp;11.9, during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder;
and (d)&nbsp;if it is ultimately determined that the breaching Party committed such material breach, then the breaching Party shall have the right to cure such material breach, after such determination, within the Cure Period (as may be extended in
accordance with Section&nbsp;11.2.1) which shall commence as of the date of such determination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <U>Voluntary Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.1 <U>Termination by BMS</U>. BMS may terminate this Agreement on a BMS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-BMS</FONT></FONT> Product basis at will, in its sole discretion, upon (a) [***] prior written notice to Immatics at any time prior to the First Commercial Sale of such BMS
Product and (b) [***] prior written notice to Immatics at any time after the First Commercial Sale of such BMS Product. For the avoidance of doubt, termination of this Agreement with respect to any particular BMS Product pursuant to this
Section&nbsp;11.3.1 shall not terminate this Agreement with respect to any other BMS Product or any Immatics Products (and BMS shall have no right to terminate this Agreement with respect to any Immatics Product pursuant to this
Section&nbsp;11.3.1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.2 <U>Termination by Immatics</U>. Immatics may terminate this Agreement on an Immatics <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Immatics</FONT></FONT> Product basis at will, in its sole discretion, upon (a)&nbsp;[***] prior written notice to BMS at any time prior to the First Commercial Sale of such
Immatics Product and (b) [***] prior written notice to BMS at any time after the First Commercial Sale of such Immatics Product; provided that, if Immatics includes any BMS Special Learnings Technology as part of BMS Licensed IP hereunder (as set
forth in either an Immatics <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice (pursuant to Section&nbsp;2.2.1(c)) or an Immatics Supplemental <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP Acceptance Notice (pursuant
to Section&nbsp;2.2.1(d))), then Immatics (and its Affiliates) shall have no right to, and shall not, continue the Development or Commercialization of such Immatics Product (or any Immatics TCR therein), or grant any licenses or other rights to a
Third Party to do so, following the effective date of such termination. For the avoidance of doubt, (x)&nbsp;termination of this Agreement with respect to any particular Immatics Product pursuant to this Section&nbsp;11.3.2 shall not terminate this
Agreement with respect to any other Immatics Product or any BMS Products (and Immatics shall have no right to terminate this Agreement with respect to any BMS Product pursuant to this Section&nbsp;11.3.2) and (y)&nbsp;Immatics shall have no right to
terminate this Agreement with respect to the <FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product (if any) pursuant to this Section&nbsp;11.3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.4 <U>Termination for Bankruptcy</U>. If either Party makes a general assignment for the benefit of its creditors, appoints or suffers
appointment of an examiner or of a receiver or trustee over all or substantially all of its property, passes a resolution for its winding up or files a petition under any bankruptcy or insolvency act or law or has any such petition filed against it
which is not dismissed, discharged, bonded or stayed within [***] after the filing thereof (each, an &#147;<B>Insolvency Event</B>&#148;), the other Party may terminate this Agreement in its entirety, effective immediately upon written notice to
such Party; provided that, in connection therewith, the provisions of Section&nbsp;7.7 shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.5 <U>Termination of 2019
Agreements</U>. In the event that (a)&nbsp;BMS designates a given BMS TCR hereunder and (b)&nbsp;following such designation, the applicable 2019 License Agreement (under which such BMS TCR is a &#147;Licensed TCR&#148; (as defined in the applicable
2019 License Agreement)) terminates (but excluding, for clarity, expiration of such 2019 License Agreement), then this Agreement shall terminate solely with respect to such BMS TCR and the BMS TCR Products transduced with<B> </B>such BMS TCR,
effective as of the date of termination of such 2019 License Agreement. For the avoidance of doubt, termination of this Agreement with respect to any particular BMS TCR and the BMS TCR Products transduced with<B> </B>such BMS TCR pursuant to this
Section&nbsp;11.5 shall not terminate this Agreement with respect to any other BMS Receptors or BMS Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 <U>Effects of Expiration and Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.6.1 <U>Generally</U>. In the event of expiration or termination of this Agreement for any reason (either in its entirety or with respect to
a given Collaboration Product; provided that with respect to expiration or termination with respect to a given Collaboration Product, the following shall apply only with respect to such Collaboration Product), the following shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) except as set forth in the last sentence of Section&nbsp;6.3.2, or in Section&nbsp;11.1.2, this Section&nbsp;11.6 or Section&nbsp;11.8,
all rights and licenses granted herein shall terminate; provided that, notwithstanding the foregoing, the licenses granted in Sections 7.1.2, 7.2.2, 7.8.3 and 7.8.4 shall survive expiration or termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) each Party shall return or destroy all Confidential Information of the other Party as required by ARTICLE 8; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) if this Agreement expires or terminates in its entirety, the obligations under Article 5 shall terminate; provided that, for clarity, if
this Agreement is terminated with respect to all BMS Products Directed to a given BMS Target, then the provisions of Article 5 shall no longer apply with respect to such BMS Target (but shall continue to apply with respect to all other BMS Targets);
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) if this Agreement is terminated in its entirety or with respect to one or more Collaboration Products, then notwithstanding the
foregoing provisions of this Section&nbsp;11.6, the licenses granted to the applicable Party hereunder (i.e., the licenses granted to BMS under Section&nbsp;7.1.1 with respect to any BMS Product that is terminated, or the licenses granted to
Immatics under Section&nbsp;7.2.1(b) with respect to any Immatics Product that is terminated) shall survive for up to [***] following the effective date of termination in order for such Party (and its Affiliates, Sublicensees and distributors), at
such Party&#146;s discretion, during such period immediately following the effective date of termination, to (i)&nbsp;finish or otherwise wind-down any ongoing Clinical Trials with respect to the applicable terminated Collaboration Product(s)
hereunder (provided that, if in the best interests of trial subjects, a Clinical Trial is not able to be finished or wound-down within such [***] period, then such [***]<B> </B>period shall automatically be extended with respect to such Clinical
Trial until such Clinical Trial is completed or can be reasonably and safely wound-down) and (ii)&nbsp;finish and sell any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress</FONT></FONT> and any remaining inventory
of such terminated Collaboration Product(s) hereunder (provided that such Party shall pay royalties on Annual Product Net Sales of such Collaboration Product(s) sold by such Party (or its applicable Selling Parties) during such period (provided that
the applicable Royalty Term is still ongoing) as and to the extent such Party would otherwise be required to pay such royalties as set forth in Section&nbsp;6.3); provided that, for clarity, such Party shall have no obligation to undertake such
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.6.2 <U>BMS Products</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If this Agreement is terminated by BMS with respect to a BMS
Product or in its entirety, in each case pursuant to Section&nbsp;11.3.1, then upon Immatics&#146; written request to BMS (which must be provided within [***] after the effective date of termination), BMS and Immatics shall discuss exclusively in
good faith, for a period of up to [***]following such written request, terms and conditions under which BMS may be willing to grant to Immatics rights to Develop and Commercialize the applicable terminated BMS Product(s), including reasonable
financial and other terms; provided that the foregoing provisions of this Section&nbsp;11.6.2(a) shall not apply unless, as of the effective date of termination of this Agreement, (i)&nbsp;if the applicable BMS Product is a BMS TCR Product, the
applicable 2019 License Agreement with respect to the BMS TCR in such BMS TCR Product has been terminated, or BMS has provided written notice to terminate such 2019 License Agreement with respect to the TCR Target for such BMS TCR Product and
(ii)&nbsp;if the applicable BMS Product is a BMS CAR Product, BMS (and its Affiliates) have ceased all Development (and has no bona fide plans to continue any Development) of products Directed to the CAR Target for such BMS CAR Product.
Notwithstanding the foregoing provisions of this Section&nbsp;11.6.2(a), neither Party shall have any obligation to enter into any such agreement with respect to rights to Develop and Commercialize the applicable terminated BMS Product(s) unless
each Party agrees to do so in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If this Agreement is terminated by BMS with respect to one or more Initial BMS
Products (or in its entirety with respect to all Initial BMS Products), in each case pursuant to Section&nbsp;11.3.1, then BMS and its Affiliates shall not, specifically in connection with the Development or Commercialization of such terminated
Initial BMS Product(s), practice, or grant a license to any Third Party to practice, under any Valid Claim (but without regard to the [***] limitation under clause (b)&nbsp;of the definition of Valid Claim) of a BMS Restricted Sole Patent that
claims a BMS Restricted Sole Invention. For clarity, this Section&nbsp;11.6.2(b) shall not prohibit or otherwise limit (i)&nbsp;the practice under any BMS Restricted Sole Patent in connection with the Development or Commercialization of any product
other than the specific Initial BMS Product(s) for which this Agreement was so terminated (even if such other product is Directed to the same BMS Target), (ii) the practice under such BMS Restricted Sole Patent to the extent used to practice subject
matter under such BMS Restricted Sole Patent that is not the specific BMS Restricted Sole Invention, including in connection with the Development or Commercialization of such terminated Initial BMS Product(s), or (iii)&nbsp;the use or other
exploitation of any composition or design of any BMS Receptor or any construct separate from the terminated Initial BMS Product(s). As used herein, the following terms shall have the following meanings: (I)&nbsp;a &#147;<B>BMS Restricted Sole
Invention</B>&#148; means any BMS Product Specific Invention that (x)&nbsp;was created, conceived, discovered, generated, invented, made or reduced to practice in the conduct of the Research Program for the applicable terminated Initial BMS Product
solely by or on behalf Immatics or its Affiliates and assigned to BMS by Immatics pursuant to Section&nbsp;7.8.4 and (y)&nbsp;is solely related to or useful for such terminated Initial BMS Product (e.g., not generally useful for Cell Therapy
Products) (but excluding, for clarity, any such Inventions that may also fall within (X)&nbsp;Section&nbsp;1.25(b)(i) or (ii), or (Y)&nbsp;Section&nbsp;1.25(b)(iii), but with respect to this clause (Y)&nbsp;solely to the extent that the applicable
improvement, modification or enhancement to the applicable BMS Receptor(s) is also applicable to, and the practice of such Invention is in connection with, Target(s) other than just the BMS Target to which such BMS Receptor had been Directed
hereunder at the time of such termination); and (II)&nbsp;a &#147;<B>BMS Restricted Sole Patent</B>&#148; means a BMS Sole Patent (filed by BMS as of the effective date of the applicable termination) to the extent specifically claiming a BMS
Restricted Sole Invention. <B><I></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If this Agreement is terminated by BMS with respect to a BMS
Product or in its entirety, in each case pursuant to Section&nbsp;11.3.1, then BMS will grant, and hereby does grant, to Immatics a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> worldwide right and license, with the right to grant sublicenses (through multiple tiers), under (x)&nbsp;the BMS Sole Inventions under Section&nbsp;1.25(d) (but excluding, for clarity, any BMS Sole
Inventions that may also fall within Section&nbsp;1.25(b) or (c)) that (i)&nbsp;are created, conceived, discovered, generated, invented, made or reduced to practice, in each case, solely by or on behalf of Immatics or its Affiliates and assigned to
BMS by Immatics under Section&nbsp;7.8.4 and (ii)&nbsp;that specifically relate to the BMS Target(s) of the BMS Product(s) so terminated from this Agreement and (y)&nbsp;the BMS Sole Patents claiming such BMS Sole Inventions (solely to the extent
necessary to practice such BMS Sole Inventions), for all purposes in connection with such BMS Target(s); provided that this Section&nbsp;11.6.2(c) shall not apply where the applicable BMS Target or the BMS Receptor Directed to such BMS Target is
Controlled by BMS (or its Affiliate) as of the time of such termination.<B> </B><B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 <U>Certain Additional Remedies in Lieu of
Termination</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.7.1 <U>Additional Remedies of BMS</U>. If (a)&nbsp;BMS notifies Immatics in writing of a material breach of this
Agreement by Immatics, either in its entirety or with respect to a given BMS Product, and (b)&nbsp;BMS would have the right to terminate this Agreement in its entirety or with respect to a given BMS Product pursuant to Section&nbsp;11.2 (including
the dispute resolution provisions provided therein), then in lieu of BMS terminating pursuant to Section&nbsp;11.2 (including the dispute resolution provisions provided therein), and without limiting any other rights or remedies of BMS, BMS may
elect to have this Agreement continue in full force and effect (in its entirety or with respect to the affected BMS Product(s), as applicable) by providing written notice thereof to Immatics; provided, however, that if BMS so elects to continue this
Agreement, then from and after such time as BMS delivers such written notice to Immatics, any and all amounts thereafter payable by BMS hereunder (including Milestone Payments and royalties) with respect to any such BMS Product(s) (or all BMS
Products, if this Agreement would be terminated in its entirety) for which BMS made such election shall be reduced by [***]. Without limiting the foregoing, in the event that BMS or its Affiliate has the right to reduce payments under a given 2019
Agreement pursuant to equivalent or similar provisions to this Section&nbsp;11.7.1 thereunder, then this Section&nbsp;11.7.1 shall automatically be deemed to be triggered such that the payments relating to any BMS TCR Products hereunder will be
reduced as set forth in this Section&nbsp;11.7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.7.2 <U>Additional Remedies of Immatics</U>. If (a)&nbsp;Immatics notifies BMS in
writing of a material breach of this Agreement by BMS, either in its entirety or with respect to a given Immatics Product, and (b)&nbsp;Immatics would have the right to terminate this Agreement in its entirety or with respect to a given Immatics
product pursuant to Section&nbsp;11.2 (including the dispute resolution provisions provided therein), then in lieu of Immatics terminating pursuant to Section&nbsp;11.2 (including the dispute resolution provisions provided therein), and without
limiting any other rights or remedies of Immatics, Immatics may elect to have this Agreement continue in full force and effect (in its entirety or with respect to the affected Immatics Product(s), as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">applicable) by providing written notice thereof to BMS; provided, however, that if
Immatics so elects to continue this Agreement, then from and after such time as Immatics delivers such written notice to BMS, any and all amounts thereafter payable by Immatics hereunder (including royalties) with respect to any such Immatics
Product(s) (or all Immatics Products, if this Agreement would be terminated in its entirety) for which Immatics made such election shall be reduced by [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8 <U>Surviving Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.8.1 <U>Accrued Rights; Remedies</U>. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights
that shall have accrued to the benefit of any Party prior to such termination or expiration, and any and all damages or remedies (whether in law or in equity) arising from any breach hereunder, each of which shall survive termination or expiration
of this Agreement. Such termination or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination or expiration of this Agreement. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article&nbsp;11 are in addition to any other relief and remedies available to either Party under this Agreement and at Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.8.2 <U>Survival</U>. Without limiting the provisions of Section&nbsp;11.8.1, the rights and obligations of the Parties set forth in the
following Sections and Articles of this Agreement shall survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are expressly stated to survive termination or expiration of this Agreement: [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.8.3 <U>Termination in Part</U>. If this Agreement is terminated only with respect to a given Collaboration Product, then the foregoing
provisions of this Section&nbsp;11.8 shall apply only with respect to such Collaboration Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 <U>Milestone Payments</U>.
Notwithstanding anything to the contrary contained herein, if notice of termination of this Agreement with respect to a given BMS Product is given prior to achievement of a given milestone set forth in Section&nbsp;6.4, BMS shall not be obligated to
make any Milestone Payment to Immatics with respect to any milestone achieved following the notice of such termination with respect to such BMS Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 <U><FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product</U>. Notwithstanding the foregoing provisions of this Article&nbsp;11,
if BMS exercises its BMS <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, then the provisions regarding expiration and termination (including effects of expiration and termination) with respect to the
<FONT STYLE="white-space:nowrap">Co-Developed</FONT> Product shall be as set forth in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1
<U>Severability</U>. If any one or more of the terms or provisions of this Agreement is held by a court of competent jurisdiction to be void, invalid or unenforceable in any situation in any jurisdiction, such holding shall not affect the validity
or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the invalid, void or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision shall be
considered severed from this Agreement solely for such situation and solely in such jurisdiction, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the invalid, void or unenforceable term or provision is of such essential
importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, void or unenforceable term or provision. If the final judgment of such court declares that any term or
provision hereof is invalid, void or unenforceable, the Parties agree to (a)&nbsp;reduce the scope, duration, area or applicability of the term or provision or to delete specific words or phrases to the minimum extent necessary to cause such term or
provision as so reduced or amended to be enforceable, and (b)&nbsp;make a good faith effort to replace any invalid, void or unenforceable term or provision with a valid and enforceable one such that the objectives contemplated by the Parties when
entering this Agreement may be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Notices</U>. Any notice required or permitted to be given by this Agreement shall be in
writing and in English and shall be (a)&nbsp;delivered by hand or by overnight courier with tracking capabilities, (b)&nbsp;mailed postage prepaid by first class, registered, or certified mail, or (c)&nbsp;delivered by facsimile followed by delivery
via either of the methods set forth in foregoing clauses (a)&nbsp;or (b), in each case, addressed as set forth below unless changed by notice so given: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to BMS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Celgene Switzerland
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">430 E. 29<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>
Flr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY, 10016 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Executive Vice President, Corporate Strategy and Business Development </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Bristol-Myers
Squibb Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Route 206 and Province Line Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Princeton, NJ 08543-4000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Senior Vice President and Associate General Counsel, Transactions Law </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to Immatics: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Immatics US,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2201 W. Holcombe Blvd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 205 Houston, Texas 77030 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Business Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With copies to:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Immatics Biotechnologies GmbH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Paul-Ehrlich-Strasse 15 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">72076
Tuebingen, Germany </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">-and- </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One Freedom Square
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Reston Town Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">11951
Freedom Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Reston, VA 20190-5656 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Kenneth J. Krisko </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such notice shall be deemed
given on the date received, except any notice received after 5:30 p.m. (in the time zone of the receiving party) on a Business Day or received on a <FONT STYLE="white-space:nowrap">non-Business</FONT> Day shall be deemed to have been received on the
next Business Day. A Party may add, delete, or change the person or address to which notices should be sent at any time upon written notice delivered to the other Parties in accordance with this Section&nbsp;12.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 <U>Force Majeure</U>. A Party shall not be liable for delay or failure in the performance of any of its obligations hereunder if such
delay or failure is due to a cause beyond the reasonable control of such Party, including acts of God, fires, earthquakes, acts of war, terrorism, or civil unrest, or hurricane or other inclement weather (&#147;<B>Force Majeure</B>&#148;); provided,
however, that the affected Party promptly notifies the other Party and further provided that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes of <FONT STYLE="white-space:nowrap">non-performance</FONT>
and to mitigate the effect of such occurrence, and shall continue performance in accordance with the terms of this Agreement whenever such causes are removed. When such circumstances arise, the Parties shall negotiate in good faith any modifications
of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4 <U>Assignment</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.4.1 <U>Generally</U>. Except as expressly permitted herein, this Agreement may not be assigned or transferred by any Party, nor may
any Party assign or transfer any rights or obligations created by this Agreement, except as expressly permitted hereunder without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.4.2 <U>BMS</U>. Notwithstanding the limitations in Section&nbsp;12.4.1, BMS may assign or transfer this Agreement, or any rights or
obligations hereunder, in whole or in part, to [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.4.3 <U>Immatics</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding the limitations in Section&nbsp;12.4.1, and subject to the remaining provisions of this Section&nbsp;12.4.3, Immatics may
assign or transfer this Agreement, or any rights or obligations hereunder, in whole or in part, to [***]. Without limiting the provision of Section&nbsp;5.1, [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary herein, Immatics hereby
agrees and acknowledges that [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.4.4 <U>All Other Assignments Null and Void</U>. The terms of this Agreement will be binding upon
and will inure to the benefit of the successors, heirs, administrators and permitted assigns of the applicable Party. Any purported assignment in violation of this Section&nbsp;12.4 will be null and void <I>ab initio</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5 <U>Waivers and Modifications</U>. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed
to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion. No waiver, modification,
release, or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6 <U>WAIVER OF JURY TRIAL</U>. EXCEPT AS LIMITED BY APPLICABLE LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY
IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7 <U>Choice of Law; Dispute Resolution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.7.1 <U>Choice of Law</U>. This Agreement shall be governed by, enforced and construed in accordance with the laws of the State of New York
and the patent laws of the United States without reference to any rules of conflict of laws or renvoi and excluding the United Nations Convention on Contracts for the International Sales of Goods; provided, however, that with respect to matters
involving the validity or infringement of intellectual property rights in a given country, such matter may be brought in the applicable country (in accordance with Section&nbsp;12.7.3) and the Applicable Laws of the applicable country shall apply
(subject to Section&nbsp;7.8.1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.7.2 <U>Exclusive Dispute Resolution Mechanism</U>. Except as otherwise expressly set forth in this
Agreement, the Parties agree that the procedures set forth in Section&nbsp;12.7.3 will be the exclusive mechanism for resolving any dispute (whether in contract, tort or otherwise), controversy or claim between the Parties arising out of, relating
to or in connection with this Agreement, including any Party&#146;s rights or obligations under this Agreement, breach of this Agreement or the transactions contemplated by this Agreement (each, a &#147;<B>Dispute</B>&#148;); provided that decisions
that are subject to the decision-making authority of a given Party, as expressly set forth in this Agreement, will not be subject to the provisions of Section&nbsp;12.7.3 so long as such decisions are made in accordance with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.7.3 <U>Jurisdiction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) It shall be a condition precedent to the commencement of any action in court (save an action for an interim injunction or provisional
relief) in respect of any Dispute that the Parties have sought to resolve the Dispute by either Party notifying the other Party in writing for resolution to the Executive Officers who shall meet (whether in person or via teleconference) within [***]
of such notice to seek resolution in good faith. If the Executive Officers are unable to resolve the Dispute at such meeting, either Party may pursue any remedy available to such Party at law or in equity, subject to the terms and conditions of this
Agreement, including this Section&nbsp;12.7.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise set forth in this Section&nbsp;12.7.3, the sole jurisdiction and
venue for all actions, suits and proceedings arising out of or in connection with any Dispute (except in respect of an Excluded Claim, where jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> will be the state and federal courts
located in the Borough of Manhattan in New York, New York, United States. Each Party hereby irrevocably and unconditionally (a)&nbsp;consents to submit to the exclusive jurisdiction of the state and federal courts located in the Borough of Manhattan
in New York, New York, United States for any action, suit or proceeding arising out of or in connection with such Dispute, and (b)&nbsp;waives any objection to the laying of venue of any action, suit or proceeding arising out of or in connection
with such Dispute in the state and federal courts of the Borough of Manhattan in New York, New York, United States and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought
in an inconvenient forum. Each of the Parties agrees that process may be served upon it in the manner specified in Section&nbsp;12.2 and irrevocably waives and covenants not to assert or plead any objection which it might otherwise have to such
jurisdiction, or to such manner of service of process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the provisions of Section&nbsp;12.7.3(b), either Party may,
without waiving any remedy under this Agreement, seek from any court having jurisdiction any equitable relief, including any injunctive or provisional relief and specific performance to protect the rights or property of that Party. Such remedies
will not be deemed to be the exclusive remedies for a breach of this Agreement but will be in addition to all other remedies available at law or equity. In addition, notwithstanding the provisions of Section&nbsp;12.7.3(b), either Party may bring an
action in any court having jurisdiction to enforce a judgement rendered pursuant to Section&nbsp;12.7.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Until final resolution
of the Dispute, (i)&nbsp;this Agreement will remain in full force and effect and (ii)&nbsp;the time periods for cure as to any termination will be tolled. The Parties further agree that any payments made pursuant to this Agreement pending resolution
of the Dispute shall be refunded if a court determines that such payments are not due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) As used in this Section&nbsp;12.7.3,
&#147;<B>Excluded Claim</B>&#148; means a dispute, controversy or claim that concerns (i)&nbsp;the validity or infringement of a Patent, trademark or copyright, or (ii)&nbsp;any antitrust, anti-monopoly or competition law or regulation, whether or
not statutory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8 <U>Relationship of the Parties</U>. Except as otherwise set forth
in the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement or the Tax Matters Agreement, Immatics and BMS are independent contractors under this Agreement, and nothing contained herein is intended or is to be construed so as to
constitute (a)&nbsp;Immatics as a partner, agent, or joint venturer of BMS or (b)&nbsp;BMS as a partner, agent or joint venturer of Immatics. Neither Immatics nor BMS, respectively, shall have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of BMS or Immatics, respectively, or to bind BMS or Immatics, respectively, to any contract, agreement, or undertaking with any Third Party. Except as otherwise set forth in the <FONT
STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement or the Tax Matters Agreement, the Parties (and any successor, assignee, transferee, or affiliate of a Party) shall use commercially reasonable efforts to (i)&nbsp;avoid restructuring
the arrangement contemplated by this Agreement in a way that would knowingly and intentionally cause the arrangement contemplated by this Agreement being treated as a partnership for United States tax purposes and (ii)&nbsp;not treat or report the
relationship between the Parties arising under this Agreement as a partnership for United States tax purposes, without the prior written consent of the other Party unless required by a final &#147;determination&#148; as defined in Section&nbsp;1313
of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.9 <U>Third Party Beneficiaries</U>. There are no express or implied Third Party beneficiaries hereunder. The provisions of
this Agreement are for the exclusive benefit of the Parties, and no other person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.10 <U>Entire Agreement</U>. This Agreement, together with the attached exhibits and schedules, and, if entered into in accordance with the
terms of this Agreement, the <FONT STYLE="white-space:nowrap">Co-Commercialization</FONT> Agreement and the Tax Matters Agreement, contains the entire agreement by the Parties with respect to the subject matter hereof and supersedes any prior
express or implied agreements, understandings and representations, either oral or written, which may have related to the subject matter hereof in any way, including any and all term sheets relating to the transactions contemplated by this Agreement
and exchanged between the Parties prior to the Effective Date. For clarity, except as otherwise expressly set forth herein, nothing contained herein amends or supersedes any of the 2019 Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.11 <U>Counterparts</U>. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same
document. All such counterparts shall be deemed an original, shall be construed together, and shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or
similar attachment to electronic mail (any such delivery, an &#147;<B>Electronic Delivery</B>&#148;) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if
it were the original signed version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the
use of Electronic Delivery as a defense to the formation of a contract, and each Party forever waives any such defense, except to the extent that such defense relates to lack of authenticity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.12 <U>Equitable Relief; Cumulative Remedies</U>. Notwithstanding
anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for
a breach of this Agreement but shall be in addition to all other remedies available at law or equity. The Parties further agree not to raise as a defense or objection to the request or granting of such relief that any breach of this Agreement is or
would be compensable by an award of money damages. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under
Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.13 <U>Interpretation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.13.1 <U>Generally</U>. This Agreement has been diligently reviewed by and negotiated by and among the Parties, and in such negotiations
each of the Parties has been represented by competent <FONT STYLE="white-space:nowrap">(in-house</FONT> or external) counsel, and the final agreement contained herein, including the language whereby it has been expressed, represents the joint
efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and
ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.13.2 <U>Definitions; Interpretation</U>. The definitions of the terms herein shall apply equally to the singular and plural forms of the
terms defined and where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding meaning. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine, and neuter forms.
The word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall&#148;. The word &#147;any&#148; shall mean &#147;any and all&#148; unless otherwise clearly indicated by context. The words
&#147;including&#148;, &#147;includes&#148;, &#147;include&#148;, &#147;for example&#148;, and &#147;e.g.&#148; and words of similar import will be deemed to be followed by the words &#147;without limitation.&#148; The word &#147;or&#148; is
disjunctive but not necessarily exclusive. The words &#147;hereof&#148;, &#147;herein&#148; and &#147;herewith&#148; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any
particular provision of this Agreement. Unless the context requires otherwise or otherwise specifically provided, (a)&nbsp;all references herein to Articles, Sections, Schedules or Exhibits shall be construed to refer to Articles, Sections,
Schedules and Exhibits of this Agreement and (b)&nbsp;reference in any Section to any subclauses are references to such subclauses of such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.13.3 <U>Subsequent Events</U>. Unless the context requires otherwise, (a)&nbsp;any definition of or reference to any agreement, instrument,
or other document herein shall be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements, or
modifications set forth herein), (b) any reference to any Applicable Law herein shall be construed as referring to such Applicable Law as from time to time enacted, repealed, or amended, and (c)&nbsp;any reference herein to any Person shall be
construed to include the Person&#146;s successors and assigns (subject to Section&nbsp;12.4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.13.4 <U>Headings</U>. Headings, captions
and the table of contents are for convenience only and are not to be used in the interpretation of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain confidential information contained in this document, marked by [**], has been omitted
because Immatics N.V. (the &#147;Company&#148;) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">12.13.5 <U>Prior Drafts</U>. No prior draft of this Agreement nor any
course of performance or course of dealing shall be used in the interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">12.13.6 <U>Independent
Significance</U>. Although the same or similar subject matters may be addressed in different provisions of this Agreement, the Parties intend that, except as reasonably apparent on the face of this Agreement or as expressly provided in this
Agreement, each such provision shall be read separately, be given independent significance and not be construed as limiting any other provision of this Agreement (whether or not more general or more specific in scope, substance or content). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.14 <U>Further Assurances</U>. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other
ministerial, administrative or similar acts, as may be reasonably necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.15 <U>Extension to Affiliates</U>. Each Party shall have the right to extend the rights, licenses, immunities and obligations granted in
this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to such Party.
Each Party shall remain fully liable for any acts or omissions of such Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.16 <U>Immatics GmbH</U>. As of the Effective Date,
Immatics GmbH is an Affiliate of Immatics and is a party to the 2019 Agreements with BMS. Immatics GmbH hereby acknowledges the terms and conditions of this Agreement (including those terms and conditions that may modify the terms and conditions of
any 2019 Agreement), and shall guarantee the performance of Immatics&#146; obligations under this Agreement, provided that BMS shall first seek performance or remedy from Immatics for such obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this AGREEMENT to be
executed by their respective duly authorized officers as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>IMMATICS US, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>CELGENE SWITZERLAND LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: [***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name:[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Title: [***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title:[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: [***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Title: [***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SOLELY FOR PURPOSES OF SECTION 12.16</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>IMMATICS BIOTECHNOLOGIES GMBH</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Title: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Title: [***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Collaboration Agreement]</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Schedules to this agreement have been omitted pursuant to Item 601(a)(5) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.&nbsp;Immatics</FONT> N.V. undertakes to provide a copy of the omitted schedules to the Securities and Exchange Commission or its staff upon request.] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>d400206dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RULES <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> AND <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> UNDER THE SECURITIES EXCHANGE
ACT OF 1934, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Harpreet Singh, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have
reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Immatics N.V.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The company&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The company&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;22, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Executive Officer and Executive Director</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>d400206dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RULES <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> AND <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> UNDER THE SECURITIES EXCHANGE
ACT OF 1934, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Arnd Christ, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have
reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Immatics N.V.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The company&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The company&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;22, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Arnd Christ</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Arnd Christ</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>d400206dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 13.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The certification set forth below is being submitted in connection with Immatics N.V.&#146;s annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022 (the &#147;Report&#148;) for the purpose of complying with Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule
<FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Harpreet Singh, the Chief Executive Officer of Immatics N.V., certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of Immatics N.V. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;22, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Executive Officer and Executive Director</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>d400206dex132.htm
<DESCRIPTION>EX-13.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 13.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The certification set forth below is being submitted in connection with Immatics N.V.&#146;s annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022 (the &#147;Report&#148;) for the purpose of complying with Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule
<FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Arnd Christ, the Chief Financial Officer of Immatics N.V., certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of Immatics N.V. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;22, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Arnd Christ</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Arnd Christ</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>d400206dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statements on Form&nbsp;S-8
<FONT STYLE="white-space:nowrap">(Nos.&nbsp;333-249408</FONT> and <FONT STYLE="white-space:nowrap">333-265820)</FONT> and on Form&nbsp;F-3 (Nos. 333-258351 and 333-24060) of IMMATICS N.V. of our report dated March&nbsp;22, 2023 relating to the
financial statements, which appears in this Form&nbsp;20-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuttgart, Germany </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;22, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers GmbH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&uuml;fungsgesellschaft </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Stefanie Fink</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&uuml;ferin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(German Public Auditor)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ ppa. Jens Rosenberger</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&uuml;fer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(German Public Auditor)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>imtx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-March-2023 [07:29:36] {AM}-->
<schema targetNamespace="http://imtx.com/20221231" elementFormDefault="qualified" xmlns:imtx="http://imtx.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://www.xbrl.org/2003/XLink" xmlns:currency="http://www.xbrl.org/2003/XLink" xmlns:exch="http://www.xbrl.org/2003/XLink" xmlns:naics="http://www.xbrl.org/2003/XLink" xmlns:sic="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://www.xbrl.org/2003/XLink" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://imtx.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV" id="ConsolidatedStatementOfProfitLossOfImmaticsNV">
<link:definition>1002 - Statement - Consolidated Statement of Profit/(Loss) of Immatics N.V.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" id="ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV">
<link:definition>1003 - Statement - Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV" id="ConsolidatedStatementOfFinancialPositionOfImmaticsNV">
<link:definition>1004 - Statement - Consolidated Statement of Financial Position of Immatics N.V.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV" id="ConsolidatedStatementOfCashFlowsOfImmaticsNV">
<link:definition>1005 - Statement - Consolidated Statement of Cash Flows of Immatics N.V.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV" id="ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV">
<link:definition>1006 - Statement - Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/GroupInformation" id="GroupInformation">
<link:definition>1007 - Disclosure - Group information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/BasisOfPresentation" id="BasisOfPresentation">
<link:definition>1008 - Disclosure - Basis of presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AryaMerger" id="AryaMerger">
<link:definition>1009 - Disclosure - ARYA Merger</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandards">
<link:definition>1010 - Disclosure - Application of new and revised international financial reporting standards</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022">
<link:definition>1011 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions" id="SignificantAccountingJudgmentsEstimatesAndAssumptions">
<link:definition>1012 - Disclosure - Significant accounting judgments, estimates and assumptions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsReceivable" id="AccountsReceivable">
<link:definition>1013 - Disclosure - Accounts receivable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssets" id="OtherCurrentAndNonCurrentAssets">
<link:definition>1014 - Disclosure - Other current and non-current assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
<link:definition>1015 - Disclosure - Property, plant and equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IntangibleAssets" id="IntangibleAssets">
<link:definition>1016 - Disclosure - Intangible assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/Leases" id="Leases">
<link:definition>1017 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsPayable" id="AccountsPayable">
<link:definition>1018 - Disclosure - Accounts payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RevenueFromCollaborationAgreements" id="RevenueFromCollaborationAgreements">
<link:definition>1019 - Disclosure - Revenue from collaboration agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
<link:definition>1020 - Disclosure - Other current liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities" id="ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities">
<link:definition>1021 - Disclosure - Share listing expense and change in fair value of warrant liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpenses" id="OtherFinancialIncomeAndExpenses">
<link:definition>1022 - Disclosure - Other financial income and expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPayments" id="ShareBasedPayments">
<link:definition>1023 - Disclosure - Share-based payments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareholdersEquityDeficit" id="ShareholdersEquityDeficit">
<link:definition>1024 - Disclosure - Shareholders' equity (deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/NonControllingInterests" id="NonControllingInterests">
<link:definition>1025 - Disclosure - Non-controlling interests</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PersonnelExpenses" id="PersonnelExpenses">
<link:definition>1026 - Disclosure - Personnel expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IncomeTax" id="IncomeTax">
<link:definition>1027 - Disclosure - Income Tax</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies" id="FinancialRiskManagementObjectivesAndPolicies">
<link:definition>1028 - Disclosure - Financial Risk Management Objectives and Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialInstruments" id="FinancialInstruments">
<link:definition>1029 - Disclosure - Financial Instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1030 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosures" id="RelatedPartyDisclosures">
<link:definition>1031 - Disclosure - Related party disclosures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/EarningsAndLossPerShare" id="EarningsAndLossPerShare">
<link:definition>1032 - Disclosure - Earnings and Loss per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/EventsOccurringAfterTheReportingPeriod" id="EventsOccurringAfterTheReportingPeriod">
<link:definition>1033 - Disclosure - Events occurring after the reporting period</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies">
<link:definition>1034 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables">
<link:definition>1035 - Disclosure - Application of new and revised international financial reporting standards (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables">
<link:definition>1036 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
<link:definition>1037 - Disclosure - Accounts receivable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables" id="OtherCurrentAndNonCurrentAssetsTables">
<link:definition>1038 - Disclosure - Other current and non-current assets  (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
<link:definition>1039 - Disclosure - Property, plant and equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
<link:definition>1040 - Disclosure - Intangible assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/LeasesTables" id="LeasesTables">
<link:definition>1041 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsPayableTables" id="AccountsPayableTables">
<link:definition>1042 - Disclosure - Accounts payable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsTables" id="RevenueFromCollaborationAgreementsTables">
<link:definition>1043 - Disclosure - Revenue from collaboration agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
<link:definition>1044 - Disclosure - Other current liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables" id="ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables">
<link:definition>1045 - Disclosure - Share listing expense and change in fair value of warrant liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesTables" id="OtherFinancialIncomeAndExpensesTables">
<link:definition>1046 - Disclosure - Other financial income and expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPaymentsTables" id="ShareBasedPaymentsTables">
<link:definition>1047 - Disclosure - Share-based payments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PersonnelExpensesTables" id="PersonnelExpensesTables">
<link:definition>1048 - Disclosure - Personnel expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IncomeTaxTables" id="IncomeTaxTables">
<link:definition>1049 - Disclosure - Income Tax (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables" id="FinancialRiskManagementObjectivesAndPoliciesTables">
<link:definition>1050 - Disclosure - Financial Risk Management Objectives and Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
<link:definition>1051 - Disclosure - Financial Instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1052 - Disclosure - Commitments and contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresTables" id="RelatedPartyDisclosuresTables">
<link:definition>1053 - Disclosure - Related party disclosures (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/EarningsAndLossPerShareTables" id="EarningsAndLossPerShareTables">
<link:definition>1054 - Disclosure - Earnings and Loss per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/GroupInformationAdditionalInformationDetail" id="GroupInformationAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Group information - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AryaMergerAdditionalInformationDetail" id="AryaMergerAdditionalInformationDetail">
<link:definition>1056 - Disclosure - ARYA Merger - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail">
<link:definition>1057 - Disclosure - Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail">
<link:definition>1058 - Disclosure - Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail">
<link:definition>1059 - Disclosure - Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail" id="ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Application of new and revised international financial reporting standards - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<link:definition>1061 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail">
<link:definition>1062 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail" id="SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail">
<link:definition>1063 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail" id="AccountsReceivableSummaryOfTradeReceivablesDetail">
<link:definition>1064 - Disclosure - Accounts receivable - Summary of Trade receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsReceivableAdditionalInformationDetail" id="AccountsReceivableAdditionalInformationDetail">
<link:definition>1065 - Disclosure - Accounts receivable - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" id="OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail">
<link:definition>1066 - Disclosure - Other current and non-current assets -Summary of Other current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails" id="OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails">
<link:definition>1067 - Disclosure - Other current and non-current assets - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" id="OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<link:definition>1068 - Disclosure - Other current and non-current assets - Summary of Other non-current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail" id="PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail">
<link:definition>1069 - Disclosure - Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail" id="PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail">
<link:definition>1070 - Disclosure - Property, plant and equipment - Summary of Depreciation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail" id="PropertyPlantAndEquipmentAddtionalInformationDetail">
<link:definition>1071 - Disclosure - Property, plant and equipment - Addtional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail" id="IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail">
<link:definition>1072 - Disclosure - Intangible assets - Summary of Changes to intangible assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail" id="IntangibleAssetsSummaryOfAmortizationExpenseDetail">
<link:definition>1073 - Disclosure - Intangible assets - Summary of Amortization expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail" id="LeasesSummaryOfRightOfUseAssetsDetail">
<link:definition>1074 - Disclosure - Leases - Summary of Right-of&amp;#160;use assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail" id="LeasesDetailsOfLeaseLiabilitiesDetail">
<link:definition>1075 - Disclosure - Leases - Details of Lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail" id="LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail">
<link:definition>1076 - Disclosure - Leases - Summary of expenses related to&amp;#160;right-of-use&amp;#160;assets and lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1077 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail" id="AccountsPayableSummaryOfAccountsPayableDetail">
<link:definition>1078 - Disclosure - Accounts payable - Summary of Accounts Payable (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/AccountsPayableAdditionalInformationDetail" id="AccountsPayableAdditionalInformationDetail">
<link:definition>1079 - Disclosure - Accounts payable - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail" id="RevenueFromCollaborationAgreementsAdditionalInformationDetail">
<link:definition>1080 - Disclosure - Revenue from collaboration agreements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail" id="RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail">
<link:definition>1081 - Disclosure - Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" id="OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail">
<link:definition>1082 - Disclosure - Other current liabilities - Summary of other current liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail" id="OtherCurrentLiabilitiesAdditionalInformationDetail">
<link:definition>1083 - Disclosure - Other current liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail" id="ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail">
<link:definition>1084 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail" id="ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail">
<link:definition>1085 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" id="OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail">
<link:definition>1086 - Disclosure - Other financial income and expenses - Summary of other financial income and costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail" id="OtherFinancialIncomeAndExpensesAdditionalInformationDetail">
<link:definition>1087 - Disclosure - Other financial income and expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail" id="ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail">
<link:definition>1088 - Disclosure - Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail" id="ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail">
<link:definition>1089 - Disclosure - Share-based payments - Summary of Employee Share Options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail" id="ShareBasedPaymentsAdditionalInformationDetail">
<link:definition>1090 - Disclosure - Share-based payments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail" id="ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail">
<link:definition>1091 - Disclosure - Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail" id="ShareholdersEquityDeficitAdditionalInformationDetail">
<link:definition>1092 - Disclosure - Shareholders' equity (deficit) - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail" id="NonControllingInterestsAdditionalInformationDetail">
<link:definition>1093 - Disclosure - Non-controlling interests - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail" id="PersonnelExpensesSummaryOfPersonnelExpensesDetail">
<link:definition>1094 - Disclosure - Personnel expenses - Summary of Personnel Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail" id="PersonnelExpensesAdditionalInformationDetail">
<link:definition>1095 - Disclosure - Personnel expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail" id="IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail">
<link:definition>1096 - Disclosure - Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail" id="IncomeTaxSummaryOfDeferredTaxAssetsDetail">
<link:definition>1097 - Disclosure - Income Tax - Summary of Deferred Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/IncomeTaxAdditionalInformationDetail" id="IncomeTaxAdditionalInformationDetail">
<link:definition>1098 - Disclosure - Income Tax - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail" id="FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail">
<link:definition>1099 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail" id="FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail">
<link:definition>1100 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail" id="FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail">
<link:definition>1101 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail" id="FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail">
<link:definition>1102 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail" id="FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail">
<link:definition>1103 - Disclosure - Financial Risk Management Objectives and Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail" id="FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail">
<link:definition>1104 - Disclosure - Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail" id="FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail">
<link:definition>1105 - Disclosure - Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail" id="FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail">
<link:definition>1106 - Disclosure - Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail" id="CommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
<link:definition>1107 - Disclosure - Commitments and contingencies - Summary of Contractual Obligations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1108 - Disclosure - Commitments and contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail" id="RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail">
<link:definition>1109 - Disclosure - Related party disclosures - Summary of Compensation of Key Management Personnel (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail" id="RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail">
<link:definition>1110 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail" id="RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail">
<link:definition>1111 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail" id="RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail">
<link:definition>1112 - Disclosure - Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail" id="RelatedPartyDisclosuresAdditionalInformationDetail">
<link:definition>1113 - Disclosure - Related party disclosures - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail" id="EarningsAndLossPerShareAdditionalInformationDetail">
<link:definition>1114 - Disclosure - Earnings and Loss per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail" id="EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail">
<link:definition>1115 - Disclosure - Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail" id="RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail">
<link:definition>1116 - Disclosure - Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1" id="ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1">
<link:definition>1117 - Statement - Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V. Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imtx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="OrdinaryShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_OrdinaryShareMember" substitutionGroup="xbrli:item" />
<element name="WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_WarrantsMember" substitutionGroup="xbrli:item" />
<element name="RevenueFromCollaborationAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_RevenueFromCollaborationAgreements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareListingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ShareListingExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ChangesInWorkingCapitalAbstract" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PaymentsForShareBasedCompensation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentForEquitySettledSharebasedPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdjustmentForEquitySettledSharebasedPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForShareListingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdjustmentsForShareListingExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionCostsDeductedFromEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_TransactionCostsDeductedFromEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalEquityAttributableToShareholdersOfParentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TotalEquityAttributableToShareholdersOfParentMember" substitutionGroup="xbrli:item" />
<element name="IncreaseThroughARYAMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreaseThroughARYAMerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SARConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_SARConversion" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreasedecreaseThroughIssuanceOfEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreasedecreaseThroughIssuanceOfEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughReorganizationEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreaseDecreaseThroughReorganizationEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreasedecreaseThroughChangesInNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreasedecreaseThroughCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreasedecreaseThroughCompensationExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssueOfShareCapitalNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IssueOfShareCapitalNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TextBlockAbstract" substitutionGroup="xbrli:item" />
<element name="AryaMergerTransactionExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AryaMergerTransactionExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAccountReceivableExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPersonnelExpensesExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDepreciationExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDepreciationExpensesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAmortizationExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfAmortizationExpensesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAccountsPayableExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContractLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfContractLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRevenueFromCollaborationAgreementsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="StatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_StatementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="StatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_StatementsLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" substitutionGroup="xbrli:item" />
<element name="MatchingStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MatchingStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="ConvertedOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ConvertedOptionsMember" substitutionGroup="xbrli:item" />
<element name="AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" substitutionGroup="xbrli:item" />
<element name="PerformanceBasedOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PerformanceBasedOptionsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPersonnelExpenesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPersonnelExpenesTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContractualObligationsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfContractualObligationsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCompensationSupervisoryBoardTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" substitutionGroup="xbrli:item" />
<element name="AuthorizationOfFinancialStatementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AuthorizationOfFinancialStatementsMember" substitutionGroup="xbrli:item" />
<element name="PipeFinancingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PipeFinancingMember" substitutionGroup="xbrli:item" />
<element name="AryaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AryaMember" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" substitutionGroup="xbrli:item" />
<element name="AmendmentIasSixteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentIasSixteenMember" substitutionGroup="xbrli:item" />
<element name="AmendmentIasThirtySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentIasThirtySevenMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIfrsThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIfrsThreeMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIfrsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIfrsOneMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIfrsNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIfrsNineMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIasFourtyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIasFourtyOneMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIasOneIfrsPracticeStatementTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIasEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIasEightMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIasTwelveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIasTwelveMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIfrsSixteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIfrsSixteenMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToIasOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmendmentToIasOneMember" substitutionGroup="xbrli:item" />
<element name="CurrentlyReportedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CurrentlyReportedMember" substitutionGroup="xbrli:item" />
<element name="ReclassficationOfProvisionsToOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" substitutionGroup="xbrli:item" />
<element name="ReceivablesFromCollaborationAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ReceivablesFromCollaborationAgreements" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentGrantReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_CurrentGrantReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CollaborationAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CollaborationAgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="CelgeneSwitzerlandLlcAndGenmabAsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" substitutionGroup="xbrli:item" />
<element name="CurrentPrepaidInsurance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_CurrentPrepaidInsurance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentIncrementalCostForCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_CurrentIncrementalCostForCollaborationAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidExpensesOfLicensesAndSoftware" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PrepaidExpensesOfLicensesAndSoftware" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NoncurrentPrepaymentsOfLicensingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_NoncurrentPrepaymentsOfLicensingAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCurrentPrepaidMaintenanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_NonCurrentPrepaidMaintenanceExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentPrepaidMaintenanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_CurrentPrepaidMaintenanceExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BalanceSheetLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BalanceSheetLocationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BalanceSheetLocationDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BalanceSheetLocationDomain" substitutionGroup="xbrli:item" />
<element name="OtherNonCurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_OtherNonCurrentAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalsOfPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DisposalsOfPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsOtherPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdditionsOtherPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrencyTranslationDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_CurrencyTranslationDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfficeEquipmentAndInstallationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_OfficeEquipmentAndInstallationsMember" substitutionGroup="xbrli:item" />
<element name="TypeOfAdoptionsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TypeOfAdoptionsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfAdoptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TypeOfAdoptionsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDepreciationExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDepreciationExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="IncomeStatementLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_IncomeStatementLocationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="IncomeStatementLocationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_IncomeStatementLocationMember" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
<element name="GeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GeneralAndAdministrativeExpenseMember" substitutionGroup="xbrli:item" />
<element name="PatentAndLicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PatentAndLicensesMember" substitutionGroup="xbrli:item" />
<element name="SoftwareLicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SoftwareLicensesMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAmortizationExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfAmortizationExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="InterestExpenseOnLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_InterestExpenseOnLease" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TranslationDifferenceOnRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_TranslationDifferenceOnRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_AccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfRevenueFromContractWithCustomersTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromContractWithCustomersTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="AmgenCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AmgenCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="GSKCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GSKCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="BMSCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BMSCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="GenmabCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GenmabCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="BmsAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BmsAgreementMember" substitutionGroup="xbrli:item" />
<element name="LicenseDevelopmentAndCommercializationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_LicenseDevelopmentAndCommercializationAgreementMember" substitutionGroup="xbrli:item" />
<element name="MilestoneAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MilestoneAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MilestoneDomain" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentForLicensedProductMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MilestonePaymentForLicensedProductMember" substitutionGroup="xbrli:item" />
<element name="ThereafterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ThereafterMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRevenueFromContractWithCustomersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" substitutionGroup="xbrli:item" />
<element name="ContractLiabilitiesRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ContractLiabilitiesRecognized" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PotentialMilestonePaymentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PotentialMilestonePaymentPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_UpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_MilestonePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Allocationofupfrontpaymenttowardsclinicaltrialservices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Allocationofupfrontpaymenttowardslicensegrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_Allocationofupfrontpaymenttowardslicensegrant" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalPaymentRelatedToPerformanceObligationsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestoneRegulatoryAndRoyaltyPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PerformanceObligationsCumulativeUpfrontPaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ContractTransactionPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognizedDuringThePeriodPerformanceObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImtxagreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImtxagreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ImtxagreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImtxagreementMember" substitutionGroup="xbrli:item" />
<element name="ImtxbMSCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImtxbMSCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="ImmaticsBiotechnologiesGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImmaticsBiotechnologiesGmbhMember" substitutionGroup="xbrli:item" />
<element name="ImmaticsUsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImmaticsUsIncMember" substitutionGroup="xbrli:item" />
<element name="Ima401licensegrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_Ima401licensegrantMember" substitutionGroup="xbrli:item" />
<element name="Ima401clinicaltrialservicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_Ima401clinicaltrialservicesMember" substitutionGroup="xbrli:item" />
<element name="BristolMyerSquibCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BristolMyerSquibCompanyMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="OtherCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_OtherCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonInterestBearingLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_NonInterestBearingLiabilityMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareListingExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfShareListingExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedPricePerWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_WarrantsIssuedPricePerWarrant" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="RestrictedCashRecognizedAsOfTheAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForeignCurrencyLossesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ForeignCurrencyLossesNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RealisedGainLossFromForeignCurrencyForwardContracts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_RealisedGainLossFromForeignCurrencyForwardContracts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrealisedGainLossFromForeignCurrencyForwardContracts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PlanAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PlanAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PlanMember" substitutionGroup="xbrli:item" />
<element name="DateOfGrantAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DateOfGrantAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DateOfGrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DateOfGrantMember" substitutionGroup="xbrli:item" />
<element name="GrantedOnJuneTwoThousandAndTwentyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GrantedOnJuneTwoThousandAndTwentyMember" substitutionGroup="xbrli:item" />
<element name="GrantedOnMarchTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="GrantedOnSeptemberTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" substitutionGroup="xbrli:item" />
<element name="ShareReinvestmentSchemeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShareReinvestmentSchemeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ShareReinvestmentSchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShareReinvestmentSchemeMember" substitutionGroup="xbrli:item" />
<element name="ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" substitutionGroup="xbrli:item" />
<element name="ModificationOfTwoThousandAndTenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ModificationOfTwoThousandAndTenPlanMember" substitutionGroup="xbrli:item" />
<element name="ModificationOfTwoThousandAndSixteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ModificationOfTwoThousandAndSixteenPlanMember" substitutionGroup="xbrli:item" />
<element name="SchemeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SchemeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SchemeMember" substitutionGroup="xbrli:item" />
<element name="ShareReinvestmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShareReinvestmentMember" substitutionGroup="xbrli:item" />
<element name="CategoryOfEmployeesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CategoryOfEmployeesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CategoryOfEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CategoryOfEmployeesMember" substitutionGroup="xbrli:item" />
<element name="ManagementMembersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ManagementMembersMember" substitutionGroup="xbrli:item" />
<element name="ActiveEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ActiveEmployeesMember" substitutionGroup="xbrli:item" />
<element name="CashPaymentAwardPerSharePayable" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_CashPaymentAwardPerSharePayable" substitutionGroup="xbrli:item" />
<element name="PercentageOfCashProceedsToBeBeReinvested" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PercentageOfCashProceedsToBeBeReinvested" substitutionGroup="xbrli:item" />
<element name="ExpenseFromTheModificationOfShareBasedAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_ExpenseFromTheModificationOfShareBasedAwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DateOfVestingOfStockOptions" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DateOfVestingOfStockOptions" substitutionGroup="xbrli:item" />
<element name="MinimumMarketCapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_MinimumMarketCapitalization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TrancheMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TrancheTwoMember" substitutionGroup="xbrli:item" />
<element name="TrancheThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TrancheThreeMember" substitutionGroup="xbrli:item" />
<element name="TrancheOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TrancheOneMember" substitutionGroup="xbrli:item" />
<element name="GrantedOnSeptemberTwoThousandAndTwentyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_StockIssuedDuringPeriodValueNewIssues" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GrossProceedsFromIssueOfSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_GrossProceedsFromIssueOfSecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareIssuedPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ShareIssuedPricePerShare" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EventDomain" substitutionGroup="xbrli:item" />
<element name="ReorganizationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ReorganizationMember" substitutionGroup="xbrli:item" />
<element name="ShareListingExpenseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShareListingExpenseAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ShareListingExpenseDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShareListingExpenseDomain" substitutionGroup="xbrli:item" />
<element name="AryaMergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AryaMergerMember" substitutionGroup="xbrli:item" />
<element name="InvesteeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_InvesteeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvesteeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_InvesteeMember" substitutionGroup="xbrli:item" />
<element name="SvbSecuritiesLicMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SvbSecuritiesLicMember" substitutionGroup="xbrli:item" />
<element name="AtTheMarketAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AtTheMarketAgreementMember" substitutionGroup="xbrli:item" />
<element name="RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_RegisteredDirectOfferingMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesExchangedInSubsidiaries" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_NumberOfSharesExchangedInSubsidiaries" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_StockIssuedDuringPeriodSharesAcquisitions" substitutionGroup="xbrli:item" />
<element name="LossOnNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_LossOnNoncontrollingInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MdAndersonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MdAndersonMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockAcquisitionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_RestrictedStockAcquisitionAgreementMember" substitutionGroup="xbrli:item" />
<element name="EmployeeHealthInsuranceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_EmployeeHealthInsuranceCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfPermanentDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_TaxEffectOfPermanentDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfGovernmentGrantsExemptedFromTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IntangibleAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_IntangibleAssetsMember" substitutionGroup="xbrli:item" />
<element name="DeferredRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredRevenueMember" substitutionGroup="xbrli:item" />
<element name="DeferredAssetNettingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredAssetNettingMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesRightOfUseAssetMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesDeferredExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredTaxLiabilitiesDeferredExpensesMember" substitutionGroup="xbrli:item" />
<element name="DeferredLiabilityNettingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredLiabilityNettingMember" substitutionGroup="xbrli:item" />
<element name="DeferredAssetRecognisedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredAssetRecognisedMember" substitutionGroup="xbrli:item" />
<element name="LeaseLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_LeaseLiabilityMember" substitutionGroup="xbrli:item" />
<element name="DeferredExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeferredExpensesMember" substitutionGroup="xbrli:item" />
<element name="RecognitionOfTaxLossesCarriedForwardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_RecognitionOfTaxLossesCarriedForwardMember" substitutionGroup="xbrli:item" />
<element name="NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesOffSet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_DeferredTaxLiabilitiesOffSet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsOffset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_DeferredTaxAssetsOffset" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsOnTemporaryDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_DeferredTaxAssetsOnTemporaryDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IndefiniteTaxLossesCarryforwardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_IndefiniteTaxLossesCarryforwardMember" substitutionGroup="xbrli:item" />
<element name="TwentySixYearTaxLossesCarryforwardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TwentySixYearTaxLossesCarryforwardMember" substitutionGroup="xbrli:item" />
<element name="CorporateIncomeTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_CorporateIncomeTaxRate" substitutionGroup="xbrli:item" />
<element name="PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" substitutionGroup="xbrli:item" />
<element name="PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" substitutionGroup="xbrli:item" />
<element name="PercentageOfPretaxIncomeSubjectToIncomeTax" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrencyRiskExposureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCurrencyRiskExposureAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrencyRiskExposureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCurrencyRiskExposureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfCurrencyRiskExposureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCurrencyRiskExposureLineItems" substitutionGroup="xbrli:item" />
<element name="MaximumExposedToCurrencyRisk" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_MaximumExposedToCurrencyRisk" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImmaticsNvMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImmaticsNvMember" substitutionGroup="xbrli:item" />
<element name="ImmaticsGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ImmaticsGmbhMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SensitiveAnalaysisOfCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SensitiveAnalaysisOfCurrencyAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SensitiveAnalaysisOfCurrencyDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_SensitiveAnalaysisOfCurrencyDomain" substitutionGroup="xbrli:item" />
<element name="EuroWeakensBy1AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroWeakensBy1AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="EuroStrengthsBy1AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroStrengthsBy1AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="EuroWeakensBy5AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroWeakensBy5AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="EuroStrengthsBy5AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroStrengthsBy5AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="EuroWeakensBy10AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroWeakensBy10AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="EuroStrengthsBy10AgainstUsDollarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EuroStrengthsBy10AgainstUsDollarsMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" substitutionGroup="xbrli:item" />
<element name="PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" substitutionGroup="xbrli:item" />
<element name="DescriptionOfManagingLiquidityRiskAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DescriptionOfManagingLiquidityRiskAbstract" substitutionGroup="xbrli:item" />
<element name="ShorttermDepositsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ShorttermDepositsMember" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CashAndCashEquivalentsMember" substitutionGroup="xbrli:item" />
<element name="BondsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_BondsMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfCashAndCashEquivalentsHeldInDomicile" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" substitutionGroup="xbrli:item" />
<element name="BondsAndShortTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_BondsAndShortTermDeposits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ForeignExchangeRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ForeignExchangeRatesMember" substitutionGroup="xbrli:item" />
<element name="DeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DeMember" substitutionGroup="xbrli:item" />
<element name="OtherCurrentNonCurrentAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_OtherCurrentNonCurrentAssetsMember" substitutionGroup="xbrli:item" />
<element name="AccountsPayableMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AccountsPayableMember" substitutionGroup="xbrli:item" />
<element name="OtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_OtherCurrentLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="LiabilitiesForWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_LiabilitiesForWarrantsMember" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAndFinancialLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_FinancialAssetsAndFinancialLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" substitutionGroup="xbrli:item" />
<element name="NetFinancialResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_NetFinancialResult" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" substitutionGroup="xbrli:item" />
<element name="LiabilitiesArisingFromFinancingActivitiesCashEffective" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilitiesArisingFromFinancingActivitiesNoncashEffective" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfContractualObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfContractualObligationsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContractualObligationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfContractualObligationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfContractualObligationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfContractualObligationsLineItems" substitutionGroup="xbrli:item" />
<element name="ContractResearchOrganizationAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ContractResearchOrganizationAgreements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualCashObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ContractualCashObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_ContractualObligationOfLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_OtherLeaseObligations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnrecordedContingentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_UnrecordedContingentLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborationAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_CollaborationAgreementsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCompensationOfKeyManagementPersonnelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" substitutionGroup="xbrli:item" />
<element name="KeyManagementPersonnelCompensationFixed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensationFixed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="KeyManagementPersonnelCompensationTravellingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensationTravellingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="KeyManagementPersonnelCompensationShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="KeyManagementPersonnelCompensations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="KeyManagementPersonnelCompensationSupervisoryBoardCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="KeyManagementPersonnelCompensationPaymentExitArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EliotForsterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_EliotForsterMember" substitutionGroup="xbrli:item" />
<element name="PaulCarterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PaulCarterMember" substitutionGroup="xbrli:item" />
<element name="HeatherLMasonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_HeatherLMasonMember" substitutionGroup="xbrli:item" />
<element name="AdamStoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_AdamStoneMember" substitutionGroup="xbrli:item" />
<element name="PeterChambreMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PeterChambreMember" substitutionGroup="xbrli:item" />
<element name="HaraldFstockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_HaraldFstockMember" substitutionGroup="xbrli:item" />
<element name="ChristophHettichMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ChristophHettichMember" substitutionGroup="xbrli:item" />
<element name="MichaelGAtiehMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_MichaelGAtiehMember" substitutionGroup="xbrli:item" />
<element name="NancyValenteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_NancyValenteMember" substitutionGroup="xbrli:item" />
<element name="FriedrichVonBohlenUndHalbachMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_FriedrichVonBohlenUndHalbachMember" substitutionGroup="xbrli:item" />
<element name="HarpreetSinghMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_HarpreetSinghMember" substitutionGroup="xbrli:item" />
<element name="TypeOfVestingAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TypeOfVestingAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfVestingDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TypeOfVestingDomain" substitutionGroup="xbrli:item" />
<element name="ServiceOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ServiceOptionsMember" substitutionGroup="xbrli:item" />
<element name="ConvertedOptionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ConvertedOptionsOneMember" substitutionGroup="xbrli:item" />
<element name="ServiceOptionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ServiceOptionsOneMember" substitutionGroup="xbrli:item" />
<element name="ServiceOptionsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ServiceOptionsTwoMember" substitutionGroup="xbrli:item" />
<element name="ServiceOptionsThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ServiceOptionsThreeMember" substitutionGroup="xbrli:item" />
<element name="ServiceOptionsFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_ServiceOptionsFourMember" substitutionGroup="xbrli:item" />
<element name="DateOfExpiryOfShareOptionsGranted" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DateOfExpiryOfShareOptionsGranted" substitutionGroup="xbrli:item" />
<element name="PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" substitutionGroup="xbrli:item" />
<element name="PaymentOfPayrollTaxOfTheEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_PaymentOfPayrollTaxOfTheEmployees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfConvertedStockOptionsInTheEntity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_NumberOfConvertedStockOptionsInTheEntity" substitutionGroup="xbrli:item" />
<element name="NumberOfMatchingStockOptionInTheEntity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_NumberOfMatchingStockOptionInTheEntity" substitutionGroup="xbrli:item" />
<element name="DirectorsAndExecutiveOfficersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DirectorsAndExecutiveOfficersMember" substitutionGroup="xbrli:item" />
<element name="PlanNameAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PlanNameAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PlanNameDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_PlanNameDomain" substitutionGroup="xbrli:item" />
<element name="TwentyTwentyIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_TwentyTwentyIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="DilutiveEffectOfShareOptionsOnNumberOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRevenueFromCollaborationAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRevenueFromCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfRevenueFromCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>imtx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-March-2023 [07:29:36] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfProfitLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfFinancialPositionOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfCashFlowsOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableSummaryOfTradeReceivablesDetail" roleURI="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesDetailsOfLeaseLiabilitiesDetail" roleURI="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableSummaryOfAccountsPayableDetail" roleURI="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1" roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_ProfitLossBeforeTax" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="loc_ifrs-full_FinanceIncomeCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_FinanceIncomeCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpense" xlink:label="loc_IMTX_ShareListingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="loc_IMTX_ShareListingExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="loc_ifrs-full_OtherFinanceIncome" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="loc_ifrs-full_OtherFinanceCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="loc_ifrs-full_OtherFinanceCost" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_OtherIncome" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_IMTX_RevenueFromCollaborationAgreements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_IMTX_RevenueFromCollaborationAgreements" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" use="optional" order="12" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="loc_ifrs-full_CurrentLiabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentContractLiabilities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_OtherCurrentLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="loc_ifrs-full_CurrentWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentWarrantLiability" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="loc_ifrs-full_NoncurrentLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="loc_ifrs-full_Equity" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_OtherReserves" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_RetainedEarnings" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_SharePremium" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_IssuedCapital" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_CurrentAssets" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CashAndCashEquivalents" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentTradeReceivables" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_OtherCurrentAssets" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_NoncurrentAssets" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_RightofuseAssets" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_OtherNoncurrentAssets" use="optional" order="25" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TransactionCostsDeductedFromEquity" xlink:label="loc_IMTX_TransactionCostsDeductedFromEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_IMTX_TransactionCostsDeductedFromEquity" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xlink:label="loc_IMTX_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_IMTX_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForInterestIncome" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="loc_ifrs-full_AdjustmentsForInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForInterestExpense" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_IMTX_AdjustmentsForShareListingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_IMTX_AdjustmentsForShareListingExpense" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentForEquitySettledSharebasedPayment" xlink:label="loc_IMTX_AdjustmentForEquitySettledSharebasedPayment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_IMTX_AdjustmentForEquitySettledSharebasedPayment" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsForShareBasedCompensation" xlink:label="loc_IMTX_PaymentsForShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_IMTX_PaymentsForShareBasedCompensation" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:label="loc_IMTX_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_IMTX_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="29" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentGrantReceivable" xlink:label="loc_IMTX_CurrentGrantReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="loc_IMTX_CurrentGrantReceivable" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="loc_ifrs-full_OtherAssets" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_NetForeignExchangeGain" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_IMTX_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_IMTX_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_InterestExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignCurrencyLossesNet" xlink:label="loc_IMTX_ForeignCurrencyLossesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_IMTX_ForeignCurrencyLossesNet" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_IMTX_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_IMTX_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments" xlink:label="loc_ifrs-full_NoncurrentPrepayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="loc_ifrs-full_NoncurrentPrepayments" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherNonCurrentAsset" xlink:label="loc_IMTX_OtherNonCurrentAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="loc_IMTX_OtherNonCurrentAsset" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccruedLiabilities" xlink:label="loc_IMTX_AccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="loc_IMTX_AccruedLiabilities" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrent" xlink:label="loc_IMTX_OtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="loc_IMTX_OtherCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="loc_ifrs-full_CurrentTaxLiabilities" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReceivablesFromCollaborationAgreements" xlink:label="loc_IMTX_ReceivablesFromCollaborationAgreements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="loc_IMTX_ReceivablesFromCollaborationAgreements" use="optional" order="1" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>imtx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-March-2023 [07:29:36] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CoverPage" roleURI="http://imtx.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsTables" roleURI="http://imtx.com/role/ShareBasedPaymentsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#GroupInformationAdditionalInformationDetail" roleURI="http://imtx.com/role/GroupInformationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AryaMergerAdditionalInformationDetail" roleURI="http://imtx.com/role/AryaMergerAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentAddtionalInformationDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail" roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsSummaryOfAmortizationExpenseDetail" roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesSummaryOfRightOfUseAssetsDetail" roleURI="http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail" roleURI="http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesAdditionalInformationDetail" roleURI="http://imtx.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsAdditionalInformationDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesAdditionalInformationDetail" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareholdersEquityDeficitAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#NonControllingInterestsAdditionalInformationDetail" roleURI="http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesSummaryOfPersonnelExpensesDetail" roleURI="http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxSummaryOfDeferredTaxAssetsDetail" roleURI="http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxAdditionalInformationDetail" roleURI="http://imtx.com/role/IncomeTaxAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesSummaryOfContractualObligationsDetail" roleURI="http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresAdditionalInformationDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfFinancialPositionOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfProfitLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfCashFlowsOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#GroupInformation" roleURI="http://imtx.com/role/GroupInformation" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#BasisOfPresentation" roleURI="http://imtx.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandards" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivable" roleURI="http://imtx.com/role/AccountsReceivable" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableTables" roleURI="http://imtx.com/role/AccountsReceivableTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableSummaryOfTradeReceivablesDetail" roleURI="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssets" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsTables" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipment" roleURI="http://imtx.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SignificantAccountingJudgmentsEstimatesAndAssumptions" roleURI="http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssets" roleURI="http://imtx.com/role/IntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsTables" roleURI="http://imtx.com/role/IntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EventsOccurringAfterTheReportingPeriod" roleURI="http://imtx.com/role/EventsOccurringAfterTheReportingPeriod" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShare" roleURI="http://imtx.com/role/EarningsAndLossPerShare" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#Leases" roleURI="http://imtx.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesTables" roleURI="http://imtx.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesDetailsOfLeaseLiabilitiesDetail" roleURI="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosures" roleURI="http://imtx.com/role/RelatedPartyDisclosures" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresTables" roleURI="http://imtx.com/role/RelatedPartyDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingencies" roleURI="http://imtx.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesTables" roleURI="http://imtx.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstruments" roleURI="http://imtx.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsTables" roleURI="http://imtx.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayable" roleURI="http://imtx.com/role/AccountsPayable" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableTables" roleURI="http://imtx.com/role/AccountsPayableTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableSummaryOfAccountsPayableDetail" roleURI="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreements" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreements" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilities" roleURI="http://imtx.com/role/OtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareholdersEquityDeficit" roleURI="http://imtx.com/role/ShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesTables" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTax" roleURI="http://imtx.com/role/IncomeTax" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxTables" roleURI="http://imtx.com/role/IncomeTaxTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail" roleURI="http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpenses" roleURI="http://imtx.com/role/PersonnelExpenses" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesAdditionalInformationDetail" roleURI="http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#NonControllingInterests" roleURI="http://imtx.com/role/NonControllingInterests" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPolicies" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesTables" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPayments" roleURI="http://imtx.com/role/ShareBasedPayments" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpenses" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpenses" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesAdditionalInformationDetail" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableAdditionalInformationDetail" roleURI="http://imtx.com/role/AccountsPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsTables" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesTables" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesTables" roleURI="http://imtx.com/role/PersonnelExpensesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareAdditionalInformationDetail" roleURI="http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AryaMerger" roleURI="http://imtx.com/role/AryaMerger" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableAdditionalInformationDetail" roleURI="http://imtx.com/role/AccountsReceivableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareTables" roleURI="http://imtx.com/role/EarningsAndLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail" roleURI="http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_876586" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_868818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentType_868818" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_868819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AmendmentFlag_868819" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_868820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentPeriodEndDate_868820" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_868821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentFiscalYearFocus_868821" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_868822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentFiscalPeriodFocus_868822" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_868823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityRegistrantName_868823" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_868824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCentralIndexKey_868824" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_868825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_CurrentFiscalYearEndDate_868825" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_868827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_868827" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_868828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCurrentReportingStatus_868828" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_868829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityFilerCategory_868829" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_868830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_868830" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_868831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityVoluntaryFilers_868831" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_868833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityShellCompany_868833" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_868834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityEmergingGrowthCompany_868834" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_868835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentAnnualReport_868835" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_868836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityInteractiveDataCurrent_868836" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_868838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_IcfrAuditorAttestationFlag_868838" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_868839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentAccountingStandard_868839" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_868899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityIncorporationStateCountryCode_868899" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_876569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityFileNumber_876569" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_876580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentInformationTable_876580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_876582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_876580" xlink:to="loc_dei_DocumentInformationDocumentAxis_876582" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_876583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_876582" xlink:to="loc_dei_DocumentDomain_876583" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_876583_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_876582" xlink:to="loc_dei_DocumentDomain_876583_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OrdinaryShareMember" xlink:label="loc_imtx_OrdinaryShareMember_876587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentDomain_876583" xlink:to="loc_imtx_OrdinaryShareMember_876587" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_876593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentDomain_876583" xlink:to="loc_imtx_WarrantsMember_876593" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_876605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_876580" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_876605" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_876606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_876605" xlink:to="loc_dei_AddressTypeDomain_876606" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_876606_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_876605" xlink:to="loc_dei_AddressTypeDomain_876606_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_876607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_876606" xlink:to="loc_dei_BusinessContactMember_876607" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_876596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_SecurityExchangeName_876596" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_876597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_TradingSymbol_876597" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_876601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_Security12bTitle_876601" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_876609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_ContactPersonnelName_876609" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_876613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressAddressLine1_876613" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_876614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressCityOrTown_876614" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_876615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressStateOrProvince_876615" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_876616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressCountry_876616" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_876617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressPostalZipCode_876617" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_876624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_CityAreaCode_876624" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_876625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_LocalPhoneNumber_876625" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_876636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentRegistrationStatement_876636" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_876638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentShellCompanyReport_876638" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_876639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentTransitionReport_876639" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_877955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityExTransitionPeriod_877955" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1336593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorName_1336593" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1336595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorFirmId_1336595" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1336596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorLocation_1336596" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_864840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_ComprehensiveIncome_864840" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_864839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_ProfitLoss_864839" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_864837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_Equity_864837" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_864826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_864826" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_864827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_864826" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_864827" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864827" xlink:to="loc_ifrs-full_EquityMember_864828" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864827" xlink:to="loc_ifrs-full_EquityMember_864828_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_864835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_864835" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_864833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_OtherReservesMember_864833" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_864829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_IssuedCapitalMember_864829" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TotalEquityAttributableToShareholdersOfParentMember" xlink:label="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember_864834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember_864834" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_864832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_RetainedEarningsMember_864832" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_864831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_SharePremiumMember_864831" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseThroughARYAMerger" xlink:label="loc_imtx_IncreaseThroughARYAMerger_864848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreaseThroughARYAMerger_864848" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SARConversion" xlink:label="loc_imtx_SARConversion_864849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_SARConversion_864849" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_864838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_864838" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughIssuanceOfEquity" xlink:label="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity_864850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity_864850" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xlink:label="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled_864852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled_864852" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:label="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864845" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1336847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1336847" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864846" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864847" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughCompensationExpense" xlink:label="loc_imtx_IncreasedecreaseThroughCompensationExpense_864843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughCompensationExpense_864843" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_864841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_864841" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IssueOfShareCapitalNetOfTransactionCosts" xlink:label="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts_1351384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts_1351384" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867239" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_867234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_867234" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_imtx_StatementsTable_867236" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867236" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_867427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_MatchingStockOptionsMember_867427" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_867429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_ConvertedOptionsMember_867429" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_867431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_867431" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_867434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_PerformanceBasedOptionsMember_867434" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_867251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_867251" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock_870758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock_870758" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/GroupInformationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xlink:label="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013_864863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" xlink:to="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013_864863" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfEndOfReportingPeriod2013" xlink:label="loc_ifrs-full_DateOfEndOfReportingPeriod2013_864864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" xlink:to="loc_ifrs-full_DateOfEndOfReportingPeriod2013_864864" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_864860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" xlink:to="loc_ifrs-full_NonadjustingEventsMember_864860" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_864860_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" xlink:to="loc_ifrs-full_NonadjustingEventsMember_864860_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AuthorizationOfFinancialStatementsMember" xlink:label="loc_imtx_AuthorizationOfFinancialStatementsMember_864861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_864860" xlink:to="loc_imtx_AuthorizationOfFinancialStatementsMember_864861" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/AryaMergerAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_864916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_864916" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864916" xlink:to="loc_ifrs-full_EquityMember_864917" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864916" xlink:to="loc_ifrs-full_EquityMember_864917_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_864918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864917" xlink:to="loc_ifrs-full_IssuedCapitalMember_864918" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_864919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_864917" xlink:to="loc_ifrs-full_SharePremiumMember_864919" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_864922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_864921" xlink:to="loc_ifrs-full_OrdinarySharesMember_864922" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_864914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" xlink:to="loc_ifrs-full_OrdinarySharesMember_864914" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_864914_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" xlink:to="loc_ifrs-full_OrdinarySharesMember_864914_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PipeFinancingMember" xlink:label="loc_imtx_PipeFinancingMember_864915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_864914" xlink:to="loc_imtx_PipeFinancingMember_864915" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_864910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_864910" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_864910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_864910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_864912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" xlink:to="loc_imtx_AryaMember_864912" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_864921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_864921" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_864921_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_864921_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_864925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" xlink:to="loc_imtx_WarrantsMember_864925" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:label="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864928" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_864932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_864932" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_864934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_864934" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpense" xlink:label="loc_imtx_ShareListingExpense_864935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_ShareListingExpense_864935" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_864936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_864936" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864937" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_864938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_864938" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xlink:label="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination_1143857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination_1143857" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_864933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_864933" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864929" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xlink:label="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree_864930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree_864930" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_864931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_864931" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsAxis" xlink:label="loc_ifrs-full_NewIFRSsAxis_864951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" xlink:to="loc_ifrs-full_NewIFRSsAxis_864951" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NewIFRSsAxis_864951" xlink:to="loc_ifrs-full_NewIFRSsMember_864952" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NewIFRSsAxis_864951" xlink:to="loc_ifrs-full_NewIFRSsMember_864952_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xlink:label="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember_1337088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember_1337088" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasSixteenMember" xlink:label="loc_imtx_AmendmentIasSixteenMember_1351470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentIasSixteenMember_1351470" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasThirtySevenMember" xlink:label="loc_imtx_AmendmentIasThirtySevenMember_1351471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentIasThirtySevenMember_1351471" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsThreeMember" xlink:label="loc_imtx_AmendmentToIfrsThreeMember_1351472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsThreeMember_1351472" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsOneMember" xlink:label="loc_imtx_AmendmentToIfrsOneMember_1351473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsOneMember_1351473" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsNineMember" xlink:label="loc_imtx_AmendmentToIfrsNineMember_1351474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsNineMember_1351474" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasFourtyOneMember" xlink:label="loc_imtx_AmendmentToIasFourtyOneMember_1351476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIasFourtyOneMember_1351476" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" xlink:to="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864959" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="loc_ifrs-full_TitleOfNewIFRS_864958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" xlink:to="loc_ifrs-full_TitleOfNewIFRS_864958" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsAxis" xlink:label="loc_ifrs-full_NewIFRSsAxis_864963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" xlink:to="loc_ifrs-full_NewIFRSsAxis_864963" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NewIFRSsAxis_864963" xlink:to="loc_ifrs-full_NewIFRSsMember_864964" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NewIFRSsAxis_864963" xlink:to="loc_ifrs-full_NewIFRSsMember_864964_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IFRS17Member" xlink:label="loc_ifrs-full_IFRS17Member_1337114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_ifrs-full_IFRS17Member_1337114" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xlink:label="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember_1351536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember_1351536" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasEightMember" xlink:label="loc_imtx_AmendmentToIasEightMember_1351537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasEightMember_1351537" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasTwelveMember" xlink:label="loc_imtx_AmendmentToIasTwelveMember_1351538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasTwelveMember_1351538" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsSixteenMember" xlink:label="loc_imtx_AmendmentToIfrsSixteenMember_1351539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIfrsSixteenMember_1351539" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneMember" xlink:label="loc_imtx_AmendmentToIasOneMember_1351540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasOneMember_1351540" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="loc_ifrs-full_TitleOfNewIFRS_864969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" xlink:to="loc_ifrs-full_TitleOfNewIFRS_864969" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" xlink:to="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864970" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:label="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351492" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1351493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1351493" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1351494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1351494" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1351495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1351495" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1351496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1351496" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1351497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1351497" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xlink:label="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351499" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1351487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" xlink:to="loc_srt_RestatementAxis_1351487" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1351488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1351487" xlink:to="loc_srt_RestatementDomain_1351488" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1351488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1351487" xlink:to="loc_srt_RestatementDomain_1351488_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_1351490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_1351490" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1351491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1351491" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentlyReportedMember" xlink:label="loc_imtx_CurrentlyReportedMember_1351544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_imtx_CurrentlyReportedMember_1351544" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_866257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_866257" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" xlink:to="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_866251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_imtx_LaboratoryEquipmentMember_866251" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_866252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_ifrs-full_OfficeEquipmentMember_866252" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_866250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_ifrs-full_ComputerEquipmentMember_866250" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_866244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xlink:to="loc_ifrs-full_RangeAxis_866244" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_866244" xlink:to="loc_ifrs-full_RangesMember_866245" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866245_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_866244" xlink:to="loc_ifrs-full_RangesMember_866245_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_866247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_866245" xlink:to="loc_ifrs-full_TopOfRangeMember_866247" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_866246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_866245" xlink:to="loc_ifrs-full_BottomOfRangeMember_866246" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_866272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_866272" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember_866265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" xlink:to="loc_ifrs-full_LicencesMember_866265" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_866266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" xlink:to="loc_ifrs-full_ComputerSoftwareMember_866266" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_866267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xlink:to="loc_ifrs-full_RangeAxis_866267" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_866267" xlink:to="loc_ifrs-full_RangesMember_866268" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_866267" xlink:to="loc_ifrs-full_RangesMember_866268_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_866269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_866268" xlink:to="loc_ifrs-full_BottomOfRangeMember_866269" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_866270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_866268" xlink:to="loc_ifrs-full_TopOfRangeMember_866270" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_866280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_866280" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable_866275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable_866275" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_866279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_866279" use="optional" order="3" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementAxis" xlink:label="loc_imtx_CollaborationAgreementAxis_866340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xlink:to="loc_imtx_CollaborationAgreementAxis_866340" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementMember" xlink:label="loc_imtx_CollaborationAgreementMember_866341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_CollaborationAgreementAxis_866340" xlink:to="loc_imtx_CollaborationAgreementMember_866341" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementMember" xlink:label="loc_imtx_CollaborationAgreementMember_866341_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_CollaborationAgreementAxis_866340" xlink:to="loc_imtx_CollaborationAgreementMember_866341_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xlink:label="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember_866342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_CollaborationAgreementMember_866341" xlink:to="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember_866342" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationAxis" xlink:label="loc_imtx_BalanceSheetLocationAxis_870968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xlink:to="loc_imtx_BalanceSheetLocationAxis_870968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationDomain" xlink:label="loc_imtx_BalanceSheetLocationDomain_870969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_BalanceSheetLocationAxis_870968" xlink:to="loc_imtx_BalanceSheetLocationDomain_870969" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationDomain" xlink:label="loc_imtx_BalanceSheetLocationDomain_870969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_BalanceSheetLocationAxis_870968" xlink:to="loc_imtx_BalanceSheetLocationDomain_870969_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidInsurance" xlink:label="loc_imtx_CurrentPrepaidInsurance_866344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentPrepaidInsurance_866344" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentIncrementalCostForCollaborationAgreement" xlink:label="loc_imtx_CurrentIncrementalCostForCollaborationAgreement_866345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentIncrementalCostForCollaborationAgreement_866345" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PrepaidExpensesOfLicensesAndSoftware" xlink:label="loc_imtx_PrepaidExpensesOfLicensesAndSoftware_866346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_PrepaidExpensesOfLicensesAndSoftware_866346" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NoncurrentPrepaymentsOfLicensingAgreement" xlink:label="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement_1351340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement_1351340" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonCurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_NonCurrentPrepaidMaintenanceExpenses_1351341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_NonCurrentPrepaidMaintenanceExpenses_1351341" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments" xlink:label="loc_ifrs-full_NoncurrentPrepayments_866349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_ifrs-full_NoncurrentPrepayments_866349" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_CurrentPrepaidMaintenanceExpenses_1337590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentPrepaidMaintenanceExpenses_1337590" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisposalsOfPropertyPlantAndEquipment" xlink:label="loc_imtx_DisposalsOfPropertyPlantAndEquipment_870283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_DisposalsOfPropertyPlantAndEquipment_870283" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_866372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_866372" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionsOtherPropertyPlantAndEquipment" xlink:label="loc_imtx_AdditionsOtherPropertyPlantAndEquipment_870282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_AdditionsOtherPropertyPlantAndEquipment_870282" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrencyTranslationDifferences" xlink:label="loc_imtx_CurrencyTranslationDifferences_870289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_CurrencyTranslationDifferences_870289" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_866370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_ifrs-full_ComputerEquipmentMember_866370" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OfficeEquipmentAndInstallationsMember" xlink:label="loc_imtx_OfficeEquipmentAndInstallationsMember_1351339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_imtx_OfficeEquipmentAndInstallationsMember_1351339" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_866369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_imtx_LaboratoryEquipmentMember_866369" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsAxis" xlink:label="loc_imtx_TypeOfAdoptionsAxis_866358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_imtx_TypeOfAdoptionsAxis_866358" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_866359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_TypeOfAdoptionsAxis_866358" xlink:to="loc_imtx_TypeOfAdoptionsMember_866359" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_866359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_TypeOfAdoptionsAxis_866358" xlink:to="loc_imtx_TypeOfAdoptionsMember_866359_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" xlink:to="loc_ifrs-full_CarryingAmountMember_866356" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866356_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" xlink:to="loc_ifrs-full_CarryingAmountMember_866356_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_866364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_866356" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_866364" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_866357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_866356" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_866357" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_866362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" xlink:to="loc_ifrs-full_RestatedMember_866362" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_866362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" xlink:to="loc_ifrs-full_RestatedMember_866362_default" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_865033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" xlink:to="loc_imtx_IncomeStatementLocationAxis_865033" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_865034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_IncomeStatementLocationAxis_865033" xlink:to="loc_imtx_IncomeStatementLocationMember_865034" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_865034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_IncomeStatementLocationAxis_865033" xlink:to="loc_imtx_IncomeStatementLocationMember_865034_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_865035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_865034" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_865035" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_865036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_865034" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_865036" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_865038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_865038" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OfficeEquipmentAndInstallationsMember" xlink:label="loc_imtx_OfficeEquipmentAndInstallationsMember_1351336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" xlink:to="loc_imtx_OfficeEquipmentAndInstallationsMember_1351336" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1351333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1351333" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" xlink:to="loc_ifrs-full_CarryingAmountMember_866425" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" xlink:to="loc_ifrs-full_CarryingAmountMember_866425_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_866427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_866425" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_866427" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_866428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_866425" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_866428" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PatentAndLicensesMember" xlink:label="loc_imtx_PatentAndLicensesMember_866448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" xlink:to="loc_imtx_PatentAndLicensesMember_866448" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SoftwareLicensesMember" xlink:label="loc_imtx_SoftwareLicensesMember_866449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" xlink:to="loc_imtx_SoftwareLicensesMember_866449" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_866435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_866435" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_866437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_866437" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_866439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_866439" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_866458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_866458" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_866453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" xlink:to="loc_imtx_IncomeStatementLocationAxis_866453" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_866454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_IncomeStatementLocationAxis_866453" xlink:to="loc_imtx_IncomeStatementLocationMember_866454" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_866454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_IncomeStatementLocationAxis_866453" xlink:to="loc_imtx_IncomeStatementLocationMember_866454_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_866455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_866454" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_866455" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_866456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_866454" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_866456" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_866494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" xlink:to="loc_ifrs-full_RightofuseAssets_866494" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_866486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_866486" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866486" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866487" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866486" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866487_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_866491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_VehiclesMember_866491" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_866492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_OtherAssetsMember_866492" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_1337743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_imtx_LaboratoryEquipmentMember_1337743" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_866488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_BuildingsMember_866488" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:label="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866490" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_866508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_866508" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866508" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866509" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866509_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866508" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866509_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_866513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_VehiclesMember_866513" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_866515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_OtherAssetsMember_866515" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_866511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_BuildingsMember_866511" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:label="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866512" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_1337804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_imtx_LaboratoryEquipmentMember_1337804" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_866522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_866522" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_866524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_866524" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InterestExpenseOnLease" xlink:label="loc_imtx_InterestExpenseOnLease_870408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_imtx_InterestExpenseOnLease_870408" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_866543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xlink:to="loc_ifrs-full_MaturityAxis_866543" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_866543" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866544" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866544_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_866543" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866544_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_876339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866544" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_876339" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_866546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866544" xlink:to="loc_ifrs-full_LaterThanOneYearMember_866546" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1351320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xlink:to="loc_srt_StatementGeographicalAxis_1351320" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1351320" xlink:to="loc_srt_SegmentGeographicalDomain_1351321" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351321_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1351320" xlink:to="loc_srt_SegmentGeographicalDomain_1351321_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1351322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1351321" xlink:to="loc_country_US_1351322" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_866552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_CashOutflowForLeases_866552" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_866550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_866550" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TranslationDifferenceOnRightOfUseAsset" xlink:label="loc_imtx_TranslationDifferenceOnRightOfUseAsset_866551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_imtx_TranslationDifferenceOnRightOfUseAsset_866551" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_876337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_876337" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xlink:label="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities_1351547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities_1351547" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersTable" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_866839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_AgreementAxis_866839" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_866840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_AgreementAxis_866839" xlink:to="loc_imtx_AgreementDomain_866840" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_866840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_AgreementAxis_866839" xlink:to="loc_imtx_AgreementDomain_866840_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmgenCollaborationAgreementMember" xlink:label="loc_imtx_AmgenCollaborationAgreementMember_866841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_AmgenCollaborationAgreementMember_866841" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GSKCollaborationAgreementMember" xlink:label="loc_imtx_GSKCollaborationAgreementMember_866889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_GSKCollaborationAgreementMember_866889" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BMSCollaborationAgreementMember" xlink:label="loc_imtx_BMSCollaborationAgreementMember_866853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_BMSCollaborationAgreementMember_866853" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GenmabCollaborationAgreementMember" xlink:label="loc_imtx_GenmabCollaborationAgreementMember_866852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_GenmabCollaborationAgreementMember_866852" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BmsAgreementMember" xlink:label="loc_imtx_BmsAgreementMember_1351454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_BmsAgreementMember_1351454" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember_1351503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember_1351503" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneAxis" xlink:label="loc_imtx_MilestoneAxis_866842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_MilestoneAxis_866842" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneDomain" xlink:label="loc_imtx_MilestoneDomain_866843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_MilestoneAxis_866842" xlink:to="loc_imtx_MilestoneDomain_866843" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneDomain" xlink:label="loc_imtx_MilestoneDomain_866843_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_MilestoneAxis_866842" xlink:to="loc_imtx_MilestoneDomain_866843_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentForLicensedProductMember" xlink:label="loc_imtx_MilestonePaymentForLicensedProductMember_866882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_MilestoneDomain_866843" xlink:to="loc_imtx_MilestonePaymentForLicensedProductMember_866882" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1337750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_MaturityAxis_1337750" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1337751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1337750" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1337751" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1337751_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1337750" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1337751_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ThereafterMember" xlink:label="loc_imtx_ThereafterMember_1337753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1337751" xlink:to="loc_imtx_ThereafterMember_1337753" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_866845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_srt_StatementScenarioAxis_866845" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_866847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_866845" xlink:to="loc_srt_ScenarioUnspecifiedDomain_866847" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_866847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_866845" xlink:to="loc_srt_ScenarioUnspecifiedDomain_866847_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementAxis" xlink:label="loc_imtx_ImtxagreementAxis_1351451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_ImtxagreementAxis_1351451" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementMember" xlink:label="loc_imtx_ImtxagreementMember_1351452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_ImtxagreementAxis_1351451" xlink:to="loc_imtx_ImtxagreementMember_1351452" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementMember" xlink:label="loc_imtx_ImtxagreementMember_1351452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_ImtxagreementAxis_1351451" xlink:to="loc_imtx_ImtxagreementMember_1351452_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxbMSCollaborationAgreementMember" xlink:label="loc_imtx_ImtxbMSCollaborationAgreementMember_1351453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_ImtxagreementMember_1351452" xlink:to="loc_imtx_ImtxbMSCollaborationAgreementMember_1351453" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsBiotechnologiesGmbhMember" xlink:label="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" xlink:to="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351457" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" xlink:to="loc_imtx_ImmaticsUsIncMember_1351504" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1351464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1351464" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1351465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1351464" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1351465" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1351465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1351464" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1351465_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401licensegrantMember" xlink:label="loc_imtx_Ima401licensegrantMember_1351466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1351465" xlink:to="loc_imtx_Ima401licensegrantMember_1351466" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401clinicaltrialservicesMember" xlink:label="loc_imtx_Ima401clinicaltrialservicesMember_1351467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1351465" xlink:to="loc_imtx_Ima401clinicaltrialservicesMember_1351467" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1351505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_srt_CounterpartyNameAxis_1351505" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1351505" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1351505" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BristolMyerSquibCompanyMember" xlink:label="loc_imtx_BristolMyerSquibCompanyMember_1351507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" xlink:to="loc_imtx_BristolMyerSquibCompanyMember_1351507" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_866862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_866862" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_866863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_ContractLiabilities_866863" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers_866865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers_866865" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers_866867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers_866867" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractLiabilitiesRecognized" xlink:label="loc_imtx_ContractLiabilitiesRecognized_1337733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_ContractLiabilitiesRecognized_1337733" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements_1337737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_RevenueFromCollaborationAgreements_1337737" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PotentialMilestonePaymentPayable" xlink:label="loc_imtx_PotentialMilestonePaymentPayable_866870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_PotentialMilestonePaymentPayable_866870" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UpfrontPaymentReceived" xlink:label="loc_imtx_UpfrontPaymentReceived_866860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_UpfrontPaymentReceived_866860" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentReceivable" xlink:label="loc_imtx_MilestonePaymentReceivable_866859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_MilestonePaymentReceivable_866859" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xlink:label="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant_1351459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant_1351459" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_1351460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_1351460" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices_1351461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices_1351461" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardslicensegrant" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant_1351462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant_1351462" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1351468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1351468" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xlink:label="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived_1351508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived_1351508" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xlink:label="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived_1351509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived_1351509" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xlink:label="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived_1351510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived_1351510" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractTransactionPrice" xlink:label="loc_imtx_ContractTransactionPrice_1351511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_ContractTransactionPrice_1351511" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xlink:label="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation_1351512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation_1351512" use="optional" order="58" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_866858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_866858" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866855" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrent" xlink:label="loc_imtx_OtherCurrent_866869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_imtx_OtherCurrent_866869" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_866871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_866871" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_866861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_866861" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_1351361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_1351361" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_866866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_866866" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_866910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_866910" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866910" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866911" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866910" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866911_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonInterestBearingLiabilityMember" xlink:label="loc_imtx_NonInterestBearingLiabilityMember_866914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_866911" xlink:to="loc_imtx_NonInterestBearingLiabilityMember_866914" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity_866919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" xlink:to="loc_ifrs-full_BorrowingsMaturity_866919" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_867276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_867276" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense_867277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_imtx_AdjustmentsForShareListingExpense_867277" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_867319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_867319" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1143872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1143872" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_1149428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_FinancialLiabilities_1149428" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_867260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_ParValuePerShare_867260" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_867253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_867253" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867253" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867253" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_867255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" xlink:to="loc_imtx_AryaMember_867255" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_867247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_867247" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_867247_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_867247_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_867248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_867247" xlink:to="loc_ifrs-full_OrdinarySharesMember_867248" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_867252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" xlink:to="loc_imtx_WarrantsMember_867252" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsIssuedPricePerWarrant" xlink:label="loc_imtx_WarrantsIssuedPricePerWarrant_1143873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_imtx_WarrantsIssuedPricePerWarrant_1143873" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143875" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense_866995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_AdjustmentsForShareListingExpense_866995" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_866988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_866988" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_866989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_ParValuePerShare_866989" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xlink:label="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate_1143876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate_1143876" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_1143877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_1143877" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866981" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866981_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866981_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_866982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_866981" xlink:to="loc_ifrs-full_OrdinarySharesMember_866982" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_866985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" xlink:to="loc_imtx_WarrantsMember_866985" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_866976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_866976" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866976" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866976" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_866978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" xlink:to="loc_imtx_AryaMember_866978" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsIssuedPricePerWarrant" xlink:label="loc_imtx_WarrantsIssuedPricePerWarrant_866992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_WarrantsIssuedPricePerWarrant_866992" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_866993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_866993" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_866994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_866994" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanAxis" xlink:label="loc_imtx_PlanAxis_868615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xlink:to="loc_imtx_PlanAxis_868615" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_PlanAxis_868615" xlink:to="loc_imtx_PlanMember_868616" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868616_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_PlanAxis_868615" xlink:to="loc_imtx_PlanMember_868616_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_PlanMember_868616" xlink:to="loc_imtx_MatchingStockOptionsMember_868684" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868840" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_ConvertedOptionsMember_868853" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868841" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_867295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_867295" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_867313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_867313" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_867314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_867314" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_867308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_867308" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_867306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_867306" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_867311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_867311" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867328" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_867330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_867330" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_867331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_867331" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_867334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_867334" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1338049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1338049" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1338064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1338064" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_867341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_867341" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_868812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_868812" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:label="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868813" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1338031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1338031" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1338074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1338074" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_867344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_867344" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_867352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_867352" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantAxis" xlink:label="loc_imtx_DateOfGrantAxis_868809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xlink:to="loc_imtx_DateOfGrantAxis_868809" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_DateOfGrantAxis_868809" xlink:to="loc_imtx_DateOfGrantMember_868810" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868810_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_DateOfGrantAxis_868809" xlink:to="loc_imtx_DateOfGrantMember_868810_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868811" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember_1338212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember_1338212" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338241" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_MatchingStockOptionsMember_868854" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868808" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868826" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_ConvertedOptionsMember_868843" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_867343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_867343" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeAxis" xlink:label="loc_imtx_ShareReinvestmentSchemeAxis_868378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_ShareReinvestmentSchemeAxis_868378" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeMember" xlink:label="loc_imtx_ShareReinvestmentSchemeMember_868379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_ShareReinvestmentSchemeAxis_868378" xlink:to="loc_imtx_ShareReinvestmentSchemeMember_868379" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeMember" xlink:label="loc_imtx_ShareReinvestmentSchemeMember_868379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_ShareReinvestmentSchemeAxis_868378" xlink:to="loc_imtx_ShareReinvestmentSchemeMember_868379_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_ShareReinvestmentSchemeMember_868379" xlink:to="loc_imtx_MatchingStockOptionsMember_868380" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanAxis" xlink:label="loc_imtx_PlanAxis_868360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_PlanAxis_868360" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_PlanAxis_868360" xlink:to="loc_imtx_PlanMember_868362" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_PlanAxis_868360" xlink:to="loc_imtx_PlanMember_868362_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember_868366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember_868366" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndTenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndTenPlanMember_868532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfTwoThousandAndTenPlanMember_868532" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember_868533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember_868533" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeAxis" xlink:label="loc_imtx_SchemeAxis_868375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_SchemeAxis_868375" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeMember" xlink:label="loc_imtx_SchemeMember_868376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_SchemeAxis_868375" xlink:to="loc_imtx_SchemeMember_868376" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeMember" xlink:label="loc_imtx_SchemeMember_868376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_SchemeAxis_868375" xlink:to="loc_imtx_SchemeMember_868376_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentMember" xlink:label="loc_imtx_ShareReinvestmentMember_868377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SchemeMember_868376" xlink:to="loc_imtx_ShareReinvestmentMember_868377" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" xlink:to="loc_imtx_ConvertedOptionsMember_868787" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868721" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_868371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_RangeAxis_868371" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_868372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_868371" xlink:to="loc_ifrs-full_RangesMember_868372" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_868372_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_868371" xlink:to="loc_ifrs-full_RangesMember_868372_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_868373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_868372" xlink:to="loc_ifrs-full_BottomOfRangeMember_868373" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_868374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_868372" xlink:to="loc_ifrs-full_TopOfRangeMember_868374" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesAxis" xlink:label="loc_imtx_CategoryOfEmployeesAxis_868367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_CategoryOfEmployeesAxis_868367" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesMember" xlink:label="loc_imtx_CategoryOfEmployeesMember_868368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_CategoryOfEmployeesAxis_868367" xlink:to="loc_imtx_CategoryOfEmployeesMember_868368" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesMember" xlink:label="loc_imtx_CategoryOfEmployeesMember_868368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_CategoryOfEmployeesAxis_868367" xlink:to="loc_imtx_CategoryOfEmployeesMember_868368_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ManagementMembersMember" xlink:label="loc_imtx_ManagementMembersMember_868370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_CategoryOfEmployeesMember_868368" xlink:to="loc_imtx_ManagementMembersMember_868370" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ActiveEmployeesMember" xlink:label="loc_imtx_ActiveEmployeesMember_868369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_CategoryOfEmployeesMember_868368" xlink:to="loc_imtx_ActiveEmployeesMember_868369" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheAxis" xlink:label="loc_imtx_TrancheAxis_868735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_TrancheAxis_868735" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheMember" xlink:label="loc_imtx_TrancheMember_868736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_TrancheAxis_868735" xlink:to="loc_imtx_TrancheMember_868736" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheMember" xlink:label="loc_imtx_TrancheMember_868736_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_TrancheAxis_868735" xlink:to="loc_imtx_TrancheMember_868736_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheTwoMember" xlink:label="loc_imtx_TrancheTwoMember_870914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheTwoMember_870914" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheThreeMember" xlink:label="loc_imtx_TrancheThreeMember_870916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheThreeMember_870916" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheOneMember" xlink:label="loc_imtx_TrancheOneMember_868737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheOneMember_868737" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_868780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_868780" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_868780" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_868780" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantAxis" xlink:label="loc_imtx_DateOfGrantAxis_868724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_DateOfGrantAxis_868724" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_DateOfGrantAxis_868724" xlink:to="loc_imtx_DateOfGrantMember_868728" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_DateOfGrantAxis_868724" xlink:to="loc_imtx_DateOfGrantMember_868728_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338316" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember_868806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember_868806" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868730" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashPaymentAwardPerSharePayable" xlink:label="loc_imtx_CashPaymentAwardPerSharePayable_868388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_CashPaymentAwardPerSharePayable_868388" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_868384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_868384" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashProceedsToBeBeReinvested" xlink:label="loc_imtx_PercentageOfCashProceedsToBeBeReinvested_868389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_PercentageOfCashProceedsToBeBeReinvested_868389" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAndOnBehalfOfEmployees" xlink:label="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees_868390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees_868390" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ExpenseFromTheModificationOfShareBasedAwards" xlink:label="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards_868391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards_868391" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_868392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_868392" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_868462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_868462" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_868467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_868467" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfVestingOfStockOptions" xlink:label="loc_imtx_DateOfVestingOfStockOptions_868483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_DateOfVestingOfStockOptions_868483" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_868491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_868491" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MinimumMarketCapitalization" xlink:label="loc_imtx_MinimumMarketCapitalization_868734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_MinimumMarketCapitalization_868734" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_868397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_868397" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_868430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_868430" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:label="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868488" use="optional" order="59" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_868794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" xlink:to="loc_imtx_IncomeStatementLocationAxis_868794" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_868795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_IncomeStatementLocationAxis_868794" xlink:to="loc_imtx_IncomeStatementLocationMember_868795" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_868795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_IncomeStatementLocationAxis_868794" xlink:to="loc_imtx_IncomeStatementLocationMember_868795_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_868796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_868795" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_868796" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_868805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_868795" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_868805" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_868800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_868800" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867389" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_866900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_ParValuePerShare_866900" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_866901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_IssuedCapital_866901" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_866899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_866899" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1351352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_NumberOfSharesIssued_1351352" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrossProceedsFromIssueOfSecurities" xlink:label="loc_imtx_GrossProceedsFromIssueOfSecurities_1351353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_GrossProceedsFromIssueOfSecurities_1351353" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1351354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_1351354" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1351355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_IssueOfEquity_1351355" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_866878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_866878" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866878" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866879" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866879_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866878" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866879_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PipeFinancingMember" xlink:label="loc_imtx_PipeFinancingMember_866941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_866879" xlink:to="loc_imtx_PipeFinancingMember_866941" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventAxis" xlink:label="loc_imtx_EventAxis_876689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_EventAxis_876689" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventDomain" xlink:label="loc_imtx_EventDomain_876690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_EventAxis_876689" xlink:to="loc_imtx_EventDomain_876690" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventDomain" xlink:label="loc_imtx_EventDomain_876690_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_EventAxis_876689" xlink:to="loc_imtx_EventDomain_876690_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReorganizationMember" xlink:label="loc_imtx_ReorganizationMember_876691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_EventDomain_876690" xlink:to="loc_imtx_ReorganizationMember_876691" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseAxis" xlink:label="loc_imtx_ShareListingExpenseAxis_876472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_ShareListingExpenseAxis_876472" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseDomain" xlink:label="loc_imtx_ShareListingExpenseDomain_876473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_ShareListingExpenseAxis_876472" xlink:to="loc_imtx_ShareListingExpenseDomain_876473" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseDomain" xlink:label="loc_imtx_ShareListingExpenseDomain_876473_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_ShareListingExpenseAxis_876472" xlink:to="loc_imtx_ShareListingExpenseDomain_876473_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMergerMember" xlink:label="loc_imtx_AryaMergerMember_876474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_ShareListingExpenseDomain_876473" xlink:to="loc_imtx_AryaMergerMember_876474" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeAxis" xlink:label="loc_imtx_InvesteeAxis_1351356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_InvesteeAxis_1351356" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeMember" xlink:label="loc_imtx_InvesteeMember_1351357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_InvesteeAxis_1351356" xlink:to="loc_imtx_InvesteeMember_1351357" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeMember" xlink:label="loc_imtx_InvesteeMember_1351357_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_InvesteeAxis_1351356" xlink:to="loc_imtx_InvesteeMember_1351357_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SvbSecuritiesLicMember" xlink:label="loc_imtx_SvbSecuritiesLicMember_1351358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_InvesteeMember_1351357" xlink:to="loc_imtx_SvbSecuritiesLicMember_1351358" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_1351359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_AgreementAxis_1351359" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_AgreementAxis_1351359" xlink:to="loc_imtx_AgreementDomain_1351360" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351360_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_AgreementAxis_1351359" xlink:to="loc_imtx_AgreementDomain_1351360_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AtTheMarketAgreementMember" xlink:label="loc_imtx_AtTheMarketAgreementMember_1351365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351360" xlink:to="loc_imtx_AtTheMarketAgreementMember_1351365" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1351366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1351366" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1351367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1351366" xlink:to="loc_ifrs-full_EquityMember_1351367" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1351367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1351366" xlink:to="loc_ifrs-full_EquityMember_1351367_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1351368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1351367" xlink:to="loc_ifrs-full_IssuedCapitalMember_1351368" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_1351369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1351367" xlink:to="loc_ifrs-full_SharePremiumMember_1351369" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866875" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866875_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_866876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_866875" xlink:to="loc_ifrs-full_OrdinarySharesMember_866876" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsAxis" xlink:label="loc_ifrs-full_CapitalRequirementsAxis_1351370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_CapitalRequirementsAxis_1351370" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsMember" xlink:label="loc_ifrs-full_CapitalRequirementsMember_1351371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CapitalRequirementsAxis_1351370" xlink:to="loc_ifrs-full_CapitalRequirementsMember_1351371" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsMember" xlink:label="loc_ifrs-full_CapitalRequirementsMember_1351371_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CapitalRequirementsAxis_1351370" xlink:to="loc_ifrs-full_CapitalRequirementsMember_1351371_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RegisteredDirectOfferingMember" xlink:label="loc_imtx_RegisteredDirectOfferingMember_1351372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CapitalRequirementsMember_1351371" xlink:to="loc_imtx_RegisteredDirectOfferingMember_1351372" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_866903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_SharePremium_866903" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareIssuedPricePerShare" xlink:label="loc_imtx_ShareIssuedPricePerShare_1351374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_ShareIssuedPricePerShare_1351374" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867057" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_867067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_ifrs-full_ParValuePerShare_867067" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_867068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_867068" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfSharesExchangedInSubsidiaries" xlink:label="loc_imtx_NumberOfSharesExchangedInSubsidiaries_867065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_NumberOfSharesExchangedInSubsidiaries_867065" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions_867066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions_867066" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867069" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughCompensationExpense" xlink:label="loc_imtx_IncreasedecreaseThroughCompensationExpense_867073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_IncreasedecreaseThroughCompensationExpense_867073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossOnNoncontrollingInterest" xlink:label="loc_imtx_LossOnNoncontrollingInterest_867071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_LossOnNoncontrollingInterest_867071" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_StatementsTable_867054" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867054" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MdAndersonMember" xlink:label="loc_imtx_MdAndersonMember_867060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" xlink:to="loc_imtx_MdAndersonMember_867060" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_867061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867054" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_867061" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867061" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867061" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedStockAcquisitionAgreementMember" xlink:label="loc_imtx_RestrictedStockAcquisitionAgreementMember_867063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" xlink:to="loc_imtx_RestrictedStockAcquisitionAgreementMember_867063" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_867064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" xlink:to="loc_imtx_AryaMember_867064" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_867070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_867070" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867029" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_OtherShorttermEmployeeBenefits_867035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_OtherShorttermEmployeeBenefits_867035" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_imtx_StatementsTable_867026" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_867030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867026" xlink:to="loc_imtx_IncomeStatementLocationAxis_867030" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_867031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_IncomeStatementLocationAxis_867030" xlink:to="loc_imtx_IncomeStatementLocationMember_867031" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_867031_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_IncomeStatementLocationAxis_867030" xlink:to="loc_imtx_IncomeStatementLocationMember_867031_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_867032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_867031" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_867032" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_867033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_IncomeStatementLocationMember_867031" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_867033" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_867039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_867039" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_867034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_WagesAndSalaries_867034" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_867036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_867036" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_867038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_867038" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_866952" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesOffSet" xlink:label="loc_imtx_DeferredTaxLiabilitiesOffSet_871083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxLiabilitiesOffSet_871083" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_867000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_ifrs-full_DeferredTaxAssets_867000" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_867002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_867002" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOffset" xlink:label="loc_imtx_DeferredTaxAssetsOffset_871078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxAssetsOffset_871078" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_866949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_StatementsTable_866949" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_866949" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_866954_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_866954_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IntangibleAssetsMember" xlink:label="loc_imtx_IntangibleAssetsMember_866956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_IntangibleAssetsMember_866956" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredRevenueMember" xlink:label="loc_imtx_DeferredRevenueMember_866958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredRevenueMember_866958" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetNettingMember" xlink:label="loc_imtx_DeferredAssetNettingMember_866970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredAssetNettingMember_866970" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember_866986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember_866986" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember_866997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember_866997" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredLiabilityNettingMember" xlink:label="loc_imtx_DeferredLiabilityNettingMember_866998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredLiabilityNettingMember_866998" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_1351447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_ifrs-full_OtherAssetsMember_1351447" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetRecognisedMember" xlink:label="loc_imtx_DeferredAssetRecognisedMember_866966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredAssetRecognisedMember_866966" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LeaseLiabilityMember" xlink:label="loc_imtx_LeaseLiabilityMember_866961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_LeaseLiabilityMember_866961" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredExpensesMember" xlink:label="loc_imtx_DeferredExpensesMember_866962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredExpensesMember_866962" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RecognitionOfTaxLossesCarriedForwardMember" xlink:label="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember_1351550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember_1351550" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xlink:label="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember_1351551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember_1351551" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_866949" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOnTemporaryDifferences" xlink:label="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences_1351555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences_1351555" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867011" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_867012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_ApplicableTaxRate_867012" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CorporateIncomeTaxRate" xlink:label="loc_imtx_CorporateIncomeTaxRate_867013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_CorporateIncomeTaxRate_867013" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_867014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_867014" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod_867015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod_867015" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod_867016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod_867016" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xlink:label="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense_876755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense_876755" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_1351437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_1351437" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xlink:label="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward_1351441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward_1351441" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xlink:label="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax_1351442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax_1351442" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_StatementsTable_867008" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IndefiniteTaxLossesCarryforwardMember" xlink:label="loc_imtx_IndefiniteTaxLossesCarryforwardMember_867425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" xlink:to="loc_imtx_IndefiniteTaxLossesCarryforwardMember_867425" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentySixYearTaxLossesCarryforwardMember" xlink:label="loc_imtx_TwentySixYearTaxLossesCarryforwardMember_867426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" xlink:to="loc_imtx_TwentySixYearTaxLossesCarryforwardMember_867426" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsBiotechnologiesGmbhMember" xlink:label="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" xlink:to="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351440" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1351443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_srt_StatementGeographicalAxis_1351443" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1351443" xlink:to="loc_srt_SegmentGeographicalDomain_1351444" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1351443" xlink:to="loc_srt_SegmentGeographicalDomain_1351444_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE_1351445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1351444" xlink:to="loc_country_DE_1351445" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsAxis" xlink:label="loc_imtx_TypeOfAdoptionsAxis_867009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_imtx_TypeOfAdoptionsAxis_867009" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_869226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_TypeOfAdoptionsAxis_867009" xlink:to="loc_imtx_TypeOfAdoptionsMember_869226" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_869226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_TypeOfAdoptionsAxis_867009" xlink:to="loc_imtx_TypeOfAdoptionsMember_869226_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_1351548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_1351548" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1351549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1351549" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureLineItems" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureTable" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_srt_OwnershipAxis_867087" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_867087" xlink:to="loc_srt_OwnershipDomain_867088" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867088_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_867087" xlink:to="loc_srt_OwnershipDomain_867088_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_867088" xlink:to="loc_imtx_ImmaticsNvMember_867089" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867090" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867090" xlink:to="loc_ifrs-full_TypesOfRisksMember_867091" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867091_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867090" xlink:to="loc_ifrs-full_TypesOfRisksMember_867091_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_867092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_867091" xlink:to="loc_ifrs-full_CurrencyRiskMember_867092" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" xlink:to="loc_imtx_ImmaticsGmbhMember_867095" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_867096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_ifrs-full_CashAndCashEquivalents_867096" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_867097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_ifrs-full_FinancialAssets_867097" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MaximumExposedToCurrencyRisk" xlink:label="loc_imtx_MaximumExposedToCurrencyRisk_867099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_imtx_MaximumExposedToCurrencyRisk_867099" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_867122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_ifrs-full_ValueAtRisk_867122" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_867120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_867120" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints_1351531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints_1351531" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints_867121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints_867121" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_srt_OwnershipAxis_867114" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_867114" xlink:to="loc_srt_OwnershipDomain_867115" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_867114" xlink:to="loc_srt_OwnershipDomain_867115_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_867115" xlink:to="loc_imtx_ImmaticsNvMember_867116" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_867108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_867108" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_867109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_867109" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_867110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_867110" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_867111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_867111" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_867112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_867112" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_867113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_867113" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" xlink:to="loc_imtx_ImmaticsUsIncMember_1351532" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" xlink:to="loc_imtx_ImmaticsGmbhMember_867119" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" xlink:to="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867141" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" xlink:to="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867140" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_870439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_870439" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_870428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_870428" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_870429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_870429" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_870432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_870432" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_870433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_870433" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_870434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_870434" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_srt_OwnershipAxis_867150" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_867150" xlink:to="loc_srt_OwnershipDomain_867151" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_867150" xlink:to="loc_srt_OwnershipDomain_867151_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_867151" xlink:to="loc_imtx_ImmaticsNvMember_867152" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" xlink:to="loc_imtx_ImmaticsGmbhMember_867155" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" xlink:to="loc_imtx_ImmaticsUsIncMember_1351530" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_867130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_srt_CurrencyAxis_867130" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_867130" xlink:to="loc_currency_AllCurrenciesDomain_867131" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867131_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_867130" xlink:to="loc_currency_AllCurrenciesDomain_867131_default" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867168" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867168" xlink:to="loc_imtx_StatementsTable_867165" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867165" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_867170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" xlink:to="loc_ifrs-full_FinancialAssetsMember_867170" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_867170_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" xlink:to="loc_ifrs-full_FinancialAssetsMember_867170_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShorttermDepositsMember" xlink:label="loc_imtx_ShorttermDepositsMember_867172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_ShorttermDepositsMember_867172" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashAndCashEquivalentsMember" xlink:label="loc_imtx_CashAndCashEquivalentsMember_876761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_CashAndCashEquivalentsMember_876761" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsMember" xlink:label="loc_imtx_BondsMember_1337830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_BondsMember_1337830" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867165" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867173" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867173" xlink:to="loc_ifrs-full_TypesOfRisksMember_867174" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867173" xlink:to="loc_ifrs-full_TypesOfRisksMember_867174_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_867175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_867174" xlink:to="loc_ifrs-full_LiquidityRiskMember_867175" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:label="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_867176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867168" xlink:to="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_867176" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867185" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_867210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_867210" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_StatementsTable_867182" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_867204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_RangeAxis_867204" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_867205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_867204" xlink:to="loc_ifrs-full_RangesMember_867205" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_867205_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_867204" xlink:to="loc_ifrs-full_RangesMember_867205_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_867207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_867205" xlink:to="loc_ifrs-full_TopOfRangeMember_867207" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_867208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_867205" xlink:to="loc_ifrs-full_BottomOfRangeMember_867208" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_867192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_srt_CurrencyAxis_867192" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_867192" xlink:to="loc_currency_AllCurrenciesDomain_867193" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867193_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_867192" xlink:to="loc_currency_AllCurrenciesDomain_867193_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_867194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_867193" xlink:to="loc_currency_EUR_867194" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_867195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_867193" xlink:to="loc_currency_USD_867195" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867188" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867188" xlink:to="loc_ifrs-full_TypesOfRisksMember_867189" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867188" xlink:to="loc_ifrs-full_TypesOfRisksMember_867189_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_867202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_867189" xlink:to="loc_ifrs-full_CurrencyRiskMember_867202" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_867190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_867189" xlink:to="loc_ifrs-full_CreditRiskMember_867190" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_1145714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_UnobservableInputsAxis_1145714" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_1145715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_1145714" xlink:to="loc_ifrs-full_UnobservableInputsMember_1145715" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_1145715_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_1145714" xlink:to="loc_ifrs-full_UnobservableInputsMember_1145715_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_1145716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_1145715" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_1145716" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignExchangeRatesMember" xlink:label="loc_imtx_ForeignExchangeRatesMember_1145722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_1145715" xlink:to="loc_imtx_ForeignExchangeRatesMember_1145722" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1145729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1145729" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1145729" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1145729" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_1145736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" xlink:to="loc_imtx_AryaMember_1145736" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_1145743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" xlink:to="loc_imtx_WarrantsMember_1145743" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1351434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1351434" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351434" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351435" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351435_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351434" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351435_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeMember" xlink:label="loc_imtx_DeMember_1351436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351435" xlink:to="loc_imtx_DeMember_1351436" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867218" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_867221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_867221" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145703" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1351430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_TradeReceivables_1351430" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_867212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_CashAndCashEquivalents_867212" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets_867214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_OtherFinancialAssets_867214" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867217" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_1145697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_1145697" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1145700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1145700" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145702" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xlink:label="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile_1351432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile_1351432" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsAndShortTermDeposits" xlink:label="loc_imtx_BondsAndShortTermDeposits_1351433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_BondsAndShortTermDeposits_1351433" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_866755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_866755" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_866755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_866755_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_866755" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351396" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_866759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" xlink:to="loc_ifrs-full_FinancialAssetsMember_866759" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_866759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" xlink:to="loc_ifrs-full_FinancialAssetsMember_866759_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember_866764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_ifrs-full_TradeReceivablesMember_866764" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentNonCurrentAssetsMember" xlink:label="loc_imtx_OtherCurrentNonCurrentAssetsMember_866765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_OtherCurrentNonCurrentAssetsMember_866765" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccountsPayableMember" xlink:label="loc_imtx_AccountsPayableMember_866766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_AccountsPayableMember_866766" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShorttermDepositsMember" xlink:label="loc_imtx_ShorttermDepositsMember_866762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_ShorttermDepositsMember_866762" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentLiabilitiesMember" xlink:label="loc_imtx_OtherCurrentLiabilitiesMember_866767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_OtherCurrentLiabilitiesMember_866767" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsMember" xlink:label="loc_imtx_BondsMember_1337756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_BondsMember_1337756" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashAndCashEquivalentsMember" xlink:label="loc_imtx_CashAndCashEquivalentsMember_1351402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_CashAndCashEquivalentsMember_1351402" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesForWarrantsMember" xlink:label="loc_imtx_LiabilitiesForWarrantsMember_1351403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_LiabilitiesForWarrantsMember_1351403" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_1351404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_1351404" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351399" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351400" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_1351405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_MeasurementAxis_1351405" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1351406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_1351405" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1351406" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1351406_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_1351405" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1351406_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1351407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1351406" xlink:to="loc_ifrs-full_CarryingAmountMember_1351407" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_1351408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1351406" xlink:to="loc_ifrs-full_AtFairValueMember_1351408" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_866769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_ifrs-full_FinancialAssets_866769" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_866770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_ifrs-full_FinancialLiabilities_866770" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FinancialAssetsAndFinancialLiabilities" xlink:label="loc_imtx_FinancialAssetsAndFinancialLiabilities_1351401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_imtx_FinancialAssetsAndFinancialLiabilities_1351401" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NetFinancialResult" xlink:label="loc_imtx_NetFinancialResult_1351419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" xlink:to="loc_imtx_NetFinancialResult_1351419" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1351413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1351413_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351414" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1351415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1351415" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351416" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_1351424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_1351424" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_1351424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_1351424_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesForWarrantsMember" xlink:label="loc_imtx_LiabilitiesForWarrantsMember_1351425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_1351424" xlink:to="loc_imtx_LiabilitiesForWarrantsMember_1351425" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_1351426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_1351424" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_1351426" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective_1351428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" xlink:to="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective_1351428" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective_1351429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" xlink:to="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective_1351429" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsLineItems" xlink:label="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractResearchOrganizationAgreements" xlink:label="loc_imtx_ContractResearchOrganizationAgreements_866728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractResearchOrganizationAgreements_866728" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualCashObligation" xlink:label="loc_imtx_ContractualCashObligation_866729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractualCashObligation_866729" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsTable" xlink:label="loc_imtx_DisclosureOfContractualObligationsTable_866732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_DisclosureOfContractualObligationsTable_866732" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_866733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfContractualObligationsTable_866732" xlink:to="loc_ifrs-full_MaturityAxis_866733" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_866733" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866734" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866734_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_866733" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866734_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_866737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_866737" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_866738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_866738" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_866735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_866735" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_866736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_866736" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualObligationOfLeaseLiabilities" xlink:label="loc_imtx_ContractualObligationOfLeaseLiabilities_866724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractualObligationOfLeaseLiabilities_866724" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherLeaseObligations" xlink:label="loc_imtx_OtherLeaseObligations_866725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_OtherLeaseObligations_866725" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_876792" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UnrecordedContingentLiability" xlink:label="loc_imtx_UnrecordedContingentLiability_876798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_StatementsLineItems_876792" xlink:to="loc_imtx_UnrecordedContingentLiability_876798" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_876791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_StatementsLineItems_876792" xlink:to="loc_imtx_StatementsTable_876791" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_876793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_StatementsTable_876791" xlink:to="loc_imtx_AgreementAxis_876793" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_876794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_AgreementAxis_876793" xlink:to="loc_imtx_AgreementDomain_876794" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_876794_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_AgreementAxis_876793" xlink:to="loc_imtx_AgreementDomain_876794_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementsMember" xlink:label="loc_imtx_CollaborationAgreementsMember_876795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_876794" xlink:to="loc_imtx_CollaborationAgreementsMember_876795" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationTravellingExpenses" xlink:label="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses_866553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses_866553" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xlink:label="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense_866555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense_866555" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensations" xlink:label="loc_imtx_KeyManagementPersonnelCompensations_866556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensations_866556" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xlink:label="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation_866537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation_866537" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xlink:label="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement_880588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement_880588" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EliotForsterMember" xlink:label="loc_imtx_EliotForsterMember_866571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_EliotForsterMember_866571" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaulCarterMember" xlink:label="loc_imtx_PaulCarterMember_866567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_PaulCarterMember_866567" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HeatherLMasonMember" xlink:label="loc_imtx_HeatherLMasonMember_866568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_HeatherLMasonMember_866568" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdamStoneMember" xlink:label="loc_imtx_AdamStoneMember_866569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_AdamStoneMember_866569" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PeterChambreMember" xlink:label="loc_imtx_PeterChambreMember_866573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_PeterChambreMember_866573" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HaraldFstockMember" xlink:label="loc_imtx_HaraldFstockMember_866574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_HaraldFstockMember_866574" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ChristophHettichMember" xlink:label="loc_imtx_ChristophHettichMember_866570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_ChristophHettichMember_866570" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MichaelGAtiehMember" xlink:label="loc_imtx_MichaelGAtiehMember_866566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_MichaelGAtiehMember_866566" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NancyValenteMember" xlink:label="loc_imtx_NancyValenteMember_1351388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_NancyValenteMember_1351388" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FriedrichVonBohlenUndHalbachMember" xlink:label="loc_imtx_FriedrichVonBohlenUndHalbachMember_1351543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_FriedrichVonBohlenUndHalbachMember_1351543" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement_866610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement_866610" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_866611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_866611" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_866612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_866612" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_866613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_866613" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfExpiryOfShareOptionsGranted" xlink:label="loc_imtx_DateOfExpiryOfShareOptionsGranted_866805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_imtx_DateOfExpiryOfShareOptionsGranted_866805" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HeatherLMasonMember" xlink:label="loc_imtx_HeatherLMasonMember_866602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_HeatherLMasonMember_866602" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MichaelGAtiehMember" xlink:label="loc_imtx_MichaelGAtiehMember_866604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_MichaelGAtiehMember_866604" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaulCarterMember" xlink:label="loc_imtx_PaulCarterMember_866605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_PaulCarterMember_866605" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EliotForsterMember" xlink:label="loc_imtx_EliotForsterMember_866606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_EliotForsterMember_866606" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HarpreetSinghMember" xlink:label="loc_imtx_HarpreetSinghMember_866595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_HarpreetSinghMember_866595" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PeterChambreMember" xlink:label="loc_imtx_PeterChambreMember_866596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_PeterChambreMember_866596" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdamStoneMember" xlink:label="loc_imtx_AdamStoneMember_866597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_AdamStoneMember_866597" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NancyValenteMember" xlink:label="loc_imtx_NancyValenteMember_1351391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_NancyValenteMember_1351391" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FriedrichVonBohlenUndHalbachMember" xlink:label="loc_imtx_FriedrichVonBohlenUndHalbachMember_1337525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_FriedrichVonBohlenUndHalbachMember_1337525" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingAxis" xlink:label="loc_imtx_TypeOfVestingAxis_866584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xlink:to="loc_imtx_TypeOfVestingAxis_866584" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_TypeOfVestingAxis_866584" xlink:to="loc_imtx_TypeOfVestingDomain_866586" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866586_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_TypeOfVestingAxis_866584" xlink:to="loc_imtx_TypeOfVestingDomain_866586_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_866591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ConvertedOptionsMember_866591" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_866587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_PerformanceBasedOptionsMember_866587" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsMember" xlink:label="loc_imtx_ServiceOptionsMember_866588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsMember_866588" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_866589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_MatchingStockOptionsMember_866589" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsOneMember" xlink:label="loc_imtx_ConvertedOptionsOneMember_870321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ConvertedOptionsOneMember_870321" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsOneMember" xlink:label="loc_imtx_ServiceOptionsOneMember_870324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsOneMember_870324" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsTwoMember" xlink:label="loc_imtx_ServiceOptionsTwoMember_1337545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsTwoMember_1337545" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsThreeMember" xlink:label="loc_imtx_ServiceOptionsThreeMember_1351389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsThreeMember_1351389" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsFourMember" xlink:label="loc_imtx_ServiceOptionsFourMember_1351390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsFourMember_1351390" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfTransactionsWithRelatedParty" xlink:label="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty_866609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty_866609" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_866671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_866671" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866671" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866671" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_866674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" xlink:to="loc_imtx_AryaMember_866674" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingAxis" xlink:label="loc_imtx_TypeOfVestingAxis_866666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_imtx_TypeOfVestingAxis_866666" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_TypeOfVestingAxis_866666" xlink:to="loc_imtx_TypeOfVestingDomain_866667" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866667_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_TypeOfVestingAxis_866666" xlink:to="loc_imtx_TypeOfVestingDomain_866667_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsMember" xlink:label="loc_imtx_ServiceOptionsMember_866668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_TypeOfVestingDomain_866667" xlink:to="loc_imtx_ServiceOptionsMember_866668" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_866678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" xlink:to="loc_imtx_ImmaticsGmbhMember_866678" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1351314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_srt_OwnershipAxis_1351314" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1351316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1351314" xlink:to="loc_srt_OwnershipDomain_1351316" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1351316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1351314" xlink:to="loc_srt_OwnershipDomain_1351316_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DirectorsAndExecutiveOfficersMember" xlink:label="loc_imtx_DirectorsAndExecutiveOfficersMember_1351319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1351316" xlink:to="loc_imtx_DirectorsAndExecutiveOfficersMember_1351319" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_866657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" xlink:to="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_866657" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameAxis" xlink:label="loc_imtx_PlanNameAxis_866658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_imtx_PlanNameAxis_866658" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameDomain" xlink:label="loc_imtx_PlanNameDomain_866659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_PlanNameAxis_866658" xlink:to="loc_imtx_PlanNameDomain_866659" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameDomain" xlink:label="loc_imtx_PlanNameDomain_866659_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_PlanNameAxis_866658" xlink:to="loc_imtx_PlanNameDomain_866659_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentyTwentyIncentivePlanMember" xlink:label="loc_imtx_TwentyTwentyIncentivePlanMember_866662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_PlanNameDomain_866659" xlink:to="loc_imtx_TwentyTwentyIncentivePlanMember_866662" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xlink:label="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule_866684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule_866684" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_866686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_866686" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentOfPayrollTaxOfTheEmployees" xlink:label="loc_imtx_PaymentOfPayrollTaxOfTheEmployees_866692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_PaymentOfPayrollTaxOfTheEmployees_866692" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfConvertedStockOptionsInTheEntity" xlink:label="loc_imtx_NumberOfConvertedStockOptionsInTheEntity_866698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_NumberOfConvertedStockOptionsInTheEntity_866698" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfMatchingStockOptionInTheEntity" xlink:label="loc_imtx_NumberOfMatchingStockOptionInTheEntity_866701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_NumberOfMatchingStockOptionInTheEntity_866701" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1351310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1351310" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_1351392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_1351392" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" xlink:to="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1351517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1351517" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351517" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351518" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351517" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351518_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="loc_country_DK_1351519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_DK_1351519" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1351520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_US_1351520" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1351521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_GB_1351521" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_1351523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xlink:to="loc_imtx_AgreementAxis_1351523" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imtx_AgreementAxis_1351523" xlink:to="loc_imtx_AgreementDomain_1351524" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imtx_AgreementAxis_1351523" xlink:to="loc_imtx_AgreementDomain_1351524_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmgenCollaborationAgreementMember" xlink:label="loc_imtx_AmgenCollaborationAgreementMember_1351525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_AmgenCollaborationAgreementMember_1351525" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GenmabCollaborationAgreementMember" xlink:label="loc_imtx_GenmabCollaborationAgreementMember_1351526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_GenmabCollaborationAgreementMember_1351526" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BMSCollaborationAgreementMember" xlink:label="loc_imtx_BMSCollaborationAgreementMember_1351527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_BMSCollaborationAgreementMember_1351527" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GSKCollaborationAgreementMember" xlink:label="loc_imtx_GSKCollaborationAgreementMember_1351528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_GSKCollaborationAgreementMember_1351528" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementsMember" xlink:label="loc_imtx_CollaborationAgreementsMember_1351529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_CollaborationAgreementsMember_1351529" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements_1351522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" xlink:to="loc_imtx_RevenueFromCollaborationAgreements_1351522" use="optional" order="16" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>imtx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-March-2023 [07:29:36] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationDocumentAxis" xml:lang="en-US">Document Information, Document [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentDomain" xml:lang="en-US">Document [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OrdinaryShareMember" xlink:label="loc_imtx_OrdinaryShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OrdinaryShareMember" xml:lang="en-US">Ordinary Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_OrdinaryShareMember" xml:lang="en-US">Common Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OrdinaryShareMember" xlink:to="lab_imtx_OrdinaryShareMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_WarrantsMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_WarrantsMember" xml:lang="en-US">Warrants [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_WarrantsMember" xlink:to="lab_imtx_WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_WarrantsMember" xml:lang="en-US">Warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xml:lang="en-US">Profit or loss [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xml:lang="en-US">Attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Equity holders of the parent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="loc_ifrs-full_FinanceIncomeCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncomeCost" xml:lang="en-US">Finance income (cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncomeCost" xml:lang="en-US">Financial result</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit (loss) before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit/(loss) before taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit/(loss) before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit/(loss) before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Taxes on income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Taxes on income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Taxes on income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RevenueFromCollaborationAgreements" xml:lang="en-US">Revenue from collaboration agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_RevenueFromCollaborationAgreements" xml:lang="en-US">Revenue from collaboration agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_imtx_RevenueFromCollaborationAgreements" xml:lang="en-US">Receipt of upfront of payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_RevenueFromCollaborationAgreements" xml:lang="en-US">Revenue from collaboration agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RevenueFromCollaborationAgreements" xlink:to="lab_imtx_RevenueFromCollaborationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RevenueFromCollaborationAgreements" xml:lang="en-US">Revenue from collaboration agreements</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gains (losses) on financial liabilities at fair value through profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xml:lang="en-US">Change in fair value of liabilities for warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xml:lang="en-US">Change in fair value of liabilities for warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gains losses on financial liabilities at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpense" xlink:label="loc_imtx_ShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareListingExpense" xml:lang="en-US">Share listing expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_ShareListingExpense" xml:lang="en-US">Share listing expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_ShareListingExpense" xml:lang="en-US">Share listing expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareListingExpense" xlink:to="lab_imtx_ShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareListingExpense" xml:lang="en-US">Share listing expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Profit (loss) from operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Operating result</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Net profit/(loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Net profit/(loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Net profit/(loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinanceIncome" xml:lang="en-US">Other finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherFinanceIncome" xml:lang="en-US">Other financial income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncome" xlink:to="lab_ifrs-full_OtherFinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="loc_ifrs-full_OtherFinanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinanceCost" xml:lang="en-US">Other finance cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherFinanceCost" xml:lang="en-US">Other financial expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceCost" xlink:to="lab_ifrs-full_OtherFinanceCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Net profit/(loss) per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xml:lang="en-US">Statement of comprehensive income [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Comprehensive income attributable to [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Comprehensive income, attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Equity holders of the parent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income/(loss) for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Comprehensive income/(loss) for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income/(loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that may be reclassified subsequently to profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xml:lang="en-US">Gains (losses) on exchange differences on translation, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xml:lang="en-US">Currency translation differences from foreign operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of financial position [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xml:lang="en-US">Equity and liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xml:lang="en-US">Liabilities and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Current trade payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Accounts payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xml:lang="en-US">Other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities &#8211; current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xml:lang="en-US">Current contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="loc_ifrs-full_CurrentWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentWarrantLiability" xml:lang="en-US">Current warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentWarrantLiability" xml:lang="en-US">Liabilities for warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentWarrantLiability" xlink:to="lab_ifrs-full_CurrentWarrantLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Total non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xml:lang="en-US">Non-current contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xml:lang="en-US">Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Non-current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities &#8211; non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremium" xml:lang="en-US">Share premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharePremium" xml:lang="en-US">Share premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Retained earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Issued capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Share capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Number of shares value outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilities" xml:lang="en-US">Equity and liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAndLiabilities" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Total non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Other non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Beginning Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Ending Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherCurrentAssets" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Other current financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Current trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Accounts receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of cash flows [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ChangesInWorkingCapitalAbstract" xlink:label="loc_imtx_ChangesInWorkingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes In Working Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract" xlink:to="lab_imtx_ChangesInWorkingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes in working capital [Abstract].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xml:lang="en-US">Adjustments for decrease (increase) in other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xml:lang="en-US">(Increase) in other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xml:lang="en-US">Interest received, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xml:lang="en-US">Interest received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xml:lang="en-US">Interest paid, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xml:lang="en-US">(Increase)/decrease in accounts receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Cash flows from (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Net cash provided by/(used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Net cash provided by/ (used in) operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xlink:label="loc_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xml:lang="en-US">Adjustments For Increase Decrease In Deferred Revenue Trade And Other Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xml:lang="en-US">Increase/(decrease) in deferred revenue, accounts payables and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xlink:to="lab_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xml:lang="en-US">Adjustments for increase decrease in deferred revenue trade and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xml:lang="en-US">Income taxes paid (refund)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xml:lang="en-US">Income tax paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xml:lang="en-US">(Decrease) Increase in other liabilities resulting from share appreciation rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsForShareBasedCompensation" xlink:label="loc_imtx_PaymentsForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PaymentsForShareBasedCompensation" xml:lang="en-US">Payments For Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_PaymentsForShareBasedCompensation" xml:lang="en-US">Payment related to share-based compensation awards previously classified as equity-settled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PaymentsForShareBasedCompensation" xlink:to="lab_imtx_PaymentsForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PaymentsForShareBasedCompensation" xml:lang="en-US">Payments for share based compensation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Adjustments for share-based payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">MD Anderson compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForInterestIncome" xml:lang="en-US">Adjustments for interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForInterestIncome" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForInterestIncome" xlink:to="lab_ifrs-full_AdjustmentsForInterestIncome" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentForEquitySettledSharebasedPayment" xlink:label="loc_imtx_AdjustmentForEquitySettledSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdjustmentForEquitySettledSharebasedPayment" xml:lang="en-US">Adjustment for equity settled sharebased payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AdjustmentForEquitySettledSharebasedPayment" xml:lang="en-US">Equity settled share-based payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdjustmentForEquitySettledSharebasedPayment" xlink:to="lab_imtx_AdjustmentForEquitySettledSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdjustmentForEquitySettledSharebasedPayment" xml:lang="en-US">Adjustment for equity settled share-based payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="loc_ifrs-full_AdjustmentsForInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForInterestExpense" xml:lang="en-US">Adjustments for interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForInterestExpense" xml:lang="en-US">Interest expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForInterestExpense" xlink:to="lab_ifrs-full_AdjustmentsForInterestExpense" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdjustmentsForShareListingExpense" xml:lang="en-US">Adjustments For Share Listing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AdjustmentsForShareListingExpense" xml:lang="en-US">Share listing expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdjustmentsForShareListingExpense" xml:lang="en-US">Expense on the closing date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_imtx_AdjustmentsForShareListingExpense" xml:lang="en-US">IFRS 2 Expense on the closing date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdjustmentsForShareListingExpense" xlink:to="lab_imtx_AdjustmentsForShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdjustmentsForShareListingExpense" xml:lang="en-US">Adjustments for share listing expense.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:label="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xml:lang="en-US">Adjustments For Unrealised Foreign Exchange And Expected Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xml:lang="en-US">Net foreign exchange differences and expected credit losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xml:lang="en-US">Net foreign exchange differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:to="lab_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xml:lang="en-US">Adjustments for unrealised foreign exchange and expected credit loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuing shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuance of shares to equity holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Repayment of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Payments for leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Cash flows from (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Net cash provided by/(used in) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TransactionCostsDeductedFromEquity" xlink:label="loc_imtx_TransactionCostsDeductedFromEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TransactionCostsDeductedFromEquity" xml:lang="en-US">Transaction Costs Deducted From Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_TransactionCostsDeductedFromEquity" xml:lang="en-US">Transaction costs deducted from equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TransactionCostsDeductedFromEquity" xlink:to="lab_imtx_TransactionCostsDeductedFromEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TransactionCostsDeductedFromEquity" xml:lang="en-US">Transaction costs deducted from equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Cash flows from (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Net cash (used in)/provided by investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Net cash provided by/ (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Payments for property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Payments for investments classified in Other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Payments for intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sales of property, plant and equipment, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from disposal of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Proceeds from sales of investments other than investments accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Proceeds from maturity of investments classified in Other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xlink:label="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xml:lang="en-US">Effects Of Exchange Rate Changes And Expected Credit Losses On Cash And Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xml:lang="en-US">Effects of exchange rate changes and expected credit losses on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xlink:to="lab_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xml:lang="en-US">Effects of exchange rate changes and expected credit losses on cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xml:lang="en-US">Statement of changes in equity [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non-controlling interests [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non-controlling interests [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Other reserves [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Other reserves [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Issued capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Share capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Issued capital [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TotalEquityAttributableToShareholdersOfParentMember" xlink:label="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TotalEquityAttributableToShareholdersOfParentMember" xml:lang="en-US">Total Equity Attributable To Shareholders Of Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_TotalEquityAttributableToShareholdersOfParentMember" xml:lang="en-US">Total equity (deficit) attributable to shareholders of the parent [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember" xlink:to="lab_imtx_TotalEquityAttributableToShareholdersOfParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Retained earnings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Accumulated deficit [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremiumMember" xml:lang="en-US">Share premium [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SharePremiumMember" xml:lang="en-US">Share premium [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharePremiumMember" xml:lang="en-US">Share premium [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseThroughARYAMerger" xlink:label="loc_imtx_IncreaseThroughARYAMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreaseThroughARYAMerger" xml:lang="en-US">Increase Through A R Y A Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_IncreaseThroughARYAMerger" xml:lang="en-US">ARYA Merger, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreaseThroughARYAMerger" xlink:to="lab_imtx_IncreaseThroughARYAMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreaseThroughARYAMerger" xml:lang="en-US">Increase through ARYA Merger.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SARConversion" xlink:label="loc_imtx_SARConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SARConversion" xml:lang="en-US">S A R conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_SARConversion" xml:lang="en-US">SAR conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SARConversion" xlink:to="lab_imtx_SARConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_SARConversion" xml:lang="en-US">SAR conversion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughIssuanceOfEquity" xlink:label="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreasedecreaseThroughIssuanceOfEquity" xml:lang="en-US">Increase Decrease Through Issuance Of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IncreasedecreaseThroughIssuanceOfEquity" xml:lang="en-US">Total issuance of share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity" xlink:to="lab_imtx_IncreasedecreaseThroughIssuanceOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreasedecreaseThroughIssuanceOfEquity" xml:lang="en-US">Increase (decrease) through issuance of equity.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xlink:label="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xml:lang="en-US">Increase Decrease Through Share Based Compensation Previously Classifies As Equity Settled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xml:lang="en-US">Payments related to share-based compensation awards previously classified as equity-settled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xlink:to="lab_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xml:lang="en-US">Increase (decrease) through share based compensation previously classifies as equity settled.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:label="loc_imtx_IncreaseDecreaseThroughReorganizationEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreaseDecreaseThroughReorganizationEquity" xml:lang="en-US">Increase Decrease Through Reorganization Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_IncreaseDecreaseThroughReorganizationEquity" xml:lang="en-US">Reorganization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:to="lab_imtx_IncreaseDecreaseThroughReorganizationEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreaseDecreaseThroughReorganizationEquity" xml:lang="en-US">Increase (decrease) through reorganization, equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xml:lang="en-US">Share options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xml:lang="en-US">Increase decrease through Changes in Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xml:lang="en-US">MD Anderson Share Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xml:lang="en-US">Increase (decrease) through changes in noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:to="lab_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xml:lang="en-US">Increase (decrease) through changes in noncontrolling interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xml:lang="en-US">Increase through other contributions by owners, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xml:lang="en-US">PIPE Financing, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughCompensationExpense" xlink:label="loc_imtx_IncreasedecreaseThroughCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreasedecreaseThroughCompensationExpense" xml:lang="en-US">Increase Decrease Through Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_IncreasedecreaseThroughCompensationExpense" xml:lang="en-US">MD Anderson milestone compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreasedecreaseThroughCompensationExpense" xlink:to="lab_imtx_IncreasedecreaseThroughCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreasedecreaseThroughCompensationExpense" xml:lang="en-US">Increase (decrease) through compensation expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Equity-settled share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IssueOfShareCapitalNetOfTransactionCosts" xlink:label="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IssueOfShareCapitalNetOfTransactionCosts" xml:lang="en-US">Issue Of Share Capital Net Of Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IssueOfShareCapitalNetOfTransactionCosts" xml:lang="en-US">Issue of share capital &#8211; net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts" xlink:to="lab_imtx_IssueOfShareCapitalNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IssueOfShareCapitalNetOfTransactionCosts" xml:lang="en-US">Issue of share capital &#8211; net of transaction costs.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TextBlockAbstract" xlink:to="lab_imtx_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TextBlockAbstract" xml:lang="en-US">Text block.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xml:lang="en-US">Disclosure of composition of group [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xml:lang="en-US">Group information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMergerTransactionExplanatory" xlink:label="loc_imtx_AryaMergerTransactionExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AryaMergerTransactionExplanatory" xml:lang="en-US">ARYA Merger transaction Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AryaMergerTransactionExplanatory" xml:lang="en-US">ARYA Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AryaMergerTransactionExplanatory" xlink:to="lab_imtx_AryaMergerTransactionExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AryaMergerTransactionExplanatory" xml:lang="en-US">The entire disclosure of ARYA Merger transaction explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xml:lang="en-US">Disclosure of changes in accounting policies, accounting estimates and errors [text block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Significant accounting judgments, estimates and assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Account Receivable Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xlink:to="lab_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xml:lang="en-US">Disclosure of account receivable Explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xml:lang="en-US">Disclosure of other assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xml:lang="en-US">Other current and non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xml:lang="en-US">Presentation of leases for lessee [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xml:lang="en-US">Disclosure of leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Revenue from collaboration agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xml:lang="en-US">Disclosure of other current liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xlink:label="loc_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xml:lang="en-US">Share Listing Expenses And Change In Fair Value Of Warrant Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xml:lang="en-US">Share listing expense and change in fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xlink:to="lab_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xml:lang="en-US">Share listing expenses and change in fair value of warrant liabilities [Text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Other financial income and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xml:lang="en-US">Disclosure of non-controlling interests [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xml:lang="en-US">Non-controlling&#160;interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Personnel Expenses Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xml:lang="en-US">Personnel expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xlink:to="lab_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Personnel Expenses Explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Disclosure of income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xml:lang="en-US">Disclosure of financial risk management [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xml:lang="en-US">Financial Risk Management Objectives and Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Disclosure of related party [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Related party disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Earnings and Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Events occurring after the reporting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Covid 19 [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xml:lang="en-US">Covid-19</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xlink:to="lab_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xml:lang="en-US">Description of accounting policy for covid nineteen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xml:lang="en-US">Financial liabilities: Initial recognition and measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xml:lang="en-US">Description of accounting policy for restricted cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xml:lang="en-US">Description of accounting policy for financial assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xml:lang="en-US">Financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xml:lang="en-US">Segment information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Revenue from collaboration agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Share-based payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Foreign currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xml:lang="en-US">Description of accounting policy for financial instruments at fair value through profit or loss [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xml:lang="en-US">Fair value of financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Going concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xml:lang="en-US">Going concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:to="lab_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xml:lang="en-US">Description of accounting policy for going concern.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xml:lang="en-US">Deferred income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Conflict And Macro economic Environment [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xml:lang="en-US">Russian-Ukraine Conflict and macroeconomic environment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xlink:to="lab_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xml:lang="en-US">Description of accounting policy for conflict and macro economic environment policy text block.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xlink:label="loc_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xml:lang="en-US">Disclosure Of Non Mandatory Standards And Interpretations Issued By The IASB [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xml:lang="en-US">Summary of Non Mandatory standards and interpretations issued by IASB</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xlink:to="lab_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xml:lang="en-US">Disclosure of non mandatory standards and interpretations issued by the IASB.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xml:lang="en-US">Summary of Application of new standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" xlink:label="loc_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" xml:lang="en-US">Description of nature of accounting errors in prior periods [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" xml:lang="en-US">Summary of impact revision to previously issued financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" xlink:to="lab_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Foreign Exchange Rates Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xml:lang="en-US">Summary of foreign exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about foreign exchange rates explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Property Plant And Equipment Estimated Useful Lives Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xml:lang="en-US">Summary of estimated Useful Lives of Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of property plant and equipment estimated useful lives explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xml:lang="en-US">Summary of useful life of intangible assets other than goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Trade And Other Receivable Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xml:lang="en-US">Summary of Trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of trade and other receivable explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xml:lang="en-US">Disclosure of other current assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xml:lang="en-US">Summary of Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xml:lang="en-US">Disclosure of other non-current assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xml:lang="en-US">Summary of Other&#160;non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDepreciationExpensesTableTextBlock" xlink:label="loc_imtx_DisclosureOfDepreciationExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDepreciationExpensesTableTextBlock" xml:lang="en-US">Disclosure Of Depreciation Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDepreciationExpensesTableTextBlock" xml:lang="en-US">Summary of Depreciation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDepreciationExpensesTableTextBlock" xlink:to="lab_imtx_DisclosureOfDepreciationExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDepreciationExpensesTableTextBlock" xml:lang="en-US">Disclosure of depreciation expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Summary of Changes to Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xml:lang="en-US">Summary of Changes to Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAmortizationExpensesTableTextBlock" xlink:label="loc_imtx_DisclosureOfAmortizationExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfAmortizationExpensesTableTextBlock" xml:lang="en-US">Disclosure Of Amortization Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfAmortizationExpensesTableTextBlock" xml:lang="en-US">Summary of Depreciation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfAmortizationExpensesTableTextBlock" xlink:to="lab_imtx_DisclosureOfAmortizationExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfAmortizationExpensesTableTextBlock" xml:lang="en-US">Disclosure of amortization expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Summary of Right-of&#160;use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure Of Lease Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Details of Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:to="lab_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure Of Expenses Related To Right Of Use Assets And Lease Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Summary of expenses related to&#160;right-of-use&#160;assets and lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="lab_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of expenses related to right of use assets and lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Accounts Payable Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xml:lang="en-US">Summary of Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of accounts payable explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractLiabilitiesTextBlock" xlink:label="loc_imtx_DisclosureOfContractLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfContractLiabilitiesTextBlock" xml:lang="en-US">Disclosure Of Contract Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfContractLiabilitiesTextBlock" xml:lang="en-US">Summary of Deferred revenue related to the collaboration agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfContractLiabilitiesTextBlock" xlink:to="lab_imtx_DisclosureOfContractLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfContractLiabilitiesTextBlock" xml:lang="en-US">Disclosure of contract liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xml:lang="en-US">Disclosure of Revenue From Collaboration Agreements Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xml:lang="en-US">Summary of revenue from collaboration agreements explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xlink:to="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xml:lang="en-US">Disclosure of revenue from collaboration agreements explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Disclosure of detailed information about other current liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Summary of other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Disclosure of detailed information about other current liabilities abstract.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xml:lang="en-US">disclosure of detailed information about Share listing expenses [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xml:lang="en-US">Summary of Calculation of the Share listing expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xml:lang="en-US">Disclosure of detailed information about Share listing expenses [text block].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xml:lang="en-US">Summary of other financial income and costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xml:lang="en-US">Disclosure of detailed information about finance income expense explanatory.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_StatementsTable" xml:lang="en-US">Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_StatementsTable" xlink:to="lab_imtx_StatementsTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_StatementsLineItems" xml:lang="en-US">Statements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_StatementsLineItems" xml:lang="en-US">Statements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_StatementsLineItems" xlink:to="lab_imtx_StatementsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xml:lang="en-US">Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xml:lang="en-US">Summary of Employee Share Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Compensation Expense [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xml:lang="en-US">Summary of Employee Related Share Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xml:lang="en-US">Disclosure of detailed information about share based compensation expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MatchingStockOptionsMember" xml:lang="en-US">Matching Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MatchingStockOptionsMember" xml:lang="en-US">Matching Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MatchingStockOptionsMember" xlink:to="lab_imtx_MatchingStockOptionsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ConvertedOptionsMember" xml:lang="en-US">Converted Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ConvertedOptionsMember" xml:lang="en-US">Converted Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ConvertedOptionsMember" xlink:to="lab_imtx_ConvertedOptionsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xml:lang="en-US">Additional Grants Under Two Thousand And Twenty And Two Thousand And Twenty Two Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xml:lang="en-US">Additional Grants Under 2020 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xml:lang="en-US">Additional Grants Under 2020 and 2022 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:to="lab_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PerformanceBasedOptionsMember" xml:lang="en-US">Performance Based Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PerformanceBasedOptionsMember" xml:lang="en-US">Performance Based Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PerformanceBasedOptionsMember" xlink:to="lab_imtx_PerformanceBasedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PerformanceBasedOptionsMember" xml:lang="en-US">Performance based options [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPersonnelExpenesTextBlock" xlink:label="loc_imtx_DisclosureOfPersonnelExpenesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPersonnelExpenesTextBlock" xml:lang="en-US">Disclosure Of Personnel Expenes [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfPersonnelExpenesTextBlock" xml:lang="en-US">Summary of Personnel Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPersonnelExpenesTextBlock" xlink:to="lab_imtx_DisclosureOfPersonnelExpenesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPersonnelExpenesTextBlock" xml:lang="en-US">Disclosure Of Personnel Expenses [Text Block]</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure Of Deferred Tax Assets And Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of deferred tax assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xlink:label="loc_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xml:lang="en-US">Disclosure of reconciliation between taxes on income and expected income tax benefit [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xml:lang="en-US">Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xlink:to="lab_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xml:lang="en-US">Disclosure of reconciliation between taxes on income and expected income tax benefit[Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Sensitivity analysis for types of market risk [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Summary of Sensitivity Analysis of Foreign Currency Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:to="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfManagingLiquidityRisk" xlink:label="loc_ifrs-full_DescriptionOfManagingLiquidityRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfManagingLiquidityRisk" xml:lang="en-US">Disclosure of how entity manages liquidity risk [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfManagingLiquidityRisk" xml:lang="en-US">Summary of Liquidity Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfManagingLiquidityRisk" xlink:to="lab_ifrs-full_DescriptionOfManagingLiquidityRisk" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Currency Risk Exposure Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xml:lang="en-US">Summary of Currency Risk Exposure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xlink:to="lab_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Currency Risk Exposure Explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xml:lang="en-US">Summary of Carrying Amounts and Fair values of Group's Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xml:lang="en-US">Summary of Net Result from Financial Instruments by Measurement Categories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xml:lang="en-US">Disclosure of detailed information about net result from financial instruments by measurement categories explanatory [Text Block]</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective and Noncash Effective Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xml:lang="en-US">Summary of changes of the liabilities from financing activities classified as cash effective and non-cash effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xml:lang="en-US">Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective explanatory [Text Block].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsTableTextBlock" xlink:label="loc_imtx_DisclosureOfContractualObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfContractualObligationsTableTextBlock" xml:lang="en-US">Disclosure Of Contractual Obligations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfContractualObligationsTableTextBlock" xml:lang="en-US">Summary of Contractual Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfContractualObligationsTableTextBlock" xlink:to="lab_imtx_DisclosureOfContractualObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfContractualObligationsTableTextBlock" xml:lang="en-US">Disclosure of contractual obligations.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xml:lang="en-US">Disclosure of compensation Managing directors and supervisory board [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xml:lang="en-US">Summary of Options Granted to Managing Director and Supervisory Directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xlink:to="lab_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xml:lang="en-US">Disclosure of compensation Managing directors and supervisory board.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xml:lang="en-US">Disclosure Of Compensation Of Key Management Personnel [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xml:lang="en-US">Summary of Compensation of Key Management Personnel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xlink:to="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xml:lang="en-US">Disclosure of compensation of key management personnel.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xml:lang="en-US">disclosure of compensation supervisory board [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xml:lang="en-US">Summary of Compensation for the Supervisory Board</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xlink:to="lab_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xml:lang="en-US">Disclosure of compensation supervisory board.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Summary of Earnings and loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AuthorizationOfFinancialStatementsMember" xlink:label="loc_imtx_AuthorizationOfFinancialStatementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AuthorizationOfFinancialStatementsMember" xml:lang="en-US">Authorization Of Financial Statements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AuthorizationOfFinancialStatementsMember" xlink:to="lab_imtx_AuthorizationOfFinancialStatementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AuthorizationOfFinancialStatementsMember" xml:lang="en-US">Authorization of financial statements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xlink:label="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xml:lang="en-US">Date of authorisation for issue of financial statements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xml:lang="en-US">Date of authorisation for issue of financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xlink:to="lab_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfEndOfReportingPeriod2013" xlink:label="loc_ifrs-full_DateOfEndOfReportingPeriod2013" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DateOfEndOfReportingPeriod2013" xml:lang="en-US">Date of end of reporting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DateOfEndOfReportingPeriod2013" xlink:to="lab_ifrs-full_DateOfEndOfReportingPeriod2013" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xml:lang="en-US">Disclosure of detailed information about business combination [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xml:lang="en-US">Disclosure of detailed information about business combination [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfOrdinarySharesAxis" xml:lang="en-US">Classes of ordinary shares [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="lab_ifrs-full_ClassesOfOrdinarySharesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary Shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PipeFinancingMember" xlink:label="loc_imtx_PipeFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PipeFinancingMember" xml:lang="en-US">PIPE Financing [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PipeFinancingMember" xml:lang="en-US">PIPE Financing [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PipeFinancingMember" xlink:to="lab_imtx_PipeFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PipeFinancingMember" xml:lang="en-US">PIPE financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AryaMember" xml:lang="en-US">ARYA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AryaMember" xml:lang="en-US">ARYA [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AryaMember" xml:lang="en-US">ARYA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AryaMember" xlink:to="lab_imtx_AryaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AryaMember" xml:lang="en-US">ARYA [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial instruments, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial instruments, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">Net Assets Acquired (Liabilities Assumed)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">Identifiable net assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">ARYA's identifiable net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Current liabilities recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Current liabilities by ARYA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xml:lang="en-US">Proceeds from issue of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xml:lang="en-US">Share issue related cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xml:lang="en-US">Share issue related cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xlink:label="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xml:lang="en-US">Fair Value Of Warrant Liabilities Assumed In A Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xml:lang="en-US">Fair value of warrant liabilities assumed in a business acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xlink:to="lab_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xml:lang="en-US">Fair value of warrant liabilities assumed in a business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xlink:label="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xml:lang="en-US">Description of how acquirer obtained control of acquiree</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xml:lang="en-US">Description Of How Acquirer Obtained Control Of Acquire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xlink:to="lab_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xml:lang="en-US">Number of instruments or interests issued or issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xml:lang="en-US">Number of instruments issued or issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xml:lang="en-US">ARYA Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xml:lang="en-US">Date by which application of new IFRS is required</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:to="lab_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="loc_ifrs-full_TitleOfNewIFRS" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TitleOfNewIFRS" xml:lang="en-US">Title of new IFRS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TitleOfNewIFRS" xlink:to="lab_ifrs-full_TitleOfNewIFRS" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsAxis" xlink:label="loc_ifrs-full_NewIFRSsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NewIFRSsAxis" xml:lang="en-US">New IFRSs [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NewIFRSsAxis" xlink:to="lab_ifrs-full_NewIFRSsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NewIFRSsMember" xml:lang="en-US">New IFRSs [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NewIFRSsMember" xlink:to="lab_ifrs-full_NewIFRSsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xlink:label="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xml:lang="en-US">Amendments to Illustrative Accompanying IFRS Sixteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xml:lang="en-US">Amendments to Illustrative Examples accompanying IFRS 16</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xlink:to="lab_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xml:lang="en-US">Amendments to Illustrative Accompanying IFRS Sixteen.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasSixteenMember" xlink:label="loc_imtx_AmendmentIasSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentIasSixteenMember" xml:lang="en-US">Amendment IAS Sixteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentIasSixteenMember" xml:lang="en-US">Amendment IAS 16</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentIasSixteenMember" xlink:to="lab_imtx_AmendmentIasSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentIasSixteenMember" xml:lang="en-US">Amendment IAS sixteen.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasThirtySevenMember" xlink:label="loc_imtx_AmendmentIasThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentIasThirtySevenMember" xml:lang="en-US">Amendment IAS Thirty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentIasThirtySevenMember" xml:lang="en-US">Amendment IAS 37</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentIasThirtySevenMember" xlink:to="lab_imtx_AmendmentIasThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentIasThirtySevenMember" xml:lang="en-US">Amendment IAS thirty seven.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsThreeMember" xlink:label="loc_imtx_AmendmentToIfrsThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIfrsThreeMember" xml:lang="en-US">Amendment To IFRS Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIfrsThreeMember" xml:lang="en-US">Amendment To IFRS 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIfrsThreeMember" xlink:to="lab_imtx_AmendmentToIfrsThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIfrsThreeMember" xml:lang="en-US">Amendment to IFRS three.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsOneMember" xlink:label="loc_imtx_AmendmentToIfrsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIfrsOneMember" xml:lang="en-US">Amendment To IFRS One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIfrsOneMember" xml:lang="en-US">Amendment To IFRS 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIfrsOneMember" xlink:to="lab_imtx_AmendmentToIfrsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIfrsOneMember" xml:lang="en-US">Amendment to IFRS one.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsNineMember" xlink:label="loc_imtx_AmendmentToIfrsNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIfrsNineMember" xml:lang="en-US">Amendment To IFRS Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIfrsNineMember" xml:lang="en-US">Amendment To IFRS 9</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIfrsNineMember" xlink:to="lab_imtx_AmendmentToIfrsNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIfrsNineMember" xml:lang="en-US">Amendment to IFRS nine.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasFourtyOneMember" xlink:label="loc_imtx_AmendmentToIasFourtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIasFourtyOneMember" xml:lang="en-US">Amendment To IAS Fourty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIasFourtyOneMember" xml:lang="en-US">Amendment To IAS 41</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIasFourtyOneMember" xlink:to="lab_imtx_AmendmentToIasFourtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIasFourtyOneMember" xml:lang="en-US">Amendment to IAS fourty one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IFRS17Member" xlink:label="loc_ifrs-full_IFRS17Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IFRS17Member" xml:lang="en-US">IFRS 17 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IFRS17Member" xml:lang="en-US">IFRS 17</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IFRS17Member" xlink:to="lab_ifrs-full_IFRS17Member" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xlink:label="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xml:lang="en-US">Amendment To IAS One IFRS Practice Statement Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xml:lang="en-US">Amendment To IAS 1 IFRS Practice Statement 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xlink:to="lab_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xml:lang="en-US">Amendment to IAS one IFRS practice statement two.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasEightMember" xlink:label="loc_imtx_AmendmentToIasEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIasEightMember" xml:lang="en-US">Amendment To IAS Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIasEightMember" xml:lang="en-US">Amendment To IAS 8</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIasEightMember" xlink:to="lab_imtx_AmendmentToIasEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIasEightMember" xml:lang="en-US">Amendment to IAS eight.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasTwelveMember" xlink:label="loc_imtx_AmendmentToIasTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIasTwelveMember" xml:lang="en-US">Amendment To IAS Twelve [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIasTwelveMember" xml:lang="en-US">Amendment To IAS 12</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIasTwelveMember" xlink:to="lab_imtx_AmendmentToIasTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIasTwelveMember" xml:lang="en-US">Amendment to IAS twelve.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsSixteenMember" xlink:label="loc_imtx_AmendmentToIfrsSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIfrsSixteenMember" xml:lang="en-US">Amendment To IFRS Sixteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIfrsSixteenMember" xml:lang="en-US">Amendment to IFRS 16</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIfrsSixteenMember" xlink:to="lab_imtx_AmendmentToIfrsSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIfrsSixteenMember" xml:lang="en-US">Amendment to IFRS sixteen [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneMember" xlink:label="loc_imtx_AmendmentToIasOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmendmentToIasOneMember" xml:lang="en-US">Amendment To IAS One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmendmentToIasOneMember" xml:lang="en-US">Amendment o IAS 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmendmentToIasOneMember" xlink:to="lab_imtx_AmendmentToIasOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AmendmentToIasOneMember" xml:lang="en-US">Amendment to IAS one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentlyReportedMember" xlink:label="loc_imtx_CurrentlyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrentlyReportedMember" xml:lang="en-US">Currently Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_CurrentlyReportedMember" xml:lang="en-US">As Revised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrentlyReportedMember" xlink:to="lab_imtx_CurrentlyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrentlyReportedMember" xml:lang="en-US">Currently Reported [Member]</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xlink:label="loc_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xml:lang="en-US">Reclassfication Of Provisions To Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xml:lang="en-US">Reclassfication of Provisions to other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xlink:to="lab_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xml:lang="en-US">Reclassfication of provisions to other current liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xml:lang="en-US">Disclosure Of Property Plant And Equipment Estimated Useful Lives [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xml:lang="en-US">Disclosure of property plant and equipment estimated useful lives .</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xml:lang="en-US">Disclosure Of Property Plant And Equipment Estimated Useful Lives [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xlink:to="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xml:lang="en-US">Disclosure of property plant and equipment estimated useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LaboratoryEquipmentMember" xlink:to="lab_imtx_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xml:lang="en-US">Office equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xml:lang="en-US">Office equipment and installations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xml:lang="en-US">Computer equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xml:lang="en-US">Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xlink:to="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xml:lang="en-US">Disclosure of property plant and equipment estimated useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" xml:lang="en-US">Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xml:lang="en-US">Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xml:lang="en-US">Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LicencesMember" xml:lang="en-US">Licences [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xml:lang="en-US">Computer software [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xml:lang="en-US">Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="loc_ifrs-full_ForeignExchangeRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignExchangeRatesAbstract" xml:lang="en-US">Foreign exchange rates [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeRatesAbstract" xlink:to="lab_ifrs-full_ForeignExchangeRatesAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xml:lang="en-US">Disclosure Of Detailed Information About Foreign Exchange Rates [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xml:lang="en-US">Disclosure of detailed information about foreign exchange rates.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Foreign Exchange Rates [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xml:lang="en-US">Disclosure of detailed information about foreign exchange rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average foreign exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Closing foreign exchange rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xml:lang="en-US">Trade and other current receivables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReceivablesFromCollaborationAgreements" xlink:label="loc_imtx_ReceivablesFromCollaborationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ReceivablesFromCollaborationAgreements" xml:lang="en-US">Receivables From Collaboration Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ReceivablesFromCollaborationAgreements" xlink:to="lab_imtx_ReceivablesFromCollaborationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ReceivablesFromCollaborationAgreements" xml:lang="en-US">Receivables from collaboration agreements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" xlink:label="loc_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" xml:lang="en-US">Allowance account for credit losses of financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" xml:lang="en-US">Expected credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" xlink:to="lab_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xml:lang="en-US">Trade and other receivables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentGrantReceivable" xlink:label="loc_imtx_CurrentGrantReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrentGrantReceivable" xml:lang="en-US">Current Grant Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_CurrentGrantReceivable" xml:lang="en-US">Grant receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrentGrantReceivable" xlink:to="lab_imtx_CurrentGrantReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrentGrantReceivable" xml:lang="en-US">Current grant receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xml:lang="en-US">Current prepaid expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xml:lang="en-US">Current value added tax receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xml:lang="en-US">Value added tax receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAssets" xml:lang="en-US">Other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssets" xlink:to="lab_ifrs-full_OtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xml:lang="en-US">Disclosure of subsidiaries [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementAxis" xlink:label="loc_imtx_CollaborationAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CollaborationAgreementAxis" xml:lang="en-US">Collaboration Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CollaborationAgreementAxis" xlink:to="lab_imtx_CollaborationAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CollaborationAgreementAxis" xml:lang="en-US">Collaboration agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementMember" xlink:label="loc_imtx_CollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CollaborationAgreementMember" xml:lang="en-US">Collaboration Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CollaborationAgreementMember" xlink:to="lab_imtx_CollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CollaborationAgreementMember" xml:lang="en-US">Collaboration agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xlink:label="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xml:lang="en-US">Celgene Switzerland LLC And Genmab AS [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xlink:to="lab_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xml:lang="en-US">Celgene switzerland LLC and genmab A/S.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xml:lang="en-US">Disclosure of subsidiaries [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidInsurance" xlink:label="loc_imtx_CurrentPrepaidInsurance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrentPrepaidInsurance" xml:lang="en-US">Current Prepaid insurance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_CurrentPrepaidInsurance" xml:lang="en-US">Prepaid insurance expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrentPrepaidInsurance" xlink:to="lab_imtx_CurrentPrepaidInsurance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrentPrepaidInsurance" xml:lang="en-US">Current prepaid insurance.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentIncrementalCostForCollaborationAgreement" xlink:label="loc_imtx_CurrentIncrementalCostForCollaborationAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrentIncrementalCostForCollaborationAgreement" xml:lang="en-US">Current Incremental Cost For Collaboration Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_CurrentIncrementalCostForCollaborationAgreement" xml:lang="en-US">Current Incremental cost for collaboration agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrentIncrementalCostForCollaborationAgreement" xlink:to="lab_imtx_CurrentIncrementalCostForCollaborationAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrentIncrementalCostForCollaborationAgreement" xml:lang="en-US">Current incremental cost for collaboration agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PrepaidExpensesOfLicensesAndSoftware" xlink:label="loc_imtx_PrepaidExpensesOfLicensesAndSoftware" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PrepaidExpensesOfLicensesAndSoftware" xml:lang="en-US">Prepaid Expenses Of Licenses And Software</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_PrepaidExpensesOfLicensesAndSoftware" xml:lang="en-US">Prepaid expenses of licenses and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PrepaidExpensesOfLicensesAndSoftware" xlink:to="lab_imtx_PrepaidExpensesOfLicensesAndSoftware" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PrepaidExpensesOfLicensesAndSoftware" xml:lang="en-US">Prepaid expenses of licenses and software.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NoncurrentPrepaymentsOfLicensingAgreement" xlink:label="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NoncurrentPrepaymentsOfLicensingAgreement" xml:lang="en-US">Noncurrent Prepayments Of Licensing Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NoncurrentPrepaymentsOfLicensingAgreement" xml:lang="en-US">Noncurrent Prepayments Of Licensing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement" xlink:to="lab_imtx_NoncurrentPrepaymentsOfLicensingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NoncurrentPrepaymentsOfLicensingAgreement" xml:lang="en-US">Noncurrent prepayments of licensing agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonCurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_NonCurrentPrepaidMaintenanceExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NonCurrentPrepaidMaintenanceExpenses" xml:lang="en-US">Non Current Prepaid Maintenance Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NonCurrentPrepaidMaintenanceExpenses" xml:lang="en-US">NonCurrent Prepaid Maintenance Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NonCurrentPrepaidMaintenanceExpenses" xlink:to="lab_imtx_NonCurrentPrepaidMaintenanceExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NonCurrentPrepaidMaintenanceExpenses" xml:lang="en-US">Non current prepaid maintenance expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments" xlink:label="loc_ifrs-full_NoncurrentPrepayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xml:lang="en-US">Non-current prepayments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xml:lang="en-US">Non-current prepayments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPrepayments" xlink:to="lab_ifrs-full_NoncurrentPrepayments" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_CurrentPrepaidMaintenanceExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrentPrepaidMaintenanceExpenses" xml:lang="en-US">Current Prepaid Maintenance Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_CurrentPrepaidMaintenanceExpenses" xml:lang="en-US">Current prepaid maintenance expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrentPrepaidMaintenanceExpenses" xlink:to="lab_imtx_CurrentPrepaidMaintenanceExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrentPrepaidMaintenanceExpenses" xml:lang="en-US">Current prepaid maintenance expenses.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationAxis" xlink:label="loc_imtx_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BalanceSheetLocationAxis" xlink:to="lab_imtx_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationDomain" xlink:label="loc_imtx_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BalanceSheetLocationDomain" xlink:to="lab_imtx_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentReceivablesAbstract" xlink:label="loc_ifrs-full_NoncurrentReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentReceivablesAbstract" xml:lang="en-US">Trade and other non-current receivables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentReceivablesAbstract" xlink:to="lab_ifrs-full_NoncurrentReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherNonCurrentAsset" xlink:label="loc_imtx_OtherNonCurrentAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OtherNonCurrentAsset" xml:lang="en-US">Other Non Current Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_OtherNonCurrentAsset" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OtherNonCurrentAsset" xlink:to="lab_imtx_OtherNonCurrentAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_OtherNonCurrentAsset" xml:lang="en-US">Other non current asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisposalsOfPropertyPlantAndEquipment" xlink:label="loc_imtx_DisposalsOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisposalsOfPropertyPlantAndEquipment" xml:lang="en-US">Disposals of Property Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_DisposalsOfPropertyPlantAndEquipment" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisposalsOfPropertyPlantAndEquipment" xlink:to="lab_imtx_DisposalsOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisposalsOfPropertyPlantAndEquipment" xml:lang="en-US">Disposals of property, plant and equipment.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionsOtherPropertyPlantAndEquipment" xlink:label="loc_imtx_AdditionsOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdditionsOtherPropertyPlantAndEquipment" xml:lang="en-US">Additions Other Property Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AdditionsOtherPropertyPlantAndEquipment" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdditionsOtherPropertyPlantAndEquipment" xlink:to="lab_imtx_AdditionsOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdditionsOtherPropertyPlantAndEquipment" xml:lang="en-US">Additions other property, plant and equipment.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrencyTranslationDifferences" xlink:label="loc_imtx_CurrencyTranslationDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CurrencyTranslationDifferences" xml:lang="en-US">Currency Translation Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_CurrencyTranslationDifferences" xml:lang="en-US">Currency translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CurrencyTranslationDifferences" xlink:to="lab_imtx_CurrencyTranslationDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CurrencyTranslationDifferences" xml:lang="en-US">Currency translation differences.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OfficeEquipmentAndInstallationsMember" xlink:label="loc_imtx_OfficeEquipmentAndInstallationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OfficeEquipmentAndInstallationsMember" xml:lang="en-US">Office Equipment And Installations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OfficeEquipmentAndInstallationsMember" xlink:to="lab_imtx_OfficeEquipmentAndInstallationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_OfficeEquipmentAndInstallationsMember" xml:lang="en-US">Office equipment and installations.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsAxis" xlink:label="loc_imtx_TypeOfAdoptionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TypeOfAdoptionsAxis" xml:lang="en-US">Type Of Adoptions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TypeOfAdoptionsAxis" xlink:to="lab_imtx_TypeOfAdoptionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TypeOfAdoptionsAxis" xml:lang="en-US">Type of adoptions.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TypeOfAdoptionsMember" xml:lang="en-US">Type Of Adoptions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TypeOfAdoptionsMember" xml:lang="en-US">Type Of Adoptions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TypeOfAdoptionsMember" xlink:to="lab_imtx_TypeOfAdoptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TypeOfAdoptionsMember" xml:lang="en-US">Type of adoptions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Gross carrying amount [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDepreciationExpensesAbstract" xlink:label="loc_imtx_DisclosureOfDepreciationExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDepreciationExpensesAbstract" xml:lang="en-US">Disclosure Of Depreciation Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDepreciationExpensesAbstract" xlink:to="lab_imtx_DisclosureOfDepreciationExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDepreciationExpensesAbstract" xml:lang="en-US">Disclosure of depreciation expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncomeStatementLocationAxis" xlink:to="lab_imtx_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncomeStatementLocationAxis" xml:lang="en-US">Income statement location.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncomeStatementLocationMember" xml:lang="en-US">Income Statement Location [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncomeStatementLocationMember" xlink:to="lab_imtx_IncomeStatementLocationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncomeStatementLocationMember" xml:lang="en-US">Income statement location.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research And Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_imtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research And Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ResearchAndDevelopmentExpenseMember" xlink:to="lab_imtx_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expense [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General And Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_imtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General And Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GeneralAndAdministrativeExpenseMember" xlink:to="lab_imtx_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions Property Plant And Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xml:lang="en-US">Accumulated impairment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedImpairmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xml:lang="en-US">Intangible assets and goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xml:lang="en-US">Currency translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xml:lang="en-US">Intangible assets and goodwill [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PatentAndLicensesMember" xlink:label="loc_imtx_PatentAndLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PatentAndLicensesMember" xml:lang="en-US">Patent And Licenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PatentAndLicensesMember" xlink:to="lab_imtx_PatentAndLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PatentAndLicensesMember" xml:lang="en-US">Patent and licenses.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SoftwareLicensesMember" xlink:label="loc_imtx_SoftwareLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SoftwareLicensesMember" xml:lang="en-US">Software Licenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SoftwareLicensesMember" xlink:to="lab_imtx_SoftwareLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_SoftwareLicensesMember" xml:lang="en-US">Software licenses.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAmortizationExpensesAbstract" xlink:label="loc_imtx_DisclosureOfAmortizationExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfAmortizationExpensesAbstract" xml:lang="en-US">Disclosure Of Amortization Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfAmortizationExpensesAbstract" xlink:to="lab_imtx_DisclosureOfAmortizationExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfAmortizationExpensesAbstract" xml:lang="en-US">Disclosure of amortization expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xml:lang="en-US">Classes of assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xml:lang="en-US">Assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_VehiclesMember" xml:lang="en-US">Vehicles [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAssetsMember" xml:lang="en-US">Other assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsMember" xlink:to="lab_ifrs-full_OtherAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BuildingsMember" xml:lang="en-US">Buildings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember" xlink:to="lab_ifrs-full_BuildingsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:label="loc_ifrs-full_CommunicationAndNetworkEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CommunicationAndNetworkEquipmentMember" xml:lang="en-US">Communication and network equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CommunicationAndNetworkEquipmentMember" xml:lang="en-US">IT and telecommunication</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="lab_ifrs-full_CommunicationAndNetworkEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xml:lang="en-US">Lease liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" xml:lang="en-US">Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" xlink:to="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" xml:lang="en-US">Disclosure of expenses related to&#160;right-of-use&#160;assets and lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xml:lang="en-US">Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xlink:to="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xml:lang="en-US">Disclosure of expenses related to&#160;right-of-use&#160;assets and lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xml:lang="en-US">Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xlink:to="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xml:lang="en-US">Disclosure of expenses related to&#160;right-of-use&#160;assets and lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xml:lang="en-US">Depreciation, right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Expenses relating to short-term leases and low-value assets (included in administrative expenses)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InterestExpenseOnLease" xlink:label="loc_imtx_InterestExpenseOnLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_InterestExpenseOnLease" xml:lang="en-US">Interest Expense on Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_InterestExpenseOnLease" xml:lang="en-US">Interest expenses form lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_InterestExpenseOnLease" xlink:to="lab_imtx_InterestExpenseOnLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_InterestExpenseOnLease" xml:lang="en-US">Interest expense on lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xml:lang="en-US">Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Later than four years and not later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Until 2025 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Later than one year [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashOutflowForLeases" xml:lang="en-US">Cash outflow for leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashOutflowForLeases" xml:lang="en-US">Cash payments for leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">Additions to right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TranslationDifferenceOnRightOfUseAsset" xlink:label="loc_imtx_TranslationDifferenceOnRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TranslationDifferenceOnRightOfUseAsset" xml:lang="en-US">Translation Difference On Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_TranslationDifferenceOnRightOfUseAsset" xml:lang="en-US">Currency translation of &#160;right-of-use&#160;assets&#160;</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TranslationDifferenceOnRightOfUseAsset" xlink:to="lab_imtx_TranslationDifferenceOnRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TranslationDifferenceOnRightOfUseAsset" xml:lang="en-US">Translation difference on right of use asset.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xlink:label="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xml:lang="en-US">Payments Of Right Of Use Assets Classified As Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xml:lang="en-US">Payments of right of use assets classified as financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xlink:to="lab_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xml:lang="en-US">Payments of right of use assets classified as financing activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">Texas</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xml:lang="en-US">Trade and other current payables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xml:lang="en-US">Trade payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xml:lang="en-US">Accounts payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccruedLiabilities" xlink:label="loc_imtx_AccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AccruedLiabilities" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AccruedLiabilities" xlink:to="lab_imtx_AccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AccruedLiabilities" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueAbstract" xml:lang="en-US">Revenue [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersTable" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromContractWithCustomersTable" xml:lang="en-US">Disclosure Of Revenue From Contract With Customers [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable" xlink:to="lab_imtx_DisclosureOfRevenueFromContractWithCustomersTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AgreementAxis" xlink:to="lab_imtx_AgreementAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AgreementDomain" xlink:to="lab_imtx_AgreementDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmgenCollaborationAgreementMember" xlink:label="loc_imtx_AmgenCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AmgenCollaborationAgreementMember" xml:lang="en-US">Amgen Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AmgenCollaborationAgreementMember" xml:lang="en-US">Amgen</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AmgenCollaborationAgreementMember" xlink:to="lab_imtx_AmgenCollaborationAgreementMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GSKCollaborationAgreementMember" xlink:label="loc_imtx_GSKCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GSKCollaborationAgreementMember" xml:lang="en-US">G S K Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GSKCollaborationAgreementMember" xml:lang="en-US">GSK Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_GSKCollaborationAgreementMember" xml:lang="en-US">GSK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GSKCollaborationAgreementMember" xlink:to="lab_imtx_GSKCollaborationAgreementMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BMSCollaborationAgreementMember" xlink:label="loc_imtx_BMSCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BMSCollaborationAgreementMember" xml:lang="en-US">B M S Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_BMSCollaborationAgreementMember" xml:lang="en-US">BMS Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_BMSCollaborationAgreementMember" xml:lang="en-US">BMS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BMSCollaborationAgreementMember" xlink:to="lab_imtx_BMSCollaborationAgreementMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GenmabCollaborationAgreementMember" xlink:label="loc_imtx_GenmabCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GenmabCollaborationAgreementMember" xml:lang="en-US">Genmab Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GenmabCollaborationAgreementMember" xml:lang="en-US">Genmab</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GenmabCollaborationAgreementMember" xlink:to="lab_imtx_GenmabCollaborationAgreementMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BmsAgreementMember" xlink:label="loc_imtx_BmsAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BmsAgreementMember" xml:lang="en-US">Bms Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BmsAgreementMember" xlink:to="lab_imtx_BmsAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_BmsAgreementMember" xml:lang="en-US">Bms Agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development And Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development and Commercialization Agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember" xlink:to="lab_imtx_LicenseDevelopmentAndCommercializationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License development and commercialization agreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneAxis" xlink:label="loc_imtx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MilestoneAxis" xml:lang="en-US">Milestone [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MilestoneAxis" xlink:to="lab_imtx_MilestoneAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneDomain" xlink:label="loc_imtx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MilestoneDomain" xml:lang="en-US">Milestone [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MilestoneDomain" xlink:to="lab_imtx_MilestoneDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentForLicensedProductMember" xlink:label="loc_imtx_MilestonePaymentForLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MilestonePaymentForLicensedProductMember" xml:lang="en-US">Milestone Payment For Licensed Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MilestonePaymentForLicensedProductMember" xlink:to="lab_imtx_MilestonePaymentForLicensedProductMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ThereafterMember" xlink:label="loc_imtx_ThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ThereafterMember" xml:lang="en-US">Thereafter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ThereafterMember" xlink:to="lab_imtx_ThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ThereafterMember" xml:lang="en-US">Thereafter.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" xml:lang="en-US">Disclosure Of Revenue From Contract With Customers [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" xlink:to="lab_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xml:lang="en-US">Revenue that was included in contract liability balance at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xml:lang="en-US">Contract with customers liability revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContractLiabilities" xml:lang="en-US">Contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContractLiabilities" xml:lang="en-US">Contract Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ContractLiabilities" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xml:lang="en-US">Assets recognised from costs to obtain or fulfil contracts with customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xml:lang="en-US">Capitalized costs of contract net of amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xlink:to="lab_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xml:lang="en-US">Amortisation, assets recognised from costs incurred to obtain or fulfil contracts with customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xml:lang="en-US">Amortization of contract costs capitalized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xlink:to="lab_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractLiabilitiesRecognized" xlink:label="loc_imtx_ContractLiabilitiesRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ContractLiabilitiesRecognized" xml:lang="en-US">Contract Liabilities Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ContractLiabilitiesRecognized" xml:lang="en-US">Contract liabilities recognizedContract liabilities recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ContractLiabilitiesRecognized" xlink:to="lab_imtx_ContractLiabilitiesRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ContractLiabilitiesRecognized" xml:lang="en-US">Contract liabilities recognized.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PotentialMilestonePaymentPayable" xlink:label="loc_imtx_PotentialMilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PotentialMilestonePaymentPayable" xml:lang="en-US">Potential Milestone Payment Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PotentialMilestonePaymentPayable" xml:lang="en-US">Potential milestone payment payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PotentialMilestonePaymentPayable" xlink:to="lab_imtx_PotentialMilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PotentialMilestonePaymentPayable" xml:lang="en-US">Potential milestone payment payable.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UpfrontPaymentReceived" xlink:label="loc_imtx_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_UpfrontPaymentReceived" xml:lang="en-US">Upfront Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_UpfrontPaymentReceived" xml:lang="en-US">Upfront payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_UpfrontPaymentReceived" xlink:to="lab_imtx_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_UpfrontPaymentReceived" xml:lang="en-US">Upfront payment received.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentReceivable" xlink:label="loc_imtx_MilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MilestonePaymentReceivable" xml:lang="en-US">Milestone Payment Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MilestonePaymentReceivable" xml:lang="en-US">Milestone payment receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MilestonePaymentReceivable" xlink:to="lab_imtx_MilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_MilestonePaymentReceivable" xml:lang="en-US">Milestone payment receivable.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xlink:label="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xml:lang="en-US">Allocation of Upfront Payment Towards Clinical Trial Services And License Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xml:lang="en-US">Allocation of upfront payment towards clinical trial services and license grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xlink:to="lab_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xml:lang="en-US">Allocation of upfront payment towards clinical trial services and license grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xml:lang="en-US">Transaction price allocated to remaining performance obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xml:lang="en-US">Transaction price allocation to performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xml:lang="en-US">AllocationOfUpfrontPaymentTowardsClinicalTrialServices</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xml:lang="en-US">Allocation of upfront payment towards clinical trial services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xlink:to="lab_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xml:lang="en-US">Allocation of upfront payment towards clinical trial services.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardslicensegrant" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardslicensegrant" xml:lang="en-US">Allocation of Upfront Payment Towards License Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardslicensegrant" xml:lang="en-US">Allocation of upfront payment towards license grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant" xlink:to="lab_imtx_Allocationofupfrontpaymenttowardslicensegrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_Allocationofupfrontpaymenttowardslicensegrant" xml:lang="en-US">Allocation of upfront payment towards license grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xml:lang="en-US">Revenue from contracts with customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xml:lang="en-US">Revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xlink:label="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xml:lang="en-US">Additional Payment Related to Performance Obligations Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xml:lang="en-US">Additional payment related to performance obligations received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xlink:to="lab_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xml:lang="en-US">Additional payment related to performance obligations received.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xlink:label="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xml:lang="en-US">Milestone Regulatory And Royalty Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xml:lang="en-US">Milestone regulatory and royaly payment receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xlink:to="lab_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xml:lang="en-US">Milestone regulatory and royalty payment received.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xlink:label="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xml:lang="en-US">Performance Obligations Cumulative Upfront Payments Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xml:lang="en-US">Performance obligations cumulative upfront payments received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xlink:to="lab_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xml:lang="en-US">Performance obligations cumulative upfront payments received.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractTransactionPrice" xlink:label="loc_imtx_ContractTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ContractTransactionPrice" xml:lang="en-US">Contract Transaction Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ContractTransactionPrice" xml:lang="en-US">Contract transaction price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ContractTransactionPrice" xlink:to="lab_imtx_ContractTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ContractTransactionPrice" xml:lang="en-US">Contract transaction price.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xlink:label="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xml:lang="en-US">Revenue Recognized During The Period Performance Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xml:lang="en-US">Revenue recognized during the period performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xlink:to="lab_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xml:lang="en-US">Revenue recognized during the period performance obligation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementAxis" xlink:label="loc_imtx_ImtxagreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImtxagreementAxis" xml:lang="en-US">IMTXAgreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImtxagreementAxis" xlink:to="lab_imtx_ImtxagreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ImtxagreementAxis" xml:lang="en-US">IMTXAgreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementMember" xlink:label="loc_imtx_ImtxagreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImtxagreementMember" xml:lang="en-US">IMTXAgreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImtxagreementMember" xlink:to="lab_imtx_ImtxagreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ImtxagreementMember" xml:lang="en-US">IMTXAgreement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxbMSCollaborationAgreementMember" xlink:label="loc_imtx_ImtxbMSCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImtxbMSCollaborationAgreementMember" xml:lang="en-US">IMTXB M S Collaboration Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImtxbMSCollaborationAgreementMember" xlink:to="lab_imtx_ImtxbMSCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ImtxbMSCollaborationAgreementMember" xml:lang="en-US">IMTXB M S Collaboration Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsBiotechnologiesGmbhMember" xlink:label="loc_imtx_ImmaticsBiotechnologiesGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImmaticsBiotechnologiesGmbhMember" xml:lang="en-US">Immatics Biotechnologies GmbH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImmaticsBiotechnologiesGmbhMember" xlink:to="lab_imtx_ImmaticsBiotechnologiesGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ImmaticsBiotechnologiesGmbhMember" xml:lang="en-US">Immatics biotechnologies gmbH.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImmaticsUsIncMember" xml:lang="en-US">Immatics US Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ImmaticsUsIncMember" xml:lang="en-US">Immatics US Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImmaticsUsIncMember" xlink:to="lab_imtx_ImmaticsUsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ImmaticsUsIncMember" xml:lang="en-US">Immatics US, Inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xml:lang="en-US">Products and services [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xml:lang="en-US">Products and services [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401licensegrantMember" xlink:label="loc_imtx_Ima401licensegrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_Ima401licensegrantMember" xml:lang="en-US">Ima401 License Grant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_Ima401licensegrantMember" xlink:to="lab_imtx_Ima401licensegrantMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401clinicaltrialservicesMember" xlink:label="loc_imtx_Ima401clinicaltrialservicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_Ima401clinicaltrialservicesMember" xml:lang="en-US">Ima401 Clinical Trial Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_Ima401clinicaltrialservicesMember" xlink:to="lab_imtx_Ima401clinicaltrialservicesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BristolMyerSquibCompanyMember" xlink:label="loc_imtx_BristolMyerSquibCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BristolMyerSquibCompanyMember" xml:lang="en-US">Bristol Myer Squib Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_BristolMyerSquibCompanyMember" xml:lang="en-US">Bristol Myer Squib Company [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BristolMyerSquibCompanyMember" xlink:to="lab_imtx_BristolMyerSquibCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_BristolMyerSquibCompanyMember" xml:lang="en-US">Bristol myer squib company.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" xml:lang="en-US">Disclosure of detailed information about other current liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" xml:lang="en-US">Disclosure of detailed information about other current liabilities abstract.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xml:lang="en-US">Disclosure of detailed information about other current liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xml:lang="en-US">Disclosure of detailed information about other current liabilities Table.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xml:lang="en-US">Disclosure of detailed information about other current liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xml:lang="en-US">Disclosure of detailed information about other current liabilities line items.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xml:lang="en-US">Current tax liabilities, current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xml:lang="en-US">Payroll tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrent" xlink:label="loc_imtx_OtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OtherCurrent" xml:lang="en-US">Other Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_OtherCurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OtherCurrent" xlink:to="lab_imtx_OtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_OtherCurrent" xml:lang="en-US">Other current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xml:lang="en-US">Accruals classified as current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xml:lang="en-US">Accrual for vacation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xml:lang="en-US">Current tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xml:lang="en-US">Income tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilities" xlink:to="lab_ifrs-full_CurrentTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Current provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Accrued bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xml:lang="en-US">Borrowings by name [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xml:lang="en-US">Borrowings by name [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xml:lang="en-US">Borrowings by name [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xml:lang="en-US">Borrowings by name [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonInterestBearingLiabilityMember" xlink:label="loc_imtx_NonInterestBearingLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NonInterestBearingLiabilityMember" xml:lang="en-US">Non Interest Bearing Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NonInterestBearingLiabilityMember" xlink:to="lab_imtx_NonInterestBearingLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NonInterestBearingLiabilityMember" xml:lang="en-US">Non interest bearing liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsMaturity" xml:lang="en-US">Borrowings, maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsMaturity" xml:lang="en-US">Borrowings maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsMaturity" xlink:to="lab_ifrs-full_BorrowingsMaturity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfShareListingExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfShareListingExpenseLineItems" xml:lang="en-US">Disclosure of Share Listing Expense [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfShareListingExpenseLineItems" xml:lang="en-US">Disclosure of share listing expense [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems" xlink:to="lab_imtx_DisclosureOfShareListingExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfShareListingExpenseLineItems" xml:lang="en-US">Disclosure of share listing expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xml:lang="en-US">Equity interests of acquirer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xml:lang="en-US">Fair value of ARYA ordinary shares and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xml:lang="en-US">Fair value of outstanding ARYA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Financial liabilities, Carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Closing price of ARYA ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsIssuedPricePerWarrant" xlink:label="loc_imtx_WarrantsIssuedPricePerWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_WarrantsIssuedPricePerWarrant" xml:lang="en-US">Warrants Issued Price Per Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_imtx_WarrantsIssuedPricePerWarrant" xml:lang="en-US">Closing price of ARYA public warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_WarrantsIssuedPricePerWarrant" xml:lang="en-US">Closing price of ARYA Warrants on Nasdaq as of July 1, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_WarrantsIssuedPricePerWarrant" xlink:to="lab_imtx_WarrantsIssuedPricePerWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_WarrantsIssuedPricePerWarrant" xml:lang="en-US">Warrants issued price per warrant.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xml:lang="en-US">Disclosure of detailed information about share listing expense [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xml:lang="en-US">Disclosure of detailed information about share listing expense.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xlink:label="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xml:lang="en-US">Restricted Cash Recognized As Of The Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xml:lang="en-US">Cash and cash equivalents held in ARYA's trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xlink:to="lab_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xml:lang="en-US">Restricted cash recognized as of the acquisition date.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Other Finance Income Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Other Finance Income Expense.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Gain Recognised On Financial Instruments Whose Fair Value Previously Could Not Be Reliably Measured</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Gain on other financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:to="lab_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Gain recognised on financial instruments whose fair value previously could not be reliably measured.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignCurrencyLossesNet" xlink:label="loc_imtx_ForeignCurrencyLossesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ForeignCurrencyLossesNet" xml:lang="en-US">Foreign Currency Losses Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_ForeignCurrencyLossesNet" xml:lang="en-US">Foreign currency losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ForeignCurrencyLossesNet" xlink:to="lab_imtx_ForeignCurrencyLossesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ForeignCurrencyLossesNet" xml:lang="en-US">Foreign currency losses net.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Loss Recognised On Financial Instruments Whose Fair Value Previously Could Not Be Reliably Measured</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Losses on other financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:to="lab_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xml:lang="en-US">Loss recognised on financial instruments whose fair value previously could not be reliably measured.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" xml:lang="en-US">Interest income on other financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:to="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xml:lang="en-US">Net foreign exchange gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xml:lang="en-US">Foreign currency gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Other financial income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpense" xml:lang="en-US">Interest expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense" xlink:to="lab_ifrs-full_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Finance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Other financial expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xlink:label="loc_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Realised gain loss from foreign currency forward contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Realised gain from foreign currency forward contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xlink:to="lab_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Realised gain loss from foreign currency forward contracts</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xlink:label="loc_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Unrealised gain loss from foreign currency forward contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Unrealised gain from foreign currency forward contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xlink:to="lab_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xml:lang="en-US">Unrealised gain loss from foreign currency forward contracts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanAxis" xlink:label="loc_imtx_PlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PlanAxis" xml:lang="en-US">Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PlanAxis" xlink:to="lab_imtx_PlanAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PlanMember" xml:lang="en-US">Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PlanMember" xlink:to="lab_imtx_PlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PlanMember" xml:lang="en-US">Plan [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Strike Price in USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free interest rate, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Expected volatility, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xml:lang="en-US">Weighted average share price, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xml:lang="en-US">Underlying share price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xml:lang="en-US">Weighted average share price of share options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Option life, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Time period (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantAxis" xlink:label="loc_imtx_DateOfGrantAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DateOfGrantAxis" xml:lang="en-US">Date Of Grant [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DateOfGrantAxis" xlink:to="lab_imtx_DateOfGrantAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DateOfGrantAxis" xml:lang="en-US">Date of grant [Axis].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DateOfGrantMember" xml:lang="en-US">Date Of Grant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DateOfGrantMember" xlink:to="lab_imtx_DateOfGrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DateOfGrantMember" xml:lang="en-US">Date of grant .</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GrantedOnJuneTwoThousandAndTwentyMember" xml:lang="en-US">Granted On June Two Thousand And Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GrantedOnJuneTwoThousandAndTwentyMember" xml:lang="en-US">Granted On June 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:to="lab_imtx_GrantedOnJuneTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GrantedOnJuneTwoThousandAndTwentyMember" xml:lang="en-US">Granted on june two thousand and twenty [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted On March Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted On March 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xlink:to="lab_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted on march two thousand and twenty one.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted On September Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted On September 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:to="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Granted on september two thousand and twenty one [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price, Outstanding at December&#160;31,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price, Outstanding at January&#160;1,</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">SARs granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Share based compensation by share based payment arrangement exercise price per share granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xml:lang="en-US">SARs forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">SARs exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">SARs exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xml:lang="en-US">SARs expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options, outstanding at January&#160;1,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options, outstanding at December&#160;31,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining contract life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:label="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xml:lang="en-US">Share Based Compensation By Share Based Payment Arrangement Weighted Average Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xml:lang="en-US">Weighted average fair value of options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xml:lang="en-US">Share based compensation by share based payment arrangement fair value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:to="lab_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xml:lang="en-US">Share based compensation by share based payment arrangement weighted average fair value per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xml:lang="en-US">SARs exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xml:lang="en-US">SARs expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">SARs forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">SARs exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">SARs granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Share based compensation by share based payment arrangement options granted during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeAxis" xlink:label="loc_imtx_ShareReinvestmentSchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareReinvestmentSchemeAxis" xml:lang="en-US">Share Reinvestment Scheme [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareReinvestmentSchemeAxis" xlink:to="lab_imtx_ShareReinvestmentSchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareReinvestmentSchemeAxis" xml:lang="en-US">Share reinvestment scheme [Axis].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeMember" xlink:label="loc_imtx_ShareReinvestmentSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareReinvestmentSchemeMember" xml:lang="en-US">Share Reinvestment Scheme [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareReinvestmentSchemeMember" xlink:to="lab_imtx_ShareReinvestmentSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareReinvestmentSchemeMember" xml:lang="en-US">Share reinvestment scheme [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xlink:to="lab_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification of awards under two thousand ten and two thousand and sixteen plan [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndTenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndTenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ModificationOfTwoThousandAndTenPlanMember" xml:lang="en-US">Modification Of Two Thousand And Ten Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ModificationOfTwoThousandAndTenPlanMember" xml:lang="en-US">Modification Of Two Thousand And Ten Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ModificationOfTwoThousandAndTenPlanMember" xlink:to="lab_imtx_ModificationOfTwoThousandAndTenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ModificationOfTwoThousandAndTenPlanMember" xml:lang="en-US">Modification of two thousand and ten plan [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ModificationOfTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification Of Two Thousand And Sixteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ModificationOfTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification Of Two Thousand And Sixteen Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember" xlink:to="lab_imtx_ModificationOfTwoThousandAndSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ModificationOfTwoThousandAndSixteenPlanMember" xml:lang="en-US">Modification of two thousand and sixteen plan [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeAxis" xlink:label="loc_imtx_SchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SchemeAxis" xml:lang="en-US">Scheme [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SchemeAxis" xlink:to="lab_imtx_SchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_SchemeAxis" xml:lang="en-US">Scheme [Axis].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeMember" xlink:label="loc_imtx_SchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SchemeMember" xml:lang="en-US">Scheme [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SchemeMember" xlink:to="lab_imtx_SchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_SchemeMember" xml:lang="en-US">Scheme [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentMember" xlink:label="loc_imtx_ShareReinvestmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareReinvestmentMember" xml:lang="en-US">Share Reinvestment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ShareReinvestmentMember" xml:lang="en-US">Share Reinvestment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareReinvestmentMember" xlink:to="lab_imtx_ShareReinvestmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareReinvestmentMember" xml:lang="en-US">Share reinvestment [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesAxis" xlink:label="loc_imtx_CategoryOfEmployeesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CategoryOfEmployeesAxis" xml:lang="en-US">Category Of Employees [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CategoryOfEmployeesAxis" xlink:to="lab_imtx_CategoryOfEmployeesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CategoryOfEmployeesAxis" xml:lang="en-US">Category Of employees [Axis].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesMember" xlink:label="loc_imtx_CategoryOfEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CategoryOfEmployeesMember" xml:lang="en-US">Category Of Employees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CategoryOfEmployeesMember" xlink:to="lab_imtx_CategoryOfEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CategoryOfEmployeesMember" xml:lang="en-US">Category of employees [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ManagementMembersMember" xlink:label="loc_imtx_ManagementMembersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ManagementMembersMember" xml:lang="en-US">Management Members [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ManagementMembersMember" xml:lang="en-US">Management Members [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ManagementMembersMember" xlink:to="lab_imtx_ManagementMembersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ManagementMembersMember" xml:lang="en-US">Management members [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ActiveEmployeesMember" xlink:label="loc_imtx_ActiveEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ActiveEmployeesMember" xml:lang="en-US">Active Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ActiveEmployeesMember" xml:lang="en-US">Active Employees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ActiveEmployeesMember" xlink:to="lab_imtx_ActiveEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ActiveEmployeesMember" xml:lang="en-US">Active employees [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashPaymentAwardPerSharePayable" xlink:label="loc_imtx_CashPaymentAwardPerSharePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CashPaymentAwardPerSharePayable" xml:lang="en-US">Cash Payment Award Per Share Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_imtx_CashPaymentAwardPerSharePayable" xml:lang="en-US">Cash payment award per share payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CashPaymentAwardPerSharePayable" xlink:to="lab_imtx_CashPaymentAwardPerSharePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CashPaymentAwardPerSharePayable" xml:lang="en-US">Cash payment award per share payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Fair value of stock appreciation rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashProceedsToBeBeReinvested" xlink:label="loc_imtx_PercentageOfCashProceedsToBeBeReinvested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfCashProceedsToBeBeReinvested" xml:lang="en-US">Percentage Of Cash Proceeds To Be Be Reinvested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOfCashProceedsToBeBeReinvested" xml:lang="en-US">Percentage of cash proceeds to be reinvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfCashProceedsToBeBeReinvested" xlink:to="lab_imtx_PercentageOfCashProceedsToBeBeReinvested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfCashProceedsToBeBeReinvested" xml:lang="en-US">Percentage of cash proceeds to be reinvested.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAndOnBehalfOfEmployees" xlink:label="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsToAndOnBehalfOfEmployees" xml:lang="en-US">Payments to and on behalf of employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsToAndOnBehalfOfEmployees" xml:lang="en-US">Cash payment to employees stock based awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees" xlink:to="lab_ifrs-full_PaymentsToAndOnBehalfOfEmployees" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ExpenseFromTheModificationOfShareBasedAwards" xlink:label="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ExpenseFromTheModificationOfShareBasedAwards" xml:lang="en-US">Expense From The Modification Of Share Based Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ExpenseFromTheModificationOfShareBasedAwards" xml:lang="en-US">Share based compensation expenses modification of awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards" xlink:to="lab_imtx_ExpenseFromTheModificationOfShareBasedAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ExpenseFromTheModificationOfShareBasedAwards" xml:lang="en-US">Expense from the modification of share based awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xml:lang="en-US">Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xml:lang="en-US">Adjustment to additional paid in capital due to modification of previously settled equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xml:lang="en-US">Description of maximum term of options granted for share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xml:lang="en-US">Share based compensation by share based payment arrangement term of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfVestingOfStockOptions" xlink:label="loc_imtx_DateOfVestingOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DateOfVestingOfStockOptions" xml:lang="en-US">Date Of Vesting Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DateOfVestingOfStockOptions" xml:lang="en-US">Date of vesting of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DateOfVestingOfStockOptions" xlink:to="lab_imtx_DateOfVestingOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DateOfVestingOfStockOptions" xml:lang="en-US">Date of vesting of stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xml:lang="en-US">Date of grant of share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xml:lang="en-US">Share based compensation by share based payment arrangement grant date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xml:lang="en-US">Grant date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MinimumMarketCapitalization" xlink:label="loc_imtx_MinimumMarketCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MinimumMarketCapitalization" xml:lang="en-US">Minimum Market Capitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MinimumMarketCapitalization" xml:lang="en-US">Minimum market capitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MinimumMarketCapitalization" xlink:to="lab_imtx_MinimumMarketCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_MinimumMarketCapitalization" xml:lang="en-US">Minimum market capitalization.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheAxis" xlink:label="loc_imtx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TrancheAxis" xlink:to="lab_imtx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TrancheAxis" xml:lang="en-US">Tranche [Axis].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheMember" xlink:label="loc_imtx_TrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TrancheMember" xml:lang="en-US">Tranche [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TrancheMember" xlink:to="lab_imtx_TrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TrancheMember" xml:lang="en-US">Tranche [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheTwoMember" xlink:label="loc_imtx_TrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TrancheTwoMember" xml:lang="en-US">Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TrancheTwoMember" xml:lang="en-US">Tranche Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TrancheTwoMember" xlink:to="lab_imtx_TrancheTwoMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheThreeMember" xlink:label="loc_imtx_TrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TrancheThreeMember" xml:lang="en-US">Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TrancheThreeMember" xml:lang="en-US">Tranche Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TrancheThreeMember" xlink:to="lab_imtx_TrancheThreeMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheOneMember" xlink:label="loc_imtx_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TrancheOneMember" xml:lang="en-US">Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TrancheOneMember" xml:lang="en-US">Tranche One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TrancheOneMember" xlink:to="lab_imtx_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TrancheOneMember" xml:lang="en-US">Tranche One [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xml:lang="en-US">Granted On September Two Thousand And Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xml:lang="en-US">Granted On September 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xlink:to="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xml:lang="en-US">Granted on september two thousand and twenty [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Compensation Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" xml:lang="en-US">Disclosure of detailed information about share based compensation expense [Abstract].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Compensation Expense [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xml:lang="en-US">Disclosure of detailed information about share based compensation expense [Table].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xml:lang="en-US">Disclosure of detailed information about share based compensation expense [Line Items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Share-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_imtx_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period Value New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period, value, new issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period, value, new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_imtx_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period, value, new issues.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Number of shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrossProceedsFromIssueOfSecurities" xlink:label="loc_imtx_GrossProceedsFromIssueOfSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_GrossProceedsFromIssueOfSecurities" xml:lang="en-US">Gross Proceeds From Issue Of Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_GrossProceedsFromIssueOfSecurities" xml:lang="en-US">Gross Proceeds From Issue Of Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_GrossProceedsFromIssueOfSecurities" xlink:to="lab_imtx_GrossProceedsFromIssueOfSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_GrossProceedsFromIssueOfSecurities" xml:lang="en-US">Gross proceeds from issue of securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issue of equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issue of equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareIssuedPricePerShare" xlink:label="loc_imtx_ShareIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareIssuedPricePerShare" xml:lang="en-US">Share Issued Price per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ShareIssuedPricePerShare" xml:lang="en-US">Share Issued Price per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareIssuedPricePerShare" xlink:to="lab_imtx_ShareIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareIssuedPricePerShare" xml:lang="en-US">Share issued price per share.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventAxis" xlink:label="loc_imtx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EventAxis" xlink:to="lab_imtx_EventAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventDomain" xlink:label="loc_imtx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EventDomain" xlink:to="lab_imtx_EventDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReorganizationMember" xlink:label="loc_imtx_ReorganizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ReorganizationMember" xml:lang="en-US">Reorganization [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ReorganizationMember" xlink:to="lab_imtx_ReorganizationMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseAxis" xlink:label="loc_imtx_ShareListingExpenseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareListingExpenseAxis" xml:lang="en-US">Share listing expense [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareListingExpenseAxis" xlink:to="lab_imtx_ShareListingExpenseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ShareListingExpenseAxis" xml:lang="en-US">Share listing expense</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseDomain" xlink:label="loc_imtx_ShareListingExpenseDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShareListingExpenseDomain" xml:lang="en-US">Share listing expense [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShareListingExpenseDomain" xlink:to="lab_imtx_ShareListingExpenseDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMergerMember" xlink:label="loc_imtx_AryaMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AryaMergerMember" xml:lang="en-US">ARYA Merger [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_AryaMergerMember" xml:lang="en-US">ARYA Merger [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AryaMergerMember" xlink:to="lab_imtx_AryaMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AryaMergerMember" xml:lang="en-US">ARYA merger.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeAxis" xlink:label="loc_imtx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_InvesteeAxis" xml:lang="en-US">Investee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_InvesteeAxis" xlink:to="lab_imtx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_InvesteeAxis" xml:lang="en-US">Investee Axis.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeMember" xlink:label="loc_imtx_InvesteeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_InvesteeMember" xml:lang="en-US">Investee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_InvesteeMember" xlink:to="lab_imtx_InvesteeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_InvesteeMember" xml:lang="en-US">Investee Member.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SvbSecuritiesLicMember" xlink:label="loc_imtx_SvbSecuritiesLicMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SvbSecuritiesLicMember" xml:lang="en-US">Svb Securities Lic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_SvbSecuritiesLicMember" xml:lang="en-US">Svb Securities Lic [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SvbSecuritiesLicMember" xlink:to="lab_imtx_SvbSecuritiesLicMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_SvbSecuritiesLicMember" xml:lang="en-US">Svb securities Lic Member.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AtTheMarketAgreementMember" xlink:label="loc_imtx_AtTheMarketAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AtTheMarketAgreementMember" xml:lang="en-US">At The Market Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AtTheMarketAgreementMember" xml:lang="en-US">At The Market Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AtTheMarketAgreementMember" xlink:to="lab_imtx_AtTheMarketAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_AtTheMarketAgreementMember" xml:lang="en-US">At the market agreement member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsAxis" xlink:label="loc_ifrs-full_CapitalRequirementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalRequirementsAxis" xml:lang="en-US">Capital requirements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalRequirementsAxis" xlink:to="lab_ifrs-full_CapitalRequirementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsMember" xlink:label="loc_ifrs-full_CapitalRequirementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalRequirementsMember" xml:lang="en-US">Capital requirements [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalRequirementsMember" xlink:to="lab_ifrs-full_CapitalRequirementsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RegisteredDirectOfferingMember" xlink:label="loc_imtx_RegisteredDirectOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered Direct Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered Direct Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RegisteredDirectOfferingMember" xlink:to="lab_imtx_RegisteredDirectOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered direct offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xml:lang="en-US">Ownership interests held by non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfSharesExchangedInSubsidiaries" xlink:label="loc_imtx_NumberOfSharesExchangedInSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NumberOfSharesExchangedInSubsidiaries" xml:lang="en-US">Number of shares exchanged in subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NumberOfSharesExchangedInSubsidiaries" xml:lang="en-US">Number of shares exchanged in subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NumberOfSharesExchangedInSubsidiaries" xlink:to="lab_imtx_NumberOfSharesExchangedInSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NumberOfSharesExchangedInSubsidiaries" xml:lang="en-US">Number of shares exchanged in subsidiaries.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period Shares Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock issued during period, shares, acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_imtx_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossOnNoncontrollingInterest" xlink:label="loc_imtx_LossOnNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LossOnNoncontrollingInterest" xml:lang="en-US">Loss on noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LossOnNoncontrollingInterest" xml:lang="en-US">Loss on non-controlling&#160;interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LossOnNoncontrollingInterest" xlink:to="lab_imtx_LossOnNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LossOnNoncontrollingInterest" xml:lang="en-US">Loss on non-controlling interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Friedrich von Bohlen und Halbach</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MdAndersonMember" xlink:label="loc_imtx_MdAndersonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MdAndersonMember" xml:lang="en-US">MD Anderson [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MdAndersonMember" xml:lang="en-US">MD Anderson [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MdAndersonMember" xlink:to="lab_imtx_MdAndersonMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedStockAcquisitionAgreementMember" xlink:label="loc_imtx_RestrictedStockAcquisitionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RestrictedStockAcquisitionAgreementMember" xml:lang="en-US">Restricted Stock Acquisition Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_RestrictedStockAcquisitionAgreementMember" xml:lang="en-US">Restricted Stock Acquisition Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RestrictedStockAcquisitionAgreementMember" xlink:to="lab_imtx_RestrictedStockAcquisitionAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xml:lang="en-US">Classes of employee benefits expense [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xml:lang="en-US">Classes of employee benefits expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_OtherShorttermEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherShorttermEmployeeBenefits" xml:lang="en-US">Other short-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherShorttermEmployeeBenefits" xml:lang="en-US">Other employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_OtherShorttermEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WagesAndSalaries" xml:lang="en-US">Wages and salaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WagesAndSalaries" xml:lang="en-US">Wages and salaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xml:lang="en-US">Short-term employee benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xml:lang="en-US">Total other employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-full_SocialSecurityContributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SocialSecurityContributions" xml:lang="en-US">Social security contributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SocialSecurityContributions" xml:lang="en-US">Social security contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="loc_ifrs-full_OtherEmployeeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xml:lang="en-US">Other employee expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xml:lang="en-US">other miscellaneous expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EmployeeHealthInsuranceCost" xlink:label="loc_imtx_EmployeeHealthInsuranceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EmployeeHealthInsuranceCost" xml:lang="en-US">Employee Health insurance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EmployeeHealthInsuranceCost" xml:lang="en-US">Employee health insurance cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EmployeeHealthInsuranceCost" xlink:to="lab_imtx_EmployeeHealthInsuranceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_EmployeeHealthInsuranceCost" xml:lang="en-US">Employee health insurance cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TaxEffectOfPermanentDifferences" xlink:label="loc_imtx_TaxEffectOfPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TaxEffectOfPermanentDifferences" xml:lang="en-US">Tax Effect Of Permanent Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TaxEffectOfPermanentDifferences" xml:lang="en-US">Permanent Differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TaxEffectOfPermanentDifferences" xlink:to="lab_imtx_TaxEffectOfPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TaxEffectOfPermanentDifferences" xml:lang="en-US">Tax effect of permanent differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xml:lang="en-US">Tax effect from change in tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xml:lang="en-US">Difference in tax rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Expected taxes on income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xlink:label="loc_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xml:lang="en-US">Tax Effect of Government Grants Exempted From Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xml:lang="en-US">Government grants exempted from taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xlink:to="lab_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xml:lang="en-US">Tax effect of government grants exempted from taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xml:lang="en-US">Non-deductible&#160; tax-expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="loc_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xml:lang="en-US">Utilization of previously unrecorded tax losses carried forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="lab_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:label="loc_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xml:lang="en-US">Non recognition of deferred taxes on tax losses and temporary differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xml:lang="en-US">Non-recognition&#160;of&#160;deferred taxes on tax losses and temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:to="lab_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xml:lang="en-US">Non-recognition&#160;of&#160;deferred taxes on tax losses and temporary differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xml:lang="en-US">Assets and liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xml:lang="en-US">Assets and liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IntangibleAssetsMember" xlink:label="loc_imtx_IntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IntangibleAssetsMember" xml:lang="en-US">Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IntangibleAssetsMember" xml:lang="en-US">Intangible assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IntangibleAssetsMember" xlink:to="lab_imtx_IntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredRevenueMember" xlink:label="loc_imtx_DeferredRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredRevenueMember" xml:lang="en-US">Deferred Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredRevenueMember" xml:lang="en-US">Deferred revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredRevenueMember" xlink:to="lab_imtx_DeferredRevenueMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetNettingMember" xlink:label="loc_imtx_DeferredAssetNettingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredAssetNettingMember" xml:lang="en-US">Deferred Asset Netting [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DeferredAssetNettingMember" xml:lang="en-US">Netting [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredAssetNettingMember" xlink:to="lab_imtx_DeferredAssetNettingMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xml:lang="en-US">Deferred Tax Liabilities Right of use asset [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xml:lang="en-US">Right-of-use assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xlink:to="lab_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xml:lang="en-US">Deferred Tax Liabilities Deferred expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xml:lang="en-US">Recognized [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xlink:to="lab_imtx_DeferredTaxLiabilitiesDeferredExpensesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredLiabilityNettingMember" xlink:label="loc_imtx_DeferredLiabilityNettingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredLiabilityNettingMember" xml:lang="en-US">Deferred Liability Netting [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredLiabilityNettingMember" xml:lang="en-US">Netting [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredLiabilityNettingMember" xlink:to="lab_imtx_DeferredLiabilityNettingMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetRecognisedMember" xlink:label="loc_imtx_DeferredAssetRecognisedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredAssetRecognisedMember" xml:lang="en-US">Deferred Asset Recognised [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DeferredAssetRecognisedMember" xml:lang="en-US">Recognized [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredAssetRecognisedMember" xlink:to="lab_imtx_DeferredAssetRecognisedMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LeaseLiabilityMember" xlink:label="loc_imtx_LeaseLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LeaseLiabilityMember" xml:lang="en-US">Lease Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LeaseLiabilityMember" xml:lang="en-US">Lease liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LeaseLiabilityMember" xlink:to="lab_imtx_LeaseLiabilityMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredExpensesMember" xlink:label="loc_imtx_DeferredExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredExpensesMember" xml:lang="en-US">Deferred Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredExpensesMember" xml:lang="en-US">Deferred expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredExpensesMember" xlink:to="lab_imtx_DeferredExpensesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RecognitionOfTaxLossesCarriedForwardMember" xlink:label="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_RecognitionOfTaxLossesCarriedForwardMember" xml:lang="en-US">Recognition of tax losses carried forward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember" xlink:to="lab_imtx_RecognitionOfTaxLossesCarriedForwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_RecognitionOfTaxLossesCarriedForwardMember" xml:lang="en-US">Recognition of tax losses carried forward.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xlink:label="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xml:lang="en-US">Nonrecognition of deferred tax assets on temporary differences [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xml:lang="en-US">Non-recognition of deferred tax assets on temporary differences [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xlink:to="lab_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xml:lang="en-US">Non-recognition of deferred tax assets on temporary differences.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesOffSet" xlink:label="loc_imtx_DeferredTaxLiabilitiesOffSet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredTaxLiabilitiesOffSet" xml:lang="en-US">Deferred Tax Liabilities Off set</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredTaxLiabilitiesOffSet" xml:lang="en-US">Deferred tax liabilities netting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredTaxLiabilitiesOffSet" xlink:to="lab_imtx_DeferredTaxLiabilitiesOffSet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DeferredTaxLiabilitiesOffSet" xml:lang="en-US">Deferred tax liabilities off set.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOffset" xlink:label="loc_imtx_DeferredTaxAssetsOffset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredTaxAssetsOffset" xml:lang="en-US">Deferred Tax Assets Offset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredTaxAssetsOffset" xml:lang="en-US">Deferred tax assets netting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredTaxAssetsOffset" xlink:to="lab_imtx_DeferredTaxAssetsOffset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DeferredTaxAssetsOffset" xml:lang="en-US">Deferred tax assets offset.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOnTemporaryDifferences" xlink:label="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeferredTaxAssetsOnTemporaryDifferences" xml:lang="en-US">Deferred Tax Assets On Temporary Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DeferredTaxAssetsOnTemporaryDifferences" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences" xlink:to="lab_imtx_DeferredTaxAssetsOnTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DeferredTaxAssetsOnTemporaryDifferences" xml:lang="en-US">Deferred tax assets on temporary differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IndefiniteTaxLossesCarryforwardMember" xlink:label="loc_imtx_IndefiniteTaxLossesCarryforwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IndefiniteTaxLossesCarryforwardMember" xml:lang="en-US">Indefinite Tax Losses carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IndefiniteTaxLossesCarryforwardMember" xml:lang="en-US">Indefinite Tax Losses Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IndefiniteTaxLossesCarryforwardMember" xlink:to="lab_imtx_IndefiniteTaxLossesCarryforwardMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentySixYearTaxLossesCarryforwardMember" xlink:label="loc_imtx_TwentySixYearTaxLossesCarryforwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TwentySixYearTaxLossesCarryforwardMember" xml:lang="en-US">Twenty Six Year Tax Losses carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_TwentySixYearTaxLossesCarryforwardMember" xml:lang="en-US">Twenty Six Year Tax Losses Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TwentySixYearTaxLossesCarryforwardMember" xlink:to="lab_imtx_TwentySixYearTaxLossesCarryforwardMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DE" xml:lang="en-US">GERMANY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Statutory tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CorporateIncomeTaxRate" xlink:label="loc_imtx_CorporateIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CorporateIncomeTaxRate" xml:lang="en-US">corporate income tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_CorporateIncomeTaxRate" xml:lang="en-US">Corporate income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CorporateIncomeTaxRate" xlink:to="lab_imtx_CorporateIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_CorporateIncomeTaxRate" xml:lang="en-US">corporate income tax rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xml:lang="en-US">Tax effect of tax losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xml:lang="en-US">Tax effect of tax losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfTaxLosses" xlink:to="lab_ifrs-full_TaxEffectOfTaxLosses" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xml:lang="en-US">Percentage on Limitation on tax loss carryforwards after prior period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xml:lang="en-US">Percentage on limitation on tax loss carryforwards after prior period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xlink:to="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xml:lang="en-US">Percentage on limitation on tax loss carryforwards after prior period.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xml:lang="en-US">Percentage on Limitation on tax loss carryforwards before prior period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xml:lang="en-US">Percentage on limitation on tax loss carryforwards before prior period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xlink:to="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xml:lang="en-US">Percentage on limitation on tax loss carryforwards before prior period.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xlink:label="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xml:lang="en-US">Effective Income Tax Reconciliation Permanent Effect Share Listing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xml:lang="en-US">Effective income tax reconciliation permanent effect share listing expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xlink:to="lab_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xml:lang="en-US">Effective income tax reconciliation permanent effect share listing expense.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xlink:label="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xml:lang="en-US">Percentage Of Income That Can Be Used To Set Off Tax Losses Carry Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xlink:to="lab_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xml:lang="en-US">Percentage of income that can be used to set off tax losses carry forward.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xlink:label="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xml:lang="en-US">Percentage Of Pretax Income Subject To Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xlink:to="lab_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xml:lang="en-US">Percentage of pretax income subject to income tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" xml:lang="en-US">Tax rate effect from change in tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" xml:lang="en-US">Tax rate effect from change in tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureAbstract" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureAbstract" xml:lang="en-US">Disclosure Of Currency Risk Exposure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureAbstract" xlink:to="lab_imtx_DisclosureOfCurrencyRiskExposureAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureTable" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureTable" xml:lang="en-US">Disclosure Of Currency Risk Exposure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable" xlink:to="lab_imtx_DisclosureOfCurrencyRiskExposureTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureLineItems" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCurrencyRiskExposureLineItems" xml:lang="en-US">Disclosure Of Currency Risk Exposure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems" xlink:to="lab_imtx_DisclosureOfCurrencyRiskExposureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets, Carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MaximumExposedToCurrencyRisk" xlink:label="loc_imtx_MaximumExposedToCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MaximumExposedToCurrencyRisk" xml:lang="en-US">Maximum Exposed to Currency risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_imtx_MaximumExposedToCurrencyRisk" xml:lang="en-US">Total assets exposed to the risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MaximumExposedToCurrencyRisk" xlink:to="lab_imtx_MaximumExposedToCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_MaximumExposedToCurrencyRisk" xml:lang="en-US">Maximum Exposed to Currency risk.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImmaticsNvMember" xml:lang="en-US">Immatics NV [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ImmaticsNvMember" xml:lang="en-US">Immatics N.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImmaticsNvMember" xlink:to="lab_imtx_ImmaticsNvMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ImmaticsGmbhMember" xml:lang="en-US">Immatics GmbH [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ImmaticsGmbhMember" xml:lang="en-US">Immatics GmbH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ImmaticsGmbhMember" xlink:to="lab_imtx_ImmaticsGmbhMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xml:lang="en-US">Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:to="lab_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xml:lang="en-US">Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:to="lab_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ValueAtRisk" xml:lang="en-US">Value at risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ValueAtRisk" xml:lang="en-US">Carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValueAtRisk" xlink:to="lab_ifrs-full_ValueAtRisk" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">Increase Decrease In Other Comprehensive Income On Basis Of Higher Lower Basis Points</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">OCI</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xlink:to="lab_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">Increase decrease in other comprehensive income on basis of higher lower basis points.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">Increase Decrease In Profit Loss Before Tax On Basis Of Higher Lower Basis Points</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">Profit/(loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xlink:to="lab_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xml:lang="en-US">Increase Decrease In Profit Loss Before Tax On Basis Of Higher Lower Basis Points.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SensitiveAnalaysisOfCurrencyAxis" xml:lang="en-US">Sensitive analaysis of currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:to="lab_imtx_SensitiveAnalaysisOfCurrencyAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_SensitiveAnalaysisOfCurrencyDomain" xml:lang="en-US">Sensitive analaysis of currency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:to="lab_imtx_SensitiveAnalaysisOfCurrencyDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroWeakensBy1AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 1 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroWeakensBy1AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 1% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:to="lab_imtx_EuroWeakensBy1AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroStrengthsBy1AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 1 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroStrengthsBy1AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 1% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:to="lab_imtx_EuroStrengthsBy1AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroWeakensBy5AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 5 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroWeakensBy5AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 5% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:to="lab_imtx_EuroWeakensBy5AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroStrengthsBy5AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 5 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroStrengthsBy5AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 5% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:to="lab_imtx_EuroStrengthsBy5AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroWeakensBy10AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 10 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroWeakensBy10AgainstUsDollarsMember" xml:lang="en-US">Euro weakens by 10% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:to="lab_imtx_EuroWeakensBy10AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EuroStrengthsBy10AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 10 against US dollars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EuroStrengthsBy10AgainstUsDollarsMember" xml:lang="en-US">Euro strengths by 10% against U.S. dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:to="lab_imtx_EuroStrengthsBy10AgainstUsDollarsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:to="lab_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:to="lab_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xml:lang="en-US">Percentage Of Reasonably Possible Increase In Foreign Currency Risk.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfManagingLiquidityRiskAbstract" xlink:label="loc_imtx_DescriptionOfManagingLiquidityRiskAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DescriptionOfManagingLiquidityRiskAbstract" xml:lang="en-US">Description Of Managing Liquidity Risk [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DescriptionOfManagingLiquidityRiskAbstract" xlink:to="lab_imtx_DescriptionOfManagingLiquidityRiskAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:label="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xml:lang="en-US">Financial assets held for managing liquidity risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xml:lang="en-US">Financial assets held for managing liquidity risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:to="lab_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShorttermDepositsMember" xlink:label="loc_imtx_ShorttermDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ShorttermDepositsMember" xml:lang="en-US">ShortTerm Deposits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ShorttermDepositsMember" xml:lang="en-US">Short-Term Deposits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_ShorttermDepositsMember" xml:lang="en-US">Short-Term Deposits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ShorttermDepositsMember" xlink:to="lab_imtx_ShorttermDepositsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashAndCashEquivalentsMember" xlink:label="loc_imtx_CashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CashAndCashEquivalentsMember" xml:lang="en-US">Cash And Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_CashAndCashEquivalentsMember" xml:lang="en-US">Cash and cash equivalents [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CashAndCashEquivalentsMember" xlink:to="lab_imtx_CashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsMember" xlink:label="loc_imtx_BondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BondsMember" xml:lang="en-US">Bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_BondsMember" xml:lang="en-US">Bonds [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BondsMember" xlink:to="lab_imtx_BondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_BondsMember" xml:lang="en-US">Bonds.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiquidityRiskMember" xml:lang="en-US">Liquidity risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiquidityRiskMember" xml:lang="en-US">Liquidity risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember" xlink:to="lab_ifrs-full_LiquidityRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro Member Countries, Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD" xml:lang="en-US">United States of America, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_USD" xml:lang="en-US">US [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xml:lang="en-US">Maximum exposure to credit risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xml:lang="en-US">Maximum exposure to credit risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:to="lab_ifrs-full_MaximumExposureToCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xml:lang="en-US">Foreign exchange gain (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xml:lang="en-US">Foreign exchange gain (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xml:lang="en-US">Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeReceivables" xml:lang="en-US">Trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeReceivables" xml:lang="en-US">Trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivables" xlink:to="lab_ifrs-full_TradeReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinancialAssets" xml:lang="en-US">Other financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherFinancialAssets" xml:lang="en-US">Other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinancialAssets" xlink:to="lab_ifrs-full_OtherFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xml:lang="en-US">Percentage of reasonable possible increase in unobservable inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xml:lang="en-US">Percentage of reasonably possible decrease in unobservable input, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xml:lang="en-US">Percentage of resonably possible decrease in unobservable inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xml:lang="en-US">Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xlink:label="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xml:lang="en-US">Percentage of Cash and Cash Equivalents Held in Domicile</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xml:lang="en-US">Percentage of cash and cash equivalents held in domicile</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xlink:to="lab_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xml:lang="en-US">Percentage of cash and cash equivalents held in domicile.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsAndShortTermDeposits" xlink:label="loc_imtx_BondsAndShortTermDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_BondsAndShortTermDeposits" xml:lang="en-US">Bonds and Short Term Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_BondsAndShortTermDeposits" xml:lang="en-US">Bonds and short-term deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_BondsAndShortTermDeposits" xlink:to="lab_imtx_BondsAndShortTermDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_BondsAndShortTermDeposits" xml:lang="en-US">Bonds and short-term deposits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditRiskMember" xml:lang="en-US">Credit risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditRiskMember" xml:lang="en-US">Credit risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember" xlink:to="lab_ifrs-full_CreditRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xml:lang="en-US">Unobservable inputs [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnobservableInputsMember" xml:lang="en-US">Unobservable inputs [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xml:lang="en-US">Historical volatility for shares, measurement input [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignExchangeRatesMember" xlink:label="loc_imtx_ForeignExchangeRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ForeignExchangeRatesMember" xml:lang="en-US">Foreign Exchange Rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ForeignExchangeRatesMember" xlink:to="lab_imtx_ForeignExchangeRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ForeignExchangeRatesMember" xml:lang="en-US">Foreign exchange rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeMember" xlink:label="loc_imtx_DeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DeMember" xml:lang="en-US">DE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_DeMember" xml:lang="en-US">Germany</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DeMember" xlink:to="lab_imtx_DeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DeMember" xml:lang="en-US">DE - Germany.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xml:lang="en-US">Categories of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xml:lang="en-US">Financial assets, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xml:lang="en-US">Financial assets at amortised cost, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeReceivablesMember" xml:lang="en-US">Trade receivables [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeReceivablesMember" xml:lang="en-US">Accounts receivables [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentNonCurrentAssetsMember" xlink:label="loc_imtx_OtherCurrentNonCurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OtherCurrentNonCurrentAssetsMember" xml:lang="en-US">Other Current Non Current Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_OtherCurrentNonCurrentAssetsMember" xml:lang="en-US">Other current/non-current assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OtherCurrentNonCurrentAssetsMember" xlink:to="lab_imtx_OtherCurrentNonCurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_OtherCurrentNonCurrentAssetsMember" xml:lang="en-US">Other current/non-current assets [Member]</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccountsPayableMember" xlink:label="loc_imtx_AccountsPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AccountsPayableMember" xml:lang="en-US">Accounts Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AccountsPayableMember" xml:lang="en-US">Accounts payable [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AccountsPayableMember" xlink:to="lab_imtx_AccountsPayableMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentLiabilitiesMember" xlink:label="loc_imtx_OtherCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other current liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OtherCurrentLiabilitiesMember" xlink:to="lab_imtx_OtherCurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesForWarrantsMember" xlink:label="loc_imtx_LiabilitiesForWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LiabilitiesForWarrantsMember" xml:lang="en-US">Liabilities for Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LiabilitiesForWarrantsMember" xml:lang="en-US">Liabilities for warrants [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LiabilitiesForWarrantsMember" xlink:to="lab_imtx_LiabilitiesForWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LiabilitiesForWarrantsMember" xml:lang="en-US">Liabilities for warrants [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xml:lang="en-US">Lease liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xml:lang="en-US">Lease liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FinancialAssetsAndFinancialLiabilities" xlink:label="loc_imtx_FinancialAssetsAndFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_FinancialAssetsAndFinancialLiabilities" xml:lang="en-US">Financial Assets and Financial Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_FinancialAssetsAndFinancialLiabilities" xml:lang="en-US">Financial assets and Financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_FinancialAssetsAndFinancialLiabilities" xlink:to="lab_imtx_FinancialAssetsAndFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_FinancialAssetsAndFinancialLiabilities" xml:lang="en-US">Financial assets and Financial liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xml:lang="en-US">Categories of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xml:lang="en-US">Financial liabilities, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" xml:lang="en-US">Disclosure of detailed information about net result from financial instruments by measurement categories [Abstract].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xml:lang="en-US">Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xml:lang="en-US">Disclosure of detailed information about net result from financial instruments by measurement categories [Table].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xml:lang="en-US">Disclosure of detailed information about net result from financial instruments by measurement categories [Line Items].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NetFinancialResult" xlink:label="loc_imtx_NetFinancialResult" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NetFinancialResult" xml:lang="en-US">Net Financial Result</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_NetFinancialResult" xml:lang="en-US">Net financial result</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NetFinancialResult" xlink:to="lab_imtx_NetFinancialResult" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NetFinancialResult" xml:lang="en-US">Net financial result.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" xml:lang="en-US">Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Abstract].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xml:lang="en-US">Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xml:lang="en-US">Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Table].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xml:lang="en-US">Classes of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xml:lang="en-US">Financial liabilities, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xlink:to="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xml:lang="en-US">Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Line Item].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xml:lang="en-US">Liabilities Arising from Financing Activities Cash Effective</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xml:lang="en-US">Cash effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xlink:to="lab_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xml:lang="en-US">Liabilities arising from financing activities cash effective.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xml:lang="en-US">Liabilities Arising from Financing Activities Noncash Effective</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xml:lang="en-US">Non-cash effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xlink:to="lab_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xml:lang="en-US">Liabilities arising from financing activities noncash effective.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsAbstract" xlink:label="loc_imtx_DisclosureOfContractualObligationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfContractualObligationsAbstract" xml:lang="en-US">Disclosure Of Contractual Obligations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfContractualObligationsAbstract" xlink:to="lab_imtx_DisclosureOfContractualObligationsAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsTable" xlink:label="loc_imtx_DisclosureOfContractualObligationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfContractualObligationsTable" xml:lang="en-US">Disclosure Of Contractual Obligations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfContractualObligationsTable" xlink:to="lab_imtx_DisclosureOfContractualObligationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Later than three years and not later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">3 - 5 years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xml:lang="en-US">Later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xml:lang="en-US">More than 5 years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Not later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Less than 1year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xml:lang="en-US">Later than one year and not later than three years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xml:lang="en-US">1 - 3 years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsLineItems" xlink:label="loc_imtx_DisclosureOfContractualObligationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfContractualObligationsLineItems" xml:lang="en-US">Disclosure Of Contractual Obligations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems" xlink:to="lab_imtx_DisclosureOfContractualObligationsLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractResearchOrganizationAgreements" xlink:label="loc_imtx_ContractResearchOrganizationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ContractResearchOrganizationAgreements" xml:lang="en-US">Contract Research Organization Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ContractResearchOrganizationAgreements" xml:lang="en-US">Contract research organization agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ContractResearchOrganizationAgreements" xlink:to="lab_imtx_ContractResearchOrganizationAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ContractResearchOrganizationAgreements" xml:lang="en-US">Contract research organization agreements.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualCashObligation" xlink:label="loc_imtx_ContractualCashObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ContractualCashObligation" xml:lang="en-US">Contractual Cash Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_imtx_ContractualCashObligation" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ContractualCashObligation" xlink:to="lab_imtx_ContractualCashObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ContractualCashObligation" xml:lang="en-US">Contractual cash obligation.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualObligationOfLeaseLiabilities" xlink:label="loc_imtx_ContractualObligationOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ContractualObligationOfLeaseLiabilities" xml:lang="en-US">Contractual Obligation Of Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ContractualObligationOfLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ContractualObligationOfLeaseLiabilities" xlink:to="lab_imtx_ContractualObligationOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ContractualObligationOfLeaseLiabilities" xml:lang="en-US">Contractual obligation of lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherLeaseObligations" xlink:label="loc_imtx_OtherLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_OtherLeaseObligations" xml:lang="en-US">Other Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_OtherLeaseObligations" xml:lang="en-US">Other Lease Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_OtherLeaseObligations" xlink:to="lab_imtx_OtherLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_OtherLeaseObligations" xml:lang="en-US">Other lease obligations.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UnrecordedContingentLiability" xlink:label="loc_imtx_UnrecordedContingentLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_UnrecordedContingentLiability" xml:lang="en-US">Unrecorded Contingent Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_UnrecordedContingentLiability" xml:lang="en-US">Unrecorded contingent liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_UnrecordedContingentLiability" xlink:to="lab_imtx_UnrecordedContingentLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_UnrecordedContingentLiability" xml:lang="en-US">Unrecorded contingent liability.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementsMember" xlink:label="loc_imtx_CollaborationAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_CollaborationAgreementsMember" xml:lang="en-US">Collaboration Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_CollaborationAgreementsMember" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_CollaborationAgreementsMember" xlink:to="lab_imtx_CollaborationAgreementsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" xlink:label="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" xml:lang="en-US">Disclosure Of Compensation Of Key Management Personnel [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" xlink:to="lab_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationFixed" xlink:label="loc_imtx_KeyManagementPersonnelCompensationFixed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensationFixed" xml:lang="en-US">Key Management Personnel Compensation Fixed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensationFixed" xml:lang="en-US">Fixed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensationFixed" xlink:to="lab_imtx_KeyManagementPersonnelCompensationFixed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensationFixed" xml:lang="en-US">Key management personnel compensation fixed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xml:lang="en-US">Key management personnel compensation, other long-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xml:lang="en-US">Variable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Share-based compensation expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationTravellingExpenses" xlink:label="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensationTravellingExpenses" xml:lang="en-US">Key Management Personnel Compensation Travelling Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensationTravellingExpenses" xml:lang="en-US">Travel expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses" xlink:to="lab_imtx_KeyManagementPersonnelCompensationTravellingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensationTravellingExpenses" xml:lang="en-US">Key management personnel compensation travelling expenses.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xlink:label="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xml:lang="en-US">Key Management Personnel Compensation Share Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xlink:to="lab_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xml:lang="en-US">Key management personnel compensation share based compensation expense.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensations" xlink:label="loc_imtx_KeyManagementPersonnelCompensations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensations" xml:lang="en-US">Key Management Personnel Compensations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensations" xml:lang="en-US">Total cash compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensations" xlink:to="lab_imtx_KeyManagementPersonnelCompensations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensations" xml:lang="en-US">Key management personnel compensations.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xlink:label="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xml:lang="en-US">Key Management Personnel Compensation Supervisory Board Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xml:lang="en-US">Supervisory board compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xlink:to="lab_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xml:lang="en-US">Key management personnel compensation supervisory board compensation.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xlink:label="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xml:lang="en-US">Key Management Personnel Compensation Payment Exit Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xml:lang="en-US">Payment Exit arrangement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xlink:to="lab_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xml:lang="en-US">Key management personnel compensation payment exit arrangement.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EliotForsterMember" xlink:label="loc_imtx_EliotForsterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_EliotForsterMember" xml:lang="en-US">Eliot Forster [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_EliotForsterMember" xml:lang="en-US">Eliot Forster</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_EliotForsterMember" xlink:to="lab_imtx_EliotForsterMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaulCarterMember" xlink:label="loc_imtx_PaulCarterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PaulCarterMember" xml:lang="en-US">Paul Carter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PaulCarterMember" xml:lang="en-US">Paul Carter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PaulCarterMember" xlink:to="lab_imtx_PaulCarterMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HeatherLMasonMember" xlink:label="loc_imtx_HeatherLMasonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_HeatherLMasonMember" xml:lang="en-US">Heather L Mason [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_HeatherLMasonMember" xml:lang="en-US">Heather L. Mason</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_HeatherLMasonMember" xlink:to="lab_imtx_HeatherLMasonMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdamStoneMember" xlink:label="loc_imtx_AdamStoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_AdamStoneMember" xml:lang="en-US">Adam Stone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_AdamStoneMember" xml:lang="en-US">Adam Stone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_AdamStoneMember" xlink:to="lab_imtx_AdamStoneMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PeterChambreMember" xlink:label="loc_imtx_PeterChambreMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PeterChambreMember" xml:lang="en-US">Peter Chambre [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PeterChambreMember" xml:lang="en-US">Peter Chambre</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PeterChambreMember" xlink:to="lab_imtx_PeterChambreMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HaraldFstockMember" xlink:label="loc_imtx_HaraldFstockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_HaraldFstockMember" xml:lang="en-US">Harald FStock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_HaraldFstockMember" xml:lang="en-US">Harald F.Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_HaraldFstockMember" xlink:to="lab_imtx_HaraldFstockMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ChristophHettichMember" xlink:label="loc_imtx_ChristophHettichMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ChristophHettichMember" xml:lang="en-US">Christoph Hettich [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_ChristophHettichMember" xml:lang="en-US">Christoph Hettich</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ChristophHettichMember" xlink:to="lab_imtx_ChristophHettichMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MichaelGAtiehMember" xlink:label="loc_imtx_MichaelGAtiehMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_MichaelGAtiehMember" xml:lang="en-US">Michael G Atieh [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_MichaelGAtiehMember" xml:lang="en-US">Michael G. Atieh</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_MichaelGAtiehMember" xlink:to="lab_imtx_MichaelGAtiehMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NancyValenteMember" xlink:label="loc_imtx_NancyValenteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NancyValenteMember" xml:lang="en-US">Nancy Valente [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imtx_NancyValenteMember" xml:lang="en-US">Nancy Valente</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NancyValenteMember" xlink:to="lab_imtx_NancyValenteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NancyValenteMember" xml:lang="en-US">Nancy Valente [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FriedrichVonBohlenUndHalbachMember" xlink:label="loc_imtx_FriedrichVonBohlenUndHalbachMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_FriedrichVonBohlenUndHalbachMember" xml:lang="en-US">Friedrich von Bohlen und Halbach [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_FriedrichVonBohlenUndHalbachMember" xml:lang="en-US">Friedrich von Bohlen und Halbach</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_FriedrichVonBohlenUndHalbachMember" xlink:to="lab_imtx_FriedrichVonBohlenUndHalbachMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_FriedrichVonBohlenUndHalbachMember" xml:lang="en-US">Friedrich von Bohlen und Halbach [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xml:lang="en-US">Disclosure of transactions between related parties [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HarpreetSinghMember" xlink:label="loc_imtx_HarpreetSinghMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_HarpreetSinghMember" xml:lang="en-US">Harpreet Singh [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_HarpreetSinghMember" xml:lang="en-US">Harpreet Singh</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_HarpreetSinghMember" xlink:to="lab_imtx_HarpreetSinghMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingAxis" xlink:label="loc_imtx_TypeOfVestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TypeOfVestingAxis" xml:lang="en-US">Type Of Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TypeOfVestingAxis" xlink:to="lab_imtx_TypeOfVestingAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TypeOfVestingDomain" xml:lang="en-US">Type Of Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TypeOfVestingDomain" xlink:to="lab_imtx_TypeOfVestingDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsMember" xlink:label="loc_imtx_ServiceOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ServiceOptionsMember" xml:lang="en-US">Service Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ServiceOptionsMember" xlink:to="lab_imtx_ServiceOptionsMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsOneMember" xlink:label="loc_imtx_ConvertedOptionsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ConvertedOptionsOneMember" xml:lang="en-US">Converted Options One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ConvertedOptionsOneMember" xlink:to="lab_imtx_ConvertedOptionsOneMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsOneMember" xlink:label="loc_imtx_ServiceOptionsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ServiceOptionsOneMember" xml:lang="en-US">Service Options One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ServiceOptionsOneMember" xlink:to="lab_imtx_ServiceOptionsOneMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsTwoMember" xlink:label="loc_imtx_ServiceOptionsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ServiceOptionsTwoMember" xml:lang="en-US">Service Options Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ServiceOptionsTwoMember" xlink:to="lab_imtx_ServiceOptionsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ServiceOptionsTwoMember" xml:lang="en-US">Service options two.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsThreeMember" xlink:label="loc_imtx_ServiceOptionsThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ServiceOptionsThreeMember" xml:lang="en-US">Service Options Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ServiceOptionsThreeMember" xlink:to="lab_imtx_ServiceOptionsThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ServiceOptionsThreeMember" xml:lang="en-US">Service options three [Member].</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsFourMember" xlink:label="loc_imtx_ServiceOptionsFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_ServiceOptionsFourMember" xml:lang="en-US">Service Options Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_ServiceOptionsFourMember" xlink:to="lab_imtx_ServiceOptionsFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_ServiceOptionsFourMember" xml:lang="en-US">Service Options Four [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xml:lang="en-US">Description of method of settlement for share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xml:lang="en-US">Type of option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfExpiryOfShareOptionsGranted" xlink:label="loc_imtx_DateOfExpiryOfShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DateOfExpiryOfShareOptionsGranted" xml:lang="en-US">Date Of Expiry Of Share Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DateOfExpiryOfShareOptionsGranted" xml:lang="en-US">Expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DateOfExpiryOfShareOptionsGranted" xlink:to="lab_imtx_DateOfExpiryOfShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DateOfExpiryOfShareOptionsGranted" xml:lang="en-US">Date of expiry of share options granted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfTransactionsWithRelatedParty" xlink:label="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfTransactionsWithRelatedParty" xml:lang="en-US">Description of transactions with related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfTransactionsWithRelatedParty" xml:lang="en-US">Description of Transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty" xlink:to="lab_ifrs-full_DescriptionOfTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xlink:label="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xml:lang="en-US">Percentage Of Stock Vested Over The Period Of Four Year Time Based Vesting Schedule</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xml:lang="en-US">Percentage of stock vested over the period of four-year time-based vesting schedule</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xlink:to="lab_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xml:lang="en-US">Percentage of stock vested over the period of four-year time-based vesting schedule.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentOfPayrollTaxOfTheEmployees" xlink:label="loc_imtx_PaymentOfPayrollTaxOfTheEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PaymentOfPayrollTaxOfTheEmployees" xml:lang="en-US">Payment Of Payroll Tax Of The Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_PaymentOfPayrollTaxOfTheEmployees" xml:lang="en-US">Payment of Payroll Tax of the employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PaymentOfPayrollTaxOfTheEmployees" xlink:to="lab_imtx_PaymentOfPayrollTaxOfTheEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_PaymentOfPayrollTaxOfTheEmployees" xml:lang="en-US">Payment of Payroll Tax of the employees.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfConvertedStockOptionsInTheEntity" xlink:label="loc_imtx_NumberOfConvertedStockOptionsInTheEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NumberOfConvertedStockOptionsInTheEntity" xml:lang="en-US">Number of Converted Stock Options In The Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NumberOfConvertedStockOptionsInTheEntity" xlink:to="lab_imtx_NumberOfConvertedStockOptionsInTheEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NumberOfConvertedStockOptionsInTheEntity" xml:lang="en-US">Number of Converted stock options in the entity.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfMatchingStockOptionInTheEntity" xlink:label="loc_imtx_NumberOfMatchingStockOptionInTheEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_NumberOfMatchingStockOptionInTheEntity" xml:lang="en-US">Number of Matching Stock Option In The Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_NumberOfMatchingStockOptionInTheEntity" xml:lang="en-US">Number of matching stock option in the entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_NumberOfMatchingStockOptionInTheEntity" xlink:to="lab_imtx_NumberOfMatchingStockOptionInTheEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_NumberOfMatchingStockOptionInTheEntity" xml:lang="en-US">Number of matching stock option in the entity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Amounts payable, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Amounts payable, related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DirectorsAndExecutiveOfficersMember" xlink:label="loc_imtx_DirectorsAndExecutiveOfficersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DirectorsAndExecutiveOfficersMember" xml:lang="en-US">Directors and executive officers [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DirectorsAndExecutiveOfficersMember" xml:lang="en-US">Directors and executive officers [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DirectorsAndExecutiveOfficersMember" xlink:to="lab_imtx_DirectorsAndExecutiveOfficersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DirectorsAndExecutiveOfficersMember" xml:lang="en-US">Directors and executive officers [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameAxis" xlink:label="loc_imtx_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PlanNameAxis" xlink:to="lab_imtx_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameDomain" xlink:label="loc_imtx_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_PlanNameDomain" xlink:to="lab_imtx_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentyTwentyIncentivePlanMember" xlink:label="loc_imtx_TwentyTwentyIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_TwentyTwentyIncentivePlanMember" xml:lang="en-US">Twenty Twenty Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_TwentyTwentyIncentivePlanMember" xlink:to="lab_imtx_TwentyTwentyIncentivePlanMember" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xlink:label="loc_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xml:lang="en-US">Dilutive effect of share options on number of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xml:lang="en-US">Dilutive effect of share options on number of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xlink:to="lab_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xml:lang="en-US">Dilutive effect of share options on number of warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xml:lang="en-US">Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xml:lang="en-US">Weighted average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" xml:lang="en-US">Disclosure Of Revenue From Collaboration Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" xlink:to="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" xml:lang="en-US">Disclosure of revenue from collaboration agreements.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xml:lang="en-US">Disclosure Of Revenue From Collaboration Agreements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xlink:to="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xml:lang="en-US">Disclosure of revenue from collaboration agreements.</label>
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xml:lang="en-US">Disclosure Of Revenue From Collaboration Agreements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xlink:to="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xml:lang="en-US">Disclosure of revenue from collaboration agreements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="loc_country_DK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DK" xml:lang="en-US">DENMARK</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_DK" xml:lang="en-US">Denmark</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK" xlink:to="lab_country_DK" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB" xml:lang="en-US">United Kingdom</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>imtx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-March-2023 [07:29:36] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CoverPage" roleURI="http://imtx.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfProfitLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfFinancialPositionOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfCashFlowsOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV" roleURI="http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#GroupInformation" roleURI="http://imtx.com/role/GroupInformation" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#BasisOfPresentation" roleURI="http://imtx.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AryaMerger" roleURI="http://imtx.com/role/AryaMerger" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandards" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SignificantAccountingJudgmentsEstimatesAndAssumptions" roleURI="http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivable" roleURI="http://imtx.com/role/AccountsReceivable" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssets" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipment" roleURI="http://imtx.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssets" roleURI="http://imtx.com/role/IntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#Leases" roleURI="http://imtx.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayable" roleURI="http://imtx.com/role/AccountsPayable" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreements" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreements" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilities" roleURI="http://imtx.com/role/OtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpenses" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpenses" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPayments" roleURI="http://imtx.com/role/ShareBasedPayments" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareholdersEquityDeficit" roleURI="http://imtx.com/role/ShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#NonControllingInterests" roleURI="http://imtx.com/role/NonControllingInterests" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpenses" roleURI="http://imtx.com/role/PersonnelExpenses" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTax" roleURI="http://imtx.com/role/IncomeTax" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPolicies" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstruments" roleURI="http://imtx.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingencies" roleURI="http://imtx.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosures" roleURI="http://imtx.com/role/RelatedPartyDisclosures" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShare" roleURI="http://imtx.com/role/EarningsAndLossPerShare" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EventsOccurringAfterTheReportingPeriod" roleURI="http://imtx.com/role/EventsOccurringAfterTheReportingPeriod" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableTables" roleURI="http://imtx.com/role/AccountsReceivableTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsTables" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsTables" roleURI="http://imtx.com/role/IntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesTables" roleURI="http://imtx.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableTables" roleURI="http://imtx.com/role/AccountsPayableTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsTables" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesTables" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesTables" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsTables" roleURI="http://imtx.com/role/ShareBasedPaymentsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesTables" roleURI="http://imtx.com/role/PersonnelExpensesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxTables" roleURI="http://imtx.com/role/IncomeTaxTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesTables" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsTables" roleURI="http://imtx.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesTables" roleURI="http://imtx.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresTables" roleURI="http://imtx.com/role/RelatedPartyDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareTables" roleURI="http://imtx.com/role/EarningsAndLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#GroupInformationAdditionalInformationDetail" roleURI="http://imtx.com/role/GroupInformationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AryaMergerAdditionalInformationDetail" roleURI="http://imtx.com/role/AryaMergerAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail" roleURI="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail" roleURI="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableSummaryOfTradeReceivablesDetail" roleURI="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsReceivableAdditionalInformationDetail" roleURI="http://imtx.com/role/AccountsReceivableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PropertyPlantAndEquipmentAddtionalInformationDetail" roleURI="http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail" roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IntangibleAssetsSummaryOfAmortizationExpenseDetail" roleURI="http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesSummaryOfRightOfUseAssetsDetail" roleURI="http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesDetailsOfLeaseLiabilitiesDetail" roleURI="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail" roleURI="http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#LeasesAdditionalInformationDetail" roleURI="http://imtx.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableSummaryOfAccountsPayableDetail" roleURI="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#AccountsPayableAdditionalInformationDetail" roleURI="http://imtx.com/role/AccountsPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsAdditionalInformationDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherCurrentLiabilitiesAdditionalInformationDetail" roleURI="http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail" roleURI="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#OtherFinancialIncomeAndExpensesAdditionalInformationDetail" roleURI="http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail" roleURI="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#ShareholdersEquityDeficitAdditionalInformationDetail" roleURI="http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#NonControllingInterestsAdditionalInformationDetail" roleURI="http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesSummaryOfPersonnelExpensesDetail" roleURI="http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#PersonnelExpensesAdditionalInformationDetail" roleURI="http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail" roleURI="http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxSummaryOfDeferredTaxAssetsDetail" roleURI="http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#IncomeTaxAdditionalInformationDetail" roleURI="http://imtx.com/role/IncomeTaxAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail" roleURI="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail" roleURI="http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesSummaryOfContractualObligationsDetail" roleURI="http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RelatedPartyDisclosuresAdditionalInformationDetail" roleURI="http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareAdditionalInformationDetail" roleURI="http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail" roleURI="http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imtx-20221231.xsd#RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail" roleURI="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail" />
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_868817" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_876580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_868817" xlink:to="loc_dei_DocumentInformationTable_876580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_876582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_876580" xlink:to="loc_dei_DocumentInformationDocumentAxis_876582" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_876583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_876582" xlink:to="loc_dei_DocumentDomain_876583" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OrdinaryShareMember" xlink:label="loc_imtx_OrdinaryShareMember_876587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentDomain_876583" xlink:to="loc_imtx_OrdinaryShareMember_876587" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_876593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentDomain_876583" xlink:to="loc_imtx_WarrantsMember_876593" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_876605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_876580" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_876605" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_876606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_876605" xlink:to="loc_dei_AddressTypeDomain_876606" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_876607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_876606" xlink:to="loc_dei_BusinessContactMember_876607" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_876586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_876580" xlink:to="loc_dei_DocumentInformationLineItems_876586" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_868818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentType_868818" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_868819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AmendmentFlag_868819" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_868820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentPeriodEndDate_868820" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_868821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentFiscalYearFocus_868821" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_868822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentFiscalPeriodFocus_868822" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_868823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityRegistrantName_868823" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_868824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCentralIndexKey_868824" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_868825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_CurrentFiscalYearEndDate_868825" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_868827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_868827" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_868828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCurrentReportingStatus_868828" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_868829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityFilerCategory_868829" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_868830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_868830" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_868831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityVoluntaryFilers_868831" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_868833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityShellCompany_868833" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_868834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityEmergingGrowthCompany_868834" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_877955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityExTransitionPeriod_877955" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_868835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentAnnualReport_868835" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_868836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityInteractiveDataCurrent_868836" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_868838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_IcfrAuditorAttestationFlag_868838" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_868839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentAccountingStandard_868839" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_868899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityIncorporationStateCountryCode_868899" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_876569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityFileNumber_876569" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_876601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_Security12bTitle_876601" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_876596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_SecurityExchangeName_876596" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_876597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_TradingSymbol_876597" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_876609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_ContactPersonnelName_876609" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_876613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressAddressLine1_876613" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_876614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressCityOrTown_876614" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_876615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressStateOrProvince_876615" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_876616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressCountry_876616" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_876617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_EntityAddressPostalZipCode_876617" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_876624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_CityAreaCode_876624" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_876625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_LocalPhoneNumber_876625" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_876636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentRegistrationStatement_876636" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_876638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentShellCompanyReport_876638" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_876639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_DocumentTransitionReport_876639" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1336593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorName_1336593" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1336595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorFirmId_1336595" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1336596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_876586" xlink:to="loc_dei_AuditorLocation_1336596" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_864698" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements_881029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_imtx_RevenueFromCollaborationAgreements_881029" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_864700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_864700" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_864701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_864701" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome_864702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_OtherIncome_864702" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_864703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_864703" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143654" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpense" xlink:label="loc_imtx_ShareListingExpense_864706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_imtx_ShareListingExpense_864706" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome_1351323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_OtherFinanceIncome_1351323" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="loc_ifrs-full_OtherFinanceCost_1351324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_OtherFinanceCost_1351324" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="loc_ifrs-full_FinanceIncomeCost_864707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_FinanceIncomeCost_864707" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_864708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_864708" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_864709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_864709" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_864710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_ProfitLoss_864710" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_864711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_864711" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_864712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_864711" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_864712" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_864713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_864711" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_864713" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_1351337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_864698" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_1351337" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_1351326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351337" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_1351326" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_1351328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351337" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_1351328" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_864718" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_864719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_864718" xlink:to="loc_ifrs-full_ProfitLoss_864719" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_864720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_864718" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_864720" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_864721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_864720" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_864721" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_864722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_864721" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_864722" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_864723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_864718" xlink:to="loc_ifrs-full_ComprehensiveIncome_864723" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_864724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_864718" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_864724" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_864725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_864724" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_864725" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_864726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_864724" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_864726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_864660" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_864661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_864660" xlink:to="loc_ifrs-full_AssetsAbstract_864661" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_864662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_864661" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_864662" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_864663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_864662" xlink:to="loc_ifrs-full_CashAndCashEquivalents_864663" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_864664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_864662" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_864664" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_864665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_864662" xlink:to="loc_ifrs-full_CurrentTradeReceivables_864665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets_864666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_864662" xlink:to="loc_ifrs-full_OtherCurrentAssets_864666" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_864667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_864662" xlink:to="loc_ifrs-full_CurrentAssets_864667" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_864668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_864661" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_864668" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_864669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_864668" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_864669" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_864670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_864668" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_864670" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_864671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_864668" xlink:to="loc_ifrs-full_RightofuseAssets_864671" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_864672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_864668" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_864672" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_864673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_864668" xlink:to="loc_ifrs-full_NoncurrentAssets_864673" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_864674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_864661" xlink:to="loc_ifrs-full_Assets_864674" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_864660" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_864678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_864678" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_864679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_CurrentContractLiabilities_864679" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="loc_ifrs-full_CurrentWarrantLiability_1351342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_CurrentWarrantLiability_1351342" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_864680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_864680" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_864681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_864681" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_864682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_864676" xlink:to="loc_ifrs-full_CurrentLiabilities_864682" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_864684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_864684" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_864685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_864685" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_864686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_864686" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_864687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_864683" xlink:to="loc_ifrs-full_NoncurrentLiabilities_864687" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_864688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" xlink:to="loc_ifrs-full_EquityAbstract_864688" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_864689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_864688" xlink:to="loc_ifrs-full_IssuedCapital_864689" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_864690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_864688" xlink:to="loc_ifrs-full_SharePremium_864690" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_864691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_864688" xlink:to="loc_ifrs-full_RetainedEarnings_864691" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_864692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_864688" xlink:to="loc_ifrs-full_OtherReserves_864692" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_864695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_864688" xlink:to="loc_ifrs-full_Equity_864695" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_864696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_864675" xlink:to="loc_ifrs-full_EquityAndLiabilities_864696" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1351346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" xlink:to="loc_ifrs-full_ProfitLoss_1351346" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1351345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1351345" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_864731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_864731" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome_864733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_AdjustmentsForInterestIncome_864733" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_864734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_864734" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="loc_ifrs-full_AdjustmentsForInterestExpense_864735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_AdjustmentsForInterestExpense_864735" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense_864736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_imtx_AdjustmentsForShareListingExpense_864736" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentForEquitySettledSharebasedPayment" xlink:label="loc_imtx_AdjustmentForEquitySettledSharebasedPayment_864737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_imtx_AdjustmentForEquitySettledSharebasedPayment_864737" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_864738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_864738" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_864739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_864739" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsForShareBasedCompensation" xlink:label="loc_imtx_PaymentsForShareBasedCompensation_864740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_imtx_PaymentsForShareBasedCompensation_864740" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:label="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351347" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_864732" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143659" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ChangesInWorkingCapitalAbstract" xlink:label="loc_imtx_ChangesInWorkingCapitalAbstract_864741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_864730" xlink:to="loc_imtx_ChangesInWorkingCapitalAbstract_864741" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_864742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_864742" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_864743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_864743" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables" xlink:label="loc_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables_1351348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables_1351348" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_864806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_864806" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_864807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_864807" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_1351349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_1351349" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_864808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ChangesInWorkingCapitalAbstract_864741" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_864808" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_864810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_864810" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_864811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_864811" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_864812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_864812" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_864813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_864813" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_864814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_864814" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_864815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_864809" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_864815" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_864817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_864817" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TransactionCostsDeductedFromEquity" xlink:label="loc_imtx_TransactionCostsDeductedFromEquity_876644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" xlink:to="loc_imtx_TransactionCostsDeductedFromEquity_876644" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_864818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_864818" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_864819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_864816" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_864819" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_864820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_864820" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_864821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_CashAndCashEquivalents_864821" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xlink:label="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351350" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_864823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_864729" xlink:to="loc_ifrs-full_CashAndCashEquivalents_864823" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_864825" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_864826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_864825" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_864826" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_864827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_864826" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_864827" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864827" xlink:to="loc_ifrs-full_EquityMember_864828" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_864829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_IssuedCapitalMember_864829" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_864831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_SharePremiumMember_864831" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_864832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_RetainedEarningsMember_864832" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_864833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_OtherReservesMember_864833" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TotalEquityAttributableToShareholdersOfParentMember" xlink:label="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember_864834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_imtx_TotalEquityAttributableToShareholdersOfParentMember_864834" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_864835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864828" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_864835" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_864826" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_864837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_Equity_864837" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_864838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_864838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_864839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_ProfitLoss_864839" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_864840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_ComprehensiveIncome_864840" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:label="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864845" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864846" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864847" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseThroughARYAMerger" xlink:label="loc_imtx_IncreaseThroughARYAMerger_864848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreaseThroughARYAMerger_864848" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SARConversion" xlink:label="loc_imtx_SARConversion_864849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_SARConversion_864849" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughIssuanceOfEquity" xlink:label="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity_864850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughIssuanceOfEquity_864850" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_864841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_864841" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled" xlink:label="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled_864852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled_864852" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughCompensationExpense" xlink:label="loc_imtx_IncreasedecreaseThroughCompensationExpense_864843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IncreasedecreaseThroughCompensationExpense_864843" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1336847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1336847" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IssueOfShareCapitalNetOfTransactionCosts" xlink:label="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts_1351384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_imtx_IssueOfShareCapitalNetOfTransactionCosts_1351384" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_864844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_864836" xlink:to="loc_ifrs-full_Equity_864844" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/GroupInformation">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864854" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_864855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864854" xlink:to="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_864855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864866" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_864867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864866" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_864867" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AryaMerger">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864905" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMergerTransactionExplanatory" xlink:label="loc_imtx_AryaMergerTransactionExplanatory_876494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864905" xlink:to="loc_imtx_AryaMergerTransactionExplanatory_876494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864942" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_864943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864942" xlink:to="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_864943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866204" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_866205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866204" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_866205" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866294" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_866295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866294" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_866295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsReceivable">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864972" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAccountReceivableExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock_864973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864972" xlink:to="loc_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock_864973" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssets">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864985" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_864986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864985" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_864986" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipment">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864992" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_864993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864992" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_864993" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssets">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866410" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_866411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866410" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_866411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866471" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_866472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866471" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_866472" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsPayable">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866774" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_866775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866774" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_866775" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreements">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866814" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_866815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866814" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_866815" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866832" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_866833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866832" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_866833" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866960" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock" xlink:label="loc_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock_866963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866960" xlink:to="loc_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock_866963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpenses">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867229" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_867231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867229" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_867231" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPayments">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867228" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_867230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867228" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_867230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866834" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_866835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866834" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_866835" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/NonControllingInterests">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867049" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_867050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867049" xlink:to="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_867050" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PersonnelExpenses">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867018" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock_867019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867018" xlink:to="loc_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock_867019" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTax">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866872" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_866873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866872" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_866873" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867076" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_867077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867076" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_867077" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866743" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_866744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866743" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_866744" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866712" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_866713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866712" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_866713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosures">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866501" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_866502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866501" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_866502" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/EarningsAndLossPerShare">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866463" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_866464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866463" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_866464" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/EventsOccurringAfterTheReportingPeriod">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866460" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_866461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866460" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_866461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866211" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_869287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_869287" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock_869288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock_869288" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock" xlink:label="loc_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock_1351542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock_1351542" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_866226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_866226" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_866214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_866214" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_866212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_866212" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_866215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_866215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_866216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_866216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_866217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_866217" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_866218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_866218" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_866219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_866219" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_866220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_866220" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_866221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_866221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_866222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_866222" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_866225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_866225" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_866227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_866227" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_1351351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866211" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_1351351" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864945" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_864946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864945" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_864946" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock" xlink:label="loc_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock_864947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864945" xlink:to="loc_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock_864947" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate" xlink:label="loc_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate_1351383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864945" xlink:to="loc_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate_1351383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866235" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock_866238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866235" xlink:to="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock_866238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock_866239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866235" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock_866239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock_866240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866235" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock_866240" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsReceivableTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864975" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock_864976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864975" xlink:to="loc_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock_864976" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864988" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_864989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864988" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_864989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_864990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864988" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_864990" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864995" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_864996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864995" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_864996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDepreciationExpensesTableTextBlock" xlink:label="loc_imtx_DisclosureOfDepreciationExpensesTableTextBlock_864997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864995" xlink:to="loc_imtx_DisclosureOfDepreciationExpensesTableTextBlock_864997" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866413" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_866414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866413" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_866414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAmortizationExpensesTableTextBlock" xlink:label="loc_imtx_DisclosureOfAmortizationExpensesTableTextBlock_866417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866413" xlink:to="loc_imtx_DisclosureOfAmortizationExpensesTableTextBlock_866417" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866474" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_866475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866474" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_866475" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock_866481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866474" xlink:to="loc_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock_866481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_866482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866474" xlink:to="loc_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_866482" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsPayableTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866778" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock_866781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866778" xlink:to="loc_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock_866781" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866817" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractLiabilitiesTextBlock" xlink:label="loc_imtx_DisclosureOfContractLiabilitiesTextBlock_870553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866817" xlink:to="loc_imtx_DisclosureOfContractLiabilitiesTextBlock_870553" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory_1351469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866817" xlink:to="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory_1351469" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866846" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock_866848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866846" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock_866848" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866968" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock_866969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866968" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock_866969" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpensesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867284" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock_870649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867284" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock_870649" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867233" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867233" xlink:to="loc_imtx_StatementsTable_867236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867236" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867240" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_867427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_MatchingStockOptionsMember_867427" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_867429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_ConvertedOptionsMember_867429" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_867431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_867431" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_867434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867241" xlink:to="loc_imtx_PerformanceBasedOptionsMember_867434" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867236" xlink:to="loc_imtx_StatementsLineItems_867239" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_867234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_867234" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_867251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_867251" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock_870758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867239" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock_870758" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PersonnelExpensesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867021" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPersonnelExpenesTextBlock" xlink:label="loc_imtx_DisclosureOfPersonnelExpenesTextBlock_871287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867021" xlink:to="loc_imtx_DisclosureOfPersonnelExpenesTextBlock_871287" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866880" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock" xlink:label="loc_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock_866881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866880" xlink:to="loc_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock_866881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_866886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866880" xlink:to="loc_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_866886" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867079" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock_867080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867079" xlink:to="loc_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock_867080" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_867081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867079" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_867081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfManagingLiquidityRisk" xlink:label="loc_ifrs-full_DescriptionOfManagingLiquidityRisk_867082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867079" xlink:to="loc_ifrs-full_DescriptionOfManagingLiquidityRisk_867082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866747" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_866748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866747" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_866748" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory_1351394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866747" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory_1351394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory_1351395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866747" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory_1351395" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866716" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsTableTextBlock" xlink:label="loc_imtx_DisclosureOfContractualObligationsTableTextBlock_866717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866716" xlink:to="loc_imtx_DisclosureOfContractualObligationsTableTextBlock_866717" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresTables">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866504" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock_866510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866504" xlink:to="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock_866510" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationSupervisoryBoardTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock_866514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866504" xlink:to="loc_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock_866514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock" xlink:label="loc_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock_866516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866504" xlink:to="loc_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock_866516" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/EarningsAndLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_1351363" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_1351364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351363" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_1351364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/GroupInformationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864857" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864857" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_864860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_864859" xlink:to="loc_ifrs-full_NonadjustingEventsMember_864860" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AuthorizationOfFinancialStatementsMember" xlink:label="loc_imtx_AuthorizationOfFinancialStatementsMember_864861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_864860" xlink:to="loc_imtx_AuthorizationOfFinancialStatementsMember_864861" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_864858" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013" xlink:label="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013_864863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" xlink:to="loc_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013_864863" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfEndOfReportingPeriod2013" xlink:label="loc_ifrs-full_DateOfEndOfReportingPeriod2013_864864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_864862" xlink:to="loc_ifrs-full_DateOfEndOfReportingPeriod2013_864864" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AryaMergerAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_864908" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_864908" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_864910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_864910" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_864910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_864912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_864911" xlink:to="loc_imtx_AryaMember_864912" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_864914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_864913" xlink:to="loc_ifrs-full_OrdinarySharesMember_864914" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PipeFinancingMember" xlink:label="loc_imtx_PipeFinancingMember_864915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_864914" xlink:to="loc_imtx_PipeFinancingMember_864915" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_864916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_864916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_864917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_864916" xlink:to="loc_ifrs-full_EquityMember_864917" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_864918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864917" xlink:to="loc_ifrs-full_IssuedCapitalMember_864918" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_864919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_864917" xlink:to="loc_ifrs-full_SharePremiumMember_864919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_864921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_864920" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_864921" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_864922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_864921" xlink:to="loc_ifrs-full_OrdinarySharesMember_864922" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_864923" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_864925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_864924" xlink:to="loc_imtx_WarrantsMember_864925" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_864909" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseThroughReorganizationEquity" xlink:label="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_IncreaseDecreaseThroughReorganizationEquity_864928" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_864929" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree" xlink:label="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree_864930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree_864930" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_864931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_864931" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_864932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_864932" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_864933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_864933" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_864934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_864934" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpense" xlink:label="loc_imtx_ShareListingExpense_864935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_ShareListingExpense_864935" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_864936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_864936" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_864937" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_864938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_864938" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination" xlink:label="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination_1143857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_864926" xlink:to="loc_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination_1143857" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_864949" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_864949" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsAxis" xlink:label="loc_ifrs-full_NewIFRSsAxis_864951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" xlink:to="loc_ifrs-full_NewIFRSsAxis_864951" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsAxis_864951" xlink:to="loc_ifrs-full_NewIFRSsMember_864952" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasSixteenMember" xlink:label="loc_imtx_AmendmentIasSixteenMember_1351470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentIasSixteenMember_1351470" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentIasThirtySevenMember" xlink:label="loc_imtx_AmendmentIasThirtySevenMember_1351471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentIasThirtySevenMember_1351471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsThreeMember" xlink:label="loc_imtx_AmendmentToIfrsThreeMember_1351472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsThreeMember_1351472" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsOneMember" xlink:label="loc_imtx_AmendmentToIfrsOneMember_1351473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsOneMember_1351473" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsNineMember" xlink:label="loc_imtx_AmendmentToIfrsNineMember_1351474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIfrsNineMember_1351474" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember" xlink:label="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember_1337088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember_1337088" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasFourtyOneMember" xlink:label="loc_imtx_AmendmentToIasFourtyOneMember_1351476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864952" xlink:to="loc_imtx_AmendmentToIasFourtyOneMember_1351476" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864950" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="loc_ifrs-full_TitleOfNewIFRS_864958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" xlink:to="loc_ifrs-full_TitleOfNewIFRS_864958" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864957" xlink:to="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864959" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_864961" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_864961" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsAxis" xlink:label="loc_ifrs-full_NewIFRSsAxis_864963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" xlink:to="loc_ifrs-full_NewIFRSsAxis_864963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewIFRSsMember" xlink:label="loc_ifrs-full_NewIFRSsMember_864964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsAxis_864963" xlink:to="loc_ifrs-full_NewIFRSsMember_864964" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IFRS17Member" xlink:label="loc_ifrs-full_IFRS17Member_1337114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_ifrs-full_IFRS17Member_1337114" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember" xlink:label="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember_1351536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember_1351536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasEightMember" xlink:label="loc_imtx_AmendmentToIasEightMember_1351537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasEightMember_1351537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasTwelveMember" xlink:label="loc_imtx_AmendmentToIasTwelveMember_1351538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasTwelveMember_1351538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIfrsSixteenMember" xlink:label="loc_imtx_AmendmentToIfrsSixteenMember_1351539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIfrsSixteenMember_1351539" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmendmentToIasOneMember" xlink:label="loc_imtx_AmendmentToIasOneMember_1351540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NewIFRSsMember_864964" xlink:to="loc_imtx_AmendmentToIasOneMember_1351540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_864962" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="loc_ifrs-full_TitleOfNewIFRS_864969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" xlink:to="loc_ifrs-full_TitleOfNewIFRS_864969" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_864968" xlink:to="loc_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_864970" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_1351484" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_1351484" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1351487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" xlink:to="loc_srt_RestatementAxis_1351487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1351488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1351487" xlink:to="loc_srt_RestatementDomain_1351488" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1351491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1351491" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_1351490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_1351490" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentlyReportedMember" xlink:label="loc_imtx_CurrentlyReportedMember_1351544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1351488" xlink:to="loc_imtx_CurrentlyReportedMember_1351544" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_1351485" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss" xlink:label="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss_1351492" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1351493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1351493" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1351494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1351494" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1351495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1351495" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1351496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1351496" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1351497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1351497" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents" xlink:label="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents_1351499" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1351498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_1351486" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1351498" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_1351501" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities" xlink:label="loc_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities_1351502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_1351501" xlink:to="loc_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities_1351502" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_866242" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_866242" xlink:to="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_866244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xlink:to="loc_ifrs-full_RangeAxis_866244" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_866244" xlink:to="loc_ifrs-full_RangesMember_866245" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_866246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_866245" xlink:to="loc_ifrs-full_BottomOfRangeMember_866246" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_866247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_866245" xlink:to="loc_ifrs-full_TopOfRangeMember_866247" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866248" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_866250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_ifrs-full_ComputerEquipmentMember_866250" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_866251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_imtx_LaboratoryEquipmentMember_866251" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_866252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866249" xlink:to="loc_ifrs-full_OfficeEquipmentMember_866252" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems" xlink:label="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable_866243" xlink:to="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_866257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems_866253" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_866257" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract_866260" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract_866260" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_866263" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember_866265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" xlink:to="loc_ifrs-full_LicencesMember_866265" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_866266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_866264" xlink:to="loc_ifrs-full_ComputerSoftwareMember_866266" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_866267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xlink:to="loc_ifrs-full_RangeAxis_866267" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_866268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_866267" xlink:to="loc_ifrs-full_RangesMember_866268" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_866269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_866268" xlink:to="loc_ifrs-full_BottomOfRangeMember_866269" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_866270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_866268" xlink:to="loc_ifrs-full_TopOfRangeMember_866270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable_866262" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_866272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems_866271" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_866272" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="loc_ifrs-full_ForeignExchangeRatesAbstract_866274" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable_866275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ForeignExchangeRatesAbstract_866274" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable_866275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable_866275" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_866279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_866279" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_866280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems_866276" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_866280" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract_864978" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReceivablesFromCollaborationAgreements" xlink:label="loc_imtx_ReceivablesFromCollaborationAgreements_864979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract_864978" xlink:to="loc_imtx_ReceivablesFromCollaborationAgreements_864979" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_864980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract_864978" xlink:to="loc_ifrs-full_CurrentTradeReceivables_864980" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsReceivableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract_864982" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets" xlink:label="loc_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets_1351343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivablesAbstract_864982" xlink:to="loc_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets_1351343" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_866315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_866315" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_866317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_866317" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentGrantReceivable" xlink:label="loc_imtx_CurrentGrantReceivable_866314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" xlink:to="loc_imtx_CurrentGrantReceivable_866314" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets_866322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" xlink:to="loc_ifrs-full_OtherAssets_866322" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets_866323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_866312" xlink:to="loc_ifrs-full_OtherCurrentAssets_866323" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866337" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866337" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementAxis" xlink:label="loc_imtx_CollaborationAgreementAxis_866340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xlink:to="loc_imtx_CollaborationAgreementAxis_866340" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementMember" xlink:label="loc_imtx_CollaborationAgreementMember_866341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_CollaborationAgreementAxis_866340" xlink:to="loc_imtx_CollaborationAgreementMember_866341" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CelgeneSwitzerlandLlcAndGenmabAsMember" xlink:label="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember_866342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_CollaborationAgreementMember_866341" xlink:to="loc_imtx_CelgeneSwitzerlandLlcAndGenmabAsMember_866342" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationAxis" xlink:label="loc_imtx_BalanceSheetLocationAxis_870968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xlink:to="loc_imtx_BalanceSheetLocationAxis_870968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BalanceSheetLocationDomain" xlink:label="loc_imtx_BalanceSheetLocationDomain_870969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_BalanceSheetLocationAxis_870968" xlink:to="loc_imtx_BalanceSheetLocationDomain_870969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_866339" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidInsurance" xlink:label="loc_imtx_CurrentPrepaidInsurance_866344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentPrepaidInsurance_866344" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentIncrementalCostForCollaborationAgreement" xlink:label="loc_imtx_CurrentIncrementalCostForCollaborationAgreement_866345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentIncrementalCostForCollaborationAgreement_866345" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PrepaidExpensesOfLicensesAndSoftware" xlink:label="loc_imtx_PrepaidExpensesOfLicensesAndSoftware_866346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_PrepaidExpensesOfLicensesAndSoftware_866346" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments" xlink:label="loc_ifrs-full_NoncurrentPrepayments_866349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_ifrs-full_NoncurrentPrepayments_866349" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_CurrentPrepaidMaintenanceExpenses_1337590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_CurrentPrepaidMaintenanceExpenses_1337590" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NoncurrentPrepaymentsOfLicensingAgreement" xlink:label="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement_1351340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_NoncurrentPrepaymentsOfLicensingAgreement_1351340" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonCurrentPrepaidMaintenanceExpenses" xlink:label="loc_imtx_NonCurrentPrepaidMaintenanceExpenses_1351341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_866343" xlink:to="loc_imtx_NonCurrentPrepaidMaintenanceExpenses_1351341" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentReceivablesAbstract" xlink:label="loc_ifrs-full_NoncurrentReceivablesAbstract_866331" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments" xlink:label="loc_ifrs-full_NoncurrentPrepayments_866332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentReceivablesAbstract_866331" xlink:to="loc_ifrs-full_NoncurrentPrepayments_866332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherNonCurrentAsset" xlink:label="loc_imtx_OtherNonCurrentAsset_870231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentReceivablesAbstract_866331" xlink:to="loc_imtx_OtherNonCurrentAsset_870231" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_866334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentReceivablesAbstract_866331" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_866334" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_866353" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_866353" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866355" xlink:to="loc_ifrs-full_CarryingAmountMember_866356" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_866357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_866356" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_866357" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_866364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_866356" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_866364" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsAxis" xlink:label="loc_imtx_TypeOfAdoptionsAxis_866358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_imtx_TypeOfAdoptionsAxis_866358" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_866359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfAdoptionsAxis_866358" xlink:to="loc_imtx_TypeOfAdoptionsMember_866359" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_866362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_866361" xlink:to="loc_ifrs-full_RestatedMember_866362" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_866367" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_866369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_imtx_LaboratoryEquipmentMember_866369" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_866370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_ifrs-full_ComputerEquipmentMember_866370" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OfficeEquipmentAndInstallationsMember" xlink:label="loc_imtx_OfficeEquipmentAndInstallationsMember_1351339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_866368" xlink:to="loc_imtx_OfficeEquipmentAndInstallationsMember_1351339" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_866354" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_866372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_866372" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionsOtherPropertyPlantAndEquipment" xlink:label="loc_imtx_AdditionsOtherPropertyPlantAndEquipment_870282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_AdditionsOtherPropertyPlantAndEquipment_870282" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisposalsOfPropertyPlantAndEquipment" xlink:label="loc_imtx_DisposalsOfPropertyPlantAndEquipment_870283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_DisposalsOfPropertyPlantAndEquipment_870283" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CurrencyTranslationDifferences" xlink:label="loc_imtx_CurrencyTranslationDifferences_870289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_imtx_CurrencyTranslationDifferences_870289" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_866376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_866365" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_866376" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDepreciationExpensesAbstract" xlink:label="loc_imtx_DisclosureOfDepreciationExpensesAbstract_865031" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDepreciationExpensesAbstract_865031" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_865033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" xlink:to="loc_imtx_IncomeStatementLocationAxis_865033" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_865034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationAxis_865033" xlink:to="loc_imtx_IncomeStatementLocationMember_865034" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_865035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_865034" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_865035" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_865036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_865034" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_865036" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_865032" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_865038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_865037" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_865038" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDepreciationExpensesAbstract" xlink:label="loc_imtx_DisclosureOfDepreciationExpensesAbstract_1351330" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDepreciationExpensesAbstract_1351330" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1351334" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OfficeEquipmentAndInstallationsMember" xlink:label="loc_imtx_OfficeEquipmentAndInstallationsMember_1351336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1351335" xlink:to="loc_imtx_OfficeEquipmentAndInstallationsMember_1351336" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1351331" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1351333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1351332" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1351333" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_866420" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_866420" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_866425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_866424" xlink:to="loc_ifrs-full_CarryingAmountMember_866425" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_866427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_866425" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_866427" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_866428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_866425" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_866428" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_866445" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PatentAndLicensesMember" xlink:label="loc_imtx_PatentAndLicensesMember_866448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" xlink:to="loc_imtx_PatentAndLicensesMember_866448" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SoftwareLicensesMember" xlink:label="loc_imtx_SoftwareLicensesMember_866449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_866447" xlink:to="loc_imtx_SoftwareLicensesMember_866449" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_866422" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_866435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_866435" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_866437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_866437" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_866439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_866439" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_866440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_866431" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_866440" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfAmortizationExpensesAbstract" xlink:label="loc_imtx_DisclosureOfAmortizationExpensesAbstract_866451" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfAmortizationExpensesAbstract_866451" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_866453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" xlink:to="loc_imtx_IncomeStatementLocationAxis_866453" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_866454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationAxis_866453" xlink:to="loc_imtx_IncomeStatementLocationMember_866454" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_866455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_866454" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_866455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_866456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_866454" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_866456" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_866452" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_866458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_866457" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_866458" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_866484" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_866484" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_866486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_866486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866486" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_866488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_BuildingsMember_866488" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_1337743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_imtx_LaboratoryEquipmentMember_1337743" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:label="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866490" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_866491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_VehiclesMember_866491" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_866492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866487" xlink:to="loc_ifrs-full_OtherAssetsMember_866492" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_866485" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_866494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866493" xlink:to="loc_ifrs-full_RightofuseAssets_866494" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_866496" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_866497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_866496" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_866497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_866498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_866496" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_866498" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_866499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_866496" xlink:to="loc_ifrs-full_LeaseLiabilities_866499" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract_866506" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract_866506" xlink:to="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_866508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_866508" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_866509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_866508" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_866509" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_866511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_BuildingsMember_866511" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LaboratoryEquipmentMember" xlink:label="loc_imtx_LaboratoryEquipmentMember_1337804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_imtx_LaboratoryEquipmentMember_1337804" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:label="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_CommunicationAndNetworkEquipmentMember_866512" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_866513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_VehiclesMember_866513" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_866515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_866509" xlink:to="loc_ifrs-full_OtherAssetsMember_866515" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable_866507" xlink:to="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_866522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_866522" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InterestExpenseOnLease" xlink:label="loc_imtx_InterestExpenseOnLease_870408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_imtx_InterestExpenseOnLease_870408" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_866524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems_866517" xlink:to="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_866524" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866541" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_866541" xlink:to="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_866543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xlink:to="loc_ifrs-full_MaturityAxis_866543" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_866543" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866544" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_876339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866544" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_876339" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_866546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866544" xlink:to="loc_ifrs-full_LaterThanOneYearMember_866546" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1351320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xlink:to="loc_srt_StatementGeographicalAxis_1351320" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1351320" xlink:to="loc_srt_SegmentGeographicalDomain_1351321" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1351322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1351321" xlink:to="loc_country_US_1351322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_866542" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_866550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_866550" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TranslationDifferenceOnRightOfUseAsset" xlink:label="loc_imtx_TranslationDifferenceOnRightOfUseAsset_866551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_imtx_TranslationDifferenceOnRightOfUseAsset_866551" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_866552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_CashOutflowForLeases_866552" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_876337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_876337" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities" xlink:label="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities_1351547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_866549" xlink:to="loc_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities_1351547" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866787" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_866788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866787" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_866788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccruedLiabilities" xlink:label="loc_imtx_AccruedLiabilities_866789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866787" xlink:to="loc_imtx_AccruedLiabilities_866789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_866790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866787" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_866790" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/AccountsPayableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866792" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccruedLiabilities" xlink:label="loc_imtx_AccruedLiabilities_870419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_866792" xlink:to="loc_imtx_AccruedLiabilities_870419" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract_866825" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersTable" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_866825" xlink:to="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_866839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_AgreementAxis_866839" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_866840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementAxis_866839" xlink:to="loc_imtx_AgreementDomain_866840" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmgenCollaborationAgreementMember" xlink:label="loc_imtx_AmgenCollaborationAgreementMember_866841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_AmgenCollaborationAgreementMember_866841" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GenmabCollaborationAgreementMember" xlink:label="loc_imtx_GenmabCollaborationAgreementMember_866852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_GenmabCollaborationAgreementMember_866852" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BMSCollaborationAgreementMember" xlink:label="loc_imtx_BMSCollaborationAgreementMember_866853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_BMSCollaborationAgreementMember_866853" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GSKCollaborationAgreementMember" xlink:label="loc_imtx_GSKCollaborationAgreementMember_866889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_GSKCollaborationAgreementMember_866889" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BmsAgreementMember" xlink:label="loc_imtx_BmsAgreementMember_1351454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_BmsAgreementMember_1351454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember_1351503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_866840" xlink:to="loc_imtx_LicenseDevelopmentAndCommercializationAgreementMember_1351503" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneAxis" xlink:label="loc_imtx_MilestoneAxis_866842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_MilestoneAxis_866842" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneDomain" xlink:label="loc_imtx_MilestoneDomain_866843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_MilestoneAxis_866842" xlink:to="loc_imtx_MilestoneDomain_866843" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentForLicensedProductMember" xlink:label="loc_imtx_MilestonePaymentForLicensedProductMember_866882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_MilestoneDomain_866843" xlink:to="loc_imtx_MilestonePaymentForLicensedProductMember_866882" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_866845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_srt_StatementScenarioAxis_866845" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_866847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_866845" xlink:to="loc_srt_ScenarioUnspecifiedDomain_866847" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1337750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_MaturityAxis_1337750" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1337751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1337750" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1337751" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ThereafterMember" xlink:label="loc_imtx_ThereafterMember_1337753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1337751" xlink:to="loc_imtx_ThereafterMember_1337753" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351455" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsBiotechnologiesGmbhMember" xlink:label="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" xlink:to="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351457" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351456" xlink:to="loc_imtx_ImmaticsUsIncMember_1351504" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementAxis" xlink:label="loc_imtx_ImtxagreementAxis_1351451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_ImtxagreementAxis_1351451" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxagreementMember" xlink:label="loc_imtx_ImtxagreementMember_1351452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ImtxagreementAxis_1351451" xlink:to="loc_imtx_ImtxagreementMember_1351452" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImtxbMSCollaborationAgreementMember" xlink:label="loc_imtx_ImtxbMSCollaborationAgreementMember_1351453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ImtxagreementMember_1351452" xlink:to="loc_imtx_ImtxbMSCollaborationAgreementMember_1351453" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1351464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1351464" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1351465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1351464" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1351465" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401licensegrantMember" xlink:label="loc_imtx_Ima401licensegrantMember_1351466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1351465" xlink:to="loc_imtx_Ima401licensegrantMember_1351466" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Ima401clinicaltrialservicesMember" xlink:label="loc_imtx_Ima401clinicaltrialservicesMember_1351467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1351465" xlink:to="loc_imtx_Ima401clinicaltrialservicesMember_1351467" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1351505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_srt_CounterpartyNameAxis_1351505" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1351505" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BristolMyerSquibCompanyMember" xlink:label="loc_imtx_BristolMyerSquibCompanyMember_1351507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1351506" xlink:to="loc_imtx_BristolMyerSquibCompanyMember_1351507" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromContractWithCustomersLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersTable_866827" xlink:to="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestonePaymentReceivable" xlink:label="loc_imtx_MilestonePaymentReceivable_866859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_MilestonePaymentReceivable_866859" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UpfrontPaymentReceived" xlink:label="loc_imtx_UpfrontPaymentReceived_866860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_UpfrontPaymentReceived_866860" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_866862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_866862" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_866863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_ContractLiabilities_866863" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers_866865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers_866865" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers" xlink:label="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers_866867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers_866867" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PotentialMilestonePaymentPayable" xlink:label="loc_imtx_PotentialMilestonePaymentPayable_866870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_PotentialMilestonePaymentPayable_866870" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractLiabilitiesRecognized" xlink:label="loc_imtx_ContractLiabilitiesRecognized_1337733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_ContractLiabilitiesRecognized_1337733" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements_1337737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_RevenueFromCollaborationAgreements_1337737" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant" xlink:label="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant_1351459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant_1351459" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_1351460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_1351460" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices_1351461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices_1351461" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_Allocationofupfrontpaymenttowardslicensegrant" xlink:label="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant_1351462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_Allocationofupfrontpaymenttowardslicensegrant_1351462" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1351468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1351468" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived" xlink:label="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived_1351508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived_1351508" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived" xlink:label="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived_1351509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived_1351509" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived" xlink:label="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived_1351510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived_1351510" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractTransactionPrice" xlink:label="loc_imtx_ContractTransactionPrice_1351511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_ContractTransactionPrice_1351511" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueRecognizedDuringThePeriodPerformanceObligation" xlink:label="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation_1351512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems_866856" xlink:to="loc_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation_1351512" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract_866820" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_866821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_866820" xlink:to="loc_ifrs-full_CurrentContractLiabilities_866821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_866823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_866820" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_866823" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_866822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_866820" xlink:to="loc_ifrs-full_ContractLiabilities_866822" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract_866854" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract_866854" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866855" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_1351361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_1351361" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_866858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_866858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_866861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_866861" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_866866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_866866" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrent" xlink:label="loc_imtx_OtherCurrent_866869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_imtx_OtherCurrent_866869" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_866871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866857" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_866871" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866904" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866904" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_866910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_866910" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866910" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866911" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonInterestBearingLiabilityMember" xlink:label="loc_imtx_NonInterestBearingLiabilityMember_866914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_866911" xlink:to="loc_imtx_NonInterestBearingLiabilityMember_866914" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable_866907" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity_866919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems_866917" xlink:to="loc_ifrs-full_BorrowingsMaturity_866919" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_867244" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_867244" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_867247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_867246" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_867247" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_867248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_867247" xlink:to="loc_ifrs-full_OrdinarySharesMember_867248" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_867249" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_867252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_867250" xlink:to="loc_imtx_WarrantsMember_867252" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_867253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_867253" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867253" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_867255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867254" xlink:to="loc_imtx_AryaMember_867255" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_867245" xlink:to="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_867319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_867319" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_867260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_ParValuePerShare_867260" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_867276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_867276" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense_867277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_imtx_AdjustmentsForShareListingExpense_867277" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1143872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1143872" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsIssuedPricePerWarrant" xlink:label="loc_imtx_WarrantsIssuedPricePerWarrant_1143873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_imtx_WarrantsIssuedPricePerWarrant_1143873" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1143875" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_1149428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfShareListingExpenseLineItems_867256" xlink:to="loc_ifrs-full_FinancialLiabilities_1149428" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_866973" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_866973" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_866976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_866976" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866976" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_866978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866977" xlink:to="loc_imtx_AryaMember_866978" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866980" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866981" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_866982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_866981" xlink:to="loc_ifrs-full_OrdinarySharesMember_866982" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_866983" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_866985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_866984" xlink:to="loc_imtx_WarrantsMember_866985" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_866975" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_866988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_866988" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_866989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_ParValuePerShare_866989" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsIssuedPricePerWarrant" xlink:label="loc_imtx_WarrantsIssuedPricePerWarrant_866992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_WarrantsIssuedPricePerWarrant_866992" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_866993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_866993" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate" xlink:label="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate_1143876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate_1143876" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_1143877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_1143877" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_866994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_866994" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdjustmentsForShareListingExpense" xlink:label="loc_imtx_AdjustmentsForShareListingExpense_866995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems_866987" xlink:to="loc_imtx_AdjustmentsForShareListingExpense_866995" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_867305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_867305" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_867307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_ifrs-full_NetForeignExchangeGain_867307" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured_1351533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured_1351533" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_867312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_ifrs-full_FinanceIncome_867312" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_867315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_ifrs-full_InterestExpense_867315" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignCurrencyLossesNet" xlink:label="loc_imtx_ForeignCurrencyLossesNet_1351534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_imtx_ForeignCurrencyLossesNet_1351534" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured" xlink:label="loc_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured_1351535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured_1351535" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_867318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867289" xlink:to="loc_ifrs-full_FinanceCosts_867318" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867359" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RealisedGainLossFromForeignCurrencyForwardContracts" xlink:label="loc_imtx_RealisedGainLossFromForeignCurrencyForwardContracts_867360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867359" xlink:to="loc_imtx_RealisedGainLossFromForeignCurrencyForwardContracts_867360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts" xlink:label="loc_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts_867363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract_867359" xlink:to="loc_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts_867363" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_867282" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_867282" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867285" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868840" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868841" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867286" xlink:to="loc_imtx_ConvertedOptionsMember_868853" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanAxis" xlink:label="loc_imtx_PlanAxis_868615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xlink:to="loc_imtx_PlanAxis_868615" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanAxis_868615" xlink:to="loc_imtx_PlanMember_868616" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanMember_868616" xlink:to="loc_imtx_MatchingStockOptionsMember_868684" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867283" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_867295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_867295" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_867306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_867306" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_867308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_867308" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_867311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_867311" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_867313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_867313" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_867314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867292" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_867314" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_867322" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_867322" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_867325" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868808" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember" xlink:label="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember_868826" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_ConvertedOptionsMember_868843" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_867326" xlink:to="loc_imtx_MatchingStockOptionsMember_868854" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantAxis" xlink:label="loc_imtx_DateOfGrantAxis_868809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xlink:to="loc_imtx_DateOfGrantAxis_868809" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantAxis_868809" xlink:to="loc_imtx_DateOfGrantMember_868810" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnMarchTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember_1338212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnMarchTwoThousandAndTwentyOneMember_1338212" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338241" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868810" xlink:to="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868811" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_867323" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867328" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_867330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_867330" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_867331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_867331" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1338031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1338031" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1338064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1338064" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_867329" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_867334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_867334" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_867341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_867341" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_867343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_867343" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_867344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_867344" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1338049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1338049" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1338074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1338074" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_867342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_867342" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_867352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_867352" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_868812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_868812" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:label="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_867324" xlink:to="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868813" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_868358" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_868358" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanAxis" xlink:label="loc_imtx_PlanAxis_868360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_PlanAxis_868360" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanMember" xlink:label="loc_imtx_PlanMember_868362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanAxis_868360" xlink:to="loc_imtx_PlanMember_868362" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember_868366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember_868366" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndTenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndTenPlanMember_868532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfTwoThousandAndTenPlanMember_868532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ModificationOfTwoThousandAndSixteenPlanMember" xlink:label="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember_868533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanMember_868362" xlink:to="loc_imtx_ModificationOfTwoThousandAndSixteenPlanMember_868533" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesAxis" xlink:label="loc_imtx_CategoryOfEmployeesAxis_868367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_CategoryOfEmployeesAxis_868367" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CategoryOfEmployeesMember" xlink:label="loc_imtx_CategoryOfEmployeesMember_868368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_CategoryOfEmployeesAxis_868367" xlink:to="loc_imtx_CategoryOfEmployeesMember_868368" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ActiveEmployeesMember" xlink:label="loc_imtx_ActiveEmployeesMember_868369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_CategoryOfEmployeesMember_868368" xlink:to="loc_imtx_ActiveEmployeesMember_868369" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ManagementMembersMember" xlink:label="loc_imtx_ManagementMembersMember_868370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_CategoryOfEmployeesMember_868368" xlink:to="loc_imtx_ManagementMembersMember_868370" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_868371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_RangeAxis_868371" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_868372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_868371" xlink:to="loc_ifrs-full_RangesMember_868372" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_868373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_868372" xlink:to="loc_ifrs-full_BottomOfRangeMember_868373" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_868374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_868372" xlink:to="loc_ifrs-full_TopOfRangeMember_868374" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeAxis" xlink:label="loc_imtx_SchemeAxis_868375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_SchemeAxis_868375" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SchemeMember" xlink:label="loc_imtx_SchemeMember_868376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SchemeAxis_868375" xlink:to="loc_imtx_SchemeMember_868376" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentMember" xlink:label="loc_imtx_ShareReinvestmentMember_868377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SchemeMember_868376" xlink:to="loc_imtx_ShareReinvestmentMember_868377" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeAxis" xlink:label="loc_imtx_ShareReinvestmentSchemeAxis_868378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_ShareReinvestmentSchemeAxis_868378" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareReinvestmentSchemeMember" xlink:label="loc_imtx_ShareReinvestmentSchemeMember_868379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ShareReinvestmentSchemeAxis_868378" xlink:to="loc_imtx_ShareReinvestmentSchemeMember_868379" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_868380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ShareReinvestmentSchemeMember_868379" xlink:to="loc_imtx_MatchingStockOptionsMember_868380" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_868654" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_868721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" xlink:to="loc_imtx_PerformanceBasedOptionsMember_868721" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_868787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_868656" xlink:to="loc_imtx_ConvertedOptionsMember_868787" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantAxis" xlink:label="loc_imtx_DateOfGrantAxis_868724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_DateOfGrantAxis_868724" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfGrantMember" xlink:label="loc_imtx_DateOfGrantMember_868728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantAxis_868724" xlink:to="loc_imtx_DateOfGrantMember_868728" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnJuneTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnJuneTwoThousandAndTwentyMember_868730" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember_868806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyMember_868806" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember" xlink:label="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DateOfGrantMember_868728" xlink:to="loc_imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember_1338316" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheAxis" xlink:label="loc_imtx_TrancheAxis_868735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_imtx_TrancheAxis_868735" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheMember" xlink:label="loc_imtx_TrancheMember_868736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TrancheAxis_868735" xlink:to="loc_imtx_TrancheMember_868736" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheOneMember" xlink:label="loc_imtx_TrancheOneMember_868737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheOneMember_868737" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheTwoMember" xlink:label="loc_imtx_TrancheTwoMember_870914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheTwoMember_870914" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TrancheThreeMember" xlink:label="loc_imtx_TrancheThreeMember_870916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TrancheMember_868736" xlink:to="loc_imtx_TrancheThreeMember_870916" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_868780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_868780" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_868780" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_868783" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_868359" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashPaymentAwardPerSharePayable" xlink:label="loc_imtx_CashPaymentAwardPerSharePayable_868388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_CashPaymentAwardPerSharePayable_868388" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashProceedsToBeBeReinvested" xlink:label="loc_imtx_PercentageOfCashProceedsToBeBeReinvested_868389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_PercentageOfCashProceedsToBeBeReinvested_868389" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAndOnBehalfOfEmployees" xlink:label="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees_868390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_PaymentsToAndOnBehalfOfEmployees_868390" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ExpenseFromTheModificationOfShareBasedAwards" xlink:label="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards_868391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_ExpenseFromTheModificationOfShareBasedAwards_868391" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_868392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_868392" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_868397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_868397" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_868384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_868384" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_868430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_868430" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_868462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_868462" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_868467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_868467" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfVestingOfStockOptions" xlink:label="loc_imtx_DateOfVestingOfStockOptions_868483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_DateOfVestingOfStockOptions_868483" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare" xlink:label="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare_868488" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_868491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_868491" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MinimumMarketCapitalization" xlink:label="loc_imtx_MinimumMarketCapitalization_868734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_868381" xlink:to="loc_imtx_MinimumMarketCapitalization_868734" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract_868791" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract_868791" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_868794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" xlink:to="loc_imtx_IncomeStatementLocationAxis_868794" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_868795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationAxis_868794" xlink:to="loc_imtx_IncomeStatementLocationMember_868795" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_868796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_868795" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_868796" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_868805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_868795" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_868805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable_868793" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_868800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems_868798" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_868800" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866838" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866838" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_866875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_866874" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_866875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_866876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_866875" xlink:to="loc_ifrs-full_OrdinarySharesMember_866876" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_866878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_866878" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_866879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_866878" xlink:to="loc_ifrs-full_BorrowingsByNameMember_866879" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PipeFinancingMember" xlink:label="loc_imtx_PipeFinancingMember_866941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_866879" xlink:to="loc_imtx_PipeFinancingMember_866941" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866885" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866888" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseAxis" xlink:label="loc_imtx_ShareListingExpenseAxis_876472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_ShareListingExpenseAxis_876472" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareListingExpenseDomain" xlink:label="loc_imtx_ShareListingExpenseDomain_876473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ShareListingExpenseAxis_876472" xlink:to="loc_imtx_ShareListingExpenseDomain_876473" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMergerMember" xlink:label="loc_imtx_AryaMergerMember_876474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_ShareListingExpenseDomain_876473" xlink:to="loc_imtx_AryaMergerMember_876474" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventAxis" xlink:label="loc_imtx_EventAxis_876689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_EventAxis_876689" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EventDomain" xlink:label="loc_imtx_EventDomain_876690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_EventAxis_876689" xlink:to="loc_imtx_EventDomain_876690" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ReorganizationMember" xlink:label="loc_imtx_ReorganizationMember_876691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_EventDomain_876690" xlink:to="loc_imtx_ReorganizationMember_876691" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeAxis" xlink:label="loc_imtx_InvesteeAxis_1351356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_InvesteeAxis_1351356" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_InvesteeMember" xlink:label="loc_imtx_InvesteeMember_1351357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_InvesteeAxis_1351356" xlink:to="loc_imtx_InvesteeMember_1351357" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SvbSecuritiesLicMember" xlink:label="loc_imtx_SvbSecuritiesLicMember_1351358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_InvesteeMember_1351357" xlink:to="loc_imtx_SvbSecuritiesLicMember_1351358" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_1351359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_imtx_AgreementAxis_1351359" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementAxis_1351359" xlink:to="loc_imtx_AgreementDomain_1351360" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AtTheMarketAgreementMember" xlink:label="loc_imtx_AtTheMarketAgreementMember_1351365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351360" xlink:to="loc_imtx_AtTheMarketAgreementMember_1351365" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1351366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1351366" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1351367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1351366" xlink:to="loc_ifrs-full_EquityMember_1351367" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1351368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1351367" xlink:to="loc_ifrs-full_IssuedCapitalMember_1351368" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_1351369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1351367" xlink:to="loc_ifrs-full_SharePremiumMember_1351369" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsAxis" xlink:label="loc_ifrs-full_CapitalRequirementsAxis_1351370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_CapitalRequirementsAxis_1351370" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRequirementsMember" xlink:label="loc_ifrs-full_CapitalRequirementsMember_1351371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CapitalRequirementsAxis_1351370" xlink:to="loc_ifrs-full_CapitalRequirementsMember_1351371" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RegisteredDirectOfferingMember" xlink:label="loc_imtx_RegisteredDirectOfferingMember_1351372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CapitalRequirementsMember_1351371" xlink:to="loc_imtx_RegisteredDirectOfferingMember_1351372" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_866868" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867389" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_866899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_866899" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_866900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_ParValuePerShare_866900" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_866901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_IssuedCapital_866901" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_866903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_SharePremium_866903" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1351352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_NumberOfSharesIssued_1351352" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GrossProceedsFromIssueOfSecurities" xlink:label="loc_imtx_GrossProceedsFromIssueOfSecurities_1351353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_GrossProceedsFromIssueOfSecurities_1351353" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1351354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_1351354" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1351355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_ifrs-full_IssueOfEquity_1351355" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShareIssuedPricePerShare" xlink:label="loc_imtx_ShareIssuedPricePerShare_1351374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_866897" xlink:to="loc_imtx_ShareIssuedPricePerShare_1351374" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867052" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867052" xlink:to="loc_imtx_StatementsTable_867054" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867054" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_867058" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MdAndersonMember" xlink:label="loc_imtx_MdAndersonMember_867060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_867059" xlink:to="loc_imtx_MdAndersonMember_867060" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_867061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867054" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_867061" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_867061" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RestrictedStockAcquisitionAgreementMember" xlink:label="loc_imtx_RestrictedStockAcquisitionAgreementMember_867063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" xlink:to="loc_imtx_RestrictedStockAcquisitionAgreementMember_867063" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_867064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_867062" xlink:to="loc_imtx_AryaMember_867064" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867054" xlink:to="loc_imtx_StatementsLineItems_867057" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfSharesExchangedInSubsidiaries" xlink:label="loc_imtx_NumberOfSharesExchangedInSubsidiaries_867065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_NumberOfSharesExchangedInSubsidiaries_867065" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions_867066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_StockIssuedDuringPeriodSharesAcquisitions_867066" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_867067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_ifrs-full_ParValuePerShare_867067" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_867068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_867068" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_StockIssuedDuringPeriodValueNewIssues_867069" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest" xlink:label="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_867070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest_867070" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LossOnNoncontrollingInterest" xlink:label="loc_imtx_LossOnNoncontrollingInterest_867071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_LossOnNoncontrollingInterest_867071" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreasedecreaseThroughCompensationExpense" xlink:label="loc_imtx_IncreasedecreaseThroughCompensationExpense_867073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867057" xlink:to="loc_imtx_IncreasedecreaseThroughCompensationExpense_867073" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867024" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867024" xlink:to="loc_imtx_StatementsTable_867026" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationAxis" xlink:label="loc_imtx_IncomeStatementLocationAxis_867030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867026" xlink:to="loc_imtx_IncomeStatementLocationAxis_867030" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncomeStatementLocationMember" xlink:label="loc_imtx_IncomeStatementLocationMember_867031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationAxis_867030" xlink:to="loc_imtx_IncomeStatementLocationMember_867031" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_imtx_ResearchAndDevelopmentExpenseMember_867032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_867031" xlink:to="loc_imtx_ResearchAndDevelopmentExpenseMember_867032" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_imtx_GeneralAndAdministrativeExpenseMember_867033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_IncomeStatementLocationMember_867031" xlink:to="loc_imtx_GeneralAndAdministrativeExpenseMember_867033" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867026" xlink:to="loc_imtx_StatementsLineItems_867029" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_867034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_WagesAndSalaries_867034" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_OtherShorttermEmployeeBenefits_867035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_OtherShorttermEmployeeBenefits_867035" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_867036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_867036" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_867038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_867038" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_867039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867029" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_867039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867043" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_867044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867043" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_867044" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EmployeeHealthInsuranceCost" xlink:label="loc_imtx_EmployeeHealthInsuranceCost_867045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867043" xlink:to="loc_imtx_EmployeeHealthInsuranceCost_867045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-full_SocialSecurityContributions_867046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867043" xlink:to="loc_ifrs-full_SocialSecurityContributions_867046" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="loc_ifrs-full_OtherEmployeeExpense_867047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_867043" xlink:to="loc_ifrs-full_OtherEmployeeExpense_867047" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_1351545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_1351545" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_866905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_866905" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_866908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_866908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_866916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_866916" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes" xlink:label="loc_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes_866926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes_866926" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TaxEffectOfPermanentDifferences" xlink:label="loc_imtx_TaxEffectOfPermanentDifferences_876722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_imtx_TaxEffectOfPermanentDifferences_876722" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="loc_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_1351450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_1351450" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:label="loc_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_866929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_866929" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_866930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_866896" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_866930" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract_866942" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_866949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract_866942" xlink:to="loc_imtx_StatementsTable_866949" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_866949" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_866953" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IntangibleAssetsMember" xlink:label="loc_imtx_IntangibleAssetsMember_866956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_IntangibleAssetsMember_866956" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesRightOfUseAssetMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember_866986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredTaxLiabilitiesRightOfUseAssetMember_866986" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredRevenueMember" xlink:label="loc_imtx_DeferredRevenueMember_866958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredRevenueMember_866958" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_1351447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_ifrs-full_OtherAssetsMember_1351447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LeaseLiabilityMember" xlink:label="loc_imtx_LeaseLiabilityMember_866961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_LeaseLiabilityMember_866961" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredExpensesMember" xlink:label="loc_imtx_DeferredExpensesMember_866962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredExpensesMember_866962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RecognitionOfTaxLossesCarriedForwardMember" xlink:label="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember_1351550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_RecognitionOfTaxLossesCarriedForwardMember_1351550" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetRecognisedMember" xlink:label="loc_imtx_DeferredAssetRecognisedMember_866966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredAssetRecognisedMember_866966" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesDeferredExpensesMember" xlink:label="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember_866997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredTaxLiabilitiesDeferredExpensesMember_866997" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredAssetNettingMember" xlink:label="loc_imtx_DeferredAssetNettingMember_866970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredAssetNettingMember_866970" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredLiabilityNettingMember" xlink:label="loc_imtx_DeferredLiabilityNettingMember_866998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_DeferredLiabilityNettingMember_866998" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember" xlink:label="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember_1351551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_866954" xlink:to="loc_imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember_1351551" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_866949" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1351552" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1351553" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_866952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_866949" xlink:to="loc_imtx_StatementsLineItems_866952" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_867000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_ifrs-full_DeferredTaxAssets_867000" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOnTemporaryDifferences" xlink:label="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences_1351555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxAssetsOnTemporaryDifferences_1351555" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_867002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_867002" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxAssetsOffset" xlink:label="loc_imtx_DeferredTaxAssetsOffset_871078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxAssetsOffset_871078" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeferredTaxLiabilitiesOffSet" xlink:label="loc_imtx_DeferredTaxLiabilitiesOffSet_871083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_866952" xlink:to="loc_imtx_DeferredTaxLiabilitiesOffSet_871083" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/IncomeTaxAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867006" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867006" xlink:to="loc_imtx_StatementsTable_867008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_867423" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IndefiniteTaxLossesCarryforwardMember" xlink:label="loc_imtx_IndefiniteTaxLossesCarryforwardMember_867425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" xlink:to="loc_imtx_IndefiniteTaxLossesCarryforwardMember_867425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentySixYearTaxLossesCarryforwardMember" xlink:label="loc_imtx_TwentySixYearTaxLossesCarryforwardMember_867426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_867424" xlink:to="loc_imtx_TwentySixYearTaxLossesCarryforwardMember_867426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsAxis" xlink:label="loc_imtx_TypeOfAdoptionsAxis_867009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_imtx_TypeOfAdoptionsAxis_867009" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfAdoptionsMember" xlink:label="loc_imtx_TypeOfAdoptionsMember_869226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfAdoptionsAxis_867009" xlink:to="loc_imtx_TypeOfAdoptionsMember_869226" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1351443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_srt_StatementGeographicalAxis_1351443" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1351444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1351443" xlink:to="loc_srt_SegmentGeographicalDomain_1351444" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE_1351445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1351444" xlink:to="loc_country_DE_1351445" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1351438" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsBiotechnologiesGmbhMember" xlink:label="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1351439" xlink:to="loc_imtx_ImmaticsBiotechnologiesGmbhMember_1351440" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867008" xlink:to="loc_imtx_StatementsLineItems_867011" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_867012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_ApplicableTaxRate_867012" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CorporateIncomeTaxRate" xlink:label="loc_imtx_CorporateIncomeTaxRate_867013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_CorporateIncomeTaxRate_867013" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_867014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_867014" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod_867015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod_867015" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod" xlink:label="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod_867016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod_867016" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense" xlink:label="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense_876755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense_876755" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_1351437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_1351437" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward" xlink:label="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward_1351441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward_1351441" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfPretaxIncomeSubjectToIncomeTax" xlink:label="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax_1351442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax_1351442" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_1351548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_1351548" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1351549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867011" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1351549" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureAbstract" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureAbstract_867084" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureTable" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureAbstract_867084" xlink:to="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_srt_OwnershipAxis_867087" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_867087" xlink:to="loc_srt_OwnershipDomain_867088" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_867088" xlink:to="loc_imtx_ImmaticsNvMember_867089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867090" xlink:to="loc_ifrs-full_TypesOfRisksMember_867091" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_867092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_867091" xlink:to="loc_ifrs-full_CurrencyRiskMember_867092" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867093" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867094" xlink:to="loc_imtx_ImmaticsGmbhMember_867095" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCurrencyRiskExposureLineItems" xlink:label="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureTable_867085" xlink:to="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_867096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_ifrs-full_CashAndCashEquivalents_867096" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_867097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_ifrs-full_FinancialAssets_867097" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MaximumExposedToCurrencyRisk" xlink:label="loc_imtx_MaximumExposedToCurrencyRisk_867099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCurrencyRiskExposureLineItems_867086" xlink:to="loc_imtx_MaximumExposedToCurrencyRisk_867099" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_867102" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_867102" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_867105" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_867108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_867108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_867109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_867109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_867110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_867110" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_867111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_867111" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_867112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_867112" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_867113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_867106" xlink:to="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_867113" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_srt_OwnershipAxis_867114" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_867114" xlink:to="loc_srt_OwnershipDomain_867115" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_867115" xlink:to="loc_imtx_ImmaticsNvMember_867116" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867117" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" xlink:to="loc_imtx_ImmaticsGmbhMember_867119" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867118" xlink:to="loc_imtx_ImmaticsUsIncMember_1351532" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867103" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_867120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_867120" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints_867121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints_867121" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_867122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_ifrs-full_ValueAtRisk_867122" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints" xlink:label="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints_1351531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867104" xlink:to="loc_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints_1351531" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_867125" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_867125" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_867130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_srt_CurrencyAxis_867130" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_867130" xlink:to="loc_currency_AllCurrenciesDomain_867131" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_867150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_srt_OwnershipAxis_867150" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_867151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_867150" xlink:to="loc_srt_OwnershipDomain_867151" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsNvMember" xlink:label="loc_imtx_ImmaticsNvMember_867152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_867151" xlink:to="loc_imtx_ImmaticsNvMember_867152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_867153" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_867155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" xlink:to="loc_imtx_ImmaticsGmbhMember_867155" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsUsIncMember" xlink:label="loc_imtx_ImmaticsUsIncMember_1351530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_867154" xlink:to="loc_imtx_ImmaticsUsIncMember_1351530" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyAxis" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_SensitiveAnalaysisOfCurrencyDomain" xlink:label="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyAxis_870425" xlink:to="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_870428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy1AgainstUsDollarsMember_870428" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy1AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_870429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy1AgainstUsDollarsMember_870429" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_870432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy5AgainstUsDollarsMember_870432" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy5AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_870433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy5AgainstUsDollarsMember_870433" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroWeakensBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_870434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroWeakensBy10AgainstUsDollarsMember_870434" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EuroStrengthsBy10AgainstUsDollarsMember" xlink:label="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_870439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_SensitiveAnalaysisOfCurrencyDomain_870427" xlink:to="loc_imtx_EuroStrengthsBy10AgainstUsDollarsMember_870439" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems" xlink:label="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable_867127" xlink:to="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" xlink:to="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867140" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems_867128" xlink:to="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867141" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DescriptionOfManagingLiquidityRiskAbstract" xlink:label="loc_imtx_DescriptionOfManagingLiquidityRiskAbstract_867163" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DescriptionOfManagingLiquidityRiskAbstract_867163" xlink:to="loc_imtx_StatementsTable_867165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867165" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_867170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_867169" xlink:to="loc_ifrs-full_FinancialAssetsMember_867170" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashAndCashEquivalentsMember" xlink:label="loc_imtx_CashAndCashEquivalentsMember_876761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_CashAndCashEquivalentsMember_876761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsMember" xlink:label="loc_imtx_BondsMember_1337830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_BondsMember_1337830" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShorttermDepositsMember" xlink:label="loc_imtx_ShorttermDepositsMember_867172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_867170" xlink:to="loc_imtx_ShorttermDepositsMember_867172" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867165" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867173" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867173" xlink:to="loc_ifrs-full_TypesOfRisksMember_867174" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_867175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_867174" xlink:to="loc_ifrs-full_LiquidityRiskMember_867175" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867165" xlink:to="loc_imtx_StatementsLineItems_867168" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:label="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_867176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867168" xlink:to="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_867176" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_867179" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_867182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_867179" xlink:to="loc_imtx_StatementsTable_867182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_867188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_TypesOfRisksAxis_867188" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_867189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_867188" xlink:to="loc_ifrs-full_TypesOfRisksMember_867189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_867190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_867189" xlink:to="loc_ifrs-full_CreditRiskMember_867190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_867202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_867189" xlink:to="loc_ifrs-full_CurrencyRiskMember_867202" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_867192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_srt_CurrencyAxis_867192" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_867193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_867192" xlink:to="loc_currency_AllCurrenciesDomain_867193" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_867194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_867193" xlink:to="loc_currency_EUR_867194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_867195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_867193" xlink:to="loc_currency_USD_867195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_867204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_RangeAxis_867204" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_867205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_867204" xlink:to="loc_ifrs-full_RangesMember_867205" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_867207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_867205" xlink:to="loc_ifrs-full_TopOfRangeMember_867207" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_867208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_867205" xlink:to="loc_ifrs-full_BottomOfRangeMember_867208" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_1145714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_UnobservableInputsAxis_1145714" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_1145715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_1145714" xlink:to="loc_ifrs-full_UnobservableInputsMember_1145715" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_1145716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_1145715" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_1145716" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ForeignExchangeRatesMember" xlink:label="loc_imtx_ForeignExchangeRatesMember_1145722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_1145715" xlink:to="loc_imtx_ForeignExchangeRatesMember_1145722" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1145729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1145729" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1145729" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_1145736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1145730" xlink:to="loc_imtx_AryaMember_1145736" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1145740" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_WarrantsMember" xlink:label="loc_imtx_WarrantsMember_1145743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1145741" xlink:to="loc_imtx_WarrantsMember_1145743" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1351434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1351434" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351434" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351435" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DeMember" xlink:label="loc_imtx_DeMember_1351436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351435" xlink:to="loc_imtx_DeMember_1351436" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_867185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_867182" xlink:to="loc_imtx_StatementsLineItems_867185" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_867210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_867210" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_867212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_CashAndCashEquivalents_867212" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets_867214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_OtherFinancialAssets_867214" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk_867217" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk" xlink:label="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk_867218" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_867221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_867221" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_1145697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_1145697" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1145700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1145700" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145702" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_1145703" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1351430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_ifrs-full_TradeReceivables_1351430" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile" xlink:label="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile_1351432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile_1351432" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsAndShortTermDeposits" xlink:label="loc_imtx_BondsAndShortTermDeposits_1351433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_867185" xlink:to="loc_imtx_BondsAndShortTermDeposits_1351433" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_866752" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_866752" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_866755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_866754" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_866755" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_866755" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351396" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1351397" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351399" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1351398" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351400" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_866759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_866758" xlink:to="loc_ifrs-full_FinancialAssetsMember_866759" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CashAndCashEquivalentsMember" xlink:label="loc_imtx_CashAndCashEquivalentsMember_1351402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_CashAndCashEquivalentsMember_1351402" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ShorttermDepositsMember" xlink:label="loc_imtx_ShorttermDepositsMember_866762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_ShorttermDepositsMember_866762" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BondsMember" xlink:label="loc_imtx_BondsMember_1337756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_BondsMember_1337756" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember_866764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_ifrs-full_TradeReceivablesMember_866764" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentNonCurrentAssetsMember" xlink:label="loc_imtx_OtherCurrentNonCurrentAssetsMember_866765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_OtherCurrentNonCurrentAssetsMember_866765" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AccountsPayableMember" xlink:label="loc_imtx_AccountsPayableMember_866766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_AccountsPayableMember_866766" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherCurrentLiabilitiesMember" xlink:label="loc_imtx_OtherCurrentLiabilitiesMember_866767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_OtherCurrentLiabilitiesMember_866767" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesForWarrantsMember" xlink:label="loc_imtx_LiabilitiesForWarrantsMember_1351403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_imtx_LiabilitiesForWarrantsMember_1351403" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_1351404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_866759" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_1351404" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_1351405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_MeasurementAxis_1351405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1351406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_1351405" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1351406" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1351407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1351406" xlink:to="loc_ifrs-full_CarryingAmountMember_1351407" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_1351408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1351406" xlink:to="loc_ifrs-full_AtFairValueMember_1351408" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_866753" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_866769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_ifrs-full_FinancialAssets_866769" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_866770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_ifrs-full_FinancialLiabilities_866770" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FinancialAssetsAndFinancialLiabilities" xlink:label="loc_imtx_FinancialAssetsAndFinancialLiabilities_1351401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_866768" xlink:to="loc_imtx_FinancialAssetsAndFinancialLiabilities_1351401" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract_1351410" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract_1351410" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1351412" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_1351414" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1351415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1351415" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_1351416" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1351413" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1351417" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable_1351411" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NetFinancialResult" xlink:label="loc_imtx_NetFinancialResult_1351419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems_1351418" xlink:to="loc_imtx_NetFinancialResult_1351419" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract_1351421" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract_1351421" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_1351424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1351423" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_1351424" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesForWarrantsMember" xlink:label="loc_imtx_LiabilitiesForWarrantsMember_1351425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_1351424" xlink:to="loc_imtx_LiabilitiesForWarrantsMember_1351425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_1351426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_1351424" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_1351426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems" xlink:label="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable_1351422" xlink:to="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective_1351428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" xlink:to="loc_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective_1351428" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective" xlink:label="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective_1351429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems_1351427" xlink:to="loc_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective_1351429" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsAbstract" xlink:label="loc_imtx_DisclosureOfContractualObligationsAbstract_866721" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsTable" xlink:label="loc_imtx_DisclosureOfContractualObligationsTable_866732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsAbstract_866721" xlink:to="loc_imtx_DisclosureOfContractualObligationsTable_866732" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_866733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsTable_866732" xlink:to="loc_ifrs-full_MaturityAxis_866733" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_866734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_866733" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_866734" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_866735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_866735" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_866736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_866736" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_866737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_866737" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_866738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_866734" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_866738" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfContractualObligationsLineItems" xlink:label="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsTable_866732" xlink:to="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualObligationOfLeaseLiabilities" xlink:label="loc_imtx_ContractualObligationOfLeaseLiabilities_866724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractualObligationOfLeaseLiabilities_866724" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_OtherLeaseObligations" xlink:label="loc_imtx_OtherLeaseObligations_866725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_OtherLeaseObligations_866725" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractResearchOrganizationAgreements" xlink:label="loc_imtx_ContractResearchOrganizationAgreements_866728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractResearchOrganizationAgreements_866728" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ContractualCashObligation" xlink:label="loc_imtx_ContractualCashObligation_866729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfContractualObligationsLineItems_866739" xlink:to="loc_imtx_ContractualCashObligation_866729" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_876786" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsTable" xlink:label="loc_imtx_StatementsTable_876791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_876786" xlink:to="loc_imtx_StatementsTable_876791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_876793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_876791" xlink:to="loc_imtx_AgreementAxis_876793" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_876794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementAxis_876793" xlink:to="loc_imtx_AgreementDomain_876794" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementsMember" xlink:label="loc_imtx_CollaborationAgreementsMember_876795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_876794" xlink:to="loc_imtx_CollaborationAgreementsMember_876795" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_StatementsLineItems" xlink:label="loc_imtx_StatementsLineItems_876792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsTable_876791" xlink:to="loc_imtx_StatementsLineItems_876792" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_UnrecordedContingentLiability" xlink:label="loc_imtx_UnrecordedContingentLiability_876798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_StatementsLineItems_876792" xlink:to="loc_imtx_UnrecordedContingentLiability_876798" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract" xlink:label="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract_866521" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationFixed" xlink:label="loc_imtx_KeyManagementPersonnelCompensationFixed_866526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract_866521" xlink:to="loc_imtx_KeyManagementPersonnelCompensationFixed_866526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_866528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract_866521" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_866528" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_866529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract_866521" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_866529" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_866530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract_866521" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_866530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_866534" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_866534" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866563" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PeterChambreMember" xlink:label="loc_imtx_PeterChambreMember_866573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_PeterChambreMember_866573" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FriedrichVonBohlenUndHalbachMember" xlink:label="loc_imtx_FriedrichVonBohlenUndHalbachMember_1351543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_FriedrichVonBohlenUndHalbachMember_1351543" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HaraldFstockMember" xlink:label="loc_imtx_HaraldFstockMember_866574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_HaraldFstockMember_866574" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MichaelGAtiehMember" xlink:label="loc_imtx_MichaelGAtiehMember_866566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_MichaelGAtiehMember_866566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaulCarterMember" xlink:label="loc_imtx_PaulCarterMember_866567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_PaulCarterMember_866567" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HeatherLMasonMember" xlink:label="loc_imtx_HeatherLMasonMember_866568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_HeatherLMasonMember_866568" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdamStoneMember" xlink:label="loc_imtx_AdamStoneMember_866569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_AdamStoneMember_866569" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NancyValenteMember" xlink:label="loc_imtx_NancyValenteMember_1351388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_NancyValenteMember_1351388" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ChristophHettichMember" xlink:label="loc_imtx_ChristophHettichMember_866570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_ChristophHettichMember_866570" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EliotForsterMember" xlink:label="loc_imtx_EliotForsterMember_866571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866565" xlink:to="loc_imtx_EliotForsterMember_866571" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_866562" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation" xlink:label="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation_866537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation_866537" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationTravellingExpenses" xlink:label="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses_866553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationTravellingExpenses_866553" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationPaymentExitArrangement" xlink:label="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement_880588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement_880588" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense" xlink:label="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense_866555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense_866555" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_KeyManagementPersonnelCompensations" xlink:label="loc_imtx_KeyManagementPersonnelCompensations_866556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_866572" xlink:to="loc_imtx_KeyManagementPersonnelCompensations_866556" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_866635" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_866637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_866635" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_866637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_866580" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_866580" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingAxis" xlink:label="loc_imtx_TypeOfVestingAxis_866584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xlink:to="loc_imtx_TypeOfVestingAxis_866584" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingAxis_866584" xlink:to="loc_imtx_TypeOfVestingDomain_866586" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PerformanceBasedOptionsMember" xlink:label="loc_imtx_PerformanceBasedOptionsMember_866587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_PerformanceBasedOptionsMember_866587" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsMember" xlink:label="loc_imtx_ServiceOptionsMember_866588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsMember_866588" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsOneMember" xlink:label="loc_imtx_ServiceOptionsOneMember_870324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsOneMember_870324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsTwoMember" xlink:label="loc_imtx_ServiceOptionsTwoMember_1337545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsTwoMember_1337545" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsThreeMember" xlink:label="loc_imtx_ServiceOptionsThreeMember_1351389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsThreeMember_1351389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsFourMember" xlink:label="loc_imtx_ServiceOptionsFourMember_1351390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ServiceOptionsFourMember_1351390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MatchingStockOptionsMember" xlink:label="loc_imtx_MatchingStockOptionsMember_866589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_MatchingStockOptionsMember_866589" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsMember" xlink:label="loc_imtx_ConvertedOptionsMember_866591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ConvertedOptionsMember_866591" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ConvertedOptionsOneMember" xlink:label="loc_imtx_ConvertedOptionsOneMember_870321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866586" xlink:to="loc_imtx_ConvertedOptionsOneMember_870321" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866593" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HarpreetSinghMember" xlink:label="loc_imtx_HarpreetSinghMember_866595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_HarpreetSinghMember_866595" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PeterChambreMember" xlink:label="loc_imtx_PeterChambreMember_866596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_PeterChambreMember_866596" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AdamStoneMember" xlink:label="loc_imtx_AdamStoneMember_866597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_AdamStoneMember_866597" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_HeatherLMasonMember" xlink:label="loc_imtx_HeatherLMasonMember_866602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_HeatherLMasonMember_866602" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_MichaelGAtiehMember" xlink:label="loc_imtx_MichaelGAtiehMember_866604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_MichaelGAtiehMember_866604" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaulCarterMember" xlink:label="loc_imtx_PaulCarterMember_866605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_PaulCarterMember_866605" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_EliotForsterMember" xlink:label="loc_imtx_EliotForsterMember_866606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_EliotForsterMember_866606" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_FriedrichVonBohlenUndHalbachMember" xlink:label="loc_imtx_FriedrichVonBohlenUndHalbachMember_1337525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_FriedrichVonBohlenUndHalbachMember_1337525" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NancyValenteMember" xlink:label="loc_imtx_NancyValenteMember_1351391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866594" xlink:to="loc_imtx_NancyValenteMember_1351391" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866581" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfTransactionsWithRelatedParty" xlink:label="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty_866609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DescriptionOfTransactionsWithRelatedParty_866609" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement_866610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement_866610" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_866611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_866611" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_866612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_866612" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_866613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_866613" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DateOfExpiryOfShareOptionsGranted" xlink:label="loc_imtx_DateOfExpiryOfShareOptionsGranted_866805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866608" xlink:to="loc_imtx_DateOfExpiryOfShareOptionsGranted_866805" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866645" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866645" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_866655" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_866657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_866656" xlink:to="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_866657" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameAxis" xlink:label="loc_imtx_PlanNameAxis_866658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_imtx_PlanNameAxis_866658" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PlanNameDomain" xlink:label="loc_imtx_PlanNameDomain_866659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanNameAxis_866658" xlink:to="loc_imtx_PlanNameDomain_866659" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TwentyTwentyIncentivePlanMember" xlink:label="loc_imtx_TwentyTwentyIncentivePlanMember_866662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_PlanNameDomain_866659" xlink:to="loc_imtx_TwentyTwentyIncentivePlanMember_866662" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingAxis" xlink:label="loc_imtx_TypeOfVestingAxis_866666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_imtx_TypeOfVestingAxis_866666" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TypeOfVestingDomain" xlink:label="loc_imtx_TypeOfVestingDomain_866667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingAxis_866666" xlink:to="loc_imtx_TypeOfVestingDomain_866667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ServiceOptionsMember" xlink:label="loc_imtx_ServiceOptionsMember_866668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TypeOfVestingDomain_866667" xlink:to="loc_imtx_ServiceOptionsMember_866668" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_866671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_866671" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_866671" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AryaMember" xlink:label="loc_imtx_AryaMember_866674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_866673" xlink:to="loc_imtx_AryaMember_866674" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_866675" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_ImmaticsGmbhMember" xlink:label="loc_imtx_ImmaticsGmbhMember_866678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_866677" xlink:to="loc_imtx_ImmaticsGmbhMember_866678" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1351314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_srt_OwnershipAxis_1351314" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1351316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1351314" xlink:to="loc_srt_OwnershipDomain_1351316" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DirectorsAndExecutiveOfficersMember" xlink:label="loc_imtx_DirectorsAndExecutiveOfficersMember_1351319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1351316" xlink:to="loc_imtx_DirectorsAndExecutiveOfficersMember_1351319" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_866654" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule" xlink:label="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule_866684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule_866684" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_866686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_866686" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_PaymentOfPayrollTaxOfTheEmployees" xlink:label="loc_imtx_PaymentOfPayrollTaxOfTheEmployees_866692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_PaymentOfPayrollTaxOfTheEmployees_866692" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfConvertedStockOptionsInTheEntity" xlink:label="loc_imtx_NumberOfConvertedStockOptionsInTheEntity_866698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_NumberOfConvertedStockOptionsInTheEntity_866698" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_NumberOfMatchingStockOptionInTheEntity" xlink:label="loc_imtx_NumberOfMatchingStockOptionInTheEntity_866701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_imtx_NumberOfMatchingStockOptionInTheEntity_866701" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1351310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1351310" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_1351392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_866680" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_1351392" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_TextBlockAbstract" xlink:label="loc_imtx_TextBlockAbstract_866466" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants" xlink:label="loc_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants_876461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_TextBlockAbstract_866466" xlink:to="loc_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants_876461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_1351376" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1351377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351376" xlink:to="loc_ifrs-full_ProfitLoss_1351377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_1351378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351376" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_1351378" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_1351379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351376" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_1351379" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_1351380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1351376" xlink:to="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_1351380" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1351381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_1351380" xlink:to="loc_ifrs-full_WeightedAverageShares_1351381" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_1351382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_1351380" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_1351382" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail">
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract_1351514" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsTable" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract_1351514" xlink:to="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1351517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1351517" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1351518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1351517" xlink:to="loc_ifrs-full_GeographicalAreasMember_1351518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="loc_country_DK_1351519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_DK_1351519" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1351520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_US_1351520" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1351521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1351518" xlink:to="loc_country_GB_1351521" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementAxis" xlink:label="loc_imtx_AgreementAxis_1351523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xlink:to="loc_imtx_AgreementAxis_1351523" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AgreementDomain" xlink:label="loc_imtx_AgreementDomain_1351524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementAxis_1351523" xlink:to="loc_imtx_AgreementDomain_1351524" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_AmgenCollaborationAgreementMember" xlink:label="loc_imtx_AmgenCollaborationAgreementMember_1351525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_AmgenCollaborationAgreementMember_1351525" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GenmabCollaborationAgreementMember" xlink:label="loc_imtx_GenmabCollaborationAgreementMember_1351526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_GenmabCollaborationAgreementMember_1351526" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_BMSCollaborationAgreementMember" xlink:label="loc_imtx_BMSCollaborationAgreementMember_1351527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_BMSCollaborationAgreementMember_1351527" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_GSKCollaborationAgreementMember" xlink:label="loc_imtx_GSKCollaborationAgreementMember_1351528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_GSKCollaborationAgreementMember_1351528" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_CollaborationAgreementsMember" xlink:label="loc_imtx_CollaborationAgreementsMember_1351529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_AgreementDomain_1351524" xlink:to="loc_imtx_CollaborationAgreementsMember_1351529" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems" xlink:label="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsTable_1351515" xlink:to="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imtx-20221231.xsd#imtx_RevenueFromCollaborationAgreements" xlink:label="loc_imtx_RevenueFromCollaborationAgreements_1351522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems_1351516" xlink:to="loc_imtx_RevenueFromCollaborationAgreements_1351522" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g400206g02d03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g02d03.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MES\J]5<*$PB81,(F$3")A$PB81,(F$3")A%4KSOK6&W'X@7]5=A16W9I"I]
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M1.Q7K"R8)&89:<RCOFY4EBSZ[H+;C+R[G,X*S=M3HZR5T)"M65%<\P@KQ"N
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MI\!75914;,CG#VL0$":RV1M'<F UDL^B84DVX41>(DVC@# W!PZ3^$"#C?N
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M]E,#MOW38MP%XK;LQB%Y. -K0EBK/U W$36AH( 3Y&MGIM@25X2Y2(79Z-^
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ML=1/[W/_ &FEP ^0C)ZPO6#P6O6?^2OC9#[IL9M730S,C<\V)3J\CT2C+J'
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M;> ^FQGEGR[Z<,FK!THMSIBZ>(_![X()<\;VKI3WN%/>XUKW=]9/3FH*74M
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MZ=]D-=F63D'Y8[DZ*GJ98>3/6L5%1U3XXX*^Z5FGZ^BM-M>^66",=LKG44E
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MG:W+?:GP>5N^U-<:[ZWUOGSLG-B'G'\R'F41;;N;$A:&&01YV=LM :7XVBT
M9P %\^9BYTU'-1\^8Q"9MAO.F(.+Q$9,;9C#W.>&;6R'$N R25VLX+Z)A$PB
M81,(F$3")A%T%Q0QR08%G(U@X*"TGJ PDNS;JD!R)+3?1%%@\43Z<,TG^FC3
M3U-NHGPZTU;Z7TII%/W?JV>=D4L#)I603NC=-"V1[8IG0[?,NEC!#)'1<Y)S
M9>TF/;?LD;3L_%]/3R30U#X(7U%.V5D$[XF.F@9/L"=L,I:7Q-F$<?.M8YHD
MYMFV#L-QW\^2^R81,(F$3")A$PB81,(F$4(V+^N=2G\92W_5PO+59?:'5/\
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MW\1(:CZZU\-)KSOGA;W-)_-.>5'2G&NU-<\?!Q_>C\%IW8_?'@7'OGHWG W
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M9,G-EB$R=H.H>%X=$+F]UC@=K#<8&2=Q[V!@XW;P .)4&1/V6/G\)B,E<Z2
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M->C_ )MO.)Z3@Y@\E9;4+P=@KJ*.)B0AXZ"HSQD71A.SCG;ZNVC2*HAMR1Q
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M35TS<.W#0*"9N^G3D>[(,'J'?W]8X]&X9X="P<R\^9?U+(^G#H(QU QY:>2
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M<*.&35I81F$#U=H%B@Y8ASTY[V?7P*2XQ5/C!80%>9Q2KJ7E,>L)5F:=R =
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1$3")A$PB81,(F$3")A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g400206g07k29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g07k29.jpg
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M,S1"<H&AL=/P)%6#H[(&%F*BL^$U0T1DP<-C<_&")?_:  P# 0 "$0,1 #\
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M&DA0./>_Y]RBUG#:;%'5./U^5^#@['CG/B;GQ,-+_P 3S'?S[^_$8UMWC_\
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M%T4.R=8R^M5)(#LO%U!200&(HD'<D'%CTMT?^6&; 5V**_5LV5+  E W5Z+
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M6C*.IP,S,%#: 1I4;@V#IA8LQ)"Z1Q&L=G9"=0WH<O$7*AZ.ICS&DC5,JHH
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MX,.ODT-;R8N=()6EUZE"U5 $6"2P*L S$%:&Y"$WY@K?.>%8M&EBVH&R0P!
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MOU=;<%T,R8^P; JFQTD=7!=YU:(YNGMZ@ IDR3KQ'DF<+JU(PTZ@QV(!5%<
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M[,Q6\63*# --9U#V8-3=ER& 2R6$EKJTLO;1:93OJ9!8LBQ35?(,#08#>AB
M?3J5_DY'M6&VA7-$C4 ;2]/,J190GLU[JWOD$VO-0E*;3UM56C8%?KNPE:)W
M9Z4-$)JFPT.I[ CMIKN!L0KX=CK;>O6Y4R&64Z5G ;+PPC1B%.8*I,'H:2"P
M# $KYA56N[JZ;S>=@]P)Q=\N4#,9%*J2I(#;N&9=(! -$J3J.U$;6:Q\K_?0
M ],HL'.E=F#B7&MUJ^G'"#COA*CK>ZV=E4*O=[.T1QGUI$KR8(;&^LOK#844
M=6I":9\820UEXK499P=/8;M!6\=*L=(9B+ %@DV=E!)W[.#98KK^40E69*NM
M3H S*H:F)W"K2G4Y Y=K&*'\(13(:^3:[!K>](*N@;W=3<K(0 Q]!I)ZOK37
M6UJ\"$4:E6$F.]DU79J3F@KG@55"M#)195U>;N"<:GA;PS"U95@HU6Q!H4BN
M-ZYL&&FZ!((!.UCE7L*&4DA2H!!)U.\9) )V1D;406T@J6 MM.*M_?198:XK
MQ0Z2NE7MQK)*2PQV(+Q6TZZF%[#TG39;*E'L_JF\N<!\FY@5<'HI:*.&YKUL
MBA*;9 5@>YP9S0I&!)'G"AI+1K8L@G\H!MM:MSH:I&7%L3(I4 UH()+!)6"F
MM07\D3N;(9>5MH]'>NC'+ATPPZ88=,,.F&'3##IAATPQ1O<IL&XZGT;LG9=&
M#K1SZB5=K:\1K9@TF43@H1)F9X_(J<D PDLP<;($3CADOA%F*Q832E8!\K3J
M2,RH[+5JI;>ZI19Y>(&WUXTA17D1&) 9@O9J[)H<[&W/D;JMKL7EU?&>'3##
MIABGM\V78=/U9:;+JP 9O=DX4ARA)-3Y[W,ZS'CDES6 UH?8FK9#"Y^,>,N9
MO7$/S(6,HO$1E)#@%-1RP1BHM@+ TZK^J@R\_M^_EB\85G4.:4FB=6FOK)TO
M_I^[&K6V^[BX5[7FN[SKO#7+/%SVK[3[K[!PP&L;Y=8TFJ$ND76>MJ7)"VIC
M-&YV"-N4:2LW"P+&\B>)<#R;KMQ(YYB79/,0JLNDW$\QV)L($.D;J06UBB0:
MK=3>VR0!G96U#Y9(!N 07,@UMLP(3AG4H(N_/%;^@W71CFQ8VOO]]K_-"_[E
M=>/TM_Z?_%_^O'K]$\Y_LC_B^.EL?]LJ_P"@)_O(NM^AOR<_ZZ?Z3B.E?/A_
M5?\ BN-+-E]QJ'7-UXUQC5+/:[PQ7Z]GJJ-%DC']9VFQK%=T:Y4.>[;JP5W"
M,+7UFM5F/930#!UE:1,MX;M^!TQ/IO,$?AZ69B%*@5VBY8 62 *T,230 &UG
M;'GI"777J"J->HFSI"!"30!)LNJ@#?4=Z%G$#F[D]>:EL/.K#M8V2B'AZGN.
M[&JX&"H2(E]AF(NMW8Z^Y9([ 6N8[-NH-5V;L>*,22<0Q2A</7S0 UD)"77C
M*A*%"A"-(1V2 >TQ2P:+L S_ %@$D@XL(7D <.&!D6('M75*H>B ="ZD3?<$
M@ '$(C\(5K$Q'57"^G7#'.QA:QS906%A2:B#0WNQF6_:_/4=@V6PVD*LU=_5
M[AVZV_7AN93:1(ZV'8:'6ZXY9X6;!D+7K24I"MOINRJA2QD&EF)"J0T;+N:+
M%0";Q;JKV0678O5!F+!!$=2@*6(99584-04,6 TUC:C5VQ)=A2;&\J-%YI3-
MEOZ*K-1MI6/I0-$ FR+*:!$BAFHV@3XMW7R "8<H#\$<5C3DF(7BHJ79'UZ^
M79<J*-V !N1W&R17?5C8C&#IHT<[9 Q!%59-51((*@&^Z])H@XM7K3%,.F&'
M3##IAC#LZ^C<F5]BV4KV1U4;S6"LEFBPDD(7A")U6)FRF67#+,%A+7;(_29E
MC\X39*W+(+G/W R?#."H)!(LJ25/@2""1^PD?83B02 0"0&%,!WBPU'Q%@'[
M0#W8S'4XC#IAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3##H?=_'_YPPZ88
M@VS;^GU7KZX[&?#,3E-,K[)^4N3QBS.&O((^<@ZA1$<6 #(U;%>XK5N!QX /
M)I4'!AP8WNI,578(K.02%%T.9^H?6>6+(I=U04"S 6;H6>9JS0YF@37(8Q&J
M=FQ;.3ORIJXVJ#^H7!Y1+;5W)*HXM/84? A//$+)(:P5,EK5.S3OE)HQ/$N:
MUL+&P$7-(C5PD(^L'8J58JP-&B*/,$@@@@@_7O1VQ+IH(%A@RAE86+!ON(!!
M!!!!',;6*)M#J^*8=,,0C9=^3:KUY=]E6&!@4DHE6>6MF$HA'(;GBHUQ#"1>
MI'+*"%G:,/<. UT)1H8TIL\&!!8T.6<V%7<1HSGDJEC7,T+H?6>0^O%D4NZH
M*MF"B^5DUOSV\:!^S%,8]S G%3.83:[M4.P0-O!:+DU?DRJV37/8;(-8^"BC
MLD;K*K95[.E-P[Y,Y])><P5SS@?T5)9H>*])GQAI)T-K$G"T;7K(##M7IK20
MUWRVY[8TX)U :UT&,RZZ:M )'*M5Z@5JN=&].^+AU=L)3M?7=.V.D"9K%MP1
M!.HE+J,2)RFF(P\DU*WP7EL%_#1.=@2L8<KF#!=F6+-F >:'E"5+HCB1%< @
M,+HU8\0:)%@[&B<9NAC=D-$J2+'(^!%T:(W%@&CN <732/W1A?T9?^%FZX>E
M/S.3]:/_ %C'7T?^=Q_8_P#H;%Z=?+X^CQ1MG_X\R_IL/[F+KZ;)?FL/ZI_U
M-CYG._G4WZP_TKC2GC879\KOMVXQ4T%=L(BTH$UQ;>]08"YM=G@V?0J6NSCL
MV5/AXV!)5-K6S7*YTW3LWXM"LK:M&6$U%-D&3CKJA#'90Q(!.BBQU*HWT]K2
M[*"03I)%UBA6<HN[% I*C785=#,>SJ[&J-7(! UJ&"@[XM(G4/;S,A?)C-7Z
M9EK#*V^G[0J)I5(S0GWO+/@?TV^!E6<KRK;E(9Q#Z2812..<RN(_=O'/QCE8
MI'1!1*)L@JM%CWD5N=^9WWQ022@@AY P72"&:PG<!O87;D-ML=J /2M?W#A$
M#7:.KW;>:D^<D.5E47071[4::11DS?EW:P5?!F02^1]1@Q5SEKA(9!@%RK%*
M&2$9 *0/R42,I-T-152H-M7($J*)^SEM%R&.M3&-& TECI5F#D4MU9 <V!XV
M=]^11K#1B2&1<BUYJ=1 8W/EE 45*G@0E/N<(!V<D@H:^+"=OS&.+"?GEAD;
MSA!!&1SY,<>.,A$ H(H%DD!0!?(G8<^XX@NY-EG) &Y8D@<QS/*]QCAXUCH2
M5A&^QU[J&1JY7.18G/%3IF;!JI+S9F6$>-CPOY).7%2.G)3F'&:4:;-LSG.Q
MRR/*RE:4N]*60=Z%D&[WKD=1OQLWSQ.N2JUO0(-:FH$4 :N@10 \*%<ACCK1
M>C;1#$_JX-"9KF@M=M8%I!KZSA$_'M15D?5YVCM/*Z--8Y6!]JM;7 E.R8$#
ML;8X)*Y',LI&1X:#1 !!I@P&QNR"#5&]1.QYL?'<W$&S%A5J5)-C2%!!4FQ0
M511 V4#]';!D:C[?;=K\C4D6OZ>IUW)>T[(O7X%2&I*%Q:=;7=5;A>9*SPK3
MB/UDEBH@<YF6 !R2UI5I$6<K1'-+S)&B,KHT*$U Z=.D$JP/*A8M;Y41X@XG
MB2J^O6Q?2:;5J8!U(\ZR0:8]X*D]QQ+LZSJ*M5_ L2ETZ%#6HPE HU;I0#3!
M1$H#8U %6M45Q0:3#@F5OW->B! #\E2H:N .8AEQ3"/*:4#910V%+=4"*  [
M@2*'($C%=3DUJ-L23J:K)(8DDD#<@$DG<@'G6(HST/VX,*I-5>=9ZH4U]6JM
M%5!Q0UFJ5^2H#;&6YJ;,+6SU(0<]1/M 3;B,R9/,N,8Y&029Y39R19<P8XR-
M.A0*910 TZQ357FE@=ZJ\6$LH;5K<DE6)+$ZBAM2P)(8*1M=@5B1U[6>DJFH
M JM<HVLDBA?DP0!)EU=JX8T1#DA4Y=+<0QPX\,C79U;2N7(_,?)#4Y&M9GX$
M$+1IX9"(!050-Q0 [Z)'[:!/C0)Q!=V-EF)-&R2>5@'GW60/"R!SQ^0]7Z)#
M\O)?KO4HOG%U"?R9!U&G0>[;%4%'EKG6?,"_'W2ZJS&#0D)CEY3T(HT^:":*
M4DC+.-"#]%!; ^:/.!-'EYP)-'F#>!>3O=_-T[LWF&AIY^:: KD:&(FYIW:]
MJ"HG[#,U]IVGU;4XESM>;M+K^KX95#D&O^5=S48M?23,H'4U=K<8C8-"+F[:
MAIQ5F0Q?FHPV,%8T&K2H"!FL*.S0[1%"[H4:W-5BP::1M.MV,FE2"Y[6_9!L
MU0+;7L";VO%HH-:ZYJJ"*JU>@4JMU>!L$_AK:"JHDZ"%ZL8 -ESJ).N '71M
ME[56L9A,<!^#!&"X V":,D,>2.P50*"J!=T  +N[H"KL WXXH7=CJ9F+4198
MDT0019-T02".\$^..D;J/5#(=.&QUCKT\2O%U]@@%-I=;*'1GU,'-7534\$Z
MV2)8765DLBZODA8P3)@9,Q%V8P^>4?(HAJU4U1%J-BO(C;:N[P[L [@DAV!8
M$,0QLAMV!WW#$ F^??CG,U;K)B15BV&N:(<51HI(*4294*^413X9O-_=H:M-
M.OSDK\4OF@OND:G(3#/S8?RN.?<8_)DJI()525\TD"U^SPY#EX8!W&JF8:O.
MIB-7/SM]^9YWS/CC$*-&Z4K^:21#I_5J22LE,SJWFHU_4UN=?-= AK'!B3(-
M1#DI*;+5R]>S( Y'F/!!#$*SE'%@CP@(@JD4:;(I0*) !(VVL  US &),DAN
MY'.H -;,=0!) -G< DD7R))'/'$-H;1H8M?!$TSJ@4*ILRW55#&UW4(!:TX8
M>8^?MJ^/$GQB3,S?1:WSL]=@,43Z.!]VES\T']SCAH* 1 %-@:1L3S(VV)\1
MAQ9#=R/VA3=MNT-]CON-SL?$XM?J^*8=,,.F&'3##IAATPPZ88=,,5'O$_2B
MO73@_N!$HYVLAI0Y6XNP42^S5V4C";C(+*1&Q7M(CR89.,B(L80")QXXIR_%
M'"/--'1R@4F33H'/4+'U;4;^[%XQ(7 BU:]ZT$@_7N"*V^O%HKUX"D )4J"$
M6+%@@R]:M7C0A@+P X<!@P@@QL(QQ!!!XXX!AH(XX8(8\(HL,,,,<>+@ "@*
M V '(#PQ0DDDDV3N2>9/B<=OIAATPQ4VZLM314,\G=5467*B!$CFFI6NN&&U
M1_.!<)IHV'%/55RUL">5H^)1DY\":;!4#$6<5.*'"1/A5]&DEU#*-R"I?]ND
M DU]FW/EB\?$U@1L58[ APG/NU$J-^57N: LXKS8-C[4:Z'1[+?56L2@K,Q"
MV=3'DE"#M<,<R%)4DD&W>3U5><<5M+5:YG0TYNV&TJI#4TTE06L;*L"D2095
M8Q#26TD$AU.D-R  >P#0 TCB&@HT@L-L643'4JE[4%&&K3L2Q,8!(U%CJ(C%
MECJ(4F\;.=:8RQ8VOO\ ?:_S0O\ N5UX_2W_ *?_ !?_ *\>OT3SG^R/^+XZ
MNPV55!)68V)J4NED@(R%Q'"F+XECXDCXDRRYBCSXPYQR\GCCCGGCG+CGGGCC
M];K3HF+/2)-U2".90R:R\BH5)!H"V%V >7+#I2;)1O$,W-)$2K%-"%P18U72
MM5&O#GC23:E>[-+A?P [SM+.O[9LRNFQ4V(*UD5+8$?O=62RV2K.Z,OA,%:Y
MFKG%BL<!Y 01@3M28QK5@%9H26"LCT),KTF9 'RV665@NA>MQJYT,64HO$LD
M$FR 01:FQ8QQ1YOHT(63,9EHE+:SU5VC'$"JP=N'0L*M D$$ K1HXAH7;;V&
M[-78["$;2;':VXH>R!;OC8FVR\-19-=X:I(A1[2BR-;8U1S1O2:9C7T[2*LE
M^GK&3&NB*<&RYU7(=)2KQ%R>7DXE,)1FHV)&C1V7#GLE;! -&SWG$MTAT=&Q
MC;-9B,IV3$V690I#\3>,QBF#;@D:A0%[#'V[=N?9$G5[7L%@NMIURBVVFHM2
MV^T'N-CIZ*V5NMH'6MT=:>S$&0*P@7ZJZ')6/F'HU@V<L1&HYD5GY@99'R'2
M:K(SY2"-7"K(3FT16 &@!B9 !>JMJ))!':HX)TAT<Q15S4\C(7:,=5+LI)#L
MR@1$D@KJWL  @C38QN".XU8(/ *-8F,(XT,0X\."4OC"*&'#&.*/#CW#GQ8X
M1XXXX\?\N...NGJW30_]%!^(3X\<_6NAS_ZJ?V+?!C&6#8>DJFI)?6G8<5;1
MAYB1&.7T'"A4+(>:.N!C)8,,1Q(,S6!8H(N,LV.1!A(XT7&<TT>&56@Z812S
MY3+*HJV;,QJHL@"R9 !9( \20,2N8Z)<A4S.99C=*L#L30)- 1D[ $GP )Y8
M^"[$TD<]<5<+8<1=EKP*9F^KPT'$[M(ML6;6.OGME46.9RX)Y(C=8*"BX(86
M6:AGB'G-R"3Q%(@Z8+%1E,L64 LHS,990UZ21Q+ ;2U$C>C7(X',=$A0YS.9
M"L6"L8'TL5HL >'1*AEU &QJ%\QC->L&LOC,S^9B_P GZGJW37T.#\0GQXCK
M70_TJ?V+?!C#-=AZ21%U\!WL.).=;76=<JP;2#@ JRV'!*YLF:)".5C%*W<8
M5ZNV![DM7X$&8IT;=ES#P&N,FAJ8.F%*ALIEE+MI0',Q@NVEGTJ#)NVE&:A9
MTJQY XD9CHE@Q7,YDA%U.1 Y"*65 S$1TJEV5;-#4RKS(!RDUGU8-'S,1;3A
MXL<L,<I9E1$4?&4LF,4>/.<D../&4DN>$>''//CSDSQPQXYRRXXYL<OTR.>3
M@'VYA/CQ'6NA_I4_L6^#&,2[!TI9(#"J[L*)\,N<.*\P(2P8M( ']>8D)WZ,
MR8'B>,5PC;!EJW"R?+ U8Q%(!-@@)@EBQA8.F&!*Y3+, S*2N9C(#*2K*:D-
M,K JPY@@@T1B6S'1*D!LSF5)56 :!P2K ,K"XQ:LI#*>1!!%@XS'K!K+XS,_
MF8O\GZGJW37T.#\0GQXCK70_TJ?V+?!CBDM&JXI((I;:=%*5)E$-'(J(PD(E
MPAD(SB@PRAXRFDP@AFGRPCXRRQABDDYXXPCRRX=6Z:^AP;\O[0GQX=:Z'^E3
M[<_D7^#'+ZP:R^,S/YF+_)^G5NFOH<'XA/CPZUT/]*G]BWP8_.=CUA'AG)):
M6,<<>.6>>>:@K'###'CG++//+*#C'''''CGG++GGCCCCCGGGGCCCIU;IKZ'!
M^(3X\.M=#_2I_8M\&(G3]P]NVP@LV5!VXENZZ,5$;(=42@K('&':*ZJM]9+D
M)3R&0QC6*IO4EG1S9YXQMJ\X5N@,B%K 0F:B1=+2"X\ME9!2FTS43BG574VL
MA%,C*Z^*LK"P0<7>;HN,U)/FHS;"GRTB&T9D84T8-JZLC>#*RFB",2[U@UE\
M9F?S,7^3]7ZMTU]#@_$)\>*=:Z'^E3^Q;X,89?L/23=D_3*MAQ,W%4-#76A4
MO@X,95Q@Q5 O5X+X$?B0E08<D9KG 8Q\0\Q2L\,^##,4F&7.H@Z88LJY3+%D
M(#@9F,E25# ,!)8)5@P!Y@@\CB3F.B0%)S&9 <%D)R[@, Q4E28Z8!E921=,
M"#N,9GU@UE\9F?S,7^3]6ZMTU]#@_$)\>(ZUT/\ 2I_8M\&'K!K+XS,_F8O\
MGZ=6Z:^AP?B$^/#K70_TJ?V+?!AZP:R^,S/YF+_)^G5NFOH<'XA/CPZUT/\
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M$,O5JPEZ=2$"J7A!P%RG3*"ADX39)).80DD\R3K_ .P%    8/G>B'-G-3;
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MN6_/QQI$XCD1RI8(P:@VFR-QN5;:^>WW<\6TOP/C "C:DB&,XQ!L&1B\*98
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MH2P +W4;1$E=RCA Q)U#MDI8:M(!HH:L[+.JEF$9!,J3 !]EDC:0H**$E )
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M.YL%D<-5+A%=4C5#6QC>'R-JQ+KRN!++:6EVP!(CD TDJ+W-H19)!# @78W
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MAATPPZ88=,,.F&-9N\-Y;:WVY;1>4%UL!+>%M;.+J&>LZN5<+4RLD \LJ9)
ME JEP82!-3\(!3YUZT0R$?/+F)NL\K*?K.4L(W*E@P4E=*ZB36PK2W,[';]H
MYXU@"F5 X0H6 ;6VE0.\WJ46!N+-7W'EC8Y><.S "9"><<"L!!CAN"PRUY7
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M?$DMF*"@ 0H&H]HT0H)4*4 ))WU [B\0^CA14B"1BQ9E+DZ!V%U N5#,P=B
MHVTD4#6-H.M<8X=,,:$^$$VAMW6&LJB=IJREU.QM+/9X3FV$%6A#E"6:GV(Y
M4J^7=SJMS10O3+D%5IZC4<DL!NT;&$#KG"QU);8VME5X3LZJ"AHV=Z'((QK=
M6%ZM.D4"QI00"2.G+(CNPD&I0%V[5V9$!-*RF@I;4UD(.UI8@*91KG=^?.]]
MW5>U;'+<UY93^WQO6*J?7DRUA3K3?WEUJMAJHX*%1C893<F,FL^'@-F:6 U
MYLD/.1:A.Q$"'LK_ "C@M8TQD @ JS%@5V /S+NR">Z\5:/Y*-@M,6E#-9(8
M(%8'<Z>6NM(%A>\@DPGP?>V-P[5I5V-W%8F5H; FT4M6Q)75> 0:%]0$C!TI
M*FJM7J0U;N@-FP<2WO3S02QN=,MRX:G/L*\@9K6V-,N[NK%S9&FC0[U!(.D
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M8!PS.:"&,@\V5JTC4VD+PUC%4U&U![0WIC]N+-F)=@:5UU!B4766XK2F[4$
M.1V.0*\A9&+BF[4]+2VOURX1O!VQ%I7W)S '<K8&FL[]%LYON:JDVE(,XB6/
M8:;M!^YN-4$.&D%3L61@\,62TB4'._"2]5$&PQIF )#EQ8NC3DL!R!)VK;%.
M-)6FQ6G2+520"@C(!JQ: *:.]7SWQ3%8[%>W76VO-=K+FT?.'.NZ[KFDC[2M
M6P+*N<3C5NO8:]1UL,MG8RQD-3<DO&&*B@!$Y)P;!8\"$<6#Z)4>/001JJZB
M25"C46(.PT@ D[ D[*#5FQOOB[9B5F<K0#%V**BUN=9) 460 +<BZ7<U>+H;
M]J&CGO,7I2JFD<1-[H\QXPL]F$Y]([!VD?N6U3<2!MAYL.&&P&9K>'&*3#A?
M!+PL7^;+XH1H]#&AYCO)YGFS:SW][;_5R&VV,Q-(.35LHY*=E3AKS!Y)M]?,
M[[XEVE]&:YT!66-1UDJ,4IFSK"PL8CF[)S.0VCKM>JD9'$[(@C(>*-%5D8,0
M8G X4.(?&<(\><LN69$6,$**!-\R=Z [_J VY8B21Y6#.;(%#8#:RU; =[$V
M=]^>+>ZOBF'3##IAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ8
M8U[[AJQI:R*:)GNR_<:_6)-A)G%*/EVF3JZ _840;(>N"8$1NTPMD;"Y$$M:
M\F+X8R!O  ;"J$A=)5YX><@0A>(VD!P5.O1V]PHNQ9WL#?< @6 1I$9 6X:Z
MB4(8: _8VU&J-#Q(K8D$T<?G4]1TO5]C[CSUW?I;%?7EDQL>W*Q/M4R\,$%A
M=111+R'-9.>-"ZGGZ)4B)*Z(0,".OK28! D@&3*A0QY4(&?2UL3;C66HD5N"
M3IL"@-M@ -A6#F0K'J6E"TAT!00.=-0U;DD[FV8D[F\;#=7QGATPQ0G<-3-*
M6NH+C-YV4:E5BN-R9PK81L8W5?"\NS5U[1F:S.V@O*])@+9:S:'B E;*P\DC
MSZ(T+"!VM4,0*2!"+<T >98I5@KS!',$BK[[&X!&D32!JC!9F%:0@<FB&!"D
M-N"H-@=W@2#"J'I[MH6;&L0^M[$-#?*CGP6QI=2VTXDGUF%<+A4MEV$ .CJ[
M-GC1T.U+32JT\NBKT8"KO,(I IXY:QLU&.JJ1ACI/:'-0Y[&HAC2@]D.5!(H
M!N\$$W9I)BHUCLMR9D';TJR EBO;**Q"FR4VJB!5N:FXU0"GL-?U-8:X^!47
MF[&V[%%:A;86NV!;;2WN-U@LA<+%D4"^)LCUF:4K8203+L9XP1Q! 1A1H;J4
MHA"" S71NF)+->YHV2:[KY5BCZ[!<$$JNDE=-H%"J1L 1I  (YU=DXONG?N@
M#_F%?X6;KDZ0_-)/M3_6N.GH_P#.X?\ $_Z3XNGKYS'TF*-L_P#QYE_38?W,
M77TV2_-8?U3_ *FQ\SG?SJ;]8?Z5QY36CM<WI"WL5QK^TK'7YH]I]T6PZPK$
MCJ;!)19;]K^[KM>W-*&@HV&R+ [YL;%3*]JIUK?@%@F- !TF7$@L,$F)[+!R
M.U*P&Q"ZE8*PI=1()%C41N=CB1-'04H".'"C'M MH9-2FWT 4#I8*"#1)&($
MJ1=]EWM:4]<;?*';'NE]3;1C8V>U$X:BU#>=F["[I;5L;4UBJ$@$(VT&M)IA
MNHM5!8QJ'!-:QK59N!HM7)88&6*M3L01J5BB-;'L(S-*60K^F54HO(U2G;OO
M>652#H90[H0J_*2*BP*DBM?8#,))#N-6IE[0\V0I]$=W&6Q-77_%D^6UFFN+
M&.XIMSVM';]E&4:RX]J^=PK86R_=6_F,-DN^M=D[ 7!<&FP$UL<;7_)FM@;_
M !#:SD1RZD:R ";#-J;2>%:AK-6RLPWY=GLZNS4R0Z9%H%F"TRIH0,.. VC;
MDCHOU-;]LK;XU7IGO7+CGM-F"7E6!0[M[*MUZ;9]J,G207#6%1K%J#K%I)V6
M=;) Y;4#:65/AAV%K.(T>97/@)I3TP:!5Y"3;DU=L0-3&M2*#1+DUJU%1J7N
M\R]I,D [*DT0@8A%W*R,P+#0%\TJ&.AZW_*4-7YAT_X061:9"9L=N(ZATOL5
M'2"D]DPF7K;@16=X)Z<MO);O99O)#'AN]T[8EUWSJ6TK9$;5HQ6M_5BC622[
M1HS%;MN$8+1Y&G"ZK8V=T.HAS:FV O4,F5O911D0L&465N(L5TIL-I 5#(M-
MLI[(2RS>WSN07W$C!1?[39Z#)=QC85NP-C%V_&*KH-\]IU^J_,0=AP.QC:KZ
MNA[G\>&7BY=R8OJ\@)8S*U5%"J]N'(&V8E=0-,Q;LB2)AYW> )=^>X%D!:IQ
M8BNZ*&TD6J!>T8ID/*MB3#8Y6"P%EM5U=IU;[@ZZMV-GOS+& AW:U#BJ)L+6
MYN42.'.GH0K<$N=6&X7=Q(@GN@;H^O8SLTL$ZDH9C#1-?2G%5!3>(2 -Q.]K
M LFAI%T2S&M5UN-J[*\AG,8B4X?(*0QH+9U,02 JB])4'8[@C4U!CMMUKC'#
MIAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&-:>[2E/
MMBZ7>TFN:MK&UF5E+#2YK+4)360M66M(RESB^*5%]E&K;FS5A449-6U9QZZ$
MMN0+@8;$MX.PDSE4LA4*&)-;A3IO8L VQ91R!(W[ZQM P60,SE  3L6&HC<(
M2@+!6/G$ T+H76+SIRR-)4:JFB#9+XE%<1K(@'+")NW"C 6"B8!M6L))L+-D
M-C%Q"<PB,+B-*PE)C)GPEXESN!0 WV &YL_M.]GQ-G&3&V8V#9)L"@;/,"A0
M\!0KP&)'U.(PZ88U9[M]6V[;% J:6K1,&@B+9U6MMOJBK+7_ "SN%93ANXHU
M( VUT5CUH>6HM!M9ND %T52JB9*ICB/.&WX6%PY2J750+(# L!ILJ =AK!0T
M2&IA79V(-'&T#K&S$U91E5CJI6)&Y*$.+4%;4WVN\6,5;=-<;?L&L>VI19=3
M(+;LO36Q- O7+NHM:2HK(^=)241ILNTTA8X(K$==#.:Y7&E5I,"M%/Q4@28\
M0JD+W@?FK*Y2,% S(\9)&D#LA2S*#6D78 V.W<#BZO&'F(<JDB2@!@Q/:+!%
M8@-=#2S$]Y[R,;\=;XYL6-K[_?:_S0O^Y77C]+?^G_Q?_KQZ_1/.?[(_XOCB
MO_[96_T$_P#>8=6Z*\R;]9/X-B.E?/A_5?\ BN//G=>G-T6NZ[2<:N>5>LP;
M6[:IM*17>>X6.N7C6-L7D;295Z[5A4IH]@#L',+*^+<_'):J@P39JIF ,IY'
MF\''H.CEG*D#7%HU:B&0C60P 4WNP[Q57OC@C>,*@<,2DO$TZ05=3H!5B6!%
MA3^BP-UMBIJ[VR=P]7RI822]"Q(9;'K=E=E]CW':+,54E=![C4&XVBW7\R'2
M^NU%C77FH#/J&0A9(:&%6EY8RK@VSU^3,(2HCD 4!MK4L"Y.G3*'.DA%!#+:
MT56MA9&+M+$Q8E=Z<*5C5=1>(H"X,CE2K -J#,6-FE;<U=3.QWN2IVJ=::RS
MVN@?%4FDO*A!<O?$V?66%6L#:MZ26TS:E>1)T<R-X\T%A0+C2-<4HB*IU^T4
MIFJ:V-NFLUAV1ZST6&5452X) 9=6MQ1(C"N !1,>EE5>R"IW(+/=VS$)=W"$
M:F#:="$, TA9"220LNI6=NV58$*"%2NJM[2>Z"V"V9JQN)5*%8[1M[)G2\]T
M728W;E5AVKOTRMDVQL_U_L9%J_A+6;KKDVKIZQ5[\$Y4TI,C:2U@<1!'50AE
M.HDU;L2O$;MC7)6HE6"4&4@!6L* 2*%3QX5T@*&I%&KA+\F=$5Z0'0O;*X)9
MD(+$C5OJMF'M!W.OLGK(MW&[D.*9U^%J98MF[!L#-E5:_)VL3B+6.>*U6A):
M\DZ>VN88Q65NOP,6&RV9GF8.-PMPL=N#)=B0\ULEF)T@PFNX7:/N +UGEJ88
MSX\9%&,5VJ 1  2)Q8&Y_P#,C(!8UH LZ5.+J[5M/;?U/ALV;;-K3V$F[V))
M85X%?L;Q\C5,8:^.LM)BD9[6*Z97P+$U%P:P(RC+BW$XRY]/7JVM\BG9FD2N
MNK60=1!%$D U1JU6@3O6_P!;$V32:2-] 12-*E22H4D7:@TS7I&U]D'N510&
MVW6N,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ88
MUR[GJ#LC:6N<M=T)90VR2Y&3UW;*^[6MY3)W.J6BIB):JK6+ CH&Q9%3.X<2
M"5QLTF1<D U,^P9HBEEGD2/%&<JLZE5"D-LX8E;0@@@$*U$\B:V%U1HC6%D1
M];%@5W0JH:I 058@LMA>8%T6 L%;!@6DNWZ]T':9=NM)E/\ 0-?P[E!:E-6V
M;@Y[;!NY3N&'WV>3=P&-<3!(C=?9+1*LGQ6.+7'9)F]DLDTM9\\B0\52-E8D
MU0XNFKMN+)Q.T"!16J%$W9.W+%I)%9 H#61#JU 4O!BX5*03J#V6-A=-*-]S
MC<KK;&&'3#&IO=?I*_[C6:U+UJ^&2VC75OLME7\FWJY:YBC,L&JM@Z\7/PK/
M1E#QW$VJK&XBNH5,J[-19E4+JL.)A@',LV.4J,X720&5B1;%>:,MVH)L:KY;
MBP=CC>"1(RVL$JR@&E5]A(CD%6(%,%(OF#3#<8@6I.W?<>M]@J[.U;:^M ]1
MS[AEZM_BW>)[!> .ZON0U[N^^O;(C@IA"JH-]9*:FS1TM&J<VY;>320/2+77
M2_&;"*J1NK D@A>+6Y!;BRK(Q(TTI0 A0"0U\TQ+RHZD ,I;A$B@0O!B:-0"
M6M@Y8%B0NC>@^V)=V;:*V=V^Z['U_?K:(^45RKZYI]46A6^VWD:/*CU."NO[
MI&SNBI4TJWO@F#B,\M7*N6U3H7*_W) ]9Y-SY([0HT:A6-@!5&Y;S5HM; $:
MN>C<+6Q-G$3R)*Y9%HLSL255?.:PM*2&T[CB&F>]P*%[T4[]T ?\PK_"S=<_
M2'YI)]J?ZUQKT?\ G</^)_TGQ=/7SF/I,4;9_P#CS+^FP_N8NOILE^:P_JG_
M %-CYG._G4WZP_TKCS:S[NKO5XMZ6>W5H!M7:/M:V:SUO64E.L:9K:B*AF]-
M8\"6\6T[ -N[S"N5IVZ8*$&IJ]$B' +/9'\5]<W>K;"5@)"P!"NRH I!.FR=
M[8L:!.R #O-60X"DQ*I.IT5W)8$*& JUTJ%&H@ F0DV*%D ]*I=[^5AVJF3<
MJO=J#:"UJ-+XT\2=\O9VMYJ *LE-RI+.Z"+$$$V/-PTS&B7R$E\#P" 1\B^[
M, FM@*.EJ VH@MPZOM$4-9LCZA7>8.7(1C?:6R=[!"\;4!V0;N.EWY;D[T.P
ML[_EMAK::SUG3EU=+[6UUA5ZAR$9@XG>W#9FA%7<A GX5TY3;;% O1:V-*R8
M/1T1XI#V$%>%!,$::T42)P0"%8ZBH7OLM&):[(8@!>9KGL+%D#EB"5,B@J'9
MKVI4E,-VQ5;9P*&H&K)J@#8NS>ZQAK4VC.#]9..*(^[:=S=Q%NQ<,!:_L:HQ
M:LBU++!3Y:F?CZ*Y>F3[/'3NL&=C5 (F$.9)C.%<N.FDEI2I4E3I,3R->S*$
MT;$<K[5&V %$W0Q580VH!QJ$T<2T+1M9<:@W.AHL=DD@["SCF;=S-JCK2PQ1
MK$3.WA]R-5[>[U6V5S'Q4IBGW*LDFP5RU J2(;*-&M?H9!H)5:@F-B6P4M!P
M&"8L?*3*:'9&KB"-@6V!-&P:WV(VH&S1H@C 0BSV^SP6E4A=SIOLD$C3NIWL
M@@ BP1BK-2][%KM,>M*=9-2G%;+V"VHPJS-58:\NK1M<O"?N4?BW(B0@TPE+
M& L[7-AR35SC%JSGC85#/"6(QLW6URB3EM(*=IB*HC33<0AK))&T36-SNOB0
M+R9=5+D2=A _,$MJ4Q#3M5V9D&KLBPW< 3C$7A%*WG1ZLP:T.UN+LVHVGK64
MK1*)!H31]U"=N:JA6$1 L/O-B75VT; [B5]3###YM[<>;76U,%/-N(IODMG6
M% %@EBJ&@*O7PPIH%B SR!16H]EZU%=Y.58LU,H4.ZV2"0(^,6!)T E4A)-Z
M0=:7I#6-\=<7 F_4>N6\RK6.DF.P>2#*I;5Q*JP)"X2)A"1#@C(!2X\?=QY)
M0I21 YRU\HI<H0><^0T6RMJ4&BM]S"B/M_\ CQ&^.9U"LRA@P!V938(\1_\
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M?0KKHQS8L;7W^^U_FA?]RNO'Z6_]/_B__7CU^B><_P!D?\7QQ7_]LK?Z"?\
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M9@*,0VXA'9VY=;B2EF 4"GT@E2=(#$:B UL&7M T@'*VYBG!A"JQ<GY/60K
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M2^[H[3-/4VJT&XZBHE>H[RT)4E1UV"FX:)2;*2ZY=I>5=$KU4811216,:-K
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M_+R9/+RYB19XPDQ0K$D,B*FC5O9+V6# 4@CC73:Q@LQ/!F!FLQ%EXVA<O )
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M2S$F]%V2Q)_)H 2=@M"A8+CR[=H"JH!$4#3Q*H!0!^5<D ;EB39 (ZQ7:!H
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M<2LB*K58L;$D<SWD _NQ>9E>1G6Z8WV@ 1^P%A^_%Y]:8SPZ88PUBB:3U]Y
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MR=%+D>).$9/HD0/DB**;G./#5%TJ%-7N37*R237U FA]6,97#NS $ T!?.@
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MK6GQ@;?-$_U/3J73/T7+^W7X\.M=$_2I_8-[L=,"]:D:BX'*[<4R"DSGBC,
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MUEKON46!CX&\8A^DZZC%QB&F4^B[G*YS6*G)0,RJYF^5$+YK(R.-=:K,,69
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MT6K50%7?9\:/AC&W_P#;*W^@G_O,.MNBO,F_63^#8QZ5\^']5_XKC46S;?L
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MV8_A#CZK_9CS\[^K!_&7%EW_ /;*W^@G_O,.O'Z*\R;]9/X-CU.E?/A_5?\
MBN--KXL[?F.Y:1A;K&,FW7DJ ]6E2;8]LI-CL]:#>ELU*^R5^HV5'#?JB-8
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MO:JA>)W:_*04PE\GN22O//.B,H\9>3I5D0Q_&7G(DDL,F.?-(2QC0MJU51U
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MPQLS'B.++,I)V &YY8^ Z7S.83I'-*D\R*'6E65U4?)H=@& &^^PYX\D8?"
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MKTJ+JS5\K/CCZ;_9N::5LWQ99)-*PUQ'9ZLRW6HFKH77.L3R_P#[96_T$_\
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MOL4:Y2O;0J>B:P15TD$RR,8/5VK+:[(/%7HX )8$<1NM[!)(9B6#5S;5; Z
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MTBZ?"Q6>2UVF=ZS?3\J69CDL^22I%Y-S6E]='MT>]107;=M363 :$(J#.9
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M-+] Z0_"M[\.#%]/Z/\ Q2^[%.[^U$3N33U^U6BVOKJF$7ZNLJJ;8FP<EPA
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M:J^86C.$:5,S'0_MIA9!$R:^$,F.LC-'Y,L='@IQ6Z]I^$2K>Z6(M7K%BO\
MEI<#8>587U?1VS:[J_:\<W:TE<5_8MDMRNXN:K://MS.[Q7UVD5\YUJ3L*+7
M(AF,#9\K86&L\O223G0K2\!9= 3+S)%->41ED=UD96N<R*( 2X,:40S M.7A
MZ-> %W6/CF+4SSPO-">N,K1(AC5T(RRQN<P:C82O8TJRK8@6[/"#L:B]>^B:
M:M]7=,E6Q<1)VY]R$^=VNC'=VP:8E0<)6-,0[/KUC3ZP4U>PODHNDW_!3TX.
MV"+QM>L,8)MA/T@49M*#3 7!ZMFNVYGD15TE%E5EB5&91 ]L0X'#-'(P='!U
M75(2TX1AUG*CAQC+Q2,VH2-"ZF9G56.82D4QDF4$X],=26&Q6[5>M;5;T3FK
MVRR4*H/;/6[&K@1OT-@;(%YSE0Z2#'M1T[5>QG(%/51,C\5Q,4H?G<_,/,F7
MIPLSQ1.ZLCO&C,C *RLR@LK*"P4@D@BS1VLX\R95265$971)'575M2LJL0K*
MU#4K  AJ%@W0NL6%UIC/#IAATPPZ88=,,.F&'3##IABT=-__ +P4_P#0-/\
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M-(K>TVS0T EG=_5G:6?9EO1>\V8V4U#03-%0K-JZ=QZPZ(4SVN\;RKX^V+U
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MG%W52WDQVA1CC* ;,XK_ !8%U5L,ZZ!TA(!M/,$ )#!FTZ495<BC8"%AJ)
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MK 2LG9+H"Y/2$@!/6)B 0+!E864+[%0;[ U$BP!5U8Q4='J2!U>($@FF,2D
M.(S89@5[9T@-18WIL XRN7=+VP8#CDS.SA\9#7 9PY>J=GB'UJ%#Q3)&SR[K
M":1$QH52#$V)1VF5SN@J&IR)+2H>PN9$Q/GV,]?E^D3#<C<RBJTV6L=E1J4Z
MFI:(-T;Q'4$]!%R!!!B(-Z@ IU4S$HPTK;6I%7C'$=W7:@(.\))LI4/"%N$C
MG&DU3M'!BW8,#-C@#\5!7E1N&5Z"X)U#L[@EI2Q7ZP*"D/RS#(!!/=\X\H2"
M[S,VQKG+9-L.R*MO,;=;'9)NL2.CU-5EXC8U#\E0 T><=5*?E$V:B=0H;XGE
MBWEV]57%!,ZL2F$&RZRLVYE;<.N/FZ''5=/3"V"P7MK8$Z4]*@KH:HT.> YZ
M>MQ93%C J^#3YXAL['/2BKS,M%2X.MR-"@$L2+ %$;D@&Z%G%1DHS8&7CL.L
M9!5 VMB0%"FB38.P!JC=#$-&[K>ULU8>X">GF@I4ELLEGY#U-M(LJDHJ3$7.
M_:; 7C4:5A0!>(03)4N=S%1\VF(>62K8N8\.<NJ^4)*OK$U4Q-&4E0O/4 +3
MZM0%]UXMY/4$ P1 DJ%LQ ,6H (=5/N1>DG3^E6(]=.\[M7HZ>V,F)5D-95"
MD/[T?4@=1;%&M90E>I!FR"JZ,M>51,.+=B:(%)<1JB[.4.8ZAG%<6 P-2YD>
M1PW2,BAB<Q-:J6*W(&[*EB*-=K2-6DT=/:K3OB5Z.5B ((:+!=5QE1;!+)!/
M9U'3J (U=D6VV)1EW+]OX+L]"^GD4,!;&*BY'QH.PS9DPYR[790K;86$=&AP
MU:#D=LVMJR"[S*I5!%3$1EMH2E=A#1SU^4&CF)0;KSI-K"^=MV-W MJ'U\P*
M]00BQ!$11/*,71<4G:^4-(32V? 403.]6[:TGN<AZ)KLB1L17 DK1E$THMPJ
M.4B:QGV94B>J?7&N(.+!7VS2F6Q:"^0\LE$Y]>;"X&<S"28<63.S/>G,3&@"
M;:0;$D C55@E2 18L'PQ#Y*..B\$0LD"@C;J 2#I)H@,I(-$6-L7!Z 2>R@/
MDT7T>K]:S'IY?7;WXSZO!Z&/U%]V'H!)[* ^31?1Z=:S'IY?7;WX=7@]#'Z@
M]V'H!)[* ^31?1Z=:S'IY?7;WX=7@]#'Z@]V'H!)[* ^31?1Z=:S'IY?7;WX
M=7@]#'Z@]V*HW?=$6E-6W#:,VOCKF#2U)+QJGKW-<#/C4 19DLF64UA9J1.1
M5PD4I)$0LAC2;'#B)>M.(SQBZJ^<S"*S<:9@H)($ANAN3NP&PW\?"SB\>4@D
M=4$<2EB "4VLFNY3_P# \2,6OZ 2>R@/DT7T>K=:S'IY?7;WXIU>#T,?J#W8
M>@$GLH#Y-%]'IUK,>GE]=O?AU>#T,?J#W8>@$GLH#Y-%]'IUK,>GE]=O?AU>
M#T,?J#W8J+>MXK6D=76G9Y]<K9RVIA<L6.#NQ)*6LC#C\?.?,SUQ%-!@65)Q
M&N3@0"%EMG9JU;%%%B5(6-23.9A$9^-(:%[RLH^\D[GD!1LT._%X\I!(ZH(D
M!8T*C#'[@.0YDV %!/=1JS:O<=3-95FHVCWKV[P5[IN]]PUA!\I"I9U#3^K
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M&BA')E)@R3RR%P#Q$A2$Z6+*WN "1]3$@'PW*G[M^[&6DZ0U;$E0?$J%)'[
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M8>+BHM%*K^NLD+1Y%:86T=<&I5?A0EI,99174<^39CY=CCX=YT\D=*; 9?+
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M(U.40,3R9TJ+_L^6W;7^<..U98D4>]B2?&ZY;8'I+HP@ SYDZ4,8^0C\S2%
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MJ6K70H%AJK!5IS7<!U<:#DJBN$AD<P^0]DM,#H>B^E2;.7RUF[K,. P(52&
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M2<(QX_09F5VH.1P@5 5F!<%R1L-()&D;D7L,<"(K(EE!4I#DLJL$;A@&B=1
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MK9S"I%V#3$C;L@J+*$%@9 I)&Q4A"6JAN 32DKBA2  @GMD,>S(&5&6+6 "
M0P:2DO4:!*@LP#8]'>NG'+ATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3##IA
MC"V3*/"NOLY2W0$6"5IE(=6P26=B"CQ!GYS+0K0EK@Q@Z&QXYF5@B*&I)9V$
M \"TZ63 66#R//D>0L_L%&SX"C?@<2.8Y'<;$T#OWDD4/$V*'>,4=VEL;,Q[
M==4\W7"_8W "K!J;-EL]3<5-XE<+,LQ"IWV%\"!LS N7W/#/)R=@1PU\?GD9
MI>,G,V5(23&FK5J HZ@0VQ[[ /[>_&DX42OITZ;L:"I6COMI)'[!RY4,;%]:
M8RPZ88C%VSBPIEMSFY<\0XUE[S+S7(+*38,8^%97EY(AZ9G'<)W&./CY6PU2
M2.R2&<0X(\\&G(N7$-YINZHW5WR[M/:OPT[WRWQ*WJ6JNQ5Z0+OOU=FO'5V:
MY[8\Y:ZSV\-V\U"KVL;N#+CCWM8FMWL"%9OS'8K'M\SW)894O%<8&QR]P*C,
M<-I3EV=89M#MN>]RGL!D!#-)C&?+SC7PU!XGY0EB!)J,>LD43<@V*C23KT@\
MQ9QUD)Q69>%^2 4$Q%!+PQ>H;1'DQU </65Y';&[7;K%>X-%ZHAV9DZRO,=(
M186#FS2\SVC@C@/#S;"U3Y9R9SVK #S3"S39RRR2O<6$DDTN>64F6T>KAIJO
M5I%WSY?I7^E\[Z[QSRZ>(^BM.HU7*K_1_P"'YO+:MARQL=3OW0!_S"O\+-UR
M](?FDGVI_K7'1T?^=P_XG_2?%T]?.8^DQ1MG_P"/,OZ;#^YBZ^FR7YK#^J?]
M38^9SOYU-^L/]*X\M=V]X>PJ1K?8K2M1T?BZU38G=K4_1TX)QABFLZ0[<MS;
M;I=A.4<O.)HRBG]7UAPZ.,B]#GI;>/"( #-8DAL,O,RJ:TZ@\JUS(5(I'5JO
M;<)=[$,-AJ&)2!6=0=6DI UV "9)8XV%UN*9Z W!7<G2PQ-K9WOR5U;(R5ZE
M9VO-OM39VL:*CK[YFZM%B)TX5MY?>2WE?K=)L)E0..8Z8LH]%6$\M 7D)ZTR
MU/J&.NN.55LTQ L)J[;(H!))T:]5@*:-QL%&X.Q)4:M-5RX)HOI 1'=B %7B
M",J 2PU;2*6.Q&X4,2NK\V+OC'K*^-\TUOF(E*VM=]>K0YK*V+N35!K7:ZS3
MMYO,-;K]#?@* $UO?5\7"*W62LILI&HH3&T*6+"OB/1FT[E=M;*!9U$*^AF
M"D4&(\XJ-^8- ER^HT'LZ%8G2-(9T,BK98$VH8DJK';92+TPQ;WZL*NN)MN[
M*@CJ]/3>L'KB=2G)MJ"IZL#<>S=/HK$:Q9+D# Z5M;*=6ZL371J_AF&=:1GG
MICD7 E.%43UNX  NRIU  2,@).UV0 16UW?,"3E@:$;%B0ND$!2Q,<<A W(
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MFSV+58R]C?%HDI-?2'HD]BR?D#CD$RJPEC_:^EU4A/F\$I\TQ-\"S@6@L)!
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MFY+2$G@2.ZV!;]P>\JKRJO N5@EM H2MSO6IP2-+-75:9J!"_P $3)ZQKS<
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M6:>JG1"<F\6'#(2DH&T@,SE I) !#,+)*AA:KJHK>X4[[XW: "1EU$HL8E+
M DJ54TH#%6IFT%@Y78L":K&P>EMC9;<U30]D2IN*Z5;JZ$T8H<&'+>!,UYXR
M';+1''(2S)P &S@+@7M\EBS)H%@.?DN R(Y$AT1M:*U5J )'.CWBZ%B^1H6-
MZ&,I$X;NEWI) -58[C5FB1S%FCM9YXO:G?N@#_F%?X6;KDZ0_-)/M3_6N.GH
M_P#.X?\ $_Z3XNGKYS'TF-;[ELI6ELS=7/3AV,H9&$>9N;><?(CG(>&3C/F'
M$*7&/GCC/C#Q<29>/R?'X^/'XN/K^C^AY\QDX)EZ0:%9%)$8RZN$IV%:C*I/
M*^0YX^3Z0Z4AR^<GA;(I*R, 9&F92UHK7I"$"KH;G88U*'[H>TQU>3(8Z'KT
MN_7:P7W2#9@2I+P<6-IK&OSV&^45Z_+I\?GJ:O5\.8PF)LPRKA4$/N $Y<WD
MP\Z>1R7T^5B7=Y(=\FMEHEUR(29*I5!)LZ? DXS/2I":CT6HC1(YOSIJ596"
MQN %V+,0-AJ!Y@8DA6Q>UJS19>>ZLT38(-F.%CK+SH^FM8M@V!?P6*F;9>ZJ
M2,+6X!X!.&6'\^?FC<!EPB2X>;S8X7\A.P!\JJPD((/5HB'(L CY;M'8@59V
M-<L4\M!;'DPCA@V.L3#0#1-_)]D&P3R!L7SQU'?<+VIL6M"0/JMI-NVL%ZLB
M[7*XU_6F\Y>R @#;!:QZWADL*Q'M\0<IK!UR+S"VSS,R\ZRR)/CPG@]#'4BG
MIA2SNR1CJ\1)D4%F5?ECVP+)'/??GO(Z7VD8=%$*D:M(>/* (B0JECPQV"0
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M  J?SL/+4']VQ_B'_EX>^\F^((OSZ1^;NGD',_WH_P"%3^=AY:@_NV/\0_\
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MM0OE6GOQ[?0V>CSC9@)E5R_#$9.F1I->HO5VJUITGQN^ZL9"_P#[96_T$_\
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M7OXK+5+RD6AE\%(T 5F45VRIL4AR4?"TYP@Q& AN!*& A55(720@$@%,&1U
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MU5;KK31(-_\ &T]8:\,/D5V3'6FBC.+K'J:L1IX#! &2F@6+8%YM]14<'K3
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MRLUD9!)_.F?*9::_<,B%B?)HTD5+Y!E\C-CF-D;/HDS(H7JN=-<SU9@"2;)
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M$71)=?Y4-CL'-[J0#E??87ZB4\X3"?U<_P!:$P:-)Y(Q$G"6&25%,_%/$XW
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M,[UK3N9K6=<5C9!&NZ4OV!8**%1JVR75RWQ->QGN;2",K-M&O6=38<;)[_\
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M/]WNBO0/[:7X\1Y>Z2L_*Q\A_P"1%]?_  _5CY[\]_\ :8OS6!]1T_W>Z*]
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MH(+7:5;RK+[[5<6M(JW-Z#HK^O+[+$6Z1U8\L/$WUABR&<G**>+(&9S'1DD
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MX6;X9AZRAC9%CTF&-J5%9%TDJ2K!&9=2D,0;)+*I6)]P_@U=0=Q(6W2K&<T
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ML[[Y%,^QPJQ?V-=6M*MW%2ZRPJM_=)$]?LVR..X NI"V1+S)Z(D,'N.PZ%L
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M,PFBR1S8R^>9B"@.T.3@G2>3.'%6Y( (/,M=WMO>QS1))TMN8R!K%=B-HSJ
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MM@S '(DCE+7@V%$88/A(.,X6S28&0P18(%600+%C]H!!(^H$?:,2*L6"18L
MT2.\ D$ UR-&O \L:<(>TVY5;7E2I5?VM5@3*1M1UNBME3:OL;&NK+J\O+FR
MFKH4+#<A+^:CS([3;%<R,^[&V#FR.L+4)< @%PU3RR$3!54. 58N#H-!BQ)%
M:[TTQ%%B;-ZJ%8W,ZEV8HU,@C(U@$J% NQ'6JU4V%"Z1ITDG5C9C4&NA]2ZQ
MI&N!VDSSBHH U1+N<7 &1RQQXRG:M_1\4Q$2[!FSG+-B6Q$$1+XI\ XIYL(,
M9,M$70BK=Z15^)[S]5GNQE(YD=G(K4;J[H=POOH4+YGGB[J=^Z /^85_A9NN
M3I#\TD^U/]:XZ>C_ ,[B_P 3_IOBZ>OG,?28TGV4Y<#7FQ0#M60\,9<7$<,)
MQ446''(8V7/&$>$N.&/'//////&/'''CYYY_9YZ_1NA\MEWZ-RC/!"[&-K9H
MD9C\HXW)4D[;;G'Y_P!+YB=.D<TJ32HH=:59'51<:$T P W).W?CPCW!X7V_
M:L+[E:IQK;%IL'5M_<*M0)Y+^['6[.UW1(M@,-L6]N7&IFGKYVO$VK; 2T"'
MB-!S.N.L5?)T1%GQYQYILWEXCF4\GY8R12$0KHCJ6*/B&:1CPR4,2Q-8HBWB
M%]O'5!DIYNJOU_,K%-&IF;4]PRR&-84 ,@#B5ID"FP:28UV,;573PF>N:5#8
MY)T^\7<E6.VP&XB2#5SB$*#3._DO;M=7;%HYV G2(*P);G<-C]9;*S2I **&
MP>6 U*:/@HEZY)^CH]7]B5BIFL+EH/\ R,RN6D)+%551(VK6[*HC!9BIH'DC
MR_2$A4=<*Z^#I+3S[F?+-FHU 569G**4T(K,9"%4,#JQFH_")5"0O"3A!N?*
MI&[2M^G$&PQS:$=3[->M?:JVGMF\A)<EVT2['RMK2G45FK\CQC75ZEW9"DWJ
ML6]K9)EC MQ>C[OJ2%#*\"R"#+%'DCAFFD"TY>D$#H6*A6<KH+(2XJ8<\!^>
M-K$23-$9LR'2.6:&",M::+=IT?2&9E0-K"N AI&O>%@1YE;#)L-;V@R0H',5
MG4S4W!/DRJ.A8],]IVP&NR-H0V78BF*8Q/9^YY:E*1ZX];+ 0N!RF55EGPL/
M8%<ZYK(W(6R,;*K:EX>7@M,N(,I(TLH=ELJ^: *QZVH=E6()/0V4SM1A<XZN
MP*,))Y@KYCK&=B6*(JK5:90MJE*)9W<6 .^X\*BH$V?J>H#(=BKUE[V?M#2#
M2NV(A"'L[#9]7L&G:]2!H44&QLP:.EL^>SYG'.&V)*=83$ BQDN3X<.$,-@E
MLSD1+"G48@))98&5X(!+Q4:!4[(:HU;BZOEM#%0"%[2ZH7*9TQ3/UR0F*&',
M!UFG,)A=<PTAUE;D9.#I^1$BAB5+=EBF!>^%WI?"^K7A LVBOU6)?;<%L"UV
MY1-AZ9UG7.VKNJW>);-4YU^W,AF+<]OVW\+9JY:>%-E5IW8LCVL)); A/XAL
MWT?I61<G&(1(XD=\M$-42Y7.9@/#INV)RH&EZ8*PU(I92)7)9_4\39N0S&)#
M&B9B0E9FSF2RQCF! (4#-WK34A93I=@KC$[6^$]B9V40+WH]WI*EAJ';.T;%
M:KA<=24W.NDZJNM8IDU=EALFUUU8:B6,BU))E%Q4W4JM\D6&M@\D28\W(ND7
M&8R1<#R<BIP)IF>2/*1Z.#(L94ZG"$,7%.LA6V4;]LQT.6SBJ3Y0+/QX(42-
M\W)KXZ,X<:(RZZ K:D:,/2N:%1B2::([^<M\6N_F)8[!7]95#0%/VUC):&@*
MFY@6.3<W=+J+8M?L)D-Q8T2%;7V';OQRL:"/^5$G)C!D189E,PDHFF7?)YAY
M2N4@6*/+QS=N&$.&,^<AE5C9CI3E=B&HV26JJSS$>;RZQ!LU,TLF8EB[$LS(
M5$.3FB910D)89K<%=6P 4-8-=#>%NU<6N4L1:AW!&8$,KZ-9<%I&KV\-%2:X
M=Z%2V.XOVRC<QR!W6/\ ^Y'5[-;-KMM>&S%<>SY@4<F+) Y,NM='%5(R -F0
M/I@RK"-8FRRL[,)"K)_:H64Q&0LI/9!!&-#D^D 6!SM4(BNJ;-+Q&F7,E$56
MB#J_]DF#<58U!"]JF!Q,]6>$+DV;L+<G&2B\4_2FJ]&#[A NUHE&]-7-6LV-
MNBDVBTH%M:N=GGQI?,&IR)J^#8U%6O,Q,9TS&O#A&*.9;Q2Y.668=2A2"++\
M<2/!#J<++/&[J%U?)_(DJ&"2<R4 *XI+%FXHX*SDLD\TYA,:3RD(QBR\B(Q8
M(.)\N Q1GCJJ<D-7<%\(^B]-T9&]USW#U0BX!Z19M"74^LBA-?*^Y78#S6.@
M6%RRK6XK 1-%L^WUUF"O'I0]Q/J\,6!6P ZC#GQEU82Y#5&K9 (9! 26@RI$
M8S4C19<OID8GBNI $8D*<Y @.*F+.Z9&7/ZQ'U@ +-F@93E(EFS(CUQ(/D8W
M4DR&,/=1&3%5"^& UN911+R-K'NCDQ8UA??UU8\VU=A9#=:,](-.X838<?.>
M[<:]"ADU@A?M,59=@'N>3%1,EPJV;$Y/"RP&<Z.,8D\G-NHD"]7RFHQ-ESF1
M+O*$"\)6.DMQ+73HU$ [G)=("4QG/IV7,;/Q\WI$JY@98Q?D=1;C,HU!>'3:
MM=!JG,7A2M9L7UMKM9KV_P"VFH+@MUY6R4JRO0*-DWUAL>OZIDJ53</M@I%R
M1J!<K$,-/GL\C7@!RM>[>(C6ZE247CIUGHXLZKDE?2XC0KEX*ED,JPZ$+,H5
MA(U?*F,$!F4D"\9]5Z1"H[9PH&C,K!LQ/<40B:;B.%5BRF-21P>*02JL%+ 8
MAKKPH;FJO[IS>]4;=H%1UGL;9M-M!!;:F7!ZW1:TTI6MR6*S@0U?9V0U;RJJ
M2Q8M[,O/C?CS5R(:5$T.>RN$U>H<QE%:3B='1QI%++&]PY9V98H%G9QI>DT*
MUN#J&@6K:M2K=<MFG2/AY]I9)8HI$ FS$:JTL[0(A+Q@OK9=*$:"'L,H4*SV
MA0_"6:VV5MZOZ?IZ_=K4^PM&ZZ*X#K5I%*7P!V7;%:06!@4'<RK#ZJ7F73U@
M;52S!5LU1RD>TPRP$H);#@,+K'-T=+,L"9)6+E@'&6@,8 :958D'5HDX+,CA
M"NED+%=5#.3+](10M/)FV4*%.@YB8.Q*0,R@$!-<?'570N&U+($#Z+,.M/A(
M;+5+YL.NN-5[<$2ZPWAL/4DTR$A-?[!M."B=K)7<E.;0DB"\@LD#J4+E;%&M
MLRPL$E0W0Y<LP')UL7Z\H\V41Y5;HY (LQ)#V8()&E$>4.:)C5#:L1I # BF
M6R"7$5T@S+QQ,O2#%ILO'-VIYXUA,F=7* 2,RD,MDDE&!#*VS*$,LI7>$SUN
MP>H$7(6UQN;0'H<ROM>7NM6"BP8=P6U]:Z<K4U5(2;9:3W9/4K?M.N0['ME*
M%L5-J7,#)-+82[;Z*K36XFZ.+*O4XQK&7*G@Y4ANL310+I*R,7"/*HE>,/&F
MZZR]*:'+]( ,>MN=!S(<<7- IU:&:=^)JC41L\<+F))"DCV&T!-3KV]8>$IU
MQMW:M2U-35V[RFMJBGXFL,RQ=G6*HPP$V"Q#6VV9?<CW:[TFOURV)$=B(V-5
MAG<590Q?@/'6"L=%/T=-,D*9-2SCSCEH="&I"%<@E@2(B0P4I;(I8,P&(E@Z
M0AA>:3-D!".R,S-K<$Q E+ 4Z3*H*E@_9=E5E74:IN?A-+ )N:2A5.LW$:BJ
MW3.DFW^TQC%06N]5[O4[<NT.T"45<CV3@YX05VP;;N"]LQN".N&\MT:AY7EU
MGK^,@KC*2?*"?AID81&&:,R/EX2'D7/97),(PK:M*/,X8NJG4JLH==FU3+YK
M@&5L[*9-(D$2SS I&V0S6=0R%ETZG6&,J$9QI9E9D?=92I\*KK9PO0,8*KOV
M",S.&>[ E9:^C>:;3%W^H:R#;[9KN&V97U<,EMMU5!F41<M>;11B#,65@HJH
M' "9C=<ST<P4C(J+_* P9;5 #(D0,R!RRDNZ@Q@-*HLO&HJZME>D5+@YRZ'R
M9$^9TSD1O*5@<Q!7 2-B)&*0L=(21CJ"Q2U^%.))1U C6VK]UR,[=>-7@Q,[
MS+20JNHUK<NY;7_;P=L%O@EV^59, GS^Q6U#0PEJAI8>;%5LG5KK"BC%JW;N
MCYG)E8S%T>A+O$+D@RP58GS466,K:7+4S,ZQ@ OJ2W0(0S73*YL,XESY&B.8
MU'/F68RQY63,B(%HPA*JJ-*2RKI?0CF0%5F5"\*31-GF4\&AT/N4L<^P+ROI
M])S%45,8.R*CZK=[SG?E[%ALT-?ZL+:CKJUO&J4@J#98,0JP"2@<M[%7E[.\
M>8Z/E*"/(:C)(J1UE\O3*R/)Q 2P&D1QNS+?%% &/4R@YR9;/PAS)G0O#C:2
M0',9@E"KQQ\,A4)UF25%# &(DD\72K$;3=O?<P-W'ZT7[.J?-ZK2XY@R5$UN
MXM4<=P0,U,V,!RBUIZK;;7#5[ ')EC&RJ[LX*S)9_&,[3KB>.(N>O+IDLS$)
M4RD*J21I>& .I4T0RIKT,#S5B'7DR@[8Y<RV<RTIB?-2N0 P=)9]#!A89&<(
M74]SJ"C<U9AOB[O6!][;;_.1OUW6_5,I]&R_L8_AQAUK,_2)_;2?%AZP/O;;
M?YR-^NZ=4RGT;+^QC^'#K69^D3^VD^+#U@?>VV_SD;]=TZIE/HV7]C'\.'6L
MS](G]M)\6'K ^]MM_G(WZ[IU3*?1LO[&/X<.M9GZ1/[:3XL/6!][;;_.1OUW
M3JF4^C9?V,?PX=:S/TB?VTGQ8>L#[VVW^<C?KNG5,I]&R_L8_APZUF?I$_MI
M/BP]8'WMMO\ .1OUW3JF4^C9?V,?PX=:S/TB?VTGQ8>L#[VVW^<C?KNG5,I]
M&R_L8_APZUF?I$_MI/BP]8'WMMO\Y&_7=.J93Z-E_8Q_#AUK,_2)_;2?%C8/
M0K%@=/9^#3C#.(H5',?!1,Y'$?.>;'R^<.)L\_(YR\G'RO)\7E>3QX_'XN.O
ME?\ :B&&)<EPHHX]33WPT5+H0U>D"ZLU?CCZ?_9N661LYQ)))*6&M;L]69;K
M435T+KG0Q/[_ /ME;_03_P!YAUY?17F3?K)_!L>ATKY\/ZK_ ,5QYN;;U)N[
M8G<NG;T_8%IUI0:Q0-8,X[*NL-OS726-3LR[.+=7 * #8EVOK09;JL.AK=J,
MV"DL$"JN,1"T(/+P8$Q;WNDC2V&95"H;#&M0=BPTV%-B@2P-#EON.%'C6(AD
M#NS.**KR** 2Y!==))*A"MD&S5@T;4MJ=\^S-=1;-KB\$ W/4_<8Z2458FJ)
M"9_M[6:_4^L*!62[4RC99DTZ_;& WQM6DF)RE)%AJ1FOAV-@6*US1>UHKSLN
ML<],I"@"BZ!$523?99Q(ZD$6I7M4#=V3+H^@DUKA!8ZK$;EW=@NQU*G#1@0:
M;52DD$8Z[7#ON.I<BVNIG]K4O=1[SQ<,LZ5FBMXEO]6-R<Z'4"3&5S3CWD^R
M.@42;93T#7=4DKTJ[59=81+ =B6^V5LQG(H6P*26:IM5/PP+$9LD ,0@HA"H
MIF(L%RP-DA2'BH:@RE;CXM@&04 6* NUW("2413M?H^X;YL&[-\J=A5>S)-5
MI9PH-:EV:!-XYV(5[V:D8^@#E%*J?G===4E5KJXK8RW.Q20X+'&,PN =APL-
M0K>J&0O(&!""M-USU,#1"C8J%8;L1=%@;482+&(XBK*7-ZZOEI0BP7:B&+J=
MDLBPNFB=MNM<8X=,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ88=,,.F&'3
M##IAATPPZ88=,,86R<0<UU]P3DZP&Y2M.",JWPPYL6,'(,_$N2'A3CDUY=8Q
M^5RKX68Y,//N(/,\>2?<^.8/(\^1Y7?[*WOPK?$CF*J[%75?MO:O&]O';%'=
MI>=JX[==4A7@6]B7!/5A$MCCV7Q8I+I(T5Y2"S$.S[7,2^<DSXX82>FCS#IF
MG'/G69I.<F4N5(=7#35JU 4=5ZMO&]R:[][YV<:3Z>*^G3I+6-%::.^VG8#Z
MA5<J'+&Q?6F,L.F&(Q=N/*IEMQ]R<S^767N'N-=],>L$OEJRL?(1^KS>OO\
MTOEX_$M]!/DKGSSF'T6V7'>X%PPW(\^1Y7?+NH@WX40? C$KYR\N8YU7/OL$
M5XV"*Y@C'G+75^Y@.WFGTRSJ-Y.@Q-[6*S71NDRV2GNUAT"3N2PL5*]&*?<7
M.YZL,& ZJ_N&LCK=8;WAJBM-4,QC/ CA!-SKK$:@\0_*,21K#%-9(JR76K7L
MDEM (W-C'43'Q68<,7&H0'0567AJ#= 1L;#=L*$UL#MYV-VNW5=>E&BM4+-E
MYN<[R#2$0]AQLK/EW9X"8P\.( [0[Y,9<NK0"#YJ'9&^3)GFS=P'G9LV.4_)
ML^T88(@:]0479L\N\F[/B;-FS9YXPE*F1RE:2QJA0^T#:E)W H4*%"JQL=3O
MW0!_S"O\+-UR](?FDGVI_K7'1T?^=P_XG_2?%T]?.8^DQJU>:6(RMCHZ0PF/
M,@F//+##"+G''G@:##Q<<Y<<\\_K8\<_K_\ /GK[?HSI%X<CEHQ&I"(0"2;/
M;8]WVX^+Z2R*RY[,2&1E+,NP -4BCG?U8TGL>GNQUB%L.V6O]3^6NJ5@N>N-
MI6-YAKJ42L6K;A5+]?*1=VIG/,26P;"+*H&-AK[F<9C89S*OB6*3F8NXEV;I
M"%M9;+94T9$<FC1FT\16)Y&0A-:DC7V;!VQBN2S"Z%3,9H7PY$5==D0A^$Z
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M24SJ1L[1Y3+HTE\0JM%[))U$#M DDT;%DGO.(?*RR!!)FYW$5",.S,(Z  T
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M<Q.8,&,?.!?CEYDYN)C&6R66)B_)DJ"8^UK[!KL]H:A54VXWQ R\RB15SN8
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M(^9@#C@I!RYM5;4H:B+ -,*(ON([B/\ ^6,8LI1F4D$J2+4V#1JP>\'NY'Q
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MQA[Y])^*K?YTP^ET\C=)?3<O[$X>5NCOH4_MQCIL;_KMNO.5,Z6Q.6LPRE[
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M1II@UBA,G5BQ!+52M<%A"&O7+PX(1 @A88AA1H8H((\(L,<>)'0O2(  SN6
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M,0UP.R6':586#(XVE,S@-,2M-6G<[&3O+,D8TV%XH@197]EP<"+6'I5G$"O
MI>2$2R<.1BJ!GE10H:/?28CQ0S*8PPT\0V!I-T2J',%)V"13-#'Q(PK,42%V
M+5)8#+,."RHXE*L6X0()MOM[\(+8MT[-I% L6A,=?K[W.$ LL8NU [C(*S?]
MNE2[H:P(8EPI%=RXC*UM:XPGQ43*3!+;P^5*["Q*I^7\&V6Z1:>2-&R_#$A
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M3 4&NY$5>PMH[F0K"SSQ>6'4)JRR!WTL ,P A5X(9U7B/$@XI$M:" O98AR
M:#H="SUFF*)J5CU8EPR9B;+LQC2:0\%6BU&12STZKP@Q ,_$\*DK'OQ:"T4"
MCUREC;)]3'=NGW*/Y]J5.)W!.NW\IGW )V%(5K-5/W#!3A<J=72[*S%>()6
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MJERGI%I#9Z_=.G]:[:5>9>C]B4Q!;1>%N;F1?C&Z7PF<X RV)#6'<XF&<F6
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M;-$YK0^3VIFRQ9VX\:ZB0/DV8E2R$A[V;9"!L-):^8WMP\P%C7J\K:0I-2A
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;9^91,>,,566)68OE<L"/)8@F_P#^D_Q)Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g400206g11a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g11a01.jpg
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M6&)D9F=WAJ:WQ^'Q&3A#<H6BQ3=C@J?#_\0 ' $!  ,  P$!
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M(CHQR@RQ-=-W&VMHL!>?,K89ZURT>\V?=I4-VK$S+;TF%'(G\$1J2A(S, W
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M3:A5A17R$QQBU,MY7A*I-W&%<N79G.&<9QS\N-<6MJWTM)/4-:USH8W/#3<
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MW6!EX2N2-<:W#:\N!93>)Q!-AEI6%8"?VNW:'D(0N$.VTCY1^\1Y%%:-VYB
MWMX]KGG+!?V*S!*CKS 2S<DN++ZX@EC[$>;?J.I5\EQO\/8+9T@FWF)K]>?E
M7;;/2E)W-@P0("+VOW;W759JL[(41 VXL,36-F+H:)(TTJ3BC08YPF.DSBR8
M:-F26\^K,<G+EK]L[<A&XPN'@F1JL/F\R(4S<+'FHQL-,;?[E04Q&6-=V$VX
M"BKK%35/ D-NGYF\'A5NN+W &K+%FD"6O,\[)L*[]HEO:XW74H/?N6)XE)?8
M!6UEF;B(VK!6)K=!)C3L(4Z5')D'AUQ.06R!(P1Q3<.J=7(.CE6 H>(!&)=8
MF5PY+97OX.G/VZKZ; [H%M>J\VZFSU7M]=&J6SFX.\3ME(1&&Q4J+MQNWO!M
M7+4N+8%-R>5>)7&S-FM];A&AUKFH!LQ([F#8<]G! TD7Y;+D6WW&I4[[-\/M
M>Q1+?"2F_6VXMX[V837RF:!.3D)<K#2Z%9R1)13!$U=(S:G>9<-)Q2RH)LC;
M4T4\X9^>@4F$MKY//F!ZQK7$9_CN9J@U[9L&S-J&L&U ^[]GW*B@;54I./B=
MMMBJ;LI>MR+97+ P4@*VR\-%[^4J%;J0S4>0_<HF\5Y4JRW7!Y*7(!>VK,@=
M-^I;^VOW]C=RMU]ZMI681@&7V8Q42).4C+77;7&%CW25W BHR+DLP1+KU7NH
M*=O2IJ=ILHA9T/7K13#B2LFS!D9%$MD#OOYO;TKL#HH31%U.W>XO:'LUNI&;
M46"OV.4F9*IPUM01"&U!3^09XF_BAICZW*6>+ME@;CU;<S1%H.KD)*AU*-,B
MYJ>=#A%2<E%E(!(ORV]'@V[2N#T_C[VKN-*V_NX-:M^8R_[KQ.U8[D<32[+'
M1:9(2J=>W$?L-8MDO7Y';:I6*]5.A7JP0\B<53K_ "!]7GHL,V!FLAD(M['J
MW9Y[%-@^/#:N?,AX@*LWS%AD^(^X\.!E?<!K_A*"D:;-AP9>Y,IEJQ."JVT.
M)L5 0'*1Y)LTT9N'6HD^!#E&IL6));FU7_ASZ\N0K=7#GOI!<2&TM6W@K,8N
M(K]PCX^6B W[%4;(:V!)Q,;+CHDR*7.6&*C98=$C@.3A'Y#,E%G#/L%LHQEI
M;A"+&V[7KU^%;RT4)HB:(FB)HBKL3$3EW+&)2.R]A*UY9P<-WW"&QFS'%9;[
M[T\)0(\R4M6<<DC.MOJSAI:59(M!\1&Y6YU-H(\QL75H7<.TESF8AT5TH,]N
M+:?JTY,19;<,FPUMVP/GS8M<A\Q0<Z :@"?7,M9<8!7A72X]5XK1T;9,(HQ6
M5+I'->TM,G%1B"=[9>)$L#I@Z=D,+F,E8YK9C(+AAMZA[DO!_P!SWA'PGDHO
M=)X43<%<"CH63PU,+C3FOJSBF&4TM"<1[6XO'AICPJIQ/$XJB;#:F*6;#HZ(
MM:^J85H2V<0?$RBDS-DH-!VYL!R$"R@#Z9/$I5$PPJ)HF637IR*M??\ <++@
M,?"F*EP0:Y%P;-D&<EU,I"D< =_[E'$8]PNQ'#?=,,W!O@]#12RTF(8<R)NG
M7&K;!3TO9M1-5LJH30\9BD]0RA@XO09A[(Y:N4QQ_E?W3\?]TK!*?'S[FO!N
MCX2RTF-NAPA^+TT])V3@3*C$!!4NI:;$S)55]=3TV'ET,<M-38=+B9-3.Z*D
MJ'Q]Z:I+OV"K5J>)8'&)FX"'ER!A">N"COR4<,:ZP,7A*.M#M./*;9)Z"._M
MI2[T4]+EB]6RGCJJF.DF=44L=1,RFJ'QF)\].V1S89GQ&YC=+&&O=&3=A<6G
M4O3J&2KEH:.6OIV4E=+2T\E;21RB=E+5OA8ZIIV3M ;,R"8OB;* !(&AX !6
ML.)*B2FY^P^ZFWT*1'"2MMI\G"@$RSI+$:R24E&&W#7@Q#B6V$Y3GIJ8#(<Q
M_:M*U\QPHII*S@]B]+"YC9)Z.2-CI"X,#C;-Q:U[@-Y:TG<%U'"O#:C&.#F,
M872/ACJ:ZBDIX7U#GMA:]Y%C(Z..5X8-I;&\[@5\_6.Y1;ZNXYIN.SW+R9G;
MICEZ&?%0,]N/1Y8]GT?SH.!N-7([(PW(7^6J3?PFDVWWK\SGW&>%@N#B'!^^
M_LK$<_!VJ]:R9[DKOWG']F>S7O[=>7K\_.^SG3WH8P-53AX&[C:G_*>I3]QO
MA5:W9^ ';^%8CZL+"QY[DEOYG^[39KEY/#UV_P!WN.>K^]'%^Z*#RU3_ )8*
M?N.<*_RA@'ZWB7_2UB5W([?W/]V>S/O_ '?_ '>\OQ:GWI8N/QC#_*5'^55O
MN.<*<OYPP']:Q$?_ -6;^$K%GN1>_P#GQW39?W^N_P#N\YZGWIXL-4] /TM1
M_E%/W'>%/Y0P']9Q#_I2Q*[D/O\ Y_NUV7Y?=^[_ .[O].KC@KBMLZBA\K4_
MY8)]Q[A3W?@/-V3B%O\ TM8E=R$X@<_W:[*_8_J@O/\ N[SC[_+4C@KBH_KZ
M'RM1ZZ8J?N/<*>[L M_>L1_Z7_HL*NY \0>?%==E>7D\T%YQ_P##K//4^]?%
M/IJ'RL_^54CW'N$^VNP&VRU3B%_">UBQY[C]Q"9_NVV4QCR>:"\_[N<?CU8<
M&,4VST7E:C_+!3]Q[A-W=@0MJM4XA?P_S6OU[N.G$0V@=>;QLCT265/-X38;
MWSPE+[X^<+Y[<8Y*RMA>>2<JQT,ISSZ6<XQH[@MBK!&[LBA^^,+VVEJ"0!(^
M/.]-D;L.J^1&>9 L?<>X3BUZ_ \Q?*JQ'>1^3->7H417<>.(C/\ =OLE^Z&]
M_E\[C.?R:>]K%/IZ,\O&SC_ZQ]*?<@X3W_#\#&7=6('/PX8L>>XZ\1.?[N-D
M>7_.&]Y_+MQJ1P<Q,:YZ/RDY_P#K!3]R#A-^4,#_ %BN_P"F+&KN.7$5GGRO
M.R'+_G#?/]V_+5O>YB?TU%X\_P#EU/W(>$P-Q7X'^L5_I&&A8U=QOXB\_P!W
M&Q_+'EL-\_DVWU(X.XEMEHC^DG'_ -=/N1<)QJK\"'_,8A_TY8E=QLXC,_W<
M;&_?L-\Y_BVUQ_+JXX/XC]-27[Y/T?(#5LVJP]R/A/MK\#_6<0_Z:5A5W&CB
M+S_=OL9]C^J*^_D\[7/Y=2.#^(?34GE9_7 5(]R3A.-5?@GZS7_],7ZUW%SB
M.([]T+QL3C#+"WU\[%?L<T(RE.<8Y;9J_59Z6.7/ECQ\\^+6C.#V)/T[34?P
M&%Y^^3;"!E_)S8ZN3PJP]R3A0;VQ# Q87_"J^^6[^;->?F4-7<7N(I6<\[QL
M7XN7+S17[Q?YM-5[0XC>_&TGE)O53W5A[E'"@#/$,$_6:\__ -<%A5W%GB*S
MSQB\;%XQG_RCOW/_ -VGWO1U88%B'TM)?ODQ_P#@SV9G<K#W*>%(U8C@GZQ7
MVZ.URP*[BGQ&*Y_U=;%^OYH[]C/_ +L\ZD8'B _K:7QYO7 ?,K_<LX4=WX)^
MLU__ $U8%=Q/XC<^*][%?9SFQW_G_P"[/4C!*\?UE+Y2;7O^0OY\E8>Y=PI&
M79^"6_O%?_TU;UX9>X]7/;W>NEWW>NQ[862E4T_%C37:I(6>4,FI^,RE^O"R
M \[3H$'$*/)89D9)*BB5&(!1&+#<'/(?'Y=)A%1'.R2IDA?&PZ6BQTCG.</B
M@AT;&AH-B[-U[:)%C<=YP?\ <XQ.CQ6EJ\8J<.FHZ9W'\122U4LDL\=C UXF
MI*=@B;):23X;BX,$>@0\N;[_ #7T*]C31%/DOGO_ !8'\Q&UO4_*CO5/^PB5
MY/CGF;]4*!K!431$T1-$31$T13V_H69]OQOYO*ZW;^#3=_I_V=4K#XCOSF^A
MZ@:P54T1-$31$T1-$61G]M:_PB/WV-:0_*Q=\9]8*6ZQSCTK;FO7%WZ:(FB)
MHB:(FB)HB:(FB*6]\Z!^N3^_1HBZIW'@QX:]P)VRVJX[70,];+C/3DY:+:8A
MQ-KFVK)M@9LQ.5HVRL*9FU4R0VM/*ICM2;.;@TQCF'F@VY%MLU)3<[_:]_2K
MF0X7]K[%4HNE7MV\;EP<3-VB;93N-N!;;<>^JX;2W+8Z<BRY&3E%F.PA6VM]
MM$*J-2ZVT[(29-H*41:B3)HDES[<]U5 <(NS(4/'PKT=.R3$;!6BMCDG3YB3
M%1%OL>V5IF!R'(_ #+[SDKM!0UMG+8R?EN+*R0201+RKYA0M$[5=SKV_IE0M
M-$O5C5>ZK87SCVHN%B9NC\K%8]M-U-H;]>)PUR[6V1EKGN#0=UY.'GUQ9E:I
M48Y!0$A3:-5SF37S2DF_M[=>\E=@7N$_9A>Y06[;$'(A7D:Q'64F5&ERE(EB
MSIP2S=5DA2^M,* "GQ$R4:V$D(D%14H$P4F,F)4(PESJ]MR[):*%U7+X,.'H
M^6B9L^G%FR,'=*=N!$O$6*>4D*TT7</>7<^O'MMH/0AQEJT[^[HYD(][#H$M
M#V'$%)C%10(@K13<ZO;.W4%$C>"#AKB519@FWHOFDK\MMW+5>]$EDE[@U+&U
MRX9=4AZG>"5NV2NUM*XDC,S7HJ1%B+ FRW)N8$,:MDVV82YW[_/K]N;<%6B\
M#6Q[%2@J24_N1+0,%&7FM)1*[CV8D^:I.Z)%>/W2HEHDVRV#K-6=RY>K0D[>
MT33YDQ9)T<J6D)ATV5EG3B7/L!LU>$;#K"WC4-GZK3KM;-Q!3;5-VVWQ\?!E
MR=JM,Q8\Q59BIB>GXVKU\>2)='B84.8L\T:E#3:SG\$BAEG$ 1$,)'DO[>W,
M/];K:FBA-$7"9#;JFRDU:K$?#8?F;M28S;JS&]>DVU25-AB[6=&PV&636QPL
M#E7>SO9.CV1)-_,EA!!KK8,<D0E_-G[="TK-<%_##8VY9JQ;1P4^B7AI2"7B
M:D+#*YB19JI4*CRAM44=,/JI=A,K>V%#%<M=0S"6?!M<%FVY=$X^=)%%-SJ]
MMO6KN.X4]@(JTNW4#;P5BTNOQA*YG,Y:7B</Q&YECW@$=;2_..L-*<W#M4M/
M27>F4>&6FH*#E\'5ZJU>*AR7]?G%C[;-BV%M;M;3=F:5#;>4!BP!5&NA@QL%
M&6*[W>^OQ$7&1H,1&Q,?,7ZQ6>;%B(^.CA!@8IJ13'"80XX.,V\22X\0F^9Z
MN78MAZ*$T1-$31$T1>ND;N<6U[%4#K[DTV1*CQM-B7[<]3:\J?/ K&X=\NDF
M*49G*B7!K=!WEW;Z?&62MDJI10D>0@D-Q02"MI$:K[=O)8="\K/W.ZD2#=@Q
M4;)$TQ=CI6X%$?2UMK6I,.%#W$O=RNYEQJH2"XIJ$W0JOFFCX*B752CD5Z)A
M7&G8223(M-Q9 [;GLOGKL+;MN=_:_A7>Y\5ZJ-W<>,LE*E ;Y$1,%)1]IVC8
MD!X.-K=(8I$*W2RX*[U>9J),B&VX7>#HB6:-LCW5<1#]3<$R0^32U6N+<M_X
M6Y++OO4H)=7JM9K+DH9..5VOPT$Y-2#((Y\PN(C1H]<H</&"@QK!D@H?)9+,
M<$&"T\\M @HXZ6VD%5:6XMKC9-O>&G>F[5 U$=9ZS1)>6A#G!!3D"GC);RR\
MH,YD@0C">>>;1##K:O13G71<)IWTV 8K.PZ+XJ.1[20T@$6M<.!:>8A?.\+J
MZIPS@UC6(4CQ'4TE#+/ \L9(&R,L6DL>',=;<X$':%\O2>Z3<:36.2-RXO&/
M)G;Z@Y_+7%9]#Q_8U^?1PBK\BV=N7_90Y=++;=2_+I]U'A@=>(Q?^'T/[A>2
MNZ9<;./%N?%XY8[,>=WM]G_5OGJWO@KM7'MY^*A^SZBGW3^%V7\XP_\ A]%G
M_P#K^QNL2NZ:<;F/^ZC%X\?+_@ZV]_)FM<\\M2,?KOIF'E$4?G^ =?(%;[J'
M"W+^<(?U&B\_\GZE@5W37C?QCLW4BL>3GMSM[V^S6>7WOL>/5NW]=]*WR<8_
M]BG[I_"V^>(06_N5#?\ 8+"KNG''%CQ;J1/9Y=N-O?R^9KE_/QZD8]6[9F^"
M.+5SZ.M6^Z?PK) [81?J5#ZJ=8%]TYXYL8_4[JQ'^;C;O.?O_P!3/B_GSU;M
M[6ZA,">2.+T:-_0KCW3N%5\ZZ,?\E1?Y<F_ALL"NZ><=6/%NM#_YM]N^?L>9
MG].K#':PV^^MY?O<?0?@@ \NH*WW3>%'=\?ZE1?Y=1U]T^X[L?L=U8C['_!M
MMU]_/]C/\^SL\>I[>5GTH._[U'YK,%_,KCW3>$Q_'XV_\E16\\%URN&[H)W1
M>:G#*^C<N!BRXN-(FIHB>H&V,/'PD,*,T4])2IAM:::%84T0*@5O&7"Y PT&
M.C1BY$\,5_E18CB,LKX@]C'1QF64RLBC;'&T E[W. #6V(M_2<YS&,:Y[VM/
M/@X>\+IIWT_9D43XHG3S.FI:&%D$+6M>997OA :VSFAHS=(]\<<;7R/8UUU.
M<<G=/XZ/J,DU<&Y^'MB)$6K3%6VEHMBAY(F.L]S@GXL*7BJ:_'2$DZ;3K'(B
MB E%NOPK*))&>KX<PSR9*S%Q'2NT3-'*U[*>6"%LL;BVHJF.C;)'&6/?QD,[
MP&EQ,8#_ (NKER\-.&C&4DHFX^*K$C::6FH*6HAE?'45<#HV2Q4SHY)"^CJ)
M&LC>\NB;Q@^#>U9%\='=0I;)_>K$<$W'YGQW7Y396HA,.S%;#,-DZR,ZY2,I
M?LZ$ %M-P*<XD%D,.,J90I#F45CJL6DTK12 -,K2Y\&@#)$USGPM)B%YAH.'
M%_&N"+9&TP\,N&DVG\*5G%F=I=)AD+&F6G8]\M.TNI;&I:&.'$7,A<"-$6-J
M?^CZ[J.K$4IN1LJTSCQ(\*I.PE74F8?#&*-+9B\XHN<'O"A@FEDMB9>6P,&4
M^[A+0[JT!5XL=#[Q4??"1'_)'6>6M+G!AT/AEK6N<0VY :XG)IL'#7AF>+(;
M4$3%S8?YICM*6->]XC/8WPRUC'N<&WT6L<XV#7$>#W'WW41(Q)3%@EBVXZ,/
MF)W FQ=5(5608R8L\(>Y8\)HF,0^!#J=94$++4AIC$/(I>=;>CSV19[+Q0 N
MXJ5P8QSY0VF)XIK7S1N,MF?>]%U/->Y '%O!(+'AM_?GPQT7.#I2(XWRS:.%
MQ$T[8Y:B%YG'8WWH-?25 <7V#>*D!(+) S.3QW=U.$F[#6"K,Z/:*R) F25:
M7M+MRN?6W:)>$@X%J-BF:HZ9+$R<E88ED4:.;)?<P3E6&\][<PG4U&*-DEA=
M$X31-B<^$QCC;321Q1!C TN>7OE8&AH<3I<A6IX7\,6S34[GN%13LA?)!V#2
M\=:HEAAA#(A"7R.DDGB#&QASCI7MD;9\<;_=6O!0,P[8CA!";BY1CDE;'U-D
MFN3G>**0"FS#^8!3D*--(W%K"()PI.'9=TM30+#J\CX(N)L4T&R&&0-,YIW
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M0TRRTA+;333:<(;;;;1C"$-H1C"4(3C"4IQA*<8QC&-?4ZM2]_
ML !D  ,@ -06312I\E\]_P"+ _F(VMZGY4=ZI_V$2O)\<\S?JA0-8*B:(FB)
MHB:(FB*>W]"S/M^-_-Y76[?P:;O]/^SJE8?$=^<WT/4#6"JFB)HB:(FB)HBR
M,_MK7^$1^^QK2'Y6+OC/K!2W6.<>E;<UZXN_31$T1-$31$T1-$31$T16"LLX
M$$[ZVZO/2(Y90\AO&,=-'9G"F7<YSS]'GCUO1T11^D)Z21[I;^2:(G2$])(]
MTM_)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2W\DT1.
MD)Z21[I;^2:(G2$])(]TM_)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0GI)'NE
MOY)HB=(3TDCW2W\DT1.D)Z21[I;^2:(G2$])(]TM_)-$3I">DD>Z6_DFB)TA
M/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2W\DT1.D)Z21[I;^2:(G2$])(]TM_
M)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2W\DT1.D)Z
M21[I;^2:(M<;O6"OUC;&[V"<-9A8B)KYQLA*R1[#   S2,=,@IYP=I#;*.>.
MDI3B,8Y^/&NNQ>1D6&5LDCFL8R!SG.<0&M MF2<@!M.Q<2NJ(*2DJ*FJFC@I
MX8S)--*YK(XV"UWO>XAK6C:219>N^L<7'#4/A."]]=KV,8SRSEVXPR.SER[>
M9>/%V8[<:\JDQ'#\[5E-K!'WUG/ORY-7.OCSPPX+7(]\&$D[?Y; >?\ I]*V
MB/QD<*B4?J^(;:)/8GQWB!QV]N,^,SGS\79K,XA0D-M5T^T?*MWWW\_L%B>%
MO!BYMCV%<G\M@U>.L^>,SA/QX^(G:#'KWJ!Q_P!,U'9]%W5!Y1O6GOLX,_E[
M"OUV#[:\?Z,[A-_[XO9[]W<!\LT[/HNZH/*-ZU/OKX-?EW"_UR'[:\<\:/"5
MCQ\1NSV/7O<#C_IFG9U'W5!GJ^^-S\ZGWU<&_P N89^MP_:7C_1J<)'_ 'QV
MSG[O(#Y;J>SJ/NF'RC>M/?3P<.K&\,/_ #</VEXYXUN$;'CXD-F\?^OD!\LT
M[.H^Z8?*-ZU/OHX.?EO#?UN+[2_,\;'")CQ\2.S6/7OL!\LT[.H^Z8?*-ZT]
M]'!TZL:PT_\ -1?:7CGC;X0L>/B3V9QZ]^K^/^FZD5E*=51#X[>M3[Y^#Q_M
MK#OUJ(>EREE<<'!\IB-2GB7V6RIL)Q#F,;@5[FA>9 ]S"58Z[V9RVXA?+Z5:
M<^+.-;RUE(64X%3 2V%S7 2LR/9$[K'/(Z+FGF(5SPEX/V9_/.&_%/XW#\YW
M^]RCI"@_T;W!_CQ\2VRV/\H%=^7:P-92C\8A\=I]!4>^3@_^6<._6HOM+QSQ
MQ<'F/'Q,;*X]?<"O?+=3V73:^R(?*-\^>2>^7@_^6<._6HOM+\SQQ\'>/'Q,
M[*8]?<&N_+M3V53_ $\7CMZU/OCP'\KX?^M1?:7C_1S<'&/[YO9/_.%7<_D.
MT[)ISJFB/_&WK3WQX#^5\/\ UJ+[2\?Z.C@VQX^)S9/'^4*N_+M3V1!]-'X[
M>M/?%@/Y7P_]9B^TO'/'7P:8\?$_LCCU]PZYC_IVG9,&KCH_&'IU*??#@7Y6
MH/UF+[2F!\>'!>W@SI\46QR.F"\A'2W%K>.DM2F\X2G^G^U6<8SRQCMSRSK>
M&H@ FO-&+PN NX9DEM@,\R>1:-X08& [^=J#-A _E,1OF-5G*!_1W\&';_71
M;'8Y>/GN+6\?E/QK'CX?I&>,%4<(,$.K%:']9C'I<O'^CRX+L>/BCV.Q_E%K
M?R_3CX?I&>,%/;[!?RI0_K,7VEXYX]."S'CXI=C,>ON/6OE^IXZ+Z1O2$[?8
M+^5*']9B^TO'^CWX*<>/BFV,Q_E&K?R_3C8_I&>,+]%[J>WN#?E.B_6(_M+G
MFV_%-PW[P6)51VLWQVOW M*8\J5\S]4N4),R^8T);#9AJ  BW2%L#+)8P^M#
M:L-8<PM?)&%*Q+9&.-FN!.NP*WI\3P^KDXJEK::>71+^+BF8]^BT@%VB"387
M%]UUOO5USDT13Y+Y[_Q8'\Q&UO4_*CO5/^PB5Y/CGF;]4*!K!431$T1-$31$
MT13V_H69]OQOYO*ZW;^#3=_I_P!G5*P^([\YOH>H&L%5-$31$T1-$31%D9_;
M6O\ "(_?8UI#\K%WQGU@I;K'./2MN:]<7?KH-N/Q?2E!XB9.C>"!Y+:^N5TF
MN39[<%8D'*WD>H<YNM&0R+HAAZH A/5:.KE?;A'^_6 JQW>.?0RV$%E)/RM9
MP@?28O)2\4'T4,)AE>(I@[MB:26O9'V38T[6.IV0Q"(WF=/5,( :WX7R=9PB
MDI,9?2<4'T,,+H9'B&8.[9&DEKV1]E &F8PP,AA$1O,Z>J:;!C?A5!O'<V].
MQ1-=J$#*4(-FTD6Z6:N+9TT1BO\ #_0]]5 4T8&.5&R4ZPU<#:PY#EF(=.E8
M);:'HY12\!T?PH!E8Z*GBDI&"<U$@J0Z0\3A-+BFC3-8S0DE J'0\6YP+GQ$
M LTO@YOX5 RQNAIXI*1@J#4R"I#Y3Q.$4F*Z%,UK-"24"I= 8W.!=)$0"S2.
MC32''1*C3\:2_5(H6+AHJY"62&A+A%V>NS<^:-PV'[>F![C^!HQF*BXL??#O
M-[=7#K;K^1I(O*)D,  DW%_">1LT9,$8CC94MFCBJ&3PR3.;@KZ1S:WBHVLC
M8,4M5.XLB'1>[[XUC'.Q?PJD;-&33QM9''4MGBBJ(YX9)G-P1]&YM;Q<;8XV
M-Q6U63&>)T7NM*QC'/N"./P4>5%AD[6$R)L=$WJ;N?@2VOS @$5MY8MW:]8)
M2F28=.5%VZ,6[LY-KB")PVADS14[7(R+"+-\T2*]J>%31(V/L%SW,CJI:DQ3
MND:V.CFQ&&:2F>VFT*AE\-E,9E=2NE,L+(VN=QPAU=PM:V1L0H'/<R.KEJ>*
MJ#(UC**;$89GTSVT_%U#+X;*8W2OI#*Z6&-C7/XX0Y2N/Z"A8RP$66DQ8!T!
M7[S-95$;DQ4Y69DZK4K:&]P]<@+2J!C&9.=L$5NX""2 W'((B)B"DAQV9L-\
M.0<EW"N*)DSIZ9C70PU4OWNL9+#(^GIL.JHX8IS%&V266/$6L+0V\<D3P!*T
MM>9=PNBBCF=/2L8^"&JE/%UL<L$CH*7#JN."&HXI@DFFCQ%C"P,#HY(G@"5C
MF/.WF^*2,:JO$98YBNIAR]@'K AVO)DI"3G+",$J=8J1:6DUT")2O< F&0BL
MBUJ<M[:UGM1DB='V(62A >P&.,$&,320Z#L),UX0][Y9FLXT0. XED=ZMT5H
M&PRU .D&/>R9LD3.Q&.Q\1C,TD/%NP@S PA[Y)I@SC13N $+([U;HK0-@EJ
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MEI127<MHS@*>G:W0;!"UEGMT!$P-T9+<8W1#;6DL-,6LZPTKV""FIFLXMM/
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MBXPN0%6"Y*C"1U9AG,R; ;Q3 ;SQ+K0W6G7T,=;;&('Y%-A--2RB9CIGO:"
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MG[3;6X,:U\*^]^Q4!9("2EZM13DVB%NF[(5P8C%@AAQL-!HCF)^1D6T&$$!
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M^.<QPBO_ ,O?+GN2->:JWN%'B&5S_P" +>97DY;6W?/V?0@OYYY\N7H;-AQ
M6O0U@U?BT_+;^A:U\SG;/-:#@_PE']@8W<:K877_ .7*J'^$GB%7S_K?-Z<^
MA^IVKO.?_P""[?)CT?)S[=;MBKNXJP<G8TW@_H6UW)V=.6S<#X3-U8#C@VYX
M37^J#VS5,1P?<1"^?1X?=[.?_HHO>?R0/E^_Y<>/6S8JX?BE6-_\GFYOF>'7
MRG:N0S".$P_L'&[:_P#9=>#?PP!9JSP*<25OM-?J[.QVZD)FP3,=$8FK'MW<
M(: AT'E-CN2DU*G0S @$6 VXHHTEYU.&F&EY3A2\(1GDPP5LCV,[&J&Z3@W2
M?!(UC;V&DYY;9H&LDG5S9]E18+PDJJFGINTN*PF>6.+C:C#ZR&"'3<&\9++)
M"UD<<8)<]SG !H-KD"_V*;,[60&R.U5"VFK#A+\)0JU'5\,LQ:UE'K%;Z1LD
M3TG',-O21[A1[@[2L##+)R.(AH9III'VD48BC9&-3&AMSF389D\YN?"OTWAU
M%'AU#2T,3G.92PLB#W$ESRT?">;DV+W%SB!DV^BVP "V;K1<U3S/G>*^T'/X
MTDM;S?)TO>'?XFH5G:F?FGZ[E U@JIHB:(FB)HB:(K #Q'_<]_\ ?M:W@U3]
MX?Z6J[-3_P P^EJK]8*B:(FB)HB:(FB)HBGR7SW_ (L#^8C:WJ?E1WJG_81*
M\GQSS-^J% U@J)HB:(FB)HB:(I[?T+,^WXW\WE=;M_!IN_T_[.J5A\1WYS?0
M]0-8*J:(FB)HB:(FB+(S^VM?X1'[[&M(?E8N^,^L%+=8YQZ5MS7KB[]-$31$
MT1-$31$T1-$31%+Z#"&&7'$/+4[EW]@\AM*<-J2G'8IAW.<YY\\YZ6/6T1>'
M2$])(]TM_)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2
MW\DT1.D)Z21[I;^2:(G2$])(]TM_)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0
MGI)'NEOY)HB=(3TDCW2W\DT1.D)Z21[I;^2:(G2$])(]TM_)-$3I">DD>Z6_
MDFB)TA/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2W\DT1.D)Z21[I;^2:(G2$]
M)(]TM_)-$3I">DD>Z6_DFB)TA/22/=+?R31$Z0GI)'NEOY)HB=(3TDCW2W\D
MT1.D)Z21[I;^2:(G2$])(]TM_)-$6D.)0^+CMA-V3C'4@"C4F:=?,-/'8%'1
M@?.,N/O.L,MMHQG.,94MU&.><8Z6.>N%B+V,H:I\CVQL;$XN>]P:QHR^$YSB
M  -Y("PJIH:>GEGGEC@AB87R33/;%%&P:W/D>6L8T;7.( VE>GK:+>3:F/<:
M\(;H;>1^,91E63+K6Q<=J<\^??Y-&/'R[/L8QZ_G,]=0NMHUE(XW RJ(K@7S
MU/\ ;:OG#P@P!VK',(.1M;$Z(YY6_K_87-Q9=^*_Q'</30C.']^-F6<XPC&<
M.[H4AO..6<<\9PN<3GL[<>+T-=<:JETC_*8-1SXZ/YOYRP?CV!FUL9PHVO>V
M(T9MJ_[9<FSQ,\-Z?V7$%LCCU]UZ'C\L]JO9-/\ 3P^59]I4[=X+^5\+_P#$
M*3]\L>>)[AJQX^(;8W'K[LT''Y9_4]D0?31>49]I6[=8.=6+8:?^?I?WJQYX
MH^&7'CXB]B<>ON[M_C\MAU/'0_2Q^4;UJ>V^$_E3#OUVF_>KPSQ4<,">U7$?
ML,G'ESN_M[C\MBU/&Q_2,\=O6I[;86=6)8>?^<IOWBL8/B1X=K/,1U>K6_>R
MUAGY@IL&(@X/=*C2TQ*&O9Z+(<=& 3I!IQ3JNQL<9AUUS/8E&<ZD/8=3VGF<
M#Z"M&8A02O:R.NHY'O(#&,J87O<3J#6M>2XG8 "2MT:LN8FB*>9\[Q7V@Y_&
MDEK>;Y.E[P[_ !-0K.U,_-/UW*!K!531$T1-$31$T16 'B/^Y[_[]K6\']?W
MA_I:KL_I_F'TA5^L%1-$31$T1-$31$T13Y+Y[_Q8'\Q&UO4_*CO5/^PB5Y/C
MGF;]4*!K!431$T1-$31$T13V_H69]OQOYO*ZW;^#3=_I_P!G5*P^([\YOH>H
M&L%5-$31$T1-$31%D9_;6O\ "(_?8UI#\K%WQGU@I;K'./2MN:]<7?IHB:(F
MB)HB:(FB)HB:(I;WSH'ZY/[]&B+U2;T<=VY6U]^XK-MPZG1SK%5'HNN\*:"1
MI]WS:6V%V=V<W.WBSN0./.CY.B]LH;>J"W&4%6GZS)3>W-:NXXKK<E7G9ATK
M!M['IU;R!:]MW^JY[8>.%2JS7PH* 2!?):=A(HETWJQ,&WB,M7#(#='!X_!^
M)+ QL1Q#AMP;CCKC@;X."#LN)>%P04$6]N4CU*%5^."ZF,UC%DVJCV+)<S!Z
M[7J9"68)P-<Y+;W7#:&$DY*_2Y # 44I^LX)EXMBFGR@K>'BXA^<-(#KF26O
M>VP7OR9;!?/P]"X[5.Z)N3DJ4V#M)N'=E6@MBR4RHTFKRUAL\'M]!;-<-URO
M;<HY4@;6#-V<.X;\" UMW+L'3)X%*U*N<:RQ'DRY3H_Q/+<CU<IY-BW1O5QI
MPVREPNE?EMNK!-PE#B6"IVR1D]7FW5RTKM5N=NO Q4;7""<3!8Y<3M18HR4E
M7$#,11Q\*4RQ*1+=H/JY-$V!WZND#TD+BMNX] ]OA;+)W?9^RQ$93S;#5;#U
M&U5:8EA-QX3AFE>+=BICQK#S+$A'';0QXPRK,').LM;@R+=7$C)**'?M*2BU
M[6V[^<#EVWZ+J3#<;LE*!3116S$E"8@*Q6+":9*VU3<6>O<;>[<K8C:0.M#,
MU%V[VA.ZMFVT+G:4N%HQ4C-U>Q59V+B#YZ=C*^62W+M(Z!<\GGMRVS7%A.Z'
M)GHNJR]/V$NLZ);(Z"2+D^U5.M/!6B:V.O&_[M>/#EGDGL#PU*VTN04I++$2
M[YH\U>."B3!IB:D*J0#7F,O1<"_GOS7Y+]GMF>(.+WDLES@1*Q,51-=AJ-9X
M%%GP0%-VVHWJ)(D8VW 1BH],6[6G21B8H25@;%96%284G$S.8">BS89HH]O;
MV]"[#:(FB)HBZG[N\0\IMK<KO560*ZXY#4K8&P5)J4()8/LTQNQO7:=JK#%"
M,(+95(YA60:DL!B-:44W,V8$<WOR)*-'64VRORGS 'K77/=#NBWF7VUOLW7-
MJ90.\1VV%DW-HHEOL-39K4A6(ZF;ZV"-LDZ:Q80$-K7(; W%KS$C23$])1Q$
M&5X1AVR; 15"G1-P#OMESCK!_CDMF&<;<7 21L',TZ5-.(MMLIU3E,-L5>$M
M%H#XM)_A=@ZF$8;(S\:R3!20U?L-ZF#9L*236)@>WP5'>'>E*]62BW7YK_Z>
M%0(WC=P'<K%5+)25EYC-Q:'7''X":KS>(2O;H3&U-$ICK;ITZX)?)-O<'<5U
M-D,K) D/#U()J9[X^6;!QU@);5S$]%_4%48[HO36!7RC=I=T\^9S:JP[K[E#
M14#(FD;;1T+C>W":_979",AHV.LJ"]AK9"S($W(P:09N7JR(1VSPATG/0Q+:
MN7+T=?\ HNS?#]NK8]V8.^REGA(>O'U7=6WT)F+AI46>'8%K"(MKF_-@&E@R
MI:BR2^F4,W&YPSA@<R'BY%@P1LH]NE;P/-'C039$M2D"@"$&DK2A3BD#BLK?
M>4EM&%+6I+;:LX0A.5*SCHIQG.<8U9C2][6-^,]S6MN;"[B +DY#,ZRKQQNE
MDCB8 7RO;&P$@ N>X-:"38 7(N20!K.2Z1USBWM8\%?9_<#9F[10\')Q!=0'
MBH&42]9ZE/#R)(1069-#+LC)"L1!I!>!A1Q&V7A,DK#;P4^/W&+8=2T$=,^F
MK(ZHO#XZAC'L>^*>/1TP6L)T6$. ;I$F[7#8OI^$.!4&%1T#Z'%*>O=,V6&L
MC9-$^2FK:<L$K7,B+A'$[C&A@>]SM)K\RT G8,KQ?;3Q(I9SR;,\"*3%YR6Q
M E]Y>A9'-86NQ#=^PRLZ-""M DH0B,2>7X+0P6D?/A6(;.Z2XSY/X7Z+\_(O
MF-!W)T[=W/YN555KXR=OJF0E@JMW(OOIMVA&,C@Q[3BK11$4EV8K) Y4BR^+
M():MLD[UAU'@QI%,L2G3DX<A\R8D#S^;GMX-]LD#"=HV;=F>=_!SFX5T/Q@[
M(G9=Q%REDE\MO$#?]C*=8B4Y*"A2;!(,..8 2T)B.BA^L%DG+%!1WS*&RG5!
MR> 5QJV^Q]::#N0<Y'JOTZN5?LWQ9[:U>7F@;*+8XN+C8VN34;/MQ:Y(*P05
MB9A\(GHP:.40<Y# 2=@@X0X]##S0TI(M#D]7Z#N43_#S^V:@-)U<N6ZWKU\V
MLJA/XT]J(^R3E=6%:R,P1Q01,H+"/NQRTQ8MA+GR$J_4D]&"8K9I)K*1W"'P
MLI*CFS<(=;1!(&N_/LVGU*= VOE[>#?ESK/QO8>.X-M_>LBK"(*VLEU/AN.-
M/."/.LL*<&6\.MQAU;"\Y:6XPXXTO*<J;6I&4JS\]PM=H<&L:=\VAE/H7QW#
MXVX&\(S?5A=1GT67Q@OU_..?ZC/H^AS_ "XSXL>3R\NS7YC;5YC,<FSK/HY5
M^*!*=CNG9MV6N+&YRUW%M:IGZZG//FRG\'EGR^A]C/;V>CR\FN0VKU9[=_FV
MG6,M2U;4/;8W.[7S[/:V6>Q4A%8:5XVLX\F,8QGE^3/DSZ_+RZW;5C?ER^U\
MR=>[+/);LK9&V^%JU$Y99>F_1N5$34FU<\83CR\LXSC'E\G\_1^QR&U6K/7E
MK]1WG58>E<MF(N&LFVS;MM;F)Z>6ZH":=SY\FN>,>+EC&<9_EY^7UO7Y;-J;
M;=6O/V%C>U[6WZRN6S$AE<VW []WAZB<KKCA5.SV_K/CY_VO+_Y\^>/Q<\^C
MSY#:MP_I'VU[LM1Z=6:YD>(CYUMFO5SZLO;6,X,9%R]9FXBR5\PN'GJ_*@3<
M)+ .*8.BY>*+:.C9 -Y/ZMDH(QAD@=U/ZIMUM"D\\IQSY+*T@C/,9W!L=?*-
MXM:]\M>2YT&)OB>R2.4L?$YKV/:;.:]ITFN:1F"'"XSN+:]2^]'AXO%OW*V+
MVGOU_KKE5N=NHE>G+'!N80WU>2.CVG7BFQTY4H(:4QE,L+'/YP9&C',@')28
M,^G'U<+W211O<TM<]C7%IU@D7\%]=ME['-?IG"JF>MPVAJZF(P3U%+#++&;#
M1>]@)( ^*'_':P_"8UP:ZS@0MRZU78*>9\[Q7V@Y_&DEK>;Y.E[P[_$U"L[4
MS\T_7<H&L%5-$31$T1-$31%8 >(_[GO_ +]K6\&J?O#_ $M5V:G_ )A]+57Z
MP5$T1-$31$T1-$31%/DOGO\ Q8'\Q&UO4_*CO5/^PB5Y/CGF;]4*!K!431$T
M1-$31$T13V_H69]OQOYO*ZW;^#3=_I_V=4K#XCOSF^AZ@:P54T1-$31$T1-$
M61G]M:_PB/WV-:0_*Q=\9]8*6ZQSCTK<J0RU)2I(I*DJQA25)8=RE2<XYX4G
M.$YQG&<9QG&<9Y9QVXUZXN_7[U$WU&5[G=^!HB=1-]1E>YW?@:(G43?497N=
MWX&B)U$WU&5[G=^!HB=1-]1E>YW?@:(G43?497N=WX&B)U$WU&5[G=^!HB=1
M-]1E>YW?@:(I+PA75A$]6(Z6,D<T]Y<YXYK3RYXZ//'/T.?C]#1%PDW;BHR1
M9!\C0ZX><8<;)EFFU>,*+*DI*L,4F1D2"7P7'GSCZ8*-432W5J(*K [$ ^XY
M%--B)(J)&R&UC<^=:V]H=OV[3*"10$G944"NIGY$&!\$> PCIE,3B1+$AO,_
M ^"AB"7&8[P)$=30SX-#[R2YW^QUKC%MX8=D;M'JB;!L]228PBW#WF6CV:;"
MC!62QLS!-A>+M(K,8EBR-R4X63+S \PV8U+23SAIZ7R5J=R4W(VG5;P<FY<F
M/V.VIE1(P"4V?V]D@84^+E88(_;^MF"1,I"0H-;A9*,&(B'&0#XBNQD; Q9@
MJ&B (6/!BQ'&@1!V&RA51'#SM0?N#9-TYC;*MS]\M,&+69.QV&MQ\[(MUT>'
MD8!^#CB90$IZ,B):'EI"/G8X)QD.:&*=9DF26UJ3DIN; ; L6X7#GM)NB+:F
M[AMC7C92Y4H_;N>M8D )&W8BER+#@Y5;;N((K%B9A7&W7$+B4R&8QYM;@Y(;
MXSS[#I1<[^7P[U5T3A<V:V^H4AMM$[90$I5)MU]^QQ]FKL9/M65Q^US=Y2W-
M"G1RHXB."MUCG9^%@V 1H"O2$J:[ 1<9A]:<DO?V\'J6P(_:BA1(H0,5MK4(
MP&,RSF-#CZ=#!"Q^1Z_(5,?(0XT<VR)EBJR\K66<L(;[U7Y.0AD=&.-)&=(L
M]9VQI5+.F9.G;>5:IR5CQ'XL,A6:G$P)T[B(:>8BL3)<7'BD2F(Q@DAF/P<X
M_@)I]YL;O2'5X41<PZH7ZF(]I<^#HB=4+]3$>TN?!T1.J%^IB/:7/@Z(J.3I
ML+-24),S%4BY:7K)!!=;E9.#$/DJ^46TE@LF$.*%=*BB"F$I9(> ='<>:2EM
MQ2D8PG!%7R>VU/FAF@IF@UN6#97'N,B2=6BSQFG(EV0?BEM,% .M-KC'Y:5>
MCU(1A03LG(.#9:6:2ITBQ&;84J1?DBI#;RK'$S,1(0$N094HDI^5@I:3(FI6
M$DGGX];AT1)S!14M(1I2G0S),D@\EEPIYQU1%ESMO4%$0Y:J%6\EUUPAVOE9
MJT9DB"=+CAX@IV'>R#WR,<)B1!8PA82F%/1PPX3F5#,MM)(HH>U-#CLP2H_;
M:H@JJXDH!6<ATZ&%S709SOWAH*"RQ'(S$"3'6'_"@T?U=F0[^]UM#W?%](BO
MH&I1-6C6(6L5F.KD.*E*1HF!A1HB-'2EM#24L QXPXK*4M--M)PVTG&&VT(Q
MR2A.,$5LL$A:5(6&\M"TY2M"QUJ2I*L9PI*DY1G"DJQG.,XSC.,XSG&<<M 2
M#<&Q&8(U@[T!(-P;$9@C6#O7%L[=5ARM!4TJH1TE5(YL5D&O3$4B9B1605X7
M'LLARS1C*&8[*4(CF<)[W'LM,,!I8889;1>61\TCY97:<CW:3W$ %SCK<ZP
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MGHC)!8KSJ0R<MD6&0W5VRB+.9297<BB1ERCZ\9;CZE(7"OA6<&J1[6'C[.9
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MLX;:<4G@"@K7%H925,AD#G1\7!*\2L:\1N?$6-(D8'D-TV%S=(@7N0N::NE
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MT3N@G3OZ-1&Y<X9^9V;Z1A*L<3E.3SQZ.VLUGQ>AV6O'\NKGAS2D98;.-_\
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M@F00PMJ.$RG!1[J77DY;"&RM&""E8PPSE:<..)RK',BC,6F+*>CAAK& 21,
M*E8AAB7'>>E(Q&&E+DHYILA2S@$)?84HP9+HZ</-9RYC#B.D16W6B?5#_MSG
MPM$3K1/JA_VYSX6B)UHGU0_[<Y\+1$ZT3ZH?]N<^%HB=:)]4/^W.?"T1?F3'
M\<\9*>QG&,9SC+Z\<L*SG"<Y_5=F%9QG&/+G&<8[<:(L),GD(8@PR0ZH((PZ
M24427W@889AM3KY!#[KB&F6&6D*<==<4EMMM*EK4E.,YP194&O.8RILMUQ.%
MN-Y4@A2L86TM33J,Y2O.,+;<0MMQ/C0M*D*QA2<XP18F93K*B$CR/6%"/Y%*
M2R7WU0Q*6VGE#D8;<5EE]+3S+N67,)<PVZTO*>BXG.2+/UHGU0_[<Y\+1%A9
MD\DY>P/(9?R.^L8C#)??<L$MX2IP=[H.*[T^A*T*6TOHN)PM.5)QA6.9%FZT
M3ZH?]N<^%HB=:)]4/^W.?"T1.M$^J'_;G/A:(G6B?5#_ +<Y\+1%HV1XF]H8
MNXS&WY%[4]<H1E+I4!'QMBDS"5^$@H@D2(S'QI+$W(1DC(A#34?$/&&0F7E.
MRS(3(Y3C'S]9PIP*@FFIZFMT9X2UIBBIZFHDDD=,R Q0,IX975$T<DC!-%"'
MOA;IOE#&12N9]1CO OA1P:X%X=[H.-8/4T?!/%:^FPRAQ*\4\DU96Q3ST$;L
M.IY)<3A9B%/35-103ST<=/5T]/-/!*^%FF;"G\1.U5^O,OMM4;Z/,W6"A [%
M)PC+4NPZQ$FM .H>008&.&^^.B5CDR 3!#AT8\6@>0'&(0\TU]Z_@SCD?!?"
M.&;\/E;P:QUS6X7B9=&&5&FV5\9,!?V5 )6PS.B-1#$)!&[1OE?R'"/=%X%X
M[PGQ+@;A./4M9PEPBAAQ'$,+CCJ6R04DS:9PD$TD#*:9\0K*45$,,TDU,^=C
M*B.-^DUNXNM$^J'_ &YSX6NB7VRZM\;.[F=D^$W?W=@R++LPU"VYF["_ ,R?
M@UV6;#2WA0:#G1CFQ5.]/L>6&0E'+M:5KN>#U*:[&\-I \1FHJ61!Y;I!ND'
M"Y:"TGFN.==?BLO$X=5RVOQ<+G6O:]B,KV-@=1-BODIA_F@:K0_+^M9L#W1Q
MRYXW:CF_L<NW;]6,?8\?+L[<Z]U;P*ECN>SVG_ER-G?CE8ZUYL[%6NL>)//Q
M@SV?,&O?M]/-&OFD"KCX_P#NCV-?9G'9O'&8Y^+/_%SGR?HQG5SP2F MV9'?
M*_WEVR^><@W^O:H[8M^C/C#ERU9;,]7,O!WYI.JR<\\\(5E\7+_^LL9X^?E\
M[?[.LW<$YA^-L-M?WEW[RWG4&N:XBS#J^<.7D]MFU1%?-*U53X^$"S9_RRQ?
M^[?.LSP7F'XTP_HG#_WIV6/F'QOX=.Y1E_-+]41S_K/K-GE_YZ(K'K>/;;69
MX-RC\9;Y(@>=Z"J;M;;P_P#^JB+^:::HCQ\'5G_STQ6/_AK[.?Y=9G@_*/QA
MODB/2]7%0#_1Z'7]2Y)0?FEC:ZQWJH5RY\,EGH-4GK)#P]AO"MTHZPM5"(DC
MF!#;*3",4.,(DPX5EY4@:(,<P4X(P]@7OK_>F7,WX%*UKBV8.<&DM;Q9&D1>
MS;Z1 +CD#;:%(G!(N"+VSOD%],PQ(QHPY@9#!89;#1(I0SK;XQ(S[:76"!WV
ME+:>8>:6AQIUM2FW&U)6A2DJQG/1$$$@BQ&1!U@[BMUGT16\E\Y5_P"Y#W\?
M3>L8OCU'?F_X>!;2_$I^\N_Q$ZJ-;+%-$31$T1-$31%<1'[&6^XY7\*-K&;7
M#WYOU'K>#5/WA_I:J?6RP31$T1-$31$T1-$5O.?1#'VA$?Q0#K&#Y/\ 23?M
MI%M/\I^CA_8QJHULL4T1-$31$T1-$5NS] 9+[KPGYE8-8N_"(N\S_7IULW\'
ME[]!]2H51K98IHB:(FB)HB:(I(7SX)]LL?PJ-9S?)2][?]4J\?RD?Y[?K!=Q
M]>1KTU-$31$T1-$31$T1-$31%+>^= _7)_?HT1>N??CA,E+YN#OC?:O2=N#R
M+I1.#P4 699CXQZ^D;(<1&[&Z.].WMEDVH21>!AMW]M;!!;:2DC(#RL9- 3A
MD?8XXZ#C2!7RFXMJO\;S@ =!S6M;;PR[CV?<?<RW0&S,1MO![D<);VT%?J4!
M([(*@*K><2W%H>6=<'\TQZVQK\XO>6IRZR]I+,* ]-R=@;M;]E#!P^64@V %
M]3K[<]6K9LVVV+EVUO<_JDS!2=:WA8=L>*[O,]N33+'$/5NNOV0">VJVIJ\L
M-9*S3:Q6JA7"X\JFDTEURDU^N$ST)  W<N13<KI<2RRB_HMT^U^?D47BLX1]
MT-[-Y@K]3BJ_%MUY_92WTR=DY%Q+T#N7LGMSQVKI<Z5%M,*=.CH3=C>O960+
M!2ZE,O!MV5A?1;#<;((#:_*+><7\UUI>2X#>('<.%W'JUFL=!I7]$)>([>_>
MJTOC2VXK3%_'VN.C8FJ5^) L.W4R:WM7N?/UF9VDNA4\&[ QW#]M\^5$OK(9
MCV2MI"PWC+P>?9>XWN)5O>^$7BMW"W'KN]EX-VBM4_*;95@#<2@B@RL7T JM
MO%P=;KR?#W$6.1L4K SU*M2]G-ZF&9V7K,=&$R6XTXS9(UJ#L@P]:* 0!8;\
MO"""<ARC+DVZUL&C<+>Y4+?^&^P+H\%7T[;;Q;X;MR;X\EMX_6ZQ4MV[AQ.3
M$-MWAR/J@VYYEJV_JV^@U;KL77;8WLP,3(6:0>CC\Q4&J0(3KSU@#GM;/S'9
MZ<O:'HJIHB:(FB)HBZ:;W[);F77<.;E*@S3R:ON34MBZ9;9">L<K#3%+&V;W
MELVY!,O#PP56G!;>NPP=TF(X6/?F:QD&;AHIL@MV-FC9&!*0<MNVUN46SSU9
M>E=:-VN%#BZN&VEPH,?NEFS1]]VY.AK'$6#?+<ZNH<W%L-5X@JS)3P]C J]@
MDAZ#&>:?8U]W;$((.GV7S,3Y<I"X,9+9NQ3=MP<P ;ZAJRRUCE]:V+-[$<5X
MTU/.52YPR*[,2EX/.B6]T[]3^^PDWQA63>#$+56ZG B U2V738BQG[<VO< X
M2>LL',-5UVCSU9S&3LW92@D;MEO,!Z<_3>^6$;AXXGHB\JFJ[;8V#KTON%2K
MFH +>6_=]K;<87M,UN(S8^L4DAC>XB^42G6;;^/,OPC>:V<0+=10TS=A/+KQ
M+C+D%O3Z+CG7%@N'OCOP-%#HWNCX1R'V?NM4KYK>Y>X=A,'W%*QOF+7KI?\
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MM$<55XE4M89@>D6J0JL3A=)MVX4?&E6<*+>A_#,Q5J);#(R-9*=(=+C!HDC
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M:$H3CQ)2G&,=F,:@8GB#185E0!<FPE<,R22=>TDD\I4F@HG&YI8"; 7,3";
M  :M@  Y L?G>T;ZTH#WL%^+U/;3$>[:GRK^M1VOH>Y*?R3.I/.]HWUI0'O8
M+\7IVTQ'NVI\J_K3M?0]R4_DF=2>=[1OK2@/>P7XO3MIB/=M3Y5_6G:^A[DI
M_),ZD\[VC?6E >]@OQ>G;3$>[:GRK^M.U]#W)3^29U)YWM&^M* ][!?B].VF
M(]VU/E7]:=KZ'N2G\DSJ3SO:-]:4![V"_%Z=M,1[MJ?*OZT[7T/<E/Y)G4LF
M*%2L-+9Q5H+#3CC;JV\1HW06XREU#2U)[WRRIM+[R49SVIPZO&/V6=1VSQ"X
M=V;4W (!XU]P'$$C7J):TGF"GL"BL6]BP6)!(XIEB0" 2+:P'. W7.]8_.]H
MWUI0'O8+\7J>VF(]VU/E7]:CM?0]R4_DF=2>=[1OK2@/>P7XO3MIB/=M3Y5_
M6G:^A[DI_),ZD\[VC?6E >]@OQ>G;3$>[:GRK^M.U]#W)3^29U)YWM&^M* ]
M[!?B].VF(]VU/E7]:=KZ'N2G\DSJ3SO:-]:4![V"_%Z=M,1[MJ?*OZT[7T/<
ME/Y)G4GG>T;ZTH#WL%^+T[:8CW;4^5?UIVOH>Y*?R3.I>2*!2&UH<;JD"A:%
M)6A:8T;"DK3G"DJ3G#?/&4YQC.,X[<9QSU!Q/$2"#6U)!!!!E?8@Y$'/:I%!
M1 @BDIP0001$RX(S!U;%R_7!7+31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
131$T1-$31$T1-$31$T1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g400206g12p13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g12p13.jpg
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M)2<U5E=C<H*2DY25EK+!T=<T67.$HM+3\-36X?_$ !T! 0 !!0$! 0
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M%$XP<C&^^1BO!;B2G7S%:C2')25.),9MEQ;X4UQ%U)92DN!382HN IRCA5Q
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MR8%7]?3U]LT2JC)XE=&_T]6N;YUTMD:ZQ5Q9 QGVFG0 5LN@$)<1TSC.%)R
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M X$PX$>"PP@Y*EI"FGYCCCBE..RYLIQ1]L 2GSPZV&G%*Z%K:5]'5V5U;%Q
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MT]T@9L2-:97DJGHDXTBHOIZ_9)87>L4[$]DC5]&N;YUSM<6ZQC'E(SU4TZG
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M7.'A;N2[EJV'#ERDQY,QU[]86($5JU!3C+\=IS]7UNMM%;@;FN(*Y#[ZTQD
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M<9WXBYG?-8/8'Q#47:REK_>(O]N+/#_-B47;YWP(Q[.00R%X\.7C:O1/OO\
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M-?5D360E$V->UAV_M(6NW.*CGY7._P#:=^-5_P"W_0?_ -4.<]_W%_Q&O/\
MG[7_ -ZKN_-NO^7/T'?^CO:'_P#"=>=?XF4.>CZ)S*P9W\1.M-7L^F0,KRLU
M76%QUHC_ -F]8LT8(F-U>EM/VN>,DOTN22 (5M:V[^(8KO8,1K>J/HWN#7=6
MM3H=[TC"KP["7$X>4]Q!(CNNKYYVX,A*>#F9/0'Z3_1;7<U=H%T#MS_1LE1_
MU5G<YGLDM.JX6J2/I.T<M3SU[L]JBFSI<X>]I2X^Z9)@\+('$ZW_ $H?ALS8
MJ?P1\79.OV2QYQ.J:2*1D\@LT[=-#,7#N4(E#CA'?/\ MO'HOC.;%'(LOO\
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MKX<Y*H2C0N'(T4<Z4X =/7!UK9& HYH<%?GL\ R!%1GR5!1B*BCT]=&-0+=
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MG*JJKE5555557UYKQ)42I1)).22222>I).Y)\S6WI2E("4@)2D )2D   ;
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ML/MJ:>;5C!X5MK4E6_0FO!'.G6W@QV);^/O<3CH>J+BYL;KI;M*>"62FFJ;
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M/Y)"2R#YA&[AHW3CVC6AJN_-&->W8[J-+V9X!,ME<EM;*[[<6%>U&9CM+<3
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M;)CBG+<Q(9BO3&4AG+\=J3)886XR%I2XZA)W-=6/N7K:4G%!,U "&[ZICOJ
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MJZO'U[V?ZE;#E_T#:2IP!*KUV=WAS3;PS_PJK4^W?M-+6#D\J);;8A0RG*<
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M43W+J-/,F<[<9,E:5W1YVV]SD:^NNOTM"VNPUMJN34^]W" BZNNN)3#3"4U
M:>9E+GVAZRZIK>NJT&-AIA5O#%HTL)*^][!@RYY>HUUML[>V7(:G?;<5;XZX
MMRB#-'9V%OHR'3$0MMX:R5E;![,.$B(A("E%8#W&4NR@RI3SZY#B^0])D)YB
MG'%%3JU+=.2.8$$('+]3:KDZBDOJ+#+4-:K;W=,B#I]RZ1V;7:(EEAQ/IBU6
M"R.]P8A0VFV;;&CP[<V$-K,1<E"I*Y7YFUJE.*4XI3BE0-Y.%=B!=&[LGJU-
M%^UL<5 DDN-"99[<7(2:JCB[(/P=:X<QUCOJ[KE^K.PU? $>6;K!Z<8, XN6
M$294CKO\^6?3S]*HKV-W!WI0O;TIXO!=BSB=B=%]Q=D=6:[M_(]O6_;&2/ZC
MI-T%V /; =]&5.^M2[#M#L#Q8S_4XVT"G4X#3]A6$$EU09VI%8J=L[^8Z8QX
M>7IG./2L1V%WIYOV62[6I>N*75+H NI]I/B;A_BMVGG[>>$'Q2KNQ\SVM5V>
ML(9F2NQ+OR())Z8@\?B*B7:5Z$P796=D@RUM-?*8&1Y9W&1YXQ[@-\^/I6QZ
M?R/\UZ^UUL."ZIL.P3ZJ"5,QC[?Q^[7Z[K=$T6^Z:%P!DO;&BLHLK6R]T@ZO
M<LUL"UQ9/CB*YE[O*69O3NWJMTI@>)^WWY^&!MX^!W%;-UEW-Y+F=G9:MUN6
MUV9PVYTM+8VVO/\ 'KO6Z6VLW=#>%A4.77,3:>Z@\?,[>:S>>0 I]W:_#Q6.
MU'6Q8^D),UE?O3=LH0-_'ZQYD>6_A\<]*],>*IK .U>69>-S#M+0-TKX_BLS
MSKFN2\=%[/B_$;4J2A[H_A_O/>@ZM]GY_7V_?C(Z9W\J5G^*4XI75,!"L(7#
M6 8IP[OYT!@\),+OX?FBF8]B_;[?=O+;K++Z"AYIMY!ZH=0EQ!]Z5@@_"KS$
MA^,X'8S[T=T='&'%M.#W+;4E0^HU6?N_KG&BYP!:BFAH[2^U&?SZ6E3),'("
M$>:DUK(()')]/0N6K$,$#F>(] B2(C4CE^7^#)XSNF;&\XA:H#2%<:3AI3C2
M#@\126VUI;*3C!'!TVZ5L;.MM41FEMHNS[B5(4C+Z&9#B>(8XTO/-+>"T]4G
MC(!W()J*Y>C.N7,F<.!>!&RCL'2U&V&N6R8D2R/'D<05=DL*4>6:69D5A$8+
M)))*A(\\<TT<GIKLUJ6UR56Z'R]\)$=I/"5 )*DE*04K( '&DA6PWV%>.WJ*
M_-/"0B\7+G>SE:IDA7$$*4I*%A3A2ML*6L\M84CVU^S[1SR8;H2QUV(I;TC4
M@.F.'*B,C)IG1PRS5YY5;+/^[-DC2,IX:DHQ(6-C25(VM]&HJZ)(T(5..*C3
MT):4M1;;=842A!)P@N!T\92/9XBD%6,D [5U"%VK<MICO5K=,A#: Y(CRTHY
MC@2 MU#183R@M65< <6$9X0I0&:Y"/#J IRODCP):K]_>10L>Y?Z55SJ^55^
MZ?TK^G,-6@99/^^X1]5-N _ZA^^M@:[:UM !"]0M8&,-7 @#T&)*-OJKL@^(
M+0G-</)B@'-_1P-&C'-_\%6"#JG^!4Y*- RP=YD- \T-N$_#A1]]6G^V?G@A
MQ%\D ]0_/X@??Q/.9^%;D+XQ/]44W8L:B?K&+2*Y5_M)++9M1/[JPK_<3F6W
MH(]7;F!Z-Q"<_P#*5(&/_1->(]VK)W#%D)/]9Z>!\4(B*S_S@^NMI%\=<-71
M2%W%S<DPCQOF(DF*!K@HX8FJ^669S1EDBC8QKG/>I;&L8BN<J(GJGI,Z'M:"
M"\_,?(\.-MI!]X2V5_!P5X\GM/OCN1'BV^,#_2+;S[@]REO);^+1K=<EA.I)
MA&666K<U?B)(Z)MG";#IX%GB]/B-:5,38#LFC56JYL2L=&JI^5OJG/9C:>LL
M7"FH#"E#<+>"I)R/$%]3@2<_U0,'IBM:F:OU).R'KO*0D]41E)AIQ_5(BI9*
MDXV(459'[V:E***.&-D4,;(HHT1K(XF-CC8U/T:QC41K43^"(B)SV4I2D!*4
MA*0,!*0  /( 8 'NK75K6XI2UJ4M:CE2EJ*E*)ZE2B223YDYK[Y-4UI_8=Z7
MEL!N--7I&X_.X_2WH+9F?$B<94TIIXK96>J>^-TX\:/9ZI[FJK?5/7@[ GRI
M41] ]K;OL&DF&WV2!KM)0W.BR6HLLT:R6FKM5E3E"L:NTJK&=EO4$V$#AKBE
MD!=H*BQIS!3);2M*)BJFP,^A\,C\1X?;]5*L9R:4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5U\J+JVJ>F[8*DL":@[7Z/#8!UL
M%(L)M;7;C94>:N2@I6_GA,^CV)\(L\:MD&GEC)C<DD+>01G \R!]1(!J"< G
MR&:U*@H*7+4]?G\]6B5%-5#1B5]<%$V$<>"-/1$:UOW>]Z^LDTTBOFGF>^:>
M2261[W9   P!@58K\O\ /TNIIK'/Z&M$MZ:U&D$/KS8FS#D02)Z*BM=]V2,7
MTDAFC5DP\S63021RQL>V2 1@[@T!QN*KI'>7&XZLZ ZEU%D9;TIO:O:./UQ)
M<SI"=?F^CBM6F:J;MZKZF"V,E7G)+ULRN=9NJI/F'.:7,Q^,D#B"#YJ'U)SM
M]@'J,U>4?9R-MA]N*L_##"/#$./%'!!!&R&&&%C8H88HVHR.**-B-9''&Q$:
MQC&HUK41K41$1.9-6:C?MW+5^JP6@B)11[.FKC-#F;L=5AM,WIJ4:6PIKVH-
MC]" C@#AX9$D@D8LT/Q195?!/+&ZE8!2<^1P?$>.U2#@_?5L.K-*;L^L.N-A
M9-8VQU>#R&E/;$U&1M-O<]76A38V-]$:Q)RI$8U$1&M]$3[)RP-P/<*OUOG)
MI3BE.*4XI3BE.*4XI5+MOY/:G+[;:Y$/#2%#9KM@G!B:>821<[)60^*P??+6
MFF1W41B:-VC(=5?"@K4K_H#H5]R6*O)37Y%X>9DR&!&*DLS3&2\4_LB@65-R
MPI7,XN=S248".'E8_I957:+)V8VNZ62R7=Z^I:=N>E&KZ[;$/)%Q3)<[57=!
M$LLJA*9-N%N;$OC7),CZ0"QCNX#==K5>4BY?:^/N:*$H4"[&H\I==DSR/L4L
M,NSLTL#']8-H(&.</+%?]A%'B6$]G,]E?GZ"U*]73-9(VI^\\B1:V5);X9;;
M#DLDKXF1,4EB&&@-B'92E)4I9PAII9.Y!%JU]EOTI9>T&YM/3R]IR==H6FVT
MIC]WNBM,LOWC5!GK(#B%0-/-,.QT1D),BX3XC6R"I)S79OE+!UOH=-2)U?LM
M.+ESC*@RZJ+7&B!D6X'4=EW>8".-<Z&OL?;#@Z&]?\U*)'!)>1555$Y\-B98
M5%<R]"(Z\WW.0\EE2D*<0N.E)<1 7<5)2EQU*]HS;GM%(!<"$ X6I2,'3/9<
MYJ2WVV;^M%FM;MSCLS&8,R+>GGT0W]71=$,ON.PK=(C97?KA!3RDO%Q,%4N6
ML)7'9CS,+H/*Z!Y-4%F,Q8#PWF^J,[0:.Z0 FMNZC->3747C[V^JU%?:LO*<
M^L.[,5N2F/'=%:.$DMYAF!PB!VU#MZ&4)994 Y);::=<X2AQMF\0;7.]A*PX
MA2%2_P!@5#"^$N$<("5YUO[*5AN4]<[G'<7!L$RXS[="+[<F%+N79EJ[M!T@
M.^2(A@S&)+&F0;LAAP*BI=3$;=4\MYZ)D^N_*T/LUV,BH.J.R@)]V!+J\]^U
M-:-DPSNNAJS(6IFQ"L=%/6AVKPH]S0 D4U1(>Z2R<>H-@93AI<S5Q;TF88X:
MA2TF2DOM<Y 82J($1UJ?2MTI2X4B2TDMME65\?"M2$\PXNHNRE[3 O*[AJO3
M3Z+%(3:KA]%RG;L\QJ-R3>(K-G>CVYN2]$#ZK%/?;FS$QTIC=WY[#,Q[N2-/
MTOFE0U@'7NFKL[=2YZ^QF6[#T%<@,%GHY:3>]2=C;_*YZC@ LT@CTS;3' 5]
MBI?Q:[X5@GP9VQ.<:/CNZ@;0F*ZAEPM.QV9;J.$+>+<F#+E,M-!*\<[CCI2O
MBRG"MCCVAZ]M[&)\F1J"V2+C"3<(%YNFG;?)[PN-;4SK#JW3FG[K<)SC\7F*
MM9BWE^1&Y/#)XXYXVRL!AR8L3WVFKT^8R]MUUN\"5J*B], *W-.;FQCK>AOM
M74E4%&VV#")M3Y*K(D[: 6>"LMY<1=Y[0Q4T@S] W.9\>Y\]YEE<23&4\AU2
M3);4R%.-.OMJ:;"TI4M10P9 !"%F,XT\&RDN\K3[UH,VJV72Z1-16*_-6N7!
M9?:L4QBY.,0Y\"U2VKA.,1YYN)'3+N[=D<=0N5#1?(5PMZYB7$VXW*P7/4KG
M].*4XI3BE.*4XI3BE><B_B*8NLZEU.OL<+J;[LS(9O<; _JG*)5PV%CC\90W
MVBEW5=;Z:TJ:Z+ O92R9,G3%S-6+?L*RX=<<8P9"53C\-SMU^?QJ:NKO*NN[
M)V1O7S>MMY5[*HO=&'K:5&Y:P7K.BJ[TW-T-SV'8 ZB:K235W-5;A58?7QW8
M'P5K#C;&8*J#+/@4QUW'AY[Y\MJTQOG-TS8=FZ/"Y[%=@:_9Y?;C]1(;FJC"
MG3'ZJQTO9^>FS@[B-P)?4 T5_P!'=B2F2;2NRE=)6YD;60RDYBXSEY9J$$?7
M\_/VUC;;\1?H>I"UY:UF[N)<)8Z^+5!Y6#"[!]1G<'AG=EZK:%667WMM00TE
M3B![*Y(I9;B/?H55D9G]BOVN,IJ"T4P?GX??MY9K:][YG8'-19=M)"465=]G
MV^'L)+L6:MKJNHP'DY1>,?:MV\J*2=RR4.IM23Z&)T?PKBN%:9(X:-RQ<4QO
MCTS]F:ZG6GGIT?VP7@ \C'I97=D:4O-9TNPDQ -0^6'+8S9A$.O7[9]*>?<9
MW>41U=@Z"PNNU6*+KH+/ UT_7V^CS2F/N!\?'YZ]/7<5<2Z2S=3VR4KHFW"U
MIZ5+I_;\!MFHLJ .F]R*WX2%?"63W(K?9[O5/3UXJ*H$.3URG7*5U@L'S_P&
MQ6=9*]B]@+V K&N(8\=KET#^RGZ!5EAFB1;Z2^=$4+*Z9T,RW 4< Z8 QZYQ
MC&^^=O>2*L^UQ>.<_9GQQX5?#*-O&9?-MT[HWZ1M!3MT+XO9\)UXE<,ELZ+X
M?[OX;CT(5GP_R>U4]OY?3EOY^<5>K/\ %*<4J$^\%_ZEX9G^J=C4B?\ FZG0
M3_[WP?7_  >J??TY(_>3[Q^?S\/&J5?NGY\:U/E^K-0GE:T#9#U-3IPQ;VAS
MF0I2:BAM8(CJ6&ST&@V)MI<RUA+9 RK28<>L#',*AFFKA1IHZYPOU*S^;LMA
M)R<9P2-_ DDG^_\ C5Q1("=R#C?S\.OCYUN86?H\'H<?=XNGJ\L83L<U0VD.
M? %IP[RGT=I!1G!70E?$./91BQG_ %.N>5'),!9!#S#2Q,>2R>I8 &<8.1TV
MZ[;^>WW5"2<C<G/F:NCRW5VG%*A+O, LVAS4SJ\NVSE9KA+'7UH8<]FZ>GBI
MKN*O**JAHB"+0"JU$^?M2AHAIU%^3CN9&H/53+R1C(R,@'W^!JE6<''S\_PK
M3>J61V?8I6AS(LK<Y^R-C6Z6W@"F#J;R[=;4,N6@@(DA@@NS:, ?4MF)%<2V
MFALT")>R2QBCBE9!.W7&Y^[T/C[OKJ$ C.?'&*L_RFJZ<4KIV->#; &5=F+
M=76 TP9P9,;91RA2(W13CSQN]6R12QN<Q[')Z.:JHOV7BE5UIF)B/*#4T\:?
M!INZNO0=R,QWY8?VWZY-#RNC09B>C/C667N\H44J)[Y'5+Y7JCE]9*?Z1\B,
M_6,#\?GQ59;E5*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2JQ>6O];"A_OP])_\ 2?F./%/]I/\ K"H5T/N/W5\<R*L4XI51\?\
MYKT/_?Z\N_\ CNOYCC^=3_:<_&KI_<^I/X5;CF15JM:V?^<_6?[6KW_DLKD*
MZ'W'[J5,WCW_ %@^C_[T'6G_ #+I>8Z>@]P^ZLBI?Y-*<4IQ2G%*<4IQ2G%*
MP)&6S!DA,I><H2I3;-;HR0BHKYY"[A:)F66V)?*.YT]FN9CCSBGRJ\I:)C*A
M9?I[6CI;++*BHJ:;)4OF*);22I?+#/&K(W7R0&N(Y/+ ;SP[5GMW6YLI:0U<
M9[26(W<F4MS)"$LPQ/5=!$:"7 &XPN:E7'D( :[^I4S@[P2Y6"HNK.L<O5&T
M69ZYP>=H[)@L=C3460S]156$84\Y049M=7UXXA3!"BB216SPR-'G(GFB1DDL
MCG6FH<-E"FF8L9II6 IMIAIM"@DE20I"$!)PI14,@X))&Y-9\[5.I[I+8GW/
M4=^N,Z,IU4:9.N]PERXZGVVVGE,2)$AQYI3S333;I;6DN-MMH62E"0,V;DLK
M9O*DLLSG["0TB4LV0VFKBWEE3T1&6F)*?.-(X@B;,EEYR6:57R2411%0]RU\
MT@[KBF&5E16RTHJ)4HJ;0HJ46RR2K(.265*:).26U%O]TD5@L7:ZQ@TF-<[A
M'2PVAEE+$V2T&6FY[=U0TT&W$AMM%S9:N*$(PE,]IN8 )"$N#%P=;]=BVEG>
M"X+%C75T13%W-O!EJ.&TMB\X8%8YXJSL(P6EGD45A6UQU-,5-+)5F5X10+H)
MQ8'QT")%2M;B8T=+CA;4XX&6PMQ32DJ:*U!/$HM*0A39424*2DIP4@C)7J/4
M+L6-!<OUY<A0FYC,.&NZ3EQ8C5Q9?CW!J-'4^6F&Y\>3)8F(:0A,IF0^T^%H
M=<2K'Q=0=2P0C#0]7==0CA:)FO#'BQ.:CA$UD3/AQZ<:)E8D<&BCC_=LNHFL
MLF,_*TE&_;E(@P0$I$.*$I=#Z0([("7P,!Y(X,!T#8.#V\>-9*]7ZL6MUQ>J
M-1+<>MRK0\XN]W)2W;2I7$JUNK,DJ<MRE>TJ$LF,5;EK-<@G4W58$-B,#UIU
M^$/;R'2VT F-S@T-I+:!VE?9R6,4-:QALEB!>70)SR6RN+#M[08A9(; MDQ,
M*&@+"8D5(65%83':2%E:5I65@( 45I<<2K.>)+BP<A:LTNZLU4^N.X_J74#S
MD-+"(CCMYN+BXJ(KT61%3'4N2I3"8TB#"?82T4AEZ'%=;"5QV5([5-UIUQG#
MZVTSW7^)H;.FK"*2GL:;*T56?4TQ9QEF545I8($! -8396-A8$ "R1"S''&%
MR1.G*GD?4W$B-*0MJ+';6V@MMK;9;0I#94I9;0I*04H*UK64)(25*4HC*B3:
MFZEU'<6),6X:@O<^--E-SID>;=9\IB7-:89C-3)++[[C;\IN-&CQVY#J5NH8
M89:2L-M(2G=N9%>)3BE.*4XI3BE.*4XI5:U\2NBWZG3Z8C& E0ZOHXGQWL,W
M+"(RBBZOM]7K-EK*49XXL%Z[]L;K5OEO&F798<#:>KEH0Z4R:[*N%3D_C^7P
MK;*OQYZ>I-)2;&JQS0=10RGSCWL-[IOJ5I+9O&G+=K"'73G[?U.$@MQF[/Z\
MT&^22_!0:ZGG/D4R?QJ,^M?#?K+K3L;5=D"WV[TYVDW^L[/"SFGM:1V2RFYV
MFJV^KN=)15.>SF>E+NV2=@Z3/UESJ3-);5N4GCI1C6H\\D]0G..FWS\XVK9:
MKQ%\<*:HMJ$#JFA;475#;Y2P **N[&!V4O,C)@3<J)]2M2WUN8APTB8^HSU:
MX2GS^8@#HZ$*MK00QH%1D^=9>/QBZ%CU%IL_Y-**31W%T[0FG$2694+;>395
MG8I)0%:2?+55+3^P*D7<6@M4$$':ZZ6ST=D.5;W5R8>I7)4^-G35)7Y&G R]
MC]"PE\%I,CGCMMO;;-TEE42YPG.0C9VVTYM))2XXS(9:QPF:) GS>"M,_46F
M-J:.P ')8J<GY^?CY^-3IQ45C5IJ=;-MTM56K<-B6!MLH(JV;8%;[%A:>L7S
M21*Q5:L:2^SVK[?3T^W%*R7%*<4IQ2H0[W<@F?RMV0J1U.>W5197ACOM#6UI
M%9>4C; I_P!DA!&L;BO4XN16P ANG.+?$(-/*R1LI.=M_P ^OSZC? ,*&0:\
MT/*ORWN.MM-FNI^JLS8]A]K;6<H7+X^CM :-3HZ\$2QO-/J-8<)8CY3KW.B6
M(4$YX0OUO57;[.EI;C,29FTL2-5U3JMNP!B.PQWRXRPHL1PL(0AM.RGWW,**
M&DDX2 GB=4%A*D!"E#Z [#^PI/:?'U!JO5.HD:*[-]'JC-7[4:HBY\Z9<9GM
M0[!8("5([[=9* %NJ*E-P&G&'G67^<TRY6,KRB\H_'R:EV'?_5?6%%U8V+/Y
M:ZWG0NCWVI$P->TN02C/[0Q?8YEY=:>EA,LGCW-[B++/W0ZDH4RPMIV!YZXT
M^%VAW*.^@WJ!#$%:TH<D6XOA<8*. XZT^MXO(!(XN64* R4\2N%M7<7_ -&?
ML>U_&EVKL8UUK1G7<:))E6O3G:1"LC,35JXC*WGH-GNME1&:MDUQIM;D9NXA
M_FJ2$.)99#\N/ZMTNG"W/\E4U6L+S;W<TQC:\8N&P2-,=:S'ZB6$P;]P95U+
MZ8J-MS#Z5YOOKW#R.6S!CGZWQH=;0XA25H6$K0I)!2I)&0I)&Q&"""-CM7P@
M]&?B2GXLIEV/)BO.QY##R%-NL/LK4VZR\VL!;;C:TJ0M"@%(6DI4 0:N_P I
MJ*<4IQ2G%*<4IQ2G%*K?W(B5O;/C!I6_9S>Q=?C)5_TXNQZSU)"PJJ??V_/Y
MNM)]/T5XL:JB^G(/4>_\#BE60Y-*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2JQ>6O\ 6PH?[\/2?_2?F./%/]I/^L*A70^X_=7Q
MS(JQ3BE5'Q_^:]#_ -_KR[_X[K^8X_G4_P!IS\:NG]SZD_A5N.9%6JUK9_YS
M]9_M:O?^2RN0KH?<?NI4S>/?]8/H_P#O0=:?\RZ7F.GH/</NK(J7^32G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*@SNOM@OKZ+.9O-YP+7;G=/N&4E+;V;Z;/@T5# &[3Z
MG2V,-=;F-I:A]O25;0*VK./M[W0T=7Z5M<597U/XUYNPM;;00R)$F2I:66E+
MY;80V$EUYU82LAMOC;3PH0I:W'&T#A2I3C>^Z'T:QJ=5TGW6XO6C3UC1$^D9
MD6(B?/DS;BM]-LM%MB.28;"YLY$2?*4_*E,1H=OMUPE'O4EF-;IO\O\ CO*8
MA_DC1=]=\97']<$T.)V'B/W,#A<V31Y3I[L6K[7O=YD;NQI6D6I5'E.PJ8IU
M./>33S0VNKS^O/DG'" G:SAMSN\FYS&;M<$-MNL,.6B>EA"PW#D-2WWV%*0I
M3BFVI+3G VI2CQO,R2"$H(K]3)?8M;+5V5S^S3LNDSKM!GW^T]L^AQ<I41VX
M:ST]<-)P+%?8<62Q'@19]YT]<&N_R(3;*'8]KN=G:X')$E"E61\M?)3I^ZZ5
MV76/7^PR7:_8O<&8M<-B\?A]!3:@J8G2@3 2:"S)K#"J^AI\\#,3H)[>Z* "
MB96.D2=K8I98<.2^V\TJ-'4B0_)2IIIII:5DE:2"M1!X4(0G*U+64I2$E1(
M)'/^Q[LRUE!US9-5:BLUXTEIK1ETB7^^7F^VZ;:FD-VM]$A%NBMRF6I%PFW)
M]#5O;A0FGWUJDA/+)6A"[!_AK>4NB7#,DO.K.NG=+9348'QORG>..!+H]WKA
M\I297KT;L36"6(DZ[3*Z+8.#+LM##:49>92S+F*H;$>IN"*GI&E=5/J:9ARF
M&5VV.Y%M,.>T7$.K##;,1$AYMSB#K+SV%*=2IHL\9XFE!"RWR7])7L.TO U1
M-GV2\76'VC:FM>H>T_4VD+DU D6N$]>+A=]3.Z<A3H)9>M=WMMG#S<:VR&+D
MS=51F0S<(SLR&W,]W^=/KX0IQ2G%*<4IQ2G%*<4JN'>7]6;WQBIH_N1/W83>
M-:GW<HN<ZM[%*,?Z?Z5C"8_<O\/<G]*<I/5(]<_ &E6/Y52G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J+^Y>NE[4ZYT.,@L?HUH
M8E=9YZZ6+XR4^GSMJ%H,Y921(GNE'&N:P)QD+/1\X2D0-5%D]>01D?=[QN*=
M:J<SL;89YC:KL3IOM:KTH:) ?-C<-?\ 8.1L9H_RN/S^AR@MI')7EHB$0#6D
M5?:B-D^7+%26)SWW>8/$'/H"15HH/@1CU_NH_L;8Z)CJKKOIOM6STIB+ !/L
M\-?]?9"MFD_*T_0:#5"U;&5XB*I$XM5%86I;(_EA!?BRL>V"Z,;!1/AD8'UD
MT"#XD8]/[JW:Y\<]%0]/];5F,L@KKM+J?06.[@,LGK75VXO]2Z[E[%I2259)
M]*$U*:.V94%S1R)5D#TR$N:-"1(EL9&"#D@Y)/B3G.<>>:N$9&.E:7_*R8&B
M#WW3W>]-:Q?D, BZGU>B'AG;^65!;O+A7-'9C>]')"6#82QS1HUZMC5RL;=Y
MJ?)6?$8)^??5O@5Z5T+0[L/N*O,P?7W7O8&5BT@\M1?]A=B9*SQ%+DZ$]CA;
M8^KK]"P"ZTVA0*2:"GKZT#Y-A\L)-A8C"CS>ZE3F00D')R,D8QT\_?4A!SOT
M'V_PJ^N=H:[+9^BS%1&Z&ISE-64-7"]WO?%75 4%>%&Y_HWW.8,/$USO1/<J
M*OHGKZ<IJY69XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE5@[L\C9.KI*D&CPUSIS;'1/IB##4DH:D82I *O]
M;85REP+9:.'-YJN/L[ ZI"=G171-$(T#+-&UDL$X\-O$^GU9/V4JS_)I3BE.
M*4XI3BE4U[^]O\NO2OZ^[^27R!]/Z/;^V/C=[O7^WZ^WT_P\TK57^_+5_P#I
MKI__ *VO^%=O[.,_J%KGR_6_LZSYY^ANTS'V9S]5>?'D=X,T/;VPF[>ZQW%A
MTEW455?0K_35E)6ZG(=C4#60-2@[0Z_N%91;*O=&&&,YMFV<:<882*XKKN&M
MJH =%F6KG/&7$D*A3%(Y;CB4)=8DM;?LI<9S+3[9X4@I<"D$ <:' E(3](=F
MO;S/T=9F]&ZJL,;76AV9GTA;[7*G2K3>M-7$EPFXZ4U'"S/LDD%YYP&*6W4.
MNO*AR8"Y4MQ^FG6?@7J>X?I[-WVEA,5UK====/:C88[QYZ!ZVZ0N][%V'U[G
MMR=G=3LLB"-9$T,99S6'U+XB\Z<3'\]39S+O:+&+AFSR'^4EZ5%CQI$"WR7V
MK9;(EN6^F9%:D*9>>CH2M;84?;0<LJ4 I#+6$A/:-3?I VG1G>%6#2>H+YJB
M!J;6EILUZ[2.T34^O(.GE:;U'<;#'N5ILEY?<B-7!3+!,>8DLW*.TKD3+G=0
MIY3OJ-J\=D>L>E L7BZ6MRV.R<^'K*>H";\ "MKA]G0*Y722O=))(]SI2SCB
MYI2C"I2#CB)R9YYG^XAIJ.W'990EMIM^(A"$[!([RT/4DDDE1)*E*)4HDDFO
ME.V7N[:FUK*OU^GR+G=[JU?YMPGRE!3TA]=DN)*C@)0VVA*4MLLM)0RPRAME
MAMMEM"$W,V6QUUKK;[.9N_FR51DY:ZNL+&MKJ:POK6^L*:NT+XHGZ*MNJ@*E
M"J+JI3[5)%@?83E(A5>/7M;8]A2GBSO@ X]>F?AN/#SKY!4K&P&]:Y\SV%Z(
MG\KFU^W\?HG57JO]W_K;>G^)$Y5RQ_65_P!7_LU3QGR'V_G7)!O]AAC*RST6
MK-V&6+M:NFNX;FISHEO6+>'CT]99TI66I<\-*R"V-"99U]D"8Z<":<H(T2<)
MHA]*T\*<@DX.^<=#[L=/<<U4E>3@X]*Z86J[)U08FAGV]ED66XT%@+G,U48X
M@.J",C:0($6?ILUI#[*R'@D9%86$)( )139)0ZL&!S(DD(R 23D[X&,?:"?N
MJ"O?;&/6NS\UV#Z^O\K6T]/Z/HO5GI_T<>O^_P GECS5]GY5'&?(?;^=2-UA
ML=#9VU]D=02/:G4]?4W=7?P!Q5TUG56I%F"\:T"&50FVU875*^<T"$  \6R#
M0>M%F$+62@@I)'4=0??G8^[SJM*N(5,W(JJM>LLIG[B]S6FLJYA5YCWV\F;/
M=.4QU7)>@?2[5\<$4\8L[RZ]7"JXJ"=88W/4=8GO>Y6.GITI6P\4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*A[OGL&TZTZPOM)
MGQAB]00519G)CFHYP3M/L+VNS%).:UOHL@0!UK%8F0HYCIQ1)8&/;)*Q>0>G
MY^NU.E5.C\?\':M;8=BQ6':.M):DMQJ]K9V5B6:6_P#--\A7_.-JJ&L8]58#
M44X@H80K8AVI*L:ROO!M(\,GQ)Z_W>E62HGT]U)/'_"5+76'745AU;K1FK+3
MZO%V=E7%!&,_-#]0KOG'55_6/>C6'U%P(4(:*Z6!4B<]LS!;2?0^!!]_QZ]*
M!1'CGWUL5GWONMEU!U33U!<.4[/[/UVEZZU-[6Q,D9EG=</T$/8]_GHBFS0L
M..;G%CS49+)F@/OAIWN=. GNLC<@ XR2,^.V<X'GMY5=)P,^GWU@$\<^GIOW
MMQDFZ>RD_.;>ZNVNM%>V1#OO*586MI8D$SSS/5TC_1S(6N<J0PQ1HUC;P0D>
M'EXGP\ZL\2CXG[ONK%W768W5-58[WHYY6%U67#)O5I0+*T?C]H'5PO,,S.HS
M<YDU83!:"Q3"BV8T MK5FRP'"G,=!['4J0,<2=B-^NQ\P<YZ@=?=Y54E9R =
MQZ^'U_G7H!CM*'L\CE=A7QR1 :S.4>E!BE5%EC#O:P6T&CD5$1%D9"4QKU1$
M17(JHB)RBKM;'Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*^'
M21L=&U\C&.F>L<37.:UTLB1R2K'&BJBO>D44LJM:BN2..1ZI[6.5) )!(!(2
M,J(!(2,A.3Y#B4E.3MD@=2*@J2"D%0!4>%() *E!*E%*0>IX4J5@9/"E1Z F
MOOD5-.*4XI3BE.*4XI3BE.*55.*BKNWN_.U%OH7FY3K/KX?J  9LLC(I+[LV
MM9HNQ#!2(G,D%/CS$F1HG3CO;/"R<V-'L<YR<IZDYZ8 QGS\]_O'EBE6LY52
MG%*<4IQ2M#RO9V#VQ+@LQI K(U TL8@W1E@EF5:NB8EM7#60P<UG4*^>!OU6
MO857^X@=/F?6>)'OGY^(I55?*.X,SW;O3%P-EM/IHX^L.^PY&Y\0%@@,D^G\
M?#6RWNDT%E08S)@.%K39&6NOTE!5S2C?(CFRV) H9&I:AA3Y]RLT:W0)=PDN
MLW)MN/#9+KBEK<MA2G)*6T<00KA+BT!2API)60D]Q[-GK0SH'M >O6I-/Z8@
M1=2: G2KAJ">8C#<9BU=HS+CC,:,S,NEP6VY*82XQ:[?.?:0Z'W6D1FW7FX>
MKNXGVI7RU?UYH[5\<<A!$.8WWCSO+B(.!BRE%"Y'K[N[5[:\4>-KGN S6:NK
M:9$5HE>2]48N+.T=K2VQUR[AH_4,.(V 7)#\)"6T G Z/%:R20 AM"W%$@(0
MI1 J[;-3=E=\F-6RQ]MG9?=KI))3$M[$_4T5R0X 2$=[N>EH%KB).,JDW&?"
MA,IRN1)90"H1'U7K3<'E\]\_B=<9"SI+Q=878DIEL)05CV=#8T5P=AK>V=1U
M[D&7D94$T1&7&ORM2&C6SF4L TD4\GF6VRWV[OQ8EGLEUNTE%ELJE,P8BEK2
ME%N9"^+F*;3Q(4<+;2I3C>05H2"">G]IMTTA;G+G=]3=H&BM(6P]H':FTW+O
MMX>=$AY[M OCS/(B6*%>KAW5]DA<>Y/0V;9)(6W'FNNMK;3G=GVC!M\N12C8
M6_*'+T&&&*)I]!U%VF +%/N<XR1;\+IKLSLRUH:E\*R(1>:*JK<V.U?8=:P+
M(QC\NZ:6U794Q7KUI:_6F.[,B(1(FP2AHK$EI122VMU20$@J4M24MI )4L5J
MV@;_ -G-_O#XTGVM]G&K9<*S7^3(MUGN]SB30R+%<D!;(U%9;''ENEQ2$(AP
MY$BX/*4 Q%<W(M145-OCB+VRFIM3=Y[6W9-M66='4:#93UA%5 -CG9PZNIAK
MB[#'$KLM7%U9KA%J5&+?6MG&F BA)Z"VH)&"3[_#(V('CMCRKY?6DD@CRK,_
MM/$J^G[,=F_[D':R)_C7&^G^_P N<:?/[#^54\"O+[1^==>>EL^SI*_+UU#K
MJH!]W16MY?:/(:7)AU-?GK@&_:T9FJJZ6:X/LRJR"K&%JHR_ED*D/.>,.,B3
MT+4%#A&^2,[;;'/CC.<8V\\]*J2D@Y.V/=7!6'6N:K*^@TN3VPMS2@B5AZU&
M$VFEIB)@8(QE-J;S/4-I5G5QR1H6&J$QG0CS10V@5?8,("@J2L8&=B!CX>[P
M^WT%4E"LG ^?K-=[]JA?3U6@[#1/]EU7V:W_ (<DG)XT^?V'\J<"O+[1^=2/
MU'4VQ>DTNT,J;2EJ#*2CSM'#>5Y=/;V+@#KFQM;.6FL81[.MKT?8 @U[;04$
M\F<6R(4)M>ZM,.MJ.3MT Q[_ ,?SWVQ@U<2"!OYU/_*:JIQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2JQ>6O];"A_OP])_]
M)^8X\4_VD_ZPJ%=#[C]U?',BK%.*54?'_P":]#_W^O+O_CNOYCC^=3_:<_&K
MI_<^I/X5;CF15JM:V?\ G/UG^UJ]_P"2RN0KH?<?NI4S>/?]8/H_^]!UI_S+
MI>8Z>@]P^ZLBI?Y-*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H&[I\C
M^M>A)\P)O9M I>N9=2TPF>SYV@)DAH/I:64Q,0+7.&BB=< LC?+Z)*Z1S6>J
ML=S:=-:/O6JQ.-H1%4+?W;O*I4MF*E/>R^&0DND!95W=W(3^[@9ZBM-U;KO3
M^B1;S?')B#<S*$1,2&],4KN8CE\K#()0$]Y9P5?O<1QT-0G_ )85X_?ZAV;_
M +G%_P#_ +.;/_)#K'^I:?\ UO#_ .W6F_R[:!_QMZ_]23?^S54O*_RMR7<5
M%UE3]26796<T.;[0 U\M^N;M,O+305F5U@0]A!8FQN&E?'8V844E>1&0)8CS
M3AG"E S$P2;UH'L\NMAN5T?U#&M,FVS;'*MRXQF,30^M^9;W VIEI7&G+;#B
MDO(*%LK2EQM;;B4+'..TWM6LNHK-:F-*3+S%O$#4$*Z,R3 D03'1&AW!HN!Y
MY/+5^TD-H4RL*0\VM;;B%M*6@W$\5_*H'N45<-MG 4O<%$"I!@@R*-4;BH'5
MD3M;DXY9'O:SW/B309YTLQN<-E:U7EU15;9%\]U[H)_2[_TA;^;*T]*=X6'U
M>V];WEY4($\I ''@*[K*PEN6VDD!#Z'F6^I=F7:9&UI%%NN7)A:HALA4J*D\
M#-Q81A*KC;@HDELDCO47B6["<4 HK86R\Y<[G-ZZS3BE.*4XI3BE.*4XI5;_
M !B3Y[([W7+]W;KN_N#0H]?NYPP&TL<=6L5WZN0>JRH(K5_3V0-1$1$1$@>/
MO/V''U?)\:59#DTJ*NS-O<9M]!09>"M?IM.MI.,9=0DE5-+34; OJUP57AEU
MY5K+&7:TU<)5PV58LTUFA4A\4 4L<T@$D ?7Z"H4<#-?77/906L$AIKN8*H[
M"K1F1Z+,ND^7EDGA3X4MWGX2'K-:9:S>U2ZNR&4AL,4OTVS<)=!6( L=#@]?
MO]V>HH"",BOWLCL<3(ARTU/*-:=A6P4B9G-1O2:=)9U>/!?7D47N?5Y6MG1Q
M%G;%MCBE8.^MK4.NB@*TH-S@;G[O4^0]?QH2 ,FJZEUX^"SF&L1)7N9U49DR
M6V$OHD\>:JFBT&NGE5OZK-B";UTL?N2-TWPW/^T:*EU8]C^S@_#KU],^ZK:3
M[7OS^?WUW/)9RW'8?6N7LD:9GA<SL]>ZGG1)*\K1UUOC:NEM317^L14]*)9W
M'TI)F/B%)L9CFL4T8$@3H^AQW>TWN<SEN8N;;;>)*?9>;AO1[D_)CM+'M-HD
MN,1^>4D*6AE+14&ENH<Y!VDDR[[IRV2,.P&[==[L8BQQ,.W"/*M$:')>;.4.
M.0FI,ONP6"EMR2MX)YS;*VHDNL[3W]?+760<<D+U;)!/"GRYU>9"Y)!+*K.A
M]I-;:UY#8RZZR#DA, ,AA*%FBFB8]-EC2Y$1T/,N%*MTK2KVVGFU I<9?:5E
M#S#R"IMYEQ*FW6U*0M*DJ(.GS($6<PIB0TE220I"T_LWF'4$*:D1GD8<CR6%
MA+L>0RI#K+J4.-K2M((PU9H+7L:TS>QU\[;:["ZCZ?=7RS1L2"M*UN I]?J#
MZX;T6$(^^M[A4LRAVQS%!5M.%*]P]<.QMYR''LS$ZW6Y'=XKFH=1!U*5'C>;
MM]VD6Z"T\YGB=:B1XPY#:R4MNO2'4@+>63C-7"5J&7;KK=G!*F,:4TD6%+2G
M@CNW:PQ+M<Y$=O' P_.E2\27&PE3K,:(RHE$= 'YN9XZ2JBVH[XP;S#F!:2D
MNV^V(FLG ,'D*8A2>V1M=9 H3678:O0:SIRS0#&2#D2-6;<.\..6YW]I#N3+
MT27'5[3;K;C2^%10<IYS#@0_&=P5L2&VWFR%H!I=CW9IJZL?LKA:)$>= EHP
MEYAUI]LK0'![7(E-%R+,9SRY,5YYAT*0X14N5:R[8S0!Z%MJM+D[IU+39PM]
MA6UDK;2NKMI+HCZE7C?4+"Q9JQQPY;2&=M?75XSZR(*:PM9#.%-@$$D>)QGW
MYSCUSX^6P\_IE9(( .-L_?6:3!8YOK[: %OK^OM25OK_ (I$_I^W]'*^!/BD
M'W[_ 'U3Q*\_NKHV!;>J6!;'+J6%&'<4E?;T,=@=]$OZV_MPJ"6(ZNEFF#C-
M!ELX;2OMAQH[."<!H7S2UAM@(32I*4IR-L>6>GN^WS^)JI*B3@G.?G\*^JW-
M"WU<!=:P@[27]H$+86=E865D^-QAD$9!$5:#\Y\G35<4LCF U5;".&+ C6I&
M^599I9"$X&W49ZGQWJDJ)\3C.WA]U=Y<-EE1$^E^B(GHB--L6HB?^*6G_P#S
MCEH_JBHXE>9^-23U":?6Z?38U;&Q/HH**BT5-!:GF6I5,09875;: #6%A,2<
MZHG:#7$@ 33R1U<Z'Q!NC!G%#"H4D).!TQT\MST_OV\*N()(W\/G?Y_C83E-
M5UBK:]I*&&(B]N:JE'FE2"&>VL1*Z&:=R>K88I3)H622JGW2-CE>J?HG%*R;
M'LE8R2-[9(Y&M?'(QR/8]CT1S'L<U5:YKFJCFN:JHY%14547BE?7%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4JL7EK_6PH?[\/2?_
M $GYCCQ3_:3_ *PJ%=#[C]U?',BK%.*54?'_ .:]#_W^O+O_ ([K^8X_G4_V
MG/QJZ?W/J3^%6XYD5:K6MG_G/UG^UJ]_Y+*Y"NA]Q^ZE3-X]_P!8/H_^]!UI
M_P RZ7F.GH/</NK(J7^32G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KQ
MP_%(M%J-ET&6CD;ZTG:,/JO^S)P*^G_Z.?0G82WS6]6I\OH$]<=#>!^-?,OZ
M19"5:,)) SJ+<=?W;)7F-^W;O]5;_O<[YW/T_P"M7S5S$?UET_;MW^JM_P![
MCN?I_P!:G,1_6778J]?J+#2Y<;!-N)NQ?K0TV$7-O^%?BZ"/U; 8$1[)&##0
MQR2-M9"XY:V6LE*$LH"@R9!)_/N_T3 M-PD7]4=%D$=3=Q3*!<9?960$QTM#
M"WI+JPD16V2'^>$+94A: XGU+&Q>)UZMD?30EKU 9*7+4J*L-O,/M[JDJ>4"
MVQ%805*F.O@Q^[%QM]+C;A:7_4?UZ_8287(O[!=6NW+L[4NUKJ<:02K=H%"A
M^JN %EG)D@&4SXJQ1NG>J-]/LQ%2-GPU/5"7.EKMK4AFWJDO*A-2W$.R6XI<
M46$/N-I2A;J6^$+*1P\6<%7[Q_0ZVHN#=OA(NKT:1<T16$W!^&TMF([,#:1(
M<CM.*6XAE3O$6TK5Q<)&0G]T;CS$K-IQ2G%*<4IQ2G%*KCXH_NNF0@'_ &)J
M=[W%6&,7^<PH?M[<N>U_\4>YDL<CO7T7U?Z\I3T'U_>:58[E5*@WN\3Y8?#Z
MQGY4SVS K+"1J>LDE1MXI<DT5/XI$[4663/F5$7T;6HYWM:CG-E)PH>_'Q^=
MO6J5#V3\:T*XS]#HAV":"DJ+T6.1)8QKBM"LQXY4_21D)L,\;)$_@]K4<G]/
M+Q /4 ^\9JSDCH<5&&2AASVG@J8(HQQ!YM;A%1C&0P1QU=@/VG@*T&%B(V(0
M/-=E:^J&9&QD3(<LL#$<H[O9;3LLCSS@?;G'3Q^?"X=T ^(Z_=\>E;QK+S%A
MUY=-L-#GJ<2[ ,KYA[JYK:M2PS!Y1B61M.(A61KX9)&JK6N1$]?7[(O+A(P<
MD#;Q('7WU0 >H!.#Y5$U]IEV%ET9>R'069<O36SK;2Q%GC)%-O:#6XR@OR!B
M(GR1SP2758<Z*5CWM=&YCO<ON15Z/HW_ .KMW\<7JU@GU$&ZCW;D''G@XKD/
M:"?_ )5V'_S>O9__ +*Q_/I72^<M[4JX$S8U.@N:01-;KM3;/HL;EI[%H[ZZ
MI*/'"L[&WU-C$6(17YBGKIR'Q&5RVAU*VZI)++VY<BW6J*U-N\EQA$GC,*)%
M:3(GS4MK+:WVVG'6&6(:'4J95+?>2%NI<;BLRW&)*&=:A1KM>YK]OL,-F2Y#
M+8N,^:^N+:[<IU"76X[CS3$E^5<'&5H?1!C,**&%M.S9$%N3$6_U!,7=95E?
M!DR!]XVLZ^P%5:9IU-J<1V 2-UWB:+'VM]C,WKJ<*';5ZNKH;$FOK[ .P#C+
M8*)]7LIP0#,2-JRRWI]YF4M^T2)-UO$R*])"'K>H7:Z2;@VQ,D(4AZ&IOO'(
M,GN[\<J <?,9CC=;SY>A=1:=C,283<:_Q(EDT_ FQXA=CW9*K'98EJ>DP(KB
M7&+@ET1.\"'WF++""IN.F;(+;#F&U]C7W?7UA95I,1U;9UX<XA,7JL9(Y10O
MPU:CD1R*]'HUT;VMD8_UCD8V1KFI[\!EV-=6F7D*;>9=<0XA75"T(6% XV(&
M.H)!&X)!!K5;K)9E6)^3&<2\Q(89<9<3GA<0XZUPD X4"<XX2 H*]E0"@15T
MMCU]KH-3<Z;&P4MP'J' &7E-;VI-(:)=5U8%1MLJPZ*KMAC1CJ>LJ!2*TME:
MH,U;(:.8:ZQD$&X(E13GQ!^_[=L?.]?4:DYWSO\ 96MKFNUT7_.10K_;3<1_
M_'/I_P#W^/*N9Z?;_"J>7Z_9_&N8;J[8:XT /;UE'1Y(0X2TL@@KTBZM[XFL
MF:;5U[/AU-:)4U\%K"#9%'H:882@"UC ((C'GQ4J5Q#&, ]=_AX?'\LU(1@Y
MSGZOXUTA<'VEG1AZ2.FH]4)601 @W\.C;4EV00L;8!2;6H+J4CK[1\+&?.P@
M&V $DR/(&F@CF0(60X0 .'.-MB/JZU!1Y'X^%<W[/]I?]H0/^#95G_Q#3D\S
MT^W^%1RSXD??^52'UGA[ZDL[W5:M:T>YNP:FG#IJDN>Q#IJ>HGLS&+/9D!U[
MSK:S+MII;!80H00X1*\$1Q;H";(^@DJ.2,> WSM\!5:4\(J8.1554T)  O>R
MNS"=0(+9Z2IO8*@ >U@B+=38J>EJR:.&EA*8]!JBZ<\ZR.)%:D=C?.MA29I9
M:AHH-QL @Y )SZ' \/CUJTO.1Y>'O_.I"Z!1@C^Q:2F]$Q=+IPQ:$:'_ +&U
M%M-3BDZJBI&M_<PU0)T@I;PQ?ZEK[NRNP(VP/&E$&H5@*('08]P..@]VWIOC
MPJM.<#/V^-6)Y%54XI3BE.*4XI4"=D4&]M^UNKS\R19,S6?R/9EK>AMO]=24
M-II(+_J67'U]K%F=#2 V)I <.MCKH-0+>TC 77B3U4[)I6ND$8/O'@,]#TS]
M73'AO4'YW(\1Y?/U9K2++L3?U'4F*NK*QU@>IO\ ;X_/:F<CK&6+1TK+R"#]
MJ@\UC6U\\MLRD.6P'SQ\5?HD*@$BFB7:1Q-+NI !)\@,C?&>F,GU\>F^VU02
M0!ZG&PZ=<X^&QQT\#XZ;!OO*,\ZNKDRME4%D8;(I=EF9:,JHKM78D=1RV=M4
MCQ5T8CHX!-'V.-:4T^[NR0SLJ1']+J  JZ[U+"?/Q/H<8./N'AXXW\&^?AG'
MX?7MX[;[=3MUY0]JVW77?.3GU.]/T!&P&"RUE]$JZXIF1L&9B>:/,FA48=79
M!%@S70=@X=QA%8]"X)' FM^X8R,],;^.^_4>_?%2<X/GZ;>.VY].OAX5C1+S
MR$(L)L[6Q6M4(W2LHK2Q,PPK!L=2P=D245,3C#3(H@-B/;]6Q+I;:Z(=>A45
M^T.4H8%AQ&-KF!M^><[>..F^WAL? @FHW\/3; &,'?W[>61L<'H*SVT([CS?
M:&HTV5#O[W)D5E,$[,!589K#UK^N.VKF0VF,L"(XP[;]LJW"4<#$>+6SR7,@
MUNPMQM>731MCUS^7V=?GK)SG;R_/P_B,Y]*BEM7WKV(E>[2-V-..^_PU>:0$
M%/7?6LK4=Y&ES3685GFLLZ%Q.*4 Z[D3(Y@DRM&0<VJ&$(, EG8;;>/^J,?;
MD#<_'>H.>(=<>/Q\OLS]>:V+N #OJPN-23GZNYIS+7K:OK1WXC0W5U5UEV'U
M_P"8$L<U,<16YB,NUFT!W4HY2V&<^&/96N>^#'*=74MN(&/M\0,XRGPW]?M]
M:D]#]?0_/]]2!U:3V]5Z;2Y2Z"A;E\G0V=7EPS:RU'^JNJEH!\7;C:*#)5^8
M1U_7.NB]8##J[\P.SG &!HLP-4V$-@.,9\3^/7J2=O/ ^O:GCC\-A[MOQK0<
MIM?)RP;@V759/&-=WS0^P2(,59066'KB!\$U[P4O\_E!;B8?6V&@IH5JZW1T
M@6"+M-1-K-%9X)K]B(&^#]HWZ^_R^.V!G: 3M^1]/=C&^VYQ@[^.OTVP\IJ_
M+4(L8=O9W%7T>\^1^IQMP^VU'90.#VTMM7'_ $S%CTP5S6=BUF7JJAUEJ,]6
MZ3.J297#:^?3UEW63@9\/WO/PV]<[YWZ_509V!STZX\=\^'AM@''7?-;9LM!
MY"5O[1YT86\U+(0.U*JG,I\R72&7SW==PWF/O"[>KK'U0@06F).RX0E1J<3I
MI3!ZLH*74$ML600,>[I]6^^ >NV#X^-#Q;C'GC?TV/UGW?#-9"?4^0Q5M:5E
M:%: I)HTJ;"0K%QOKLG1N[QPF9S=QD[8WV#Z^:_Z0L=MN-3/,;I!LOH*H*$X
M>B6-^>/8'R>NQ)SY;X Z9'GUIOD[_9TWVP>AR/?@_"IRZLU5S?T+*W5P$Q[3
M.CA!ZQ[JJ6M$?9$(1**YGI[@V'FU,8%V=7"2N;7PW->_X<(Y@C5@]3CIDX^>
MM2#GSZ#K\C[JD[D5-0-Y*Y&_V'4ER/E 76NESMQDMS2T['(V2[+PVIJ-2^EA
M5?U*M1*LD$%OJB..G&1RHQ7<@YVQX$'X'-#N"/.H>RG96(V=5#;4>AK9&._=
MF %E0!6]0:Q58167543)&;568<K7PE!&11RQR,541T:L>Z^%I(R"/C]]6""#
MC&_I]]-7V7B,952VUYH:YC$_=A@"%0'7%P:]4:-5TE4-)(;:V9DKF0BAB122
MR2/17(R-'O:*D@9R/JW/PIPGI@U&AG7VPZ[ZAZ6[,OZ(Y;+%]@=A=B=DYL&"
M4ZRSF;[CET\UI.P49DI)9.%;=TLUX,+%-)\L%=$1HL8WHM@'"@LCQ42/+B\?
M#IX@YQOOMFKI'LX'EM]53!4[/(WH UI3:B@M*XN-LHQH-N 0/*QR(J>V2.=R
M(Y/7T>QWH^-WJQ[6N143(XDGQ'Q%6L'R/PK0.TNP*@//GY3/$BZ?L'9@&YW%
MXVG*'.N+>WMA9@QYY!8)'O"I:]95.N;@SX%?7UX\\LQ#7_"CDI6H!)QN3L #
MUS\Y]P-2E))Z;9W_ !'OJZ?767?A^OL+BY"&%R9#&YC+O*C1R,)?GZ0&I<0Q
M'(CD9,X19&HY$<B.3U1%]4Y9&P \@*O5N/)I3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*57'O_Q:ZK\DFYS^4@*R(ERJV/T<BLLRZV8=EK\I\_&YXTL?
MQ&3J"(KD>CO186^WT]7>OOV+5-_TR91L=R=MYFAD2N4VPYSA'+A9"@^TZ!RR
M\YCAX?WSG.V-;U%I#3>K$Q$ZAM3-S$$OJB<UV2UR#)#0?*3'>9)Y@8:X@LJ'
ML# !S5;?\JU\8?\ 6FP_]J;3_P#GYL/\J>O_ /C)*_T>!_W2M8_D>[-?^*L3
M_2[G_P!]JFWFGX&8CJ?#X6PZ)SVPN]OH^R*O,,KUMK&U;,";1Z F19(I9'P#
M01D!#23FS^V(>-CG.<B+Z+T'LX[3+L[>+DYK#4*G+-$L4N6I,AF*G_"&Y4%#
M(92PPVZ[(<#BVF64$J<4YPA.<%/->U'LGLL>R6IO0^F$(OLW4,*&A49^8L]U
M=AW%;YD*D276&(C9:;=D/N)"6D-\15_15>/PI\*:7Q^I(=ALXQ;_ +<NQ(UL
MK-[4F&SPTGI*E+2)(U5@@A<J?'G3TF*G:LLJHGLCCY[KW7L_6UP!(7#LL1Q?
MT9; O(0#E)ERRD\+TYY.RE[H80>0Q[/,<=Z;V<]G-NT%;2 6YU^FMH^EKL4$
M%>#QB%""AQL6YA>Z$;.2'!WB1[9;;9]!N:!72*<4IQ2G%*<4IQ2G%*TS%86F
MP0V@$HY#WCZ/8Z?;F1G3Q3-'M];926UM" D(XZ05WSTTTHP[TFDB^*]'D2JJ
M*C&/OI6Y\4K3.Q<Y-KL)KLV(YL=A;4%D/4SO]/02Z:,^:D.3U5$1X%M$&9&J
MJB)) U5^R+P?[L^?A2J81;W7WS(DJ: NF)40 LJE=GWZ+4 ,L H#H8+V.RT6
M#QV3LIA"8#QJ@[7W6C@K2@#;C,5TAL(#[G&H_NIVQU/@=O D=,^_T%6N$#]X
M_#^[\*PYE?+(/N['7W&EJ[BISM=O:2JCKZBB.MTZ^%U(-XRHUF>O[P&"6\H=
MU-E[HM]=0Z#/@2A7%4AS ?J8E!X@<G.<;8P =B,>/U_5XC-5IX2,#<>O]PST
MK>:#KJ*H@<K[JRKB"4;*8-A95ZYK_FG(BRJTS&K4ZRWC5_JOQ]?J--93N_>F
M'D3+[DK#8ZG)/OP/LQD>6<]:H*SX;?/K64J^NXNQX;3)&7Y5+LNLK)MWB]F+
M7ULY\^4["B?*97:RO9"&%HP[30YJW&MGK]/MK%<_074MNS1#SVY/O6&_O6%R
M2V8[<Z!-2T)D)U:VN-;',[O)8?1E3$R,'7T,O<+J.6^\T\RZTZI!U?4^E8^I
MFH;HENVVZ6U3Y@7%EMM[EHE!H2HDJ,[PHE09?(C+?8#C#G-C1WF)##S*%C?:
MGKT3KN#HS&.+CNI(^Q-3?WEJX% &W^H.Q/8E\5<S@*4>L366A;YZT*8TUM7&
M+5Q#3K]+#?'B7Z[KO=S>GJ:,=M26&(L7F\X18L5A#$=@.<#064-MA3C@:;YK
MRG'E("W%5FZ8L+>F[-&M2'A*=0Y)DS)H9[N9LZ;(=ERY2F>:^6PX\ZH--%][
MD,):CI<+;2,2%VC'&P/%V*-1IM9V9@E!)1$^,*MO?C9NQ^"_]6?.TMU9UI'H
MO[P0TB)WJUZ\\<^&/,?Q^SY\*V"HPA\9JAV^LM(?I22,5/L4WU;UR'4#  0Z
M60@2Y*6YN5++)MZ=^QA,V,-0&%1Q.MCG#6LUO5L>%/O2M<21:&8+4)M%R3;3
M:7[RY(6\ZJ$$.1F^[1N6VB/)3;E-VY4AQV41':"V$1WR'4<T1V;0S?I-R?N+
MKEG7=Q?(VGF8K;#"+BI;,MTRYA===E1#=D/7=$1EF"GO3Y;DKEQDJ9<L[S1J
MZ73BE.*4XI3BE.*4XI6EZGKK#;:<0K4YBJN#08I!P[ @?X=D.+*]))@HK$9T
M)S09Y$22<'YCY2=[6OFA>YK51CY^'Y4K8J>FJ,_6!TM#5U]+45\*0 5=4&.!
M7APHY7?"&$%CB@@9[G.>K8XVHKW.>OJYRJJE9+BE.*4XI3BE.*4XI7RYK7>G
MN:UWM<CF^Y$7VN3]')ZHOHY/X*GW3^"\4KZXI6B]B=AYWK'.LTFDE<T4F\SN
M;KQ8BJ@,JRN]3=@T-2")->V=-5M>\LYDY,A=D+ +7CF&S2MA%D5) R<"H) Z
MUS@=C]>6L1$]7O,990B?/?-S :BC,B&^F/J667S$@YTC(?I[[^B8=\16_*/N
MJEL_PUL@TF8(Z@BF1YCXUUF]I]8O:KF=C8-[4T ^35S=?GW-35%).X7,JJ6*
MI^T!+1B7#TW_ &1F0>=8QG)%)[6#Y&F1YC;KOTK!2=Y]2LN<U3M[ R,[=:/H
M74=P/I\_-0&6&:L<=6&Y^.U;:? ET9)&YHWUU,/\8PN%2I$8Q8HFSL'?8[>G
MOW]VU,_/KY>^LWG>S\/I2 J\+0U8MY8DZ$>OS-E95HFE.9F;V^SUF:'1J;(>
M37H=FKA\!<$3XWBAS3/^$L,\<+!\OD_WT!!Z>-<!W;W5E;< 9\WL+'P7-E:7
ME(+7KH*U\_UC-"J;H*LKX9#V 'U R>\\4]XTP[G,B>Q)GLC<P?(_#SZ?&F1Y
MCX^77X5T8.Z^K"M#1YP;<Y8@G3@RF9LZ#14,U3H)X;Q,Y+3TA\=DYMK>1VZ_
M*/JP&$$,F187(DZ?"XP?+S^SK]],CY]>GW5@6>1/5<81UK;:"'/4]<^M85<7
M9-8/6M^KT'6&AKI82!;$SYL0@;MW'"_/B-G A.)(9.3&,T4HQ@^7SO\ ;L:9
M'S]6_P!OR*E(35Y8^&0@'2T!@\(1EE-.)<UQ$,5=7F$UYY\DL)+V,"!/",!,
M*<Y(!C!"1II&302L8P?(TR/,>?7P\ZP8_:76);Z2(7L;"$R:8B4/-QCZ_/S/
MT!<)SJN86D9'8.=:D16;'5TL "$2QG-<(YJ$-6-&#Y';KM4TRO96+V]WI*/)
M7U;HILG#3R7)U+85]K5P3W4MQ#!7H=7%E,2R$?2%_4 IFPS")**KD=\;T8P?
MCTIY^GY _C6]\BE.*5%VHZ0Z;VUG)=:_JSK[27,R(D]M<Y&B/LYT:B-8A!Y
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M_9.YUV29:Z795-MFC\N/)5CWAAFFT57>C:K0YMS4#O#;<NM-J'6@\M.0.))
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MGS10/'X]>GVD?#\*K5T&_GTZ?4<#[<GS/G9/DU13BE.*4XI72L*VNMQ)0+4
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MNOQ][1%W)Y5O95;=3+JA#LS);G2D6!XU:[,#VP*V91=@*-H&A?&2M'K(HJ5
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MC?15*D@[]#6,_9(;_7<__D1\53R_7[/XUJ^SZCSN[S-KEKV<QX%I UB3C*R
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IM*EE8I4 N]1:U#S4#BA0J?XBHK:>*4XI3BE.*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g400206g21p27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g21p27.jpg
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MP=$60N$D,S0U8G)S=(*4E;*S\253=7:TM=+5-C=#1%158W>2DZ3"T]36_]H
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M<K]J+"YU-VIQ<B(MEI)5I#>]+*!CLR<#/-C.-\$$_NV7G_X4_%*\F?%_Q&Y
M3\A*;4^Q\XLGA_YT>1/*K- Z#?SW=CQSQ5ZF]LF#Z^;MHV8$CB+4U<(HT'+
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M8F3 &F]=\BNQS[L,-B[8)D3;?*-=OA5QP8[<:>\H&)*E_P Y2US'*>4* X>
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M5755\<.X-RB<H_82-"Z=<;):9R$-$#UTG "A:985--;4T/4S/9C:"08BM1P
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M;KT:9IVH<1ZHRG#)VUVUZQ/+8MRO+6LKP2VK5FU.1(\,B@ADEDD(>XANP+B
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MTYUGB36X].J2U*\S3JUN%T=.%A#I*_:AS/7YVC>*M6^M+S/Y!/)&VM$XRR-
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M_P#;\,J4_(/_ *A.V_\ A)T;_@\QDZG_ &MO_P")V?\ 8O6"]'__ (=\&?\
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MJM9@-IZ,"2+?DCNF$!W0K;8B;6VR=DG,U8"0HA.J\Z321$;\D*9 S+/. 3;
M0:E12+(M^)GDV>+72QF/+:^539<_T&;5Z8#*7>=7QL0KU\=8:^Z9F[Z''(N1
MRO'QQ#D\\)49%.'4L=86[MS=FH]7$ZNT@BT@WX >0I)9!B!YO= %"K'"M/YU
M%J%V*P0;F6M'%J3RI3IZ#<>@6:$^$$3*D0+C S3++VVK1+DD"DZT#(=C=(K(
M<<\<.C\TZL+N=G[&=Z6!@T;H834>R3"\HC$.WHUR:>XV+04G&$CZQ$9YS*=@
M@X$Z$+#R"/L&"FOJ2$A\BN7A$PB81,(F$3")A$PB81,(F$3")A$PBC7KW_5^
M9_\ O*Y_Q.&PH/0^PJ,<]"L+58W^75_VU:O^%^39;;]MWO\ U"K/V&^W^*VK
M+BH4R<W_ .KNA?ZEU;_<<'/.O0MTPB81,(F$3")A$PB815L\LC%B#\4L7Y6B
M=;DF24H8,85Q<$@_;XS+TG3TIV4RC6R@^L.QX[D*REZTG=L'BY3SM8V@UN&X
MC#:])+'ILW8MU R/='&#ID/;V6AS@7$M'[1D):"V:2'^J&,<708EY"-X]'52
MG;XJHB_+PS%6@BM6'CBRX:6E2NC@>V-C)'.96EU!LCVS:=6U%[=+GMQ1QZF?
M43.#C?$+H_\ *!R2(Q,M_.K0?ILY=4-0N:UNYU(/4$CX\=(FJ$ =_1&M,8T*
M%_3MSW2 L'\]>TJ;"P$IVA5OAZYZWI[6NLTYY:SNPD;2KV:T=<,:!' ^&WB=
MLC& <Q>R+(P1$T=?3Z2M";HO$3GU]+UW3M/U:NS4Z,VOW])U2SJHG?(+6IU[
MVB-.F2T[%QLXA;6L7>Q+71R79Y&N(M+F=7/EYD5/KA^Y^8ZB(.P%>@TB%-*\
MZ64X5SVXZK :"/467$K/D;9K<V]2Y:JF=)$R $YSXR_8()65-C2 P,*5+,E]
M*KZC+9XBS'-)<K-?+4Y]+I6A7A:SM"V'6;%CFJO=#*YSHI*CS,R4O#HX89)6
MO[SJ?"U+2O1KV5NC7T+6I*M36Y*_&6MZ4=3MR3/K$7N!-.TSL=8A;J=%D<=N
MEKU,Z?+2;'/'>MW8*4E;TWS=5P9,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"+"G#E="0W';&9#AX+B%-..F",,='6A:=I4C;DQYE&_<G>]>W
M2O7>M^FL(JX([/4&3C'. 72XE@B- I+KTRMU$W;K"*A:<@Q10_1*M.S1CQ&1
M"=(/Q2*P;B8K QAXA%E.RT2)$9\-^\ #)_#V'V=ZG;OV]I 'OST\,>/?W*"O
M(KL%(K&J<8USGM06.J:,JY*]@ 4&+(BU@5+3)C@6:N;>($;:7+?-E0:TSNL/
M/B=3RTY)."ZI8\KIO%C:4+Z$UJ.U7=/,VO+J-;<PP1O;(('P"*PZS+.7OBJM
M%63LG.GD#X_LR]E]%575M8J\0T*$^D:@=-JNU#3^&-5>VN;^H7(I*K]0@U6:
MUIE72J.F,@KV=9DGUBJ+;6:? *EL!T]&5:9/$UHI$-(Y9VFPG/H9>Q<ZU$N9
M?/B09"8[<U<(0/MX@3$DJ;E-1'YZQ22Z8TEZ J4F+(DL.9G3=!IT9&V(S9L3
MECA'-;>TNC8_',&1,C@AC<YI#7/$(EY,L<X!SFG1=;XPU35()-.=%IVFTS,Q
MUBKI43PRQ+ X]GVUN>Q=MS0L>.T9 +AIF5L<XA,L<4C88ZM9:G0*.:M,.K=_
MH8UMMZ #8'1^?6:K"C4Q;\<8B6VQ+NI\174$MMQY#B%)# H.DMQVH,1EIG6!
MUO1=,TZG8NBS>HQ-:1%'#B:JR9X/9-(=4MSPP%^&G#FPPMP&B-H:%O?!'$6O
M<5\0:;H\ND:'KMF:5DMZ>W*--U&S1KECKCXY#K6C4+FH>K!\C&AC[U^<.<\V
M)WO<9TYU?Z*YSRLD(M:Z+RDE]1JT.-66I6*U/_C$^"Y%(R3YT,R;&V$=-B2E
MQ=/J-PG$#VH&A_X-H= :A;'HL<$>F5G05):;)F"=T,S^VF[20#F?+,'R=J]V
M!A_-O&&@-8UH8W1.-WV_Y3:I4MZO3ULZ;,=/KWM/@?3T]U6OGLHZ=*2"LZI%
M&7O[6'L0?6G6)7RV9)7V9MZYWU>D]&F-SU]'IQ(B!*&!T6N#]LA7V";2GQNR
M;T4D9)$9[CPIY>QRHNX\1B,7EM2V94YMI<'*>T_._P"[].Y:FK ZWI6M;3O6
M];^^MZWK>MZ_IUO7VWDHO[A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81:W<8P*95+%'L[^HE>6&(*,3/G+CJ@P&HSCLB<U);UMV-(A(1N5&DM
M:V]'?9;>:U\Q"<(J>.$^@:6O0^#*FP-*](<LA4@44C*C:UKY4B5$WUP;IN2Z
MG^<<;7#%*TM6].0!ZO=':NY?X#Y]ZM89XGY]RWF5&J;-!&EQI<R[<7;,3=;W
MH3&=,D;=(&MQC%>)5UPM!@Q1,4,.@)0TJQ0HL8<("%4V2>MQ! K;R0[SR>[.
M^^>BN?5+<;!OCT[_ ./CNM%22MZ_1%H22!5]:%),& =7#N$QL':=_43(NV>F
MV%]A;+?N5]3& '7HW_+('/\ LWM-9+\= /GVE4 ,SU)]O^X*[8V-!ACH$06A
MEL9%A18PYN,K2X[<%AAMJ(B.K2E:4RF.EM+2M*5I3>D[TK>M^N[:N+NX1,(F
M$3")A$PB81,(JX>5?,2?5N.FZ^""DK(>ARX!8/7H%\-4*.7D1W=QI,<J\+(#
M1UHA,#I<V:S2K9+CU*S$HL" :G"65),0,/KM%]_3I88XWS2M<R2.%MJ6JV5S
M3@MD,<D;9VACG/%:=[:\\C6,E?&T]HS=_1[K\/#G$U:[:M5J-2:"Q4M7;&B4
MM;?5CE9SQR56VZ]F?3)WV(H87:UI4;M6TRO+8GI0VW@TK/:\6ZM,J?%*?"E7
MF=?6"$-!D7/F4:J\Y9#"R+#"XM:'5*ICX<49!$[0XG6BDLZ:=E/2ESCDY.V-
M-3H<#J^FUV.M.M!S1(QYJ046QL> 1#'6KL:V-D9SL]TLA<7<TKF\H%GCW5*V
MK<3ZA9K:/#HO9O-:>&+6-5UZ2Y8@>]LFI6M4U>S8FLV;>6E[J\=*F(V1]C1@
M=VA?87,NM.7G:UP>P3O,[5P(6"PWP.%;:MI$\A0SD\[G"9NR4FGT=TQSC8"?
MW()/E0'8[M6NX5\:* _,FV.S'""QHB9J(TJ9_$8LOEDM1Q 3NF'+I\E/FYC!
M4,M-T3]4B>6 &O;B='%#ETL\CG-B?VG^6=&'T9/TFM1T[1K=AGT6VDYECB:+
M72TP-U'6F4^(OI"OP9J#(Y"\ZOH5N&S9N\M?3M-HUVSVJ_HEFW+BR81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PBU:SW6K4UB._9#,4;N:\F./B;T[*)
MDY*M^B8PL3";D$R<C>_^Q@Q)#FM>JE)TG6]Z$X11]*Z#=#.EIJE18"1M[]K1
MJ^R%LN+1O?VDQJH$=>(/M;U]],&#-9FZW]G&&]Y4&./=CKU_@/Z%27M'G[/X
M_P"]89T'82ZEKM-\LQ-+F]*V, R-4D*PKTUI28VJZJ/8W&5;]?YDM9RR?3[;
MWO?KO=0C ZDGIY#X;G?VJ@O/<,?B?W?HOH72*@%>5)&UP1'F.*VMT@J&U()O
MKW^MR03E)>(2'-_M6_)<7O?WWO*@QHZ-'Z_K\E4EQ/4JO9=^:KOXMG>B+,Q,
MIE8O5C@#;G CB40=1R4FI"*NELC1FI["W8KMLMI1C?SI#S2X$R*MJ+NWOS[$
MC?&XS@>6!L",XSL/9NJQCE.<>6,C)\SD9]@\-M]AHWEN!L!&V<H=KHH?(,%W
MR]7!% Y270.CQ24G<4G*&@>O2F2E9J0HG @*W,!R@4VQV-R(I5;VM\;(0G2.
M,:UB6WI#JT,;II9)*L$L,SJ&HMD=B1\<&K2"2K5C?&TDQ/@DLSEKA6!<UV/H
M+T*ZCIE71>,V:I<LQTJ4=+6-0IWJ<'$G"TU6$35(K>H\$POJ:KK5RI9LM$%^
M+4(-+TMDP&J 1VXW&=&W" 7H-)$-I,2T0.>+ASX[!QNV%=_*1OT>L4D[]//B
MQU2H#+;=H;=61N1K<9@FVPP)5MW<X&&&*"(\Y,<$;'<\KK$GU6 'M)I,/E=D
M;RN'-(?K$9<0N$:C8;;O7[+! &V+MF=@KTX=.KALLSWM["A7S7I1<KOV=2$F
M*LS$3#R,:5"W0QUKL'!'R0AVTK,5^S'BQ?8WJ0_E)-H>B61?-NVYO8PA4M+B
MH><49I)%#(KUV[,AE($E3"T:_P 4P6IM)<^J+)?7>99!!JC=,'8AKC*Z=TC)
M*\\30/KUY@QKFEQ;+&[!/1/1+J&F4N+(Z^J#3#!J4 I0?27"+^+RZ])+%ZG%
M2KUK-74M/M22_5BU'3GRSQ/#625;,+WL4E\8&RAWC<#9A#*@"5-JI<P/&USG
MMGC5QB(<=GF&-/<_*$$V4A-F,S=O&86IC#QPI(ER8;++,UF/KU\-QF'0: $5
M: .A[5D=2M-6B#)G.E:37L.=*V1P?S3<QPZ1SGM^J0L?Z4[0M\?\0N-S5[\D
M%N.C/;UO5M/UJ])/I]>&C*/I+2XH:,M6)U?L:,4+2:U2.&K)))+$]YZ? 84$
MW7CT><,F$ /U<1H?&+*KDRJ,*;;DM38-:KB8$2PU5#"TM)(@++"3N(O<5,!:
M]:E[WF8P"3MMW9 P#OG Z^.<^"T!YZ8.,^&1GW]#^Y3,Q00(S:UUEPO375+V
MYK\I&)X:"EW?K_.N 6GEUN6KUWZ[U.#2FU;_ ,9"M>NMU]FWN&/852'N&W7V
M_P >JR\4KU !M&FRP2^P4:5[V+#$16+$OU^^E)/5Z&Z!?VG7Z*(RJ? ^9OTV
MZ11]U:I,9[B"//8_'IT\AOX*H2#O&/,=/AU_$K8QO7:XY+AB[/%)T4O/D?20
M8MH:CLCR,K:?<E@;8A\F?79;SWHKZ>'LFR3=TG>]P$*]4ZH((ZC'M^<*L$'H
M5*GZ_P!6%*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBC7KWWY\:U^Q
M<JO(5K]BD.64.A:%:_:E:%*2I._LI.]IWK>M[UA0=@?85&.>A6%J<5*='7-Z
M2G6]G+6O>_37KM?Y5Y,CW[W^U7LUI'N_7[=:3Z^W7IEMOVW>_P#55G[ ]O\
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M:W3Y5:VGKQ K,(E9#UKYJ^.MI0Q8C"+AN8J(H@=MWY^MGO!R !GR'L*C:P?
MP58ZX825#>,A2]GN1?%>JY>WE*E)FDBO3O-/J^K?XQ7TD7D45XI,G<.I[LL
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M(T]T&ATF?SB#:B)"KV!SH)%ZGC1&$:\ @D';EQ@^&?,=<CQ[_%>D/BKX/D.
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=1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g400206g21p28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g21p28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X45_:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S
M;V9TPJX@4&]W97)0;VEN=,*N(&9O<B!-:6-R;W-O9G0@,S8U/"]P9&8Z4')O
M9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&9X
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^"B @(" @(" @(#QP
M9&9X.DU325!?3&%B96Q?-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T
M.61A8V8Q7T5N86)L960^=')U93PO<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C
M+30V,S,M-#,S,2TX-S$X+3)B,SAA-#ED86-F,5]%;F%B;&5D/@H@(" @(" @
M(" \<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V,S,M-#,S,2TX-S$X+3)B
M,SAA-#ED86-F,5]3971$871E/C(P,C,M,#,M,C!4,3<Z,# Z,C):/"]P9&9X
M.DU325!?3&%B96Q?-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A
M8V8Q7U-E=$1A=&4^"B @(" @(" @(#QP9&9X.DU325!?3&%B96Q?-3%C-F8Q
M9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7TUE=&AO9#Y3=&%N9&%R
M9#PO<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V,S,M-#,S,2TX-S$X+3)B
M,SAA-#ED86-F,5]-971H;V0^"B @(" @(" @(#QP9&9X.DU325!?3&%B96Q?
M-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7TYA;64^0V]N
M9FED96YT:6%L("AW:71H;W5T(')E<W1R:6-T:6]N<RD\+W!D9G@Z35-)4%],
M86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M.#<Q."TR8C,X830Y9&%C9C%?3F%M
M93X*(" @(" @(" @/'!D9G@Z35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S
M,S$M.#<Q."TR8C,X830Y9&%C9C%?4VET94ED/CAF-C<R-V(S+3DT-C<M-#AB
M-"UB-6)B+69B-C<P-C!D,#%D-#PO<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C
M+30V,S,M-#,S,2TX-S$X+3)B,SAA-#ED86-F,5]3:71E260^"B @(" @(" @
M(#QP9&9X.DU325!?3&%B96Q?-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S
M.&$T.61A8V8Q7T%C=&EO;DED/C)D.&-A-C@T+3AD860M-&$V9BUA,&-C+3=F
M8C!E-C5C-65C,CPO<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V,S,M-#,S
M,2TX-S$X+3)B,SAA-#ED86-F,5]!8W1I;VY)9#X*(" @(" @(" @/'!D9G@Z
M35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M.#<Q."TR8C,X830Y9&%C
M9C%?0V]N=&5N=$)I=',^,#PO<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V
M,S,M-#,S,2TX-S$X+3)B,SAA-#ED86-F,5]#;VYT96YT0FET<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A
M=&4^,C R,RTP,RTR,50Q,#HQ-CHR,2LP-3HS,#PO>&UP.D-R96%T941A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 S+3(Q5#$P.C$V.C(R
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,RTP,RTR,50Q,#HQ-CHR,BLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H
M/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:&5I9VAT/C@P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"
M06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!
M04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!
M1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!
M;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X
M<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X
M03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G055!14%!=T52)B-X03M!04E205%-
M4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+
M0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],
M14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC
M645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9
M,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"
M<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q
M9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X
M03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%9
M14-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(
M4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*
M0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L
M9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A
M;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E36$UC<DIY:&%K<2]9
M0DI#;G!5)B-X03M';FI3;&%';4MQ148P5TI"<4A8*SAI8C=3;G=0.65H-UEQ
M:3%D5T919F]X5G9&5D,Y=G)3>70S=6)U45$R.&%L-5IM,E)&549M6FTV)B-X
M03M+;T%Q4V-646IE6G9,:3-5;&]D571F<F-4*VY,8F5T1UI68TM72W-L95%0
M1E,S5&]#96=X5EI&-7(X<WI7:C-K3W$R<W1R149A5V1*)B-X03M56D5$;FEV
M3F=31G%F2$95>FEL:6UI4U=*>$I&24%Y3W!Q0W S0D)'2W)S5E=V27%J9G(T
M67%H6DHU4W=605=K8EI50F]0;7@W1#,O)B-X03M!23=9<6E963)22TTU9&IU
M>DAX.6@R1TMR.%9D:7)S5F1I<G-69&ER<U9D:7$R5U Q27EN2FM*-D]P;U%E
M>$=+;U):6F]I<V,W+W9E)B-X03MI;71!.4LW<EAV459)-V9J:7%+4U972&<S
M:&EQ+T960RMV8E=W<W W,C=K159R8DDP<SAP0DE214A*;4Y+;6=!<6-64WE$
M>G U5FYK)B-X03M-35=P46TU1'E20S%*26YA4TE6:VI716=3338Q,U96<C=9
M<7-N.#@K56]0<D%M,4]+3U,Q579C=TYY17-A<D@V>DTX5E!55E5J*TII)B-X
M03M6*TAV5$95>C S5DY0,4]Z:79B0V1B:3%M6&Y&2VQA1F%L83<P-W%C5E)7
M2W1->7%+:S!X5D1Y5$5K54I!3WEG9%0Y,D96.7-K=W)*)B-X03M+>F-N,T52
M24E194<S52M0-%E&5G-657 W8U-R54AH24(X3&IS845#;S=J9F]C5E%N<511
M:VED4W9(+V0V:CDR448U1G5P-$0O5RLX)B-X03LT<6E9-VUQ9S=-<#-$1'5$
M:7)R:4]Y=31*3&$U:E-A0UI74U='5E%Y36IG<7ES<D-H0D)O4FEQ6'HV4#57
M4S53865Z=$)C>4XX3G<X)B-X03MA96]Z=#A&1$M257-W:TDS3E=Q974K06M$
M;7EJ06YL,%9)=DQV;'5',FMT6710=%DW85964U=&23!62%=0-T-S;T9#1C9#
M=E%95TM-)B-X03MH5S%T-'A&0T]%84M&4TYA.%%&1D%&2%%9<3%,9$)63$5H
M14%Q>D4Y0CAZ:7%J>'5*:4)'3TM-1S54=#%7;7<T<5(X5F4S8D955D)B)B-X
M03M246<X4E8R*S-)9#)A:$HS4#!M9S9$=&EQ<&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5E=Y4G!):%)H5E-+1VA)4#!%8FI&54I):S!,)B-X03M#:71,2#A4
M1U)A17)1,4$T:F,W8D-L8U9623=M=&%%3T%3<#,V16)%67%U;E<P=7)E4S-U
M63%L9VU2;S5O6D9$;S9/2TUR2U%15DE.)B-X03M#1&EQ1"]1,VQQ,FMA-T9H
M85)3*W$Q=S V=WAH+U9K*S-+5T,Q-4@Y<'9V>%9P=DPO;&4T-7I.<'1J36)K
M35I*1$1%,W%#4U P,C5.)B-X03MX*TQN2#A*.%8R-EEQ:F]K=$QD94U+2D=T
M4V5+2T%+<WA::G0T<WA*.3A68S%X,E5F5&EQ2$5R>D5'265R=4MT,%-H2D))
M8F]A54]W)B-X03MX5EAH<S1K65-0.$%V2G@P:V)T5W8R4C!863 R-FIR6$96
M9D9867$W1EA9<6].6E%(-T%-4D%)6&=A058S<G@K>%@U:D963DQ3-%)7)B-X
M03M$4VE5+W-66&=F.$%:145J-VQX5FDR=GA8=#%Q;&]J>&E*3$ME3C5::V-!
M0596>65B<7!&1C-.1F(U9S5I6GE$26529'!O=E)J:V1V)B-X03M613%Z*S<Y
M<DIM:3%(;4%S54I4=7AL64@W=E10-CAY,U9R-4Q3-&-R>&U%82]T:%9Q,RMX
M66UG*VQ4:7%Q=&Y!0U=+;'E3<DAM4W<U)B-X03M*,$E"*T94,RM%1$968D98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%P4&$R-TUZ1D%(8W%8
M9&%Q>D9E;%=7:$]+<5 Q)B-X03M/8U1&:%!723<K;7E!:V5Y<W!8.%%C5E,S
M6%DW.6]'=&\T63-7645++TUG:6Q.>4-L0C$O;7A65W-O9%-3>70P4T]**TUA
M<7AE6G$Q)B-X03M!;V$P:4ER:7%-93%U6&I!5U)9<$0Y;SA3.5!L57(K27A6
M971J1%)225=L255Q4S4R64XQ-4E+269U>%985E9647%G2W%I:7%.9T%/)B-X
M03MW>%9V1EA9<3=&6%EQ-T9867$W1E=,-CE.14QI-VE,9D<T-#!5335(-W!3
M4U9133)W4%EF:5)M1FU0<4QT9$Q%.$U4*T]A=&\Y.#%Z)B-X03ME47)*8U-.
M27!*6D=,<'E::UDQ.4YU3W@S24)88G="1WAX5$IK3C)';WAC35112#)D+V8K
M4'1:1FU9-C$R2W5X5EIC2DDX16E2=5DU)B-X03M'5FQ2>#%5:U5",T(V9DQ"
M25=%2&MX<&)F>B]&8FA%=4Q385%)=$AL<EAK2"M)3GA55G%N9GAZ1$5C-$A-
M3U!7541M1C P6&Y&3'4X)B-X03M.;&1W6$9S0S=2>'E&5VM75&M'5TQ:5D%(
M1'A09D1+3UE%,%)34TUG2F\W2S)H<C4P83AJ:S%D<F1B4#!V:6AJ<#9G;$MR
M,4E$1%EH)B-X03MU:F0X3TAX<G5D5E,T=D9V,59424UY,TED:7%X-31%;&IH
M95)6;&QR-E5:64)N-&ER8U%D>E%D85EQ=GA6,DMS63%3,S@W4EA.-6-A)B-X
M03MF3VLX56MK9C%7,5!$-$4R1&LX*TDX5#ER34Q*2$U#5$4S,T)X<&I+0U-(
M5W1L-7AA,RMR6$=O=R]765)B3GEJ2SAQ07-*95E+5DE9)B-X03MD4$=N>G=X
M>#5Q;VYU+V%S635+,U!D*S%&-DA:*UI98G@U3E1U4DQB3DAX5TQK<DUS9TDK
M2W%X>#%$9D8X=F9*-%E:06959'9X-4)L)B-X03MJ:DU(,4A:4$UY5SDR2W5X
M5D%A=$Y(17%/-T)1;UEM<$$R1D\U24=+;T-/-61%8U)V24A026]$>D$U0W!O
M061V=3)0=FEQ9EEQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9<3=&5U!A,5ER
M3F5F5V9H16QS-&M2=4EQ9C-F17%71D=)-'4Q2VYQ83EQ6E9K>$-7+U9Y8T=P
M34Q(.$I()B-X03LW9C!.-DI92D9E3F-N:5I,:"]663A6<5 S65-G66=S0GA2
M83!0564Y36-E25(S-G)N,4IN44<P44LK,B\P<V=Y,7AN67$W1E5*<2MR)B-X
M03M71VMA8F-A;G%%:&ES<E)0575:9W)0=VI(,FY)544X5D<U,C)'2W-.;B]/
M2#AU<G5/97AK=EIG6E,Q=$I(-D5Y4'EA45%&465);V54)B-X03LP<C(K9497
M32M8.5@O3'9Y<G(P*W(O-&PQ4R]L:W,U23=U3S56-4EA:619,VYK-'AR>&QE
M5T=I,4\S2VQ"6$978S9.*UHS:R]7=&)/)B-X03MI86)D4UA';V\P:512:4=5
M0TIO;6Q2;&M9<495,70S<'8K<UE&6E9I<G-667)Q,%=T9C1L,%5'-G1U6DXQ
M-D1F5C5+2U!31F59.68T)B-X03MT=D%R:%9K.$%N15-I9#%K;4$K3C!5;W!0
M<W!:>5 X06=J9U9F:7)(9&(X+V57=$8Q239:9GEZ3&5I13-*:6IT-7!"-DMQ
M>G,O2D5+)B-X03LP0WAU978W2CA-5F5D851E+VPS6F5B8F97-%!-1W)Z5#):
M8W9A37-K;'5Y,T9T2DI$1SE)>5=73T(V4G%$,55(8S=K<3E+.'5E9'9,)B-X
M03MV;4LV=G)84W)H<&)J5%-I,W-B4G9'63)K0DE5.'=.>'A)23A29U908U9D
M:7)S5E-F>D8Y831X9E8S5DAO.4]A2S1*<79I0U)T56)E)B-X03M/535:1594
M;&%E15I!.%$O1S974S-,.#0W>$ME<&)"=U%Y9VAQ8FM53F5R27!"-FHV8VA0
M3V5J8FHP;W5P9%=6-6MU03=&6%EQ-T98)B-X03M9<3=&6%EQ-T9867%P5'E/
M=G!O;$$P:F-1>$912TM7-D%I=C)F2$95;74P.5-A86%2;5!!,&%.4U96=4%O
M9'%N-U9-5F)S,$M3>%12)B-X03MU=S4W3$=X3$M053)',5(Y;75+<'A"23=E
M;VHP3%)T>$Q!54)Q;V)O4V%F83AC5E9C5F1I<D)V3G9M,CAS.5=L,%<W.'-Z
M87IP9'=))B-X03M20SA58GEX=7I",TEM0E)O=W%V14\O9D-R1DY%.#1E5R]-
M;&YA1WHX9WE.84EX5T=A4TI05&A-4S-C-CA7:E)Y4#,P4EAB8FQ*,3A6)B-X
M03M6,$]S85!-,%0V:BM8>E-V2D,O<%,R,6\W2T$P-$1Q5$I':F9%6D]9*TAR
M+T%-1FEH1C9:-78P-GIV175T4#A!>3=V<E,Y;&-X+U=6)B-X03MT:VIR>3E7
M5&XV9UAK43=T261X6&-K:F9&3#!$>70U9T]V-E-.4BMP>3)3=$DX46EN<'E*
M:5!#46EN-TEK1$M$*S!"56)(07%B-'$W)B-X03M&6%EQ;%AM6B]-0V%9:F%#
M<V(S+T%.6G166DI10W8Q9#=H175',UI+8TE76B]O-DA&6&TK;V%B-30Q2UHW
M,U4O2SEJ8S-$5SES<'5N)B-X03MT64AU16MA-6=J=D565&-(:VE7>GIC4&HK
M3&E02#1I<6Y93BM9>6%A=&QF+T%*9F%E-4AQ4U-+:VM,4F,S6C=C:%)Y,R]W
M0D9!,S9K)B-X03M!2U16<7%Q:C=+-R]!1$$P<2]U>G!V:U14-T=!4E!3-FAM
M579,-DMN:7!726-I2$MF1#%/-#)*<4U696HV4F-8,7IP9')C6#EU3%<X)B-X
M03MM:E=383%"<C9434LX0V9&96@Y.$-O=D981W1$5'(R>%9J*W9X>EA$>%%V
M33!::C5&;FAQ:&%V1VY5=%%E3UDR;T8P-3)I;G<S=&9,)B-X03MM;$IT14MM
M5G!:9E-I<41#2&](-&9A-6UN5GI8<&U.=W5F-&@U54Q05W58=3EZ3#0U<%1-
M<71X2WEO6D5O0T-O57)S9'I8-UAT;7ED)B-X03M%<C1Q-T9867$W1EA9<3=&
M6%EQ<V5A1TYL5C-66&5V0E-25G%D841V:7%#=61245)M65%Y;%E#6%9I06]*
M04MK55IL8G5D>5!F<&EQ)B-X03M64UA282]-0E)E3&A864-1,&8Q1%$O6FIF
M:%=O+V$W-V5/2W1W,VY'+T5(14)61'-O.51:4%1.05!I4U!N47%E:F1T.%94
M4S Q0TIQ)B-X03M396I+;W5#1S5L459Q449(,D=C:G Q-EEQ:FMM:6M,0TXQ
M8V]A349)3D0T1VU+<G-69&ER061:+TQV>DIC-GAF871P;FUM-7-B:3AK)B-X
M03MQ<U1"<$EO;W8S0312<'I52V8S5#%B=E5B0VU&5419+VQL-3AS-U9O6790
M1GAZ:VAC4WIT13!J=&1'3# P;DIE4FEA1E5*5W1.<5EQ)B-X03MZ6'ET<%=R
M-EAP2S)M<39M*W(S4W5Z9E<U131.>&)C2V0R<E1F9D%Q8C1Q-T9867$W1EA9
M<7=R>F0U1#%Z5V1C+U1';2M9<FI3<%DW)B-X03M63&$R=#!$4$%S:6DU-7I-
M9V1!>G0V.&1$,C1B,3(T<7!6<#,U865E8E<U13AN;E<T;&%7571E<S!B1G!)
M=E5,<$=P85)U05%/>6IJ)B-X03MH5FLO:VYY+S5J,%=X;&<Q,UA8,39E47%Y
M>GE2:4EQ471';T%Z8DUD-F1S0W-J>%9B2DI(1T%:1T-!:T%&:4)U96<S>%9$
M4&9";F5')B-X03M+3U-O<7!M2S!25%19+T563$0O5GA6:F5S-FQ/.35:<6=7
M2U,Y;FMG:#5T6"LW1D<U4G%J5BM*3WHW5C,V6FHU*V-2,W5F;S1N:&Y+)B-X
M03MR15)F-"]"57(Q<$Q:-$%#:GA44W=24W=S>F9'6C)686@Q:BM$;%5K9R]2
M5$E4>&E.8CEZ6F=Z2$IE,C1"3BLT6'DV+VDW6D1$9F=T)B-X03MY345J1S-$
M4D@P>7),43A3859)6G501VUW*VI-=#%I3VIU-V549T$T1'E#<5)T.$QK1'(X
M1%5B.$U65F-69&ER<U9D:7$R5U9),$QT)B-X03LP07)18FLP,V]!3W!X5D-0
M3F-3.%-0,TUF5FPV=5%61WA),E=H<C!R.#A66%)79T(U0F%-44%Z=%5U=U55
M1E=.5U P-'$S8U=-8W-,)B-X03M)+WAD1T$O>6Q)6E0Y0D9C5E<S9&YB=$(V
M:VM13'!X2F]A1V=9359R=G-3359D83)C0U%&,&I(<5!Y24I.5%)M3&AA-V)!
M=&EQ-D-X)B-X03M32T5);G<Y5TDO>6U*6FHY2DYC5E=V86A73#AA3V%69&%H
M<4$Q;U-+1VU&6$QC>GA636<Y84]P2EE#:G%/=S1G9D94-D14>$]"55=J)B-X
M03MO-CAK64UU-'%014=H2#!(1E<X5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M5'5I27IU=U9&0DQ-5%%!1'%38U91,&QX2DEP5T=S935()B-X03MQ34XY;6]E
M2VYB8V1#9G5X5F%T<TA:6$LX;55S5F0Y>4]86&E4,"MJ0W%S3&-F=$=O-VI!
M<6E.3W,Q=%5J:VA6-#1'-7AO4E5,=V)K)B-X03ML2SDQ,F]F<'=%07-O>4UE
M4E$Q;'!&;5=75U-&5S1#3#!34U-684E-=DMP<#A2<60O1$5G1EEZ275J>E)5
M9&I%<S@P>7!W:VQ)-4Y7)B-X03MV24M+3#,X34Q&9$IA,6]302]%:&QQ2VM%
M9$--5E4P831I8V-8-7@Y1VIK<5-..7E(,U!F;V$O4FEQ26=U67!Q:%12,2LS
M1V1M6&-G)B-X03M62'9X3D0S>%96>%93=4QH659"3S=S47%*6&-K+W="3W Y
M<U91-DI*22]..3532V)6-'%+,6]0-&YV:%9&4GA+=2]6=DA!<2]&5D<Y)B-X
M03MV8D]X=$IB>3EN:G1R5T9E8S X<D)%5E(S6FUO0FEQ2&TQ6%1+:4MA47%(
M5FU"6EA64W%/14QC-D)A0FE.-CEX,D]+;U-(>EHU66%X)B-X03LK=5%A:D1*
M<#8W9E<T,DQW06QW;$1+2V]$>6-#;&4K2W!J<"MO,D=O,F-D-UE4<&,R:W1F
M5&UI64UP-&MQ=W%/-%E%161J=&EQ27A6)B-X03M4:VA$8FI:<U91=VI-535K
M5#172DAQ<4M58T%%0W4S879565928U5G:VI6=T-T4G5P<%5(=411:U9'0E8R
M2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A68DQ):U5:9'I25C8Y>CAG0C%/2V])
M1V$T65-307%U>E)1-V=R,2LS=CA2,S9D0BM/2V]U3T5$9'1Z-%EQ<5EQ-T95
M<V9Z3C5A)B-X03M#,TIF5F))2F%-63=S;31I06E914MY>69&.$I$1VA">%9Z
M83DU8G19<$I(,4\Q:6EI4EI:2&MU27=Q>'1U<FMS,4%P.&-64F1R<5=N)B-X
M03M88G9(85A53GA*1W%V26M5:7565GEW4FU#:S!$1D=P-#!0:&EQ27A683AA
M=4XK=EDT<6A*-$-(5G=!2EDV;4=1:79%:U4Y=G!'1E9E)B-X03LS=5!5-4MW
M<$EM>F)%03%&87%4,2]H9U9D3$=8<%-M,6-66&]G555(,&Y&5SA69&EQ;&0R
M9'!E44=#-V=J=4E'2W-9<%9$;U=29S9()B-X03MI=TEQ<DM#4&9&5TU3*UAR
M-C-E+W-B2%-D24=H>FU*64QC5W="2U0Q1C9*;RMA>'EC:6MF.'9W-S!C<49:
M5E(P1%1D8FU73WHX=V58)B-X03LY3FIT<G!7;#%-,C!56'!.8W%T=5E7-$Y*
M25=!84]11FU&9FAJ27!V4E9L9&I95TYH85(R9&IB>%=L<$-+4E<X0TQ(1V=*
M<E)554)2)B-X03MU8U96.%9D:7$R4TU/4&9S8U95171:23=G5$EW05E5;5=N
M,F=+.&0K>%=V*V4Q1E54:7)S5F1I<G-69&ER<U9D:7)S5E%D=WI.4%(K)B-X
M03M15TTQ44ES:$)*1S5B:71/+U1F-RMI<2M/84I"57))5R]W0TU5;B].3TMR
M+T%+,48O3$HO>4MK+S5P>%8S,7%,*U=4+T%*1E-F.# T)B-X03MQ-#-54D9/
M36TO.$%X6$HO>E1I<D-T53AQ-DQP;'-T<F]8;&5+-W,W<4=71R]T;$1W07)$
M13 P02M+9TIK;FI20S%+-V=K,%A&56I/)B-X03MH5W-.>&-#4#AV6DIO3'%.
M65I:54U58G1$8U-24UA33W)80G!U,&I"47A(2E)V=GE#;#9"<$=K-D9P3%-V
M<#EO.$5L=W-A5$]5;61M)B-X03M7245)<%HK4BM(:S,P:VYQ5&EH369R55@X
M<VXO04-+:R]W0V%C5F0Y86DO;&LO-4939CA!3D]+=6$U:%E%1EI+2"]I=50O
M;6Y&54Q*)B-X03MX2E8Q1#@T>GEJ2FIK1R]3;&5$57%$431Q+R]:/"]X;7!'
M26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I&-D1!,C<S1D$P0S=%1#$Q
M04-%-$(P0C<P145#04,U.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I&-D1!,C<S1D$P0S=%1#$Q04-%
M-$(P0C<P145#04,U.#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C@W,#A$1C$V+3@Q1C M-#DT
M,2TX1$0X+48R,T$Y1C4U.#)#-#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D8U1$$R-S-&03!#-T5$,3%!0T4T0C!"-S!%14-!0S4X/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D8U1$$R-S-&03!#-T5$,3%!0T4T0C!"-S!%14-!0S4X/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z.#<P.$1&,38M.#%&,"TT.30Q+3A$1#@M1C(S03E&-34X,D,T
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S
M<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D8T1$$R-S-&03!#-T5$,3%!0T4T0C!"-S!%14-!0S4X/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S
M+3(Q5#$P.C$V.C$Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&-D1!,C<S1D$P0S=%
M1#$Q04-%-$(P0C<P145#04,U.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP,RTR,50Q,#HQ-CHR,BLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E
M9F%U;'0B/E!O=V5R4&]I;G0@4')E<V5N=&%T:6]N/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!G,C%P,C@N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(S-S<Y-3(F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#(Q+4UA<F-H+3(P,C,@,3 Z,38Z,3<F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,C$M36%R8V@M,C R,R P,#HT-CHQ-R8C>$$[4V-R:7!T(%9E
M<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @
M(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C
M>$$[)B-X03OB@*(@-C@@8FQA8VL@=&5X="!C:&%R86-T97)S(&-H86YG960@
M=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI
M8G)I)B-X03L@(" @(" @(" @0V%L:6)R:2U";VQD)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \9&,Z8W)E871O
M<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^4V%B<FEN82!38VAE8VAE<CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O
M<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE
M;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @
M(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C<U,2XP.# P-S@\+W-T1&EM
M.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C(R-BXW.3DX,#4\+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB
M;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @
M(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:2U"
M;VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4
M>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^5F5R<VEO;B V+C(S/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^8V%L:6)R:6(N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FD\+W-T1FYT.F9O;G1.86UE/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S
M:6]N(#8N,C,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YC86QI8G)I
M+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%10
M9SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @
M(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E
M9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" "D A4# 1$  A$! Q$!_\0 '@ !  (" P$! 0            8'!0@#! D"
M 0K_Q !9$  !!0 " 0(# @D&" 8/"0$$ 0(#!08 !Q$($A,A,11!"146%R(R
M46%Q(T)4D935)%-B<G:!L;4U-E)UDJ$E)C,T-U5C@I.BLK2VP=$80T=S=X:S
MM]+P_\0 ' $!  ,  P$!              $" P0%!P8(_\0 11$  0," P0)
M P(#!@0%!0   0 " P01!2$Q$D%18083<8&1H;'1\!3!X2+Q!Q4R%B,T0K*S
M,U)T=20U-G*T)6)SDK7_V@ , P$  A$#$0 _ /[^.$506FKTV5U+ZG0.'?G;
MXMOY(:1L$,,33B$>]^.N6,<J0V<7PY)J.Q5D(UT&YM>[_LR&]UG9H!-C<<#]
MM/-5<2!<6YY>>JD7Y067_+B_]$WE]@<3Y>RIMG@//W6<JKMI7B I6QS_ ,Q_
MZL<O[OG\FO\ W?1R?3Y_+E7-MIF/3M5FO!R.1]5(>45TX1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A%\O>V-KGO<C&-17.<Y41K43ZJJK\D1.$42.T,OQ58#
M[$B8JHLKV>Y9%_:UJ^/:Q%\^/*>YWR5?;].:!G'R69>;Y6MZ^BQ!FMFKA"K
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M.$3A$X1.$3A$X1?CG-8USG*C6M17.<Y41&HB>5557Y(B)\U5>$40L-!(LGL
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M",BL^,5.)(DL$BL<GU3ZM<G['M7Y.3^*?+ZHJ+\^" =4!(T*E@6B@D1&&-^
M_P#QC45T2_Q1/+V+_J<W[_<GTYF6$:9CS_/=X+0/&_)2&.6.9J/BD9(Q?HYC
MD<G[?JBK\_W?7E%=??"*G?4#TGF/4;TWO>DMG87E5E^PZB.FN+#-D BW@HT5
M@%9-DKB+("T!BF6<&)BN(KR6?"=(B1HY6O;!%Q8[T6I_;?X-KJCN+M;9]E7_
M &1VY5U/8.BI-_K>L:*PQ$&)LNULMTJ=T#E>RXS#\/8;<*YH>NBQA8J,37Q8
M\^WJ*NVM,\;-$5&7!;<G/([LM=-?LI#B+6W:=^[AY* O_ _^DNLFH[3K^'9]
M4ZC/9Z@@K=;@CLX'=.['RVPZMW%%W6>RXS%S4V?8@UUU'F8S(3:R;%6U<7>A
MV61(2T?+&V1GNON'&][^W!+GCKKY>RPNU_ Z^G3LHO/:GL+>]O:[M6@V>W[2
M3MZT*ZZ38F=N;;9]&:Y_9" B]=08ZIM\X'Z?,)AL[44.8J\O#@Y;ZBM*2UEM
M93F-D;\]?$VS\NSM2Y],NS3GNXW6P.P]"N?T'8W;^YRO=_=/5M)ZA65\_>O6
MN%DZQ?C.R;RLPT?7$6@-(UW6NIUN=.L,@)55-]!D=-0U]TREK9R16E-*G*DC
M7,@&]_ANE].7SY^RI/K;\%;F^H*+I"HZS]47J!Q9GI[!V5'UM?T.4]*X%D+F
MMYGL-F])27@</IQ;0::4\3KZB*(U-]3'[8HYQ<YNE*;)%'#&SIF<M-. '#@$
MOKS[>-[:Z76TGI:]*K?2M3761S_=G;'86 ,MM/=YS"]A"]6+48:PV6VT6^T<
MN>M,7UKCM4<VPO=/9?R>KT&C8,(D$(C8%C5[Y M\'V 0F_SY[K;'DJ%P3DCC
M-]\\K(F_=[G>%7_-;\W.7]S45?W<D G102!J5&C=']6 L_<L\J?^Q'Y_J<_^
M"L^_EPSCX?E4+^'C^+=_PA1>662=[I97NDD<OESG+Y5?_HB?<B>$1/DB(G-
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MM?#I8FIY=)&U/VN>U$_ZU3A1<<1XKJRV8$**KRX?E]S'?%=_T8_>O_5R0"=
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M5SI$7W.6=HM!)=D,R76L -;FPL+9\NQ!'MN:UK"YSB&M:T$N<XFP :W,DDV
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MJFV-6)BMS*6=+A[N+.:^',-7.-CV4V=NIH@+:+)273PY)&R2HV!?B\^:'2[
M'S5E/'5S2U%":X2PQX=B3I)78;4MI*]M&/I ,0=25#FQ3MH75!C)!=9OZET
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MHZN1NTU:TU7H\T^=K2;JU@Q^J/S-3ZA[W&Y6M@&7\6Z_LJGZRDQZ9V5M'AZ
M"QI;G#W<C+4.NRD4!]T%:@QU9*DS!_'0= :RCA?4SLH*V6C@Z5U.'4,+6'J*
M_%Z?!SA_TCA3892Q2TU1AM21/'#0M;+41SQ"&3;='\M#T+JJ6-]1,VBJY:6#
MI)/0TD36GJJS%(,+-'],[J*"GBDAGH)R)8XZ,-DG9-&(G[3F5!A?1SNM;E!!
M[+*5^6_%MGHA+L/42TN8_+ANHP/7F>BT]4%G.NRF8^SP*Y0VBJ)8,Z+;6TUI
M?Z2OT]996YUK:]#AO0#$JZAC9-0PT74SU;*F.M--1C$A6X7A5(VMACI,*?\
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MK.NATN+RFB% ,&%O<]46T)8,!018V[/,7W$^JOKA0G")PB<(G")PBKG;=O\
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M/VM):6?9&O9HL'>!==DW]?3Y%[=C231&0Q%)())S%W$\=>\*/]!_@Y+GT_\
M9_7VZH]\FJ Z[[#P4(%1IM+M2*.PZIQ_X/CJ#T?IIX,!,\["9;U"C[+K(ZW"
M[!HZQ;@WJ36ZSKRUUKP=*X"E(7 WRU\CM$^%CIQMP7J]PJIPB<(G")PB<(G"
M+Y?^H[_-=_L7A2W4=H]5YC]8["D-Z]Q:U:V]["+EJ $@O-YK2:2OA-"JA!C0
MWV-#4V("%ADQ2C%C?:/C#$1203LCEC>Q/'*"3K:2G,,<\[6PQ,+Z>FJ)XP]C
M&M<WK(8GLVFN!:X!UVN!! ((7ZLZ48/6T_2+&Q5FBP]\N*XA/'#B>*89AE2Z
M">KFE@F%-B%935'4S1/9+#+U6Q+&YLD;G,<"8Y+M<HW2F6DEX%$)#VCCZ.;X
M[GP%PWLG5?9;(Z*6NF8RPCO)'S0MCIWBMLI'2Q(P5RR,]U340]7(XO MC-'$
M6D.#Q*<,KP(C&0)!*20!%L[9) #<UV#,$Q5V'14K:&=\K^B6,5[#&&R0OH&=
M+^C#GU[*ECG4SJ!C6/+ZULII6AC]J4;+K3?::^F R.D)M&7M($E':,?97^4U
M-!4PNF"FBB^TVUU3 UHS9)'LC8\@J)CGO:U'*KD1=*MYBI9WRQ5,,?4R R3T
MM3#$W:80-J26)C&W) &TX9D#5=+@N$5E1B^&PTC\/KJ@UU*6TN'8OA.(5D@9
M,QS^JI**MJ*F4M:"YPCB>0T$D  E;_XG_B9D?]&*#_=0G/5J#_ T7_24W^RQ
M?G#'/_.L8_[IB'_RYE)^<M=6G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(HCKC;&*.BJ:HUU6;I;Z.F;:L@'*FK8(:FWOS9QQRXYA92I@J,@$5Q$
M4T(Y!D1<L!#!U'E@[N9_)\@>]%%]&ZVQOV(P6Z/N*VP9<UUA5WZCG-2>+.7%
MR#8"$L'@GC<TBH0,P*1\@1 ALDD<4$X[%F$V'CZ$_9%0U/051U36&6X -S9F
M5X9-A9V00I19A4XT4D\KGRQ/2&)9'.^ &.D084'PQ0X(!H8HF38</@T\$7TW
MXTWPLJ\B9])#?W!;AI'K++,$/GLF^"CF,D5QDE-&=;3%H"Z=85C@#K%:M2+$
M$D;[=I],O/EP1<=Y45E/36UM3UX5395E:<>(96BP!2_%$%E(; 1]GC8TL$A8
M_@G5Y39@C1GR#E02Q/5O! /VY?/#BBV&J$L=D3H;"6]N*@"MT-MG*JOIYA!F
MQI0$OKC+(R64(B4LLVPB)DB@E>\" &,.-!5(<7+,_'E[Z'DBD>1-/+K)X+,K
M[<?4VMK2D6'P8AW6"5QDL(YLL [(QXB2!/L\AC!XHAD+6?[-#% L<;912CA$
MX1.$3A$X1:/^J_5=O8_L3TPB8+N6'K7)=L]L:+K#;P&8O%WT%=5YWTX^H_O>
M75B7.F'D=6F./Z@H:(Q"WRTXU$1:E_9V'OB+@*PM9V0R%]_$#<1Q54X7\(3H
M.P;'-9C/](UI.LTG<0'70\Y'8>PS>!;CCO3]9>HUG9@NEWW1V+UUK7S8RDM:
MJK!K^MIJ:\OWTQ%5KR<G9%:BK)L[R<K7W&]B =#Q._=GO5?YC\*!K=9CLKJ*
M;TOWEB3V:?6IU16TM[VWJ(]35?F=C[BU"6KLIZ:[R]J]'DQ;//86PK\UFMQE
M$[ ,NZP[=U=+F+"_E)LYZZ:Z9&]MY'CS&6:V$ZR]2_<.^QOK,U>DZ\RW7P?1
MUP97]5B/MM"?M9AW>G/KKNF$/MO)6^=IPL]J*DG?UT%J%1WUF+&5-999T#?R
M5BU^U*" +;^/#7=Q'SD*#QWJJ[PR>EZ=PW8FPJ^SG=K83TI=FQ7N8Q]!D--D
M2.[-[)B;S$Z\12K3.G9S22I*=@;8"LRNA;!F=N"18V,P8UH$3=?G\^9\]U[A
MZJ];^L[8T&,Q-1TQ34W8)5;K=5V[BM+V/JLY>=*9?&'=3#7%#H:O1=*4U_:]
MQ,#[=HKP?"PT5;AK#.Q":.G[>L\_K,/::4A%M_[^.G/RR-H33_A+J<*KP>S[
M2ZN@Z[ZM[!P?3?=(G80W8L&K QO1_?=7V)%UOJ>R@V8^C;F]B3N<IC,)<X^G
M/U.?@.[+K#\]V%J&9Z_#@*=G=O%[BULQK;CY'+18MWX3"^&H.U=59^E;M *C
MZ:ZLV6P[!]K=C)/E=WA?3-6^I6\PVBT9'5@?5%73_9;&/JX32-[0,U,_8[P6
M+UFS)6@6ID)L\Q<Z>-OF6F_<M@,_ZMK]>ZLYZ<=_U.+E>Z+ZQS=L_/9[L!-G
M15_4.AZ^[$U,G;+[^?&94DFMI-KUE>]1V]3%1M:/M+7)R,N)*G1AF-*+97[?
M*WNMU^%"<(G")PB<(G")PB<(NH? 04":,(;+6E$"$0#6,$0T\]>1-"^.$V&
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M 8.&$>/9K0W3QWGM/<LB2=5)(8)B)$C@C=*]?YK4\^/WJOT:G[7.5$3[UX)
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MV5<U^LA[DT/6F:] "X[/9?076HM"^S7=E':+LBNIF:&S?5=3[\#/ 4UE(,H
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MW>1V*6\S6B<(G")PB<(G"+I6=96W5<?3W%>%;5-J&576E79B0'UUE7FPO&,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g400206g21p29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g21p29.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -(!<0,!$0 "$0$#$0'_Q  ?  $  @,  P$! 0          " D%!@<"
M! H! PO_Q !*$  !! (" 0($ 0<'!@T%   $ @,%!@$'  @1"1(3%!4A,187
M.$%XM]<8&2(V45>7"B,R<7>8,S5"4E1688&1DK:XT20E)BBQ_\0 ' $! 0$
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MV5M($08V0&;KH?(JG")PB<(G")PB<(G")PB<(G")PB_/.//CSCS_ &><>?\
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MJ8''SF&V2X7ZD^YDZ1/==DWL(&WL1XQH,R%8.]_$>8!@_BRF#9-%:WV;5J)
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M7GR2T-IRC _5<8X5A,'P:E\.DUU3#U:+!B@T,JUC7J.#W5B.9SFW'(Q[W?#
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M!EY&2F*#4[K'T*(EI./S,1X]PFA%CQ;[[V2R!8\HM&3[CK^%1[FWX"HSK?\
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MEV36:IV4[(T#4%^ML\=;IRU:7I.V+# :YD"+I*/ERMU88AA,1H5LE#Y.0G!
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M'=7K_P!=M.6K<DJ?U_%F!*E+CEN6;:M^,V3(UHV7B9JO,BQDX$#'(B%Z(F8
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M<94K.,8QGSG/C'"AN"-P5673>KNWX?4/ICU ^&C6YOK.^:O;;")N.<9A4O\
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..B<(G")PB<(G")PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g400206g21p30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g21p30.jpg
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M"YI*^L\^2B/D=GC\DU/2M:7Z+.FH, LZW_11WTRXW<?]F U^?R-E>'0F][=
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MTC5:OR<(=XV4CDC4BSUCN=&:.7Z39]MNGH_<YUVVP4._/UZ\]E)?Q1/$54E
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MG#EE=8[&5'X@VLXR5+@6@;_=T(VL"#MR)(YW/-2"Y9@UMP#Y->G@URWDZO\
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M/O8F0W]-J_\ 7VK3:&;Q[6@LNL0_#[$.3DNVL[Q,L+_Y/V*:8#;3#,>VR/\
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MJ8O7KS;4'7C]M5=C3IW7J;4.CI(MA!Z+)'OWC(8^6?%2!<:\-Q?6]AJ1T)V
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MMQR355GHY?L4G'Y_V/A/_"\._P#14W_M+W/^T?M%-O\ Y@9TU-A_VIQ[P_\
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MG/R'/+PLFAX[*^C:^<5?<+B46B*E$-6&HBD1S2.VE,H_%7 ULB<D>%Q!*'C
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M=E\15H7G\?3^U)=T//XS:(F'2FU)=Q'9M=:OH$L<!06QN)[0*6S'WDJ'LI<
M<36.6#('J3"2#1[V)DV ]0BY:%W))P@X;%H.M;38.'^8$?*ZZ;RQPO7'.L6J
M)R96TGMU5B$LP>K;#3$AB3<BXN:R9K;ED,A\)0E18.SBQ";SXV[$!#:\E=C6
MK0!E<N^)!&!!$H3>_I\MOH6^"G%XHH,=*\2AND[%>2PU,=XW'CW'77/)$I""
MP"2Q@DSZK4I-N[F[4]N201;OH>(J)1@W&.A+[^5V,LM_Y(<@&_6?EH.L/\37
M?Y;_ *K1N9_CW"5M'I>XZ)D$5ORRII<\(N=_( <--UK#A9FKJ@J2E( Q%PU:
M=S)R[9M(Y349DIQG(I":$EIDZ7?_ ,4BV$@DF10F_H"!Y$DG7GJ2K(/%%&V]
MN?=;FG?+<W1D36.+\Y=!IW>[1V!X)N9HS1HR]Z<0B.K_ $(C]PNJ+BZU)*D3
M52+I)_PKD;H+UW,;$6)4&P(ZBWS!_)0BYG^*."U4E8L>OHY!.DZZ,4U">:ZX
M@I^JD1(^.4A7UC7G90#2:;EY7,4999JA"]BX9W-@+.%-FX^,B'P<(,)$""FA
M4N.EM+$NTZFP_+SWN3=6RL&#(6Q9C!C-J/&CFC=@/8,4$FK)BR:(Z-VC-FU0
MT30;-6R"::+=!'31)%+31-/3737&,%E1WZUY]UZ?HJ54YI(FL/>2(K B3:4N
M 6)#L*UAED0^?.$$QV"(A53^82BG\1MNF2;X;Y>:.]]'6K;]58J#;X$?$642
MX_\ &XDSZRFEW2BR1,IID_+N@;,#4TK!7C&2MY_T]5-34_:3:2V+I-%V!Z!H
MQJL2+V, 6$% FVI*>$M"<E(-(\*T<E2=+6UTUOI87Y6WUWNK&8-!8G6L7&PR
M$!D04;%;D5VK!)=X\54>F2CTZ;*D")%P\*%S1XZ3)'#YPL]>ESALB0+EGKPB
M]<N52RMM\1/$3Q$\1/$3Q$\1/$3Q$\1/$6N3'"V8C*<-L*Y<9CAS#?"&-\K9
M6R,=82PCA/\ ]3*N5/M_'C3_ +_O^GV_[^GB+XA83%>WFVU+Z1<?T)NET?P]
MP+\?-AY<ZSQ%.!YZ@A!PI8%T/\/M?O!R&K6-3'&LDEVFJ!< ]E[-H3=MW11G
MC:<_3\?TM\UY?=N[:P>YW(W (L/(_#3Q79MI%\@,OH/@][1].](2U_\ '/QQ
M1O0<]W;20=!$YIT#)ST:EQFOK&#6/(H[*;?'MN;:VL2)D(M!ATIDC&4W@*W?
M,M2C,:.(C\?KZ\>@*"WO$D>\2/3^(6!L+V^!77NI[0^2"VND;=MFNZ+ZCB49
ML+X]^[XQR7B+G:W5B(Z"LHQ2$GK&XF(:*V:0L(3>MEEU)#^,#(X=';1#.Y=4
MT/BD0(Z5U94L%U&AH N6GWFDC6]M;C:Q&Q-KC0ZZB^E3^20H+RM:$;8Q[J _
M4T][&FD5X''FW75HR!P2.&>8J> 6%>]KMXT'+7$3JJD[B,69*H" 08/2AFVU
MWS6(CT]%7,ACSZ^/UZ*<QL+-]ZUMPXD#6VIL+V/4Z@*X2_Q34I(/A:BQ":RN
MS0#FY'9$A+I+F2Q@Y9[R <"] 3Z(S6<!'2@LRF7?3**1V>D $B;ZK-9"WT1+
ML,KMUD/%!^__ '?A=S1IZ&RIQ<]1]F=\<,R6$'Y_/;(!W1SGQ+-K$F,"H.2T
MT7HBYIQV[1L3-0."R4$.$_W83*:9>RBR21!JY,ILQ4=5E# F)@\K'"&D/AU'
MXB_UT6B UV@'NN-M;WL+ZC3PYZZ]%'-VUZLLZM^[;ZZ?"W!$C37XN+3B<=&E
MW\X!1Z-63Q\^YRJ_2P B^C@<U:2:;W)%+JLL*X^[5Z2C!ABIMAZR1764J&PL
M&D??OI:]CY'D+ BPL;[C5?<XTSG+5MG.?KG+='.<Y_\ .<_CU_WGQ>)>QXB>
M(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(H>]Y]!S'EKE^979 1<9,RB.S
M2C8XR'2]H4? %65FWU656'5738*8 D=W3,!-"CT3ND4110,-V"[Q!\R2<,'1
M5H!.O1QT\&D^/14)VI\[_3<"5Z-@3"K:(<7!7W;TOK:IV! +8& !KC6%6+T1
M6,BM25,D;'0(D)\&FO.Q:(/2@0J'B^9!,XGKO%&B3G"+@M\ TU-BT&_5QMH.
MNX/QZ*P)'Y; ;3Y-9?R7(B=*A><X^SF54HV(ZER32SF/3M:5G'[TG#>2CGDD
M3'BZ<0K<L?B3 ZK&6ZF+7@4D";R-S^9L,1*</N\6M]_#AO:_G?Y&ZX-"_F,M
MR^3,ZC-)QRCX^0GW8W.7.W+I:=)R&89'U5=M/RRW-+INB'12P(T7)/S "!EW
M@&!!S-?$(J\DH*(S)]M)09Y)5]?JG"+ Z[$N&FX-K#>UKZDWV-N2Z+!ODGZL
ML<=\?4^CT.YQ3!=<N*HCQ:BF&MERR^I,]4F$ACW4EIPPDS,A8S5]+\\QL0RG
M;0[,8_8J<Q:D$XN1-Q ^^C_\X3A'O#6XN;FP%N0ZDN\-O$7(DMT]WK*.8>D+
M'$RH0)+<XTMR+7-_S@1$X*2DM\2V76C?4OI$&&A1I_:<0@PL*(<!@I5\.+14
MP4*X<D4F9EBIAHCDH!>W4D^5@+J*G2'S*RBM)]086*4VK78QEU45HOMJ$]!L
M!*ED4Y!A86E9:XGT-.5-;$FK5TS;5[=(6QMS6QV9B5(ZR(M%V8XF.=)^;*AF
MA-_W;BP.NI%N1Y$;;^"U#DGY6>K.C2M2RXU%*$C-6V9\BQ'EAE'F4%L?:<$*
M%L3D!'KF@+$92U[;VP45.,15/1I-DW4%*@I,E)QC@$+ANX!UI(2.:&^?#?R/
M$6D?)?1)XL)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)
MXB>(GB+E5FT?4US.8 ]M&" IH\JR:L;&KMT816W<1"<#6CP>RDH99!9!1L12
M8$'S'.^=MTEF;QRV734074TV*@D7MS%CY+9:^K^%53"(K6M<1D3#(%!P8^-1
M&* 6NK(+'@ IOHU&B1;33.=6S)DW3T1;HZY^FB>N-<?ZQXA))N=25KUQTI57
M0<!+U9=,'"6-7A[=HH:B,B267#%,L5]7+;5\W160RX236TUWR@IOLBI]/M53
MWTSG7)0&VJZAKKKIKKKKC&NNN,:ZXQ_XQKC'TQC'_P#6,8^F/$7[XB>(GB)X
MB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(N7W)3-<7_ %Z5JNVH]M*8(:*Q V2"
M:ES@++@G YE'[ BKG!..$A!='^+EL7!E<HH/TF[[#++ BD[&N7;1<J"1MT(]
M"+'Y%1/D'Q<<*2D[().>HIL0D$H86F,-%]YW9J3UTRNF\-.C;(125;S-'+'^
M=N'"LJ;J,,-E0#=Z3C,=W$Q0H1!N2O$=K\P=ANT6'P'\UM2_QU<7.HPPBCRA
MHN]9C[D>= :&GS^2/9P^MHE8)2SRLJ-V*Z-+3R0ZEY:;*[EP!V1D8T5CSY>%
MOP[B&YP!U*<1WORMRVVMX>FRQ1WXT>(32=AY94.!@Q"S997$\/GZH-2RHI,(
MFE2#M!5>R> 2*M#T6,5B7CS/5;7]BO'D9U++/RSDXF3<&2RKQ^:<1Z]1KKOO
MOOZK$B?B^XNCMD57;$3KR=0J:4M Z]JVNG,%Z!Z'A0,37%7%DCT0@Y.(1:U!
M,2ED83.)[&9"'EP0ZRFI1R^(31(^[(/E7!7B-B--;D^ZWGXVN/"VW)<S[0^.
M(]US85H2%*[04#A%Q\RU[SC.8D^J<G,#V6]<7J8NX3)X_+V5LPMJ*U(.3+B-
ME@KN+%E=VFB9!@<8.,90R0. MIJ"3>_(BUK6];W]%TMW\77$96*&(?)*G-S)
MA(W%Q/)08G%O7/,YK*W]\0 35EE$I7/Y+8).;20H1KP!'XF"*&CSTC"QH$/O
M#'(%Z/;N]"<3A;7:UM!R-QRZZK %OCD@(.P.=#-%$8Y3=<5!T2'Z5L*"YC,Q
MG)VSIO!^9L\H5D.C\O-VHT%5C'8S4^6XXR-:0>4XDCL''2"&X$@E)'DI)Q:$
M'4VL#?;WN(\M;GQY\]+60^+*>(GB)XB>(GB)XB>(GB)XBPTC?E1<>/$P()64
M'!P8H_#1E @Q$KR(JS8KN!P)$J442&#%2[Q-$>F0(JI,66[C#EVIHW34VP14
M(61\S4JJ7DFI+#L*-49%^G;4Z#OFNW=?$)TZ:5C!ZNY[[$D?/5A3=0Z?+1H]
M-'@F/L(X,%IB\!'TJF9]S,D(J"@4:EP^.EO@UMK:P-[<W-N/J^PZKN]$_)?/
M)]?MKQB8UZ*+TXTCO9DIJ1"EXE/9]=&XSB;IR)\RRUO(8Z%>R/,_+6J2ES6;
M08;!8P$=!!S-:/N490[<)%DRA;;S]V][ >\+C?:VQOHILT!VE5/1<^F=7QB*
M7I ; @<0B\^.Q.]:(M"C3BD.F1F31Z/2(0-LR.1UV9$OS<.DHW5Z.17;Z/!#
MQ#93"J*FNI0@C>VO0@[>1/52X\43Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1
M/$3Q$\1/$3Q$\1/$6G6"8F("%2,O7T.;V!-F(U52,0UY)6D.8'S&^VB31F1E
M+YF20 C-5%/V"1/066=MF*+C=@(*OL-A[DBHY4^9I897OQIMI VI,1=786U"
M3:\Q1F5;Q>(U53%JV&A6S^0PT>?E"$B.'S$CW+(Q!%9Z5&" T*G$EE^Z: H4
M+.EO@U=:Y &AMZB^X^?DNI\H_*%/[/UL<_<53NB49S2%5],U6 YKK6TK3L]E
M6]LW[>E$C(),H0$WEQ^8SN-N*?82P])H<$!!-1)X[JO&!32&NRQ(H6[ ;Z@W
M(M<"Y-S8 <K$W^-A8-SEUM6'3SRR1,%!6U$I'4A6.")Y$;GJ&?TQ, CJ6A,R
M*.J*1>Q08 TJS*AOM?M'J;/+=5#=/?13;533.2A!&]NNA!^8)"D]XHGB)XB>
M(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(H_D.5>=2U>
M.ZH*T_"B5>O95))LXC+\9EXTVE4PLM[<4G,IN'"JA!NY.682?2\AHW=I-UB3
ME33*.&><-<%;GY6]+6_#1>>O^7^?ZKM"P+HKRJXM$[/M'#C$XEPINY3>F-7Q
M%,T7U0:JN51H360G$4#\HU ,A>LID#=N=D6"9=!%YH4N>J@[2%F,[*^67JC+
M.'63$/Z-Q9SO7KG%D00[!<R5U'.E.O?S2J$8.-T/[9 "W[FO]>F8G\P8W^!W
M^DNI^LK]"IV'F?P"D_+.[.7HDF1T<V</)$A91N*>A10XRX)I+[%D!3_?5-0>
M@ANF)_(N]??:X^[]1FXRWPNM^))3KK$.U;(F'-F#\<AGF@G93RTM/#4OG:XU
M#*>8AKH6,(I^)\LMGW[N)_ 'OX6NX95Y_P J48D#L5CEEBE;#)##%.Z4.,S8
M9" 8FM(ANZ22SK\#'<'$ZP/3*WZ2HZWCSB,5M8@>6'FHMP:<#1[<JDLD+:N6
M;-P\VV>CVJ/XTG)!FCMC"F5,[.-,XTSKC;.OO,%SKE;,56^AP7&:;$*N.!]4
M^"%D[7-@C?'&^0F6&-O"U\T;2 XF[Q86N1[3#,SX#C-0ZDPS$H:NH9$Z=T4;
M)FN$3',8Y]Y(F-L'2,%KWNX:6O;W+@M<Q5;4"]$T]:=MMR#IZK(-:O%@R[R(
M1L4@DN5D3X:7/A2!]='1PG_%P^'-I%.)/NF[;1B.%GS;#-7E*]]]?7U;JN/)
M=/R]U=/.=?YI(_%X+?\ %K"-MI78)M*+ST 7A81Q(V@)U4Z0LJ09_O!4FKXL
MI*9#%C8%4N.$KQEP5;GVP,M6T)OM;3S\?K9<W,=L3@ AT>P,TD+&3*I[^Y_H
M&LHPO9NCI"?FNE7]7 ZX.S8Z-ASUK7[!H4M$>2F#0"VL98)&AC]R.7/&,:!]
MBEMM=P3\+_I];KW"_9TIB7,/7=Q2^LXXUL[CPG94:FL&%3P@Z@TC/PN"QFRX
M\]#3M_#1QAC'Y7")S#B[U5_"]W\:?/BH?*!K42D4(DMJ .=K::[VV\_%1OEW
MRGD8</2;G /+D=>L.@)E1QNT97U6\"<P//ZGSF+Z$P9C%TYIEP^?E7&AEM6Y
MB,K0C#B.SU@9%I/CVS5'#A]?HM<.E];6!VN=3;:_A?X::W7=R'?;H<=XY8DJ
M4D4;&]#0:LYQ>&)49_B))ROB^'4>@M$QN9Q_<+MN:/V!>,@4JS9NJYCF ZL:
ME!9QJHN/2#N"S;?7;;QMO8^ U6%COR-,W;[M<-**K7!R#EV2$A59!!\MT*.N
MBF:LS/5'#F,=4<Q\6E'9I)[KCVE>+1C&9"B$5F5=DW9=326-VR)+: @[WOX6
MZ^FHZZV&BU*K/D;DMHSOG2";Q2@:W+71SY2%XDAED7\7#'GC^V9W8<+*0&G1
M"-5KJ66:C&*\7?-UWJL3V*KR *R79"\;J.O%2+7WT)&W3KKI=2FL:^+<WO S
M0O/]7P&>RJ!57#+?LLQ:-GGJQC8H+9<HL**5K%(ZYC-8VD2+R:4O:FL5X4>O
M!@T5$1@82X7U..)&W:,BEA:Y/.VU_P QU"TZ9?(MS9!&MENY _G[5M5K&_?Y
MLLM6$['Q0S*>9XO*YI;E?P^;F 0R(RB9@XG")1(F0T:8W;F!00NL/>++!C3<
M<0 D@=;?/;;ZVZA9ECTK9M<QR/R7J:K(G76UDFXI&*HAU-S2<WK/S<WD@.42
ME]79L!I4,':-S\=C,6(%UC(,L;!EMF)QBV_4W&B%Y.2W0W\].=NOBIFMG&CI
MLW=)ZKZ)N4$G">CENX9N=-%D]5--7#1TFBZ:KZZ[8PJW<HI.$%,;)+)IJ:[:
MX*+S>(GB)XB>(GB)XB>(GB)XBCZARGSDWA59UVG3L)VAM-OH81K (L+PY3AC
MNO2V#D+W$O'*BI'"4?+Z_OLVKEXX:[+[;Y<(K:J;Z[%;G?G]!>W3O,5!<_F9
M_(*9JV,5Z8M$HB7G+X"@Y34,N&Q*0&FC-/1RZ<HAP3$U+)49'QH&F-CH\O)Y
M$49"T'QLFX=$))W-[*"O"UJC+1ZU^3&?HQ*R*_'?VOF)LL#MJ!GZXF#1,%0B
M+1R^=Q:1-FY5 :[PVW>"GNR/X20_=%XUSNDKIG.F,=(]D;&ESY'-8QHW<YY#
M6M%]+DD +$TC((GS2N#(XHGRR/.H:Q@<Y[CPW-FM!) !.F@6YVM\JG,M=KA4
MXT\,VTB62>[NG$$3:I:A%6F[;5-$HE)U@*N,OM'&5&:K35TGMALYU6V1VT3P
MKW=E_L!SUC+:HUL5-EUU.Z(1LQ9TCC5-D#RYU.Z@95M_JBP"1LAC<.\C+ \%
MW#\P9N^UMV69;DH6X9/6YP96-G,LF7VPM% ^%T0:RK9BLF'.'?B0NA?")6'N
MI0\L+6\<NZ=Z2I>^=B+:KIR*E1,&/'$) .'ID,*AM"65$T-'"SIBU;K_ /N$
M'"&%&JBVFVR.V^,_9MIMMUUF3).9\I"&3'L)J,/@JIIH:.>8P\-28.%SRQL<
MLCV^XYC[2-:0' '4$#N/)7:=D?M!-3%E/'Z3%JJ@IZ:HQ&EIVU ?1-JN)L;9
M7RP11O\ ZR.2/BB<]I+"0>$@G\MVZB-3$XVGI3%R63&R+4@1ELKJR+M)BC 1
MK,B#$MEB$59E=)]+R!!T<_<0C];Q292%,&$D)=49KHP;(/\ BBY]]?7+XV7#
MI/T_<$/M2G8V>HV/LX/>827.XFPQ9+]U>T3?PJC"=PGGMFUJQ@+N'!(Z+D(K
M%.F2$5M&:I"YM)Z]<).B2,RP.#E;:$WVWZ;VT/76]B!I?HN'U1\@\YM*KJI)
MBH90I"[KNLZ#59%ZICEW3 BC6<@D]+3B_9 TOIT7ID!+(,9BM<UE.WK,(.AA
MQ.6EA3(8/+L&A!8R/*D6)WT\/&V@OK\5TJ1=NG0_'R'1F*\B(N<-^@H_S+)X
M7*K(="*]B]D9[2'\43PP]LY*%.7ZL B<TR=E[$\I!F;\Q%AK3+L0%=/5M&).
M'6VNUQIK:W$-+\QXZ>*BO/?ES)PR.PLMBM:/V)G(]UP4RS+])O1L?MN0\L6U
M6]3LH%RG)FM-DWMYS"ZR<_WVK,-K%HR_?G SJ+_JN%\*$TGFJ&WYG=HVVXK[
MZZ6MXJ;$A[%U ]75KSNK7KO6*3*/ 64HLUZ;2;9@EQ6#&++GM8U03CZ(]VU6
M?'812]A/SQ-21-,@S!:K S9@6WL%BNW+-M+_ %X_"X\[^"C='OE%V,<]='VB
M[IG0=:E-6T4JZ 4_B>9<ZVXV-S$K"ZGG+63?U)%W'XK)2D=G"<T=:QDWO"4Z
MKLY^EJ>&1Q-X[*\.VNA%[]/,==O.XU70Z6[Q+W1?HVG6@:BX=HK!:<FJP&4W
M>21N:0M[3I0=<9#:O:U0KC9K*!D/;D%1;\DO)A6'#<43+*H,-4?U-2EM+Z_#
M3EN5VQ[?-O2N]+"JJE*M@$HC5'OJ]$7!,+$M$]!'VTDGP$?-]XM70$!5]@(F
MR$9KDW')60(R8O%19 E) T69J):Y,R(&2V@-][Z>7\_KDN7R/Y*Z#:0J22.'
M#["E1Y&+O3M9QHS )I7#*YR+6TH51FPB 2Z;QT:!)MAMQ6774*DYMHH]:@<3
M$4=30*"=\+;E>$\[#KK>UA?EY'X+J[;H>8UR]AT1Z3A48C]C68?),*VC//QJ
MQ[TTD 8")8E9<:)ZO:CKPH!0AG[Z2153^.)($&"H\H/WT>OG,?%%+7V^=AS\
M_)2V\43Q$\1/$3Q$\1/$3Q$\1/$3Q%AI&\-#X\=?QL,A(Y$Q#%'@&/.2N@)L
M>--F*ZPL,X.*M""89 H^T08JE5&#W0<FOL\W:.=4<H[D5&1COCMMUR545N1Q
MOS"TZ"F%_=84DC1+>*VG8I:[[*IKIFP:@K>HZ4;#I9!7H6.+0Z!2*26]T!--
MU1M?A .DY?UPT"OBK$"6^$<7/ALTD] X W.AYG0 :[771Z'^1BY9ET?<,0G<
M##R:K6(/MT]6<+IR!2HO>()/B#JJ(\PEA$BT<S(H/L(Y;RDLUFT?8A8O!MXU
MD<K'\_V/"^"B10M &^ON^5G-+OEL5LG,ETH7G\GG0DJ;U?=-3Z#>#>7H_F/W
MG71&M)4^V;=!]:$<F!H0DX<KO(^M@IADW*Z;X26(L"C3&N-V6^=B$6 VW=L0
M>3>BL<LVA*AN)B/&V/"1\B8BGJI)DV_<+"$TWRZ.6ZCI7^"("]G:V$=E$T]G
M>R_X=55OPX3RLKG?CF.92R[F2*&'&L+AK8J>5TT3.]J*8"5[> R.]DF@,CN$
MD-,A?PASN&W$Z_I,4R]@V-,CBQ.ACJ8XGNE8WCFA D<.$O=[/)%QNX20"_BX
M0YW#;B=?>XO#XU# XD#&1#46,!BV@48EIE5PX;BV**3=HTW?O%'!!SHBB@BG
MC9VZ75VPEIG??;.N,^]M08=0X934])0T[((*6".F@:"Y[V01-:R.,S2N?-(&
MM8T R2/<>$7)(7[Z2BI:&&&GI860Q00L@B:+N<V&-K6L89'ETCPUK6B[WN)L
M+DD+9/?M7ZE&FR><G-C7G3=W_P":+/B2M*J%5 -?1L94R\*.9DK?8;+]9$YD
M]92*<;ZR@#^ "]_AYB'V&-&R;V/;!S&ZY)4J#8$6&OG^JY$6X/%2$K>Y>1]
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MQ2-'$W[84D<<'-\NGKM^\"E-TWB223911NZU;ZY;:M]L^^RU5X_*ZOILS5&
MG%(O9JIN'X&ZJ<,/HJL3,IVU;ZH]Y))-)2SD2-:UCG,D# 6!A7ML$J,6>:J#
M')L)->SN*@4>%NG=[)2U D9"*AU0>-[Y'P2D/: PEKPV[ TGN/N4KWR>(GB+
M3K!(3D5"Y&_K2,@IC/FXU7,3C4GDSB&QLJ:4VT2:)'I0S!2AZ%#H[*9=$GK"
M.''^C1!;1B+>N]T4-R*F&+=Z=?3:I/CAL*+;\[%IWU=&JO+RRAA\&L@Y8<^W
M,SN-M;QEL1(LYX/#4?35'U$1,3HA94U0LI,A,,1B"+B6S\^'2D!;+0"X:V&Q
MN!RYBW,VV/Q67Y!^3&X[.VL@Y;U8;3P$XHBI^FZRAW,U82X]9T9A]L="] 42
MA5TK!/YM(]I]*HLWIP1+R\Q"MH0U40)3#3:(,V<=:J+/K_5'- M8ZWL;^0-[
MZ#F=+_%=7X'LY&XNM?DDG"4"LZMTB4KY:9_U*X84\@,X:?QU"-V6RY&,$%G#
MAJS??BRY'+;J;:O&2B3C7&-=\8\OZ6V/YA9<- #8@@@C0@@DZ="K+S5>0218
M%ZFXA'2> AH?(A.'0EGO^@;%;;[CB3?Z):_8Z:;**92W_P!XQ]^V,ZYQG./>
MRIL9Q:C]H]EQ&M@]JIIJ.H[NHE'?4M0 )H'^\;QR!K>(> -P0O1UV6\OXE[(
M*[!L-JO8*ZFQ*C[VDA/L]?2%SJ:JC(8.&6$N=P'4>\0002%LK0:.8;;[,6#)
MGLIC&JFS1J@WV4UUSG.N-\HIZ9VQC.<YQC;ZXQG.<X_\^_%)/-, )9I90VY:
M))'O )W(XB;7YV7M(:6FIRXT]/! 7 !QAACB+@+V#BQK;@7-KWM<KW?>)>=1
M(_XJD$NAIQT2QZ(N=D<F\>91'$2V$449C$-B0T'EDSC$!>R6F3<RC 3,HVWL
M@HQ0E*Z4FF^&SF5X.A!HH&Q*WT L-/.^_/7T\EH+_@T0://K+D%]7.:O[,LK
M"5QR]EF-.#Y1#O\ $$?MF)P^.@XB&JD=6+F.KQF^KJ#R5(]"C)@VA9LBSH:8
M?HQ/6-$ORY:_/_0?#SOT-7CFL75 QGG<D5EAF*!+>@UYFSIA:./9-/K(B?2@
M7JX^:FF/ZVE&725G6X+?D)X-#QH*-5%R0V,C+2-)9&[#B7UOYCGII;36^G+7
MSNLE<?(]3WB35>31(NF,7YUN?F;>-A%18T(E!+M,U6<.E&">!2KT7+(T^J*,
MJ0HJ->M6P)55Z[_CW+Y(6Z'$!M\0?A?3R-]5R-]\<E#FW)N72EY+)3=QJV*R
MN;'1!C^I_P"8!,QJ)2NDX3H$+L8HS!#@#,3602/D0*4?R/+A2LJ9D$UO[(1W
M4)<[7TUTY:_ZKU&?QL4*SDL)EF#-BKEH-#KVB#'\AL-HQ+YO&1V:?UDDA'H1
MU%J3DM4-KNNR.U.^_&BV  [9FJ99F>?D&[]H0N)%N6GII;YV%_(+H-5\?-:8
MG^9E7]X6Z+ D(]5,=E=;.F-/%(C+T:@K855T:>DR9"J7$^&/'<?"CG1C$9F@
M)JX*H[KM&S)LLHSR2^EOKE^BV$]S#E>Y)'<D NRW*??6'I"L6W$8*E5I&)V:
MY@*&1@ N4TL.M)R>BY]:,:MH4;-0(Y%GA:*#Q+??9 T$"'AQ+Z6L#T.MQ\[>
M.WYJ)]4?&<+S5PZ*]#VE/Y\9'5Q9M;Q(2#,147'*88V9;D5MXH>JLZ'KJ*R]
MW*V,MK.K#T;/6$]ER\3>Q!!@&1U&/"J91]?7UR"I=K< ;W\_/7IO;>Y7:["X
MD>W!"1L&N#IR[+*8L94/E&Q,_#N86)MLX#X'9"K10I&N? 3NO)*'78NWPRP(
M&K'YX/?R VNPD+35"*I1<I?6X 'Q_,_R4ZO%$\1/$3Q$\1/$3Q$\1/$3Q$\1
M/$42;!X+XRM<=%Q%D<TU#-!D)-6/(XBP/Q <^:QL];\J7G%HEPZ*FGV,2$^E
M[E>12ITAC14P54RZ=[*;XQ]"T'.%['>P/IH/@NHPGG>BJVL6>VY :D@,/LZT
M,)8L&=1^-#!DDE>$E\.]_P"6)MD-%UOW'VNA$I]FR?\ +E$TRA3]P@GHYU*7
M-K7T&MO-0)I"QU+%^67JC*E?637_ /2N+.=X%IBR(XUCN9CI'^E.O?MG$(_6
M+%?YJ '?V\_UX\O_ ![@A^J[_(-:_BQ]Y4CW1J-SZ:-5K?BRGB)XB>(GB)XB
M>(GB)XB>(GB)XB>(GB+^=_O^S;\?V_?]NWV??]?L^_Z9^W[OM^N?M^OT^[Z?
M[^GU^G^_0WL;6O8VOM?E>VMNJAO8VM>VE]K\K^"BY0_0#BUREN-BK^O4!]22
M5[%C+N/%#"GU68(:KJR!58RU:-$HRMNW--&A#"V<++ WKC&<-/QJ[<#REF^3
M,$^8F5$V#,AR]72T%3)1SU)]Z)H<ZL<ZICCC;0O,=5'%-Q'B=22OTCLX\4R_
MF)V+RXRV9^',CP>JDI)WT\TQUC;Q&I<9V,8VD<6SL9+Q>\:>1WW+./']EY5V
MX9?-AY$Q#>2 A%R.<OARSD3)N@R(]PJU?MVCU+=-V*K)!PENW643_"Z-YPJE
MG/[6=](UQPNQ#M1J96135.&=GE+,^!\L+GT]=G":%[HYF1RM(DI\":]I8YS>
M&2J]YI/>DB@]-Q5>>II&QR3T.3X)7Q.DB+H:K,4D3W,D:R0$/APMKFECB+/G
MLYI]^XI9QQ2(QB"@!T6AP$7&H\*1P@/$!V:+)DWT_P#.VV$D==?R+K;_ %5<
MN5<J.72^VZ[A5593=3;M3#\.H<*I(:##:2GH:.G;P0TU-$V*)@W)X6@7>XW=
M)(Z[Y'DO>YSW$GGE)1TM!3QTE%3PTM-"WACA@8V.-HYFS0+N<?>>]UW/<2Y[
MBXDF/L-YI6B'0<SZ!_RA*2Y2=-G@TW%7K$;H!R%^UKH"%MMDO_<I:1O0>.3'
M.<YV<;I(.=%M\Y(.]M^'89DAV'9PQ/-_[=KZF?%62P55!+#"*3V:T8I(&%IX
MVBB$,+89-7EK'M<?ZZ0GCE%E=U'F.MS%^U:N:6O;)%/2/CB%/W%F"GB:1[P%
M*(HA$_5Y#7!Q_K'WE)[GJY8GB)XB>(HCE^">,#Q2KS9CF>H"!:E(^$BE2/W,
M/';N:[C4<-K20$#B>^-,?Q T6><*EFK5KC1+1]MA?.,[Z:9U*\1U%SKO^'X+
MJM6<\T91Y6>G*?J:!5J8M$Y_9+")0V-# +N7&L.RI#1X968(([.<)$CY\F@U
M_P"UFW)GSQ)%NF^-$W#HA)-KF]M H$<&V.I:O7OR4S!6OK)K'=S,>7A^8G;$
M<:Q69-\"J'088?.@[,L:02'D\(_NB7&'^^SI@LBONDCMOE/4AY>7YE6M>*)X
MB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(L-(W!YI'
MCSJ*BQAR4-@Q1Q&PIHPXCP8N>18KJ!Q9:0- \A= QA AJW:/S#8 <<#&JRKU
M$.340U9+D7S@V1\H?9D)YRKF>.5:4'V:("?*/;5I80A9XQ"YVQX#ZP&TG&J,
MKQ-W)@9</M/8])D]%)B]P2E&F\>8D$A&SHH213?C]7Z+R<(OSL> :G4<8O?:
MVFWJI1<]_(3?DSZ9N2*S"(M[!KM #W,>@-2U1"4$KDARG%'64/YG&Q]V2/SM
MF%EYZZ14J6FVK<OF*-@Y49D<)>*"=U5M7U]?04+1:XY<()ZES>+Y;'T6]\R7
M 2NGY/.A),4I6Z:+7'<&\O M(K>8&)QZ5$T6_0?6A#60#6<.FT[&JQ]SN24&
MMG+@LV?;$191)0<D@BV<NIZ$>=OR)63L-;ZGKX=0%;UZJ)XB>(GB)XB>(GB)
MXB>(GB)XB>(GB)XB\:R6JR2J.^=\:+)[I;934W24QJIKG3;*:J>VJB>^,9SG
M51/;7?3;Z;:[8VQC.(YH<US3>S@6FQ+38BQLYI!:>A!!!U!!4(#@6F]B"#8D
M&Q%M"+$'H001N%4P[YKJ_-S$N<:#9GXS'7H,28ZHE"$M/DMOZ?N]P1C=8,]G
MQ%PFT/3%=/=R3<::)NVL=45RFHZ:.# ];Y[DR3@1S+-DO*4570T4E+3U.?J]
MF(5D_P#U;WHFHL!C,LSVQU>).!DF>.&2.C+K&2-U3 [J!^6,*_;<F6<O,J*2
MF?3PS9LJFUE3(?8B_O*7"F=Y(X,J*UPXI7 ->RF<;%[#/$ZUD,&%1T0, @A[
M02%#,6HP4,8HZ-V; >R1T;M&C5!/&-$D&Z">B:>FN/IC77'_ ,_]^[^IJ:GH
MJ>"DI(8Z>EIHHX*>")H9%##$T,CCC:-&M8P!H Y!=MP00TT,5/3QLA@@C9%#
M%&T-CCBC:&L8QHT:UK0  -@%DO>=>5/$3Q$\1/$6G6"YGS2%R->K1$4.V'J-
M5TB(R='2L:ARYI7;1%LK)#0,%)3+00S_ ";/7FHL(^?NTF^637#=9SJZ0(OG
MO%?*)U:Z@G&DV56J[\LHYYY"NRZX_F#$%'=Q%>H.SH)RD9B5<.M)8UV@>T"#
MR0C-ARJ;"6.'QU[&1Q5/ G]S1\Y_7UY^87DX6Z[\P-1R;Q GEY^%UW7C'Y'N
M@+-4LTS9M<O[K9.Z#J/I>"5USE AS6R8*QM;HWHNC'-.$T)A9#$',"$/$TT%
MESV2$C,2**;8GN,B7"30*.1*.:!;EJ0;\[ &^@\;6\M]2NV<#62^MCK;Y(YJ
M1J^SZ>=/Y9RRUW@MP"(Z$G(_4?0C9IH[(#XM*9B'2:$M4\/!NZ!YPJJS52W<
M(ME<[(Z/2WP_(E9/+R_,JV#Q1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1
M/$3Q$\1/$3Q$\1/$3Q$\1<-D',/-LL%Q4'*.?Z6D(6#3LS:,+$&JOA),7$K*
MD<B(R^13^.,'@19J%F9^6&"TG.24<DW,%Y"3?F2#QP1=KN5"MSU.UM^5K6\K
M:6Z+8XM25-0:>3FTX74];Q*S+/RRVLBPHU"8V#FL]V&XSAAF8R@:-;&I)EG]
M<Y;Y+O7>4]L_?K]-O]^)<VM<VZ<O@J\J/L$I8'RR]4Y*5;957_T[BWG>#L,6
M0UAS;,^&@NE.O?UK'@_]/F<RPO7\E_:W_KSB2YC$K4_2=_R\2#_1O^P5(LT:
M@W)VOIHW0W ^5QXJUSQ93Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%R6\[6&TK5
MLKL-^C^\X$,<( 0^GW[+GY035T'QP$W32QLNIN1+.&R*V6^BBK=G^R[_ ![:
M-]_IQ[-68(<L8#B&,2M[U]/%P4E,+\=97SN$-%2L#07DS5#V->6-<YD7>2<)
M#"O3X_B\6!835XE(WO'0L#:> 7XJBJE(CIH&AH+CWDSFAQ:"6Q\;[$-*U#F2
MIB565SA:7+Y)6C8)1U8-JFE?LW7>S*0_:Z=C]5-,?;AA'T-D@S%!#.K/3]5P
MY;(HX>*:>];D;+T^ 8-Q8B_O\>QB>3&,?JG<)?+B=9:22$%N@AHVEM-$QA$0
M+'R1M8)2%^+*V#RX3A@=6.[S%L1E?B.+SNL7/K:GWWQW&@CIP1"QK?<!:][
MWC(4B?<S7)4\1/$3Q$\1/$3Q%PU3F+FU5S4KU3G^E=G="?7%'./\7PG"M.ZY
MRVV^RK]\!,9@B>%&3);5.,?QFFCABR<::ZKLVRB16YZG7?7=;'7M)4U4A.<&
MJKJ>MZV+V;(=Y;8Q2!PF-Q(A/)0KNZ54D,P> 1K!Q(S.ZS]^XW)%U';O9R0?
MN,JY7?.E%B$D[DFVUU7GP;8)6SNO?DIEAFK;*IQ\XF7+S#>#VRVAK29-$A=#
MH,423E&!S2?1W XRFCJ1$[(2-=WNP70V?M&#K*C1(AY:WTY7ZGJ K6_%$\1/
M$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%35\N'9W
M0')C.H\T"4C;%Z0@O1=Q3Q(U&@D@V1@]  Z]*$3QO^R'H^@G5X)2;I[64.K]
M4[?!9L^!:U%$CSAI(]6A;: =^H%N9O?0:'732]A?<K3*7^03H.4==6I#GP+2
MX*\5_P">36%T15\7BHBUX?GBVW:#K.%/D)+,YM%Q!AU?@JV#$CW0GI:+B&+S
M6-)@R8X=J1T>D+18:V/NW_Q<6O/06&P_(+IO,EKRJW_D\Z$D<NH*X>=B+#@W
MEX*A#;K6JA:3EF2'0?6C[23#MJ?M*VHY@"Z7(.!3?5_(6)O! .2RN&089'/B
M!0@ "Q!U=M?HWJ ?DK>_%E/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$4(99K_GK
MJZ.P7&,NJXYC;C["F>F<_>Q+V](FJG] #K:_[T6VBH?+J2:[Z;?1)ZLLP>)?
M]VF,]6X@/Z6]H%%A6LF"Y&9#C&)#>*HS'6,/[(IG#4.-!3=Y6AP/NRN?#(W:
M_!*P#,.;J6@^_AN56QXC7 ZQS8S4L/[.A(U#C20\=3<'1[G1O&RF][M)<[3Q
M$\1/$3Q$\1/$3Q%3+WOVK?5 ];T#6U9F(VSJY1A2,HN[4A& Y?(J-6]UG7G/
MV2,O>EC@R5X"DPAZ3#J\1I,),Y8PLYL.?V:,$5MO_)*EIH!!N-=;:] 3MX:$
MWTLN?<9_(CTI91NU7\T@)3HI)W2D2OZ'U#0T:KV,V-6CF3=7=$<^/*?5(V'9
M<*B,BQ'XQ4P67O"LSED=D>S\-8FK5,EA6/QYD0M_P\M;D7#03L#S/CN-K+O?
M U@R"S^MODCE\GJ&R:,+O99RRV6KNV5*]5FHQ-A0C9J@]?[U?/K+A^6I5)/5
M\/PREKQSAHLGA^V8NOR-DR.%K:@Z;B_4]0#\E;!XLIXB>(GB)XB>(GB)XB>(
MGB)XB>(GB)XBQQ<L, "B9TT^;# X9@\*E23Q35%F/&CVZCM\^=K;?31%LT;)
M*KN%M\XT223W4WSC77.<>:GIYZNH@I::)\]34S1T]/!$TNDFGF>V.**-HU=)
M)(YK&-&KG. &I7YJRLI</I*JOK9XZ6BHJ>:KJZF9P9#3TU/&Z:>>9YT9%#$Q
M\DCS8,8USB0 5H4%NFI+.:F'U>V/#IDQC^S30X]CQX>2:"=W^KC9EH_<MUMT
M6V[G5HYV1U5WUVWU14VQCZ:_7WM\6RQF+ I*:+&<%Q+#):P2&EBK:2:"2H$)
M8)3"Q[ Z01F1@<6@@%P!W7'L SQD_-4-;49;S-@N-P8<86U\^&XA3U4-&ZH$
MA@;42Q/<R)THAE+ ]P+@QQ L%^E+KIH'MMH:MNLA&^F,YWT*3V*C]M<:X^N<
M[:NRJ.=<8Q_O.<XQC&/_ #Y3Y7S-5@&ER[CM2#:QI\(Q"8&^UC'3NO?E96KS
MSDF@<6UV<,K43A>[:O,&$T[A;4W$U6PBPWOLM-==7<P,L[:N.B:1UVTQMG;1
M.T84OOC[?]9Q]B!I7?[L9_U]F-?NSG_6,9][*/L_SW* 69,S20;6)P'%&C7;
M5]*T6YWO:VJ]+-VN=E4%Q+VDY$:1>[1FS GNTW'"RN<XGP OT"]FK^FZ'N@\
M]C-760%F9L<.<EGC(6@5U_$.9NV+)RYPY>#VK-75-R28Z?8BX45WU<:*Z:;(
MZ[J:XQW(V;,LTD5=CV"56&4LTS*>.6H=3GBFDCEE8S@CF?(TN9!*;N8&@L+2
M0X@'R94[4NS_ #Q7SX7E/,]#C==34TM9-!21U8X*:&6G@EE$LU-%"\,EJJ=O
M"R1SR)6O:TL#G#NWN)KGZ>(GB)XB>(GB+F]C4W4-P(QYO;=5UO:*$2.-Y/%$
M+%@\8FR49DC3Z8:R&/)R463T"G&V,8PW+#=6S]'&/HFXUQXK<C8D+V E357&
M9U++1CE:5_'[,GK4<RG5B!(;'!4ZFC(.GHD):2R6L!K<_(VPM))-(<@8(/$F
M2::>C;1+737&"ESM?3HJY*0FTMFGRR]49E=1S2I<Q?BSG>(QW$S,UT8S8L9#
M]*=>_P 79\8_QY-II@9$I5^PO@.*FF8O.VGZ+C^?B(?"C3]@M$6:W4&Y.U]-
M&[W ^6GBK6_%E/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1:!:EAAJGKF96.?VQ_&1
M "^,*HYWPGN^<HI_C'"T=\XSC5R6)*M!C7ZX^F7+M+&?IC.<^]1C^,4V7\&Q
M+&JL_P!1AU)+4N;<-,KVBT-.PG025$[HX([Z=Y(V^B]=BV)081AM;B=1_P!U
M14\DQ;>QD<T6BB:3H'S2ED3+Z<;Q=<BY+KPS!ZF;')GKMO95K%R-K60Y5T_&
MOB23'?1^F,V3S]=FR8(3_'"<L==]F[9VV>;-\:Z+9Q[CO9[@U3A67F56)@G&
M\?J9\P8T]PL_VW$B)6P%IUC;24_<T_<@ED<C)2P /LO39/PV>@P=L]=KBF+S
M2XOB;B+.]IK2)!$6FY8*>'NX3&"6MD;(66#K*3GN<KE2>(GB)XB>(GB)XB>(
MN;RZFZAL"4PF<SRJJWFTVK1^H4KB82Z#QB22F $U5$%52,)D!D6]+15^JJV;
M**.P3M@XW4;H;[*9V13SJ1>Q#*FJNN"TT/5Y6E?P,Y9!W,HL0S#(;'(N6GLF
MV_-]TBFA$&-8O)2=S^RX^I8XL^?Y_87^KC_U5/N*W)M<DVV\/)5R\&S66V!U
M[\E,EFU1S2D#Z\QY>9K0"?F:Z/21FU'T.@T9%%R-63:P8ANS.-DDR8])M)5W
MZ#1PDD59CWVJS1(J=.'4'3E?J>H"M:\64\1/$3Q$\1/$3Q$\1/$3Q$\18XH7
M$@V>Y T4'!V">Z::CXH];#V:>ZNV-$M-W+M5%'7=3?.-$]=M\9WVSC77&<Y^
MGO-!35%5((:6":IF<"6Q01/FD(:+N(CC:YQ#1J2!8#4Z+\U764E!"ZIKJJFH
MJ=I:UT]7/%3PM<\\+&NEF<Q@+G$-:"X%Q-A<KU&DGC3\4Z.L9"#> V.KG=Z9
M:%F#@4ST9I87=[NB*+C=FWU:H9PLYV66TP@EG"BN==,_7WDDH:Z&HCI):.JB
MJI2P14TE/,RHE,KN",1PN8)'F1_NL#6DO=[K;G1>&+%<+GHYL0@Q*@FH*=LK
MIZZ*LIY*.!L#.\F=-4LD=#$V&/WY2][1&SWGV;JH8%NPCEC%R,2Y$J][>9 <
MX4'EK0*/OZG1L<>ZXUQOKM+76G[,Q<M,[:*KBHPE][IMOHN.).=-LYU[-I^S
M>EP6F@Q'M&QZ+*D,[!-3X%!%^T,UUL1V(PZ,\&&LD +65%>ZT<@+)X&."Z2K
M.V>OS+65.#]C>59\^U--(ZFK,U5<YP?(6&3ML'!V,RM[S&Y820^2CPEA,L1$
ME-52@Z>!7G'INTD5MKTZL-1@80343=P#F\ Q@@AFBMC.J[1&>'VY>8%FJZ6?
MQ*:$FB><)YWTQG;"F^<[&=<C8"YHRIV?TM=/"X&/%\ZUDV+5,KFZLD=A-(^F
MPZGD8[WFF&1PN 38@6\3^S3M3S8UYS]VN5V%4E2U[9LN]F6'4^ 4<#)-'PLS
M!B,=;C59"]GN.;4PL/"2-0YU\!7_ ,7G)4-&Y9G(:5L-[@F4>I$I5*)*EKJT
M<D'2PMFJ&!%Q(!=46*4:"U'R@O\ ,04:[OM]&^7.6R7Z\8[>.T/$YQ+2XG3X
M-%[/!$Z##Z"A<3(R&-L\K:FKIJBL8VHJ&R3MA;4<,(D$0+^#O'>OR[]E/L>P
M2D,%?@E7F.;VJJG;58MBV*L BEJ97TD+J&@K:3#GOI*1T-(ZH=2<=2Z$SN;&
M93$SO8OC7E$1IKHTYYJ17&N?KC).$A#6_P!?I]/]J&6K]3/_ /W;/^_IG_SC
M&?<2J.TOM!J3>3.68FGI!BE52C_+2R0M^2[!I.Q/LBH@&P]F^37@6L:K :"N
M=I_;KH:AQ]2MR:<Z<^L,8PQHJG&>-<Z[:X:UC"6_TVTSG.F<?B":?3.F<YSK
MG'^]<Y_U]/>MDSIG&6_>YLS-)>]^\Q[%'WOO?BJCOSZ\U[J'LU[.:< 09 R5
M" 00(LJX%'8M-P1P4 U!-P=P=5&KE?G%*G+IO^=)5&M!1]GE42$9>;2&(%&4
M?!I:#'9&*#1@!ZNZ&(&96\.G$T4D-!C0**CHW.47+--+;FV?LZNS+EC*&$NS
M$S%IL"IWPUT8H\1@EK*IQGC@Q">>LB9'.ZFP^.DI7.+S/)55%;/[[)"X=8=D
MW9FS)6>.T3'V9.DP"GS75QU.%SNQ'!:J##J!C:6:JPBFI<.GDEI&5N+SXA7M
M8Q@I8J&DPVF)9+"UAGS[J-?0J>(GB)XB>(GB*EGY<NS;RY5*4,+JB49KV+R*
M ]2W'9<Z:"JM,&LCN;8E7\I800**M]5",R)U+!<JE1?,)!O8_8,XVAR$<A\T
MA'[A>5"2VT [ZZ@ :\[ZZ:V'76Q(T.RY[0?>_2TU[%MF&(X6NZ/*->[<1_F"
M,AZS@DSK1+DZVN?*_IH@G*I4^C#Y@\Z!CEI2&1$_\O2W4'_(; MXJYCXL:3;
M/R$ -Z'W=;WN'!Q/PL!U7;>9+&LRS?D\Z$.6ISY-^;S[/@WEX4RA<\FE23DL
M7$(]!]:/$90U*TW.[!C;8<[>O7XE(>0,-3B;D,Z<N!J3!T.=.RR=AK?4]?#J
M K>_%$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%"7H/\ _P Q773_ #8VSEQ&V2VM
MW7*EIC[T=XE$WVJ,,C;[ZZ[)*-Y/+L:8>M-MTG&C5BW>)XVT^GUZOSA_VDS/
MES)+#QT4;AFC,K1JTX=A\H;AM%+<%KF5^(V$L9+7M9%'* 6V7!<Q@XUCF"Y8
M82ZE8X8[C8&H-'1R!M%2R"Q:65=982,)#@UC9 " %-KW:"YTGB)XB>(GB)XB
M>(GB)XBI,[Y[:NZA^TJ-JJ,2=>"TTW@E4V5.G L%64A-V:[L3JF%T&0A+<'8
M"K:225B %R 8X>!Z@+Q:=#-YJA+EC9A*.BX!-"VT @]=>NFEP=-M=-=-=MR.
M?\0]]]6VG(KF5)Q]]U84Q341ND;25>:TQ6TEI:82+K'HZC"M'(RF4FX%'-FD
M?@%5A)<HG;4J<3UP2C<S6:EB"1P#'V!' "UM-3KK8BS3?SN3L+*2? LUG5@=
M;?)')K&IR54/*G<LY90>5O,I/74P/"V[.A&S=D]<'*KELVAKA$LVT3?MDF,@
M<N6R*VJ+]%JZT40T+)_=UOIX]3U 5L'BB>(GB)XB>(GB)XB>(GB)XB>(N#=/
MBJP.4#:8BY#+&/5X_BCY$X>?8_)_#+XRFJ%*,&^,;*O#(\XF-=@V#=-9R_+(
MLV;=!=5?1'?EN1*C':7-^ 5&6J:6LQF'$(GTM)$;>TMLYM53ROT;%334AGCJ
MY7EL<5,Z61[V-:7#K[M5I,JU_9YFVCSK6P8;ENHPBH97XA4#B]B>"U]#5T\8
MN^:MIJ]M+-04\;7RU%8R"&..1\@8ZO+F+F&4W%5->1ZQFYJON6HH/;NHK4+9
M9R"E5YEG"V2A&RK@=,U='S$ ?*KK%(]"6[OZH,-Q^N[K9L.9E#?<>>L]4&6\
MP8S68*^EQC/V(3/97YC>UE7A^5*=C?9X<#RW'(TQ2U='3L;!68J^/WI1,6L#
MYI8*7YP[*^RO%<Z91RYAN98Z[+O9-A%-%+A&38WR8?B^?:R20U=5FC.DL+Q/
M3X=B-7))58=@,<Q+*<TX=*8J:"JK[;P( %%@XZ/1D.,CX$0VT9BPP9BV&BQS
M1+Z_C;LF+-)%LV1U^N<XT23UU^[.VV<9VSG.?GBKK*O$*F:MKJF>LJZEYEJ*
MJJEDGJ)I';OEEE<Y[W'JYQ-@!L%]B8?AU!A-%38;A=%2X=A]'$V&DHJ*GBI:
M2FA;]V."GA:R*)@N3PL:!<D[DE9?WYE^Q/$3Q$\1/$3Q$\1/$3Q$\1/$6K2N
M#0F>-AC.<0Z+3-F%,L9&&:RN/"9$V$R$9G?8:=&(%VCQ)@9'Y54RQ*-=$GS3
M*F^6ZZ>=]OJ1?HZ$0L1)C\U$Q"+BYE*T!S642T< $LI-)&PA+* EN?/-FB14
MP@+0SE$<B1=N4V26<IMM4M/]>(JS*0EL[EGRR]49G54EJKS'>+.=XQ$\%I7#
MI5_D&&"^E.O?X2RQV8>5*8CXR3_G<X:QJ2_Q\J%_I;_RPUK^=#[RIV'F?P"M
M;\43Q$\1/$3Q$\1/$3Q$\1/$3Q$\18XP7&@!)0Z9>(CQ 4<]+%7[C;[&[(<.
M;*O'SM??_P#:BV;(JK*[?_MTTVS_ /+WAJ:B"DIYZNID;#34L,M143/-F100
M,=)+(\\FLC:YSCR )7BGFBIX9JB=[8X8(I)II'&S8XHF%\CW'DUC&EQ/( J(
MW((DC*A]@=)2=HJVD?0,ER:"-7>FNKD)5D=PJ&KH/]OUWUTV6%IJEW"R&^J1
M#1^R<J)_FTSMGKOLYIYZ^'&,ZU\;F5N;Z[VJECD #Z7 :+BIL%IK:@%U.'5+
MW,(;,V6*1PXA<\.R9#+5QXCF>K8YE3F*J[^G8\ /I\)IN*##8+7(!,0,SG-(
M;*'QO(XA=3*]V4N;)XB>(GB)XB>(GB)XB>(M6/06$RHK&3LGAT5D9R%$%2T-
M,GH\(,%8D573T27)QDB09N'8$@LDDFDJ]%+-'*B:>FFZFVNFN,$7['X/"XF^
MDA2*Q"+QDG,2VQ^7D8^ $AGTJ.[Z?CW-21V.:-G!PMLGG.FQ$FHZ>;:9^W*V
M=?\ 7B*LS@V6SN;=>_)2?L>J"]+RE:8\NM7$$-RN'31^T9,J'0;#2>YZ"%3,
M>62-,TTB2#9%]L[9)KZMGR2+I-1/!4_NZWT\>IZ@*UOQ1/$3Q$\1/$3Q$\1/
M$3Q$\18>0R$)$P1>3R4HS"1\ .=ES)<@MJW9#AK!#=P[=N5M_P#6B2**>^^W
M_G;/T^W37;?.NN?TT='58A5T]#102U595S1T]-3PM+Y9II7!D<;&C4N<X@#D
M-R0 2OQ8CB-#A%!68IB=7!0X=A]--65M94O$<%-34['2332O.C6,8TN.Y-K
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MT 7TN6ZB][$7<>FAL/Y$+<>;K![O/]Z=7R.[^<*/@O0(S@?FQO7%8QN^RQF
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MC\G]:#7Y-W\=M*RS1ASO(.C-FD%Z8O.0/G(J/$XP,5JUFWSQ4R_/=9/>4(O
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M*%G'0EJC9R<BL)&$'Z@"N(D1F4O-KCQ!,ZLR&C6>$6#!%$2&*$B4ADQ0!$P
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M6E$NA5(L>/"KBNHTLVB,_A5&<IWQUB\-(I#,-Y2GFK^A#4\$"SNKI(;I$G"
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IX*LFY1)B<,-WA.(\]=]R=R+$[[_HI]>*)XB>(GB)XB>(GB)XB>(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g400206g21p31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g21p31.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M9B2$IJ@J";$30[ 3,B8F=5$^J^K]K6P4JN7B7K4JT+,;(U93##M<NM=M42H
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M7TKME6B@V3L88)O; [<]?=JV4AW D0+#;+W-A@[#:M4%?TV.L+A$122SK@9
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M-D6V^7*0&'.8V&W8J-7A)6SB5,DU*E DO@XF61 R;DI\&8I#6?09+Q'P[/\
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M(REUW.7%JSS2Q[V]^>NB[KA$X15=^L\1V*.],_MQG7=9 6=<[3]U&W1!\^Z
MP#U]+K99-ILHA;4&?]7.AV$QW1@%:8K1-QQQMR=&PC"LQUCV/V5;1P.DCO,^
M]_WL)U;Y_9CKGSX\_H2H_C\?^SX_^O L(M A#<SN5D%E!LV4 9KTB3.AQC0V
M:*D2ADQ\>2CL3XSL5YX?/C+;DP9K3;JG(LR.XA^,^EM]I27$)S@0# ,D2"8,
M&E;[;T/93TZ2)$BH,2+$#7ULJNM,^C;TTT/LN@;9UR$V6&N&M#3)ZJR7=JVB
M;%CS6V),-]F;"?D*9G0"4&9*@D(3V<LRH4B1&>]R'E^?1Y'P[PGA^>QN)Y7)
M-P<[B_K!^(7\Y>,4@DR  )@Z&]9@+L_Q#\9_B;XI\*9#P1QWQ;Q+B'A7AK<B
MW(\%Q#AC)Y5O#\)^!E6X3"'$-P\+$+&@$0T!H%YM=;1A"?&/XJ5G^JE95G_G
M_3^'VY[W:;P ?( +J\")[D^I)^Y\K"@4!NV?IYZM[?V@_:KU<[_6YMAZR[!Z
MMRH]2?KK45FF[$V;JS:10_'P8 %GL6:"9U.%'P'''7!6!A$HF0-?E9B28Q;:
M\MB(HX.KN 1O:JU6SZ2'74?MW;6Z0EEV,'M^V^TFB^U<Y#<^OS156M>C+J<V
M=!IU0AD:_*R(HMXV?;KG?[T-2ZN:6L=GG2V"$3+4;+9.<P!2 TMU_P KF]_I
M046" _0\Z6!QVH8\B/L0^6H(_: 79E@.7,G)G=CP&[:U8 ^V@NVHC#D87%BW
M<^=;OA%[7L&E3&;:&$SH\A"(^6U$+R9ZQ;2(@C6D14FB^L7Z,^A-?FS]ZT1M
M7>6D=K2.Q".Q5'V6&LXK8IG71E_2<_0AFEBA>YPNQ0)^H'Z0?M*RKUJ'%[;)
M*&(67;.X)K-=$CR<Q@" 0!RQTGFT(K,>E=9SL+Z7E5I-@Z53=8=B]Y:^JG18
M!+"ZJHT,5I*QCK#-M HO7MIV:]G;9J4U:2Q_;5<.$!=J6/,"1@A^0X:HHRI&
MU?/X)S&MOFH>U#OH0/RIB7WKK5-@]A.OG8PH:L,.U]<Z_NRO50) <&IKQJ+O
M,521-C?L+<@?().2!+%&'.!,C2 ]M#TN;F>B:C+"&2SI';Z3^Z@?+])"GN:5
MW)U:&]I>R8;J?M(5L>!7NO,1.E'ZMJA_:%M=NYQ=.MT_4,K9I 0%L$LI(IU9
MM=T. P3166B1%*NLCWX3^?K^VBT'$$$ 2-:R:16L?1;"O_IFT;>V:&[VBW'L
MCLC+H>N>T&K(DF\5+1M6;(5+M*"UF"LK<@3JW5%% PS%(QK.$5H5A%B81P<9
M,DIQ*>3S%#H&DYB+0*@TF[9BY._V4Z]1T*3JO5FN=92[E9]AOZ]I%8I2[W=7
M8$BX6_%8#0PS=BM,D7"'#Y=A+-PT3#$R+ B-2Y[LB3\!"G<XX634G3H++8G"
M)PB<(G")PB<(G")PB<(G")PB<(HKUW_WU]N?]V/0/_U0[&<*Z#N?LU2HX43A
M$X1.$45>\L6D3NF_:&'LHH1"4"5HC:3%P,AP#=J+"J^[33"")$57'GH[)LE#
M84J1!&OR8S$J4VTT_)CM*6\W#8S:#*HF1$3(O].E]X5=GI- ]LAK-L?&P ._
M!8-=(JK5=F[BZC]>.N$*=AN?(^XD]I@X6+6N;F)EIR7 L#;,6&TM$N.I4IYQ
M. ['SB?IW^LZH_0"#%X+B.XD=NVI5WO*HG")G\9\?;/[L_GQPBJ+Z6M[*;]2
M3U3<;0DTN284UU*77ET:.:C#FZ"NI[1516"Z3CSTA=L8KOR;=H>AY0)>,8DK
M%MHAY:QR:GL/2OYGZ+1_M;?6_E,=)MJK=.594+=G^GITUW/>K%LO:'7NAW*\
MVEV(\>LQ9!?)(NL>.BBH/SBXQ-AK.(L"'&BL^UI.$,LH3A./;C.?PYGAG#LY
MB-Q<WD<MF<1HY1B8V#AO>QH,@-<X$Q/6A/IR#A/B[Q9P'+8F3X)XEX[PG*8F
M+^N[*<-XMGLEE<3%Y>4NQLOE\=F%B$M :2YAEH@R)!E/1J/5-:4ZM:_HH6)6
MZ=3@H^NUD! ^+\D'""HZ(@X;$P\XZ[B-#BMML,)6XO*&D)1[O"<<_=9>A<YV
M(XO>9>XRXTJ?*!Z !:I[&==:IV4KFNZS;C5A!P];;XTAV $OUQP:W)G6?16Q
M FR*X'(Y)CR+2@)<J"CP3:(S<<@H>\]B!.A2?8^@H"1,:@CR(A02&>C;UF'W
M/2-\?L^SB)[1H[M'!"_-DZ]@=9W.S5\W'L+ZC;QC%=:AE".F3>^]I9U%(:;C
M9!JLTB83P6GIS)66N<UM4@^FVTZ[K#IGH:=2S>M[12K99]OV>TD=3=>M/4/:
MTJVLB;EJ*M=8=7T[7NIY5&@5\>*I[I00<JDC:#[UGK9]E5]LY^9#9A#GHL",
M3G(BU)\Y,F:ZVI%%D>R/1'Z0[+N)RY$ ^PP$JVZH[%:UMXRM[$LS04X8[,S(
M!._[/9"FIQL,#N;!ELV?%#@PV)1%V*POFR]/*D!%?>%E XCU::U/RV\O8U78
MW+TH ^P-);ZU3;^V/84Q;>TUQH]D[$;I<"Z&1>MDU_6=+"T:@:\2*_8^JE5&
MJUP=60)1,RI5L3;B=@CDYY6S2XIPB/<)S&00 (J!6 9G>?4E3$WEU;'=C.L,
M_K-MC95YL$<Y$UVBS[/CPZ0$O-B*:]NU4OC!R2/"50=1!TPZ9J<1!:(%J(T4
MU$F3&A4 ?G$=;)0&#(6M[ET::(]EK1V<U1V+WCU]LVUA&M@._JGK9G4Y>H[I
M&ZF7.8I4@NULS6=\,4ZQ1 )*94)]FH!6N%9=66U#9=A$X[)=))I! -X)F1.T
M$#U!6C _I15B!HB[]7R_9C>-IZ^VO8(?90;6IBMZ!CL4JQC.U(3MM+6*M873
M@J\GH9F^"R *=!NUELT)FJV$E$'QX<V,'FC2I<29@3!&MBWEWV4S^MO6*E]6
MX6VJ_K@P?S1]G;GNFZQ5"(_2$5C5A;8>!T^X536\,6,'*#4@E;8YBYQ@,A<Q
ML6;LYQ ]UB \Q$8*$S'01WBT]A3L I)\*)PB<(G")PB<(G")PB<(G")PB<(J
M$M#[ZL^].\G9_LOKC3%FWK^@H#?6S3>!5AJM/J]:T]3+(3=O%TB6.WSXT,C8
MML;<%68>#'"V59E5ZAPY):>*'/#Y$O(,DP)(I?2I_C;K1;( :T3RS\QF9)(H
M" 8,#6_D9-U6J]E ]MT@7> $4J-CSI!861"'HB8!^MV.N%YU>M%8/0D/2&HQ
MFNV 62#D6V),F+F5#<<B2I,5;,AS2QJ1MJ*@]O?30K86<^,9S_#&<_\ Y_E_
M'A%Y?>P]XO%_[);*VV(U?ZEFB;5*^'JRSAM7]!=<[\H=T%ZDMES%5"]A[OL.
MJ3I<MBT@B39-AP<RPRP.EPX*7YB83,C.-?\ (;TD4L!0ZU!CZVV! $\AIHZ#
M7<3Y']E>+J7M,.-]:GNP>U=;[6T8 $%;,+=JNRZ'88VT%A 5PEU"L'Y^NP0.
M58(Q&]QV1AL?7!8D@_'P98AQW)C;>)*]3K7SI]]]%F#,4.M.T_07ZK!F/4ZZ
M02!&KSK.\Q+@O;JI*:G*17+FI,-$.ZIUM+EW1&*[\77<"/L%::8Y/OB*[#_4
M6?IJ7U/)7A*1[ZV]4@UI:09,5'WIM,;+Z'/4OZ4-O[*C*W<+R_JIUIFR,MUR
MYNNE''[SC6+2:$VU7%KV9[]C931TJU\FR(S9E)%^_P"84E.4C>_KM;NG*ZDB
M)MVB9.U*B=.M%&3U.KZ"[->D;V8VIH'<3XVD3]*;!M#IX/784U5SK5:%'QUL
MUN8&6X<R1K"R!&*^&//8A0+17YHU^,UB+*0\G!UCV*-'SBAD$")BNA'KV/DK
M3]6_\,M<_P#82H__ "^/X%AI0(:$ZU/W6=\JB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G"**]=_]]?;G_=CT#_\ 5#L9PKH.Y^S5
M*CA1.$3A$X10!]2[:^KM>]3MDTS:&S@>GFNP5<N>@Z7L"UEI];J(.]7G75SD
M@W;3:AT6;(K(1;(:>B263%?7A?PH;++S\MEM4)C6)H#U5;,B-*^0(\M=;U52
M'I:;EZF]?MIQZ)&OW0]-UW:[2M4485U"WUV W7:K-84*+$O]IZ]M@F2'5>LQ
M6(+CR"X7"<QY4AN'.=RPY'\P0*?*#:ADWM6O\K3@XU^8P":\L>409IOZ45PF
MT_4.Z_Z1VW8-2;:C[,U](!T'8.Q8M^LVM[' UA:@FJJI NNP8U+M^8ZF;,3K
M-=(L2YC V*['>DI>%PI4DFWF)G2Q!B1!T@&HJ1412WK1:2(>L-U0%5>2>)A=
MZ03X<K;HEPUB_J"Q_M2H0&A4VM;$N-^N=/1[I(6@@:-<:O9Y=C7(=:4..0DQ
MV'IGS$1C/,-CZ; '\@?Q57E),#ET@ET DDB+':5O'7/J&]<-I[ODZ)JA6UNF
M%?K*(!O<^I$AVJKD=UR)"G-B5>H7N3E TQ8*,'L V?9(24,MPF<R_9(>7"DI
M;LB8\[4]>B<KHFD?_P! D=Q< Z'SU47>BH(>#]17U2<BMEV/:H\ZGJ=:8]BL
MEB%6=P:BRU;:1;%0"$@T.%$:JU2Q(^B5H:XF3+&B8T:))G2W6U/K:GR_/\>R
MJ;-,#6PC8;FIBOV5P_*LIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB@?ZC&[[-IWK<8":QE-HWKO<^"Z^:&C><9>_:9M)]8.$<]OA6
M40Z4$4:NI&0I.6H\, M;N<)5CS"8'4T'<^_X5;5PM J9FP!VW-.O2X@9T9J6
MTC=CM3/2JST+7?5'3VNJ)UA'7R_T QL!KL1M'4<P\B\[AIT85<Z/\L(&$3Q"
MNILBR)*#<SD8D^N(Y''QI"(.AH*"QGK;[&IVUKA;F$DDN.X!L+5T(I2-U<II
M[6474=%@U!DT2LQ!12QV:RV@PB*T3L]ON5A)VNV6"7'@M,0H:BM@,$)3(^$R
MW#'15L0(J<,1F_.EGK$4'H+"M?+1;-5Y\9\?GSCQ_7SCQ^[/_+/"AL>M/7\[
M=5Y_;UZDG:^+4]Z]F*@7Z5C=$:,O^XJ_^P6ZVFU,]CK[4M&78Y2[:9B%H9=D
M" LUB=K!@E3P+E8),.QUCD3)3F9'O7F;FD D=:7_ -><KR<@,#YI,&0( G0U
M$WKIZ*X+?0[=6Q>O-Q']:+?5=>;BN-3B)U]=+R/FD0-5DF<PEOF)8\='F/ND
MAX=^8Z)2J)-B-&D0G9L63$;>97JX[ZC\+ B:U$V%+:$][]%3$GTBM^?H^KT,
M;:.OU/K5KTU6= ;S9#O[.L)#]*53L0[V"<V322Q^"U+/[0OA@M96;BJTX%BV
MBY-DR.D+:C)'XS!%CI$^<@QJ:F9UKN#L.%9$UYA00#$1T TV^BZQOT>.QD4K
M0K#'VSIMTKU6)BY'5N,]"NR(-SAP>U+?9.1C?+R(BGQK\F,RS34HIK9E+,A+
MEB^.MQ>(.$'4BEKS (-:W,5HG,-!$WV_MB@]_MCOJ =)-%:.]);:TSL^:KI?
M=E*IG9&T4:UB+U?J13\;JW[;;AM1ZIU2NQ;($'6N+FPDLBZT,N <J_/AB\>8
M#&),F+D0.6O4^IG2)KV\D:?F$4$M&]!2?29B%Z&-6?\ #'7.?SYH=0^_GSY_
MV?'_ '\^<^?/->_<K"SSA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1<9SA.,JSGQA.,YSG^&,8\YS_=PAI[_=5MTSL"&(=EB^Z<T;
M8T'0FV-=:9TSKW=LX(,;HUCN W8NT7QLE,=HV]<!53M\O8=>$TVXFZL-KA\A
M(:^7((A$ TPE)G3SI!^JIM$B1)(VH)DVH!)KVE62_GE43A$X1.$6CNR=XH.J
MM&[1V]LNJ,W2H:CI%HV46 K##CLJ9&J ,@6?:&0BJ%PDD7X[#T6-(>4RTSF0
MI3S[;&75<'KI7T0 R()!)BD]O=#:UH@9T2[>ZP[0;!.TE[K70]1;+I-4(7A]
MVK&=;; '#L"MMWW5$H<S::>/BN1BC3U1AF(LQII(TP/-K<"3Y\8>_+>R#I$:
MT[D:4T]PM.:X7<2#(@R-&W%C<]CI9==V!]-3878[=?8"^[ W_72- W/I2V:$
MJU5F:JES;7I.A6JK9ASX^N+-^OXP&*1+7=D;<K87GTZ66LL<9$K3D^")8C(C
MTBLSTMIK]?I(VB P! J#-[F]:$QI2TV6C+#Z.^U+*0N^RYO::O1M\[E!;9UM
MN2WQ--*_1I34.X-2:RTL< 4ZH.WI<P!:0U5U17R@>QSSQ:,L^0+*EB%0,QV$
MR.M:SYQ:M#0;J\UA @"E3(,D^8DG5;QTUZ5@O5^YHMA.;+@WG0E1.]@;;KS3
MA"DH8+Q3W9NKAZAM*%=;BHW)C6NL9"P2\<$(:KHIYK]0RL$)LQ,6-CECK:WI
M!G?4Z5.J%TB8,P*C8&1 W)_CIK3TSJQUVI/>OU/:7U?J%;HFKZ@YU7J[M7J=
M8G5((,NH&M;3&7=N.+G01ZGEXL$66API%;?'DE(^:@3)45;;RH(D@6'36L_A
M'$D-F\'6XI'W_=7A<TLIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G"+C.<)QG.?/C'\/OPB\PG<2S;&]0[U58'3'2I(D(HG5F@28NW]JB7
M%)1K$AM:'%C;/-UZ:G"H^-D/Z]>8U12DJ2Y("D+9<S:<,K#)>1@U=R[:C:*S
M]!M6NR\C8:SF.M0+$;2+7DG6+:D^D+6>MZ7I[7]0U?KL%"K%'HH$;6:N!'H^
M'%&B!45N+%81Y\K<=4EOXLF0ZI;\J2X])D../NN.*VO'N=29*SKA%^5^?;GQ
M^?S^[]V?/[_MPH8@S:U.J\0&_;B.NES[%'8G7[J9KNVZ4M7879^Q?KW3 #:B
MUDO:=NQ===;.JAHQ9!$J38]@[\6*LFR"]SK;N"4J%:Q<@:\Q#'O+5X[S0:W'
MH-#)O/5>8 @ <SB# @.,6EQI8#80#!.Y/MAJ;LA^L5U^6,2$E/A!3TD,A.&T
M")#D".MX8EO&,80F YE45*<8\8PUC&/MSR+Q?59!PB<(JO/6<L*J]Z:/;=2:
M%8[Y@SIZZ@%)KL 00S3TDZV61F]FTER$#Y.NUKX?QRI =\X5BMO-KA0)*_=A
M$=8]BJVKFB8J//IW].\2K"-6_P##'77[L_H2H^<>/'W_ $^/\_;]WW_=^[\?
MNY5%G?")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(NJ.FQ=
M:"EK";D_)!P8Z:6*3/@R)'RH\=&=F3)&6(C3\E[X,9EQSX3#+KR\)REIM:\X
M3DGYIZK2.O>U6@-JVARF:^V- LUG8>D1Y(F()L;#T.5%&L&'XLYV<&BQH,I
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M#4OE%%QM),F9PMJV6!E,^*WG(QM=>9FJ?%RK P6@$H4--^FNGK[^ZD& :5=
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M3JZS3LZS:U3 ?GA*IM$>2LP*MQQPN)-KMFE,++ K/"BYA68:_'+1GWFW\*X
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ME<,%IZ@WI!M!\_)&@A[0120#200:@B.DD&0>E0KI=5_\,-<?]@ZA_P#+X_\
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M^7]/W?CE65GO")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*J#M/=[9W#W
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MNM%I%G-E[.*LT^IZ[*/2)=\/U>KFP@I 0P/?*LR1Y%4"$W@=/6.]@9L0K&Y
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MG")PB<(G")PB<(G"+#[ZB\.58DWK@C51-Q5\K])(7424-UF/[9;"IN28P*8
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M;=35:[/4<C'[ [#J(2?M:^WR<_8MF293T1ER-5YI>>M_]/BJ_$Q$&LU&O)'
M!3D3,>/#5EK#JJ !;6I.I[RL.,G0@$Q%J?Z5C/*HG")PB<(G")PB<(F<^/\
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MUK>@6$^F;=="['[S>IO>^N0Z,/U[;4]4[!*6Q2+!K]PK="U6VC.NIV< LP8
M8R2,6!^9.($Y0Y/U.4ZN4A]]*_?F"),=)%JUTZTT]:H00&SUBQI3;S_U"O!Y
MI93A$X1.$3A$X1.$3A$X1.$7X6XVWX]ZTH\XSG'N5C'G&/SG'G]V/.//\.%"
M0+F*$^0$GT%>RZBP62OU,"7M%G-BZ]6P Z87-G3,Z,.$B18YAR3.($9\MQJ-
M$AQ([3KTB0^XAMIIM2UJPE.<\*]-9CS_ (@_[52/73LA9=DW/LWNW7/5+;NW
M--[MN@&+IO:"OV<U]J^U^J:\K=)DQDAMBW&M'A^FYM@%&#E5L>!LZ(5P?/SD
MA$J<;7/@,DU[#\CH9^\*D0 "0.6YD_*22>M1K80/([IZ]:)ZN^G/U_3?=C"M
M$:8LB!TP]N+:ORP8(B2=-$99B2$:MY9F.?+B0JYC=>K(SXGQI,$;";A"T/.8
M8Q  W;N4+B\T,S$":4I.L?84&M=<N=GNVG<M21O2+76=+Z3GI]C_ '![$5@E
M =.#'<^Q9'0VDIGR9ZTN+;SET3:K^V!JSOA2TCR",-X79)M;?]A?U@:U2 )Y
MC)B>5LFHT)TTIK>()41[R9WGU_ZP[OI>O)^]NQ_6#7L#;,?9&TGJ7JZ%LRPG
M&2IV9N0#3+$F_P!5>_1$FW/V@:<MP_35@DTR,^=:J\@RT%BRX,F ;F+R+_8$
M>]E8#G-)@.,& ;'0G:@@01-*@PM$]-.DO9'OP=)]F.WTNPZRU;L\2.@OUT<H
ME6;]L[5L+,:17]-U5F1E!O3O5MMA#3DX-'<'W_<$S#MAM,J$-G08C< )F>GF
M+\M; &^]EHN:T0VNQ-8.AI<_0?;TSTJB4S7%4K]&H=7!5&G50=%$5NM5\7$%
M!@@Z&UAF/$'0(C33$9I",?AM&%*5E2UJ4M:E9VO'K.IU66<(G")PB<(G")PB
M<(G")PBIX[4>H=<=$=F[-I&@:JZX2)P:B4.V'KGOSM'K[KW-LC-KF61@=#J@
MP^*(%+-" 9$S6ILIQ]I,.;.RRU&0T^V_(A,4 D[2![]]8K6 B9U,  F( &EN
MVAE6\BY+DP=!ENI90Y)AQI"TQGTR8R5/,H<5B/)0E"9+&,JSAJ0E*4O-X2ZE
M*<*PG%61^3T--Z"OD/RH>=G>EE8[66*D2K_LW9(JA54G5RYK5%:52HU2O)"F
M6^%=Z]).E2=.*7<4M@X-'YG?I.U <$8,)B&][<9<=7")U/E]/0U5:2V8B3,$
MUB;TH.GUF\Q6SZ-N@T/%)L;:.[XQ0.1A3]$$D6"JK?ZSI@[ESOMJ)J=MVG+C
MOQU[(]LY[];LVMYT.AL%E[$)I'ARCKTDS&M)_,[6HM!Q&@C7K0"HII2D6!O;
M6WJ,:@IG43T?>QNLJ91+YMUIC5.VADNTNQJ[8+B/-[/5:K=>-OW8C*S7XL,7
MBS%21VT2:_$2[%^>::%!G6FVV$0T:>Q^LR??EH$!EXM-*=&P !]  /)7#ZL_
MX8ZY_E0ZAC_QQ7Q^,_\ GS2RL\X1.$3A$X1.$3A$X1.$3A%C5OM8VDU^?92T
M2P3H [X&7XM7K%@N)MSYB2U%1\G7JL-+')_M<>0M[$* _EAA+LA["&&G'$D6
MLM3=AM>;JDDHU%B["4@3).P9D^T:IV31A"2-8/RZM8!3)BYU8$-E%Q%@@3Q1
M 3%E/$8TJ#-2[&2F*^IL)U$'8_Q*$$ &D$Q_<TF(D& 28-@OL[#[>A:$TCM#
M<1"-&FL:\IARS)A32+ >%,DCXBUPHLTM(0XR-B/S%,-RYRVW<1(RGI&&7LM8
M:6)BJ1) W,3M[\U4JUV)VU2+B@-UI[)=,^T>YNV>UHS1RG_57 8;5=QB:F@1
MG[N.CT6W76SV/7(&D:GBPYP$E&A&YA>:-(YM ]F=(B)S.Q!G3;TN/(=P%H ?
MY!S0!>AF\3\H@SY1NI&5WTVXVT# V]]^MO67N/;X$UHP+UZ:9S3.LE,((4EU
ME-8T:%?^CG%05^6F2^Q)MM)2FL)7(2VYC'ML:DD_0#L!^93FB0T #>Y]=.PV
MF58-8*J9BT==6U*3KFLR,.-!A5N;FH1C=>K\.)(CY7&9J40C7HKL=<!IZ%'8
M9GPFHBGD2$)<^#AE=]_NL]?6L3WO_,03"T]USTMM/2T,N#MVX >QJP0.WVUQ
M!T+6;=+(0;+L38!W89Z8LJW<+ F6/24LA:-!&_(L*8BN1??,><CJR\][>ZJF
M#8$4BY/W\NWFI/\ "B<(G")PB<(G")PB<(G")PB<(G")PBB5W:U=KC9G7G8#
MNR<U:(/H=7NEW#'KT<N@*C5<S%H5K!*L%R?H)VO6*36(04\70:C0B"9&(+SL
MJ#ALG%@R&(;'L;VMKT5!((C4@'>.G7Z1,T597HR1-:OS]N&*'T^L.DO L$*S
MOD->MWVO1N]AS$^5(:=U?%WTX+N<-N ^I4N0]BMKAN-2$-MGYV$X1F- K2/6
MOK!^BN(22T\W-T :()N3%[]-;T5XMRK$:ZU6Q5*83/A8MD#$@CYBJG"%:LPM
MDG$=AN3Z_81+T<D$,14.Y>'E(+S<J%*0V^RO"T8SC2P14&D@S6OEU!UJ/HJ[
M#/I)]2;" =%&F=MD3I6PWVP778TC<5W_ &F;*1M*O5^I;&KFPKDV0;(6.I7&
MKU2M #%=6F- 4,"0&(B(BTO.O2!U,S))))F)^RUS'H+0(H(U D1KJ>LV6YM;
M=!NNFI=X$]^TD!8H-LE2;<4#UV1;CL[7E,/; @@QU^LE(HTF2L)6[!=8=<%1
M[$2AL_$F-,NH;2PF5)PZ@3.O<GTV\DDQ$C32I L#VZ1I2BB]TOL5JLGJ2>J5
M+MM$GZ_G08_4D*-&$#84ZZ9K@:H[/'U^X,203\F-$AVX6U'.1!$U;984S+3"
M*,-3&74)"Y[#[FONO1( :V#O-[GEFY_=6Y\JB<(G")PB<(G")PB<(G"+$KS?
M:5K.L%+IL*UUVDU(*PJ47LEI,CP(0='1C.5O3"921%AL)PG&<X^(]A2O'A&%
M*^W'ORU/8"IZ*@20!<_N )V$D"322)(7G"WMZ[^MPG<;5KVJKABW].**/-A-
MZ6817YDMRR'K#E6&#M3;DPV2I0;KC,$3*^.,;^ <8,'FX:"&(T%U7$.(^+<O
MD/$7#N RQPSC?_N,9P/+@OQ#&6:'@B"\\TTB>2:.7T/X+_X[^)/&/P5\>?&'
M+NQ,+*>$LY@X.0R8Y7XG%\IEOF\1YG"PFASN7A6#B8#S('ZC?ZHM,X!:>^5W
M ZW>H>3E;.[+=D=/Z6Z!ZZM\B%4^O5FV=6J]L+L5<*S.:DLVG?-:08P<&Z\B
MS&D3*OJA<1,P\IN,8L[+D546$KEQ DB?E!@2:GJ?N =#6R^>BTL#0!\Q8PN(
M!Y07-!/+S":DTD3RU,2 8 ]Q_6%G6OL/- ]4MDRR&B=7&J>(#S->6S9&NJZF
MI0JH+587V8=69K;90FQ92Y2+#081903 ZF#X\.K?)29KIWCG'O$V2X#B<.P<
MRX<V>S(P8$<[,&QS/S$-&"'EK220Z28;==U_";X$^,/BYP[QOQ'PUAN=E_!'
MAMW&<QA?IOQ69_/A_P"HSA. [ 9B/Q.(8^49F<;+8+6$8C\ ,>6_J!PE!U?E
M[B[ MTSL3=NF'87OKO1+Y274]G]C=BZEUUU2UPF(9(CQ\_2-4;D.B",/Y>"T
M^Y=X>MYIPM.P]+@3VDY3A'(6GF:W$ )#@',)( +7 $$:?VD$TN5TJ\##>_")
M_2>PQB83F.;B,<!9X< 000YL3H9-(6U=F=O?5EW-M!_KAU<-=3 ^T!TN/%V/
M)U%7K?MZH=?(+RO8\O;6Z[NL'08UFCM85F+1JC1K-9WWF5)=A0VD>]T2Z8$3
MKTV,G[1IUHA@DGF(TO)[  T/>D]*[QK/5_U4J/I\[T\_:KIV^Z\OZK6R=[-2
MPN05ZKH3:)4F;V-&A5.,48B-DT$+#86ZTTQ63$=$:5$PX:%^UI N@&H)GK ]
M(G^/LLDL)FK38-&L5F8%!T(KJ#>\\$)8 A X.,M;D<,+'BF''/'Q%LCXC,1I
M:_&,8]ZD,I4KQC&/=G/C&,<TL^_V7:\(G")PB<(G")PB<(G")PB<(O+_ .KW
MK_L8<[%F[33]=!C-9A4.D -=HK_5;KYOB^W\\4 ;.G/8=,;-&E+@R.K%]$52
MNV**):2/I]5N4>XH9EK3,97AP).L1% -9&M=IZ:KR,@"=9DF7"*TZ&GUG65Z
M8:HF6FLU],^,J%/2$%)G0UY8RN),3 CIE1E9B-LQ<J8?PMK/RS3<?^S_ )EM
M#?M3C:\:[_A$X15B>LK^T/\ R:';[&OOTAA6=+7K]9JM_P!8RC&O_P!-%?U1
M^F\!_P"U^KO@?+_0OJ7^J/B_%^>_L>WQ'6/8_9:;_<.XC6LZC;M/93_U9_PQ
MUS_V#J'_ ,OCOZ_\^59][K/.$3A$X1.$3A$X1<9SC&,YSG&,8QG.<YSXQC&/
MOG.<Y^V,8Q^<\(OYX?94K"4O-J5G/C"<+3E6<XQY_&,^?QCS^/Q]_P <(NL.
M6$!6!,\]938FO Q49<PF8.$(@D6.B-XRIR5.(3W8\6+'0G&<K>?=0VG&,YRK
M&.$E4S]L?6XZZ:<U]>K!U]BE>TEAISP\<0):^#'9&F:X2)EQXB.BX;H;@JIL
M'W/SD-1H068<)39KD:*F,RAUR2U^;-YG#RN5Q<P[F(PV/=\H)_M:YT0 9<>6
M@D#K>/;<"X-F^/\ &>%<$R9PAG>+\0RW#<IAXV(W"!Q\YBLPL''?BO(P\/+8
M;WC]=[RWE;)D"HJD]/7UB.S@Q9?KB(ZQ6?N/M&QEMJ[<K)C75J!UZ3&EW>QS
M;M8X5P:+0V@8>JP+S8C$C%@668>8C'@P:,/DO--?$XMX-\1XWB#)9IV9P7X.
M9RV:<'L>US0<![9P7 N)<7$T<120XAH!$?0'_)CX(<-^"_BG@>1X)QO*\?X)
MQCPWE,WE^)9;,9?'_P#R&6>,MQ?+8C<L[EPSA9HX>+E@[F+LGF\NUSG8S,9Y
MW<G;!?9)M6T?6 T#W9<&@G9!<1U^"]=K$6Z3:Z;@J=?C%; G7MCNA+<IB&RC
M,AT]L)$@-%5EQ46LP6T-91S" 2.:0.84@P 29-"9(CJ*BE2OFMWRM<6<M! )
M<.9SW$-8V: #F-I!B0#, [M]*/L5TNVQV9[%Q-;"IP6RS[HNP=;/UU:[D:G&
MM/IUY4J>;>U_7KH9(JK<K$G7DTB1B18L4U"I)*M@WUM!QJ!L/U'#>-Y+BN8X
MGE<H\NQ>%YC]#&!,AXY07.9!,@.EE)^:0!0SV%XU^&/BSP'P3P-X@\0Y!^6X
M9X_X"[Q!P3$+'->S+C,OP&9?-B(;FG8?Z>;#&2W^ES&7Q>8.>6M]%^/QC^F.
M>Y77:YX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%6OZK"[B(ZE6V^52LD[7
M UDFQWN^#!6[;3HJ2C7PW7-X@V>8BPU(%82-A?BQ22'!U8>@MQ7BOR!E4MA\
M*QG,-C^Y'V5;_=U, 4G6?+:I[#50<](FP'1N]]MZ\M+Y>27DZ0UWLD>Y_CWV
M7N> 2#L%F-#FHR&YHR,#HYN*[#]TI2):IY.'(C9C-R(&,R$QNNMC>:'R'OR6
MGZ&@N/[>3;3WYKT%\TL)PBXSC.<9QC[9SC.,9_GX^W[L_P#+/].$52'3$=>1
MGJ2>J2Q?K.&M1*1%ZC3P\T'7':S'@5&=3]G2:H F0WBQA4\L ".Q!A0ZE^*V
M:F,.3TC1^'\1D07/8?E4P0V!%73UM)]8D4UD2K<.51.$3A$X1.$3A$X10*[M
M^H)I[HPO4.=I.O.,;2NF ,ER%AQ]ZHU&#'4[9MB%8<9$B;) UIZ0(8F1X<9<
MN1DEYB?%7'<:S^#.\3R?#G91N;Q1A'.9AN6P9KSXKQ\K0 #<TG<A<E\.>$/$
M7BP<==P#AF8XDWPYP'/>)>+_ *#:9/A'#G8+,UG,5Y^7]/!=F,$O:)>,/]1X
M!#3%+W:+_"/]9#U3:SUP9KM>;0XJ*G:6Y19LL4)>[RSE[7&A*7(=NYJ8XI6'
M1,G9!77(*0M*42W%-J^_[2X#4=#I&E+[7 U7'&LYN4F' Q;6>I,0=A)$"^E=
MMN[!;IV#@-O+;6IB%LCDG_G*=O?U5+3FI:QA3W6W%M.]>.BVM%+^M.Y6YA0A
M4()LDCAU2<2BB5Y<=QAQI4$V%:03,&!M>H/TKY6M95A>UK7 M<6@D .%^9K7
MD03>&QJ0)(I/VH7,W2\[:V%=R@VPV)G8MM(3Q[=1:U@W:GW;.0)F\-TB-(%%
MP$-V7(D-CAA!]HM"@-X#Y5%8C1XK/6W'N+G \8\/R)RF%BX#SEAF,T[*<S<,
MO!&$'8GZ+G D5<6F&<V$Z0YCI^VOAE\,QQO_ (Y^.O&#_%68X9QCA?\ V(X-
MX8P..862S/%</*-:_C6/@9#^OP6X@P@YHP!BY5^)G7X'$\L68G]5E3@VZU_5
M:>X-9TG:]1^E7N#KQU6!+B&"?9WKW1HNP^X%_L :(Q$-3*^=EVNIN1 1Z:F2
MF18/H=O3G*)'TYG*\NLL=E""9#8!)C6)/4TC2^H"^))Y21S@Q ^9SHB9$S+I
M)TD $P( "A#OO6/6G2.UAE%U@_M,C6*A.B6J^U?L!3+'I#=JB<TBU/DZ[O#T
M<_&B65@A6T)EQ+8+KH2:VDVUA!";[$Y9ZY\:<2RN3S7!V?\ 487$3C/#\?'Q
M\F,S^GP_F@X3#!+/G+<0%L$\E:%?9/\ QB\$\8\6^'/B9FL'XI9KX>LX3PK&
M_P#IWAN3\:'P\.+^.L3"./D79O 9C8;<SE,')9?%X<_%(+L,\0#V\QPR%;UI
MS<][M>L+><ZZ7?=6N_1X%;.8 ;3KM'N "U=KM'5M8]]5K37FH4T[>-===)IU
M]IXLC!$G?A@-9(R Q&"2I7.Q,-P=A,<PN&$6L<UID%C2R0T 6 ! B]-(D_'>
M9&,,;$&8(.89C8[<27C'^?\ 4/\ =C\H&*0?U!AFW*:R:KUE]9=?=?=<:7I(
M7K &IHG34X3%.U*31U,2Q%@AEF42DV-TRVX_)L)$LE>),\X2ES2<Z0I:YLEQ
M["_'E$12R_(9)EU]9W_VM^<J)PB<(G")PB<(G")PB<(G")PBX5G.,9SC'NSC
M'VQY\><_NQY_=YS^<_N_/"+Q@]_MTZ1[8]SK[*TI=2]C.AQICKQLUDUU9[![
M'NNIWJ\+V;K2W8U 7UU'R,<@SY5V_6;<0BH6P_>:E6R[Q64+S\BWAT&!6XT/
M7S[VL8J#'E:"T5%ZR2! H1--K7O7=>R*K,8BUJOQ<29TW$8(*C_-DT+;)2L,
MP6&\2"#;B4N-S7L)PY*0M*5H?4M*L85C.,;7A'EV&D4CR*[WA5.$57?K.UB7
M9O3/[<)B7ZR4+Z%IZZV:2NM2 \==OB!ZV6=?H9OZP.)(>K=G2YB.78')A&'&
MF&_IY*&XE2\QUCV/V6F?WM[CUF_EI7N%83JW/_HRUUY\>?T)4<^,?]GQ_P",
M?PQ^. 01(4-SW-K>2SOE43A$X1.$6J=S[7!Z7H9&^GH94K%@RA0R"%!(C.FC
MQVP%(8*O@Q;<V5!@)E%3)&%#^:(SX L<TZZ1*SX(V)+ELPEK6N<XP&M+MS B
M:7--E*_XCF,/,3 Y6L<]SIW:UM-22 *D*K#1GKK=)-BUTR<V[<A76Q8]\ID3
M#V1:Z\2=L\ 9.;AN/A8]<D33*ICS4D<3BC902,\0$E(TX0X3:CE,C_R9+/Y;
M/X)S&6Q!B80Q,3"YAJ_#/*\=VN!:>H,2O=\>\.<=\+\0/"O$'#<QPOB/]'P[
MB RN9:68IR?%N'Y7B>0Q^5T$,Q\IF\'%9,$@U:UTM&J.P/KZ=)T:ZV0,U#0]
MV]J%9I5ICS&:GI&Y)U:]#>"3V)/ZXM%L'@8D.EN-KRW82#42<VT(=D/):=1]
ML_J+V-ESYY6U>0/\1/-6P@ U-%ZEN#B/<&-$/<>5H)@\Q( %Q62* ^8HO/MU
M2[9=NI^_90;J7JOK,G=F_3Q4CKG)#6=9"GM5N8K+\<P)UY-R6BUH ,@T$*],
M,P+3.,PWIB3A".V7+$)+$_A?AOQ4..<2XSDS@'"&4QIR1Y"UN-E6G]-SY=!+
MCB /B@Y'MI+3/T]\=/\ CUC?"7P7\+_%7_88>>/BW@SCXFRK<U@XYX)XCQ7.
MS^7X>681+VL'"L7!RKW.F<_P_.X@<UN,QC+DH'I)>H'V)(0[-W+[&:IL)5+[
M<UAF],V_L8Q77_/G*:]JIUO3O7 2ZSA*<-YG:WN?M7CW*ER<XRXOFD$BIKYQ
MZ4'J"OF'G;'RM-8-*0 -Y)VU%S0W4Q+SZ4%F8UC&R#[*[BVYM2BD*X?U-5]A
MF:+0NMU:L $U!FL.2-#:YUO!US-"HA-SHCH@O7C/QHDIYJ)*'$51C$.Q0BX)
MF'5$]HK&D]J*#$(((EK@U[ ]A<UX:^"X<[7!S9@"CAVNN]]/?I=V=TGM0OL3
MLVUH1R1!![.A4K&D18T-'B3-M;#'W^W.&FF:!624_#D^(N, 9>+.C:J#2W7Q
MX^2WG)!,#0#(:QM.7Y6AM!$ P!(IK,0 +5CG\PK+I-\0<Y;<GD+RYS)+B''#
MY>>3S4HK-MZ5B!=-3["J14K= 8>R4FU!2Y;7,>9+OD$82$2(A!^H11P@\0D6
M+$-U](EL>(($%S5M)@1'YBF$\/:U[2UP?!%V$-(\R:3T!UZ*,)8]F(.26/:\
M%['X@#A_;\@(:X2!/.8!@Q$KSC]>O26ZOG-MV%(HSZ@NL#5(NDC.@+[)H.T-
M2)'U^/JRJ2<V.9<S6E*X)@$X-WEV^##'FR@U@TV'&C) 8E$EXP1X[PGPOP?@
MF;QLWD,',,QLP(Q7?JXCP\%XQ3//+22\W :1$7*[A^('QW^*/Q1X+P/@'C;C
M^!Q/@WAS$9B<)R8X3P+(C)%F5_HFG Q.'8.%FN4Y6,,M<XX9@'D'Z;2VR5CL
M)VVZ.*9%=Q*].[(]=H65-1>W^G:H[F[T8.UE*&9?8O3()E^0U'AL)4X5V%K5
M@@%0VG$HC7QJENJ3R.3-=:SM:^GF*= %T^&M( 80(% 30@1_:8$TM->N]F.L
M]IZYW-2@>QM4W6M[ HUDB(G [152L0P'(1UX_+,N&ZXVEUI7EN1&<RB1&>2M
MF0TTZA2,61>:;K-C!WCW]5GV,XS^,XS_ $^_")^/SPBX\X_CC^_'"+GA$X1<
M><>?'G'G/XQYQYS^_P#Y<(N>$3SC^..$D;VNGX_/"+C"DJ_W58S_ $SC/\OW
M?S^W"2-]_I0^AH5SPB<(G")PBCUVS)7D-UA[ E]8AXMBV(,T]L6;2@$RL2KM
M&-V:/4RK@<0[3H4:9)M.",W#,5-?1$DX+J=3!<8=;?6A4-C&R"):"8!< =*3
M6#(@QKHJH?1PH;M -[;@L0=M XQNNU@X3"7_ -/&F]*1#1Y<Z6W)>'6.J"!^
M;[/80Z[$R)D29<<1#SF9%]N);BU1L5@>H@W/D?*UEI]8F*3$.YAZ6W/UZJ^/
MFEE.$7&?QGS^/&?/_6?M_?PBIUZ*#ZD,]1OU56:?>BFP(#\WJ[-*%"UTS>'@
MUFF5[:LBQT^*14_(^DCJD67*!CZIA3>*Q%A-B,,M?*Y1B6)KL:Z7_;R5)D-)
M@7 TF@[3Z5BM5<7RJ)PB<(NL+&PP&([/-EA@>"PA2W9A6?%'Q6DIQYRIR1+=
M990G&/OG*EXQC]^>$6LZ#V"T9M2SV"EZRV_K;8=KJ<*,1M "DW2OV@I7H4U]
M<:)(,Q0L^:X/;D2&W&6LRL-Y6XG*<8SG'"5I0P=:WK>G3UI"\R7>[UNM\Z+[
M.7ZNZB?%$=>Z'M-XK&P=?XID8I/-3ZPX] &L3K(6E09GQRLZ*Z6(IK3T&,!J
MT\4MIXL900B)XSQ+Q/D^&\;X=P;&Y?U>(M!:XN &"XDLP@_6,9[7,;6>:)H9
M7=W@KX%^+?''PN\??%'A67?B<'\"#*,S0:U[G\0YW_J<3=DH!!Q."Y)V6SN=
M!!!RV,YP/.>10E['^M-ZJF_P:'-42^LG177AN(Q*@E+9O;2K&TI0D@S\2-)?
MF7ZS9*C?C,.MNMN"*$,GI]R/@/J<YR+F<8B!)BI'3<=>O[]+?IM:2'$N,_4;
M6%QN+@B=:*[#=-L?JN\E]F;YKO9FZF)41LY?8MULFT8\Z#(%LS7QL"RFFQ[:
MHD%Y]R%*1#\#43LJ9BK?;;2^WP3Q?P;+\4S/#<3-9W&RXP'.9E6X>.S# S3W
ML+<0AV'B$D@"2VK0TQ\H?/U5_P =_B[Q[X9<(\>93@'AG@W&6\<R67_^HL?B
MO!<UQ0O\/9=F8P<UD [+\2R0P<!YS#CBLQ6?HXKL3#9BXO.[+-'4: [;V;K+
M>E"*C4!.NS]<)RAY&T:WU+KBV[Q)$V9SB9C O8FU6-@M4>8RM*8D8E2P2$,X
M;0ZT->5E2W>;88?A,8S$/-B,8UKWT<7/#8+IH#)J2 T'867S%G78>+F<T_#P
MOT,'$S&-B867 <P8.&_%<6X08Y[W-;AM/(&NQ,1P$2YQ!<K ZM3NU?:2X.[2
MUIZ5&]M^W ZO+F=W=K]B[ZV(\[F3X5AQLO"(Z+UTQ&4EQ3C0Y<62-PTM3;<=
M4;&6T^6X=\IJTB9DUFU *'3Z%?D;\E0\M<".7D+09IU)@BCIN"087V+W(9TJ
M\UJ':?774%<*:R8W)1]\:K!$:U@9L&\[*)%7IQ-JP#FS"*M+U!B13AE#C"RY
M'--*4LIF.0;DER.<<(XKXDS&4\3\,X5AY1[\B_#&%GL<9<XGZ>8Q@X9?$&-R
M'E.%_E7E ?)F"OJ'P-\$> ^)?@'\0/B1Q#Q/PK*^*.%9W Q_!_ 3QS!R><XE
MP;@[\+$\0X3LD['&/C8^:_5?A9!X;S.QLBYI8\8K7*^#7424"HU0&]UROK-5
M>JBZV$BXFTYT0]UW0(8'1FHOTTQTM#NE8M:5$1CY!9)<>0Y!4W\5YY6?/.<2
M?\I%8IJ:UH :D$D5J14W7RZ\%KWM'Z;H<Z#$$B26\P)(YX(#BV9=)M:"/:+0
MGI56S;.O#?7OM82DL[QNU8UQ?*V>,VR\'M4RI,50W.T[6]L<C$OT$.W*2,@E
MQMJ>6VX2)*FCR$(? EP&N,>(>%<!SN8R&-Q;$<S,.<.'Y)@Q,5H=BUQ1/(YK
M8Y6D &231IL%WC\)OB#\9O"O"O%F1^&F8>.&X/#V^)/$OZ? ^!\9P\+A^7?A
M<-PL;&_[/+XV:9@X+\U@MYLNYH8'#$> T.>+'[7Z&NP^N"JEN_TM.S5CH6XJ
MG5HX6PTG;<^):=7[S$LH4]/#6#,8;F)!A'UY<R@1.&E*U&?>PL9^GUY7/YR<
M80P@UC29PVAM3S$P(K,$&D;Q*Z.Q,R['<]^,UI<][GES<,8#0<0EY+<)AAH+
MG%T@Q6GRBD=^LO?+8G1?;DW7M_T;==$0B\V0:W/T;*M.RAM?ES'79-DWYT1L
M4AQZ#<Z++>1*-7#1<$G)F1$XGE:-F:AJ4PP!(-HW&VLC<&#(%0;+);S">:8F
M'=@8#A0ZT-.L17U3:RW9JC<55I5SUG?JQ<:[L*NN6FGSPY6*\LX#C.0F)TZ)
M"4XB=E R60APBS;D=#PJ?(:@D$1Y:\,YWI.EITG:5X]Z6B1M-IV6T^$3SC^.
M/QY_\/X_TX1.$3A%QE2<??*L8Q]OOG./WY\8_OSG&,?SSXX4D;A,9QG[XSC.
M/XXSYX57/G'\<<(G"+\J6A.<84M*<YSC&,*5C&<YSY\8QC.<><Y\9\8Q^?&?
M'"2*UM4]!($GS('<@+]?G\<(ORO&<ISC'VSG_P"_"'_4[Z+RV=C_ $BO4'[*
M=@K-M79MHZ;W:JQ=AFSFLPT.=>=,V,13\')4BLC[/;M2Z>%[ -&8X949DJX_
ML65$?G8?=;RK.<.JQ!F8;?J#Z@3/G'1;#@  .8&(-9K%X)W^O0E>H,-%=@B1
MD*0EI+\0?#C/)8>?D,I=8CMM.8:?E9S)>;PM&<(>D9R^ZG&''L_$4KFUA=EP
MB<(JXO5JU75]P>GMVBJEAKX&P$F=664K1_U$RRN""V"V,ECJA8VI3Z<MC)@H
MF3PMDIE2?D$./2%*2VVM6(1(-H@F20 (!,GH(F=$GE(<9I,D D0(D=ZTUK2Z
MJ#Z]>OM!I1JP4?L-2HM@HE6E+J.NS_7:A[!M9T^&K@M<(19<CR,V7'+!;%)
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M=ZUOIT&(^9@G<5Q*1$R)43,H=H'L!.C8E0I#D2;&R_%UDZUB1$E,NQI3/O\
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M>*\ R'$\OQ+"Q\',8;.(-PS@\:R+WX)Y6?TV>PGXF7#X)R>9RQES@^)JA?\
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M!,DDT I<T7EP<KF,SBX6!E\'$QL;&Q,/"P<+"8[$Q,7$Q'<K&8;& N>YSA
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MDTY;26N@]K)JE)RTXE1;'QXOA,1M;K,=IU7+L+F;AX;<5S7XP8T8CFM+0YX
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MH2Y]?-4&M@;AU_'NXRDG2D30![2M4DV\[KF41?W'6-S,3;"^(=A5/XHPUJV
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M+Q+G+@ 2+5+=S^J&1;\V&\2E"V(4:9#=>3*9&=$$2"21&HO:WOHJ.-=^F]W
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MF#IM0+R<P!!_NAH!,5IZUWB^]2K[= 4ZX:\T=J*A7\F&,W6EZYIU6LQ2O0I
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JCLMIQA*&F66T-MH3C&$H3A.,>,<(OJX1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g400206g30f01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g30f01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
M]0(C P$1  (1 0,1 ?_$ !X  0 " @,! 0$            '" 8) P4*! (!
M_\0 0Q   00# 0 ! @0$ P0) @4%!0,$!@<  0(("1$2$Q05(187,4$8(E$R
M-GFW(T)987%XF+;6)($*)B=)4K'!X?#Q_\0 '0$!  $% 0$!
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M*E*7)45?!*]L"JR$WE 5!SR./T^Y!*PDRB^>.2* _M>>2B-G0Q$+R[V+)$Y
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M,R*OEG_*S3-27M):OEU>6:WJR"V2K1T_]-H)Q%6IHA>:='.O0_5:/QW\3\V
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MWKA/GKK?TPB[7")A$PB814!^0K_<[S3_ .=KS)_[R6S>-"?\WJ'_ ,GZB_\
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M7P>5?0W*Z<G#F;2R1:;AK%"Q1T1M<B^</"I":12;DHN_2Y4C;IND^>\9D_\
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M776D&3!JX<J_9SUW^&EU]O/77TULGKUNJZ^6(M(GH>6>@+%#N MG>B2 V7/
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MB2",GCHE_(N)4T$J=-M:E,?CA!9=9JP78/"*MQ_XU*'4D"DEK"06/YW)-[O
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M558Y9H"7PRR0N<UT;G1/?&YS' ![2YA&[' @.:3LX=00L4I?Y"(=>)^,IQJ
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M QPY(KLX1,(F$3")A$PB81,(F$/0^"U7=DI0>/6&^(3^S^%6EK6T';("[/L
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M03N=]A\/#Z>1/@L1K[X](]"6/:2UB.';UV5]%FWO(.'L8X!1?>C8-$(4>:A
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MKT-GUZ]?!%NJPB\JWO: ^_Y%\F]:7#$_.UPN. "7IBHO,L_A<\AI*M D&?\
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M:D0&S-C-)WI7C>]=)<0*#?Q+,U5?OU^'I)(#VITIO7'/.^MZUF46O+7K8/\
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M05)"Y *;I.Y:&TX=+!9-.9?''[A!#?3@<@>B\B#_ *ERTZ)AB#)-=JKKE/\
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M*#.,3N.,UT"2O)IF43[9[;T.TZ>A-E<;_;I*DL+*$K7NJ.B>P/%J1K&O=%N
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M>,U+;J8]CFL;'M!3#7QPM(8QVS-B'ASP0YQ*VI4=4@"AJ?K6F8LX</(_6,,
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MY_DNHA_IFC)D6AL596A7[&P9X&9G8[6;JP8 1GCUB_#$I$TVV#QF42!N4VX
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M]]]]$6%7#3%8W[79ZI[>B3&;5W*% RDBBA%<@V&&= #@V1C&Y'0QXQ7<LDC
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7A$PB81,(F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g400206g35a35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g35a35.jpg
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M 0$! 0$! 0$! 0'_P  1" $& 8@# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M          @)!@<$!0H# @'_Q !$$  !! ,!  $# @,#" @%! ,$ @,%!@$'
M"  )$1(3%!46(7@7.+<*(B,Q.5:6MA@:)#)8E]37&2<S0E$E)B@U07&A_\0
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MJXNMZ=UMMZ&DZ+!U_GV!VI4;\1,;"N5A73JK!3<F'RY(:UN\;_&DAL.KSER
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MLVAM=VN(H^M:SIK;\-O^+N=D!NEE-FK-9[SM2N0YUK"CG86.BH=4N#"NO(-
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MQ$\1/$3Q$\1/$3Q$\1/$3Q$\1/$7FS^:6S:JTCTUSCT7+?*Q'_&[MV&T_?\
M6M9%KW)9_3=YV)2++:(V7L:K&#!'DK_@)B6BH94-%W2K2$ #:HHJ;K$@+/\
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M=KXQ0L!$CD#O-T294V\P^T(AUIUM6,*0XVI*TJQC*<XSCZ^(S\;?YF_<+?\
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MJ=K5FN&(L.LZPJEQLF<-UFG668(/<B41H@L2]@HQEUT9M_!9M5J<+K%N>&M
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M4%F #>TC.?5N?N"K8OARU'6=,Z)V-5ZWP1L_@W!>T")N7@-P;18V_>MLRLA
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MVRX_;9MWMILO18F3C:9KR5VG38NO'HD';7,UZP"Q\B2&Q!;(MJ)65%@R'GG
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M$:Q:EUEKM>Y)%0Z:=<I[()*]B:RZK+)'/7BF_P!2O)$)(7M,A8Z.0![7-(<
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MJYN_F_X9N<>?^>.IMV2$S.V62W]8JO:JAI/8Y0EHR9MP[9=L^RL4_P#M0)K
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M_:6QM:<]Z<UQ99V5B$0=/BKA3M;UNO37Z&.-E8:2M4.)+1I0N24R]743]F"
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M&_X<#KK$=>82O:C@H<IPQ+DS(B4]<I&1;3ZJW&&R: (Y[<U=/H46[:=.K5&
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M14J:K-2KSZ9<U&F]GC,+:@TM]%Q$KG9FHW8P7RD$ RQ21_ &MSN:"NRZ%/M
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M@BV'"BWG"67!E(8<4AII6>KJTM/FITO&Z:J7-M> -G%'2_# #&[1&'['1B+
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MS7[]6+Y#RYQ^:^82+F*+F28]IIY92(Y!&<$8Q.T^@\-:ZE5+6EQ:WP(]K2[
M<0 W +@UH)QD[1GL%K['0_1EJ"&*?I/IR6*":>2&)VC:?X<4EAD#9I&1BN&-
MDF;7@;(\-W/;!$UQ(C8!9RU\%'Q9,.E/,\TR[;IKJ'RUHZ(ZCQDAYL=D5#KO
MTW5]%.)&'88PO./N_$RTC.<I0G&*G3-/(:#2JD,!:T&",AH+BXAHV\ N<YQ
M\R3W*\\G0/0\K((Y>D>G)(ZL;H:['Z-0<V")\TMAT<33 0QCIYYIBUN 999'
MD;GN)YU[^%;@^U:/:T!5*9>-0TI&Y0M[OR5#V%-V"Y&WT&@2^LTK)M.YO[6#
M\0+]3EUBO0 N!H])@04B.V.7@ITNSZ%.2LZH8&-K.(<8HP8FY#@\$>&6D'<
M3@C/GE>BWT;TO=T&7I>71:<>@3O9+)I=)LFFUS)'99<:]O\ #GU9&.]YC9*X
ML>W>00_<TD'%N<?@_P"0^9MVT/?%2M6\;C:==O60F"@MCV/74Y3GR+12[)1#
MGI6(A]65TTU0T+:I1V/2F58;'DDB%N(?P/AI6*II5"E*9JT'AR%AC+O$E=\+
MBTD8>]PY+1SC/'=:WIOV;=%=(WY-4Z>T0:=>DJR4WSC4-5M9K2R0RR1^'=O6
M81ND@B=O$8>-N&N +@<0^8WX[N=-Y<Q;[Z-EZY;HC;_.G*>_;#JDC6MHEJ6
MN>KU&L%V@4SM>K6!QK5^*R1 *VA3VWLNLJ="3C+;ZDY]5BM7L- L013AF2T2
MQM>&DCD@.!QG SCNNBU70-#UYL$6N:/IFKQUWN?79J5*O<; ^0-;(Z)L['B-
MTC6M:\M +@T G@+K/B/^-'EC6?)FE-V&428O&P>H>2]!3&ZHW<TN5LJM'RMD
MHM>O%B$"IMT8D(J!'?LTN<X_',B);;:0P&MO[!D8PKUJ]=I%>"* /P7"*-K
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MCT7TCJ]R74-4Z9T+4;TXC$]R[I=.S9E$,3((O$FEA?(_PX8XXF;G':QC6C
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K;;2E"$)2E*<)QC'BA?;Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g400206g35a37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g35a37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6*9:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C M8S P," W.2XR
M,3=B8V$V+" R,#(Q+S V+S$T+3$X.C(X.C$Q(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0
M;W=E<E!O:6YTPJX@9F]R($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E<CX*
M(" @(" @(" @/'!D9G@Z35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M
M.#<Q."TR8C,X830Y9&%C9C%?16YA8FQE9#YT<G5E/"]P9&9X.DU325!?3&%B
M96Q?-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7T5N86)L
M960^"B @(" @(" @(#QP9&9X.DU325!?3&%B96Q?-3%C-F8Q9F,M-#8S,RTT
M,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7U-E=$1A=&4^,C R,RTP,RTR,%0Q-SHP
M,#HR,EH\+W!D9G@Z35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M.#<Q
M."TR8C,X830Y9&%C9C%?4V5T1&%T93X*(" @(" @(" @/'!D9G@Z35-)4%],
M86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M.#<Q."TR8C,X830Y9&%C9C%?365T
M:&]D/E-T86YD87)D/"]P9&9X.DU325!?3&%B96Q?-3%C-F8Q9F,M-#8S,RTT
M,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7TUE=&AO9#X*(" @(" @(" @/'!D9G@Z
M35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S,S$M.#<Q."TR8C,X830Y9&%C
M9C%?3F%M93Y#;VYF:61E;G1I86P@*'=I=&AO=70@<F5S=')I8W1I;VYS*3PO
M<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V,S,M-#,S,2TX-S$X+3)B,SAA
M-#ED86-F,5].86UE/@H@(" @(" @(" \<&1F>#I-4TE07TQA8F5L7S4Q8S9F
M,69C+30V,S,M-#,S,2TX-S$X+3)B,SAA-#ED86-F,5]3:71E260^.&8V-S(W
M8C,M.30V-RTT.&(T+6(U8F(M9F(V-S V,&0P,60T/"]P9&9X.DU325!?3&%B
M96Q?-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7U-I=&5)
M9#X*(" @(" @(" @/'!D9G@Z35-)4%],86)E;%\U,6,V9C%F8RTT-C,S+30S
M,S$M.#<Q."TR8C,X830Y9&%C9C%?06-T:6]N260^,F0X8V$V.#0M.&1A9"TT
M839F+6$P8V,M-V9B,&4V-6,U96,R/"]P9&9X.DU325!?3&%B96Q?-3%C-F8Q
M9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7T%C=&EO;DED/@H@(" @
M(" @(" \<&1F>#I-4TE07TQA8F5L7S4Q8S9F,69C+30V,S,M-#,S,2TX-S$X
M+3)B,SAA-#ED86-F,5]#;VYT96YT0FET<SXP/"]P9&9X.DU325!?3&%B96Q?
M-3%C-F8Q9F,M-#8S,RTT,S,Q+3@W,3@M,F(S.&$T.61A8V8Q7T-O;G1E;G1"
M:71S/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A
M=&]R(#(U+C0@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z0W)E871E1&%T93XR,#(S+3 S+3(Q5# X.C4V.C0Y*S U.C,P/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M
M,#,M,C%4,#@Z-38Z-#DK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @
M(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3 S+3(Q5# X.C4V.C0Y*S U.C,P
M/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIH96EG:'0^.#0\+WAM<$=);6<Z:&5I9VAT/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM
M9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y
M:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-
M=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!
M0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'
M0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/
M1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E'
M:%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!5D%%04%W
M15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!
M449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%1
M04-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!
M1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2
M>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=:
M:$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR
M:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K
M0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!
M04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:
M17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S
M4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM
M<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!
M.54T<3=&6%EQ-T9867$W1E=.*V0F(WA!.SE&,3-63%,P5%-P84-'679C,C,Q
M<65W.55&1U9'*W,R>79+4%-K26LT56\Q3CA6658O9T0X>E P:5HT=%8Y0S,O
M4V=U<%8O4TXT+W(F(WA!.U%F5UHU3UAP;$]%5DE:630O4U4X5S163T98<D]"
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=*9610
M3"\F(WA!.T%*;#%/+W-:=$MU94YV0VMI3D8Y8W5,2#!P;5I3='A7,E8O6&]I
M<VYP=CA!1'98>'A622]*=FLW.'A.3C%45$IT4C%.0F\Y<S!H=4XF(WA!.TPK
M=#-.,B]*-U99:7AM;59424=N47EH1S)4;5%/,D98<$]"6%EQ-T9867$W1E5,
M<7%A9RMM6&%A8WEP<411>4QA3S="1E=5<5%J1FHF(WA!.TA/0E)V1TYV.54Y
M3599:$DS-6LV56=V.5$Q1WAN=%DT8DM'5S,Y37EC-3)K4TLT9&5#5W!1<U=,
M0FEZ3#!54G)X3$]64FYN-WIF<4<F(WA!.V=84&QU>C V3T-7-S%Z5F]B0FMN
M5UIG3&1G>E1/;G!D1U5!8G1S3W1+1$LU4V]G2D1,8VUH,DMU>%8R2W5X5C)+
M=7A62E!.1B]W0V$F(WA!.V)73S%J.'4V6D1Q1GAC4TUK<VQZ4#9%34-I3FU6
M,S1Q-W-'64)F:%A&5391<U9"8T%.46-G1%5!.39'9W(Y,DMT-'$W1E5J.'HR
M-E0F(WA!.V96=5=P>F%D>#4P.45Y:FY8:C$Y2FLK>C<K3UDR;W=3;E9336$O
M2&4Q6DUF1C%P9T]P,S!1=EIU2#5K3G X6#%E>5HW5C1A=6E'>&PF(WA!.V(Q
M5CE2=59:;S%E9C):5G)7;$=V>'A):4%D-EIX1D%$;7!3+U<W:E=5=$0U.6MJ
M=EIP>$=L<DA&95)X>5--,GEG;5-I<31/,T9Q1&LF(WA!.T-P<'='5%-Z4'EP
M-5<X>F%6<3 Y,W%7=E-A:EIY46U/2WAB,5=62D1*>CE4;$Q*2U-E4'<P-UE%
M<W-X5DLO36-'=GHV96ME:%1X,CDF(WA!.S<V.$IE5U9G<6E&6D%::#A53GAY
M3$I5055(*W--5E-7,6XX.#9D9'=N5C=Y>75,92]W0E9K:6EG:FED;FIT2DDR
M84I&;4@Q8T%O54XF(WA!.V558FLO=T$R2W%U="MC+W%8;FY1=DMK05)R:E99
M<#=M8FUJ35)$0E0W2D)65G(X6%=V5'!G=F5K<W!W;V1I<G-69&ER<U9D:7)S
M5F0F(WA!.VER<U9D:7)(9DMV;G91+TY&,7%%3VMU2EDY4&-)8FA:-U-66E%Z
M3V]D16=M;6U21#9D5DUQ2GE&0W12:7%V-7DO=T-59FTO-'I7,R\F(WA!.T%&
M17@T:%="95EJ3G(S+T]19FQR4S0Q1%=8;&943&I68GAX5&%7-V(P66Q.9CE2
M5T@K6D5+=5AU5#!E<UI.1'-69&ER<U9D:7%1,T<F(WA!.W!E85(U<VAS3&94
M-UDV0C93>5A/;WDS0E=B;3-Q07AX46A$5FQ+;V1Z4V@V,7<P:7=N,D)+4F5A
M=C=M,R]W0EIV,41-=E-C>31/=#4F(WA!.T)/3%0O95=(+U58.5%Z1VYZ3&U1
M*VM+=5):3WA60U@K<C94<#-P+W!#.6=S+U9R-E@Q:59)=5A';DQJ>DER4V]R
M:TI:27@U:T))0DPF(WA!.WHR8E-034=R-C5.93)K9FQJ5E9K5S)K;EHT+UAE
M36TP:EI(2E0T,E5Y;U=I3$YU:$AZ1FE';V9+4&Y/,G9K;3 O4U!+.$IJ;FE9
M2# F(WA!.W R949F4TQS5C0X3C%U4&I594(Y9V-65%-W=79Z:&QK;FML:C!&
M-&5C:V-):&MU1U9F4VM:870S-2]S=79+9TLY=#A66$1Z4C5N.',F(WA!.V58
M9%<X>"]M04Q23%-Y9V=A3S,P:$I:5'IQ>7E516YX5FMD,%93>D)2,S1I<'=+
M;FYK:GIH<&YN2'EZ8659=$UI;6AS<C!Y0TM/-58F(WA!.T9L2'!3=$4S24DP
M:2]A43 K3'!I<F9M6"LO,%0O='!2+W=$2FU81EAL:U!M1W=F+T%*>4$X>6$Y
M9D\X=6YE5V1/=#E&=&AB>%-Z4V8F(WA!.U=R<B]!16=O<V-3<S!J9D1-=7=/
M4FE/6E-78S-N-7AE47),,&MV8C)7,75:230U6'1*8F5:6F]L;45B2C9Q8V%Q
M4W-Y=%1W<C1:2D,F(WA!.V)A0C4W.'%A+TUK1VQ8=VYN95 Q5FE-8VMB8T]+
M4%@Y-'$O<WEQ861D.%94+T95;W8Y8W4W9E=B6%1,9E-R<3=78TLX.39G5EE)
M63(F(WA!.UIL2DQU5C5-=D=P4F0V2$95,WA62F1).'=8=6]A>'%&:3)K6%9P
M83),=$5U;U0X1FIM9%-0-W1A.'EP5G5186Q/;S)/2W Q:7%387(F(WA!.S5J
M=DQ05S=,4W)84C=U+TYY1F5E-VE#2F)W4DY)23)D-4I'54U5<GE+3#A63V=/
M2W S:7)S5F549FQ2-5%S<E18=GI!+W="16MI<W0F(WA!.U=V1VA!5T(W83)-
M355T>D0V55%+2D=X5#1Q;4IM5VA88TY61E949E=F>2LP:E-B4V95-')Q.6UU
M3T]M,G=74V)G;G R:S!A4F-L:%<F(WA!.TQN.$HS1#AG971+-%93=CAS1S!E
M.3@X+VU(-7=.>F)Y3DQQ2V%3;'E'059)=$]H5EA!6FQ1+W1P>DY3<&]+8D-P
M<FID;$IE<'1.0W(F(WA!.V-':U983DM+4T%D-C R+S)**S=*;UAG9VEO,T)X
M5C)+<%1R,VUJ4SE%93)J=7A.2E!E1FAB5SET0S@X:FA#;V-H54).1C5G;D95
M,G@F(WA!.U9J9#0V9C1K:6)K3TE:2VUU,U1--D$O9$8Q,E$O=F=Y5')U37=8
M67!:<E=N5S%W:5-U4VIH:U1K=$YW>D)A1W!!-S5B:GIM2&TT*V8F(WA!.T%*
M*SE53GA:-F9083)29%E5;D1#24Y7<D]P6&)L,'%A-51K>2MR8S@R64U95D96
M='15,#(V;$U6=&125'5!4U)%-G93;E@W2E!J:UDF(WA!.WII95):4GE24$DR
M:7-M>E%L+W!':S9J-F8V47-O3'HP<2ML.5EI4UAJ>7!Y-#AW859O2S5#5T]-
M=5E"4T-1>'IZ1BM6;FLS6'%.9%<F(WA!.W)W4W!B>3)T=DIB4TY&-DM3>$I$
M*S=J1EEG55-*94AW8E5Y849#=R]*,WE,6C96*VI&=$I:3%IP9EAL-7IY8VYL
M-$]J3V5"541K2D<F(WA!.S)5065!07A64'9,=FQ44F9,>5AA85A%,%-8:S-R
M>7%Z1C9.>$,P5715:&1Q,#A38U959E!Q<3-K9GI!<F5N>$]N6%E0<DU%:G V
M3&8F(WA!.V)::7%G935)1TMS8R],4%%,4S@O2S-2.4YU3'1R,D<S;#E32S=7
M83)N6FIA,W!L:5!/,V4U9S9X:7%R22](-U!):U9X5F1C*U5D2#@F(WA!.W-Z
M,G0K;#-D4#EA,75857)U4S1N8C!L931H:V%9*VI%231E23161E5*1RLK1E=+
M+VLW;S-M1%AF260Y-6AG,4<R<TPO04TP87ID86LF(WA!.SDO8E<T9&IA9W1!
M155/131396]R34AP558X4V-I1DQ,53!F>G!E6%1T82MA<E8K1F1P3DUJ6BM.
M2TQ6*U-B:'=$.49+9#AT;&I-95DF(WA!.V$T6DEY-494,3-44$Y/;#(P9#=D
M961,6%-B2T(T*U4P=&Y"16IY3D0V2V\W8VM(1G R1&AF64QK1WAM*VYA:EDV
M;%E16#EH371X6E@F(WA!.U-#5S-N5&184FA535!9-$93=E9B:3146$Q/3DI8
M5TYV5#5)1TE5,6M)3E%->3A546-:3F0O=T)Z:%IP:UI99TAU*SE037A(3E-0
M4W(F(WA!.VDT9EA,>4XU6&%.9E4T;U=*555K049!8WDX<U%-64YD,S-/1FAM
M5&QK0V4O-S X>D5C,4E.8G5B;5!68F1)-5A21U9+<7)%03%C:F\F(WA!.TUZ
M345164=W-$=O;5)K04)4+TU.>C-9<3A8+THK.3AP,VYM;GIB-6ET0VM.,5I#
M56%J.55U63=U,DMZ,TTP>G-R43)D;SAW-5%S.%0F(WA!.VPU4UDR07%#3T-Q
M<VPO36(X>69+9&HU4#%/-48V<GE7;'9A,S9214]N<6\P:U5S87AS-%979&Q:
M9F="-41K=%%+:D971V519DQ94&LF(WA!.T1Y,#)O-D)&<DXS<556-7%D+SA!
M6')M35%X1RML5U%+.%5H67,X:4)1<%!2<3$V;DEW1D)35510-5<P>2]U-W$U
M=2]),7=:-S936#$F(WA!.WI,<DM&955J4TY)4W9Q2&EQ=$LQ2TQT6&]-<W!&
M<W$X<G1*;W5P,T5/;BM86'1R4SAV0D108WEA9VLQ62MB3DAC2W)U94M%4TY2
M5D8F(WA!.U0X=#A#<SDK=E=62R]72395<EAM=E%':%!8>#)W2E-86#E4;&IM
M:49R3TMC4U<T14AC.5!W3UIE;7AX:T198TQ6-4I226]P,3EE<W$F(WA!.U8K
M<U(P<%=V3F5H3D%E=FIT;4DU<5=4,C)I='%K8G9);DYG-TUN2D]"84]H3E)7
M=%)Y<5)4-35A3E))1&AC95=#0FYA6B]88DMN.2\F(WA!.TA48CET9C)V<SDK
M+V)+;DE36'IJ<55-6&PK-&5#84YP03A816-X5W%Z2514<G5-:&M"-%=V3&9$
M<S@R=CE9=DHW;S-6,G8Q=%<T970F(WA!.TDU5W%G1#12>$,P;V9$34ME26YC
M-SDU9&9K>&MK13<Y-2]9>5 X=6)H2CEA:TMU1'AT5RM%04%G0F]X5'!836I$
M1TE/>FLV94UB,F4F(WA!.VI::T]7-T9867$W1EA9<7@W.'<W,4Q0>59R13!M
M;2]P94@V<SAC*VU!>G%:-'!"=VM4;&)26$UQ,5)J=45O3S555EE+<V(O2TLX
M.' F(WA!.S)(-6)A9G$K;F%19DQM;F%R4'HK;T-3-'4V5%140S%J67E32TA0
M<6-%*TQJ>#<Q<'9I<5$O;C$K665I,C,U95AS,FY846YV67(V5%,F(WA!.VQH
M6&Q(2CEA94-72FA(>4-L=4AQ8W53,4AH6$5O2D$U<WHO3$4R96YF;#-O;'%8
M0VEY=%EO6F8Y8TM+,$%R5W!Y1T=81TYM<D9M16\F(WA!.V-84D9E6$QI1TLV
M;CE2=V]:9&EE;7AR=64R8DQ61#!H>$Y'4GA&1RM9-3=*<DY)-4E98G-#5DI"
M2$UN<4E':5!.5SA!>7-!4FU.9W@F(WA!.V-2,V-R55I406))<E1D4G0U8D]-
M<WE237%G1TUF06]&841I1#)Y3U=(1$MM5TA*>%)T0EAU;E)4-G!$2W1Y941C
M;5DX-FQ05$E*0VLF(WA!.VYB-U@P6EI$56--94=M;DIP*TM93G!T-CEO62M(
M<DQ19TM$>C,K255(>%9R52M/55AU-59B56Q6:G!K548O2F-M.$1P=7DP9C1M
M,W$F(WA!.V5:0C,S*R]-:65E-#%4:30Y3G=Z=2]X-7!V.$%78F%T4%93=%%+
M8V@Q27%->&Y,4VDK,'DS=3<Q3&AB<T-/9TUG-3%+:75X43$R0D\F(WA!.UI/
M4%!W>'%N1GDV8FEL9'!S2C=:044Y5F%R.$\W06UQ:F5T5%=U67AC:TPP;6EK
M<C9B<3E!0V5*0C)05' T-'!E8B]L4%DO5CE:.# F(WA!.R]79&)B5TPV931"
M=30R,'@Y3U9'4S1U66UD6D,X<5A3>4]J2W)H;4MQ9U%K54-Q<6Y0;FIY;#58
M;#AS,VM485):8UIZ85%3+S901C@F(WA!.U536%-&15!W-W%P66Q2,G)I9W!P
M-5%T;T(U9719<$9H;&%!4$%8:D-S;$EP1U910T(P1DU%5&%);7=H-%!1+WA)
M.650<$5V-&-D,5 F(WA!.S!:;GE(-W!W26ME36U/=F%D63-':5@Q=$IY=#0U
M-$AH3GAB55-A34]P45!'=W!X6F565E!B34]-5$DP-3@U0TES;V9Y=&\K:E=7
M;4<F(WA!.TMX5U=73G!(95-7-V1P<&YD>4=9;#-,2&,Y:'-/=W<U24=*;W-C
M95%41F@R<S9-6G T-5EN4TY825)L86EG13=#;FHX<W5W-7A!55@F(WA!.T@Q
M1T%Y24E+85$R3G9(17-:4EI#;T%,37$Q3D18=SAC>#5'>35C4E%9;C4W;64P
M=G1+.41J0C9R5&9V54-H9S-W95!W:T9D='=C>$XF(WA!.U1E>$1I-F]Y0D9-
M:C!72T-84TQ+5G=S<G9$17I31E9*3&-183=!1%DU:UDW-%)B:UDW-%)F8VQV
M;3AA8DYP8S)L>'9#=7!86$9B84,F(WA!.W%,27I--FXR<'EP,W=3;D<V2C5O
M;D]0,&LW;&<Y:C59.'I78W-C<F%E.#!T>%9)-C K1&E2475184E0;C%W=V=!
M:DAJ-&9-<W(X<2LF(WA!.U1,>E0Y5$=Q,W)W<DYW6E!1:5%':&)A=DQB9C59
M.$%U-EI$2$<W<F1M1U-:=7A6,DMU>%8R2W-E+TU/0TMF>4YR<5146$U%0S)5
M,&LF(WA!.WHR9G!E=5DT,$QU:65U<G@O1W%L5%5D1#%(6$951"M7:T]I,U!K
M4WE3,&$V=C="<')H>$YQ,&QT9#-%<W$S8VI.3$I.8D=30U@Y.$,F(WA!.WE/
M<D=U>')81E90>E8U3CAP4W1O<U5M:3)*:D]R2DU6*W)X1#DV,%5H3#=,.6]L
M4G8Q,GA)=$)&:6M8-4]S=$]G3V\R159U=D=Z=5,F(WA!.W%K<7!50F1L;U16
M<3%"3RM9,FXR=4DV1GAT2T)'-&IK0VU/;6I36G(W57)72T]+4C=E4E9L5V=A
M9V1&8FEF:&].-C=6>DDX67E*0E F(WA!.TIN:31E2U%(978Q>4A4-V933#8U
M:VE20DA&2DM:1E-R0F=H*TPT4E=U0V,K1TI,3$U1245N;%-P<&DV9F5A9&(S
M0U)23W-S4VUO5D,F(WA!.U!';3%2<S-B>'AH3&E!3$Q(24=)25-V>D1.83)'
M<C9.2SA33&%Y>7IX,T)%66]$26Q!4U%2,S8W1W566EHX36\Y>E1M>6--;SEY
M9D,F(WA!.WES>%-K164S1VYW3"MZ.6YT,C=:935+2$569S$V.6]B5TMQ>$)W
M94MB<$EZ06IJ4W1+<G9K94QE;5!&=E-)*W R;&$K:$A514=V0F4F(WA!.W%I
M9U!4<TUK>5-Z5UI,2WAL,#9.-U=),C$S8T,Q;$I694MH:V0P0DA"='5A*S)6
M-4HX2DAM5VY,:S142'I.2VPQ9CA!;"LP=7IB6%@F(WA!.V]W4SAF5D)K5E%'
M16Q14T0O<U181U=724Y%<W!:67A.13!R-E9F-E!E;SAM;79'-%AI<VYP:FE2
M469#0TM!.4]M1T=337525$1*1U@F(WA!.TDR.',O3&$O1VHK669Z3C%/.71,
M4EE,5S9E-VUU8D-F-GA03VMC=# Y2C!7-6UG:6Q25C1H3TU49#5":S)A939P
M*UDK9V$S65,V9EHF(WA!.W@S6')&9$YU969O;#1W=#%.1S9Q>E%M6&=6<%)I
M.49R,T]&5UHV16]7>6M546E&5G5B:TMO0V=%0UHY=T9*>4E114%I-E%V;6QR
M16\F(WA!.U9N.45816%';D%K<U%1;SA24W1-=$]P;%A$.7)J1$1%6D]8-FLU
M=G)7,W5,9#!N6&MO0DY244552%EN27=M66UW,S5)0U%O<% U3'8F(WA!.W10
M=CE)5S5T:TM413AB<$=02FMC9G-K.4]M-'E0-6<U9'IT-4Y':W)H,D9(<70X
M.%0S1G9P9'9D44)M83)U;W R4E-25EDV<U%A9%(F(WA!.W1V:UI#,BM9=$QR
M=CAY.4Y%9D=X9V5A8W)7<W!%8V$Q2&,O17AO9CAN-F-R;FMK3U%A<VUA4352
M<W-:,4=85F9-9'E$25AV:&)H;F$F(WA!.S-T,4-C14PX4UEH=5<W9'EC:&I%
M<%AX34U9;$LK3E1B>F1F1%-O3DUG:VIT3$].0D=W53AP1UAC3GE:>3%+,#=F
M<7=%.4PR66U1-5@F(WA!.S953C5D;'12<F5N2W!(3#9Z1C!',695*S=U36Q!
M06-G;D=!1'-(<W5:1&U/>%8R2W5X5C)+=7A6,DMP2#4V2$QY6G)C66%66&US
M8FDF(WA!.TM0-G9%2C5Y.&MB26EW=VQO+U9K6FI2135$:V1Q-'%X5'E8-6=G
M.'$O;&AP1GIQ,7)D>#@W:#=C=U!P;'9P139T3F-Y8U,Q:D4T:&DF(WA!.S(V
M8U<U4V)50F1W<%92<F5D=$@X=U@Q:D)92F,X<DA8;G-:2DAH67=T2F)24'E:
M6F\K8UA&9S1+.&U$2'=W<6EV2C,Q5WHX=V$Y<&XF(WA!.S%S5#-);3ED:'@T
M<V953$]3,VE6-4%6>D,P.4-C;S(T1VMQ335X=7ID+TY:2S$Q<'8U:G),54I9
M-G=G:F1I5C-M=#1H.$\Y1#EK<FDF(WA!.V)J;3AP351C3E(O4FXY-%I6<6M1
M;3 R-VE.0TI)6D5)64)H.%-%8F<W2$UQ675*8S=)3&E2-4U:+TQ7.'9*9$QU
M8D\X:4U.>%E40T(F(WA!.S T8U8K1D98-E1T=C1::F%/4C131#!C4',K8VI!
M:5%O>$Y)+WIJ-6-86#=&8E):4%-U63%E83!L-T-694E8;'-F:%!+:'EE;WAC
M67 F(WA!.W,Q96XX5TYC:GI(=E8O2C)P4V%J-6)S<FU58UIU0FIM5VA&2&I9
M;W<S<C-82F%E9D9!1FYP36AN:D)03FIV;6I6,C!0>GA9,V9P<4DF(WA!.TQU
M,E=+855S<3$T>4YY<GE:4G-P1RM9*V%F0FQ"-W<T;6]Z949N0C931$]L64UO
M64=O27%$.#AZ;EIP1#4S,"LK=G1%.5!4-D<O:6TF(WA!.U-E,4)P+V51,6M(
M54U0,F1S>#E417EJ='IC6%=9-5-H569Q=7@X3C-M<F58=E!K9G!#4S!5>C9N
M5EEO1V5R2C9A.'%M<&%.86AY,W@F(WA!.T=T46,Q,V<U3S=M-F)W9%-/63-L
M.6XV1V1E479,3W9A3SDS3'$Y=W-R>G!%26QJ9FMQ.%,S245C549A8V1X;61P
M<TUO6'A/>C!/;GDF(WA!.UDW37ID,2M/4V(K5W9+,FXK6')55SEN4&4S03E/
M3TYN=F(R-G9+*VM#059795-2238Q,T5A<5!B65IL=7=796-V*U5F;2\T>E<S
M+U4F(WA!.U1(:49D-6)U<E5Z86Y:>'EK>E$S<WI.135024(R-59!66LX86LK
M,E9W;T5H<7@P0U%L4&Y29G%M<#)M=4M'<G W44-C24MK=WE.2GDF(WA!.S=R
M6'!10W9F1$YC;F8S37=6;%I1>6UQ<TMG:G5$:S(Q-3=P96XS2&QV>DA9>G@Q
M8E1D6%)9>7@V2S=G2&EE;31A;%!&9D=M5CA)0C0F(WA!.W5R5'=!2&E(6&UZ
M=38O=C=0+VI-9BM436U43&%73RM99GDK,&Y5:T0R87!9,TLO>4Q33G1T9WE#
M;%!M=C0T:T$X,%-G0TM+1SAL*U8F(WA!.V(W4G16=4I,:3%J4D1#63!U67!7
M6E=Q>6UG4FIY+UHV:UE)-#1J:WAH:6I(:S<O;%<R;%1A:&545&5R1D%Z9S)W
M:61E:DM#,6%O4TLF(WA!.TXP,WE61&UY-%)D,&YU;F564$PK;FQ7=#=.1$MP
M1$-A5#DT-%ID=W=,5C1N+U9P:7E48D9867$W1EA9<3=&6%EQ-T951')7:#94
M<F0F(WA!.V=D4#%A,6IV8D9N:FME,FU(2TYM:6-32GI5-TU/4VI9-TAV:7%R
M<'5L-EIP9&Q(639:85$R3FQ&6#!R5S)J4T=*951&;31O9U925FDF(WA!.U-D
M=75+<&(U;"]V.44O-V%59CA!>5IL>%9,=%=U23E$.#%J5DAJ55<R;S)J474U
M8TM7=4EF:E%56G8R;S$T:6<V.6-X36@T36Y&,$DF(WA!.RLQ=V-K=D1Y.%A3
M47(T:CEI;#5M;D8W;T@V9# T8S5.3759-RM-37!"2U)O;VQ1.4=(=VLQ<#19
M37@T;V-C96AT:G%J>%DO16HO0V4F(WA!.TPY9C)-;V4T:'5D36$T9V-347EW
M;#0S6&]66F%G:DUK:T=.:'IE24=.:G59-$QE2%-04#!::55X5RMU,CAN24QX
M-$YD470V:D5G54DF(WA!.TI2:6$W,5 T559W6F9+42LQ=RM%63@K,TM9*S!-
M;F(O04AR:B]W0TUC;B]%:WI)-G5D,5ET;VPQ2&\S;3-5.41U2$5C3V]0*VM.
M334F(WA!.T5$:UIQ:59&,S=/<&]->'-:-$UH:65U-&-$1$E9.#!S6B]I.55F
M:GHK,4U03E!L*TA83$,W=$=25&-I2DAS-4<O66Q5=58S-T%N62LF(WA!.S)7
M6G-1;4-/<F1Q<T%Y>$UE=E0S<&0U9#@K,C@W4U=7=4$V9'%K1#A*:VQ!5TU%
M.4)Y-D%5-D9U=58T=%5/53EI,#9F6$-8<&XV6FHF(WA!.VUY:#5%:TYR2D=W
M9$=E<75P<4-$1S%#0TUY4V54;EAD2RM36D]X5D-A=DQQ35=L6&MU;5%R8V%I
M:T5J5V-%:&]R>D)363%9:W!S5W F(WA!.RLP4&U/=4MS2#%A."]-,CES2DE,
M:E$W65%M2WAD9TII<B]70DY',#18,%1D;&Q$02]#54%684AM-4I64W%):CAR
M96(T9DU-;7,R67,F(WA!.V).-6EZ4W=#-&UL46QQ8VQB.7A&>41'<F1Q2' T
M-41G1$1W>&1H17A,-7<Q:E1:5&9A5F%E;&9W4D0P<' U8E-3355,<E904W5Z
M>E4F(WA!.W9U1W!1:G9K=7))2T]H>"]M1EEA63EP2$9A>D-Z:SE'3DIJ2GE+
M:%90-W!Z-DEA259O<%!Y-UE!2S5-67@T4E%A,6%W.#(V=EIP;VHF(WA!.V%B
M87='>FIT<FE/+TXS345,2#%)*TE!=%="9%%H3$M(*TAK=GA(1VA7-F5%1555
M6D<S;G4P=4Y0=#=M1S$Q0D%Z:&)G3DMN>&E'47(F(WA!.S8P:6\O055&3UAP
M9&%$<6-6,U)T-W%V;D\Q='I.*VAB2V5H5F94:'8U,V,X,D,Q02MP1%E6<69B
M0WEB=4Y7.#!7=VI.>EDV5D%*<$8F(WA!.VAI36UP>DIZ:V,P5D8U5U%Q>F1G
M359563EE.#%F;W!.5'5T3# K=W1M:%<T;$8U<4TP3%%Q>6AI2G56;%)#=&9I
M<61S5E@R5W(K8V(F(WA!.W5.-44P87AJ5EI':E5Y6#@V.'=P;TI%+S!),5)U
M<6YU35982G%N;DYR,E<Q+U%T:U!3:FIL.6,S.#1I8C%'9&5#3CE3,UI05'%W
M-T(F(WA!.VPX8U921G9Q4&U.9%%T<F4O=T),9VIT-VIM1&,R='I,8V5M555S
M4%56-V%!04Y39U!,<FEQ8UEQ-T9867$W1EA9<3=&56\X>C-0;5,F(WA!.S,P
M*TXO3#%P1F58<&YJ5U-+66=+25-F:EE6:V@Y="M7=W%W5GE/1$MS9FUN.#DS
M:VQQ.3EO.$519S%P:F%+2FE'*W!R131I:VPY25@F(WA!.U-I=DDX;7%V*W%-
M2V\S>F1986QQ96<S54XO<%5.>$1#<'5&:71B<5)R9W1%0W=%24YR=3=#<6=D
M-C!Y<DQI17A284Y2<#0U63A-=50F(WA!.W9,*V=A>F\K;%1A5V)E,G9B5U8S
M3DQI-V1J-F)Q1CE.<5=V>$-G>4],0TE2-&59631.34UC3T,K265F,TI0;T]I
M9FU"83)02%0U<F$F(WA!.TA3-6<S;S9:<4IL95-"2"]!1V5A>&\K,UED37$X
M2$I$84HR.#-':G!S,E!B2$E'2&1,<#A5,#%Y>#AX-B]$2F)X,C!E;3-E;3-+
M3F$F(WA!.UAW=5IA1U%22R]/3696>#9K9$IE0C9F14-/,EA:<UA'3V1%3U9Q
M34AI4F](:$DS0E@V9$XK6457<'@R,F]W5T8R:3)Z15A-5%1W<5<F(WA!.T1)
M=GAU635&-6YR>$-J231X:W8Q57=W1$]*979H27)P9')03E=L86AR359N85AM
M;'A'4C5I3&$Y=')Q45-7>D-.<$,W4#E7*T9'.4PF(WA!.V@P3E=+.39%4WDT
M67I&1FYQ3DY(2TML,#5%8W=H.4]K.#-E6$Q76F16=6)B5V)H-&UA>'1H3WDS
M8V]T,&52-#1L.49M;F-G+U!(1FHF(WA!.VQ(;6)2<'-5-$%I5750-$QF379L
M97IU+SE.=C=+># R-&%244Y1:3%"-V1Z2DEW5E)Y3G1X6FUA9T915%AP:V-M
M;6A09G%W>C9(2&LF(WA!.TYK5DQV1WA3-WEH-4XX>6%D9E%A=D5):&)K3U)9
M,V)S:S0U2U9!:VM&=5-#2S$R1U8T=$IW4W4R<E0V031P.%%L63=Q2#-S>'0Y
M4C@F(WA!.WAZ4S--9C9-9VHK<E-#3&Y*8WEQ<VQ9,&LU>$@V=#A3+W9/3F8U
M9U(R>DQD:6E,4RLQ4G(O=T-Q6&QK<TMM27EP8U%Y4$Y(54U&-$TF(WA!.WI2
M4E5B96](:&EQ65EQ;%AM:GDU6F5:3D1U3D=V<$I9<F$U2T8S9TMH>#9C:7E#
M;DY86'%N9&-66&59+TPY;G(K:%AE:3-K:W-D<F4F(WA!.TE)-5AH64-104U'
M,EIW-'(X4&-9<6A03"]K=E-D13!'-#!/,V5A97EU;6UA8C$R57-F6$9(2#=T
M67@P-S!Q>'%Z17-34W%X;E,O23,F(WA!.VMF>5)R1G!F='%.,G0P9EAA0F)K
M;S9T-C=1=U!5>'=Q44$P<UDK,$%X24QC=4-L5E5!,VQJ.'!5,4YF35 K2TE9
M,6UV:'%%6D8O6FDF(WA!.S-A83)E4S5:5E!(-TLK<WI.4G512&-B-%959D\K
M9V9L4&4K634U3F,X>696.50Q2F]3,75J,F),1T9H-%)'4E1"2T56,&M"-7HO
M85@F(WA!.S1+;4US:$-O,WI6;U U8V5:3%-W=' Y86UU25EB9&10="\P5S!D
M-4M&<D)C:5=35TM'-6Q3:7AX<UA:9V=6=5(V9S169$QP,S579C0F(WA!.TIT
M=DQF*TM);C!R5'!6=GA*1&57<C-$*VI/,#E0,V%T=#9I:V9U:T1B8D=U0E9U
M9S98*U9M:F588C=4-UAZ4D)(6C8P<UIK;&YU8D<F(WA!.TIW06YW.%EV5&IJ
M1E8O6F%-,%=I04)&5E9+<#4U42]+<GDW-58Q>3<Q:E1B:3AK;G4Q:U(T6C5)
M,FE54WE,23-!3$=J9F%8=7@K+V8F(WA!.T%Q0W,O=T%L+TQL='%C97!(54Y2
M;G59-S%D4C544W=S5VQ785-E:DU)4354;DMA1&PX4#=*0EIY>7$W>D(K5%AL
M>EAF349X<G0Y9C8F(WA!.VHY875&9%!217-,44ER>$-%<7-C:U5G2V-11'=A
M<44O84)Q87%S,W-R4T]Z<S1,4TES,&1V1VM333=&;4MO;U5&;4\U3S(U>%97
M>%8F(WA!.S)+=7A6,DMU>%8R2W!4-6<X=#)/=69O-S8S2DQ(*VI,,DQ525!2
M6E8U4W=6-'$O2E<K2#1U,40T15EQ;V5B+THR;65A<D]Z=$Y1;'4F(WA!.TE9
M-TLW:G9O;71816)M4TI844%S5EDX4TI$6&I1*RM+=%<S:WI3;U!,3FXU941Y
M=EI75'=Y47E%;W-N2T-95'!S:4I';S5R.6Q%54$F(WA!.V)+0G125FHS;'9Y
M.35%+TQY-'9B6#E+4V\K;TI#,7@Y9EI"1W%+<S=),T]/2TM.45)&2U-73S%/
M,V163"],,VQ8.'$Y0S%V4TQY>C@F(WA!.WEX=&1M4C,P=3)K=G)1<D\Q>$=L
M<'AJ4E96;BMW1DA!-W1S83E-5E-R5F9,=C5.42MA<BM8579.9F\V<&14=DYE
M23 Y;DA"1DMS+W$F(WA!.W1'-W)!<V-4:&\V04\S<58K269V2U!H5DXO3C-L
M+SA!3&I7.6145SE1,75:5W5,5C1L;G-Z0S%N2$%I>7=02DYC<$))<UDU4T]T
M6C4F(WA!.V5026-2,T=+=3AY5U U5S9N-5DP;4,W.'EX;E-D0T17,79,8EA&
M<F-&,SE!5WA%:2MN3TA+2DU#>4)E3R]W06%L3G-#;W%W,% X=4DF(WA!.TY!
M:CAQ,B]M2THT3&DV:75K:DXS84Y023EW955+06-A2#%E4'=K3'IC,69K6$IB
M0W%:*U10>78P4'EH86%H8F%695AR1%555T]35V$F(WA!.U-->5)H0315>$9)
M-#9%96]A5G)486U"54XU4B]+1'DU-5@Q4S,Q2WEU-S(T=4QA27=*.5IA0G%Q
M63%J<3=2=WAU>#1R,V)F-&$Q0U(F(WA!.VA&54Q.*U-(;&EB5W)R5TIT43%/
M5S=V2E!5;$1Z4DUO2FY%.4%$150X3$-I8C%4<6A69W)"5C9(:7)S5F1I<G-6
M66@K65 X07ER4W4F(WA!.VYF-#,K<2]A8CE'9E<K5E!5-7AC=E1P*S-Y-&4O
M1W8W4$Q&5T=Z9CAQ0CE'-2MT9E=Q96YD9E=F<E@V83E4;R\Q<FPV=G@K<GAR
M>B\F(WA!.T%'*U!$='=W<7$V-2]W07%"+U-E=2]P9FPY92MP5V8V8C4O<% O
M94]K4#%B-U!W.&%E;EAH=C$U9G191E104U K5E!F-&8P+SE%97 F(WA!.RMI
M4%@O=T)%*W$O<$@W6&]28R]6-&9V4%(Y2# O53E8.3,P-3<T5E-7-"\V1B\X
M07%-6'(O6%!Q6'%X.$]8-F(T97)W*T1N,G(V6$@F(WA!.S=F.$%U=FA8-$]'
M2W%'<2\Y0S)C8C<Y2U8Y4#!94')0<B]P6&@V6'=E:C969F@V8U W<G14=&ER
M,F]5;TMD3S%-0W5X5C)+=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R2W5X5C)+
M<T<X-R]W1$MQ+S Y868T;SE(.5 K:W8V3G V+S%Z:"LY-"]69G$O-S-L6&XO
M9&9&>30Y*T=+<UDF(WA!.W-0.$%O6#<Y2V%..5@Y6#8O=T17<E@Y1&5T*VQQ
M+U=+:C!/2'$O1"]!2&QE5F1V535C=FHU67%O83<O,$QJ-F9M2#E,,31F<%4O
M-&<F(WA!.S4O<%@O:F\O=F5V2'0Y=6Y$-$LP<"MZ:7)+9%@O=T-662]5=$LK
M=&979G%V,5-0.4AF52\P;E0V=GE(,68Q4'%U+TPQ2V5H-G9X97 F(WA!.R]D
M+TAI<D=X+W="0R]F;W)3=E8K<R]O-S%R;CE'+U=F,'IX-2]"-CEF5C,T5C0P
M-2]$>7)X*TQL:%96<W8K:&9V<FUM96XO=F(K:TPF(WA!.U Y1V979C!L-G8Q
M>FMF<69(,2]I-&9Y,2]D.&%F<S!W2SED>%8R2W5X5B\O,E$]/3PO>&UP1TEM
M9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HT,68P,C4W,"UD96-D+34Y
M-#,M868V9BTX-SDU,CDR965F,C,\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-#%F,#(U-S M9&5C9"TU
M.30S+6%F-F8M.#<Y-3(Y,F5E9C(S/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z,C!&14(Y-D$M
M0D1#0RTT,$)&+4$W,#,M130V0C!$-#!&0T8W/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC
M94E$/GAM<"YI:60Z,34U-#<T934M,35E9"TX,30R+3EE,C8M9&)E8S4S-3<R
M,&)B/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C$U-30W-&4U+3$U960M.#$T,BTY93(V+61B96,U
M,S4W,C!B8CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C(P1D5".39!+4)$0T,M-#!"1BU!
M-S S+44T-D(P1#0P1D-&-SPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12
M968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HS,S(Y83!D82UC9C8T+3,X-#0M.#,P82TS,#!B
M-&8V9F(S-S,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#,M,C%4,#@Z-3$Z,C0K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#IC9#(R934P-"UA,#ED+61B-&,M.64Y,"TX-&4V-C!F-S%C8C8\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#,M,C%4,#@Z-3$Z-3$K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R(#(U+C0@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO<&]S='-C<FEP="!T;R!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0S,C$U-V$V+3!D-3@M-F4T,BUA
M-&,T+6-D-#EE-V1F96$Q.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,RTP,RTR,50P.#HU-CHQ."LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@,C4N-" H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C0Q9C R-3<P+61E8V0M-3DT,RUA9C9F+3@W.34R
M.3)E968R,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,RTP,RTR,50P.#HU-CHT.2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@,C4N-" H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-
M.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG
M/2)X+61E9F%U;'0B/E!O=V5R4&]I;G0@4')E<V5N=&%T:6]N/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B
M/D9I;&4@3F%M93H@(" @(" @(" @(" @("!G,S5A,S<N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(Q-3$Q.#$F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(#(Q+4UA<F-H+3(P,C,@,#@Z-3$Z,S,F(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,C M36%R8V@M,C R,R R,SHR,3HS,R8C>$$[4V-R
M:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S
M:6]N.B @(" R-2XT+C$F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T
M=V]R:R8C>$$[)B-X03OB@*(@-S,T(&AA:7)L:6YE(')U;&5S(&-H86YG960@
M=&\@,"XR-2XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:28C
M>$$[(" @(" @(" @($%R:6%L350F(WA!.R @(" @(" @("!!<FEA;"U";VQD
M350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @
M(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!G,S5A,S<N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(Q-3$Q.#$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4UA<F-H
M+3(P,C,@,#@Z-38Z,CDF(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C M
M36%R8V@M,C R,R R,SHR-CHR.28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-2XT+C$F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:28C>$$[(" @(" @
M(" @($%R:6%L350F(WA!.R @(" @(" @("!!<FEA;"U";VQD350F(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU9
M2R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y386)R:6YA(%-C:&5C:&5R/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @
M(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA
M=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \
M+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T
M1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ
M=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @
M(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A
M9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA
M;"U";VQD350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E
M;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1FEL94YA;64^87)I86QB9"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4
M/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N
M,# S/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I7U]?+E!&0CL@
M87)I7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y#86QI8G)I/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B V+C(S/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R:2YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E
M871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R
M96%T;W)3=6)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ L@(F P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            '" 8)! 4* P$"_\0 6A   00" @ % @$$"@L,
M!@L !0(#! 8!!P ("1$2$Q05%B$7(C$W"B0V05%Q=WB!MB,Y5E=AEI>UN-?8
M&24S-#A4<W5VLK2W&"8RA;'P-4924V)TDY6AL]3_Q  = 0$  04! 0$
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MWKVEZTGNCVQ>R!L-O"3KZS;6USLJ@;)HE!IT>MW6F46@I:J.X3-\':_A#K?
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M=]PIV,^&E4F*5T*ZK!X.VR6\P\S48"VUO9Q2&>'/':C?ER;W3QT,?:B!2SP
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MHW8V1L%Z)BP,3)-M?UV*!=<\%VIL+V*0/E&&HV'RLD,AD[_7MM]&Q'[]]\^
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M%P!3,X<PFM,!@T62Z*QA^T/&+.HG8S;!.Y)]^6OXR,<8RG/:S_C%'_Z&Q?\
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M8^JU^F *U>K:]8&KI+"/O,W36S$.Q,Y"G<M5P_JDS)M3E=L^$;%,-P&5#P[
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MA3]C;-;:W)V([S]NK?9!+59V!(R)G@ !)P@)/;'MFPC5T.#HF%V0F,6"T.S
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MZ:1J4U9Q<\1J\N>N\BJ ZMMFZCZA V(-J9.,#6:&47;$L-7B%A@^\U#M$]J
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MG&_>0MC,UE;ODTM.$>K*<JSZ<*P/#ND3\0256J-R5HHD$MJ2.7I(1UHV53R
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M]Q^:9E[,GD9ONHFI=:FR)^Y=HSL2V%MR6)MW.2XSK,B0AQO:_P#0C6_=4_\
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MSB500&!5@"I!!! (((V((/8@CL0>Q&4LJO&Z.JNCCE=' 9&5E8,K*00RL.S
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M-G1<<8R(_@U6-MUO"*04Q9B%>DE4VM.0/T!,6&ZQ$ER/CY.X,(+*>FPQSDE
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M#QJ2TTQ(B+ @0+V9CW\A<8\<"AZ>:U?7M+FAT_0M+2*IZC8Z]S5JKT;EZ-Q
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M]7]?GC=].CL"&(Q=&:&*032231R>KRUUE:.S81^G'.I3G]5@M!TFU;6Z+V#
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M8BLNROE#G6([Q-G*<M*%,KG)<CJ&K3*O3#!*3U8HW9D:/G91S!&[L@?]I02
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M4HBN3'T'P-5@V +F*PRXT\Y)40>8:0AI?J7A]3>6WD+4RY*D@[C;<GS.P[@
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MY"L^DGJ7H) /;7U3UVI&4YW=2W)D"T'M9=-.2XP0!8=O:4G#9$N :KX4N[+
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MN0(]8LU1J,C:T.Z,UL+,BF+)6"()NJF%L2CI4*R=OCN-M^WR)V^?8_GMEV]
M;-*[;ULW:CXH>'L(F^;@UC9(@>3)E!7[+I3;]ZTU8BX1R:VW.:!GS5"G'0T2
M?AR? &$8D&=(DRH[TAUD'L?N^1[C*A[)[7;3J6U[)H*SZ[UX^;O<FIB]6K)M
M7G%1?K]YW,*U3(EV2=80009MO >CV0'L&^!]8/)'4FP'@6FK8<B3+36[X69.
MPVW[^>X^C?Z/=Y[^('EG5Z^[QWJUG8;3NO::*J-$VU1.N>W6XA@P^;5M6W[B
MV%H9XMK9*H<: YKZO72GULBQ@VQDJ?K%M*O(=!3*.ABWL$;;?$;_ $;;_7Y?
M1\1EYMQV"_5>BD3FNAH0@9'NMRB#IP3=;0@778C;\PV3%4;78HI=-@V!N-&Q
M$"4JO9'$#4^8TEDBVICXLME.:SS/B,6:NU^N;WM^E855UDOK ,V6\=F KF7D
MV#91+2]SW7:-%T_;D((S1Q2A4RECZFY/L#*8DZX#20(C'%VA5:"DV5<N_@1X
M['P]X&^V^Y\?+Z_';8!HG9MWNT_;U+V4+JL&\Z:V &I9B?1WB[E5L$>QZLUW
MM,<2&1CN%E1KD!F_N5B9$F2I:YK]>S8F\CXQZ.%&,@^7Q&_VD?NRK.]/$0KF
MJ]T7[4]8#5:YJUEH#=^Q[,[(O$$,6F;;UH(UE9J_J$2*1'(3DLRJG?VC]UMK
MT%Z#7XTH?'$1SQ )>8-99(';??;N/J.XW/TC_+MOB)3NKLK7AG<.N,ZZU?F=
MU'''+1N^2!?/!:[9*(.KFDK^+B:@!91(D!;',H>Y)LN8S8IA8; M=):KK*9H
M^[L62KL;#Q\-]MOIW\?#W?;\-CL8VELVG:;U]:MG7\JV'J5/%K)E9:O0I]Y2
MG6H8X4-CK<;S/.'2LF"$ "F5?*+FR \7#2Y*ELMJ92.^:U O?*\7$'H_8!#5
M=/#4Q^Z;H';=V/''6_;M$TX4HO8.3U\K8P9L"B#G L,O8JZ]8"9VVS'8PL8&
MF1S;\!JB$#)86R=O+S[?:-_S[\LOUE[-6W=9V'%M-7K@(-L#3-1[":L=K\\G
M,)1*#<;-90<2MWMH@TB.FVCQ@^K')!$0I@;)F60W7&AC.*:@]:&"-ON/S_.^
MWRRZ7&1CC&.,9BEWI%6V/5BU+N@E!JN&FXR9T%4F; ?0_ FQB8PB.*"Y,(L&
M-!BT*"8!'0\Z 9!&8$ N'GPB4*+*98SYT.A536=7@4VE"U"*^/DF)[<=X@4,
M3I96Q&B%DL9PR;.321P_8+)8RY6P6*PG"1$V>.DR!<O/F$9LF2ZQF7\8RL4/
MIOUS'#"8H;09@QD@_678<T9?=D#CU0CTJ<=(T\/K*S0K>Q8]35FK2;19\5ZJ
M:Q*U&LAHMEL, >)CP#9.-*9.Y_.WV^_YG)^JM6KM'K%=I=0#P:]5*D#%5JM
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MKZ[WH-<^W%)F=3Y]*(*VYJ.AZ"UAN&WZN["[(17+2FU3@6QB&N];ESD!FI@
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G[C658SEMSVW%H]:/)7H6M/GZ59QEC/IQC'&,<8QQC'&,<8QQC/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g400206g36a58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g36a58.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ PP(] P$1  (1 0,1 ?_$ !\  0 !! (# 0             '!08("0$$
M @H+ __$ %\0  (" @(!  4#"PT*"@@'  0% P8"!P !" D1$Q05$A97%R$T
M-W1WE)>SMM08&1HQ.$%3>).WT=76(B-16&%Q@9&AL20E,D=6=H>UP<8*)S-&
M@Y+2\$-25&B$PL3_Q  = 0$  04! 0$             !0$" P0&" <)_\0
M6!$  @("  0" @P)"04%!@8# @,!!  %!A$2$Q0A,4$'%187(C9159&5M-,C
M5F%Q=7:4H;4()#*!D['1U/ E-3=%P4)&4K/A,W2%P]+Q)D-E<H/$5&)S_]H
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M7UAU\!U%$]QMA4PJ8B8ZP\^6=!P@VA%2]6V,A->UN^%)<I@&0-IUMA8._)]
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MK[!>UTW*=7AGJ/8!L&5T(19OGMXHQTRP;JN5$DA(PP5\^T$%+LH-P2^&+JK
MO(M<U"WLK3MKMOL:RNR&*;8JFWLO, MB]?QJ"*N18+3KMAH68<.-6J8P4;NM
M,#6QF E]692%Y:S>)5/)4W+%<*^O[=-*A!M-E8.'!!299#X2BX&V@BEAA-KO
M@"ADJC(@<5E?#C*X-BG6L,L7Y9<>TC7<78/B*3:V%2B6OJ'J9@86!Q5[)FPN
MFTN9*D]HO$.W'EMJ_JG0-,V0J7>7M2U4KL=2OH6EC9ZWM;4&/C]8-H"ER.!V
M#)QJ1EN+*MO[)-FL>/ U/;[KLH%3AU?W>(JX"MVPV]JDP^'+&P8FQ4+9C#Z&
MQ]N$T)&%R *V :WOI1$,4HF0GR-DY9VN';!2Q-'4UKH!Q#7HK<BV.M*47]=[
M4.O"4L@C9KSV79:XI!K17+8DA5&0IO"J^+ZCPU.DJ.M]<G[-SKV.=@LB Q[6
M[/5=QQ;W99/V5636FL]W6P:L,U=D,LJB\YF)41J<0O;GXB[%6'>_2FKL;UG$
M@Q8NW0HP[DE#A4Y%C6SJ0[(/:AWADWQO]1V#!96"LB:@DJ9A(QFS1HU\.%->
MG3.[*([SE&Y+Z^RC:GW30NPCQ+J)T9$$";!KQ7(&' W%GUZ:.?2<^=8XQCC&
M>RA>GJCRUTG3?$/7=B>B6YY5O1L5IEG<&=J?TLI76=;@U+9^6KJXP 75_5]S
MU&]8=-]JGQYM";?4EKGO H'%66,9\5JJ9P_L[/$5Q*BK*?QJ\(K!73:$WWBL
M48ON$C=>K;!0=N@'X.*U@U\Q/N#(_9++5;_65>'JCFC98C@JN?B66'59!%(*
MU^:"# $T;.O<?<V!Q)S8KK9,$/;."J/C]YB4*OWS;%F>8['IE1:>:OC.BU(F
MKS"ZU3*J>/NHM<[+UM0K+<$:-? 1>]3U!,OH>6S];],$D%JC9D=9G8$Y8X$X
M]OPW;;4H(5-*S87PQO&[!KPJV/$;C87:-VVBLUAE%386&';\!=@&RB5QR&1B
M9')J>(Z:;6P>R+E:NSB72*UZD'9KS7U&NI7J51]E2@B;5"NH*GCJ76N'PR8Z
MNKE!80^)7S/K_7DW2-XQIY46P?(_Q"[;"Q5UU%2KM1JGY,SM]JL$0XRS&/*E
MB4Z<QK)'AC!U'72(_8Q_M8==3Q#XEWM):U<LAU/2\1=LI>J;5:W8T<+H TB9
MS\25F!7SGGS=$\Y]><UP_-9/MU5VG:E5O=</=P84R*MFK7W1,OFJ("(\,-<B
M9/D/))1RCU9.*]%XI7%9W8:_JGQ[I&ZX=?[OKU 076I7X+1'3*N>0]1&H+78
M !&;G JVL_'TFZY51U822!G[.$0MQ),^A49\BC;OZQ]EVPW%K5S;U;K;JUBH
M6VZ'Z>S-M=,Q[4C67N!J>(4D8)*Y(51"I;&20+T-@.\FCJ*VRBILTU%6D6QU
M76G<5HJ'<$I9U6#T\VNPUTS#F0)-F6PN<O/5&'CB&SUK831=-$;'U[JOQ;BB
M.V<IV\QUQ6E:#?F\76_Q==#YA$.@+XNK4VJF%'6Y#Q/($)9LR07%U.S[[UMA
M.Z(+R1G912N7][,A19K@NO8W4:I6H*Y,'"CJ&^-@%L^<JEHA#2E4+C-FA[3
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M^3)_P_V7ZV[3^'Z?-\_/@V>B<<8QQC'&,<8QQC'&,<8QQC'&,<8RD-J\@?\
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M$(&)F,HG-G-7'&,WT>@S^U3Y*??Z$_FRI//''\HGX\T/U8UWV[:Y[G_DR?\
M#_9?K;M/X?I\VO;KV]9=866E#)D(EC >H;208K(*G5R3MAKEJ6JH?4[A!;?#
M1(.KVT,._P"*#\R(Q8\8\8_9Y9=^6N(M]<TUS7!7JA<7:JW2-!&22.P&PT=*
MKRL"I_96/MFYC?YNV2$(Z8CIF<^Q[W=6M3:HBBN%I=BO;(TD9)DG#=T]2O\
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MXR@1G;/B>U7NMK3KYLJ#9C58[Q';:I+]M1U*)0@*9C8D6W@:0L>F>R#)[I%
MQ,1(/,JWL)6%K+KR66N2P"F+T*RS1EJD,1M6UX7+!<+AG31RUDE8;6UA+?\
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M)55K;J5<Q0IK 1F0.EM@O=BUZTL;(%7%K6O;/V51\@*ZS/8>[@5"WLTR:1U
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MQK^<R[N+*CP1-DKI'0\3[;>TY.F\WK]N#WP\0QK9CO\ +Q4[KE;BM,<XB93
MQ5(E3'%3X0EY6R.EXCVS]JR;-QG7[:%N8WG@)CO<O$>VW\YBORYQ$DJ!\-)+
MRHR^/GCNJC0Z\E13#='KK#\V4N5KNF>4"I:;1F3B!5/V[S]P"4%UJE2C"]$0
MQB8B81!Q^Q*98$92X6X41%;5%6(.ZJW-.O-[8S((2W6.>*#FS/:7793UI N#
M$5PN! >DW060N'.&TQ7UI5R&&KLS51-R],BI3->UPI+OSVUH.I1D0@A$(#I
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M0<M:I9+!!9!?4N_O+$K$$F75!DXR+8P :SJ?7%Y+#1^0"L\+)">KZ*.GB2[
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M1=5;J5*4QV?AG%3K2Q!L!;6#30\V%#*\PB&&DVFN6E6AJ F5S+E@T)&QTLE
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M:\IM 2["4U4*&\B1LRA"U$\E! Q@#1:"!@%(6$&NM(0BW87/346H*STRJP)
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M-4,.%$<0)DN"F (AB9@2D>4E$3,1,S'/*7S)EF.,8XQDFZ&_='^,W\8W1O\
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MQM9'L<K6ZU![& 6*JRM8:ZZ3N]-73:77"VZX@7)I"QKC;&N5/A8ABF"U3)D
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M6W;*3<ZHOGKZHFT.BL\%:E-3;6Q'9_S6A6MU%2XQ@S'2CL;X&3M378@4OZI
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M%)W<*M%=]H[@A,1SK+36?),Y]12OI6!D:H.JE>46I0\)IYVAN P]ZDU]--E
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MY=4FLH&W7Y@X%&7<YK@Q$I&6C?L,O[FG_)9\Z#)O/EU;C^W=O+[]6U_S]?\
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M+&+$#)OG.F_:D]55M)'B86DZZF:VF'9K]%FS/16E 5EI<-H[-AC$\XA2F$P
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M9(B*>9$4SYS,S,S,SYS/G.=;E<ICC&.,8XQCC&.,8XQF6-38^6V/>MUM5%N
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MU*" !D^TA%0^398Z(9#R/M64B,%MZ=2M7IE77 $PV@+(<3/&50JZ]B;LB1%
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MB,Y+'=LZ*84EJ@5H2U$WJVZ&I,#FTV:HO[!6(:X4_P#)G2@T;-(X>9P_/'/
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M&G!F0CU!4470$",,)I#$"8@N$N2F1N.,8XQCC&.,8XQDQ:>W(YTTP>M48/;
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M'H6'64ETK'SZ0'GR 8F>D8B.>4GY&???JZPR[[^3WGZOD]^OY'77RN\_VO\
MD]8_7[R_:]7U_7ZN9.<?+^3^OY,QYQUCEEUEWUCEWUCUUWEWUUWWUCUWWUCU
MWEWU];KKO+OKKKU_M]]]==?7[X_Z^C&>7<4G7RO7'GU\GO+K+UX9=?)[P[ZZ
MSZR^M];O#O+KK+U^KY/??77?J]?7'./EC_[^CZ<<I^2?_MZ?HR2M#?NC_&;^
M,;HW^=&J<YCC3XI\0_HB_P#9F9T?!OQMX?\ TKK_ +6K/J$X?86/W+C^1ZYX
MNSV;GHH6K[8.U/OL[0_/M_S]'N#_ (G\(_JOP_\ PJIGY>\?_'KC3];N)?XQ
M;RD<Z+.1QQC'&,<8QQC)R#W68.II0,RC(DS6TT#JDGFNW;7("TCF5'V)4D+0
MXF(2MCKZQ+E#5D^*\#MLQD+FSE$'"!#YEG#:S?LF#8Z%[@3K;)2JU9$-HFN_
MU+@DJ"66S;=&"O6):[L*@!Z6$QC.K5Q0P*^K45:6,T9!:U;6V[5CM; &:V!8
M0O<8KI F@4C0K0E4V'2922@4I5X&>5-P+7FJI$2HE;,"> .&U;VQS'-"W":+
MVGSGR8/I9+KE[JTZC2Y63,S*M_"D72;(:-9C'+'KX'UZVJ>-IX.%BFFQ%>A7
M(2KM2Y'@H35&-;'6GG9BG"XN=^S-B#ETR,FWV0=DQ+:\U*YH)3D@JQ9V-H2"
MRIZ;/CY=;(MI,KL3%6;LLFC**GAI 40)17M?:+;;=C%LKH(<4X97\+RFP*/8
M&G1_%FS:*1DR9D$F&9+\6WP-/AGGU&KK"E"CAQRA5X2RSFBTB-#4.G681J-W
M>@9!2EJGL(1(I2D16N&RCQ-B8B9?=?:LE,$Z1'G^(=_8XCNKO6E MRZ_AY*&
M.<UH^)LV!)[GF;&2F+/A*T3,0BA6J51B11!3&/)K(''&,<8QQC'&,WQ^@P[_
M /59Y,_Y-^A==?BNHW?^_OOGCC^43\>:'ZL:[[=M<]S_ ,F3_A_LOUMVG\/T
M^;[>?!L]$XXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQFB+R+U?Z
M3<#S/WSMGQO@V 52"->6F#4\3/95:[U3([[\4\%%6PAU_:]]25LMP'Y&*5/<
M59=^/-<%(^,OKRQWB,K"ZIEF9?$CRB)Y>GS^7ES^7E\GKB>?JY9>ESF]+57+
M9OI'7\KSL&GJ0JM6-,V:O]>'U9=60;)OI0+ZJB]G::]. #;XU'U:6NU*'<]:
M_-5\9F"+K$C60BM!/:V4^#Y>J?/GZ9CU_P!?GY<N7H\^<SE)J(OI7K1?M),]
MKQ;5KE8K^T?$^V;."UTV\3Z^B(0N="WNO>1%!ZK&<]GL%JIE6W:55+'<+(PV
M),Q<UAS-UJ.B)[%0ES4]_?\ DQ\'E/+E/E/IY^J?*?D\X_N\_3YWC<ZMYFU"
M]^7%IJVL/)>[[9L^R%'>B-ITSR%U*NTPF\>7+32BKNJ5/3NWKY9M?)MD418'
ML5\Y^=7C3.39"5]GG4;0%97E-)VQ'+R\X]$\^<3Z?/EZ//EZ(]/Y>64VAS^E
MEF4:_LFW<[F#,SO_ (_H]D4+42KQ")L=>IXWA%KFP[7ME;-O9LU<+7N_.EQ?
M:)L$4NT'/56MZSB;J!4$L. N4C'P?1$^J?.>?G/5Y>B/_#RGT1Y\^?R9']?2
M^F)I5%5Q54.+,M+KV:K Z\<S:";KXG,OCA;W\ESPM#1W/9&5R7>0BNIU"M+W
M-RZHQ$=D-EM"\FHX?.*ML?!Y^?HY^GS]'/\ )^29Y\HCT1R]<3=0BKTO-F;)
M(<+M=M?TJ)NH7CL'%;\.&.SF-*>[@\@5C.Q;*@7*+!1@-F5+3@VC7\8FNP(*
M20X/%]M7V["*\5:-CX/Y/1Z//ESY1Z/7Z>?I_=Z<G/Q*LOI'76_%\?E!06-1
MT[)XSUN:SR%6#0;JN]>2,-3\<BF75"&UT(-L=&M.L3SR+66)3;W%^KF)=.1L
MJO9%:AHI6F,3T\O*><\_DF)Y<Y]/J]'*?+-G1OV&7]S3_DL^,MSY=6X_MW;R
M^_5M?\_7_/;7"WQ:T'Z'UWV16>*N*?C3Q%^F=G]L;D>\GLA,R-TDYIR&F[H,
MM-DU_&8;2S$=9H%PI9CQE;W;I-8EX[A+; Z-9)J?E1^Y^GH& UBJLSJ[]T?$
MR65$N<,DT-M%V6V=8*$W)$;0M?;KV14NNI34G*FURM)BSXKEVBDDO%57Q4C$
M--8-E]:RLJOLB>ZI!E6)2*MBJ33L-:MP0Q5@:CYK35Y]X8%R);:\+!3*1:Q6
M:+C<7BBS9>_C :L0E=%UMA<08J'U8TSO6F;[>S*W:CH!H^BZ3[C:L5=BU2HK
M5H85NN, 1E2P:78D<53[RPYI>MWZPZ)9?:/0\*QS;[+%785J@K;"V);6U)U^
MXF^Q]<'N Y8R8IS-CEG2,V&A,H(0H**"0=@8J=Y;:?>VIV*%0HU=60?VW4%I
M>:4&, $3<B$>4?:^8>-%&IR"HWBS4O*[5%]98W1@:'"\H'>QN[-D'5K$\DDU
M&ZFL6I:M7)PF!>">^EPGMJTT6 ZS?J[8Q:O-NV&[M66V:J+,5;"DRH"=-1RJ
M78ZWI5$;%<)V+WP0#+:@2"WK85Y3*XK5J5#TM:NFO9=7\37:^&$*O%);<[\@
MAS9G7ME^O0F0,H5;F#-+ &BY=@V-ZFV=B>/K75UO6UIAK0NR&Z_J*=D(EUB0
MG?63=R^70G=BV54W\E!4QH:8:!7=I#8A=MJ[F0:?89NZ>+\]\"B+M?3W 7ZQ
MO"Z* N66 3;PL2G5G&W[%*PF+;);9 W:\NKMNZ0!(^(GPLC%M^WJ64K (.E+
MBJ5EF*Z)+:[9A.J[UVNV:BX36-:KP]'<1,F3B\/'BN9:[>=CG(XXQCC&.,8X
MQCC&90>,5FT75VFPB-S8G]$N=<7BKTPON@)]A(U#)_1;>'FWF6LK$EF7VR)O
M\VEM-;PA-QE<[5JTFDKK !19E,%O$;5X4XUDATJNU7V1\8VFU@)MUB[<&M+8
M.O*N^=E<DN60"UQ#@-B&3>D?JT'<+9=?-E*TBL7A%W%+-M6P,LD#<J1L0SLA
M69 L$"89S*3%;US"M::49LO&A^ULFIO=-23J#MP8%5<@E?;%>5SI.*I22M6:
MGH)=G(G&.L^;2JY5FYD5JHUMRX/O]Y8.P*L-'&O: &[4M.PZM@+!UTB\1.NS
MPMJ6,$SV%L41!"B%V._5%UAZE!4J H[!2 ,UAGI6FVA T"4>Q@D3(6%^)J]*
MY *%0GE(D_N([%F4H2UAW+9M% S4+M;P]CM YS2?69=*SM-4FNM:DU:2VL#O
MN!-XU0!LE5B'U77H6:ZLLZUMHB\F!!:]POA$EU-!I.(FS 4Q$86OXCFN0KB\
M-J$6(JO]L!6E74S=R0,3-]T@;P?KHJ"1W/"1%42M=5$VQ)#?X>APDR:15I>@
MK*9H$QS(A>E@36X=>F#!#$; K1"%3QDS9(:O3=!4X ;Y=U=[;4A%</K+HT2C
MU9=<K'3*[E5*K8[D()+TS9IT>=>J>0_486:Q4T,^;BKIR\6M'>.!F+'IF;UV
MI4]5=L/%ZQ*U8.LFR[Q%A%8BCH6UO>L=7,H8Q8]YG;4Q:N8R'0'*;1J&V%$D
MDL(:R LNK)\.AUD1GK8I79K],0,@MA=E?<:#&\B@^LH3Y)Y&XXQCC&.,8XQC
MC&9%^..PDFM']NL+>\6FID24MPK1JD81Y]?M[AK'\.A5[ $ :K_B517#E$NR
M$)8K-=8V  *5I! K,-(PAMU3;=572NK7L#%E9M8T@!U=:YZY94(UGT6#D15#
MA(#0!FU<D8B,S&GN+I.L.99?7F:S5J!0F:;#&1T0NV(L#KK@)$TE$+ <0"I@
MP!%.9$P^6=4"!I,C3,ZY'@:5=ZBNJJ82YB5MS1QZ;KRI4*F*UC?8C8>ON(Y:
M\_FV2VK$5>J+M1.O.3(.[L,,[%AYX?L&=J%]%8#V:ME69!52<NV5F[8MV6&N
MDN7+Y.3%);Y=84R#!CHJD2REAWZ!"M+).P8:UNOLKF+,);5BM3KU*P RVR%,
MB4MFZQ/9KM7(&I,6A!HXB;TL--MFU[C9:"18"ZN[,"8B$6>,>%Q*>2I S?92
M#B]]C" ]/^V>*<.#K"(-/T +'%#A#U%AT.J39KT*R+<)%ZA,"%$E*X"&'V8Z
MB^$1]GM]TY\S9UE,SSYS [1U:Q?LNJ$XD-(3$GP,-DI6'=F8'X(CWNOMB/*!
M7T#$1$<HR,UEYGL:6LUVBM*)[?D-/74Q.S4MK;/W">#3MC[(V*OD3R&!,<D1
M:]K9J(0LR@QSAZGUTN$81F)2LEL,->X:7:9=<AJJCK)V6 Q=>.8'9I4J1PV!
M,.\)KKVA9!<IY73()%HP93%'B0ZRZ:GI9;56"LLULL3,&%:[>N!VY(#E1 =B
MJ0<N<05(!."471'[6SR\4VF@5^DQH+S63T>O:53N[I5KIBKL!0],J%>K?S0D
M[R )ZQU^_8*3;"X7Q$0RS-)J]-F%/C5_8NJ5^'F5[;K,NJO!MRU9\-8K2Q4%
M9LN?XF/AC_/% P4K.8*("'1!1W^:Z/X@6^HFM"K*354K5ILHL]MQ#7KI1X:?
M@E'A&FLW,")&9829D9\/R;:.I/).MZR%L(9-$+>0,=K5_8X6 #)95>B8D-C3
M.5R]M"C30KH<J_"K-SK(BQ;%7U[*P,L^TOP^&(&78V&E=>))#:%4AKW4BDP9
M8Z9<EBC-<M;)SWI8,/(SEQ@D([O7,E&O0W*:0M$JI-Z[Z;HP!A7@NRY;0!D*
M5 1"H NP !"0-QSVNB(":M=/*U=>:8[H]DJSFP@?-.&MU5LT>Q"O5I2Q!1E@
M;IHP4"!ENIW]EJ<^P;F$^+?B-7/:%5!C!BCQ>$8ZV@.K95:186D_$2YZUJDE
M&#'6F&H 81"J%)L#4K&H4DM?=.>KNRJ,MG?#:K,K/0QP>'A"&&V!<$@JJ$,8
M:Q FRU]>;=@72X6,[(1T]KNSCSH;]T?XS?QC=&_SHU3E.-/BGQ#^B+_V9F4X
M-^-O#_Z5U_VM6?4)P^PL?N7'\CUSQ=GLW/10M7VP=J??9VA^?;_GZ/<'_$_A
M']5^'_X54S\O>/O/CGC3];N)?W;BW&4CG19R..,8XQCC&.,9DNWETS8]>:Q6
MISRE)5(.>LME]DU=*HMS9(UBU6*=VF<1NCH+HS^<A5P^9"P[-9VN0CS=.(4X
MP,S-QQJ!XBI[;=.L*!X;-=5.FZ+MFQ0KV4SNS5XBN591:Y/@UZ_VS<J'=ZT8
M^'*P;137[FP7#%W3:%%9S*YZIUQ^\ZZ-:ML;-6P'#ZV^%LC:<.S?-X]E[5(;
M*.S4 O%!66DGV9;+V3XWSLG1&2%&14RZU6\9E851%K+XEI]3U-7L40"SJOVG
MU0U>QA=6 BP";'J)[%GG8)VY5WRF5RM(%>GXP%%8(M60OKN7.E[;YW:H(]MK
M-OQ373;H_"NTV>$&HS4;!2414&NO6P+Q1T3-YP2=BT<TZAZ]E*CU(7K54;;'
M^TM:E%1*(I[#X.ONJ\8=Q>[UKGOFX=EFSDT%8QUW:YJSEY7Y*T=66LP:%B,]
M;5"M9U5&>=+>;DQ3>P5R(*UG[4&FGUA;+-VI@]GB'&O^5-V!W-)UW#=>]7K6
MXNKN(%EI)U47[D7K*E#K->FQU/&U<CI;L%77"/?+G+";R&&P,<7Q39U]FW3F
MBVC8)=1R[=G742U]5S2VNR=5Z4%4HSU)UC:""+PP=,*%/,I3U3"_.BSF,<8Q
MQC'&,<8S?)Z#'KKZEODUZOVN]^A?S74;K_P]?/&_\H>>?'%#GZ8X8UO/]MVD
M_P#7/<_\F2>? &S_ "<7;3^'Z>?^N;[.?!\]$XXQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&8T^9FU;CHOQ(\F-T:\% -OFJ=%;2V
M%30V@4C):59JC3'#U) >OA)#E-$E8 CX$"QEC9SQ991]3Q=Y?+Z96(YS$?+,
M1FF'R!]*%YN:KLFY' FCT:.G:;G\M";Y0FJ6.Z[!J-1USI'P$EU3;1W=#MC6
MLV6&N[B\MV-TV0,L[,Z,TZN<0"=K7U1(D*9=TQ,1RGSF(_-SF2CEZ.?HB.7Y
M?EB<O!OZ27>JN_;*UW9=D:5IBU?Y#:OI#[>H%;1W727C+I2Z*]USP/-I/Q-H
MA'5G<AEJU?6M76VE[F7T)-2[9?TMU1&7&C'CAC.?^&('G^6>7.(]<SY>7+Y/
M3/ESYQ'+RGSS-?P\\HKCO#=6X*?=]YZ:--H9S))6-%UBC3UW85DH"M'K(^L>
M46![/8[]MWKO;,EH9O:U '7#JI"DLM6KH-O96*IV1E8&6S'E$\I\_7ZN?GY?
MU>7]?/TQ,9LD-^PR_N:?\EGQE,^75N/[=V\OOU;7_/U_SVUPM\6M!^A]=]D5
MGBKBGXT\1?IG9_;&Y'O)[(3)J\>]>)-I[634VPSGQ*R$&P'TD"KHS)FW,I>O
M+5=%=<7X+D]@92&V=I7PZ\/$M2LV4LK/&->',;E!CW&;BXVA0992(2P74U1+
M.GH6-FY7K,<<FU(0"%N)Q2;0"("9,H""R2U-1=Z^JLZ3A9*MMF%]76PJU.Q9
M6D(!;CDGL2*8@%&?-GP!DN49DGN3Q&BH^M^G]6%DL%FQLCJ)U I+N+099F+L
M#8M0'H==A)H2T-I8E"*EBW&SJ'+@*_JE#+(YA4UBU2P(FA=;Q#-J[V7EV4=A
M4KE@UEDR#ITK,VW2-HR6EC;15J[%**HQ@=(6&&P!B7V&@\+3AR1[KN\V&PL[
M#!7(V[E>*B8*JL3<I58;#UL:-L%GUG66"S*9-2^(&L'3*IL8:[L:.KVDK6J&
M=*6P<5_8%/K]C;DJ=C[VN:2Q:^$Z!H-!SA#Q"9+\3:*?.XBR.N,,B1PJZT6\
M17E!8"74I?7&\Z&B"W5++DK%E+4U6IN%U7+<2<DL^BV KF!K3W5,G>7P_28:
M#A5R$.*DDED9IMUU.,@N[6RIU0>FI4F @37!52)D2=F.VU>8S^16EJEJVJ:]
M:( ;. 8];OU/O]@81&+[_75=$U+9U6RZJ/@G69!H+ XO5D"!]B2V6YKEBP(=
M@6V5OS2YO3;.Q?L7%N-!"E:6="@D3J.9;V*&4;!=UD$Y*ZB".)%;(-C"(!6:
M@&%V^M1114-0O$FL<'6TX(+25U=>]=VO$+#I2YEIXAR)@="P"#)@-(L3>=!D
M%CC&.,8XQCC&.,9/.A=7C[58;$52UBZV(JOZEV+<U$]/RRRA3.JG5F;U418A
M(Z\[F8*6!P$*?$.$M#+(6?!G&RDRCZ *BMK>F@%-D/JI%VPIUF19\I:NP\$F
M*2ERH!@"<LZI%L=(3$KCGUC*:JC%\[:Y19<2J%RRN:_H4RO78Y9.&$MDUF00
MOI@E3)'$P<S'04B[7T0O0=:E?T>B;&85BTIE&=AKQ(]D#V00>)+05%@/R6-J
M#",@0V:V7<.LZZM"T*WUIVX(Q5#SL'BXY/EI:_:F[VP3:MTP?7:R%.&4E2$"
MBVQ(=Q=N2<Y->J3[B#*L]2X[A""C%F;E_5@KVO=5JW#184N6I*'#=(AFH#C[
M;*D"I+WV@13L+&RAK)Z!DF@:LR9 \)M;=[ O5+L2_9581K?(R_:TPNS-H& )
MKZJ5_8^G*_1 [1&RJD(9KS8=6V2S*5MRITX3(GYMNDB^16O?@LH,^)[W@ZMI
M)TG-9I:EZ:H+(RN6'4MBZV2)"Q) JG8I+ UQ#"7'?4T^X:2"9#AJIXNU6<%U
M"@W-JC%DS$!J(5<URJHV.Y7@#;<1=,ELF5"9=EJPE8. \%]\4)3K^RUH%:AL
M-,,>45%9;#0+85(98Z(\8%-19$;.4A4D.P^(K5ZVVKAV*L4X9/95P\^1?L\3
M2>JU-MEQ#C-J;(JM-0FW7&!1;4 K*&KB&-'X!F=<Y!A 3$&0],3TCS.UJ+J.
M2(*=6)M53G5+!23JC3)@RIDRM11UK!=@(-8G"GA!=7+J*$.2F1F.,8XQCC&.
M,8XQCC&9::0U!7[;K2TWRZZ[V0WKBN]46KJ[=0^F+,DUTRN5$PL5.'KXB,X7
M/.'7;2U,)6Y; ;N*VM=:)X,X9''0+[G]IL75[J*E6Y26]E6T\Z]OI 14%:U*
M;).)HEYW KA"Q">===YL]4*ZDSVLURK%)]NS3NL2%JJ@+%3K,C:=FI#JPJ%1
MC,Q398/N$8\K!TEQ,2SH=/D'B_J4RR6NO&"/4+Q=TDM"-%+/:AO:KG%,%L]8
MUNW7-*_+=5MZL Z/83&UI(J^SL0:L%$TUZ'9XNLEK^)G>; 45W"2FI.6H:WE
M7F8-=DD/N+-;HJG523:85VRY:2,VA<)$_#3*#I:!N>DA<EP0MZU3+XYBRL#J
M]-@&J;(6G0NX=A4*8X5@HZ8OY2#=<;Q077G;A ?F+(<C:,%!D@)4)P69:TN8
M(C,,T?+,<P7*:#/(<J#/.$B+O"6+++#/'OOLE,%REN#J@&K!@P0R)=)C!#U#
M/*1+E,<QGSB><3YQG(-626L4<C)*8:RD2@AD@*1F1*.<$/.)Y%$\ICE,>4Y2
M^9,LQQC'&,DW0W[H_P 9OXQNC?YT:ISF.-/BGQ#^B+_V9F='P;\;>'_TKK_M
M:L^H3A]A8_<N/Y'KGB[/9N>BA:OM@[4^^SM#\^W_ #]'N#_B?PC^J_#_ /"J
MF?EYQ]\>>-?UOXF_C-S*1SHLY+'&,<8QQC'&,GJ?5L,:G2K_  J.PNU%R%(+
MMLHP1#64P5?;^DYI]6Q'0B1CQ$+" O<19\FO?1A0F61T^)D,7.7'=E+^(JLW
M]3XC7F(4!-@(%9MH384J[UVF$9"X&=TQA'X,&<E#*R+.O/0 -?A:Y&NW/AMF
MLF;(@4=@F+3LHK-=0@*BX 30:NRLIL3W&+F6G#!')4G\>*QWWLTC,X<$E76$
M3JDU.:Z)DEE!B-,K<AQUL47H.L6&.7,!K[DO5XI11R6)^14+>4(%;C88,>+;
ML>TP0HV@^[;K[*^.NL6:;)4NY"ET;&L9=J2,-1+6NFR9@E/05<6-=-3H#X,U
M\SO3EH*-%"I:U>N+:5JMY4-92)KMC6VRJ%P2)5B%(KQ6 #<Z6#9)2D>,BSR(
MUO7=871<DK&+G%8<BG9X]O.BXC,\H;9:D,6?N3-0C;@Y=A(P\3HF"V*(AOBR
M8HIC*N:B,GG.$MQ;W6N=9NS7ERK0IGPW;)<05"C:*.XE]E#8[EEDK)3B($2E
M-H5W5V5CSW&FDI:':(JT(M0AM0GQXON"V9#8["F,RI]:I85/:J+[HN0(G8AS
MJAMH-J,*!.=1G(XXQCC&.,8XQF^;T&7776J_)7OK]_?0???^?ZF-)Z_W==<\
M<?RB/CS0_+PQKOMVUSW/_)D_X?[+];=I_#]/F^KGP;/1..,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&?D1AW+!/'U^
MW)#)AU_GSPRQZ_W\8SYD?F%KFRZ6\MO(G7-T (5L1MM7FP*9"8LXHVM9M5F:
M/J\W%DRQQCGA+7'11321=Y10LAC@>\NIA9<,?8G 6XJ;3A?4]A@RVG312L!U
M1U+=64"2$AY\XY]'6/.(Z@,2CRG/'_'FHMZKBG;D]1]J[<L7D,Z9Z#3;:3A(
M9B.10,D2SY<^DP(9\XY9CW[>#^&B_E,/Z>=IG&]8_+^Z?\,YZ(AZ[Z[ZGCZ[
MZ[Z[Z[ZDQZ[Z[Z^OUWUWUEZ^N^N_VN^,=8_+^Z?\,[RYX8H(R+5-B%I68;)?
MF0";F+/D"Y7%)VX>4L$F&?8S-4:8M/@[R]F6"40+/CG!-)AE8:P9'2P!,8(#
MB#&"CK48L67*8F.I;!$PGTB8B0S$Q$Y<#I7/4MA!/28<PDAGH8!+8/..4])K
M(@./00%(S$Q,QG2]YC__ %&'_)^3_P"UQ_Y/J]7R?^5_R?5];U?M>KZWJY?E
MO6/R_NG_  SCLB'OU>N>/OU=>KKURX]^KKU]]^KK^Z^MUZ^^^_5U^_WWW^_Q
MCK'Y?W3_ (9Q[>#^&B_E,/Z>,=8_+^Z?\,>W@_AHOY3#^GC'6/R_NG_#'MH>
M_P!J6+O_ .)C_3QCJB?1SG^J?\,Y]M#_  L?_P ^/]/&5ZH_+]$_X9Q[>#^&
MB_E,/Z>,IUC\O[I_PSGVT7\+'_\ /C_3QE><?E^B?\,>VB_A8_\ Y\?Z>,<X
M_+]$_P"&=Z%X:."<L';$0+6F0>3("$Z2,0_M=G+(![X/A)U$3T')/+(+U-CG
MU!))E)'UCGW\KEDK61@9 $FOJ[9R,20=<1!]!3',>J(B"Y3'.(Y3SRL.F!((
M84 ?3)C$E GT<^CJCT%T\YZ><3RY^6='WB'U=]>WC]7??7??7M,?5WWUZ^NN
M^^OE>KU]==]^KO\ >]??^'OE^6]8_+^Z?\,=D0]]]]]SQ]]]]^OOON7'OOOO
M_#WWWEZ^^^,=8_+^Z?\ #./;P?PT7\IA_3QCK'Y?W3_ACV\'\-%_*8?T\8ZQ
M^7]T_P"&/;P?PT7\IA_3QCK'Y?W3_ACV\'\-%_*8?T\8ZQ^7]T_X8]O!_#1?
MRF']/&.L?E_=/^&/;P?PT7\IA_3QCK'Y?W3_ (8]O!_#1?RF']/&.L?E_=/^
M&/;P?PT7\IA_3QCK'Y?W3_ACWB'U>KVT7J_;]7M,/5Z_\/\ RN,=0_+^Z?\
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M7'O ^Q3^+)?6FT_S><=^@EUAW_SPWK_01+U__HY7W[O9(\O]NAY?_I^O_?\
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M_*;3-T7L /;8P3+[QJGTC%/M@L$D1! YJ_!OVL9#32#L0RHO5AB\_ECZ)_\
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I109&1(BV >&8W,,$,7,C/#N7* 6"+O+Y$6'73*<YGTSSR1.,8XQG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g400206g37a37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g37a37.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ Q ): P$1  (1 0,1 ?_$ !X
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M%B+.+\<J63-DYZU9S]N5*E2G5*\?Q^.<\Z-..Q]:(BO1IHB.T0FLE41'PB
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M8LR QGD2&9B8_+'ZX])])U\,6MP$MH"P"C@@,8(9_)/OCUB?6)[QWU&64/4
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M^E)49ZH(7R,QK7[3V;J=;V'JR$LZ&F:RV7J>\WP0>$"SUD.G2H,WKABO1*O
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M^/;!R&9+/OT+%I[7O;MR]!V6P=W"LC%2K<F9H-K5\?DK^/E#-KY_;5A)F9Y
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MC"6?*,5"PK5>)'DCA,@!>P^P_P YL9.R8K>QS/\ -V,)8]KFG*/MLT)9./\
M/DYZ2O3R7+H;,;GPI\\]P8U@?*/RA.TLO'B!-N+T1_.F=PUII1>]IB%?*4*C
M)^SPO@AQW$!$5Y5SK52HFX!I_L/OVL.1:FUK/8?=DBT3Q8+08M&S'THM<>AU
MPA0IH9JI-5:HF6H-@#37"1Y\A(APXD,;!CN2'%Y=_*;>=4VEM:[!WRS.)\-T
MDGV2C7I84>:!Y2XG*KL%?*]?KDVI87":H)!C38YI0$1@X[#[F1=WMO+'RO'#
M@<WXK/&Q%W(6<AGC@<BO#T'X9M0<:..QMH57:K9L7#>Q2EK0D".9V>UWS=]#
MG9NCA&/:;S/ZN:_L!6_IU@+1.J,*Z;O#1[1B()#0UR"(C756+ECD,#,?G*<^
M$H*G$3U-S7'\.ABMM9548Z%'1QB][96HC%3FW2J^S';:L'2\Q]A@@JQE[U=%
M5EI8*B//FO5E/4N!S\CF-V8=_P J$X,CEW>'N&NV,S& KPW&JRN[:H9#RZ]5
M4FZM@\=9LW%4VFV2]FBS<ATBV3VBH;:W[=[/1J97=G2I=.L&[-C5<3NES6M=
M]]NFO:EJT3>(\UH6X('5M"T6U)RF,V@6+A"B;3+KL6$_-B9<7@Y# [5QM/)Y
M&WA 7D*NVL1>?MR,S<A>-RU_./QAKE\/=<F)H36R4TGN:])$(L8*F<1L,;N3
M>66R&(Q5'/M9B[NZ\YCZ^ZYP-'S<KA<;MZMEUM&N59% 9C)1;Q(Y"O757L"!
M$M1N7S,/UH[?!T_7+LNSE*?4K'K/ND-;U]!J ]BCVNW ]U6!8P/.#)$+A.&+
M& <^*.3GFT$5Q1$YV#*;9L!SW_H;M7%M3F!721D+]/->'+IRS<@T\I1H6=N5
M(=859]HAD5Z=J/(A03*1.PL6KDJM64\SC[>80_!DS(V<9C;V \5$1A4XU 8C
M(Y.INJX5>LVK%4DS:O4B]HEIC#Y75:26"-VY#LG%[ ;@K(P6#UY8EJET?I]2
MK6C4LK70EJ#/V,1U4#)C -);%@(AR1 J(:.2O-BAX+.14OO!Z<+B(QB;'B6#
MVIM^Z]]G+5(A>3\0<E0G/!E[!-5ATYVRA]K)$^TRJ#;]@TXRFSR(9(C9R+SG
M[6;+Z]Z;FH5Z]3"WIEN)\,<3DHVV>#K"IN<L;=JV$5,2->DNVQ.,JK?E[RO:
M"7!G5Q==<1+5JV>'V$W3\OU!TOMT1 HM@VR5!3-T@JF(V"9 B(6L,6,35+ +
M#48#5E3[#>4."8SXNM,DFQKT4*N0Q8?/,7A,VGMSVO("C;]AN4J8%%I>V[5^
MQB:]JPS-^QOOU'6<G:OPFIBR&P8ON$F7B=F *I'EQGJWKNOV+&'9W+63B+NY
M+--NZJF-K9NU3K)V_P"W5L;=KU<12QWG7<O!5EG7H#8\@PJ287>6EL(BB1#_
M +,4;$L(&<^>I^@;A9Z]%6DH.+![D%JELP(GL1HKL:8DC#>D+]&*^EQ/JKQA
M;"UI1X8EC*,J^-+V5+2AJY'=="E;/E#J]C'6;]'SU&9BQ4I8(QU,"8[1\TXB
M9YSJV'5=\ 4+O4VG<QFS<ID*2RBPBS5RE7'9+V9P+62VB]1&70LX+YTQ$A,Q
M'&M!]EV;4VR-+:FUGDZ$K;YC2,*ZTXD$#/A3$#: 5+UHM0J;-&E;W.6/(N1T
MDK$BQ@*T#.8;K[P@E(>6M68_#4L]AMQY[,^RV;@U]R,QN039LC9KNPEF1I47
MK4Y&+3#4P7DTYIV[EJM,VQL($8C6#5S]_;>>VKMK >V5*)V=IJRN+?4JG4M)
MW!5ZLAD:S6HLYATH?(0^\-ZG0J6^FF=9YG,SI-J[&=E@&O-6F)NTLCK%M0'N
M:QX><H5&"C:.YKX[7ZQ6$6&2:"$VODIU!.78+M/Q"S9%*2QFNJAP6UP7MG1V
MALVUELW75@_.IX.UMVGTCE<G9=DXRU6W=O34"M9049*)2JIC%>9['')1;AK2
MAHZG(;YWY3PFWK3=P2B]N*INF]U%A\15KXDL+<IX^A%T[52Q'R44/9=RKO*F
M],P'L,J4,J*4A&XNP-PW!:M=Q-@"1L!N5;ZT''JA5])DY36-3N%:CMNDPXU,
M<FES!NRYCV)LIFR9H$B!(D5Z( AD(T=YW1V-O;3Q^WZ.69B7O:2\?=LNAMOV
M:MD3ST5[^ R3#R,*KUZU/JIDB*?RJ#0"VRT:3,1Z&MN?>F3W/D<(K,UD($\G
M0JI\JE%JWBQVX5G&;EQ2UXLFV;-N]Y=V+,WYPII8=-5-3@61:SIK>&SA0KJ"
M)G[2/7<5;@-6KUU!," ;VRFKG.+QQ!!JTMV2JOD3U)I[,:8,M!P!8!ET!28\
MJQV269BN,M+S-P[:PKW^(%A6#JXUU"U>MXVT3[0X:<<JN=A)42I7A35R61(U
M.HU;51^-M 84Z2ZS!(HP-K;LW!6K^&=9VX;N6KY*ECJ65IA6J'GARKK(5GAD
M1OXXWW,3BQ6U&0MT[M?*TS [UYEI9 )=LW((UZ/TXTTXTTXTTXTTXTTXTTXT
MUKEM@H(5PLPM.%*;ANRFOI]</1$YDM^7/XLJRWZ><_3\%:L9^F<\SL:XD7JQ
MQ/$$T5E\)!L]!<_B@N8^F(GW:U^42+\?:"8[BHFC\8-4>8/$^[F1Z9^B9^.H
MU@;#>C084=>4K4Q$CLJ6I.<J4IIE",J5GR_52LISG.?QYSG/-Z["K-S3CF(-
MAE$07$1!%,Q$1QVB.?37.IW :TJ7(R4K6 24QS,R P,S,\\S,\<S/OU-O.4U
MV6G&FG&FG&FNLN#4]G;+B=F]55VIUW-1N7:,BLKL27:,1)E6B"']<&+"MZK9
M%+F%"R!XB.FI/CB66'"<O&2RP\<6A\C,S;^%PS-EYRW>M_*&.V2J$8D*4L7=
M8^,Q7J0-V'P"$2VP<WP:KJ%(3Y$6#?(I@16-S^>7O[;M''4IQN4\0738S;<A
M"V8Y=:<%9NR6/]GEMBS":P1C30_H*PS_ &F:H5Q-\T+ZN5:R'.S%CONL-:6P
M]L2VO$M=G;)6JU8C$00C4=&J\)OXD4&2YH5,>U!C+[,9IY.&,KR1;2E4K*E<
M[&][U.KLRGBLUF:%7$4!3EZM.[<J5V6)S^3NM+R4/6JS)T;-<2,AF2B/)F9@
M.(ZJ?#['7KF_;^9V_@<E<S>2)^$MWZ%"]:56';6(QRA\^Q78VI 9&K:,%B<0
M'/GQ$2SF<)7-<;FUB:T18@5"#WAVE=6Q&E[2,Q>!U:6/LL272)TB3$ES1LYD
MC 2JMRXZ'&4-Y7EQMS\%/T5D7,OMW-5]T5+64L8T<EO9^XJ+ODQMR&TC#)J$
M&+6Y1);,7%G,%,\1!#Z^F)1P>Z<!9V?=J8>MEBQ7A]5VMD:_RLBA*;ZF8EQF
MMC4.%Z8FBP((8CF2$NT=I])OK!=]N-[X.7S8%OUX3V[(9 PZ?4I5 ,5Z)3:<
M&:'4%!8F9H9NPXFH.NG+7*S7CX141\VKW'$$DTN7G[K;UQN G:]7%XJAET8
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M*D(6RS:M6&E)%T@$$QAE,D9EQ/;J,IB(F==@\;06@.IL&)8.VA7.R]NN1F2
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MKM1*\E8?5I8^<;1IY"NC()34G!(P/LKA?/EOH^2CVDJ8*0#;-FZ;R;YX2CG
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M65 E-,Q[L;Q(2$@Q-.(C*.R$)ZS]GKI?-V'T<<H1 L:BRJZ06!K-A3#17?"
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MVYO3=!!V]HOWXQZ6<?\ %$TKV/;'/KQ--<1'N]8UQL[V]G#)SZ$GI3<HD?\
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M\Z<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::QQC^"2G]'3?\
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MK:/^S./L+^)/X/#^F,'_ *EI]GWPH_"<_P!![A_TK3]DWZ3_ ,L$C^SK:/\
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MFN!++"H$D=#G$Q\*67F?#A,67,C1I)0A[B0)^XCF'G$.S9GPT25(>[1DNO\
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M&1\R3QP1T5SM=?LB^5KE83(SI@7;&R*Z@>V#N1P8@39#EP')B2\MXAV>RB&
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M+H2\$D+3E<-*]M%W/IS7?<76&R:'=YQPG:[0Q1=I0Q8R2K6JJO9YQ6LY(0+
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MN:RXN,6GB-GVE@]F-QJL'>WA6QM7*#D[:LC0V[4NHKV+^2!^9A"RRY,0A/\
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M6#JX*R%G X?"J&CB,4Q93(DFF'(6''$D-FS=FS8M";%O8:F$O79!*@::]I>
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M2;%,$,M5DBGGOZS,S],SQ_EV^&L^&ZY>S^!63-B':=TC7S_7/9P.H,&IU2A
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MJ0&(P69K3F>T\S]?TQ,Q]?$_C[ZRVD>BW5'7 X/"C5.3L*UZ]-W %#V!M$+
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M'#F)/HK6Q+>F-)<ACB<B&TUL@.S5RS#HI>NG1!T7-D$(D,B)(Q"$*7*%2Y4
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M"59]1G'JM>+B/%&/5;_"_#3XM->[C33C36.,?P24_HZ;_AG>7ZO])K_]=/\
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M_C-DE-<FUB/#;'688M;.I%S<UE)3$2727(UA*)&9 I77B3$&,N<E3]$$S">
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M4TB'>I^:L,I;5)GGGZ>_Y??/:(YUV#<:IIQIK'&/X)*?T=-_PSO+]7^DU_\
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M_,O=6[2%N_\ .#7QDS!QM+;9MJT#'F)A>3R,E[3<](AB1(EBR.NO87';5_\
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M94J0\O/BMU^0^M;KSB\_53CBU*5GZYSG/.[6M:0%2E@I8# @M8B  ,>@B Q
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M^?CY/O?>EC\T?^6GREC_ +\K?G@_:U^9M-;QC.<G!GT^OTF,YS_TQA><Y_\
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*IQIIQIIQIK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g400206g38a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g38a60.jpg
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MTMK#CJ+%1W3#C7FEAP,B[(2R):H6B4&:"G[Z+K#URLFCL%S'ILW3N.KEA2Q
MR-%9K"%B8]1RY;YO6UU"MSO<]"?DI-O%XU< YBMXZ"O%WC1\P>1NXEA< Z8D
M[KW),G(?P_FY=H0NY<W?-E6^:+N[A>Z^"G>J=HHM33TWJ!*'L=>I:JUNE 1F
M1#,;!TX-&,(>/S+,"@HKFQC6(NP5ID3%G#8TADW9)W>,#!1FYNHW(.TUB*,8
MKI'3S_<*NXXV?3/NH'K.1\904 "O(6IK#5,;(G8;(-AQ 5&8T"9N1QT^2@L
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M)X[6\NCEEGDDICACBYYOZ2S;Y7ROC;&V+C#'+-&][]%<<<LD[Y6M>]$.Q_\
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MY7A3J%[L'RJ!<'M:)1'24/PGVT]7>46V]KG7>N_$SG6DDAI4[']8-498G"Q
M%'9.^#+IY(RA65O!<KR*ER('<+FS--;"[1<GSTWL-NECOD-S?,0.5;EF.T9K
MJ*;:9XU^3<VQ(M!!8#K=*(E=J[R?/K<@HG/L)5!)!/L1+A,<\CB$?CLMC1&'
M.UW;[ FX*,1BP\I9M[ 7[3A<7O;NL/YO[E:3RBDTVCK3:6K]E:5CBDKVO .&
MWE&Y7KD'B)=G,2,X"0_0Q.+M,@K!-1X<S5+,T,D@#/&[X]DE<4QM=RZ3Z%Q
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MT&<89'2!Q<W+8V#<LK3MJ;RQQ%P/=E986_$2=.RIBCB+&QO+[@ESB^G=K>P
M;3S3M;8?FDNZ_P"$ :]'M?)=W$QE[VZ74N\5O_\ <^<6QO\ 'ACC?XZU#&#?
M$)_](B'_ /)A/L)(6\8$W+A=-_J,SC_SY /< 5N=8Q9=*(JO\S_:Q[8]Z0_R
MI!51OY.^!4.WFWXA6@J*I1$HB41*(E$2B)1$HB41*(E$2B)1%RR2X(<?H%Y2
M: \F(^*D2<^G,0Y [$("W)V[B(#-A)(ZSA;V9A!7A,"#4J9C^S)PW*LG1A]'
M\W9]R49A69-%H[;[+-Q?Q!4<-T_"<M>78%2S^D0TG)@#@X223-8ZH$8J'PLF
MEDE9$^0L;(YIM:.(,U6#@KAJGXIJ>,X<.:WB&KIQ33UO.G+2SE10.>RF=(:>
M.9\$,<+YF1-D=&TB_P!Y*7]3:UI;4E$2B)1$HB415DY"^S;B/\)M/Z/V_P"B
MHV=X?,*S=%$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$4*[92Z. BW3_+1?)=?_"S;9]/]]6S</N[%4WHZ)WZ@\?M6H<3
MML^C=^9DS?TF,_O^KJK^VQI$QJG9H@."'R@N5U[-!HN,EGRPL5(B+Z-DFK$$
M3)MR85<</+N54A[Q\@8$K-&SA1PF389IXNDL_("8W@ .)8X!I-@XEIL";BP)
MTO<6ZC=:U"0)8BYQ8!(PEX%RT!P)<!9URT:@977(M8[*I_ HP8+PB88O1Y-J
M.%'TPS1X=G<GEQ8N]&NC+58BB)DVZ-VN8>"<Q].+.!XA.0#;Y%%C^&+(@.:#
M#Q7HI'$M=>]@; N>YQ)%P39TLQ8",I#<PL2[0BQ/KKPT2,L1<MS$-C:P .#3
M8EL$ >X.S@NRG0#4.+FCLM#T^ZC 7'ITZL4U/Y;+)7K\?;Z_'6GXD[-75)_\
MTM_2 WY+><*;EPZC'6%KOUDO_<MDKPK()1%5_F?[6/;'O2'^5(*J-_)WP*AV
M\V_$*T%15*(E$2B)1$HB41*(E$2B)1%6,7R*DLB2?/XGQBW[*0+8])@#.1#2
MW&U@-,JQ61E8N0?CFDDY#@CR0]<D'>9,O.X86^4;=TJX8ML\[I8DW62]6[8_
MN0^17XP\4OSG*(GJW;']R'R*_&'BE^<Y1%0SG-R>Y&Z2C;3DKK[B#LOQ&K-?
M3Z+.7>QR>GS,6!N]G3;2S9G)Y !U'O"6S@K&H^/BQQX8P$-6/<+7&YDBP0#D
M9D03.\,X51XWCV&X57XE#@])6SF*?$9PTQT[1')(V^=\<8=*]C8(S)(QC9)&
ME[@T%:]Q7C%=@'#N*XQAN%38W6T%.)J?#*<O$M4XRQQNMRXY9"V%CW3R-CC?
M(Z.)S6-S$*4^&W-7>_(#CO MJ3KAYMFTCD6!E-T3UX]TR$@DB1%&R MK)(D(
MVUOF+3X>%,-VF#ENW.#'"?;NJJ(-2$*H../[Q/A5'@>/8GA5!B46+T=%4"*#
M$80T1U#3&QYMRWR1ET3WNAD,<CV&2-Q8<I"<)XQ78_P[A6,8EA4^"5M?3F:H
MPRH+S+2N$LD;;\R.*0-F8QL\;9(V2-CE8U[<P*M!ZMVQ_<A\BOQAXI?G.5@5
ML*_"F\MBI)J*J<1.16."6&:F=_2'BG?IAAC?+*_2W)R][]+6O?I:U[W_ %*(
MI?U_-!6R('"=B 47[<'/8C&YH&;E$4&Y- 5*0S(X.1(H-7+ULB_29OD<':+=
MX[03<8J8).5T\<5<R+;J(E$59.0OLVXC_";3^C]O^BHV=X?,*S=%$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$42;83ZL
MPROZQR[3_E4D<O[*MAX?=]Y4MZLC=^ESQ^Y:OQ.V\5(_\LDK?UM8=O\ V?5U
M1[E L)2XV[\Q.%(\%%N].;)&.24K>)L(VVN6B!<8WL:=*NV.*;!=R[1;KXXO
M&RRUE>Y06P743O6Q3VY,URT QO%W&S1=I&IZ:ZK5J6_I5/E#G$3Q$!@N\V>T
M]D6-S8::$=190]PM)LE(U,@.$C>'RP$F!\ZXO#7&L_DQL_#6NTQP(<9=>Z[B
ME\7-FCA7NSHYR=M;&RN.31@LV;6ZZ8]ES<SG%I%P3 ;7 M8P,8W7H1?3N%@N
MZM!S,=E#0X.MV:EM[.UTJI97Z7&K7!OB02NQ )/N0@=+]C%C\+_?Q:)6O?X[
M];W_ --:15G-55+NXU$Q'@9'67T&B;DHZ1OY:: >R)H65KSKU)1%5_F?[6/;
M'O2'^5(*J-_)WP*AV\V_$*T%15*(E$2B)1$HB41*(E$2B)1% O&G[4C+^'6Y
M/GDGU%&[#P'P4]452B)1$HB41>,C]CWW[S=?U&=$4&\4/:M<:_P Z<^;N.41
M3]1$HBK)R%]FW$?X3:?T?M_T5&SO#YA6;HHE$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBC/::?: LU+?72*HVO_JJ-7EK
M_P"U;"WQUG,!=:KE;^:G<?$B2/Y$K7>)6WHH7?EJF@^!BE^8"I9O=@U):2V\
MR>.HD/06UI.+W)ST4P.0D2JC&B2[<Q+!!04='$H\)<)I$B[-Z$+MEV+5;!4:
M^PO=LIM$NL4FK1]V_5P!:.R=7 AP+1N00;CN.RT^G)$\) >?O8](R6R'M"[6
M.!:0XC1I#@;D:C=5SX3925$;M)D7V.E/@"DT=%X(D^CK&(3 1$WAB2B!MIA$
MV.C]$91@S=./XQ\J!(QV0%&4JBLI47DUVSEE'P'539[/#GAX+KL[(:\-)<!G
M8(H<KNSE+2UQ#FN[6S6^BNRET1;%RW9 )+/,C"\-:3D>9ZC.WM9FN#F@L>SL
M7!<[M*V3[ENW2Z=.Z123Z?<[&&./3XNE:$]V9[W?F<YWM)*^CQMR1QMVRL:V
MW_I:!\E]JXKFE[VM]>]K=;]+=?U;_<^_1%5_F?>U^,>V.E[7Z"0]K]/U+^E(
M+UOOU1OY.^!4.WFWXA6@J*I1$HB41*(E$2B)1$HB41*(H%XT_:D9?PZW)\\D
M^HHW8> ^"GJBJ41*(E$2B+QD?L>^_>;K^HSHB@WBA[5KC7^ '3GS=QRB*?J(
ME$59.0OLVXC_  FT_H_;_HJ-G>'S"LW11*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%H6R4^W%U\OV%VS4_C5[G^UK+8*
MZU<T?FCD;[LW[5A.(&YL->?R2Q.]KLG[E0;DM) $1X];MD,H,@H^#8:MG&+X
MQ)AN)J/,O&QY^/:YF0N; K@9'J/'3=!R(R%DL2B:MV-V#NSCPZFVS.#897.(
M #'7+A=NQ N"#<7TM8WVL=EI-,USZB!K&N<XRQV:PY7&S@>RZXRFPT=<9=[B
MUU#7!A.&V"3(7$0T%0RQEPUT=DD!V!MG; B2%SB&;]YW\^V\#'''3QDZ7=.5
M(TR*G&4>3+X+9YM'!E3Q71"6LBF+0T%H<YSF/DD#CE+C]Y( 21O;,X-!&UUZ
MJAKY)Z=KR\AY:QK9(H87-;G# .7"XML189BUI=;0$#3LW6AKZ.E$5<N0FMS.
MRTX&*'P\!(A;&1^<9 8(%DALEC+%KFQ<I+07-TP>-1DA*+M[-%):AFB>C0I-
M]C&\FQ8LB7$%"/5<C;;?U75.]K:2F^N>+VX4RY49',\8OIL:87B"[(JIM"00
MB4O?339$QL;BZ-F![;?GP/Z2*,[NY0C:.-+Y3!?/N<DJ/D?@5#MKU;X;CY^/
MKZ+JC47)*(E$2B)1$HB41*(E$2B)1% O&G[4C+^'6Y/GDGU%&[#P'P4]452B
M)1$HB41>,C]CWW[S=?U&=$4&\4/:M<:_P Z<^;N.413]1$HBK)R%]FW$?X3:
M?T?M_P!%1L[P^85FZ*)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(M1G:?>Q0OC^M3;J6Z?_2>ME+_ ),+]?\ 1UK(X2<N
M(4YZF0?JBD ]Y"Q6--S895#HV-WZ9HW'W JF^P#9"-0.;2,3'LI<5C\1DAL9
M%,%\6N<G("@SU^RCV#K)L]Q;9&G*"8W%?)F[Q1NYLI=LO;'NL]U>2UKG 9BU
MI(;>V8@$@7UM<Z7L5\_C:'R,:YV1KGM:7D7# 7 %Q%Q?*#>UQ>VX4*\*-A27
M8PM5 ]#9?'D@L[)I>>9?'-AQ-60F"\]E1<Y@"";1C,6EGHR.:+!W8%YFQ<#V
MPTTVBMGF9B*FT4/%)*XT=6XM<W+#4:N#V7<6R$AHD:UV4=G*;6LX,W:5DF0M
M;B-$UKV.SSTW98Z-^5@=$!F=$][,YLX.%P;M+[97M*ZP5HR^AI1$HBJ_S/\
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MI8SS#8B.SV]L@D Y/Q:D#34V4 ^3XEAA:72#7$A:[J*NQ+P/(PD[V3K;F3$
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M;.PZ@(IE'K.^YZ]U][>KVK1%/)8:NO!H_KM/9<ZRC,0))%HTW<B(4H]2>/\
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MV>.6%_O96O:_Y+U0;$$;@@^PW4<+@CJ"/:+*G>6-\,LL;_7QROC?[^-[VO\
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M3C7I0,5CD[*N)$09ZO83=:3&"K4:T+RAT1M%7+5EX?75L^O7<Z:;"WQT[_\
M9;E(YCRR^IZ!'8]%7CS>L:V*.>3&,H 0 =M-87'I<1+'(O'<#)PH,983*',&
ML3&26Q=-1F4*)',<FF":F"93NUMIO;;O%AK[O*U]JW,]G^5"%"'HTQJ**'2
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M=2X\&'074&#,7Q!SDM=F,98V<.U\E+HH**7RKCV6 #LM:+- T:!?0 ;#4V
M\ JUI.C6DV%[-%[- U-AL /(!;U]?ZU<E$HB\9'['OOWFZ_J,Z(H-XH>U:XU
M_@!TY\W<<HBGZB)1%63D+[-N(_PFT_H_;_HJ-G>'S"LW11*(M2GKZ3"X/+R4
M+$('Y@/C)U]%0;I2R34Q(V@QTN%&.5+N&EL$'Q)-LV5RR=M<;8*WO=RWM^G8
M=<I>V*1T;0Z0,<6-<2 Y^4Y&DC4 NL">X$KA)F#'E@#GAKBQIL YX!+02;
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M*1I>XW!"[9Q.'CT@/YA:",_XLI)MY7O8=VN@5>97$>%,IW"@0D\G,!]@@MS
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(E$2B)1%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g400206g41a63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g41a63.jpg
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MTV/2:[BKO896=Y:]K5/ZUSNVHRR;0TA=*6(V9I //&!3]IU0[.CN2;Q@+93
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MU)SVOR6-R0!B2S;" ZIBG1$602;PJ$RX\EN7T?27T_U.H]+H6]'KZ70$],]
M3W5&Q\N-C9CR9!M.4 8*2_3T<,0IW8PQ [S77YV;K;%ZQJ[.P:/C9BAN3*==
MYM@'X=9$):P^HKBH^W^_\C<,YP]F=@?[+AK.',N^3/CQO3?R]Z[\9V;AOQZ]
MN<X]^,5/*EY?-Y<G*SCF;&Y>>[&_&W.>F,YK@0=PZC*/WB*,VGKDC)UEZ[&R
M8\&[UF6_K[,=,A<C%X9CDW'*GZA$.6I[W\F!ZI,60I?EPP[E,"2,[\.AY?\
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M221%;2R,MQ8;R3DV,^Y8P2TAMGADD;+U]\\ <7?3KA&SUF=E.M:=(ND<0*,
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MEF.  !DDG  'J%>N1HD2)&@VI&BHBY)VH@"J,DDG  &223XDFJJMG[\>A?\
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MTZM;VU#>V(/V1"JM"WULG:-JDVT)E4(/<+<\8 2[RU$#6M=6BAR($L752Q!
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M.[4+.W.&(_13+<-(/<28UPW>.N.^J+V;WGW:+TSIP+57:K#[% =DR:OVD4^
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MO:*&9MWZ5X6!1XSO0 EDW@&2)NH60 '(.Y5RN<W^958-.*4XI56F?W^-$?\
M+V#_ '=1YSG$'=:?;/\ PBKK.%N^_P#_ !MO]TM;&4_1C^;']G.:KK*_>*4X
MI3BE.*4XI3BE.*4XI3BE8_[/SGW\SC^#$)OP_P#=_M',\ZG0/[BX_P!5?]@K
MC>)O_B+;_1;_ 'FJWYOZYFM4V[/2&W+4,Y^7C6]=,U6L=Q+EI'84_)0K'( -
M':VT>-W9L?:D)IMI]F58*E67+ =?$O8:&S1%>>BH=CRY2);.!+>-&3A 56Y,
M3G)R(D@6:20?]RJ6..["X[SFMM!IR3 #FLKO9I/&-H(:XEN#!%"?$*[;5#=2
M&8'N&*OA7;<C+[LQNM(>M@Y.M!VL;<:MFSY!60W,@;3K W7ESFT>%$2C OW<
M%UIM"@6HT4D25+7F["6(Z6$CIV9%[M![5R HV"-RTF>HD7EMLQC&!'(C$Y_Q
MJ!W&L?L8%B;EG82F1 D0 P87:2,.3WY:6*15 '_RSGO&.AZW=K=H=DJIM] >
MC4JF;#$2*;?M+#[46L6*_;.MFZ(2B^DMM6I$(:Z<AEC0P+>XAJJ#V&6,V:FR
M C9L5'FN%AU,-P\ZR855<;'BW%MK02Y,4K8&02%<%!_B0C< <BJYM(K9X=TC
MO&V^.<H%W)<P';/"F3M(4M&5<Y]"0-M; #0VG]M]\;"DTS5-9K.H&=Q6/979
MFJ.; EO7*?I8K2NL!:N5RU7FK!(LJ+:YLDO=KM6-?KK[MG7&KIR!=9^;%8&:
M]#&F:5N)7VQJL?-+SJ7](Q%8"JNZC.XY=U3:3A6#^D=H#5O9V\>^9WFY"QVK
MB,!!.'NE=TC9B"@"QQM)N"Y92@V*6)6/2^_%V=KG5&Z01NF!LG?UCU+226BB
M=GL<_<1.RVW:7Q8[8GT I'B#*\W5-/88+VYDO8 [[=V"UTM!DKI!-P8B;!NV
MVV[@1CG-&AB+'FEFDY<FP]!MB&6R5],*1Z!Q50T^,-=H3.PMUFD%PJH(0B0\
MV$2 DMOGZ)M5AL9@1S!G%V=G>VYSKQOKJ[KW-/$F=;;@;V%,VM<I1&9%+ZZ#
MA+YU^U)3S@N&RTY!G#)&QNPU31<)!)<=@'58Q,[[0VT/D9S<GN&AFMX]H*2[
MS(V3E 'AC4@=Q!>9=Q. %R:LVMFMS;W4F\K+#RQ$@ (E)CN)G4GO!$5L^P#.
MY\+CJ*A^.^XP9V%W]2;6"@B-%Z5HKLZ!L: DV>M5XV"!M]/H]NKM=K J%)65
MCQKU=XFK 0T6S+L!;9=:L@9J,M"QWK:>U@33(R@11)D."2SR!E1E50.N'<1@
M#+&167'=578";>W=&)GGDP8CM5(XV1W1F8D8)CC,K$G:(F5NG6K,E]XM3CHS
M,4K5=P#;T[M03IA6I7M<$I6S&K]9-;6/;%4AJ""Y,\:^"L]+JY6>.N4,U*I\
M)Z/,C6 Z%4$LB@M?:HQ@%9 YD$7+V$R!S&TB@@9&&120P)4==Q7:VVWV&8DD
M/"8^49N<)0(C&LBQ.=S8.Y'=04*ASD;5;<N[T3.^&DT5BO6<,)VK;L%J9<-A
MGZ_4];'B]KUS3->6<A2+X9V$!PEB4$>J]S#'JN[7X>2MI/&*[8FJ@#L;(,F_
M&&[BVA@)&RK.P5&9D1&*N77O&U@5VC+,5;8K;3@+"?>RLT*8=(U=Y5"2O(@D
MC6-NH8,C*^XX10R[V4L :4V;Z0U8L/V ET'6UE>':1L_6AL=L68!)6ZF;%I^
M[KIIR*0EUD36'(]AE'I=-V3.G442,28E6#V.,61'4M6*](M27F!-L1CRF@&_
M!=765HL[0IW%BLA* 9S@'_MJ_%IN6MQ)*N9TNB8PP1XI($F(#L^5"AX@)"VT
M+DKG_%5\H[MZG=$H6S7=HKO6=D6#4[NG5TI47:4.Z5>FB]CG(L\/-)1@4$5#
MUX?KER38I5D: 2AEFK<"&1D6(\+"2KO:H\=TF_>8^5L(DW*H<@@D  (5?<6V
MD,H!+, <?L,V>K1"/E+-S]^83&SF)2& +%C*K)L"[@4<D!59A[P'=G3MSL02
MN4 7M+8;YK2E8[ >\*7K&TF!@?6]TC["55)!YSV-B8+M!\IK.S5H917H2KG*
ML;38UL'GV8N\+D7,;,%02/F)9LK&Q C;?MSTZ,QC90GZY88V]#@UC,BLTABC
MVSO;X>5%+21F/?MZX**)59I,[ O7=U4'@O=XM4Q8D:/*J>X&;Q)W.YU_QJEG
M7DPEL9K::M/R]\P ;HH1-(!_=I/5D9%J9M;9YRICH<C/P@-ALC3F14=JC &5
MDWF7D\O9EQ)RC, 0"1@QC=NW;0#Z3##8GL$V3Z</+$ N.<9 (N5SA;ELL VX
M2G84V[R1Z*ME=WM"]ZNOYVLV.SPREI9:K%4I5IGA2-2*C;))=O>TKAHX74AH
M6:EF3.NX[<U%L&L+#6F_"6$MZ!L*8I,<T)ES)%U$59@6]%48@J0V7D>(*!WE
MQ*C1LO>& 'B*AK"X5E4JOIO(@8.I7]'$DY<L.@0P2+*K=S)DCJK 9B\R*PZK
MQG.<=C-0^&<X_P#)F_\ ]_5N<UQ!WVGV3_QBKK^%OU+_ .VU_P#YZV%\YRNI
MIQ2L8]E]E E>(8I6MH"ME[*F+5%AA0>%S18V3X9PIPQ/B*RA?LN?%<F##>]8
MREIW!"4*1CU_.YT/@FZO(O.>MRC1-$B DDN;HK%/.@ZA;>*7!7F# 265=K%E
MY$=PWH5YSQ%Y0K.PG\S\/0'B'B&8F*&SL\S6UO)C&Z[GB)#<HY:2"%MRA&$\
MMJ,25Z-2Z++P["O;&XR3=LVC/QAR(RK*'@].8SA7JH8MI.,1E38R%K;2_&0B
M'!RIQ _#KBG",JOB'BNVELUX?X;@.GZ%#D2, 4N=2;(W23DDN(G(#%9"99L*
M9BJA8(Z.%^"[J*_;B?BRX75.))@#$A*O::2F#MAME Y9FC#,H>,"&'+" ,Q>
MXERCYP=>DTXI3BE.*4XI3BE8S]PMQ/:)ZY;/V(/?]GL$,'[EJCB?+EUJTV:2
MR "S&D+_  7<B91#!IUK/S+C#7\>&?HSV?D^X>7BCC#1-(F7?:277:;X'.UK
M&R1KNYC8CJHN$B[,K>#S+7!>4[BA^#^!M?UN!]E[%:=ETYNFY=0OY%L[650>
MC&VDF[4R^*0/GIFOCB<<<><6ZZM;KKJU....*4MQQQ:LJ6M:U9RI:UJSE2E*
MSE2E9SG.<YSS]#  H"J JJ %4    8  '0 #H .@%?EZS,S,S,69B69F)+,Q
M.2S$Y))))))R3U->')J*<4IQ2G%*<4IQ2MT/HJ=I2"8G;&A2<E;S4*"WMJE-
MN*\<0WH#\(%=8;*EYRK*9T6: FL0V?*A#L0G,RA2W7EX^=?+CHB07.@\4PH%
M::5M U(J.L@E62ZTR0@# ,4D5U$\C9)62&,$!5!^IO[/'$#W-IQ)P=<.66"$
M<2Z4&/\ =-"\-GJT2YR2)8I;29(EP T<\N"69AM/YXC7T%3BE41MWK=JC>+Q
MB1L0,0)NGM,;0T$25#-DQ6'=:;AGTLE>12$P)#.&9T^90*RY$+MX20&IBOMP
MWVT3)"5VI(8Y<[P3F*2$X)'H2E"XZ>)V+@]X_;5^&YF@"B-@-LT5P,J#^EA#
MB,]1W 2-Z/<<]0<"HV8Z?:!.6G==UF4Q:+/V$FZE(;5*Q#!:*]8)>DY0R90'
MF$-2\,B%0G0HE)7(EN'FP-CH2#69OLK&6Z3;0EI7*^E,8S(03Z1B(*>.!C S
M@#=CKFJUO+A4@02>A;"80@JIVB<$2>&6SN.-V=N3MQDUS5]3]&KJ3=0S4<>H
M:VYC>K=@Q/EXNB=I8W#G>N;1BX8<]_\ KU[!4N0Y#S-]WKKZUU%47-95D7F>
M1%MV[ ?TG-R2=W,YO.W;L[AZ?7 .-OH8V>C4=KGW[]__ ,GD;<#9RN3V?;L_
M5_N^F<9W>GG?UJ"5OHKH^N5O95)7.VM8Z+MN/>DWJF6W;=Z/ 2Y/8Q;WY:+0
MA,DO@E#NCQ3.98VY12+5E"O8:>%$XCT:*XQ0MK"%D3TV23?O5I)""9#N9NK9
M#9ZA@0R_X2,#%Q[^=FB?$*20F,QR)#&K 1+M1,A<&,#H4QL/<1CI4@']0]>"
M YJ&(N^]!=FLUHA6VT;+@[KOS.R+01&5MJGBH-AL>2RFRU<$5IAF (J\N Y7
MQ4Q#EC'CHUJE3#LBH6Z $!I0S,&9Q*^]B%V %L]5"] N-H/I ;R6JDWDC,"8
M[<JJ%%B,$?*0%RY*IM]%BQR7!W,,(Q* *).0ZP:@F:4K6@8@<R#U_3"%-.5'
M(2TV&+::_:*!;QM_JMNC7!XC*L4ZTPKJ)AV>>9-3RDFQ%537;+DNV3)-2ZC!
M&8A" 0BE"N&;<&1@ZMO)+%@X#%B26.2Q.3F@74PG:X+!I'#J^Y%*LDB&-T*8
M"A#&Q0*H&U<;-N 1':WT^T]49.NB-><V! -ZSO>Q=A!;"O9-RGGS!K;IUFS;
M.A7$L3*S)5M W8]%@DS08TN3%4\/AM1,1(S:F%TBWC785W@H[N#O<DF1MSAB
M22P9L$@Y'08P*J:\F?F!N65ECCC9>6@4+"NR(H !L:-<A67!ZG.2:MZX:HI%
M\L]+MUH%.$C%!CW.)759FRV(;46_5_-8M#$V$PZW'GMSPV<Q4XE(<S&SG+L?
M+;N?-RXT:LRLPR4W;>IZ;QM;([CD=.M64EDC5T1L+(4+= 23&V],$C(PW7IC
M/CTK'RH]$- 4V)'APHM_,-P6>NL 2JU;,N=G<" >J.R<;6T/60N3!:4D;7Z3
M;DX?S!C(0JP1E/HLKY>3,FRY-E;6%1@!C_<@;I'; MY.9"HRQPJ-UP._KNSD
MYR7O[A^\QKGM).R)%W-=Q<FX9MH&6=/$_JG&W:  *D1TGOK?9B[;AC[$'PJQ
ML+:K=[N#<4[L_$BRZ]5KBO4(EHTUJ!RUJT3/#&_@Y"EE]CS*S*MTIC"E('L'
M4Q3\2CLS<YY-X"O)O8 OZ2;%0Q&+=RB&VY,A4L?5G#"]VZ/LJ0&,EHXMB96+
M"2<UI!.LP3M 9=Q C#A,]"2N5-ZQ>FVJ(^L2FGWCVWRE"?;U\U611K;]\+/Z
MY1JBSBKGK5S7Q.<8>(@I],LP"OE!1B1)(FG\@1,,L1)#H;</ET6T80QYD*80
M*#*YV<LAHRA+94JP4@Y))49) Q6/VV;FK-MA$@YF]EAC7F\Y"DO, 4!@Z,P*
M@!1N8J 3FI]M/K]2=O@=;A+46OT23J>V0KQ1[55[W8JO=1=IAT>W:Y67=M(B
M9'*3I!"H7JU"RGMCSR)^2[TI].92&7FZI(5D"!BX,;;T9796#;&CSN!R<J[
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M!D%E(."#AD 95(P0)&(.X*5I7492%%RJW:I,)U$Y8X8(ZE>A&4<LC.IR&,2
MC;N#=I#Z;F!-?U&S7-Z6&J7?1/PI!:NN-9UMJH2. ZSN=9KU<.ZPD4)BL9J<
M^O9?JX*S#Y_LL8Y$L840Z[/EB8TP01"V(6,"5E>+<L;JD8"QLJJ8]FW:5]%6
M!QD,HZXR#2;U6:8M;JZ3[&E1Y9F+2HS,LO,W[PV'9",E2K'H&PP\2/2.!*UU
M0]&0]S;#AZ!J,#7,8QK=\+KH@3M\[7-I'79!B?L%ZGMVH:2O%H%1"U[E#WTR
M7I"I;E,D4AZ0EYD;4;$B$KB%-F4(0EC&P<$N5W LPRY'7_(4/6I%\1)).88S
M<.9=LH:0*@E0Q[1'O*$1H2L8/3&.9S,5:&\NKE#[ '8Y:\S3'L2-#]@- 2PP
MY<5B/+K7869J2;8C:)BX[LZ#8ZX[J$*[6)L-YK$*5/ES5H<E1H+C%<L"3'+D
MXY,T) ('HS&(L<XR&4Q+M([B2>_&+,%U);KB,+GM%O<!CGHUL)@JXR 5;G-O
M![P .XFJ5SZ//6:Z2%I[E[V)[6&T_ UQBYIE 7+?.N\#<83L&K>I"9."SAT[
M9A'= -O8)?VX7*K10S-GHG WX4ER+FWV./8%WR9$83?D;RXD$W.)((,AE&\Y
M!4L3E2#BK_G&7F,_+CPTIDV$,4$9A:WY  8$1"!N6N"&4 88$9J: .G8R/=J
M[M.Z[-MM\VB+W4#W07M4P55P$,S)JND=B:*JM)BUX"*BP M0"US9-@/I2TY,
M/3;5+FSIIIV!+:&0ZQ;#<LC.SR"42EB%&2(GA5<  ! KD@#KN)).#BK;7C;'
MB2-(XF@:!4!9BH>>*=Y"S$EI&:)5ST4(  N1DPV1T+&C43W-?;MV3K@E9P&Y
M:3?2H850S$JTT7<NY[_NV4,8:L]8+Q:_8:/8]F7"!1[./87[,,-3<6$18I*1
MSPZDVH&=DLB%A(KD!#N225Y2,,K ,C2,$8#H&.X-TQ<%^21S((Y55H7C5FD4
M))#!' "2C*6618D,B'Q4;64;MW=S^C-,4]<!("\6JM:ZN,+KEB1KR'!K\R")
M-=9+#KPA0BP<_/'/6!IF56]:@ZD8$S)LV&_'>FEV%,$ULN,C:IZ05F5&Y)*#
M! ,#(4(8@M^K&%()((Z]#5(OY,(61&E0W.)26!872RB0,H(7HTK.I !R #D=
M*Z_9_077.RK99+_).J1<36[9^ZX+MHI%!V-51\TWH?5F@3]2F4RZ@2@DK7B5
M>U+6;,Q,PN!9A=M8:DP#K8=$L-/26B2,SD^D9>:-R(Z@F%(2I5P05(C5O!@P
M&&QD&8M0EB1(POH+ (#L>2-R%N);A7#HP*L&F=,=5*$@KG!$JG],:<0K^X@&
M+G:0OQS]9]7]9CA"H#J?37 ('5TC=4L?::L)K=<'UD,7+R=WGU$0K /%33&&
M#A\<&W >GQY,FV4K(-S#F6\=N2H5<+'S2&4* H),K94#;@  8R*I%ZX:%MB'
MD74MTH<NX9I>0"CEF+,H$"X8MO\ 2)W9P1C<[Z/2PT YJ&9I38^:E.C=N"/8
MG8%HKM!U+315.C-]+-F]<H NCZP#T^/3'Z^6*2Z4,.!W83UA?%G;.:1:6#K+
M)R/9[&4,?*?:1<F=V"1J%_Z22 !8P@3!)0,,;L%B&#8:LGSBLBS">+>#9BVC
M5I)G+GML5R2\K2%]RJ'*G.P%5785]&I=)Z%#QFT.FLL*3-&JGHHKO.\[:M)\
ML)8+;6MM[O03=(5JU5\2('P"$N5V0?SO03*$Q10FDE:=(#C8K4.S>S+J[(!)
M;$$E8C*\C$C,K.XE&X  $F?],",!2I 'I51V\F*]# *]P+>.%%#$0I$C0G:S
M,2 +;_IV!+-('#$^A6ROF;6LJC+U<86O=NZQN)*"1)PAP*ZQ7((=IF02<7+>
MKJD.-LOOQFO4M^H5ZYQ3^,H\R?!"_'/A4O"UWQ(0;6\L+46IVN+V66-I#/U7
ME+'#+OV\H[LE<97&<G$'C*QX35UO+#5+WMP5HVT^"&9(A;$[N>TMQ#L+\Y=F
MT/D*Y.,#,BL??MA"'&:KKI]3WX6$2[&90RAI6/'&/6#1L5U;O_Q)P48SCPSC
M&<^/CC>6?DD?*MJ&LJ%Z%H[.V+%@?\L\\BA>G<3;MG.<>!YN_P#+@@#+IF@.
M6Z[9;^\"A3_W6UO$Q;KW@728Q[^E&2M^V':[[[.U+Y;JY4E+RA^L:OK<=+4Y
ME6/]I&E3Y9>,_AI>/#.$DW#S7X'C[(C*O-SJX^$;/A]$?0-*T^]U#'HWVNWL
MA:%P?1=(H[9T+#Q-NMFW7',.,5Q<O'%_Q.\B<2ZUJFGZ63MDT[AO3XPLR'&^
M.2:6[C<*PR0+EKY>G]T,UD-KKL'U=U6/S J%7MPE;R$HG%)5?C2C)'*?!6,S
MR;A9R2ZCS_[1$5K+4%A:E9C16<*SCG':SP=QWK\W-U&^T^X"$F*WCNI([:#/
M3]% ML$4X]$R,&E< !Y'QFN\T#COR;\-6Y@TK3=5M6< 37,ME'+=W&,=9KAK
MMG9=PW")2D*,3RXDSBK+1W:TBKZ7K6W_ $Z_C/\ ^$Y?-&?)AQ0.Y=//V79_
MYB%="/+#P<>]M47[;$?\3FN0GNIHU7TD;&C^E796?_P<7R@^3+BD=T-D?LO$
M_P"5%7!Y7N##WSZ@/ML)/^&-<A/<[1"OI.&T?TZV4SX?F-+_ .[QY0?)KQ6/
M_P"UM3]E[!_RPJX/*WP4>^]O!]NGW7_"&N2GN/H17TV<FC^E63^?_P ("^4'
MR;\6#NL8#]E]:?\ ,HJX/*QP0>_4K@?;IU]_Q :Y".X/7]7AXW.4W_3JUJSX
M?S^0,O\ [O'E!\G/%P[M-C/V7]A_S<BK@\JW Q[]7D7[=-U/_BT-<E/;GKXK
MZ;\I']*K7/\ _P UY7*#Y/.,!_\ I /V:AIG_P#VC]_6JQY4^!3_ /K9'VZ9
MJ_\ Q8&H59^ZVJ@IL#&"NR[: GM3<&R@N&3@3@+[3D5,+.!QT>,238DH<DJ>
M]GE-NQ\1\*3AY;B&E;.Q\F.OW-K=O="/3KN%H^RP3RP317:,LAES-:37!@9"
MJ!=\;*^__" 6&HU'RO\ #-G>64=FTNJ6,ZS=LN;:&Y@FLG5HA">SWL%L+A)%
M:0ORY%9!'D!RP4X/>E=VS6;OUJULFD'XAD0>VS%D3W(BW&WV5!*E85I'$H;R
M&I4)[#Q:++5&F,LNY4Q'>0E3>4KSZ1Y"^'[[2N,M9\Z6DEM<6N@ND2R!61Q<
MW]H#-!*I:.5=MN\>^)F7TG0D,"*\J_M%<3Z=K/ 6@G1[V*[M;WB2-YFB+*Z&
MTTV]86]Q$X66%]US'*8Y41O01P"I!.@RJUHO<[/7*?7X^)9ZUG@]:"1,K2UB
M47.D(XL;'RXK\%O#\R4RUE:OP485YL_-C//J:^O+?3K*\U"[?EVMA:W%Y<R
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M2"QO8H[F5S?*Z-#<NOZ,K@DY6 [RU0_I/9AW7,@]$LBP\8%-04BPI0IY3%@
MC;!&BE LY2YH,W!CDVHA@-+6X^.(,OQEN.>3"U;7AC75XDT:UUA+62S%P]U$
M8'ECG4/:74UH\D%S$!'<VTKPM);W$859HF5PJYP--Q?PV_">OWFAR7D5^UK'
M9S"XCBDMG*7MG!>QQW-I,3-9W<*7"Q75K*6>"970LP 8Y'>C:,O"NX^J8R%J
MQ%L3-UKA%O&<XP]%)46QJ:0KP^E+9"/!D9QG&<9RQCZ,^"D\?Y8[=9_)YKLA
M YEFVF7D)/\ ADAU2S#$>\PO*G_U^/<>Y\A-TUOY4.'8P3R[Y-6L)E!QNCGT
M>^*@^L"=(7P<CT/7@U] ^<9QG.,_3C.<9_GQ\W/E:OLJL)^Q6]]R4G:]6U-I
M\1J9R>7T%O'>I:P;6)6:- B1=-V#5(5NO0(-;]0XZJR.[)2S,,S)\:/6(L5P
MZJ(=S$P )XTTLJR+'&(\F&:4M(6 '*:(!<+_ )N9@L3Z/ZV&QM.=;00/"\T[
M3 +/! %A"$DS+,VXEL]$Y6=H!+D[<KG<,:-%]MK)9MSQ3K0XABK]FMR=: <"
MM6@T1E*U<!V!Z.JR=C'(H*-E34&,479J0/$DV&XD2)/D%RDY<?WBME6+,-P6
M<-@[9Y8@ Q/Z-7L3/@>&=R $= 22>^LFXLU2':2-]K!<L610.:T>I"VRQ[R-
MKD@Y) 4#.*L:M=SMCGBNG#1BJU6EZ@O^SME:R(;,D KI<Z\1N->[/VKK]1-?
MMF:O+Q$U>=NL$."+5^XW^(0I%NN-BAT 6^**R(+DNL7+DQDJJQM))&7*NP++
M.T*)E3B-G !5GRCN0@()&;3642K,H=WFCBBE$09(V"-:I<22;7&9E0EE9(R)
M$13*P*@@3/8:#^X^XI309?9NQM;T"A]::1N$()U=<9^O#^PKI?=G;,I9PH2L
MP/+%BGA]2"]?53**Y"(,UR60VM'D7$8:0BO,Q9?=)<F$NZ(L"2*$8HSL[R*Q
MW#KB((OHYVDR#<#@53'M@LUN5BBEDDNI(6,J"18DCBBD50C>@&F,C^D06"Q$
M(5R^:)H.Z]VZRWOOF$^4!;(TM)[V:0T&LE;; <F[-CO;'Z<=4\13=82-A0:"
M#KT"WEXEK,!1PQ$.TDKI="8^-49,"/\ ">TLLL<TP)$D7:X8<L3O',M;;JN
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MR2L;2<R)0PW*FR596R0<G<G*)*[O2!7JFX8QTM+5X^T!YUA$5PY0\MI=]O)
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MU\)]9I-:,R )=-$N,?K)L+7EC'2+$,\CI4*3V17*$]"L;T#WP@ 6LDQ3"K)
MAK225&>I/KS[SUS]F>_W9J#W?T>LXL(#SZ^6J"[9 [1]B>P5@@JE7'7XK8 _
M>SFT!<(38;?09+-LCV6CU78$0(/.28MA@3@4$_4%B8HRQM$PRF?X ?=C^)&?
M=_&(63T;EZLUH&#GMEU,;J2K:^L6N:)7&!MI)DJM4['TP<ZNHK;[!0JZFXN
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MQ><X6AU\E!0C/E2*6G&$\[6T\H$US$MEQ1IUIKUD<@N\4<-[%D8WQNJB$NH
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M"88P73-HC&'( N$Q#@P!ARN6*'E]+$9MMEE'O-@7&^9"<+<EIRK.5>'CZMY
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M6;Z(L8*J, L[D9)]*1VD<]<][LQQW#.!@ "L621Y6#R'<P2.,' 'H11K%&,
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MWCI=1)-B/3-0D:U26_DTN'MZQV[=B,^HQ2V4 N>699XV"94%JZ?=_8A&GS<
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M1\?2"3V1/CM^53Z+P^W/\ ?F4\G9[\D=2_2XE_D?'T@D]D3X[?E4^B\/MS_
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MI%6UO:%P.R-DL!].Z=3S]UZ7"BV.GO;(0&,;2U_ LM/61KBKX:IH87.>L8]
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M$U->*&5:M(735DTU\5;52&"9=I SM.5DQ=+3MW958HQ6O2IE8!'Z(!D56H-
M955:52?O/B?Z[^F.ON\>^J+WHOM38^V(9T -W0>(:H[&VZT:8I"]8PV>L?Q9
M9]'5M013[W8=OHHT;QM13LM=CM","Y6V8Y>"@K'AS*,S78];M+KU_P!?U_7V
MF1C!^SU]<[AX?9[OV^%1&@N=N[?(ZK7C9^S>S& -8[/U&7L0,&TK<Q%P 0;'
MU7WQ7+*S>AA7JMK9=LUE-W03UL*=E5*DV.D:\S;K.;>V V'#50[K=4].N/\
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MR,C<,Y7(ZC.,CJ.E08W"HQ1PLF1&Q4A7*G:P0XPVTD [2<'H>M1*P;YT;4Z
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MIZC::1IU_JM_*(;+3;.XOKN4C.RWM8GFE8#(W,$1MJCJS84=2*^,O?FY[/V
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M^P(??LRL!:KLJ18M@C 5<@56 6MK5@B;/)68<RW)UV_.'7I SW,83>2G.!S
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MI%4']&0"2!AB<@[>I)VL&4Y ]('&1@FF2!XDB=BOZ52P4$EE'0@."  65E8
M$^BPS@Y M[ERK-.*55IG]_C1'_+V#_=U'G.<0=UI]L_\(JZSA;OO_P#QMO\
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M\G@+6M6'LV1J(Q C$H")RR,)+',3=QK$2+E0J2%HQ&N81&Q<;^;Z)R<+&=V
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MU'DW"];2H@@1/MU-NU@U->]LW6OB]G;5KFVSM>N"MEW"V5AXX@1M6P5N(&,
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M?>M]<=>>6IQUQ9\8I;CBU94M:E9E^.5*5G.<YS].<\\O62!555DB55 55#J
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M3(=BLK<==<5E2W%K4C*E+6K.<J4K.<YS\^<^/.6P#WC-=D&([C74?)-T-^(
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4*4XI3BE.*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g400206g42a64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g42a64.jpg
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M 0$! 0'_P  1" #W F # 1$  A$! Q$!_\0 '@ !  (#  ,! 0
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M*Z8S@/1."3:G2Z/"V5Y6[[+=@[.R9:Y;*8#5;&G*-I\O>=G!'6>>*H:>T(0
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M&8U6_K,\8'K1ZJ>.XJM-$%CY;((EU;8"R$72V TC86E):!S==L>77ZJNMO\
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M'+%(UT<D;T54<Q[7-<BJBHJ<(HTZMLJ+^EH'26%<W[RYPPGRZ.-O\,]8%/\
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M?7SPK@OK:*AI+>[F@E)CJ*PZR<+!-7CD%?1#2$(*/-;'U=7$02Z-(('V-G7
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M:PO8]51\-ZQWL16,>KUZ_-%)>$7/NF[GT-/IKS,U^"&D(IOI9&2Z+52T<EB
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M*=3&/8GV3VO14\^[W*]?HBDG"*A=YF^C*6\L-+N"X:N[T;Q2CH7:_4B27*@
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M]<Y76:O8US6N<U'/548U7(CGJU%<J-15\N5&HKE1//A$55^R<(OUPBK/,I^
MS-5/R4]M=75*YGZ1UMG4W-A4T#G.=]HQ[*D! I45[VM0T"CA'AD(MB)5@?'Q
M&_QQ_'HDE9G)1.$3A$X1.$3A$X1.$3A$X1.$3A%#+;3.?=,R&?1"]%(,TVR(
M]GR@96KE5S(K.X>BHQ2S'M?'14J/:9;S1S3^V"I"LK$2,[X]8WW^NR*1UE8+
M4BH*+\CO+WSD$SO^4LTN54=.89-X:LQ,[D]TC_#6-1&Q0LB@CBB9*+8<(J:[
M@Z3S/;M>%*7,1G=E0-(=D=W410NNJ%Y2Q.+KR8ID2"]R]LZ =M]E[-75]A\
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MFZRQ'',R>*M/7BN35:CZP[#U97JBJ\OV'2 W5QH>IXE%TM3#?F5E=#7.L8#
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M(F >-&_3@3Q"CP1I7EPC$/0']?7K<]0NER[RE =,PZWK WC#%&$1DG"P20B
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M05K"D%-;%6'7H8-<18M?/02Q)]/'#SV32];LSRAGOQ8R61L%F[;PYG(]PBE
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MOVN/J+RRE:9\BN,#8]E8S-:4J5I)ZRMB$EL0G'H7\$5X<(5"K;.4P>JO4JU
M6UJ\, =CG[*-K"\MSRE[F@.>1DX+R3N=]RJ-3US6-:?$[5M2NWQ7[05H[-B2
M2"HV7D[1E2N7""I&\11AT=:.&,B-@Y<,;BP9?4%N:>W"Q5]U#:NWAHRSB5U9
M8J0&?&BD-0Z*8(*V%'"<HI+E>^TGCC:/,DQ,2Q2_%Z%B\ ^NF^W?D^9 V\%
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M5:,CYLB!6A<YSW*Y[G.<Y?+G.57.55_555?*JJ_S5>>,DDY)))ZD[D_-9
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M6B[$ZSH<]HV;0JHL=W@KZ$)!;RWHBT/J;RODL'Q5R68=BC+0:8L@(FNM&RV
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MX1.$3A$X1.$3A$X1.$3A$X1.$3A%'+?^BNLH0W[/FL+*K<J?Q')H[&RD:O\
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M9CK2HD8G\ODR&:?)_P"5,Z5Z_P![EX1:TX;SC,4?X^Q-OV&GG^"_";F*Q?\
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MD1S7-5/LJ.145%3[*B^>2B_$L,<S?;(U')_!?T<W^]JI]T_\R_Q1>2"1N%!
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M\.!9<TM/B.X_H=L;?FKS79'GW_NK"H 21!)2;!K6VUN4^TM&L>DC829HXH8
M62,7XY8ZJO'#JHR(V1(8T+ZU\;9R9E6%4MYPB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PBBA:_@%PMIY]M/>2C#7'\6@V_MB"
MK+94^RM'.B8/363_ #(D4D5*0V,<:.V+X_7K]/X12OA$X1.$3A$X1.$3A$X1
M4+H.R<_C-#:-J-'B="7I;.O>1E$TTW[V"WD( -*1)7U&?I]3:6@*U%8"8:(R
MK&*JF5MD<V2R::P4"._;?)_/H<?(=.NWGL5.]KW% _&V>UL:SM-VMJ-!^\XI
M>&ZNU1[@2K4*FQ\>8=5:RMRTVARA@(5(W4%ED4($$P+]H5:XL6FB/HL-KM*"
MS2=).+(=6>)(G583--SN(BY.RP ^*3F EYW1QQM G?-"V+M6=!]FU^ZS7VZ+
M7&D34^((S5OPZYJ;-(H,CIMDO-OQ:D_G-35*3(9QII@K7[=V2>32*NEZM+J8
MTRW ^NJ^T[+SV4UMR07N\69(%8E"]9!=7AT.@N:2S^FL,\;IR._-E%94 6EK
MRJF\IP1ZLXXJOFH[8M@CK>F,Q&E\.03MK777H[L +9 VJU@@DEB?A['2B>?G
MBCF8YDD8#'%S#'(>7M(W;;Q3Q@>%=2UC1JG"&M\/:W"V:K%+Q7=?)J.GTM1K
M"2KJ-?2F:%H;ZNI6=,M06].N6)+<$,5J.]3@=/[E>@WNZJ2<A^]^V"DN.N<2
MIMOK]2O8(/5=KGLQ86Y<EOH;$>_;WSBEIZNTM#B[P\>^*N$@LK0C\--KZIP=
M4+>U+AROSV;QO,H0.<^Q8,[(W0QO>XNED$CIX!&Q[W.D>)'/P]SN1S6EK!C^
M'>-)];.C</R\):IQ1KS8:6BZ4.'+TM74]3KU(&5--J3:=_8FN^^W*E.&"E7D
MT^&D7U*T7O,%FT)KDOMZ1O*>QPK]P4#V2-V)H#,V5:V%SU=IV44)>)(,E%S&
M=!R4&K@GQ"3W.F97ZB"YU;[%VB/MQ=#:#C5=;7>OAZE#!3=/&)G3V"T6'RQ.
MB'-!SM;' T<P=7:Y\CHI6OF$HE<X2N:0QGB]JMV>+6X^'6-T^#1M%[>SI4-+
M48]4GD_M=E5\]W6+0;#)#KDT%.A4U#37T=*&G&A% =,AF[>S<OBG[*I=I>TX
M=Q?XG,$T-M-8.S,^G*376)K(+6HK6S4&BH,G:5M7,Z::U#*40B>Q^F&A^ 9G
MU;%S_P =NNW3I]/GM]ERY7]R43A$X1.$3A$X1.$44F7\?N&BL_-39\J$@V1/
M\W8:"!6SA -\^4E'I%6*S+<UOM_%_P *BA)2:LM1$>OV12OA$X1.$3A%%[IC
MZDR/3CL>^*$=H>A@C:Y[YZ:-\LT1\4345\I=#--.4V.)5DGK"K:"(<P]:V)C
MUZ^'[HI-'(R5C)8GLDCD8V2.2-R/9(QZ(YCV/:JM<QS51S7-54<BHJ*J+PBI
MMQ/[_P!\VS<OR8O+V$C,_#_W#2Z4"1\).FF;]T)J:$ELH.8:]$')MH3]+'$5
M&-D[2*MC<_B/=T'UW/Z#Z]V+;W=P^?[*=11/F>V-B>7.7_8B?Q<O\D1/NO\
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MX_7]_7R5AY[34NI">=2FH2R&9PIHTL,X=E5FL8Q\E?;U9D<%C4V$3)(WR V
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?'N5SOS.57*J\(MKPB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g400206g43a64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g43a64.jpg
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M O2-+W 09U)VKO>LJW5->WH68U^]UI[S4'J=,/[%*&=NNB[Q754V]$=M66-
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ML]?!AD!V0N($!4ZO@@K(\0-CPD5EJ3G>Z5VBE 6,D: YN<U?5DK:WD,E[O\
M1?M];]:JY!YO43KJ0%D0TW6L.0.*S%RIS"SUL];L=X=;A4@"W)2>3+BT^7!O
M]Z:FT>(^Q3ISESM4F6">E6 J]+N:^J(D^0KM'T8HO',AA"IOF-L0:B5).1S?
M(5Z?+GMWX.>_!SP9*BG7C3!HB'*$J&,D2P9XM9H2<2R\>&^;-[ 7M:=-,C8Q
M%D;8_3LAQZZ#XUAB%(8>P/R2 B/!=DOY<J:NH"$FD(O \$=A2EQ\GE4I3A7(
MW2/7^@KCVXXXST%: U('A@X$6J*DQ:SD2FN(-6"T6)P#& 6BGW0"-#R+ :)R
M!H8%9]?TTJ%!PW60XEROP8X^#'AX=CNG5FJ[N97NHB7<915 !6,Y"O+?+C<\
M\]^_ 7PG->M+;W;RX^8\C'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8RP*?\ LTY_#3_;R.>E_1[OJ_Q=#\Y9DC_9:_\
M#E_MGFGY]#SAXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQFJ#'0EBAJ(U\R*.CT32(U<X,1B%(:"(B=(%EH"I4)Y]A,T63B2AQ&+E>'
MX4Z-(B26VI#+C:8$>R/IPWR=S[,E$:1'AI*:2Q^T1/<YSEPF=ZDR=O[!"6#
M =LVO31]UOIBRA[570;)*CQ.O=UBDEWPW!&T$D1J\*#UV.380BP3)8MEBLK)
M1&<9((SC72WHT2/,J(>78_$\<>10?:SOF2M4A%+VOEB"+YO$*VBI?[0M.>>>
MV;6/1.HPF*2 ,)U/"CAJ8V6,#,VP8VH507:?KFGM&R3+AOWH-9<IFO\ 68EL
MU*]J L:$"+3+RJ0IZ2K2I/)1'DLXC42^]A48E]J#(75:7>W*CAYE<I4>[<IM
M?-XR&V^K=(0H&$-N=GU[ K@]P&Z+&%=OE4#0H/;)$#6ZZ"$#\W/+0+5MR*2*
MPR(I8]B%K*3,B "<4*AT0-F0X8Z( L0*H9-!) #GB"UQ\/ UP58=95B29-CY
M>5@*KQS,+N3<Z4OES(M6L^FE1NK=:L<"IU^YWR!8)+@AJWG1,N+":%.74Y>Y
M$"!8HK=-D)A:HARO\4$L!BC<BC5P?'LJ'@ 2-$ECI#2 ROBW_4R[\/D^+A\H
M#QD$M5++2*%[1+O:1Y.;9_!R.Y=O+DQ0-ZR1JM8JE#/ BM5VRP/-3JR(V!8+
M/#GC-AW5(")::F&%V$H[4*Z9OMI]Z1:Z3' @X5BG/6&:3AS(KQ*/-:=,;$E3
M1);)2H0MH9/Q1HOF[YR/VEC2,.+8@C$M)*%I$^&5J< ]L_+(CJK(<I$^#:=?
MH7)L][!TZ4)VHJ)BWV:\W%NS[#J+RQML93L1RPWF:P7L5+-YL,1^P2(SLD1B
M6MC''[/RHQ[I%)?$R;3A\UO*-E^F/VGF*EP148_"1C47MY:CP)7'KF^#=6]$
M $ADBZ&VUD#(Q)'N2;%;2+ZW4/Z]DQTDY!(_+?.,0']3ZW<%Q3;A&,)S30>!
MC,1,3&%#2TRJCV^:_P"'O;S\$>_^$PZLV[EW^43_ !=J.%WSM*7<WWS;N]>-
M.K)#34:G($&Q"8;(XY7#EEK!N+#@D[>8;&),UTR+)K#225]MTDH$=E."#.33
M[1>%.88AMQI\.%C5)V11]7N(UYFSLWSZ9'B3Y&5C=B"<D2Z1+J,0>Y7"<YG,
M:(U-%, [!"ID(>;K9,67"E!TXN.FP9P9_94B I+T(C'4]&2O<.SVI4"3EZ 1
MB74Y!(QI4*0F.VV0*2-4V592;O9_SROWMO(WRI+L2D:>^WW._DCSW-I66WR^
M5QQC'&,<8QQC'&,<8SV1^7'\_P"N>,9$>?%\[&.,9!JAK'7= +7H[2*36:H9
MV=:,W7890 'A#)USMJA< ,JQ6.1$9;<*%E#!<&(N9*4XZI#'K4K+KKRW+2G.
M1$E)D0CM@*NV-K1[%JUDJM"J!1;V.]'RYRA=M==]=[=VP'.6+8$X3:Q=9BI@
MU>OXH8JQS:]$,9F8:+E,5]R]6&B?665$FZR6*3:K$MK#%@BQV3 V"N+EAJST
M]-"(Q9/F=Z$D]#=L)UQ8$MMCPY))"@*OUMY^7-#7L77VY15LZ!_)6+3!C5ER
M?'1M:AZ4 )0K%/3 B%L:_)T4E6#YH?7JTIN[1\/T]TA:*/,E52-:CJJZ58N%
M;37%PR^6/56:AJ1'>R1B<F\D2!E+R?%Y9&YB;C;*^+&IQ*P;O\;$%NN'AIHX
MIOBW]6]/=8Z:LTDI N%N*+LM(AZ\AA[*<A^E"X.L];:[*$*RF%'&K'E"U*TO
M599=H4RA;DV 1+.+S%CC8P?'/J)ZA3&)4V:@\W.<P;NPEJ2KY(>]PS9'(<-\
M'SD\^B7)[_5]<4 =!*0#^G97LS89)QJ7$0;6^-UK!P?K@\+UQ!P:ZMH/0QS0
M3#47JWK/*CM>0,/Y4_95L$(\EZM2:K+U4FZA _PUO=JNJKS-N_&GQ*SX>.);
MCJ2?0_'U9+WE_GE\NUCS>UJ/1/758LP&P3[?>+D/#B(===I-MDB25 D5L%+N
MLJHUR'44C&1(L#547^RCQ(5EA\4/#RV086$&"0H(V,EU,Y18D815W;HV3W.W
M=)E:LI;(J]U+;54S4K@Y6SAMJ^;OFB_?OWSM(<-'!X$06(@0A8R PW%@CAT5
MB# A1FL>EJ/$B1FVH\9AM.,);:9;0VC&/"4XQS656U5>Z\K]N4S-XQFHE6 #
M!,":[--B(=@/1R<P&"E$H4<P9B!<1%&90D8Z\B:1CB4D(&2;\-AYJ!B;$S*4
MUB2SZYI104*%IH6Z%[%TU?>FNV*>]<'=]K[9M^1C,:7,B#XSLR?*C0HC"<*?
ME2WVHT9E.581A3K[RD--IRI24XRM6,94K&,9\YQCC&9/&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC+ I_[-.?PT_V\
MCGI?T>[ZO\70_.69(_V6O_#E_MGFGY]#SAXXQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQD$UWK#76HZ\]4]74BL:_K,@[8K.\!J0:""%
M.V&V&)E@LAA<(>RPPJ>9,SY<^=(RCUNO/9QYPVAM"(C&,2HA$M: "UM:/=RT
MI2FW.3)H+DJU$ +?0 #.3MK]--)W*][ V61O1V@7^WG*E;K)9*^;KU>*,L 9
MG7[%'@SY^8#)9=?@VWK/3YP1<DBU/9(&;X-!EH&3V<0<4M*"RFK&35R$$#8G
M/L.F)S?*#SF2.M,C& $HQ$!%.34)(75IJR'CTBIQE;C.B&M3A NU_C$7: 'G
MZ'==*B: 1J0>8*'ZNU]U0J4.[,&Q85%B/ICG]$5%R8P,-YI\</:8,=$:&7EA
M9HRO@QE?F::8;4&B.F786_ =N*3MQ5G7E1Y!3=&;(46<M58TM'&I+TW6/-7=
MC8Z&5!NQ#+$QM?:[6:Y7:@$IX%9(!-JE1EU&\]?-C-% E>( I<".LO;>N%1)
MF6,IRX159+JB9+D8F5W-8MX)8[YV ':HTPEP51;IB^]ORJ/':39#EDR:=TMQ
MJ1I1](ZD@]JC1P[I#M/I_0=I7\U8"NP[<$(6$JB_)K(K%$=Q%M@V@"]6,VN&
MZ;J9:P2!,(*-K'S%5ESY=&G&([SIP(12<E15S+2C*2LI%I(#;W BML52@X>+
M[W=96.M*,0J*!MMW=F3*J)!:KS6ZGA*S1-]+->1CK467M2\_53ZW;B8 L3ZB
M(Q=CH;LT [,EKB4 #P$6.3;![&)?01<AN"M=/JU^+ &"6'CH^0Q'@Q/WFWE"
M@D^)XBU7^)>>X*6WEG6D\D8T>4:D[1TG2(BO%Q+>>6(^E9!W>A;M7VCIJW:W
MN+K%7U\0JTDX!L<_Y>%,CU6N=:*.RE^M@JVV-M^7:AUL 2:Y'GEJLW1=D$47
M^,_8X0N#3&X\&I08O$:L?8-,I J7&F5\.V3N+[9)KW&9*/,AI#DMU9=U6/FU
M7=0[X&QJV3]%Y)"!">'QIDZ'$D%IBQXIB3)98>)SVX$XJY!'M.K0N;,;%C"1
M)<:,EQY$ ?.F*1B/$?<;S_S[9KT\\=N7Y%U;]J'UN9?&,<8QQC,:),ASV<28
M,J--CY=D,8D1'VI+.7HDAV)*9PZRM:/=C2F'HTAOU>MF0RZRYA+C:TX8S)XQ
MCC&.,8XQCC&>R/RX_G_7/&,B//B^=C'&,K'7^L(^OSNT#S-XV7;E[1O.;S(%
M7VY3;2#HSN0 6O\ X6UF-E--MTZDI0%26378BGV$FR9>?A[&)B66;RGN(&V$
M=D=MQB19<KNFGQ2YK<\T!Z9*W7 4584O*V^[SW[U7MG.6[>IA3:NR]A[6%WL
MC5K4]HB'0-0/B)B CU-V@Q5NS5/;V+/L(H'^-HF107L$ZV#:KEJAQF)L>68F
M!I1@77)T3+IZY"$=-B2CXN[4LO=#=HRV@NUMTN=T>U @R&T9T!0^:V^;+BU3
MQWCS9^%Y5FP.MO8X=/-2:'>+'8P#ELJ$,< D]C=U@25HH\G=FCK \/LA21*F
MN:WCZQU;2MATJ58:1/M]IVJ*NQ<U91LBPRB L_>.MHH$HD6I*^#II&7A:L;
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MCNC%*J-KZ*1KND> 7M)R6YE&DDO)IQF^64HMK+: (@MG P2Z]^;,,@%*B"K
M61=R0GL+,%&H5D<*OUYW7%M['#:87CU:72!,*YT<Z,T.^Q&LXLTJ1%(%PL6Q
MA8BRXF:;K+72XA<DG3=IM=2FMI<:AW'O0GJVCH1:63MO3XH!W&FINW.V0ZGP
MIR#3PU=^XNRU^"WJP:SUM7]?YM57OVC C(ZY[$E@K7<A&P;OJ^%8#@RFP]=V
MJ3#U2R%O)&LO;6C3RDB!?@1FO,U)2X."G+SU9$F,2-DH%2E2VPM#:^2I4SYJ
M0FWURD-**$I,MK'45C$2.V,T&3*/GN)+97,4;YRM0OQ!BMM. *Q3]-BBE@LU
M,TO98@\GLXF%573&V9O7]B57;VU_A40) F*_ W\-,"[&%&VH3;H=8.18N19:
M&7' Z^.J$8"I%K<E,MG$O(H&\1I$./6I\ !930)3+(B) U'=%W%KX:,7:BG<
M1=G2>^[VP[9^#Z[1*$/D3K?:ZW7++;-PD:]4[*D")U;/#AA3[^J7;"C;5ID;
M,=:&Z=+5T2>9B4JVR995J4/='-2:Y*6T(]T%G0T10/+>]W? @\/+326ALCNE
M*5$12,+2V=KYPV!#^T%BLHGJ.0O7_P 0G85P$UB,WHVEE[,6J^AE29(K>0D8
M%F7/=DS2(MF4-KTRJ%=@IU: *[@E"#=Z'5VT*"VRBVJG2ALJ2.>,IK'7DT;(
MVD&]X%S8'PHRVFY%IJ46+[Y:73QBOGD ZG?35VP)O>R&YV%19%DB7L.UL/>:
M_A)9^LP:%KK%C"7=R&HA=-HS!@K\*P.[C'6:VRRT:MZ^*2Z8&K54+ [.,N%R
MP*278*?51%?N$*JW#,>76D*;8V/=EQ7C>&V$5B B2:OV:E4&A%IW2I.Q"V_
M=4"Y&Y41C'M7+'=&_P!!^_IF'329JU46@#R51:IB+6&.;G2"NTF/8@U0/F[K
M5J)_A@HW<== FK5)KHLM5HD^X7"[5DW5 FOL3V''&GCH*D>"-C.GD%D1V6Q+
MH8VJ(1LP]/S1*3>ZDA<>&0#+=1)VVC1&*2955_3?FQFMGLC\N/Y_USQC(CSX
MOG8QQC*QU_MRH;+/;0KE9;LR"6H+SG7EO4?I]GK$%=AQ7PMDRJMDCXH?!M@?
MZ<>@X2;KSY 8M_W$(DJ1[+KUY:<H$&6VM2.^-2C)K<Q\P*Q;B\-/XU+% 6O,
M64CQ:<T\-G9YRG=T[G12KU%H6P->TTQJDG1C6PR5G(W=S!5J/3+5KRO-P'*.
M6HK5:<GO7B_T](F20V*.&LP&"9N?-'2!L0:1R:>GNBRA*1J$HQ(D>/,3;W$M
MU$82NH+= (J21LL6["@][]1OL/8OM6:5SOCU]R@._"(V\E#L9C6X&MSX]+-1
M(5B*[3I%&V+6(0)\NR,P4DHJ6SM>D"T:&EV4/=M46!EAV>,L,<-/ZMJ\\1-I
M-3=&PA*496"IYH3"^^WYESX<N> H5Y.-JC?MR)S[?5>WUQW-U!MZ\T^E:T39
M[<W<1]Q*QK4.$(36!@RIC:68CD2DV1+:D,Q+./O(EP)AJ(]-8E-RAQ^$%(M_
M*\B?3ZFG&4IU':Q$7FY,B@KO%BWZ5R*9#"0*T4AWY7DX^JG\RSG-<2[W=<@;
MV6S]E. &40;*9?E&*H=AX9KM8FVD5*LV!ZHBC4NOD#%&N0H02'BYC4Y^N3)?
MAH3*$D2(Z;62R(\AQ*/Q)%(W=#4HJ*?$'>PGPY/:GMZG=KC[++^OY.2N)VQU
M/+8/)<=LX4Q6B->"&@%GJA\(3%G+3<!%""#Y[*H$E2$OVD\+ANS829\1$*1]
M7CN2AN$R%PZ&H;>R2)2&,A&,8LE.3]V*TTV4T\9#%]K[O"-T*^OL/Y=\APCO
M3HB<FE,$"A@80O,^('#877CR!)(GC-(BG7 !$L+"2["&K179%'&E2<(2B0RJ
MQ,RG!K,</:E5ZSTVKYJ!(EOFC8>:K!:9$9(+SMH;8[IV2YX[7;Q\^&EI2+]W
M?DOQ@]^>NTP6L[()W0&#R*&E81JR:_M5?%%<'Z]5[751XP@4'QHLDI;*Y< 9
M8'%RZWA<:0M)!T>^C#*WZKK7017FPG%2EC)05",HH_,XO&R7;B_:R^%%X]!&
M\QK#WXT<&KLRP#8>P;2B,-^:8B :624F>8^E&CV:G!+S\P@$BQ( 5>W'%,LE
M7!WTJKD9B"2VYH#ZS)TNJNU81;_>F<%A:%M;I1CVNY!7$J&G):X^NSMQS[UR
M>GK]== 4/=%-V,3/"*V@^N;6+6?I1UN6!G,I$6&M-MJ*PS*VD/X >5KRD2JP
M?2LV.-B.8KJ2H H&+$L,M.4 6JE$D<G(]J]_G5UV:1"J)W]0?L?S^RZ[/-Y;
M/*9&.,8XQCC&.,8XQCC&.,8XQCC&<7]_-0;@WOUQGZQT<>E5B\'MI:$D23T4
M\;KOTRB@]WT [LR3*EUJXZ^L4\:WKX=9,DZ\!NE;,V:!\P %EHDXBPZG/TT]
M/3U2>H7$AJ<4-R=.1 +C(%DE+%!Y2C+02,A>P/WTUZ/K7IGS6OG1_P"($*[&
MWJS:2W"=J^O)'7L_IW6YEO:E^S!#[!_Z)+U,J>P#52N6VKTRY28.[T*,NL2J
M[9MMAK>U6+<BY6FOLV!I6Y'J.F=*)J0BS\4U)'AQMCXVYB2CIQ\SI\=XP2XL
M13+DH[:2V[>!:W"@T<I\PJ_6LPAW4'O@9$I@:HE[1ZD5EW='7:U@*E?.QJM^
MGJD?U7K3=<O:.S3Y;_$"SHLVK-L[,):2 V/4L2U*)7057K-:S%>J)*Q3D13K
M].-S-/7?#UHK'2\(D3GI[('D*G"!J)/:$=Q$E*N3*-V^;B5H5>ZJ/DQ+IO[Z
M,DFSNH7>M[H*WH:!?MJ;"W.&[BWNX2]@"]LBZUL2[Z-)[.V)81)I!]_8%+&C
MOG@M@!R6* Y;0\<)&8C@V8C$<4Q$3$-?ICJ7580CINA&)%@RA'4(P$H@O")N
M(\]_6\$H[R7 ;3BE!H*[7_7?,61U?[\/5&H9VA!NNV@0J7T^D;HT[2.R<VKV
M+<PC7O5B[:]VP'K.Q3%SJ"XDF-V *T79EFB6.STZ%M1NK$,SCTU3[;1)XO3;
MG8Q@IKD-26C9ILM<GILHD96.D2@,8R86&V)V@8%TD>)4[;KDJP/\-G U>55L
M#HE\4VYZJ/#:WV4O>M['$Z3$]=P*W$VHJUS[7>)^W>RNS*CK7\?DSL&<(V51
M:SCK#J8]V$FJ5FTTV3LIA!B7.EL&1=X]3T<9BZ49#U!*V&TC$T]*#/8",)R=
M;4-,;C(AY> R=\!O;?FN_LB77S\S7HUZ9<NX-#?$YM^SNZ-XKS[<*C=@>N&_
M]"ZFH@?=C@HUK&R -6!877W:4*.HG J]:(VS8H_8DE\Q6"_XO'(VN%<N"AT*
MB1G(6.&ITA#IXOQ:6KI:DYNG>\9KJP4&4B,&)24[';>ZL@8! ]8R%:6[2SWX
M._O7%WE3Q.EWQ+:RC0[#5XM-Q :;M784EM:C-;OL(P!OZ@&.S&@KGJ_6=-/6
M?;%AV!11\S55:MY4(_>[A99=?*@S^I;,?5KS8+KT[)^L=(NH[8Q=2.D0EX0N
ME,T=6,YR"!&:38CMC&Q)ANA66W0Y]%JE.3RMK12C\O4D<F2,WT][UV9WO%7&
MF+R$+;K[-T:V:?V:8W8:>IX+1\+M_5+M9:]@!4>RHFUQ![^E_GG9E<JU=TV;
M0 KY:B"[;-)V6"IJIK],'3MQ33T91G TS<ZG@,1W2TF-[^!6<;23&AR"438J
M>41*YO:URB=Z/NLHO+1V!TL[J;EZR= ],R=T7W4NP=<B+4/[);:3LFUV2UA2
M^-8' 06RB"=)VW03FP2<.Z*'DM=3['8[/'%.( F=DUBS_*'PTRD=?I]/6ZG4
MV1G"3%TM/8 F\6*2A,@;;)U$OD@EB"424FA&J.UGJ?#Q\ROD-9G*ZU=RV>S]
MAM;+.S\9SN?<-O)=@8G9!#%0O'6*PZ;ME;UCUOK.E95@DP:?L"N7XE2BB+5,
MU@/K5>-U CL.';39.PS 3YUM#P8QN']GIQ-+P>8ZQJ1=36E.O-%B2").Y$B#
M&(60,=I:=@K;ZB7)?4JRK5NOF1CI]U"[;CA>I*%V&%7H/J>O6#LB*M[,[?\
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MN*K<=K<KI:.[3BPUI1EJ:D=+PR*19O8E(ER$6UV_(O*'WYWY%=,J/1-J;FZ
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MDE-Y:)-^$7OV%.!OY/"_8N4'=*/TE+K#XA[5INJ!FGI@UIXS1=A4*K 1L]X
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ME/S'3-N!G6G&!()R723TD=#= @ZT=/I[C)6,I/.H@(WRQU"^*BE6Y'EVV5N
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MJ1:DD42VWF)M:)SO^(G"9+3L24O*L/-K0I2<RPBK)B*QV*EW%;8OHB^F5)R
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MF6EIS(DH"0XB<\%!1S[ 8CK:L&4HS1GS) \W=Y*KU?OS3?\ 0KZG_BJ\7;_
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MUJ1%E1W7&)##C;K3BVUI5DB*(B-(\(G<3T3';OF;QC'&,P!HLO>"LH0(EO"
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M>+H*J(0Q1+0T$)FZ.,J8ZY4FDZ[U.$MKI*13F#2"!*CZ\KE2GAI%CS3I&)I
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MS7?F>+V?Y<5OHY0:Q;A%UA;,W1.-5V33%UO)NP4XS' #:4P4@1:\-1/H;SV
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M6V6JTD6)Y?$CMEYN=.*QO;LM*9+=P6]EB>\GFJJMQ3S\(UV"_P#KYUVN>EK
M >G7F39:^.TG4Z(?P:L=FMA>R;##H".EKO%E6A,DJ 8+$F+65-Q)5FM#5E*6
M:*6CP*B5'629>\6KJQU!J)%=24B@B1@W4:C0T4#M&)&KD(0K*1*^*\RE 4<\
M<=_2N"JKDJNJ3TN9#&/*&H965EO01(=$C"LQ5&C<^,&#8E^C*5IAY*3XGS:T
MYQEN-[J\9QZ>5T-)U];3TCOJ3(V>AWD_9&W[,K$W2#W:SH*LU^#500P .RZN
M,-C^UF1(4E<N=*<6N1.)SW4I1A\B4G.R")&3E.%29TJ0^O'J<SSW,(1TXQA
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M(_IB>V$CIC9@(A3)$B,Y-D29$%OW)B5(;E.,M2FY3.'I*<)992SE;WFOI'Z
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M8QD;H_%%XD?-BT@^C5(GOF2>EJ0(RE%(RK;+O%XNB1PIV0[(CG/6PCPN+=+
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MX7CTD1L+'G\F4L"V9>,H_P!_415A7_+'/._3;?5:9[:,?QG-_K_O-;7^(/\
M+?WK_P 9;G./F''&,<8QQC'&,<8R?U']EGOX6/[>1STWZ._'J?QNG_.67_N.
MI_A2_P!D\U'/H6><QQC*7VYC'O5O/[\-F_'\U!_/].<[Z1_L]/\ UO\ M<ZG
MT5_:ZO\ #/\ <93_ #D9W,Z@I'_S+J'V\?\ BN ^V?MG'_543[9Q^[GI=/\
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M>:CGT+/.8XQD&V1CS32OZ.%?YX?/C/[O!P;G*O\ FC\V/]\8YK]7_P"7U?\
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MI:O&R$9$N>;\U45ZLO?T;]+YFCU$-/IM;219SG&4>.*&-VV5\/SY>W?-QK4
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MU9:FE/6GK.^1*<)3C")!XC,(QA&)XES0ME*[S-H:<-*"0DR)3W*U98!%X&@
MY\S];6=7OTJN2(TJ(2'M%!:DX^7&3VDRX8YM#*4K^1;<2MU#REI6ZB1E:Y#&
M7%-1%L-Y4A746CU0%HM?L/?Y'?,]'/'?OG,FJ-AUP/5G8L,%'K\E^4>QBP%G
M10Z4D)")$I#+ECFSUH7&D,#(ZDQ<RE3&T9Q&7*8PO+[7/+_1_P"E&CUW5QZ-
MZ'K.FU9ZFKID=<TH:FDZ)-U'J=&6I&>B?LYL2IS8[648R6,>?T_7QUI1@:&K
MI2G*42,R,9Q8LK\336+"HQ9'+)CM4%8FG=?M[[%D&Z0.-U"MV" ]G)T\%(DH
M(PIB+F-$>I$5XP.DRTS$9;>GFL--!XK.(B:_,/\ LM9$=/K/I70T5AH_M9K4
MF$BHG9=],6?L @G/%#MRU2/'$I>M=CZWW^H^OYQJK[4AU)0NC;3!,:O--):&
MAR*I3DK7-J6VG*4+K5OE8;0U.EY3EY0&S9'V'#KWI3@JO*ICGGM32=1EJZ4W
M7%93$K6@O+XD"[!?C@R@]W;V-=BMR'=;;QYB^>3^9P_)X+9.V^OUJ97(9N=\
M@JUEL @DEUA_,"07<BO2XH]\@AM4.%)(-QW6QK<Q]G)"4G$2'[TE:&E8(Z<I
MDV)>R+.7)9$04+M"Q:&BUH%R 6Z].7^O^,DW*9&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQD_J/[+/?PL?V\CGIOT=^/4_C=/\ G++_ -QU/\*7^R>:CGT+/.8X
MQCC&.,8XQCC&.,966U )RP H$:OQ$RR#);W%84_%CX9COBBL+YA:Y3S"5,L2
MY,-V0VTIR1EE"U,,/N(2VK5ZO1GK:<80JS4C+E "I"\^U]CGVS<Z'6AH:LIZ
MBD?#D<%VW%#[:2_3UXO,*GU0J$N1V7(@8:%_+D&QQ!,B*MJ4@H2B$$LLQT/K
MF-+BHCY9EYEQH[>74(S$7(:7E2&EHRAU&MJ-;)AMYM;I>.Y25SWOC)UM>&IT
MO3Z0N^#)F4E=PY[-W?'VUVRVN;6:6.,9%[?<J_10^3ECF+BPUSH N(S'CR)Q
M D6*RFX0T4+'1&WIA C.E.H;8BQ67',X]QY>$,,O.MUE*,"Y-%@>JJT '*JT
M!EX0EJ2VQ.:5MH +57L'OGA<[]3]>B\&+B?@@X;CF&(B9"UNSB4M7CVX(@9&
M0\2+D'<YQAJ -BRI;N<XPAG/$YQTRYR(G8]U]@+5?0!7VQ#3GJ-0BR>[[![R
M>P?-:RJ:V5V?9[ :M\"DL577AH(Z))TVWR9,&Z[';S[<:.<<B1'U0=?$1XWY
MJ*'615-+F&%Q8%C9"QHPN4&T=?IY=5YR)II%([[WZG/&X[0C5[;N7/)$SH]/
MU,.D_9RFZHRN6WX-/A^%[R5K=7E]E;NY=> M63"[4L*^38LXC_BI%8L,GY(Z
M(<4E;6'I(?*&7),5*LN)BE(KA )-4CWQ\^8VEM[G*GISTY;9Q8OL_F/9/F69
MV=/4T]6)+3D2'V>3ZSN/R<F!?4%.-%)9:4V1;D3GU293<>=EMAQ]S/EUS"5-
M..-Y=7Y6O#;J4X6I6481Y\8IE\Q#VJ: [ETP24^(BPX45N2[@HB&/8AC(3,-
MER0[,2XEA#$**RVX[EYM&4M^ZYG+BEK4QD:=M>2XJ-5=6Y?'5IB.B'(ORFU^
MPF%XS[K=)Q-0I9XG(0K*D6=UIRN1%O?.1'S\ME\<SN]/T<]5)3&&GZWQ*7RB
M/(/^)X]KS0ZKKH:(QTTGJIP=XQ^<D[I_A/MKUV0P9!#P(HP:PF-"A-89892I
M:\X3C.5*6XZXI;K[[SBEO2)#ZW'Y+[CC[[CCSBUJ[48D0C$"(4!Z!GGY2E.3
M*2LI*J]U>[F=R<C'&2"M&.,S !^;[XXR<<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC/9'Y<?S_KGC&1'GQ?.QCC&.,8XQCC&.,8XQCC&.,8XQCC&:LX%
M%V0(8KIN(B>%/BR 4O!<6ZVW-%E8CT&?$6XPXT\A$F(^ZRI;+K;J4KRIMQ"\
M85B18I(:1$?9&Q^_';.-V?AS=-TT<7K:=J!=BHH*-8XE=K-RV'M2\#:PBTUD
M33B;M61;[N;=K,V+60D$372 )T?.J$=1!=3D!7S!=Z=G_6]?<R)A)16,-.*H
MLC=MB6*JC9+C<-%7WSN[I:M .UOH'OS[^N6D4ZE]=3P0[6[#JT%8P%IVB&W1
M:A%CDF+! M>RP$,-!$66TQC!*:W9,Q&J\$=^DF\3@;\X;&)R1CQ%.92J&OJB
M)-&,'3B@#&"JD4..[R4TT-<97<G9KBN ./Y?9SD'ST"Z>9!NUE6B*DJO+9KT
M:,&5(/*'"8U2VU:MYU>/7HJC&6JU'KVTKM:;,&8KZ1K0Y!B0!BH;K;<<.S;]
M9U[W>(WSS4;;A'3;:\UPC$;NZOXN<G=+W?7\0'\ S8B>CO5\-<SNPX^M'9US
ML-SI]^FG[!>-B6B9#L5!NQ79%1Q7DV6V%F*H #WTX8MK=0K#(BI23A.9-FA)
M+CRN0]1K,2&_RD91 C$$E$A*ZB;EB$=TKD!0F-TJJ^.2J/6OESV[MN:@%\/W
MJ#6G[<\'TR-83=(K(XC"D6:\$!04*S>QNSE5JA!R-FE"]8U.5L$.)MQ*IZYA
MU:N%#8V#+)"Y68K"42]5KRVWJ-Q;';$5VL-TDC<Y$%B2GN04$O#.2!?;DX/J
M]N>..?3ME_:RT[K'3,*V#-6TT/2!MXOMGV?:!X-MZ/!*7RYOL2K18LQ%O.1X
MDHU*C-29;$!N+"S(PX\W%;<>>4O'/4GJ,6<F3&)"*]R,>Q\Z^=OSR%7NWQ7V
M&65RF1FH-5\#9(>1]A"BCL#*O7\F7'Q",;"\8SC#B69;3S:7$XS^BXE.%IS]
MTJQGEHSG!W0E*$CM*,F+]XC@4[*?5QFI52Q>8*AC96[QAJF,QOI\/8^P(D),
M7*,-?*M18UF;99C8:Q[28[*&V4M^6THPC.<<VSZ1ZV)1U$_MVR?OE%?QRYJZ
MA^\_:#^8O\LQQ^NZ8.?@RVP;,Z8+:0P*G'94^R3Q3+?CT,BIUAE%)8UK'C&<
MMP7HZ%9PG*DYRG&<:^KKZVM+=JZDIRJK7T]N**X[=LJR5M;:J_D^GS[9->8L
MC-<6$"CP^4(.#(!@5.:4Q-&E(<>? ELJ_,U)B2FW6'F\_O0XVI/G&,^/..3&
M4HI**QD<C%1'W$Y,"G(T^YG"VT*6L:S8M;:>&;;+LOLHBS:%.J\JP:@C27FH
MI&#]*M5U+5=53?B/.1Y\:92KF\P'GH0\R*Q)BK8YT='4MCK:\M"+=FJ3(Z[R
MBRT]*.IX@EDO&TKF=Y(\Y8R%&>WZ[\W?ND1O_P#*/)ZYU)I5&T&==@XFX&![
M5W@MJA37X$]H@J?$CI;3#G$7H^,Q4EG6_4@AB(](CO/-?.(<;S)5&8U.H\%U
M9/3LO#>0D;:7N1+7:/PW35#R6TGMW.WM]5?=\ON]JRUN8,KCC&.,8XQCC&.,
M8XQCC&.,8XQCC&3^H_LL]_"Q_;R.>F_1WX]3^-T_YRR_]QU/\*7^R>:CGT+/
M.9%;W=:WK6D7'8MR)-!JA0JM8+G:2[^<88%URKB99LV0=SG*<>W#&P9,A?G.
M/*6\X\XY$DC%DM$15]@+7[LF,64HQ.\DB?6M'XN?/TC\4W0L77NH]D"=>;_M
M@?:]$WYLF0'K&OPLVWZNJ?6&TU>E[TE;0JTRY#RPTEK^RVR ,*5^JL6\](>B
M$_IXV7B,WE_7>JTR,);=1)QG*B(RB::$]Q?&UD<%YL'2ZF^<&6F,)0C;)(R=
M06&UKDD146C/TOXL?3G_ !C8T/$M-I);)G[BU%IL.(@5A3K)R;NND!KS3KZ*
MENSF4/:S8BGQ5?L-E?3'E!+;/' 9(A3YD&X3?K6COV#)DRC$J/??'<2/\M(+
M[H4WC]4UMF^@CLE.U](.UCV^)1H]0><UE=^+EU%LARE5B/,V".LFQ*AUIO%-
M"%ZM B3#H#M+M@5IJC.0G46!^"[-K-M/!9.P!J9F9H6O$FS(AFP-1B#4,=7I
M+&/F&1IL1"TU9[(O=[23=Z@V7S4O1ZP2?*D69)%X\..]OCU/A]WCC-S5/B@Z
M+OVP];:PH=(VW:;;M/5=EVW5AK<365=ES0==+;,!(#C1]TVA6B5JL14QJFR0
M$1:1#LXZNN3ZP_>"E5AV&%)XCU6G*48QC-E.$IQ*B*19"%R+E<'B-AQ:7D/2
M:D8RE*4 A(BVR>Y%NR* ;X]Z5NAK*ZM?QC.N] U6#W'L+5'8JBTJP["VKK<7
M(LM<U3'G23.CU6R/MB6S#A[BG8E0J<4H]G!K@P795EL9H<F!3:_8USAZI<2Z
MO3C$E*.I$642R/+"]W[WHB5W7@%RT>CU)S81EIRD1C)IDT3IA?E]20^P=ZR]
M]B_$/TI0-C[7U+$K.T]@W[3VHXVZ;."HM=KSBIU1;34R%HA )ENMU1@3[30*
MI?J)>[M7),F!/&5"Y5V?"23FD$#4WEU$(RE"IRE"!- .W"U:<Q)19#5$CUXS
M''I]248SN,8SFZ9:_%S5T-$F,HQ?5$],C*OB::4BUD"<-:[WE7CEQUGJK9]$
MUZ3JE2DWF\#MY[5D:>T]7J[" 7TV%5:+_:VX<H7#)G1HT97RD0M92P1+!1@=
M'ZS !8S%C&48T;I$Y;(@$GF356A2-]ZDZ::H2TVI2C)MJ.R.^:NWM$N_6R@>
M+B-G^+KU3H$4>ULN'M+75H=&]FLG:1:*H'18*=;NJ->JEIV/KBR31EI)55NX
M'0MWJ\G6CPJR%:C>WC8D<,M2"9@1"GU>KTHUNW1E^T&*<DM(&45NK1-M*2LY
M,L='JRYCLD?LZ8K2:JD9%Q&A'=8)7;/I?7S<.R@0EC'8>P//B!IN!B2A+4C$
M,K"9G1</MI6XEM[##Z,.H2XXE"_4G"U8QA6=D;!/4'[\UDI1]%/NSB#<03L1
M-W-'M;86;_AG6(3T:GDJ(+KEYM5?DS6&FBEDCU:SGP+&;0197)&L$_HEJ2"%
MY5&&#77YDZ?(T]4UW6);7PXB08$9RBO>6V4@)/(.V=1X"U7>T9=,:.RSQ9OG
M-1E""':.Z,9>4>:N"O=H,OC4%%UTZRWL$>,N)NX/JD09=NVZ/.8V''=CK4U)
MAMLV:#!R AIRM36(U7'C ;[>,8CH>;1ZL9]*&G_:!-GR,]4D:GS*D&T3TB$:
M['.8-;4U.=-81@<[-%CX?U^5;?=DLO?+^YFS7S3F*^#L#3+1L0/*HBN^_$S.
MB,R'(4C&/&),)YQ&7H4I&/R28JV7V\XQE#B<XQGE90C,J<8R/:0)^.6A.>FW
M"4HOO%1_#^O3LYKFZE%93A$<]?6$><YRA.R+ZZCTY_\ ,0F58W\,-I_4E,?V
M<)Q]D^,8QC&!Z/IG^Z#ZI3/P)!FT=?U1QXM_7&#^+&_Z^K//%&K2Y#,LA#F6
M"3%>1)A/VTV=N+@^0W^1\:JU$C'TUY/[G8'RZ_\ O<O#I]'3;AIQ$[-6GU,K
M?QS%J=5U&J5/5FGL.T^TC0_;>2WF;,&.,8XR05_-]L<9F .W]?7CC)QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SV1^7'\_ZYXQD1Y\7SL8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MD=M]KK]#J=HO-L(I$56F5TW:[*66Q*E(%U^NC9)@R17%@L2ILE,(=#DR5,0X
MTB4]AK+<=AYY2&U3&+*48Q+E)(AP6K06T%KZ\8"VO?C.9F>^74F04* V-S!'
M382SAZ>7#MA[6LJ./V#1ISLB"CRQZ0&9;,,OIBM6&XCC"VL!I>0I.O,D%6F%
M("(R_JVO0^&TBC92&H:3S=6:B13OR-;><G;+V]+_ /=M_-K\>W.:T/\ $#ZG
MFJ=(OS6Q3PFJ,:FVGO7!&V:DW+27YFH-+0Z"0V/L$4*N&OP9@Q7 </9]'?AS
M!4"9FRI-*Q5D&E#"Z8$O3:T9;6(RWPTJC/3E6IJ,B$5C)!6$AM\J>:K+G;*Z
MKFP[CS*Z.'UI_GFXSWEZR)+[5$JOQ;"-*F0%:V.?_P -]H*I86S62Q56I#ZQ
M#O2*:JGV&R,6&[58:9 ULV6*U]PLAXY$'Q8L]^(_5M:H.TO4%A'?#<Q"4F6S
M=N(U&2* UQ=EQME0UW[<QMXOM?'VU^6:6?\ $(ZB"C6R@A/;.1Z]3U_:UEM9
MJ71MC,U"8.T5'=D[GCT:[*J/X2V<<U:W'D)O-:UN9M5BK\B+,BSA;<F%,:8?
MJVND$TUWL"(2BO[3C3W1);H$_P!UF1'CGDR=DN..]5R>O:^>!]%HR\]5;YU%
MO#-DSJ>\B;RQ4OP;DY-"MSG!K#>P:#6MH4V1#)OQ&!Y>*=HEOKEABRQ$F=&;
M8)MQ93K!!F5$8QSTYZ=;XL=VZAJ_+)A*SN)**4@\>W.0Q2K*N_P:?Q,MSE,C
M'&,<8QQC'&,G57>1'"V.0YZ\ML15O.8::=?=RAJ))6KVV&$.//+]*<^AIEM;
MKBO"&T*7G"<^F_1WXM3^-H?G++_W/4?PI?[)Y\]1?Q,^GIH+8#@VY[,=;KE]
M&ZKDAY/6OLN+MI;9Y6$6*,ZZJ-,+:B@6N[7>$(!%C9ZL5 .;,5D#"<.6.(*$
MJ;F+]W^L:2*2EQ+97AZ@LF_+$8C*7"H"ART9Q/U76L*AS%G?BZ2$2C<I-(BH
M"H+P*YJ.SW:'HE;.I@6T;YV)(*=8NRBG:? GUVL;6-*ND8<-L%SLU8,AM?U@
MG=0@V$ U[<&MCCK")$1A0@)9P%P3!PF?!S&KJ:$M(=27[+4XL)-U:B1%.(NX
M0X$:QI:6N:J:<?VNEYD6!M[ C*0/,C;2VHEYQIL+4OP@J[ <"M/WJO!J[L+9
ME&:U-UQE]EX#1&9V&T_I#=^V]?5_5V@(6#%DU+;=4 -5[&O 6L")VM1+1&>^
M86.+F#<-W#.'2'%R E(V:;J<NI#3G*)'3+8RB0E(/*6K5N9XSZQ;J"L8N_4\
M)_LY:D(29S:)DF<8LDDM5Q3EEE;K\(0+)E'95VUM!)_C+K+VJ'&QN;4X:5(V
MC9];UGK\1I!(8,>)SJ+8['I[7L,C0JF]*K@G\/CYMZ!B8CR);EV72'.Z%WIZ
MHEWYI1(;:+8LH1\L>#:;@RI'K$V[94QU-)&J=I)G8M$@E*I<+;2YK3^I?A+:
MXE;)K]@2W]:Z%N=,+;?(F%[>M5DU'*U*1LM@ZMSA*1,$J5LT];U\/0B\&G8L
MDHU&.M!;Q$7E<&,F&'2QW#WT/!95O6#%73>!55;(W?J'&"?5RVH<:YJQC\ 3
M) :EV@5L*6N11><QZ2S\*U%WZDFJILB]$3-6D*)=9-7R;'V(("'K:]LO:6M9
MA5C3A*&XEO8M3O9K:@6XL&*] L=/'A31G8,"!7:.@J#1_5=VDQE)KG3C>HE[
MI1O97Q$F0V"4K0+DOZVQUHL8T\:DJTQK9"5;Q^%B13E'@BVTZ38!CX2%VTT\
M%O$;89K4^IMY;J "YO\ A-VMD-HWGV*MNY%[*SKHN.UZLG>K!#N;&SIHT[KM
M^PQM8F1(^>/)5]V/77G(D]+*-29,83F#MU'SZC/=3MY;W4E[4[]L1.K)B$"4
MX:;6_2/)I$-NXWU$V[1)5N&J><EFQZI\)W5UIUIV'O<J/#NG;D-LBZ57>HX?
MM>S'-HZ^VKKVFZXMTN\[#J8,OD+J./3]D:^:#-[$(@*+3ITZN&0_TLF.S*CR
MQZ6+'47S:Q*4=2I+.,XD7=(.(5*-;J(\)5.1&75R)Z<3C18DH7 (2A)D;8RD
M7+=!O;;*D]<R;>7^%C<9UTH5HM9@<[IG12]9.7%6-XU &"HO1RUKV(3DZFW&
MT+%5JT;)Z[7& H]8B^K[8>OM=)B)+!;"T"R45B5Z66Z*OD@QW5J 1T7<[)T1
ME+3>78LBF^!P1ZN(2C$\\]]>22NL;0G!5(3':$P'WY,@)R@?"9L.F87X\KVV
M;?5]C::[.V.;F^Z[[963<%_HUQVOUVA[_P!IV,(4I<O:Q>T#]D0- DA%VD!T
MFJP(&C[!17H-)KI:>)KLZ5@;MZ,-25R-1FDI:7B32F3(EX;NK@Y/+;EMW5DZ
MCX9*,](\LM(A&1'4=.!YB ;=YM[*T^9+[BHW?OIHNEZ^=KNR3(JI&ZAKTC1W
M[1JW<U55,HUQV#6])Z^LSF+C0A$Z-6+!>;%6P8^T%6XPB1%)Q[(Z037%.F49
MS7T:C4D$&-QF>5D0BW*)PJ%O'K=<Y@ET^MN;B7ND-3A+S$6<CRR;2(M%O%5?
M&2L;WRZO&]DUK4=?O%FLE[MINU  PVLZ?W/9!>95(V?8-,VD@5M0/7T^IUZM
M"-F56Q59^WV V,JCLD3+G1C+XI*9ZI\?29$"2R5 (33B3!;(H!(3<NWB[KG*
MO3ZQ!FQ"("K. TQ)GE9$E8HT%_*\[ YES#CC&.,8XQCC&.,8XR05_-]L<9F
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MCC&.,8XQCC&.,8XQCC&.,8XQCC&3^H_LL]_"Q_;R.>F_1WX]3^-T_P"<LO\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g400206g45x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g45x63.jpg
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M 0$! 0$! 0$!_\  $0@ Z )= P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M       '" 8)! 4! PH""__$ %P0  $$ @(  P0$" <*" L)  4" P0& 0<
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M8]1G^%5MVO)O$C7B[5&IFPY=/18HAR)6),ERX1:D]6$5%FRSHU=7L-99.O\
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MG9'"4&&R/"G(PAD<";"Q$"TA?7I5NYIKCP7M(LM7AL]:!NO:+KR[;NWX.JH
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M[E;L)+X(. . . . . . . . . . . . . . . . . . . . . . . . . .
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M%.(K%9F7RL5MN 2>CVU$FPB:@4)/%]@*EPYSH"2U6H,(Q5<PWYAUN6$.!I"
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MJU'EHAO2HBY3$*478ES(\-4@F]#9?;%#R9)44?*!NV;,KK5A%6ZN +6"D>^
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M7:)]]LMGM)NX9<GRLG3A>2-FDI&4NRA+,C#LV>(L\]ST_/IX]5]Y<G@HX X
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M7LMZ>#8@4^75[<,S8[3L0J1'W264;9.V&1#7F- 'SC4>+.AN0B@Y<.)[OEA
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M^M%4T3>K7R>=GUZW>N=WU[]5,O>*='B]9[_$E$9PAHY-H]>64&Q94N;":-[
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MX#(9&9-3KP'+5M%A='IK2IHIQ(V2LR/+D@(ZS,1H]C][76%V.NN*A,3[5+/
M*]43]A$ WN\=&YYWMN?>U>Y="D$)-$JLDL@;[\[7!3LC AB?$&O85 94V]$@
ME6VR(YJ0SZ'OAD[#LD:IQ4%Z3+7'S)>%62WOT^>WGMV&O;P^+:Q<;SVI+02%
M,=$R+V"D PE%:K9,'7!$B5<\QAD>]4IMZFW-$=QN1"0\#*//"_<E-&Q(DS+F
M.DP7#H[M-?5KH[':]_KV($EM$T&?FL1I=PN6'X92<;>DV@<PR0#A)RPNO I-
MFR6H6^V=0R<GN5VWTL4UEAJY"&HDR)(R#OUZ?QWO=PZ>K8F9GM"@Y4H^C+C
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M.0/,V#")Q7X)&'%(09*,MR8<V.S+BR&\YQG+;\=]#C+J,YQC.4N(4G.<8^7
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M'!VO*$.$5X:U#!CQ5W9O+A_'7ML66X*4"["?;N\._P#JG;W[J*MP"_O ' '
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MXIK'8ZBD3%4V=5*J4"0*Z9DS(]NE.8,BZ],S%ER$0))...G,1I<KT0<38)"
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M\O++QZO'?H5_T4^EKS)^A,_?_@Y>L_\ ^&N?_O4K_P#@<S\H^"[G[3#MB_\
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M?XB'VQMS_P!>J'W>5'F@.4WX]8__ (Z#\,HSM7*]\HNTOSN'?A&'D@]Z_P#
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M?A;9WZNJOO*.YZ"_86[L?H_L#[HYG,^3[Y-^4+Z'BGX),/JY*/DTY0OF,6_
M(C6-UC^TCH#]=.K_ -]@G-6[(?&O9KZ^PG[_ "#2VQ/QQV5_>+!/Q.E(O_""
M_MW!OU!:_P#WGV!SU)M'\(+Z/*_S3#G?='_*!3_NYAOWO$BU?73_ )O7V/\
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MU3@R$T=CUU^5+6[::_:HD>(/9$=]S:M?3+=QW6\(Z+177Z3IA ]R=L:R7F7
MU?2M99^)+*0Q4ABFD+(7Q94@)-@-"1E@-S[2202<!QQ4% B( K\2&P%K@6%"
MEDM$EV%SWMOK\6[DMW _G$[5_G4V3^G]R_>$ES3W]S_9]1_*O'OAG%OK2O\
MOTX_IBZD_FJUI^@-/_=\?S:N'?L-)]&I_L99_4;"_@W#OH-)]WEDA<^T^X<
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MVV\%' *!=A/MW>'?_5.WOW45;@%_> . . . . . . . . . . . . . . .
M. . . . . . 5(-])]('^R8?M7/:NZ=J!)OQ**W%O5@BTQX@JKURGN39M-:E
M8"S)#P2GU5IQ3S"DYD !\M*$R$.N/!;3HT+;\ UF]NNXW9+2,TQ_!%U6L>R
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M[:S2A%R$)'2Y"((Z'*G2E-X8BQWGUH;4!GGXV7:?\GA==J\X_)G^&GH'\_\
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MR%$RX$>H5@-.I:9OT;^]]&;,*#[SL7>"_NTK7X_LCI0#0C!<98[%#',1M4[
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M'9',0*_;J_?8@O1KEQSTUW:Z76_MM(+Y"A="-8P]F[(J(&]]N]U0CC-Q-ZX
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M%8@N!@U:K&0*V,V]&1*,%)TKU/J%2MT]+U)3X*. . . . . . . . . . .
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<WC?TDM<%' ' ' ' ' ' ' ' ' ' ' ' ' /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g400206g45x64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g45x64.jpg
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M0F>2L;;7&30V0T=(9')XE)6AM\?1V/#_Q  < 0$!  (# 0$
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M19=DDQ>EI/4FL =MW2'LUHP? EM.QA(%=A9N1*[S=-.9). .0QCD-<G19\[
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M4A!"&HDWI*9(8@H:+'D9B228V"D HH<\O7KZXT6OKK;VY^T'V-;(F)V1U,&
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M74M!8K9<=IG.N5/072JM$;'6ZS122]G4U-7<)WQ4D\E&<]O044E16L(<V:.
MC)VBFV6G-'45UWN%#L_&VWS5EO@NCIFU]WE:P.IJ>BH(8IJIC*LG$5?5QT]
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M)-=>[AW\#T/AIQUT4TM,L;!%U-K@?;!"BMELTRO-WDAQ<2X0[941H^)51SL
MTQ /R7R<+Q)D0+#$$1(8)>AF&(U8K2"JR7PB<(G")PBTN_;MAB&=+ZY@R>B*
MS@'?5%F0)B;G:5$ MST%5-A357CU W^8BJY8%3UF B*_D9]F7?K#4H[L=D 7
M\#KGH4H=!\_AKZ^6N%:N[YF#C,=+-E;TTCVE!W3O^N1/7BQ2O6#?&[ZM5:)
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M$X1.$3A$X1.$3A$X1.$6KW[4R<N5 U10MKUD;0\Q%U"[8AK17NP>BJ]M^E%
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M$O)2\WA]I?I=PG&%X_6\?7G'V6-WO=A&=XEQ/9L)))R23C4DDDDZDYSJKO.
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MVJ6P?.4&MU5T?W$OPC2F%91=(#+R'\-K%RY*H*2RNN6-,23(]>O7FOJMA59
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MVQT!J:SVB&W15M6Z5D=5,R9TT4]7.XSU;C3]MM"HVA.N&HX0&QQ7:V+B;"'
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MI8)2QU>)>R,^MA@I++^&^P*LM.J%)&)2VYA*\L$,/83EMUM2K[/<O_/XL?\
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MIPSY*GW5J&6V_J:0U4QLVX4C[\>A&IF^UQ$,U>\Q<5+"3!;$07F-1 1A\RX
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#B__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g400206g48z31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g48z31.jpg
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M 0$! 0$! ?_  !$( ,D"6 ,!$0 "$0$#$0'_Q  >  $  @,! 0$! 0
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MY-"58\W%]E9CHWR0Z<ZC*W,LA-/OIYSCO'5X<OV7%Y+.(6*" ?O5XM;; OO
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MG^D=TTG[1SOC;?"PWSW/5DQ:V*W6J2K6LITU%##J"#TOO4_TNM51\?G?'NL
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M#DM.LN82XVK&,@'8WZS'(UT,^_$1Q$\QCSK SJQV5$EYPED(1'^RFGD+2.
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M+*6.;'E!*:$RIJ2#.LRE9("?D<-2)8SVAPO9JG XG5G8V5::ZZ[ZCBY%==[
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M:6KOINK_  I=58EJ(7K5Q6[J<+(X?AY3A[\='L'*RVC==R.A_IV5W5LEM=J
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M>;F9Z<&_PU!>Q4J5[$ZC,O;&QK;TK\5JPI6O600Q+*O48F-F7A1S;8UXUO*
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MC%<E/Z@"JIR<:Q37D&M0AKLQ;CROD-6ENAG6RS%O;Q6K5;:;7"\UU#$K]X
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MG';J*U5-NXQ]/[B$U-46W%9_JX=CU>6?SS],_GP#T'NM4[]P4$_7;K*#W/\
ML']Y>CIK;\-3A*SC[SUUVR]G/])*]L7;#*OW9'2UC']7&./-O]IO^L94O8?
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M(P"Q(5Y30S3P8C3; @<C'+;4&>*.RRRRVE;;1"6&6&$DI99;;3MU 50J@!0
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M<L%BC2XR0L@MCS(?'C9(P<M;$O\ $I,IJ> Q\*F4FQV<C8GG;>R=]M]M$ [
MUK7PZ=)'*-: UWU\_P!YSJZ4P^KC6XE\J50LL+L4S3=O>J=UT%?3R(LIF+6S
M[JNS^L[H2LEN.CK(&@I<2+)X @DI%?,]D7DEA6+K\C:)!7F&PR]>H[@CIVZ=
MI2O,-@=='J#^X/OZ_OKK.O\ 69AZP5^'FB8>4KQ4E'CE%P4TQ[>5AS'&\>[C
M#D8[MK?"(PZ.H@9;H9>&\%!/D"/,/N6#T_TEP=?]9G.(E:]^10$E@Y9X_NL
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MNFU.OK\_EZ[W^<CS^/\ N)_;_67JXDQQ$<1(]:UC51=ED[9CQRHVX2=<15+
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MR%U>IG>AE5WK4J_BW5VGF)#&@D"I;'3V:^KC=0HM0J[8 $9F"KD/&O@Q;+#
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MOLVA:L1)/^[WRGVF(0_:&TY79\VGUH2E'GM1CBDY]O)W^1$<#-=%\N^' :5
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M8:957$+@[NMU>;1AY>)XE2"LI9]H5\ N6L3P_L/-IVL'+N741_B<N*NWT;3
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M18W2)D;ITB_R+^S:%M#8-#LC$M%;GD=6L5.?C]-;'AUR<AL<(JO3]8/&M<=
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MT2TMZZO$)J:PYT1-7^<!K.-D323*N?L+&G*'-7Z?2#*,PCS%?LR0\1TA$FP
M225/?W _(^?PWT_*8O8/VB=(+U;(VG3 <Y\UJ+Z<;/3Q-LZXN]1AMAZ7W?U!
MZ[U YL^CHD_EPN>@UQEM,?CG<%!RD)(FU.3LE?;AY^&9FTC7K[_,>0,D7I!Z
MC=B]1=TZH2[)"*JM#U9NJ;U)KRO2&JK;4+!D>F.DQ4W.3E]GKG)P]XD)J4&=
M,<A("C4_%'!=B@9 VQD223DH(UKX;/S^O.7CXD1Q$<1'$1Q$<1'$1Q$Y5;.Z
M_KYKKJ4O6L&ZIJ*9HU%ZANECI\567+U,1>_[D9U,Q>LGU7:@53$3(0UCCM:O
M;)5/VB!7D!:Z)3;?8%6 !<9D=25 ?'L3\-;[_'1DE;H^T7UMJ*B[IL>=8[ND
M[=J#7R-H#Z]L&L+I09B_4==I137+55R)^ <=37XV><8'GWY"-'EX 8V,D).#
M9 E8\DE( V1V&SK>_K]9N+W6G28&RWP*VM3P:(H;00=.UH#KF]*W=)7#>(EX
M)A:@?57!G1SYP]NFR$@T'%X89J,'"V2=O1\5"Q[TF*@ GZ].^_SF)L/VC73C
M7X>M2GH[>GS['6]U6IRI5/2NR++=*M&=.%QB:%O9-YK45 /GU K65IEV(J:9
MFTBIDRDMC5=R?+E8 >71RGW?GZ]1^?\ OU-QU;UAU;;?47L+0E7H]Z?BZ;JG
M36V8;;R8227KRX06XQ+I)0_L9-R.'& &^'U1ER%D'C2$V4PB<CQA@GZL;DM&
MN@.^Y(UZ:U^^Y;_B1'$1Q$KSU6Z(9ZF>G[8^D'9IRMNW<&&Q'V-AR38*K\U7
M+-"6V!G 2H20B9D&1B)N! D(Z1B)2/DXXX<<X P8H=IU"2#H[])J)W1-H$JV
MP=E"@I^N14,C3N"-;5:US=?U382.GHT21T:;8J%'$LPQQ&L3(R%<@4L(#%.8
MKM8C[*-.QM9@@X]&S^_Z]Y.]EUK5+;<M;WR:$)>L>J)*R2U-)9-(''#-ME7D
M:?,K+$:5AD]#T'*&,,MDI6D=Y:"6L8=;2K"1-#M73GK^V;8$W,0;=X2W+K5:
MIEJ&JUVGZ]6]D5&E3MFLU,K6QJ]'E-Q]GAZS.76XE!"/(8P>':K! 3RIBMRI
M<.XD[Z:_@34:9T@:MI-?IE2$F=FSM3UI9M?676-;MVQ+!9(O7F-6C2P5'@JS
MB1><+Q"1 ,P^"]B8+EI:7##B!9F7D&8>-0,D$[ZS)R/2=IV0T;JWI^0#98JE
MZ1!U\-J28@+?/P5]U_(:NAVH"E6*NW>+,&G19Z/AVWXH\ITAX6PP\E-0-B"E
M8&<EXPU)V=DGJ2=GT.^O431)_H1TI:U-KL\UN.Q.RE0%U]LE^:W'?))[=M
MM]FO491]OK+EG<VJI1-CNUT5$U\;X3&QE?M]EHX([%%F3:TZC?\ I[OA]>_N
M 9F;!T1=/EH<F'IBNSKS\RC<RG2A;=88PT"0WIMG6V\+E.PA\:<(="V"/VAJ
M2@VNFS,:2,=43X-K,.ZPEQS&4;/KZ?H"!^A(]_G,A*=)-&FCJ'8)6_;P)O-
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M_M'OZ+O]=:$^<UUH[[K&PK'4$[&UM:;W4]A;SUG9NGSY#; V-6M;:HZ=]A[
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M<OHRZ<WK%)V<NC2D@;*3%BGUQLEL/9<E5(^5N.Q:YMBYOP%).N#]/K;-TO\
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51'$1Q$<1'$1Q$<1'$1Q$<1'$3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g400206g53n05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g53n05.jpg
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MAU=EK6U/BKG:U%#=;F4OG"#_ />"K6*-1;N?SZGZ7^QK>5.)DFA@9]/VL/\
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MT![^/5[1,7G0I[ F55$B[ETXEM>V/.X[=@BX8_8!$I/W.9'%]7A:3OR)4EO
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MAP2U8^#D*<U@@"/\^= 4W,A, )/)2H^"B3!JWHA(Q@I(@V8J,JLB[ LBJH*
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MV/A&+86&! @W:'0(T0&$#&22+,<+%CVS=B/8-$4FK-H@BW;I)I)Z:8*NU_\
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MEF2V(ZUQ8@Y"]M/4B_.V0TUN!?;IOJN <K":V)3D#/Y%O:5N5A3T>:P6(DI
M@,,VE8T/K,9(9B=UU;QN&1,4>FX+#\M)# [<BN[:A(VU.2-^/$.2@!-[< 3K
MR!/H%AW_ '#S2UF5JUJPG1:46C2@@^;LJKH97ED2ZQ8VR N(HT3PO$ $2?F%
MEI6XFT;TKC1NV4ULY)V^>U_O(QX&0NQ1+'7NY>^LZ#CJJUCOECH@D-Y@-H5[
M<6P+I6NZ2M-P:P,@NK&D8=T9:L?H^FB%M:.)ZW(?7,+7DC.*91KQA/=@FK,L
M;.98!&6CYP5W3GU$CMW1<VOR OG;QR4T5CW-64G)W<SM<Q7%#LZFN$]5P=[.
M+6$-M)D/'&)6(!2G=\;#1:+BG,MTA9\L-B :43$V*&,E?VEV"DDE1R92VEL\
MN'N_EKI<9G ?&.3&F^1!!D,18EPY>_NU28DL,=MWXTF-?]K=".V)$>^:**M7
MK%ZU52<M';955NY;JIK(J;I[Z[9*NU']+/[&J_WBQ3Q%1 =_\SB8?W$*W_[@
M;5\67\'_ )?97O\ %BGB)XB>(JEA[_K$AT 2B36$:MIBZQ^[I>QL#A6I8FE%
MGYI\TC+UYHA@UO&AYM^?7#H*O5V;<D5>ODA[7]2>.L^@5/P\Q.FV89M*ZJI7
M,=2P5SZ("3I64=0&.C>)2-QTHCD9))%NM#6[P$CWM#7>34?Q>P2MVWDV*90U
MS)&5U5AD>).,?028C2&1LT1IQ^]9"989(8Y[N+WAA=$R-QD;;3WGZ]93Q$\1
M/$3Q$\1/$3Q%QL^8Z'S.TZ[I:GJV?D7DZL":R7#> 1#FR$WS8T^B<=CR):9,
M8]*I[T#S0,HV/,V.&B4NGX"V(I/'?ZH""PLX,+.,;."R;D22#:VH-K<N!OV6
M/DK4_&NPBH;C2J8W#H["X<*AKZR8*]A<$IDM0(B%RF"VE-(A-8B2K W;-Z$A
M4OCDO"G!,W.K6W.T9S+6IF=,9 ]82-JIEY*.U.O>;\.=AZ"VB_5VWM=]>=C<
MIU.&#5LE1%Q ;IVDYTF5.KV&1FM?UM)IHR$-1Z(70'$8@(2%!';N1ZD98:DC
MDV^':1R.-HUH^E9 !8GB+>:HV1^3?I*R.,[/Z*K/G>.TM):QM"HHG( UX&Y\
MH14@,T9U\^+V3"(NXJZ'9F(*6NYJU85 ^?&XZW-P]TI/Y6WC$B#+U._*[H#@
M";WY=MN/GUY=:]?^6_U3/>E^B*%@V\.0;N@7<<%I@-%8&U,6O5TZY5"\P-8G
M9!Y:7S]E#9\TL<OT*5,CXF>#PL*WT$P(;J9)(%#J[XEA8'L)SU!)%M+Y6]>I
M?CO*_K]CGQF='U]9?)?3<VE\I^/:[D;*N0 \Y:7KV&2 _24\$GR4]Q^^6LY,
MBO'$],2B9,*XIXXR'#W6PZ(H2@BURRW*L WFFX'U#+ZL\QID>ZY'6MRZ;I8/
M-.DZ$L-^@BV4 <Q.8WN<VD;QFZ'?GI8'?--FP7;7<1MKAG^T"2I%\GOKLH[;
M95U_]V-5$O8]A<?JL&V0QAM,PSRRX]2BFII*-CZ9]1-AM1'OSU8ECF:QK6-<
M^**SF-9])<:ES1X[\0Z&GQ[%\,V=GE^6AJ:(8C63PU996NH*'$(S)!3TQIY8
MS-)4OI60/D)9(Y\I<&"FWG5^&U#6#Z.U$,#5K)9@PG<')SUU/GC8;O-(R##)
MM)J<&RQ^6<BV0\D4(D (=R!CSPJHGJ<RWW%;"!9)X/[EVT>T4<^+56*8OAQK
M:3$X</PW 712-PZIK9GR8?3U5)%'3BH^6I60SSLFG$3)S3F1DX?*P2]>_9O!
M'MBIL$@J</PXT4DV-8]25D@J8Z6*,3ST<CS42T<U94,?:5P;(:*.4&2/I QK
M=G>[0M^HMI(9W,JB(AS0WZ%I>/G5'/XR99BL+#%T)E-!L9%.VFP=UKLY)/-"
M43+-W'TM7.$'&BJWW_:.)L<VF@PS"\5@Z&<&JIY*3:"CQ5M14N?5E^$X;%63
MT[#4F1L4+*BDJH;-=()BQT8Z>BV-DAC&)"JQ.EFJ_EWC#+G#:_"(Z>DCIZ&,
M8O65\$,M3'3,A,TTE%5,>_I8H?D]\2J9(JC*I*5+D6-BBK/:&VC9L[8")!%I
M$S(M&:2^Z*(3.KJ<1YNW:.%=]"3G+IN_?Y51_,.7F=$'"/15@V=>UE)4;-?L
M*NB<Y\-4Y]5!$]SW />71Q854.E<SZX:<4I;"&DNCC;=KNUAAV\PTBM9M)-B
M^&R7;+0.H(75\!:PN9&9:F3&(.B:6ALU6[$'-D+@V)Y>X%N:AL_E*C/72);?
MLNDV:(#VVC&1#0[IJRT<ND-6R+-V/_(Z,-%VVZNB>44VJ:VJFN<)YW2Q[B8C
ML/3X=57JJFKKY7.,I/[+K9Z2>[8IMV2IIJULX?NO+'M,K9"S<>USG;V]\\*^
M*%5CE&]]+2T6'1V$1,F.8?3XE X/J*=TK*2LPYT#XPZ%LL3S%)$)!)%(QK2U
MK<@\D<V*NGFDLM"038#JKC+^$-GD V'Y1^VEKEF_6,5\99$T=54MG&$FVRSK
M"WUXRKOIHFDG/^/4KV1NH\*.$U ;]%<]^,@%^\ZSHH7UHE@);9N_+-T9!!LR
MY<>9#MO5T;GMK<2@QR('ZJ>,X:RI8"&Y2U--$VCGW;DF.FH^DN" 7'Z!=+F6
M2QD_!'S:+!L V00\X8+L]$(^V2RZ49LW&^Z:,:$A!V,XU4T3WWP-;JJ;)_<V
MQC&VJ:>D[3X/B.#U\<>(RB=]3 VHADZ2ID+H-]\;"YU2-^Y+'.W6R3,:'6;*
M_5>@;([3X;M3A\U5AK'Q-HZDT=5%)T%XZIL44LC1T#W7:WI0T&2."0EI+H6'
M)<RNJZA3;=9V/=$2L&40V]R,/C</KR4NQ"TX@P*,8C0'8E!2D);I9'I!BK]L
M8DQ:0&7@]V%=%TBHMXR?M BCGTG9MTE5L?A.&U=-0XALV^OJI\7PN*2GH,7-
M7\Q5,IL5@KJB:.269K!%24U-3M(F; Z%XD8:AK-.QS:B'#]J<8I/EJJGQ&CP
MV";#L2D^8FPRI:^&GDJ,/E934E0*;HNEZ>>2;><QCVS!K 8GNP%9G^R:[!(_
MME+F4SK".1A8MF:2.H,%Y$Z8ME5EEMC2,4M^ F/_ &=G]*CJ1MH80%+(I.73
MEH,T15=+7&\%^'-5B$]/AKIZ3$I*T0QX?28S'%3-<\#*G?/A.(QN E):VG=6
MQR-=NLCDD)$;,,!VEVVJL*H:ZLP9K8YJ43.E?1U+Y!8D[SX7U%!(QDD=GL?N
M2?2XEX&3WRC")_8QHR)+02 PTD*T#;JQ495L\9M6II@36W>-5R=02*28A:#$
MYHNL]4EJ2A0RAA5-49N^26R[TZS$,"P:FII(ZRMQ&.0S!M7/C.%U+Q&Z)H8[
MH<:H\ K*QSX2&L%&YT4!LYLKXW-#7<VDVBQJHG8*>"AE<1>.FH30-F8'F]I:
M"MVMH[ G>)GZ#I3O-='$X&S=_(61W$$AS@*&Y_6&/,E/_<V[210^,-_RSPPB
MHW$X5U?V(Z5+Y345V<$=\L6)/\5$$&(S.Z>F>-AV'_#UE5'+/CM+)!'">DAE
MH-HZ\R2B(ATI='A^%M9"#=X889'1$-N^07(^F+U&W$U**>BPW%J>2:9@=5TD
MVRT#Z:%I$F4%5B=297O<UL%FU;;MD<\AN[N.VN57[/F<G!!KA0LVM8F88M=-
M\QUE#*W8/WFZ&^[X4[F9\_():9?*.<)LV.U>.:Z*M-ML+K9W9JY>M^%28'A\
ME%45.%##L0JX)'FTDU9BLC&"3=CFCP]E+00P0M9>208A'BC'M&Z&]*WHG=N_
M&L1IY(H\0BJ61.:W?+:-^'%I#;N8^I;)B5+-(YV0=!64#6G,G<.\-QA=N5Q'
M9/NV@U#FQ\E)?<9OIW-I77JIXR/152SE^;L)U.YS+C8_5+.SI/8P2>.TD6^4
M-VR+K+=HIQJW!<6J:(S56+?,4D!:YM#A^'8JR"&5X=]$- [#L.HJ9X(W"&,B
M:XNWHS(P.>/K3;48&VK92M$=-5RL>XOK*S#]]T<9;F^JCK:ITS2'.<"V24,$
M;FRF-YC8^9G=AW89;3A]7,(J62-@XHDWB2+ZUCS5T8E*2>NPI$LJRK9X&9"W
MN^V<K98G'RJ:>&^=7&,.\[MM;BI<)CDI&5]9B<!=-&*YL6%Q.,%.7$2N@=-B
M$+YI66L&O@B83O?4=P-?L@J)YHY)*5E),S<<8'BK+FR/L-S>,<+VM8;W):]Q
MM;+,[LA4\?GTBK6&$;9"1Z+6JXCHM>PXK%R#HD%CTH6;:[D1XYR^UP\49IK8
MV_+[*[NM/I_'5N1)M]$R#GC8I'AT6(UL>$5%1588RHD;0U%7$V&IFI@X]&^:
M-N37ENN3+Y.,<9)8W[4SIW4\+JID<=28VF>.)Q?&R0CZFL<<R =,S;3>=J9&
M<.&[1NN[=KHM6K9%1PY<N%=$6[=!'3919==93;5-)%)/791113;73337;;;;
M&N,Y]P6M<]S6,:7.<0UK6@N<YSC8-:!<DDD   DDV"^Q( ))  !))-@ ,R23
MD !J5A8I+(O.XX'E\*D026Q20,DR(*21LHR- S#!7.V$W8TH.6<,GC?;;7?3
M[K=937&^F^F<XWTVUQ]ZJDJJ&HFI*VGGI*JG>8YZ:IB?#/#(-6212-:]CK$&
MS@#8@Z$+&*6.:-DL,C)8G@.9)&X/8]IT+7-)!'6"M@]QUFGB)XB>(GB+DU\O
M0I.=TI4U)H3"R8P9NRYTXD+80J^X!S;#90@ K6Q+#.A+PLRPJ=O4=M4RP&'/
M]24,8UM)7$YD2D;C9(6[CKTSA,?%9-RN; V%\[\P+Y%N>?-3-\:<BU+<QLHV
MJ3-OR=63V;U,:9$CM*RD''G\'(HL$05>2B@*=H.MS];-Q*@Q[$'[&J(@538/
M\L#8QL19+()%':WM8',:^.9)[<SGH;*__BB>(JK]T_U(^QO[J_0G^$DN\5;J
M.T>JL9&/YM1[_88G_D&_BBSGB*$>F4)VYYOZ!;5;L=ULUQ2-K(5SM%W"[23:
MSM6!GDXAM'7391%RV.XD&P_(APW6271(?EU$E$U-==L$4/!.)JL4#"%"DXZ^
MP3W&,-R.-^^^Z$]\/MFB6SO&Z:?16J:>V'&5,;:)ZZZ:9_'777&N,8]+#K\3
M^5;GJ\!^%D_\B.GO_KCKS_[_ +NO_P C/+#K\3^4N>KP'X3_ "(Z>_\ KCKS
M_P"_[NO_ ,C/+#K\3^4N>KP'X3_(CI[_ .N.O/\ [_NZ_P#R,\L.OQ/Y2YZO
M ?A:+3D(;U)V/8M<1B:7*;A+OF>L9M^@6I?5V7>V8RE[:5J@7I<,O<\_GKP"
MN]$B!C)ZD%<L&SM-BWW<(**IX4];6_V3ZH3?EX >BOMXHGB)XB>(GB)XB>(G
MB)XBYL_*E6Y>QN86#6(,WA"R1EV4+BL66+NM>D BLVD-OPR*B%9"3J&W*4DT
MJ:LU#.7HV-MYNQ)Z'&XTY%<IRT.%5U+)IL>&CM0#P)X@^GE=5/5AUD,?A\;1
M"4\Y/G\O.6C]N;5I*J+FO1$E8PJ8=KK/YE=CBCNEK#Z.FDYL(7618I>P\?:\
MZGWV)T@V-OVN0;-".H%<BZX-AP)RX:&P%N60"DCXD T:B#7HN%P.OG<<KX;)
M:\+12<RGDNH.0K)GBA>-E$Y .F$+I*NJHA,K:PHH/PG'9:W@PI[EC(UA#U5\
MLP_.N"CN&8TX$GU)(726_*-C'0\!85Y+BAX0('V?25JI/(XL/0);G:)N2"7;
M%V"BA,<4:Y$E)+7XD8?2U:ZO%@;LBB.>#GZC8@U* V\"/$$'U6#A_*M!P&ZI
MCT5$8 B'NNPVQEE/+"3D$K=&ID/-+1A;]-D^KXZZ8&Q8#$/!MH,+(,W ^NV&
MI0; VT<82"0-B9+FUN'#JUTY:Y@:\53IG\3=%L&/,89I8EP(Q_F^NZ/JQZ"_
M4((JRNV&<WVP O2F1UIK+0-5^BI$[8CC23K+UZ[@^3C9Z6 F-'8EVB@T*[YS
MTS)/'(N%C87MF,L[]2Z&E*KK XV>,C5<0(NS(GG$I(-"D/CQ!L_D[MOAHZD;
MQ!V.62='G+375JX+KZ;D%F^N$%'&R6,:^+%5#^,YDS&\ECAPYHV8#V'0?;+)
MBQ9()-6;)FU[8Z%0;-&C9#1-!NV;()Z(H((Z:)(I::)IZ:Z:XQ@LGZ_^+/[6
MJ_/BQ3Q%1 =_\SB8?W$*W_[@;5\67\'_ )?97O\ %BGB)XB@B.='U;)YT0K\
M<5=)%V*C]!)\_:Z- I-P,^YE\@.?[N,[*;H:(+J:[N6[5%RFAONT57URGG?<
M:_83:+#L'@QJ>FB=2S-A>Z&&0RU=.RHW1"^>$, :'E[&D1OD=&YX$K6'>MYU
MA?Q3V/Q?:*IV:I:V9E=3OJ8V3U$(AH*N6DWC41TM2Z0ESHVQR/!ECA9*R-SH
M7R#=WO\ +U3=G6VM\\<H /K\CSN.:7?:S1=':1;;0!]"VP21N1T!$B=TL!4I
MJ+%[-0*^$4DGJ$V&EW*A=^1_,N2'Z-QFDI!\":7<PC$!*<#PD",1/^=95">F
M#JR8A_2FA?,UT[6F[#1R1-$,<>ZV/7**BPV/;J3$.CPADHQ&MJC7B&F:'=-#
M,U[F5'1@_,/AD,3Y-\.=)OETCB2YW^O5NY;.TL+M'"#I';.V-5FZJ:R6<ZY_
M#;&%$]MM,YUS_#;&,_CC/\,_Q]^1'QR1.W)&/C=8'=>US'6.ALX V/#)>R12
MQ3L$D,L<T9) ?$]LC"0;$!S"02#D1?(ZK[^P7T3Q$\1/$3Q$\1/$7.'Y.J.:
MVIS[^V 2N24]M6KY'$UH&["#;AE!N(QJ;6#!(Y<LD'5[1]N4I/;+6"U;J?D*
M,&#39H3.O0#)L*;/G^R3!V5!S[>SNU!MFH]^)EE?42J2;5G:U1M:S@45E)F0
MU(2_=?:-0FY6TL"R[8/2$A)HC<EWWS8&Y\ZS2B5KE7T@E0XF')6V]KLP#2/0
M$L_?E76OER%\P> X@ =6G#7-=17\:CA4N!D!0 $)'HJH25C!M^*8O"\<5,,=
MAA=4"2<(*/0ZA4;ON/);CUF^SYCOLT=95;[93R6*2*-1R7AWD=EH )*(^0RV
MR_!2(4Q-AWV6;M!^TR\&$D'+)SEJ^:MGK;*R&_V';=!RE]*R*>^I%KXNK:R!
MSR26H%KF""+/F0T<&E]CBXA'Q\\E8</HBF)%227M!Z,A.#1:;=OH.8E"+IJR
MT01U;)):I:8U)<Z7RY*K?R:__+<^0;^Y!U?_ (#3[Q9,_6W^IOJ%2WI=1G*K
M*CS 443:.IY5=*TJ<5(.V0O,,BZ,[EKZ;3%!Z])C- 1!]#9!+!45-KN<I.I.
MU -FK???5QMK[+L945,.QT\E/#7N=AN.UV*Q_)QS2"MJQ@L,5#0R,ACD=/!'
M714E15Q[H8RGZ5TSFL(*\?VICPZ7;_#&8H[!_EY-EYH&MQ0P-<P2XQ3_ #$T
M#JAS8A-T(,<&9<7/?N NLKCUR- F&K%LQS&#@=F2?LG+D:6RF@!%Q<\LCOA1
M8/HNJ,:FI/EV-W</6B:^C$81U^ANR^XX2T">/$Z4SXKBK:UM9+%'%3/K8YQ-
M+/54X:V7>G:UTAIJ'=F9(TN,<LU&[>!(!W"%V$5(I,"P9V'F@C>ZJK(<.EIS
M#3TE/4&7H3'3N+(Q6UYZ)\9:ULT,5>RWTN(LL.3DPPJ>77;G&;)59E^246(;
M34.KIHALFKE!EC5G)6>/JQI^&Z65=5%%-U'*?VTD<9UHVL-+Y\"#J>[\9!;7
M9P)Y=?U Y:<];]O+GHTSJ6IK);&%9!"QX\\0:.&:EB0#1NUF09PY^]MH^:2$
M4S0E LLU666=:*/1Z[5NKNMJ[W<(K.4U>QI,6KZ,Q".H?+!&]CS15#WS4,P9
M;]W/2/<89(R&AI!:' !IC<Q[6N;\9:6"8/WHVA[@YO31@-E:3_$V0#>:ZY)X
MC7>N"0:!QRF[JB<H+4@."!C,+%% \UBO0\>D[Z# "X,@M(L?LY9-95W>=-N7
M<W%D6&[<ZZB+3]DCB)%D?R !N-U1&OHE1M-AU13P8V<0#ZE]/+15.SU;!35U
M=3S1?+VJ,-QC$L"QD?(R1O!IV8@_YV PR4QK)V-;(M0BV9IX'344=&^.$RBI
M;5TU764M(\2.EWF34-+B5'&V9K[](*=@@=OM>(F$EJU;3ERT9P[=I2YZ\C2B
M:B>JNK3I=_MA1'"V_P""OZ-(())I5G3[FJ2K=<7>2F-=,IH8?:.-5/PY7_/,
M,H[?)N=.0#;>P&FB<"6M!'3P8I1TKA8N:=[!7-O<[I;:\_XE23.<9J"D)<02
M7S";>LX[OTSTL\N1N1NUE]!?ETJYGJH?44$*1YAL!4R0E+XVY4 IGLI??<C!
M#;?1\]D=BV82)D/Q9[+N'^#0MJO]_7*,=';_ 'EWWGFT&-S8[615,TM;((:9
ME-'\[/3SO:QCY'AL0I:*ABAA_>?1#T<KVD&\[VEK6;+A6$T>$PRQ4=+1THGG
M=42BCI_EVR2N:QADE'22.DE(8 Z1S@2 !N-L;U>O/C> 6)T%,+I4DLW8STC#
M((":+B9 28A(9@2H:&Y>[1\0 V&G&TC:DV>\AUEK@YG9K'6B0M07G1NEILV
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MG^'"OY+W\.[?WN*4-&3:QXY;[NJ=(ZW55<6!&%QQ(>JWGF3VBK2,+FQ3,B\
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M-LDDDC86=%"U[W.;%'OODZ.,.)#&=)(]^XVS=][W6WG$G$-:TN+6M!<=YQ
M+G6#=YQ&IL +FYL - %B<Q (F03)L&^13S5PDX7V&[8:HO/MJ:J;)NFVNN6^
M^%OI^E95--)PIKG.NZVVN=M<_.YYINBX(RMRR]_=9@KLGH-?;K+K-4M&J^ZK
MEOHLHNWTT3VVV62T;8V<;;IZXSOC".,J?P_D?Q_#/BR43C7[P>)1.1XM*INX
M(:L&ZNK@<04$*80RHW</FB+Y%NNTQE3"FR^&Q!7^7CZE4E-----:>5@+7[==
M"?(+ &PR)=W$\]/*^?/BI#8DI%OJYR2CF$-DGBZ+?#(LR=?F6B>=<(N\??\
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MZJJ:::[NF"J[17*B>NBV,HJ[XUU4QIMG&^NVN/%I6,9(YL<HF8+;LK6O8'W
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M1Q]G+T"@&69)!W><N1^C=;/U^+)A.\W,_J'J%>.ID,:.Y2Y_#\,KLJ\2S_\
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M882GV+3%3^2 6Q)NH&D<V@5TVA;]DU;(2+-?35:"2.9?<19(,I*SC\7825L
M8$=:^7AR/+07]YG4VH+<^TN?L5>UY!7<?D$[7$M V2Q])R;9(MF1( 6;.V<=
M*.'<98'=7\3BBV\F8AV\C7TB\<;+E5&H(4BT)<^^_P#)6O6!RCSI:0]\*G=1
MQ(Z,(@X3&'0_\LZ&,\QFNVTY'1".-VX=T/29 !@:S;#C;@*RU;C3$3FLFB1M
MJ2C1AZ*5)<CCU]_/R'?GJM;[HQC'$?8N,8QC&.5NA,8QC^&,8Q4DN_#&,?\
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M=6F/KUQC\--_JT_'/T_5GLJ\_N<*;G]&&@9BWZJZND\/KR.=Q8Y7L.FPP?\
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M;WS-SSSSZ\\UT8\43Q%5?NG^I'V-_=7Z$_PDEWBK=1VCU5C(Q_-J/?[#$_\
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M+-#;\H>D*QH,WB946W3SRMGU\!ZGTXT;F=S_ "@2/AJV[#M88AR[<$%M"F5
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M64,C&*N<)O'X[5RU;*9QHLKIM_#Q%N7B+G/\G! UCGUE&8\=*H%YG,A8D="
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M9B/[4-$9!41QPQPNHVU WHXXW.!=*ZI=O%Q):QD;+FSG.MA/?YBS3_=.1_\
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MMU*49UQ$4TLSR\V2S5O9DU*RX4$%@R3BWHI]X<)C1YZ;)QUL5KZ3RT"&2+R
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MVYWYDY6(Y\5)/^25UG_K3^IO^!? /_B-XF\/Y&^+_P#V5=^8J?[JN*O95*;
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MLLJ*.#W L@DBX2K+"B"JC1TMHFLGG&Z6^<;Z9QMKCQ+CD//\K/?N$Z7_ /\
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MO@MOU-J&7W?'8)*&>PYN_5)M-1VKEXS0:O6*SE<\CY?E+97WAQY\+=76M_\
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M_LE^U82)),$[4LD'5T>ETWDAC*[.!5H,D!K+J4SXLQ<"@@H47<X1>+L]FN2
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g400206g92o71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g92o71.jpg
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M,B5!41@S-$(90V%2_\0 ' $!  ,! 0$! 0            $#! (%!@<(_\0
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M-HUGCG0JW&^U[UR+<UG<=CT?QFW+4<#NV[8?F4^#\UE=BY"P''./UO9ZVO\
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MS@<CA74]SVJIE<)F=4X[XKXQU7/8C+5\JO(4,YK6M\*\:V,+DDO&Q2V#7%;
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MRII U!</J>#>"L:@.>@B.+8\;)9-<Y47+TS5&8169E\IJNIE*^EE4J0-))+
MC:+$C$)R7EGY7W9KMH<J7\37)-\JYA@-$N+R4(^LZ[D0>JO<Q;_:02(>K6"2
MR]?V75O\+DE4,:2D <O4N8_]NN\D;8UT\OE<OF10K45KRR>>SFM23+-K752T
MAU:R[ZB3>S21#M5\P?(K&_@8_*<J92_?R5?'>CIUW2*UA+[0'+6C3'74P=6)
M@8@R"&R4E$*$8[@V3H,IJ4\NAI@>HEZD];#69M'3&&I2HM4J"10(K5%6"31\
ML,= U'4Q?21-P -).Y)RY3R[\D,?C+5A?*>18^M5_-6N=:T[V-)2?H-A\:X2
M0.))2V_6!0KN(B7GWW"Y;*3#9<7VEZ@_^]_;?CJ1!RJ5&2G29B!45:E6D"S0
MQ%E!!4[$;=[ XB%#SD\D;97 _P"I5@UJ$'5;5/!Z?;!K$P?Y]%L3K*(4Q+!!
M0!W+?L9VZ53/UC<N0RA!8T %'_F_[/;M?WM?&FMD*5.I1II4AWKO3>GFSY;"
MF&9:=4J@5@K@!EVU @[3C!C/-'RCMU5N/EF\$R,K2#=7T8&6F1'N3CB=>")4
M)S"8E0@/^VU?3'?L.UR&18:EH@B]]=2+>[XKSV67)5EHUJ:+4>'559RI0 $
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MQ7]D=,)1P,%W[S)Q)=P,S_6>O^*P0H@RQ%R6(U$7!X WN3;],()![;CFV_\
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M#8^W'TL,>#.K](N>7U.KW*"0]C=CS7_7T[B60NU];A@"F:_11!\T*(>H-?I
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M2L"\YM(D38+4A! :60,RJ5>I%$^Y0(>T%'[7'=CBC4#.:98D?$T$'2L?"1,
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MZWG08PQ8*!D2<@4+GV"0^=K41:"-772')B58@RQ@2 09D\Q,@W&/.RU2I2S
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M."ECGVI,G-F(*()IL@)GOUGH8C,:CU&FM!!N525'L.@VCYXP,Y:P)"C99L
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MXH!F03:]SO._?>!(]N8E#L-,K5VPZO'TQ80ASA'J KN):SFM)P0]C[S K_\
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MN$#,0"^HG]P?_M,Q,_J/WU,1'_$3/<5ES "V/4R8VD=[;]C?MR3/'W'W;BP
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MA3K@,V1KE:%*DM2K3J-I/G!EL =4Q8]-[8F.%<6&R2L=6PZRPR4U[ A;L'=
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M]GJO'FB[YF=U/?,;2QV5UK*<7:ULF&SUG+ZE?P2L[K.53#'14S'<[P-@#)O
M$&=XQ:6<_P I/BCK5S+T<];Y9QK\9E)URF+>%>27SM.XX[E;BG@[<=$TM=/
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M48+'Y"TU;HJW*\[MD]15+91T0RP%SZR:9A7J4!D?->5F*I2E60D A2-+*A4
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M+\8JQC"N,R 4;!NNV'8T:]K\>JU5:S'VL!2U&8D)1'J7SU:U<4Z]&DE:*C2
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MPX82L^*M*NY5FJ4FTF0#3>F3>/B6HW'1/81 Q?4I/F)1$#TE2:<%E#*I'J9
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ME?6!-, "Q@WQ),=9#\2]5Q-V]-I1Q^5-Y+&7D+D7DTH:QT&<,[4/V1(IZ-A
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M%%=VSRAP]@-BO_156]*OZ\6[-PO5FF)..?LF@Z (TV&5V&G^W#9>M3=6%7S
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MDFN@R#UDI !(9$A.)CW6II3\LN-=QJ326M8F(!D#IVVC&JCG*]0UF!%#S:2
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MH=M)O-IW)B)N;VZX^8J,SL2Q()F0+"29YDWW)WGG:?&,W*K876'.5J]9[/\
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M$@N!_, Y.DS(!],7VC%H3NFI[GCD8JOG4TKMV(**QR2[BSB2)40!P(,@B#]
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MUXP$(P)N 3^@GMS!_P 87U->OY*H:<EBT6*-C[*UZMF:P6JSJ1*A9(A3(('
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MC\YZ;8IRGXR\#9R[<SP:10U+9KS2LEL_%=_.<3;==80Q/>1V_C'):GL%X?\
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M@M0G-1Q;D-9S=/DEV)BXC1K%$PV9F,^Q4FQ)4CCH;7WVVG?%DN\DO':ML?\
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MBN15JMW'N;16=!V0:_(S"ZRJHUZU9220=FX]RE19M/H,40M98$_[2/=8^4-
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ML4OX:]"LWFTVJ4UTHU9AHG4U@ #U F9B!S;##KU:YE,R>3ITFPA2*5BS]ON
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M\!1HT?LLH6B)L65F,@@#'V+[I(R$H"8[]2643!>T2)1'5%)D+.?_ )"!&UB
M(CH8$Q&PD<D1 ^FUON,(Z^.<L.F6$.JV9>B7!(%"$?49_>XHB?I@60)@$%'9
M1/<QU$_%6H0"1<"0 +6N;]>E\64J35F1$G6[A$$$:GL0/8@]/TQ6.K\F:;EL
MKL%+"_R%X]>:NC_--Q[E8'*WI@V#& R!A(9+\(8)>1LUB.M6?ZI^PF%^J*=:
MKFZC*E,I3IO#,9EEBV\";S\K]_L/'?PCFOP]D,AFO%:U&GF/$: S%+PP-&<R
ME*8UYI-4#U"!  ]4B<*COA=5+&.8ZRQ3FVU3W_\ <:R/KB&0(CVN!"?UW/\
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MCLDQS7UX4L+-EWO,M-D3TR>^_<Y*61!#[G#(ZCT:*K3IBG386&EM((B3)!,
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M7.!P*WOV(;+@J&M5HBFI_&F$2IAE->(73A90R)(CD%E %U4=4(4MI+:A$V8
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M'7:9(TD@7CDD^KB!$?*!:)!$69*EVF^VFKF<>]U93E+B:L"/W+:4]6'P JF
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MO.S99755>'Y#K!@?VH>4#39#&Q8,6#[G(C)^HD10/%.:8T^5I63#L1ZH,3:
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MT,Q\MK45-$* 3,@$[@F>W%N('UQX^8H9C*UAYE)@P?4-(.DH(*,IN/4D$F2
M3M&&JM<F_FP65G(FEY/FNNDUMR85-F&FLW_7]@JFJT1^^)&:PL7"_J8 F-34
MPE"#5"$[$W-NPMS&Q,[<QZR5GS&::JF4HLJK34AY*#T[P& E@"6DGU01 QLU
MK.;Q57*71K6;:;%3#4 H&$>UM E-RM'NTP8W\D6A8$R-@B:IKQ*V$#&%YOD-
M6,U%5A&_%K [Q)!(W@3],.=)3*40%5&J9RM5S-.)TU4J(U- =EHO$LK2S%00
MX POA5Y^2QZ[&0.RR]=4L+ME: M DJX U3AKG,VK+7H-Y6#76DP84!$_0$?.
M])HTF50! &P)"R1M?;D7^F,5;,TJP\QZ I,JZ $,4W<L')53J8+I)@:B>9QM
M)D?#+GJR8VZ'%[\>YKRL33G<-">BJ0^W]2DMF@#!I>I@*P. B2%G?Z&/)3,4
M5&EJVKD13J 3,&Q!B=QP+BVV/#_AZEK29'(! F2?BO\ D9.^/&0\0O):S*UK
MXT%:ZHB4&C;="25HDL825A [*/I$ ?0RX/49DNXF)ZCE,QEP6+/(<L"-+PH(
M(U&%OP;7^>.30J_[2>A++\[:CWGK;:^&V?#OR>.R+[G&I7 :<$Y8[CH2C&!G
MVC^_^JA"(F)](] .51)DOJ?69L&8RH 05(55(G0\,=YC1(WM.QZVQ(H50/@N
M?_);1L3>_6/K-H5'X=>2=P/6SQHQ*S%<,1.ZZ.Y<?1_9,"L=I@"*"CK^QP'9
M09R91V'"U\NC*PJ@@38(X_\ KL>W:1TDY>H>(/-Q?\^AO>_-\*Z'A7SR$8C&
MW= NE1B'%DKJ]MT.&@1%[H#Z(V288"2 !B5 4P!$,>W<]P^<0"L]-@'.G2K*
M3K %P#$+V+$=-@(D4*BG;4!M< =>LX;\KX8>1WYWV(X\L96I4<I2 /;./JQV
M:E=/HLA8S9P.O)^LP<'$D1,B2B!]YB:69HZ"6J+2=U *A'(0P!NJD&.2-S]<
M=^4Y(M'4E@?G:_ZX39/PS\D+[7VZO%;J+".7 BQNO'EHOM^N(*!:O:!$(@__
M ,?N9A:H(3G]P,V)FJ%-*:&MYA$@G144*"9)@J9]ATZ;1Y50DRNVQE?5[^HP
M>O6)YQ]I>('E#3N5S/BTGUQ$0L2&Y<?&TU'[2\ FQMXB;#CH/M(0F)*)[D8G
MJ//R94D5-+G8:'(&^_H[FP(ZSCK15Z3\U[7W'0;X>K'B3Y#W FFGA8,=72('
M7O/WG067RL' $TV%7VAP%ZS'IT01!]>WM'<D5"5*5,ECFB^HF4"55 $6@L#(
MFT3(-YYQ I5/]OU((]]_SYB#(PS'X2>05ECT'QQ9KH^MZUW/]7\?,<?V!(2:
M '8Y))'_ /K!]>H]B1_N8G2,[23X:MIF-#[]3( (XC 4G_V__L-OS^OY8SXC
MP?YVQM+)*#CO("<K1%-4[AH8A:*9C[HLL7M1_P!(GHV%( QDQ,*A?Z[FIXA3
MJ-3)\HA"VU-Q\6D<KVW%X'!@8>4_ (^:[?(\]/SYQX=X1^0S1K7!T(PO@\76
MA+:M']6 LIZ0@HV8XZ8/KW#96$=1_P"_<1#9^F0ZZR0RD#TL "2(MIF!P/\
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MWU'^5<F2+$$0"9G&BCFM IZJFH4W+:(<3(4!@PD B-B.!B<TO!GRQK4K*_\
MHUCIF*24T:CM_P!%<"6,6O\ *$NMK %K%\/8*H:\>F+/[6LDQ7F_ZKD_5JS
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MV U;F?,9;6>.G9K"VE&S[]DV[ 9[4<7.)=EJ.4V+#W:.(O9$)JOLL""#'O\
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M\S:)XG[%Y98C#U-'GC>]0PNH;?K^KY'0*^S6=SNYW&;Q9Q4EI-_6[5G/46(
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MG7%*^+JEX:&R<>>+V>SSN1-BV7E3%ZO@=>SNA:SQV&0P^4L9CE_%U+NN-SK
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<^,,'QA@^,,'QA@^,,'QA@^,,'QA@^,,'QAC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g400206g95r13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g95r13.jpg
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M 0$! 0$!_\  $0@ U0#M P$1  (1 0,1 ?_$ !\   $% 0 # 0$
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MN=NJU)UO1X37MOI)=?RH6B3DK9-C29-O%B,GQ0(=&E2&B</*JP,9.=R0,>8
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MDS=]ZI6M#Y7"4H6C]PV4=4P4C&<YPAIB.:<RPUZY]W6<(QC&/YZD) (Y2#S
M$!)"LCL<#?OU(W/XT^9VST]>?R^GG5B/&S0=*U9J2HZ]CX6-7!5RN1, E+(H
MXZG P@F6<L+PTWCW3[*QE2G$J==],J<=RO.<X@Y!!(P/,]/([[].IP=LX(&Y
M$D$$@C!QG!\CT/;K3^<:+C7"-X;AUO&NC8EJG2J%+$!L8SE3$3,S-Q' RK*<
M8:;9^U'GM#LMX3_5M3BO.5>>@SC?KZ\B:BIW=32CI2D=&:[U_"E68Z'HU.B3
M;JZ4_<C(RLPH!5M?.60X:]9B!06GIYTQPLI93DJLM9"R2%.Y6IYS*E*5@X[
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M_'LP,/),D(?CV'32S2#L,MM.O*6([]SZC!8I5QMDS3NC.'^L>*.J+0YJ-G3
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M$JP "< ')QO5],MIF.2IY(0C)5S>&UL=\A3JPG&,]^GX5%KO$4/5D?6Z_M$
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M1@XA#0Y+2%L^,T>O7^:5_0*Z4HZ4HZ4K.!S9O;@_?-XQ:YL2D2- /X1DVHB
M>&2Z*Y9A=L;4&"E'_B8R4^H<83 S"%D)9%R^ZZVA*WG5+4J'_?*XHU+77 V2
MVW<IF)LUIJ^SP9'4)1,84_*QS.Q[/'QD_ G&&&FCF +B'GGAAFF!4C/ACD-N
M8>%3Y@]CU^GK?\,_>H!!_/\ +KZ_Q71_3M("W)Q\F[9) ULZX?O*U)CP%,NQ
M,)7/C*.;7$00,9E+<=][)6)5Y;^"'B776L+<6.P,VT]?CU']_P *D[=?6>E5
M/=^2(K_$'EOJZ7IM0I1]]OW[AV;>G)R'"FXF3EQX@2GQ&28E]I#*OHXDI.1Q
MC&$M.RHP1JFLOLK7F?7K;UY^2M/] XD0/)WB3HMH"^KU_"&5&M25I@(5I# ,
M_7)>IX3/5MAI&<-!XDD.I#>><9,0.(LI#:$$N((;>AZ];5!('XY_*LU?:VT%
M2JAW7N7NJZ:4@.M:EC;97Z:R8*J2QEB-N%>C!%&/-NMX<>$Q[.DNJ2M9Y+:U
MJ;PK*L)CH/H.G3^^/T'TJ:L7[U/"ZR1'%XK9>XMO0;=#HNPRMA1D974FYLEG
M)G1VZ^'46<2GM&,E/R$H*P \VV^W',(??=&>QA7I/K]/TI20[-7&V9WKV_M8
MEU79:Z%-YV);AI24A_QF)AP.*M4C&,BN?>!.82D"-80XP@@;/SNJ:3\S;BL*
M4]?K_:E4O]]SC[KCB=R_B3=33D\NU7YV>VE,S!,M\IL3+MGBCB%QN!\-_7S(
MFLD2V2EI60DUM:F7<,YPTVIZ]&M#_;LJ&R-L<+^,-Y/D";';0(B-LUKCI IV
M"5:(1;.?J#'R.'&V7SEAX^\P0:I+!;[W^[\MXSC$=^^_VV_O^U*4_8BI6L]<
M<]^Z]1-1-?#1ZN7H*/#9^1I_(\J4YL^8L87V6LK^PB/GY21 9RXXXMED9L;W
MREE/4TK4MTI1TI3#U[C#H.J'VZ7K>L:_"S-Y"M\;8IP!4BQ.N1E_G'+/=HR'
MFTG?E:O&VFRN_N*;CZN7#AR$ZT++OLKD Q"&%,^OITKC \0>-4=%Z^A!M0UC
M,3JOY$4  K,F>-70ES$'8<0S"#Y G[E=8L-8K,^'6I/)M? G*Y 2X4:/(PT:
M2,J<G[U)'I45F2_4A0$[8FNW&)7OD1(#<JI*1P4TE"G@!X^M %DR#&'&7T?8
M"89<)&RMI:4DM,YSCQCSB]V!M]4\/1XC4]=O9D754-]8::D-VZ,\^6W'/_0J
MY"I&?CP <XJPZHG/6[3]UF,/B,\S%5X4@I"_ ><4EIEU0/\ _$AQ8\4G;! /
M6JLI._P=FG[5K3 !]5!G0Y_7S%V<N5K9L3I#;9@<3FW.YD?J2T/(3K;:#XLX
M=P45@_+CZB6Q5H>\PV[VD^)S-_7.O=V@S[!)?_\ MZ=38K;[G%MSR@ESW!3;
M/O7OD>)L)*G5..!"D@)2I"4^OM0?Z>-PM/ &)Q8TAQ#U7?>)#%BAZPDVMV0E
MRR3V'HJ)TV!%@N!Q)6AI?*SRX0KD(2E.0*@MVZJ=8->5OD/&R$69$7BD5>8J
MSS6&_.1RXR6GF)QUHG_Y/GC6Q&21\BXPTG&/M>^5I3A&QO:;N'/P!T$F+M9M
M0\3H#,UXY#3L-#$J9!A+!'QL3'7TN*;24M.(2V%)6M((\Y>S<WI_6/M:< V=
M0,QW8+DZ?=6XSX0KFN5L@L/VQIY#W,E %R"0XT$H\53B0K*@"75C&D2!+D.7
MAU^/L@Y-<EAT/O-9,C9UE<::RM;3C2U>6B<N(_U$^'FVW,*2I"5I\M:+OKFE
M]7::U&RH(<L=Y@W'FYUM LL/I$IE3C92M+4F(I^+(2DA+L9]YES+;BTG[[>T
MSH"'Q*X#\3])/LL&1)TG<[A9GW6P1;]06%G^.V">@I0M:##N]MA/'PQE:$*:
M5E#B@9(P&S];ZY'B]?@4>95$5!IB!=G&)M+$DHR-:; DWQ8Q\);J1,ELE-M"
MJFAEOC(9SG(OE+#6T-0>T-QN;UE=;E%U7"9MK5RD(C:7?MB7;:B$U(4&XYD%
MWF2I:&T<RTQU!',I(!QS'Y&Z(_TN[CK[A58M?KXHW*VZ\U+:OX\RPRM;UK;3
M.8,F!%0^P\DM H6VESD06DD <F<DPMV?66A.>,7?&"!K/'QNB,7JDGS2DRP[
MY&#S@HN5P-+-Y9677G#%/MPZF26T240.,\P\I#S*?1NM^+$C6W <:P@QW;5<
M[@_$TY>HT!2XZK=<TJDNS/ >8PH,*:\!1=YD@A9(4.5./-G";AU.8XNZ6X(<
M:H[A_AO$B+I34*7W7FU76"['>EP75*0,J1/0XTD;!+B$J)Y3D58!HG<]IFK"
MY$296';$T$9)P<C'!#1;TNU&CND25?DQ8E$7'E>T4D@V+)(0G*" G!2<%H):
MPQY[X,\7YVD=01;1J6Z3)ND;Y-B0I:;C)>F&TRI"VX\2;$=D.K<907RAN0A2
MR@!86.3*R?7'MQ>Q9I7@]I%GC3P1MTFS1].RF!K#2<9QYZ!.M3KA2J?'!2H1
M/=>9!>0 $.[ $*4<UT\*I9FCS_,2RD1N9F0 V-'CA1I!"W(9PZ:LMM'_ "TT
MA*D$%BQA@.&<C8RRAX\ID?+C&7T+;]+^TMKW4NBK#:['I5YJWHOL^69]Y8_F
M3TQ8T;9F$X%$1U2%8<*MRE*5J 4-CY9X$\'K+[37%K1FC-0WU^V:.?L[VII\
M&&_[K)OB6@TMN&VXG=(4VYNWN,9*DE24D*[E,@WD#I6[!R,+!INU) 5?:Z=
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MSIG0G'"F[&G!J";L"GIK-<'.AK$>TQF-CXH*1D#3HN./ @ HM<@$\:?-/1H
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M'2E'2E8T^^'R$J/&_O#\:+G>C'XBL2_"4&JG608!<J[5")/=&W2XRQ*C&_\
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MEHZ3BRWI4>NQFP(Q^0,""+?+!64^TXXW@U@9:V_5.$84A:46(DJ.2<D #/T
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MI0Y4! 4HN*PD$@%614%-^L7^F0SEG5"3U:(EY)C%?)=C2(Q;3+1F&/B';?\
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MTJ!*=^525*0L#^I"E)/PDUM?VM;=#N?LU\:69L=,EN+H&^79A"D!9;GV6/\
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MN)0AB)!CNR7W%K)"4 -M+.5$ X.,TY<DW%RD+M46!;:635-G!KDF1U)?=S$
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MI2CI2CI2CI2CI2HS[:Y$2%&V/7=.:[U+;]V;1F:7,;,DZY69RE52.J>OH>8
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M)C@Y=3!]=\D#\\[>>*7%]Y9:4U[QYN/*"4GI62U+1XDN7F)"'KDTJ<<;$,9
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M4=*4=*4=*4V-FTSJZY6%ZUVBE0TU8B/\8?-+&-O*+<_POL$G:VK/92'D(_\
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D1.P0H23U/KUC[#RI_.E11TI1TI1TI1TI1TI1TI1TI1TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g400206g98m33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g400206g98m33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2)F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (DJ^AW@X0DE-! 0      $ < 5H  QLE1QP"   "   < E  $%-A8G)I
M;F$@4V-H96-H97(< @4 %U!O=V5R4&]I;G0@4')E<V5N=&%T:6]N.$))300E
M       0<:3.<GY,P#2C5F/=I?7A+SA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#
MO_XU  (  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8             !$,   <(          $
M                     0             '"   !$,
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !$,     4F=H=&QO;F<
M  <(    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   1#     %)G:'1L;VYG   '"     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 80"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M86/=CT;+[WY-I)>Y[]LRX[O39Z;*F^DSZ-7\A)0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM_ 9-E:7U=@G2'>5L='4)C0U-SE"15)B:(>1H;6XP>'_Q  < 0$  @,! 0$
M            !08!! <# @C_Q ! $0 !! $# @0"" 4$ 0,$ P   0(#! 4&
M$1(3(0<4,? B014646%QD:&Q(S*!P=$(,^'Q0A<D)1@T0U)35&+_V@ , P$
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M>D(_'S%;RZLF;V4/W1.EYRT+N9'%Y*[*KD=8P/?.%VCQ9G][H9+0O / / /
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MVYL6DM"B-4RUXNGMH\+0AH<+'38\,HZ262U%F"[\J*<I.!Q%QL\:K:Z@;R\
M\ \ \ \ \ \ \ \ \ \ \ \!6MUSV98O/_8'#7/L4CT-*Q'IL'UR4FY0^T,K
M2$.M0-)XLF)IQAP/-#Q[5(H:S^I(/Y0:5V7&?[L?L/<_\Z\!FWQW]9G.J>#>
M:NK+CQ!H-*KE@:$DDC,&LY!0UB75,&1VK0+K)315\B@JB,U53;O3+YQG?*V<
M+;::XQJ!5[TA\N?3=4_(OGD*'PJC_P!=:[.8Z_K.EY=&;2<7=TU4]U#47]AW
MY5UIBY"/J2*Q.K56TH8NF9^/GM<KQ(CH2(MGCAL/R!V-? / / / / / / /
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MT?>$S8C$+/DB)Z.R(@@ZB,@=B6BD3@^H9FA"!^NS'4N>747(+ 69^ > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > KX^2F<637E"Q63U.;O@;
M,65]T)ON(H*JI9:YV5PU.UHLO: .6"X37-AR,1"DZN1F9DF1'ZQ=9\_%#(]H
M><J&=(T? JKG=E_(8O<MP+,'O:;&L5;/EC:ZL1^G)7D=!*$SVY1X6G#?)>K>
MLG1B43 KQ6]LX[8:%=(S:8"7V#A$X/%3\4"9MP+$>9;HZXB-4</C;^B0\NM=
M!EY6\OD=B%3L3OX2_P QRZY["34RKY""-8ZF=>U_7</1F#!Z8 &V<F.&\/A#
M5V.W:K@6E> > > > > > > > > > > > > > J,[0ONR87VOR?4]77A9U?\
M]0,#$LMJ(N*M#2RBCE9I"IX#&#=#;&HI593V]II8J\3;Q(-%YV-!1Z)PV0G)
M"%V<$Q#.4@53Z]<_)0)Y^$,DK$Z$-SZ-/[\9Q.[(W48>RXKU?T/#:_YN*T;4
MT6'$^-JA+0^A[&D<QND$8T)5V(DK>6U_)AHJ\R8X+IG4#L?12W;(<W\=I:>U
MQ"XV,S BMC0:71.T#<S('H^+EX^*Y0ED6+55!FT.,+ZE61#],1*9TR2VP[9_
MRBNJ"+QT!(WP#P#P#P#P#P#P#P#P#P#P#P#P#P#P'K661;(JN'"J2#=!)19=
M=935)%%%+7.ZJJJN^==$TD]-=MU%-]M==-=<[;9QC&<^ Q6"6!!;1BPV<UK,
M8Q/X4:4))AI=#3@V21HOL'*O@93(LX'<NQI!-B8&$!KA5FY62T>,W"/WYW2V
MQ@#+O / / / / / / / / / / / ==OY:I]T+2U[Q:: W_3A.K; A,:AT#B'
M/75LJJDDXL",.IV?GKI*GZYY1Z0FLCS_ $V]C#@O,ULB@0UNQ8#UM4G*Z.70
M$@H.VO\ A7QDV+:L;Z,M^+6;:K*(6A"9!TT9D=A2GGAH7S7$<D$#=R8SSR\E
M+\1LJ'E)EH<DG-F%8R\FB[DM#LB@JC[8/?O?W^)7Z4[G^2=</7IZN1M_YLW-
M)!CL!YVGE,QJ9-+Y:*UKUH1G=L3>?@^?ZM?MGHJ?5U3&T#8 &=,IK1R2PUC)
M:Y5-6<@V1 EY4/;W759\L7W?A&+*]?U#3UBG'XFWKG/I<LV9*:@%4O2LL/D(
MS"HIS6O&YTN#MR2W#!6+A8-72"24+:B718V]0?%$GX_?[]_H"^CP#P#P#P#P
M#P#P#P#P#P#P#P#P#P#P#P#P#P%9-C?)@T@=G6168;BCN"T\UC*]X:6G-=P6
ME,P4V61#!CBZL7?3B_(0>*C46QQHAL14CK1LH]3=MT-ULME-_ 3.Y\NAKT'4
M\?M9K7EFU3@X3F09U7UQ !D8L:-$X--Y' S#60APIV3"$<."L9>/P[L8?*,"
MH)V,*M'6Z#W3&H&W-R(]/9YJH^9Z;#TM5W^N[E#79BCOILIHL\QMOC+9+9/3
M9351;[--M-=ML9SKC.< 17Z6WT4G7%>^FVN^F_6"&^F^FV-M=]-N;.D,Z[:[
M8SG&VNV,XSKMC.<9QG&<9^G@):> > > > > > > > > > > > ^=V[:L&CI^
M^<H,V3)NL[>.W*NB#9JU;)[+.'+A93;5-%!!'3=5553;71-/7;?;;&N,Y\!
MW7Y5OC*WVUTT^03C3?;?;&NFNO2-1[;;;;9QC777&)9G.<[9SC&,8_OG.?IC
MP$^<;:[8UVUSC.NV,;:YQG&<;8SCZXSC/_'&<9^N,X_X> _?KC_M_P#)_P"O
M_L\!%1U_UWP6/_W5)9__ %MR%_\ V/ 2K\ \ \ \ \ \ \ \ \ \ \ \ \!U
MVK3^8RUX%6<VD Q'EDS,*]M;LX(__#)Y&[A\Z <ICX26C550!PWE"!-U<]W-
MIDHWA))QERQ<:1HP38U^4TV_CF8>_?\ P8Y(/F@NA"<D84Q$\QQ1O*;%F$6
MS"=%I0F"YP;0:P^NH7O&^GTT)J+US.Y\SY=9O(DV'DJ^;LB<^4';#Y A&VKV
M3O?OW^8-[\C_ "N6QT9;S&-E*6CN@H[5DKEVE'05_P#M=+P,Y":XY3G2[Z;(
M3261:)XBTY>=&%@T0U(L(8HW2AXUYL<..#[D>& LEXP*N3M(D#3P$9C#LKT#
MV 0<QR18%X/ 5W?7-X+JB#. 90X&P3'[[Y:O?XHR5'_L)*?ID':'V+[@2L\
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MR5CL^58-G/X476[ML!M'@OY-+BZNO/6 SZE@T%A,W@A&Q:U>BF\E3-- #/\
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M&FJR.S<2YWWQ]H$5OB9BYN)5_; N1'0!$NG*8SJ[#CKG[3M0['=DP"NNK63
MNWFH^QJY<.<?[UB$$#6@Q^@FJN\_*^:?=J!;3X!X#UK)[*HJI:JJ(;*)[IZK
MH_CRLCMOKG7"J6%DUD?R)YSC?3\J2J?W:X^]/?7ZZY BSQF-<AJ4)B7ALM)7
M8SH/L%BYD1[43H;.+M>NKQ15*EM0(H&$U(O]],N7F!(84.PX44_3'M$/L0T
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MV^T"O^,NLF4CFKJM@#KFZ[4#5AL0YN0O8,+4K>2:OI<T 1ETRD9MS'&V5"Z
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MPEH2%E(AFD6IN-D2;:>EI:R=GB1U1HQ'C'>@[0"^_P  \ \ \ \ \ \ \ \
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M8H@MN];H/'+AL/;(( ;V^3?K>U.18[2LNKF158/%'9V\'SN*2M(,<MNPP:6
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MG+\;Y4Q*XT'1":#P4DPIME3!T6W:E/OSG;]K[LYSX#6[K_KO@O\ T5)9_?\
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MF8L-E,WE&7;-AV8L=9T,JKP@17NE5O\ ,J2.;(][8G\6+'!QA^)K6\>P:_\
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MRELIIC??&FV<ZXVVQCZY A?WGT=?O+]8JV]4--PRS()6L?E=K7\8FLZ=1'^
MJBO<!'DE"P-B*$FR)VSSP(B<.1;4HU8PYHUA9EN<*ID"8)D] EI7%E0:W8@-
MG];2-C+X4:7+(!).*U<;!CB84P_!/" -ZN@BD9"+D!KO(B0#-G0,^/PW, 2!
M(.]9/W $2^UNPF_.M:3 K7ABK3-@P<[5;>RM)L=(.XW0%>V@?<AF=VW7'85L
M[G0NL1N!S]1V6;M&#1!LD[//RC"-@CQ-D!L3CWI)3J"HW$T*Q@?#9O$)K*:M
MLN. )0RG<.93Z$N&Z!=Y + &H-!\Z@)UF]&2&)21%F/>+ARS=B=$A9&P,!V
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M BS\??=D?[FK,W(VL2>Q.95\_8QJ>_Q[E.05;)S*O\DWVE]&V$EE+2R*J,O
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M?^*$=IEL[1;0&GU;.91D5/YX-BT<&B$3,MGQ@S)YC)/Y4Z1<-6SID)' 3E\
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M72273PJEOC19--37Z;Z:[8 Y/&,8QC&,8QC&,8QC&/IC&,?VQC&,?VQC&/\
M3'@/WP#P#P#P#P#P#P#P#P#P#P$>[<Z@J.C)O5,#LMY,09&YYC'Z^A!]M6EB
M'*_WFTN(J!HA%I#8X.,$8-$SDK,IY%@!DC/C7C]WNCG5'1NNBON!7YT=VQQ)
MT1R$WE4IL2^JPK^=&V4PJ.UHY15Q,K CINE60:_!?1,$ JUV8>$JZJ-$")G<
MCGA0 _K+4</<@9,Y<MR2HMV!)?C'CB.<[LI',3\@KZSK5G$MG4WTG<&K%G6$
M5BXJU&E=.)K&ZOAV)7/',+BEAR:N@UJSD2QECH-(+0-R&4,AP=J^9B6($\/
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MOU! ,,U9C!S?*ZRJVR+1LEILLJJKMKE13?;8#*/ / / / / / / / / / /
M/ / / / / 1:ZUYCSU=7D>KM:XK)IMD LNN+2R8K(?6C\N4D%3S()8L$;/\
M%FP"P!N@T//(S&Y+NBP'LEB*P=(62<.P;PD,> 1*)_$C3CZ6G9XVN>^Q4N;3
M<Y8],%V1"K5=>=)E,KY;=+6$5K(>_JUX.,I3ZWF^QD^,M1K8@YN%<+1< V#!
M?Q-TP,L.\U51SDE\=E?P( BYS7?08Z&CYQ(F@DC89IDES?TFX(/I%*6XU@Y>
MOSA-9T7+:-46(O9^[6_2&LFFJ#5$"R[P#P#P#P#P#P#P#P#P#P#P#P#P#P$,
M+_Y*-WI>W/ER_P".4IB(;GPJYD@2ITX="95!C<Q?*Y9N)X]3D@UT[;S5E$W)
M:)1@Y][O^D&9TP6CS5D=>;$< 0?5^%.N,QR:,Q?0%BPV7608L%&<RBN*UH6O
M09&O;5I470UAP0'6$7K5A7,4=2>&!AA1[.PL?1E^TQ:IG-WRC1- 0B!-(95-
M:5MVC53B!0*(1%^<Y:Z$;R$M'XZ($F9+J"LODUF(5DI=BS0(R%R/;JKIMG1A
MR\<)8<.,Z*8RNKG<";O@'@'@'@'@'@'@'@'@'_P?_P O]? / / ?FV<ZZ[;8
MUSOG&N<XTUSKC;;.,?7&NN=MM=<9VS_;&=MM=?KG^^V,?7/@*7K"^6V00"K3
M,[=<ON'$G@YSMDK9T#7N(4UWBE1<(2D7';=E0J2LX05&RNP"6L@!*12O&C=@
M"(/EB;1>R&S >W+D@.(S\PADO.@5<PWF74U);LFI^*<H*F+C0CX2S&<,MJW*
MEF1RV7NE<%GM*X9/*7E4G!"Q@RU'1P$0C[5WN#/."@H2!R_/7S)0R^3T$,J4
MC*(31L^#NQPZQ5Y ZF,Y'6D!Y;KOKB60]]4,-AI4H\C JM; P(%3&/R(T5D$
MRCY 8W@[8<_#EGH&^OC )00O4]_D:P%HA*]=]G]+*P\0VB)*!-AP/:7M\M&J
M$,+AX^2C:2>/N^P6\"#%F^,_YFB?W?W LH\ \ \ \ \ \ \ \ \ \ \ \!U[
M_FLYFA=H3;F@Z.@EXG['L [)X-("O.D66L>U=X-!89))@*:#(=-+2KZH!T?8
MR DJM)#+_"LT=:O!K8)ATQ:E/U'OW^H]^OVEA-6<X(3'X[J\YP<LR E%W5L4
MCZS#INGXG+BB6 Y=B7_2MBG6,P=10B[6_C]6[\(PFRB+391%VQ,:.FR*FKT!
M#'/P;P-[!!=0G.C;'+U$0@8>.V7&-XO'])!,)9&(9?L&BDCC4P</GJ\ B\<!
M] %F0ROFHHZR:#H- A+,TU8,3:1T#V]1<4Q^A_C[[?G%@REA=]YG@4NN?>WG
MT$#PA[&9>%J&LJD .*^"C"!E6&;L8;4,-R[>,SKI\1/ID2O[#5NX9C!Y?\?O
MW!>AX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X#J?\ ?[SL2I^N+1!1N.]2
M7NE8+Y2VH7&>>.N_D :.*]J@ILC%(^A)*OYQY7GL%K@>]DT8EB 1OM*BCXPN
MR*NMUMM4L:I@=E7G:L2%.T[$*\)S^PK-=!<R%[K+[6/D95/W#*2RDW*1@20R
M0Q_X7-J0\:::0]@2+8U)NA0%@H0TT=Y6UP!4P^^7JPU[_N#GR/<\0I:1"+E#
MT?1AP_;TC#QZ>R-_T$M0S^0R<JC4C\8I% RK)_(Y&\IXA;JT#/ZCJ?L?6(V8
M3P*:@;C!]< NH!'QJS7>$3>$RJP[R8S$L#VA=B':^ $&_.W3 LX%%WA_0PFL
M9)AJ79/$Q.$33 X5':H/5(^Q6469MP+;_ / / / / / / / / / / / >"F=
MM4U-M,?7?&F^=,9QG;&=L:YSKC.NOUVS]<_3^VN,YS_IC^_@.KK!ODZ[_FDV
MA-&O[.IBO.E9XU%#!5861\6?;D'B;&>FQNRXT&4LF8]$QMTQARY;&&"=@D8(
M/T6%_0YB-)[;?QF,;^^_[^@_K_R7/])=<S;F24\QQ\[4P2P1EXS8+7,J(Q2Q
M-Q\YC!M8(5/RV50ZJG,.*.)S *]  2\OGQIU,HNK&HNBFX30+O5-&N^1^OO^
MA ?'S6']X+N=1Y'<[37>GT^HV<-WO,2F,<<MJ\[+])Z3%67_ .'.R3>V?Z30
MS&=JFU"KA=)<HGKFT/Z=SD]@"P(+:\+LOLZIDXH\*.' OE7H%\11(QN1!=6R
M1ZR>2GP_5%Z7%LAI3?9#7;\^0STBDVWU^Q=33.Z?W@3D\ \ \ \ \ \ \ \!
MK"[)6$@E.6K-)))#$. 1:NYD>+RJ.Z,UI''F(R/$':Y>.($&A!BYD+#1++@$
MT=,'R+LKHT;;LG>%?UU/ER*YKFHYS%<U41[>/)JJBHCF\D<WDWU3DUS=T[HJ
M=CTA>V*6*1T4<[8Y&/=#-U.E,UCD<L4O2DBEZ<B)P?TY8Y.*KPD8[9R1@^/#
MG6U>;N?!D9N6Q#,VGLJ(*3D^$>DG!@+7QB1-T7IF, "I+7<P3VW*J.R4A).G
M&C,C(G9!^Q'M]W+U\4@M.8:S@\>ZE:RUW,R.MVK*6KRM65C;$JR)"U4Y.5K=
MU>Y7/=O*^1S$CC5D3.C>*FO,7XBZFBS^(T3@=!U8\-B<6[#Z?21*LTV.J,KR
M7I>21Q))(J)#"V&O#PI05([#K5IDUN>=WI\YJ5??*#?W0'.E>UW.Z<E12 0Y
MH<E3JZ9Z)YJ(]-+12)BXRH]$D'\;2L"K@<5"9+Z_:6EDCFPQDS0UU20;OEU,
MIZ :G^+'IN_NOU9E:A7I6#WUS\%;'Z]=,M>:F_.MA ;=9J04^+=-$@5T7:(D
M</=0TZ;1?KN3D=*,#6HS5L,(-E5G;0"4B7QB<,:QM"(NZ(9FH\WG4@LG#"43
MVTY9LXETO211FCH@^DTX+$"8F<X;MU9W%B3MU%)NY01>2L(8=IZ+8 YTO\<W
M%!Q:PW1&@8QL^M&4MIK+2;0M+AA?64-94>G&I>)%QDB9DZZ7<3&52B3$4J\=
MQ9J5-R60$2:#MR:)*.0,WKOBSEBI;*9V[6E)PZ$SX;$1L&%EH^D08#Q$;$Q:
M,P9BW#QA-_\ TH)(IPF&1.'+2$<$:R)Y%8Z(CSPJX$,4&>@&G/CQ(D"\1Z=)
MEH^1BI)[W#T\N\CI9T&?$A"^TQ;XV9O'<>)F0CA9/Z8SLH-*/FN<;8^Q?;/U
MQ@"P3P#P#P#P#P#P#P#P$*NZ^JI/R-4H2PHI5A"TB9Z?Q6$(L4G>[,4.7D+_
M %;M4R*C))\:4(R-QKI&8JW&BGVKB3E!B+G[MU&HTK ZCS%G!X[SM3$W<S*M
MFM E2BB+*C9Y$8LKNSG\&[\6\(Y%65\;7HR-7RLZ5X5:$Q'B'JEVG\WK;!:"
MI-Q.5R7TUJ!SFU9)<?4?/'3B570P=61R=63S%JLC:<%I\"V+3(:L\N(N8=R&
M-1X^^ %XJ]-A!1=Y&)!AC@['71%B@\< C6!CPB.P5$JK;L"&&#]ZSP[05PV=
MN$?L5WG&.5[&.5CHU<UKE8_CS8JHBJQW%SF\FJNSN+G-W1=G*FRG.[$389YX
M63Q661321,LP=7H6&QO<QL\/7CAFZ4J(DD?6ABEX.;U(XW[M3G??1XCP%''R
M^5JPF9[GY,Q6E@=0/SAF5-JZYV%4-5-UQ,'((U%R!64V2Y2*73S!9P)5U'7:
M0!\48W,2CR2F!0_2,M21E/)<#:G%O=]#X^/7_%T36DDJ6.<_,(W6A*ETXPV
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M 7-@S>MK&%:-80&.1ET?EI$$3:SDG+3^TR<2Q2/CWS4>T3$IA]GX?T]_=O\
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M O(Y#B%3<;(S<N5FX60!;CMD.9K*0.YU,K+**TZ]83)%2J6!V=6'.I">$P?
M8686E)1B_:+"?U&#4#-J>^/7DZ@[$ V74M</8@9BH!D!BP-M-YR^@D;W95M#
M:=S)0D"*2)[$V$V?U;7\/@I:9I"L2,H!#_A?$5G!$NX( 87\=9S^IH9TR?\
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MFUCW,D:QZMW1KG1O:U=E<QR)Q727Q_U!TU6L>N63=9&(Y(+7M.TE9(N5%O\
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MJ.R^+415X"3 C#??*C<J'.BHNU)C2*"F<[HO6;I%REOG.VBFN<_7P$JU/O\
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M=-L4D^/OQHR5L4\:2PS1N8Y\4\$K'(L<T$DD3E1S4?R8Y$V)GI;G+&,YS?\
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MXI:8B,,(16#292 %6\VC\A)90 J#$C#Z*O7K%F#D;]LU59HHD,(+J85523V
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MGTCG-1R-<YJ/;Q>B*J(YO)'<7(B_$WDUKMEW3DU%VW1#<O\ LV\[?]P=+?\
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M#R=OH-&F^T;C8IVZ G#X!X!X!X!X!X"A_K;Y XC;L;L^&U^P"V)RZ)HR[?\
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MFKEDYUVV;O&ZS5?7115'?9%PGLDKKHLCNFLEMG3?;&JB2FBJ><XV3WUVQC;
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M%@:<]'0MJTQ8K4$PE; /"VNA@"Y8$@7BO8Q&--)E.2D7F5%R6PB$8DDM,2(
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M">EG&--5'2OU EMX!X!X"D;YI;!=P&/<OK0^\X;S);92RYXWK^^+*Z"A_/\
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M")?'G',3I)]*;WDL5&">BKP5-RFRD13E%U'*]WFTC<3)_5T$U:MFC7 *..7
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MNEP1-/*L8,R^- @\W%_<U5S@["WQ\)MILW5U(Y2>,]UP)N> > > > > > >
MQF:3&,UY#Y3/IH8:1^(0J/&97*#K_?*;(/'X^/<%3!-UMKC;;"#)@U<.%,::
M[;YU3SKIKMOG77(&B^8(=)FD8D=NV0(> [8Z /:61,(^3436(0$!LP;BZRJ1
M39/*B#=2MH&U$"Y&W8+*"GMD/)_*&'T_J9?.X$FO / 5W?*!H"CO*,PMYW'1
MY>3U,0BA"*F#%FW/4 &&:S"=1*$R>8RJ?T(09V)'X7%(X:?2J7$QS<LV&! #
MDJ^%NFS!33P$*?B)[0M6YK*NJ@YO)*^N&'Q!$O,:[O&K[<F%QQ$D'$*UX <A
M0<TF-50$M*X>])2A^SCDM*G9B<=S>"7#&WA9VSBHYSL!?/X!X!X"O;XZM)0G
M#>G=)HX NI1KW+U)@NXB[,@/ JN/ZW2RGD:S*OB1!!'#?*.N^KI\XWV6PKOK
MMKIMIIJ!83X!X!X!X!X!X!X".W5\PDT-H.?*01UAC8TP0#536#W.,;:CK,N&
M0B:O@)E=/Z9SNPC\HEHR0%LXQG\(@6_<;YU21WWU W%"8?'Z\AD1@$38Z"XM
M!XP!A\:&IY^J8\!&130*'8Z9S_?.C0<R;(:YS_?.$\9\!D_@'@'@*G>^ZLJL
M)+&5ZW1\E4TXEA4D&1>N6,;.FN6D*J+R>.J3 TU(QYMTC4UA883<J+-D4CG]
M+/V&Y80!&;OV:VHA);0#,*%&QKE3D>TKWK*_3G:$=GI%.\0UA6)*ZYBD0+!M
MXW"X.GI%S=)5./AD?@#()$]9)LXBM;G'I<DN:)I-C)0QC98"*H_YT*Z4KB)7
M86H"9L::7KR-2:S)8,G46.FH',Y?4%W71'X8$BJ#)IO-QJ\8HXNT(RA0O%'@
M<S*8P.(11)RC*DHT!LFRNX MT<I=+Q>R8$0I2VH=+&=0&('H7=V:(<'R\(IR
MWP+P3.XY&!HS=@]AEO1+#Y0V. :CCZ9L8GN_9#T2[T%]%W]/F7)^ > > > >
M > > > T5TC91RK*?DQZ&M69*R3:H: 5*'(9S^@6MBQ3+&%UVV)ZZ9_-@"VE
M!L>5E3E'7?<;%!QPMOK^!@MMJ!F%15F"IJL('5<:5>.@T#C F.-B))3\Y8TL
MP:Z)OY ;=?\ 2>GI$1R[.'2"F=EB!@@]>K;;JK[[9 V+X#7MAU/6=M(1%M9L
M%C$[;P&>Q>TH4C*!#0NG%[&A3E5Y$IJ$U=IJ8'R2.NEUEQ!1#&CIDJKOLCOK
MG;/U T[?'$7('44AC$MZ*YJIBZ91#4<-8S(+%@$>DY@2QU=;/=1B) DR6<JB
M</-U'>!+E1<;APLNMAK^1=7;<#@W'Q^<0NKJ:]'+\JT9O>[&1AY>SMC%>1[2
M<-91'T&38(>;G4V>KM$H*0',4F+Q/?55OJT0_'MC*>N< 9T&Y+YECT?J2*@J
M)J\1'*%F)&PJ7##XB):L:OFYAV:?EI1"44F^N !DF]D1QT0>,,I*/%BCS=QE
M3*N? 2&\ \ \!UQ?DCCEUW7T3,6L?HKMB(,X;6DLYY:V'2G*7+/44"N6J[0#
MP.:F3XLC?%@1$G7YT-)]C<.6'A0KI7[P&Q;8^XU((#A8%LWQ[N[?<<I5XVN\
M99(B;!'TTC#5I;L+@M=6'O"(Q-#P"N7DDA-;O"<0CCI]!1X!XD-&ES:J+99'
M^0-ER&7)!P'OY?V_[,TD'%'),KD-J2V2<ZU*:DUWCFPJV3K^&B5RDZ9,WD?(
MM]#CS9#\RJVA.)10IL\1V0>JE8Q'2:KC=^$&.&H&+W+ H55U9<[UY7,6!PF#
M1#H;G<'&(I&QS82#!"FD_&ZMV0Y@TT30;I:_7;?;[=?O664466VW6544VPO?
M\T_144$R/9 \ \ \ \ \ \ \!#J0[XZ Z,80=';]JI^72X&:V HBMG+*4]$/
M1C8]64">)ZXRD[9U+%RPZX3[);'T2F4EI0HR7PZCQ9MJ!,7P#P#P'#R$\*BH
M Y*#SK]$'&PY,\9>_A7<?IB@[)<@1=?KM4EG*_Z[-NLK^%NBJNK]GV(I**;:
MZ9 Z>4B[*B\(ZOD'8T&Z,XBLP=FWY[-ECQSY89=I([2YC,A)"E5U'NN.F-/S
M^-Q,K7[XE#I6%#Q&(EK'VE4):L-%\R8Z:*JOT_$':BLGE6@+?LF'6]9-<#Y7
M8M?B" &'R-\6D:.P0.6U?IEF" M@9:!5T"J)-ZV)X>#G.Q!JKJT=[+-D&Z20
M&N4OCUXI2$Q8)GF^MG+"&S4E8@/#\8Z)/<S,SO'=RYPV4(/7)25+%,P^(8(M
MI2\,L'J<2BR3EJHG' VC(#GG7_7?!?\ HJ2S_P![D+_^#_3_ /X!*OP#P#P#
MP#P#P#P$0+G^MSW+7_.+;[UH?$]8]?U^9_!^5D^CP*0.<4O6;M7/TTTVGUEQ
MQS,BK?'YD7D/J,_&C#78;-4<J@2_\ \ \!5K\ME[0BL.825:F[F@%*S>\GHP
M+ S%I6O+J%@4I'0V80J3VA CEV0D*;DE>ZS6M=9#&$R$?1;29TB7=(QY^.?:
M?RC$"&OPO]$L"%@7'S)'9IS!+8"@/+7E6X'G_LNY.PG=017"U;P1S6CZ3VK4
ML9?C8X[DZY^?,/Y.P'[[8Y+33./P\='VJB[4"ZFW>AJFHQ_ Q-DG30XO9IE\
M @P>.P*P;!+G20MHD_*8T%UY%I408,!C)9)T1,%&[$0Q0WPHZ?(Z_7. -)E_
MD7XL!OK %D+W ?RU9R!"*R8.Q 38L9>2%>6'('L*@X@3&7Q*T'+*;1B31(M_
MADUER861QN0!B^[$@$)H-0,PKGMOE.W;%$5365V1&;S>0Q$=. #"/X+/A)R/
ME8C&K 9;!Y;H-Q$"9K>!3**3=>*,CJ\J9Q"1")*]"MPKY![N!J?X]QRXF+]1
MCG)@H?7:]S]1IJ&#7\=_*/\ ;,T0W_*\_B1PD=^37&V$\?JCFJ?X]-/JGG?[
MM]@)_P#@'@'@'@'@'@'@(DV=E&P^I.?ZS^JBPVI0\QZ9E>B?URAH8T'OJ<J0
M64T^F=%&QAU-[.E@W3?&,Z&JN9O$\_D9ZYU EMX!X!X!X#KS_-UT'S^(/4-1
M$@L&CXI=JJTMEK(O<UN3BJ0]9Q$S%C#<+,,OH)3UREU3SV;1<49KY_M'V(X5
M,H"QW*E5&;G:-R4"Q[D&JZ\GWQY\_54^.#IC7SVG80*3D=26U9:HTTT!J-'@
M\U#+<8LJILC9'9^,;/6IAD*A+G7.F[)L)'"]4Q^H'WB/C.X8!O8J\'<\Q;1.
M'0I]  XET8F)&-.(^2&3\,]7DD5(R1W&YE*5Q-JV6.VG4O%')OJTG<J1TD.N
MII[A4#%;FYVIWF;B"^H'2L1VB4=)CEI,7U=2"42TV<D#A2+A,ECTJFIJ12DX
M]0! 00!@J6,O/XT"$#A!^&PL8R:(!Z%BO@'@'@'@'@'@'@'@(AEL8M[K>/@_
MQI/(1RE&_P"N2JNJOY$5+_M@*6C4.'[83SG74C7],/9H:*CG?^B%T04PDG^5
M!JLF!+SP#P$;K#Z=BU;737U(F*XOLR3L,<F3;6+#Z5G,II2(ME')9KG%B6T)
M&K0^#K(9#KN':1Q^WRR8NASYYE!J_;J[@=6'@#Y2'=B_*L&L@MT[*IU47R#S
M?IBH8CSP8+S+$0YW'U45")\ER<6&,#V\.&G[HB,'EFA72(O'2KXO-&#@KG+Q
M17;P&S/AU[0ZNKJE_C(HJTAU2'^>.SR/8E95M/(Q+9R4Z9A<PJZ26M8+B93Q
M23(KPIP!748EH^P%"63]Q'FR$?,%#:WY]P.7OW\C">B?]?F2(^.H_;52?+9=
M7.5EENL*HB4KX[#6/7U%=4=#J]5%;>DP2U/X.6='QR?B97-(C6^GZ.-(VYK8
M85'*O=W;LMH%%,A[,6R&3LM^ > > I5^1SY&Z_YZE\.BK7H:>\SN:\GC?_&*
MSCG)]YVS3[0&9B6A.-QTSEE4.\/L,;*C) $$W7KJZ(9*XR8>:(MRJZR9D>S
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M/O:AR$6/KW,O;92H0/D1SE=+*_=TDBM8K*]6!DEFY8=%5K123S,:NMN$W?\
M6]&M.@2[-VVGG31HA<LZU?-"37<8Y):H1V)0P5L5;,UWT6KR QZ+PF-'FC)B
M,FK$+M8;1IHK,72SC8Q]V+(T:E^%DT<5RO%8CCLQ.AG8V5B/1LL3N['M1=EV
M5S5_F8Y[%:Y8W4^G[>E-19O3-^QC[=W Y.YBK5G%7(LACIYJ<SX7RT[D/P30
M/5O)JN;'*S=8K$,,[)(63.]N$$/ / 5G_)=V78?&T,J>1UY18J\7TVFIP*X
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MP!"X %!F4+>!5Q:\5M@GCE7_  @ZGZK#C>HI]&R F.9A_00@@#A<RG[9['W
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M,'9NA*Q@HZB@M0P@(#U_'82Q0S&9RDF8OW8<HZ%8L=85JUJ"1-1NT.VZK_\
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M(A$ICSU9B?8-'J+0T#>/QKA5F[15:NM$7.^S=PDH@KC173;7 +Z+\B8A<N*
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M [6/#%5+1=;#WR$_,P63;/$%AZNPZ-/6.7FR+M5B] SK_95KSZ__ !;]*_\
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M Z^LQO3?Y*(G3S9"HV$)NM@F)NFAPSA$-U9S3>7/]O+IT;;H"XFBS"MB0P5
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M2"+AB1'/FJJC=TT=(*H+I;[:*:;:YSCP&$4Q1E2<\0A"N:6@H6OH8W(/"O\
M#!M72F')1_A'1T2(OR#EZ4*/U&[5FRU=DGKMPB-8#AB"B8\>R;( ;7\ \ \
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,3AQNHKN!FW@'@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683375200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immatics N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">76,670,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Paul-Ehrlich-Stra&#223;e 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">T&#252;bingen<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">72076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers GmbH  Wirtschaftspr&#252;fungsgesellschaft <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stuttgart, Germany<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Edward A. Sturchio<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2130 W. Holcombe Blvd., Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">810-7545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationDocumentAxis=imtx_OrdinaryShareMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#8364;0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMTX<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationDocumentAxis=imtx_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase ordinary shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMTXW<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationDocumentAxis=imtx_OrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationDocumentAxis=imtx_OrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationDocumentAxis=imtx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationDocumentAxis=imtx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683162160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Profit/(Loss) of Immatics N.V. - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">&#8364; 172,831<span></span>
</td>
<td class="nump">&#8364; 34,763<span></span>
</td>
<td class="nump">&#8364; 31,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(106,779)<span></span>
</td>
<td class="num">(87,574)<span></span>
</td>
<td class="num">(67,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(36,124)<span></span>
</td>
<td class="num">(33,808)<span></span>
</td>
<td class="num">(34,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="nump">29,954<span></span>
</td>
<td class="num">(86,294)<span></span>
</td>
<td class="num">(69,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Change in fair value of liabilities for warrants</a></td>
<td class="nump">10,945<span></span>
</td>
<td class="num">(10,990)<span></span>
</td>
<td class="nump">17,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareListingExpense', window );">Share listing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other financial income</a></td>
<td class="nump">9,416<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">2,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other financial expenses</a></td>
<td class="num">(8,279)<span></span>
</td>
<td class="num">(1,726)<span></span>
</td>
<td class="num">(10,063)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial result</a></td>
<td class="nump">12,082<span></span>
</td>
<td class="num">(7,041)<span></span>
</td>
<td class="num">(142,126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before taxes</a></td>
<td class="nump">42,036<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="num">(211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="num">(4,522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="nump">37,514<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="num">(211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the parent</a></td>
<td class="nump">&#8364; 37,514<span></span>
</td>
<td class="num">&#8364; (93,335)<span></span>
</td>
<td class="num">(211,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Net profit/(loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic</a></td>
<td class="nump">&#8364; 0.56<span></span>
</td>
<td class="num">&#8364; (1.48)<span></span>
</td>
<td class="num">&#8364; (4.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted</a></td>
<td class="nump">&#8364; 0.55<span></span>
</td>
<td class="num">&#8364; (1.48)<span></span>
</td>
<td class="num">&#8364; (4.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RevenueFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RevenueFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683061456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V. - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="nump">&#8364; 37,514<span></span>
</td>
<td class="num">&#8364; (93,335)<span></span>
</td>
<td class="num">&#8364; (211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified subsequently to profit or loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Currency translation differences from foreign operations</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss) for the year</a></td>
<td class="nump">39,978<span></span>
</td>
<td class="num">(89,821)<span></span>
</td>
<td class="num">(218,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Equity holders of the parent</a></td>
<td class="nump">39,978<span></span>
</td>
<td class="num">(89,821)<span></span>
</td>
<td class="num">(217,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (557)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683105200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Financial Position of Immatics N.V. - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 148,519<span></span>
</td>
<td class="nump">&#8364; 132,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">213,686<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivables</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">13,838<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">377,154<span></span>
</td>
<td class="nump">152,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">13,456<span></span>
</td>
<td class="nump">10,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">13,033<span></span>
</td>
<td class="nump">9,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">30,666<span></span>
</td>
<td class="nump">22,439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">407,820<span></span>
</td>
<td class="nump">174,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payables</a></td>
<td class="nump">13,056<span></span>
</td>
<td class="nump">11,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred revenue</a></td>
<td class="nump">64,957<span></span>
</td>
<td class="nump">50,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Liabilities for warrants</a></td>
<td class="nump">16,914<span></span>
</td>
<td class="nump">27,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">106,452<span></span>
</td>
<td class="nump">95,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Deferred revenue</a></td>
<td class="nump">75,759<span></span>
</td>
<td class="nump">48,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">12,403<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">88,204<span></span>
</td>
<td class="nump">55,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">714,177<span></span>
</td>
<td class="nump">565,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(500,299)<span></span>
</td>
<td class="num">(537,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="num">(1,481)<span></span>
</td>
<td class="num">(3,945)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders' equity</a></td>
<td class="nump">213,164<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">&#8364; 407,820<span></span>
</td>
<td class="nump">&#8364; 174,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682695472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows of Immatics N.V. - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="nump">&#8364; 37,514<span></span>
</td>
<td class="num">&#8364; (93,335)<span></span>
</td>
<td class="num">&#8364; (211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="nump">42,036<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="num">(211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestIncome', window );">Interest income</a></td>
<td class="num">(2,476)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">6,967<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestExpense', window );">Interest expenses</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForShareListingExpense', window );">Share listing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentForEquitySettledSharebasedPayment', window );">Equity settled share-based payment</a></td>
<td class="nump">22,570<span></span>
</td>
<td class="nump">26,403<span></span>
</td>
<td class="nump">22,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">MD Anderson compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">(Decrease) Increase in other liabilities resulting from share appreciation rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PaymentsForShareBasedCompensation', window );">Payment related to share-based compensation awards previously classified as equity-settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss', window );">Net foreign exchange differences and expected credit losses</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="num">(2,408)<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Change in fair value of liabilities for warrants</a></td>
<td class="num">(10,945)<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
<td class="num">(17,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in accounts receivables</a></td>
<td class="num">(429)<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">(Increase) in other assets</a></td>
<td class="num">(7,872)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables', window );">Increase/(decrease) in deferred revenue, accounts payables and other liabilities</a></td>
<td class="nump">45,559<span></span>
</td>
<td class="num">(31,784)<span></span>
</td>
<td class="num">(23,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income tax paid</a></td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="nump">100,131<span></span>
</td>
<td class="num">(84,746)<span></span>
</td>
<td class="num">(80,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Payments for property, plant and equipment</a></td>
<td class="num">(5,738)<span></span>
</td>
<td class="num">(5,106)<span></span>
</td>
<td class="num">(7,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Payments for investments classified in Other financial assets</a></td>
<td class="num">(216,323)<span></span>
</td>
<td class="num">(11,298)<span></span>
</td>
<td class="num">(58,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Proceeds from maturity of investments classified in Other financial assets</a></td>
<td class="nump">12,695<span></span>
</td>
<td class="nump">24,448<span></span>
</td>
<td class="nump">49,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Payments for intangible assets</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (used in)/provided by investing activities</a></td>
<td class="num">(209,791)<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
<td class="num">(15,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of shares to equity holders</a></td>
<td class="nump">134,484<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">217,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TransactionCostsDeductedFromEquity', window );">Transaction costs deducted from equity</a></td>
<td class="num">(7,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="num">(2,843)<span></span>
</td>
<td class="num">(2,707)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="nump">123,710<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="nump">207,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">14,050<span></span>
</td>
<td class="num">(79,866)<span></span>
</td>
<td class="nump">111,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
<td class="nump">103,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents', window );">Effects of exchange rate changes and expected credit losses on cash and cash equivalents</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="num">(7,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">&#8364; 148,519<span></span>
</td>
<td class="nump">&#8364; 132,994<span></span>
</td>
<td class="nump">&#8364; 207,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest income expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentForEquitySettledSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for equity settled share-based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentForEquitySettledSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase decrease in deferred revenue trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange and expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in working capital [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effects of exchange rate changes and expected credit losses on cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PaymentsForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PaymentsForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TransactionCostsDeductedFromEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs deducted from equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TransactionCostsDeductedFromEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683874704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V. - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital [member]</div></th>
<th class="th"><div>Share premium [member]</div></th>
<th class="th"><div>Accumulated deficit [member]</div></th>
<th class="th"><div>Other reserves [member]</div></th>
<th class="th"><div>Total equity (deficit) attributable to shareholders of the parent [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">&#8364; (40,835)<span></span>
</td>
<td class="nump">&#8364; 1,164<span></span>
</td>
<td class="nump">&#8364; 190,945<span></span>
</td>
<td class="num">&#8364; (233,194)<span></span>
</td>
<td class="num">&#8364; (770)<span></span>
</td>
<td class="num">&#8364; (41,855)<span></span>
</td>
<td class="nump">&#8364; 1,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="num">(211,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,284)<span></span>
</td>
<td class="num">(557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income/(loss) for the year</a></td>
<td class="num">(218,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,284)<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
<td class="num">(217,973)<span></span>
</td>
<td class="num">(557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseThroughReorganizationEquity', window );">Reorganization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">MD Anderson Share Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">PIPE Financing, net of transaction costs</a></td>
<td class="nump">90,077<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">89,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseThroughARYAMerger', window );">ARYA Merger, net of transaction costs</a></td>
<td class="nump">238,044<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">237,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SARConversion', window );">SAR conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughIssuanceOfEquity', window );">Total issuance of share capital</a></td>
<td class="nump">328,121<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">328,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,629<span></span>
</td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation</a></td>
<td class="nump">22,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled', window );">Payments related to share-based compensation awards previously classified as equity-settled</a></td>
<td class="num">(4,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughCompensationExpense', window );">MD Anderson milestone compensation expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">87,387<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">538,695<span></span>
</td>
<td class="num">(444,478)<span></span>
</td>
<td class="num">(7,459)<span></span>
</td>
<td class="nump">87,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="num">(93,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income/(loss) for the year</a></td>
<td class="num">(89,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,335)<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="num">(89,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation</a></td>
<td class="nump">26,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">24,063<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">565,192<span></span>
</td>
<td class="num">(537,813)<span></span>
</td>
<td class="num">(3,945)<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="nump">37,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income/(loss) for the year</a></td>
<td class="nump">39,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,514<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">39,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation</a></td>
<td class="nump">22,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IssueOfShareCapitalNetOfTransactionCosts', window );">Issue of share capital &#8211; net of transaction costs</a></td>
<td class="nump">126,242<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">126,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">&#8364; 213,164<span></span>
</td>
<td class="nump">&#8364; 767<span></span>
</td>
<td class="nump">&#8364; 714,177<span></span>
</td>
<td class="num">&#8364; (500,299)<span></span>
</td>
<td class="num">&#8364; (1,481)<span></span>
</td>
<td class="nump">&#8364; 213,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreaseDecreaseThroughReorganizationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through reorganization, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreaseDecreaseThroughReorganizationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreaseThroughARYAMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase through ARYA Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreaseThroughARYAMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through changes in noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughIssuanceOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughIssuanceOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share based compensation previously classifies as equity settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IssueOfShareCapitalNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of share capital &#8211; net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IssueOfShareCapitalNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SARConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SAR conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SARConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635687003040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory', window );">Group information</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Group information </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics N.V., together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (&#8220;Immatics&#8221; or &#8220;the Group&#8221;) is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Immatics N.V., a Dutch public limited liability company, was converted on July&#160;1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became wholly-owned subsidiaries of Immatics N.V. as part of the ARYA Merger (see Note 3) on July&#160;1, 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics N.V. is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 T&#252;bingen, Germany. Prior to July&#160;1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Immatics N.V. is the ultimate parent company of the Group. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These annual consolidated financial statements of the Group for the year ended December 31, 2022 were authorized for issue by the Board of Directors of Immatics N.V. on March 22, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Subsidiaries [member]; Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCompositionOfGroupExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686961104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of presentation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Basis of presentation </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (&#8220;IFRS IC&#8221;). The consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. For technical reasons, the information provided in these financial statements may contain rounding differences of +/- one unit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc., are fully consolidated from the date upon which control was transferred to Immatics N.V. All intra-company assets and liabilities, equity, income, expenses and cash flows relating to transactions between the Group are eliminated in full upon consolidation. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">The consolidated statement of profit or loss is prepared based on the function of expense method. The financial statements were prepared in accordance with the historical cost principle and on a going concern basis. This excludes financial liabilities for warrants, which are measured at fair value. The presentation in the consolidated statement of financial position distinguishes between current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets and liabilities. Assets are classified as current if it is expected to realise to sell or consume the asset in its normal operating cycle. Liabilities are classified as current if it is due within one year. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reporting period for Immatics N.V. and its subsidiaries corresponds with the calendar year. The reporting period 2022 began on January&#160;1, 2022 and ended on December&#160;31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;1, 2020 and as part of the ARYA Merger, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of MD Anderson in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V. See Note 3 for further details. The consolidated financial statements comprise the financial statements of Immatics N.V. and its wholly-owned subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Going concern </div></div></td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Group&#8217;s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketed any products commercially. Immatics&#8217; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics&#8217; cash and cash equivalents, bonds as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the financial statements. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. </div></div></div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not result in a negative impact of the Group&#8217;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#8217;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2.3 Russian-Ukraine Conflict and macroeconomic environment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683372160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARYA Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AryaMergerTransactionExplanatory', window );">ARYA Merger</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ARYA Merger </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2020, Immatics entered into a definitive merger agreement with ARYA Sciences Acquisition Corp. (&#8220;ARYA&#8221;), a special purpose acquisition company sponsored by Perceptive Advisors. The transaction closed on July&#160;1, 2020. The merger (&#8220;ARYA Merger&#8221;) was effectuated as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The shareholders of Immatics Biotechnologies GmbH exchanged their interest for ordinary shares in the share capital of Immatics B.V. (&#8220;the Reorganization&#8221;). The Reorganization is accounted for as a recapitalization, with Immatics Biotechnologies GmbH being the accounting predecessor. The Reorganization resulted in a &#8364;0.8&#160;million decrease in share capital and an offsetting increase in share premium. Subsequent to the Reorganization, Immatics B.V. was converted into Immatics N.V., after the share exchange of Immatics shareholders. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As part of the Reorganization, the minority shareholder in Immatics US, Inc., MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) exchanged its interest in Immatics US, Inc. for ordinary shares</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in the share capital of Immatics N.V. (&#8220;MD Anderson Share Exchange&#8221;). This resulted in a decrease to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#8364;0.5&#160;million, with corresponding increases to share capital and share premium. (See Note 19). </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">ARYA merged into Immatics N.V., with former ARYA shareholders receiving one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares in ARYA. The merger of ARYA constituted a transaction by Immatics N.V., which is accounted for within the scope of IFRS 2. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As part of the transaction, former shareholders of ARYA received 17,968,750 shares of Immatics N.V. and 7,187,500 warrants (&#8220;Immatics Warrants&#8221;) to purchase ordinary shares of Immatics N.V. In exchange, Immatics received the net assets held by ARYA, which had a fair value of &#8364;90.3&#160;million upon closing of the transaction on July&#160;1, 2020. The net assets included &#8364;128.8&#160;million of cash and cash equivalents held in ARYA&#8217;s trust account and current liabilities of &#8364;3.9&#160;million as well as the fair value of the warrants in the amount of &#8364;34.6&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS 2, the difference between the fair value of the net assets contributed by ARYA and the fair value of equity instruments provided to former ARYA shareholders is treated as an expense, resulting in a &#8364;152.8&#160;million share listing expense classified within the financial result (See&#160;Note 15) and an increase in equity. The 7,187,500 Immatics Warrants give the holder the right, but not the obligation, to subscribe to Immatics&#8217; shares at a fixed or determinable price for a specified period of time subject to the provision of the Warrant Agreement. Those instruments were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32. Due to an option of cashless exercise of the Immatics Warrants, which gives Immatics a choice over how the warrant is settled with a settlement alternative, that results in Immatics delivering a variable number of shares. Therefore, the Immatics Warrants are accounted for as financial liability through profit and loss. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Immatics N.V. raised an additional net &#8364;90.1&#160;million in net equity proceeds through a private placement of ordinary shares with existing shareholders of Immatics, ARYA and other new investors (&#8220; Financing&#8221;). The PIPE Financing is treated as a capital contribution, which resulted in increases of &#8364;0.1&#160;million and &#8364;90.0&#160;million to share capital and share premium, respectively. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both the ARYA Merger and PIPE Financing closed as of July&#160;1, 2020. Upon consummation of the transactions, Immatics N.V. became a publicly traded corporation at the Nasdaq Capital Market under the ticker IMTX. The Immatics Warrants are traded under the ticker IMTXW. Immatics incurred incremental transaction costs directly attributable to the issuance of new shares to ARYA shareholders and the PIPE Financing of &#8364;7.9&#160;million, which it netted against the equity proceeds as a reduction in share premium. Immatics also amended existing share-based compensation agreements held by employees of Immatics GmbH prior to the ARYA Merger (See Note 17), in addition to making additional cash and share-based payments to key management personnel (See Note 25). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AryaMergerTransactionExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of ARYA Merger transaction explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AryaMergerTransactionExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683146480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory', window );">Disclosure of changes in accounting policies, accounting estimates and errors [text block]</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Application of new and revised international financial reporting standards </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Application of new standards </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December&#160;31, 2021, except for the adoption of new standards and interpretations effective as of January&#160;1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">New standards and interpretations applied for the first time: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment IAS 16 &#8211; Property, Plant and Equipment (Proceeds before Intended Use)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment IAS 37 &#8211; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#8211;Cost of Fulfilling a Contract)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 3 &#8211; Business Combinations (Reference to the Conceptual Framework)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 1 &#8211; First-time Adoption of International Financial Reporting Standards</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 9 &#8211; Financial Instruments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to Illustrative Examples accompanying IFRS 16</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 41 &#8211; Agriculture</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Those amendments on standards and interpretations had no effect on the consolidated financial statements of the Group. </div><div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Assessment of potential impact of future standards, amendments to existing standards and interpretations </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December&#160;31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:14%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Potentially<br/> material&#160;effect&#160;expected<br/> on Immatics financial<br/> statements</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">IFRS 17 &#8211; Insurance Contracts</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 12 &#8211; Income Taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment to IFRS 16 &#8211; Leases on sale and leaseback</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment to IAS 1 &#8211; Presentation of Financial Statements (Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities with covenants)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr></table>  <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.3</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revision of previously issued financial statements </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the preparation of the unaudited interim consolidated financial statements for the three and nine months ended September&#160;30, 2022, the Group identified an error in the presentation of &#8216;Net foreign exchange differences&#8217; and &#8216;Effects of exchange rate changes on cash and cash equivalents&#8217; in the statement of cash flows. The error resulted in a presentation of effects from exchange rate changes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency denominated cash and cash equivalents in Immatics N.V. and Immatics Biotechnologies GmbH as operating cash flow instead of presentation as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items in &#8216;Effects of exchange rate changes on cash and cash equivalents&#8217;. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This error had no impact on the Company&#8217;s consolidated statements of financial position, of profit/(loss), of comprehensive income/(loss) and of consolidated statements of changes in equity. The Company assessed the materiality of these errors on the previously issued consolidated financial statements and concluded that the errors were not material to any year presented.&#160;The impact of the revision of the previously issued financial statements is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,477</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(85,611</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,914</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80,697</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,949</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,949</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,914</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">111,238</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,061</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,962</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,408</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(81,785</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84,747</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,493</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,493</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,613</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,613</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(76,904</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(79,866</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also reclassed &#8364;51&#160;thousand from Provisions to Other current liabilities as of December&#160;31, 2021. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for changes in accounting policies, accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Section Accounting policies<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS08_g7-31__IAS08_g7-31_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682193696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of accounting policies applied by the Group for the annual reporting period ending December&#160;31, 2022 </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the significant accounting policies applied by the Group in preparing its consolidated financial statements: </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment information </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#8217;s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group&#8217;s resources. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds), short-term deposits and bonds with an original maturity of three months or less.</div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Initial recognition and measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. </div><div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Short-term deposits </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics has short-term deposits with original maturities between three and twelve months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Bonds </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics holds bonds with an original maturity of more than three months, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Receivables </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has receivables from collaboration agreements. Receivables must be capitalized at the point in time at which the Group has become a contractual partner and an unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, receivables are measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group&#8217;s receivables have an expected maturity of less than 12 months. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Interest and other finance income and expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income and expenses from financial instruments are recorded using the effective interest rate (&#8220;EIR&#8221;). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Profit/(Loss). As of December&#160;31, 2022 and 2021, Immatics is not a counterparty in foreign exchange forward contracts. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Impairment of financial assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses on financial assets are recognized as financial expenses. The Group recognizes an allowance for expected credit losses (ECLs) for financial assets, see Note 16. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-months</div> (a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing information (credit default swap values) published by credit agencies and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL. </div>  <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expenses when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1&#160;&#8211;&#160;10&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 15 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Office equipment and installations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2 &#8211; 20 years</td> </tr> </table>  <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.5</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5&#160;&#8211;&#160;30&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 5 years</td> </tr> </table>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.6</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Research and development </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research costs are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2022, 2021 and 2020 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">laboratory costs; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">5.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">6.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. </div> </td> </tr> </table>  <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.7</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities: Initial recognition and measurement </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company&#8217;s financial liabilities include accounts payables, lease liabilities, warrant liabilities and other financial liabilities. Immatics recognized accounts payables and other current liabilities as other financial liabilities at amortized costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. </div>  <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.8</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted IFRS 16 (&#8220;Leases&#8221;) effective January&#160;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Group has elected not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Under IFRS 16, leases are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset with a corresponding liability on the date at which the leased asset is available for use by the Group (lease commencement date). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">fixed payments (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed payments), less any lease incentives received; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">amounts expected to be payable by the Group under residual value guarantees; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease term consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#8217;s leases, the lessee&#8217;s incremental borrowing rate (&#8220;IBR&#8221;) is used. The IBR is the rate that the individual lessee would have to pay to borrow the funds, necessary to obtain an asset of similar value to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset in a similar economic environment with similar terms, security and conditions. The Group used an IBR for each respective lease to calculate the initial lease liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the IBR, the Group: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">uses a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-up</div> approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Immatics; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">makes adjustments specific to the lease, including lease term, country, currency and security. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost comprising the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the amount of the initial measurement of lease liability; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any lease payments made at or before the commencement date less any lease incentives received; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any initial direct costs; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">restoration costs. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are generally depreciated over the shorter of the asset&#8217;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is depreciated over the underlying asset&#8217;s useful life. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments associated with short-term leases of equipment and vehicles and all leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> assets have a value of less than &#8364;5&#160;thousand. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group&#8217;s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December&#160;31, 2022 to determine whether option extensions are reasonably certain. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue from collaboration agreements </div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place, one with Genmab A/S, Copenhagen /Denmark (&#8220;Genmab&#8221;) and three with Bristol-Myers-Squibb (&#8220;BMS&#8221;). During the year ended December&#160;31, 2022, the Group entered into new collaboration agreements with BMS. Three of the Group&#8217;s strategic collaboration agreements are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage and the BMS IMA401 collaboration agreement is at clinical stage. The collaboration with GlaxoSmithKline Intellectual Property Development Limited (&#8220;GSK&#8221;) was terminated in October 2022 and the collaboration with Amgen Inc., Thousand Oaks/CA/USA (&#8220;Amgen&#8221;) was terminated in October 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the contract(s) with a customer; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the performance obligations in the contract; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">determine the transaction price; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">allocate the transaction price to the performance obligations in the contract; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">recognize revenue when (or as) the Group satisfies a performance obligation. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under the collaboration agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Identify the performance obligations in the contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> collaboration agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-targets</div> using Immatics&#8217; proprietary technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> participation on steering committees, and preparation of data packages. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group&#8217;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#8217; research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group&#8217;s XPRESIDENT technology and database of target and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> data. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical collaboration agreement (BMS IMA401 agreement) </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Immatics granted to Bristol-Myers Squibb an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401. Under the Agreement, Immatics is also responsible for, and will bear the cost of, the first Phase 1 clinical trial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The license contributed under the collaboration agreement represents a distinct performance obligation, because they are separately identifiable from other promises in the BMS IMA401 agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Determine the transaction price </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Upfront payment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Group&#8217;s strategic collaboration agreements includes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment. The Group records these payments as deferred revenue, which it allocates to the combined performance obligations for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div><div style="background-color:white;display: inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using direct costs and directly attributable personnel costs is considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#8217;s collaboration partners, due to the nature of the work being performed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Group&#8217;s BMS IMA401 agreement, the Group determined the underlying stand-alone selling price for each performance obligation to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price requires significant judgement regarding the estimation approach of the stand-alone selling prices for the distinct performance obligations as well as significant estimates regarding the expected cost for future services, profit margins and development timelines. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reimbursement for services </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are part of the transaction price and presented as revenue and not deducted from expenses. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development and Commercial Milestones </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales-based milestones and royalty payments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to fulfill contracts </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to obtain a contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.10</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Share-based payment </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 17. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.</div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5.11 Foreign currency </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Transactions and balances in Germany and in the USA </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements are presented in Euro, which is the parents, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Profit/(Loss) is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Euros per U.S.&#160;Dollar</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.93756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.94888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.84495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.81493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.12</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value of financial instruments </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the principal market for the asset or liability or </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 &#8212; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessing</div> categorization (based on the lowest level input that is significant to the fair value measurement as a whole), at the end of each reporting period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.13</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Provisions </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the effect of the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects, when appropriate, the risks specific to the liability. </div>  <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.14</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred income tax </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (&#8220;Income Taxes&#8221;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682538560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting judgments, estimates and assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant accounting judgments, estimates and assumptions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Significant accounting judgements, estimates and assumptions </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Group&#8217;s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. In particular, material management judgments and estimation uncertainties apply to the recognition and measurement of income taxes (incl. deferred taxes), the revenue recognition from collaboration agreements and the measurement of share-based payments. Management bases its assessment of these judgments and estimation uncertainties on past experience, estimates from experts (lawyers, tax consultants, etc.) and the results of carefully weighing up different scenarios. Actual events and developments that lie beyond the control of management may deviate considerably from the expressed developments and assumptions. For this reason, the Group examines the estimates and assumptions made on an ongoing basis. Changes in estimates are recognized in profit or loss as soon as better information is available. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taxes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expenses already recorded. Deferred tax assets are recognized for unused tax losses to the extent, that it is probable that taxable profit will be available which can be utilized against the losses. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Due to the Group&#8217;s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group has not recognized any deferred tax assets on tax losses carried forward. Changes in the estimation of our potential to use tax losses carried forward can have a material effect on the Group`s net income. For more information, see Note 21. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition from collaboration agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the collaboration agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. For the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> collaboration agreements with Genmab and BMS, the Group assessed that these promises are not capable of being distinct within the context of the contract, which results in accounting for all goods and services promised as a single performance obligation with a single measure of progress. The performance obligation is accounted for as a performance obligation, satisfied over time using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method as the customer simultaneously receives and consumes the benefits from Immatics&#8217; performance. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the BMS IMA401 agreement, the Group assessed that these promises were two distinct performance obligations, the granted license and the conduct of clinical trial services. Since the collaboration agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation and allocated the transaction price to the performance obligations. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group used for the performance obligation related to clinical trial services, the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. The Group decided to estimate a stand-alone selling price for the performance obligation related to the license by using the residual approach, since it is a unique license and there is no available market price for the license. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-front</div> licensing payments are initially deferred on our Consolidated Statement of Financial Position and subsequently recognized as revenue as the performance obligations are fulfilled. Milestone payments are included in the transaction price at the amount stipulated in the respective agreement and recognized as revenue to the extent that it is highly probable that a&#160;significant reversal&#160;in the amount of cumulative revenue recognized will not occur. To date, no milestone has been included in the transaction price. Changes in this estimate can have a material effect on revenue recognized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics provides development and manufacturing services to customers and recognizes revenue over time using an input-based method to measure progress toward complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before the Group can use them for recognition purposes. Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which includes total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on revenue recognized. For more information, see Note 13. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management determined the value of share-based awards with the assistance of a third-party valuation specialist using certain assumptions, such as volatility, risk-free interest rate, exercise pattern and expected dividends. Changes in these estimates can have a material effect on share-based expenses recognized. For more information, see Note 17. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684534352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock', window );">Accounts receivable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accounts receivables </div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Receivables from collaboration agreements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,111</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">682</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, and 2021, no expected credit losses were recognized. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfAccountReceivableExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of account receivable Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfAccountReceivableExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686823712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current and non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other current and non-current assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Value added tax receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Grant receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">On May&#160;27, 2022, Immatics US, Inc. entered into a Research collaboration and License agreement (the &#8220;Editas agreement&#8221;) with Editas Medicine, Inc. (&#8220;Editas&#8221;). The Editas agreement became effective on May&#160;27, 2022. Pursuant to the Editas agreement, the Group paid upfront a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> fee related to the Groups access to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> right to Editas CRISPR technology and intellectual property as well as for services provided by Editas. The Group will together with Editas combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. The Group determined to account for the upfront payment as prepaid research and development expenses. The prepaid expenses will be consumed over the term of the research and development activities. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include expenses for licenses and software of &#8364;7.4&#160;million as of December&#160;31, 2022 and &#8364;0.5&#160;million as of December&#160;31, 2021 and prepaid insurance expenses of &#8364;1.2&#160;million as of December&#160;31, 2022 and &#8364;1.3&#160;million as of December&#160;31, 2021. The Group accrued &#8364;0.4&#160;million as of December&#160;31, 2022 and &#8364;0.7&#160;million as of December&#160;31, 2021 of incremental cost for the successful arrangement of the BMS collaboration signed in 2019 and the Genmab collaboration agreement. Additionally, prepaid expenses include expenses for maintenance of &#8364;0.7&#160;million as of December&#160;31, 2022 and &#8364;0.8&#160;million as of December&#160;31, 2021. The remaining amount is mainly related to prepaid expenses for contract research organizations and prepaid rent. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other assets include receivables from lease incentive, capital gains tax and prepaid deposit expenses. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets consist of the following:</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,545</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">636</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion of prepayments for licensing agreements of &#8364;1.5&#160;million, prepaid maintenance expenses of &#8364;0.3&#160;million and accrued incremental cost of the BMS and Genmab collaboration agreement of &#8364;0.1&#160;million as of December&#160;31, 2022. Other assets include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion for prepaid deposit expenses. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683919696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Laboratory<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computer<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/> equipment<br/> and<br/> installations</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,322</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,436</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,630</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,470</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,661</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,761</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,476</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,428</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,665</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,569</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(219</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(256</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,052</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,966</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,237</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,255</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,578</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,504</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,424</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,506</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,630</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,470</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,661</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,761</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,737</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,898</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,303</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,938</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,052</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,966</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,237</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,255</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(653</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(333</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,129</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(180</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(210</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,279</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,636</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,567</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,482</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,262</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,456</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Groups additions within Office equipment and installations include leasehold improvements for the research and commercial GMP manufacturing facility construction in Houston, Texas of &#8364;2.5&#160;million as of December&#160;31, 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(890</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,129</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,574</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,102</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683919856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patents<br/> and<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Software<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,132</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">738</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,870</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,551</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">908</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,459</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(554</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(957</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(160</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(480</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(664</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,144</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,071</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">244</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,315</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,029</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">988</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,017</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(480</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(664</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,144</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(158</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(218</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(559</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(826</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,385</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,470</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">162</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,632</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(218</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(160</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(126</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128__IAS38_g118-128_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683192208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of</div> use assets consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,033</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,982</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities &#8211; current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Lease liabilities &#8211; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,562</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,853</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additions to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities were &#8364;6.7&#160;million and &#8364;6.7&#160;million as of December&#160;31, 2022 and 2021, respectively, including for the research and commercial GMP manufacturing facility in Houston, Texas of &#8364;6.2&#160;million as of December&#160;31, 2022. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Currency translation differences included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets were &#8364;0.1&#160;million and &#8364;0.3&#160;million as of December&#160;31, 2022 and 2021, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Expenses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation charges of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros&#160;in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(277</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(59</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,620</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,526</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,195</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses from leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(613</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(288</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Expenses relating to short-term leases and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets (included in administrative expenses)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total cash payments for leases were &#8364;3.6&#160;million, &#8364;3.2&#160;million and &#8364;2.4&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the Group has committed lease payments associated with lease liabilities of &#8364;18.6&#160;million, of which &#8364;3.6&#160;million will occur in the next 12 months. The remaining lease payments will occur between January&#160;1, 2024 and February&#160;28, 2033.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount up to &#8364;24.6 million until 2043 for the year ended December 31, 2022 and up to &#8364;10.4 million until 2043 for the year ended December 31, 2021. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For commitments for future lease payments, refer to Note 24. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683358960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Accounts payable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,009</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,056</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,624</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities classified within accounts payables mainly relate to outstanding invoices totaling &#8364;9.0&#160;million and &#8364;8.6&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686858880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from collaboration agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Revenue from collaboration agreements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place after the Amgen collaboration was terminated in 2021 and the GSK collaboration was terminated in 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As part of these collaboration arrangements, Immatics grants exclusive licensing rights or options thereto for the development and commercialization of future product candidates, developed for several targets defined in the respective collaboration agreements, in addition to research activities, including screening of highly specific molecules for reactivity with the specified targets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-targets</div> using Immatics&#8217; proprietary technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> participation on a joint steering committee, and preparation of data packages. For the preclinical collaboration agreements, these promises represent one combined performance obligation, whereas for the clinical stage BMS IMA401 agreement, the promises represent two distinct performance obligations. Immatics reassessed the total forecasted cost as part of the Group&#8217;s annual budget process and adjusted the total forecasted cost accordingly. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has not recognized any royalty or milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of December&#160;31, 2022, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenues are contract liabilities within the scope of IFRS 15. </div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Each of the Group&#8217;s strategic collaboration agreements included a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment, meant to subsidize research activities, recognized as deferred revenue. For all collaboration agreements these upfront </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payments exceeded the Group&#8217;s right to consideration for services performed under each collaboration agreement. Therefore, only deferred revenue net of contract assets is presented as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genmab Collaboration Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Genmab to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, Immatics and Genmab conduct joint research to combine Immatics&#8217; XPRESIDENT and Bispecific TCR technology platforms with Genmab&#8217;s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The two companies plan to develop immunotherapies directed against three proprietary targets. Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Genmab collaboration agreement contains a maximum of $550&#160;million of milestone payments for each licensed product resulting from the collaboration. In addition, Immatics is entitled to receive royalty payments. Royalty rates are based on aggregate net sales of a licensed product. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under the agreement, the royalty rates begin in the high single-digits, increasing to the low tens as a percentage of aggregate annual net sales of a licensed product. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;46&#160;million ($54&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;9.6&#160;million, &#8364;6.9&#160;million and &#8364;11.2&#160;million of revenue associated with the upfront payment and with reimbursements for research and development costs performed, for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;12.1&#160;million and &#8364;19.9&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BMS Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2019, Immatics Biotechnologies GmbH and BMS entered into a collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, Immatics may develop T Cell Receptor Engineered T Cell Therapy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TCR-T)</div> programs against solid tumor targets discovered with Immatics&#8217; XPRESIDENT technology. Programs would utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#8217; XCEPTOR TCR discovery and engineering platform. If Immatics develops programs against the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> targets, Immatics will be responsible for the development and validation of these programs through lead candidate stage, at which time BMS may exercise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-in</div> rights and assume sole responsibility for further worldwide development, manufacturing and commercialization of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> cell therapies. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Immatics would have certain early-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-funding</div> rights for selected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> cell therapies arising from the collaboration. With respect to this collaboration agreement with BMS, Immatics may be eligible to receive up to $505&#160;million for each licensed product in option exercise payments, development, regulatory and commercial milestone payments as well as tiered royalties on net sales. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under each contract, the royalty rates begin in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digits,</div> increasing to the low teen-digits as a percentage of aggregate annual net sales of a licensed product. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;68&#160;million ($75&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On June&#160;1, 2022, Immatics Biotechnologies GmbH entered into an Amendment to the Strategic Collaboration Agreement originally signed in 2019 (the &#8220;amendment&#8221;) with BMS. Pursuant to the amendment, the Group received a </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>18.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million ($</div>20<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million) upfront<div style="display:inline;">&#160;</div>cash payment related to the performance obligations under the contract. Under the amendment, Immatics will undertake an additional T Cell Receptor Engineered T cell Therapy (TCR-T) program against a solid tumor target discovered with Immatics&#8217; XPRESIDENT technology. The program will utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#8217; XCEPTOR TCR discovery and engineering platform. The increased consideration reflects the stand-alone selling price at contract inception and the amendment contains performance obligations that are distinct from the original performance obligation under the contract. Therefore, the Group determined to account for the modification of the Allogeneic ACT agreement signed in 2019, triggered by the amendment as a separate contract.&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The Group recognized &#8364;</div>23<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million, &#8364;</div>13.1<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div>11.5<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;</div>37.6<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div>41.9<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BMS IMA401 Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On December&#160;10, 2021, Immatics Biotechnologies GmbH entered into a License, Development and Commercialization agreement (the &#8220;BMS IMA401 agreement&#8221;) with BMS. The BMS IMA401 agreement became effective on January&#160;26, 2022, after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on January&#160;25, 2022. Pursuant to the BMS IMA401 agreement, the Group received a</div></div>&#160;&#8364;133&#160;million ($150 million) upfront cash payment related to the performance obligations under the contract. The Group identified the transfer of a global exclusive IMA401 license including technology transfer and the contractually agreed clinical trial services including participation in Joint Steering Committee meetings as distinct performance obligations. The Group is eligible to receive up to $770&#160;million development, regulatory and commercial milestone payments, in addition to low double-digit royalty payments on net sales of IMA401. Immatics retains the options to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-fund</div> U.S. development in exchange for enhanced U.S. royalty payments and/or to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promote</div> IMA401 in the US. In November 2021, Immatics filed a Clinical Trial Application (CTA) with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401. The clinical trial, which commenced in the second quarter of 2022, will enroll patients across various solid tumor types. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the BMS IMA401 agreement represent one performance obligation, combined performance obligations or multiple performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group concluded that BMS is a customer since the BMS IMA401agreement does contain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and BMS. The BMS IMA401 agreement clearly states deliverables to be delivered by the Group and BMS as mentioned below and creates enforceable rights and obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The manufacturing of the product for the trial is already completed. The clinical trial will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors, but there is no modification planned as part of this. With the end of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> phase, there was no further enhancement of the products planned. We therefore concluded that BMS can benefit from each performance obligation on its own and they are separately identifiable from other promises in the BMS IMA401 agreement. The Group concluded that there were two distinct performance obligations under the BMS IMA401 agreement, the granted license and the conduct of clinical trial services. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">At inception of the BMS IMA401 agreement, the Group determined the transaction price. We evaluated inclusion of the milestones as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The contractual agreed milestone payments with BMS relate to the license. Based on that the Group concluded that no variable consideration was considered as transaction price at contract inception. At the end of each reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group is required to allocate the determined transaction price of &#8364;133&#160;million ($150 million) to the two separate identified performance obligations of the BMS IMA401 agreement, based on the standalone selling price of each performance obligation as the upfront payment of &#8364;133&#160;million ($150 million) covers the cost of clinical trial services as well as an initial payment for the license. Since the BMS IMA401 agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation, to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price included estimates regarding forecasted cost for future services, profit margins and development timelines. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The most reasonable estimation method for the performance obligation related to clinical trial services is the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. On top of the forecast of expected costs, the Group added an appropriate profit margin based on average company profit margins for clinical trial services. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To estimate a stand-alone selling price for the performance obligation related to the IMA401 license, the Group concluded to use the residual approach due to the fact that the license is a unique license and there is no available market price for the license and hence no specific stand-alone selling price apart from the residual amount was identified. The Group concluded following transaction price allocation of the &#8364;133&#160;million ($150 million) upfront payment as of March&#160;31, 2022: </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.&#160;&#160;&#160;&#160;Stand-alone selling price for clinical trial services: &#8364;42&#160;million </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.&#160;&#160;&#160;&#160;Stand-alone selling price for the license grant: &#8364;91&#160;million </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group evaluated each performance obligation to determine if it can be satisfied at a point in time or over time. The control over the granted license is transferred at a point in time, after BMS obtains the rights to use the license at the effective date of the agreement. The performance obligation related to promised clinical trial services is satisfied over time. The Group transfers control of these agreed services over time and will therefore recognize revenue over time as costs are incurred using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method. At inception of the BMS IMA401 agreement, &#8364;42&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended December&#160;31, 2022, &#8364;6.9&#160;million revenue was recognized based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method as well as &#8364;91&#160;million revenue related to the license for IMA 401. Total deferred revenue under the agreement was &#8364;34.8&#160;million and &#8364;0.0 as of December&#160;31, 2022 and 2021, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allogeneic ACT Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;1, 2022, Immatics US, Inc. entered into a License, Development and Commercialization agreement (the &#8220;Allogeneic ACT agreement&#8221;) with Bristol-Myer-Squibb Company (&#8220;BMS&#8221;). Pursuant to the Allogeneic ACT agreement, the Group received a $60&#160;million upfront cash payment plus an additional payment of $5&#160;million related to the performance obligations under the contract. Applying the foreign exchange rate of June&#160;1, 2022, the received payments represent &#8364;60.7&#160;million. As the contract is accounted for in the functional currency of Immatics US, Inc., </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US&#160;Dollar, the &#8364;&#160;amount is subject to currency fluctuations. The Group identified the transfer of an exclusive right and license with the right to grant sublicenses under the Immatics Licensed IP, technology transfer, contractually agreed research and development services including participation in Joint Steering Committee meetings and the delivery of research progress reports to BMS as a combined performance obligation. The Group is eligible to receive up to $700&#160;million development, regulatory and commercial milestone payments, in addition to tiered royalty payments of up to low double-digit percentages on net product sales. </div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the Allogeneic ACT agreement represent one combined performance obligation or multiple performance obligations and the determination of whether milestone payments should be included in the transaction price.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group concluded that BMS is a customer since BMS obtains through the Allogeneic ACT agreement the output of Immatics&#8217; ordinary activities in exchange for a consideration. The Allogeneic ACT agreement clearly states the deliverables to the Group and BMS as mentioned below and creates enforceable rights and obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group granted to BMS exclusive access to licensed products and is performing research and development services. The research and development services performed by the Group will cover preclinical development of the initial two Bristol Myers Squibb-owned programs and is not distinct from the licensed IP, since the preclinical platform does not have a standalone value without further development. Based on the facts and circumstances, the collaboration agreement contains multiple promises, which aggregate to a combined performance obligation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At inception of the Allogeneic ACT agreement, the Group determined the transaction price. The Group evaluated inclusion of the milestones as well as potential cost reimbursements as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. For the contractual agreed milestone payments with BMS, the license is predominant. Based on that the Group concludes that no variable consideration is considered as transaction price at contract inception. At the end of each reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group allocated the determined total transaction price of &#8364;66.1&#160;million ($70.8 million) consisting of the received payments of &#8364;60.7&#160;million ($65 million) as well as cost reimbursements to the single combined performance obligation of the Allogeneic ACT agreement. Based on the facts mentioned above the Group determined that the combined performance obligation related to promised research and development services is satisfied over time and therefore revenue will be recognized over time as costs for the research and development services incurred using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> method. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At inception of the Allogeneic ACT agreement, &#8364;60.7&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;4.9&#160;million of revenue associated with the upfront payment for the year ended December&#160;31, 2022. Total deferred revenue under the agreement was &#8364;56.2&#160;million and &#8364;0.0 as of December&#160;31, 2022 and 2021, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amgen Collaboration Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2016, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Amgen to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers. The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;28&#160;million ($30&#160;million) upon signing of the Amgen agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The collaboration with Amgen has been discontinued in October 2021. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#8364;</div>10.2<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2021, no further revenue will be recognized from the collaboration thereafter.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">The Group recognized &#8364;</div>10.2<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million and &#8364;</div>4.9<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million of revenue associated with the upfront payment during the years ended December&#160;31, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;</div>0.0<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million as of December&#160;31, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GSK </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, Immatics entered into a collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of &#8364;45&#160;million for two initial programs upon signing of the GSK agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using forecasted costs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The collaboration with GSK has been discontinued in October 2022. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#8364;36.8&#160;million as of December&#160;31, 2022, no further revenue will be recognized from the collaboration thereafter. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized &#8364;37.1&#160;million, &#8364;4.5&#160;million and &#8364;3.7&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#8364;0.0&#160;million and &#8364;36.8&#160;million as of December&#160;31, 2022 and 2021, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements were realized with the following partners: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="9" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genmab, Denmark</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BMS, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amgen, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK, United Kingdom</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">172,831</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,763</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,253</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue related to the collaboration agreements consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">140,716</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98,627</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost to obtain a contract </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Group incurred costs from a third party, who assists in identifying collaboration partners. The Group recognizes an asset to the extent these costs are incremental and directly related to a specific contract. The Group</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">then amortizes the asset consistently with the pattern of revenue recognition for the related contracts. Total assets, net of amortization, for these capitalized costs of obtaining a contract were &#8364;0.5&#160;million and &#8364;0.9&#160;million as of December&#160;31, 2022 and 2021, respectively, which are classified in other current assets and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets. The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of &#8364;0.4&#160;million, &#8364;0.3&#160;million and &#8364;0.3&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. <br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">, the Group is potentially liable to pay &#8364;</div>1.9<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">&#160;million ($</div>2<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"> million) to a third-party upon successful completing the milestone of the first clinical lead selection in connection with Immatics&#8217; collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFR15_g110-129_IFRS15_g110-129_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683916768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory', window );">Other current liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212; &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual for vacation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,366</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,552</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other current liabilities are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> and are due within one year. The carrying amounts of other current liabilities represents fair values due to their short-term nature. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current liabilities. [Refer: Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684041232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share listing expense and change in fair value of warrant liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock', window );">Share listing expense and change in fair value of warrant liabilities</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Share listing expense and change in fair value of warrant liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 3, the ARYA Merger led to a share listing expense. Immatics issued shares with a fair value of &#8364;243.1&#160;million to ARYA shareholders, comprised of the fair value of Immatics shares, that were issued to ARYA shareholders of &#8364;13.53 per share. In exchange, Immatics received the identifiable net assets held by ARYA, which had a fair value upon closing of &#8364;90.3&#160;million, comprising of cash and cash equivalents held in ARYA&#8217;s trust account partly offset by current liabilities by ARYA and financial liabilities in the amount of &#8364;34.4&#160;million accounted for the 7,187,500 ARYA Warrants considering a fair value of the warrants of &#8364;4.82 per warrant (price of ARYA Warrants at Closing of the ARYA Merger). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The excess of the fair value of the equity instruments issued over the fair value of the identified net assets contributed, represents a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expense in accordance with IFRS 2. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> expense as a result of the ARYA Merger, in the amount of &#8364;152.8&#160;million, is recognized as share listing expense presented as part of the financial result within the Consolidated Statement of Profit/(Loss). Details of the calculation of the share listing expense are as follows: </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Euros in thousands, except share and per share data) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares/warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) ARYA Ordinary Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,968,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8364; Fair value of TopCo Shares issued to ARYA shareholders <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a * b)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Outstanding ARYA Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,187,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8364; Closing price of ARYA Warrants on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) Fair value of outstanding ARYA Warrants<br/> (d * e)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Cash and cash equivalents held in ARYA&#8217;s trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Current liabilities by ARYA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ARYA&#8217;s identifiable net assets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(g-f-h)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 2 expense on the closing date</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8364;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152,787</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the ARYA Merger, ARYA Warrants were converted into Immatics Warrants. The financial liabilities for the Immatics Warrants are accounted for at fair value through profit and loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants decreased from &#8364;3.88 ($4.39) per warrant as of December&#160;31, 2021 to &#8364;2.35 ($2.51) per warrant as of December&#160;31, 2022. The result is a decrease in fair value of warrant liabilities of &#8364;10.9&#160;million ($11.5 million) for the year ended December&#160;31, 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants increased from &#8364;2.35 ($2.88) per warrant as of December&#160;31, 2020 to &#8364;3.88 ($4.39) per warrant as of December&#160;31, 2021. The result is an increase in fair value of warrant liabilities of &#8364;11.0&#160;million ($13.0 million) for the year ended December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of warrants decreased from &#8364;4.82 ($5.41) per share as of July&#160;1, 2020 to &#8364;2.35 ($2.88) per share as of December&#160;31, 2020. The result is a change in fair value of warrant liabilities of &#8364;17.8&#160;million ($20.3 million) for the year ended December&#160;31, 2020. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share listing expenses and change in fair value of warrant liabilities [Text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683195216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial income and expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Other financial income and expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income and expenses </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income and financial expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,476</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on other financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,416</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,675</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,949</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(566</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(289</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses on financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(741</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(884</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,279</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,726</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,063</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income mainly results from short-term deposits as well as cash balances for the year ended December&#160;31, 2022. Interest expenses mainly results from IFRS 16 and from negative interest rates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency gains and losses mainly consist of realized and unrealized gains and losses in connection with our USD holdings of cash and cash equivalents, short-term deposits as well as bonds. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Losses on financial instruments includes expected credit losses on cash and cash equivalents and Other financial assets for the year ended December&#160;31, 2022 and losses from foreign currency forward contracts for the year ended December&#160;31, 2021. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on other financial instruments includes an unrealized gain of &#8364;0.9&#160;million and a realized gain of &#8364;1.2&#160;million from foreign currency forward contracts for the year ended December&#160;31, 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683916768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17. Share-based payments</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immatics Biotechnologies GmbH previously issued share-based awards to employees under two different plans. Under the Immatics Biotechnologies GmbH Stock Appreciation Program 2010 (the &#8220;2010 Plan&#8221;), the Company issued stock appreciation rights (&#8220;SARs&#8221;), which the Group accounted for as cash-settled awards. Under the Immatics Biotechnologies 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;), the Company issued tandem awards, which allowed employees to exercise their awards as either a SAR or a stock option. In 2020, prior to the ARYA Merger, Immatics N.V. established the new equity incentive plan (&#8220;2020 Equity Plan&#8221;). As part of the ARYA Merger, the 2010 Plan and the 2016 Plan were converted and were superseded by the 2020 Equity Plan as described below. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). The 2022 Equity Plan allows the company to grant additional options. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of 2010 Plan and 2016 Plan in connection with ARYA Merger </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Payments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the employee award agreements, holders of vested awards under the 2010 Plan and 2016 Plan (including any awards scheduled to vest prior to 2021), agreed to receive a cash payment of $10.00 per award, less the applicable exercise price (&#8220;Award Cash Proceeds&#8221;). Per the terms of the employee award agreements, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">active employees were required to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-invest</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">25%-50%</div> of the Award Cash Proceeds, net of taxes, with management members required to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-invest</div> 50%. In total, employees elected to receive &#8364;8.9&#160;million in net Award Cash Proceeds before taxes, which were paid during the third quarter in 2020. These proceeds mainly covered wage tax obligations by the employees. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These cash payments represent a modification of awards previously issued under the 2010 Plan and 2016 Plan. The Group recognized &#8364;2.6&#160;million in operating expenses related to the modification of awards issued under the 2010 Plan and previously accounted for as a liability. The Group also recognized &#8364;4.3&#160;million as a reduction in share premium, associated with the modification from previously equity-settled tandem awards, which were settled in cash as part of the modification. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Awards </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The share-based awards, that were received by employees as part of the conversion, consisted of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Shares, Matching Stock Options and Converted Stock Options as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In accordance with the employee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-investment</div> elections, employees received 733,598 shares in Immatics N.V. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Re-investment</div> Shares&#8221;), which had a fair value of &#8364;8.5&#160;million based on the ARYA share price of $15.15, as of the merger on July&#160;1, 2020. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Shares issued represented a modification of awards previously granted under the 2010 Plan and the 2016 Plan. This modification resulted in additional operating expenses of &#8364;4.1&#160;million. For each ordinary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-investment</div> Share received, active employees and management members also received two stock options (&#8220;Matching Stock Options&#8221;) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $10.00 and vested in full on July 31, 2021. The award recipient must remain employed by Immatics or one of its affiliates through the vesting date, to receive the option. The awards have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> contract life. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Matching Stock Options award agreements had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the July 1, 2020 grant date the Group assigned a fair value of $10.59. Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,406,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,554</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,348,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,348,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,406,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,413,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,430,818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January&#160;1, 2021, employees received replacement stock options (&#8220;Converted Options&#8221;) to acquire shares in Immatics N.V. The Converted Options have comparable terms as the previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V., are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period. The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V., and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the terms of the Converted Options award agreements, the awards had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the July&#160;1, 2020 grant date the Group assigned an average fair value of $13.79. The incremental average fair value of the Converted Options compared to the share-based awards under the 2010 Plan and 2016 Plan was $4.83. Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Average exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">566,311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">525,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">594,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">566,311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">632,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">594,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional grants under the 2020 and 2022 Equity Plan </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Options </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the ARYA Merger, Immatics N.V. established the 2020 Equity Plan. After closing the ARYA Merger, employees, directors and officers received 1,087,242 employee stock options under the 2020 Equity Plan with a service requirement (&#8220;Service Options&#8221;), to acquire shares of Immatics N.V. The service-based options will vest solely on a four-year time-based vesting schedule. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). The 2022 Equity Plan allows the company to grant additional options. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted Service Options, which were accounted for using the respective grant date fair value. Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options, with a weighted average fair value of $6.93, $11.22 and $9.35 for Service Option granted during the year ended December&#160;31, 2022, 2021 and 2020, respectively. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,725,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,619,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,129,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,438,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,910,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,967,708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">149,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,725,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,963,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,910,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance-Based Options (&#8220;PSUs&#8221;) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, after the closing of the ARYA Merger certain executive officers and key personnel of the Group received under the 2020 Equity Plan PSUs, vesting based both on achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $1.5&#160;billion, $2&#160;billion and $3&#160;billion, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted PSUs on September&#160;28, 2021 which were accounted for by considering a fair value of $8.00. A Monte-Carlo simulation model has been used to measure the fair value at grant date of the PSUs. This model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#8217;s fair value at grant date. In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> September&#160;28,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted 3,644,000 PSUs on June&#160;30, 2020, which were accounted for by considering a fair value of $11.10 and granted 255,000 PSUs on September&#160;14, 2020, which were accounted for by considering a fair value of $6.41. A Monte-Carlo simulation model has been used to measure each fair value at grant date of the PSUs. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#8217;s fair value at grant date. In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December<br/> 31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,696,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,666,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,644,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,696,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,899,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,644,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized total employee-related share-based compensation expenses from all plans for the years ended December&#160;31, 2022, 2021 and 2020 as set out below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,570</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686854592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity (deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Shareholders' equity (deficit)</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity (deficit) </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 1 and Note 3, Immatics N.V. was founded in 2020 with a share capital of &#8364;0.01 after the Reorganization. On July&#160;1, 2020, upon closing of the ARYA Merger, Immatics N.V. had 62,908,617 outstanding ordinary shares with a par value of &#8364;0.01, resulting in a share capital of &#8364;629&#160;thousand. In 2020, the ARYA Merger and PIPE Financing led to an increase in share premium by &#8364;327.8&#160;million. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group issued in 2022, 2.8&#160;million shares under the ATM agreement with SVB Securities LLC and collected a gross amount of &#8364;20.8&#160;million less transaction costs of &#8364;0.6&#160;million, resulting in an increase in share capital of &#8364;28&#160;thousand and share premium of &#8364;20.2&#160;million. On October&#160;12, 2022, the Group closed a registered direct offering, of 10,905,000 ordinary shares with a public offering price of $10.09 per ordinary share and received a gross amount of &#8364;113.4&#160;million less transaction costs of &#8364;7.3&#160;million, resulting in an increase in share capital of &#8364;109&#160;thousand and share premium of &#8364;106.1&#160;million. In addition, the Group issued shares from exercises of stock options by employees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022 and 2021, the total number of ordinary shares of Immatics N.V. outstanding is 76,670,699 and 62,926,816 with a par value of &#8364;0.01, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other reserves are related to accumulated foreign currency translation amounts associated with the Group&#8217;s US operations. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683209760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory', window );">Non-controlling&#160;interests</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest </div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest related to those shares in Immatics US Inc. which have been provided to The University of Texas M.D. Anderson Cancer Center, Houston/Texas/USA, (&#8220;MD Anderson&#8221;) based on the restricted stock acquisition agreement described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until June&#160;30, 2020, Immatics and MD Anderson were partners in a Restricted Stock Acquisition Agreement (the &#8220;RSAA&#8221;). Under the terms of the RSAA, MD Anderson was entitled to additional restricted shares in Immatics US, Inc. based on performance of certain work orders between August&#160;14, 2018 and August&#160;14, 2020. MD Anderson performed services in connection with our clinical trials in our ACT platform. The RSAA was cancelled as part of the ARYA Merger (See Note 3). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;1, 2020 MD Anderson exchanged all of its 379,420 shares in Immatics US, Inc., that they acquired under the RSAA for 697,431 shares in Immatics N.V. The shares of Immatics N.V. had a fair value at the date of the exchange of $15.15 per share. Immediately prior to the exchange, the carrying amount of the existing 5.14% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in Immatics US Inc. was &#8364;0.5&#160;million. The exchange resulted in a decrease of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#8364;0.5&#160;million and a corresponding increase of share capital and net increase to share premium for the issuance of shares and derecognition of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. The RSAA was also cancelled as of July&#160;1, 2020. Any future services rendered by MD Anderson will be paid in cash. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The loss allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest amounted to &#8364;0.6&#160;million in 2020. In total, the Group recognized expenses in relation to MD Anderson&#8217;s performance under the RSAA of &#8364;0.04&#160;million for the year ended December&#160;31, 2020. </div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683379872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock', window );">Personnel expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(42,924</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29,098</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,711</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,639</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,570</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(73,205</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60,587</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(51,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other employee benefit expenses include employee retirement fund contributions, health insurance, and statutory social expenses. Immatics US Inc. sponsors a defined contribution retirement plan for employees in the United States. During 2022, 2021 and 2020, total Group contributions to the defined contribution plan amounted to &#8364;0.9&#160;million, &#8364;0.2&#160;million and &#8364;0.2&#160;million, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2022, 2021 and 2020, other employee benefits also include employee health insurance costs amounting to &#8364;0.8&#160;million, &#8364;0.6&#160;million and &#8364;0.4&#160;million for Immatics US Inc., statutory social expenses amounting to &#8364;3.2&#160;million, &#8364;2.4&#160;million and &#8364;1.7&#160;million for our German operations and other miscellaneous expenses amounting to &#8364;0.1&#160;million, &#8364;0.1&#160;million and &#8364;0.1&#160;million, respectively. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Personnel Expenses Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683205152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the year ended December&#160;31, 2022, the Group generated a net income due to the recognition of revenue in connection with the license component of the BMS IMA401 Collaboration agreement. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> revenue is not accounted for under German GAAP and consequently under German tax accounting. Instead, the Group recognizes revenue for the BMS agreement over the period of the clinical trial service. The deferred tax liability arising from the temporary difference related to delayed revenue recognition under German tax accounting is offset by deferred tax assets on tax losses carried forward that were previously not capitalized due to the Groups expectation of generating taxable losses in the foreseeable future. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Group&#8217;s German operations were subject to a statutory tax rate of 30.4% during 2022 and of 29.1% <div style="null;text-indent: 0px;;display:inline;">during 2021 and 2020. The Group&#8217;s German statutory tax rate increased by 1.3% in comparison to the previous period due to increased trade tax rates. In the U.S., the Group was subject to a corporate income tax rate of</div> 21% <div style="display:inline;">for the year ended December 31, 2022, 2021 and 2020.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Immatics Biotechnologies GmbH, the Group recognized a current income tax expense of &#8364;4.5&#160;million for the year ended December&#160;31, 2022. The current income tax expense is calculated based on taxable income of Immatics Biotechnologies GmbH for the year ended December&#160;31, 2022. Since no deferred tax assets have been recognized as of December&#160;31, 2021, the Group took into account the tax losses carried forward that can be used to offset the taxable income generated in the year ended December&#160;31, 2022. In accordance with &#167;10d para 2 EStG (German income tax code),<div style="display:inline;">&#160;</div></div></div>60<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">% </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of an income of a given year can be offset with tax losses carried forward. Accordi</div></div><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">ngly, </div>40<div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">% </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the income before tax of Immatics Biotechnologies GmbH are subject to income tax. </div></div></div><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As the profit is considered a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> profit, no deferred tax assets exceeding the deferred tax liability <div style="letter-spacing: 0px; top: 0px;;display:inline;">on</div>&#160;temporary differences have been recognized in respect of tax losses carried forward. The current assessment regarding the usability of deferred tax assets may change, depending on the Group&#8217;s taxable income in future years, which could result in the recognition of deferred tax assets. The Group continued to generate losses for all other entities within the Group during the year ended December&#160;31, 2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> as well as for all entities during the year ended December&#160;31, 2021 and 2020. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation between taxes on income reflected on the Consolidated Statement of Profit/(Loss) and the expected income tax benefit, based on the Group&#8217;s German statutory tax rate, for the years ended December&#160;31, 2022, 2021 and 2020 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit/(loss) before taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,335</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(211,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected taxes on income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effects</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Difference in tax rates</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(599</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants exempted from taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent Differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization of previously unrecorded tax losses carried forward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-recognition&#160;of</div> deferred taxes on tax losses and temporary differences</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes on income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,522</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2022, permanent differences relate to share-based compensation expenses, to transaction costs directly attributable and incremental to capital raises and to the change in fair value of the financial liabilities for the warrants. For the year ended December&#160;31, 2021, permanent differences relate to share-based compensation expenses and to the change in fair value of the financial liabilities for the warrants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the main permanent difference relates to the share listing expense of &#8364;153&#160;million, which does not have a corresponding taxable expense. Other permanent differences include transaction costs directly attributable and incremental to capital raises, expenses for equity-settled share-based compensation, as well as the change in fair value of the financial liabilities for the warrants. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and deferred tax liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:60%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">As of</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,133</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(947</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of tax losses carried forward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recognized</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">27,319</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(27,319</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">3,927</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(2,629</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Netting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">Non-recognition</div> of deferred tax assets on temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net deferred tax assets/liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">For the years ended December&#160;31, 2022, and 2021, the Group had accumulated tax losses of &#8364;357.2&#160;million and &#8364;353.1&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, that may be offset against future taxable profits of the Group subject to certain limitations. For &#8364;319.4 million and &#8364;353.1 million of the accumulated tax losses no deferred tax asset has been recognised in the financial statements. For the year ended December 31, 2022,</div> &#8364;26&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of total tax losses is subject to a twenty-year carry forward period. All other tax losses have an indefinite carry forward period.&#160;</div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitation on tax loss carry forwards in the US Inc. is 80.00% of each subsequent year`s net income starting with losses generated after January&#160;1, 2018. These have an indefinite carry forward period, but no carry back option. Any losses generated prior to January&#160;1, 2018 still can be utilized at 100.00% and are subject to a twenty-year carry forward expiration period. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. For Immatics Biotechnologies GmbH, we believe that the ARYA Merger did not lead to a forfeiture of tax losses carried forward in accordance with &#167; 8c KStG. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686856192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial Risk Management Objectives and Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Risk Management Objectives and Policies </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s principal financial instruments comprise cash and cash equivalents, short-term deposits, accounts receivables and bonds. The main purpose of these financial instruments is to invest the proceeds of capital contributions and upfront payments from collaboration agreements. The Group has various other financial instruments such as other receivables and trade accounts payables, which arise directly from its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The main risks arising from the Group&#8217;s financial instruments are market risk and liquidity risk. The Board of Management reviews and agrees on policies for managing these risks as summarized below. The Group also monitors the market price risk arising from all financial instruments. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exposure of the Group to changes in interest rates relates to investments in deposits, bonds and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regarding the liabilities shown in the Consolidated Statement of Financial Position, the Group is currently not subject to interest rate risks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Group to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents, accounts receivables, short-term deposits and bonds. The Group&#8217;s cash and cash equivalents, bonds and short-term deposits are denominated in Euros and US Dollars and maintained with three high-quality financial institutions in Germany and two in the United States. The Group&#8217;s accounts receivables are denominated in Euros. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The maximum default risk is &#8364;363&#160;million and &#8364;146&#160;million as of December&#160;31, 2022 and 2021, respectively. These amounts consist of &#8364;149&#160;million and &#8364;133&#160;million cash and cash equivalents, &#8364;1.0&#160;million and &#8364;0.7&#160;million accounts receivables as well as &#8364;213&#160;million and &#8364;12&#160;million Other financial assets as of December&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cash and cash equivalents are held with banks, which are rated BBB+ to Aa3 by S&amp;P and Moody`s. Short-term deposits are with banks, which are rated Aa3 and A1 by the rating agency Moody`s. Bond investments are with banks, which are rated AAA and AA by Moody`s. The Group continually monitors its positions with, and the credit quality of, the financial institutions and corporation, which are counterparts to its financial instruments and does not anticipate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance.</div> The Group monitors the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from equity measures<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. The business transactions of the Group are generally conducted in Euros and U.S. dollars. The Group aims to match EUR cash inflows with EUR cash outflows and U.S. dollar cash inflows with U.S.&#160;Dollar cash outflows where possible. The objective of currency risk management is to identify, manage and control currency risk exposures within acceptable parameters. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s cash and cash equivalents were</div>&#160;&#8364;148.5&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million as of December 31, 2022. Approximately</div> 87% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of the Group&#8217;s cash and cash equivalents were held in Germany, of which approximately</div> 49% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">were denominated in Euros and</div> 51% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">were denominated in U.S. Dollars. The remainder of the Group&#8217;s cash and cash equivalents were held in the United States and denominated in U.S. Dollars. Additionally, the Group held bonds and short-term deposits classified as Other financial assets denominated in Euros in the amount of</div> &#8364;123.3&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million and U.S. Dollars in the amount of</div> &#8364;87.0 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of December 31, 2022.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized significant foreign exchange income and losses in 2022, as Immatics N.V.`s and Immatics GmbH&#180;s functional currency is Euro, due to significant holdings of U.S. dollar amounts. The Group recognized significant foreign exchange income in 2021 and in 2020 significant foreign exchange losses. Cash and cash equivalents and Other financial assets balances denominated in U.S. dollars held by entities with functional currency of EUR are as follows: </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics N.V. held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82,788</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,410</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics GmbH held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71,588</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,787</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2022, if the euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s profit would have been &#8364;14&#160;million lower/&#8364;17&#160;million higher, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(820</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">836</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,942</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(709</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,740</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2021, if the euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s loss would have been &#8364;2&#160;million higher/&#8364;2.5&#160;million lower, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(946</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The wholly-owned subsidiary Immatics US, Inc. is located in the United States and has US Dollars as its functional currency. Therefore, the Group is subject to currency fluctuations that would <div style="display:inline;">a</div>ffect the other comprehensive income and equity of the Group. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(193</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,065</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2021: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group continuously monitors its risk to a shortage of funds. The Group&#8217;s objective is to maintain a balance between continuity of funding and flexibility through the use of capital raises. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, and 2021, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132,994</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total funds available</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">362,205</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">145,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market risk and currency risk of warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s activities expose it to the financial risks of changes in price of the warrants. As the warrants are recognized at fair value through profit and loss on the consolidated statement of financial position of the Group, the Group&#8217;s exposure to market risks results from the volatility of the warrants price. The Warrants are publicly traded at the Nasdaq Stock Exchange. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of &#8364;1.7&#160;million with a corresponding effect in the equity as of December&#160;31, 2022. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of &#8364;2.8&#160;million with a corresponding effect in the equity as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The warrants are traded in U.S.&#160;Dollar while the functional currency of Immatics N.V. is Euro. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of &#8364;1.5&#160;million /(&#8364;1.9&#160;million) with a corresponding effect in the equity as of December&#160;31, 2022. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of &#8364;2.5&#160;million /(&#8364;3.1&#160;million) with a corresponding effect in the equity as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The risks associated with our warrants result in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> financial statement effects and have no impact on the Company&#8217;s cash position, operating expenses or cash flows. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital management </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s capital management objectives are designed primarily to finance our growth strategy. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group reviews the total amount of cash on a regular basis. As part of this review, the Group considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year. In general, the aim is to maximize the financial resources available for further research and development projects. The Group is not subject to externally imposed capital requirements. The Group&#8217;s capital management objectives were achieved in the reporting year.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684417696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"/>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below are the carrying amounts and fair values of the Group&#8217;s financial instruments that are carried in the consolidated financial statements as of December&#160;31, 2022 and 2021, respectively.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">148,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">154,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154,930</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,756</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,111</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,402</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,914</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,563</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365,718</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,914</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,352</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,984</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,994</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">682</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">691</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,624</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">727</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,859</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,853</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146,490</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,859</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,204</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196,553</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Short-term deposits&#8221; and &#8220;Bonds&#8221; are classified within Other financial assets </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In all valuation categories with the exception of Bonds, the carrying amount represents a reasonable approximation of the fair value based on the short-term maturities of these instruments. Set out below are the carrying amounts and fair values of the Group&#8217;s Bonds as of December&#160;31, 2022 and 2021, respectively. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,756</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,300</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,113</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following methods and assumptions were used to estimate the fair values: All financial assets are categorized Level&#160;1 and therefore are valued using quoted (unadjusted) market prices. All financial liabilities are also categorized Level&#160;1. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The bonds&#8217; contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Bonds are classified as Level&#160;1 of the fair value hierarchy, as they are listed on publicly traded markets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants are comprised of the Immatics Warrants issued to investors with a cashless exercise mechanism as a current liability which the Company accounted for according to provisions of IAS 32. The Company measures the warrants at fair value by using the closing price of warrants at Nasdaq. The warrants are measured in each reporting period. Changes in the fair value are recognized in the Company&#8217;s Consolidated Statement of Profit/(Loss) as financial income or expenses, as appropriate. The warrants are classified as Level&#160;1 of the fair value hierarchy. The maturity of the liabilities for warrants is dependent on the development of the share price as well as the decisions by the Immatics Warrants holders. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Groups net result from financial instruments by measurement categories are disclosed below for the years ended December&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(884</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(712</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(286</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,082</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,041</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,661</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear:both;max-height:0pt;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table shows the changes of the liabilities from financing activities, classified as cash effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> effective as of December&#160;31, 2022 and 2021, respectively. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,843</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,655</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,707</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686805040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2022 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligation<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,250</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,469</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,392</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,456</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25,568</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2021 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract research organization agreements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,659</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,370</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,972</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligations comprise of obligations for leases classified as short-term and low value as well as obligations for leases signed but not yet started. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will expire five years after the completion of the ARYA Merger or earlier upon redemption or liquidation in accordance with their terms. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">As of December&#160;31, 2022, and 2021 the Group is potentially liable to pay &#8364;1.6&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million to a third-party upon successfully completing the milestone of the first clinical lead selection in connection with Immatics collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.&#160;</div> </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635685239072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party disclosures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel have been defined as the members of the Executive Committee of Immatics N.V. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation of key management personnel consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,706</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,317</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">886</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,574</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,814</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,387</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed and variable key management compensation represent short-term employee benefits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board of Directors of the Group received a fixed fee. Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;1.7&#160;million in 2022: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen<br/> und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nancy<br/> Valente</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">379</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,336</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">258</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">246</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">232</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">217</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">217</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">220</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,715</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;2.1&#160;million in 2021: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen&#160;und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">348</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,751</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,223</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">179</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">167</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">157</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,114</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On July&#160;1, 2021, Immatics changed its structure from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-tier</div> Board to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tier</div> Board and Supervisory Board members became <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board of Directors. Total compensation for the Supervisory Board amounted to &#8364;4.1&#160;million in 2020: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Harald&#160;F.<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supervisory board compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">282</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment Exit arrangement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,394</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,436</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,584</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,116</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the ARYA Merger, Immatics N.V. established the 2020 Incentive Plan. Immatics N.V. granted certain service-based options out of the 2020 Incentive Plan to its management and directors and in addition, performance-based options to its management upon closing of the ARYA Merger. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Group&#8217;s 2022 stock option and incentive plan (&#8220;2022 Equity Plan&#8221;). Service options granted out of the 2020 Incentive Plan, will vest based upon satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. Service options granted out of the 2022 Equity Plan to the Board of Directors, will vest in full after a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> service time. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance-based options will vest based both on achievement of certain market capitalization milestones and satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. The following options were granted to Immatics&#8217; Directors: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Type of options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant&#160;date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strike<br/> Price&#160;in<br/> USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration date</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managing Director</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Performance-<br/> based options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,598,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Matching Stock<br/> options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">264,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Converted options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">July 1, 2027</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Converted options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">January 1, 2028</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 13, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 13, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Matching Stock<br/> options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 14, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 13, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 17, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 17, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nancy Valente</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">March 22, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">March 22, 2032</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An additional aggregate of 652,500 service options to purchase ordinary shares, were granted to other Immatics&#8217; key management personnel in 2022, who are members of the Executive Committee but not Directors. Certain key management personnel were also participants in the share-based compensation plans of Immatics GmbH (2010 Plan and 2016 Plan). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the replacement awards issued in connection with the ARYA Merger (See Note 17), these key management personnel received in 2020 cash payments before taxes of &#8364;3.4&#160;million, 417,415 converted options in Immatics N.V. and 750,076 matching stock options in Immatics N.V. The cash payments mainly covered wage tax obligations of the employees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until December&#160;31, 2022, no options granted to directors and executive officers forfeited or were exercised. Refer to section &#8220;18. Share-based payments&#8221; regarding further details of the Groups share-based compensation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no outstanding balances, including commitments, other than the above mentioned with related parties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group did not enter into transactions with related entities in 2022, 2021 and 2020 other than the mentioned compensation contracts. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684439760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings and Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings and Loss per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26. Earnings and Loss per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group reported basic and diluted earnings per share. Basic earnings per share are calculated by dividing the net profit or loss by the weighted-average number of ordinary shares outstanding for the reporting period. Diluted earnings per share for the year ended December&#160;31, 2022, are calculated by adjusting the weighted-average number of ordinary shares outstanding for any dilutive effects resulting from equity awards granted to the Board and employees of the Group as well as from publicly traded Immatics Warrants. The Group&#8217;s equity awards and Immatics Warrants for which the exercise price is exceeding the Groups weighted average share price for the year ended December&#160;31, 2022, are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares. The Group was loss-making during the year ended December&#160;31, 2021 and 2020, therefore all instruments are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including the outstanding equity awards and the 7,187,500 Immatics Warrants issued in 2020 and outstanding as of December&#160;31, 2022. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net profit/(loss):</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(93,335</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(211,841</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,220,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,912,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,001,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,824,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,912,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,001,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683359120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events occurring after the reporting period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events occurring after the reporting period</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Events occurring after the reporting period </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated further subsequent events for recognition or disclosure through March&#160;22, 2023 and did not identify additional material subsequent events.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683316160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock', window );">Going concern</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Going concern </div></div></td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Group&#8217;s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketed any products commercially. Immatics&#8217; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics&#8217; cash and cash equivalents, bonds as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the financial statements. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock', window );">Covid-19</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not result in a negative impact of the Group&#8217;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#8217;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock', window );">Russian-Ukraine Conflict and macroeconomic environment</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2.3 Russian-Ukraine Conflict and macroeconomic environment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory', window );">Fair value of financial instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.12</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value of financial instruments </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the principal market for the asset or liability or </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 &#8212; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 &#8212; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessing</div> categorization (based on the lowest level input that is significant to the fair value measurement as a whole), at the end of each reporting period. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.2</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds), short-term deposits and bonds with an original maturity of three months or less.</div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment information</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment information </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#8217;s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group&#8217;s resources. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Initial recognition and measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. </div><div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Short-term deposits </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics has short-term deposits with original maturities between three and twelve months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Bonds </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics holds bonds with an original maturity of more than three months, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Receivables </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has receivables from collaboration agreements. Receivables must be capitalized at the point in time at which the Group has become a contractual partner and an unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, receivables are measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group&#8217;s receivables have an expected maturity of less than 12 months. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Interest and other finance income and expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income and expenses from financial instruments are recorded using the effective interest rate (&#8220;EIR&#8221;). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Profit/(Loss). As of December&#160;31, 2022 and 2021, Immatics is not a counterparty in foreign exchange forward contracts. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Impairment of financial assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses on financial assets are recognized as financial expenses. The Group recognizes an allowance for expected credit losses (ECLs) for financial assets, see Note 16. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-months</div> (a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing information (credit default swap values) published by credit agencies and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECL. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expenses when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1&#160;&#8211;&#160;10&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 15 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Office equipment and installations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2 &#8211; 20 years</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.5</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5&#160;&#8211;&#160;30&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 5 years</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.6</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Research and development </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research costs are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2022, 2021 and 2020 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">laboratory costs; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">5.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">6.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities: Initial recognition and measurement</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.7</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities: Initial recognition and measurement </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company&#8217;s financial liabilities include accounts payables, lease liabilities, warrant liabilities and other financial liabilities. Immatics recognized accounts payables and other current liabilities as other financial liabilities at amortized costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.8</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted IFRS 16 (&#8220;Leases&#8221;) effective January&#160;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Group has elected not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Under IFRS 16, leases are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset with a corresponding liability on the date at which the leased asset is available for use by the Group (lease commencement date). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">fixed payments (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed payments), less any lease incentives received; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">amounts expected to be payable by the Group under residual value guarantees; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease term consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#8217;s leases, the lessee&#8217;s incremental borrowing rate (&#8220;IBR&#8221;) is used. The IBR is the rate that the individual lessee would have to pay to borrow the funds, necessary to obtain an asset of similar value to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset in a similar economic environment with similar terms, security and conditions. The Group used an IBR for each respective lease to calculate the initial lease liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the IBR, the Group: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">uses a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-up</div> approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Immatics; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">makes adjustments specific to the lease, including lease term, country, currency and security. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost comprising the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the amount of the initial measurement of lease liability; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any lease payments made at or before the commencement date less any lease incentives received; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">any initial direct costs; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">restoration costs. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are generally depreciated over the shorter of the asset&#8217;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is depreciated over the underlying asset&#8217;s useful life. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments associated with short-term leases of equipment and vehicles and all leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> assets have a value of less than &#8364;5&#160;thousand. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group&#8217;s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December&#160;31, 2022 to determine whether option extensions are reasonably certain. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue from collaboration agreements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue from collaboration agreements </div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place, one with Genmab A/S, Copenhagen /Denmark (&#8220;Genmab&#8221;) and three with Bristol-Myers-Squibb (&#8220;BMS&#8221;). During the year ended December&#160;31, 2022, the Group entered into new collaboration agreements with BMS. Three of the Group&#8217;s strategic collaboration agreements are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage and the BMS IMA401 collaboration agreement is at clinical stage. The collaboration with GlaxoSmithKline Intellectual Property Development Limited (&#8220;GSK&#8221;) was terminated in October 2022 and the collaboration with Amgen Inc., Thousand Oaks/CA/USA (&#8220;Amgen&#8221;) was terminated in October 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the contract(s) with a customer; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">identify the performance obligations in the contract; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">determine the transaction price; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">allocate the transaction price to the performance obligations in the contract; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">recognize revenue when (or as) the Group satisfies a performance obligation. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under the collaboration agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Identify the performance obligations in the contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> collaboration agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-targets</div> using Immatics&#8217; proprietary technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> participation on steering committees, and preparation of data packages. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group&#8217;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#8217; research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group&#8217;s XPRESIDENT technology and database of target and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> data. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical collaboration agreement (BMS IMA401 agreement) </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Immatics granted to Bristol-Myers Squibb an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401. Under the Agreement, Immatics is also responsible for, and will bear the cost of, the first Phase 1 clinical trial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The license contributed under the collaboration agreement represents a distinct performance obligation, because they are separately identifiable from other promises in the BMS IMA401 agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Determine the transaction price </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Upfront payment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Group&#8217;s strategic collaboration agreements includes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment. The Group records these payments as deferred revenue, which it allocates to the combined performance obligations for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div><div style="background-color:white;display: inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> basis using direct costs and directly attributable personnel costs is considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#8217;s collaboration partners, due to the nature of the work being performed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Group&#8217;s BMS IMA401 agreement, the Group determined the underlying stand-alone selling price for each performance obligation to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price requires significant judgement regarding the estimation approach of the stand-alone selling prices for the distinct performance obligations as well as significant estimates regarding the expected cost for future services, profit margins and development timelines. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reimbursement for services </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are part of the transaction price and presented as revenue and not deducted from expenses. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development and Commercial Milestones </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales-based milestones and royalty payments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to fulfill contracts </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost to obtain a contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.10</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Share-based payment </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 17. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5.11 Foreign currency </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Transactions and balances in Germany and in the USA </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements are presented in Euro, which is the parents, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Profit/(Loss) is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Euros per U.S.&#160;Dollar</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.93756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.94888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.84495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.81493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.13</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Provisions </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the effect of the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects, when appropriate, the risks specific to the liability. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income tax</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.14</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred income tax </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (&#8220;Income Taxes&#8221;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]
Effective 2023-01-01: The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]
Effective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]
Effective 2023-01-01: The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.
Effective 2023-01-01: The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for conflict and macro economic environment policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for covid nineteen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683981648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Summary of Application of new standards</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">New standards and interpretations applied for the first time: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment IAS 16 &#8211; Property, Plant and Equipment (Proceeds before Intended Use)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment IAS 37 &#8211; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#8211;Cost of Fulfilling a Contract)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 3 &#8211; Business Combinations (Reference to the Conceptual Framework)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 1 &#8211; First-time Adoption of International Financial Reporting Standards</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IFRS 9 &#8211; Financial Instruments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to Illustrative Examples accompanying IFRS 16</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 41 &#8211; Agriculture</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January 1, 2022</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock', window );">Summary of Non Mandatory standards and interpretations issued by IASB</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December&#160;31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:14%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Standard/interpretation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Effective&#160;date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Potentially<br/> material&#160;effect&#160;expected<br/> on Immatics financial<br/> statements</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">IFRS 17 &#8211; Insurance Contracts</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendments to IAS 12 &#8211; Income Taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment to IFRS 16 &#8211; Leases on sale and leaseback</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Amendment to IAS 1 &#8211; Presentation of Financial Statements (Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities with covenants)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">January 1, 2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">No</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate', window );">Summary of impact revision to previously issued financial statements</a></td>
<td class="text">The impact of the revision of the previously issued financial statements is as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,477</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(85,611</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,914</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80,697</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,949</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,949</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,914</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">111,238</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,061</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;reported</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;revised</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net foreign exchange differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,962</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,408</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by/(used in) operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(81,785</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84,747</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,493</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,493</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash (used in)/provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,613</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,613</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase/(decrease) in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(76,904</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(79,866</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at beginning of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents at end of the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the nature of accounting errors in prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 49<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_49_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non mandatory standards and interpretations issued by the IASB.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683359120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock', window );">Summary of estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives are generally within the following ranges: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1&#160;&#8211;&#160;10&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 15 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Office equipment and installations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2 &#8211; 20 years</td> </tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock', window );">Summary of useful life of intangible assets other than goodwill</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Category</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5&#160;&#8211;&#160;30&#160;years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1 &#8211; 5 years</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock', window );">Summary of foreign exchange rates</a></td>
<td class="text"> The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-end</div><br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Euros per U.S.&#160;Dollar</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.93756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.94888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.84495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.81493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about foreign exchange rates explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of property plant and equipment estimated useful lives explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635834240576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock', window );">Summary of Trade receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Receivables from collaboration agreements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,111</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">682</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other receivable explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635716928320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current and non-current assets  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Summary of Other current assets</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Value added tax receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Grant receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Summary of Other&#160;non-current&#160;assets</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets consist of the following:</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,545</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">636</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684090512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Changes to Property, Plant and Equipment</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment consist of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Laboratory<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computer<br/> equipment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/> equipment<br/> and<br/> installations</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,322</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,436</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,630</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,470</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,661</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,761</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,476</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,428</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,665</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,569</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(219</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(256</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,052</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,966</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,237</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,255</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,578</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,504</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,424</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,506</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of January&#160;1, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,630</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,470</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,661</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,761</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,737</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,898</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,303</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,938</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of January&#160;1,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,052</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,966</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,237</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,255</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(653</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(333</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,129</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(180</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(210</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Accumulated depreciation as of December&#160;31,&#160;2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,279</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,636</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,567</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,482</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value as of December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,262</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,456</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDepreciationExpensesTableTextBlock', window );">Summary of Depreciation Expense</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(890</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,129</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,574</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,102</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDepreciationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDepreciationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684415456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Summary of Changes to Intangible Assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patents<br/> and<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Software<br/> licenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,132</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">738</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,870</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,551</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">908</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,459</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(554</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(957</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(160</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(480</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(664</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,144</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,071</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">244</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,315</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,029</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">988</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,017</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of January&#160;1, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(480</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(664</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,144</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(158</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(218</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(559</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(826</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,385</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value as of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,470</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">162</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,632</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfAmortizationExpensesTableTextBlock', window );">Summary of Depreciation Expense</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(218</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(160</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(126</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfAmortizationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of amortization expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfAmortizationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684443600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Right-of&#160;use assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of</div> use assets consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,033</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,982</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock', window );">Details of Lease liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities &#8211; current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Lease liabilities &#8211; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,562</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,853</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Summary of expenses related to&#160;right-of-use&#160;assets and lease liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Expenses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities consist of the following: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation charges of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros&#160;in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(277</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IT and telecommunication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vehicles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(59</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,620</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,526</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,195</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses from leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(613</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(288</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Expenses relating to short-term leases and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets (included in administrative expenses)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses related to right of use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684724256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock', window );">Summary of Accounts Payable</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,009</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,056</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,624</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounts payable explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683173872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from collaboration agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractLiabilitiesTextBlock', window );">Summary of Deferred revenue related to the collaboration agreements</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue related to the collaboration agreements consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">140,716</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98,627</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory', window );">Summary of revenue from collaboration agreements explanatory</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements were realized with the following partners: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from collaboration agreements:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="9" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genmab, Denmark</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BMS, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amgen, United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK, United Kingdom</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">172,831</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,763</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,253</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfContractLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfContractLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from collaboration agreements explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683996272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock', window );">Summary of other current liabilities</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212; &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual for vacation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,366</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,552</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684410208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share listing expense and change in fair value of warrant liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock', window );">Summary of Calculation of the Share listing expense</a></td>
<td class="text"> Details of the calculation of the share listing expense are as follows: <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Euros in thousands, except share and per share data) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares/warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) ARYA Ordinary Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,968,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8364; Fair value of TopCo Shares issued to ARYA shareholders <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a * b)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Outstanding ARYA Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,187,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8364; Closing price of ARYA Warrants on Nasdaq as of July 1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) Fair value of outstanding ARYA Warrants<br/> (d * e)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Cash and cash equivalents held in ARYA&#8217;s trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Current liabilities by ARYA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ARYA&#8217;s identifiable net assets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(g-f-h)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#8364;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 2 expense on the closing date</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8364;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152,787</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about Share listing expenses [text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682131904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial income and expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock', window );">Summary of other financial income and costs</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income and financial expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,476</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on other financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,416</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,675</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,949</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(566</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(289</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses on financial instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(741</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(884</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,279</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,726</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,063</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about finance income expense explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682244064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock', window );">Summary of Employee Related Share Based Compensation Expense</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized total employee-related share-based compensation expenses from all plans for the years ended December&#160;31, 2022, 2021 and 2020 as set out below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,570</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model</a></td>
<td class="text">Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Summary of Employee Share Options</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,406,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,554</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,348,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,348,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,406,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,413,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,430,818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matching Stock Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model</a></td>
<td class="text">Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Average exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Summary of Employee Share Options</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">566,311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">525,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">594,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">566,311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options granted in June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">632,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">594,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of options granted in USD for June</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember', window );">Additional Grants Under 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model</a></td>
<td class="text">Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Summary of Employee Share Options</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,725,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,619,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,129,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,438,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,910,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,967,708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">149,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,725,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;in&#160;USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,963,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,910,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service Options exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model</a></td>
<td class="text">In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> September&#160;28,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December<br/> 31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying share price in USD</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time period (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Summary of Employee Share Options</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,696,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,666,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2021: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,644,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,696,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;exercise<br/> price in USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on January&#160;1,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs granted in 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,899,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs outstanding on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,644,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PSUs exercisable on December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining contract life (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684410080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPersonnelExpenesTextBlock', window );">Summary of Personnel Expenses</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Wages and salaries</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(42,924</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29,098</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other employee benefits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,711</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,639</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,570</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(73,205</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60,587</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(51,403</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfPersonnelExpenesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Personnel Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfPersonnelExpenesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635717573488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock', window );">Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation between taxes on income reflected on the Consolidated Statement of Profit/(Loss) and the expected income tax benefit, based on the Group&#8217;s German statutory tax rate, for the years ended December&#160;31, 2022, 2021 and 2020 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit/(loss) before taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,335</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(211,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected taxes on income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effects</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Difference in tax rates</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(599</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants exempted from taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent Differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization of previously unrecorded tax losses carried forward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-recognition&#160;of</div> deferred taxes on tax losses and temporary differences</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes on income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,522</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and deferred tax liabilities consist of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:60%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">As of</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>assets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deferred<br/>tax<br/>liabilities</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,133</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(947</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of tax losses carried forward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recognized</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">27,319</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(27,319</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">3,927</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(2,629</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Netting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">Non-recognition</div> of deferred tax assets on temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net deferred tax assets/liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation between taxes on income and expected income tax benefit[Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684687392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock', window );">Summary of Currency Risk Exposure</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics N.V. held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82,788</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,410</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and financial assets Immatics GmbH held in USD </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets exposed to the risk</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71,588</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,787</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Summary of Sensitivity Analysis of Foreign Currency Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(820</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">836</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,942</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(709</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,740</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics N.V.: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(946</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics GmbH: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit/(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(561</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(193</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,065</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sensitivity analysis Immatics US Inc. for 2021: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion<br/> rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 1% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 5% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro weakens by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro strengths by 10% against U.S. dollars</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfManagingLiquidityRisk', window );">Summary of Liquidity Risk</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, and 2021, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132,994</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total funds available</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">362,205</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">145,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfManagingLiquidityRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of how the entity manages its liquidity risk. [Refer: Liquidity risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfManagingLiquidityRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Currency Risk Exposure Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686778144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Summary of Carrying Amounts and Fair values of Group's Financial Instruments</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below are the carrying amounts and fair values of the Group&#8217;s financial instruments that are carried in the consolidated financial statements as of December&#160;31, 2022 and 2021, respectively.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">148,519</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">154,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154,930</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,756</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,111</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,402</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,914</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,563</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365,718</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,914</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,352</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,984</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying amount per measurement category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;fair&#160;value<br/>through&#160;profit<br/>and loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;amortized<br/>cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.12.2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,994</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,994</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">682</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current/non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">691</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Current/non-current</div> liabilities</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,624</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">727</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,859</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,853</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146,490</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,859</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,204</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196,553</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Short-term deposits&#8221; and &#8220;Bonds&#8221; are classified within Other financial assets </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In all valuation categories with the exception of Bonds, the carrying amount represents a reasonable approximation of the fair value based on the short-term maturities of these instruments. Set out below are the carrying amounts and fair values of the Group&#8217;s Bonds as of December&#160;31, 2022 and 2021, respectively. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,756</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,300</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,113</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory', window );">Summary of Net Result from Financial Instruments by Measurement Categories</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Groups net result from financial instruments by measurement categories are disclosed below for the years ended December&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(884</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at amortized cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(712</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(286</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit and loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,082</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,041</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,661</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory', window );">Summary of changes of the liabilities from financing activities classified as cash effective and non-cash effective</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table shows the changes of the liabilities from financing activities, classified as cash effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> effective as of December&#160;31, 2022 and 2021, respectively. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euros in thousands</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div><br/> effective</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities for warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,843</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,655</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,707</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective explanatory [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about net result from financial instruments by measurement categories explanatory [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686980272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsTableTextBlock', window );">Summary of Contractual Obligations</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2022 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligation<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,250</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,469</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,392</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,456</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25,568</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual obligations for 2021 consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments due by year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/> 1&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;-&#160;3<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;-&#160;5<br/> years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/> 5&#160;years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other lease obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract research organization agreements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,659</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,370</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,972</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,735</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfContractualObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfContractualObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683325920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock', window );">Summary of Compensation of Key Management Personnel</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation of key management personnel consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,706</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,317</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">886</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,574</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,814</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,387</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock', window );">Summary of Compensation for the Supervisory Board</a></td>
<td class="text">Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;1.7&#160;million in 2022: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen<br/> und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nancy<br/> Valente</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">379</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,336</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">258</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">246</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">232</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">217</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">217</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">220</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,715</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total compensation for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board amounted to &#8364;2.1&#160;million in 2021: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Friedrich<br/> von<br/> Bohlen&#160;und<br/> Halbach</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">348</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,751</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,223</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">179</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">167</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">157</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,114</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On July&#160;1, 2021, Immatics changed its structure from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-tier</div> Board to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tier</div> Board and Supervisory Board members became <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> members of the Board of Directors. Total compensation for the Supervisory Board amounted to &#8364;4.1&#160;million in 2020: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Euros in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peter<br/> Chambr&#233;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Harald&#160;F.<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Michael&#160;G.<br/> Atieh</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paul<br/> Carter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Heather&#160;L.<br/> Mason</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adam<br/> Stone</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Christoph<br/> Hettich</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eliot<br/> Forster</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supervisory board compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">282</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Travel expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment Exit arrangement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,394</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,436</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,584</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,116</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock', window );">Summary of Options Granted to Managing Director and Supervisory Directors</a></td>
<td class="text">The following options were granted to Immatics&#8217; Directors: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Type of options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant&#160;date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strike<br/> Price&#160;in<br/> USD</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration date</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managing Director</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Performance-<br/> based options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,598,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Matching Stock<br/> options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">264,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Converted options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">July 1, 2027</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Converted options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">January 1, 2028</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harpreet Singh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 13, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 13, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Matching Stock<br/> options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Peter Chambr&#233;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adam Stone</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heather L. Mason</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Atieh</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 30, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Carter</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 14, 2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 13, 2030</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliot Forster</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 17, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 17, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 9, 2031</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Friedrich von Bohlen und Halbach</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June 14, 2032</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nancy Valente</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Service options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">March 22, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">March 22, 2032</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of compensation Managing directors and supervisory board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of compensation of key management personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCompensationSupervisoryBoardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of compensation supervisory board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCompensationSupervisoryBoardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682224640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings and Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Earnings and loss per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net profit/(loss):</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(93,335</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(211,841</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,220,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,912,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,001,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,824,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,912,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,001,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682241920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfEndOfReportingPeriod2013', window );">Date of end of reporting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=imtx_AuthorizationOfFinancialStatementsMember', window );">Authorization Of Financial Statements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013', window );">Date of authorisation for issue of financial statements</a></td>
<td class="text">Mar. 22,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which financial statements are authorised for issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfEndOfReportingPeriod2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfEndOfReportingPeriod2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=imtx_AuthorizationOfFinancialStatementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=imtx_AuthorizationOfFinancialStatementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683724320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARYA Merger - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase decrease through Changes in Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareListingExpense', window );">Share listing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 152,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Increase through other contributions by owners, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">&#8364; 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Issued capital [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseThroughReorganizationEquity', window );">Increase Decrease Through Reorganization Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase decrease through Changes in Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Increase through other contributions by owners, equity</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseThroughReorganizationEquity', window );">Increase Decrease Through Reorganization Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase decrease through Changes in Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Increase through other contributions by owners, equity</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 89,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=imtx_PipeFinancingMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="nump">90,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseThroughReorganizationEquity', window );">Increase Decrease Through Reorganization Equity</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase decrease through Changes in Noncontrolling Interest</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree', window );">Description Of How Acquirer Obtained Control Of Acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net Assets Acquired (Liabilities Assumed)</a></td>
<td class="nump">90,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 90,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents recognised as of acquisition date</a></td>
<td class="nump">128,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current liabilities recognised as of acquisition date</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareListingExpense', window );">Share listing expense</a></td>
<td class="nump">152,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination', window );">Fair value of warrant liabilities assumed in a business acquisition</a></td>
<td class="nump">&#8364; 34,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of instruments issued or issuable | Warrants</a></td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of instruments issued or issuable | shares</a></td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of how the acquirer obtained the power to govern the financial and operating policies of the acquiree so as to obtain benefits from its activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreaseDecreaseThroughReorganizationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through reorganization, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreaseDecreaseThroughReorganizationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through changes in noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=imtx_PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=imtx_PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683617856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentIasSixteenMember', window );">Amendment IAS 16</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendment IAS 16 &#8211; Property, Plant and Equipment (Proceeds before Intended Use)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentIasThirtySevenMember', window );">Amendment IAS 37</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendment IAS 37 &#8211; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#8211;Cost of Fulfilling a Contract)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsThreeMember', window );">Amendment To IFRS 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IFRS 3 &#8211; Business Combinations (Reference to the Conceptual Framework)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsOneMember', window );">Amendment To IFRS 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IFRS 1 &#8211; First-time Adoption of International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsNineMember', window );">Amendment To IFRS 9</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IFRS 9 &#8211; Financial Instruments<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember', window );">Amendments to Illustrative Examples accompanying IFRS 16</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to Illustrative Examples accompanying IFRS 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasFourtyOneMember', window );">Amendment To IAS 41</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IAS 41 &#8211; Agriculture<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date by which the entity is required to apply a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TitleOfNewIFRS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TitleOfNewIFRS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentIasSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentIasSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentIasThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentIasThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasFourtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasFourtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683487088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=ifrs-full_IFRS17Member', window );">IFRS 17</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">IFRS 17 &#8211; Insurance Contracts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember', window );">Amendment To IAS 1 IFRS Practice Statement 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasEightMember', window );">Amendment To IAS 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasTwelveMember', window );">Amendment To IAS 12</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendments to IAS 12 &#8211; Income Taxes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsSixteenMember', window );">Amendment to IFRS 16</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendment to IFRS 16 &#8211; Leases on sale and leaseback<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneMember', window );">Amendment o IAS 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Title of new IFRS</a></td>
<td class="text">Amendment to IAS 1 &#8211; Presentation of Financial Statements (Classification of Liabilities as Current or Non-current and Non-current liabilities with covenants)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Date by which application of new IFRS is required</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date by which the entity is required to apply a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TitleOfNewIFRS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TitleOfNewIFRS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=ifrs-full_IFRS17Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=ifrs-full_IFRS17Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIfrsSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=imtx_AmendmentToIasOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683097744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss', window );">Net foreign exchange differences</a></td>
<td class="nump">&#8364; 2,953<span></span>
</td>
<td class="num">&#8364; (2,408)<span></span>
</td>
<td class="nump">&#8364; 437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/ (used in) operating activities</a></td>
<td class="nump">100,131<span></span>
</td>
<td class="num">(84,746)<span></span>
</td>
<td class="num">(80,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/ (used in) investing activities</a></td>
<td class="num">(209,791)<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
<td class="num">(15,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from (used in) financing activities</a></td>
<td class="nump">123,710<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="nump">207,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">14,050<span></span>
</td>
<td class="num">(79,866)<span></span>
</td>
<td class="nump">111,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
<td class="nump">103,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="num">(7,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">148,519<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss', window );">Net foreign exchange differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="num">(4,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/ (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,785)<span></span>
</td>
<td class="num">(85,611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/ (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
<td class="num">(15,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="nump">207,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,904)<span></span>
</td>
<td class="nump">106,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
<td class="nump">103,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss', window );">Net foreign exchange differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,962)<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/ (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,962)<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,962)<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
<td class="num">(4,914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=imtx_CurrentlyReportedMember', window );">As Revised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss', window );">Net foreign exchange differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,408)<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/ (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,747)<span></span>
</td>
<td class="num">(80,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/ (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
<td class="num">(15,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="nump">207,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,866)<span></span>
</td>
<td class="nump">111,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">&#8364; 132,994<span></span>
</td>
<td class="nump">207,530<span></span>
</td>
<td class="nump">103,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="num">(7,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 132,994<span></span>
</td>
<td class="nump">&#8364; 207,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange and expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effects of exchange rate changes and expected credit losses on cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=imtx_CurrentlyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=imtx_CurrentlyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683999520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Application of new and revised international financial reporting standards - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities', window );">Reclassfication of Provisions to other Current Liabilities</a></td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassfication of provisions to other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683011408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Office equipment and installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Office equipment and installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems', window );"><strong>Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683904784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licences [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems', window );"><strong>Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licences [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems', window );"><strong>Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems', window );"><strong>Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems', window );"><strong>Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686989008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Detailed Information About Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="nump">0.93756<span></span>
</td>
<td class="nump">0.88292<span></span>
</td>
<td class="nump">0.81493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average foreign exchange rate</a></td>
<td class="nump">0.94888<span></span>
</td>
<td class="nump">0.84495<span></span>
</td>
<td class="nump">0.87621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635686778144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Summary of Trade receivables (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract', window );"><strong>Trade and other current receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ReceivablesFromCollaborationAgreements', window );">Receivables From Collaboration Agreements</a></td>
<td class="nump">&#8364; 1,111<span></span>
</td>
<td class="nump">&#8364; 682<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total</a></td>
<td class="nump">&#8364; 1,111<span></span>
</td>
<td class="nump">&#8364; 682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ReceivablesFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables from collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ReceivablesFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683234544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract', window );"><strong>Trade and other current receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets', window );">Expected credit losses</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an allowance account used to record impairments to financial assets due to credit losses. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683909216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current and non-current assets -Summary of Other current assets (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 10,450<span></span>
</td>
<td class="nump">&#8364; 3,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Value added tax receivables</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrentGrantReceivable', window );">Grant receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">2,357<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total</a></td>
<td class="nump">&#8364; 13,838<span></span>
</td>
<td class="nump">&#8364; 6,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CurrentGrantReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current grant receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CurrentGrantReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683618384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current and non-current assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrentPrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PrepaidExpensesOfLicensesAndSoftware', window );">Prepaid expenses of licenses and software</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Non-current prepayments</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrentPrepaidMaintenanceExpenses', window );">Current prepaid maintenance expenses</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NoncurrentPrepaymentsOfLicensingAgreement', window );">Noncurrent Prepayments Of Licensing Agreement</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NonCurrentPrepaidMaintenanceExpenses', window );">NonCurrent Prepaid Maintenance Expenses</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CollaborationAgreementAxis=imtx_CelgeneSwitzerlandLlcAndGenmabAsMember', window );">Celgene Switzerland LLC And Genmab AS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrentIncrementalCostForCollaborationAgreement', window );">Current Incremental cost for collaboration agreement</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Non-current prepayments</a></td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CurrentIncrementalCostForCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current incremental cost for collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CurrentIncrementalCostForCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CurrentPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current prepaid insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CurrentPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CurrentPrepaidMaintenanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current prepaid maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CurrentPrepaidMaintenanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NonCurrentPrepaidMaintenanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non current prepaid maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NonCurrentPrepaidMaintenanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NoncurrentPrepaymentsOfLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent prepayments of licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NoncurrentPrepaymentsOfLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PrepaidExpensesOfLicensesAndSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses of licenses and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PrepaidExpensesOfLicensesAndSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CollaborationAgreementAxis=imtx_CelgeneSwitzerlandLlcAndGenmabAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CollaborationAgreementAxis=imtx_CelgeneSwitzerlandLlcAndGenmabAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683211136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current and non-current assets - Summary of Other non-current assets (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivablesAbstract', window );"><strong>Trade and other non-current receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 1,906<span></span>
</td>
<td class="nump">&#8364; 636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherNonCurrentAsset', window );">Other assets</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total</a></td>
<td class="nump">&#8364; 2,545<span></span>
</td>
<td class="nump">&#8364; 636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_OtherNonCurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non current asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_OtherNonCurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681589072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">&#8364; 10,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">13,456<span></span>
</td>
<td class="nump">&#8364; 10,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">7,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">7,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember', window );">Office Equipment And Installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">3,736<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">27,761<span></span>
</td>
<td class="nump">22,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">6,096<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">33,938<span></span>
</td>
<td class="nump">27,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">19,630<span></span>
</td>
<td class="nump">15,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">3,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">22,737<span></span>
</td>
<td class="nump">19,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">4,470<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">4,898<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Office Equipment And Installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="num">(17,255)<span></span>
</td>
<td class="num">(14,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="num">(3,129)<span></span>
</td>
<td class="num">(2,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="nump">20,482<span></span>
</td>
<td class="num">(17,255)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="num">(12,052)<span></span>
</td>
<td class="num">(10,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="num">(2,143)<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="num">(14,279)<span></span>
</td>
<td class="num">(12,052)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="num">(2,966)<span></span>
</td>
<td class="num">(2,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="num">(653)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="num">(3,636)<span></span>
</td>
<td class="num">(2,966)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Office Equipment And Installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Cost</a></td>
<td class="num">(2,237)<span></span>
</td>
<td class="num">(1,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionsOtherPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisposalsOfPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Cost</a></td>
<td class="num">&#8364; (2,567)<span></span>
</td>
<td class="num">&#8364; (2,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdditionsOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions other property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdditionsOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CurrencyTranslationDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency translation differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CurrencyTranslationDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683266464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Depreciation expense (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="num">&#8364; (3,129)<span></span>
</td>
<td class="num">&#8364; (2,574)<span></span>
</td>
<td class="num">&#8364; (2,102)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="num">(2,039)<span></span>
</td>
<td class="num">(1,684)<span></span>
</td>
<td class="num">(1,502)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="num">&#8364; (1,090)<span></span>
</td>
<td class="num">&#8364; (890)<span></span>
</td>
<td class="num">&#8364; (600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683394640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Addtional information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember', window );">Office Equipment And Installations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions Property Plant And Equipment</a></td>
<td class="nump">&#8364; 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imtx_OfficeEquipmentAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681479232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Summary of Changes to intangible assets (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">&#8364; 1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">&#8364; 1,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_PatentAndLicensesMember', window );">Patent And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_SoftwareLicensesMember', window );">Software Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Patent And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Software Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Accumulated impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="num">(1,144)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="num">(218)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="num">(1,385)<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Accumulated impairment [member] | Patent And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(480)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Accumulated impairment [member] | Software Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="num">&#8364; (826)<span></span>
</td>
<td class="num">&#8364; (664)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_PatentAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_PatentAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_SoftwareLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=imtx_SoftwareLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683264272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Summary of Amortization expense (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">&#8364; (218)<span></span>
</td>
<td class="num">&#8364; (160)<span></span>
</td>
<td class="num">&#8364; (126)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">&#8364; (125)<span></span>
</td>
<td class="num">&#8364; (125)<span></span>
</td>
<td class="num">&#8364; (95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635684034448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Right-of&amp;#160;use assets (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 13,033<span></span>
</td>
<td class="nump">&#8364; 9,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">12,409<span></span>
</td>
<td class="nump">9,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">IT and telecommunication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="nump">&#8364; 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682076272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Details of Lease liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities &#8211; current</a></td>
<td class="nump">&#8364; 2,159<span></span>
</td>
<td class="nump">&#8364; 2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities &#8211; non-current</a></td>
<td class="nump">12,403<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 14,562<span></span>
</td>
<td class="nump">&#8364; 9,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683459936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of expenses related to&amp;#160;right-of-use&amp;#160;assets and lease liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">&#8364; (3,620)<span></span>
</td>
<td class="num">&#8364; (2,526)<span></span>
</td>
<td class="num">&#8364; (2,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_InterestExpenseOnLease', window );">Interest expenses form lease</a></td>
<td class="num">(613)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expenses relating to short-term leases and low-value assets (included in administrative expenses)</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(2,036)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">IT and telecommunication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="num">&#8364; (23)<span></span>
</td>
<td class="num">&#8364; (8)<span></span>
</td>
<td class="num">&#8364; (8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses related to&#160;right-of-use&#160;assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_InterestExpenseOnLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense on lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_InterestExpenseOnLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=imtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681464992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">&#8364; 6,700<span></span>
</td>
<td class="nump">&#8364; 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TranslationDifferenceOnRightOfUseAsset', window );">Currency translation of &#160;right-of-use&#160;assets&#160;</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash payments for leases</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments for leases</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="nump">&#8364; 2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities', window );">Payments of right of use assets classified as financing activities</a></td>
<td class="nump">24,600<span></span>
</td>
<td class="nump">&#8364; 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Until 2025 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments for leases</a></td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments for leases</a></td>
<td class="nump">&#8364; 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of right of use assets classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TranslationDifferenceOnRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translation difference on right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TranslationDifferenceOnRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682215776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable - Summary of Accounts Payable (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Accounts payables</a></td>
<td class="nump">&#8364; 4,025<span></span>
</td>
<td class="nump">&#8364; 3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">9,031<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Total</a></td>
<td class="nump">&#8364; 13,056<span></span>
</td>
<td class="nump">&#8364; 11,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682131904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">&#8364; 9,031<span></span>
</td>
<td class="nump">&#8364; 8,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635678130208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from collaboration agreements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 770,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 98,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers', window );">Capitalized costs of contract net of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers', window );">Amortization of contract costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">&#8364; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PotentialMilestonePaymentPayable', window );">Potential milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Receipt of upfront of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,763,000<span></span>
</td>
<td class="nump">31,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived', window );">Milestone regulatory and royaly payment receivable</a></td>
<td class="nump">&#8364; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ImtxagreementAxis=imtx_ImtxbMSCollaborationAgreementMember', window );">IMTXB M S Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">18,700,000<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember', window );">Immatics Biotechnologies GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Transaction price allocation to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_AmgenCollaborationAgreementMember', window );">Amgen Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Contract with customers liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractLiabilitiesRecognized', window );">Contract liabilities recognizedContract liabilities recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember', window );">Genmab Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000,000<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Contract with customers liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember', window );">Genmab Collaboration Agreement [Member] | Milestone Payment For Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MilestonePaymentReceivable', window );">Milestone payment receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">$ 68.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Contract with customers liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember', window );">GSK Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Contract with customers liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">&#8364; 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember', window );">GSK Collaboration Agreement [Member] | Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_BmsAgreementMember', window );">Bms Agreement [Member] | Immatics Biotechnologies GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Receipt of upfront of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 133,000,000<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant', window );">Allocation of upfront payment towards clinical trial services and license grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000,000<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices', window );">Allocation of upfront payment towards clinical trial services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_Allocationofupfrontpaymenttowardslicensegrant', window );">Allocation of upfront payment towards license grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 91,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_BmsAgreementMember', window );">Bms Agreement [Member] | Immatics Biotechnologies GmbH [Member] | Ima401 License Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_BmsAgreementMember', window );">Bms Agreement [Member] | Immatics Biotechnologies GmbH [Member] | Ima401 Clinical Trial Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_LicenseDevelopmentAndCommercializationAgreementMember', window );">License Development and Commercialization Agreement [member] | Immatics US Inc [Member] | Bristol Myer Squib Company [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems', window );"><strong>Disclosure Of Revenue From Contract With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Transaction price allocation to performance obligation</a></td>
<td class="nump">60,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived', window );">Additional payment related to performance obligations received</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived', window );">Performance obligations cumulative upfront payments received</a></td>
<td class="nump">60,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60,700,000<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractTransactionPrice', window );">Contract transaction price</a></td>
<td class="nump">&#8364; 66,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation', window );">Revenue recognized during the period performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation for assets recognised from the costs incurred to obtain or fulfil contracts with customers. [Refer: Assets recognised from costs to obtain or fulfil contracts with customers; Amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 128<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_128_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets recognised from the costs to obtain or fulfil contracts with customers. The costs to obtain a contract with a customer are the incremental costs of obtaining the contract that the entity would not have incurred if the contract had not been obtained. The costs to fulfil a contract with a customer are the costs that relate directly to a contract or to an anticipated contract that the entity can specifically identify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 128<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_128_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 120<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment related to performance obligations received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation of upfront payment towards clinical trial services and license grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation of upfront payment towards clinical trial services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_Allocationofupfrontpaymenttowardslicensegrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation of upfront payment towards license grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_Allocationofupfrontpaymenttowardslicensegrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ContractLiabilitiesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract liabilities recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ContractLiabilitiesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ContractTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ContractTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfRevenueFromContractWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfRevenueFromContractWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone regulatory and royalty payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance obligations cumulative upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PotentialMilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PotentialMilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RevenueFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RevenueFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RevenueRecognizedDuringThePeriodPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized during the period performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RevenueRecognizedDuringThePeriodPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ImtxagreementAxis=imtx_ImtxbMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ImtxagreementAxis=imtx_ImtxbMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_AmgenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_AmgenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_MilestoneAxis=imtx_MilestonePaymentForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_MilestoneAxis=imtx_MilestonePaymentForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=imtx_ThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=imtx_ThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_BmsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_BmsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=imtx_Ima401licensegrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=imtx_Ima401licensegrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=imtx_Ima401clinicaltrialservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=imtx_Ima401clinicaltrialservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_LicenseDevelopmentAndCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_LicenseDevelopmentAndCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imtx_BristolMyerSquibCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imtx_BristolMyerSquibCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683981392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current</a></td>
<td class="nump">&#8364; 64,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current</a></td>
<td class="nump">75,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 140,716<span></span>
</td>
<td class="nump">&#8364; 42,000<span></span>
</td>
<td class="nump">&#8364; 98,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683328320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities - Summary of other current liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of detailed information about other current liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income tax liability</a></td>
<td class="nump">&#8364; 4,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Payroll tax</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">&#8364; 1,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrual for vacation</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Accrued bonuses</a></td>
<td class="nump">680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherCurrent', window );">Other liabilities</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 9,366<span></span>
</td>
<td class="nump">&#8364; 2,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current liabilities line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_OtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_OtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682699424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current liabilities - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=imtx_NonInterestBearingLiabilityMember', window );">Non Interest Bearing Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of detailed information about other current liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings maturity</a></td>
<td class="text">one year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current liabilities line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=imtx_NonInterestBearingLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=imtx_NonInterestBearingLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681730384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForShareListingExpense', window );">Expense on the closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 152,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Gains losses on financial liabilities at fair value through profit or loss</a></td>
<td class="nump">&#8364; 10,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (10,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of ARYA ordinary shares and warrants</a></td>
<td class="nump">243,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA ordinary shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable net assets</a></td>
<td class="nump">90,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 90,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForShareListingExpense', window );">Expense on the closing date</a></td>
<td class="nump">&#8364; 152,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_WarrantsIssuedPricePerWarrant', window );">Closing price of ARYA public warrants | (per share)</a></td>
<td class="nump">&#8364; 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Gains losses on financial liabilities at fair value through profit or loss</a></td>
<td class="nump">&#8364; 10,900<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">&#8364; 11,000<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">&#8364; 17,800<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember', window );">Warrants [member] | ARYA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of ARYA ordinary shares and warrants</a></td>
<td class="nump">&#8364; 34,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">ARYA Shares | Warrants</a></td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_WarrantsIssuedPricePerWarrant', window );">Closing price of ARYA public warrants | &#8364; / shares</a></td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA ordinary shares | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member] | ARYA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfShareListingExpenseLineItems', window );"><strong>Disclosure of share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of ARYA ordinary shares and warrants</a></td>
<td class="nump">&#8364; 243,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA ordinary shares | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">ARYA Shares | shares</a></td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfShareListingExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfShareListingExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_WarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_WarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682859616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>Warrants </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForShareListingExpense', window );">IFRS 2 Expense on the closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 152,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_WarrantsIssuedPricePerWarrant', window );">Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 | (per share)</a></td>
<td class="nump">&#8364; 2.35<span></span>
</td>
<td class="nump">&#8364; 2.35<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="nump">&#8364; 3.88<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of outstanding ARYA</a></td>
<td class="nump">&#8364; 243,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate', window );">Cash and cash equivalents held in ARYA's trust account</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current liabilities by ARYA</a></td>
<td class="nump">3,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">ARYA's identifiable net assets</a></td>
<td class="nump">90,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 90,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AdjustmentsForShareListingExpense', window );">IFRS 2 Expense on the closing date</a></td>
<td class="nump">&#8364; 152,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">ARYA Shares | Warrants</a></td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_WarrantsIssuedPricePerWarrant', window );">Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 | &#8364; / shares</a></td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of outstanding ARYA</a></td>
<td class="nump">&#8364; 34,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems', window );"><strong>Disclosure of detailed information about share listing expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">ARYA Shares | shares</a></td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Fair value of outstanding ARYA</a></td>
<td class="nump">&#8364; 243,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AdjustmentsForShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AdjustmentsForShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_WarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_WarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682161632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial income and expenses - Summary of other financial income and costs (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract', window );"><strong>Disclosure Of Detailed Information About Other Finance Income Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnOtherFinancialAssets', window );">Interest income</a></td>
<td class="nump">&#8364; 2,476<span></span>
</td>
<td class="nump">&#8364; 133<span></span>
</td>
<td class="nump">&#8364; 850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign currency gains</a></td>
<td class="nump">6,940<span></span>
</td>
<td class="nump">5,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured', window );">Gain on other financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Other financial income</a></td>
<td class="nump">9,416<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">2,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expenses</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ForeignCurrencyLossesNet', window );">Foreign currency losses</a></td>
<td class="num">(6,500)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">(9,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured', window );">Losses on other financial instruments</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">(884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Other financial expenses</a></td>
<td class="num">&#8364; (8,279)<span></span>
</td>
<td class="num">&#8364; (1,726)<span></span>
</td>
<td class="num">&#8364; (10,063)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Finance Income Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ForeignCurrencyLossesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency losses net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ForeignCurrencyLossesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain recognised on financial instruments whose fair value previously could not be reliably measured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss recognised on financial instruments whose fair value previously could not be reliably measured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682597232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial income and expenses - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract', window );"><strong>Disclosure Of Detailed Information About Other Finance Income Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RealisedGainLossFromForeignCurrencyForwardContracts', window );">Realised gain from foreign currency forward contracts</a></td>
<td class="nump">&#8364; 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts', window );">Unrealised gain from foreign currency forward contracts</a></td>
<td class="nump">&#8364; 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Finance Income Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RealisedGainLossFromForeignCurrencyForwardContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realised gain loss from foreign currency forward contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RealisedGainLossFromForeignCurrencyForwardContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealised gain loss from foreign currency forward contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682768112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2021 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Time period (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember', window );">Additional Grants Under 2020 and 2022 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.44%<span></span>
</td>
<td class="nump">82.18%<span></span>
</td>
<td class="nump">78.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Time period (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.07<span></span>
</td>
<td class="nump">6.11<span></span>
</td>
<td class="nump">6.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price</a></td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="nump">$ 14.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">77.16%<span></span>
</td>
<td class="nump">78.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Time period (years) | yr</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="nump">6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Time period (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PlanAxis=imtx_MatchingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PlanAxis=imtx_MatchingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635676274816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Summary of Employee Share Options (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Warrants </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>Warrants </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Warrants </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">SARs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">SARs exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at January&#160;1, | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at December&#160;31, | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">SARs exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contract life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Granted On September 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember', window );">Additional Grants Under 2020 and 2022 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">SARs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">SARs exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">SARs expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">SARs exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 9.86<span></span>
</td>
<td class="nump">$ 9.86<span></span>
</td>
<td class="nump">$ 9.86<span></span>
</td>
<td class="nump">$ 9.86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,910,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,910,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">SARs exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">SARs expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,129,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,910,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,910,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">SARs exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,413<span></span>
</td>
<td class="nump">1,438,413<span></span>
</td>
<td class="nump">1,438,413<span></span>
</td>
<td class="nump">1,438,413<span></span>
</td>
<td class="nump">557,401<span></span>
</td>
<td class="nump">557,401<span></span>
</td>
<td class="nump">557,401<span></span>
</td>
<td class="nump">557,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contract life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember', window );">Additional Grants Under 2020 and 2022 Plan [Member] | Granted On March 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember', window );">Additional Grants Under 2020 and 2022 Plan [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,963,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">SARs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">SARs exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">SARs expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">SARs exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">SARs exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">SARs expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">SARs exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,258<span></span>
</td>
<td class="nump">392,258<span></span>
</td>
<td class="nump">392,258<span></span>
</td>
<td class="nump">392,258<span></span>
</td>
<td class="nump">193,727<span></span>
</td>
<td class="nump">193,727<span></span>
</td>
<td class="nump">193,727<span></span>
</td>
<td class="nump">193,727<span></span>
</td>
<td class="nump">53,856<span></span>
</td>
<td class="nump">53,856<span></span>
</td>
<td class="nump">53,856<span></span>
</td>
<td class="nump">53,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contract life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">SARs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">SARs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">SARs exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">SARs expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">SARs exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at January&#160;1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">SARs forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">SARs exercised | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">SARs expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options, outstanding at December&#160;31,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">SARs exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,004<span></span>
</td>
<td class="nump">1,348,004<span></span>
</td>
<td class="nump">1,348,004<span></span>
</td>
<td class="nump">1,348,004<span></span>
</td>
<td class="nump">1,413,302<span></span>
</td>
<td class="nump">1,413,302<span></span>
</td>
<td class="nump">1,413,302<span></span>
</td>
<td class="nump">1,413,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contract life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">SARs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">SARs granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment arrangement weighted average fair value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnJuneTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnJuneTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnMarchTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnMarchTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_MatchingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635677866096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Additional Information (Detail)<br> $ / shares in Units, &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 14, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Share based compensation by share based payment arrangement fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price of share options granted</a></td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="nump">$ 14.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MinimumMarketCapitalization', window );">Minimum market capitalization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MinimumMarketCapitalization', window );">Minimum market capitalization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MinimumMarketCapitalization', window );">Minimum market capitalization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement options granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">3,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Share based compensation by share based payment arrangement exercise price per share granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Granted On September 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement options granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Share based compensation by share based payment arrangement fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Granted On September 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement options granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Share based compensation by share based payment arrangement exercise price per share granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Share based compensation by share based payment arrangement fair value per share</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Share based compensation by share based payment arrangement fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member] | Granted On June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement options granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Share based compensation by share based payment arrangement exercise price per share granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember', window );">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CashPaymentAwardPerSharePayable', window );">Cash payment award per share payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAndOnBehalfOfEmployees', window );">Cash payment to employees stock based awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember', window );">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Share Reinvestment [Member] | Matching Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement term of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfVestingOfStockOptions', window );">Date of vesting of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 1, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember', window );">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Active Employees [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashProceedsToBeBeReinvested', window );">Percentage of cash proceeds to be reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember', window );">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Active Employees [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashProceedsToBeBeReinvested', window );">Percentage of cash proceeds to be reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember', window );">Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Management Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashProceedsToBeBeReinvested', window );">Percentage of cash proceeds to be reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndTenPlanMember', window );">Modification Of Two Thousand And Ten Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ExpenseFromTheModificationOfShareBasedAwards', window );">Share based compensation expenses modification of awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndSixteenPlanMember', window );">Modification Of Two Thousand And Sixteen Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Adjustment to additional paid in capital due to modification of previously settled equity awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndSixteenPlanMember', window );">Modification Of Two Thousand And Sixteen Plan [Member] | Share Reinvestment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ExpenseFromTheModificationOfShareBasedAwards', window );">Share based compensation expenses modification of awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Share based compensation by share based payment arrangement options granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value of stock appreciation rights | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">&#8364; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndSixteenPlanMember', window );">Modification Of Two Thousand And Sixteen Plan [Member] | Share Reinvestment [Member] | Matching Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Share based compensation by share based payment arrangement exercise price per share granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare', window );">Share based compensation by share based payment arrangement fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAndOnBehalfOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to, and on behalf of, employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAndOnBehalfOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CashPaymentAwardPerSharePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment award per share payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CashPaymentAwardPerSharePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfVestingOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of vesting of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfVestingOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ExpenseFromTheModificationOfShareBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense from the modification of share based awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ExpenseFromTheModificationOfShareBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_MinimumMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_MinimumMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfCashProceedsToBeBeReinvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash proceeds to be reinvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfCashProceedsToBeBeReinvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment arrangement weighted average fair value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TrancheAxis=imtx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TrancheAxis=imtx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TrancheAxis=imtx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TrancheAxis=imtx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TrancheAxis=imtx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TrancheAxis=imtx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnJuneTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnJuneTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfGrantAxis=imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imtx_ConvertedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PlanAxis=imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SchemeAxis=imtx_ShareReinvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SchemeAxis=imtx_ShareReinvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareReinvestmentSchemeAxis=imtx_MatchingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareReinvestmentSchemeAxis=imtx_MatchingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CategoryOfEmployeesAxis=imtx_ActiveEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CategoryOfEmployeesAxis=imtx_ActiveEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CategoryOfEmployeesAxis=imtx_ManagementMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CategoryOfEmployeesAxis=imtx_ManagementMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PlanAxis=imtx_ModificationOfTwoThousandAndTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PlanAxis=imtx_ModificationOfTwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PlanAxis=imtx_ModificationOfTwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681588800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems', window );"><strong>Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">&#8364; (22,570)<span></span>
</td>
<td class="num">&#8364; (26,403)<span></span>
</td>
<td class="num">&#8364; (25,519)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember', window );">Research And Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems', window );"><strong>Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">(12,925)<span></span>
</td>
<td class="num">(15,564)<span></span>
</td>
<td class="num">(14,546)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember', window );">General And Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems', window );"><strong>Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">&#8364; (9,645)<span></span>
</td>
<td class="num">&#8364; (10,839)<span></span>
</td>
<td class="num">&#8364; (10,973)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share based compensation expense [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635674278960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity (deficit) - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 12, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 12, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Number of shares value outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 629,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 565,192,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=imtx_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">&#8364; 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">113,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ShareIssuedPricePerShare', window );">Share Issued Price per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Issued capital [member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium [member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">&#8364; 106,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_InvesteeAxis=imtx_SvbSecuritiesLicMember', window );">Svb Securities Lic [Member] | Issued capital [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_InvesteeAxis=imtx_SvbSecuritiesLicMember', window );">Svb Securities Lic [Member] | Share premium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_InvesteeAxis=imtx_SvbSecuritiesLicMember', window );">Svb Securities Lic [Member] | At The Market Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_GrossProceedsFromIssueOfSecurities', window );">Gross Proceeds From Issue Of Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EventAxis=imtx_ReorganizationMember', window );">Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,670,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,926,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=imtx_PipeFinancingMember', window );">PIPE Financing [member] | ARYA Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 327,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,908,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_GrossProceedsFromIssueOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issue of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_GrossProceedsFromIssueOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share issued price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalRequirementsAxis=imtx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalRequirementsAxis=imtx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_InvesteeAxis=imtx_SvbSecuritiesLicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_InvesteeAxis=imtx_SvbSecuritiesLicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_EventAxis=imtx_ReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_EventAxis=imtx_ReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=imtx_PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=imtx_PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ShareListingExpenseAxis=imtx_AryaMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ShareListingExpenseAxis=imtx_AryaMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682311040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Ownership interests held by non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase (decrease) through changes in noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LossOnNoncontrollingInterest', window );">Loss on non-controlling&#160;interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughCompensationExpense', window );">MD Anderson milestone compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_RestrictedStockAcquisitionAgreementMember', window );">Restricted Stock Acquisition Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, shares, acquisitions | shares</a></td>
<td class="nump">697,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest', window );">Increase (decrease) through changes in noncontrolling interest</a></td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MdAndersonMember', window );">MD Anderson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NumberOfSharesExchangedInSubsidiaries', window );">Number of shares exchanged in subsidiaries | shares</a></td>
<td class="nump">379,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through changes in noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreasedecreaseThroughCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreasedecreaseThroughCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_LossOnNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_LossOnNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NumberOfSharesExchangedInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exchanged in subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NumberOfSharesExchangedInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_RestrictedStockAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_RestrictedStockAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683851216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Summary of Personnel Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="num">&#8364; (42,924)<span></span>
</td>
<td class="num">&#8364; (29,098)<span></span>
</td>
<td class="num">&#8364; (22,245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Total other employee benefits</a></td>
<td class="num">(7,711)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
<td class="num">(3,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">(22,570)<span></span>
</td>
<td class="num">(26,403)<span></span>
</td>
<td class="num">(25,519)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total</a></td>
<td class="num">(73,205)<span></span>
</td>
<td class="num">(60,587)<span></span>
</td>
<td class="num">(51,403)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="num">(33,694)<span></span>
</td>
<td class="num">(21,993)<span></span>
</td>
<td class="num">(15,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Other employee benefits</a></td>
<td class="num">(5,662)<span></span>
</td>
<td class="num">(3,550)<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">(12,925)<span></span>
</td>
<td class="num">(15,564)<span></span>
</td>
<td class="num">(14,546)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="num">(9,230)<span></span>
</td>
<td class="num">(7,105)<span></span>
</td>
<td class="num">(6,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Other employee benefits</a></td>
<td class="num">(2,049)<span></span>
</td>
<td class="num">(1,536)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="num">&#8364; (9,645)<span></span>
</td>
<td class="num">&#8364; (10,839)<span></span>
</td>
<td class="num">&#8364; (10,973)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncomeStatementLocationAxis=imtx_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681460880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Classes of employee benefits expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Post-employment benefit expense, defined contribution plans</a></td>
<td class="nump">&#8364; 0.9<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EmployeeHealthInsuranceCost', window );">Employee health insurance cost</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security contributions</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">other miscellaneous expenses</a></td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_EmployeeHealthInsuranceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee health insurance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_EmployeeHealthInsuranceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682987488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before taxes</a></td>
<td class="nump">&#8364; 42,036<span></span>
</td>
<td class="num">&#8364; (93,335)<span></span>
</td>
<td class="num">&#8364; (211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Expected taxes on income</a></td>
<td class="num">(12,774)<span></span>
</td>
<td class="nump">27,160<span></span>
</td>
<td class="nump">61,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Difference in tax rates</a></td>
<td class="num">(4,868)<span></span>
</td>
<td class="num">(3,274)<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible&#160; tax-expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes', window );">Government grants exempted from taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TaxEffectOfPermanentDifferences', window );">Permanent Differences</a></td>
<td class="num">(1,123)<span></span>
</td>
<td class="num">(10,881)<span></span>
</td>
<td class="num">(39,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Utilization of previously unrecorded tax losses carried forward</a></td>
<td class="nump">7,067<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences', window );">Non-recognition&#160;of&#160;deferred taxes on tax losses and temporary differences</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="num">(12,953)<span></span>
</td>
<td class="num">(19,222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="num">&#8364; (4,522)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-recognition&#160;of&#160;deferred taxes on tax losses and temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of government grants exempted from taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TaxEffectOfPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TaxEffectOfPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682824688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Summary of Deferred Tax Assets (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_IntangibleAssetsMember', window );">Intangible assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">10,328<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesRightOfUseAssetMember', window );">Right-of-use assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(3,239)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredRevenueMember', window );">Deferred revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(23,133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_OtherAssetsMember', window );">Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,964<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(947)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_LeaseLiabilityMember', window );">Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,560<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredExpensesMember', window );">Deferred expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_RecognitionOfTaxLossesCarriedForwardMember', window );">Recognition of tax losses carried forward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">11,467<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetRecognisedMember', window );">Recognized [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">27,319<span></span>
</td>
<td class="nump">3,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesDeferredExpensesMember', window );">Recognized [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(27,319)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetNettingMember', window );">Netting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DeferredTaxAssetsOffset', window );">Deferred tax assets netting</a></td>
<td class="num">(27,319)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredLiabilityNettingMember', window );">Netting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DeferredTaxLiabilitiesOffSet', window );">Deferred tax liabilities netting</a></td>
<td class="nump">27,319<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember', window );">Non-recognition of deferred tax assets on temporary differences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DeferredTaxAssetsOnTemporaryDifferences', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DeferredTaxAssetsOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DeferredTaxAssetsOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DeferredTaxAssetsOnTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets on temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DeferredTaxAssetsOnTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DeferredTaxLiabilitiesOffSet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities off set.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DeferredTaxLiabilitiesOffSet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_LeaseLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_LeaseLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_RecognitionOfTaxLossesCarriedForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_RecognitionOfTaxLossesCarriedForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetRecognisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetRecognisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesDeferredExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredTaxLiabilitiesDeferredExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredAssetNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredLiabilityNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_DeferredLiabilityNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681360432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="nump">29.10%<span></span>
</td>
<td class="nump">29.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_CorporateIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod', window );">Percentage on limitation on tax loss carryforwards after prior period</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod', window );">Percentage on limitation on tax loss carryforwards before prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense', window );">Effective income tax reconciliation permanent effect share listing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">&#8364; (12,774)<span></span>
</td>
<td class="nump">&#8364; 27,160<span></span>
</td>
<td class="nump">&#8364; 61,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Tax rate effect from change in tax rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset recognised</a></td>
<td class="nump">&#8364; 319,400<span></span>
</td>
<td class="nump">353,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember', window );">Immatics Biotechnologies GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="nump">&#8364; 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">GERMANY | Immatics Biotechnologies GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward', window );">Percentage Of Income That Can Be Used To Set Off Tax Losses Carry Forward</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax', window );">Percentage Of Pretax Income Subject To Income Tax</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_IndefiniteTaxLossesCarryforwardMember', window );">Indefinite Tax Losses Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Tax effect of tax losses</a></td>
<td class="nump">&#8364; 357,200<span></span>
</td>
<td class="nump">&#8364; 353,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_TwentySixYearTaxLossesCarryforwardMember', window );">Twenty Six Year Tax Losses Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Tax effect of tax losses</a></td>
<td class="nump">&#8364; 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_CorporateIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>corporate income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_CorporateIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation permanent effect share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of income that can be used to set off tax losses carry forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfPretaxIncomeSubjectToIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pretax income subject to income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfPretaxIncomeSubjectToIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage on limitation on tax loss carryforwards after prior period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage on limitation on tax loss carryforwards before prior period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_IndefiniteTaxLossesCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_IndefiniteTaxLossesCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_TwentySixYearTaxLossesCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=imtx_TwentySixYearTaxLossesCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681986032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCurrencyRiskExposureLineItems', window );"><strong>Disclosure Of Currency Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 148,519<span></span>
</td>
<td class="nump">&#8364; 132,994<span></span>
</td>
<td class="nump">&#8364; 207,530<span></span>
</td>
<td class="nump">&#8364; 103,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCurrencyRiskExposureLineItems', window );"><strong>Disclosure Of Currency Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">148,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCurrencyRiskExposureLineItems', window );"><strong>Disclosure Of Currency Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">34,225<span></span>
</td>
<td class="nump">11,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">37,363<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MaximumExposedToCurrencyRisk', window );">Total assets exposed to the risk</a></td>
<td class="nump">71,588<span></span>
</td>
<td class="nump">11,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCurrencyRiskExposureLineItems', window );"><strong>Disclosure Of Currency Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">31,350<span></span>
</td>
<td class="nump">10,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">51,438<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_MaximumExposedToCurrencyRisk', window );">Total assets exposed to the risk</a></td>
<td class="nump">&#8364; 82,788<span></span>
</td>
<td class="nump">&#8364; 10,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCurrencyRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCurrencyRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_MaximumExposedToCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Exposed to Currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_MaximumExposedToCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=imtx_ImmaticsNvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=imtx_ImmaticsNvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635674440480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">0.93756<span></span>
</td>
<td class="nump">0.88292<span></span>
</td>
<td class="nump">0.81493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember', window );">Euro weakens by 1% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0773<span></span>
</td>
<td class="nump">1.1439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (709)<span></span>
</td>
<td class="num">&#8364; (117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 71,055<span></span>
</td>
<td class="nump">&#8364; 11,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember', window );">Euro weakens by 1% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0773<span></span>
</td>
<td class="nump">1.1439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (18,873)<span></span>
</td>
<td class="nump">&#8364; 28,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="nump">&#8364; 189<span></span>
</td>
<td class="num">&#8364; (290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember', window );">Euro weakens by 1% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0773<span></span>
</td>
<td class="nump">1.1439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (820)<span></span>
</td>
<td class="num">&#8364; (103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 81,968<span></span>
</td>
<td class="nump">&#8364; 10,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember', window );">Euro strengths by 1% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0559<span></span>
</td>
<td class="nump">1.1213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 723<span></span>
</td>
<td class="nump">&#8364; 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 72,491<span></span>
</td>
<td class="nump">&#8364; 11,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember', window );">Euro strengths by 1% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0559<span></span>
</td>
<td class="nump">1.1213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (19,255)<span></span>
</td>
<td class="nump">&#8364; 29,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="num">&#8364; (193)<span></span>
</td>
<td class="nump">&#8364; 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember', window );">Euro strengths by 1% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0559<span></span>
</td>
<td class="nump">1.1213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 836<span></span>
</td>
<td class="nump">&#8364; 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 83,624<span></span>
</td>
<td class="nump">&#8364; 10,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember', window );">Euro weakens by 5% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1199<span></span>
</td>
<td class="nump">1.1892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (3,409)<span></span>
</td>
<td class="num">&#8364; (561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 68,349<span></span>
</td>
<td class="nump">&#8364; 11,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember', window );">Euro weakens by 5% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1199<span></span>
</td>
<td class="nump">1.1892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (18,154)<span></span>
</td>
<td class="nump">&#8364; 27,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="nump">&#8364; 908<span></span>
</td>
<td class="num">&#8364; (1,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember', window );">Euro weakens by 5% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1199<span></span>
</td>
<td class="nump">1.1892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (3,942)<span></span>
</td>
<td class="num">&#8364; (496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 78,845<span></span>
</td>
<td class="nump">&#8364; 9,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember', window );">Euro strengths by 5% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0133<span></span>
</td>
<td class="nump">1.076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 3,768<span></span>
</td>
<td class="nump">&#8364; 620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 75,543<span></span>
</td>
<td class="nump">&#8364; 12,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember', window );">Euro strengths by 5% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0133<span></span>
</td>
<td class="nump">1.076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (20,065)<span></span>
</td>
<td class="nump">&#8364; 30,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="num">&#8364; (1,003)<span></span>
</td>
<td class="nump">&#8364; 1,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember', window );">Euro strengths by 5% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.0133<span></span>
</td>
<td class="nump">1.076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 4,357<span></span>
</td>
<td class="nump">&#8364; 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 87,145<span></span>
</td>
<td class="nump">&#8364; 10,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember', window );">Euro weakens by 10% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1733<span></span>
</td>
<td class="nump">1.2459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (6,508)<span></span>
</td>
<td class="num">&#8364; (1,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 65,242<span></span>
</td>
<td class="nump">&#8364; 10,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember', window );">Euro weakens by 10% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1733<span></span>
</td>
<td class="nump">1.2459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (17,329)<span></span>
</td>
<td class="nump">&#8364; 26,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="nump">&#8364; 1,733<span></span>
</td>
<td class="num">&#8364; (2,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember', window );">Euro weakens by 10% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">1.1733<span></span>
</td>
<td class="nump">1.2459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (7,526)<span></span>
</td>
<td class="num">&#8364; (946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 75,261<span></span>
</td>
<td class="nump">&#8364; 9,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember', window );">Euro strengths by 10% against U.S. dollars [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">0.9599<span></span>
</td>
<td class="nump">1.0193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 7,954<span></span>
</td>
<td class="nump">&#8364; 1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 79,740<span></span>
</td>
<td class="nump">&#8364; 13,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember', window );">Euro strengths by 10% against U.S. dollars [Member] | Immatics US Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">0.9599<span></span>
</td>
<td class="nump">1.0193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="num">&#8364; (21,180)<span></span>
</td>
<td class="nump">&#8364; 32,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints', window );">OCI</a></td>
<td class="num">&#8364; (2,118)<span></span>
</td>
<td class="nump">&#8364; 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember', window );">Euro strengths by 10% against U.S. dollars [Member] | Immatics N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Conversion rate</a></td>
<td class="nump">0.9599<span></span>
</td>
<td class="nump">1.0193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 9,199<span></span>
</td>
<td class="nump">&#8364; 1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Carrying amount</a></td>
<td class="nump">&#8364; 91,986<span></span>
</td>
<td class="nump">&#8364; 11,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The measure of a potential loss exposure as a result of future market movements, based on a specified confidence interval and measurement horizon.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 41<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_41&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other comprehensive income on basis of higher lower basis points.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Profit Loss Before Tax On Basis Of Higher Lower Basis Points.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=imtx_ImmaticsNvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=imtx_ImmaticsNvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635676683584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro weakens by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro strengths by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro weakens by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro strengths by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro weakens by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember', window );">Immatics GmbH [Member] | Euro strengths by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro weakens by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro strengths by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro weakens by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro strengths by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro weakens by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember', window );">Immatics US Inc [Member] | Euro strengths by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro weakens by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro strengths by 1 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro weakens by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro strengths by 5 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro weakens by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_ImmaticsNvMember', window );">Immatics N.V. [Member] | Euro strengths by 10 against US dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems', window );"><strong>Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Decrease In Foreign Currency Risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Increase In Foreign Currency Risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy1AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy1AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy5AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy5AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroWeakensBy10AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_SensitiveAnalaysisOfCurrencyAxis=imtx_EuroStrengthsBy10AgainstUsDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=imtx_ImmaticsNvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=imtx_ImmaticsNvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635717263072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail) - Liquidity risk [member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk', window );">Financial assets held for managing liquidity risk</a></td>
<td class="nump">&#8364; 362,205<span></span>
</td>
<td class="nump">&#8364; 145,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember', window );">Cash And Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk', window );">Financial assets held for managing liquidity risk</a></td>
<td class="nump">148,519<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember', window );">Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk', window );">Financial assets held for managing liquidity risk</a></td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember', window );">Short-Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk', window );">Financial assets held for managing liquidity risk</a></td>
<td class="nump">&#8364; 154,930<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets held for managing liquidity risk (for example, financial assets that are readily saleable or expected to generate cash inflows to meet cash outflows on financial liabilities). [Refer: Liquidity risk [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B11E<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B11E&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682938528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 148,519<span></span>
</td>
<td class="nump">&#8364; 132,994<span></span>
</td>
<td class="nump">&#8364; 207,530<span></span>
</td>
<td class="nump">&#8364; 103,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Historical volatility for shares, measurement input [member] | ARYA [Member] | Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonable possible increase in unobservable inputs</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of resonably possible decrease in unobservable inputs</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities</a></td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="nump">&#8364; 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities</a></td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="nump">&#8364; 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=imtx_ForeignExchangeRatesMember', window );">Foreign Exchange Rates [Member] | ARYA [Member] | Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonable possible increase in unobservable inputs</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of resonably possible decrease in unobservable inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities</a></td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="nump">&#8364; 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 148,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile', window );">Percentage of cash and cash equivalents held in domicile</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">&#8364; 17,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="nump">&#8364; 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Euro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Decrease In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_BondsAndShortTermDeposits', window );">Bonds and short-term deposits</a></td>
<td class="nump">&#8364; 123,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | Euro [Member] | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile', window );">Percentage of cash and cash equivalents held in domicile</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk', window );">Percentage Of Reasonably Possible Increase In Foreign Currency Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_BondsAndShortTermDeposits', window );">Bonds and short-term deposits</a></td>
<td class="nump">&#8364; 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member] | US [Member] | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile', window );">Percentage of cash and cash equivalents held in domicile</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_BondsAndShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonds and short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_BondsAndShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash and cash equivalents held in domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Decrease In Foreign Currency Risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Increase In Foreign Currency Risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=imtx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=imtx_ForeignExchangeRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=imtx_ForeignExchangeRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=imtx_DeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=imtx_DeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681894592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">&#8364; 408,984<span></span>
</td>
<td class="nump">&#8364; 196,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">58,300<span></span>
</td>
<td class="nump">12,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">148,519<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember', window );">Short-Term Deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">154,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember', window );">Bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember', window );">Bonds [member] | Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember', window );">Bonds [member] | At fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">58,300<span></span>
</td>
<td class="nump">12,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Accounts receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentNonCurrentAssetsMember', window );">Other current/non-current assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">2,402<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_AccountsPayableMember', window );">Accounts payable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">11,735<span></span>
</td>
<td class="nump">11,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentLiabilitiesMember', window );">Other current liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_LiabilitiesForWarrantsMember', window );">Liabilities for warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">16,914<span></span>
</td>
<td class="nump">27,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_FinancialAssetsAndFinancialLiabilities', window );">Financial assets and Financial liabilities</a></td>
<td class="nump">14,563<span></span>
</td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">16,914<span></span>
</td>
<td class="nump">27,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category [member] | Liabilities for warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">16,914<span></span>
</td>
<td class="nump">27,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">26,352<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category [member] | Accounts payable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">11,735<span></span>
</td>
<td class="nump">11,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category [member] | Other current liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category [member] | Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Carrying amount</a></td>
<td class="nump">14,563<span></span>
</td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">365,718<span></span>
</td>
<td class="nump">146,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">148,519<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member] | Short-Term Deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">154,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member] | Bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">12,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member] | Accounts receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member] | Other current/non-current assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Carrying amount</a></td>
<td class="nump">&#8364; 2,402<span></span>
</td>
<td class="nump">&#8364; 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_FinancialAssetsAndFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets and Financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_FinancialAssetsAndFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_ShorttermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentNonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentNonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=imtx_LiabilitiesForWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=imtx_LiabilitiesForWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635678101552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems', window );"><strong>Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NetFinancialResult', window );">Net financial result</a></td>
<td class="nump">&#8364; 12,082<span></span>
</td>
<td class="num">&#8364; (7,041)<span></span>
</td>
<td class="nump">&#8364; 10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems', window );"><strong>Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NetFinancialResult', window );">Net financial result</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">5,119<span></span>
</td>
<td class="num">(8,959)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems', window );"><strong>Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NetFinancialResult', window );">Net financial result</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(884)<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems', window );"><strong>Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NetFinancialResult', window );">Net financial result</a></td>
<td class="num">(712)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems', window );"><strong>Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NetFinancialResult', window );">Net financial result</a></td>
<td class="nump">&#8364; 10,945<span></span>
</td>
<td class="num">&#8364; (10,990)<span></span>
</td>
<td class="nump">&#8364; 17,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about net result from financial instruments by measurement categories [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NetFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net financial result.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NetFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635717386608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems', window );"><strong>Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective', window );">Cash effective</a></td>
<td class="nump">&#8364; 2,843<span></span>
</td>
<td class="nump">&#8364; 2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective', window );">Non-cash effective</a></td>
<td class="nump">15,655<span></span>
</td>
<td class="num">(7,324)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=imtx_LiabilitiesForWarrantsMember', window );">Liabilities for warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems', window );"><strong>Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective', window );">Non-cash effective</a></td>
<td class="nump">10,945<span></span>
</td>
<td class="num">(10,990)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems', window );"><strong>Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective', window );">Cash effective</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective', window );">Non-cash effective</a></td>
<td class="nump">&#8364; 4,710<span></span>
</td>
<td class="nump">&#8364; 3,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Line Item].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities arising from financing activities cash effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities arising from financing activities noncash effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=imtx_LiabilitiesForWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=imtx_LiabilitiesForWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683611952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Summary of Contractual Obligations (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsLineItems', window );"><strong>Disclosure Of Contractual Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualObligationOfLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 18,566<span></span>
</td>
<td class="nump">&#8364; 10,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherLeaseObligations', window );">Other Lease Obligations</a></td>
<td class="nump">5,002<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractResearchOrganizationAgreements', window );">Contract research organization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualCashObligation', window );">Total</a></td>
<td class="nump">25,568<span></span>
</td>
<td class="nump">16,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsLineItems', window );"><strong>Disclosure Of Contractual Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualObligationOfLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,613<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherLeaseObligations', window );">Other Lease Obligations</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractResearchOrganizationAgreements', window );">Contract research organization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualCashObligation', window );">Total</a></td>
<td class="nump">4,250<span></span>
</td>
<td class="nump">4,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">1 - 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsLineItems', window );"><strong>Disclosure Of Contractual Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualObligationOfLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,045<span></span>
</td>
<td class="nump">4,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherLeaseObligations', window );">Other Lease Obligations</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractResearchOrganizationAgreements', window );">Contract research organization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualCashObligation', window );">Total</a></td>
<td class="nump">6,469<span></span>
</td>
<td class="nump">5,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">3 - 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsLineItems', window );"><strong>Disclosure Of Contractual Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualObligationOfLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,872<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherLeaseObligations', window );">Other Lease Obligations</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractResearchOrganizationAgreements', window );">Contract research organization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualCashObligation', window );">Total</a></td>
<td class="nump">5,392<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfContractualObligationsLineItems', window );"><strong>Disclosure Of Contractual Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualObligationOfLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">6,036<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_OtherLeaseObligations', window );">Other Lease Obligations</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractResearchOrganizationAgreements', window );">Contract research organization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_ContractualCashObligation', window );">Total</a></td>
<td class="nump">&#8364; 7,456<span></span>
</td>
<td class="nump">&#8364; 2,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ContractResearchOrganizationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract research organization agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ContractResearchOrganizationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ContractualCashObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual cash obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ContractualCashObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_ContractualObligationOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_ContractualObligationOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfContractualObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfContractualObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_OtherLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_OtherLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682236800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_CollaborationAgreementsMember', window );">Collaboration Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_UnrecordedContingentLiability', window );">Unrecorded contingent liability</a></td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_UnrecordedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecorded contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_UnrecordedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_CollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_CollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682818784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Summary of Compensation of Key Management Personnel (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract', window );"><strong>Disclosure Of Compensation Of Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationFixed', window );">Fixed</a></td>
<td class="nump">&#8364; 2,706<span></span>
</td>
<td class="nump">&#8364; 2,481<span></span>
</td>
<td class="nump">&#8364; 2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Variable</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation expenses</a></td>
<td class="nump">14,325<span></span>
</td>
<td class="nump">17,016<span></span>
</td>
<td class="nump">13,841<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">&#8364; 18,574<span></span>
</td>
<td class="nump">&#8364; 20,814<span></span>
</td>
<td class="nump">&#8364; 17,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensationFixed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation fixed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensationFixed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635676713488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Summary of Compensation for the Supervisory Board (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">&#8364; 379<span></span>
</td>
<td class="nump">&#8364; 348<span></span>
</td>
<td class="nump">&#8364; 282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PeterChambreMember', window );">Peter Chambre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_FriedrichVonBohlenUndHalbachMember', window );">Friedrich von Bohlen und Halbach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HaraldFstockMember', window );">Harald F.Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MichaelGAtiehMember', window );">Michael G. Atieh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PaulCarterMember', window );">Paul Carter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HeatherLMasonMember', window );">Heather L. Mason</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_AdamStoneMember', window );">Adam Stone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_NancyValenteMember', window );">Nancy Valente</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_ChristophHettichMember', window );">Christoph Hettich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_EliotForsterMember', window );">Eliot Forster</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation', window );">Supervisory board compensation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement', window );">Payment Exit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_KeyManagementPersonnelCompensations', window );">Total cash compensation</a></td>
<td class="nump">&#8364; 220<span></span>
</td>
<td class="nump">&#8364; 163<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensationPaymentExitArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation payment exit arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensationPaymentExitArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation supervisory board compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensationTravellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation travelling expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensationTravellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_KeyManagementPersonnelCompensations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_KeyManagementPersonnelCompensations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PeterChambreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PeterChambreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_FriedrichVonBohlenUndHalbachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_FriedrichVonBohlenUndHalbachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HaraldFstockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HaraldFstockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MichaelGAtiehMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MichaelGAtiehMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PaulCarterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PaulCarterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HeatherLMasonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HeatherLMasonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_AdamStoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_AdamStoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_NancyValenteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_NancyValenteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_ChristophHettichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_ChristophHettichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_EliotForsterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_EliotForsterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635682237728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Key management personnel compensation, short-term employee benefits</a></td>
<td class="nump">&#8364; 1.7<span></span>
</td>
<td class="nump">&#8364; 2.1<span></span>
</td>
<td class="nump">&#8364; 4.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635675215056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_PerformanceBasedOptionsMember', window );">Performance Based Options [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Performance- based options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">1,598,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Peter Chambre</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Peter Chambr&#233;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Adam Stone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Adam Stone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Heather L. Mason</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Heather L. Mason<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Michael G. Atieh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Michael G. Atieh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Paul Carter</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Paul Carter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Eliot Forster</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Eliot Forster<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">September 14, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 9.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Sep. 13,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Friedrich von Bohlen und Halbach</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Friedrich von Bohlen und Halbach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 17, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 12.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 17,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Nancy Valente</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Nancy Valente<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">March 22, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Mar. 22,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 17, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec. 17,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Peter Chambre</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Peter Chambr&#233;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Adam Stone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Adam Stone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Heather L. Mason</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Heather L. Mason<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Michael G. Atieh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Michael G. Atieh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Paul Carter</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Paul Carter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Eliot Forster</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Eliot Forster<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember', window );">Service Options One [Member] | Friedrich von Bohlen und Halbach</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Friedrich von Bohlen und Halbach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 9, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Peter Chambre</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Peter Chambr&#233;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Adam Stone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Adam Stone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Heather L. Mason</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Heather L. Mason<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Michael G. Atieh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Michael G. Atieh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Paul Carter</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Paul Carter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Eliot Forster</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Eliot Forster<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember', window );">Service Options Two [Member] | Friedrich von Bohlen und Halbach</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Friedrich von Bohlen und Halbach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsThreeMember', window );">Service Options Three [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 14, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsFourMember', window );">Service Options Four [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Service options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">December 13, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">388,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Dec. 13,  2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Matching Stock options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">264,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_MatchingStockOptionsMember', window );">Matching Stock Options [Member] | Peter Chambre</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Peter Chambr&#233;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Matching Stock options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">211,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ConvertedOptionsMember', window );">Converted Options [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Converted options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">30,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jul.  01,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ConvertedOptionsOneMember', window );">Converted Options One [Member] | Harpreet Singh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty', window );">Description of Transactions with related party</a></td>
<td class="text">Harpreet Singh<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement', window );">Type of option</a></td>
<td class="text">Converted options<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">June 30, 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of Options | shares</a></td>
<td class="nump">145,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike Price in USD | $ / shares</a></td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DateOfExpiryOfShareOptionsGranted', window );">Expiration date</a></td>
<td class="text">Jan.  01,  2028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the method of settlement (for example, whether in cash or equity) for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DateOfExpiryOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of expiry of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DateOfExpiryOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HarpreetSinghMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HarpreetSinghMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PeterChambreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PeterChambreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_AdamStoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_AdamStoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HeatherLMasonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_HeatherLMasonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MichaelGAtiehMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_MichaelGAtiehMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PaulCarterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_PaulCarterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_EliotForsterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_EliotForsterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_FriedrichVonBohlenUndHalbachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_FriedrichVonBohlenUndHalbachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_NancyValenteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imtx_NancyValenteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_MatchingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_MatchingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ConvertedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ConvertedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ConvertedOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ConvertedOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635675204560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of share options forfeited in share-based payment arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts payable, related party transactions | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=imtx_DirectorsAndExecutiveOfficersMember', window );">Directors and executive officers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of share options forfeited in share-based payment arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember', window );">ARYA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NumberOfConvertedStockOptionsInTheEntity', window );">Number of Converted Stock Options In The Entity</a></td>
<td class="nump">417,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_NumberOfMatchingStockOptionInTheEntity', window );">Number of matching stock option in the entity</a></td>
<td class="nump">750,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember', window );">Service Options [Member] | Immatics GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding</a></td>
<td class="nump">652,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PlanNameAxis=imtx_TwentyTwentyIncentivePlanMember', window );">Twenty Twenty Incentive Plan [Member] | Service Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule', window );">Percentage of stock vested over the period of four-year time-based vesting schedule</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_PaymentOfPayrollTaxOfTheEmployees', window );">Payment of Payroll Tax of the employees | &#8364;</a></td>
<td class="nump">&#8364; 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NumberOfConvertedStockOptionsInTheEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Converted stock options in the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NumberOfConvertedStockOptionsInTheEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_NumberOfMatchingStockOptionInTheEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of matching stock option in the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_NumberOfMatchingStockOptionInTheEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PaymentOfPayrollTaxOfTheEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Payroll Tax of the employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PaymentOfPayrollTaxOfTheEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock vested over the period of four-year time-based vesting schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=imtx_DirectorsAndExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=imtx_DirectorsAndExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=imtx_AryaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=imtx_AryaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TypeOfVestingAxis=imtx_ServiceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_PlanNameAxis=imtx_TwentyTwentyIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_PlanNameAxis=imtx_TwentyTwentyIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683302288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings and Loss per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants', window );">Dilutive effect of share options on number of warrants</a></td>
<td class="nump">7,187,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive effect of share options on number of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635683266480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss)</a></td>
<td class="nump">&#8364; 37,514<span></span>
</td>
<td class="num">&#8364; (93,335)<span></span>
</td>
<td class="num">&#8364; (211,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic</a></td>
<td class="nump">&#8364; 0.56<span></span>
</td>
<td class="num">&#8364; (1.48)<span></span>
</td>
<td class="num">&#8364; (4.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted</a></td>
<td class="nump">&#8364; 0.55<span></span>
</td>
<td class="num">&#8364; (1.48)<span></span>
</td>
<td class="num">&#8364; (4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic</a></td>
<td class="nump">67,220,824<span></span>
</td>
<td class="nump">62,912,921<span></span>
</td>
<td class="nump">48,001,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted</a></td>
<td class="nump">68,824,906<span></span>
</td>
<td class="nump">62,912,921<span></span>
</td>
<td class="nump">48,001,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139635681365936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">&#8364; 172,831<span></span>
</td>
<td class="nump">&#8364; 34,763<span></span>
</td>
<td class="nump">&#8364; 31,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_AgreementAxis=imtx_CollaborationAgreementsMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">172,831<span></span>
</td>
<td class="nump">34,763<span></span>
</td>
<td class="nump">31,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DK', window );">Denmark | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">9,617<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,228<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">126,100<span></span>
</td>
<td class="nump">13,138<span></span>
</td>
<td class="nump">11,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">United Kingdom | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems', window );"><strong>Disclosure Of Revenue From Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imtx_RevenueFromCollaborationAgreements', window );">Revenue from collaboration agreements</a></td>
<td class="nump">&#8364; 37,114<span></span>
</td>
<td class="nump">&#8364; 4,468<span></span>
</td>
<td class="nump">&#8364; 3,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_RevenueFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_RevenueFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_CollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_CollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_GenmabCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_AmgenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_AmgenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imtx_AgreementAxis=imtx_GSKCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>d400206d20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:imtx="http://imtx.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imtx-20221231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn01_26_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="P06_30_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:EventAxis">imtx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredTaxLiabilitiesRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:LeaseLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:RecognitionOfTaxLossesCarriedForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredAssetRecognisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:ShorttermDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">imtx:ForeignExchangeRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredTaxLiabilitiesDeferredExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredAssetNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredLiabilityNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis">imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanNameAxis">imtx:TwentyTwentyIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:ShorttermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis_MilestonePaymentForLicensedProductMemberIMTXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:MilestoneAxis">imtx:MilestonePaymentForLicensedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis_ThereafterMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">imtx:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:EventAxis">imtx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredTaxLiabilitiesRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:LeaseLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:RecognitionOfTaxLossesCarriedForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredAssetRecognisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:ShorttermDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">imtx:ForeignExchangeRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SchemeAxis">imtx:ShareReinvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheOneMemberIMTXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TrancheAxis">imtx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheTwoMemberIMTXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TrancheAxis">imtx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheThreeMemberIMTXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TrancheAxis">imtx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredTaxLiabilitiesDeferredExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredAssetNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AtTheMarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:InvesteeAxis">imtx:SvbSecuritiesLicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:ShorttermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">imtx:LiabilitiesForWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imtx:DeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imtx:DeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imtx:DeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">imtx:DeferredLiabilityNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis">imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:ChristophHettichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">imtx:IndefiniteTaxLossesCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">imtx:ForeignExchangeRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">imtx:CurrentlyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HaraldFstockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:ChristophHettichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">imtx:CurrentlyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CollaborationAgreementsMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentIasSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentIasThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIfrsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIfrsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIfrsNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentsToIllustrativeAccompanyingIfrsSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIasFourtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">ifrs-full:IFRS17Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIasOneIfrsPracticeStatementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIasEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIasTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIfrsSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">imtx:AmendmentToIasOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:IncomeStatementLocationAxis">imtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CollaborationAgreementAxis">imtx:CelgeneSwitzerlandLlcAndGenmabAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:NancyValenteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ConvertedOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HarpreetSinghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PeterChambreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:AdamStoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:HeatherLMasonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MichaelGAtiehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:PaulCarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:EliotForsterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:FriedrichVonBohlenUndHalbachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:NancyValenteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">imtx:NonInterestBearingLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">imtx:IndefiniteTaxLossesCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwentySixYearTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">imtx:TwentySixYearTaxLossesCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy10AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy5AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroStrengthsBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:ImmaticsNvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SensitiveAnalaysisOfCurrencyAxis">imtx:EuroWeakensBy1AgainstUsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_BottomOfRangeMemberifrsfullRangeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis">imtx:ActiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis">imtx:ActiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ManagementMembersMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:CategoryOfEmployeesAxis">imtx:ManagementMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndTenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfTwoThousandAndTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SchemeAxis">imtx:ShareReinvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SchemeAxis">imtx:ShareReinvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:ShareReinvestmentSchemeAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:SchemeAxis">imtx:ShareReinvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:ShareReinvestmentSchemeAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:DocumentInformationDocumentAxis">imtx:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:DocumentInformationDocumentAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">imtx:ForeignExchangeRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DirectorsAndExecutiveOfficersMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imtx:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AtTheMarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:InvesteeAxis">imtx:SvbSecuritiesLicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:InvesteeAxis">imtx:SvbSecuritiesLicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:InvesteeAxis">imtx:SvbSecuritiesLicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401licensegrantMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">imtx:Ima401licensegrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">imtx:Ima401clinicaltrialservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GenmabCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:AmgenCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:GSKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_PipeFinancingMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">imtx:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_MdAndersonMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imtx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_RestrictedStockAcquisitionAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:RestrictedStockAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">imtx:AryaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020_AryaMergerMemberIMTXShareListingExpenseAxis_PipeFinancingMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:ShareListingExpenseAxis">imtx:AryaMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">imtx:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanNameAxis">imtx:TwentyTwentyIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:TypeOfVestingAxis">imtx:ServiceOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">imtx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="P09_28_2021To09_28_2021_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-14</endDate>
        </period>
    </context>
    <context id="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:PlanAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P06_30_2020To06_30_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnJuneTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P06_30_2020To06_30_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:DateOfGrantAxis">imtx:GrantedOnSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P03_22_2023To03_22_2023_AuthorizationOfFinancialStatementsMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">imtx:AuthorizationOfFinancialStatementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:ImtxagreementAxis">imtx:ImtxbMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:BmsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imtx:BristolMyerSquibCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="imtx:AgreementAxis">imtx:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imtx:ImmaticsUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="P10_12_2022To10_12_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">imtx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:MatchingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">imtx:CurrentlyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrentlyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">imtx:CurrentlyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:ConvertedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imtx:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CurrentlyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">imtx:CurrentlyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:PatentAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">imtx:SoftwareLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imtx:OfficeEquipmentAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imtx:TotalEquityAttributableToShareholdersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Warrants">
        <measure>imtx:Warrants</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_EUR_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To12_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To12_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001809196</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P01_01_2022To12_31_2022">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P01_01_2022To12_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2022To12_31_2022">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2022To12_31_2022">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P01_01_2022To12_31_2022">001-39363</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">Immatics N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">Paul-Ehrlich-Stra&#xdf;e 15</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">72076</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">T&#xfc;bingen</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="P01_01_2022To12_31_2022">DE</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Edward A. Sturchio</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2130 W. Holcombe Blvd., Suite 900</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">77030</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">810-7545</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">Ordinary shares, nominal value &#x20ac;0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">IMTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_OrdinaryShareMemberdeiDocumentInformationDocumentAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">Warrants to purchase ordinary shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">IMTXW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_WarrantsMemberdeiDocumentInformationDocumentAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">76670699</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2022To12_31_2022">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2022To12_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To12_31_2022">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2022To12_31_2022">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="P01_01_2022To12_31_2022">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="P01_01_2022To12_31_2022">1275</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="P01_01_2022To12_31_2022">Stuttgart, Germany</dei:AuditorLocation>
    <dei:AuditorName contextRef="P01_01_2022To12_31_2022">PricewaterhouseCoopers GmbH Wirtschaftspr&#xfc;fungsgesellschaft</dei:AuditorName>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">172831000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">34763000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">31253000</imtx:RevenueFromCollaborationAgreements>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">106779000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">87574000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">67085000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">36124000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">33808000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">34186000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">26000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">325000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">303000</ifrs-full:OtherIncome>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">29954000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-86294000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-69715000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">10945000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-10990000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">17775000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <imtx:ShareListingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">152787000</imtx:ShareListingExpense>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">9416000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5675000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2949000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">8279000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1726000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">10063000</ifrs-full:OtherFinanceCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">12082000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-7041000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-142126000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">42036000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4522000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211284000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-557000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">0.56</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">-1.48</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">-4.4</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">0.55</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">-1.48</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">-4.4</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2464000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">3514000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-6689000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">39978000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-89821000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-218530000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">39978000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-89821000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-217973000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-557000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">148519000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">213686000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">12123000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1111000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">682000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13838000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">6408000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">377154000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">152207000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13456000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">10506000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1632000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1315000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13033000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">9982000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2545000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">636000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">30666000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">22439000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">407820000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">174646000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13056000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">11624000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:CurrentContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">64957000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">50402000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentWarrantLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">16914000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">27859000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2159000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2711000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">9366000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2552000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">106452000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">95148000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">75759000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">48225000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">12403000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">7142000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">42000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">68000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">88204000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">55435000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">767000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">714177000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">565192000</ifrs-full:SharePremium>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-500299000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-537813000</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-1481000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-3945000</ifrs-full:OtherReserves>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">213164000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">24063000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">407820000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">174646000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLoss>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4522000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">42036000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2476000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">133000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">850000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">6967000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5260000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">4424000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1038000</ifrs-full:AdjustmentsForInterestExpense>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">566000</ifrs-full:AdjustmentsForInterestExpense>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">289000</ifrs-full:AdjustmentsForInterestExpense>
    <imtx:AdjustmentsForShareListingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">152787000</imtx:AdjustmentsForShareListingExpense>
    <imtx:AdjustmentForEquitySettledSharebasedPayment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">22570000</imtx:AdjustmentForEquitySettledSharebasedPayment>
    <imtx:AdjustmentForEquitySettledSharebasedPayment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">26403000</imtx:AdjustmentForEquitySettledSharebasedPayment>
    <imtx:AdjustmentForEquitySettledSharebasedPayment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">22908000</imtx:AdjustmentForEquitySettledSharebasedPayment>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">45000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-2036000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <imtx:PaymentsForShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">4322000</imtx:PaymentsForShareBasedCompensation>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2953000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-2408000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">437000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">10945000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-10990000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">17775000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-429000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">569000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-294000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-7872000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-483000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-1600000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">45559000</imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables>
    <imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-31784000</imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables>
    <imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-23387000</imtx:AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1649000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">175000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">808000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">695000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">566000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">289000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">224000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">100131000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-84746000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-80696000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">5738000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5106000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">7420000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">216323000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">11298000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">58087000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">12695000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">24448000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">49662000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">477000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">551000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">104000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">52000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-209791000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">7493000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-15949000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">134484000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">94000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">217918000</ifrs-full:ProceedsFromIssuingShares>
    <imtx:TransactionCostsDeductedFromEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">7931000</imtx:TransactionCostsDeductedFromEquity>
    <imtx:TransactionCostsDeductedFromEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">7939000</imtx:TransactionCostsDeductedFromEquity>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2843000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2707000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2096000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">123710000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-2613000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">207883000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">14050000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-79866000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">111238000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_EUR">103353000</ifrs-full:CashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1475000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5330000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-7061000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">148519000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1164000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">190945000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-233194000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-770000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-41855000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1020000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_EUR">-40835000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-6689000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-6689000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-6689000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-211284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-211284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-557000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-211284000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-6689000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-217973000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-557000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-218530000</ifrs-full:ComprehensiveIncome>
    <imtx:IncreaseDecreaseThroughReorganizationEquity
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-833000</imtx:IncreaseDecreaseThroughReorganizationEquity>
    <imtx:IncreaseDecreaseThroughReorganizationEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">833000</imtx:IncreaseDecreaseThroughReorganizationEquity>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">7000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">501000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">508000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-508000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">104000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">89973000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">90077000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">90077000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <imtx:IncreaseThroughARYAMerger
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">180000</imtx:IncreaseThroughARYAMerger>
    <imtx:IncreaseThroughARYAMerger
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">237864000</imtx:IncreaseThroughARYAMerger>
    <imtx:IncreaseThroughARYAMerger
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">238044000</imtx:IncreaseThroughARYAMerger>
    <imtx:IncreaseThroughARYAMerger
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">238044000</imtx:IncreaseThroughARYAMerger>
    <imtx:SARConversion
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">7000</imtx:SARConversion>
    <imtx:SARConversion
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7000</imtx:SARConversion>
    <imtx:IncreasedecreaseThroughIssuanceOfEquity
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">298000</imtx:IncreasedecreaseThroughIssuanceOfEquity>
    <imtx:IncreasedecreaseThroughIssuanceOfEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">328331000</imtx:IncreasedecreaseThroughIssuanceOfEquity>
    <imtx:IncreasedecreaseThroughIssuanceOfEquity
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">328629000</imtx:IncreasedecreaseThroughIssuanceOfEquity>
    <imtx:IncreasedecreaseThroughIssuanceOfEquity
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-508000</imtx:IncreasedecreaseThroughIssuanceOfEquity>
    <imtx:IncreasedecreaseThroughIssuanceOfEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">328121000</imtx:IncreasedecreaseThroughIssuanceOfEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">22908000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">22908000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">22908000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4322000</imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled>
    <imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled
      contextRef="P01_01_2020To12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4322000</imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled>
    <imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-4322000</imtx:IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled>
    <imtx:IncreasedecreaseThroughCompensationExpense
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">45000</imtx:IncreasedecreaseThroughCompensationExpense>
    <imtx:IncreasedecreaseThroughCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">45000</imtx:IncreasedecreaseThroughCompensationExpense>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">538695000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-444478000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7459000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">87387000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">87387000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">538695000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-444478000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7459000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">87387000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">87387000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3514000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3514000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">3514000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3514000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-89821000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-89821000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">26403000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">26403000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">26403000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">94000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2021To12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">94000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">94000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">565192000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-537813000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3945000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">24063000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">24063000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">565192000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-537813000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3945000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">24063000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">24063000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2464000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2464000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2464000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2464000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">39978000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">39978000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">22570000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">22570000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">22570000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">311000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">311000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">311000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <imtx:IssueOfShareCapitalNetOfTransactionCosts
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">138000</imtx:IssueOfShareCapitalNetOfTransactionCosts>
    <imtx:IssueOfShareCapitalNetOfTransactionCosts
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">126104000</imtx:IssueOfShareCapitalNetOfTransactionCosts>
    <imtx:IssueOfShareCapitalNetOfTransactionCosts
      contextRef="P01_01_2022To12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">126242000</imtx:IssueOfShareCapitalNetOfTransactionCosts>
    <imtx:IssueOfShareCapitalNetOfTransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">126242000</imtx:IssueOfShareCapitalNetOfTransactionCosts>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">767000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">714177000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-500299000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1481000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_TotalEquityAttributableToShareholdersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_EUR">213164000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">213164000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfCompositionOfGroupExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group information &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics N.V., together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (&#x201c;Immatics&#x201d; or &#x201c;the Group&#x201d;) is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Immatics N.V., a Dutch public limited liability company, was converted on July&#160;1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became wholly-owned subsidiaries of Immatics N.V. as part of the ARYA Merger (see Note 3) on July&#160;1, 2020. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics N.V. is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 T&#xfc;bingen, Germany. Prior to July&#160;1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Immatics N.V. is the ultimate parent company of the Group. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These annual consolidated financial statements of the Group for the year ended December 31, 2022 were authorized for issue by the Board of Directors of Immatics N.V. on March 22, 2023. &lt;/div&gt; </ifrs-full:DisclosureOfCompositionOfGroupExplanatory>
    <ifrs-full:DateOfEndOfReportingPeriod2013 contextRef="P01_01_2022To12_31_2022">2022-12-31</ifrs-full:DateOfEndOfReportingPeriod2013>
    <ifrs-full:DateOfAuthorisationForIssueOfFinancialStatements2013 contextRef="P03_22_2023To03_22_2023_AuthorizationOfFinancialStatementsMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">2023-03-22</ifrs-full:DateOfAuthorisationForIssueOfFinancialStatements2013>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (&#x201c;IFRS IC&#x201d;). The consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. For technical reasons, the information provided in these financial statements may contain rounding differences of +/- one unit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc., are fully consolidated from the date upon which control was transferred to Immatics N.V. All intra-company assets and liabilities, equity, income, expenses and cash flows relating to transactions between the Group are eliminated in full upon consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;The consolidated statement of profit or loss is prepared based on the function of expense method. The financial statements were prepared in accordance with the historical cost principle and on a going concern basis. This excludes financial liabilities for warrants, which are measured at fair value. The presentation in the consolidated statement of financial position distinguishes between current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets and liabilities. Assets are classified as current if it is expected to realise to sell or consume the asset in its normal operating cycle. Liabilities are classified as current if it is due within one year. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The reporting period for Immatics N.V. and its subsidiaries corresponds with the calendar year. The reporting period 2022 began on January&#160;1, 2022 and ended on December&#160;31, 2022. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;1, 2020 and as part of the ARYA Merger, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest of MD Anderson in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V. See Note 3 for further details. The consolidated financial statements comprise the financial statements of Immatics N.V. and its wholly-owned subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Going concern &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Group&#x2019;s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;marketed any products commercially. Immatics&#x2019; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics&#x2019; cash and cash equivalents, bonds as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2019, a novel strain of coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;)&lt;/div&gt; emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; will not result in a negative impact of the Group&#x2019;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#x2019;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.3 Russian-Ukraine Conflict and macroeconomic environment &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. &lt;/div&gt; </ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <imtx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Going concern &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Group&#x2019;s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;marketed any products commercially. Immatics&#x2019; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics&#x2019; cash and cash equivalents, bonds as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</imtx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock>
    <imtx:DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2019, a novel strain of coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;)&lt;/div&gt; emerged. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. With &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; vaccines becoming more broadly available, most of our employees have returned to onsite work. However, there can be no assurance that future developments regarding the spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; will not result in a negative impact of the Group&#x2019;s ability to conduct clinical trials, including potential delays and restrictions on the Group&#x2019;s ability to recruit and retain patients and the availability of principal investigators and healthcare employees. We will continue to closely monitor the effects of the pandemic. &lt;/div&gt;</imtx:DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock>
    <imtx:DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.3 Russian-Ukraine Conflict and macroeconomic environment &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The conflict between Russia and Ukraine has resulted, and is expected to further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia or Ukraine, it does not expect that the ongoing war will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain fiscal policy changes in Germany, such as new tax legislation, economic sanctions and comparable measures. &lt;/div&gt; </imtx:DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock>
    <imtx:AryaMergerTransactionExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ARYA Merger &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;17, 2020, Immatics entered into a definitive merger agreement with ARYA Sciences Acquisition Corp. (&#x201c;ARYA&#x201d;), a special purpose acquisition company sponsored by Perceptive Advisors. The transaction closed on July&#160;1, 2020. The merger (&#x201c;ARYA Merger&#x201d;) was effectuated as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The shareholders of Immatics Biotechnologies GmbH exchanged their interest for ordinary shares in the share capital of Immatics B.V. (&#x201c;the Reorganization&#x201d;). The Reorganization is accounted for as a recapitalization, with Immatics Biotechnologies GmbH being the accounting predecessor. The Reorganization resulted in a &#x20ac;0.8&#160;million decrease in share capital and an offsetting increase in share premium. Subsequent to the Reorganization, Immatics B.V. was converted into Immatics N.V., after the share exchange of Immatics shareholders. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"&gt;As part of the Reorganization, the minority shareholder in Immatics US, Inc., MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;) exchanged its interest in Immatics US, Inc. for ordinary shares&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"&gt;in the share capital of Immatics N.V. (&#x201c;MD Anderson Share Exchange&#x201d;). This resulted in a decrease to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest of &#x20ac;0.5&#160;million, with corresponding increases to share capital and share premium. (See Note 19). &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;ARYA merged into Immatics N.V., with former ARYA shareholders receiving one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares in ARYA. The merger of ARYA constituted a transaction by Immatics N.V., which is accounted for within the scope of IFRS 2. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"&gt;As part of the transaction, former shareholders of ARYA received 17,968,750 shares of Immatics N.V. and 7,187,500 warrants (&#x201c;Immatics Warrants&#x201d;) to purchase ordinary shares of Immatics N.V. In exchange, Immatics received the net assets held by ARYA, which had a fair value of &#x20ac;90.3&#160;million upon closing of the transaction on July&#160;1, 2020. The net assets included &#x20ac;128.8&#160;million of cash and cash equivalents held in ARYA&#x2019;s trust account and current liabilities of &#x20ac;3.9&#160;million as well as the fair value of the warrants in the amount of &#x20ac;34.6&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"&gt;In accordance with IFRS 2, the difference between the fair value of the net assets contributed by ARYA and the fair value of equity instruments provided to former ARYA shareholders is treated as an expense, resulting in a &#x20ac;152.8&#160;million share listing expense classified within the financial result (See&#160;Note 15) and an increase in equity. The 7,187,500 Immatics Warrants give the holder the right, but not the obligation, to subscribe to Immatics&#x2019; shares at a fixed or determinable price for a specified period of time subject to the provision of the Warrant Agreement. Those instruments were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32. Due to an option of cashless exercise of the Immatics Warrants, which gives Immatics a choice over how the warrant is settled with a settlement alternative, that results in Immatics delivering a variable number of shares. Therefore, the Immatics Warrants are accounted for as financial liability through profit and loss. &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Immatics N.V. raised an additional net &#x20ac;90.1&#160;million in net equity proceeds through a private placement of ordinary shares with existing shareholders of Immatics, ARYA and other new investors (&#x201c; Financing&#x201d;). The PIPE Financing is treated as a capital contribution, which resulted in increases of &#x20ac;0.1&#160;million and &#x20ac;90.0&#160;million to share capital and share premium, respectively. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Both the ARYA Merger and PIPE Financing closed as of July&#160;1, 2020. Upon consummation of the transactions, Immatics N.V. became a publicly traded corporation at the Nasdaq Capital Market under the ticker IMTX. The Immatics Warrants are traded under the ticker IMTXW. Immatics incurred incremental transaction costs directly attributable to the issuance of new shares to ARYA shareholders and the PIPE Financing of &#x20ac;7.9&#160;million, which it netted against the equity proceeds as a reduction in share premium. Immatics also amended existing share-based compensation agreements held by employees of Immatics GmbH prior to the ARYA Merger (See Note 17), in addition to making additional cash and share-based payments to key management personnel (See Note 25). &lt;/div&gt;</imtx:AryaMergerTransactionExplanatory>
    <imtx:IncreaseDecreaseThroughReorganizationEquity
      contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">800000</imtx:IncreaseDecreaseThroughReorganizationEquity>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">500000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <ifrs-full:DescriptionOfHowAcquirerObtainedControlOfAcquiree contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis">one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares</ifrs-full:DescriptionOfHowAcquirerObtainedControlOfAcquiree>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="0"
      unitRef="Unit_shares">17968750</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="0"
      unitRef="Unit_Warrants">7187500</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">90300000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">128800000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">3900000</ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <imtx:FairValueOfWarrantLiabilitiesAssumedInABusinessCombination
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">34600000</imtx:FairValueOfWarrantLiabilitiesAssumedInABusinessCombination>
    <imtx:ShareListingExpense
      contextRef="P07_01_2020To07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">152800000</imtx:ShareListingExpense>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="P07_01_2020To07_01_2020_PipeFinancingMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="-5"
      unitRef="Unit_EUR">90100000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To07_01_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-5"
      unitRef="Unit_EUR">100000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To07_01_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-5"
      unitRef="Unit_EUR">90000000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To07_01_2020"
      decimals="-5"
      unitRef="Unit_EUR">7900000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Application of new and revised international financial reporting standards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Application of new standards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December&#160;31, 2021, except for the adoption of new standards and interpretations effective as of January&#160;1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;New standards and interpretations applied for the first time: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:14%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standard/interpretation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment IAS 16 &#x2013; Property, Plant and Equipment (Proceeds before Intended Use)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment IAS 37 &#x2013; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#x2013;Cost of Fulfilling a Contract)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 3 &#x2013; Business Combinations (Reference to the Conceptual Framework)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 1 &#x2013; First-time Adoption of International Financial Reporting Standards&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:14%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 9 &#x2013; Financial Instruments&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to Illustrative Examples accompanying IFRS 16&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 41 &#x2013; Agriculture&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Those amendments on standards and interpretations had no effect on the consolidated financial statements of the Group. &lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assessment of potential impact of future standards, amendments to existing standards and interpretations &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December&#160;31, 2022: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:14%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:18%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standard/interpretation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Potentially&lt;br/&gt; material&#160;effect&#160;expected&lt;br/&gt; on Immatics financial&lt;br/&gt; statements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;IFRS 17 &#x2013; Insurance Contracts&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 12 &#x2013; Income Taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment to IFRS 16 &#x2013; Leases on sale and leaseback&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment to IAS 1 &#x2013; Presentation of Financial Statements (Classification of Liabilities as Current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities with covenants)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revision of previously issued financial statements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the preparation of the unaudited interim consolidated financial statements for the three and nine months ended September&#160;30, 2022, the Group identified an error in the presentation of &#x2018;Net foreign exchange differences&#x2019; and &#x2018;Effects of exchange rate changes on cash and cash equivalents&#x2019; in the statement of cash flows. The error resulted in a presentation of effects from exchange rate changes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency denominated cash and cash equivalents in Immatics N.V. and Immatics Biotechnologies GmbH as operating cash flow instead of presentation as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; items in &#x2018;Effects of exchange rate changes on cash and cash equivalents&#x2019;. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;This error had no impact on the Company&#x2019;s consolidated statements of financial position, of profit/(loss), of comprehensive income/(loss) and of consolidated statements of changes in equity. The Company assessed the materiality of these errors on the previously issued consolidated financial statements and concluded that the errors were not material to any year presented.&#160;The impact of the revision of the previously issued financial statements is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net foreign exchange differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash provided by/(used in) operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(85,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80,697&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by investing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net increase/(decrease) in cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;111,238&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effects of exchange rate changes on cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,061&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net foreign exchange differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash provided by/(used in) operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(81,785&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by investing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,613&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,613&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net increase/(decrease) in cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(76,904&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(79,866&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effects of exchange rate changes on cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We also reclassed &#x20ac;51&#160;thousand from Provisions to Other current liabilities as of December&#160;31, 2021. &lt;/div&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;New standards and interpretations applied for the first time: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:14%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standard/interpretation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment IAS 16 &#x2013; Property, Plant and Equipment (Proceeds before Intended Use)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment IAS 37 &#x2013; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#x2013;Cost of Fulfilling a Contract)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 3 &#x2013; Business Combinations (Reference to the Conceptual Framework)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 1 &#x2013; First-time Adoption of International Financial Reporting Standards&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:14%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IFRS 9 &#x2013; Financial Instruments&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to Illustrative Examples accompanying IFRS 16&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 41 &#x2013; Agriculture&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;January 1, 2022&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis">Amendment IAS 16 &#x2013; Property, Plant and Equipment (Proceeds before Intended Use)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis">Amendment IAS 37 &#x2013; Provisions, Contingent Liabilities and Contingent Assets (onerous Contracts&#x2013;Cost of Fulfilling a Contract)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentIasThirtySevenMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis">Amendments to IFRS 3 &#x2013; Business Combinations (Reference to the Conceptual Framework)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsThreeMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis">Amendments to IFRS 1 &#x2013; First-time Adoption of International Financial Reporting Standards</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsOneMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis">Amendments to IFRS 9 &#x2013; Financial Instruments</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsNineMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis">Amendments to Illustrative Examples accompanying IFRS 16</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentsToIllustrativeAccompanyingIfrsSixteenMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis">Amendments to IAS 41 &#x2013; Agriculture</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIasFourtyOneMemberifrsfullNewIFRSsAxis">2022-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <imtx:DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December&#160;31, 2022: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:14%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:18%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standard/interpretation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Potentially&lt;br/&gt; material&#160;effect&#160;expected&lt;br/&gt; on Immatics financial&lt;br/&gt; statements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;IFRS 17 &#x2013; Insurance Contracts&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendments to IAS 12 &#x2013; Income Taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment to IFRS 16 &#x2013; Leases on sale and leaseback&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Amendment to IAS 1 &#x2013; Presentation of Financial Statements (Classification of Liabilities as Current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities with covenants)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;January 1, 2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;No&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </imtx:DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis">IFRS 17 &#x2013; Insurance Contracts</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis">2023-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis">Amendments to IAS 1, Presentation of Financial Statements, and IFRS Practice Statement 2, Making Materiality Judgements</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneIfrsPracticeStatementTwoMemberifrsfullNewIFRSsAxis">2023-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis">Definition of Accounting Estimates (Amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIasEightMemberifrsfullNewIFRSsAxis">2023-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis">Amendments to IAS 12 &#x2013; Income Taxes</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIasTwelveMemberifrsfullNewIFRSsAxis">2023-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis">Amendment to IFRS 16 &#x2013; Leases on sale and leaseback</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIfrsSixteenMemberifrsfullNewIFRSsAxis">2024-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:TitleOfNewIFRS contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis">Amendment to IAS 1 &#x2013; Presentation of Financial Statements (Classification of Liabilities as Current or Non-current and Non-current liabilities with covenants)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="P01_01_2022To12_31_2022_AmendmentToIasOneMemberifrsfullNewIFRSsAxis">2024-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
    <ifrs-full:DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate contextRef="P01_01_2022To12_31_2022">The impact of the revision of the previously issued financial statements is as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net foreign exchange differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash provided by/(used in) operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(85,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80,697&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by investing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net increase/(decrease) in cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;111,238&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effects of exchange rate changes on cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,061&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net foreign exchange differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash provided by/(used in) operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(81,785&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by investing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net cash (used in)/provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,613&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,613&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net increase/(decrease) in cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(76,904&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(79,866&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effects of exchange rate changes on cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents at end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4477000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">4914000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">437000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-85611000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">4914000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-80697000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-15949000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-15949000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207883000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207883000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">106324000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">4914000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">111238000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">103353000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2019_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">103353000</ifrs-full:CashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2147000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4914000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7061000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">554000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2962000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2408000</imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-81785000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2962000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-84747000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">7493000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">7493000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2613000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2613000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-76904000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2962000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">-79866000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">207530000</ifrs-full:CashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">2368000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021_RevisionOfPriorPeriodErrorCorrectionAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">2962000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">5330000</imtx:EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_CurrentlyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:CashAndCashEquivalents>
    <imtx:ReclassficationOfProvisionsToOtherCurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">51000</imtx:ReclassficationOfProvisionsToOtherCurrentLiabilities>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Summary of accounting policies applied by the Group for the annual reporting period ending December&#160;31, 2022 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following are the significant accounting policies applied by the Group in preparing its consolidated financial statements: &lt;/div&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#x2019;s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group&#x2019;s resources. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds), short-term deposits and bonds with an original maturity of three months or less.&lt;/div&gt;&lt;div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial recognition and measurement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. &lt;/div&gt;&lt;div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term deposits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics has short-term deposits with original maturities between three and twelve months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Bonds &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics holds bonds with an original maturity of more than three months, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Receivables &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group has receivables from collaboration agreements. Receivables must be capitalized at the point in time at which the Group has become a contractual partner and an unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, receivables are measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group&#x2019;s receivables have an expected maturity of less than 12 months. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest and other finance income and expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Interest income and expenses from financial instruments are recorded using the effective interest rate (&#x201c;EIR&#x201d;). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expenses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Profit/(Loss). As of December&#160;31, 2022 and 2021, Immatics is not a counterparty in foreign exchange forward contracts. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Impairment losses on financial assets are recognized as financial expenses. The Group recognizes an allowance for expected credit losses (ECLs) for financial assets, see Note 16. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-months&lt;/div&gt; (a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing information (credit default swap values) published by credit agencies and recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECL. &lt;/div&gt;  &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expenses when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1&#160;&#x2013;&#160;10&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 15 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;"&gt;Office equipment and installations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;2 &#x2013; 20 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&#160;&#x2013;&#160;30&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 5 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research costs are expensed as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2022, 2021 and 2020 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;laboratory costs; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;5.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;6.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities: Initial recognition and measurement &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company&#x2019;s financial liabilities include accounts payables, lease liabilities, warrant liabilities and other financial liabilities. Immatics recognized accounts payables and other current liabilities as other financial liabilities at amortized costs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. &lt;/div&gt;  &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group adopted IFRS 16 (&#x201c;Leases&#x201d;) effective January&#160;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. The Group has elected not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Under IFRS 16, leases are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset with a corresponding liability on the date at which the leased asset is available for use by the Group (lease commencement date). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;fixed payments (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-substance&lt;/div&gt; fixed payments), less any lease incentives received; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;amounts expected to be payable by the Group under residual value guarantees; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The lease term consists of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; period. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#x2019;s leases, the lessee&#x2019;s incremental borrowing rate (&#x201c;IBR&#x201d;) is used. The IBR is the rate that the individual lessee would have to pay to borrow the funds, necessary to obtain an asset of similar value to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset in a similar economic environment with similar terms, security and conditions. The Group used an IBR for each respective lease to calculate the initial lease liability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine the IBR, the Group: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;uses a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;build-up&lt;/div&gt; approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Immatics; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;makes adjustments specific to the lease, including lease term, country, currency and security. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are measured at cost comprising the following: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the amount of the initial measurement of lease liability; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;any lease payments made at or before the commencement date less any lease incentives received; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;any initial direct costs; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;restoration costs. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are generally depreciated over the shorter of the asset&#x2019;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset is depreciated over the underlying asset&#x2019;s useful life. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Payments associated with short-term leases of equipment and vehicles and all leases of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-value&lt;/div&gt; assets have a value of less than &#x20ac;5&#160;thousand. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group&#x2019;s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December&#160;31, 2022 to determine whether option extensions are reasonably certain. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue from collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place, one with Genmab A/S, Copenhagen /Denmark (&#x201c;Genmab&#x201d;) and three with Bristol-Myers-Squibb (&#x201c;BMS&#x201d;). During the year ended December&#160;31, 2022, the Group entered into new collaboration agreements with BMS. Three of the Group&#x2019;s strategic collaboration agreements are in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage and the BMS IMA401 collaboration agreement is at clinical stage. The collaboration with GlaxoSmithKline Intellectual Property Development Limited (&#x201c;GSK&#x201d;) was terminated in October 2022 and the collaboration with Amgen Inc., Thousand Oaks/CA/USA (&#x201c;Amgen&#x201d;) was terminated in October 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;identify the contract(s) with a customer; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;identify the performance obligations in the contract; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(iii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;determine the transaction price; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(iv)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(v)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;recognize revenue when (or as) the Group satisfies a performance obligation. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under the collaboration agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Identify the performance obligations in the contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-clinical&lt;/div&gt; collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-targets&lt;/div&gt; using Immatics&#x2019; proprietary technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; participation on steering committees, and preparation of data packages. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group&#x2019;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#x2019; research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group&#x2019;s XPRESIDENT technology and database of target and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-target&lt;/div&gt; data. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Clinical collaboration agreement (BMS IMA401 agreement) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of the agreement, Immatics granted to Bristol-Myers Squibb an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401. Under the Agreement, Immatics is also responsible for, and will bear the cost of, the first Phase 1 clinical trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The license contributed under the collaboration agreement represents a distinct performance obligation, because they are separately identifiable from other promises in the BMS IMA401 agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Determine the transaction price &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Upfront payment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Each of the Group&#x2019;s strategic collaboration agreements includes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment. The Group records these payments as deferred revenue, which it allocates to the combined performance obligations for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div&gt;&lt;div style="background-color:white;display: inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using direct costs and directly attributable personnel costs is considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#x2019;s collaboration partners, due to the nature of the work being performed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the Group&#x2019;s BMS IMA401 agreement, the Group determined the underlying stand-alone selling price for each performance obligation to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price requires significant judgement regarding the estimation approach of the stand-alone selling prices for the distinct performance obligations as well as significant estimates regarding the expected cost for future services, profit margins and development timelines. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reimbursement for services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are part of the transaction price and presented as revenue and not deducted from expenses. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Development and Commercial Milestones &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales-based milestones and royalty payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost to fulfill contracts &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost to obtain a contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based payment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group&#x2019;s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 17. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.11 Foreign currency &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Transactions and balances in Germany and in the USA &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements are presented in Euro, which is the parents, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Profit/(Loss) is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Transactions in foreign currencies are initially recorded by the Group&#x2019;s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Euros per U.S.&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.93756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.94888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.84495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.81493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in the principal market for the asset or liability or &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;1 &#x2014; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;2 &#x2014; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;3 &#x2014; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-assessing&lt;/div&gt; categorization (based on the lowest level input that is significant to the fair value measurement as a whole), at the end of each reporting period. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the effect of the time value of money is material, provisions are discounted using a current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate that reflects, when appropriate, the risks specific to the liability. &lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred income tax &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (&#x201c;Income Taxes&#x201d;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority. &lt;/div&gt; </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#x2019;s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group&#x2019;s resources. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds), short-term deposits and bonds with an original maturity of three months or less.&lt;/div&gt;&lt;div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial recognition and measurement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. &lt;/div&gt;&lt;div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term deposits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics has short-term deposits with original maturities between three and twelve months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Bonds &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics holds bonds with an original maturity of more than three months, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Receivables &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group has receivables from collaboration agreements. Receivables must be capitalized at the point in time at which the Group has become a contractual partner and an unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, receivables are measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group&#x2019;s receivables have an expected maturity of less than 12 months. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest and other finance income and expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Interest income and expenses from financial instruments are recorded using the effective interest rate (&#x201c;EIR&#x201d;). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expenses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Profit/(Loss). As of December&#160;31, 2022 and 2021, Immatics is not a counterparty in foreign exchange forward contracts. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Impairment losses on financial assets are recognized as financial expenses. The Group recognizes an allowance for expected credit losses (ECLs) for financial assets, see Note 16. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-months&lt;/div&gt; (a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing information (credit default swap values) published by credit agencies and recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECL. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expenses when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1&#160;&#x2013;&#160;10&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 15 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;"&gt;Office equipment and installations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;2 &#x2013; 20 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <imtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022">The estimated useful lives are generally within the following ranges: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1&#160;&#x2013;&#160;10&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 15 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;"&gt;Office equipment and installations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;2 &#x2013; 20 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</imtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P2Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&#160;&#x2013;&#160;30&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 5 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <imtx:DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&#160;&#x2013;&#160;30&#160;years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1 &#x2013; 5 years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">P30Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All research costs are expensed as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2022, 2021 and 2020 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;laboratory costs; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;5.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;6.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities: Initial recognition and measurement &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company&#x2019;s financial liabilities include accounts payables, lease liabilities, warrant liabilities and other financial liabilities. Immatics recognized accounts payables and other current liabilities as other financial liabilities at amortized costs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group adopted IFRS 16 (&#x201c;Leases&#x201d;) effective January&#160;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. The Group has elected not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Under IFRS 16, leases are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset with a corresponding liability on the date at which the leased asset is available for use by the Group (lease commencement date). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;fixed payments (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-substance&lt;/div&gt; fixed payments), less any lease incentives received; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;amounts expected to be payable by the Group under residual value guarantees; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The lease term consists of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; period. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#x2019;s leases, the lessee&#x2019;s incremental borrowing rate (&#x201c;IBR&#x201d;) is used. The IBR is the rate that the individual lessee would have to pay to borrow the funds, necessary to obtain an asset of similar value to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset in a similar economic environment with similar terms, security and conditions. The Group used an IBR for each respective lease to calculate the initial lease liability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine the IBR, the Group: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;uses a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;build-up&lt;/div&gt; approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Immatics; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;makes adjustments specific to the lease, including lease term, country, currency and security. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are measured at cost comprising the following: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the amount of the initial measurement of lease liability; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;any lease payments made at or before the commencement date less any lease incentives received; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;3.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;any initial direct costs; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;4.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;restoration costs. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are generally depreciated over the shorter of the asset&#x2019;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset is depreciated over the underlying asset&#x2019;s useful life. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Payments associated with short-term leases of equipment and vehicles and all leases of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-value&lt;/div&gt; assets have a value of less than &#x20ac;5&#160;thousand. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group&#x2019;s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December&#160;31, 2022 to determine whether option extensions are reasonably certain. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue from collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place, one with Genmab A/S, Copenhagen /Denmark (&#x201c;Genmab&#x201d;) and three with Bristol-Myers-Squibb (&#x201c;BMS&#x201d;). During the year ended December&#160;31, 2022, the Group entered into new collaboration agreements with BMS. Three of the Group&#x2019;s strategic collaboration agreements are in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage and the BMS IMA401 collaboration agreement is at clinical stage. The collaboration with GlaxoSmithKline Intellectual Property Development Limited (&#x201c;GSK&#x201d;) was terminated in October 2022 and the collaboration with Amgen Inc., Thousand Oaks/CA/USA (&#x201c;Amgen&#x201d;) was terminated in October 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;identify the contract(s) with a customer; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;identify the performance obligations in the contract; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(iii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;determine the transaction price; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(iv)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(v)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;recognize revenue when (or as) the Group satisfies a performance obligation. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under the collaboration agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Identify the performance obligations in the contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-clinical&lt;/div&gt; collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-targets&lt;/div&gt; using Immatics&#x2019; proprietary technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; participation on steering committees, and preparation of data packages. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group&#x2019;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#x2019; research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group&#x2019;s XPRESIDENT technology and database of target and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-target&lt;/div&gt; data. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Clinical collaboration agreement (BMS IMA401 agreement) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of the agreement, Immatics granted to Bristol-Myers Squibb an exclusive, worldwide, sublicensable license to develop, manufacture, and commercialize IMA401. Under the Agreement, Immatics is also responsible for, and will bear the cost of, the first Phase 1 clinical trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The license contributed under the collaboration agreement represents a distinct performance obligation, because they are separately identifiable from other promises in the BMS IMA401 agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Determine the transaction price &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Upfront payment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Each of the Group&#x2019;s strategic collaboration agreements includes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment. The Group records these payments as deferred revenue, which it allocates to the combined performance obligations for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div&gt;&lt;div style="background-color:white;display: inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using direct costs and directly attributable personnel costs is considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#x2019;s collaboration partners, due to the nature of the work being performed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the Group&#x2019;s BMS IMA401 agreement, the Group determined the underlying stand-alone selling price for each performance obligation to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price requires significant judgement regarding the estimation approach of the stand-alone selling prices for the distinct performance obligations as well as significant estimates regarding the expected cost for future services, profit margins and development timelines. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reimbursement for services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are part of the transaction price and presented as revenue and not deducted from expenses. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Development and Commercial Milestones &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales-based milestones and royalty payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost to fulfill contracts &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost to obtain a contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based payment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group&#x2019;s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 17. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.11 Foreign currency &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Transactions and balances in Germany and in the USA &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements are presented in Euro, which is the parents, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Profit/(Loss) is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Transactions in foreign currencies are initially recorded by the Group&#x2019;s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Euros per U.S.&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.93756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.94888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.84495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.81493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <imtx:DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022"> The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year-end&lt;/div&gt;&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Euros per U.S.&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.93756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.94888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.84495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.81493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022"
      decimals="5"
      unitRef="Unit_pure">0.93756</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="5"
      unitRef="Unit_pure">0.94888</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021"
      decimals="5"
      unitRef="Unit_pure">0.88292</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="5"
      unitRef="Unit_pure">0.84495</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2020"
      decimals="5"
      unitRef="Unit_pure">0.81493</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="5"
      unitRef="Unit_pure">0.87621</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in the principal market for the asset or liability or &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;1 &#x2014; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;2 &#x2014; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;3 &#x2014; Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-assessing&lt;/div&gt; categorization (based on the lowest level input that is significant to the fair value measurement as a whole), at the end of each reporting period. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the effect of the time value of money is material, provisions are discounted using a current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate that reflects, when appropriate, the risks specific to the liability. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred income tax &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (&#x201c;Income Taxes&#x201d;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant accounting judgements, estimates and assumptions &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Group&#x2019;s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. In particular, material management judgments and estimation uncertainties apply to the recognition and measurement of income taxes (incl. deferred taxes), the revenue recognition from collaboration agreements and the measurement of share-based payments. Management bases its assessment of these judgments and estimation uncertainties on past experience, estimates from experts (lawyers, tax consultants, etc.) and the results of carefully weighing up different scenarios. Actual events and developments that lie beyond the control of management may deviate considerably from the expressed developments and assumptions. For this reason, the Group examines the estimates and assumptions made on an ongoing basis. Changes in estimates are recognized in profit or loss as soon as better information is available. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expenses already recorded. Deferred tax assets are recognized for unused tax losses to the extent, that it is probable that taxable profit will be available which can be utilized against the losses. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Due to the Group&#x2019;s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group has not recognized any deferred tax assets on tax losses carried forward. Changes in the estimation of our potential to use tax losses carried forward can have a material effect on the Group`s net income. For more information, see Note 21. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue recognition from collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the collaboration agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. For the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; collaboration agreements with Genmab and BMS, the Group assessed that these promises are not capable of being distinct within the context of the contract, which results in accounting for all goods and services promised as a single performance obligation with a single measure of progress. The performance obligation is accounted for as a performance obligation, satisfied over time using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; method as the customer simultaneously receives and consumes the benefits from Immatics&#x2019; performance. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the BMS IMA401 agreement, the Group assessed that these promises were two distinct performance obligations, the granted license and the conduct of clinical trial services. Since the collaboration agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation and allocated the transaction price to the performance obligations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Group used for the performance obligation related to clinical trial services, the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. The Group decided to estimate a stand-alone selling price for the performance obligation related to the license by using the residual approach, since it is a unique license and there is no available market price for the license. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Up-front&lt;/div&gt; licensing payments are initially deferred on our Consolidated Statement of Financial Position and subsequently recognized as revenue as the performance obligations are fulfilled. Milestone payments are included in the transaction price at the amount stipulated in the respective agreement and recognized as revenue to the extent that it is highly probable that a&#160;significant reversal&#160;in the amount of cumulative revenue recognized will not occur. To date, no milestone has been included in the transaction price. Changes in this estimate can have a material effect on revenue recognized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immatics provides development and manufacturing services to customers and recognizes revenue over time using an input-based method to measure progress toward complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before the Group can use them for recognition purposes. Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which includes total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on revenue recognized. For more information, see Note 13. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management determined the value of share-based awards with the assistance of a third-party valuation specialist using certain assumptions, such as volatility, risk-free interest rate, exercise pattern and expected dividends. Changes in these estimates can have a material effect on share-based expenses recognized. For more information, see Note 17. &lt;/div&gt; </ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <imtx:DisclosureOfAccountReceivableExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts receivables &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Receivables from collaboration agreements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,111&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;682&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, and 2021, no expected credit losses were recognized. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; </imtx:DisclosureOfAccountReceivableExplanatoryTextBlock>
    <imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Receivables from collaboration agreements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,111&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;682&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock>
    <imtx:ReceivablesFromCollaborationAgreements
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1111000</imtx:ReceivablesFromCollaborationAgreements>
    <imtx:ReceivablesFromCollaborationAgreements
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">682000</imtx:ReceivablesFromCollaborationAgreements>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1111000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">682000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other current assets consist of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Value added tax receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Grant receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;On May&#160;27, 2022, Immatics US, Inc. entered into a Research collaboration and License agreement (the &#x201c;Editas agreement&#x201d;) with Editas Medicine, Inc. (&#x201c;Editas&#x201d;). The Editas agreement became effective on May&#160;27, 2022. Pursuant to the Editas agreement, the Group paid upfront a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; fee related to the Groups access to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; right to Editas CRISPR technology and intellectual property as well as for services provided by Editas. The Group will together with Editas combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. The Group determined to account for the upfront payment as prepaid research and development expenses. The prepaid expenses will be consumed over the term of the research and development activities. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses include expenses for licenses and software of &#x20ac;7.4&#160;million as of December&#160;31, 2022 and &#x20ac;0.5&#160;million as of December&#160;31, 2021 and prepaid insurance expenses of &#x20ac;1.2&#160;million as of December&#160;31, 2022 and &#x20ac;1.3&#160;million as of December&#160;31, 2021. The Group accrued &#x20ac;0.4&#160;million as of December&#160;31, 2022 and &#x20ac;0.7&#160;million as of December&#160;31, 2021 of incremental cost for the successful arrangement of the BMS collaboration signed in 2019 and the Genmab collaboration agreement. Additionally, prepaid expenses include expenses for maintenance of &#x20ac;0.7&#160;million as of December&#160;31, 2022 and &#x20ac;0.8&#160;million as of December&#160;31, 2021. The remaining amount is mainly related to prepaid expenses for contract research organizations and prepaid rent. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other assets include receivables from lease incentive, capital gains tax and prepaid deposit expenses. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets consist of the following:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,545&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;636&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses include the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion of prepayments for licensing agreements of &#x20ac;1.5&#160;million, prepaid maintenance expenses of &#x20ac;0.3&#160;million and accrued incremental cost of the BMS and Genmab collaboration agreement of &#x20ac;0.1&#160;million as of December&#160;31, 2022. Other assets include the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion for prepaid deposit expenses. &lt;/div&gt; </ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other current assets consist of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Value added tax receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Grant receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">10450000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">3781000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1031000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">915000</ifrs-full:CurrentValueAddedTaxReceivables>
    <imtx:CurrentGrantReceivable
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:CurrentGrantReceivable>
    <imtx:CurrentGrantReceivable
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">762000</imtx:CurrentGrantReceivable>
    <ifrs-full:OtherAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2357000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">950000</ifrs-full:OtherAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13838000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">6408000</ifrs-full:OtherCurrentAssets>
    <imtx:PrepaidExpensesOfLicensesAndSoftware
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">7400000</imtx:PrepaidExpensesOfLicensesAndSoftware>
    <imtx:PrepaidExpensesOfLicensesAndSoftware
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">500000</imtx:PrepaidExpensesOfLicensesAndSoftware>
    <imtx:CurrentPrepaidInsurance
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">1200000</imtx:CurrentPrepaidInsurance>
    <imtx:CurrentPrepaidInsurance
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">1300000</imtx:CurrentPrepaidInsurance>
    <imtx:CurrentIncrementalCostForCollaborationAgreement
      contextRef="P01_01_2022To12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">400000</imtx:CurrentIncrementalCostForCollaborationAgreement>
    <imtx:CurrentIncrementalCostForCollaborationAgreement
      contextRef="P01_01_2021To12_31_2021_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">700000</imtx:CurrentIncrementalCostForCollaborationAgreement>
    <imtx:CurrentPrepaidMaintenanceExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">700000</imtx:CurrentPrepaidMaintenanceExpenses>
    <imtx:CurrentPrepaidMaintenanceExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">800000</imtx:CurrentPrepaidMaintenanceExpenses>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets consist of the following:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,545&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;636&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <ifrs-full:NoncurrentPrepayments
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1906000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:NoncurrentPrepayments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">636000</ifrs-full:NoncurrentPrepayments>
    <imtx:OtherNonCurrentAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">639000</imtx:OtherNonCurrentAsset>
    <imtx:OtherNonCurrentAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:OtherNonCurrentAsset>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2545000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">636000</ifrs-full:OtherNoncurrentAssets>
    <imtx:NoncurrentPrepaymentsOfLicensingAgreement
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">1500000</imtx:NoncurrentPrepaymentsOfLicensingAgreement>
    <imtx:NonCurrentPrepaidMaintenanceExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">300000</imtx:NonCurrentPrepaidMaintenanceExpenses>
    <ifrs-full:NoncurrentPrepayments
      contextRef="PAsOn12_31_2022_CelgeneSwitzerlandLlcAndGenmabAsMemberIMTXCollaborationAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">100000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property, plant and equipment consist of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Laboratory&lt;br/&gt; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computer&lt;br/&gt; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Office&lt;br/&gt; equipment&lt;br/&gt; and&lt;br/&gt; installations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,322&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,436&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,761&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of January&#160;1,&#160;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,428&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,569&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(508&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,052&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,966&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,578&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,504&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,424&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,506&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,761&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,737&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,303&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,938&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of January&#160;1,&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,052&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,966&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(333&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,279&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,636&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,567&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,736&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Groups additions within Office equipment and installations include leasehold improvements for the research and commercial GMP manufacturing facility construction in Houston, Texas of &#x20ac;2.5&#160;million as of December&#160;31, 2022. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,502&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(890&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,129&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,574&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property, plant and equipment consist of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Laboratory&lt;br/&gt; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computer&lt;br/&gt; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Office&lt;br/&gt; equipment&lt;br/&gt; and&lt;br/&gt; installations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,322&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,436&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,761&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of January&#160;1,&#160;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,428&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,569&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(508&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,052&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,966&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,578&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,504&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,424&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,506&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,761&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,737&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,303&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,938&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of January&#160;1,&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,052&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,966&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(333&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Currency translation differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation as of December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,279&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,636&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,567&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,736&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">15968000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">3322000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3146000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">22436000</ifrs-full:PropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3487000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">1105000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">489000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">5081000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">144000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">144000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">319000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">43000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">26000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">388000</imtx:CurrencyTranslationDifferences>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">19630000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">4470000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3661000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">27761000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10476000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2428000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1665000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-14569000</ifrs-full:PropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1501000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-508000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-565000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2574000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-144000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-144000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-219000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-30000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-256000</imtx:CurrencyTranslationDifferences>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-12052000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2966000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2237000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-17255000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">7578000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">1504000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">1424000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">10506000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">19630000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">4470000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3661000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">27761000</ifrs-full:PropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3006000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">409000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">2681000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">6096000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">148000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">9000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">7000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">164000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">249000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">28000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-32000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">245000</imtx:CurrencyTranslationDifferences>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">22737000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">4898000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">6303000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">33938000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-12052000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2966000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2237000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-17255000</ifrs-full:PropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2143000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-653000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-333000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:AdditionsOtherPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3129000</imtx:AdditionsOtherPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-96000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-9000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:DisposalsOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-112000</imtx:DisposalsOfPropertyPlantAndEquipment>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-180000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-26000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4000</imtx:CurrencyTranslationDifferences>
    <imtx:CurrencyTranslationDifferences
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-210000</imtx:CurrencyTranslationDifferences>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-14279000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3636000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2567000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">20482000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">8458000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">1262000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      unitRef="Unit_EUR">3736000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13456000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-5"
      unitRef="Unit_EUR">2500000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <imtx:DisclosureOfDepreciationExpensesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,502&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(890&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,129&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,574&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfDepreciationExpensesTableTextBlock>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">2039000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">1684000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">1502000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">1090000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">890000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">600000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">3129000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2574000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2102000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Patents&lt;br/&gt; and&lt;br/&gt; licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Software&lt;br/&gt; licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,132&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;738&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,870&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,551&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;908&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,459&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(957&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(480&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(664&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,071&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;244&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,029&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;988&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(480&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(664&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(559&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(826&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,385&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;162&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Patents&lt;br/&gt; and&lt;br/&gt; licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Software&lt;br/&gt; licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,132&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;738&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,870&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,551&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;908&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,459&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(957&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(480&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(664&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,071&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;244&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,029&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;988&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(480&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(664&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(559&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(826&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,385&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,470&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;162&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">1132000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">738000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">1870000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">320000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">162000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">482000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">99000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">8000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">107000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">1551000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">908000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">2459000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-403000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-554000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-957000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-54000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-106000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-160000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-27000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-480000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-664000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1144000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">1071000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">244000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1315000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">1551000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">908000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">2459000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">405000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">73000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">478000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">73000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">7000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">80000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">2029000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">988000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">3017000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-480000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-664000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1144000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-60000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-158000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-218000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-19000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-559000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">-826000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1385000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_PatentAndLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">1470000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022_SoftwareLicensesMemberifrsfullClassesOfIntangibleAssetsAndGoodwillAxis"
      decimals="-3"
      unitRef="Unit_EUR">162000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1632000</ifrs-full:IntangibleAssetsAndGoodwill>
    <imtx:DisclosureOfAmortizationExpensesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfAmortizationExpensesTableTextBlock>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-93000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-35000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-31000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-125000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-125000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-95000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-218000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-160000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-126000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of&lt;/div&gt; use assets consist of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IT and telecommunication&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,033&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities &#x2013; current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Lease liabilities &#x2013; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,562&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,853&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Additions to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and liabilities were &#x20ac;6.7&#160;million and &#x20ac;6.7&#160;million as of December&#160;31, 2022 and 2021, respectively, including for the research and commercial GMP manufacturing facility in Houston, Texas of &#x20ac;6.2&#160;million as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Currency translation differences included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets were &#x20ac;0.1&#160;million and &#x20ac;0.3&#160;million as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Expenses related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities consist of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation charges of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros&#160;in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IT and telecommunication&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,620&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses from leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expenses relating to short-term leases and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets (included in administrative expenses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total cash payments for leases were &#x20ac;3.6&#160;million, &#x20ac;3.2&#160;million and &#x20ac;2.4&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, the Group has committed lease payments associated with lease liabilities of &#x20ac;18.6&#160;million, of which &#x20ac;3.6&#160;million will occur in the next 12 months. The remaining lease payments will occur between January&#160;1, 2024 and February&#160;28, 2033.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#x2019;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount up to &#x20ac;24.6 million until 2043 for the year ended December 31, 2022 and up to &#x20ac;10.4 million until 2043 for the year ended December 31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For commitments for future lease payments, refer to Note 24. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of&lt;/div&gt; use assets consist of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IT and telecommunication&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,033&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">12409000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">9028000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">392000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">669000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">90000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">177000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">126000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">74000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">16000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">34000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13033000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">9982000</ifrs-full:RightofuseAssets>
    <imtx:DisclosureOfLeaseLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities &#x2013; current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Lease liabilities &#x2013; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,562&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,853&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfLeaseLiabilitiesTableTextBlock>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2159000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2711000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">12403000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">7142000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">14562000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">9853000</ifrs-full:LeaseLiabilities>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">6700000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">6700000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_USsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_EUR">6200000</ifrs-full:AdditionsToRightofuseAssets>
    <imtx:TranslationDifferenceOnRightOfUseAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">100000</imtx:TranslationDifferenceOnRightOfUseAsset>
    <imtx:TranslationDifferenceOnRightOfUseAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">300000</imtx:TranslationDifferenceOnRightOfUseAsset>
    <imtx:DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Expenses related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities consist of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation charges of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros&#160;in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IT and telecommunication&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,620&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses from leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expenses relating to short-term leases and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets (included in administrative expenses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3151000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2199000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2036000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-277000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-162000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-103000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-98000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020_CommunicationAndNetworkEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-101000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-66000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-59000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-50000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-23000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-8000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-8000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-3620000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-2526000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-2195000</ifrs-full:DepreciationRightofuseAssets>
    <imtx:InterestExpenseOnLease
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-613000</imtx:InterestExpenseOnLease>
    <imtx:InterestExpenseOnLease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-288000</imtx:InterestExpenseOnLease>
    <imtx:InterestExpenseOnLease
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-260000</imtx:InterestExpenseOnLease>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-190000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-95000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-51000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:CashOutflowForLeases
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">3600000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">3200000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">2400000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-5"
      unitRef="Unit_EUR">18600000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-5"
      unitRef="Unit_EUR">3600000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">24600000</imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities>
    <imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">10400000</imtx:PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payables consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,009&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,615&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities classified within accounts payables mainly relate to outstanding invoices totaling &#x20ac;9.0&#160;million and &#x20ac;8.6&#160;million as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payables consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,009&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,615&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4025000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">3009000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <imtx:AccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">9031000</imtx:AccruedLiabilities>
    <imtx:AccruedLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">8615000</imtx:AccruedLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">13056000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">11624000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <imtx:AccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">9000000</imtx:AccruedLiabilities>
    <imtx:AccruedLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">8600000</imtx:AccruedLiabilities>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from collaboration agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of December&#160;31, 2022, the Group had four strategic collaboration agreements in place after the Amgen collaboration was terminated in 2021 and the GSK collaboration was terminated in 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As part of these collaboration arrangements, Immatics grants exclusive licensing rights or options thereto for the development and commercialization of future product candidates, developed for several targets defined in the respective collaboration agreements, in addition to research activities, including screening of highly specific molecules for reactivity with the specified targets and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-targets&lt;/div&gt; using Immatics&#x2019; proprietary technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; participation on a joint steering committee, and preparation of data packages. For the preclinical collaboration agreements, these promises represent one combined performance obligation, whereas for the clinical stage BMS IMA401 agreement, the promises represent two distinct performance obligations. Immatics reassessed the total forecasted cost as part of the Group&#x2019;s annual budget process and adjusted the total forecasted cost accordingly. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group has not recognized any royalty or milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of December&#160;31, 2022, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenues are contract liabilities within the scope of IFRS 15. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each of the Group&#x2019;s strategic collaboration agreements included a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment, meant to subsidize research activities, recognized as deferred revenue. For all collaboration agreements these upfront &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payments exceeded the Group&#x2019;s right to consideration for services performed under each collaboration agreement. Therefore, only deferred revenue net of contract assets is presented as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Genmab Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Genmab to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, Immatics and Genmab conduct joint research to combine Immatics&#x2019; XPRESIDENT and Bispecific TCR technology platforms with Genmab&#x2019;s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The two companies plan to develop immunotherapies directed against three proprietary targets. Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Genmab collaboration agreement contains a maximum of $550&#160;million of milestone payments for each licensed product resulting from the collaboration. In addition, Immatics is entitled to receive royalty payments. Royalty rates are based on aggregate net sales of a licensed product. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under the agreement, the royalty rates begin in the high single-digits, increasing to the low tens as a percentage of aggregate annual net sales of a licensed product. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment of &#x20ac;46&#160;million ($54&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using forecasted costs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized &#x20ac;9.6&#160;million, &#x20ac;6.9&#160;million and &#x20ac;11.2&#160;million of revenue associated with the upfront payment and with reimbursements for research and development costs performed, for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#x20ac;12.1&#160;million and &#x20ac;19.9&#160;million as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;BMS Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2019, Immatics Biotechnologies GmbH and BMS entered into a collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, Immatics may develop T Cell Receptor Engineered T Cell Therapy &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TCR-T)&lt;/div&gt; programs against solid tumor targets discovered with Immatics&#x2019; XPRESIDENT technology. Programs would utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#x2019; XCEPTOR TCR discovery and engineering platform. If Immatics develops programs against the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TCR-T&lt;/div&gt; targets, Immatics will be responsible for the development and validation of these programs through lead candidate stage, at which time BMS may exercise &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-in&lt;/div&gt; rights and assume sole responsibility for further worldwide development, manufacturing and commercialization of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TCR-T&lt;/div&gt; cell therapies. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Immatics would have certain early-stage &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-funding&lt;/div&gt; rights for selected &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TCR-T&lt;/div&gt; cell therapies arising from the collaboration. With respect to this collaboration agreement with BMS, Immatics may be eligible to receive up to $505&#160;million for each licensed product in option exercise payments, development, regulatory and commercial milestone payments as well as tiered royalties on net sales. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under each contract, the royalty rates begin in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digits,&lt;/div&gt; increasing to the low teen-digits as a percentage of aggregate annual net sales of a licensed product. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment of &#x20ac;68&#160;million ($75&#160;million) upon signing of the agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using forecasted costs.&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On June&#160;1, 2022, Immatics Biotechnologies GmbH entered into an Amendment to the Strategic Collaboration Agreement originally signed in 2019 (the &#x201c;amendment&#x201d;) with BMS. Pursuant to the amendment, the Group received a &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;18.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million ($&lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million) upfront&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;cash payment related to the performance obligations under the contract. Under the amendment, Immatics will undertake an additional T Cell Receptor Engineered T cell Therapy (TCR-T) program against a solid tumor target discovered with Immatics&#x2019; XPRESIDENT technology. The program will utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#x2019; XCEPTOR TCR discovery and engineering platform. The increased consideration reflects the stand-alone selling price at contract inception and the amendment contains performance obligations that are distinct from the original performance obligation under the contract. Therefore, the Group determined to account for the modification of the Allogeneic ACT agreement signed in 2019, triggered by the amendment as a separate contract.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;The Group recognized &#x20ac;&lt;/div&gt;23&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million, &#x20ac;&lt;/div&gt;13.1&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million and &#x20ac;&lt;/div&gt;11.5&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#x20ac;&lt;/div&gt;37.6&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million and &#x20ac;&lt;/div&gt;41.9&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million as of December&#160;31, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;BMS IMA401 Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On December&#160;10, 2021, Immatics Biotechnologies GmbH entered into a License, Development and Commercialization agreement (the &#x201c;BMS IMA401 agreement&#x201d;) with BMS. The BMS IMA401 agreement became effective on January&#160;26, 2022, after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on January&#160;25, 2022. Pursuant to the BMS IMA401 agreement, the Group received a&lt;/div&gt;&lt;/div&gt;&#160;&#x20ac;133&#160;million ($150 million) upfront cash payment related to the performance obligations under the contract. The Group identified the transfer of a global exclusive IMA401 license including technology transfer and the contractually agreed clinical trial services including participation in Joint Steering Committee meetings as distinct performance obligations. The Group is eligible to receive up to $770&#160;million development, regulatory and commercial milestone payments, in addition to low double-digit royalty payments on net sales of IMA401. Immatics retains the options to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-fund&lt;/div&gt; U.S. development in exchange for enhanced U.S. royalty payments and/or to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promote&lt;/div&gt; IMA401 in the US. In November 2021, Immatics filed a Clinical Trial Application (CTA) with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401. The clinical trial, which commenced in the second quarter of 2022, will enroll patients across various solid tumor types. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the BMS IMA401 agreement represent one performance obligation, combined performance obligations or multiple performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group concluded that BMS is a customer since the BMS IMA401agreement does contain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and BMS. The BMS IMA401 agreement clearly states deliverables to be delivered by the Group and BMS as mentioned below and creates enforceable rights and obligations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;The Group transferred license rights and is performing clinical trial services. While the clinical trial is a prerequisite for approval of the product, it does not modify the underlying product. The manufacturing of the product for the trial is already completed. The clinical trial will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors, but there is no modification planned as part of this. With the end of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; phase, there was no further enhancement of the products planned. We therefore concluded that BMS can benefit from each performance obligation on its own and they are separately identifiable from other promises in the BMS IMA401 agreement. The Group concluded that there were two distinct performance obligations under the BMS IMA401 agreement, the granted license and the conduct of clinical trial services. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;At inception of the BMS IMA401 agreement, the Group determined the transaction price. We evaluated inclusion of the milestones as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The contractual agreed milestone payments with BMS relate to the license. Based on that the Group concluded that no variable consideration was considered as transaction price at contract inception. At the end of each reporting period, the Group &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group is required to allocate the determined transaction price of &#x20ac;133&#160;million ($150 million) to the two separate identified performance obligations of the BMS IMA401 agreement, based on the standalone selling price of each performance obligation as the upfront payment of &#x20ac;133&#160;million ($150 million) covers the cost of clinical trial services as well as an initial payment for the license. Since the BMS IMA401 agreement consist of two performance obligations, the Group determined the underlying stand-alone selling price for each performance obligation, to allocate the transaction price to the performance obligations. The estimation of the stand-alone selling price included estimates regarding forecasted cost for future services, profit margins and development timelines. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The most reasonable estimation method for the performance obligation related to clinical trial services is the expected cost method, due to the fact that the Group is able to use expected costs including a profit margin to estimate the stand-alone selling price. On top of the forecast of expected costs, the Group added an appropriate profit margin based on average company profit margins for clinical trial services. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To estimate a stand-alone selling price for the performance obligation related to the IMA401 license, the Group concluded to use the residual approach due to the fact that the license is a unique license and there is no available market price for the license and hence no specific stand-alone selling price apart from the residual amount was identified. The Group concluded following transaction price allocation of the &#x20ac;133&#160;million ($150 million) upfront payment as of March&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.&#160;&#160;&#160;&#160;Stand-alone selling price for clinical trial services: &#x20ac;42&#160;million &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.&#160;&#160;&#160;&#160;Stand-alone selling price for the license grant: &#x20ac;91&#160;million &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group evaluated each performance obligation to determine if it can be satisfied at a point in time or over time. The control over the granted license is transferred at a point in time, after BMS obtains the rights to use the license at the effective date of the agreement. The performance obligation related to promised clinical trial services is satisfied over time. The Group transfers control of these agreed services over time and will therefore recognize revenue over time as costs are incurred using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; method. At inception of the BMS IMA401 agreement, &#x20ac;42&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For the year ended December&#160;31, 2022, &#x20ac;6.9&#160;million revenue was recognized based on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; method as well as &#x20ac;91&#160;million revenue related to the license for IMA 401. Total deferred revenue under the agreement was &#x20ac;34.8&#160;million and &#x20ac;0.0 as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Allogeneic ACT Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;1, 2022, Immatics US, Inc. entered into a License, Development and Commercialization agreement (the &#x201c;Allogeneic ACT agreement&#x201d;) with Bristol-Myer-Squibb Company (&#x201c;BMS&#x201d;). Pursuant to the Allogeneic ACT agreement, the Group received a $60&#160;million upfront cash payment plus an additional payment of $5&#160;million related to the performance obligations under the contract. Applying the foreign exchange rate of June&#160;1, 2022, the received payments represent &#x20ac;60.7&#160;million. As the contract is accounted for in the functional currency of Immatics US, Inc., &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US&#160;Dollar, the &#x20ac;&#160;amount is subject to currency fluctuations. The Group identified the transfer of an exclusive right and license with the right to grant sublicenses under the Immatics Licensed IP, technology transfer, contractually agreed research and development services including participation in Joint Steering Committee meetings and the delivery of research progress reports to BMS as a combined performance obligation. The Group is eligible to receive up to $700&#160;million development, regulatory and commercial milestone payments, in addition to tiered royalty payments of up to low double-digit percentages on net product sales. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;Under IFRS 15, the Group applied significant judgement when evaluating whether the obligations under the Allogeneic ACT agreement represent one combined performance obligation or multiple performance obligations and the determination of whether milestone payments should be included in the transaction price.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group concluded that BMS is a customer since BMS obtains through the Allogeneic ACT agreement the output of Immatics&#x2019; ordinary activities in exchange for a consideration. The Allogeneic ACT agreement clearly states the deliverables to the Group and BMS as mentioned below and creates enforceable rights and obligations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group granted to BMS exclusive access to licensed products and is performing research and development services. The research and development services performed by the Group will cover preclinical development of the initial two Bristol Myers Squibb-owned programs and is not distinct from the licensed IP, since the preclinical platform does not have a standalone value without further development. Based on the facts and circumstances, the collaboration agreement contains multiple promises, which aggregate to a combined performance obligation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At inception of the Allogeneic ACT agreement, the Group determined the transaction price. The Group evaluated inclusion of the milestones as well as potential cost reimbursements as part of the transaction price under the most-likely method. Milestone payments are included at the most likely amount in the transaction price. However, variable consideration is only included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. For the contractual agreed milestone payments with BMS, the license is predominant. Based on that the Group concludes that no variable consideration is considered as transaction price at contract inception. At the end of each reporting period, the Group &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of milestones and, if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties will only be recognized as sales occur since the license is the predominant item to which the royalty relates. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group allocated the determined total transaction price of &#x20ac;66.1&#160;million ($70.8 million) consisting of the received payments of &#x20ac;60.7&#160;million ($65 million) as well as cost reimbursements to the single combined performance obligation of the Allogeneic ACT agreement. Based on the facts mentioned above the Group determined that the combined performance obligation related to promised research and development services is satisfied over time and therefore revenue will be recognized over time as costs for the research and development services incurred using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; method. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At inception of the Allogeneic ACT agreement, &#x20ac;60.7&#160;million were initially deferred on the Groups Consolidated Statement of Financial Position. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized &#x20ac;4.9&#160;million of revenue associated with the upfront payment for the year ended December&#160;31, 2022. Total deferred revenue under the agreement was &#x20ac;56.2&#160;million and &#x20ac;0.0 as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amgen Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2016, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Amgen to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers. The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment of &#x20ac;28&#160;million ($30&#160;million) upon signing of the Amgen agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using forecasted costs.&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;The collaboration with Amgen has been discontinued in October 2021. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#x20ac;&lt;/div&gt;10.2&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million as of December&#160;31, 2021, no further revenue will be recognized from the collaboration thereafter.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;The Group recognized &#x20ac;&lt;/div&gt;10.2&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million and &#x20ac;&lt;/div&gt;4.9&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million of revenue associated with the upfront payment during the years ended December&#160;31, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#x20ac;&lt;/div&gt;0.0&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million as of December&#160;31, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;GSK &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2019, Immatics entered into a collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment of &#x20ac;45&#160;million for two initial programs upon signing of the GSK agreement. The Group classified the initial receipt of the upfront payment as deferred revenue, which recognizes into revenue as on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; basis using forecasted costs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The collaboration with GSK has been discontinued in October 2022. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of &#x20ac;36.8&#160;million as of December&#160;31, 2022, no further revenue will be recognized from the collaboration thereafter. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized &#x20ac;37.1&#160;million, &#x20ac;4.5&#160;million and &#x20ac;3.7&#160;million of revenue associated with the upfront payment for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total deferred revenue under the agreement was &#x20ac;0.0&#160;million and &#x20ac;36.8&#160;million as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from collaboration agreements were realized with the following partners: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from collaboration agreements:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="9" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genmab, Denmark&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,929&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BMS, United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amgen, United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GSK, United Kingdom&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;172,831&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,253&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue related to the collaboration agreements consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,957&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;140,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98,627&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cost to obtain a contract &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Group incurred costs from a third party, who assists in identifying collaboration partners. The Group recognizes an asset to the extent these costs are incremental and directly related to a specific contract. The Group&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;then amortizes the asset consistently with the pattern of revenue recognition for the related contracts. Total assets, net of amortization, for these capitalized costs of obtaining a contract were &#x20ac;0.5&#160;million and &#x20ac;0.9&#160;million as of December&#160;31, 2022 and 2021, respectively, which are classified in other current assets and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets. The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of &#x20ac;0.4&#160;million, &#x20ac;0.3&#160;million and &#x20ac;0.3&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;, the Group is potentially liable to pay &#x20ac;&lt;/div&gt;1.9&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;&#160;million ($&lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt; million) to a third-party upon successful completing the milestone of the first clinical lead selection in connection with Immatics&#x2019; collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <imtx:MilestonePaymentReceivable
      contextRef="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis_MilestonePaymentForLicensedProductMemberIMTXMilestoneAxis"
      decimals="-6"
      unitRef="Unit_USD">550000000</imtx:MilestonePaymentReceivable>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">46000000</imtx:UpfrontPaymentReceived>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">54000000</imtx:UpfrontPaymentReceived>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2022To12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">9600000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2021To12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">6900000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2020To12_31_2020_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">11200000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">12100000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">19900000</ifrs-full:ContractLiabilities>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</imtx:UpfrontPaymentReceived>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">75000000</imtx:UpfrontPaymentReceived>
    <imtx:UpfrontPaymentReceived
      contextRef="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">18700000</imtx:UpfrontPaymentReceived>
    <imtx:UpfrontPaymentReceived
      contextRef="P06_01_2022To06_01_2022_ImtxbMSCollaborationAgreementMemberIMTXImtxagreementAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</imtx:UpfrontPaymentReceived>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">23000000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">13100000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">11500000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">37600000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">41900000</ifrs-full:ContractLiabilities>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">133000000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</imtx:RevenueFromCollaborationAgreements>
    <imtx:MilestonePaymentReceivable
      contextRef="PAsOn01_26_2022"
      decimals="-6"
      unitRef="Unit_EUR">770000000</imtx:MilestonePaymentReceivable>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">133000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="PAsOn01_26_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">133000000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_26_2022To01_26_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</imtx:RevenueFromCollaborationAgreements>
    <imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant
      contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">133000000</imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant>
    <imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant
      contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</imtx:AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant>
    <imtx:Allocationofupfrontpaymenttowardsclinicaltrialservices
      contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">42000000</imtx:Allocationofupfrontpaymenttowardsclinicaltrialservices>
    <imtx:Allocationofupfrontpaymenttowardslicensegrant
      contextRef="PAsOn03_31_2022_BmsAgreementMemberIMTXAgreementAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">91000000</imtx:Allocationofupfrontpaymenttowardslicensegrant>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_EUR">42000000</ifrs-full:ContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401licensegrantMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-5"
      unitRef="Unit_EUR">6900000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P01_01_2022To12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_EUR">91000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-5"
      unitRef="Unit_EUR">34800000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_BmsAgreementMemberIMTXAgreementAxis_Ima401clinicaltrialservicesMemberifrsfullProductsAndServicesAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-2"
      unitRef="Unit_EUR">0</ifrs-full:ContractLiabilities>
    <imtx:UpfrontPaymentReceived
      contextRef="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">60000000</imtx:UpfrontPaymentReceived>
    <imtx:AdditionalPaymentRelatedToPerformanceObligationsReceived
      contextRef="P06_01_2022To06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">5000000</imtx:AdditionalPaymentRelatedToPerformanceObligationsReceived>
    <imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived
      contextRef="PAsOn06_30_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">60700000</imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived>
    <imtx:MilestoneRegulatoryAndRoyaltyPaymentReceived
      contextRef="PAsOn06_01_2022"
      decimals="-6"
      unitRef="Unit_EUR">700000000</imtx:MilestoneRegulatoryAndRoyaltyPaymentReceived>
    <imtx:ContractTransactionPrice
      contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">66100000</imtx:ContractTransactionPrice>
    <imtx:ContractTransactionPrice
      contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">70800000</imtx:ContractTransactionPrice>
    <imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived
      contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">60700000</imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived>
    <imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived
      contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">65000000</imtx:PerformanceObligationsCumulativeUpfrontPaymentsReceived>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="PAsOn06_01_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">60700000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <imtx:RevenueRecognizedDuringThePeriodPerformanceObligation
      contextRef="P01_01_2022To12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">4900000</imtx:RevenueRecognizedDuringThePeriodPerformanceObligation>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">56200000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_BristolMyerSquibCompanyMembersrtCounterpartyNameAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_LicenseDevelopmentAndCommercializationAgreementMemberIMTXAgreementAxis"
      decimals="-2"
      unitRef="Unit_EUR">0</ifrs-full:ContractLiabilities>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">28000000</imtx:UpfrontPaymentReceived>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</imtx:UpfrontPaymentReceived>
    <imtx:ContractLiabilitiesRecognized
      contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">10200000</imtx:ContractLiabilitiesRecognized>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">10200000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">4900000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">0</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">0</ifrs-full:ContractLiabilities>
    <imtx:UpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-6"
      unitRef="Unit_EUR">45000000</imtx:UpfrontPaymentReceived>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis_ThereafterMemberifrsfullMaturityAxis"
      decimals="-5"
      unitRef="Unit_EUR">36800000</ifrs-full:ContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2022To12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">37100000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2021To12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">4500000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="P01_01_2020To12_31_2020_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">3700000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">0</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">36800000</ifrs-full:ContractLiabilities>
    <imtx:DisclosureOfRevenueFromCollaborationAgreementsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from collaboration agreements were realized with the following partners: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from collaboration agreements:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="9" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genmab, Denmark&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,929&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BMS, United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amgen, United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GSK, United Kingdom&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;172,831&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,253&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfRevenueFromCollaborationAgreementsExplanatory>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">9617000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">6929000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020_DKifrsfullGeographicalAreasAxis_GenmabCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">11204000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">126100000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">13138000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020_BMSCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">11489000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">10228000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020_AmgenCollaborationAgreementMemberIMTXAgreementAxis_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_EUR">4865000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">37114000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">4468000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_GSKCollaborationAgreementMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">3695000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2022To12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">172831000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2021To12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">34763000</imtx:RevenueFromCollaborationAgreements>
    <imtx:RevenueFromCollaborationAgreements
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsMemberIMTXAgreementAxis"
      decimals="-3"
      unitRef="Unit_EUR">31253000</imtx:RevenueFromCollaborationAgreements>
    <imtx:DisclosureOfContractLiabilitiesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue related to the collaboration agreements consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,957&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;140,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98,627&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfContractLiabilitiesTextBlock>
    <ifrs-full:CurrentContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">64957000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">50402000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">75759000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">48225000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">140716000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">98627000</ifrs-full:ContractLiabilities>
    <ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">500000</ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers>
    <ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">900000</ifrs-full:AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers>
    <ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">400000</ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers>
    <ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">300000</ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers>
    <ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">300000</ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers>
    <imtx:PotentialMilestonePaymentPayable
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">1900000</imtx:PotentialMilestonePaymentPayable>
    <imtx:PotentialMilestonePaymentPayable
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</imtx:PotentialMilestonePaymentPayable>
    <ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax liability&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014; &#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrual for vacation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Other current liabilities are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; and are due within one year. The carrying amounts of other current liabilities represents fair values due to their short-term nature. &lt;/div&gt; </ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory>
    <imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax liability&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014; &#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrual for vacation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4298000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">3426000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1760000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">806000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">607000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">680000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <imtx:OtherCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">156000</imtx:OtherCurrent>
    <imtx:OtherCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">185000</imtx:OtherCurrent>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">9366000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2552000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:BorrowingsMaturity contextRef="P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis">one year</ifrs-full:BorrowingsMaturity>
    <imtx:ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. Share listing expense and change in fair value of warrant liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in Note 3, the ARYA Merger led to a share listing expense. Immatics issued shares with a fair value of &#x20ac;243.1&#160;million to ARYA shareholders, comprised of the fair value of Immatics shares, that were issued to ARYA shareholders of &#x20ac;13.53 per share. In exchange, Immatics received the identifiable net assets held by ARYA, which had a fair value upon closing of &#x20ac;90.3&#160;million, comprising of cash and cash equivalents held in ARYA&#x2019;s trust account partly offset by current liabilities by ARYA and financial liabilities in the amount of &#x20ac;34.4&#160;million accounted for the 7,187,500 ARYA Warrants considering a fair value of the warrants of &#x20ac;4.82 per warrant (price of ARYA Warrants at Closing of the ARYA Merger). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The excess of the fair value of the equity instruments issued over the fair value of the identified net assets contributed, represents a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; expense in accordance with IFRS 2. This &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; expense as a result of the ARYA Merger, in the amount of &#x20ac;152.8&#160;million, is recognized as share listing expense presented as part of the financial result within the Consolidated Statement of Profit/(Loss). Details of the calculation of the share listing expense are as follows: &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Euros in thousands, except share and per share data) &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; shares/warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) ARYA Ordinary Shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,968,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&#x20ac; Fair value of TopCo Shares issued to ARYA shareholders &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(a * b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(d) Outstanding ARYA Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,187,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac; Closing price of ARYA Warrants on Nasdaq as of July 1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(f) Fair value of outstanding ARYA Warrants&lt;br/&gt; (d * e)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(g) Cash and cash equivalents held in ARYA&#x2019;s trust account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(h) Current liabilities by ARYA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ARYA&#x2019;s identifiable net assets &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(g-f-h)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 2 expense on the closing date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x20ac;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;152,787&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon closing of the ARYA Merger, ARYA Warrants were converted into Immatics Warrants. The financial liabilities for the Immatics Warrants are accounted for at fair value through profit and loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of warrants decreased from &#x20ac;3.88 ($4.39) per warrant as of December&#160;31, 2021 to &#x20ac;2.35 ($2.51) per warrant as of December&#160;31, 2022. The result is a decrease in fair value of warrant liabilities of &#x20ac;10.9&#160;million ($11.5 million) for the year ended December&#160;31, 2022. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of warrants increased from &#x20ac;2.35 ($2.88) per warrant as of December&#160;31, 2020 to &#x20ac;3.88 ($4.39) per warrant as of December&#160;31, 2021. The result is an increase in fair value of warrant liabilities of &#x20ac;11.0&#160;million ($13.0 million) for the year ended December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of warrants decreased from &#x20ac;4.82 ($5.41) per share as of July&#160;1, 2020 to &#x20ac;2.35 ($2.88) per share as of December&#160;31, 2020. The result is a change in fair value of warrant liabilities of &#x20ac;17.8&#160;million ($20.3 million) for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; </imtx:ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">243100000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">13.53</ifrs-full:ParValuePerShare>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">90300000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">34400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="0"
      unitRef="Unit_Warrants">7187500</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">4.82</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:AdjustmentsForShareListingExpense
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      unitRef="Unit_EUR">152800000</imtx:AdjustmentsForShareListingExpense>
    <imtx:DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock contextRef="P01_01_2022To12_31_2022"> Details of the calculation of the share listing expense are as follows: &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Euros in thousands, except share and per share data) &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; shares/warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) ARYA Ordinary Shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,968,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&#x20ac; Fair value of TopCo Shares issued to ARYA shareholders &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(a * b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(d) Outstanding ARYA Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,187,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac; Closing price of ARYA Warrants on Nasdaq as of July 1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(f) Fair value of outstanding ARYA Warrants&lt;br/&gt; (d * e)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(g) Cash and cash equivalents held in ARYA&#x2019;s trust account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(h) Current liabilities by ARYA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ARYA&#x2019;s identifiable net assets &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(g-f-h)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#x20ac;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 2 expense on the closing date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x20ac;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;152,787&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="0"
      unitRef="Unit_shares">17968750</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">13.53</ifrs-full:ParValuePerShare>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-3"
      unitRef="Unit_EUR">243071000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="0"
      unitRef="Unit_Warrants">7187500</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">4.82</imtx:WarrantsIssuedPricePerWarrant>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-3"
      unitRef="Unit_EUR">34644000</ifrs-full:EquityInterestsOfAcquirer>
    <imtx:RestrictedCashRecognizedAsOfTheAcquisitionDate
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      unitRef="Unit_EUR">128849000</imtx:RestrictedCashRecognizedAsOfTheAcquisitionDate>
    <ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      unitRef="Unit_EUR">3921000</ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      unitRef="Unit_EUR">90284000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <imtx:AdjustmentsForShareListingExpense
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      unitRef="Unit_EUR">152787000</imtx:AdjustmentsForShareListingExpense>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">3.88</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.39</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">2.35</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.51</imtx:WarrantsIssuedPricePerWarrant>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">10900000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_USD">11500000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">2.35</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.88</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">3.88</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.39</imtx:WarrantsIssuedPricePerWarrant>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">11000000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">4.82</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn07_01_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.41</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">2.35</imtx:WarrantsIssuedPricePerWarrant>
    <imtx:WarrantsIssuedPricePerWarrant
      contextRef="PAsOn12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.88</imtx:WarrantsIssuedPricePerWarrant>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">17800000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_USD">20300000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial income and expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial income and financial expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,476&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains on other financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,416&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,675&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses on financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8,279&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,726&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income mainly results from short-term deposits as well as cash balances for the year ended December&#160;31, 2022. Interest expenses mainly results from IFRS 16 and from negative interest rates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency gains and losses mainly consist of realized and unrealized gains and losses in connection with our USD holdings of cash and cash equivalents, short-term deposits as well as bonds. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Losses on financial instruments includes expected credit losses on cash and cash equivalents and Other financial assets for the year ended December&#160;31, 2022 and losses from foreign currency forward contracts for the year ended December&#160;31, 2021. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains on other financial instruments includes an unrealized gain of &#x20ac;0.9&#160;million and a realized gain of &#x20ac;1.2&#160;million from foreign currency forward contracts for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial income and financial expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,476&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains on other financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,416&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,675&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses on financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other financial expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8,279&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,726&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2476000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">133000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">850000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">6940000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5542000</ifrs-full:NetForeignExchangeGain>
    <imtx:GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2099000</imtx:GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">9416000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">5675000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2949000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1038000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">566000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">289000</ifrs-full:InterestExpense>
    <imtx:ForeignCurrencyLossesNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">6500000</imtx:ForeignCurrencyLossesNet>
    <imtx:ForeignCurrencyLossesNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">276000</imtx:ForeignCurrencyLossesNet>
    <imtx:ForeignCurrencyLossesNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">9774000</imtx:ForeignCurrencyLossesNet>
    <imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">741000</imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured>
    <imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">884000</imtx:LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">8279000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1726000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">10063000</ifrs-full:FinanceCosts>
    <imtx:UnrealisedGainLossFromForeignCurrencyForwardContracts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">900000</imtx:UnrealisedGainLossFromForeignCurrencyForwardContracts>
    <imtx:RealisedGainLossFromForeignCurrencyForwardContracts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">1200000</imtx:RealisedGainLossFromForeignCurrencyForwardContracts>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17. Share-based payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immatics Biotechnologies GmbH previously issued share-based awards to employees under two different plans. Under the Immatics Biotechnologies GmbH Stock Appreciation Program 2010 (the &#x201c;2010 Plan&#x201d;), the Company issued stock appreciation rights (&#x201c;SARs&#x201d;), which the Group accounted for as cash-settled awards. Under the Immatics Biotechnologies 2016 Equity Incentive Plan (&#x201c;2016 Plan&#x201d;), the Company issued tandem awards, which allowed employees to exercise their awards as either a SAR or a stock option. In 2020, prior to the ARYA Merger, Immatics N.V. established the new equity incentive plan (&#x201c;2020 Equity Plan&#x201d;). As part of the ARYA Merger, the 2010 Plan and the 2016 Plan were converted and were superseded by the 2020 Equity Plan as described below. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#x2019;s 2022 stock option and incentive plan (&#x201c;2022 Equity Plan&#x201d;). The 2022 Equity Plan allows the company to grant additional options. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion of 2010 Plan and 2016 Plan in connection with ARYA Merger &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash Payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the employee award agreements, holders of vested awards under the 2010 Plan and 2016 Plan (including any awards scheduled to vest prior to 2021), agreed to receive a cash payment of $10.00 per award, less the applicable exercise price (&#x201c;Award Cash Proceeds&#x201d;). Per the terms of the employee award agreements, &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;active employees were required to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-invest&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25%-50%&lt;/div&gt; of the Award Cash Proceeds, net of taxes, with management members required to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-invest&lt;/div&gt; 50%. In total, employees elected to receive &#x20ac;8.9&#160;million in net Award Cash Proceeds before taxes, which were paid during the third quarter in 2020. These proceeds mainly covered wage tax obligations by the employees. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These cash payments represent a modification of awards previously issued under the 2010 Plan and 2016 Plan. The Group recognized &#x20ac;2.6&#160;million in operating expenses related to the modification of awards issued under the 2010 Plan and previously accounted for as a liability. The Group also recognized &#x20ac;4.3&#160;million as a reduction in share premium, associated with the modification from previously equity-settled tandem awards, which were settled in cash as part of the modification. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The share-based awards, that were received by employees as part of the conversion, consisted of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-investment&lt;/div&gt; Shares, Matching Stock Options and Converted Stock Options as described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In accordance with the employee &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-investment&lt;/div&gt; elections, employees received 733,598 shares in Immatics N.V. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;Re-investment&lt;/div&gt; Shares&#x201d;), which had a fair value of &#x20ac;8.5&#160;million based on the ARYA share price of $15.15, as of the merger on July&#160;1, 2020. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-investment&lt;/div&gt; Shares issued represented a modification of awards previously granted under the 2010 Plan and the 2016 Plan. This modification resulted in additional operating expenses of &#x20ac;4.1&#160;million. For each ordinary &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-investment&lt;/div&gt; Share received, active employees and management members also received two stock options (&#x201c;Matching Stock Options&#x201d;) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $10.00 and vested in full on July 31, 2021. The award recipient must remain employed by Immatics or one of its affiliates through the vesting date, to receive the option. The awards have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten-year&lt;/div&gt; contract life. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Matching Stock Options award agreements had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the July 1, 2020 grant date the Group assigned a fair value of $10.59. Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,406,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,554&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,348,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,348,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,406,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,413,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options granted in June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,430,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value of options granted in USD for June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January&#160;1, 2021, employees received replacement stock options (&#x201c;Converted Options&#x201d;) to acquire shares in Immatics N.V. The Converted Options have comparable terms as the previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V., are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period. The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V., and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the terms of the Converted Options award agreements, the awards had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July&#160;1, 2020. Based on the July&#160;1, 2020 grant date the Group assigned an average fair value of $13.79. The incremental average fair value of the Converted Options compared to the share-based awards under the 2010 Plan and 2016 Plan was $4.83. Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt; June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Average exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;566,311&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;525,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;594,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;566,311&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options granted in June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;632,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;594,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value of options granted in USD for June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional grants under the 2020 and 2022 Equity Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the ARYA Merger, Immatics N.V. established the 2020 Equity Plan. After closing the ARYA Merger, employees, directors and officers received 1,087,242 employee stock options under the 2020 Equity Plan with a service requirement (&#x201c;Service Options&#x201d;), to acquire shares of Immatics N.V. The service-based options will vest solely on a four-year time-based vesting schedule. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Company&#x2019;s 2022 stock option and incentive plan (&#x201c;2022 Equity Plan&#x201d;). The 2022 Equity Plan allows the company to grant additional options. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company granted Service Options, which were accounted for using the respective grant date fair value. Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options, with a weighted average fair value of $6.93, $11.22 and $9.35 for Service Option granted during the year ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,725,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,619,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,129,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,438,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,910,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,967,708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;149,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,725,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,963,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,910,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance-Based Options (&#x201c;PSUs&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, after the closing of the ARYA Merger certain executive officers and key personnel of the Group received under the 2020 Equity Plan PSUs, vesting based both on achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $1.5&#160;billion, $2&#160;billion and $3&#160;billion, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company granted PSUs on September&#160;28, 2021 which were accounted for by considering a fair value of $8.00. A Monte-Carlo simulation model has been used to measure the fair value at grant date of the PSUs. This model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#x2019;s fair value at grant date. In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt; September&#160;28,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company granted 3,644,000 PSUs on June&#160;30, 2020, which were accounted for by considering a fair value of $11.10 and granted 255,000 PSUs on September&#160;14, 2020, which were accounted for by considering a fair value of $6.41. A Monte-Carlo simulation model has been used to measure each fair value at grant date of the PSUs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award&#x2019;s fair value at grant date. In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&lt;br/&gt; 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,696,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,666,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,644,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted in 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,696,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted in 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,899,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;255,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,644,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized total employee-related share-based compensation expenses from all plans for the years ended December&#160;31, 2022, 2021 and 2020 as set out below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <imtx:CashPaymentAwardPerSharePayable
      contextRef="PAsOn12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</imtx:CashPaymentAwardPerSharePayable>
    <imtx:PercentageOfCashProceedsToBeBeReinvested
      contextRef="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_BottomOfRangeMemberifrsfullRangeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis"
      decimals="INF"
      unitRef="Unit_pure">0.25</imtx:PercentageOfCashProceedsToBeBeReinvested>
    <imtx:PercentageOfCashProceedsToBeBeReinvested
      contextRef="P01_01_2022To12_31_2022_ActiveEmployeesMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">-0.50</imtx:PercentageOfCashProceedsToBeBeReinvested>
    <imtx:PercentageOfCashProceedsToBeBeReinvested
      contextRef="P01_01_2022To12_31_2022_ManagementMembersMemberIMTXCategoryOfEmployeesAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis"
      decimals="INF"
      unitRef="Unit_pure">0.50</imtx:PercentageOfCashProceedsToBeBeReinvested>
    <ifrs-full:PaymentsToAndOnBehalfOfEmployees
      contextRef="P01_01_2022To12_31_2022_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis"
      decimals="-5"
      unitRef="Unit_EUR">8900000</ifrs-full:PaymentsToAndOnBehalfOfEmployees>
    <imtx:ExpenseFromTheModificationOfShareBasedAwards
      contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndTenPlanMemberIMTXPlanAxis"
      decimals="-5"
      unitRef="Unit_EUR">2600000</imtx:ExpenseFromTheModificationOfShareBasedAwards>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis"
      decimals="-5"
      unitRef="Unit_EUR">4300000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="0"
      unitRef="Unit_shares">733598</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="-5"
      unitRef="Unit_EUR">8500000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.15</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <imtx:ExpenseFromTheModificationOfShareBasedAwards
      contextRef="P01_01_2022To12_31_2022_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="-5"
      unitRef="Unit_EUR">4100000</imtx:ExpenseFromTheModificationOfShareBasedAwards>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <imtx:DateOfVestingOfStockOptions contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">2021-07-31</imtx:DateOfVestingOfStockOptions>
    <ifrs-full:DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">ten-year</ifrs-full:DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis">July 1, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXShareReinvestmentSchemeAxis_ModificationOfTwoThousandAndSixteenPlanMemberIMTXPlanAxis_ShareReinvestmentMemberIMTXSchemeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.59</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.15</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="1"
      unitRef="Unit_Y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="4"
      unitRef="Unit_pure">0.0029</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,406,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,554&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,348,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,348,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,406,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,413,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options granted in June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,430,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Matching Stock Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value of options granted in USD for June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">1406468</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">11910</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">46554</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1348004</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1348004</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P7Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">1422556</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">9254</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">6834</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1406468</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1413302</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2021To12_31_2021_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P8Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1430818</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">8262</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1422556</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2020To12_31_2020_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P9Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_MatchingStockOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.59</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P07_01_2020To07_01_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.79</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.83</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt; June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Average exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.47</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15.15</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="1"
      unitRef="Unit_Y">5.6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0029</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P06_30_2020To06_30_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;566,311&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;525,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;594,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;566,311&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options granted in June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;632,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;594,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value of options granted in USD for June&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.64</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">566311</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_shares">12328</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">20337</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">8465</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">525181</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">392258</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P5Y3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">594844</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.3</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_shares">18548</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">8180</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1805</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.64</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">566311</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.61</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">193727</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2021To12_31_2021_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P6Y3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2019_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_shares">632384</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">37540</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">594844</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">53856</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P7Y3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2020To12_31_2020_ConvertedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.83</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.93</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.35</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.39</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.39</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.7</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.8544</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.8218</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7883</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">6.07</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">6.11</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">6.56</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0348</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0127</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0037</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,725,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,619,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,129,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,438,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,910,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,967,708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;149,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,725,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;in&#160;USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options granted in 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,963,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,910,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service Options exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.57</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">3725619</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_Warrants">2619720</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">182832</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">16312</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">17035</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">6129160</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.33</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1438413</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2022To12_31_2022_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P8Y10M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.87</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">1910182</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnMarchTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_Warrants">1967708</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">149178</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_Warrants">3093</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.57</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3725619</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.86</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">557401</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2021To12_31_2021_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P9Y4M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2019_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.87</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis"
      decimals="0"
      unitRef="Unit_shares">1963566</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">53384</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.87</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">1910182</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2020To12_31_2020_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P9Y8M19D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <imtx:MinimumMarketCapitalization
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheOneMemberIMTXTrancheAxis"
      decimals="-8"
      unitRef="Unit_USD">1500000000</imtx:MinimumMarketCapitalization>
    <imtx:MinimumMarketCapitalization
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheTwoMemberIMTXTrancheAxis"
      decimals="-9"
      unitRef="Unit_USD">2000000000</imtx:MinimumMarketCapitalization>
    <imtx:MinimumMarketCapitalization
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheThreeMemberIMTXTrancheAxis"
      decimals="-9"
      unitRef="Unit_USD">3000000000</imtx:MinimumMarketCapitalization>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P09_28_2021To09_28_2021_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt; September&#160;28,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&lt;br/&gt; 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying share price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time period (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.92</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7716</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.75</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0149</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P09_28_2021To09_28_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P06_30_2020To06_30_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3644000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P06_30_2020To06_30_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.1</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">255000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare
      contextRef="P09_14_2020To09_14_2020_GrantedOnSeptemberTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">6.41</imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.76</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7893</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">6.98</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0066</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P12_31_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2022: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,696,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,666,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,644,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted in 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,696,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;exercise&lt;br/&gt; price in USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on January&#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs granted in 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,899,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;255,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs outstanding on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,644,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PSUs exercisable on December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining contract life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3696000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_GrantedOnSeptemberTwoThousandAndTwentyOneMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">30000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3666000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2022To12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P7Y11M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3644000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.92</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">100000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">48000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3696000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2021To12_31_2021_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P8Y11M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_GrantedOnJuneTwoThousandAndTwentyMemberIMTXDateOfGrantAxis_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3899000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">255000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">3644000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P01_01_2020To12_31_2020_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P9Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized total employee-related share-based compensation expenses from all plans for the years ended December&#160;31, 2022, 2021 and 2020 as set out below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-12925000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-15564000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-14546000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-9645000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10839000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10973000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-22570000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-26403000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-25519000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shareholders&#x2019; equity (deficit) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in Note 1 and Note 3, Immatics N.V. was founded in 2020 with a share capital of &#x20ac;0.01 after the Reorganization. On July&#160;1, 2020, upon closing of the ARYA Merger, Immatics N.V. had 62,908,617 outstanding ordinary shares with a par value of &#x20ac;0.01, resulting in a share capital of &#x20ac;629&#160;thousand. In 2020, the ARYA Merger and PIPE Financing led to an increase in share premium by &#x20ac;327.8&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group issued in 2022, 2.8&#160;million shares under the ATM agreement with SVB Securities LLC and collected a gross amount of &#x20ac;20.8&#160;million less transaction costs of &#x20ac;0.6&#160;million, resulting in an increase in share capital of &#x20ac;28&#160;thousand and share premium of &#x20ac;20.2&#160;million. On October&#160;12, 2022, the Group closed a registered direct offering, of 10,905,000 ordinary shares with a public offering price of $10.09 per ordinary share and received a gross amount of &#x20ac;113.4&#160;million less transaction costs of &#x20ac;7.3&#160;million, resulting in an increase in share capital of &#x20ac;109&#160;thousand and share premium of &#x20ac;106.1&#160;million. In addition, the Group issued shares from exercises of stock options by employees. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022 and 2021, the total number of ordinary shares of Immatics N.V. outstanding is 76,670,699 and 62,926,816 with a par value of &#x20ac;0.01, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other reserves are related to accumulated foreign currency translation amounts associated with the Group&#x2019;s US operations. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <imtx:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_EUR">0.01</imtx:StockIssuedDuringPeriodValueNewIssues>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="INF"
      unitRef="Unit_shares">62908617</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn07_01_2020_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn07_01_2020"
      decimals="-3"
      unitRef="Unit_EUR">629000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="PAsOn07_01_2020_AryaMergerMemberIMTXShareListingExpenseAxis_PipeFinancingMemberifrsfullBorrowingsByNameAxis"
      decimals="-5"
      unitRef="Unit_EUR">327800000</ifrs-full:SharePremium>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis"
      decimals="INF"
      unitRef="Unit_shares">2800000</ifrs-full:NumberOfSharesIssued>
    <imtx:GrossProceedsFromIssueOfSecurities
      contextRef="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_EUR">20800000</imtx:GrossProceedsFromIssueOfSecurities>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P01_01_2022To12_31_2022_AtTheMarketAgreementMemberIMTXAgreementAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_EUR">600000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis"
      decimals="-3"
      unitRef="Unit_EUR">28000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis_SvbSecuritiesLicMemberIMTXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_EUR">20200000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis"
      decimals="INF"
      unitRef="Unit_shares">10905000</ifrs-full:NumberOfSharesIssued>
    <imtx:ShareIssuedPricePerShare
      contextRef="PAsOn10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.09</imtx:ShareIssuedPricePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis"
      decimals="-5"
      unitRef="Unit_EUR">113400000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis"
      decimals="-5"
      unitRef="Unit_EUR">7300000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IssueOfEquity
      contextRef="P10_12_2022To10_12_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis"
      decimals="-3"
      unitRef="Unit_EUR">109000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P10_12_2022To10_12_2022_RegisteredDirectOfferingMemberifrsfullCapitalRequirementsAxis_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-5"
      unitRef="Unit_EUR">106100000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis"
      decimals="INF"
      unitRef="Unit_shares">76670699</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis"
      decimals="INF"
      unitRef="Unit_shares">62926816</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn12_31_2021_ReorganizationMemberIMTXEventAxis"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn12_31_2022_ReorganizationMemberIMTXEventAxis"
      decimals="INF"
      unitRef="Unit_EUR_per_Share">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest related to those shares in Immatics US Inc. which have been provided to The University of Texas M.D. Anderson Cancer Center, Houston/Texas/USA, (&#x201c;MD Anderson&#x201d;) based on the restricted stock acquisition agreement described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Until June&#160;30, 2020, Immatics and MD Anderson were partners in a Restricted Stock Acquisition Agreement (the &#x201c;RSAA&#x201d;). Under the terms of the RSAA, MD Anderson was entitled to additional restricted shares in Immatics US, Inc. based on performance of certain work orders between August&#160;14, 2018 and August&#160;14, 2020. MD Anderson performed services in connection with our clinical trials in our ACT platform. The RSAA was cancelled as part of the ARYA Merger (See Note 3). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;1, 2020 MD Anderson exchanged all of its 379,420 shares in Immatics US, Inc., that they acquired under the RSAA for 697,431 shares in Immatics N.V. The shares of Immatics N.V. had a fair value at the date of the exchange of $15.15 per share. Immediately prior to the exchange, the carrying amount of the existing 5.14% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in Immatics US Inc. was &#x20ac;0.5&#160;million. The exchange resulted in a decrease of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest of &#x20ac;0.5&#160;million and a corresponding increase of share capital and net increase to share premium for the issuance of shares and derecognition of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. The RSAA was also cancelled as of July&#160;1, 2020. Any future services rendered by MD Anderson will be paid in cash. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The loss allocated to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest amounted to &#x20ac;0.6&#160;million in 2020. In total, the Group recognized expenses in relation to MD Anderson&#x2019;s performance under the RSAA of &#x20ac;0.04&#160;million for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory>
    <imtx:NumberOfSharesExchangedInSubsidiaries
      contextRef="P07_01_2020To07_01_2020_MdAndersonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="0"
      unitRef="Unit_shares">379420</imtx:NumberOfSharesExchangedInSubsidiaries>
    <imtx:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P07_01_2020To07_01_2020_RestrictedStockAcquisitionAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_shares">697431</imtx:StockIssuedDuringPeriodSharesAcquisitions>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn07_01_2020_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15.15</ifrs-full:ParValuePerShare>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="P06_30_2020To06_30_2020"
      decimals="4"
      unitRef="Unit_pure">0.0514</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <imtx:StockIssuedDuringPeriodValueNewIssues
      contextRef="P06_30_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_EUR">500000</imtx:StockIssuedDuringPeriodValueNewIssues>
    <imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest
      contextRef="P06_30_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_EUR">500000</imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest>
    <imtx:LossOnNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_EUR">600000</imtx:LossOnNoncontrollingInterest>
    <imtx:IncreasedecreaseThroughCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-4"
      unitRef="Unit_EUR">40000.00</imtx:IncreasedecreaseThroughCompensationExpense>
    <imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Personnel expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Personnel expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wages and salaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Wages and salaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(42,924&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29,098&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,711&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,639&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(73,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(51,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other employee benefit expenses include employee retirement fund contributions, health insurance, and statutory social expenses. Immatics US Inc. sponsors a defined contribution retirement plan for employees in the United States. During 2022, 2021 and 2020, total Group contributions to the defined contribution plan amounted to &#x20ac;0.9&#160;million, &#x20ac;0.2&#160;million and &#x20ac;0.2&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2022, 2021 and 2020, other employee benefits also include employee health insurance costs amounting to &#x20ac;0.8&#160;million, &#x20ac;0.6&#160;million and &#x20ac;0.4&#160;million for Immatics US Inc., statutory social expenses amounting to &#x20ac;3.2&#160;million, &#x20ac;2.4&#160;million and &#x20ac;1.7&#160;million for our German operations and other miscellaneous expenses amounting to &#x20ac;0.1&#160;million, &#x20ac;0.1&#160;million and &#x20ac;0.1&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock>
    <imtx:DisclosureOfPersonnelExpenesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Personnel expenses consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wages and salaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Wages and salaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(42,924&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29,098&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,711&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,639&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(73,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(51,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfPersonnelExpenesTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-33694000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-21993000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-15277000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-9230000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7105000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-6968000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-42924000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-29098000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-22245000</ifrs-full:WagesAndSalaries>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-5662000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3550000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2624000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2049000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1536000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1015000</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-7711000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-5086000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-3639000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-12925000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-15564000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-14546000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-9645000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10839000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberIMTXIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10973000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-22570000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-26403000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-25519000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-73205000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-60587000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-51403000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">900000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">200000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">200000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <imtx:EmployeeHealthInsuranceCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">800000</imtx:EmployeeHealthInsuranceCost>
    <imtx:EmployeeHealthInsuranceCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">600000</imtx:EmployeeHealthInsuranceCost>
    <imtx:EmployeeHealthInsuranceCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">400000</imtx:EmployeeHealthInsuranceCost>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">3200000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">2400000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">1700000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherEmployeeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">100000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">100000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">100000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During the year ended December&#160;31, 2022, the Group generated a net income due to the recognition of revenue in connection with the license component of the BMS IMA401 Collaboration agreement. This &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; revenue is not accounted for under German GAAP and consequently under German tax accounting. Instead, the Group recognizes revenue for the BMS agreement over the period of the clinical trial service. The deferred tax liability arising from the temporary difference related to delayed revenue recognition under German tax accounting is offset by deferred tax assets on tax losses carried forward that were previously not capitalized due to the Groups expectation of generating taxable losses in the foreseeable future. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Group&#x2019;s German operations were subject to a statutory tax rate of 30.4% during 2022 and of 29.1% &lt;div style="null;text-indent: 0px;;display:inline;"&gt;during 2021 and 2020. The Group&#x2019;s German statutory tax rate increased by 1.3% in comparison to the previous period due to increased trade tax rates. In the U.S., the Group was subject to a corporate income tax rate of&lt;/div&gt; 21% &lt;div style="display:inline;"&gt;for the year ended December 31, 2022, 2021 and 2020.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For Immatics Biotechnologies GmbH, the Group recognized a current income tax expense of &#x20ac;4.5&#160;million for the year ended December&#160;31, 2022. The current income tax expense is calculated based on taxable income of Immatics Biotechnologies GmbH for the year ended December&#160;31, 2022. Since no deferred tax assets have been recognized as of December&#160;31, 2021, the Group took into account the tax losses carried forward that can be used to offset the taxable income generated in the year ended December&#160;31, 2022. In accordance with &#xa7;10d para 2 EStG (German income tax code),&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;% &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of an income of a given year can be offset with tax losses carried forward. Accordi&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;ngly, &lt;/div&gt;40&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;% &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the income before tax of Immatics Biotechnologies GmbH are subject to income tax. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As the profit is considered a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; profit, no deferred tax assets exceeding the deferred tax liability &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;on&lt;/div&gt;&#160;temporary differences have been recognized in respect of tax losses carried forward. The current assessment regarding the usability of deferred tax assets may change, depending on the Group&#x2019;s taxable income in future years, which could result in the recognition of deferred tax assets. The Group continued to generate losses for all other entities within the Group during the year ended December&#160;31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; as well as for all entities during the year ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation between taxes on income reflected on the Consolidated Statement of Profit/(Loss) and the expected income tax benefit, based on the Group&#x2019;s German statutory tax rate, for the years ended December&#160;31, 2022, 2021 and 2020 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit/(loss) before taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(211,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected taxes on income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Effects&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Difference in tax rates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants exempted from taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent Differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization of previously unrecorded tax losses carried forward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,067&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-recognition&#160;of&lt;/div&gt; deferred taxes on tax losses and temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,953&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxes on income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,522&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2022, permanent differences relate to share-based compensation expenses, to transaction costs directly attributable and incremental to capital raises and to the change in fair value of the financial liabilities for the warrants. For the year ended December&#160;31, 2021, permanent differences relate to share-based compensation expenses and to the change in fair value of the financial liabilities for the warrants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, the main permanent difference relates to the share listing expense of &#x20ac;153&#160;million, which does not have a corresponding taxable expense. Other permanent differences include transaction costs directly attributable and incremental to capital raises, expenses for equity-settled share-based compensation, as well as the change in fair value of the financial liabilities for the warrants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and deferred tax liabilities consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,288&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(947&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Deferred expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Recognition of tax losses carried forward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Recognized&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,319&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27,319&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,927&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,629&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Netting&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Non-recognition&lt;/div&gt; of deferred tax assets on temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Net deferred tax assets/liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2022, and 2021, the Group had accumulated tax losses of &#x20ac;357.2&#160;million and &#x20ac;353.1&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, that may be offset against future taxable profits of the Group subject to certain limitations. For &#x20ac;319.4 million and &#x20ac;353.1 million of the accumulated tax losses no deferred tax asset has been recognised in the financial statements. For the year ended December 31, 2022,&lt;/div&gt; &#x20ac;26&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of total tax losses is subject to a twenty-year carry forward period. All other tax losses have an indefinite carry forward period.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Limitation on tax loss carry forwards in the US Inc. is 80.00% of each subsequent year`s net income starting with losses generated after January&#160;1, 2018. These have an indefinite carry forward period, but no carry back option. Any losses generated prior to January&#160;1, 2018 still can be utilized at 100.00% and are subject to a twenty-year carry forward expiration period. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section&#160;382 of the U.S. Internal Revenue Code. For Immatics Biotechnologies GmbH, we believe that the ARYA Merger did not lead to a forfeiture of tax losses carried forward in accordance with &#xa7; 8c KStG. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.304</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.291</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.291</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.013</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <imtx:CorporateIncomeTaxRate
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.21</imtx:CorporateIncomeTaxRate>
    <imtx:CorporateIncomeTaxRate
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.21</imtx:CorporateIncomeTaxRate>
    <imtx:CorporateIncomeTaxRate
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.21</imtx:CorporateIncomeTaxRate>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-5"
      unitRef="Unit_EUR">4500000</ifrs-full:CurrentTaxExpenseIncome>
    <imtx:PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward
      contextRef="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</imtx:PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward>
    <imtx:PercentageOfPretaxIncomeSubjectToIncomeTax
      contextRef="P01_01_2022To12_31_2022_DEsrtStatementGeographicalAxis_ImmaticsBiotechnologiesGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</imtx:PercentageOfPretaxIncomeSubjectToIncomeTax>
    <imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation between taxes on income reflected on the Consolidated Statement of Profit/(Loss) and the expected income tax benefit, based on the Group&#x2019;s German statutory tax rate, for the years ended December&#160;31, 2022, 2021 and 2020 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit/(loss) before taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(211,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected taxes on income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Effects&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Difference in tax rates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants exempted from taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent Differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization of previously unrecorded tax losses carried forward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,067&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-recognition&#160;of&lt;/div&gt; deferred taxes on tax losses and temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,953&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxes on income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,522&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">42036000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-12774000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">27160000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">61646000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4868000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">3274000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2582000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">53000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">599000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes>
    <imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes>
    <imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">45000</imtx:TaxEffectOfGovernmentGrantsExemptedFromTaxes>
    <imtx:TaxEffectOfPermanentDifferences
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">-1123000</imtx:TaxEffectOfPermanentDifferences>
    <imtx:TaxEffectOfPermanentDifferences
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-10881000</imtx:TaxEffectOfPermanentDifferences>
    <imtx:TaxEffectOfPermanentDifferences
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-39288000</imtx:TaxEffectOfPermanentDifferences>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">7067000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">7176000</imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
    <imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-12953000</imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
    <imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-19222000</imtx:NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">4522000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <imtx:EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_EUR">153000000</imtx:EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense>
    <imtx:DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and deferred tax liabilities consist of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deferred&lt;br/&gt;tax&lt;br/&gt;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,288&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(947&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Deferred expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Recognition of tax losses carried forward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Recognized&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,319&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27,319&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,927&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,629&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Netting&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Non-recognition&lt;/div&gt; of deferred tax assets on temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Net deferred tax assets/liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">10328000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1288000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_IntangibleAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3239000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesRightOfUseAssetMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2629000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">23133000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_DeferredRevenueMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1964000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">947000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_OtherAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3560000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2627000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_LeaseLiabilityMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">12000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_DeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11467000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_RecognitionOfTaxLossesCarriedForwardMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">27319000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">27319000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021_DeferredAssetRecognisedMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3927000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_DeferredTaxLiabilitiesDeferredExpensesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2629000</ifrs-full:DeferredTaxLiabilities>
    <imtx:DeferredTaxAssetsOffset
      contextRef="PAsOn12_31_2022_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-27319000</imtx:DeferredTaxAssetsOffset>
    <imtx:DeferredTaxLiabilitiesOffSet
      contextRef="PAsOn12_31_2022_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">27319000</imtx:DeferredTaxLiabilitiesOffSet>
    <imtx:DeferredTaxAssetsOffset
      contextRef="PAsOn12_31_2021_DeferredAssetNettingMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2629000</imtx:DeferredTaxAssetsOffset>
    <imtx:DeferredTaxLiabilitiesOffSet
      contextRef="PAsOn12_31_2021_DeferredLiabilityNettingMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2629000</imtx:DeferredTaxLiabilitiesOffSet>
    <imtx:DeferredTaxAssetsOnTemporaryDifferences
      contextRef="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:DeferredTaxAssetsOnTemporaryDifferences>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <imtx:DeferredTaxAssetsOnTemporaryDifferences
      contextRef="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1298000</imtx:DeferredTaxAssetsOnTemporaryDifferences>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="P01_01_2022To12_31_2022_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-5"
      unitRef="Unit_EUR">357200000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="P01_01_2021To12_31_2021_IndefiniteTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-5"
      unitRef="Unit_EUR">353100000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">319400000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">353100000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="P01_01_2022To12_31_2022_TwentySixYearTaxLossesCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_EUR">26000000</ifrs-full:TaxEffectOfTaxLosses>
    <imtx:PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.80</imtx:PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod>
    <imtx:PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod
      contextRef="PAsOn12_31_2017"
      decimals="4"
      unitRef="Unit_pure">1</imtx:PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Risk Management Objectives and Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s principal financial instruments comprise cash and cash equivalents, short-term deposits, accounts receivables and bonds. The main purpose of these financial instruments is to invest the proceeds of capital contributions and upfront payments from collaboration agreements. The Group has various other financial instruments such as other receivables and trade accounts payables, which arise directly from its operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The main risks arising from the Group&#x2019;s financial instruments are market risk and liquidity risk. The Board of Management reviews and agrees on policies for managing these risks as summarized below. The Group also monitors the market price risk arising from all financial instruments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest rate risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exposure of the Group to changes in interest rates relates to investments in deposits, bonds and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Regarding the liabilities shown in the Consolidated Statement of Financial Position, the Group is currently not subject to interest rate risks. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Group to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents, accounts receivables, short-term deposits and bonds. The Group&#x2019;s cash and cash equivalents, bonds and short-term deposits are denominated in Euros and US Dollars and maintained with three high-quality financial institutions in Germany and two in the United States. The Group&#x2019;s accounts receivables are denominated in Euros. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The maximum default risk is &#x20ac;363&#160;million and &#x20ac;146&#160;million as of December&#160;31, 2022 and 2021, respectively. These amounts consist of &#x20ac;149&#160;million and &#x20ac;133&#160;million cash and cash equivalents, &#x20ac;1.0&#160;million and &#x20ac;0.7&#160;million accounts receivables as well as &#x20ac;213&#160;million and &#x20ac;12&#160;million Other financial assets as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The cash and cash equivalents are held with banks, which are rated BBB+ to Aa3 by S&amp;amp;P and Moody`s. Short-term deposits are with banks, which are rated Aa3 and A1 by the rating agency Moody`s. Bond investments are with banks, which are rated AAA and AA by Moody`s. The Group continually monitors its positions with, and the credit quality of, the financial institutions and corporation, which are counterparts to its financial instruments and does not anticipate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-performance.&lt;/div&gt; The Group monitors the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from equity measures&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. The business transactions of the Group are generally conducted in Euros and U.S. dollars. The Group aims to match EUR cash inflows with EUR cash outflows and U.S. dollar cash inflows with U.S.&#160;Dollar cash outflows where possible. The objective of currency risk management is to identify, manage and control currency risk exposures within acceptable parameters. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s cash and cash equivalents were&lt;/div&gt;&#160;&#x20ac;148.5&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as of December 31, 2022. Approximately&lt;/div&gt; 87% &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Group&#x2019;s cash and cash equivalents were held in Germany, of which approximately&lt;/div&gt; 49% &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;were denominated in Euros and&lt;/div&gt; 51% &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;were denominated in U.S. Dollars. The remainder of the Group&#x2019;s cash and cash equivalents were held in the United States and denominated in U.S. Dollars. Additionally, the Group held bonds and short-term deposits classified as Other financial assets denominated in Euros in the amount of&lt;/div&gt; &#x20ac;123.3&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and U.S. Dollars in the amount of&lt;/div&gt; &#x20ac;87.0 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as of December 31, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized significant foreign exchange income and losses in 2022, as Immatics N.V.`s and Immatics GmbH&#xb4;s functional currency is Euro, due to significant holdings of U.S. dollar amounts. The Group recognized significant foreign exchange income in 2021 and in 2020 significant foreign exchange losses. Cash and cash equivalents and Other financial assets balances denominated in U.S. dollars held by entities with functional currency of EUR are as follows: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and financial assets Immatics N.V. held in USD &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets exposed to the risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82,788&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,410&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and financial assets Immatics GmbH held in USD &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets exposed to the risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,588&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,787&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2022, if the euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s profit would have been &#x20ac;14&#160;million lower/&#x20ac;17&#160;million higher, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics N.V.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;836&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics GmbH: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(709&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;79,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2021, if the euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s loss would have been &#x20ac;2&#160;million higher/&#x20ac;2.5&#160;million lower, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics N.V.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,915&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics GmbH: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The wholly-owned subsidiary Immatics US, Inc. is located in the United States and has US Dollars as its functional currency. Therefore, the Group is subject to currency fluctuations that would &lt;div style="display:inline;"&gt;a&lt;/div&gt;ffect the other comprehensive income and equity of the Group. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics US Inc. for 2022: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OCI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,065&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics US Inc. for 2021: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OCI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,791&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group continuously monitors its risk to a shortage of funds. The Group&#x2019;s objective is to maintain a balance between continuity of funding and flexibility through the use of capital raises. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, and 2021, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132,994&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;154,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total funds available&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;362,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;145,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market risk and currency risk of warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s activities expose it to the financial risks of changes in price of the warrants. As the warrants are recognized at fair value through profit and loss on the consolidated statement of financial position of the Group, the Group&#x2019;s exposure to market risks results from the volatility of the warrants price. The Warrants are publicly traded at the Nasdaq Stock Exchange. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of &#x20ac;1.7&#160;million with a corresponding effect in the equity as of December&#160;31, 2022. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of &#x20ac;2.8&#160;million with a corresponding effect in the equity as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The warrants are traded in U.S.&#160;Dollar while the functional currency of Immatics N.V. is Euro. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of &#x20ac;1.5&#160;million /(&#x20ac;1.9&#160;million) with a corresponding effect in the equity as of December&#160;31, 2022. A reasonably increase (decrease) in the U.S.&#160;Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of &#x20ac;2.5&#160;million /(&#x20ac;3.1&#160;million) with a corresponding effect in the equity as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The risks associated with our warrants result in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; financial statement effects and have no impact on the Company&#x2019;s cash position, operating expenses or cash flows. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s capital management objectives are designed primarily to finance our growth strategy. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group reviews the total amount of cash on a regular basis. As part of this review, the Group considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year. In general, the aim is to maximize the financial resources available for further research and development projects. The Group is not subject to externally imposed capital requirements. The Group&#x2019;s capital management objectives were achieved in the reporting year.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">363000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">146000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">149000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">133000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">1000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">700000</ifrs-full:TradeReceivables>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">213000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">12000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-5"
      unitRef="Unit_EUR">148500000</ifrs-full:CashAndCashEquivalents>
    <imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.87</imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile>
    <imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.49</imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile>
    <imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DeMemberifrsfullGeographicalAreasAxis_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.51</imtx:PercentageOfCashAndCashEquivalentsHeldInDomicile>
    <imtx:BondsAndShortTermDeposits
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis"
      decimals="-5"
      unitRef="Unit_EUR">123300000</imtx:BondsAndShortTermDeposits>
    <imtx:BondsAndShortTermDeposits
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="-5"
      unitRef="Unit_EUR">87000000</imtx:BondsAndShortTermDeposits>
    <imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and financial assets Immatics N.V. held in USD &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets exposed to the risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82,788&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,410&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion rate EUR/USD as of December&#160;31, 2022: 1/1.06660 &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and financial assets Immatics GmbH held in USD &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets exposed to the risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,588&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,787&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">31350000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">10410000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">51438000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:FinancialAssets>
    <imtx:MaximumExposedToCurrencyRisk
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">82788000</imtx:MaximumExposedToCurrencyRisk>
    <imtx:MaximumExposedToCurrencyRisk
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">10410000</imtx:MaximumExposedToCurrencyRisk>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">34225000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11787000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">37363000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:FinancialAssets>
    <imtx:MaximumExposedToCurrencyRisk
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">71588000</imtx:MaximumExposedToCurrencyRisk>
    <imtx:MaximumExposedToCurrencyRisk
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11787000</imtx:MaximumExposedToCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">14000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_EUR">17000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics N.V.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;836&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics GmbH: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(709&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;79,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics N.V.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,915&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics GmbH: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics US Inc. for 2022: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OCI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,065&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sensitivity analysis Immatics US Inc. for 2021: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;br/&gt; rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OCI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 1% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.1892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 5% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0760&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,791&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro weakens by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euro strengths by 10% against U.S. dollars&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.0193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.0773</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-820000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">81968000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.0559</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">836000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">83624000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.1199</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3942000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">78845000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.0133</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">4357000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">87145000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.1733</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-7526000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">75261000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">0.9599</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">9199000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">91986000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0773</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-709000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">71055000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0559</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">723000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">72491000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1199</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-3409000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">68349000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0133</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3768000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">75543000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1733</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-6508000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">65242000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">0.9599</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2022To12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">7954000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">79740000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_EUR">2000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-5"
      unitRef="Unit_EUR">2500000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.1439</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-103000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">10307000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.1213</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">105000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">10516000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.1892</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-496000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">9915000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.076</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">548000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">10958000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.2459</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">-946000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">9464000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">1.0193</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">1157000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsNvMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_EUR">11567000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1439</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-117000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11670000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1213</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">119000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11906000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1892</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-561000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11225000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.076</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">620000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">12407000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.2459</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1072000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">10715000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0193</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints
      contextRef="P01_01_2021To12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1310000</imtx:IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">13096000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0773</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">189000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-18873000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0559</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-193000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-19255000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1199</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">908000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-18154000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0133</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1003000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-20065000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1733</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1733000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-17329000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">0.9599</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2118000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2022_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-21180000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1439</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-290000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">28961000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1213</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">295000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">29547000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.1892</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-1393000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">27858000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.076</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1540000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy5AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">30791000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.2459</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-2659000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroWeakensBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">26592000</ifrs-full:ValueAtRisk>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">1.0193</ifrs-full:ClosingForeignExchangeRate>
    <imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3250000</imtx:IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints>
    <ifrs-full:ValueAtRisk
      contextRef="PAsOn12_31_2021_EuroStrengthsBy10AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsUsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-3"
      unitRef="Unit_EUR">32501000</ifrs-full:ValueAtRisk>
    <ifrs-full:DescriptionOfManagingLiquidityRisk contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, and 2021, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132,994&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;154,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total funds available&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;362,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;145,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DescriptionOfManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">148519000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">58756000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">12123000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">154930000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">362205000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk
      contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_EUR">145117000</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">1700000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">1700000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">2800000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">2800000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">1500000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">1900000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk
      contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="PAsOn12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">2500000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities
      contextRef="P01_01_2021To12_31_2021_AryaMemberifrsfullBusinessCombinationsAxis_ForeignExchangeRatesMemberifrsfullUnobservableInputsAxis_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-5"
      unitRef="Unit_EUR">3100000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Set out below are the carrying amounts and fair values of the Group&#x2019;s financial instruments that are carried in the consolidated financial statements as of December&#160;31, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying amount per measurement category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31.12.2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;148,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;154,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,111&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="5" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="4" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,563&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,352&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408,984&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying amount per measurement category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31.12.2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,994&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;682&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;691&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="5" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="4" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;727&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,859&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,853&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146,490&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;196,553&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Short-term deposits&#x201d; and &#x201c;Bonds&#x201d; are classified within Other financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In all valuation categories with the exception of Bonds, the carrying amount represents a reasonable approximation of the fair value based on the short-term maturities of these instruments. Set out below are the carrying amounts and fair values of the Group&#x2019;s Bonds as of December&#160;31, 2022 and 2021, respectively. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,113&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following methods and assumptions were used to estimate the fair values: All financial assets are categorized Level&#160;1 and therefore are valued using quoted (unadjusted) market prices. All financial liabilities are also categorized Level&#160;1. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The bonds&#x2019; contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Bonds are classified as Level&#160;1 of the fair value hierarchy, as they are listed on publicly traded markets. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants are comprised of the Immatics Warrants issued to investors with a cashless exercise mechanism as a current liability which the Company accounted for according to provisions of IAS 32. The Company measures the warrants at fair value by using the closing price of warrants at Nasdaq. The warrants are measured in each reporting period. Changes in the fair value are recognized in the Company&#x2019;s Consolidated Statement of Profit/(Loss) as financial income or expenses, as appropriate. The warrants are classified as Level&#160;1 of the fair value hierarchy. The maturity of the liabilities for warrants is dependent on the development of the share price as well as the decisions by the Immatics Warrants holders. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Groups net result from financial instruments by measurement categories are disclosed below for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets at fair value through profit and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at fair value through profit and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,082&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,041&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The following table shows the changes of the liabilities from financing activities, classified as cash effective and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; effective as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,843&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,655&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Set out below are the carrying amounts and fair values of the Group&#x2019;s financial instruments that are carried in the consolidated financial statements as of December&#160;31, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying amount per measurement category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31.12.2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;148,519&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;154,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,111&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="5" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="4" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,563&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,914&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,352&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408,984&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying amount per measurement category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;fair&#160;value&lt;br/&gt;through&#160;profit&lt;br/&gt;and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;amortized&lt;br/&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31.12.2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,994&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;682&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;current/non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;691&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="5" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="4" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current/non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;727&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,859&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,853&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146,490&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;196,553&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Short-term deposits&#x201d; and &#x201c;Bonds&#x201d; are classified within Other financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In all valuation categories with the exception of Bonds, the carrying amount represents a reasonable approximation of the fair value based on the short-term maturities of these instruments. Set out below are the carrying amounts and fair values of the Group&#x2019;s Bonds as of December&#160;31, 2022 and 2021, respectively. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,113&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">148519000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">148519000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">154930000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_ShorttermDepositsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">154930000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">58756000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">58756000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">1111000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">1111000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">2402000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">2402000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11735000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">11735000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">54000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">54000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">16914000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">16914000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">14563000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">14563000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">365718000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">16914000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">26352000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">408984000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">132994000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">132994000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">12123000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">12123000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">682000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">682000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">691000</ifrs-full:FinancialAssets>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_OtherCurrentNonCurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">691000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">11624000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_AccountsPayableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">11624000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">727000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">727000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">27859000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">27859000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">9853000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">9853000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">146490000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">27859000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">22204000</ifrs-full:FinancialLiabilities>
    <imtx:FinancialAssetsAndFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">196553000</imtx:FinancialAssetsAndFinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">58756000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">58300000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_BondsMemberifrsfullClassesOfFinancialAssetsAxis_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">12123000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_BondsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">12113000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">58756000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">58300000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">12123000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_EUR">12113000</ifrs-full:FinancialAssets>
    <imtx:DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Groups net result from financial instruments by measurement categories are disclosed below for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets at fair value through profit and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at fair value through profit and loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,082&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,041&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </imtx:DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory>
    <imtx:NetFinancialResult
      contextRef="P01_01_2022To12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">1849000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2021To12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">5119000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2020To12_31_2020_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-8959000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2021To12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-884000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2020To12_31_2020_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">2099000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2022To12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-712000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2021To12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-286000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2020To12_31_2020_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-254000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2022To12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">10945000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2021To12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10990000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2020To12_31_2020_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_EUR">17775000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">12082000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-7041000</imtx:NetFinancialResult>
    <imtx:NetFinancialResult
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">10661000</imtx:NetFinancialResult>
    <imtx:DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The following table shows the changes of the liabilities from financing activities, classified as cash effective and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; effective as of December&#160;31, 2022 and 2021, respectively. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euros in thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;br/&gt; effective&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities for warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,843&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,655&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2022_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">10945000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2021_LiabilitiesForWarrantsMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">-10990000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective
      contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2843000</imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">4710000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2707000</imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3666000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2843000</imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">15655000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2707000</imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective>
    <imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-7324000</imtx:LiabilitiesArisingFromFinancingActivitiesNoncashEffective>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual obligations for 2022 consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments due by year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&#160;than&lt;br/&gt; 1&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&#160;-&#160;3&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&#160;-&#160;5&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&lt;br/&gt; 5&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other lease obligation&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,469&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,568&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual obligations for 2021 consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments due by year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&#160;than&lt;br/&gt; 1&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&#160;-&#160;3&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&#160;-&#160;5&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&lt;br/&gt; 5&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other lease obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,726&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract research organization agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,659&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,370&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,972&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other lease obligations comprise of obligations for leases classified as short-term and low value as well as obligations for leases signed but not yet started. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The warrants will expire five years after the completion of the ARYA Merger or earlier upon redemption or liquidation in accordance with their terms. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;As of December&#160;31, 2022, and 2021 the Group is potentially liable to pay &#x20ac;1.6&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million to a third-party upon successfully completing the milestone of the first clinical lead selection in connection with Immatics collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <imtx:DisclosureOfContractualObligationsTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual obligations for 2022 consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments due by year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&#160;than&lt;br/&gt; 1&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&#160;-&#160;3&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&#160;-&#160;5&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&lt;br/&gt; 5&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other lease obligation&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,469&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,568&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual obligations for 2021 consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments due by year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&#160;than&lt;br/&gt; 1&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&#160;-&#160;3&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&#160;-&#160;5&lt;br/&gt; years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&lt;br/&gt; 5&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other lease obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,726&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract research organization agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,659&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,370&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,972&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,735&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfContractualObligationsTableTextBlock>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3613000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">5045000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3872000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">6036000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">18566000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">637000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1424000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1521000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1420000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">5002000</imtx:OtherLeaseObligations>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">4250000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">6469000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">5392000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">7456000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">25568000</imtx:ContractualCashObligation>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2913000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">4477000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2007000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">932000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:ContractualObligationOfLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">10329000</imtx:ContractualObligationOfLeaseLiabilities>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">66000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1258000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1362000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2040000</imtx:OtherLeaseObligations>
    <imtx:OtherLeaseObligations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">4726000</imtx:OtherLeaseObligations>
    <imtx:ContractResearchOrganizationAgreements
      contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">1681000</imtx:ContractResearchOrganizationAgreements>
    <imtx:ContractResearchOrganizationAgreements
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:ContractResearchOrganizationAgreements>
    <imtx:ContractResearchOrganizationAgreements
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:ContractResearchOrganizationAgreements>
    <imtx:ContractResearchOrganizationAgreements
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:ContractResearchOrganizationAgreements>
    <imtx:ContractResearchOrganizationAgreements
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1681000</imtx:ContractResearchOrganizationAgreements>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">4659000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">5735000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">3370000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_EUR">2972000</imtx:ContractualCashObligation>
    <imtx:ContractualCashObligation
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">16735000</imtx:ContractualCashObligation>
    <imtx:UnrecordedContingentLiability
      contextRef="PAsOn12_31_2021_CollaborationAgreementsMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">1600000</imtx:UnrecordedContingentLiability>
    <imtx:UnrecordedContingentLiability
      contextRef="PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis"
      decimals="-5"
      unitRef="Unit_EUR">1600000</imtx:UnrecordedContingentLiability>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related party disclosures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Key management personnel have been defined as the members of the Executive Committee of Immatics N.V. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation of key management personnel consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,706&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,317&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;886&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,574&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,387&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed and variable key management compensation represent short-term employee benefits. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board of Directors of the Group received a fixed fee. Total compensation for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board amounted to &#x20ac;1.7&#160;million in 2022: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 36%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Friedrich&lt;br/&gt; von&lt;br/&gt; Bohlen&lt;br/&gt; und&lt;br/&gt; Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nancy&lt;br/&gt; Valente&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;379&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,336&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;258&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;232&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;220&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Total compensation for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board amounted to &#x20ac;2.1&#160;million in 2021: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 34%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Friedrich&lt;br/&gt; von&lt;br/&gt; Bohlen&#160;und&lt;br/&gt; Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Christoph&lt;br/&gt; Hettich&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;348&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Travel expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,751&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,223&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;179&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On July&#160;1, 2021, Immatics changed its structure from a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-tier&lt;/div&gt; Board to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-tier&lt;/div&gt; Board and Supervisory Board members became &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board of Directors. Total compensation for the Supervisory Board amounted to &#x20ac;4.1&#160;million in 2020: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Harald&#160;F.&lt;br/&gt; Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Christoph&lt;br/&gt; Hettich&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supervisory board compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;282&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Travel expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment Exit arrangement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,394&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,436&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,584&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,116&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Prior to the ARYA Merger, Immatics N.V. established the 2020 Incentive Plan. Immatics N.V. granted certain service-based options out of the 2020 Incentive Plan to its management and directors and in addition, performance-based options to its management upon closing of the ARYA Merger. At the Annual General Meeting on June&#160;13, 2022, Immatics shareholders approved the Group&#x2019;s 2022 stock option and incentive plan (&#x201c;2022 Equity Plan&#x201d;). Service options granted out of the 2020 Incentive Plan, will vest based upon satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. Service options granted out of the 2022 Equity Plan to the Board of Directors, will vest in full after a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; service time. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The performance-based options will vest based both on achievement of certain market capitalization milestones and satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. The following options were granted to Immatics&#x2019; Directors: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Type of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Strike&lt;br/&gt; Price&#160;in&lt;br/&gt; USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expiration date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Managing Director&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Performance-&lt;br/&gt; based options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,598,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Matching Stock&lt;br/&gt; options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;264,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Converted options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;July 1, 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Converted options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;January 1, 2028&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;135,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 13, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;388,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 13, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board of Directors&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Matching Stock&lt;br/&gt; options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 14, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 13, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 17, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 17, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nancy Valente&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;March 22, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;March 22, 2032&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An additional aggregate of 652,500 service options to purchase ordinary shares, were granted to other Immatics&#x2019; key management personnel in 2022, who are members of the Executive Committee but not Directors. Certain key management personnel were also participants in the share-based compensation plans of Immatics GmbH (2010 Plan and 2016 Plan). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the replacement awards issued in connection with the ARYA Merger (See Note 17), these key management personnel received in 2020 cash payments before taxes of &#x20ac;3.4&#160;million, 417,415 converted options in Immatics N.V. and 750,076 matching stock options in Immatics N.V. The cash payments mainly covered wage tax obligations of the employees. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Until December&#160;31, 2022, no options granted to directors and executive officers forfeited or were exercised. Refer to section &#x201c;18. Share-based payments&#x201d; regarding further details of the Groups share-based compensation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no outstanding balances, including commitments, other than the above mentioned with related parties. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group did not enter into transactions with related entities in 2022, 2021 and 2020 other than the mentioned compensation contracts. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation of key management personnel consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,706&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,317&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;886&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,574&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,387&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock>
    <imtx:KeyManagementPersonnelCompensationFixed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">2706000</imtx:KeyManagementPersonnelCompensationFixed>
    <imtx:KeyManagementPersonnelCompensationFixed
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2481000</imtx:KeyManagementPersonnelCompensationFixed>
    <imtx:KeyManagementPersonnelCompensationFixed
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2660000</imtx:KeyManagementPersonnelCompensationFixed>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1543000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1317000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">886000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">14325000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">17016000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">13841000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">18574000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">20814000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">17387000</ifrs-full:KeyManagementPersonnelCompensation>
    <imtx:DisclosureOfCompensationSupervisoryBoardTextBlock contextRef="P01_01_2022To12_31_2022">Total compensation for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board amounted to &#x20ac;1.7&#160;million in 2022: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 36%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Friedrich&lt;br/&gt; von&lt;br/&gt; Bohlen&lt;br/&gt; und&lt;br/&gt; Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nancy&lt;br/&gt; Valente&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;379&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,336&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;258&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;232&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;220&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Total compensation for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board amounted to &#x20ac;2.1&#160;million in 2021: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 34%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Friedrich&lt;br/&gt; von&lt;br/&gt; Bohlen&#160;und&lt;br/&gt; Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Christoph&lt;br/&gt; Hettich&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;348&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Travel expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,751&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,223&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;179&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On July&#160;1, 2021, Immatics changed its structure from a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-tier&lt;/div&gt; Board to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-tier&lt;/div&gt; Board and Supervisory Board members became &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; members of the Board of Directors. Total compensation for the Supervisory Board amounted to &#x20ac;4.1&#160;million in 2020: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Euros in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peter&lt;br/&gt; Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Harald&#160;F.&lt;br/&gt; Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Michael&#160;G.&lt;br/&gt; Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paul&lt;br/&gt; Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Heather&#160;L.&lt;br/&gt; Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adam&lt;br/&gt; Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Christoph&lt;br/&gt; Hettich&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eliot&lt;br/&gt; Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supervisory board compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;282&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Travel expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment Exit arrangement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,394&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,436&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,584&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,116&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfCompensationSupervisoryBoardTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">1700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">80000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">55000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">52000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">32000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">379000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">178000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">206000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">177000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">177000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">177000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">177000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">64000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">180000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1336000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">258000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">246000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">232000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">229000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">217000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">217000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">96000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">220000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">1715000</imtx:KeyManagementPersonnelCompensations>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_EUR">2100000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">80000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">55000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">53000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">348000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">10000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">15000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1143000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">30000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">114000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">114000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">114000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">114000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">122000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">1751000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1223000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">51000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">179000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">167000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">157000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">154000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">163000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">2114000</imtx:KeyManagementPersonnelCompensations>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_EUR">4100000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">140000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">16000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">28000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">26000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">20000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">12000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">282000</imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">4000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationTravellingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">4000</imtx:KeyManagementPersonnelCompensationTravellingExpenses>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">2394000</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationPaymentExitArrangement
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">2394000</imtx:KeyManagementPersonnelCompensationPaymentExitArrangement>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">1046000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">0</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">70000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">70000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">70000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">70000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">70000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">40000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">1436000</imtx:KeyManagementPersonnelCompensationShareBasedCompensationExpense>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">3584000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_HaraldFstockMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">16000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">98000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">96000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">90000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">90000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_ChristophHettichMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">90000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_EUR">52000</imtx:KeyManagementPersonnelCompensations>
    <imtx:KeyManagementPersonnelCompensations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">4116000</imtx:KeyManagementPersonnelCompensations>
    <imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule
      contextRef="PAsOn12_31_2020_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule>
    <imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule
      contextRef="PAsOn12_31_2022_ServiceOptionsMemberIMTXTypeOfVestingAxis_TwentyTwentyIncentivePlanMemberIMTXPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</imtx:PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule>
    <imtx:DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock contextRef="P01_01_2022To12_31_2022">The following options were granted to Immatics&#x2019; Directors: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 21%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Type of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Strike&lt;br/&gt; Price&#160;in&lt;br/&gt; USD&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expiration date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Managing Director&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Performance-&lt;br/&gt; based options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,598,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Matching Stock&lt;br/&gt; options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;264,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Converted options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;July 1, 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Converted options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;January 1, 2028&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;135,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harpreet Singh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 13, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;388,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 13, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Board of Directors&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Matching Stock&lt;br/&gt; options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Peter Chambr&#xe9;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adam Stone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Heather L. Mason&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Michael G. Atieh&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 30, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paul Carter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 14, 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 13, 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eliot Forster&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 17, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 17, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 9, 2031&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Friedrich von Bohlen und Halbach&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;June 14, 2032&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nancy Valente&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Service options&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;March 22, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;March 22, 2032&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imtx:DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">Performance- based options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">1598000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">168000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">Matching Stock options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">264624</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_MatchingStockOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Converted options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="0"
      unitRef="Unit_shares">30939</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.06</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_ConvertedOptionsMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">2027-07-01</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">Converted options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="0"
      unitRef="Unit_shares">145371</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.17</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_ConvertedOptionsOneMemberIMTXTypeOfVestingAxis_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis">2028-01-01</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 17, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">168000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.7</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2030-12-17</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">168000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">135000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsThreeMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">Harpreet Singh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">December 13, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">388000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.75</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsFourMemberIMTXTypeOfVestingAxis">2032-12-13</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Peter Chambr&#xe9;</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">Peter Chambr&#xe9;</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">Matching Stock options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="0"
      unitRef="Unit_shares">211974</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_MatchingStockOptionsMemberIMTXTypeOfVestingAxis_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Peter Chambr&#xe9;</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Peter Chambr&#xe9;</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PeterChambreMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Adam Stone</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Adam Stone</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Adam Stone</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_AdamStoneMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Heather L. Mason</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Heather L. Mason</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Heather L. Mason</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_HeatherLMasonMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Michael G. Atieh</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_MichaelGAtiehMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Paul Carter</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 30, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-06-30</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Paul Carter</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Paul Carter</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_PaulCarterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Eliot Forster</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">September 14, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2030-09-13</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Eliot Forster</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Eliot Forster</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_EliotForsterMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">June 17, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2031-06-17</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">December 9, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">15000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsOneMemberIMTXTypeOfVestingAxis">2031-12-09</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Friedrich von Bohlen und Halbach</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">June 14, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">25000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.94</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_FriedrichVonBohlenUndHalbachMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsTwoMemberIMTXTypeOfVestingAxis">2032-06-14</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:DescriptionOfTransactionsWithRelatedParty contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Nancy Valente</ifrs-full:DescriptionOfTransactionsWithRelatedParty>
    <ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">Service options</ifrs-full:DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">March 22, 2022</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">30000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.4</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <imtx:DateOfExpiryOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_NancyValenteMemberifrsfullCategoriesOfRelatedPartiesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis">2032-03-22</imtx:DateOfExpiryOfShareOptionsGranted>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ServiceOptionsMemberIMTXTypeOfVestingAxis"
      decimals="0"
      unitRef="Unit_shares">652500</ifrs-full:NumberOfOutstandingShareOptions>
    <imtx:PaymentOfPayrollTaxOfTheEmployees
      contextRef="P01_01_2022To12_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_EUR">3400000</imtx:PaymentOfPayrollTaxOfTheEmployees>
    <imtx:NumberOfConvertedStockOptionsInTheEntity
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_shares">417415</imtx:NumberOfConvertedStockOptionsInTheEntity>
    <imtx:NumberOfMatchingStockOptionInTheEntity
      contextRef="P01_01_2022To12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_shares">750076</imtx:NumberOfMatchingStockOptionInTheEntity>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_DirectorsAndExecutiveOfficersMembersrtOwnershipAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26. Earnings and Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group reported basic and diluted earnings per share. Basic earnings per share are calculated by dividing the net profit or loss by the weighted-average number of ordinary shares outstanding for the reporting period. Diluted earnings per share for the year ended December&#160;31, 2022, are calculated by adjusting the weighted-average number of ordinary shares outstanding for any dilutive effects resulting from equity awards granted to the Board and employees of the Group as well as from publicly traded Immatics Warrants. The Group&#x2019;s equity awards and Immatics Warrants for which the exercise price is exceeding the Groups weighted average share price for the year ended December&#160;31, 2022, are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares. The Group was loss-making during the year ended December&#160;31, 2021 and 2020, therefore all instruments are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including the outstanding equity awards and the 7,187,500 Immatics Warrants issued in 2020 and outstanding as of December&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net profit/(loss):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;37,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(93,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(211,841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average shares outstanding:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,220,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,912,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,001,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,824,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,912,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,001,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <imtx:DilutiveEffectOfShareOptionsOnNumberOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">7187500</imtx:DilutiveEffectOfShareOptionsOnNumberOfWarrants>
    <ifrs-full:EarningsPerShareExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net profit/(loss):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;37,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(93,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(211,841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average shares outstanding:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,220,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,912,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,001,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,824,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,912,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,001,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_EUR">37514000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_EUR">-93335000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_EUR">-211841000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_EUR_per_Share">0.56</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_EUR_per_Share">-1.48</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_EUR_per_Share">-4.4</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_EUR_per_Share">0.55</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_EUR_per_Share">-1.48</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_EUR_per_Share">-4.4</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">67220824</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">62912921</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">48001228</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">68824906</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">62912921</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">48001228</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Events occurring after the reporting period &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated further subsequent events for recognition or disclosure through March&#160;22, 2023 and did not identify additional material subsequent events.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>155
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MT.K0-(#YOC_ $EO-3F^-\GR(J63 2A5+5K6-<8L>Q7GIQG%1M%6%ULZA2_S
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M@)O* =]3,ZT*-F<VS=7N$;/.LL\8O,LK0M[+QGL/:1_GZSB>SPVW,G!SN?]
MMDF*+V;;;F;,+G_\ 3K&1]FTUPD6Z 0+1PU&-,HJUI38@ G6@0F6D@E?V1IL
M6U?W&5V<[KPEEH$@]"S(]5X9:FKO=8(%\@J0QT]<G4&CD4%CB9UMN_(9;A_Z
M:BO[NI3,[:[#@"VKVXO#"TYJ6;MM6=Z>;7(GL*4R@ZGMU@D62"N0M%MB)YG%
M4C37=TVNCQ*[DWUT#GUTE'V\P6SSDY39OTFSGY!U2^D_<>"6CEB"9W)UKD0C
MP2;0F56H$RS2"19K AM0PSU0PU52X\L*7)7-8J_JM@$@>$[;G8&,)DJLJ31Q
M!0:X'$=$"]O@+A>!SI1"G6"1+'N/F^VBS?S8:-!2[]!23]G2Z\_7 0BSDJV!
MV6KX9U#B=K]'ZZ0DR5Y12"NV^)8UV!/R\0W#Y?JR%*V@P2^&11O/%\YV@;*2
MJ=W3"1:-&HE84\A!G_U#GWUEGZ]N_KP"7W#]@.MI3?:%TI#I&1;7P:5H!CWN
MZKV20;D>OS,*E(5,;;-.L&C<6,2:8@[Z#(U>PS&4G;Z]NF'=+!_9:?K$]5L-
M,/7,W*&I3LT2DSEG$VA-*M2*%FE%BW6A#?EQI/%!)3_VVDY&R*[5/=AY@!R+
M8E+"0*%_)O(@XG=C$COD>SP9I&"FR5^KU65,)H1.M$A>@X/X?;;$[O0E&_;B
M%52K5T$KS,T)IC3'ZWW_YHUHOVX5%K8%.[EV[Y '+4(^O]18JA.8NM,:%S30
M&C34BA:-*R'6%71(C%YD@VJ5[3IY:11[ FJ\UY1?15H).T#RE-1KTHC8CUFU
M(_D+2/.$D.P^8Y8)Z>3?5Y9)R211FRP3(9Y,6A6Z<4$#K4%#K6C1N!)B74&'
M9.IU.J@6ZHYW>T668T*K$@\IA)^;8^GN#XH:$R]N+]4)3":&5OU.*UJH%2W2
MBA9W:(Z\4T/R]&(@5*N!0;D^?7>EN9D@88RH9GFNZ?'[28F9<.%=28QLTW-\
M_O:*Q&YNL7\N=V(/98:N9?/"W;@:8O7@O75F]PH?5$M\;[H9 T41SK0AOP]4
M1YX\I76B!5K1PE'C$8VRBG5E-N1#+^M!M:XWZI8,E,A/OFD*=S_5L28S0"=:
M,+*&4&O4:&346%?4(0MZ)1"JI<#ON8$#105L[OF>N$/4*;NMM*(%LAJDY!#M
M9!-_W(C$NFH8-KV7!:%:%_R>K:1$#G,LP^1;KE."6XT+&F@-&FI%B\:5$.L*
M.GP^II<1T?_(B*TH5&V;[K.]X#.NTXS(MX%(E/?XYU.6ZFA363 B8J U8J@5
M+1J1?ZPKXK#_O4R(U#*A>@$/I3R0R'^6X? G!(F9N("7&-F.#7U^FR^QF]NF
MZT$N:B@S-(7GK:)Q-<3JP7MK<XZ>7E,+@&]:P".)A&7Q=U^6ZLB3)ZI.M$ K
M6CAJ/*)15K&NS(9\Z'4_I-;]1BW@D:@ZF:ZX@U.'FDP K0_4C2LAU!HT&A<T
MUA5T2(%>K4-JM>Y[5N](U.I,W^<UD*4Z@\G,T"K7R4J0,4,TD\WY4>,1ZZI@
MV/%>8D/_([&]?>F.1)D*(9M_7GBI3F!RPT<%#;0&#;6B1>-*B'4%'1*CE_>0
M6MZ;LG27R%.0W[2KPTVFP8B0@=:0H5:T:$P!L:Z00PKTBAY2*WJ?"=F)]_:;
M=V\0A!\G/0"$1/4*(@=9_%T^F9W)W_R7@PD/A 7J\B;W7ZN<-W) 8EU1AQ3H
MY3RDEO/4&S@D;;4GW E"T!3>75E*[%R'?^A'9@0MR#\5%TCLYK9A(-_GK]T2
M0VAYD+]XCRLB5@_?U/8LCMZZ:][S_)+4#QD[^^;XGL$;9\TK?_7^U<G]!UIM
MVQ?Q[BI*JZ(]W.!DC>O&@/U^7U7T]4/S;M_A!=;+_P!02P,$%     @ TS9V
M5E_9]W9U!   #0H  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R=5EEO
MXS80_BL#!0AV :]L*V<3VX"=;'>S0((@QQ9%T0=*&EM$1%(EJ3CNK^\,)2MV
M+BSZ(I&<F6_N(4=+8Q]<@>CA297:C:/"^^JDWW=9@4JXV%2HB3(W5@E/6[OH
MN\JBR(.0*OO)8'#85T+J:#(*9]=V,C*U+Z7&:PNN5DK8U0Q+LQQ'PVA]<",7
MA>>#_F14B07>HK^OKBWM^AU*+A5J)XT&B_-Q-!V>S/:9/S#\E+AT&VM@3U)C
M'GASD8^C 1N$)6:>$03]'O$,RY*!R(Q_6LRH4\F"F^LU^N_!=_(E%0[/3/F'
MS'TQCHXCR'$NZM+?F.5W;/TY8+S,E"Y\8=GP)DD$6>V\4:TP6:"D;O[BJ8W#
MAL#QX!V!I!5(@MV-HF#EN?!B,K)F"9:Y"8T7P=4@3<9)S4FY]9:HDN3\Y)LU
M=052-^FE.(WZGF"9V,]:B%D#D;P#,4S@TFA?./BJ<\RW ?ID3V=4LC9JEGR(
M>(Y9#'O#'B2#)/D ;Z]S<B_@[;V#=X=/'F:ER1[@KVGJO*5:^/LM1QN8_;=A
MN#].7"4R'$?4  [M(T:3W9WAX>#T R/W.R/W/T+_M4Q\"/&V@<,87D'#A>)%
MYN J_AGWP)L%^@(M%9\O0'H'WY!8-?5JZF0NJ5V?16;2>,P*;4JSD$BL*OT.
M0N=![CZ^C3>D>L]B][=PH3-2]FEWYSA)!J=K2M@.3\%8:"ED2F-S2_H,TH&
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MFOJ/J\)Y.N"F=%O"7=.NJ/-I'M"U!'2I8*B2]<72>"QJ7Q@K_V58$I+.U2$
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MX,QXI>(O+#E8YPI><N[[IU#:M>5)?7R3;-%F\_O*W1+%57$,N[KOM4P_W +
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MZ.1H$%MU<Q-LR1_Z%C8$6_!EIH!.1POP?FEA:GU#"MHOOY?_ U!+ P04
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MJ<]\OGR=;B[F9%0P'I^B5,98$VHF<$8XM$7Y\_)RR8X:&0+3[9_=XK8+GN/
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MQB(GNS!ZP',V*SO+T2P%V"V@V9+D6V>>[ MH.O"IDA":*&&FM*5BO6SI>3E
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M*A=@STLBLW-<@?')3?\!4$L#!!0    ( -,V=E9;6I2[?P0  $8+   9
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M@E $,TK,1C>8VRZ4[%H-?/#+IC1K3&_;_/6<$VV&+!N-Z:PWVR;!O.H* 97
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M'JB^/.PG1K:N)%M*@P6>&ZZQHA;*'L#]E93F:6(O&&KTQ;]02P,$%     @
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M=K)E(2W>Z/K/JG3K:91'4.)2MK6[T]M?<&=/YOD*7=OPA6UW5X@(BM8ZW>S
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M.<HB,%VO[A9.;T)_7&A'W39,U_1[@\9?H/.EUNYYX07L?YAF_P-02P,$%
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M@#&1V#*)-DQNHF<17V,V@C@<0A1$T3-X\3:RV./%3^#=&;18.>&3KY>@?*1
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M.QF24>O_)Y%B9L5C.S<DF'H)SL&?.K.SV)E.O)/A8F1#MQW<766T])'(E/Q
M+[70;PW66+LA>'W"H.VMSLY)__;=5MR^\/J&]ZC'6G9(X!= ?CT,#@_'F_H6
M?IB.X%.CI,((:?[;-=$[:^O1TMGOKU5\EJ.F-"V1;+3C(S]&RP"$D7,616N(
M)>;AWS2]S4 0.W$T.QGF"'BD[RT/9Q;X)UO AX;=<'F:G>;K?,P\)XC7+KQ_
M=WL'@=V5>#L^^KF'=4O7)">!,XVG-D=?=R;D3@<[.S$TPQZ;#/M2F2T,R\?.
M[5ZJ[?K]HZV?54^4P#3<UDS#V;+1]RH7O%GF6#L\8\ID"VGWQO9MO7JS3?!
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M)3WH4%D!VE](:;83:Z![(LZ^ U!+ P04    " #3-G96/SF^NR$/  #8.P
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M4*RT)6XJF@I0:T [5M @(@8R*P D;8?![&*T,%R-[*J*D"!/NX9NFCMOZEY
MI4]=K^":/*):0^VDLE\"?J1Z?8< P*[;JI[.R2BJWN&JAM)0N(&\B!7Q(CI9
MMZQ"05;4C@9=X>1<9/D-5V@]XMNX@.)<%CF@\S(G4VCV%&N[AME3W1(JO@&=
MR7:'")=$TQ^@"P"#<'.@].A4 XH#!1.-!B9#.9N3D4">EF]54&G98*7&77=
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M)9G4Z+I#KD;!!@!'J">*+%=/C;(5H%E\;E,7&;9AA3/#\9RFW=NM-?: 18+
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(56;6_C-@S^*X1O.]R
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M'>9X^0S>E:JIIM1Z"3JLABQF*@4V@%U,9ZX+YXKC?K;K58,'$$W+7>M*O&>
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MD1E>',/$Z2[<\@OM\&8(PS6BS,8+8'^ID?+=Q!O8/_OF?P%02P,$%     @
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M3=QGK<J5,]YHW[AAB#%*<RHQ:X4:#E;$P3OJ'OK[KO/9SU(B$2!RW.-@__V
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M0E>R6AL0508_*6.@1@UWN= X#2PY8+4@W8(M6K#X%; HAL^JLKF!#U6&V4N
M@)CU].*.WB(^BGB#Z0"&D0]Q&,='\(9]N$.'-WP%[RL^65@4*GV WZ^7QFKJ
MBC\.!=K")(=A^*1<F5JD.//H*!C4C^C-W[Z)QN&[(R23GF1R#/W?UN0HV&&J
M\7@ 1[S UQSA!ZV:FLY=K;3%C%M?IDXWDT7#.]@!L)UANP$LG-:^!/B7BB)M
M"N'0G@GF46:D!9:<531^:JU6TH+24# ;4F')QITKS,[%(VH:$U UY9)@U8HT
MR9XF2>O" ,T<8XDA@]*X<N8M?]XA+E)E [AYE7YO]$PR0&YAH 9$YZ]K0O]
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M++12QH'&DD/'H[.3!&S?^;WAJ8W=MB;/O1N7-0]+M,&!STLBOS="@F'\YK\
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M;W_Y]>(=O)U=-,&/6YXN7LP V0;(B ?1HGX".N2F!;MQ5;:]S1Z@_"Y/7SD
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M\.<40Y!^2U?U3"J 1/[WG-@/K?S."> >$Y1@KKQX;2@",\:EV+LZZ6QG7W<
M$B_48[<L>X\=;]\;ZOC"F*)$7ZMQ>ISP1K8YZ<P)L<^7[>"#B[&DR=A^1F\/
M*(;'1]U))ZI"=Q/[:?A(2]>7CSL</P@J9/Q/XHZDD3=RK(]CY'7;>*C0ZHUJ
M"S_T$P 3=T=G=72%R'>[Q0PE-Q1&V+@./SO$Q@\XX!E2@8*="">R,U=Q@N!_
M4TJA-?8@<<8.DRQ4 RGK%5ZMYT?F_3U:7V\5MBCY$'.(Y$41[R%PO&+0[/7$
MP'RHW()<^L=#AYN(-Y?6CT))6C PWQUC(C;#6.U:.B0S%]VQ!*;APY?W/+9U
MX"8[[X[PB5S]0[;E;HP$8XY^70:QP LYJ1Z+&B;,NKP;./QOO7G)?G8QG16)
MGM8*<H/@1@=M8WU+5#!I(Z%%%#UR>ZL[EI&H,GA=OH;K!IBB/F0D&.YZM#(;
MN8P'A)S%W6=1PV3:?^;"81'N0@;&F?O<S9M'/+M B1%SK@[]JMC.BM_L;A@S
MJZC]+Y9H//S68NL6MP3O?7V+J"/CK>)=<J5+KLVDVXY1GQA/,:<.QND].Z@<
MB"_O#FR*VO/L$D?WI3.N#OQ&,8?9JZJ+)IPGF9#\&\>)-H)Z *8'%RB^UW@T
MQ%7.+2B"LW!Q.&<EJ:'YFZ>/!XK)C8TEF3X[MMOQS4J?.DH/U3\PAT?YHUS*
M6-Y3C@:)$?XKS!)1#N^X'</CE>NWTCMY"=X8DC.:$!TBR;/2N@EM9@FW-GS/
M&%N6A)EBV1X_;1XX&&XNGI;QRNSPK%R]9%0$L1INY?+=:NWNG>7J>$">.N!<
M4W;2I8E>NZ3_XKLG;:KMZ);9T.R77B'CK# VP#F%$?432H6=W=*HPW.TZ?7X
MC3!WR33ZA:BE+[B5K'^/#5+=:@[#^(",=I2NY\5;?;)IKO@4SL2WZ/C\ U:X
MB$V/9W.ZX;'1#&#MVBZD/LV@::,!^B#]'?-OF&:W8L4/P98NUQ WQD<-!'+'
MKQ.,A(S8\(VA3=1(Q5?..X^GH_X@&G]Q1<PTMPZRA=,H<45A4&@8>,XA)S)5
MB MW;BZF[\>\Q%8I414BN*-EMUMOV3S-1D"-7(?D_+1$BD@"K<QN4GQ0@G)1
MD8<I]IQ@N;L5D%1UWSBWP<_<M359TT-TDOL\^#[X$SC"KL*3B9JH(A;ZIQT^
M*)52OH3>F:N?59=O$?%+[!//?ME)UNBM:8!W>  [^>*2-^8^(#'\=/G5^KZQ
MI <(>$:5]&<$>/3XV=Q':+ZJ?V0O LP'8J)7XZ[+CK,?<ID.7V#@)H7E&LAP
M822$X[J:)X<=[DB0,"8J<M.H2WPMQN&]=;>K(OQ"YBN9/@7>!$G1;GFE(P]>
MNF"<@F@Y6R+M0F&FF,DUGQ*@< ?=8OH2N@\R^.Y:4T:E9QH$2,\B&\+)OB2'
MB%5C=Z]&N,!7!CJ)Z%\OS^]XR7D:&\'K[_O61)$-ZZ5V4'?XQ_S7N1]=D(,(
M<W<.[?FQ%C,L.L@68TO:BD\IPY)8\D5LO/?4RIWW_EX!0!RG9NB(Y1&/1'"V
M[WCW >TV+(]A!^:\-SJLAPBXRR#<T;A74!["L/](FW.XUAK0WJ*-OG)7C\S3
M XZN4)!E7-]T&@#1'2-Q@TE0K."KN<Y>3B!'8AB=F]\%B 9/]Z-4,BF+L:P*
MIQ#_Z,&.KEU?6M+W'>SM(.$SMFI<%7L3]4$@Y)_JU=_$Z@H3\(RG?^'K);CP
M^5R>^7KY;G"S;3$HH:>G*'?DHT*6W.B(<$CG^]?YY9Q<5[!'JMV_O$>M,S3E
MA!-.]_X#5-8)CJ">"\/<^L$]WA+P/@-_A[Y0FYW.7SQ^=O84_W_R_/ES^/_Y
M\^6+)?[_Y,F+,_Q_\>3%8_S_V=/E8DIGA4L9%].W,GY".TM=/J/::OIET%:/
MLP A_G' _X,Q/[H]R;> 1J',@TIO, E,UPIA7S;Q[$.^?$KN:^#62QS_I?P"
MI8A+*Q%T):4+O-RK[_!NC'2:3M<K4Y#W=#"(YX<$?2* NG71C@Z*_6QYW,A=
MF*JE\<65YB9!5V%(F@_C?H3?:/0Z$,7=V3&(XA3[0E8BO564EBIF<G>)POE
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ME1'9@FF#Z[F*->O<\5D"^NBD:Y 8P7>CBL192<)[A83KL6N9F:5F%UD,\39
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M@#3H[@X**N^89=E,XY9H[^UH?A)2#=%.'%?^I[Q8[7:YB[/9HBBP5=:X"RZ
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M*=$CI27M1+R!XH(D\9#0B-(.O*1U,7%XR3MX]PHTU(:Y*I ;(KS+6- XU1J
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MAB:/6^8TZE%9 _J>26GV&QN@_>=A\2]02P,$%     @ TS9V5D4,@3P$ P
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ME@T/+5?CN*&%<:^(VCA%Q@9%M#PMN2+E2N@4ZH8$^HO2Y)$W81O8'NZK-L,
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MHO$Z*0P]VW6!TX74)B'\!Z%*UFZ>"#4_@!]"X,=K44;'=I4 4!3 '[:=H)=
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M68JY/IQQ!N5;#8#[CT*4RQ.EH/F2_.)_4$L#!!0    ( -,V=E8Q!2_35@,
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M)JMK7/6AQ=)>G69"XT7,#A=X\P5I%N#_5 B]^3 !FKOT^']02P,$%     @
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MK&U)A80%0XFU'( **9:$=W#1RL #3,&.BN@4D#].1C>[6J,*B J"1<TU0U!
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M965T-3<N>&ULS5EM;^(X$/XK%BNMNE*W)*:E+PM(]$W+Z5:JRN[=A]-],,D
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MCIEW J)L\TYT9R>%U9P.,.]DKZ"W'/2H>2<@S#;O1(V9IL^;Z2&,D[V:WJH
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M ?3/\DZBY;8L*2N *R8XD;":.C/_8M$W_M;A%X.MVEL3HV0IQ*,Q;M*IXYF
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M.I,%8\^Z\S6?6HX& @J9U Y8O38P TJUD<+XW7I:W91:V&^_N'\RN:M<%EC
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M)M5A;9J%NDZ!ZP#U?<F8?.GH$[N[H-._4$L#!!0    ( -,V=E8QP\#_NP,
M %<-   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+57;6_;-A#^*X0*
M%"VP1F^V[*2V <?)N@#):B3K]J'8!UHZ6T0ITB/I.-VOWU&293F2E;3POE@D
M???PN8<\\CC:2O5-IP"&/&5<Z+&3&K.^<%T=IY!1?2;7(/"?I509-=A5*U>O
M%= D=\JX&WA>Y&:4"6<RRL?F:C*2&\.9@+DB>I-E5'V_!"ZW8\=W=@/W;)4:
M.^!.1FNZ@@<P7]9SA3VW0DE8!D(S*8B"Y=B9^A<S/[0.N<6?#+:ZUB8VE(64
MWVSG)AD[GF4$'&)C(2A^'F$&G%LDY/%/">I4<UK'>GN'_FL>/ :SH!IFDO_%
M$I..G:%#$EC2#3?W<OL;E 'U+5XLN<Y_R;:T]1P2;[216>F,##(FBB]]*H6H
M.?C1$8>@= B>._2..(2E0ZZ<6S#+P[JBADY&2FZ)LM:(9ANY-KDW1L.$7<8'
MH_!?AGYF\MFDH' BI4 80D5"A!0?JK[68#3Y0*9)PJSLE),;46P>NPCOKL!0
MQO5[-+G^<D_>O7TS#*/>Q_>D;! FR!^IW&A$UB/7(&,[KQN7["X+=L$1=GY
M[J0PJ2;7(H'D$,#%4*MX@UV\ET$GXA7$9R3T?R&!%P0MA&:O=_<[Z(25_&&.
M%Q[#8SKF4F\4$+G$7%IHEC"J&&CRU=H29B#3?[<I5P#WVH%M]E_H-8UA[&!Z
M:U"/X$S>OO$C[V-;U"<".]"@5VG0ZT*?S!6L*4MPJZ .5,1 X E/*0VM&Z;
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M)UN[KF6))8PY_4$RE8^<>P=EL,(;JF:\^@Q-/59@RJFT3U0UN9Z#THU4O&C
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MQH)8:+(7-W&X3PQZN&\H;V;-M-X0EQ[N$PXM06:BBR%.,T8\C\N$5ARB1W%
MP"L<JW7!N[CKLN*!+S+-] )>LH.P*^QE=Q<G'":>;02AF53 3'H.Y@H'9Q+K
M]CJ,?(^B1.N% )A5>Q!7. B3"NO$E\O,Z% S.LVK N;5U^#MA9NX< 0G8\DU
MUM!"$[Z8W@3^#GJN;BAO9LVTYA"PYG@%_KJ6[,1Z6NPRPT)X5GRA%AUAC^B
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MFKNHG0.=%TK9G>$NZ"=Y^A=02P,$%     @ TS9V5M9*+P!T!@  W2H  !D
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M\J2E4E,>_/SL9S)T.8CI4JITWHVEO[+R+&5Y(]BF.([XP(1@27&YIGY(LUQ
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M5;;JAN9ZC"^2J[M4Y<GH"R@.!+I&+_4<$5NC:I;7;'U%LN+N _:=NU( (D*
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M658=)D!6P'6 NK]F3+Z?Z+V1=B\L^A]02P,$%     @ TS9V5IS ,*QG @
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ME7D)%98C7@/3*RLN*JQT*-:NK 7@PH(JZ@:>E[@5)LS)4CLW$UG*&T4)@YE
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MM %F?RN$/CAV8H8',OT#4$L#!!0    ( -,V=E8DN\^N;Q(  %XI 0 9
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M61J1F$5B-HDY).:2F$=B/HD%)!:26$1B,8DE))9"F)!;YD-NF2K]O-W!RMM
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MFA GYE"8-O><I_J%L])JYM"X0#4+U6Q4<\S=&9R?Y@0ZH"<9<#0YE04%.FZ
M:B&J1:@6HUJ":BFEB6DRM)]-=?MYG]/1VG^T+[=YG6?735XK3U*K!SLX<]!.
M-*K9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6DII8H090X2]>B?:1#O1J&:AFHUJ
M#JJYJ.:AFH]J :J%J!:A6HQJ":JEE";FV-")-M6=Z+T/[- ^-*I9J&:CFF/N
M]J'EQUDN.JZ':CZJ!:@6HEJ$:C&J):B64IH8/$-QVE3V*,\O%FOY49^_6+3'
MA+.U=E%433Z[759E==-]>(B[N/+4!X)0<[//*%*S4,U&-0?57%3S4,U'M0#5
M0E2+4"U&M0354DH3<VSH:YOC5S\01*O=J&:AFHUJ#JJYJ.:AFH]J :J%J!:A
M6HQJ":JEE";FV% 1-]45\4]=.VG5:-6U=M<7E]HO^^Z2-*70;CBJ6;WV^.*V
M/I*^+<SN%Q7>AJH_G6;'03?/134/U7Q4"U M1+4(U6)42U MI30Q6H9"MZF>
M;/M#65:S[76^1^ER7XMLJN]9/5]KLW:U8I:56E,7[?^[S2AF[6%?MIQKY79F
M7.VFSIX)([3@C6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6F9$9U^9_2I%]4_:<T
MI39/#*.AE6VJ6]E_*HRDT8-6MU'-0C4;U1Q4<U'-0S4?U0)4"U$M0K78E)3[
M#7GRH-5M2A,3:JANF^KJ]GX)]?(N$=K<1C4+U6Q4<U#-134/U7Q4"U M1+4(
MU6)SMSI_ILMS">V 4YJ02^.A SY6=\#_Y!6[S8*9>:+??\Z)YG;1I;RBI]ZB
M0S,,U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;64TL2<&]KI8_VUK^B-T8HZ
MJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHII8DY9@PYIJR.GM\GUW677+,^
MN=9/WA L32NTB(YJ%JK9J.;TVHL?5NNBPWJHYJ-:@&HAJD6H%J-:@FHII8E!
M-'3,Q^J..7;@>'E_5O[+YJS\Y_M+A,I#2+2XCFH6JMFHYJ":BVH>JOFH%J!:
MB&H1JL6HEJ!:2FEBX@WE]K'YZH>0)IICI&:AFHUJ#JJYJ.:AFH]J :J%J!:A
M6HQJ":JEE";FV%!N'S.3D:N9@\,);:RCFHUJSE@R&;DI?7<@.JXG&??IM"_H
M@ &JA:@6H5J,:@FJI90FILE0,1^_5#'_V1-2:-4<U2Q4LU'-Z;7'+W/YA6H7
M'==#-1_5 E0+42U"M1C5$E1+*4U,HJ&1/E8WTN\;"%:;2&6UVIR7ZGKFE]6B
MS:!9D97%'SL34RUVSUM]_:SYR]GC,U47==$&6:G%/_):^_S[77'5H:ML^>,!
MD"8<VE]'-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"VE-#$%ARK\^/35SU*A
M97A4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)*$W-L*,R/U87Y0SYH8;P[
M/_;VP]^>'A)=J@<].'S0QCNJ.:CFHIJ':CZJ!:@6HEJ$:C&J):B64IH0/I.A
M%3]A9D97,X?N&:&:A6HVJCF3W8G*QQ-#=@X+'=?KM<=O\GAZBAP=,$"U$-4B
M5(M1+4&UE-+$-!FZYQ/US.A?ZFRY;M.D._6TJHM9KF7#NP&;2EOE]755+[)E
M^Y/JJBQN-C^1YHTNV=&1?<#'I7J3#LX2M$Z.:@ZJN:CFH9J/:@&JA:@6H5J,
M:@FJI90F1I,Q1).Z3OYA/B^ZL,G*1P=:9=;D\^>#::T\%IOL]J6EG]UVJ=ZR
M@Q,*K9"CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:6)"37TS"?JGOG'9S)H=K>X
M:X.JC:&GLRF\D$^[<W<_MPN%UL)1S48U!]5<5/-0S4>U -7"7IN\^,R,^B6%
M.9DF8W&A&-VX!-522A,S96AR3Y0-R^'T3O/TR$R:&.;NXS*1?>KCI7K8@Q.#
MU&Q4<U#-134/U7Q4"U M1+6HUW3]T1-]>O+F]&FND(,FJ)92FI@K0[-ZHFY6
M?]KY]%UM?E<7RQNMN<V[HZFBFA]RM@<M8*.:A6HVJCF]]CBP3>E;=M%A/53S
M42U M1#5(E2+42U!M932MO%TO+[-\\;*FNS\W2*O;_++O"S; Z/J;MET!SB/
M;FT3Z;J-+_WM!^/H>.?V"_WMI2ZYW=+?VK+;'?VM+[L]UM\FF]N/A\TY?[?*
M;O(XJV^*]J"MS*_;33MY,VU_$75Q<_OP35.MVK\\1]I5U3358O/E;9[-\[I;
MH/WY=54U]]]T WROZM\V=__\OU!+ P04    " #3-G96B?PU,Z4"  #W!P
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MFIV\8U;8C8;N0*Z)[;ATQ,T=MS5/4\!@P.\KYVA[" &&^5S\ 5!+ P04
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M B0L!,$TU0\/JA^:Z//0N[DEZHY=J5B)/.^@\H:0BWO-)&\3LY'95<PE;%S
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M]-@K!K&7#&*O&<1>-,CY,LB#WGC[,B;HH"&J1?L]A)@:5(]4VVEQS)V6AU_
M?<U';LV#=0X/VEY!-0_5?%23J!:@6HAJ$:K%E*9'L>W".(=PPA<'K<6@FHMJ
M'JKYJ"91+4"U$-4B5(LI38]H6XMQS"=\^7[ON9LGUCFV:%4&U3Q4\U%-HEJ
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MS:=F[5[,IWRGBIS!O2!R5Y94/"VAX(>9Y5K/"ZM\FRF]8,^G%=W" ZBOU;W
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M'(AA3CX@[C\2PE]/9 '-SL+Y?U!+ P04    " #3-G96A-<!+TX$  !!$P
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M<FMS:&5E=',O<VAE970Y-RYX;6RU6EUOVS84_2N""Q0M,$<627^UMH$VV=
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M36  $R<$,&E%>P>:%%$;3<.];UFJO^)*KK][V; D9W=RU.@DD1:BVGQKU.9
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M&>%7$D@3@.-S(?1+Q]3AQ7?7\!]02P,$%     @ TS9V5N K7VBZ"   *D\
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MI:,=NY#>FTQ\6*);%?1N=D&OCIY7*=H]@?.-$#0-G\JDF)$_:ZV=^?/;S#Q
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M@?Q]R7F^.RDJJ#^/-_L74$L#!!0    ( -,V=E;PD-*#@@@  'I0   :
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M 7H^X5P]=LQ%N_JPBOX!4$L#!!0    ( -,V=E;/NGSLR00  %@:   :
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M2:QT8NS6B>]7=(UN154:P^ >[/VD Z@RA$+K.TZ)R#CX\1-M#-0TT<4/$HU
MH?7CIQ1S[%;,_HDV-K0(#Q/M"!MBL+$EVEC)YM@MF\<\M02JFF-7";0C.KI*
M&BM]&[NKI#Z)U@WE31A49L9ZO=7FFX,'UXYHQQ,2;6PJJ0[3D\E(2[0&(UNB
MC95^C(_HQ_&)-C8\#J8E6H-1$&M,="-KHE4*,78KQ'_1<OF,_J*%7*SF2(#*
M0E T H76]YU2D/'\#>1:T!X$4#0"A=:/GY++L5LNGY!K=:VK_1KD_E)O%WV/
MCH1$Z? $OITXT6NCR>!>MG!_K?<3M]]#<R=*<R=@?<>)7F4]'[8=N[_-VS??
M0\\F2L\F;CV[R'A>BVJ3H1LF1&Y^-L>-X?TP-VB/,A1:WW]*0"=OH$<Y 97P
MH&@$"JT?/[4Q2*![E-V WL[4!;WV%(_;ID]<J?[DU9W';@1OIJY>X8[HZ';B
MY.#("L S*V /K8 ]M6)T^3E1FXL$OIW8#>GM(U?AN".NF]@VB(G:&B1@3<)N
M)&_"(Y[:,]C8-I*)$M.)6TQ_*/)*H(\5KRW-2.[QWCQ!53846O]L%Z6RTS?0
M]YN"%MU!T0@46C]^:@.00O?]IOH^0"O:CK A!IO <M!4JC1[^NJ^7S>"]V(P
MM'4,B8YN^TV5MD[AVG[=4-Z$025N.KJ@G2K=FL*W_::&CE[M?!>3$<;#:.M&
MMO-=4J5(4["VWPZI=X#;,(TN#$9!,OQ5WV 4#R_0Z<%1DVO&']HC.VLY29D&
M=L<N[C_='POZOCT,<_#Y=?".[ [W5#"[LT8_4?Z0ES4JV+V$G)TUT^*[XSMW
M;^06O3W0\JX2HEJW+S-&5XPW!O+O]U4E7MXT7[ _1/7J_U!+ P04    " #3
M-G96>SU?-^P"  !W!P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL
MK57?3]LP$/Y73IF$0(*F24-!T$:B+=.F":DJ8GN8]N FU\;"L3/;I?2_W]E)
MLP(MXH&7Q#_N^WQWW_D\6"O]: I$"\^ED&88%-965V%HL@)+9CJJ0DD["Z5+
M9FFJEZ&I-++<@TH1QMUN/RP9ET$Z\&M3G0[4R@HN<:K!K,J2Z<T(A5H/@RC8
M+LSXLK!N(4P'%5OB/=J':JII%K8L.2]1&JXD:%P,@YOH:I(X>V_PD^/:[(S!
M13)7ZM%-ON?#H.L<0H&9=0R,?D\X1B$<$;GQM^$,VB,=<'>\9?_J8Z=8YLS@
M6(E?/+?%,+@,(,<%6PD[4^MOV,1S[O@R)8S_PKJQ[0:0K8Q590,F#THNZS][
M;O*P XCZ!P!Q XA? Y(#@%X#Z'T4D#0 G^JP#L7G8<(L2P=:K4$[:V)S Y],
MCZ;PN72RWUM-NYQP-IVA8!9SJ)BV&\BYR80R*XT&SN"^+@50"QBKD@K-,*\5
M%1O8 FF_0OW$C2*;D6(ZA^,ITRAIS_*,B1,XGJ!EG 9G</LP@^.C+Y>]?G)]
M LT N(0[+@2QFD%H*1[G59@UOH]JW^,#OD<QW"DZS<"MS#%_21!2(MILQ-ML
MC.)W&2>8=: 7G4+<C>,]#HT_#H_VP"<?AW??B:;7:MOS?+U#?*V:3D)6JI6T
MAE*>K;0FR><;(*TXR>X$K;0B*9V\9/N(&RHR2?>>;K@%DMDH*5& <8)G5!W>
M/*]9#%+U4!7M0CPS)\/?;&ZLINO]9Y_ =0#)_@!<R[LR%<MP&%!/<V=CD!Y]
MB?K=ZWWB?";9Y)/(7@B7M,(E[[&G/PZE/]NYAJ=@"J7MF45= I:54!M$F*/$
M!;=[;U-]Z*4_U#T'3VG4N1B$3[LY?&L3=Z*7-I.W-LF.31UQN-.22M1+W]H-
M!4 U6-_'=K5]/6Y\TWRU/J)7I7X$_M/43](=TTLN#0A<$&6W<W$>@*[;?#VQ
MJO*-;ZXLM5$_+.AE1.T,:'^AE-U.W 'M6YO^ U!+ P04    " #3-G96^/-+
M_ 41   _J   &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&ULO9UM;]M&
M%H7_"N$NBEU@*_,.7R1F'0-)W+1;K-N@:;L?BGY@),82(HE>BHX;H#]^25K6
M7-GD/3-#BOW0^&WNS(C2<RR?N8<7]WGQ:;?,LM+[<[/>[EZ>+<OR]L7Y^6Z^
MS#;I;I+?9MOJ.Q_S8I.6U:?%S?GNMLC213-HLSY7OA^?;]+5]NSRHOG:N^+R
M(K\KUZMM]J[P=G>;35I\>9VM\_N79W3V^(6?5S?+LO["^>7%;7J3O<_*7V_?
M%=5GYX<JB]4FV^Y6^=8KLH\OSU[1B]<JFM4CFA_Y;97=[]C'7KV7#WG^J?[D
MWXN79WZ]I&R=S<NZ1EK]\SE[DZW7=:EJ(?_;5ST[3%H/Y!\_5G_;[+[:S8=T
ME[W)U_]=+<KER[/9F;?(/J9WZ_+G_/[[;+^CJ*XWS]>[YO_>_?YG_3-O?K<K
M\\U^<+6"S6K[\&_ZY_Z18 ."H&. V@]0S;H?)FI6>966Z>5%D=][1?W35;7Z
M@V:KS>AJ<:MM?5G>ET7UW54UKKS\.5NG9;;P;M.B_.(M5KOY.M_=%=G.^\9[
M_W"IO/RC]]-M_1CNO.^*=%O_>)E[U^DVO5EM;[RK55$]Q'GAI=M%->8V*SZO
M=GDU[O$;.^_O5UF9KM;_N#@OJS77,Y_/]^M[_; ^U;$^4MYUOBV7.^_;[2);
M'!<XKS9[V+%ZW/%K)5:\RN83+Z!_>LI7RMLMTWJS?_/.]Q\*,P2'QS1H9@@[
M9GB7%<WK93O/O-?5,V9Q>/A^O\XV'[+B#^\O[_NTJ%Y'U>ON??48+ML>&'&2
M^N7Z8G>;SK.79U6=7?6@9V>77W]%L?\O80OA80MA4SWH>I .3X3ZZI?55=^E
M\X<]?,C*^RRK7Y/ZF;.J'L+?ZQK>JLPVNS_:MA.>8#O183N1>$6NLMV\6#47
MH=[/+WP_]ZMR>;29+VVKE^M+%_-HP?%AP;%8\)<OM\TCGS=K;EN0/)X]!;]I
MJ+78EY*>W]/#XJ9B\08"WJ)ZP-H6)H_]X:YZD@1^\^KSA;7,#FN9B?5^O*M?
M4!Q1?[6^D!_6]E K:FK5@O7YDJ)DYOO52CZW+"(Y+"(1%U%]O/J4>>^*5?6*
M7VV]7]]?5<OH8LK#4AXJDL_7TK$,\C7,?7$AW_YYNRK2YFG>=7E A>KZ3)KK
M4UV@0+I Q!2&Y$>G%H3J@7&"H%S;$1ND]-K5V!S<SSCPCK0VD2Q._5$()C!F
M(6DQ(E$<#&@("CP^!3$#24L*R<R7*0@&FV*0M&"03'P[$.Z+'9$P[@8A:6D@
MF>\N*-R7-&.A%@:2E<&$A7(%<Q9JH2"@%-TL?)>5U?5[LTPW'XKVU8JE'<&A
MM+8H?VP4*E&+7'>DA4G)PM0?A6 "?DF__DH%@;AN+4I*E @#'(("YCA46E>4
MC'T9AV"P*0Z5E@PE$]\.A_MB'(<JZJ2ATAJA9,R[T'!?THB&2LN#DN7!@(:@
M@C$-E18+!<2BFX:O%NG&>U_FV_:EBG5=P:&E1<U&1Z$H1:X[TKJD9%T: (7R
M!%W7\_@/+%J, OEM"D8@*&".P$#K22#C7D8@&&R*P$#+1"!3W@Z!^V*&" S8
MW\)DM+L@<%_2"(&!EH1 E@0#!((*Q@@,M$($0"&$-\=96BZK"_B?B7>=[CJ>
MY6)U1VP$6E6">&P0!J(*N>Y(2U(@2U)_$(()Y*MZO&HM2('\3L4 AW(!"QQJ
M30EDY ,<RH--<1AJR0AEXMOA<%_,$(>AUH@0_#', 8?[DD8X#+4\A+(\&. 0
M5##&8:C5(@1JT8W#Z]5\F69K[[N)]ZHB2>M?"^7JKIX),TW&=TU.89N$6I["
M4QLG8 +YJAZO6LM2V-<] 07,<1AJ90G[N"9@L#$.M62$0QHGX7/G1,*AUHAP
M>.<DM+!.(BT/46_K!%0PQF&DU2)RMD[>I7=K[TWUJLN*UK6>PC>)M+A$H_LF
MT2E\DT@K4W1JWP1,T'E!CQ>LQ2CJ:YJ  N80C)@/W\<T 8--(1AIH8B&-$VB
MYZ:) ,%(*T,TO&<267@FD1:%J+=G BJ80U!K1.3LF7R[7N6E]S8O=ET8/(5G
M$FM1B4?W3.)3>":Q5J3XU)X)F$"XI,=+UEH4][5+0 %S$,9:3N(^=@D8_#Z[
M+9O7@$<AI&&L%2,>TC.)K3R36$M$/+QGLB])BBTFF5#<L19V"JNW:P(J5)=J
MXE& >1AKN8B=79.WQ2I;5 _<TOM<+?EUOEQ7A+G;+KSOT_6'=-[ZGEF>S14H
M6G+BT;V4^!1>2JSU*CZUEP(FL+O*QT?\M'1-^SHLH( Y-:=:?:9]'!8PN/GU
MD:8-,$E:CE:6Z9 .R]3*89EJ*9D.[[#L2QX!D]3$CSH6HS5DVMMD 16:WR#K
MRU034[Q.6E*FSB;+C^EV_L7[+:U>0AVK/87#,M4*-!W=89F>PF&9LL/#IW98
MP 3")3U>LM:H:5][!12P8*&6F6D?>P4,ODZ+2CZ4>NB"D,YA:\&8#>FOS)[[
M*X'?"<.95HC9\/[*OB016\QT$G8L1:O#K+?! BI45VG27*0:A>)5TF(QLS-8
M?JI0874@6Z[O2(^9UI?9Z!;+[!06RTR+T^S4%@N8P/A ]DRKTJROP0(*F -Q
MIH5EUL=@ 8.OLOG^'?44]Z:PYI1!NU-:VE.$0]DS+16SX5V6?<DC*":3.#GZ
MKZ-M1FM&TMMT 16:;K['WQ:EBY9H"4GL3)<GB(3GM.7RCCQ)M.PDHULOR2FL
MET1K5G)JZP5,8'5..]%:E?1U8$ !<THF6FZ2/@X,&'R@9 +?12=:3)(A39BD
MI7.E^UUTHM4C&=Z$2=I,&.I8B1:-I+<) RHT4/3\!+^'3EB+HYT+\X2*\GEM
MN;9KSYO/^R)'-V(>IQQZ4ZROTC^U%X-F,#JU3;YB2^[KQ: *%JU\/FN*]/O8
M,6BT!1;)9UV/_I!^S&,U0S*2SSH=_>$MF<>:1G DG_4Y^KT]&53"G(_DL\Y'
MW\Z7>?K6VN X-YC"F2FL:=(?W8YYG'+H3;&F2__4C@R:P>)4-_%V?M"-;X!+
M4,$"ET<=_7U\&#3:!I>\55_NG+?%)3VW8R1<\@Y[T 'OA$MJZWGIPB5OG0>M
M[R:X!"4L<,G;YT$+/,"ER7%O,(4K67C3/8UNSY#<Z.^\*29DH(=_ %R"&2Q.
M?1/O^ <-^R:X',JH(=[T#[K^$2Z1>IGCDK7SD]Q=;XM+]=RPD7#)NO )=,D[
MX5*U]<1TX9*UUA-HC3?!)2AA@4O67D^@11[]55(^#@ZJ.^?H,!U2HQLW)&<
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MO,_6Z)#;\I!B\8'$MK(9-MD,W[>:*]JP-77!"$(GA-W=V .$8Q>.86>QQ[M
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M,KI#3$5+FCK(Q,RR9?E1JN9]*IC\-I)Y8OP$6T@W@!:,)DC"8C*CC.13LF0
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M$#3)#E= 0F J0'Z_H%3L3]0-RG]2C/\#4$L#!!0    ( -,V=E9$I"A/B@,
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MJK<'Z!U4[P#0.ZC> :!W4+T#0._0W2P!Z!U4[P#0.ZC> :!W4+T#0.^@>@>
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MXMS(XES)XMS)^J^7LKZ/X_X?QR_/N*_:X34_6?Y;X>8G4$L! A0#%     @
MTS9V5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #3-G96AC> .^\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #3-G96F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( -,V=E;0ZI]A; <  '\C   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #3-G96],R[PGD%
M  #7%@  &               @(&P#P  >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L! A0#%     @ TS9V5GV,?&G- P  W P  !@              ("!
M7Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -,V=E;-
MTW6&GP4  .H9   8              " @6(9  !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"% ,4    " #3-G96Y1Q!D_0(   L*P  &
M    @($W'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MTS9V5A;\M:!G"   S#H  !@              ("!82@  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -,V=E9?V?=V=00   T*   8
M          " @?XP  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " #3-G96I@AK1!@)  "'%0  &               @(&I-0  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ TS9V5A-5I(^#"   !18
M !@              ("!]SX  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( -,V=E8_5F8 %0@  ,L7   9              " @;!'  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ TS9V5EU=Q!)?
M'@  :V   !D              ("!_$\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " #3-G96)8K("7X)   9&0  &0
M@(&2;@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -,V
M=E;#A67(< (  'X%   9              " @4=X  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ TS9V5EM:E+M_!   1@L  !D
M         ("![GH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " #3-G96*!_UV=($  "O"P  &0              @(&D?P  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -,V=E:F_CIXJ@,  #P)
M   9              " @:V$  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ TS9V5FH**&>4!0  ^@P  !D              ("!CH@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #3-G96T4HE
M3+X"   C!@  &0              @(%9C@  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( -,V=E9>PCC,,Q0  .U'   9
M  " @4Z1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MTS9V5K6<6]*K @  [P4  !D              ("!N*4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " #3-G962DL6 :L%   4$   &0
M            @(&:J   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( -,V=E8OR?"6^ ,  "X*   9              " @7RN  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ TS9V5C\YOKLA#P
MV#L  !D              ("!J[(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " #3-G96LBZJ:'T$  "@"@  &0              @($#
MP@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -,V=E:/
M8^P[L@,  %8(   9              " @;?&  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ TS9V5@+'O^EE!   *PL  !D
M     ("!H,H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -,V=E;#L;=NQ D  #,>   9              "
M@1_T  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ TS9V
M5J&9[OH6!   =0H  !D              ("!&OX  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " #3-G96+F-,;FL"  "*!0  &0
M        @(%G @$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( -,V=E:Q):[ $",  #=S   9              " @0D% 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ TS9V5BC5Y1=(!@  )A(
M !D              ("!4"@! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " #3-G96JQ$(TM,#   K"0  &0              @('/+@$
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -,V=E:ZJ4P%
M4P(  !0%   9              " @=DR 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ TS9V5L_ D_?< @  ^ 8  !D
M ("!8S4! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #3
M-G96UW^8P(H$  !O"P  &0              @(%V. $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -,V=E:J4"/KUP,  -@)   9
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M970T-"YX;6Q02P$"% ,4    " #3-G96X];&V+$#  !("   &0
M    @(%C3@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M -,V=E9%#($\! ,  ,8&   9              " @4M2 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ TS9V5KX1UR5D"0  52X  !D
M             ("!AE4! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " #3-G96,04OTU8#  "G!P  &0              @($A7P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -,V=E;>4#+%MP0
M %<+   9              " @:YB 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ TS9V5OE,<+(!!@  EA0  !D              ("!
MG&<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #3-G96
MP=$\G&(&  #B$P  &0              @('4;0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -,V=E9"?J!9- ,  #<'   9
M      " @6UT 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ TS9V5A$2'!E@!@  Y14  !D              ("!V'<! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #3-G965_K;(ZL"  #.!0
M&0              @(%O?@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( -,V=E;V8DA+Q0(  #0)   9              " @5&! 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ TS9V5A23*NJQ
M!P  '#L  !D              ("!380! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " #3-G96P,;>Z.$$   5&@  &0
M@($UC $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -,V
M=E9\/8Z:L@0  #$7   9              " @4V1 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ TS9V5H;ZEW31!@  C2L  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( -,V=E:@J:)U6@(  -X%   9
M  " @4ZJ 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
MTS9V5MZ[F L_ @  +P4  !D              ("!WZP! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " #3-G96?36JU[H"  "L!P  &0
M            @(%5KP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( -,V=E8QP\#_NP,  %<-   9              " @4:R 0!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ TS9V5G.Q)^!T @
M=@8  !D              ("!.+8! 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    " #3-G96%$PWH8$(   ./0  &0              @('C
MN $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( -,V=E;F
MU:F06 ,  '0.   9              " @9O! 0!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ TS9V5K7&I@!] @  U04  !D
M     ("!*L4! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -,V=E9-01=CS00  # ;   9              "
M@9+8 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ TS9V
M5E.92/TU!   8Q8  !D              ("!EMT! 'AL+W=O<FMS:&5E=',O
M<VAE970W-RYX;6Q02P$"% ,4    " #3-G96-6X%PG0"  !C!@  &0
M        @($"X@$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0
M   ( -,V=E8NB:V20@(  "P%   9              " @:WD 0!X;"]W;W)K
M<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ TS9V5B2[SZYO$@  7BD!
M !D              ("!)N<! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q0
M2P$"% ,4    " #3-G96B?PU,Z4"  #W!P  &0              @(',^0$
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( -,V=E9FU"B,
MW (  +@(   9              " @:C\ 0!X;"]W;W)K<VAE971S+W-H965T
M.#(N>&UL4$L! A0#%     @ TS9V5NJMQSU< @  JP4  !D
M ("!N_\! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " #3
M-G96C_HD\>((  ! :@  &0              @(%. @( >&PO=V]R:W-H965T
M<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( -,V=E9[2':(S@<  $=/   9
M          " @6<+ @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#
M%     @ TS9V5I]-R+:L P  /@T  !D              ("!;!," 'AL+W=O
M<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " #3-G96$1-7M(P"  #+
M!0  &0              @(%/%P( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM
M;%!+ 0(4 Q0    ( -,V=E9ZP3Y?F0<  *]&   9              " @1(:
M @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ TS9V5G5<
M\S[B&   ZY\! !D              ("!XB$" 'AL+W=O<FMS:&5E=',O<VAE
M970X.2YX;6Q02P$"% ,4    " #3-G96 C7>=T\0   _^P  &0
M    @('[.@( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    (
M -,V=E89FI,W<@,  '@.   9              " @8%+ @!X;"]W;W)K<VAE
M971S+W-H965T.3$N>&UL4$L! A0#%     @ TS9V5I6%^\V#"   W5D  !D
M             ("!*D\" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"
M% ,4    " #3-G96QV^'&EP%  !E*   &0              @('D5P( >&PO
M=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( -,V=E:$UP$O3@0
M $$3   9              " @7== @!X;"]W;W)K<VAE971S+W-H965T.30N
M>&UL4$L! A0#%     @ TS9V5@PMI)\9 P  1PD  !D              ("!
M_&$" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4    " #3-G96
M"^@_N#D$  #!#0  &0              @(%,90( >&PO=V]R:W-H965T<R]S
M:&5E=#DV+GAM;%!+ 0(4 Q0    ( -,V=E;)BM@?K04   <J   9
M      " @;QI @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%
M  @ TS9V5OA45N'I!0  T24  !D              ("!H&\" 'AL+W=O<FMS
M:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " #3-G966.9ADD,$   6&@
M&0              @(' =0( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+
M 0(4 Q0    ( -,V=E:T [/T# L  +IN   :              " @3IZ @!X
M;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( -,V=E9-)Y;K
M1@<  ,=+   :              " @7Z% @!X;"]W;W)K<VAE971S+W-H965T
M,3 Q+GAM;%!+ 0(4 Q0    ( -,V=E9<-RE*/@,  (,-   :
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M,3 V+GAM;%!+ 0(4 Q0    ( -,V=E;/NGSLR00  %@:   :
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M,3$Q+GAM;%!+ 0(4 Q0    ( -,V=E;X\TO\!1$  #^H   :
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M,3$V+GAM;%!+ 0(4 Q0    ( -,V=E9$I"A/B@,  'D9   -
M  "  6#B @!X;"]S='EL97,N>&UL4$L! A0#%     @ TS9V5I>*NQS
M$P(   L              ( !%>8" %]R96QS+RYR96QS4$L! A0#%     @
MTS9V5C,DU=NS!P  44P   \              ( !_N8" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( -,V=E;),"%3. ,  !=$   :              "
M =[N @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -,V
M=E:\;2HCC (  &-!   3              "  4[R @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !\ 'P +"(   OU @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>602</ContextCount>
  <ElementCount>419</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>177</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Statement of Profit/(Loss) of Immatics N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV</Role>
      <ShortName>Consolidated Statement of Profit/(Loss) of Immatics N.V.</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV</Role>
      <ShortName>Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statement of Financial Position of Immatics N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV</Role>
      <ShortName>Consolidated Statement of Financial Position of Immatics N.V.</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statement of Cash Flows of Immatics N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV</Role>
      <ShortName>Consolidated Statement of Cash Flows of Immatics N.V.</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV</Role>
      <ShortName>Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V.</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Group information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/GroupInformation</Role>
      <ShortName>Group information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - ARYA Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AryaMerger</Role>
      <ShortName>ARYA Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Application of new and revised international financial reporting standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards</Role>
      <ShortName>Application of new and revised international financial reporting standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Significant accounting judgments, estimates and assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions</Role>
      <ShortName>Significant accounting judgments, estimates and assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Accounts receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsReceivable</Role>
      <ShortName>Accounts receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Other current and non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentAndNonCurrentAssets</Role>
      <ShortName>Other current and non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IntangibleAssets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Accounts payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsPayable</Role>
      <ShortName>Accounts payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Revenue from collaboration agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RevenueFromCollaborationAgreements</Role>
      <ShortName>Revenue from collaboration agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Share listing expense and change in fair value of warrant liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities</Role>
      <ShortName>Share listing expense and change in fair value of warrant liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Other financial income and expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherFinancialIncomeAndExpenses</Role>
      <ShortName>Other financial income and expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Shareholders' equity (deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareholdersEquityDeficit</Role>
      <ShortName>Shareholders' equity (deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/NonControllingInterests</Role>
      <ShortName>Non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Personnel expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PersonnelExpenses</Role>
      <ShortName>Personnel expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Financial Risk Management Objectives and Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies</Role>
      <ShortName>Financial Risk Management Objectives and Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Earnings and Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/EarningsAndLossPerShare</Role>
      <ShortName>Earnings and Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Events occurring after the reporting period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/EventsOccurringAfterTheReportingPeriod</Role>
      <ShortName>Events occurring after the reporting period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Application of new and revised international financial reporting standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables</Role>
      <ShortName>Application of new and revised international financial reporting standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Accounts receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/AccountsReceivable</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Other current and non-current assets  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables</Role>
      <ShortName>Other current and non-current assets  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/OtherCurrentAndNonCurrentAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/IntangibleAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Accounts payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/AccountsPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Revenue from collaboration agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RevenueFromCollaborationAgreementsTables</Role>
      <ShortName>Revenue from collaboration agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/RevenueFromCollaborationAgreements</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Share listing expense and change in fair value of warrant liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables</Role>
      <ShortName>Share listing expense and change in fair value of warrant liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Other financial income and expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherFinancialIncomeAndExpensesTables</Role>
      <ShortName>Other financial income and expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/OtherFinancialIncomeAndExpenses</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/ShareBasedPayments</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Personnel expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PersonnelExpensesTables</Role>
      <ShortName>Personnel expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/PersonnelExpenses</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/IncomeTax</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Financial Risk Management Objectives and Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/FinancialInstruments</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Related party disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresTables</Role>
      <ShortName>Related party disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Earnings and Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/EarningsAndLossPerShareTables</Role>
      <ShortName>Earnings and Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imtx.com/role/EarningsAndLossPerShare</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Group information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/GroupInformationAdditionalInformationDetail</Role>
      <ShortName>Group information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - ARYA Merger - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AryaMergerAdditionalInformationDetail</Role>
      <ShortName>ARYA Merger - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail</Role>
      <ShortName>Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail</Role>
      <ShortName>Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail</Role>
      <ShortName>Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Application of new and revised international financial reporting standards - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail</Role>
      <ShortName>Application of new and revised international financial reporting standards - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail</Role>
      <ShortName>Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Accounts receivable - Summary of Trade receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail</Role>
      <ShortName>Accounts receivable - Summary of Trade receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Accounts receivable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsReceivableAdditionalInformationDetail</Role>
      <ShortName>Accounts receivable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Other current and non-current assets -Summary of Other current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail</Role>
      <ShortName>Other current and non-current assets -Summary of Other current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Other current and non-current assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails</Role>
      <ShortName>Other current and non-current assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Other current and non-current assets - Summary of Other non-current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail</Role>
      <ShortName>Other current and non-current assets - Summary of Other non-current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Property, plant and equipment - Summary of Depreciation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail</Role>
      <ShortName>Property, plant and equipment - Summary of Depreciation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Property, plant and equipment - Addtional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail</Role>
      <ShortName>Property, plant and equipment - Addtional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Intangible assets - Summary of Changes to intangible assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail</Role>
      <ShortName>Intangible assets - Summary of Changes to intangible assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Intangible assets - Summary of Amortization expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail</Role>
      <ShortName>Intangible assets - Summary of Amortization expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Leases - Summary of Right-of&amp;#160;use assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail</Role>
      <ShortName>Leases - Summary of Right-of&amp;#160;use assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Leases - Details of Lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Details of Lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Leases - Summary of expenses related to&amp;#160;right-of-use&amp;#160;assets and lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of expenses related to&amp;#160;right-of-use&amp;#160;assets and lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Accounts payable - Summary of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail</Role>
      <ShortName>Accounts payable - Summary of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Accounts payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/AccountsPayableAdditionalInformationDetail</Role>
      <ShortName>Accounts payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Revenue from collaboration agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Revenue from collaboration agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail</Role>
      <ShortName>Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Other current liabilities - Summary of other current liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Other current liabilities - Summary of other current liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Other current liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Other current liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail</Role>
      <ShortName>Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Other financial income and expenses - Summary of other financial income and costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail</Role>
      <ShortName>Other financial income and expenses - Summary of other financial income and costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Other financial income and expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail</Role>
      <ShortName>Other financial income and expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail</Role>
      <ShortName>Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Share-based payments - Summary of Employee Share Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail</Role>
      <ShortName>Share-based payments - Summary of Employee Share Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Share-based payments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail</Role>
      <ShortName>Share-based payments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail</Role>
      <ShortName>Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Shareholders' equity (deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Shareholders' equity (deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imtx.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Non-controlling interests - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail</Role>
      <ShortName>Non-controlling interests - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Personnel expenses - Summary of Personnel Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail</Role>
      <ShortName>Personnel expenses - Summary of Personnel Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Personnel expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail</Role>
      <ShortName>Personnel expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail</Role>
      <ShortName>Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Income Tax - Summary of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Tax - Summary of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Income Tax - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/IncomeTaxAdditionalInformationDetail</Role>
      <ShortName>Income Tax - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail</Role>
      <ShortName>Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail</Role>
      <ShortName>Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail</Role>
      <ShortName>Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail</Role>
      <ShortName>Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Financial Risk Management Objectives and Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail</Role>
      <ShortName>Financial Risk Management Objectives and Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail</Role>
      <ShortName>Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail</Role>
      <ShortName>Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail</Role>
      <ShortName>Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Commitments and contingencies - Summary of Contractual Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail</Role>
      <ShortName>Commitments and contingencies - Summary of Contractual Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>1108 - Disclosure - Commitments and contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>1109 - Disclosure - Related party disclosures - Summary of Compensation of Key Management Personnel (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail</Role>
      <ShortName>Related party disclosures - Summary of Compensation of Key Management Personnel (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>1110 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail</Role>
      <ShortName>Related party disclosures - Summary of Compensation for the Supervisory Board (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>1111 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail</Role>
      <ShortName>Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>1112 - Disclosure - Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail</Role>
      <ShortName>Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>1113 - Disclosure - Related party disclosures - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail</Role>
      <ShortName>Related party disclosures - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>1114 - Disclosure - Earnings and Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings and Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>1115 - Disclosure - Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail</Role>
      <ShortName>Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="d400206d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>1116 - Disclosure - Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail</Role>
      <ShortName>Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="d400206d20f.htm">d400206d20f.htm</File>
    <File>d400206dex121.htm</File>
    <File>d400206dex122.htm</File>
    <File>d400206dex131.htm</File>
    <File>d400206dex132.htm</File>
    <File>d400206dex151.htm</File>
    <File>d400206dex417.htm</File>
    <File>imtx-20221231.xsd</File>
    <File>imtx-20221231_cal.xml</File>
    <File>imtx-20221231_def.xml</File>
    <File>imtx-20221231_lab.xml</File>
    <File>imtx-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g400206g02d03.jpg</File>
    <File>g400206g07k29.jpg</File>
    <File>g400206g11a01.jpg</File>
    <File>g400206g12p13.jpg</File>
    <File>g400206g21p27.jpg</File>
    <File>g400206g21p28.jpg</File>
    <File>g400206g21p29.jpg</File>
    <File>g400206g21p30.jpg</File>
    <File>g400206g21p31.jpg</File>
    <File>g400206g30f01.jpg</File>
    <File>g400206g35a35.jpg</File>
    <File>g400206g35a37.jpg</File>
    <File>g400206g36a58.jpg</File>
    <File>g400206g37a37.jpg</File>
    <File>g400206g38a60.jpg</File>
    <File>g400206g41a63.jpg</File>
    <File>g400206g42a64.jpg</File>
    <File>g400206g43a64.jpg</File>
    <File>g400206g45x63.jpg</File>
    <File>g400206g45x64.jpg</File>
    <File>g400206g48z31.jpg</File>
    <File>g400206g53n05.jpg</File>
    <File>g400206g92o71.jpg</File>
    <File>g400206g95r13.jpg</File>
    <File>g400206g98m33.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="1339">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>160
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d400206d20f.htm": {
   "axisCustom": 17,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 45,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1339
   },
   "contextCount": 602,
   "dts": {
    "calculationLink": {
     "local": [
      "imtx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imtx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d400206d20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imtx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imtx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "imtx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 817,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 141,
   "keyStandard": 278,
   "memberCustom": 115,
   "memberStandard": 48,
   "nsprefix": "imtx",
   "nsuri": "http://imtx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://imtx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Application of new and revised international financial reporting standards",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards",
     "shortName": "Application of new and revised international financial reporting standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
     "shortName": "Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "4",
      "lang": null,
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
     "shortName": "Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "imtx:PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_EuroWeakensBy1AgainstUsDollarsMemberIMTXSensitiveAnalaysisOfCurrencyAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "imtx:PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DescriptionOfManagingLiquidityRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail",
     "shortName": "Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DescriptionOfManagingLiquidityRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Financial Risk Management Objectives and Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
     "shortName": "Financial Risk Management Objectives and Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:TradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:FinancialAssetsAndFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1104 - Disclosure - Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
     "shortName": "Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:FinancialAssetsAndFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:NetFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1105 - Disclosure - Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail",
     "shortName": "Financial Instruments - Summary of Net Result from Financial Instruments by Measurement Categories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:NetFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1106 - Disclosure - Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail",
     "shortName": "Financial Instruments - Summary of Changes of the Liabilities from Financing Activities Classified as Cash Effective and Non-cash Effective (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:LiabilitiesArisingFromFinancingActivitiesCashEffective",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfContractualObligationsTableTextBlock",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ContractualObligationOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1107 - Disclosure - Commitments and contingencies - Summary of Contractual Obligations (Detail)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
     "shortName": "Commitments and contingencies - Summary of Contractual Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfContractualObligationsTableTextBlock",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ContractualObligationOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "imtx:UnrecordedContingentLiability",
       "div",
       "div",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:UnrecordedContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1108 - Disclosure - Commitments and contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "imtx:UnrecordedContingentLiability",
       "div",
       "div",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:UnrecordedContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:KeyManagementPersonnelCompensationFixed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1109 - Disclosure - Related party disclosures - Summary of Compensation of Key Management Personnel (Detail)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail",
     "shortName": "Related party disclosures - Summary of Compensation of Key Management Personnel (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:KeyManagementPersonnelCompensationFixed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1110 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Detail)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
     "shortName": "Related party disclosures - Summary of Compensation for the Supervisory Board (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:KeyManagementPersonnelCompensationSupervisoryBoardCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "imtx:DisclosureOfCompensationSupervisoryBoardTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1111 - Disclosure - Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail",
     "shortName": "Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "imtx:DisclosureOfCompensationSupervisoryBoardTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1112 - Disclosure - Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
     "shortName": "Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_HarpreetSinghMemberifrsfullCategoriesOfRelatedPartiesAxis_PerformanceBasedOptionsMemberIMTXTypeOfVestingAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1113 - Disclosure - Related party disclosures - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
     "shortName": "Related party disclosures - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AmountsPayableRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imtx:DilutiveEffectOfShareOptionsOnNumberOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1114 - Disclosure - Earnings and Loss per Share - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail",
     "shortName": "Earnings and Loss per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imtx:DilutiveEffectOfShareOptionsOnNumberOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1115 - Disclosure - Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail",
     "shortName": "Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:RevenueFromCollaborationAgreements",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1116 - Disclosure - Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail",
     "shortName": "Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfRevenueFromCollaborationAgreementsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_CollaborationAgreementsMemberIMTXAgreementAxis",
      "decimals": "-3",
      "lang": null,
      "name": "imtx:RevenueFromCollaborationAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Significant accounting judgments, estimates and assumptions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions",
     "shortName": "Significant accounting judgments, estimates and assumptions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Accounts receivable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://imtx.com/role/AccountsReceivable",
     "shortName": "Accounts receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Other current and non-current assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://imtx.com/role/OtherCurrentAndNonCurrentAssets",
     "shortName": "Other current and non-current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://imtx.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Intangible assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://imtx.com/role/IntangibleAssets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://imtx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Accounts payable",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://imtx.com/role/AccountsPayable",
     "shortName": "Accounts payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Revenue from collaboration agreements",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://imtx.com/role/RevenueFromCollaborationAgreements",
     "shortName": "Revenue from collaboration agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:RevenueFromCollaborationAgreements",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Statement of Profit/(Loss) of Immatics N.V.",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
     "shortName": "Consolidated Statement of Profit/(Loss) of Immatics N.V.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Other current liabilities",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://imtx.com/role/OtherCurrentLiabilities",
     "shortName": "Other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Share listing expense and change in fair value of warrant liabilities",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities",
     "shortName": "Share listing expense and change in fair value of warrant liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Other financial income and expenses",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://imtx.com/role/OtherFinancialIncomeAndExpenses",
     "shortName": "Other financial income and expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Share-based payments",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://imtx.com/role/ShareBasedPayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Shareholders' equity (deficit)",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://imtx.com/role/ShareholdersEquityDeficit",
     "shortName": "Shareholders' equity (deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Non-controlling interests",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://imtx.com/role/NonControllingInterests",
     "shortName": "Non-controlling interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Personnel expenses",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://imtx.com/role/PersonnelExpenses",
     "shortName": "Personnel expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Income Tax",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://imtx.com/role/IncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Financial Risk Management Objectives and Policies",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies",
     "shortName": "Financial Risk Management Objectives and Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://imtx.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV",
     "shortName": "Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://imtx.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Related party disclosures",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://imtx.com/role/RelatedPartyDisclosures",
     "shortName": "Related party disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Earnings and Loss per Share",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://imtx.com/role/EarningsAndLossPerShare",
     "shortName": "Earnings and Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Events occurring after the reporting period",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://imtx.com/role/EventsOccurringAfterTheReportingPeriod",
     "shortName": "Events occurring after the reporting period",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)",
     "menuCat": "Policies",
     "order": "34",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Application of new and revised international financial reporting standards (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables",
     "shortName": "Application of new and revised international financial reporting standards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Accounts receivable (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://imtx.com/role/AccountsReceivableTables",
     "shortName": "Accounts receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Other current and non-current assets  (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables",
     "shortName": "Other current and non-current assets  (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://imtx.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statement of Financial Position of Immatics N.V.",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
     "shortName": "Consolidated Statement of Financial Position of Immatics N.V.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:OtherCurrentFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://imtx.com/role/IntangibleAssetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://imtx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Accounts payable (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://imtx.com/role/AccountsPayableTables",
     "shortName": "Accounts payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfContractLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Revenue from collaboration agreements (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://imtx.com/role/RevenueFromCollaborationAgreementsTables",
     "shortName": "Revenue from collaboration agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfContractLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Other current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://imtx.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "Other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Share listing expense and change in fair value of warrant liabilities (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables",
     "shortName": "Share listing expense and change in fair value of warrant liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Other financial income and expenses (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://imtx.com/role/OtherFinancialIncomeAndExpensesTables",
     "shortName": "Other financial income and expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Share-based payments (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://imtx.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPersonnelExpenesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Personnel expenses (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://imtx.com/role/PersonnelExpensesTables",
     "shortName": "Personnel expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfPersonnelExpenesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Income Tax (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://imtx.com/role/IncomeTaxTables",
     "shortName": "Income Tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statement of Cash Flows of Immatics N.V.",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
     "shortName": "Consolidated Statement of Cash Flows of Immatics N.V.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForInterestIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Financial Risk Management Objectives and Policies (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables",
     "shortName": "Financial Risk Management Objectives and Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://imtx.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfContractualObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Commitments and contingencies (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://imtx.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfContractualObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Related party disclosures (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://imtx.com/role/RelatedPartyDisclosuresTables",
     "shortName": "Related party disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Earnings and Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "54",
     "role": "http://imtx.com/role/EarningsAndLossPerShareTables",
     "shortName": "Earnings and Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DateOfEndOfReportingPeriod2013",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Group information - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://imtx.com/role/GroupInformationAdditionalInformationDetail",
     "shortName": "Group information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DateOfEndOfReportingPeriod2013",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:IncreasedecreaseThroughChangesInNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - ARYA Merger - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
     "shortName": "ARYA Merger - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P07_01_2020To07_01_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TitleOfNewIFRS",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
     "shortName": "Application of new and revised international financial reporting standards - Summary of Application of new standards  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_AmendmentIasSixteenMemberifrsfullNewIFRSsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TitleOfNewIFRS",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TitleOfNewIFRS",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail",
     "shortName": "Application of new and revised international financial reporting standards - Summary of Non Mandatory  standards and interpretations issued by  IASB (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_IFRS17MemberifrsfullNewIFRSsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TitleOfNewIFRS",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
     "shortName": "Application of new and revised international financial reporting standards - Summary of impact revision to previously issued financial statements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2021To12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis",
      "decimals": "-3",
      "lang": null,
      "name": "imtx:AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V.",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
     "shortName": "Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ReclassficationOfProvisionsToOtherCurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Application of new and revised international financial reporting standards - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail",
     "shortName": "Application of new and revised international financial reporting standards - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ReclassficationOfProvisionsToOtherCurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of useful life of intangible assets other than goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail",
     "shortName": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022 - Summary of foreign exchange rates (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "5",
      "lang": null,
      "name": "ifrs-full:AverageForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock",
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ReceivablesFromCollaborationAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Accounts receivable - Summary of Trade receivables (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail",
     "shortName": "Accounts receivable - Summary of Trade receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock",
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:ReceivablesFromCollaborationAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Accounts receivable - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://imtx.com/role/AccountsReceivableAdditionalInformationDetail",
     "shortName": "Accounts receivable - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "imtx:DisclosureOfAccountReceivableExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Other current and non-current assets -Summary of Other current assets (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail",
     "shortName": "Other current and non-current assets -Summary of Other current assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:CurrentPrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Other current and non-current assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails",
     "shortName": "Other current and non-current assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:CurrentPrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentPrepayments",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Other current and non-current assets - Summary of Other non-current assets (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail",
     "shortName": "Other current and non-current assets - Summary of Other non-current assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "imtx:OtherNonCurrentAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
     "shortName": "Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Group information",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://imtx.com/role/GroupInformation",
     "shortName": "Group information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDepreciationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Property, plant and equipment - Summary of Depreciation expense (Detail)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail",
     "shortName": "Property, plant and equipment - Summary of Depreciation expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDepreciationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Property, plant and equipment - Addtional information (Detail)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
     "shortName": "Property, plant and equipment - Addtional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_OfficeEquipmentAndInstallationsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Intangible assets - Summary of Changes to intangible assets (Detail)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail",
     "shortName": "Intangible assets - Summary of Changes to intangible assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfAmortizationExpensesTableTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Intangible assets - Summary of Amortization expense (Detail)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail",
     "shortName": "Intangible assets - Summary of Amortization expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfAmortizationExpensesTableTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Leases - Summary of Right-of&#160;use assets (Detail)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail",
     "shortName": "Leases - Summary of Right-of&#160;use assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Leases - Details of Lease liabilities (Detail)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail",
     "shortName": "Leases - Details of Lease liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfLeaseLiabilitiesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Leases - Summary of expenses related to&#160;right-of-use&#160;assets and lease liabilities (Detail)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of expenses related to&#160;right-of-use&#160;assets and lease liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://imtx.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Accounts payable - Summary of Accounts Payable (Detail)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail",
     "shortName": "Accounts payable - Summary of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfAccountsPayableExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:AccruedLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Accounts payable - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://imtx.com/role/AccountsPayableAdditionalInformationDetail",
     "shortName": "Accounts payable - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Basis of presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://imtx.com/role/BasisOfPresentation",
     "shortName": "Basis of presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn01_26_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "imtx:MilestonePaymentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Revenue from collaboration agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Revenue from collaboration agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn01_26_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "imtx:MilestonePaymentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentContractLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail",
     "shortName": "Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Other current liabilities - Summary of other current liabilities (Detail)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail",
     "shortName": "Other current liabilities - Summary of other current liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:BorrowingsMaturity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Other current liabilities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail",
     "shortName": "Other current liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_NonInterestBearingLiabilityMemberifrsfullBorrowingsByNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:BorrowingsMaturity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:AdjustmentsForShareListingExpense",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
     "shortName": "Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022_WarrantsMemberifrsfullClassesOfFinancialInstrumentsAxis",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imtx:AdjustmentsForShareListingExpense",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail",
     "shortName": "Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_AryaMemberifrsfullBusinessCombinationsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "imtx:RestrictedCashRecognizedAsOfTheAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeOnOtherFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Other financial income and expenses - Summary of other financial income and costs (Detail)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail",
     "shortName": "Other financial income and expenses - Summary of other financial income and costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeOnOtherFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:RealisedGainLossFromForeignCurrencyForwardContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Other financial income and expenses - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail",
     "shortName": "Other financial income and expenses - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:RealisedGainLossFromForeignCurrencyForwardContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
     "shortName": "Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020_MatchingStockOptionsMemberIMTXPlanAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Share-based payments - Summary of Employee Share Options (Detail)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
     "shortName": "Share-based payments - Summary of Employee Share Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2019_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:AryaMergerTransactionExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - ARYA Merger",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://imtx.com/role/AryaMerger",
     "shortName": "ARYA Merger",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imtx:AryaMergerTransactionExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P07_01_2020To07_01_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "imtx:ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Share-based payments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
     "shortName": "Share-based payments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_PerformanceBasedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TrancheOneMemberIMTXTrancheAxis",
      "decimals": "-8",
      "lang": null,
      "name": "imtx:MinimumMarketCapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail",
     "shortName": "Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imtx:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Shareholders' equity (deficit) - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail",
     "shortName": "Shareholders' equity (deficit) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn07_01_2020",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:IssuedCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Non-controlling interests - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
     "shortName": "Non-controlling interests - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P06_30_2020To06_30_2020",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfPersonnelExpenesTextBlock",
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Personnel expenses - Summary of Personnel Expenses (Detail)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
     "shortName": "Personnel expenses - Summary of Personnel Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfPersonnelExpenesTextBlock",
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Personnel expenses - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail",
     "shortName": "Personnel expenses - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "imtx:DisclosureOfPersonnelExpensesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail",
     "shortName": "Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:TaxEffectFromChangeInTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Income Tax - Summary of Deferred Tax Assets (Detail)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail",
     "shortName": "Income Tax - Summary of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Income Tax - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
     "shortName": "Income Tax - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
     "shortName": "Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imtx:DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d400206d20f.htm",
      "contextRef": "PAsOn12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis_ImmaticsGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 177,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "Denmark"
       }
      }
     },
     "localname": "DK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Texas",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "US [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "verboseLabel": "Accrual for vacation"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r59",
      "r307",
      "r311",
      "r315",
      "r316"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "verboseLabel": "Accumulated depreciation [member]"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "auth_ref": [
      "r172",
      "r183",
      "r268",
      "r281",
      "r284",
      "r307",
      "r311",
      "r315",
      "r316"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated impairment [member]"
       }
      }
     },
     "localname": "AccumulatedImpairmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions Property Plant And Equipment"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "verboseLabel": "(Increase) in other assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "verboseLabel": "(Increase)/decrease in accounts receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 25.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other liabilities",
        "verboseLabel": "(Decrease) Increase in other liabilities resulting from share appreciation rights"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForInterestExpense": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 21.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for interest expense",
        "verboseLabel": "Interest expenses"
       }
      }
     },
     "localname": "AdjustmentsForInterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForInterestIncome": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 19.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for interest income expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for interest income",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "AdjustmentsForInterestIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "verboseLabel": "Adjustments for:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 24.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "MD Anderson compensation expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r92",
      "r96",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r21",
      "r139",
      "r151",
      "r152",
      "r177",
      "r213",
      "r214",
      "r216",
      "r222",
      "r243",
      "r269",
      "r273"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
      "http://imtx.com/role/LeasesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an allowance account used to record impairments to financial assets due to credit losses. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Allowance account for credit losses of financial assets",
        "terseLabel": "Expected credit losses"
       }
      }
     },
     "localname": "AllowanceAccountForCreditLossesOfFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AccountsReceivableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation for assets recognised from the costs incurred to obtain or fulfil contracts with customers. [Refer: Assets recognised from costs to obtain or fulfil contracts with customers; Amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, assets recognised from costs incurred to obtain or fulfil contracts with customers",
        "terseLabel": "Amortization of contract costs capitalized"
       }
      }
     },
     "localname": "AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "auth_ref": [
      "r67",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amounts payable, related party transactions",
        "verboseLabel": "Amounts payable, related party transactions"
       }
      }
     },
     "localname": "AmountsPayableRelatedPartyTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r17",
      "r127",
      "r128",
      "r130",
      "r206",
      "r208"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets recognised from the costs to obtain or fulfil contracts with customers. The costs to obtain a contract with a customer are the incremental costs of obtaining the contract that the entity would not have incurred if the contract had not been obtained. The costs to fulfil a contract with a customer are the costs that relate directly to a contract or to an anticipated contract that the entity can specifically identify."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets recognised from costs to obtain or fulfil contracts with customers",
        "terseLabel": "Capitalized costs of contract net of amortization"
       }
      }
     },
     "localname": "AssetsRecognisedFromCostsToObtainOrFulfilContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AtFairValueMember": {
     "auth_ref": [
      "r92",
      "r96",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "At fair value [member]"
       }
      }
     },
     "localname": "AtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      },
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate"
       }
      }
     },
     "localname": "AverageForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]",
        "terseLabel": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]",
        "terseLabel": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsMaturity": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, maturity",
        "terseLabel": "Borrowings maturity"
       }
      }
     },
     "localname": "BorrowingsMaturity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r132",
      "r164",
      "r216",
      "r258",
      "r259",
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [member]"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]",
        "terseLabel": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CapitalRequirementsAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital requirements [axis]"
       }
      }
     },
     "localname": "CapitalRequirementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CapitalRequirementsMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for capital requirements that the entity is subject to. It also represents the standard value for the 'Capital requirements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital requirements [member]"
       }
      }
     },
     "localname": "CapitalRequirementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r53",
      "r56",
      "r85",
      "r88",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r172",
      "r183",
      "r184",
      "r330",
      "r331"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r56",
      "r88",
      "r93",
      "r95",
      "r96",
      "r172",
      "r183",
      "r184",
      "r281",
      "r283"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r14",
      "r102",
      "r123"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 17.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "periodStartLabel": "Cash and cash equivalents at beginning of the year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "terseLabel": "Net cash provided by/ (used in) investing activities",
        "totalLabel": "Net cash (used in)/provided by investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 11.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "terseLabel": "Net cash provided by/ (used in) operating activities",
        "totalLabel": "Net cash provided by/(used in) operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "verboseLabel": "Cash payments for leases"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r131",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r82",
      "r131",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of employee benefits expense [abstract]",
        "terseLabel": "Classes of employee benefits expense [abstract]"
       }
      }
     },
     "localname": "ClassesOfEmployeeBenefitsExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r212",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r183",
      "r186",
      "r188",
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r183",
      "r186",
      "r188",
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r212",
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      }
     },
     "localname": "ClassesOfOrdinarySharesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      },
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Conversion rate"
       }
      }
     },
     "localname": "ClosingForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Communication and network equipment [member]",
        "verboseLabel": "IT and telecommunication"
       }
      }
     },
     "localname": "CommunicationAndNetworkEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "verboseLabel": "Items that may be reclassified subsequently to profit or loss"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r1",
      "r33",
      "r111",
      "r113",
      "r121",
      "r256"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income/(loss) for the year",
        "verboseLabel": "Comprehensive income/(loss) for the year"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "verboseLabel": "Attributable to:"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r1",
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r1",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "verboseLabel": "Equity holders of the parent"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComputerSoftwareMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software [member]"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r133",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "terseLabel": "Contract Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit risk [member]",
        "terseLabel": "Credit risk [member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r202",
      "r217",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk [member]"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r22",
      "r117",
      "r256"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 16.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities \u2013 current",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r23",
      "r119",
      "r256"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities recognised as of acquisition date",
        "terseLabel": "Current liabilities by ARYA"
       }
      }
     },
     "localname": "CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions for employee benefits",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Expected taxes on income",
        "verboseLabel": "Current tax expense (income)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "terseLabel": "Income tax liability"
       }
      }
     },
     "localname": "CurrentTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Payroll tax"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r234",
      "r236"
     ],
     "calculation": {
      "http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 19.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "totalLabel": "Total",
        "verboseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail",
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "verboseLabel": "Value added tax receivables"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentWarrantLiability": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current warrant liability",
        "terseLabel": "Liabilities for warrants"
       }
      }
     },
     "localname": "CurrentWarrantLiability",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date by which the entity is required to apply a new IFRS that has been issued but is not yet effective."
       }
      },
      "en-us": {
       "role": {
        "label": "Date by which application of new IFRS is required"
       }
      }
     },
     "localname": "DateByWhichApplicationOfNewIFRSIsRequired",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ifrs-full_DateOfAuthorisationForIssueOfFinancialStatements2013": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date on which financial statements are authorised for issue."
       }
      },
      "en-us": {
       "role": {
        "label": "Date of authorisation for issue of financial statements",
        "verboseLabel": "Date of authorisation for issue of financial statements"
       }
      }
     },
     "localname": "DateOfAuthorisationForIssueOfFinancialStatements2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ifrs-full_DateOfEndOfReportingPeriod2013": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date of the end of the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Date of end of reporting period"
       }
      }
     },
     "localname": "DateOfEndOfReportingPeriod2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Date of grant of share-based payment arrangement",
        "terseLabel": "Grant date",
        "verboseLabel": "Share based compensation by share based payment arrangement grant date"
       }
      }
     },
     "localname": "DateOfGrantOfSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxAssets": {
     "auth_ref": [
      "r16",
      "r18",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets and liabilities [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r18",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedLabel": "Depreciation, property, plant and equipment"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]\nEffective 2023-01-01: The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for deferred income tax [text block]",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "verboseLabel": "Financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments at fair value through profit or loss [text block]",
        "verboseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "verboseLabel": "Financial liabilities: Initial recognition and measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "verboseLabel": "Foreign currency"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]\nEffective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "verboseLabel": "Provisions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "verboseLabel": "Revenue from collaboration agreements"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]\nEffective 2023-01-01: The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for restricted cash and cash equivalents [text block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "verboseLabel": "Segment information"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "verboseLabel": "Share-based payment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "verboseLabel": "Summary of Application of new standards"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [line items]"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [table]"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfHowAcquirerObtainedControlOfAcquiree": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of how the acquirer obtained the power to govern the financial and operating policies of the acquiree so as to obtain benefits from its activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of how acquirer obtained control of acquiree",
        "verboseLabel": "Description Of How Acquirer Obtained Control Of Acquire"
       }
      }
     },
     "localname": "DescriptionOfHowAcquirerObtainedControlOfAcquiree",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfManagingLiquidityRisk": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of how the entity manages its liquidity risk. [Refer: Liquidity risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of how entity manages liquidity risk [text block]",
        "terseLabel": "Summary of Liquidity Risk"
       }
      }
     },
     "localname": "DescriptionOfManagingLiquidityRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of maximum term of options granted for share-based payment arrangement",
        "terseLabel": "Share based compensation by share based payment arrangement term of stock options"
       }
      }
     },
     "localname": "DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the method of settlement (for example, whether in cash or equity) for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of method of settlement for share-based payment arrangement",
        "terseLabel": "Type of option"
       }
      }
     },
     "localname": "DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the nature of accounting errors in prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of nature of accounting errors in prior periods [text block]",
        "terseLabel": "Summary of impact revision to previously issued financial statements"
       }
      }
     },
     "localname": "DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "verboseLabel": "Time period (years)"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk free rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfTransactionsWithRelatedParty": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of transactions with related party",
        "terseLabel": "Description of Transactions with related party"
       }
      }
     },
     "localname": "DescriptionOfTransactionsWithRelatedParty",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Significant accounting judgments, estimates and assumptions"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SignificantAccountingJudgmentsEstimatesAndAssumptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]"
       }
      }
     },
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]"
       }
      }
     },
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]"
       }
      }
     },
     "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]",
        "terseLabel": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]",
        "terseLabel": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for changes in accounting policies, accounting estimates and errors."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting policies, accounting estimates and errors [text block]"
       }
      }
     },
     "localname": "DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCompositionOfGroupExplanatory": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Subsidiaries [member]; Parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of composition of group [text block]",
        "terseLabel": "Group information"
       }
      }
     },
     "localname": "DisclosureOfCompositionOfGroupExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r179",
      "r186",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "verboseLabel": "Summary of Carrying Amounts and Fair values of Group's Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Summary of Changes to Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "verboseLabel": "Earnings and Loss per Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events occurring after the reporting period"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EventsOccurringAfterTheReportingPeriod"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Other financial income and expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r179",
      "r186",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Financial Risk Management Objectives and Policies"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of non-controlling interests. [Refer: Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-controlling interests [text block]",
        "terseLabel": "Non-controlling\u00a0interests"
       }
      }
     },
     "localname": "DisclosureOfNoncontrollingInterestsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/NonControllingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other assets [text block]",
        "terseLabel": "Other current and non-current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other current assets [text block]",
        "verboseLabel": "Summary of Other current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other current liabilities [text block]",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [text block]",
        "verboseLabel": "Summary of Other\u00a0non-current\u00a0assets"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "verboseLabel": "Summary of Right-of\u00a0use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Summary of Employee Share Options"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]",
        "terseLabel": "Summary of Changes to Intangible Assets"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Revenue from collaboration agreements"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Shareholders' equity (deficit)"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2022"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Net profit/(loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "verboseLabel": "Summary of Earnings and loss per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r0",
      "r41",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r171",
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]",
        "terseLabel": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]",
        "terseLabel": "Friedrich von Bohlen und Halbach"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]",
        "terseLabel": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r17",
      "r25",
      "r110",
      "r112",
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 11.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "verboseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "verboseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Fair value of ARYA ordinary shares and warrants",
        "label": "Equity interests of acquirer",
        "verboseLabel": "Fair value of outstanding ARYA"
       }
      }
     },
     "localname": "EquityInterestsOfAcquirer",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Strike Price in USD",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Adjustment to additional paid in capital due to modification of previously settled equity awards"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "terseLabel": "Expenses relating to short-term leases and low-value assets (included in administrative expenses)"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedTotalLabel": "Other financial expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "totalLabel": "Other financial income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "totalLabel": "Financial result"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r188",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Financial assets",
        "verboseLabel": "Financial assets, Carrying amount"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets held for managing liquidity risk (for example, financial assets that are readily saleable or expected to generate cash inflows to meet cash outflows on financial liabilities). [Refer: Liquidity risk [member]; Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets held for managing liquidity risk",
        "terseLabel": "Financial assets held for managing liquidity risk"
       }
      }
     },
     "localname": "FinancialAssetsHeldForManagingLiquidityRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r212",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Financial liabilities, Carrying amount"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r199",
      "r229"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r212",
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ForeignExchangeRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange rates [abstract]"
       }
      }
     },
     "localname": "ForeignExchangeRatesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on exchange differences on translation, net of tax",
        "verboseLabel": "Currency translation differences from foreign operations"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r9",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on financial liabilities at fair value through profit or loss",
        "negatedLabel": "Change in fair value of liabilities for warrants",
        "terseLabel": "Change in fair value of liabilities for warrants",
        "verboseLabel": "Gains losses on financial liabilities at fair value through profit or loss"
       }
      }
     },
     "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 9.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r211",
      "r242",
      "r261",
      "r278"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r211",
      "r242",
      "r261",
      "r278"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r53",
      "r85",
      "r94",
      "r97",
      "r172",
      "r184",
      "r188",
      "r268",
      "r330",
      "r331"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      },
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]"
       }
      }
     },
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IFRS17Member": {
     "auth_ref": [
      "r230",
      "r328"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 17 Insurance Contracts."
       }
      },
      "en-us": {
       "role": {
        "label": "IFRS 17 [member]",
        "terseLabel": "IFRS 17"
       }
      }
     },
     "localname": "IFRS17Member",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "ARYA's identifiable net assets",
        "label": "Identifiable assets acquired (liabilities assumed)",
        "terseLabel": "Identifiable net assets",
        "verboseLabel": "Net Assets Acquired (Liabilities Assumed)"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r39",
      "r45",
      "r46",
      "r47",
      "r75",
      "r125",
      "r205"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 28.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 12.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Taxes on income",
        "negatedTotalLabel": "Taxes on income",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "negatedLabel": "Income tax paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "terseLabel": "Net increase/(decrease) in cash and cash equivalents",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities",
        "terseLabel": "Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities",
        "terseLabel": "Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill",
        "verboseLabel": "Currency translation differences"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through other contributions by owners, equity",
        "verboseLabel": "PIPE Financing, net of transaction costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherContributionsByOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Equity-settled share-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r12",
      "r88"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 23.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r89",
      "r245",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r124",
      "r204",
      "r209"
     ],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnOtherFinancialAssets": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on other financial assets",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOnOtherFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "verboseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issue of equity"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 15.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Number of shares value outstanding",
        "verboseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Issued capital [member]",
        "verboseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, other long-term employee benefits",
        "terseLabel": "Variable"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Key management personnel compensation, short-term employee benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel of entity or parent [member]"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r222",
      "r269",
      "r272",
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than 5 years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r222",
      "r269",
      "r274",
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than four years and not later than five years [member]",
        "terseLabel": "Until 2025 [member]"
       }
      }
     },
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than three years [member]",
        "terseLabel": "1 - 3 years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r20",
      "r280",
      "r282"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r269",
      "r271",
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than five years [member]",
        "terseLabel": "3 - 5 years"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]",
        "terseLabel": "Lease liabilities [member]"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LicencesMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Licences [member]"
       }
      }
     },
     "localname": "LicencesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiquidityRiskMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liquidity risk [member]",
        "terseLabel": "Liquidity risk [member]"
       }
      }
     },
     "localname": "LiquidityRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]",
        "terseLabel": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r21",
      "r139",
      "r151",
      "r152",
      "r177",
      "r192",
      "r213",
      "r214",
      "r216",
      "r222",
      "r243",
      "r269"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
      "http://imtx.com/role/LeasesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "auth_ref": [
      "r185",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk",
        "terseLabel": "Maximum exposure to credit risk"
       }
      }
     },
     "localname": "MaximumExposureToCreditRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r92",
      "r96",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r300",
      "r310"
     ],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Foreign currency gains"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NewIFRSsAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "New IFRSs [axis]"
       }
      }
     },
     "localname": "NewIFRSsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NewIFRSsMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "New IFRSs [member]"
       }
      }
     },
     "localname": "NewIFRSsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]",
        "verboseLabel": "Non-controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r22",
      "r118",
      "r256"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 21.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 8.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Non-current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfDeferredRevenueRelatedToTheCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 9.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities \u2013 non-current",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/LeasesDetailsOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r23",
      "r120",
      "r256"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 7.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentPrepayments": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current prepayments. [Refer: Prepayments]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Non-current prepayments",
        "label": "Non-current prepayments",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "NoncurrentPrepayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails",
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other non-current receivables [abstract]"
       }
      }
     },
     "localname": "NoncurrentReceivablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r19",
      "r151",
      "r152",
      "r222",
      "r269",
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than 1year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "terseLabel": "ARYA Shares",
        "verboseLabel": "Number of instruments issued or issuable"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r157",
      "r162",
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of share options, outstanding at December\u00a031,",
        "periodStartLabel": "Number of share options, outstanding at January\u00a01,",
        "terseLabel": "Number of share options outstanding"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "SARs exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "terseLabel": "SARs exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "terseLabel": "SARs expired"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Number of share options forfeited in share-based payment arrangement",
        "label": "Number of share options forfeited in share-based payment arrangement",
        "terseLabel": "SARs forfeited"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "SARs granted",
        "verboseLabel": "Share based compensation by share based payment arrangement options granted during the period"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "totalLabel": "Number of shares"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office equipment and installations [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r78",
      "r304"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Ordinary Shares [member]",
        "label": "Ordinary shares [member]",
        "terseLabel": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAssets": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAssetsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets [member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail",
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r32",
      "r40",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "verboseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 20.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 18.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "verboseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEmployeeExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other employee expense",
        "terseLabel": "other miscellaneous expenses"
       }
      }
     },
     "localname": "OtherEmployeeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceCost": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 6.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance cost",
        "negatedLabel": "Other financial expenses"
       }
      }
     },
     "localname": "OtherFinanceCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncome": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 5.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income",
        "terseLabel": "Other financial income"
       }
      }
     },
     "localname": "OtherFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinancialAssets": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial assets",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r74",
      "r231",
      "r232"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 10.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 25.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 10.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 12.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r6",
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "verboseLabel": "Other reserves [member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherShorttermEmployeeBenefits": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other short-term employee benefits",
        "terseLabel": "Other employee benefits"
       }
      }
     },
     "localname": "OtherShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Par value per share",
        "disclosureGuidance": "Closing price of ARYA ordinary shares",
        "label": "Par value per share",
        "terseLabel": "Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020",
        "verboseLabel": "Par value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Repayment of lease liabilities",
        "terseLabel": "Payments for leases"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToAndOnBehalfOfEmployees": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to, and on behalf of, employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to and on behalf of employees",
        "terseLabel": "Cash payment to employees stock based awards"
       }
      }
     },
     "localname": "PaymentsToAndOnBehalfOfEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities",
        "terseLabel": "Percentage of resonably possible decrease in unobservable inputs"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities",
        "terseLabel": "Percentage of reasonable possible increase in unobservable inputs"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined contribution plans",
        "terseLabel": "Post-employment benefit expense, defined contribution plans"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "verboseLabel": "Proceeds from issuance of shares to equity holders"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments other than investments accounted for using equity method",
        "verboseLabel": "Proceeds from maturity of investments classified in Other financial assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities",
        "verboseLabel": "Proceeds from disposal of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r210",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r210",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r31",
      "r99",
      "r111",
      "r113",
      "r206",
      "r207",
      "r256",
      "r277",
      "r279"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 29.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNVAlternate1": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "presentationGuidance": "Net profit/(loss)",
        "totalLabel": "Net profit/(loss)",
        "verboseLabel": "Net profit/(loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfComprehensiveIncomeLossOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "verboseLabel": "Attributable to:"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r34",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "verboseLabel": "Equity holders of the parent"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r174",
      "r231",
      "r232",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Profit/(loss) before taxes",
        "totalLabel": "Profit/(loss) before taxes",
        "verboseLabel": "Profit/(loss) before tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r244",
      "r305"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating result"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r56"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 22.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Ending Cost",
        "periodStartLabel": "Beginning Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r57",
      "r245",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interests held by non-controlling interests",
        "terseLabel": "Ownership interests held by non-controlling interests"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedLabel": "Payments for intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investments other than investments accounted for using equity method",
        "negatedLabel": "Payments for investments classified in Other financial assets"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Payments for property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r132",
      "r164",
      "r216",
      "r258",
      "r259",
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r132",
      "r164",
      "r216",
      "r258",
      "r259",
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 8.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r108",
      "r215",
      "r299"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 13.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r6",
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "verboseLabel": "Accumulated deficit [member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]"
       }
      }
     },
     "localname": "RevenueAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Contract with customers liability revenue recognized"
       }
      }
     },
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 24.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sensitivity analysis for types of market risk [text block]",
        "terseLabel": "Summary of Sensitivity Analysis of Foreign Currency Risk"
       }
      }
     },
     "localname": "SensitivityAnalysisForEachTypeOfMarketRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "terseLabel": "Share issue related cost"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 14.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Share premium [member]",
        "verboseLabel": "Share premium [member]"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "totalLabel": "Total other employee benefits"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r76",
      "r77",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]",
        "terseLabel": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SocialSecurityContributions": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Social security contributions",
        "terseLabel": "Social security contributions"
       }
      }
     },
     "localname": "SocialSecurityContributions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense",
        "terseLabel": "Utilization of previously unrecorded tax losses carried forward"
       }
      }
     },
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect from change in tax rate",
        "negatedLabel": "Difference in tax rates"
       }
      }
     },
     "localname": "TaxEffectFromChangeInTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "negatedLabel": "Non-deductible\u00a0 tax-expenses"
       }
      }
     },
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of tax losses",
        "terseLabel": "Tax effect of tax losses"
       }
      }
     },
     "localname": "TaxEffectOfTaxLosses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxRateEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect from change in tax rate",
        "verboseLabel": "Tax rate effect from change in tax rate"
       }
      }
     },
     "localname": "TaxRateEffectFromChangeInTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TitleOfNewIFRS": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The title of a new IFRS that has been issued but is not yet effective."
       }
      },
      "en-us": {
       "role": {
        "label": "Title of new IFRS"
       }
      }
     },
     "localname": "TitleOfNewIFRS",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail",
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r132",
      "r164",
      "r216",
      "r258",
      "r259",
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r235",
      "r303"
     ],
     "calculation": {
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "totalLabel": "Total",
        "verboseLabel": "Accounts payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail",
      "http://imtx.com/role/ConsolidatedStatementOfFinancialPositionOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current receivables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Accounts payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeReceivables": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "verboseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r182",
      "r187",
      "r268",
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]",
        "terseLabel": "Accounts receivables [member]"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transaction price allocated to remaining performance obligations",
        "terseLabel": "Transaction price allocation to performance obligation"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r176",
      "r180",
      "r181",
      "r217",
      "r218",
      "r219",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r176",
      "r180",
      "r181",
      "r217",
      "r218",
      "r219",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnobservableInputsAxis": {
     "auth_ref": [
      "r129",
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      }
     },
     "localname": "UnobservableInputsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnobservableInputsMember": {
     "auth_ref": [
      "r129",
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]"
       }
      }
     },
     "localname": "UnobservableInputsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "verboseLabel": "Unused tax losses for which no deferred tax asset recognised"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_ValueAtRisk": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The measure of a potential loss exposure as a result of future market movements, based on a specified confidence interval and measurement horizon."
       }
      },
      "en-us": {
       "role": {
        "label": "Value at risk",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "ValueAtRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "terseLabel": "Wages and salaries"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "SARs exercisable"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "SARs exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "SARs expired"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "SARs forfeited"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Share based compensation by share based payment arrangement exercise price per share granted",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "SARs granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r157",
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price, Outstanding at December\u00a031,",
        "periodStartLabel": "Weighted average exercise price, Outstanding at January\u00a01,"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Fair value of stock appreciation rights",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining contract life (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Underlying share price",
        "verboseLabel": "Weighted average share price of share options granted"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]",
        "verboseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShareSummaryOfEarningsAndLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_AccountsPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts payable [member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AccountsPayableAdditionalInformationDetail",
      "http://imtx.com/role/AccountsPayableSummaryOfAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ActiveEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Active employees [Member].",
        "label": "Active Employees [Member]",
        "terseLabel": "Active Employees [Member]"
       }
      }
     },
     "localname": "ActiveEmployeesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AdamStoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adam Stone [Member]",
        "terseLabel": "Adam Stone"
       }
      }
     },
     "localname": "AdamStoneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Grants Under Two Thousand And Twenty And Two Thousand And Twenty Two Plan [Member]",
        "terseLabel": "Additional Grants Under 2020 Plan [Member]",
        "verboseLabel": "Additional Grants Under 2020 and 2022 Plan [Member]"
       }
      }
     },
     "localname": "AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment related to performance obligations received.",
        "label": "Additional Payment Related to Performance Obligations Received",
        "terseLabel": "Additional payment related to performance obligations received"
       }
      }
     },
     "localname": "AdditionalPaymentRelatedToPerformanceObligationsReceived",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AdditionsOtherPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions other property, plant and equipment.",
        "label": "Additions Other Property Plant and Equipment",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherPropertyPlantAndEquipment",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AdjustmentForEquitySettledSharebasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 23.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for equity settled share-based payment.",
        "label": "Adjustment for equity settled sharebased payment",
        "verboseLabel": "Equity settled share-based payment"
       }
      }
     },
     "localname": "AdjustmentForEquitySettledSharebasedPayment",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase decrease in deferred revenue trade and other payables.",
        "label": "Adjustments For Increase Decrease In Deferred Revenue Trade And Other Payables",
        "terseLabel": "Increase/(decrease) in deferred revenue, accounts payables and other liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredRevenueTradeAndOtherPayables",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AdjustmentsForShareListingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 22.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "IFRS 2 Expense on the closing date",
        "documentation": "Adjustments for share listing expense.",
        "label": "Adjustments For Share Listing Expense",
        "terseLabel": "Expense on the closing date",
        "verboseLabel": "Share listing expense"
       }
      }
     },
     "localname": "AdjustmentsForShareListingExpense",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 27.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange and expected credit loss.",
        "label": "Adjustments For Unrealised Foreign Exchange And Expected Credit Loss",
        "terseLabel": "Net foreign exchange differences and expected credit losses",
        "verboseLabel": "Net foreign exchange differences"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeAndExpectedCreditLoss",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of upfront payment towards clinical trial services and license grant.",
        "label": "Allocation of Upfront Payment Towards Clinical Trial Services And License Grant",
        "terseLabel": "Allocation of upfront payment towards clinical trial services and license grant"
       }
      }
     },
     "localname": "AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_Allocationofupfrontpaymenttowardsclinicaltrialservices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of upfront payment towards clinical trial services.",
        "label": "AllocationOfUpfrontPaymentTowardsClinicalTrialServices",
        "terseLabel": "Allocation of upfront payment towards clinical trial services"
       }
      }
     },
     "localname": "Allocationofupfrontpaymenttowardsclinicaltrialservices",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_Allocationofupfrontpaymenttowardslicensegrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of upfront payment towards license grant.",
        "label": "Allocation of Upfront Payment Towards License Grant",
        "terseLabel": "Allocation of upfront payment towards license grant"
       }
      }
     },
     "localname": "Allocationofupfrontpaymenttowardslicensegrant",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_AmendmentIasSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment IAS sixteen.",
        "label": "Amendment IAS Sixteen [Member]",
        "terseLabel": "Amendment IAS 16"
       }
      }
     },
     "localname": "AmendmentIasSixteenMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentIasThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment IAS thirty seven.",
        "label": "Amendment IAS Thirty Seven [Member]",
        "terseLabel": "Amendment IAS 37"
       }
      }
     },
     "localname": "AmendmentIasThirtySevenMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIasEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IAS eight.",
        "label": "Amendment To IAS Eight [Member]",
        "terseLabel": "Amendment To IAS 8"
       }
      }
     },
     "localname": "AmendmentToIasEightMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIasFourtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IAS fourty one.",
        "label": "Amendment To IAS Fourty One [Member]",
        "terseLabel": "Amendment To IAS 41"
       }
      }
     },
     "localname": "AmendmentToIasFourtyOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIasOneIfrsPracticeStatementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IAS one IFRS practice statement two.",
        "label": "Amendment To IAS One IFRS Practice Statement Two [Member]",
        "terseLabel": "Amendment To IAS 1 IFRS Practice Statement 2"
       }
      }
     },
     "localname": "AmendmentToIasOneIfrsPracticeStatementTwoMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIasOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IAS one.",
        "label": "Amendment To IAS One [Member]",
        "terseLabel": "Amendment o IAS 1"
       }
      }
     },
     "localname": "AmendmentToIasOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIasTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IAS twelve.",
        "label": "Amendment To IAS Twelve [Member]",
        "terseLabel": "Amendment To IAS 12"
       }
      }
     },
     "localname": "AmendmentToIasTwelveMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIfrsNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IFRS nine.",
        "label": "Amendment To IFRS Nine [Member]",
        "terseLabel": "Amendment To IFRS 9"
       }
      }
     },
     "localname": "AmendmentToIfrsNineMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIfrsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IFRS one.",
        "label": "Amendment To IFRS One [Member]",
        "terseLabel": "Amendment To IFRS 1"
       }
      }
     },
     "localname": "AmendmentToIfrsOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIfrsSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IFRS sixteen [Member].",
        "label": "Amendment To IFRS Sixteen [Member]",
        "terseLabel": "Amendment to IFRS 16"
       }
      }
     },
     "localname": "AmendmentToIfrsSixteenMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfNonMandatoryStandardsAndInterpretationsIssuedByIasbDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentToIfrsThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to IFRS three.",
        "label": "Amendment To IFRS Three [Member]",
        "terseLabel": "Amendment To IFRS 3"
       }
      }
     },
     "localname": "AmendmentToIfrsThreeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmendmentsToIllustrativeAccompanyingIfrsSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendments to Illustrative Accompanying IFRS Sixteen.",
        "label": "Amendments to Illustrative Accompanying IFRS Sixteen [Member]",
        "terseLabel": "Amendments to Illustrative Examples accompanying IFRS 16"
       }
      }
     },
     "localname": "AmendmentsToIllustrativeAccompanyingIfrsSixteenMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfApplicationOfNewStandardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AmgenCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amgen Collaboration Agreement [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenCollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AryaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARYA [Member].",
        "label": "ARYA [Member]",
        "terseLabel": "ARYA [Member]",
        "verboseLabel": "ARYA [member]"
       }
      }
     },
     "localname": "AryaMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AryaMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARYA merger.",
        "label": "ARYA Merger [Member]",
        "verboseLabel": "ARYA Merger [Member]"
       }
      }
     },
     "localname": "AryaMergerMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AryaMergerTransactionExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of ARYA Merger transaction explanatory.",
        "label": "ARYA Merger transaction Explanatory",
        "terseLabel": "ARYA Merger"
       }
      }
     },
     "localname": "AryaMergerTransactionExplanatory",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMerger"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market agreement member.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "At The Market Agreement [Member]"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_AuthorizationOfFinancialStatementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorization of financial statements.",
        "label": "Authorization Of Financial Statements [Member]"
       }
      }
     },
     "localname": "AuthorizationOfFinancialStatementsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/GroupInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement [Member]",
        "verboseLabel": "BMS"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_BalanceSheetLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_BmsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bms Agreement.",
        "label": "Bms Agreement [Member]"
       }
      }
     },
     "localname": "BmsAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_BondsAndShortTermDeposits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds and short-term deposits.",
        "label": "Bonds and Short Term Deposits",
        "verboseLabel": "Bonds and short-term deposits"
       }
      }
     },
     "localname": "BondsAndShortTermDeposits",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_BondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds.",
        "label": "Bonds [Member]",
        "terseLabel": "Bonds [member]"
       }
      }
     },
     "localname": "BondsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_BristolMyerSquibCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol myer squib company.",
        "label": "Bristol Myer Squib Company [Member]",
        "terseLabel": "Bristol Myer Squib Company [member]"
       }
      }
     },
     "localname": "BristolMyerSquibCompanyMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents [member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CashPaymentAwardPerSharePayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Cash payment award per share payable",
        "documentation": "Cash payment award per share payable.",
        "label": "Cash Payment Award Per Share Payable"
       }
      }
     },
     "localname": "CashPaymentAwardPerSharePayable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imtx_CategoryOfEmployeesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category Of employees [Axis].",
        "label": "Category Of Employees [Axis]"
       }
      }
     },
     "localname": "CategoryOfEmployeesAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_CategoryOfEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of employees [Member].",
        "label": "Category Of Employees [Member]"
       }
      }
     },
     "localname": "CategoryOfEmployeesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CelgeneSwitzerlandLlcAndGenmabAsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celgene switzerland LLC and genmab A/S.",
        "label": "Celgene Switzerland LLC And Genmab AS [Member]"
       }
      }
     },
     "localname": "CelgeneSwitzerlandLlcAndGenmabAsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in working capital [Abstract].",
        "label": "Changes In Working Capital [Abstract]",
        "verboseLabel": "Changes in:"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_ChristophHettichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Christoph Hettich [Member]",
        "terseLabel": "Christoph Hettich"
       }
      }
     },
     "localname": "ChristophHettichMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CollaborationAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Axis]"
       }
      }
     },
     "localname": "CollaborationAgreementAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreements [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "CollaborationAgreementsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ContractLiabilitiesRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities recognized.",
        "label": "Contract Liabilities Recognized",
        "terseLabel": "Contract liabilities recognizedContract liabilities recognized"
       }
      }
     },
     "localname": "ContractLiabilitiesRecognized",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ContractResearchOrganizationAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract research organization agreements.",
        "label": "Contract Research Organization Agreements",
        "terseLabel": "Contract research organization agreements"
       }
      }
     },
     "localname": "ContractResearchOrganizationAgreements",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ContractTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract transaction price.",
        "label": "Contract Transaction Price",
        "terseLabel": "Contract transaction price"
       }
      }
     },
     "localname": "ContractTransactionPrice",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ContractualCashObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual cash obligation.",
        "label": "Contractual Cash Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractualCashObligation",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ContractualObligationOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation of lease liabilities.",
        "label": "Contractual Obligation Of Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "ContractualObligationOfLeaseLiabilities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ConvertedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted Options [Member]",
        "terseLabel": "Converted Options [Member]"
       }
      }
     },
     "localname": "ConvertedOptionsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ConvertedOptionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted Options One [Member]"
       }
      }
     },
     "localname": "ConvertedOptionsOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_CorporateIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "corporate income tax rate.",
        "label": "corporate income tax rate",
        "terseLabel": "Corporate income tax rate"
       }
      }
     },
     "localname": "CorporateIncomeTaxRate",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_CurrencyTranslationDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency translation differences.",
        "label": "Currency Translation Differences",
        "verboseLabel": "Currency translation differences"
       }
      }
     },
     "localname": "CurrencyTranslationDifferences",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_CurrentGrantReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current grant receivable.",
        "label": "Current Grant Receivable",
        "verboseLabel": "Grant receivable"
       }
      }
     },
     "localname": "CurrentGrantReceivable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_CurrentIncrementalCostForCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current incremental cost for collaboration agreement.",
        "label": "Current Incremental Cost For Collaboration Agreement",
        "verboseLabel": "Current Incremental cost for collaboration agreement"
       }
      }
     },
     "localname": "CurrentIncrementalCostForCollaborationAgreement",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_CurrentPrepaidInsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current prepaid insurance.",
        "label": "Current Prepaid insurance",
        "verboseLabel": "Prepaid insurance expenses"
       }
      }
     },
     "localname": "CurrentPrepaidInsurance",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_CurrentPrepaidMaintenanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current prepaid maintenance expenses.",
        "label": "Current Prepaid Maintenance Expenses",
        "terseLabel": "Current prepaid maintenance expenses"
       }
      }
     },
     "localname": "CurrentPrepaidMaintenanceExpenses",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_CurrentlyReportedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currently Reported [Member]",
        "label": "Currently Reported [Member]",
        "terseLabel": "As Revised"
       }
      }
     },
     "localname": "CurrentlyReportedMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DateOfExpiryOfShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of expiry of share options granted.",
        "label": "Date Of Expiry Of Share Options Granted",
        "terseLabel": "Expiration date"
       }
      }
     },
     "localname": "DateOfExpiryOfShareOptionsGranted",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "imtx_DateOfGrantAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of grant [Axis].",
        "label": "Date Of Grant [Axis]"
       }
      }
     },
     "localname": "DateOfGrantAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DateOfGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of grant .",
        "label": "Date Of Grant [Member]"
       }
      }
     },
     "localname": "DateOfGrantMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DateOfVestingOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of vesting of stock options.",
        "label": "Date Of Vesting Of Stock Options",
        "terseLabel": "Date of vesting of stock options"
       }
      }
     },
     "localname": "DateOfVestingOfStockOptions",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "imtx_DeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DE - Germany.",
        "label": "DE [Member]",
        "verboseLabel": "Germany"
       }
      }
     },
     "localname": "DeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredAssetNettingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Asset Netting [Member]",
        "verboseLabel": "Netting [Member]"
       }
      }
     },
     "localname": "DeferredAssetNettingMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredAssetRecognisedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Asset Recognised [Member]",
        "verboseLabel": "Recognized [Member]"
       }
      }
     },
     "localname": "DeferredAssetRecognisedMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Expenses [Member]",
        "terseLabel": "Deferred expenses [Member]"
       }
      }
     },
     "localname": "DeferredExpensesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredLiabilityNettingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Liability Netting [Member]",
        "terseLabel": "Netting [Member]"
       }
      }
     },
     "localname": "DeferredLiabilityNettingMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred revenue [Member]"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredTaxAssetsOffset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets offset.",
        "label": "Deferred Tax Assets Offset",
        "terseLabel": "Deferred tax assets netting"
       }
      }
     },
     "localname": "DeferredTaxAssetsOffset",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_DeferredTaxAssetsOnTemporaryDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets on temporary differences.",
        "label": "Deferred Tax Assets On Temporary Differences",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOnTemporaryDifferences",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_DeferredTaxLiabilitiesDeferredExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Deferred expenses [Member]",
        "terseLabel": "Recognized [Member]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpensesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DeferredTaxLiabilitiesOffSet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities off set.",
        "label": "Deferred Tax Liabilities Off set",
        "terseLabel": "Deferred tax liabilities netting"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOffSet",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_DeferredTaxLiabilitiesRightOfUseAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Right of use asset [Member]",
        "terseLabel": "Right-of-use assets [Member]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssetMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for conflict and macro economic environment policy text block.",
        "label": "Description Of Accounting Policy For Conflict And Macro economic Environment [Policy Text Block]",
        "terseLabel": "Russian-Ukraine Conflict and macroeconomic environment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForConflictAndMacroEconomicEnvironmentPolicyTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for covid nineteen.",
        "label": "Description Of Accounting Policy For Covid 19 [Policy Text Block]",
        "verboseLabel": "Covid-19"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCovidNineteenPolicyTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for going concern.",
        "label": "Description Of Accounting Policy For Going concern [Policy Text Block]",
        "verboseLabel": "Going concern"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022Policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DescriptionOfManagingLiquidityRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Managing Liquidity Risk [Abstract]"
       }
      }
     },
     "localname": "DescriptionOfManagingLiquidityRiskAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DilutiveEffectOfShareOptionsOnNumberOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dilutive effect of share options on number of warrants.",
        "label": "Dilutive effect of share options on number of warrants",
        "terseLabel": "Dilutive effect of share options on number of warrants"
       }
      }
     },
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfWarrants",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/EarningsAndLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imtx_DirectorsAndExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors and executive officers [Member]",
        "label": "Directors and executive officers [Member]",
        "terseLabel": "Directors and executive officers [member]"
       }
      }
     },
     "localname": "DirectorsAndExecutiveOfficersMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_DisclosureOfAccountReceivableExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of account receivable Explanatory.",
        "label": "Disclosure Of Account Receivable Explanatory [Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisclosureOfAccountReceivableExplanatoryTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfAccountsPayableExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounts payable explanatory.",
        "label": "Disclosure Of Accounts Payable Explanatory [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable"
       }
      }
     },
     "localname": "DisclosureOfAccountsPayableExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfAmortizationExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of amortization expenses.",
        "label": "Disclosure Of Amortization Expenses [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfAmortizationExpensesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfAmortizationExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of amortization expenses.",
        "label": "Disclosure Of Amortization Expenses [Table Text Block]",
        "terseLabel": "Summary of Depreciation Expense"
       }
      }
     },
     "localname": "DisclosureOfAmortizationExpensesTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of compensation Managing directors and supervisory board.",
        "label": "Disclosure of compensation Managing directors and supervisory board [Text Block]",
        "terseLabel": "Summary of Options Granted to Managing Director and Supervisory Directors"
       }
      }
     },
     "localname": "DisclosureOfCompensationManagingDirectorsAndSupervisoryBoardTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfCompensationOfKeyManagementPersonnelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Of Key Management Personnel [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationOfKeyManagementPersonnelAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of compensation of key management personnel.",
        "label": "Disclosure Of Compensation Of Key Management Personnel [Table Text Block]",
        "terseLabel": "Summary of Compensation of Key Management Personnel"
       }
      }
     },
     "localname": "DisclosureOfCompensationOfKeyManagementPersonnelTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfCompensationSupervisoryBoardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of compensation supervisory board.",
        "label": "disclosure of compensation supervisory board [Text Block]",
        "terseLabel": "Summary of Compensation for the Supervisory Board"
       }
      }
     },
     "localname": "DisclosureOfCompensationSupervisoryBoardTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfContractLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of contract liabilities.",
        "label": "Disclosure Of Contract Liabilities [Text Block]",
        "terseLabel": "Summary of Deferred revenue related to the collaboration agreements"
       }
      }
     },
     "localname": "DisclosureOfContractLiabilitiesTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfContractualObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Contractual Obligations [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfContractualObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Contractual Obligations [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfContractualObligationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Contractual Obligations [Table]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfContractualObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of contractual obligations.",
        "label": "Disclosure Of Contractual Obligations [Table Text Block]",
        "terseLabel": "Summary of Contractual Obligations"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfCurrencyRiskExposureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Currency Risk Exposure [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCurrencyRiskExposureAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Currency Risk Exposure Explanatory.",
        "label": "Disclosure Of Currency Risk Exposure Explanatory [Table Text Block]",
        "terseLabel": "Summary of Currency Risk Exposure"
       }
      }
     },
     "localname": "DisclosureOfCurrencyRiskExposureExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfCurrencyRiskExposureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Currency Risk Exposure [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfCurrencyRiskExposureLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfCurrencyRiskExposureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Currency Risk Exposure [Table]"
       }
      }
     },
     "localname": "DisclosureOfCurrencyRiskExposureTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of deferred tax assets and liabilities.",
        "label": "Disclosure Of Deferred Tax Assets And Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDepreciationExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of depreciation expenses.",
        "label": "Disclosure Of Depreciation Expenses [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDepreciationExpensesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDepreciationExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of depreciation expenses.",
        "label": "Disclosure Of Depreciation Expenses [Table Text Block]",
        "terseLabel": "Summary of Depreciation Expense"
       }
      }
     },
     "localname": "DisclosureOfDepreciationExpensesTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective explanatory [Text Block].",
        "label": "Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective and Noncash Effective Explanatory",
        "verboseLabel": "Summary of changes of the liabilities from financing activities classified as cash effective and non-cash effective"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNoncashEffectiveExplanatory",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Abstract].",
        "label": "Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Line Item].",
        "label": "Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about changes of the liabilities from financing activities classified as cash effective and noncash effective [Table].",
        "label": "Disclosure Of Detailed Information About Changes of the Liabilities from Financing activities Classified as Cash Effective andNoncashEffective [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndnoncasheffectiveTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about finance income expense explanatory.",
        "label": "Disclosure Of Detailed Information About Finance Income Expense Explanatory [Text Block]",
        "terseLabel": "Summary of other financial income and costs"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about foreign exchange rates explanatory.",
        "label": "Disclosure Of Detailed Information About Foreign Exchange Rates Explanatory [Table Text Block]",
        "verboseLabel": "Summary of foreign exchange rates"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutForeignExchangeRatesExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about foreign exchange rates.",
        "label": "Disclosure Of Detailed Information About Foreign Exchange Rates [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutForeignExchangeRatesLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutForeignExchangeRatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about foreign exchange rates.",
        "label": "Disclosure Of Detailed Information About Foreign Exchange Rates [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutForeignExchangeRatesTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfForeignExchangeRatesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about net result from financial instruments by measurement categories [Abstract].",
        "label": "Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about net result from financial instruments by measurement categories explanatory [Text Block]",
        "label": "Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories Explanatory",
        "verboseLabel": "Summary of Net Result from Financial Instruments by Measurement Categories"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesExplanatory",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about net result from financial instruments by measurement categories [Line Items].",
        "label": "Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about net result from financial instruments by measurement categories [Table].",
        "label": "Disclosure Of Detailed Information About Net Result from Financial Instruments by Measurement Categories [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNetResultFromFinancialInstrumentsByMeasurementCategoriesTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other current liabilities abstract.",
        "label": "Disclosure of detailed information about other current liabilities [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other current liabilities line items.",
        "label": "Disclosure of detailed information about other current liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other current liabilities Table.",
        "label": "Disclosure of detailed information about other current liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other current liabilities abstract.",
        "label": "Disclosure of detailed information about other current liabilities [Text Block]",
        "terseLabel": "Summary of other current liabilities"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Other Finance Income Expense.",
        "label": "Disclosure Of Detailed Information About Other Finance Income Expense [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherFinanceIncomeExpenseAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based compensation expense [Abstract].",
        "label": "Disclosure Of Detailed Information About Share Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based compensation expense [Line Items].",
        "label": "Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based compensation expense [Table].",
        "label": "Disclosure Of Detailed Information About Share Based Compensation Expense [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based compensation expense.",
        "label": "Disclosure Of Detailed Information About Share Based Compensation Expense [Text Block]",
        "terseLabel": "Summary of Employee Related Share Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationExpenseTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareListingExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share listing expense.",
        "label": "Disclosure of detailed information about share listing expense [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareListingExpenseLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about Share listing expenses [text block].",
        "label": "disclosure of detailed information about Share listing expenses [Text Block]",
        "terseLabel": "Summary of Calculation of the Share listing expense"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareListingExpensesTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.",
        "label": "Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill explanatory.",
        "label": "Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill Explanatory [Table Text Block]",
        "verboseLabel": "Summary of useful life of intangible assets other than goodwill"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.",
        "label": "Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about useful life measured as period of time intangible assets other than goodwill.",
        "label": "Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutUsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwillTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfUsefulLifeOfIntangibleAssetsOtherThanGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expenses related to right of use assets and lease liabilities.",
        "label": "Disclosure Of Expenses Related To Right Of Use Assets And Lease Liabilities [Table Text Block]",
        "verboseLabel": "Summary of expenses related to\u00a0right-of-use\u00a0assets and lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expenses related to\u00a0right-of-use\u00a0assets and lease liabilities.",
        "label": "Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expenses related to\u00a0right-of-use\u00a0assets and lease liabilities.",
        "label": "Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expenses related to\u00a0right-of-use\u00a0assets and lease liabilities.",
        "label": "Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfExpensesRelatedTorightofuseassetsAndLeaseLiabilitiesTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of lease liabilities.",
        "label": "Disclosure Of Lease Liabilities [Table Text Block]",
        "verboseLabel": "Details of Lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of non mandatory standards and interpretations issued by the IASB.",
        "label": "Disclosure Of Non Mandatory Standards And Interpretations Issued By The IASB [Table Text Block]",
        "verboseLabel": "Summary of Non Mandatory standards and interpretations issued by IASB"
       }
      }
     },
     "localname": "DisclosureOfNonMandatoryStandardsAndInterpretationsIssuedByTheIasbTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfPersonnelExpenesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Personnel Expenses [Text Block]",
        "label": "Disclosure Of Personnel Expenes [Text Block]",
        "terseLabel": "Summary of Personnel Expenses"
       }
      }
     },
     "localname": "DisclosureOfPersonnelExpenesTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfPersonnelExpensesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Personnel Expenses Explanatory.",
        "label": "Disclosure Of Personnel Expenses Explanatory [Text Block]",
        "terseLabel": "Personnel expenses"
       }
      }
     },
     "localname": "DisclosureOfPersonnelExpensesExplanatoryTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PersonnelExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of property plant and equipment estimated useful lives .",
        "label": "Disclosure Of Property Plant And Equipment Estimated Useful Lives [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of property plant and equipment estimated useful lives explanatory.",
        "label": "Disclosure Of Property Plant And Equipment Estimated Useful Lives Explanatory [Table Text Block]",
        "verboseLabel": "Summary of estimated Useful Lives of Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312020Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of property plant and equipment estimated useful lives.",
        "label": "Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of property plant and equipment estimated useful lives.",
        "label": "Disclosure Of Property Plant And Equipment Estimated Useful Lives [Table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reconciliation between taxes on income and expected income tax benefit[Text Block].",
        "label": "Disclosure of reconciliation between taxes on income and expected income tax benefit [Table Text Block]",
        "terseLabel": "Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit"
       }
      }
     },
     "localname": "DisclosureOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfRevenueFromCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from collaboration agreements.",
        "label": "Disclosure Of Revenue From Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromCollaborationAgreementsAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfRevenueFromCollaborationAgreementsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from collaboration agreements explanatory.",
        "label": "Disclosure of Revenue From Collaboration Agreements Explanatory",
        "terseLabel": "Summary of revenue from collaboration agreements explanatory"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromCollaborationAgreementsExplanatory",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisclosureOfRevenueFromCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from collaboration agreements.",
        "label": "Disclosure Of Revenue From Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromCollaborationAgreementsLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfRevenueFromCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from collaboration agreements.",
        "label": "Disclosure Of Revenue From Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromCollaborationAgreementsTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfRevenueFromContractWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Revenue From Contract With Customers [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractWithCustomersLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfRevenueFromContractWithCustomersTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Revenue From Contract With Customers [Table]"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractWithCustomersTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Table]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForEachTypeOfMarketRiskTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfShareListingExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share listing expense.",
        "label": "Disclosure of Share Listing Expense [Line Items]",
        "terseLabel": "Disclosure of share listing expense [line items]"
       }
      }
     },
     "localname": "DisclosureOfShareListingExpenseLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of trade and other receivable explanatory.",
        "label": "Disclosure Of Trade And Other Receivable Explanatory [Table Text Block]",
        "verboseLabel": "Summary of Trade receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivableExplanatoryTableTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_DisposalsOfPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals of property, plant and equipment.",
        "label": "Disposals of Property Plant and Equipment",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsOfPropertyPlantAndEquipment",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax reconciliation permanent effect share listing expense.",
        "label": "Effective Income Tax Reconciliation Permanent Effect Share Listing Expense",
        "terseLabel": "Effective income tax reconciliation permanent effect share listing expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationPermanentEffectShareListingExpense",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effects of exchange rate changes and expected credit losses on cash and cash equivalents.",
        "label": "Effects Of Exchange Rate Changes And Expected Credit Losses On Cash And Cash Equivalents",
        "terseLabel": "Effects of exchange rate changes and expected credit losses on cash and cash equivalents",
        "verboseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectsOfExchangeRateChangesAndExpectedCreditLossesOnCashAndCashEquivalents",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail",
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_EliotForsterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eliot Forster [Member]",
        "terseLabel": "Eliot Forster"
       }
      }
     },
     "localname": "EliotForsterMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EmployeeHealthInsuranceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee health insurance cost.",
        "label": "Employee Health insurance Cost",
        "terseLabel": "Employee health insurance cost"
       }
      }
     },
     "localname": "EmployeeHealthInsuranceCost",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PersonnelExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_EuroStrengthsBy10AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro strengths by 10 against US dollars [Member]",
        "terseLabel": "Euro strengths by 10% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroStrengthsBy10AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EuroStrengthsBy1AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro strengths by 1 against US dollars [Member]",
        "terseLabel": "Euro strengths by 1% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroStrengthsBy1AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EuroStrengthsBy5AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro strengths by 5 against US dollars [Member]",
        "terseLabel": "Euro strengths by 5% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroStrengthsBy5AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EuroWeakensBy10AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro weakens by 10 against US dollars [Member]",
        "terseLabel": "Euro weakens by 10% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroWeakensBy10AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EuroWeakensBy1AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro weakens by 1 against US dollars [Member]",
        "terseLabel": "Euro weakens by 1% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroWeakensBy1AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EuroWeakensBy5AgainstUsDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro weakens by 5 against US dollars [Member]",
        "terseLabel": "Euro weakens by 5% against U.S. dollars [Member]"
       }
      }
     },
     "localname": "EuroWeakensBy5AgainstUsDollarsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ExpenseFromTheModificationOfShareBasedAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense from the modification of share based awards.",
        "label": "Expense From The Modification Of Share Based Awards",
        "terseLabel": "Share based compensation expenses modification of awards"
       }
      }
     },
     "localname": "ExpenseFromTheModificationOfShareBasedAwards",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_FairValueOfWarrantLiabilitiesAssumedInABusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant liabilities assumed in a business combination.",
        "label": "Fair Value Of Warrant Liabilities Assumed In A Business Combination",
        "terseLabel": "Fair value of warrant liabilities assumed in a business acquisition"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilitiesAssumedInABusinessCombination",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_FinancialAssetsAndFinancialLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets and Financial liabilities.",
        "label": "Financial Assets and Financial Liabilities",
        "verboseLabel": "Financial assets and Financial liabilities"
       }
      }
     },
     "localname": "FinancialAssetsAndFinancialLiabilities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ForeignCurrencyLossesNet": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency losses net.",
        "label": "Foreign Currency Losses Net",
        "negatedLabel": "Foreign currency losses"
       }
      }
     },
     "localname": "ForeignCurrencyLossesNet",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ForeignExchangeRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rates.",
        "label": "Foreign Exchange Rates [Member]"
       }
      }
     },
     "localname": "ForeignExchangeRatesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_FriedrichVonBohlenUndHalbachMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Friedrich von Bohlen und Halbach [Member]",
        "label": "Friedrich von Bohlen und Halbach [Member]",
        "terseLabel": "Friedrich von Bohlen und Halbach"
       }
      }
     },
     "localname": "FriedrichVonBohlenUndHalbachMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GSKCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "G S K Collaboration Agreement [Member]",
        "terseLabel": "GSK Collaboration Agreement [Member]",
        "verboseLabel": "GSK"
       }
      }
     },
     "localname": "GSKCollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain recognised on financial instruments whose fair value previously could not be reliably measured.",
        "label": "Gain Recognised On Financial Instruments Whose Fair Value Previously Could Not Be Reliably Measured",
        "terseLabel": "Gain on other financial instruments"
       }
      }
     },
     "localname": "GainRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "General And Administrative Expense [Member]",
        "documentation": "General and administrative expense [Member].",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses [Member]",
        "verboseLabel": "General and administrative expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GenmabCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genmab Collaboration Agreement [Member]",
        "terseLabel": "Genmab"
       }
      }
     },
     "localname": "GenmabCollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GrantedOnJuneTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted on june two thousand and twenty [Member].",
        "label": "Granted On June Two Thousand And Twenty [Member]",
        "terseLabel": "Granted On June 2020 [Member]"
       }
      }
     },
     "localname": "GrantedOnJuneTwoThousandAndTwentyMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GrantedOnMarchTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted on march two thousand and twenty one.",
        "label": "Granted On March Two Thousand And Twenty One [Member]",
        "terseLabel": "Granted On March 2021 [Member]"
       }
      }
     },
     "localname": "GrantedOnMarchTwoThousandAndTwentyOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GrantedOnSeptemberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted on september two thousand and twenty [Member].",
        "label": "Granted On September Two Thousand And Twenty [Member]",
        "terseLabel": "Granted On September 2020 [Member]"
       }
      }
     },
     "localname": "GrantedOnSeptemberTwoThousandAndTwentyMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GrantedOnSeptemberTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted on september two thousand and twenty one [Member].",
        "label": "Granted On September Two Thousand And Twenty One [Member]",
        "terseLabel": "Granted On September 2021 [Member]"
       }
      }
     },
     "localname": "GrantedOnSeptemberTwoThousandAndTwentyOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_GrossProceedsFromIssueOfSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issue of securities.",
        "label": "Gross Proceeds From Issue Of Securities",
        "terseLabel": "Gross Proceeds From Issue Of Securities"
       }
      }
     },
     "localname": "GrossProceedsFromIssueOfSecurities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_HaraldFstockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harald FStock [Member]",
        "terseLabel": "Harald F.Stock"
       }
      }
     },
     "localname": "HaraldFstockMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_HarpreetSinghMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harpreet Singh [Member]",
        "terseLabel": "Harpreet Singh"
       }
      }
     },
     "localname": "HarpreetSinghMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_HeatherLMasonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Heather L Mason [Member]",
        "terseLabel": "Heather L. Mason"
       }
      }
     },
     "localname": "HeatherLMasonMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_Ima401clinicaltrialservicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ima401 Clinical Trial Services [Member]"
       }
      }
     },
     "localname": "Ima401clinicaltrialservicesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_Ima401licensegrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ima401 License Grant [Member]"
       }
      }
     },
     "localname": "Ima401licensegrantMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImmaticsBiotechnologiesGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immatics biotechnologies gmbH.",
        "label": "Immatics Biotechnologies GmbH [Member]"
       }
      }
     },
     "localname": "ImmaticsBiotechnologiesGmbhMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImmaticsGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immatics GmbH [Member]",
        "terseLabel": "Immatics GmbH [Member]"
       }
      }
     },
     "localname": "ImmaticsGmbhMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImmaticsNvMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immatics NV [Member]",
        "terseLabel": "Immatics N.V. [Member]"
       }
      }
     },
     "localname": "ImmaticsNvMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImmaticsUsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immatics US, Inc.",
        "label": "Immatics US Inc [Member]",
        "terseLabel": "Immatics US Inc [Member]"
       }
      }
     },
     "localname": "ImmaticsUsIncMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImtxagreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMTXAgreement.",
        "label": "IMTXAgreement [Axis]"
       }
      }
     },
     "localname": "ImtxagreementAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_ImtxagreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMTXAgreement.",
        "label": "IMTXAgreement [Member]"
       }
      }
     },
     "localname": "ImtxagreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ImtxbMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMTXB M S Collaboration Agreement.",
        "label": "IMTXB M S Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "ImtxbMSCollaborationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement location.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_IncomeStatementLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement location.",
        "label": "Income Statement Location [Member]"
       }
      }
     },
     "localname": "IncomeStatementLocationMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in other comprehensive income on basis of higher lower basis points.",
        "label": "Increase Decrease In Other Comprehensive Income On Basis Of Higher Lower Basis Points",
        "terseLabel": "OCI"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherComprehensiveIncomeOnBasisOfHigherLowerBasisPoints",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Profit Loss Before Tax On Basis Of Higher Lower Basis Points.",
        "label": "Increase Decrease In Profit Loss Before Tax On Basis Of Higher Lower Basis Points",
        "terseLabel": "Profit/(loss)"
       }
      }
     },
     "localname": "IncreaseDecreaseInProfitLossBeforeTaxOnBasisOfHigherLowerBasisPoints",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreaseDecreaseThroughReorganizationEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through reorganization, equity.",
        "label": "Increase Decrease Through Reorganization Equity",
        "verboseLabel": "Reorganization"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughReorganizationEquity",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreaseThroughARYAMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase through ARYA Merger.",
        "label": "Increase Through A R Y A Merger",
        "verboseLabel": "ARYA Merger, net of transaction costs"
       }
      }
     },
     "localname": "IncreaseThroughARYAMerger",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreasedecreaseThroughChangesInNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Increase (decrease) through changes in noncontrolling interest",
        "documentation": "Increase (decrease) through changes in noncontrolling interest.",
        "label": "Increase decrease through Changes in Noncontrolling Interest",
        "verboseLabel": "MD Anderson Share Exchange"
       }
      }
     },
     "localname": "IncreasedecreaseThroughChangesInNoncontrollingInterest",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreasedecreaseThroughCompensationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through compensation expense.",
        "label": "Increase Decrease Through Compensation Expense",
        "verboseLabel": "MD Anderson milestone compensation expense"
       }
      }
     },
     "localname": "IncreasedecreaseThroughCompensationExpense",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreasedecreaseThroughIssuanceOfEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through issuance of equity.",
        "label": "Increase Decrease Through Issuance Of Equity",
        "terseLabel": "Total issuance of share capital"
       }
      }
     },
     "localname": "IncreasedecreaseThroughIssuanceOfEquity",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through share based compensation previously classifies as equity settled.",
        "label": "Increase Decrease Through Share Based Compensation Previously Classifies As Equity Settled",
        "verboseLabel": "Payments related to share-based compensation awards previously classified as equity-settled"
       }
      }
     },
     "localname": "IncreasedecreaseThroughShareBasedCompensationPreviouslyClassifiesAsEquitySettled",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_IndefiniteTaxLossesCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Tax Losses carryforward [Member]",
        "terseLabel": "Indefinite Tax Losses Carryforward [Member]"
       }
      }
     },
     "localname": "IndefiniteTaxLossesCarryforwardMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_IntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Member]",
        "terseLabel": "Intangible assets [Member]"
       }
      }
     },
     "localname": "IntangibleAssetsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_InterestExpenseOnLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense on lease.",
        "label": "Interest Expense on Lease",
        "terseLabel": "Interest expenses form lease"
       }
      }
     },
     "localname": "InterestExpenseOnLease",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_InvesteeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investee Axis.",
        "label": "Investee [Axis]"
       }
      }
     },
     "localname": "InvesteeAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_InvesteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investee Member.",
        "label": "Investee [Member]"
       }
      }
     },
     "localname": "InvesteeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_IssueOfShareCapitalNetOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of share capital \u2013 net of transaction costs.",
        "label": "Issue Of Share Capital Net Of Transaction Costs",
        "terseLabel": "Issue of share capital \u2013 net of transaction costs"
       }
      }
     },
     "localname": "IssueOfShareCapitalNetOfTransactionCosts",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensationFixed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation fixed.",
        "label": "Key Management Personnel Compensation Fixed",
        "terseLabel": "Fixed"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationFixed",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensationPaymentExitArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation payment exit arrangement.",
        "label": "Key Management Personnel Compensation Payment Exit Arrangement",
        "terseLabel": "Payment Exit arrangement"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPaymentExitArrangement",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensationShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation share based compensation expense.",
        "label": "Key Management Personnel Compensation Share Based Compensation Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShareBasedCompensationExpense",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensationSupervisoryBoardCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation supervisory board compensation.",
        "label": "Key Management Personnel Compensation Supervisory Board Compensation",
        "verboseLabel": "Supervisory board compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSupervisoryBoardCompensation",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensationTravellingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation travelling expenses.",
        "label": "Key Management Personnel Compensation Travelling Expenses",
        "terseLabel": "Travel expenses"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationTravellingExpenses",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_KeyManagementPersonnelCompensations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensations.",
        "label": "Key Management Personnel Compensations",
        "totalLabel": "Total cash compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensations",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "verboseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesSummaryOfExpensesRelatedToRightOfUseAssetsAndLeaseLiabilitiesDetail",
      "http://imtx.com/role/LeasesSummaryOfRightOfUseAssetsDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail",
      "http://imtx.com/role/SummaryOfAccountingPoliciesAppliedByTheGroupForTheAnnualReportingPeriodEndingDecember312022SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_LeaseLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability [Member]",
        "terseLabel": "Lease liabilities [Member]"
       }
      }
     },
     "localname": "LeaseLiabilityMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_LiabilitiesArisingFromFinancingActivitiesCashEffective": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities arising from financing activities cash effective.",
        "label": "Liabilities Arising from Financing Activities Cash Effective",
        "terseLabel": "Cash effective"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesCashEffective",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_LiabilitiesArisingFromFinancingActivitiesNoncashEffective": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities arising from financing activities noncash effective.",
        "label": "Liabilities Arising from Financing Activities Noncash Effective",
        "terseLabel": "Non-cash effective"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesNoncashEffective",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_LiabilitiesForWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities for warrants [Member].",
        "label": "Liabilities for Warrants [Member]",
        "terseLabel": "Liabilities for warrants [member]"
       }
      }
     },
     "localname": "LiabilitiesForWarrantsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialInstrumentsSummaryOfChangesOfTheLiabilitiesFromFinancingActivitiesClassifiedAsCashEffectiveAndNonCashEffectiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_LicenseDevelopmentAndCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License development and commercialization agreement.",
        "label": "License Development And Commercialization Agreement [Member]",
        "terseLabel": "License Development and Commercialization Agreement [member]"
       }
      }
     },
     "localname": "LicenseDevelopmentAndCommercializationAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_LossOnNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on non-controlling interest.",
        "label": "Loss on noncontrolling interest",
        "terseLabel": "Loss on non-controlling\u00a0interest"
       }
      }
     },
     "localname": "LossOnNoncontrollingInterest",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss recognised on financial instruments whose fair value previously could not be reliably measured.",
        "label": "Loss Recognised On Financial Instruments Whose Fair Value Previously Could Not Be Reliably Measured",
        "negatedLabel": "Losses on other financial instruments"
       }
      }
     },
     "localname": "LossRecognisedOnFinancialInstrumentsWhoseFairValuePreviouslyCouldNotBeReliablyMeasured",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesSummaryOfOtherFinancialIncomeAndCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ManagementMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management members [Member].",
        "label": "Management Members [Member]",
        "terseLabel": "Management Members [Member]"
       }
      }
     },
     "localname": "ManagementMembersMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MatchingStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Matching Stock Options [Member]",
        "terseLabel": "Matching Stock Options [Member]"
       }
      }
     },
     "localname": "MatchingStockOptionsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MaximumExposedToCurrencyRisk": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Exposed to Currency risk.",
        "label": "Maximum Exposed to Currency risk",
        "totalLabel": "Total assets exposed to the risk"
       }
      }
     },
     "localname": "MaximumExposedToCurrencyRisk",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_MdAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MD Anderson [Member]",
        "terseLabel": "MD Anderson [Member]"
       }
      }
     },
     "localname": "MdAndersonMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MichaelGAtiehMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael G Atieh [Member]",
        "terseLabel": "Michael G. Atieh"
       }
      }
     },
     "localname": "MichaelGAtiehMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MilestonePaymentForLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment For Licensed Product [Member]"
       }
      }
     },
     "localname": "MilestonePaymentForLicensedProductMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable.",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone regulatory and royalty payment received.",
        "label": "Milestone Regulatory And Royalty Payment Received",
        "terseLabel": "Milestone regulatory and royaly payment receivable"
       }
      }
     },
     "localname": "MilestoneRegulatoryAndRoyaltyPaymentReceived",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_MinimumMarketCapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization.",
        "label": "Minimum Market Capitalization",
        "terseLabel": "Minimum market capitalization"
       }
      }
     },
     "localname": "MinimumMarketCapitalization",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of awards under two thousand ten and two thousand and sixteen plan [Member].",
        "label": "Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]",
        "terseLabel": "Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]"
       }
      }
     },
     "localname": "ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ModificationOfTwoThousandAndSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of two thousand and sixteen plan [Member].",
        "label": "Modification Of Two Thousand And Sixteen Plan [Member]",
        "terseLabel": "Modification Of Two Thousand And Sixteen Plan [Member]"
       }
      }
     },
     "localname": "ModificationOfTwoThousandAndSixteenPlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ModificationOfTwoThousandAndTenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of two thousand and ten plan [Member].",
        "label": "Modification Of Two Thousand And Ten Plan [Member]",
        "terseLabel": "Modification Of Two Thousand And Ten Plan [Member]"
       }
      }
     },
     "localname": "ModificationOfTwoThousandAndTenPlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_NancyValenteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nancy Valente [Member].",
        "label": "Nancy Valente [Member]",
        "verboseLabel": "Nancy Valente"
       }
      }
     },
     "localname": "NancyValenteMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_NetFinancialResult": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net financial result.",
        "label": "Net Financial Result",
        "verboseLabel": "Net financial result"
       }
      }
     },
     "localname": "NetFinancialResult",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfNetResultFromFinancialInstrumentsByMeasurementCategoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_NonCurrentPrepaidMaintenanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non current prepaid maintenance expenses.",
        "label": "Non Current Prepaid Maintenance Expenses",
        "terseLabel": "NonCurrent Prepaid Maintenance Expenses"
       }
      }
     },
     "localname": "NonCurrentPrepaidMaintenanceExpenses",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_NonInterestBearingLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non interest bearing liability.",
        "label": "Non Interest Bearing Liability [Member]"
       }
      }
     },
     "localname": "NonInterestBearingLiabilityMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-recognition\u00a0of\u00a0deferred taxes on tax losses and temporary differences.",
        "label": "Non recognition of deferred taxes on tax losses and temporary differences",
        "terseLabel": "Non-recognition\u00a0of\u00a0deferred taxes on tax losses and temporary differences"
       }
      }
     },
     "localname": "NonRecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_NoncurrentPrepaymentsOfLicensingAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent prepayments of licensing agreement.",
        "label": "Noncurrent Prepayments Of Licensing Agreement",
        "terseLabel": "Noncurrent Prepayments Of Licensing Agreement"
       }
      }
     },
     "localname": "NoncurrentPrepaymentsOfLicensingAgreement",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-recognition of deferred tax assets on temporary differences.",
        "label": "Nonrecognition of deferred tax assets on temporary differences [Member]",
        "terseLabel": "Non-recognition of deferred tax assets on temporary differences [Member]"
       }
      }
     },
     "localname": "NonrecognitionOfDeferredTaxAssetsOnTemporaryDifferencesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_NumberOfConvertedStockOptionsInTheEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Converted stock options in the entity.",
        "label": "Number of Converted Stock Options In The Entity"
       }
      }
     },
     "localname": "NumberOfConvertedStockOptionsInTheEntity",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imtx_NumberOfMatchingStockOptionInTheEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of matching stock option in the entity.",
        "label": "Number of Matching Stock Option In The Entity",
        "terseLabel": "Number of matching stock option in the entity"
       }
      }
     },
     "localname": "NumberOfMatchingStockOptionInTheEntity",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imtx_NumberOfSharesExchangedInSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares exchanged in subsidiaries.",
        "label": "Number of shares exchanged in subsidiaries",
        "terseLabel": "Number of shares exchanged in subsidiaries"
       }
      }
     },
     "localname": "NumberOfSharesExchangedInSubsidiaries",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imtx_OfficeEquipmentAndInstallationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office equipment and installations.",
        "label": "Office Equipment And Installations [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentAndInstallationsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/PropertyPlantAndEquipmentAddtionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_OrdinaryShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Share [Member]",
        "terseLabel": "Common Shares [Member]"
       }
      }
     },
     "localname": "OrdinaryShareMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_OtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current.",
        "label": "Other Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrent",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities [member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_OtherCurrentNonCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current/non-current assets [Member]",
        "label": "Other Current Non Current Assets [Member]",
        "terseLabel": "Other current/non-current assets [member]"
       }
      }
     },
     "localname": "OtherCurrentNonCurrentAssetsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_OtherLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other lease obligations.",
        "label": "Other Lease Obligations",
        "terseLabel": "Other Lease Obligations"
       }
      }
     },
     "localname": "OtherLeaseObligations",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_OtherNonCurrentAsset": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non current asset.",
        "label": "Other Non Current Asset",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNonCurrentAsset",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PatentAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and licenses.",
        "label": "Patent And Licenses [Member]"
       }
      }
     },
     "localname": "PatentAndLicensesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PaulCarterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paul Carter [Member]",
        "terseLabel": "Paul Carter"
       }
      }
     },
     "localname": "PaulCarterMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PaymentOfPayrollTaxOfTheEmployees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Payroll Tax of the employees.",
        "label": "Payment Of Payroll Tax Of The Employees",
        "terseLabel": "Payment of Payroll Tax of the employees"
       }
      }
     },
     "localname": "PaymentOfPayrollTaxOfTheEmployees",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PaymentsForShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 26.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for share based compensation.",
        "label": "Payments For Share Based Compensation",
        "negatedLabel": "Payment related to share-based compensation awards previously classified as equity-settled"
       }
      }
     },
     "localname": "PaymentsForShareBasedCompensation",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of right of use assets classified as financing activities.",
        "label": "Payments Of Right Of Use Assets Classified As Financing Activities",
        "verboseLabel": "Payments of right of use assets classified as financing activities"
       }
      }
     },
     "localname": "PaymentsOfRightOfUseAssetsClassifiedAsFinancingActivities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PercentageOfCashAndCashEquivalentsHeldInDomicile": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cash and cash equivalents held in domicile.",
        "label": "Percentage of Cash and Cash Equivalents Held in Domicile",
        "verboseLabel": "Percentage of cash and cash equivalents held in domicile"
       }
      }
     },
     "localname": "PercentageOfCashAndCashEquivalentsHeldInDomicile",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfCashProceedsToBeBeReinvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cash proceeds to be reinvested.",
        "label": "Percentage Of Cash Proceeds To Be Be Reinvested",
        "terseLabel": "Percentage of cash proceeds to be reinvested"
       }
      }
     },
     "localname": "PercentageOfCashProceedsToBeBeReinvested",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of income that can be used to set off tax losses carry forward.",
        "label": "Percentage Of Income That Can Be Used To Set Off Tax Losses Carry Forward"
       }
      }
     },
     "localname": "PercentageOfIncomeThatCanBeUsedToSetOffTaxLossesCarryForward",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfPretaxIncomeSubjectToIncomeTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of pretax income subject to income tax.",
        "label": "Percentage Of Pretax Income Subject To Income Tax"
       }
      }
     },
     "localname": "PercentageOfPretaxIncomeSubjectToIncomeTax",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Reasonably Possible Decrease In Foreign Currency Risk.",
        "label": "Percentage Of Reasonably Possible Decrease In Foreign Currency Risk",
        "terseLabel": "Percentage Of Reasonably Possible Decrease In Foreign Currency Risk"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleDecreaseInForeignCurrencyRisk",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Reasonably Possible Increase In Foreign Currency Risk.",
        "label": "Percentage Of Reasonably Possible Increase In Foreign Currency Risk",
        "terseLabel": "Percentage Of Reasonably Possible Increase In Foreign Currency Risk"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleIncreaseInForeignCurrencyRisk",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock vested over the period of four-year time-based vesting schedule.",
        "label": "Percentage Of Stock Vested Over The Period Of Four Year Time Based Vesting Schedule",
        "terseLabel": "Percentage of stock vested over the period of four-year time-based vesting schedule"
       }
      }
     },
     "localname": "PercentageOfStockVestedOverThePeriodOfFourYearTimeBasedVestingSchedule",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage on limitation on tax loss carryforwards after prior period.",
        "label": "Percentage on Limitation on tax loss carryforwards after prior period",
        "terseLabel": "Percentage on limitation on tax loss carryforwards after prior period"
       }
      }
     },
     "localname": "PercentageOnLimitationOnTaxLossCarryforwardsAfterPriorPeriod",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage on limitation on tax loss carryforwards before prior period.",
        "label": "Percentage on Limitation on tax loss carryforwards before prior period",
        "terseLabel": "Percentage on limitation on tax loss carryforwards before prior period"
       }
      }
     },
     "localname": "PercentageOnLimitationOnTaxLossCarryforwardsBeforePriorPeriod",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imtx_PerformanceBasedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based options [Member].",
        "label": "Performance Based Options [Member]",
        "terseLabel": "Performance Based Options [Member]"
       }
      }
     },
     "localname": "PerformanceBasedOptionsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail",
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PerformanceObligationsCumulativeUpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance obligations cumulative upfront payments received.",
        "label": "Performance Obligations Cumulative Upfront Payments Received",
        "terseLabel": "Performance obligations cumulative upfront payments received"
       }
      }
     },
     "localname": "PerformanceObligationsCumulativeUpfrontPaymentsReceived",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PeterChambreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peter Chambre [Member]",
        "terseLabel": "Peter Chambre"
       }
      }
     },
     "localname": "PeterChambreMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfCompensationForTheSupervisoryBoardDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PipeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PIPE financing.",
        "label": "PIPE Financing [Member]",
        "terseLabel": "PIPE Financing [member]"
       }
      }
     },
     "localname": "PipeFinancingMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan [Axis]"
       }
      }
     },
     "localname": "PlanAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan [Member].",
        "label": "Plan [Member]"
       }
      }
     },
     "localname": "PlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfOptionsGrantedPricedUsingBlackScholesForSarsTandemAwardsConvertedOptionsMatchingStockOptionsAndMonteCarloOptionPricingModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PlanNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_PotentialMilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payment payable.",
        "label": "Potential Milestone Payment Payable",
        "terseLabel": "Potential milestone payment payable"
       }
      }
     },
     "localname": "PotentialMilestonePaymentPayable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_PrepaidExpensesOfLicensesAndSoftware": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses of licenses and software.",
        "label": "Prepaid Expenses Of Licenses And Software",
        "verboseLabel": "Prepaid expenses of licenses and software"
       }
      }
     },
     "localname": "PrepaidExpensesOfLicensesAndSoftware",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherCurrentAndNonCurrentAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_RealisedGainLossFromForeignCurrencyForwardContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Realised gain loss from foreign currency forward contracts",
        "label": "Realised gain loss from foreign currency forward contracts",
        "terseLabel": "Realised gain from foreign currency forward contracts"
       }
      }
     },
     "localname": "RealisedGainLossFromForeignCurrencyForwardContracts",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ReceivablesFromCollaborationAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentTradeReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables from collaboration agreements.",
        "label": "Receivables From Collaboration Agreements"
       }
      }
     },
     "localname": "ReceivablesFromCollaborationAgreements",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AccountsReceivableSummaryOfTradeReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ReclassficationOfProvisionsToOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassfication of provisions to other current liabilities.",
        "label": "Reclassfication Of Provisions To Other Current Liabilities",
        "terseLabel": "Reclassfication of Provisions to other Current Liabilities"
       }
      }
     },
     "localname": "ReclassficationOfProvisionsToOtherCurrentLiabilities",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_RecognitionOfTaxLossesCarriedForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of tax losses carried forward.",
        "label": "Recognition of tax losses carried forward [Member]"
       }
      }
     },
     "localname": "RecognitionOfTaxLossesCarriedForwardMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering.",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ReorganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reorganization [Member]"
       }
      }
     },
     "localname": "ReorganizationMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Research And Development Expense [Member]",
        "documentation": "Research and development expense [Member].",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development expenses [Member]",
        "verboseLabel": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfDepreciationExpenseDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeRelatedShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_RestrictedCashRecognizedAsOfTheAcquisitionDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash recognized as of the acquisition date.",
        "label": "Restricted Cash Recognized As Of The Acquisition Date",
        "verboseLabel": "Cash and cash equivalents held in ARYA's trust account"
       }
      }
     },
     "localname": "RestrictedCashRecognizedAsOfTheAcquisitionDate",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_RestrictedStockAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Acquisition Agreement [Member]",
        "terseLabel": "Restricted Stock Acquisition Agreement [Member]"
       }
      }
     },
     "localname": "RestrictedStockAcquisitionAgreementMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_RevenueFromCollaborationAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 11.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from collaboration agreements",
        "label": "Revenue from collaboration agreements",
        "presentationGuidance": "Receipt of upfront of payment",
        "terseLabel": "Revenue from collaboration agreements",
        "verboseLabel": "Revenue from collaboration agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreements",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail",
      "http://imtx.com/role/RevenueFromCollaborationAgreementsSummaryOfRevenueFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_RevenueRecognizedDuringThePeriodPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized during the period performance obligation.",
        "label": "Revenue Recognized During The Period Performance Obligation",
        "terseLabel": "Revenue recognized during the period performance obligation"
       }
      }
     },
     "localname": "RevenueRecognizedDuringThePeriodPerformanceObligation",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_SARConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SAR conversion.",
        "label": "S A R conversion",
        "verboseLabel": "SAR conversion"
       }
      }
     },
     "localname": "SARConversion",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_SchemeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scheme [Axis].",
        "label": "Scheme [Axis]"
       }
      }
     },
     "localname": "SchemeAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_SchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scheme [Member].",
        "label": "Scheme [Member]"
       }
      }
     },
     "localname": "SchemeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_SensitiveAnalaysisOfCurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sensitive analaysis of currency [Axis]"
       }
      }
     },
     "localname": "SensitiveAnalaysisOfCurrencyAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_SensitiveAnalaysisOfCurrencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sensitive analaysis of currency [Domain]"
       }
      }
     },
     "localname": "SensitiveAnalaysisOfCurrencyDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ServiceOptionsFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Options Four [Member].",
        "label": "Service Options Four [Member]"
       }
      }
     },
     "localname": "ServiceOptionsFourMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ServiceOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Options [Member]"
       }
      }
     },
     "localname": "ServiceOptionsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ServiceOptionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Options One [Member]"
       }
      }
     },
     "localname": "ServiceOptionsOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ServiceOptionsThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service options three [Member].",
        "label": "Service Options Three [Member]"
       }
      }
     },
     "localname": "ServiceOptionsThreeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ServiceOptionsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service options two.",
        "label": "Service Options Two [Member]"
       }
      }
     },
     "localname": "ServiceOptionsTwoMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment arrangement weighted average fair value per share.",
        "label": "Share Based Compensation By Share Based Payment Arrangement Weighted Average Fair Value Per Share",
        "terseLabel": "Share based compensation by share based payment arrangement fair value per share",
        "verboseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedPaymentArrangementWeightedAverageFairValuePerShare",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://imtx.com/role/ShareBasedPaymentsSummaryOfEmployeeShareOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imtx_ShareIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issued price per share.",
        "label": "Share Issued Price per Share",
        "terseLabel": "Share Issued Price per Share"
       }
      }
     },
     "localname": "ShareIssuedPricePerShare",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imtx_ShareListingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share listing expense.",
        "label": "Share listing expense",
        "negatedLabel": "Share listing expense",
        "verboseLabel": "Share listing expense"
       }
      }
     },
     "localname": "ShareListingExpense",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/ConsolidatedStatementOfProfitLossOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_ShareListingExpenseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share listing expense",
        "label": "Share listing expense [Axis]"
       }
      }
     },
     "localname": "ShareListingExpenseAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_ShareListingExpenseDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share listing expense [Domain]"
       }
      }
     },
     "localname": "ShareListingExpenseDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share listing expenses and change in fair value of warrant liabilities [Text block].",
        "label": "Share Listing Expenses And Change In Fair Value Of Warrant Liabilities [Text Block]",
        "terseLabel": "Share listing expense and change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "ShareListingExpensesAndChangeInFairValueOfWarrantLiabilitiesTextBlock",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imtx_ShareReinvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share reinvestment [Member].",
        "label": "Share Reinvestment [Member]",
        "terseLabel": "Share Reinvestment [Member]"
       }
      }
     },
     "localname": "ShareReinvestmentMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ShareReinvestmentSchemeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share reinvestment scheme [Axis].",
        "label": "Share Reinvestment Scheme [Axis]"
       }
      }
     },
     "localname": "ShareReinvestmentSchemeAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_ShareReinvestmentSchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share reinvestment scheme [Member].",
        "label": "Share Reinvestment Scheme [Member]"
       }
      }
     },
     "localname": "ShareReinvestmentSchemeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_ShorttermDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShortTerm Deposits [Member]",
        "terseLabel": "Short-Term Deposits [Member]",
        "verboseLabel": "Short-Term Deposits [member]"
       }
      }
     },
     "localname": "ShorttermDepositsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/FinancialInstrumentsSummaryOfCarryingAmountsAndFairValuesOfGroupsFinancialInstrumentsDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_SoftwareLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software licenses.",
        "label": "Software Licenses [Member]"
       }
      }
     },
     "localname": "SoftwareLicensesMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IntangibleAssetsSummaryOfChangesToIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_StatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements [Line Items]",
        "terseLabel": "Statements [Line Items]"
       }
      }
     },
     "localname": "StatementsLineItems",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail",
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_StatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements [Table]"
       }
      }
     },
     "localname": "StatementsTable",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfLiquidityRiskDetail",
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/IncomeTaxSummaryOfDeferredTaxAssetsDetail",
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/PersonnelExpensesSummaryOfPersonnelExpensesDetail",
      "http://imtx.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Acquisitions.",
        "label": "Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Stock issued during period, shares, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imtx_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, new issues.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Stock issued during period, value, new issues",
        "verboseLabel": "Stock issued during period, value, new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_SvbSecuritiesLicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Svb securities Lic Member.",
        "label": "Svb Securities Lic [Member]",
        "terseLabel": "Svb Securities Lic [Member]"
       }
      }
     },
     "localname": "SvbSecuritiesLicMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TaxEffectOfGovernmentGrantsExemptedFromTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of government grants exempted from taxes.",
        "label": "Tax Effect of Government Grants Exempted From Taxes",
        "terseLabel": "Government grants exempted from taxes"
       }
      }
     },
     "localname": "TaxEffectOfGovernmentGrantsExemptedFromTaxes",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_TaxEffectOfPermanentDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of permanent differences.",
        "label": "Tax Effect Of Permanent Differences",
        "terseLabel": "Permanent Differences"
       }
      }
     },
     "localname": "TaxEffectOfPermanentDifferences",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxSummaryOfReconciliationBetweenTaxesOnIncomeAndExpectedIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Text block.",
        "label": "Text Block [Abstract]",
        "terseLabel": "Text block [abstract]",
        "verboseLabel": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://imtx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imtx_ThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thereafter.",
        "label": "Thereafter [Member]"
       }
      }
     },
     "localname": "ThereafterMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TotalEquityAttributableToShareholdersOfParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Equity Attributable To Shareholders Of Parent [Member]",
        "verboseLabel": "Total equity (deficit) attributable to shareholders of the parent [member]"
       }
      }
     },
     "localname": "TotalEquityAttributableToShareholdersOfParentMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficitOfImmaticsNV"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche [Axis].",
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_TrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche [Member].",
        "label": "Tranche [Member]"
       }
      }
     },
     "localname": "TrancheMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One [Member].",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche Three [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TransactionCostsDeductedFromEquity": {
     "auth_ref": [],
     "calculation": {
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs deducted from equity.",
        "label": "Transaction Costs Deducted From Equity",
        "negatedLabel": "Transaction costs deducted from equity"
       }
      }
     },
     "localname": "TransactionCostsDeductedFromEquity",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ConsolidatedStatementOfCashFlowsOfImmaticsNV"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_TranslationDifferenceOnRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translation difference on right of use asset.",
        "label": "Translation Difference On Right Of Use Asset",
        "verboseLabel": "Currency translation of \u00a0right-of-use\u00a0assets"
       }
      }
     },
     "localname": "TranslationDifferenceOnRightOfUseAsset",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_TwentySixYearTaxLossesCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Six Year Tax Losses carryforward [Member]",
        "terseLabel": "Twenty Six Year Tax Losses Carryforward [Member]"
       }
      }
     },
     "localname": "TwentySixYearTaxLossesCarryforwardMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TwentyTwentyIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentyTwentyIncentivePlanMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TypeOfAdoptionsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of adoptions.",
        "label": "Type Of Adoptions [Axis]"
       }
      }
     },
     "localname": "TypeOfAdoptionsAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_TypeOfAdoptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of adoptions.",
        "label": "Type Of Adoptions [Member]",
        "terseLabel": "Type Of Adoptions [Member]"
       }
      }
     },
     "localname": "TypeOfAdoptionsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/PropertyPlantAndEquipmentSummaryOfChangesToPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_TypeOfVestingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Vesting [Axis]"
       }
      }
     },
     "localname": "TypeOfVestingAxis",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imtx_TypeOfVestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Vesting [Domain]"
       }
      }
     },
     "localname": "TypeOfVestingDomain",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresSummaryOfOptionsGrantedToManagingDirectorAndSupervisoryDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imtx_UnrealisedGainLossFromForeignCurrencyForwardContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealised gain loss from foreign currency forward contracts.",
        "label": "Unrealised gain loss from foreign currency forward contracts",
        "terseLabel": "Unrealised gain from foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealisedGainLossFromForeignCurrencyForwardContracts",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/OtherFinancialIncomeAndExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_UnrecordedContingentLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecorded contingent liability.",
        "label": "Unrecorded Contingent Liability",
        "terseLabel": "Unrecorded contingent liability"
       }
      }
     },
     "localname": "UnrecordedContingentLiability",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imtx_WarrantsIssuedPricePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Closing price of ARYA public warrants",
        "documentation": "Warrants issued price per warrant.",
        "label": "Warrants Issued Price Per Warrant",
        "terseLabel": "Closing price of ARYA Warrants on Nasdaq as of July 1, 2020"
       }
      }
     },
     "localname": "WarrantsIssuedPricePerWarrant",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imtx_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://imtx.com/20221231",
     "presentation": [
      "http://imtx.com/role/AryaMergerAdditionalInformationDetail",
      "http://imtx.com/role/CoverPage",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesAdditionalInformationDetail",
      "http://imtx.com/role/ShareListingExpenseAndChangeInFairValueOfWarrantLiabilitiesSummaryOfCalculationOfTheShareListingExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfCurrencyRiskExposureDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskDetail",
      "http://imtx.com/role/FinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityAnalysisOfForeignCurrencyRiskParentheticalDetail",
      "http://imtx.com/role/RelatedPartyDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Error Correction, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/ApplicationOfNewAndRevisedInternationalFinancialReportingStandardsSummaryOfImpactRevisionToPreviouslyIssuedFinancialStatementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/IncomeTaxAdditionalInformationDetail",
      "http://imtx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imtx.com/role/RevenueFromCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Section": "Accounting policies",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS08_g7-31__IAS08_g7-31_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_10_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "128",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_128_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFR15_g110-129_IFRS15_g110-129_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11E",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11E&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2025-01-01",
   "Number": "17",
   "Paragraph": "C1",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C1&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r232": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r235": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r241": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r242": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r243": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r245": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r246": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r247": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r248": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r249": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r251": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r252": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r253": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "31",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_31_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "31",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_31_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r256": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r257": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r258": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r259": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r26": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r265": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r266": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r267": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r268": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r269": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r27": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r270": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r271": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r272": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r273": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r274": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r275": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r276": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r277": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r278": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r279": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r280": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r281": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r282": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r283": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r284": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r285": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r286": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r287": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r288": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r289": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r290": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r291": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r292": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r293": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r294": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r295": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r296": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r297": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r298": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r299": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r3": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r300": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r301": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r302": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r303": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r304": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r305": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r306": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r307": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r308": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r309": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r310": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r311": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r312": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r313": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r314": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r315": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r316": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r317": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r318": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r319": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r320": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r321": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r322": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r323": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r324": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r325": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r326": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r327": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C3",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C3&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r330": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "136",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_136&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>161
<FILENAME>0001193125-23-076227-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-076227-xbrl.zip
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MW7 G^+4R3*:A_.*:=SV7-*(U%(O'_VV=QB818L:<$1#"GP\&7U/B^H+B( N
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MQQ,YP4E,-VA G88\8]RCYMCA-A^!9_KT0ZP%0\XBD7<207CJH=2E;-A)KY:
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M.V=#N$F=A17SDK+[6;0I)AS4D2MSUF7NSS2/,5NUVQGBC?1VB)O[:'FX\^#
MOV,V+0#SY\>3/L>]0(9G+G?.4R:UJAI2L#*0*=N6F5< U?/7\HN>U+WE"_X'
M)3^!(F>S>F-$L/$[]QQ7?L,DO+A VD.288F&AD-L,G,9,"AD17$5V0Z4RGJ,
MJ6($J\D7?G<3=A07:#T/!CSRQAIJ.8':>H84%VR1&+W34,L!U-:QH[A 2PB1
MAEH>H+:>(<4%6^P<U#36<H"UM?PH+M22SH$&6Q[ M@%'B@NWG<Y"2QL;V6><
M0D]E7VTJJ_&:"[SJ^;#&:Y'PJB?5&J]%PJN>F6O %@JP>GJO$5LLQ.H8P::
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M>FBT[KI%@,8J-L$0]N\^E45K;)%J^((+RD9.Z]$<$V=$N\2;SP=SY_ !EL/
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MO0?F_9L*F\!<R3:!/$"H"1DT$N>*LL_FY!L1*_NLGMAH_%5"Q*7@KMLD0LS
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MU/Q,K1$14\'O3=44!C)N*.[3MHECN7L3MY=73;_\PQ?,M9B)U$.!8TER&ES
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M=-%>F=2^[O]3$STE'*U P6P>0WX:[1>71.'#47@'IA@WQ+7(7T;/ [5LX/%
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M;7303VI?EHU-WJY_"1];_@ JX."A)5T(GPS]OIU3IWXR.#H):!)8JJ1Y.LX
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M9@8T1T*H)>@I:@[NN_8LY'365X_S&&5!Y26I@0M]:D#Q.$/6)"@GH1U%P%#
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MRW#;D&G.XR1VZDGFC#0$-02W@."'FHRA-CR/NI[<41.!3AUI5^GVJ< 4PO[
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M R'Y/*(T6[?]3O=9;?2;K><UT!BX_^,3QWM6(^WKQCD%.7U.*THLI8WQ(GE
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M;>B]<7IL_ YJ*9%-3^8://ER?FQTH1O&!:@S+J*,THF<!/+]=\=&1V6'"/;
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M/^''W2,\,B-1*++($N?B2S>% G*)\/#=SX'I9F 5W"W>AL^@[7DWG:"3LYR
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M\TDXGX1'.0D:[*X.)\>LRP!%8.!&Z&AP^:G8H-6%$IZIOWV6W[/\?C#Y-7R
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M!C'+KAWV0A(1 >UU'O#>+H+GK_[WB^^>??E?VC] ,')N5ZX5DL)+]+8JUWV
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M[G;[$@/I702BE0I&=_!?V?&,+S<3+GGPF.S-^\R^_QX&VO_!!9FXFI1B=FT
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M/VKX<UZ:D HK=[NA;LQ/O+D.VGX<_"$Q<9B@8[VHR0<L>88WO@;_V@DICE]
MPG4*2L3K#?850:7&WB*]G1RP$11+7L6$W6&S1JR;I(ZVZ)T(CB9L:[F+/HI?
M3[8R9<=SE_^FDQ8&--1?T/U&<!+:C#8R-[QE"#+"#?0"U%@/Y<*'!^_* 7H?
MS:=@PJAU98.[5$0S>56]DW=_U^:@ ZK%37'"XF UW5#P5,3%T?# 8LG0=<))
M_R2QFYZ/5Z!E-0L"[26DY1GY>D-8RH YPWR5F.^!(% [&1]@7O$C+A$YD\:7
MHA44+3$YO6P*>[>^J9NJN9:*$26XC<_Z1%!-Q]9N;JV6<:%4-=-++,7!Z\-1
M]J]_P"4-M7E;7C<MT1#,H,E&0ZM:9B8=LBKHS'IO ;5BZCU1G2A9ST^Q@^0O
MYPZ23 ?)A]H!NGAR+#E3;\P#):[N#S'N_8*8A&>KPS/Y9SCN')-X82Z[Q$&\
M"5Y6%'OQXA@8S2^F'--9G+ 03?GS1\4Q6/(4,9$5VMZUZ)>]6%"0D ;6V?-7
M=<T#'F2I"5^+X*'K?D"RRV]).F?.7H5<A.VKO_"JQ%:MX5>W)O( 8J1U]GAT
M,ZX%TS00J%M-(<:F+*[KAOB)>54?_D:,:W>3OZ:FLX)3 &S&_;XA[4BPF$DG
MJ/]C13%R/A[VVM*[&Z;7SHY2@4L(F31V2:0-@<'IE$61K U@XN 1A!4MXN/-
M+TS E]L5;QV2JT2RVY4!_Y&CF)GG)[,XI\/KS1\F69R'>B ?)%!.7& ^("&W
M8]) H")1ETK>IG7;%MBU!PT*X(F&7P=_.BFGA[JV.&Z(.>8BYI-HAQ,8J*)2
M-3-MFP+[U'IPW)[9[&\.%7HS^:M<NL>IE8QL)AR4!*M!-KQ8_-S,1:PRRK(B
MV2*ODTND:V3<KB7<>HE[TX0K_ZM$_ALEI;)6C-Y0; )A[3-R/ Y^>PX46:';
M#,YRBQH-QQ3J8:>SVA+9S+T>G_2[@!.<XD8VBBD9BVS^$50Q=$CVT=L-/BR%
MWS?TV'G23O^L*2NP^+GG?1WI_J)2;S,"V69 RX-\,7*O7T+5=@)1HZ^93DRD
M7]5I82^C:TE%Q\[=\M^0@L_A=.W]7BAB9K?WWVQ:#=C&@>2E9$[$:>15'VGD
M(]4N&:T_DIBD;U7E6RHG228VP=84[YQ,F^9#X:GSIOF;OY>[?BEI%R#X!%Q+
M;EGTVWO7+#0@D-<D+7B*N@OMT_5DJV66I7P<GV1'F)O/_/,\NQHY(\T)6=7P
M:_V1S<2#)GW?)R4<3H*:=PKPT<(]II(<HN%\F81!JCO7#WL;?$#BZ=3]OA=F
MI#J]$Y-&6QQ9%NUBJ-_Z*]9(KYO<3PR:EC9]O;2XW*F#APN,TCIR[+P=)X),
M?_1)^KUQW.3DT9N2IKIU(:<O!U,6'[CL.<CPAM+AW SF]MU2IA8[;AXS24E_
M;E=-6Z/X/7#M#5E(]L>@8T+1NY_ DX<KACFQ1+=#DXK%T1*2;5S;#'!B* _&
M.+$C-4EY-/+[KMMB$Z8B1V.:WK'NJ<9%]R#^,>9Q%"2Z/T2$N@0S#RDGTJH$
MPKM7DI1Z+C>+]_ ZAF1+*NA<VS$Y*+5?:K;22RF*O%R(Y*QVVMPAX;M%-9DZ
M@R[\0)0XRY&4RMXW41*:_#Z!A-.KO-6" 4#F@J XNY+!H].^R9;CL49K6WOJ
M&'+& YS .4O*V-K--HO03@.]5&@(_'<*S!Z]SJ?*,OUS;CTB]\.,)T#-G8<P
M.)#Y@BR,7(265;.JLA7=>+TB@C=;&W\HB9]C&9?^QI_K;"3&%X[95<BQ_T__
M%2[V5<7*5<)WQ %H77)/>&['WA5Y/"W AU6I2FW^6E=%N7N:P G>FDW&3=SI
MG=<,L9;2.HJ)_?;]Z%6L6_S?_]=?_O+%'__V=50(SZ1[K!]3VVDKSM7WE]]'
MHO$[4'H<_#O2TH\-GU=B?/Y6G6NI8D))CV<X-LP/]%LI'7!Z]>]^NM)KP_,X
M1A@2U?6X+R?KY@F9@DEY<(R"U#,4A'_(DE*E>30?Z?8Z\D#O)EWAR;@M)&S@
MC5>.U&63E!+\%;<#"F63C>;F!.6Z89//)VBBY(9.8MZ54B=GS@OVD@LJ5-+)
M10;=I,I%54UN*"A*"O+(5,4*Y_L[B]IS_JS9/J.0=>0Q6KMV&<E_EK+5256:
M2H$HX,4JZ$9V>>!H!_JF&SKT[6M6Z8B,C*1?&QABX,7$:\'%TZ:+.U>\=<H#
M,)X;P#,Z]<W<XC-W<7U!+]0VP_7-&#/B<VIU;%J!H_0.&-.FYE,;D3I%GR0)
M!N;AKHXOPL=6@X%@Z.2"<^V]J(H%O5C?N#"-$<2'1QHHH11BS97C)D=-+_IK
M;4HI&YX.$*8\H2IFR24!*=Y3WF_G-P$)QT^XMO)?Y]K*QZZM-$'#CT^HD3O3
M3T:.:SBV/]A(3&OT@MFA)P :4> \$%[$+%K3AD_H(>CNWM]0RS_7%W+Y_,K5
MUY3#R1Q8[N^-R1M)3D UVZK1T/%\8/0)0C,1;,AB537-AM]DN7#^R%NV%(I2
M:65,RW,28_L;''G*D9TIP\!44LA594&=A[%C66G,O&*7I"(UK(>GR&<(/KY^
MO>)^,?(D*FKC(N@86$;2=IK)KIKZ&N%J<.E(G$P7LO="BOXF6)VQ;\^!P[MY
M4/!O0!8FW&L:$@C]&@?[;IPBS(4<]N%^=<V>R'7^[?+NT1/9.7J%Y;2=YR#G
M6:A2AKX$15A!;6 T^*"-P.-.J237]PMYT(5VT)E\AG04\"+IGS?>^=4LC=<"
M30<CB#(ARG4L'^-)QAGKC/ZE&NW-U*I+JD)=^F*4:I;B5R9Q@Z>(N7M*(H^<
M,MN\-Y,*CS$N,D=^O39\27JRCBL7=EC>]'&:<9!?;ER=^_KR'M]J-IDA>N4:
MP4ZKR74?" P[[-_M48^-$IK)Y>YNM+TKC$X7K;Q@X>_6F,ZVD*J*/#SW/::9
M4* '?;_[/T%H#8(ZK7EYEYTN4VX/\^]]2FXEU$)&S9@TH6&DV?3Z&\$/))S<
M28^]=5VB2,^L6^>)QO>;:%3"N!HU5-<>(69TT\;CN0YFS?M'$8[3\//*6"-@
M4VOAF1A)N_E?;,OJC.-PEOU'D_W05I+U,S'>Y';[QKLX9<49->^/%37#'.Z'
M/BO]38U<WEE.SW+ZF#H:?O()5,+SS>9GB3Q+Y*-(Y!%]2<'1IBWNQO72R+ \
M:__/XGD6SP\MGMJ"C&YI21( BELKR]1NX@0)3[N""B:]+R+.T7*Q:GZC=$71
M\OPO92[E<EX%Z\=GB3Y+]*,!'_WPW64BPI/N^S>$?/^]U[&#]!7[ .IEJ5W*
MBY][0A>X9A6]^)X'C% *N^P 2_"SC[L6_Z0*N8A\/!ZJO<\"?1;HQ_1I-VZ-
M=FVJ7N^:V]E2;H"^X%$,=$Z<9?$LBX\<7]DYRNA#),,>G!N_IG)%#=7K:A]P
MK65:D]O[SY)YELS'DDQ.]T,VI5WIQE%AM@P0$C=%N]-J!.9C.#F;@'[&DC59
M\S#IYMJV:<\0B6>1?3R1)0/>NOW0L].YP[06E09_#YB"-+099M6D188/V+A3
MLEC?E.Y6^@H47'2F<5*F0L@Q\;^C,D<AR&]S1>?0ZVP&AZN#!:K0YG*9#M-A
MM]]][_X;&3;"(EH *,8L%K9K@H?R/Z2!Q''R'),3# @E3314/D*'M[DR3>S)
M!<*<XNA*3]6,_[KIRE[GC;C/E.7F8R_,I"S1\E<FGV\C>E!N//AU;F8)-R(U
M"@#K"<$T/R[U!*.']D9HU5!*]V;*5/C"F!KE5WKJ[2';A#YR85N[%L!$[8"=
M6SS_$?I<)G+PT_R:2+\T>A> &6_*[]1MR"MV9%NLE57L>1ZRD[$DGKH?#RDM
MXWN[>H,A1W^I32.B AHX[JDA/=KU@J%&CS=IT[:#K:X-OJSVC=P6;1A<0,5
MI"4BCGW27:=??G%N._W(;:<R?*CPG)N=/Q&$5?SQ\3P*TX*@2%0Z&)-K@ \3
M<N__B#*_TFRWS_P=GW7>*]_*),OH62,4 $U3,Q E6RQ@\,O8RQ9=?JK]]FI$
M]+B&B1I%5YQ31T>Z[50=;]S.!ZG(!EI6OZ"19-!Q7]XVO;!J,+PJNST9._L[
M=TI>MXY*476!8)X4\.ZD66/98_\FSPA!+MU>AL33@4]"L1P$-@$<<MV-)*T
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M'+)5SX77P7(A&,?TDR2;O)HRHP-M'"K(CC'^ 3-:&X3@SJBX.+ *OS)0L45
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M1[F,IX\[DLSF&4ZL^S#1P51Z5(T<K%=@M902A)PB$1I^B]J??].5.P CDPF
ME 69 B+GM[-0ME\)_J@3Q[1 V">)SN]-7FL<!RA<B7_#Q189$B&?(<%F?,BK
M2\;\AE#9N3A%,DB9Q@W;#\D'F_P+ITB$G7>!--.#G"-- 'C-/F$%)I3#-LE>
M$]HGS[)(G.(?9=/8<-M0)UA>[NG0RNS:/C&6IDGZAL H9WES\B+U,'^.K/6
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MEV&TS//E1)U8LZ)!G[\BMQTNQ579=8J9?*E B%=!'CX3L-]75Y=7 LW[^1)
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MTJ^0&U\J2T&>RS1L12!2?X<TVONES=Z4W=O%FW2T\Z5UWF@)J6OPM008SV.
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MCFAT<(@GT20[& T/T:T<)AU;0M[0]LOX/B*?& \<6FF_"^M TY9N37-!A%^
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M ,)ARE866JV9H3J9[D1V<4WOH70,&#C>$6'+F$UTNN72 ^EZ0CC65^Y<?)W
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M'MMHAZ='=&N=]=,$2TK?: 4J@M"?9,V]M#>D*Y=;\4CPHZ=.\H1C)U7J<D8
M@DK +T3:.5GD/WP);XV<(/Y7N3$<NK"O!,T\,.UDBU1TN<&4Y2@EO+"@+P&\
M13*?Q>B9^N(WMO9;YR:_;*2-=.B81[00Z"U_C57;%"0;H[>.KR9.\5(.%?N[
MD0U5^N.E5_<!7A!Q2<&]L]K ^#AL<@*9K3?->S)LG?0IF]8NIG5<E9L(JKQA
MT)P&^%*$ODXY<)J@RF/92ALSN7BHY97HB98$M8#D;&(1FERM=5OR2 &0X*,Q
M3743]A'*69ULC#M83D[%.549G>B1"(034N:;9M^'!Y*\'8NI_DG9E),K!/\U
MY,.5-FL>_W&<<=\/?>)J6N,DGN'O 5:'S/Z;Z43H%7(,KV4B]/>.I?,+B8#6
MIR9<"[6L>:3Z%8)718::0,X?G5;!C)[4Q_? =!/^EJ0&8>9F"1/6:[-K,??^
MF8;9.L9\*NL^EH*GAM<)Z)WV .M@M+%)R[!5MO4];$&D8=>YR>=O7B4;F2&0
MN. O(4@O.F)(6@S!]21( >')8!^SJ X$ DN.$V8$1GQ\'"8)$/*GG(__YIR/
M_\CY^$9;D48C+@H9A48TII1-418D!<BX>43C'2GAO#=CV(\2[CC65F&V&-DE
MS1.@<#8E/)]2R_)X%T?PL;\<CZM(516!A5,XAI.+*?> ;M-[?RZIJP?=JT5>
M^JKSK]$<G ND6?. $VFZ#TP/18H_%KC*-YSN<_-M=2-72L:N%4Y1&EQ[<OK#
M8Q/( Q3)*I)RHG\IA*35P5+A$*IK\=8EB=8Q^ORZ:2AMSD,NEKODU>CFWB+\
M=6QMHPS^*>J;6?63J!M_NA@M4B[U[:LWWWW_YMGS5S_]=/GZY^__JO\XKEO&
MIV#E7\:U?_TB.<V$PKXOX%G^C__X@O^;:++DO_E9@H(PRJ1$S/77XK8I-_*U
M37K@__B?\:7Z3?8K7__GWVBVGR1;E()?H/]8X)__XS](*= E_O+55W^:O\:7
MV6MD[FROJI?(_=+LX2+=ML6\LCEQ#T;J[S_^)PX43B,FV8P _@T"A1?P_]/2
M_Y!,G$7L+&(/$S&%^+'HS0HB2I&G<7+/,G>6N4>1.5-H,S&182KARO19WL[R
M]BCR1MG&]KJQ)0ZIMI<*KX4B?$B),Z]L3XD>M_D;^$+/DGB6Q$>PMI0]RF"U
M<?;4"4S[<M$!G\3VSZS<&+OEXGZA_$BC*),H41)I:?]NT5*5G3G,RW:Q&?!5
MG$T=0+EN7>!M0?V<XD:E7:&T/T:\UX$S"_$PHD9)L0F96MOX ,['H+%IHVPM
ME6VQ08F%W)X4T-W_LF_6C;"7-O-,!N'Q#B:^SOI21VX %'T=#O>!;[$A>F*I
MI)Z<OPP91UQNECKC9V4=J*I#9HA3$Q/')XBTIWC,*C:N?.K4:#*>]>/SUTOD
M.P,AY%+S(_CWKJE)L/%O9M 1*I6B.OQ;DR>$Q<KMRSW#7NEP^20)(H".+D[]
M0EPD[X"?H=[3N@WHX)%'5/@1SK_([Y!MZIB]^+K5.1+_Z%L>I0\TTY2"/DCO
M4KDOM$N3-EW:)BXKOYB4L^$<C"18F2[5D-\HL<=A>33]G<F:"MQ<-D\3N9A0
M7NGV5!K5V0-'?7.\KL1V403NATQV"L=,V7\R7" $U,:P3#;WRS6??574RW .
MEE1W#;WR>=)D"%0$K0FR=;%X9;.Z^3P=WFT6'2VF;1329*,DX^/\%?5;A6\O
M%ZNAMS,6%?ILAR[FFF5U P2T(,S9]J;9QZ(_UY8\S6H4PY+E3Y2AKIE55HDZ
MP2%0S*R-=NB.=UCQ-D@?TXBMD,PX:1%P>=JYN)J9 HQ<$G-&&ZJG"43T4E@V
MI"*L?-'W-!E]*.[<!+!Y%WM7XEBM=J7&Y&63M8+Y!&H YK5!]B-Y!);*>=,6
M=[E$*_IFY_*J5S?CQ\V3BW"WH)(8>1&_QE SE6UI2%YX67CL.6IXN>VT8C<5
M%H4-X>Y)Z>@[Y8<RMF_0QX?:XCP^P:RN&;7*[#/]]2$Z(9Z/#FK67I*O.%^'
M=)%V80HW;0<.'J:DV%7R/E_7+$"3&B$2%H:-$:#5W@_Q=UO?*(T[=RV8EH"'
MW5J@^KL$1((:.%CHA4K7%%'"B4#K\[0UE?N="F;OA505M>#!4<ZBH48)M$Y3
M1]B#]@W+4J_16-F^'6$VRJ _[1F#Y.?5<NC$+6H+RZ-=*"..4B>H"^1N@6PS
MI[-Q4,GKU':O>_&P2:@B)Z]64YPE@TU:,\*D(NM(^4J3_#1<6- N]>5F&FUB
M%UL67>BDYK;??0/KL?Z'T%$@DR00=Z_P==V>K'G@:DJB/1.UK [*U!7U(RC5
MPK$-L%1)NUORSF*;*3HAP4Z68#HB$KJ;O!::(.#+<,QVZ&3V%*@&0LHU9@E,
M;T0O8:D0II>Y7RWRX:-G^)2[$_YX[D[XR-T)H:I=4!JOCS@<O6%Y&,L_Z^.\
MV0@#9?N$-'/.9?Q9_%)N5M 3H>!5_4@=B ZF<RU4WT=R&A@67SE];'2I"X-6
ML=CZ1;CU08-U>UTA:,\@1Z?>!YYID.^ELY%\,I?">>-O>HL0BCEICM!]S^!E
MHMV1U%7F[W-]&J$/OZ.;1[QE 24P/.;1NV'S*0K,I+1$T<AD% F%;B\4EOQY
M-M 8=7F@V3]V1F2?1'K2U>7>%1N!E!%N;\-*L5#>$WWZE*Z$!UZ)$LBH54'F
M\<Y0!\19^?2SD$_BK0LH^Q4][6U)3MNMHU&<)9/(4\&<UHC&R(:=_]!OAK\:
M-:?NO=A0)]FPJY/;2NP58#SL8WV.Y$? =;I?-AE0C?%?R9;,OB)U+Y<R;&%\
M<15>X\_OFX[S-H+B;SJAC3?(IX_\NVZM!$Z3PW@?S[K0VTUGDA/K%UYB; O#
MTZ-MF7$G2P[YUS?YZRU'5PM7X(ZHLC6W3JCN5LYT;A(1<"?G" EDNNUXM"[;
MD!E0L\QU \!O!AXSG@W;D"Y>KDP,WL]F3VX0P1^;.4;^319U!2,2MML\[C+W
M+ LKT*?@X\:SE/=V-=URDE?)*4'M0)U/"F)RVI^3LDV38S[<H( GP']->9I^
M=R":EY7!3;QBG9? [<<%-DO("BMIXE,K5:1\71$![GOR;>O%WR\6/[;4BE0O
M?N[=;O&<[GB%L6Q,%E GNL3"/_%5<,#ZQ3^O>"9O\1F*?%_\S7^ ?WWYM\\7
M+]<\=BQC(]7B9P(, W_6WYNAZ\E07'EE_P1SW5?^,-+9XHB<WM; !)+V*V^;
M/FW=Y)D<"Q<Y!D[3=LFN]R+)F'H850)W5. ;3LZ/USJ]>T;E6O?7NKGS3S Z
M8._T!<Q@/&NVS_P3////$J38_M^"N-NS7/ 'LT,TO>8U<.,_IGY+[TR%/?O%
M3;.>L=R'BCS!CK*PT<VBK^H78F+;@\]7,DHI0+:R86!&?XCG23GPGNMA-*3)
M%H(/4/#BG@)1:&A'S^IEPK_,]0&O<O7\^S<ZE--QP$P?0RPICY/"3"HL4/(A
M%:&E6I?^83W99:F^]6 #\/J9!\>9F9ZR+!57;KPN*+L;@K=>ORVN S^AWR@?
MP7W\)7R3E(3,.#GC;8@SY7ZCR3"=BO<*S0$/GZ$^T4+-K=)W4BJ><9URUIQF
MNRDMR1EU.2FH=G=1\V+OLHA/YDYM-[[U7,!$E),K-X%Q/;FVNPP]YS]\=QF3
M, ]^4B&D*VR-F'3,,,MTO_?+-12, U76R,]%WIZ(UJ;UQF)+><<[(#SO2DM.
M \'CZIA&'6@\CP6S_*NG95E.00X;1JW@VJ^FR!E9(CV>D@FU<P&6G2*I(Q9!
MKPF<J3!QQ54,GX]+[.S&3 :-E_;U<("QVS]>O8Z%4I,JH]_;8BM?0C&K.%PV
ML\JN]EJW4>Q#&:N#\#-@^8ZP/YX":^7%]D&2*4A]24.*/53!6@A^6HT19AU!
MZ+1U(C8XP*OW!G\]VW&A29&'=UF<V/R22F$(=/I#$+GW;X\YN1_&%@<L@A]%
M<DY'\@Q;Y0P_^BGS'H&JO9G4Z!<CH(MW4ER*TC%:S67X(-9%TNC2,/%2V8_N
M?O_-533?17%&,1$(X.(>X3I$+F8% 6:U8DS4@^(M>82262JHYMSQ;#84BFYM
M4@Z*Q4F)KRGI,4H%9/S,,H+0\EA3/NF1YNW$NUG>1T@9*8U.0IN@46-[7 (U
MX"9NXXGJ.^V6DI2"4A<,(8$0V0LLMR^R!&B=R'NX<S#_VML4TQHA^Q%2DHP,
MO4G7_#C2B;1G#;T%4?A$"QE_.A<RWK>0\5[V_7M%HAJU!R#!C% 1.1HH>)99
MFM>#?Q6PC7,3AQDJH914>7)UXG<[WEG)I3L@.(3IQUBO'%D:G#N!JN'>5W7:
MEB&0 ^Q9!"% -E*_Z_VZL?H())* B0;?=.726T.1,B\$6@"]J99)1[1M9/L@
M (HBKX.5@!L$4)Y,;4=43GC\7G#Z8B#-U,!!<:$-A(N[HS5?9LM& 0]G7K$%
MY06,FG8 %@2C'8>V,VGC&"')'=-K^N388#'!;+/R#S[Z4%2GR2:G^6A+C#*3
MFP[6.Q(&Y3/0BH;&U 8Y:_<.2<TG!5&<"]Y)F:Z)8D"[H;C[9(T4"!Q5:M Q
M&2:XP4S8QTU2-/11")(Q8[?11X>&0J78_FEC(V ^W-6FN209"6Z,*8SC)4OE
M)-3^II;J9 2@U"K\E6100L-*!YID4WX#PC%4&-=M.T5]5N\2W>=$KUC?NKI4
MH"ANK\#&2K\4SCG#B1:=Q*HLGH'N)#3E0&U2]]/6'R6.<W<<6KO-Z-SW;GU3
ME_\?>V_;)+=Q9 O_E8Z]L4_8$2 MR2]KK>+>"(J2;.Y:EPR17NU73'?U#,1N
M8 PT9MC^]4_ER9?**@ ]0VK$$??V%YLB9_!2R,K*EY/G_&,4; I,D#R&\4#'
M1Z,TRO5'F!Z2WARQAK0,.63K"BU7?G,GFBBP;/K"62BMP=?@XUEK.0LK#B=X
M"4ZK47V>+5N^/RT>V#>[')N-8J>>V5K-IV=:B#NAT6I\>SG+MX&VBV\Y!_#3
M2)0[__) WG^E]C=[L-:3$B:W!9<IA*XI]1BZW0AW0<X_/F/U'C,*YIH=,E/0
MJUH@=^AA^VDB+/HDV :_DW0 'S\Y+2UW=YQD9O4'5>4I7;)IWE!YMJDOVVY
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M^/8M"C+S(=6D%QS#H5054MU(62K$#>6,0%+[G"OZY.5>[U>R'&&?#3'Z=Z<
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MWS^E*I2+F<2#7A'N1XCW\BV#.AL4W('ND\H+6Z?Z(PO!<_H,R>99=9V!@9M
MT GZ.7E?" /H^Z$19E(/<&U+W^L^K##G2.4<J=P=J6#&>_X 9PS_D$*7A*YB
M9#,"=3Y62>Z5="_X9.5_HHR!&-59BF03M$IU]+[R(K1AVQQ2+N<H3"26F9;(
MEE-I&B/YYS]W\E3#0<X><9ZG[INNT5VP/#@+-=G;LX:Q'M[PA>YZE$JT@PRY
MZ>BD^N:T@E;ELL J?Y/_67R'OS_W0/_'\AU^><J[?F2W1LN:]B^=FLWVV(C*
MI,:?6@D#_.O:BT)OT3;N)5F A])_D\N=RDI2DH"JE\0CR@1@5T66H9?G@_VV
M;]1_;KKUB&N(.^!@H-X'56>']MS/>#!243PN9  T>M(@2"/>FI1<D9>?NDPZ
M&<HX]1R.G,.1!PU',BH@YNPQG&I,6+,)T8P&BRLC,GXHC=<JGV$3IHB4,7HX
M4\F=\%Y$/.-U_!\KC;@^,A"/1"NAI1[Y99+"(Q::M,G6NU"3B[KJ"/O&T83
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MSKCQE'C,',SMY2UI@HP^>:M=)5Q\VK\VV)ZROLAL'/HUG*V@UDGIAR=MJ&R
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M%\/),0]]F(V4&0&LK4R_!L8<7C:>!:-/8E4# G>V!]LO"%QT<?4S)9T$I29
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MBHPD_4UX5_,+_27$+%S1KAT/?&N#.*D*6GM7$!;<!A:!=GQN*>]D\5#)-.:
MAFZO$2'$C,41" \&5ZV$BU_?1M,CZX)H-0</3Z>^AFRIX)RY^NAT!4ECZYBN
M#AHB;Y[.,@ _?]>LX__V1M5E4!0"_$5+Z5$.2JWV&7X,6B79D>7F2PM3N66A
ME*K>-%W-N:"MTF, \CY@YZZ8ZB-:)P/>55\'[E085=M+$*O]Z W,,\RS,?K"
MY6D8U ?&&V\05DPO-_M:,I]4-[V*!X:Z7U]57I9-B.4HAG61)9<4WS^T08&5
M;IL4%?PB"5 IN3I+YRV?^03"RY<I,N?JV$BE%J[5SA34*&1JD9#Y$.KY#R_=
MZT\ZV<!>UZC?T7+2EV 4#!(/P_9'.T35IQ!<<7H6B?)'@$(.P*)M-&\.ELMQ
MDR.%I=8[XN+-8T6DWP2:;K4&9I%-VL+LXPX>>^WL+7XM"1_=UYINK1/?+S7C
MLXBXW?@OZ&A*/4CM<*C7;TD>-(T$1@]],^XH8%*57<X2F7#6)EM"?.!-%C&N
MCU1;-L(7OG3E],)]CY^"D36;#1%JQSBL?LM;,?2]EH2E3!'65ZV=A 8.2%2\
M)DLP.[JMBQT]'0OB[FD#X276W28X31WZG%LFI&H&!(Y92WW=71\=/NXV7 QD
M Q3+ 2J"MZO*-CPTA86E;\@2"X_#OI2!)OEY2L;$-IB[*AZ$NR!QH^A=QO-!
M].!)L.NN\N^=/Q"O%2_UI-L^D0E0VUE<*;;O>1T##;3D]*4J8Y5/FWNH>&*!
M=SR%*#WB3 JZ#_C"I$@7@Y=>QL9W8*T?6QW(04!%G:P^^^K@1455A8SMR>&*
MXO,5:8,/Z_J:XFVTE!3\I_:-ODG/!%]4/0+5*>1CAH[>Y^!O"S,=3"IF^5BF
MD1UJ,1Q2P5JZY7K?O)SC0KNW(7[>GK0&HUU?"JQ.V=_[_7;DFAO9[(YID'>W
M /0D Z+F7K>_!0>B_BY_Q(&=$+Z)]-*9;G43I 6EY-1I*X@U2WE.GA(9P(X0
M8O'(M'F)W]GMHG]K!PM'"G%N.FU1L@.:=74X7H<A\X[\\5*B-W.--(4I30 $
M=N)57=U?(TFZ$1*5\B9/5]^-/3USI0-W=VZ(YR__Z\4W3S[_TAB7XV-2GKP2
M42EV/"*+G CZKT,7GQDYA\7T5]T^J$GF7I*;$>)VN40=5([57_]3[@#\Z=P!
M^,@= '8_<2?T6Z;WZ3M2&<JJSPE->3G6T9<<@@-4IM(N-W_EO[DUA8(A$:XI
M\!=P:H5G<YR"&%U:MT#P*@:9>VV\EX63$1LVXR"?!):/@-G9IC9>9:$*$R3(
MT\D<Z6W@Y*0C/(9X6_*?"/?T.)3F<97%XEJ0D!8)!7/V5U[KZC 74,=3E6!I
MUWWCNACMMI&8(!\U=66]>XS;:K&5W@ #L#1:8;S?73\/3ZSN#/,MI*<3Y&14
MGS'O S + ]ZN_OO5#]^^?O'-M__W33S_;D6_E'[ _0/]Y47MAW%82[?+>B4>
MME<N[R;LJ*TM#7^/$U0DH&Z((C]!K53E!PR#!T@%%XV$J;2#[L]!%&\+7/Y%
M&AU%88WN289&EQE;A(E[JAC1,5/B(%F]![K:/+4A1JIY19EYY%ER;>N,%1.X
M)#!;08:GW2@+>Y5]CHC4%AS_?8SJ+_G4=]F=ZWSQTU5R6W^[*<@S-0$Q2^KU
MJC'C1$G_'!QQIKCI-\2,#K.1,#!34)JV5]BFB4C_O95J+@B;GK]Z5@FYH"=6
MD(NYZ7EI7F;8Z3E$J%<$5:OPA<T!<:H.U=""\W=K\X\=-Q>%(SET:G%_2Q\S
M/ASOR03IRO:Z?L+2'=*W<)\Q\^MQ#U&UF!]/G\H23U>M<;X!;Y2@&I*B;4\[
MJ+N>GRM+FF7G(5FJ9%J]4Q*!=%9I'52U2>GQ!?K7>,WLRH):WOZ\XYFVTJ3[
M8JK)4$%$>EU[<M_J4Q)>I5MW.U^^F<F_GZ[>,, 4XND' 12UQ\Q!3\\T[;YF
M/L$H-[6&K4[""7T/A=,M_]6S4*"?I[G]T94 LP%LI+SIJ N.@V%RYA5?/C/8
MO,GM6B0QW1)HHG5.9@:X4FG<FGU;SBCR.N8B--QN*"M/8V>_^B+C*WF/M"?(
M5XU<[U@8>W.5ULFJ=2(*[)=,QBX,+9_-OQJPP>\T^>U';$=S6$V;G?"0\26T
M'WD]6; ZUW%A\(N>:\&H6A:LAMB'1^H]S5&V(+K61\'TWR58#WM^')Y,]4L;
MYM<T1><[M[AV2$_?29HZTH-@1;Y\8)7F#P6/DAJNZ*BZ?V%08Y7CY6[KGC6-
MB+> 9%QTB4VTJ&, 81LN8]H5X)Y%;<ZM.OEKYT1O081@G:T4,!QL#3D5%S&\
M<(.JB#8K!,SHC-9-PV7!ZHOOGWWYQ\\0"U.,]N2:!/3B^MQ0"M'B^-:KI\4F
M;@F:U#S(:)I];&PN"U"(3#JN;Z.--A<A)8 BBO?C@4C$[/0H;.<W_J?C-HCO
MP<R0^.??QA6Z(L9EG'=T0YX0]K=NW(2-OUCE&O9L3DC^^G12PF:ERN.[T]FQ
M:;WJU)M,70*8SZ,DA.G=BAT#(6_,)@'/;IW5A8U3Y1WB)8\9UP!4+!@4<,YS
MUEG.^X^GJV_)+=0^ =?1X%M)>D2OT1UV3HL8H9G.)?O&_@]QM_>;71ALLB ^
M4\.0(63W4$YG-JEJWG58O'?6#3Y3_'T Q9\*_6U$KNQ4AM_U)T.)K\ZTDV>;
M? B;%#R:9#<NWR@;V2VB)70S-DV=F![.EGBVQ >Q1(K/2)^9$5-%*0VM/JO$
M'L;-T5?7AK,1GHWP08QPBBAG0<+0&MTM,H]=8\-59]L[V]Z#V%[-Y$K*J3M#
MKW2(E[1FE^4V(#TF=9^0\Q%B)BI<'L\&>C;0AW&.+N]/G!BW-2;\NYECF24"
MP<1S=I-G*WP8*]1DF<:P=[N!*:4X<.3Y+U*=1^4VL;9S-LWZ\Z!)3-(29[L\
MV^6#V*5V'8$5&L.B77VBH+A_.X/B9D!QY_W]_\S^YM91QN3E&Y4+==S9VJU2
M9)Q/G;-5_ORD,5"M+*1V<[.V1JK 9)I[Z6[_XAW)[U+37+!'CG&!9K2:M9!V
MEFU(-_1Z %71>AVNV<2I2H,,6.A0IU.BBW  1H0H6P]P.ZR&(P(8TZ:EM61N
M0\(=<//Y5OB7C *RJ&#FLZCT<5X1F=7J\V6D!#?\2>PWK5B!Y]JF@2O^;0:Z
MX06S&=8+S$\<_ CK%*,+Y>'53^/F<F_8X<-!!AJ$9&U/#!U\:>%4$CGIBFGX
MNEU0AJ*8"5;*0YL>&9@X_FTBVGBW=BU9](N'A);3W]$98(;!I;]/E+FT5%A_
MG?=*K,G9O,9%P7F^8!RY7 @NW';N,5ZD+W%@P)U<'S_*BI7X$KQ> Z?),B<A
MZ]P1I/"R$RP#/H!;;JR1&U>W,>C$G#O86JJLCBI[EXL^&5FAQZRD8:^S*VQA
ME=^)ZQJ:F/I"3&S/;Z2THS7X/O-K8"+-,)_I<M,/NK"?61$LL12^_^9V*/2%
M#;X,Z?*3O3Q:O#NIH^-G2$MQF((B8H89IC+P(MW"J2T(=_SUG?"17P?T[F]-
M1GO/F$KFD0?Q2-B X ](IE.+]%@HN>] 9D 55J(X;?;!*4] *\%S@4S?RP-%
M:89,K$I%L>9POWMJHO9,*+1@Q#;IJ7\!CH(N3<[:/SC0?\EAFZ( ^NEA,.6
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M+_Y\;NY];,8+B0DER".N']@PT]RX[4J6>B?U"[U.=./MX 288?&;0"<DLU_
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M+CA=8VC2U=3R8?IMS7V) ".NF'1P (K+]1*B88S1)Q^KU=#9:K( S3L.LOI
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M8JC]M "6ETH=H35=(_L!)ZM+Q%M76LVH@8LP/"-DD$HOO8SG^:EP\M*:2NH
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M&5_26_#VXWC5_;L.PS*E4]OVPO;5L2_UNR-1]JE) ]]^ 93VWO8=%9(3EHK
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M-7(8:V<#7+:_?7I[AO<8A5+P<S0NF2M!:]J,$*K?M#MRA+ 6)++MJBEZY$(
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M B/ .)^R]=^(V'<JX\6_YL6QO_KB.%CCXL 8_[=5Z;&@_1<Z*X1BR4TC'B9
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ML[5$D)L%25VH1:I@GNQ=/Z12'X[AZD5^(PO1TM6SINSJ/G:R5-;2\]GX6_;
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MW2WMIL=DJ8)Q2+!@N@/FT]DD%Q(AKQ?(UMYN= ^GTO=1<5D/=N_UN*/Y$"Q
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M:^-7%;EN)5\?#'OC"@+6Z>:"#6H.NNB$J'@(?WUCF>'=&8<\I^0"\,=V"#H
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M1S*E@$J:$\&*8Q)G4)XKCH_W2IP3FA[)E/V4C T70MEPT%N,L[;)H7QZH[<
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M+(:GO<F3/[LV4I$/FY9TI&]H80H5_IHPT+4$^Q+D4:]DN'#[2G93:^T]+%L
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MS +B>JA<!X"RNECO$W97E<M."-;^4:S2^PC.=/2D1'7N"?<UL.)0$5&[X4%
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M4HM@!<=U!8'<^ MO9?UZ5^S8:BOK;QRR\.L_RD+H8NHG>!BCEY0N2/-@*,#
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MF.B4\IF;LTH8;IH*5ZV3;HZF6)[#GOXS\8"0RR-R@3:R#E\/6(?(Z6%QU\%
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M8[>,=\OXHRQCBPFQN@8K]\U+3*YABI #=M;[,3H09&J4%1K_A7E(A)**&?S
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MWF9HG%G*D-,[\L<P6M7':3CE"U:HA>AWO!+H>+P&85VMT'MJNYP40*6 $2=
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M1:)7GI8MOKU5D3<H;?H,K_2W9]G1\Z/LX.AKQ9SYJ_$!1W5?#TS@Y:4GGN<
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MT&4SV4,SO(H';LJGJ'A:*)@*_2Q8+PA*JPKA' 8+B#52B75S3,.["H":0Q*
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MC=L>[62"=8()SC!_R/\!AX8&+W'RBIQ2 T6B<6&Y=KGLLU$+!T44B."( @7
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M\WHT#36)-\;R1HS<TUANI%LFV#U_[]!(D%&"+7A:VC@*M]MM=[S?,:7S,8G
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M[U.[1GJ_H/W2*T35/>'Q8PA_[W,*KSP?H"\'3/X@N,YY0:'U-,#%F:'+U%R
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M T0;A70_/[%:$+OQ$YW7=KI^^V!.&<[&3WQ</W'?;^_,J09Z8C=Q$UM]-I'
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MR,/K, \5=;(3%$X4QD@B7IZ&091IT*>;0.-SX7/PR],@S1'M*?# 0B%LE[C
MY>#?I@$\$O%SX*33 M&>6][]C[W:UK;@"O9:^P^_@4>^ $23P>P/G$/]"C Y
MI&\ARXMA*&=!V&3=5A7SYADS3%+JJ/*R G\$A*0&XQCLV:M;;QH%.7P;/L2'
MW157K]5Y^$WOMO8>\Z;MRIV+UN<C:'.E;3_]_2*L5L*H6E&4(+"2S:?<!4+
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M2*I?!GF"^#'K<52.D*PI:H+_P-9-\-3F8(]TMK?O&V8H1?9V#NX;\N@2<R+
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MC)VJ/+D',Z)DQN71]&9>G[.3O2K9KEGDUL>"+I:ZU<F@=?"F)26**X3N+%&
MJ@Z6E #4'$X(0@LD0;O2$MI(:(VKGB&C]I87+&MQE6SF:>VNDI:!6OP9CX61
MONH9LOM99-WV88-"##/=M:.&#7T[TR TCDF]%:^STP2DB?T[W"U6:_5YV97Y
M.YO*_(=6YM^),?[]W\KMP-C<&M0PN&:T4"(!CE4DO2TNR ZP4UZ89CO!FC1
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M-%>)@]KK)91OZ5-,N@$L-04"Y!R'@8#@U.:,?2<C?SFP#<84P/?6@2KP(8O
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M%(7GAAQ70X[[SY\<;:@^"Z(2DF(*%EQ<:%.LP43343F&T78D'HNV^+;J;2,
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M'#HC7A9$[J\%2H_K11S\$/#U?&GDI!=_.#V;LV ].?;6&>WQM771J@X23IR
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M_2)E,IJL!0"^%E$0D .:H)8 :8BVV6+J9)>GF#I]@\[[?#/:P[-3R$HC:^U
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MLX+SI'MW9.U3<-53V$FWWMIV56,/FR[V\(RQAX:&(>_IP3([E=C^ O#'T<<
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M]XNXRR*N^9!\(0^XD+_4+UI)?3NECCI19:VHJ*A(TY)DJ/G@<1H03EL!K".
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M6,NJ"X]=JYK'IJK4YRQHDM2^=:6A"Y<-3'?XW3JYU<@6+=)1DBEV;Z*S#]]
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M3D+JY+A+U!&D(\@G(,@)85]1Y-B.*0W9FO]\S'*^HNZP0,F8PY/?OF'N&MS
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MB(.R>->/^][FUMA@A\#5J BT]+N>J:L"QDW26^^@WP]"-.YPT*V]L;</)-,
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MV-P8FZ5>1EI);*;&XQZ#'AP!H:)095ZYV?:]SD:G0S(.?FBWO'>6AT471)A
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MNI^(5:1D[/CZE'2[;@M.JZ>GKU'>3Q!RH!<VR>0:H$<C9,HX+)W6?NJ3:08
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MQE)",<ZI,3^NT?_Y_/7I]KZ*%_AY\^C(I:3C+6$\I@ 9@YGAH9MU4Y9X=/>
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MJ%MRRIQK6@.-E@,D",);LP6RY4:XXFT4;/\*1K7]CBFHU&F4E#;#1RQ1M]Q
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M^/6]#2+L,HW@?+6($Q5*:-\R=HR]$H!ZU "M$4P@ GD4=K]$Y917V9"DY6O
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M29W%91CLJ)-0VDFVQ.C#**Q#I(*QW,Q<-]U?D"RX-(W3H[0E2?S2U8U?U2I
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M<GS2KYG'Q7O6:HT9(WI6,Y%D*5$3O_DA HC$T[& -S+380H"G$1YND2'\$/
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MX"Y6:U-'4%'MB_HMP58!KX:A;2.7]AB-$5)8Y<#H/I\U<$B,)#GM6O\$!AH
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M-L^;0!FB:F-C>$3<->;1C 0>:0:P_V2(G6?2.T@'TQ'43H@4*@KP M.=$D&
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M0-B-A1%\;!FCO*Q4_ 51MTIVR)[TBM+B&EE.4]S/E6_7&M??E4IT^806J/Y
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MBW)TA4&0Q.T/G,XPF0*JZ":!0Q?^G6AQ>5HO>R</WL"E94D5J.;=X(Q,@B=
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M3%<AB_HSPBLVY55ZJ=HO,L1,&XP>3IG[E*N(A$&[&(Y U^5HN=&"B!$T'IE
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MW\^NG=O?FY?.V7_]O+C]I_GE/$+*\\QV';_[W 1&$JU$9;@\\<8+H@Z 9[Z
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MY=_1X6\[N0.'XUJUWW-8I3J@)M!=S.ZP]G28T*Y3U)8?0V"C-D$R24/AW,-
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M4Z*;JJH9AQ'0Y>I>*?512_L(K16LGR?3CDS\\V+NVL1!G+YQ\)E;4I,ETLO
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M0O'ZGTWG1C[$:1I%JMC"LPZR\&CG'VLH"^'0=AI'!T='RU_;WH+I.0LI5CM
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MV4)7A)C[:AG=[IKMOLZ:TW1PA'109KO6GMGJ%_EN&D(&V@[1=DA=UJ?MD/K
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M]V9':/PRX= V0BMF!O\YX@-6?LX8M3RP0^:XL>$%401?!5M$V!M0([NF;EQ
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MT&D-^L;W__5+YZSS<02(RGQ34"D<\VWH(IH&R_ U%\X*\<TRH@FB?0YY_,#
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M_ZZ !+X2#%RHY<Y*)KZ&TU_,P&YQTDO_;+_9]LGDK-WNR7BI?'*ZY7(SJQ;
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MC?(M%.CRP[-?WVS6ESDDY (*[Q#?]>27I%QN8V(86P,!1/["'C@8Y$&U3UL
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M#W,A YZB_R6@#J+LT<J@D6_Q82V'V\RL8A16COWU>7R"S\3CU$I@^ PZ/YX
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M@;HWFL0T44M#,8UBFM+&1D.9YK)>GE'U9,7**)H!]',*>U3\H/A!\8/BAQ:
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M>[A9Z4'8IL^P_S]@ZN"%X*<\,.W-QUOMYN/5J-</W]D1BTN\T'NR-3@K,..
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M&VO!?]P!X/$(\!WYZ98@Q? XM4/U+GZ6]FP).EU@90)[,S83#DK42B%>1 .
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M6"G9JI0LFP%%K;7+W!/7KT+XOCCVH^'"!]SWMO-NN3+M9\;>,(O-C<3PJ]I
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M#--ESX8U%WVP=E&C(!1!3K@:;GN"$-\M5M<W"6C-3_@(+_L#WP4$&H2)XC[
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MI)[X ;2:U-/1NIU>H=1#F2H*&R*?N,U=PQ)VB#%^,FW3\UT@N&=.IDBQID@
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M#+D!J-TLW92S6+:8#MY,GB:SU?"?/UCF: FC8( X .IONUS*I20<BT;H.SR
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MB4ZTU"/@92\<O7##]6WX6QZK?UL!5R2FL.L(<)<'(>PG1$2 L&]WU]<AIAI
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M\RAZ)6"0QF V]]$G0T",YSR,[[A\Y#R"Z$>UXDS@SV<.(@8C22!N;"E>0!2
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M?9B[3I X[,P]<$2\-T>U3Z/6K_48)APZRY9PEE>!\5K/$-[;T$$ !>,'[P1
MTIX)96H\M_N$IJ4UV_E/ C_/D:P9T%ET&\YA6VNW:5;SZ1%;^* 27=<&G:0D
MX_PP2W,$%5:D8?1_/7)=8S6ZES^/R;\K8E!U2^OW-^NG2/@>8B-EQ.WABG6W
MV.UK>E).%ME)A6/T<(VZ.\-.UWJ=0BU?\EH+5+9!$"NX(7OV?/+S1-'T*$'I
MBHK&,L;MGJ['=3U?17 GN-?E5>27+55%6SF_[&;5&,2T5W7BY^R6H867:RN
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M'4J-=7&*D%?0,>5:SOE *_KK$GZ_VT&;(FQ"*(-<\..]R\>F?^O>ARV<5B(
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MAWJ]D1W!D%(8/[[5 &'^6#;7RV?SE"VO"->Y</G)$5X2EQ=D E7'TMG6 22
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M(](@-T93)#J/_S6';0A9\;\@@4#>F/;(>>(H45Q,%V8OIC\-2>R1V]P58LO
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M\\%!M>=L2W?3Z,?K-><]6&/0UC3Q\V%"37K0SC;VM32_%_-H4=:<L/4T.E+
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M;\^ >$J--5?#[NEVJ =PZ;'F:I"*WM2&W8*IA6+-M;&D58HUY]*4H\9F=.4
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MF#P&MIC#E2O\I9I',7<K]^""<D(Y-79^D%7NEGNZDI-=2J_5'W0K.A60(.;
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M'JDU;Y.[1'<6]U\+5MCO8QMN^0.;-C=(@V@^_U$H2GCW-#%U(?]EGP'I@65
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M0B-/:"C5<!R*VE+4JC()5AD=\CL.!@TE5VC@3J J4;\TH8^(!\0#X@'Q@'A
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MW&A<?@R ?VT:5O$ QP,.<+Q0*W!^X["+YS=N?'W*EJW:G(38:>KQ-JSZDL"
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M['7V_8%'/*1#RF:-Q3';;:LCUI>$%MN#88HBP\N7\253PM=,H2F-3%SF\%_
M8'5V=<>B/.8"W[/QQ_:]MZ^U/?6\W?239AJJ9M3NFV#W\:^SW=.+#KCB4;7
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M3F1V)CGV';#V2N'PQY6"5.JH?!$+CEE\&096)[!+(7 :!9S/+/@6JF53D$*
M UB Y[/%C$M2$.5;/P^3&)B@"L$XX[?W[NLK<I-FND4;+>IP;QW>^J[Y%Q6Z
M^PXSTG!MS[3%I3]N/U1$E;*J#_WX =C]^#PS79'\V.+'D6NT85RC4?9OD4G+
M@'<TAZQ 9ONX\-FP*91X<R2>WX!6ZZ&JN#*.]<6JL>N=LVJ?-Q^HI[LFG_7<
MC.]@'NJ)I33O7Z8_B1$8S/=:E6+,K3.74O\6GNT@)I(?WY=+M7RY<O?2X]E5
MU!KAS6U=G,K/A@X\-G8O17RE_H0MXMZ"LBV^-OG)<?F!F7P)^;LV9]>N7="7
MJ(R443NQWYR+Z5AB"7Y=7=*K"*1R,^;)&E!-Q;3!"E])M\-K7CLER[[PLYD7
M*A0YGYOQ%]OSW8#IROLL5KZ_V!73Z$HA!:]=]N*E%)U%*45GY_&W_8M1J].1
MYECGJL+KXS-U==.C/!7%\10J,@29VE$NY(?2'[<??LRH^X-W(+TX9R>B.NVZ
MH&G_@8)7 /$Q@B>"YN$@D82 C.J/JY(EKLZG\(@3UJMS0YOS K9S:B?&D&[Z
M&(*Y+9PP%#1AV+M$$><)Q<4Q!RAE92,+3@>*$#K. F2>!>ROR"R#_P&&_C4)
M_8_&#T;\%8[X#]!Z%0)]#.$;$\)_U7Q]PO8DL5U,&,C+%,@?K)KH!X3_0N3[
M,;0O7 T8X,L<X!^JS@S#?'70:PW4M&-D*QBA-3O,/Q%%&.Q7.-@_6/=5"/DQ
MMU_+B<%[QV9*VF<-ZGB+P$G!H>%+06I9-(/3@&(%CU. _*< Q:@RP_ ?\'#1
MO:A'R%:'Z+\4 &41^;<[:><G51!%I03^!:E]_Z#?FA.%CQ1#3/-C-'\(=&^B
MXWTQH)<LH,]/,QC3ER=[#.N+#^MSTV:6]3N]?JL[5.H1E-4QM"\*1)E$]\JP
M'D"2(KK/3_-[!_B:'3#64Q'CCS"OCS,!>6KVMYL'S@/**CS>I1>LW"]'[A^H
MSC\FRA!G 5+6]QRD3ZSAEPU6,A3WG *A#&8 %^UA36!4L<*>P_2^;_R_,F1@
M,3_&]L4 ^.[)P=A>PMA^EUXPMB]'[@M'?<%#>P5#>ZE#^QWJQ-!>-EC)%]H?
M!J$LDOL*%NW+$-OO4OS!L3T?,KKI0P8F]W$"4,X$8 )WP2F C%. G9K!24!9
MDN=%/DI/G$R/<P"YYP"[M)GE+*#;QUE +6<!!X(H@WG L'U1DVW@U9X&[-3\
M05MWQ:#131\T,,&/\7W&\&7GBV-X+V%XOU,Q&-V7)/CE8FP7 _P*!/B[%)KE
M]MP19OEK&=\?B*%L*GCZ]<!1I</[G8H_O(2G6TJ$CWE^*0^5?.=HKL%.&X\.
ME3SEO'$\U:Y^SU;/IF1^MGHVA:=*5FJLJF/.ZCN%AWL_T::@S;Q.QN!M$-'(
M3R_4;O<24U8RZ 6S5<7+'*DF\D]2%:#'+-FC<?E9JO14\>A!UNC24U-%*!WI
MHC'*+RG*/Y#:_&ASP%C_F'BE..W@23(R: 'G /G/ 0K39I8S 45I70QK4D!8
MAZE 62#""4'I$X+B5%^%:0$&_!4+^#.:S^ZBS<)HO[3L)#+)22EV))NH4HJ_
M0!HYS/)+%=J7 B!DFB@]KB]([T@T@=%_Y:/_7<1:&/V7%K@@UYR48D>.B<J$
M_L71S&&!3RU#_\))YI!<0H;(/RN*.626P(!^[X#^VM"FM[YCYU:6S!H@O 4,
MX4M7!@;O!0L<"W+R#]OS5B(&[)+!*;N O6#H8/5-Z;%Z[AJO0M$-)N<QEC^R
M"@'#^6(#$RS&D4_F6(E3F;@>RW"JA2BY0GNLP6E@=%^3 AR,WAL8O>^J(L#H
MO=CP XMIY),Y5M)4(W3',IIJ(4JNT!UK:)H7N=>A@ 93\[4,[G^EFC^A[F]?
M-<^Q\RHV"!LAO[4);P=C?"G4@D%^"4+'PIL"CFPI0)$8YDL&J0Q/:RD>/EB
M4WJ@7XC6JU"$@S%\0V/X7>4%&,:7%8A@L8V<<L>"FTK%\UAT4RU4R1?28^%-
M0Z/ZFA3?8!8?9P GE"C@#*"LT 4+=N24.Q;M5"?\Q\*=:J%*OO ?BW>:&?W7
MH8 '@_J*!?5?37VB4>OS-8!RDE<Y0M@(^=PFO!V,Z*50"X;S)0@=2W,*.*2J
M $5B("\9I#(\GJIX^&!I3NEA?"%:KT)I#J;O,=(_H5P!@_VRPA4LX)%3[EC
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M&\'P70:58/1>ALQGOLB_A!$\EMCD$\$7H$P,X"5#5'8!?/'HR2!^OV@K@WI
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MSQ'Z:0;.5!G%/U\^8.]L8VM%2>OJW?Q-RO.FPB QNS] #]VS#4XE9>A8)S2
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M1[93JJ)!$N5S*D$%+J3210TSX>N%J -OY6!74R+A<IW@3$>SF!8SL:$W$KH
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M76]</<?.S4;%[-*/\8[ID<B$:]>ZK&?T;WLFYG_8G;T_,P2O2E-4Y@,8C9N
MJ/-%(&WVC>BS'3]G(49.#N/3'IGFZ!/P/3)]^V"_G>M_A69%50X^-[X]V.:0
M>V#A+X=ARM@%CLY<"@<7<V$E="IDH[25:@';CG:SMK3+#/Q'G,8C&*^WT+\T
M*MG?3E+F5.B/+!C4?YOY%U!+ P04    " #3-G96QL^<DUL'  ""&0  $0
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MC=V'8D&.AORBQ)?J0_1/4$L#!!0    ( -,V=E:MHO+[7@,  ((+   1
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MLNU1#W[4?NU. P"2[0,@Z$>[.YG: _ACXCOVA*\<WRY6P>#C8]_] 3\QSX^
MY)#AP6B8H<&\A$"/84KBE#Y\Y:N*GV_XGK.7OF;U>"J1!! 5Z*I>OFBVRIU:
ML\'*5RW+NK$:G4QP%I9SSP_TWID\(;YEM(K:S0W H])F=^T"JS4JAVHAZ6>S
MJG4 *) 79O'IBE6_LAH6:W^O=?[':M7+C2JKURM9G4B5R!KHV.NSOTU'#J>6
M8H&5CDJEM-/1Z5A;TFQ*BA'R;R!4X)U"Q(#PH/_W9<R"R?/ B>[9&2;>AY?&
M]H-S< \<Z<^#>P?8G/.[/7BRGP.415^N6ZQ=^Q]8Z/$'^4H2<;__QR?Z/Q_8
M]UJU<_W7#\6CH_]4$*D :5JMC95_VH%URA=UBS4O6:4)2VYTVJF8$SNE%W%)
MU![H(X"J]?9MN5)K7/WUP]$'^ONV7*W*OR. !%97M5IT7:R!7SD@1GC;MGZ7
M_YB[Y3A\$B#  Z(EMKZ*?U1A]YVJ^HM]$T_P[87+_,\/_$9QF[A\)B^_\OGC
M-SY_?OK*%\S_-_RGQ2^TY'EH9... A#4O]L_/+?'ECZ/<T24]#4J_ GWM[H[
MUOFM=U@-4"J2$5PHI1'T+1P+)^&EUD('&Q)!"L%KIW1MU:ZN.X!D4=0++X=K
M.UM\R\F'U>$6T7I\^\"O/BP+EY1'PY6??M!%6$QFL50V+2XAC_^]>'A$@F?B
M_)S _E#%_?U 7GP)/_]:;H'Z ZRUR*K69:U10^6PC5QW+5@?,Z=*^JV-YO=6
M^78AYKTSUI76=<NVX>Z;$(*0/WK6&X'^L345#XO'I>60?]X=J)$@'97K.E$=
M,JM<N49%J7-ML4O0/9K?07%AH.;=M-EUN4W7;ZQR Z]6K7:E5;NPJF"5T ^5
M9JMEM6^;#=1V6-NJD!E';ZNU-7.N!C=4RAUX\,*"+_R>!1T7S[(G9",^UBD^
M2BSF7@ C$M#5*K< Y6];S:M6^28[L7*4/3H:N3)+KFP&(NNXM\Q_WXK+6R(1
M2X?%M\O#"Y!OD@<<&@9@&,#[*I9OQ,Z-(#LDM,,B0TII617KMM-LM3_3GYUR
MZ\KJ&-EI2&?S2 >1%C6_1O6NTD%;)*'R@9W3(O.%K" PB(0LP ?:F>#SB<%G
M@\]S\/D8#/+*=:-9;U[]P3JM<J-]:;789:MYPU2PL--$/,X$?<\-^AKTG8.^
M)\SZ1ZW=01]1K?'-:H BH:%QAHC[R2"N0=PYB'O*[FZKY8Z%"O!5N45>3L5P
M;^OE#F@2-QIOS@*)CXTRO,-(O!7NF'<(3X14I?RRAI0,*6V0/-@(TD-B.RQJ
M2C]WQ%!HHU-I9>:1,91C*&>.)@7_=[8%2P[%IL+I3-#7.& ,^LY#WV/-BU@O
M-\B#J*LLF;D.CT\-YNXNYFZ%]G_\=NV_TKRYK=?*C8J%Q/2MUN8)?X:<##EM
ME" X!MT;ZU):Y;K!3H.=&X>=)7;5_&:U&C=4\H)&80TK=AIED?EY>W=1KU58
MLW55;M3^I]PQ;-8@\D8B\C$@!2O?=:Z;K5HG&[?Z!J0+&Q3=4!3="$6<" 5#
MJY7Z'2G,K%YK9Y>490C&$,Q<GG[*;JU6FU>@E#OE7Q5'30W(.FM CEG5^F;5
MF[>H$A?83;EQ=UFN=.Y:%JG'E>;-C=6JU& S7!TVW--PSU_2CW?\'D45&JVE
MDU<FE1;''PUM[2YMO1%ECZG&(4NGGL%.@YWSL+/$JC6X:C4JEL%/@Y\;A9\;
MH<D0E1SSS$&KW98YNYFI\J8<PA#,/(9^PKY<-D%#EDW3'MV)<Q",[:[S^\A[
M\NTQ!L0/-%WZRV]X_U=2J9=Y-,6JY2]HWN)?GUD+#Q)KXQK65;-3$_<84C&D
MLF&D<AJB*K#W"G+W6W+MU&XS0]J3U^2ZPLV_4;] ?(Y]&<]HA9@0F4P_Y?.L
M.K6Z3/0\S)O6E.MI3;GB=>QA_V5W-'5Z^_-:$)NFF"_O*9GERU2[S/-?MEVF
MWD;R/=ZWK%3)ZKLK>]-:&G)NG.(C[UC%;[, OUB%F'MCPI'_PHZ5;T03_H&O
M+>OJKE[&RN[L07!2S-ZL.'F76S;1K%@>U3>%P#;AVQO45NZ8:@A#@F4WY0XH
MSYDYS RY&G+=M&]O&+F6V.UUN753KC2_U:YJ]3+%@C*BU@UHB+V[U/H*U?5]
M=2<=;9;Y[TIUS??6C(^ST(S#G+-:XRI[*!CZ-=)VT[Z]4=+V6/0\#<NZC: U
MA+HYQ&((51%J*:T)0T;4^D+=PE"KH=9?C%J/64053NL(]"M3;_%H PGOK3DD
M\W\.-W:^&8CZF86E0R>BF/XMSI9W-MTVH&S>R)C-X_.OYGJ'+_2\;[\<$H4>
M]3\RDS2&A@T-;]BW-X@^3Z@<"Q.8:YV.E5T2OR%30Z:;]NT-(],2D(QHV@=V
M7?DJRPP"0ZV&6M]5,5Y/#MT&4?3?FC6J*[(L\LTH"6Q(VI#T)I+T+R^ ,8?/
M:F.Y1:U]C56"G]F-9>&0)2.&#<UN%-T8FE4T6P(BO;D 5?FZ=IL9F6Y KRE#
MIIM'*H9,%9G2O(?;9J-=NZC5:YU:AHXH0ZR&6#?LVQM&K">L:E7DS(B,J'0#
MFB09*MT\2C%4JJCTE-W4&G<9]F7:!!HU.3[9HZ.>XW,JVZ=_HS$#&Y'DLP$]
MD8PHV3QV_EJV=_KK)?EH-$V3^BKEEIR4FIGP,51MJ'K#OKU!%'L:[<)L:-30
MZ.;0B:%11:,E3 RXI2BCK+@RU&JH=9,HYO5Z\B^7\P-ZLD4=@=M<3;XN-ZY4
M:\I6LTX-A\N5_[ZKM6N=3-VKAM8-K6_8MS>(CD\I&4B50E>:%2.F#>D:TMT2
MTM6Z&)"P;5E50[^&?K>#?E^N9J^G"=<&T7C<'=VI*'<TNVM4K18K'14_,6IR
M?M%LT6 #5KYJ618?_O'K$KX)EV:/OWJX](Q=UK ?0JU<9QVK=?-J@_"=0Z:?
MLD=5(Z-V1T:=_7HAT[O;RQ8.EKHM_Y&IT#&4;"CY72GYEW/JMJRV56Y5KOD\
MQ/(-X%L[P[P'0]"&H#?LVQM$K&?DN<TZ[^$U-)K?[H%V9J+=.T'23+3;K(EV
M<B%GKYP )R\?OVF"W&OGUA5_J;EU[\#*M_E-6SQA3GY_,[0('=[+_/>=%(V8
M&K$1L'CS-)/W4<%0KRN]Y44;I*-:L*(:BD!E69)%"7_>-EN_M*=H=T>'K\O$
M>PD]'>\(/0D7*RK,M<:W9JV274GDZ6M&F1LBVF(B.MD1(JI8K4ZYUF!5Z[+6
MR#8Y=4N(Z 5>T&VDD"U01L]0A+V/YJV.['@SMHI) JWF'^5ZEJUR3C=@CJR1
M9NN39L?1,/TV2[-(ZI?(^&2&H Q!K9F@=L5GP4GG#TI2RXQZ-F!^HZ&>=5+/
MKG@H6A;*GTQM*D,[OQCM[(IC0DJ>YN5EV^KP?/_K6JO*;LLMN"R<?X:P#&&M
MB;!.=X2PL"+NKMYNMOY@]5K%:K0SM(LV8%JH(:)U$M'9CA"1%GO*WKNP'51D
M_.;9^\U/=MEO?E.K6^U.LV$HT<BS]<BSDYUQG+>LJ[MZN8-*H2$C0T;K)J-=
M<9>+/"3J]Z6KB"G4E;T'8P.&C!DJ6R>5[8I;O5T&&MH$.64HZ!>CH%UQKL^0
M4S'"REY$;<#,+N/9V K/QNDN>S8D'5(43/6X^W+9I$G3O(CUT9TX!\'8[CJ_
MC[PGWQXCE1\(#_^7W_#>K_F<ZH9E:-H(S;4(S=.=\9$TJ<4SN\QNEKNAG5^-
M=G;',5+K8+.[EE6[N;AKM:D5 +;K8%:U1NU9.U;ENM&L-Z]>/3[,4)>AKI=1
MUZXX1!K6]RAEO4 UK K=<!,(< ,&2QIS;RO,O;-=-O>P&PZJFB OI7/F34UB
MWTR7&]#!V C&]0G&LYTQV2IWK9;5J&0GT0SE_&*4LRL&6Z?\#ZO]F7VO=:ZO
MFW7LSF9HR-#0>FAH5\RR>KF3?0SMS'35V #:V JCZN,N&U4MJ])L5;';&K96
M!>OJ,_SS6\WZ;@C3R+5UR+6/.V-5"5(RA&,(9SV$LRM&5<8"QW2A^<7H9E<,
M*:F[X="TS*8[; GY&$,J>T/J?)<-*95_J+?CR#ZOT)#GJ@=QSA<56T&8G]Z*
MG=')HAM$E?_\RU_^\J_-F")Z]IK6./DM'X-DYB"]$RC-'"0S!RGM^?/3=0Y2
MFO_O54CF39^#I F]U:UO!R89_2HV3O%H)W6I:/9=J_FMULZR?^>K=*F7637A
M$7S<4-LDLL(-09(6F, @Q3^J'GJ?60V4E7K=JG3N..K<6F 9;[%*;HQC'3J;
M@7<ZNBSSWU]G0AV%5W?3Z_;AJV0R5+!_U2JC3=1ILHOL<L(-1S&:XI)T6=I1
M17$&44K_N*%,0YD;3IEO'J.UH939OKO@Q)EAVOK9=C0Q-&28/1F^N2OOAI)A
M"W&),F[+M89591=_L,ZU11'C#-ME&\(TA+DD8;ZYJ=2&$J;UCUJ;FFYL>2^I
MLQ-#RH:4ER+E-S<,V%!2;J#!>5NO@7C->IJ+H49#C4M2XYLKS3:4&FN-=K/^
M+<N. V?;T9/8$&'V1/CF+.4-)<+F]X;5:E_7;@T-_LHTN*.A0*#;PR*KUMJ5
M>K-]U^(]O&L-$#J=IL%Z@_6[B_4EIC@[)@<KWX5L9,AJMP4,B5/:<*MV<=>Q
M*&VQ7KYHMLK4NS?L<9C/(=W@W=KCAG0,Z>PDZ1RSOS5KC4Z6*+X=S74-BF\K
MBI\P,+TMH0EEFK)K,-U@^BHQ_91=WK4ZUU:+E2O98KKIU[P!F+X5OJ8W%]YN
M+DG>EK%&$<R(<JT-Q"CL\912 %C[S4VMT\EN?H@AV$T@V!VE R#RPR*+48/!
M=(/I.XGI)</C#>9ON5+V]A+>S:51(,BV5;DCKR]J9#=EI-=&N5&Q(LYC+J^X
MUL9]9.)*9O2['>W.=YQ^=Y0JD.9!28MCO\%U@^N[B>LEA>L'&#SD$3^0#=6[
M2H>U;ZU*[;)6,4+ $,:O1AC'L# T67A<O-9@<Q2FS*C@DZ$"0P6KI((36%@;
M&#]8!!N(_Q^WH]']CN/_=ICR.]S\Q&I<-EL5JC3;;-/=T.LFT.N.4@'2.)CN
MC2;@OI%(!L-W%,-++,[N&Y>M6N,JVT)C@_<&[U>+]SQ#MVJU,D/QU\Q/R&]W
MU_8?IFG[^T#2-&TW3=O3GC=-V]?"RF>^R31M-\K).R@GZ"9MM._JG3(?G*N%
M#K9*73$:N4'ZI9'^E+6M3J=.AF=F6&YZN1HL7RF6GXD(&#K1<<SF-ZN586]&
M@^\&WU>+[Q_91:W9KMW4ZN46*]_>UFN5<J9%= ;E-P'EMR/(^^9.^IM+G*)N
MJ&.U;ICUCP[V[LZ2*$TK0T.42Q+EFYOH;SQ1UFN-OY>OL@LZ&V(TQ+@D,;ZY
ME?[F$B-6%E*J+LA(J]T)1ZX;NC1TN>ET^>9.^IM+EZ)_'+NLU3,<-V.(T1#C
MLL3XYE[XFTN,5>N2B!'S$.KEVDV;7;2:=X!C?/A,K57->OR,(=1-(-0=17\D
M[L.B7N1H\-S@^8[B>4DK!<D:V4T#WPU ]NW0OMX\^V1SR3+23ELOS])_@,TL
M&C;V=Z"@@^OF=S%JS%"UH>I-I^HW#U/97*K^<O'UGRVK;;6^6=5_R:1N0X^&
M'C>9'G>XX6R[?&,IZ:K$[1T6#[$R*QT5/VU ;&#UI!J>S,?-);C((C<#?=#]
M5:E;[!R3NB]K56R7#XON9#:R[J-IF&_8^C)L_?QPA[M<-)J-<*B7(45#BAM.
MBCN<BRC<YU>M\DW8(U 7EMB4H-FZ$=5039K%@0]E-U[)$*XAW"4)=X?S%?5X
MP'+4:^C5T.N&T^L.IS3RKFT;1YMF@H*AS>5H<X?3&JU_5*S;;"OC#!UN !WN
M*'H#[1X6V975L%KENL'P7QG#MT+2['#.;OFN<]ULU?['JK(-\(":R0L;0)([
MBNE QB!T#)(;)-]Q)"]1(3_-5=@ ;#=C1 RVKQ+;CUEJQ"C#:)#!>(/QJ\3X
M$S8[U&+0_M=&^ZTPIW>X"$-I7IWK6GL#,D$-41JB7(XH=[B& D?+M6I8=R[Z
M1+0_:Y:13-[F[0BQT7R]_#TK@CTWLTX,P2Y'L#M<9'%[=P&TF&%6_*O(,+_5
M\UC,.)9W J09QV+&L:SB^?/2F\:YS/KW*N2SF<P2D:MF,LO.:2B@?AT6V6W+
M:K=9RZI;961<7&V!U94[V4Y,-%:$0?V5HGZ)H:#'!,5RG6%#U%:M0NF*K-G8
M@*#CN9E/9/!_E?A_C*S_6ZUYUZ[_P6KM]AVVW-D8[F^P?P.P?RM\2,6CMR(I
M;&(3B?36:MW4.AU%EF4AG2[9/__RE[_\*S/2-/-F-H T=U8P%8_0* D1WJ"Y
M0?/=1/,26]C'L&4=:*3P6;0S%,_E<PN>Q)YKC8Z@HDP;(9X?&V+*GIBV0YU[
M<XN>#57G[GA7^4;Y)KO>\88.#1TN2X=O[L^SH718J=<:(%#KK-.JE>OH^KZJ
MM3NM[.+TJZ?)S>YT&,63C6MS^ DP1%>E>$/J[^56J]S ?"R<9O_-:I3?X"U;
M?.AS;S1,WC#YUS#Y3V]OA[BA/'X^Q:(:=M'L7&<]R<<0JB'4)0EU5Y6QQ80J
MZX0R(U(SAL@0Z7)$^N;&B!M*I$J_W0AZ-*T'-H >=]0O#S1\6&0W99R1#!A?
M(8^=]8]*_:Y=^V;5_PBG)93;;2O#] A#!(8(5DD$VFB\A4&J6N- D(6(,N5S
MJFC44(BAD-VD$-ZS XMC:HV[6N.*M?#HVJ(24U)/?O&LN@3YL V@'E-S;:AG
ME=1S II4NX-D PJ6EH<==@7AXZD, 1@"V$D". 6DHL;E=:PZ #JX:KTE@F3P
MW>#[1N/[&>(['W1SU\XPY&+P? /P?"N\N6\>F[&AWMPE8J,WACY_:?K<63ET
M<EAD9=';S&+6Y:4%RM<WBU7!VBADA?.?3*7S!N#\5LBD-X^+V5"9%(DP9BA^
M#"EN BGNK/C!B3$;9?8;?#?XOE)\+\WP\U*_\VQ=O ;W#>ZO%/>/MSV&;BC$
M4,A**>2$5:Q6IUQKR. Y;SK>JLK,_-V(IG\RS6PV@(ZVPL!_\Y2^#37P;^XZ
M=Z#VO;E2SI"B(<4UD>*;)WQL*"E2:\-R[<9J94:$JV^M8RJ>WU#Q7#QB-="[
M;AHXCHEWGH$+[;L69L1O1HWS&E#(\/%=X./83FQ'&7F,1MG%'YF&3EY#D?GM
M'C?AFGD3[P-),V_"S)O0GW_31\]/S)")=WJ3&3*Q6)%_NVJQ^5K4FQH.ST,B
M8TD82V)[+(G=[,+RF:7:$EDW>C"$:0AS6<+<S<XK2)@+ YZ5YD'5^F;5F[=6
M588\;UO-ZETELXG-AG(-Y2Y+N;M998.4"T18L:H93I#Z9-H+&C)<D@QWL["
M:[9O#%P9,C1DN"XRW,WT'R3#>NVFQBM.T<=?KY4O:O4,AZ-_6GU73Y."\)84
MA"+K6*T;*D[&?]0:;QH&]<XN0],2UG#TI3AZ<4>3#Y"C(UE^9M8_;FNM3 >U
M&6K<!&K<R2H%1'.DX4,NC0R&&PS?50POB6X8J)T+]['A[0;SMTC3VMW@K&8
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M',:F94?.<LQIY(.KUFVB5$>EO#'B07R'U,O,CU"/9-Q6:N7$P5VXU,"70B[
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M5E3IK=A"\1X;^QA%I_GS"6D2&Z@$/=<).T]&9PZ%\P+9$N,"%X\(C"YOZ3&
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M% L!:\\.7(S&:IX7"CUQYR5Z 'T'=UJ0L-1<R3*@JUU*B>T60AU2]\,1V:?
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MY.\]E)Q"6NX[*TRF.RA!XLV)TN2.UKSCKB0TNFG.'&?KQ2?HNB_/W'*OM!$
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M<?!6-57<6L CT)0&BS]B'D59J H_B ?0U+48HC,8D>9,3)5*.<F"2DSLK"#
MTMY9)/]F-&%&;M\,@=LV&-PQ/=I%1A!L%DAJWAV/ZM!D7+C$OT[M7\\MWZUV
MS''JJ&TW,897O _9?6T#5?Z',^)HZ7!P%Q8 616D ="'1UP =O$R(00(J.C!
ML*K7BD Q\&FZ6B*5TWNQQ8Q/2'X)9D; 9X/*O#LOPIO-^J2:G[RMIA]1105K
MP35A>H!2@247M4].N"^F*O:Z9>K0MMXN/#L<5/5%OBS_1_ 05 *5^@*H@<T<
M_?(:L]^C$ (B^T9.VUJSN_Q%96$7($Y$<I5L^CWVD3^7ES7BNWLQ)AG671:?
MU'IE*N:4+!P.["0?8(NMC ^@WP]YVH8#>]S0;^!L*0,9 LUU0B!3Q/"Z;_0<
MPE%Q>G'*N.'-%<ZC09<!_K)$.+,#,4P0QP-&N7RB6$]/XRUS'#.I0PAG:;SG
MD8@;CJBR8&J0!][YTR\W>OO-,7I[C-[^J:.W=W:0V$/"W_W3VRE]3I(4[U'4
MHN&X5A17$ XDI#IMF:T2,8[2J-:$3=JJ&L2U 6=%65JR%A--K#:+65R:+ DM
M[_XD/2Z0ZUA$3WI82S(3UCKJ)6>NCS2EEQ-6LP"50@$?F,IFJB!1 1[NOR;Q
M\E;S.6(FQ/>8U@0,@A?@;#ADROY_<BW;+B":V:E*-H;&!8]!VG.U67M7ZH$M
M%1E#O654^RG07I=B^Y#T@':H^,]T8OJM[JZ3$VP;<=L_T+Y1@>M#6S?I,M)(
MF(FWY2-R5PZK+NY7,D9@S&(6+CO >>YC'8T,ZS0VTZ(R/Z^NM9]?C[RST8F4
MQ.CS<!Y3,D3HN_;K[Q8YV/>P/4H<])JT/&^B>$;#P9N5G(6TEG=[3P<CIFAK
M%6"F 7861">W+ B:L.B;!F0Z!L5FG;M),AC2<SW#S[O)^\!8ZZKN<H>"2&G"
M'$JHZX.L(53 U<K&D.2EAQI#!$5D@9]>&.\O)]]KX-5WWX3L3GN0G.4]Y*OV
MOUE\L1XJVO;BW1NVA5_\^L;0NS+F4L0P^UA<,A(*:/[+_5Z_!)M51^JYXVCL
M'T6ZHU76%[7T<,Z[1BBS>P]02F>ISQRA#*0;,\*Y,%>$>GZ(0X\#'@ZH@H<L
MX9Y@W^'1/)_SK]$6;M9%/LLN8<L6VU?U?#RZ+L?CQY$]Y<,*'[^R[80\E6]P
M5<]1\O1*GGT"V \7H>ZY L/!#G=@;$+< 4"^WWIZ>%/X6B)>[Q ;Q-B=,Z<
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MI*VK4*H9O="*\__\XBW\YY>W]-"??WTKHL]1C8NLY,KI&ZIIM=BGWU>6Z+Q
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MS1&5WH8!)_<6E@E(0=IY&Z.0<O=EC(9.X0PL22Q$O+AC'+^L?2H2)X+VR/'
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M4/^)WQOQ$GR83'8Q"MOGTX_+ZF91S"ZLV4_9GEWI*Q%A79=7?"OA0L*HI8"
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MV\1C',A^I+7.I^#14A^NZ%#"JRKL 1%L7CM%U2H"M>S_+FS=**!A[0EU(JR
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M<"P,J7+L5D5[1U#\FTG6QGYU?%1=3>SG0#' M,3./6&BF:.?G2D)V>%N=47
M+3'(>BMIS)<8HWSVU3%&>8Q1_LO$* ^@]B5",\\-\6@<OD^8P]>P5 0QT\?A
M6!/;RQTTT]:@]@/E"%3C2@T#1E'T EU5HWYB6PNFU[^];) .^DR8'5FY)1@\
MFK@!@!AO. 2UUIAJ$OE (G/=LS@FD&Q\(R*>6.*\PNXFY,F&A(6DZQ.KHNY
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M";\<=P9(U%Y\5R"9*?9Z]U)WK;USU(#LY<W84N_(M5(KK)Q JYEX;'VCF'C
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M_%-$+3_!.$/14?JTQ[[Y#<N4L5Y*+0PR+-EJYIFQ+0F1-1PDW2@=S.F>-H5
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M$\OBHD+>68[\R%6@10V\3?I-<&;YBNR]_(<N_FGK8D?7P:D#NM.T+;G.@7H
M<E[@@8:;C;C0VG;IR%IMG.Y_*,YA-9$&<_>B@^(W/^Q;_+F&%?J!%U4UR^8Y
M@R=G,J2/1;%R)Q\YA$J\(IH4T '3#4JZ%6TC'O?]0;9<Q;BX(-%:YXNFZIY=
M!($N_,FQ+:A!P-3L=+878H(< X\OGL1IHKF<9F>.:$ JY0]4S5E",Q,?%=SL
MEH*FY1@_C)KM4*EFXI]'C_)FMQ'(T4$_^1P'G;WK8+H/8RN 33,<&(5E3X63
M[)]GY?>0Y_<P@#XIW@$][Y+==S\!+=D=[7_PYON;L>UC&+<EW$.-!0,R6V.V
M]O[T&&>08433O,&&>M$X47(9T5O,,:#54%P='KZIK4PYS?X)#ZS <EN45QR+
M"U 7NS]<$^7:G_DAM7R@D<++@751]_8:'^L3]6/6\>&]T$3?4% J<+:]5J&P
M2B.:>=ES9.]\45N^UNB38'Z<TS5"!Z$T)S<59Z01XS&D,5L/8:Q>&V5ZQ6/#
M+I4UG=OA8&39(?$>X[_PPWFVKC?%!(R0&BOLZ;A@4\\%V/+PC]6MJM[/LS[<
M:7QT*^LA,:0:@4.-8D\F,/&+_**(#%9Q/\E4(ADL#= )4$=6)Z9=V+.&GYQS
MXC *^ =CZ.@=92S,O2I4W<Q@'?7CNX<O],'!E7:/D8 (HIML&O]4^X<S* #F
M:BESY("(8;;^\M?#%?8&"V*2 G(C1Z4<.6>UW._\&,;C %)Y\_DW'G8]G*@'
MY7GG[KQP-9S)LL]0<6"@5FXFJ*W-:EY73*4@B*==DW\*9_IBLQC?'K,8QRS&
MGSJ+L9=]12P\UK%G,=-O^]\-FX2;N!,8X',(=&'0<"AC+TQK^Y(4U$XRO)*>
M=V=CE9=AW$,M.K.JK7S]Z$RQXJX\G@[BC_)K)M (<^86&OW V?/AX'[2YP_O
M/DQ#]V%/5^%01)K#SM_SZ>7T YF[5<&"+&9CN+,I>'A.YZ&-XWUMP;LF8CL@
M\_<[:P,!;4W:V(&C1'P:!Z8!75V PR,#J060:2(RDKAXE5ZS*?(:WO>VKB[J
M_,J,<QP9GUZVR"K&2/#4O-#297Q3].DQ3=7)1Z^ZC+RZ5R?W,238;-Q"'84E
M0RQJ%(;$B<D>&!)N02(TG\YVPH;CY]!#KPN7YVQE$F9$ZH<:'/.;D?9)9#H_
M@VB4@BL\#US1D)E(";SV97%=+*K5)/LU7V[FJ+UKLMK EKLJZBG8;+ AMFJB
MX:5Z<?:N<6I1B=O&$T+2!TD8-$!)O9#!^SE#44&62'AW,8O]\/#UYXAW,8%@
M!=]CY9*!H#]P%<9SQJ"_V-1UL9P*?N:,(=57D1QU$H8(&^%04UNCE]5BD8.=
M<(XZ#4/)=;YLYA*,RL[SY4=2JA=+\@J,RA4'@0[[<$#VT#5QU1E#[A039M=@
MADA[6B[9@<]BO(N>MJBP&^V4QU^RYM8A^<*BHD;/AK^!Q8C+95$S!+Y9NU-R
MQIE*',-[%!]Y/7.U5#@@_ .-EG.2:%. MX0@$K@B</X:O*^$L%W52&%8D#S(
MX5KAS.?E,E_BW0'W%I;"53$,!PC<K9?B7Z')3#_ (ZJ:!J-E1X^!_W[.^.\/
M^:>B^2NE!BZK!<J)^SFQAT&M8$ (%J[1I^!QO/HT+5:N7I0RM#?D,CGTKHIT
MJGMD 4OQ*BP=(/\4?5AR#Q"7GJUQPMFBN"XQ3[YT66Q,[B*QE[L>Y9I-^6M3
MEQ9$E HW-#\LY^%T%%K"JC]2_H#W^C-L]'=[CZ8<,Q\O;Q;?9?%#*=5".Y2S
MJX>Q\[+FRX?%N06JGH+X@_%J7Q:+F;A6J'1]19Y/W\#&GGD]_$M^PW6W(ITT
MA6_?0\3M-)0;OUI12OZMD1H!_1D>/9RA8#8HJF*H7.%G_85&++D-%B]&ZR5%
MT7X'%0%B\0K6$2(I:% ^BR$?V&@G9Q-V$YD)FO6S5:FV")7N#96GVMR7V3CZ
M(XEEER5$4PO+$QR!6SP_#)4M\O***_RPF(9P(L6GXFK%,!$/#N.]9K1];;?"
M5E[6!5QEK'3P\!9T_3%4=2M%*27Y@P5A+0BW95.C)"&$'"XZ:^Y\;2/7A4N-
M-XR/*XQ9M!''&Y1>=K/ V++6-:PP1+>6:%I\/+]TC/QWQ^CR,;K\IXXNWU4!
MEA20$_%#98@=D9/7;S7$T@1E8&"G:!V8UV 7://6:@O_#/L$WM>*BO"R\ZKZ
MR,P5_*D)Y^A=G+3%+D%;Z ;T\]7YW\?)Y+^ZP;"78OP(2RK"B++K'*E?IC!0
MKN NHEZ0QD.6\:*1HGT@426!T(0_E\TE)?[UY0(>='J#U88\PFIM5(51C9H\
M C5J!C_+EUZY1[WPHS5:%Y$XJ3*\YK+:+)"HU17>PNS,7J#E6J'&#NA*Z$6H
MN$L$#([4CRX=G/ 6[-L+<+C@2E#XB)V)_5\/6\,3O)7G.S' KW9:6I8!SL.K
MW^$0S#%F/=)05\ZYB)6&'<T7."I'^_^A!O<1Q4[V1K[_LMBLF^EEL4.1(3_G
M!#2[0V[]BA)LF5^MQYD<TU<;G/>6M_KRY?CCY'(N<>W'KJ679@)0=FZ*(-GA
M'>0D(C5Y6V%$DTSD(K6*L$XOOH1M"W2T#>!*-KU<PKVN&O (U7+5&T0.I$.+
M^FO9<W9MR2M+:/^](+Z(A1W%0FEV2[+6* 0VL@%+8^/-B@5\!:SDV*G/T,E>
MB!6/DX>SQM\5/XHAC\MX E@3G)@![GHJ:JKW6QXGUILW''4TH;KB;);#C^A#
M&F,"RM$Q, %LM!?6#H/R-+X!FH>AH;==HAE1:4*T<L0\W [_+@(Y#)Q\N&S1
MR.#==^6RLH5B<#?&UJ23>XXSP#%@/'.!,<+(KY6)R.A1@.9F]*HQ-,"(AQ1K
M7?$L,-N3E?;PUZ2,9E"]$=*>Z"B"97!,JIV*Y%W!LXN^'ZH@>CR\K9Z"XX>P
M,C3IN4C:BX15#0M;;3"<,&4A++5 0=FQ+Z3F?6J\3DMM40@AI1,@+$)^\HX=
M*HK42UTQ. WHD[CX 7Y9I6]93S>+O(Y4I^S/3P5R/2RR7\LER/R: &X_442*
MZO)]6C4<)+8(8_R4XU9R8TUD5D'"+A60QR%F= YAU9MU$&3QAT8..OAG.1F;
MQ:<5"DFT4YK-@L)?K1M[]T#88<E1B8V\%-N9M+/P:=C MMN<7/0O^;L,+F01
M/=O KV =IQO\S>MW[X>#GU#P;M5^_SSYBT:X,2W!+K,1)2B^QWA(2801-+!!
M3QH4Q;QD*P.6'74;W'FXV,R=)N:'=EVA]<9;4=TLA=J, KUS.4(^0F8BD_*N
M&[BKV 'I1D3IBV)Q@67];Z[**5S7[._JFK]>3K%D1CWO:(S9"X1FKBK#3O+[
MDJ*H[]?$ -4S%EIAZG[(MAR-'?MX@"<N0/:@3T?( O'M5U^/\O'HZ5=C!P%]
M]^(T>T,F#[@85:TR(*S*"-A(Q,"U1H(_"UCWWGL8LIW/PJGO_6(&9I %UG))
M!2>-;4')1%?>@@\I5Z60,3E9U$/1+UFQ220BV51=P#E;X-2MDIG8A2+$JS6(
M<#YT"8U%(0A9WRL 18P)R+2")!.1&[M<PYF]UMRAJ_B4X^<G;E=V,%#_>?*=
M24_O !,P=[JBVU:4%TMLS@CN[*(@@K1<&HWQZOGM()V7##I[\Y'44;6!K<;%
M0LBZ!I]JUKR3P!$BO8UBF>L MI+HV'-/"MYEIK'L:CA@OP^)%<$<A"_5]E:,
M[]WU,Q5CASA].)>=';TO-O#VEV/@[1AX^]<)O!T$(R'.*X9J9)3\9$-O"Z>-
MQY*@CQ[KVE2!L&;+)U[_U+<3SG-/,)\\P73QU6HBT9I:*NC_<?9A0G4AC72/
MK*\I XTRS5F&#3>+9D%'B<^@>-#,S^:--%)87J$]-1,%$RK6L"_2_\_>N_:V
MC23]H^\%Z#OPS0$L@/&.G?O.8@''<6;\/(F38SL[9W%P7E 297,BB_Z3DCW>
M3W^Z;MW5S28EV7(TF36PV(EMB>Q+=75=?O4K G (A!&FCA=MX:BV_&\/HN1+
MN!09I7)2=\FQO\<>@H,7&+N$W38[7QON:NU8%ER3%B P+*M9[A )+FFW^I;W
M>Y)B+M@5UPM,$-Y:P%EHY)*+(W8:S1P+IV>QD20A#@E^<::XT\A! ]H-6!"P
MC !U ;RQK7>W0_U 6VC\O!!PAG41.D# ;<L]RWEO?_<%-!D:768SJEK"A3<S
M-]-$!]@6586SFFOF+8(ZP_ KR./F5]S^%'\]OZS*Q05$C.&^,4L<62>&-WHO
MX9ITRH52QG_<BJAS;BP_6I*K%D;7[S7V%P-&X>?-FVJ',/3UB;5VU1<$5X)A
M-L4%',XD=;PECK0K,MC8>_6>8Z3*QBGDA(W*&H*WI=%)1$C($0F)H+'<ZW>)
MCS]9(%1,,9>Q#^4/P5AN1F,[1+@<8,1&M!Y%E C #QG[#27$_/L:&, =Z39&
M'>T%")><&2P&*?%F!<+PBYPPL-[D[Q1?C?$OKFUC7Z/$@_-HYZRQ?92C)OF&
M:)?Y8=&8=0SO=U$:DQC/'-S#;-3RS>OBC>:YT2<"RH@ ]13B5$9Q9).D/$LT
M:.6:/'O+3!A=Z> +:I8<2C^D2$?*Y?'],D6$3W/Z/+=EEL'P83]I2\9<@5G1
M@;36>94;>9K1)S$1L17$48[FP ?VS-X;HPF(@X_-GLTN4'4<8Q2"D4@A9 4L
MN)$%3DX]$@Q5+,V^<"IA1C+]?(J*%!3/D"Z<T;RLS"E5%X#YB:PW0.VC!,5P
MI2P<ZG5WGH&(CK'G"K<YX"%HPQT(^,LPG^43C"(%%(C[+W]2H16+K].#A3<N
M*MO6#@R"7?!5OC_X#4G*/H)\^P34!S.L_BGJ:XP=\#D-D"%R.#->()<HTHP@
MI %IT9 F%0XZGM5L-*H6.>,# 16"F6#SOQGD]MA]%R80_,__-8!;&MP3J!R^
M+@NXN2$YP?%C"*S@]^ Z7Z#3S'$ZHS4 JID:'^-@-\5E^'=9?=/_LBT.Q,9@
M,"W>9'O[?_]I+\EVKW9E+M3=<9SAM8^7-?>4%A989MNWBZAK=_H]4(QCJ-'>
M80M!.DA@+"FQ:T+3 5Q3/ !DC#'H#3$@]8O' LTAP@[!E^$%P1_M7N _:("4
M/#?V&[:)@,>"_S0P!W4*<?=Y;G?1]9\8@P$0IO;@LUOHOOQJ]S4(\REB9VMS
MMN:4X_S9_/.FR&^W!D%^31!D'A@-X[? /VC4UJH 5Z0),AS<I@UKI$,GO5).
M1]0E7GD 0;;O.YH6I-IMO<8A6$7\6FMT^72ZT8'L<PPR!,,A(Y.K4(;<CD6;
M!>T.X*,IY5/F1IBS>NZ0@724S*3NX.2#]DT=DP$Y\.:Y(,H5;[Q%40_OX$R#
MKU9CRP_$4(_QUVK$H==1ZUH!>9!W#0U203$@(( ( 5.K!0X!G#V4T+YP@&"5
M',ZEL=5BWMCQ=&R.7NHJ][+H2"\'J7^(:D-3"K-84\N80'<0KA4Y*GXY(0J:
MTM\E0RF,DKL2J^1'C 6^^NDI%O@4"_ROB07>ZW;:I]O)W9%!!W&R@;T04Q ;
MP:>DFE /BGYL!$ 1OZCJ!#\S<;!@8O00YIV*-:4K!5%=797@-576,S8R(-D<
MWCC_H<D.ERK@30-_\AGBPXL-[M@P"O1\=V_WQ<XX,JH1HU]NL:H&M2OQY:7)
MXAK\#O]JHU0KE H9,P4+=T>Y\Z#]@?-%/N>\(P((Q,4(/]F-I#_@6IT&EIXO
M:<J_ 2X%!,J\:(S'=Y8)U^ SN&4O9D:Z;$X++%L"5W(-"2QGC2$>=X2"G2!(
MA'6[S!?-OJ!-RS+G#92];;1==EC(*G2=JF2XJ(&:M$XN@<)Q(*%4 L.+21#X
M+5=&3;&JTL,#-:1Y#QHBOA?2I7%4 D)(&*H-B>^I*(#&T&'1(+M9;OR!.[0H
M4A=24RMZ9905A7H$NP/)7:_&T%-)A5ACKDK0:(U+!YG*;A!*&G['T=B2D[U2
M8X^%JTS4WY^5Z)N H3NO"@K,XBFE*)+7^N[ #&MD!. -OM7C9F.$%IB/\#?-
M"*'5_;"Y:+ J%#3Z#^QNE0/W)CG^-WGMXK651:0I3%>=7&"J-(\H!R,,NV">
M+:9SVV$+7UZA'E6!]X*B/3 ^O?S9L"94UZR88$%$50$IPEDP 8';0:F<=S94
M@!G:10C[%86:82GQ=)#?#K<KQD/Y4%%#0#*;2;=@WSKF'W0Q.9@45?N:ZV_$
M:BA<8B?R/$J'L=";$QT[1=R"^7 L&ZY@/LW-57;OEY RK[O6BO8\N\_04333
M/]16S+$:I_\ &5(+MY*560NCY6&8_^3&\3)'$H X8)&/T+('I]]ZR@(J)O<:
M7^YU/R-'H2 'I#DH!!FV/AXT>//YDR[?PD$*,<&PDRE:DL:KH[>4S\(0,)!#
M6F('H?<02PX^/6A&VSQ1Y$JHELF&[&A<8S84 A4?ONVMFOF;6V>, (6;U+)B
MC>D6RT8))J?9231;6 OFR06:FAA,L>5R OC5/5<"@:0LB1_);O"NJ)SEG&E7
M4FHE=>E16BY5\<O;2"WFS\K)L^MR]"V?\TT@%P*YWU3ZR]A'Y8O'-)K-["@C
M1*L<2L#.9@Q=M=A].GS;J")^38%4B3T!\'1*MO37:PZ:F<D7E3V&O+.B6&!U
M&,<$U_OO9CU&UA82-P>_W.^5GJ;!R/L,X$X6O.=LSR[S%BWVB()PIP$&U:8N
MA/HM6A%P"+BNL;E^_FV^TKP**14",98:#(*%K!!?C:F]AUVZQHM=J>AJ(Y;2
M$3W!;I0R;DJ$!OS8BOX)3'6 'U/8],[8(]FP(/NHLJ+(OXFN@:=4VH9D!=U;
ML:W$3M\@(D2<;TW3$?81Y%+T&,+!Q@WE"@N!E5F\\Q0$]2@S;;2XW\0L#>46
M&K;!9['%2H.LMY4>ACA8K2IR D.GZ5N!<0$O=2P(_$E.0HE9B;59$@>8VH=G
MNFI=:Y=#%&1^F^<S50'10>".;J#>''%#:6+.?!"8 <5KM*),&5.JT!EI0$$;
M1)7=<"B$:$SGPA9=<%-0MW!<M+LZJ*1)2K/REN[X#&5Q%J%4!:'M)YP[&.^"
M-_#0_ (,$.71PI/G<4 ;CX[KH31JU3B-..-Z7LP7<^H.> F!7#1Q'-0%[,?9
M(I>VT.I3*FLNZ;<6$A\=N8_\N;U;K@>;\=^\$E<HV'CA(4C!'G58G#MO^0ZA
M%)Y.C_[U^^PJNZ!&[$J(T9(!V=K]Q[M__N/87/1_._XG%3'^J#'JO:<8]5.,
M^K\F1GT/X^0M&"=XLVPFB7N/(>S]%-);V2:8:R)GY9ISD01;"6E[:I)"YNC"
M*TSUN1B$#4G7R=[>[FO\NOG'VV9&N,L5VG_Q" <00LRGY\>''X\2X%8V"KI]
MIQY# 9CW?SPVRNKLZ.SGY-CHK(\?CP[/OQY\3+Z<?OYR='K^[V6C>ASY80@
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M]^7N<[A%!K!: ?0$>)P)?H*9.08&F5\B&1>@^R&?+!T1A,J1/@8?(4-'_Y9
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M?BNYL3W7<<Y8K7QST*6)P$RV+2.M#WVYTHL;W6<Q?J>Z" ;3,3NVP*:EY]L
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M<2CHZ%S]=30_U773&8L=+F*PL-(-#;VJFT+:A;5/I6M=?'>UG)G#MS=P')1
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M1<?KN'_**C;\HS^NIV4Q;Y@I$OD-K1 BU?F!@Z>OGH*G3\'3I^!INZ4P6R,
MR0@<0=B('9KU>]I[1[0,I5(AI.!Y]HAY0?^$(1&PCYU>_B;]Y93,EONYK^:Z
M]"%>U(?S,3!>PYSX"V59^+;6\93' YC1RR/!%NL+]GM;<P;+-:05%1>J(XZ1
MNLI=<D;(\^CPHFS$XC*KI280Y5^A+!W//MRG;':0_>57Q(69SY7!BYL] :H;
M+(B'M5>XKB/VL'ZO35Y\PF^'#G'C?1@XI!49LK?[\@T5D)6ZIAVTB<V2N#I<
MMT?F\]<"";%F8-8L731&%.@V=+L)7]E>K$@%6"L5F<TO@_H:FY]NU!!A^]@
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MFA0WZMZ[9371G 6IUY1,!2]5K<8 ',%O\$OU=U6^8?Z^P"Z@$V#I1)KO#*)
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M:P844"X)<Y1L"O>E<<U)('40V?_NA?()QV.-95S^JC%1>Q[A<,H)QI7-D4.
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MG7P].C.>^F^_'N%D[-(E,,"SLZ/3<\(6FD&<GQ[ T,X_GY[K9Y\<_6*.VA'
MFP"*=W9^>GQX;K%@]H$#F!0"HP#JAX\[?O>5MNS403@)SW=\JC;";(X,#U%P
M=L%#N!U]5GWFUX,SLVM')\G!^W^99[\W?P8PG=EOBQC]!' _\T'8<+/ A\<
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MUKB@-ZB;VJ4%@<:KJB7'MAE][\:["=W/_-QGRI),<^>:T4<MTI-R#K,T.I\
MFI&50@'6 $RP#@ \,LE@?<;\)GX+LV.C(6*DQ8')(X9:N-Y=@1(<"!R#O_M
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M190K11[G[!Z[L7<GL_F3KA;Z9'VNGF*#H>38H]0G9W(7RE'^4\OFU/R#JF%
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M&AODBMMP0I&" 6ROK)PS)ACO9Q!8B(# 6K+9.!: <4T'SY(A@5PTVX\_E4=
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MH/@ #(,^A;0D079>8!R)D3$E3P0%U8T,;!Q7QK00IA(TA9] 8Y<JU8B6O$K
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M.6<&5Z1.I5$![/2R4,6%:_%\4F5%,4ABM3Z1'F:P";</]J)(C@T#>G]"C])
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M0@0E&0D0V[5:!P6S8=5-1@H#()(5_?0D$D4J?:X2$B(,&]*Z("Q!8 ELB 8
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M1=)E[=]%7!?'QMFN3%G_+J;C0QS+&WY &_]K1>*).]],[ Y#+N/XMM0<6Q:
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M![S[^\M/..L/YM7G/_3%U<\_?MGIA1VF_?705VX[_+,O)]4BBS<[_Q\+_GK
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M?>;6QUSPR)'KC=*EA^X[_C3B%NF-W:]]T#AWA^X%H[6;K^_L?43@J*<NO.;
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MT[2QM1:^7)[3WT[>X=</YW<ZXDKBH.DS+BA,IP]3I),.OVMJ]4YAZC/77?+
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M,[[GD;C%8T](\1)^_;[H5[I#Y'5C[;5.W4UK3=-=ML;#3!"HV)^8N'C K]]
MS@)]M/ 68\ >(L.X\3Q(R5-QS4NOHQWB'RNS7,>CS?.=%X=6,O0;4_]G7J]&
M':2LJ*.'$W6\L]1OPC7\<.1;!7UN^IO#9;FCL.5?*(V_O$5JD[3R?GA.!GAV
M'WHD?@_- 0FC96^*69_&%M%;<&!5\ IQF%C%'RG;VUDFAM_W*Y;J!Q(,AR2A
M</!F*P?^8,+%(0GTV'. +;' ;QBDG[WX"S'P%X+.-[3QLHXA^C7 ,C):^X^]
MIZ01QIVCWKC* //)4D0,D< ;"G2]+0:XPFZ$[>M7"].DIJ]#D,-?=+WY+EE^
M7"ID(0XO1@Q^2W2$M""_E9I!9I-5D)J!X>O1K0%Q_]+(G[.R"'*F3FV><3JD
MLV UUH:TVVBPVI8]F$UH)*:^A!\R4L&8ZY']VI!VSY=5NC48ZK WX, #G81W
M""UQYIH9S+7?+J$3@;3U!0H2N <A0  _?DI^RO+IMN?1%&= Q%11,_A!,[P+
MKB<2$KO4J&'(H##'M9HJ[K%736-XOP[>C.WJS)E!F-Y4*:Y)G4L$:2GI/L#1
M#]$'5F43(+,D?_CY^6HJR[K,P4B?C>'SC+#N$<BC0 ;+M#?6P7:UU?EVR#??
M'5*T[P;9@+2]9,:-B82E-=L@W11=U?+51GVMUUT:B[@&G+ZI]YL<?!:2 UN4
MYHYS1P]EVBG7J64=DR3FUBD.;&Y_C J3G+C#7.TA;79.SM[]F0W@+D\%I?S9
MN7-?=,%!\?)A<W@]26#]\/0UVQ=)=;T>$9TVXF2SX%]M TA('&,]\TW93OBX
MB,IJ LR(,Y&DOC>#;3B\W]_# '(X$ F?AN.$4!Z\@Q(2/INMC_1.0G<F4Y1E
MT-_67+$36QUBF?@7[Q<\+4;.;\8B<[2'$G]8Y G,-1A@4UIA>?D*A[5%K+*O
M'97QIVCY$+;3G"W&65P=2+SAA33+P%M!?/V"!$E!8,$T-@(_/L8[*O'=>G/]
M[@K/[4L -5AZ\T&(_-P;?]UU 9CR]5XQY@N"SO+3+IG'D4WZ01)X8(2*S7*9
MJ[[M,<W &-8_9;@ZV6](BH#,[L4FL;T;!Y=YYCH8D-?E[P#Q;4Z(DQ^VI:OG
MP0F\)4?9S!S'[F Q7'<0-FDXB*-.C3R1E*=W"VE.VW]YPC@+C &DBD:D,.4&
M4E$]&#[BVVEC6$N?T[HK$D#LP2./S7@8.FV/]K^U+=_ZS_P36)P[D,OKIQSY
M\2.[131_Y3 '3-H<G7I:U4%G>RH1@F8ZN9'E^]39&D73'%$;UB%'Y[%;-J<E
M^KJ/D@L"1^G[I1U) @I#VBP 6D(2GZ.'=+5]OWF>PX7J?",E[.2]<%5@ZPT%
M:7)M--54+'^NJ7P<-S74F*0%CM[9Z&S L@G9J(5+\D2,V&H9^4R49^DFI4B.
M 6+8W>D/=U* \[&V^0.X)+=](X <R)RDMKT["J<<LCQ:'W%D+X6#P^?]R(WF
M/9;Y.L@\L=Z&/U9X]8;?43 =A>U\4\I+J1CRF0O+)88H1GB%*M>QW$:!QPRO
M6BN_,L8I3HH&VG7;@-NONZ\Z,Y<G07L^0XX[/;DL;?^P8<SD/X%G=P%8VV)Z
MHGHP<HLL2$T6IBQ^4X%ZM3=%5]%;JV'2;EJK3< ![[JXGMM4T\]U-UG8A"8'
MHGW:M1IJR>+^P[/2&6E2MO6:9XM]/O>$'/)(6^#B*NANA?6G%S9#\<_>['5.
M.6KO34X3K6XKVX%SF\5KB(L?EP;M>@763##DUC!A,NKF9.K'G< T)63LMV>$
M=MR!4&5:1%[<;2"L,+E-N(0S^WR.F44AT9(F!CIWWV0]KY%Y(9%&REU'5K"*
MVU.V\P;6@*&O4X7#.+S2TR4$8HORF^?:V6/45FSR%[F#?O+^" ;A"90\RLF%
MX"W;@]).R<"1^^\QH\T!?6%DY].>/9I^:G(H1(0E5IJQ5]4:-5TE;-X""OR&
MV6V3'O*;R=R8*3$I=E0?RMT!^'P3GCEN:ZLTMTI@!4F#OQ TX[N#SO4_?[<5
MC*F]^(TMV&PT[\8?,_6I9^X64.BZTD3$;[(.=Q<4^V"/2_MH9F?<C1 *1;.S
MC!5^85Z+T/M(.Z<N,KPF]'SWI(FVNZ*_?>[>*U>VP7FWCB0^*,1&%%5;22GH
M[.&OMV+S$@8CHK,C,YG_,/>90I!:SR"QA<,U%N\D-5UK)-,TT3!%H@Z\.(,,
M9Q^M)@]XKOYR,)NDII#BUNBCG,>AV&12B5A%H)03S4P9(FN\R,.[VI 9RV6&
MD(D 2Q<M0RXIV4FDRMK/D%NZ"]^F$*;5;KMOC"K<_W03TA?_JO)O9;+_?C\K
MFBU(N6E;]8^(>EVE#=U62?LL,V5H@2)/C<#OW%T$AE;D$F;R@0@>CI,P71Z-
MU'&:(WU5/?NGE0Z-[D=E:7YI04RJ_U1Q7BY+M)1+PJ=$:B"=M[KD'X4KTZ?E
M2(A*&9FXW7;=)NTGD<03Q/H()2B*"?5R7=:CZI &C;2KQ'O/8S-($*+6'03O
MW_+4V&.@P43(B8@7D8Q(' 1MNH/C ?8,).8UX2BBS2M:_D#+Y>_O6FJ8NX";
MGHYUK/'_YWV\JLQ\M.I*XO3BKOXDM_$S2^\O(#@R*DL2LJ1]1MSU"6TD\T%=
M0?-V+K:6PZ53:V2\6J!4P\Z2PK93]TL8+\^H,.\[2]>SR^5/T$0?PI*S$-DU
M+J8*3IEO2G&78U@WK&[3R>AI?LIAEB"8J)6?CJ7O*<TNA/6R. G6Q6.R%9[@
M:%(M"Y7BY,PT)FWG]@?N&'6/SF#_;O].J0O1)$0<]4VM=?F8#U-99^(]D4_
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MKGFD_?_;!GT%B]M_/(&W39URKR;K44%T8>*+M/0(O('TL]Z*)Y_[+ #&IY\
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M465E, 9D$9FQT@GHVT)V<2@<-J[PF_\P%P)L*QLV<BX>VX^NC$R!Q[-8'^%
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M)X0:9A7C.[BX4YT\"-485)>O2XM\=#=\5FW.3=.HN;0N9UC5>K2=MH<)[%&
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MM"O*Z0H1*CCM4UE86P**!WN=,Z@N+2T^[TBHB"L1EM%4T599K:O.\S_HKE.
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M06@94HP$:7DYS>!PLU!BZ C1F.00,KW6GJSG@AX]4$(_IA!12)>Q]+LV!GN
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M08GWN-2*1FJR$WQBH$C8;2*!-6*#1V2Q'.H6,YX3='(^U6EV&2Q5=CILNYA
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M)^**7,0$3]I^.($EF"J@4^: 9>=Q'B:^VJRTS+0I?H'.G:H9I^20*FJ:K;I
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M7DQBDR]T=O*2V^%N0!V]+W1[ Q!)+1CIS7_I$^4J/$ILI:!H<MG]^KYJ9S-
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ME+<SI.T'5WU16OA4]9&O\E4+5GN$[':BN?C*$/[\6?X[;=Q=2AE(X[&L>T$
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M7G7:+KCA!$VQ Y6S.)PK723[@GOS>O9+)#DD@A#%$Y$P1G5[IO37V&%-Y0M
MJMQ5#8KWTPK4(G&<A"#.566(\?CF[PCM,32@SK!1;TXW!;,B3'"@.8T;? PT
M]-D!)(N7QZ\BMUB+B,C*JB\BK^0Q.D5><E:!P\+ @;[6UI**WCBL?J<;[IE
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M)B1\VO@ULK;E$F=:F)<WOD/?UF1P-(F$R2VPR$./ +6I;8Z#H(P=!Y?*\<S
M .)V#MA2P46_U7AXIB2C<,[[)EJ(4K*.^I.M9:Y=0=9&N%TU+<_NB<O;=VA=
M@LHQ:UF]S*Y/6= )*_%I9E5$NAGODI]IPUI3\@T0(+3A_U#5<NX$"^>/ XF,
M)J-"9.OOBF')\L1]7P9@K^,ZS2OB@8J-;K>)(3<?J"K #'_PWM8-LT2"I:'
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MAY9'AI=$&4H%0\!Q\_*%X.O5XT?H4C=!ZV4\L<6,1UMLMAQ:LI'5^,CYBS<
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M-VLR.2YJ<&>TNUFR[,BU)?:>/NM+0TACF<E*!B71(X#4(\L0Z-M #P1^RH!
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MI9^<OF]^.&FI:=9K#7RE_L38Q$__P2^[I-^_5L-?%_A;6.EO/1#B0,@O* Y
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M-Q\$[QGRA*ZD!' N?OE.HNF :G7E!HI9?:41*[R!M,:#866OX$Y_Y02F)?X
MTL:O$?ZKH'705KXA-^#PZ"];06V,>G7%RV]N+_/X!CR+<-6Y!(B,<[A5S&BF
M7N(M6-P\-VU*_=L(:>XSPI?G(6IR*FL%)JCY21+*?3'C6[LJ@@<.,3D9HF-\
M[-#2,E!_*+Z6!FIEJ?%;G%[M3!0]C/?>CF56?[#,#-&4=85X5R0MB-QDE8>N
ML)-[!7^/DX0 2_7U>HZ_ 5<HKYYP^.09NFV46KEO95-EG?@>)@==>K0Q_$4I
M%PD;CG1(9U#& [N6G4J #>?I$3<8/0:WRDDB:]UOP+PH'RO@XQ)<U*PSJ\7
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MGLHFN#;*?G9%!-A"H_Y8(I.?<*]M"P7-\)!P+R?:#62;8T"[\)7*EA1+/!D
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MEM!.Z*UFX/;)E:CTV8/E'\Q#;'I?F7DY?+NW&+YUS#@-?HTVMVSWA3&U5.6
MUO1AA;?QX?.@37,-CXU\C!%Y[ X!<GC-567WN4C6R"\&RVS5&G)!E [5P<Y)
MC ?8=,D'<ND>WL\:U(R5V^42VLZ'MZ0P'(YT;0EDRY&,<C:NA/[BN/'Y<0Y8
MGVR7(B*]WW[9ZHD.L]>]B)J'3F7W'YCF#;HHC$*$*I-\&L?# :CD0"9GR.VN
MKB/[X[$74>I3_5+XCIGG-TYDBB+-B63<M\E_W,C-UY<(6%3YY4Q"XT7,B$"C
M5[]&E'>#/J48>L5LBIN-V[)UG]TY5L&76NPRO#=Z6T!C]T8 $.&J4NQ3<X[;
M_#9Y$P"T3#;+,A$"!A9Y8(3A1K\3L]9LUYH(QNT%1,FGRZVR2$%Y7U,N&X 1
MF[AS=H[I5L]WBAD7 JU]=.-GA(0))"Z10EWE4$;O+ OM[U>-REZ.H#?CC7Z'
M%Y]9WD(KLHBFR0*_]ZE#(?-F"T+<>XH0ZF#YP(N5;F'PWCL;S_Z%NJY?R-=%
MJ('%\\!!X.D$/C0Z6CU>)7;F/:2RA\K] ?)M3&&],F;S-:XBKV3/_BGB1 71
MQ*(LH)P<* \/&C5G%B7W#D/F;ED/M&_./V;9!\3X=7LRM89!#\*^+9-"6&VB
MEK+LA3"VFL0]]]V$W5;M(T!S4"LHY9)7UT*0H^85>0Q\$FKZV9T[F'F(H([U
MGGEC$>&+;-#[4#[LKB4I\#*'4#<;+FN# -V&]_T***A0-LN34^A0@I^DOY8(
M/D'(Y9/'SXT@7<4U8ZK3: G3$'MS;W/1MIU>.85LI+L71I>M!?%D>35:9^\
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M3DY=W-%C>ON@'+3@UQYHWRH"WFKY\E'T*<^7C4S)/=+PSMXS7F5D4_%=P&Y
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MJ&:*GX.P8E3<:B %[!:32AE5>G0QO=\D4KP,8I!MP7@X2J(;)0B&I>A\D%)
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MR0C$"\!^ ]NAY^-&8O89.':J3^>(ND1A$#$F>*B9YC-:K)B,R2;<.U7(9J!
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M :L/C*;Z E)H(;^4ZJ60Z22<KB7<.PJ#(V<C# \])$3I)%D U]%\+(]0#+J
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ML!%A>0F@9]=:Z D  I4<!$%)+@O31E?30;-#S951DRZM6&K7DQ"U"7MYP:R
M1XZ2/2@KS$U?'&;RD5QDIE.N9:DXU+C #$,*OM_K],BL-($*8"CBO+"+%K9J
MB2XUQPF]RG<A,2[=94:-Z3LQ3 [,;=.:A#H#C,A, %/* P0Z,5-L3 1='@U5
M(4U=G2:!=" .&F/Z9%R6U!O"4GW8#0 >DS3$L&G=J<-D.#&,XI=]B.$D@92K
M>G%H3/KBYC">E$;8%R')K_4@+I& 1Q5(:'AJGRWF-\BY&@0"Q!8WY KKU2+
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M$!!EP0+(+2?%C0$1]C+23@,#/E\<C2F@( DDJX PKJ!R@CJ+W.<Q&(P^AUY
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M&'1$_42>3)A%)&0ZO<X^=!&#RA2SV32F@",24JE<OI#)8W/H?(Z8Q:.PTZ\
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M57/?,?S,);)OP>7/ T-*1I9:<P\O;C#OD//-LB+&\&5M=Y':-#^4"6RYVN;
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M>PZYJL\/?]Z-B%]_M OTD<1/7L 6&I UQ?KS3[_M2<14/X@Z(M\(AHAVF.Q
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MA3<]T91ZL(UF,*^VNX7Z=Z#/52P+E:9:5[@]%*=BJ_:$CLO@P_C.RQ@G,3'
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M3UFU5!C7<!1-' A,CY5=<O@J"=L*V)E59>JP8(7/%.T53O6R(XBE&(+92<3
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M#5X[[E;\'+U4W>@SFJMES%"@Y178T(+4QUSH!U[ KOEY>+$@>]+#/Y,3:,1
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M2UF_*WDZ<ZYK0I8>-_]$RE<C5\0Q&2%'10RE JPB34#!51'[]7?V@F7M[KY
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M+G+V5*TG8C/EJ$)QAMH60(L3 ,+ZE%)YK-&QW"I&;P&:M\<_=*V/K8]%+P\
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ML)W4;,HK0+8"V0R^T:5*KE:=48?=C.)HUTZ_G2FV\/_">3/V?OA>K)<;Y8[
MY/$SA[DGGHY4UEA9B^.U=I=(VCNDBUNFW/4J&.#-RPL:;AF:I_:MWQT^LS(S
MW-C>A&6V1^26%U=5R=5R>,(R-2H=<'#4*6?W 9R[1>L)\D*>/7 :2QQM[)&Q
MTFSVM5K-8[IF4&W;6Y*0@Y [:NS1X'I)FOYJ^[4D<4:#2,H('>OJ#G")42@]
M4>=KB@1H=%C4."JKHI@I;A, 9:UJ&/Y$SY^")(X1)"0D#Y#:8L8Q<AST7/@]
MO&NSBIGR/3"WBEF<\>I+E[5<D?JAR.$1P?3UD\NS3?B;*Y.&]&_F0'1Q4(U5
M^LO3K.<T.G'4M^<%WYA^A(4,<VREV@J-T>1?Y22K3BD%X;_0IV&4<3KM1WQ_
M FWRG1FZH&D7UU%6&-_/W&M/"W8HAK;% ,(ILA"6DD/-D1I&JS7F^-\D",]2
M]FNO@Y50-[=[Y<KMJ$-=V-KU8A>?6D"B6G<5?TVES?+(DY2M 017_$G6YW%G
M#]<8?<&['S7D&ZQ?W[+<:F-K.J('"NT8P]B4.<4[CGE;")DZ=@CF<O.A_*%R
MX<:F2PYCX2#*<$$7\HGK_:]LZ4$*)MQ<[OSC-;8.=IJK.Z*Z/BOVV^=F/)*[
MOUIB&G1OE!GW;'15A"-N"R!Q!8%1-"W#J"O/!*&ADZE*PLN/1G@!K&F.>.8I
M0CD,,9GC9P'$4<Y7-++E7L8#'\/!JLC2S]K$XQ;A(O?EA+Y2[ N@LZC]G/U1
M772(/;[)1D>-=Z'2B*BDNT.?D&#@Q%^M?GO'_()?KE>/Z7OMU]F5ZPPG[7>8
M4AXK*<U7H#@F-2OR(2(3Q]?I4]4?$E@SOUJ'ZE8"#,K^ 9ZRLCKGX5.% BE)
MURXH)ASKG>RK'FA87:5_:ODZ/CPE6"T8Y?)ZO?/0BHSP)!;>9)]@J; KVDVJ
M;S",'8UL2[_Q/:]GL4U#Y;L[FYO,H,"M;*$60NPMIUT)X3'AD63HD/7I)2U6
M+( [_Q,L+0^.KR!M7%UG-6P9& 'I42/7]5CZ:V5?JD(<0\<N9[LY$H(7>(D1
M#]+]B7L1P%,'OD"AM^LG%2"K3V62UK -R3 XV<@IVN>#?B[W?O;X@TB5%MI=
MG4M;)+FD_C1NCH!4AOJR0C-\-@0"*[/7 ,%-M-V4:9UQB3E=QE.\\R6SO63-
M 9?1K@[;<$'5(RY$!3:0&!XI_=#9B/3Y'Y:ZX&O\V%[X9[[ZD:R^<7MU16\0
ML[4.;)&K*X13^TZJZCVAMU,F'4@7//O1MO4CZUYIR*?FB)Z'9.K[*8LK>ZZF
MLFJ.<8=F/:[1)O5^M]?B)(/ZH2S%3 [A<*U4(8=/-WC[Q\TWO_&V09PC .]V
M!EOR$3F,GJZ/+P< ^:X6RTU)N6(NQ1:4F3Z6D4QU YGCE#W 19(L*"1D'%Z]
M#?O*:[OE/##[TE-<TKD[$-)J"RE[Y_&TE7G@OVAO6CAJ);H3LO?8CX>P]L:X
MW&%M2/V\:9DK.NZ^>\_5-,=@,+-.0PCEMB$X6XCM5*$EUU2NQ#6%^LV9PH6K
M8$\V-SDI]N4%XQ[W7S#B>H^)HB8RZE5N%2M].F-+_&%@R9E?V]0#W\Q0I@:[
M0T[]2LF#CS-[A8KN D^H,_4]"G(R=='QO$L=V%#[FVHPJ;K[]I^/3B6U[)8>
M)Q0%W7<NS<WM\V6"@!=P1G6@]8R,\EBQ6H>.N=L*5GDL\KJU/L>>'G<F$_ <
MFB&55EH>G86M3)Q9F]U\>.ZE97E4^#]/6O#_^4[OA&Z\%ZFDF,!BGK :QFVY
M2U58)%#PR14]RF7R6WS>-,GTO2\L].5U7WHE9.@V7B\=7 T:F+UO><%B]DLG
MY?[$OT)22^C"V+VM[YPI*'M/VO%74T"@;KVTOLCV2.*XB#7M!9]M1]@S$++M
M[]]<;RHK"6UX58+^+<V%4SJE2_RFQ7'BEXLC=/ 1"ZTRU=\.3PHE3_I5T1S3
MU(@&TU%#D5.9R>.O8E/T'N#CY 832*GHZ8DX$TGED@)]Y*T?@_^X7<+]+O$A
MK0E+3K4#>ZX%@JK#0'+Y:53F@-LZ' 1&]>-6DF>:/P<U?A"0Y_&;S'Z5'^K3
M=[D)'T$!F:VA5-O#C"4326&O.^*=N4>,MSCY09C^/5\S;#]AL+]APOM(15$J
M"*TDC^,OB73O:%;"KSY;?DP>JH:S*H("9#4+T+VM#QR"$=5D=P,6XDV_3/U\
M]+:3(R:L&07MB!V@81K?H(J%[Z.:^G3+JXA).LI3JH0&YK[KFX]VE1Q?2R)D
M1,VLGSBK<;U=&T$\Z_^1RW9%FBP,_U.94YM1:[!M/QZB!K!11D#O5V4,_2!A
M#%M=/(KBG!P)N="5$TEG>5$=B3ERMORV##R&R<)(*4&Q5EJ*\KM8+>%44:)\
M\%KB3U^,<WQL=*],N'NYANV?E8#L?:6]?;P]28-)ZR:7-VZDZ9K8,E+<'U ]
MQ3>S:EYR_"76IL\PQ>O',2S;W9?%D1W;"=LTEYK5]$KP#0S>^A>9\_G*5F>9
MM-/[N\FA'-$_5<OM"O3Q$Y6&L[KBHZQP*)0PE&2FAND'T"X6D GESC%0\(7,
M:EY2B].[,NJBS?#*4H(2Q5HZ*=O+6Z/4KU_B?PL "_L@(UKZ73'+UL4**K8#
M7C:'?8<YHHNAOITJ#CPE1MO<V_,G7JA.[#=\&Z==9N0$K2)ORL9:*4][%Q7R
M(707]%,V;&Q0B'C&-O:6&4F G[B526,"HTX"7,#/RHO&D_.FPU@C-[9^D<6
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MAL!?C1\X&YG[V/3@.-'BU,2U" ^K?$IH]7L1,UCY%_!D_^Z&]"\@,-K<@OQ
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M=IM%[HKFLIUFIKF>N:<V-YFX.X41B;JKND)6RERS<DY6Z9*WNE'9!/93@=V
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M*%ZQUIM0Q(LTLAF]/X WET<MM.W0.';WE03/_9N%NO):]8,SQ_KG4W/7N;^
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MX$!&;\%%12/'N%=2QY+"$CL1$LUW1_NM6RC;IB,(J# 4ST4]UJ!7ITF0+(W
M%?SJRN'F<\JPVTQZ'JP$@4$A?9"G$WSM4S44U_?0_F0Y9!UQHE8"N;<AMW /
M_*<F;1B:D.G92/8KA0PGG#A50:79AU@6E?B*E++A-#:[LK?IGCCT['*&1'[H
M:%MRX8+I%=['K/$"2FVIK %[76>)^DQ,BW!E$&/BJ VAH"KC3E!OD*Z9HXQ+
M+4_N@:B\IC;NA3EMSD\$+2FEUBL60@$AQ8!<&UU]M6$),B!XYH6PT@PUQ&NV
MO0GRCP-1C_"B:;0YL?PIS\#R_I_)U/4Y:J%[.-BG2V3P^D6?'+9!_3HD;V60
MMQ=K['=TS16#S]/L!YS7!S8RC>E_SEXGI#\$!)\M]S#9WROK[,G*1!?\N7D9
MGOR0$VC+\;SZD9KCZN>OM;KW"A,_$SZ/!@422CX?O<9X>2UX-:SS!/\CK+/_
M_4>3Z7UD]G?JURDW_WZY]7["YU_6O^T^3PQ\=4!>X@KT"W]D.MZ3.?Q5_)OL
MX^3 !/7KBX'[L=?9T3U3KCL4;R/L_KQ9& V<^2%_S_D7D!N=)?QQ*_HR[:,
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M<)'"03C9?9;1W2A5RQ>/8&X$9HXL "*8KQJ /0WL!Z >%^EAK<L2 .9.T8$
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M3!DHH9J2)IAV_EU<:M;1*N42VV8^&X2CR\\@$MM*H=V,=84.72B4+5/?HF8
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M)DA@*IRL'Q;Y<<Q *$95,TL=S-!+$XS,CLVX;5%N3^JUEIO R7Y"/BZR2B&
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MDZ1&X'"2J#.J8!K&=B PJH*LB7<G< ZQV.WU3NDX9.QUEG7$X\!N1$N6#;7
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M_OX7N9LRT&[<9_;^(>[;Q=T?P/[%F],_@/-_HK<6/W9;>*R?I/\#^/AZ[0^
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MU.KF!OJH]L'2I//9"BEG%G)-=ZEV.#Q!>LJZ*U5;X02OLRH)G)[$TG.<<^K
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M%;9$NBK"M#P;DBJH>X#[Y\ F!DUF1N]8;1K.J"?.-X6+K**B386_DG2[$!D
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MS].[F]J3SM*WZ0^K/^[?[WR8/7W_V_,/H)[[\+TOG)_9E!]I^ET=K1-:-2O
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M/$AEK,5]HQO831OPQ2EF]L!#PXV]9L8S[FG>XR#L'.&VN3$7KWF6K?T YD2
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MVS>:GN^K<V\\C H*B*RM:RKWM 6V&G9-B8.;QY[=P?JEGVE5=N*%GXYTWFF
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MZBB2Z+%^KJBZR53GR2[HH3<%-C%*ILO1Q$PZL]4-24=IZ !%S8""G0PJK8/
M.J!]7S,V; *W>KIW=GH&ATLF5S[ATN3IR</0 *Q')+4I#A%-;#GTY3F4=^0%
M65SJ?"&7%]TOK-!.%ID@1*)H(8E:>@?IF9OI5BH7E2R(@[2R?4S-I+IHG2&[
M3BTRN/67YX;MON$]]8)>8B;SMXIE??=?R;=GD=9_ 2/3V4A)F TBF4O=NB8L
M3%5QPR',1AIH7RN."K^N,/E7+G;OO*96I4B!CR@R&%1"$,^(B&JN'W;VU/;P
M6Z[M.[0C&KNAOZ'(.HXJ]WD5A2&I/!4;]602<,:Y^T?A"25-UAP&8PC XXN=
M;LB;N>'('3Z8**ZBMFNC=!U]X\K[3)[=AO&MX%<BH[OCY15AO39<EGI^&?:=
M1> &FO\\=?O&>?_-]U84ZI8ZU) >T\%)Z6F+48^,TS(4S<<D>Z)EY-UJNW7)
M8+.:)IU*WAT$(!&Z8DF'O*4;1M*+DC)Z9,F;=JZ@?UMNUXP *J(.99 =19B&
MM.YW \.$U/-5'&["'%Q@9EPZ13=T6:PNO!QE,*R):$;7S;O#]<$<E:5D=] I
M:[Z9'1'@<H&8YZ3:I6T767/IP'I,:C[O?=@6WD3DB(ZNNAVGJHX6D;<I0A1_
MJ?(O0"6]NTGZQC3D=.POX(_<NQ2F9W'0A5C\/ZNLI@21@Q(6,R1A#XM^0YO,
M<B?3ZJ)AE9\$MXE//.-*R+=&F-9'GRIW<UQEZ@K,>]KG,UD<MN L*K#ED?XF
M2(A%9WW*+4B;%HV,ZW\P[6ZM) H_?2(/%43B"9VMF!_\6A9[UI] *2172MW[
MZ30M!2T*^YV%0(-J !6J^.!EQ[)AQT]1T.%RFMUN@IO(*-%HHS/BM0F0\EVI
MQ7QYGOGE(Z,?@YB XO2B=>(>'+99EITKLFZ-@$;XQ="'O=QO?SI7L_)=ZK;B
M1;1^[+0Q_094R/CD^)V<TRP4X_H^GX79H\D]M<Q(G8?M7-=IO-1/M4U@HR$W
MUG4JH$7=5G'#'/ITKMXQ6RM&66CG<!K.GM.,]-9=([3>] D=%DS O#H=3>9?
M;6N>*.M>:]?3!VQ'_)II2K0NT80A2E6G\;M(&SWE?!01]K4PU73R"R63%!ZN
MZ4U5JIP]?4=RG,+OKI>HV5M=60('2<.< 3X^KH=OQE1C=UE8&IP$2ONE/6'"
M,7-(:ZN?3D"_W"3SB@V.>+B0[-N1;X[[TNG>^O1O)Z\PMJC5\F"TT(>N)8A)
MNU5<A=1*Q8NS9E;5_\R36\_M>EX7;#NU>I'SVDT4:7:[K,$K>[ )4Y5$5:S8
M<$W2.1+<I^O'/;Q:U#4^$*3H$DS !&2ZTG.[C(<JCY9](9 ^:C0A:#>.OP _
MNKYJ-)E,0S;P*)S4J&:?[YY1=;JD2K[/%?+X*7]/EM@R+4X8<$/N=L5MVMDM
MOO)L>6FYR_5^ZW][=BI>)@MEODE@7/>E7K;J3?D+,-KP_5[WN^[]=$^LL5+]
M(E$B_64<O7-1+)?W.A/#X+FPK=!_>WSUZ9*4\YRK;^-@78C^7_4.K@+_H]&^
M?*D*47C@-HG0F?2;PWJS(;!;L[_$BQ9]N+YAME%OY49\"O*C[<69*9(#)$LH
MK?^Q T0!K5',1(KLLR&B)F)33C,<WQ_-Q]9\DW/OKM8-955F6+E&(S,?1 B4
MPU/^"Y"A1M![I$S;H(.U$^,92-R-[GK':S0$*!WZV%)1P!((3)BA7F,4<)H-
MH=+Q/(INM,1FD@C,I")G:"+ELIP6*)_,LW0V3;@/X Y,W1QQ]F_'Y-U)IZ@1
M\_:]2Q8%#)N]H$&VG_OUWO5^SO8$F*C^AW9(W4H"^.PWV<B^77VV%WO]EEA[
ML2)DL0 .@ PWN*M5S/K1CBA>D97VTDQ^8K::4A:3'E%#T"('7;"Y3 F<1C+T
M<@(%#5!'<[#IALQH"R0>YK-BQD30,*DB(\[_9)G)HC;]-AQF?%\)??\+"#"?
M+CA/YZ.=(:\NDB5W@_Y<<ZS*Z/F[VS/D1L6W#[3^ZVI5_^DIS.-'_?J 9F3]
M7+W]5&X\\'RQ#BN>K:FI9M7=EL5=\,M<UVM)R0X/;(5S'4U;\7E?&@5,QM2"
M$85'9%$9 [-^SQ*6H_^RK@3-[KC"DPU-W)C59MNGU:/F@_S036(!MI7A5J@B
M&>1-D_^<[>?_80B$'G/13YN-EAW-O$<YPWK$%D8<#\V1@$[V^8C'0(XCD9A#
M#-=[B\3,$[>X/I/K5S'5SZ_/1T]])L* Z;P=%PH+AL2PM]L.WS9OH%6/P]'Z
M>?:#:_9;[=2)M.^O*KQ@]HK:_,5^-,C__#:C:LPCW6_+/VA1%R9BY*M?#SL>
MO[E[EFS;W_G*?L<P'=6'AD3D/1[[-[3C*?A<HG4-VTE-W#/WKU_4N3;+CL3,
M:1HS9BK;0:9I(]H <Z\)-KT(83TQ;U5H>(S]$M,_.>!ONQ579YP3$$^1B.EB
M64<JVG!H$B5.XX8Z7_0\7!TAVCK^9+75V;9827H,00BU;7\!3JL1\>&KOY#<
M3E=+;N[8VFO;^R$H-I%$]F2'\3[I7MY6(/:-+=L#\_)8V53\00EU\-!Y21'5
M")_JZMAHM%9MLV570#081\U[L44F+*-.J;6B[<5.![EFNK*5LC;6 WEL %<N
MTNB7*,SJHCVE?:)'J/:*FJ:5F4K[Q0>QAJ%>DIT=>IM/ZUA]I#,04=AFF2%+
M5,F5R@J^D6C47#M0>>HS@L74R9!M21E;:EG1LIF.4A#ZG/N&X^5$B4KH:=LE
M2P.*'52&XI?RW2$[)B?.FIAK]'2J&LBRP?[U7"VPL;C(02A?.NUMJU'?C$8_
MG5N:3R6L4,:+MH+\>II6(30;<V-CAW-/ISUQ"(*\35?+.^&Q3L^+%=1"C]H!
M@#-M+2*2D ESE36LYE%R@:((-0/0A+:2+%K1KN;L)A8XJD^B!N,$(:(,46#*
MX+, J'TJZJX#&GI7MUN,K5L/!WH'RZ]SXNA78](F!(H>?MK_-&D6_Q*$SC("
MSN-U$<Z [\DV/64<$V/@S!-D/O2 /@:'*@K9/RZF#*WEJS&#\'Q<&%#(G$7/
MI4YA1)Q+;7:-L]OLEY**82]^LZ&ERLW57\YZ;P^N6'BM?ONES_/L%WY[>R/8
MJ-N:C'+5M;P.G]^:/TRV)WEDZD/4O-9?L%OIE1[)D/_#Z Z\Y;C#3HQJI;@F
MU$%#K"$3!2V$XL]Z=.-)\.7VW:B"U6BC8U:=6BD7F;6L^<U[^$0U88/*KCY*
M6Z?O_I5[<##Z8J^F8+4.\E3^J2O *L/? YX+4K;:G5QI;^F#'3$GTZ[D9@]-
M# <US6V\O;?!@F[W3C4LG_QD5@F:J+H<=K$_G0E)G<6N@998M0PIVZ1)-__6
M1+OV$T'I>J'S526[V,IQ736)@ .GB,$20_H?W[S_A6%MVKS;3+-WL5IH\;%1
MKW;K7$5?NE8'/Z%L:2MW)>-'?7>9Y+PV6:$2NFA$45]?6F046^)5!R\0\"5K
MZ 8N51DZU<S=@1&+)\<4&3.W'EJ" @LR"N2"CI>?V;=E,W';3A$?6DG:[XUH
MAM*QHR=XIP]]CX6Q9]9^<;2O1?U6@>KIR$M7<IAWPJS1[;_3A4S&3(_V94Y"
M@PX!7-)" 8@[IN!+5S ;J#(S)V?</QFD":D".1<SA Y[O_!/V#<A;M7VF\XL
MZ%#N,&Z(Y 23@$Z^MW32(J?NKQL0[T\/'O9&)W59W>DSFO=,;U_&(*M6#/5+
MK69T:_RNFJE^J6G\9&=-*S J\#(W.!C!QH7'PMJMNW+MAF]Q9L'OX6*:4A2B
M&*ZH31_F"%\J33 )Z>T4=G9;B]I H A'U5>R1J9KNBFS0XB7'+65P?%L5!8Z
M'Z?[?\$#N&\<#O.>[5>8CMMG@<V;/:E5S7\1@.']X3@/4=5ITD@L'\G J(+%
M\R($9S@R&'2@V:!=HK-=_\:K 9V[Z;YXHG>;]6VYZU&Y[;7V9CLT0=DUSUIL
M)2U]\P+L-]^^L+>E%V@,GDX$]A*"?[QV3A&) H'4^?**& 7O:8'22'3OQ!C9
M<"SMI!&OX(J??;K?QXD4#Q5(!Y@(=K&1B%%VH/Q^2^'+ <>\W8<)[#$=-M;W
MV!5M8@U)BI/LLLAAN(+AHBEG$64)N("\XY]B. 7'>7[4-%&#:4#@*-:UU!E9
M*?@)"B(:(N%K?T^*WR/DT(*'$H 0F2 )"G4:XWUL I2W03**A[',HAN@N<[S
MKF11*GB%PTQA^\XK161+JT%M;=RYR<1X"U0J<F8@<N7V1$?_S2!<=#9F:&W+
M:+7JIV&.:1/BA> QE6FQ5*PN&ZL"'JB-V(\J%H6FO83H9<F+F]'3/"*'D[!"
MW3T<&1&*)P2Y&DJ;+;FD[FILSC;?;:QT-<W(^<)9;5:C$;[N+"OXO"J/YR@N
MRF$&+.8]G@Y%,N<Z":?& GJH$_SGU(-_^$RK5,(6IM.]!*!/+_A=M_ #S\;1
MNH K^5?"O$Y5JN&Y%TJQ56<.GE=Q[-+_"D5Z^"_B5>Y_$*\69_,8!;^S^.R+
MO!XD)[N-@8;I0(_CV?'CB7$=XP6"O[^N_7;R_<U<G(\@:SGH 2N[A@*0F_KL
M(O!Q5X&;J& UH4NM?PM%_6";".]$VO;3H SACM_-3K]3VI$9_BK1RW;.KD='
MWQJ"YW< 1*/6T,_4>=;,;U:,[;7@9W*@WG[1Z4HUX(;CTU%8V,]J>3A+$=PG
MW#RPY&K]\(86D8L1B/%FP^;-R?=@1D@_TBH/4D<B9>0S#BR%'1QAA@H)L*<X
M^$0,)82?7KQ*; M>Q!9&D64!H3K(.?5V_8RL]PMF[5O=T=U-K<%13UY+)@H8
M&EH2YL^V%P4:,QGH< YJ,L$?C(W77:.T>[;:RCHMV/O_:&\G@:+29@X0M#F+
MY= W_(Y'&Z^CD)7TC*/H,39;;A+3K%"O.^'+)H'8\YK=O'02,II^H+S$W8$%
M57*2'Q$-0+4X$-$XMV)"#<@:A)=;0?YJWOL3]>D]OF%KBGF;=A5W+?=M=N-R
MT3WPLG$[,E#HHGPM(: ]<\)WPXK8)/#RRA$Y@H3[GZ,N;"8BW0O958L<Q\=P
M@_8X7R .$IGLIK^;S;5+2>@]780%PV=.B,UI%W(9M9PPR9W-A8N-;0$OF<RG
M+1M%SK_87.<*ZPJF0FU=G&:]3$HVO42+90K<^J"I?#1.S?T+X/U)99^L$[?6
MW_NRLQIS'7IU,Q!_8M9+M\G:4SL[]=V]Z0I%O%MRT;Y%I'0B[1?SFO=P?2/>
M]^I8,?>OMO&(46A*.4DE'VE3$XN=;M0]\9^B\W=+ER0[$7F/Z<[O&]^%F[.5
M</U;);9/3,'@%(X0@26>= &&J&8[N(5,)S)ZBQ>U[]2YO8":A&EWK]X;)P1W
MM,@F?H_;,5%BR^QMO#_KZ%G<:S.U\6L&UUQWI 4)E[0_2@0Y10'.FEA!5+Q)
MP(=HU\V*%*[L=!%>-)(4J^PP5Y(&*SHZ*@)ACVA=5<H;Q'$T<1U$*Y8]#8LD
M,=!';3*-QDFRT@BWCX^.KNG41*\Q7=08GRV3+&U61\Y*M\:=3<P*S,Y/^'T#
MIM\R_4/J#=T]-V0Y>FU.F_8G^C^R6="16CXY&8!T\);L#9E^FS8]A ^/+$L-
MY:VMWU?O4LY<0#TZ,9%,J'>6Z%D%$HUY< LF,1QQN>@]X9GP*YZ7GG)U32K7
M$.<R*3@T7]B4'K:6*H8A@K)P1VQR5HF>[9SH2XF@6UIKNRR,J+=#D0HF@ 8X
M2DZV^88W]@_6.*DN8QH@YP26]M-42_9_EA?ZM?/4R*U"!#\K? *,]5/S305B
MABWU(1S4T]0<^W.Y5]*-KM[&[DM4:2(_!VYE>K$>JLRDBD8-T><?TE$Q;.=,
M##5M\ ,=(A/S$*3WD7ZI^H[D-^GGS.]Q[I]GG;7?FQZIQ4;H[[!_H^?)_Z;R
MG;X;EOI8>U;KQN#BOI8,O&=?N!A)7**OZ_O@^3^___OOY/XS\_CDOS2_6A?^
M!02S__[\D2_P[RJ-6GCQ0YL(C+[_K"OFDUQH_NEG=&"D*DU@LBCXY^'_ONHF
MQMU^^B0I4[EKEL'.A/-'K4NN@.PSGD-/(#MS@D@@.SG99_QK[[=7]I?J]$S:
M\O3J%GQIHBURF,3JOP KG5!K%JS-T"SJ/A,2T/I?P#;SUZ+"]QFAA_^1CA85
M2W\\^ W\PYPHYMDPO$'TT]$A90WH65^LD-\*[]FJIEZT<[O:\M)FUK[U9=>+
MIE)71[;?VJIV91%^:&VO]XI>L%J]IU1AB//HB3#;J$J0A$(;S@INT%5V6)[&
MECC9#_4+%3.5GH1FTG%S+:P3 7STBKA0PL#%SDT?[P7?CSLXJ[;^F_BP'L51
M>R7[L7?&H=.W@Z%03SMDV3^[+GK0N.EUR,2P[-LORPUV*FLC.F2-<WS3E\*<
MU;47M*??:&%3SJU-<:@R*--"!BW]=L)+A\1E2FX'DDH=;"PB]4OR5:C#8(62
MPDMC%<I9$#\)H^5W,VC;.=[']-_M/3^W?VN]R:7U8)"LEIUR99*Q7^HE!64W
MVF7D#U!;X8$<1#!7]#V?C'271%Y[,-&WK%C-<KC)6Q2(HFSI=*Q- 8";LIL'
MVML[WY328W:7;DRX#);NKK&ZD11A_8B_ #;J(IZ85=SI/=F=(/[E]=V)G];V
M<PTW@*#OYQOKMS.55OUZ)L<>CI#U=L^?#2!>]U_UZ[%V-GRL\.5J*X-Q'@VK
MU3;MO2%_%I'Y=2]72G"-PS.TRH((;:,I]2<Q*!B;%SR00UO5\>BB$2R&H2-@
M+_S4X5O+X:B8_OB8)\Q24NK*::.8J>PV%E__GC2ZM=AH#PA<Z<#UG0^D,!&)
MNM7A38R9VZW(L1]C61:INQHN:55N,+ ;K3A3KB7-LLNU1$SVD<G069B:08&&
MSP8\IGVJ1L9&U$3# Z1K01H^-#6PZREA,Z+R5Z.N)TB@"0?QRY((PY.MNW%:
M(D@?=ML,8EP.MYF*-SV&+A<V2BLVS+MUT?4T;SRRZ[BZOD':FOF<K< NWWFM
MRB'T2\9'!A$NJL&_';>M5SHW%9-T%]""5Q!!:GD*-/F:C+UC!9YH.ZC-'?:H
MTAD.\2Q(6;KIZ@ C3BP#S_@7>1CJ@L$[#%WYKFC9HN\LA]%FM[.#J(X\5RI9
M>(K*F_G?^9;O&YHDJS,X9IJ1(Q*C-2,SMCJ:E^Z>TY\]^%F(%540C<$\-;.O
M%ATT/DMII7*G12739D'JZYNPP6,5'D;%.'5%>U&P88WK-9+RNC>4*[K59V-&
M[S^DUS:Z"?"V(H>YL=<,9"I48040L\BV6"2VY$D,W#=Y,;GYC.\JCVNX@Z/2
MMT:0N,7X)ZYGOX-:#T?A;Q%44%ZI/6J_BDE CD/]8'/"IS$K/>ZHHY :,W!]
MX<A3HS9)CH4UU'OA<S_WUM00=]QHMK>2,N,KV'H2O12:L]FZU#G5?Y.5?]UZ
M"KKF0Y/LO_)MZ.SBHJ0EG3'CZ'#U/?&HT5)36I8YA:I7V FG]-'J"K'7H$S7
MB:<LV0FY+<IVG92&@H"MB7=L1J 5 3J;*]!'X!*]<!Z+_,B]HM*M>D%=MGE6
M_QULO16MZ?6U ;M6N^[;R<4^*R%.+9(XQS0FE;O\-C)MKX9"H:&U)-I G@QB
M4I]QW%6QXVIZ=4J;I5  756\#EV1!,T&C+G$: SX!J@97J$YF-:"E46!+2_$
MQDJO#K"EN85!!9WS ;UGC&B98,\(9?5<2D*Q&I^.?$=++998=B<:UMD+-[0X
M.95(_<>J*[(Z^_(0BO#PI%>??F)G4-7G#949A2K+;S<CQS)(F%HB*Q#C4B+9
M%7? +J5T%,L#* HV4?VXX+7!L2! D!1\2LHS$6P5RP"?*.E5)4G'_Q-R(8XU
ME>%'0]^<YBX4'I(^F'*U2<':'%E$HC!O6K*5M@'5]-S!^Q1L&E5<39L?!C/0
M>F$YH&?Z(/)*)CE_C>/P"YE_WX4ZZ_C?.,5["C@B*C&D1SA>M@X.,WX>JR*[
M7_HMOD#7$>7R&8BJC*H< E&X9B0K \)_4#C,H&3N_)BGIS>50_,/]"$L/Z+G
M!LLK<%;4ZP>55F%ND[T#_NQ]V IH,%\L5US;,.DFO-O2! Y.IZ,ZF.A;L B9
M18UN"S15&+CE9HI(Q8/ON!X-0Z940@E^Z0(S4R@OLL>_Y(\)_'HU0-.4OTXA
M'!&@GH?/B\W$W+/MKN$'^G>WOC0.J_Z<]E?<*Z_IQO45[[Y;W6PD-<HY:Q<Y
M:6C9'O9\5*_=&KM%[3C:6Z/[Y@>-F_M(&C/^;>8G;81V#Y" F*1WH&KFRY96
MIC7(:N&F\\ZU8, 2EELASGIZCO?'"AG]"9(Y;$Z<[R2.R@0?$T]JH[S(:)Y'
M4IXN^"!0'@YV1%UI&+_*$>MX7)U$%.Q#"NDVZAKU"Y6YC/*T4FWN&9>7"0_-
MY>F9M]E/@!F>;6I3RW"U%JT%B"RC\&Q.LZ3TCH:EJ+#Y@.D,Y&HC<AIUD[WF
M,R],+OSO&N[GV0JHS^N%XH%,_8M_ 9&G#UOM)!#(RG_"%US_$[X@)_?'"^-7
MX5/AO\,71HFM_P(2N?[D8MR:7UTTF^0,OU7^5DG,GOOCP7^%\=0@TK;;>W#-
M)/MMHYY98_%7URH?O6?;9SE5I#&"BI8R8=>=;:=,,T$Y=H$<KIBOP#42(8&)
M7G1? ^\?40!N4 HQ:L],C;UJT4.]&Z4F(ZE^H^.0T;446D1QM#QNOL1J61F:
M)X!.P2(^?.TP^QQMT&AR:?B3O;7? U!W8M*XW-I^MF]E<VLL)J'O-;=6)BI?
M0'?/Q(?U)/";0E.VNL"ID/F4**Z92"O<,7T]U\I;A-!5@HX!SP@*4FW[1!&V
MPF*C3E!%_-B@[/ZU@D:M"I -J>1-7-K+'*!SB#@5I(1F(%^>,.*$P\E<^VA^
M%^<[]>L[S]IK5%I]O==ZK53.U$9WJC;1NGW=\K?<&=ZNWVB_D $JS@$F^(CU
M:XI3#F5V#,J.R*"FQJ@GJ^5.H[;F8&L-Y#?"(&09>.HY)OY3-&C#OE*)ZW-=
M>ODEPH6)6G P7W$T4YWGIGPOQVCO6U-M ]UV-Q/BY=/37I/OH0?C9'M1]>7
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M1TC%)*V;D1O0C3?,V#D>IG//(&>U*=/@19 =^;(>;"-_%5.D<QNAH=/*U&[
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M\^SOP_S]Z#5BZ:D?DN]-_]6D1\0;G=>/V;OAFL1RR[\ S+YK422,,:+Q><X
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MKL)2T\YCD4GZY!MI=1*GZ#S&G"N=I,B1!$(ROY91EQ0-1-)G<&<N5LS6.N]
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M=G?W#>B#PA([RKSZ=\9I10BS?CRR\4V<^S4SYA30 >\5*Q(OJ67 ]Y@#889
MEZY&JB;])$!Q?%B@3<U$AF+8%.IH5@X*;55/.8N=H,[U]6MNCXG<*O=%\:IS
M,>A1@D1%]LJS]6NG>]/V1?].>T$7 25?H# :G2\8\[F9VO!T)HEL64_E\4/:
M<2"^CR%Z)86L;"9"-9=79P<'80JZ.#'V448>)H*P/84;'8B;++5&A>F EM8_
M%5QMQ#Z*AXH83U)3'!N3Y]FK$NQDKZ9ETJ"OQ]"".<H)Y7$;6QB<*NAID2]L
MD:M@F@K@_4%0HU)3H5]_6:RNU<AD\2Y!2"7$D*4QW,63M1D+/R 9YS+EFDW/
M1],&AZN1ODVD<:A7A&S>H@9(Z\YP&4Y!:>>Z[,15K=#(X#")HEG[V]LZ_C_S
M6NC?AQ)MO^-'=IF[BLN_(&P*<$RTM5166E9=Z&.!9A(+\8\R,9NR0# ?W[4&
MP0K$;Q-%R%@QD0>L<"<R0N*1KADKX06P4'JE-%.;_@  8VM>0-0WP06@RX>&
MKM>X7!NIU7>8I@>FJKV_9J&DZ5TS#"&D:^3F74/G;50<]#_73"+8&_)K%-35
M#K=K['V73J5L-L'[!M>5GVRPB%Z4?EC:V3SI->S-%9K[#^K;6"+@S:85^NO8
M^!6E=<=_7[CW=27SKS-5\.,PUS=#]60$CBA=I!W4=\1;J7,I3)]?"@F[-_"J
MWX@\OTO(Q*&XBZ42K+>;]%_$U/#8B:K3]W?<][SN)^,Q/6Z_%J>"X+B3@API
MV^M)#GIQ>3$^DG[QV[+6%K8=#NXI/O\)<WJ-4O=!ZJB+C@@KKC%#XY.ZMZGT
M>;+^"O%A,.)C=4JNZK1W7 \QHZ86I>YR>_1.Z_.RX=_HO""VNJ(#%=.Z4OH*
M+2[9O1M53.MIM'+E0!;$E_-;8;)G'#.(RU]7/WI486*GRL)9ERT*:L,SL&LY
MYS$%'XPF-GS9A?R:_W)M8/9>]=/97\#H7\#%>,-7B9-7AC\\<9\[>7YF?O@+
M2'W_2YXZ\/-_]&V^^Q_[-G_["PAR?V(4VC+;C]79SNYFA;8W)-77.:G6+U48
ML&S[.2NM.V/[%$/-KE2:E/"]E+W_Z F)HPEWI^ :[%I^+-&=)<3X;?(78$2(
MFLB2QDO@ED7.I,!_JTF8..#E<K!W X<6$]/:,B;XK^/66'(P'!VDP+?L"T4*
MHDS&>J4 A:($(_EFM/'R)WH*1J&U5@6Q>]2M)@V"^TOUJ^=QNT4+F4WQ1OS-
M,RK+GL[4T'J.(2&<"]"&>H'RRPA.H$5^5;TX=IM0<R77%FB/0KE^$;F \3M]
M"H-N#G[XD#WOB$V&.U$&>(TL0MWRB&Z2JXB&("&8+);26&68T\9R1.^-,"[A
ML$7M'9TA%%22BJJ H$J\W^;VV?^G'F6UCZ>D407,*KK#2/PA<[)M-+$51T@U
MF*[.? W^%A_?)H:2@NMTVDJ/?.'ME>V)K:X6$<2Q\ +9()J<\S<G*#96^Z76
M&39LA5V'K#8^LT#MB2K/VSIPJJU]->)BA!NK4VQG;]9!S^].[$0,5XOUV9B2
M,K5*M0&#(=8>!I/UGUS!/=^#6R\#(C"/!S[!8*-G&!YK8: H&*EEH\X_\@![
M+J,-2&W-&:B6HL^[K&.W<@-R8W)-/M9=,<*,?DJ'0/ *.G)^59L_2RW61=AW
MP*@NA=O$VK(7.7B)IEW43:#+X(=J @U*5U!R"WGY$R;V2+CQ;:;MAV"H=E:3
M]$>RO(GB.H@T.BXBKZO\?1"-8XCA*G%BBF)/.<\:"2:KGM,FT_)TD'H@^;4+
M;4+MIF*?O:[EV.3WOP";JL4ER#=_TW?WPUH] "".A=FFR!S5_:P.8W8T66KI
M7C7F7K-H.4JYDOZ;%7(\1=:DD9 P)"L/!MH4U,P#@HFOG%&***6+"^1"=/0V
MMFS+64J.ZN$>\C(DG<_V6_UX1_CFB]5EIGUD:7\>@YUNC9<D-H$SC%Y<*1_;
M*RO+C0S*&AMI IM54"".EPMYYN<1"7\H<7R^Z\8>C+Z,W#_$Y<J.O>@K8M$/
MUV;N35DE6KO5NJPP99GJ, F5IR*]BV.(+LV+,))OCU55O'>X<J<CZ %&9M!0
MJMP,D8@BF')10?6F%[=_[&(0JFLVTQ[Q/RJ9NE"BF86;+T/;O-,&-=3>?O@.
M7IJ07UT!@QM5FWSE4IV<A<SDL8C9%-SUOL&+LCBO3.2_+]BQ*6:A[  'XFCA
M<7QPK>HE3F5Q9+XU]"KT$L-;YVXO"RB]H:$V0R;44076!*_IM/TJ/9JMLT_1
MA?6.KEJ7'//'T$VFFOI4>:0'9LJTV1E44G[X\:+'_]S)M<,UKD)X?:A9J+>B
MV ;.Q?SD:B:$6/K#MGQ_DT"+[X&:D^A2X0,'C_)6;!$M#K9[.F47NOUT<=8#
M\H?+*X$T)(Y&;Z(J!!R<MPJAA.<\$/$)Y'@R[BYG>#R&UK%"[]0@D1J= NO,
MAL= _;BNCX'W(&3V)J9]R25K\V.GIWNR0I.J.FX;];.-5E]6.Y=LG44=FY6J
M0-A &EKY'/-HG6&^,K^39.1I0G.I@9B.R5J\>!WU#G-Z" CQ%H57.F8*@V,=
M)TC/KCEIX&8Q<W^*G,^(FD%97ZJ1?#IGIBJEA^$=0EU<<IH7DEI,VTAP<-G5
M)XQ ,\$#NZ5^)7S/ER*2#.RV?L3I -FGGK[T6C77T?5B/8IE?O5-BP?3^A7+
M,\&2H"?>+5)P;8BN6+;$[?2"?10\ XG6FS=T1']V&M\*J*@N:D8UWEAQ%L?*
MQ+O(:$K2"S+DBNM2(J!(S&; 'D!!67ZT@S<BC%I*5_E8-"0]N>I?WX^MF*Y<
MU17K;,P(]4BZ5$)USIU9+988PRWK5UWHUY;KO#7H$E,-X]BST[# ?2,6_-P;
M=5;M35R]&D!F\+K!''J+ITJZP)@()H,BP[,,^7ZM8_6@7DH*1:P; J*LC)TC
MGX1)_KM>#O0L;898"M68J5ZAS'_\G7XA3#[HRLAC"%]!J4$WB<ZRXI\,O<O-
M847AC8^CF<<@25_:@TW$:M_0]C0PSKJ^LF@5;SDB<W35*2P?_;:BA.(WZDCG
ME*VR@P7>/ZX=Z66'Y^>W$VV<&AL,17O\+1RY1BDE"=W2>UX\>,##(L1TL[>*
M\OS,H@R>0[D&)B$9]A-#$_0JJ38L_,Q6XON\":/4X@18?W*V)-AP!!7BQ*UT
M+\<V'[PSK-EC'ITS#&JX.UQ'7%^%\5;6S]L'.2&SY4\BT*Y*@JFB49>?W/,F
M"D*I<^ASJIR_V2V#5<#]IE&1$6-#2J?/3$6G>QD5CCK$"Z"ZF?8Z)ADQ1@TH
MI4K9N5QKKX+#P1GZ_C8-7QNS=J'/$AE>6+9&T8IWV/3N!8<Y.Q2T);AZ[&IT
M61UJH.-H)E6LO;+]P^<T49>02_#":#4KY>IW+]@G<?G;->:@KHV YJ^ >X,3
M:^H?\&U:L[BFA-ERV6*=6))/G#6J#+!W02WJ#*BT?&,(R"1OPBJ58@:QD<.Y
M!Z^&T=+,$F=XM1(B]2I<Z&*]UO6S!M'DN/RC)FXR\8CU3X:VHR-S@EFV"CY%
MB#AIQZ^NXHR%C=:HK[17"(;#EB!U0MV_R7W/V.*Y:5D]4;UEG0P-Z\!KM)V&
M=_L/N>C?E!M@Q]F:R&0[7@X)&GJU'O3=N2*60ZFE,O9+C,&=P618Y>-%QWQU
ML 2_U*-U.X(BMP7%ZUJ&?3X2-' P1MDX5;;O]B]Z_XTGJ<YBG&;1&MU'&^32
M#7;!*2J:]?J'31:7X[OC*%KBP93,L8G:_IW\5#W<52_'7.\&Q9&X<%;(0.N&
M[QG]_?A;0ED%"&NLMT!JN]Z6!:ONJ#[<!VEBI5MV3/J-6F\P92D/9R))%PO=
MGN-;%25Z>Q3@:'P28851?@E"_>.T385Q_/>/H((X66@=_8FDPO$);V;0\9+<
M)=U.9NO&QI5"C$O(\N^XH(<"2?U\]E6O^I0DBI=JYQNB.FE;HDK,R+ MM9<)
M6<47"@\#'1("-NB[(5FX&GHCJ3<M*S=F"'!^GO[T*6Y'GH 3"8Q;96V)7%OQ
MK@K52A&.G#C(.<C:A- 9VRC9O/4ZX] #.>I?54+H=>SS#UA%GJ[[J8P9'/<\
M]D/]P^H"N]9!VI7?"O'71\&4IF=.DE'"8';\26R&3-264O;G!:8+Q&14408)
M+C$;.SC'>)E@>V02"?TP(5T)@E;O<]E$.*D!<\3=..O^^3)!A6&:%KP5NJ$\
M3V%+16>1,MJ&2_GVTX]P0<FO-05?U-C<*8#49<=?]-D*]9<@KQ%;$]SWL%4U
M_,4]#"1,0SW5CW*?:VI>WXEY7>QUN$D/*0M367;+P+F''";>81CJ/%;!X<W$
M,34Z.7!75^(,)K1&WC6#TA2U.,MT _ [&%XYQM31SKN%J+1M&X)Q*_N("=RX
MIOA[@RMS="Q)AFU0X55#^G@GA'@8<V'C+R"N=((Q[!8[N]:PW$Q77B!@^:7Q
M'<*"6J5BU+;[Y."](/'86/K"-\3T$K9N^<$\1WIML>IW2N7M:8=M*%D"J0#\
MG(=>:"Q=^16@4Y54\1^Y<YHPPA;&T5+/F)_7" ?P5I19AKGS8$$@,[Y95;KN
M-7L(F:%$:679^+':XL$N:LFFR\$V,XB;PVTISQO^1-GD1\.MUU?8\(%E)5/L
MNBZ!R7_MJ\!@+#&W95 @A3>-:RK:8982E1!;/0 ZCFJW+]HTG&D'3K4LKE//
MK."$*J$I$:,:)+[!PQ"PPSJ5\"-2(BL=B1E8Z%'#0K&M\PFUJ?6-K!S2^A%I
MN5+&W$,:"F\8P A8Z2[2JB7I:JSS^>)<7L0?XMQXU%"3FNI[+<K3P ',OS-T
M@M[Q8[$-ZH:ZC[_[S6SMT#KA/(&<*H\DNICAI:LAXH"=6[Z/,QFIES82*S!=
MJ1"K;PH$X*=3+1H5K>8I4WH]&U3=U3+0XO"+(Y2A)G,6F3TC=@EC/P8Z;, H
MI6(^@"K4)/.6+?P,]A36J%R$QG>M/@FV.3+XS-M2G-'K-[#4KYVJ5V)1O&*Z
M<$#G%U"#@ .Q4Z2AJ>*V*%ZM^58V;T:0;=4\'#E!!U:(.8O2I=Y(%'B6N QP
MSB2!:*9N&BG,F%;T-:IO:9(R<F4AU%;*@@?TZ<Y^6LY+\XU)[1M-%E),%6OY
M/0L8$5+5?H3MOT_\URAV.DP+?NVM"0X5'( 6C>ZB6S R\[-B/N!$DR]'\XY!
MB&JWV4_%4<A"#*$H*(SGZ[&,L;K:. 2S*4I4905!BA30<(NO7CK 0,MY)W28
M.#YC,(2'2J<G@H+)N6>.L0E'3,3)B^GKML;RCS<>OI1CATA!>FOE0 #TJ W]
M)PP%!*%3N3)N,#JSQ'XD>+I^:X"#3F#Z'G/F4U4C<4TNL6B]T-&5H+"/CMKB
MI B<#H3(G!#)6JK3WCE@BPV/0(33R--EY6J4F5$M^=LD(2%%6=D2( [F1]I^
MI6,=!9D0JNBPZ.# N+-=5B]ZJ,#_8_]1A[,O?P%^;'\!18Y_ 7=#+[>?-M[\
MXN!]F?^TFDSS1>;3?NZ'Y@\O! ?>+[].WA8=@+X;*Q[&K9VI'(S'T,8F\1[
M 4?35!X4&!X'N8S1G'>W)\PF/^^F"_T./I->NH^;?_A:@/7U.3_)R+_$+DV>
M:2)+ 3G:<N(=DH4H=M '9:_^0)Y"N!Q1#$-B!BNOX@ABW&9:6<'DL?N)M296
M5F=56PO#6I8XET+=)UNSQRVZ^J6GX/C)V_EK@6Z$E>:*E:4\/>(EM"T?8JEN
M[!5R UN.0,1&AF,=G&A<R^[W15K-TT03^LH,1>O5'Z(9W;.>N0+T>JN*VGQR
M<&T,/0N$]M0TD4-+DF15CJSJ&3V >.X) 3F,.KP8-9G* @@BE^1[P5]+E(W?
M)B:Z6WC7Z53$93%<3?NL&2GD3=-,553(GP5(Z@_4;/?5?=%TKFDDFD:&<"E(
M5K68$R24[[_QH8I^E1+XE7_8J5-L(#;>NE!2C5D&RP[30Q_@M:'%&K 7\XH6
MSD8@SXP74E"RI$_-504B%27YF4Q$IG#&>8-6@CYC7B>0P)AV3->^L->JO M.
MSQ$\ZBUNT60.,]WZY4PWX.35,H<,%6Q^[:<:QO4_BJ4RZ!Q>R3E2IDY6^M2R
M)Q(AE2C68&9SM1SE^N,O8+,Q_:)/ZI,]\46?>$-TN>#Y8J6B'K6IS>&%ISX_
M8"SX W];S*D98?UF<Y=>KGN _F=KY^ARIQL,W])Z4/QI[?+N(B0!(KRK<;&<
M983'[TP:D\(2;V%M;C03CA '2J4;D0F/_@?JX9C !(4!;TV+769X+ D7=RU"
MTJ&MM TF6>$D+0%+P\./W#>3&8G(M7JVY)AD&UH3H+CI.Z=9/X6I$#F SVC5
MZY"P;*TS)4U3<+.?L5.58=LCWV+&QMU<@5.?TT9I)8=YB:=/%(Q)T'+%P9G5
MWWPPV3(ZUSA*H'E,7V>8)/&K)&JS@%H:FE(B94?N0@-W(45KH05/G=.FQX!G
M4\)J6;=MJ;+>B(Y\EORE;1N?+%AEFOQ9EE#5E(<6V!07\04;MR255@BS+MO2
MF6G,5,"6)JCJ!<VF/=>:>R][U0S2K!D"!1($A@KVZ+"<\& 1<O)*3S#NE8G-
M.CA4CAR*(0%MXWEI>9 _L:RLA>=B?B7 <08MQY LR49RRQ9$?:@4)/*=EI>U
M8Z222]=2-"Q@JF%Y^)H)7J#@!--RBD?\M.@)HF(9&^Z$NT0&P"6!31"HO=T&
M!=7\2)[^"#[HD7@[X&MY5J=5,%T[-LE6A"*QX7YIQS2:Q$&.1([HFQ]^3I=3
M&^8RZ)ZNHW'P@9(BJW-]C!@O[(*H*RO4#Y6QVEJ)RB,HW5 <NF(=\MP0)1P)
MVM),-QNS.;'/I3>Y$ A-7?>U B79<Q7TS[AIU3H&BZXY"?BF:6NPM*4$IJG@
MJ(QY:UOXI\<.<N]@N JIH^U*=I-C\M"7H(R.!YWVA_D5>BNKN7>74AL6;6PI
M6H,2EI)L",:L%\I$O!=]$S;+Q!R9@63#(ZG42RA3F5_)4X S].D4Z'"^6,'N
M&[A+@SJ5=O?N,#&X<PJ&I7>BS=_:1HW#QNVUV9=V9NFSZ.6K4(/'79C?8Y P
M0XZS^J/-O6."D.JG1_PV;@,XHX;+:M&Y]]8F %=6<) Q8(T=E]NQ(&<N+U(Q
MI*B^.,.WM/NZEBB2I[>K/B?I81H;2M2:.#Q5ZP!#U;"CEWT!L\W2@]>K^$BP
M90UU?X);X7Q-E-19OQ:&@THZ.YF,>"#"8L>3C]!%-6WN=@RS+LXZ:-&%-_>,
M2=R@3-Q(-$E\8Y*^]LBDVOAY@'@1 H-\610F0'2,VW!'D!<%+:[\P!N'IKP1
M@4%G)]BW$H<R K'VL+ "$5D^M;.L$:]1&;]51?OTLH>BX?EFZKR*6[A-C<M%
MNF01TOUPU(-J:A\T37E5^.2Q#>*$07]4?_</WYS*=#]3FOW6K]/9O&32\-!;
M_)EL.<K._K/V*=X=6YQ63!,^<^_JE$2RF$,B.@ZM&9(POF ICCR%K/O'MD5;
M!HN;;)\4LH<C*77K9.Z]LF C:ZX58C4/HE1C((<K*J?M'^(9@;V2-C:A0/M%
MR<Z%MA>DU#.7G'7BJ(-&5I,K]@W,QQ3J3V)HE?;US12'NRB<"6/=B7$>;VVZ
ME=CW>62^;@. "$P0KT2@:'/MG=(HR   H\''7=+(I&T#]\X&5B*VT*!CI@$'
MH]0-==C\N.$)@QGNKH)+J.W8A/I9=<-/)U]>U<RA R])/9^VK^,>WER5_[P=
M/]I)?6AZ1>^GDGS^_F>1]+A1JK3RM>^K6>COUB\T-*9G;U7?-L;O#>\6_@5<
M\7Z$()V+?>K9)CY]NZEZN_=?VC?XZ?C+S\Z3A; _<^__D*#]ZC7_$_ZG[_V_
M[PR-V1G'>XZW='\!J:2K?P%OEI,+?SW]!3C&WX/?:B_^WCEMD/ZS89Y,^'^<
MR/^5OJ,S5=SME%YS37YZ\C?(JLV46Y%4'QC2/(5C>S_NT="89X[@_^QM>)M^
M>'_XLS?HYY_ RA=QMA23ZFD&N@PXS?;. _K#\\BRDT37SL^G%ZSWN;/M-G;D
M8$5ZMG)\#NVT[T#2 "4ITZW;K+4]5&V59U:9V!.$B0-<8!A;UW"237*AWWCN
MN^E\OY-"D7]\MWZ_3/Q>ADL84PG<DDZQF,[LC->[OI(FBEF);'_CCCGD6"G7
MKUO-# <O<C />B>=O-=?K/;"T/_J0,15WE+K2W+"G!)0/]2^>\$>5LFM;A X
MS/P- \:#NY'R+3-$CI$X8OY 2(A_:T52-Q<.F6=*;ZZ!J]4+60TX(E[^(,NC
MKWJSP!34E#E],]RJ[ R/(6&=/:T9:1*0[I!F?;L@.2#X;KS?5*J]73 L^'W;
M/>/#]#46A%>_K9*$\'$QV-)O<ZI=X.-5DZ4\E]>+74?W#$&6)D+?T#:- [P2
M&WX4GI<[-T'R,S=QK$@PCQ64__Z(0UG/)1;'JG5'D)J:W(6.;VOJ_.OZ"K4U
MV[.D4;C8-:DZY;)!4GETK\I#(&I[5#5L[:V"ATM6-]=>"72+P:1NN?XLT.LJ
ML01*ZVY4 D&?K.L)@Q</KI8MLXHZ)^H*Y';6V6F7X?H$2V,PLSL[[0L[Q%K'
MG%UM(QX_(GAAKHU@1X@I.^QA \3\(.OZ48:AUB4=>CH"66LI#E?),\)]8GVI
M4OU6/HE=B;;K&Q"-*^@.#"C5[>F1X%*8'+B)_F2,D&V3H4/44'-Z7"]?Z.M$
MJ8E_/L@D3Z)_NV) *LF/+';2(>\6IF/<3EWS&+FN56AMA6)8JVI#AQ*5W\<P
M$0GWZ@LGN,//:EX(\6&P^@!<<DG4WMHIW<JNJM9[2<P.S5DU,X3XVBV_K($H
M+4!MW>4]G3JWE LN;D28VU_E.)(UEW70S5&;J BFN,3QOS6?,/DL-,]-I(QN
MJ@+PH%?F;*0YI';UB=IWVF/=4%;NH4ST[HQT6M*UQ:[89]Y#'BM>W;[O]QU+
M_JU8%+:I%\L_+MGI5V$*CJ2V:_8%-K5A8LU;Z@TSREMPCS 0K+K$4'3]N#5)
MQJ+X:,1#-5(C>/17[4BX-(;K+\Q"YO2@L)V>W]2))EX>%,^L1,3+U26T.*=A
M(D:1B!A6W8@IWM]CZ7'OVYB:3S)IJF$^**GY>4[40AA3I$ZYBP4."9)KRX?W
MY,R342JGCP)&F \O4VG[@JXW!"75=UC: GEA="JIA1E-VLP6!0&<RFV_RO\"
MCEW*%$>B*DI:*\9H'X*<NJ$2G5123&2GRV. ^K<.Z>PA^BO#QC@LU %/09)?
MP*5Y=+!DANQXY0Q09YQ46RN"9<]S>Q9?AW:]H<,J#*0PO+D6N%%D*JW-*:JH
M=5Y/()PK#&MQ%\"^__SK+!H"?#9&Z=<(X:!#[L!W0-I:!86>/E#MAX6="],4
ML'F@6E&\&]0;&6SO6PGMM;K[GJX]^R!X_MC3#@QM,\;;=1D46L+57L!?]E8M
M:,M<I7<2OI GT8/CT4&B,%/2%&JQ,P4>XA 2CRA.9ONXYM.<4,*%288B95]Z
MN%?0T2P[2RTH4(,^4W_4 *A4@WCQX/ ] 5W%5AE+FX4\(F!S9]Z;H%;ELUZA
M(L?7O$")A73.FOS*HF\UW9'6P=)]!747;08+&4(RUX&%U8 MK3SCK9%=-!AY
M)?)4>;ZWF^>B(XJ9AZ9[RCQ)2)I\!)Y@ Q2<. @(CS5+BM?/4NNDD9!<2Z7#
M1$C ^ZC>^ZVD*DR.ZXHF7>S9L7Y-8S-@#9,X!-(7P81^AT%4R)Y-A6R%(2HJ
M&3:/Y!\5,JF7<XVXJOCM*)(W$E-[,H*L36W,)KQ>6>]<0"3Q^%)Q;X(E@ 7"
MD'*4P#A]%(K $!N5:A_5[_/M7H'6Q4*[2+IECO1M\=(KE^]$U$M]P_CG1=6K
MM[MQ;K0/O($"3Y:GWE+3IG=T_;!*FD_J/*V?/E*A2V*;S4BN!5!K-J\&Q7RH
M.?NG2S3B&SG2%DT?FFC=R[9=>LKS;O>3AX57I:>]@?#YT<O%[>A_1\GW_RW0
M__7WS_]Z(-'_:Q#KDAF;=W66?'$O0C@ER%V@D$^\-<C'O(/,,J@0$>*V7+>(
M]!&MM"#V=14JT6-Y"_+\H#>T<Y(44./K+BJLEQGHJ\/O''3:)K<1E&MY()#Z
M@=7PI=8\9M2^A.NKRXQHO8]U7!S%A7&YH><*,&LZ/O(\D0,WZ) 6FE&MS*D0
MYNPYA,0"[G<\."!GQ YJ/N9TI+'S5;#F+$JUP3 )^;A)^H1M9E*+/W%*'Q/)
MB&@E#7P9I7B=Y6J0J_YA]#T5Y]'4//E]1?;&^R]$WV1.K7XX7@_/GP=G]1S*
M!1MH2/R!FCO\^26"%T#6!PULB@LB C!X>)2Q)3H09#'5H1=-C.C,D8E68.MX
M:!0L.BO1)C#$.6=6.(_'W$^G9-%HXF-QDI\ 4@4Z%/NUG_\,:6YAW)"E(B.'
M6,4@*A12.$OX OX?/0Q-#M.1KI:SFH)&4Q==-)LM7]@5-B):ZAKDC)A?/;BM
M*&S54?^NMO\5-%I'7S=S*L;Q<O?*J="MI"_1>"N\0M9,/CG%MC]!GC^NJ Q
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M=Y[(T^-#*^0E?$_4GH&=#*QLCM9S&J@B.@ 1&(/N)G.GR;RFR8%,_.QNR]Y
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M?'"UP-]7+/,^:C_W8>ZH=<35%4CC(,O1_T/[&:E$WNG[>@<M(FN^$_/NY5]
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M1*#VE;R%;D'4+@I]VLBAP_'K0Y2='DXM1TA4:H,?&/]8?YAYV'@#.Z7(D[A
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M0>4/5-L=P@HB%&143[:1B\I34PD+9[U69&,!15:J%:QF_'!C'$3,>D\OKU8
M>CJ0TQ"5U![+ B5//PX5&"<,F#S .+<!&.AC'?\3M;3:[L!;,E&B.%865RI2
MLR6X[TV"O UD#MH!88C?6G':?BE!VE5/1QJ[U@+=Y'I&_" 2ROR32NH?FYV%
M68KJLW8S3Q?3:?K"IQ!K94X@V@VM  "^GI!L#F#0PQL6TE<^EZF895R>BM:*
M+[L5CDZF3:5U&I>DM0TCD\)"JS*FR<$SI9GM<^=]B" JX*+8JSU+LN2U,V!!
M2IR6Y4A75D#B[9@MQ6K)VG\OX3)T@602U3Y^ND@5PSNPD=.S%IZ 0CGD'.Q4
MS:ZKKZ3<8:3IHZG3>2UZ+$:UI4(TIE[KB<BPO*G:\<+6MG[HD@RH6STB&S>I
M_7JBY +CU^),;^%Q2V&+,^.^K;JL[V<MG7D(Q0K8*4+EI7#WE*H&1CM\B8,*
MX+5.8.:FRZ1+1"^^UVUR-?13\1[?VV[G4%<W[9UV<HP/86J>A?EXQY=C(6T"
M9(V=\X(G?SKU,WTVZ6!0M**WUH_V);3%,@^]7<>8D/^@J,XKDR< .)H7L?>B
MK44SH,E&BHW#(JAL8;681:$S%)4A,7/@LT&B;^'C<W)3D\IL)CCGK6$S_&"[
MI9_E359U=L#?C-Y=4:IW*817 ]WCJRCXV#;.HV7T7?_F4<SC&F>1D=!#(B.B
M&-< 0N[RM;^5/%STH*]3H?3$W[OX<V)XU[3R77@(F8TE7K3];$I.9$R:YY9)
M!MIP1P/+O;#51;5.'8OW5KO:@%.H+>2J2IU.&G^!FY7<A@^TRDMD*EIDF5BC
MX%Z9!TK["5+YA-'8X=:/2,+6^X0V.T]Z,YB5/9!T6J!F^J>T/L*UPZG+.<_<
M "M[QUN/-%-^QLR9P IK+"L\OH8"+B]I@V]IEB Q/N%W";=MNQ16'"X?C<>T
M:D\$"39; A=9?$^'085>E\A,Z9V-9MZ*"%Y?I84GK@$\O16#52IL&5]!-'R,
M(X3@4%E1B][8\6V#7LS[R"#BO=AL6RKT0J!AIMOYX\[0#O( NL\S4 TAZ,^8
MLZPLNF-T-A5$'U)D=(G!,E;G<Y.2-Y65.+;T3;5/YC@"0&@5M JR9G?P6)V=
MAX5B7JAZH<D*K+ 78!V:/)/1YZYZGH(282<VL[%A]L/XT)KE].D><QF15$)0
M%N9PAMS6J>Y0Z>)K)FRAF8O]_*%P3%N71(RN_*(S<-[WY,H0LKCQTMQ1WMC@
M2E9)4R-HR(/1C,Y"T0DSR&GM\T].R2Q)H:V9HJOPSIE98:>?&D5J)I-S[^7]
M0J"%(J%6<L9D_ '-D\F+"T<P7<J3-%RK;H(:*TK&.X]1'@L^-EV36 5&KK[S
MQ1/1E[J!^.KBDQ!T^2B75T_=Y7"-PA<):W4N$96EO1JZX^RV=@4_E<W34M<K
MS,X+^FTMIM%5+)Q0W-=CT\J#KLN*4<O@X&>!4ZF..YW_P"V^%NM]/(VS>3+;
MX<G!&G>OTPW'[94=C$5B:&.'9JKI6<.RNY;KFM"[CKJ_XWJ?]MET_4V7]0'R
M&99R,$[IQ/<0]];VB8BJ6?)IYV-ATLM-T;_!D09P2-J'CHS#D?^T7(':2B;E
M//'\%O:N7UAF?EH.,@P8?-UQ_N,A=-GCK5:]U/)G_$,,3GO>B]R?;<V$=X;4
M@<Z?YQ7>?#5J,U\$S3<G?ARLMWY0^K2C?&MYB?C=N?-Y\DOC^1KO)X695Y(_
M%*+K=N?O7QTD 1(6P=<=?^%$R!_W1*MTOVU]M*8>B3&:?:/[Z,P\%E/_KK_C
MRQE]2&^UWG0P.=>5]2^W2]"G"LWKBE_-CV$_.W9^'[MN>%WD:9;;OB5^Q/F/
M1L%W,C +KZ<0;.$1X7A"BHDAN7E%O/MB2-" VR'D_DYD9FIB^B[(S"!C(F7B
M\*@IZR^<(VTTXY1;6;*$NL2/)9UOL@85F'4"(<(O'Y]<0#:0,WQEALKH]EX)
M4/:EMH 79_?BZ)__S]\=9N;_M4$S4;H\$/0!^A=NS/WT=&>UH-?*E[.H_X.%
MD7<E"DQJ'>NHI;%YY]Z4,4ECME>XTP"N!-'*M*D!Q1@Z4MJPG;C)"L!E:^3!
M;:.Y^V&A9KQ_3J]JF:?'1H[EI.4#X-_4M0H#8.,8WPAK'QG&VN!<S;- [UA*
M\(^)31G22S&V4.8,^9U5'7T76@56C06[^G"Q%W1_DIPS$EHYQJ%_NKX&?]:]
MQ$"VZ=5EV0*KB[[!0K^0 ].M/#+3+&M)FV*L+0P;/.6O[9O$.&$+:A4L" DE
M<OH,7VP+E2ZDB2H#];#W,CA32C*,#I"3Z_"Z?7TP8:NU(PI(9,YZ%:D*HM=N
MW[LN3!*<:C]MK_:O!BX08[56@N/W&3^O)4W-QV@QC!OP'^UKMH@BXSMG/F#[
MZJ7WLUT#32WQ!WT8![:,>0KCB08KLAT+]#]@8>(5,,"-TI3AUE19 8@!V.D$
M,?'1)=/ H\--%&DI(A;,]MW0=&V"ZY"4+M<"E*LO;#Z$9K,9^I6%+ *U/O;O
M_<ZL"+^#*ZR_(6;J0$-\3;V5]1L;V:TYYL<8A 'NB<-?*6,PL64ZH:28DR2X
MX6U[GJN#2QB";(315_)+%LX*^  KX?B6'*'&INQ,NB&?,I*>HO3)YA[[HHY+
M$^O_WJ-D__LH>I1BP]Q-0Z.9/+-!F)[M"Y8(S!J59F&TF_9 0T3@9)WGV:3N
M "S"?7]#<R_NS[S[Z_0=_4+:B>\K>^"/AEOZ7&@OH;=YQU,3^<X$1'NO\LSQ
MJ--4A_"K\68.TJ,E_N;15I!A18_2DID.)@_.0ONLZAG#0C*)\GGYK"BXT/,,
ME*_A8<NI%V. +>"XBDQI4.=*OIO_??]Y:SSC_'"@2%35<,G(_GM'4>A+E $;
M!0P6[)#8?!Y-3^PB#K7MI/;P_) #"HSIV@CFN40:,&J!W>&]].T/_(5;?O;[
MK1J,],S^2?R46K[#Q+>+&$OH_Z4]TQ,K="!'C<##?L;%:5UD(/F*9) 4SIY+
M3^6Q87!C(>9?O0*X$,HH&=U?9Q=8ZE'K4 ELCY'*Z 8 ])H46'\2BQ77<UN(
MUKU&MXCN6?8?0-G5M6:MQ=$.D'8OZQ5*;M]-\S X8>F"Z.ISC-JOTHVEZ#VM
M*>4FQL 4/.XU4EZ$(#]'[$4\6/-><ZE LYC_YE[CGH%9IGV#5JOMZ9G8)'^D
M[*9[2^O)7C&"]3L<&IS%[QFD'A>+:)*.E&D#:GFG<[NH106"(II3K=<D%K%D
MC\C$X 7..Y>%N%;P7+'?L$Z5(JN1*EFI[#6BHXXO0A0& =M_ZS_Q\08S!RO>
M#E%16?047O04\>81M.X)*C\R+'$3SQR*^X5+ZXD/37_A) ->0Q+/B6/HLQ,5
M*NAPT9D6G%-\=U(2S@'Q,\6S2C:V@)EFN#6Z9-]':^6K@$#8.BU$S+;I\4-V
M3Z5%]V52I;5_=$^FREB="Z'JXUV:KZ.=^&CV4',"6UA2],"I>^ZF'6]3G%5&
M7D)7#O@<S1@$Z=!;2J/(YP>OC *9TU(CURN2@@M0(5;=@.%O>K/@J!_'\J8^
M<K2_-$*IM,-?,*XZUHP/=5::!]8H!;L'G"J\W1<$F<#*@9Z2G^L\UO<RWF\(
M6(^%1;/#. HA1FSH"6CQ^4K)DB*J[.BQ@&YFBE7&HF15@)'J(8_9RA:6-UDK
M!%Z2.<3F*TV1G"-?=RK, -N[([-$S\%4CU49(7K$4@9&U>&CO>6N?JCOL6)D
M4[4#G,6Z#=TQ7IF</W*H7-O-I]A*H4L\8(V/#]7TFP;Q3.3A'P[2\>8ZG(0;
M0M9-XS;2IS/H$63IBB#Q,ND8-_H0\SG8#'XS6 \A;W<Y=BV4G3X)XZHGM'J3
M:-GI3)O\>YQR48)/U[!>!F5E>UCZ^FZ,I2RMZ)\Z24=3+D6U!I1!3AOCG*YY
M44K/IJR)">I72:1R/>XS'/^&ZDD1D1J-@BG;Y&RLC@@P/ %>I\<$R2N]] NF
M%DTA HHO+R(KL-JR5E7IF,QYR,'6.OA.^7[[6?C*M8.37I#+?\XY&PO$Y^:;
M(U<_E<9AH@XJBD"WF0O1L3&YTZG=/1#*&K>VUF\<Y^(>S_)![-DU_@MG->.B
M2C7) %NR2>?\HR'Q&P^5D9#2+/ASQZD/O*)S% L.7(.WE#+3;J_K??XS\E5,
MAT6I%?=VH+$<O9T&!!#^B-.4BR(" S82G)VI(26TOF.E6/,A?!J8EZ0Y1-0W
MY9!.(TC=)#O42]R5&9RR/<^%D?D IK^-0^LKTEEO<8X>DI+-K*1%9L>B]%&-
M#?7]CK5PZN#-6')=6Q5B'HAZ/)\8MP]4\,O8U9W"5S?TMM/HT'K4_6K6F/ML
MB'Q.AFRD=%31.DB)&K(*_:8.Z6SKJF;^";IH>2.H NCP&JH ?=D:9&EXF[*O
MAL=CP-_V?EB:"&ZS(V*Y6&.DL5:8_+XE^<[3H&5-=H'90WW@-;N\#G&;KM:&
M'G2YVKN;=1[(5&,0:K9>R?Z:566T@OL5%7Y.7B##<G]?K2;V& .8@TG:(IMY
M/3_O5.5-C_6>%2':%(M RV:-_AL-!CL41*Z\O3?GD\SRK$SQ3[?[VCH[SHYF
M!?-4E:@:.O,H]'2OVG-F6O%_@B5OLE_RJ66H7]K&GZ!OGX?B)!A%.@RW+,BQ
MC8K?'J+&^WTAK!=8TI#8F9E*XX\?0O'DGPJ;)TO<5>%O5 4@<Y>4()",&U)V
MKEK%__9S"+&O$S0#"V[M#@E6S;1OHR.X0E_I'&1^LJ1=M),OZ+Y*+8H^5\ZM
MD8.TV3@ZN)@"7H;[51N@G$=Q9ZV.$*!R! *@4$I7R$6ST+,['QW3<32Q_%17
M:5I9[4)A?NF$]]NR.2YT*9"A2 YGD2%#82P]<)[VKF425[F@:%2/'F=V6!0.
M&PZ&*2U%: PG A\[3#7\JEO77"W8:/\&3*OJ_ZFI0\*QT2Z-5?=LF^Y#%4W'
MV#5-G4]F*<_Q4[SK0>]8G>T+_[Q:]VE=7A0&KXT'U/IW'AJ\^A29DC&!,OU@
MNKS5'-)-8U/1;,N,B;R=%54H98E14BC\@'71$1>QK6GG(.Z,Q>KV$RY"':82
MKO Y81\J62$A;70;#@S+,&P<KXS<K-U.)0PL[L:@'S&C'FD"+YYJ*^$ABEA[
M\HTF$9LN'&U6FJUOB91G@P.IB4Z!?:V* 38/%B#F?=]0WYVJ8O+4=\2";RYA
M(<2-(\K\Q+.#J,:QQ+T2L-O5],]2Z(1@U7%?V[!2S:,C?MJ6.->=8@)AC4RA
MO/F(0GVHS!;0=[0 C!)'+(B][,LVN64W7&EUH,U,TU.RU<$V#?4/BR/USY&W
MXT.,">(E;1! 06)=LR $ZX@X@,WD(KZ\;QG8&;28JA'-,$49FC3A<-1:-9HE
M;38?8Z9TGI2_);MRRS5I?R+1:8T0]T]6Z7.O6*#(F0C]%>W!K4PJW@5@C=4"
MN/W2\SD9?OZP>G6W@^NQG H_#T;3=11H1VQ*L&Z''095_O[SI6A C%5,^/JF
MY2;+IM$)@XWXY;"^)TW.I?B3N5&P3DDND):I@8&&NS2582K2[1 93G$!L2YI
M) 1N\*,*]11^]^92V@8K0IL2?5*FMIR63-GBEAX?,D5T%;05/#U]* _9O6KI
M3I<',X@GRO(U Z2M])69/?1=YPA_>6\UN0H*K;.K[EDJ.-ET4B**\1TYLH!=
M;DO:[MM_S)%R3WX092QY\%%8_6K-T%> C\ +HOB5D(QW"+F"S,YESF1[0L:D
MP:)8/NH@<5Z=FX<B\8XACQ8HE-/%6P^)+5RFAA==)90L/(] R2#-'=H4I%A]
M1=^.'\9C228&U.AZZ9G6MIAJ@G8G,&J+D;U&Q79%9.U.X,)WUNIMCU$(3^14
M0-O+[Q?H%EDS12EF&7 ]1*PP(FE*Z&6R+/JZ4>0^.+*>EC4,%N*.B.5A44RB
M^2")8&'Z[T[ZHE[X4A0U21A<C72JR(=W.E8Y%GW4A>FNV)G6"3<L.]G/2R5\
M4/^5"<VR0/3/Q3VRA8VS+-XF6HY8^,/ECF""2?!LYA7)V2<R9LKISA7TE_4#
M3=.DM,CR8WRJFH3WC#G8Z]C/^' :MXM,\R(Z[=H&8:N!K#9[WXSO@3V?:Q(Z
M0CB Y MD@<;N'ATMZ'/%2V,X32,;U\3&;!N+FI"9J%T"=[I]!P&Q3%X\SJ C
M1ZF>H;]P1!'AS]Y=[6U%JAP-DX 7E"K:=2WE.@:E.*:_<%6E?0=^Q4T\\HEG
MGA0".M#\'95:Q=@H4SWX9,44"S$L@SF!1+?@J*>: <=N> =L(Q'^G$@0-/*@
M"3K@$?6L4&7-[GULTYE7)K9,V+/T8V'>WX8G"WH@^YKY3>^4 FN5II24HIFG
MHXT6N<ZH2&I]?$W])Z'N'+!B2,RI[\8FCE@V_%JC;4056T]>+%Y\I$N,STSY
MDTU16S=3HG6P=,,6<7W5;)*?\JK*$-]R=?H@8Q.K$^]LK_C*U%@A'@#OF)C'
M\WTNMS6U,/%13IY(5^ZX,6,V$]=4>DGNJ]$K2J]$:8V^KHO0*%;?-(/^_"E<
MSEV)&#RS3;7+I_8M1H>FUDZ +WM1_M.]IA"1@+.I7%,!^7B'H9*V1A-B[@)E
MC5]8+YYP*( ''\P*>9*W/13DD6<!HFK94J<N[C-GS9>1JU5@>!,C8539VC(X
MP]AFJZ CW-^%HV=4#C\)B6'3HH$9"'3JH<Z=\&GD@7MZ]]IQ29B=P0YU6N[
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MUNL]D2)V-QT#',)'<D843Q'L5^3&?N:R7S+Z81O%.2/].L=R^<FH%<[_'<H
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MLEUYSD[3D",;L**:GXHR6RMOLCQ>):3ZK!\K%\[.7NE=0S"BH:G_B[HN_U%
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M1(Q-@Q2^7H]GK;+68>]0P!DWBB+CIKM^/A:+Q45=Y>7H^&X8C"X",-IPP<G
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M0B-)E7)'VGA'84>B%$IG Y_,&'>D @=P= 3,56^21[&"1?^'!&;X#X'A_YO
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MR+&7F,9TX-T=T5;LW3]6\IT3):QO#(_:GY0__AVC/^OS*X"WUR.JBE$\I/!
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MJ\%Z"+C8'R?B;;RT9$ZZ67"8Y.APYVLRF8NMUIRL#QV&146F9+I7B>+7C(L
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MP9T(19:9JFT KF@5+,BC<D2-A8<L*Q$DGC68?FT05?H1'NB0O.>JQ:3<Q\D
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M:TPN5VGK==VOED.%%*+9F!Q#0V%+CZA>C6!+P0IS':RG<&G>4$9S&(+03%I
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M=C[*C':6L(9/IJR>UPC'TEVA!0T=TXN8U5PB'J7U%!0P6,FE^[5VM=CEQ?Y
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MAT;OA&DL<&5*9%>Z1W;E,6$?A:J&+5V43?K4,R>Y%-<_P/M1.@>@8"P>"_N
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M4N/JKYAR*+G\F'] C":A ![U'C[A>XZMV%ZT^J]+_D,<W[$NZ13%K,]^<2-
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MU"YE:KP>A7]I=OZN'%.O+OS[]LHFN\T9EP>?I3DZY-#3";N< ]AJE7_3__\
MC<UNYKMZR6X7YV.>RG7.L]5I;&LF^.ELK1:PO?]G!T>M1<!-<'!'=V;M<B6O
MS@=^Z^9)65E-AD*2_N7=Y5H;OW06;DV.D=[4=)7O0E9RM"G'$G7I =)&*6Z_
M5V)MZA25'+J6;Z_*4I&P;SH'%",*=-?:;;4)I-=R;1)..#:U;,"=9<'3JXT\
M]O0MN-PB*4<D6E9>];]*V1D;9VK1C)>_*F#E2J>1)PNLWJK\ $34D0B!>SL(
M><G[K3%S&[FIY%+B,5'M:HX3"_7M":*[$3HOX]I^"FF9,41F)T%&AC_&"+>7
M[6(PH#?H3'1T%2HSL$G-1:FU5@1=1ELR8E':1H\,&*W(S"[C7T, "XSS2[A6
M69M_7'1EB;R IJHE"J"?/\25S.<<4MDO)26ZFIIT+]3T=;<$3;%;?MJNH-B3
MZ(K6$)I0*EO8)X093F2@C<\9!S%5,/]^GXWZ7:$B,";LDXCDQQZ)R)3$S[W:
M!S>K;12Y07/V=\Q;?^_-4^OV!]+)X!R+;#]*]:L7)<14L.GTK>M,5A&MF/-_
M!B95\#ZV<L=$>R#Y,2 ;]&.D#(B\_U:!L7IP,['V4SAJ,R"X.5$DA7(]8C>N
MBZ')?LYCBB).=W.VIF$T6$>1J,B5PG:)KJ&^DCQR;"$W7R2TFG+4WE9?"*]1
MIM& T>7T\O!F=Q73O!W1V@.3FE9"[D2X'@'#9+<^0?*$/R5^MX0W5\3U>3I7
MDWR%(:!\+G,TN>R7[/H4VWT\EL342%),BN.2AIDLQ60U/KNK:%\Y U1^Z:&"
MY]AZ]:=,@\R*S?GYF<GP<@4K%M^ JF$A51'4\OI\.\S1-45^E_Y2M "1HRZ[
MAS18H_\=*@*Y&]/Q\9C@_*&E>0Z;2*\QQT$Z#;ME#3%BR*[M;,IX:QW^0OZ*
M<B('3IO&5/6B2;P6 3V2ROK$C6RTL03G)44@BE5% $'L%Q\.[S5XR7& 7A]B
M5(MIN9;8)X$P5PMQ"HCEKSZZE%C34F5:OIP&$4+FAQ)G=#H/ R',41TAYB1/
M?&TLFQ9'60''6!%.GH[&Z[+F$XR;][33Q[.([9@14E6#:"T9$YJZ5,C]MB;1
MKA^=ZKNX#A%IQOL:I.0D7 H5MI+2_ .2>^8.*G1I"9*O[P>B&\<C#&QLYV><
M31,1FQ)@Z=\I6^4$X'_"-6Q;.ZWJ%QD4#4#%1R=F\:[1V!T(C0:!4/0-TV*E
M 2E"("16.S2I:)3T7?<69X:0W,#_V->'^;9[6 LURDB=VS/&DM'X,F'>J]<<
M[267W>6VA!?[E#2B9K04/15_7)*='SQ-XAHE2T2^$/WZ@CCPT;\Q%J^JR8XB
MY-=%W2UO"1KB(HM"K? ,ME&![2?4JX;&AA+F+:%5J;61$Y/!4C3X<$MT1]I.
MB[S-XF05ZFVU7 -MBT4)\J'Z58T/C7NU]X?5C<<M&\LOF.M[ ^[%:ZNNHQ2T
M\OC;PM(8"5Y%YHLQ1$@<3>*&L5_7Z)OI.G1-<Z5#;9IU-O^&F4;5\L\!49YE
M>KX+;4_/6478;]QIQ8UV7E-3S!TTI(W&!<MRZU3U_>1F_S9$ELW<'#J5MT -
M./</P.N)^TI,$3<&^.D_,\GP_BO7ODT^IFH29!EJO+*.YU)X+,^..N\^CJ:K
MB;+W$6/[J^NP'7W[[PECO\^];GOIPLR'EE=*F8[:E)E7B[!TO$@1D+S88W(V
M7Y$*P*:F6Z@>;^_!009K@/H\B?@YH0P%0EWWQ: X/AF]IA01 5C+P0_.7(])
MXB0>F#_/368/.8^F='X(R![55O5")EY<V)OJI7V*,+/5NY'?F1ZUF>UBS'8B
MPB%TC=2[\T(^P8YK*]2VA@ZTG+ON@,;<UHYO?.8ZW9LZOQYK>[C=%7M/%A>M
M"08M^7#UO<*$3)F]J8M'_'+)DS1@2_1C\0 4//J"U'A[8=HPR== 1ESY8$JD
M@.'MX^MT\<FN-03^32^&7.,Q"5YX%_CIS.ARGH/&9\/!\5FKQZ=V=1H[MYW@
M:-7C9Y?IIN%!P1N:QZ*SQGL(BM9C(N(KC'YU62L0C,6G58*^M+,2U?'4:=KB
M(TB4;S379FKGS]7@\/=0]6U >0RO ?:!LD"IDY_73!9W3?3L2;G8??-*^][I
M*XR2 -/>I.KQL6T.,U4<5P<>YQ5=M.,)IA[/7_!3(O:]O=U6;7?E_AZA^KEM
MO>!]TTJG-S@U>Z8,P;EZY;1BYW'5"V[3%YGQ=\6MS):8"_CA;8@3H=?,"6_-
M(^%<Z"/QF4V3GH_@XN3ET='Y@8>;QM7OT\=9;RMFO;%*_AE7:1_BJ*X+9=7+
M'J>1K;;?F5-N)7UT?U>;<6HA4/&T-%)WOT;F\[.8WL@I.0G)%!N+PB #&13:
M3W:X@)8/B+ \;(;;<@AJ]PJ&7)&UG=]N6*8&31)&AO*L@?7O=6^Y8.87(WPD
M)AQP!EM.K>0$D(C.6BTVY)9BA>]R'2]Y+#5Q-#XR6.F:))X&PC9.F)N/3_.?
M@_'UR!87=&2!PVN"H.CB87: K3?18ABJY0RF34'N8LYV&*AN=3,[XJLN;=J3
M8V!\X4RY/6GH%Y'6)SKJ.%'W3H(^OE0Z%B A7;WTU,A";98ZB75-<V-N"2BJ
M5@S7:&-0B+?; LCB^PH349;,A,AE/J@H20F%E*%QI&E:?M4,-?%TP@3P<$AA
MLN;%_7K@"<,;6K_XFSZ('."A*G(^M?8K:?CYH!\@ ][U=-%+6-(,E>9ET4+H
M,SXDX]DAH_&>"(31DNDNXHK10. :2?T5LZN@?E!CP5:!X<LV,KW7\QLAEGW"
MDX&2Q"TX( 3[O/)SH^@,,D*S!4=V;V*&1F;!M$%,3:&F,__%3'UKTF!!#HA
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MO!.D!E1L"P\G0W6;,FXRPG-4/\1>C?VM_:/9@EAU7U$YH82V-Z[<0$+1(;)
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M,SC4N?6Y48Q)U3.YJRG$;/"\CU%U9^$FM"(AWOXL/:#!J\>P2="HKGO>7_5
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M5J)Q6T!FR>]86(Y$+;4>Q^]@015T!J@[!<"^VA,#BSD?O?9<?1AA'YE,]&Q
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M:[ZPZWS^>;#N%U7!MF$_)@?-I:+'3@T?CC#TO=\JL661%\?KD="[E?$[3[S
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M(":6*[RGI*2 RUU9;V'R/ZH5I0/S$HG;5V=S7(Z*AF;%6P\6)SFER#+R965
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M9-XFJMY>(P(B!G!#=O,W*9Z:&/X] OJ9 ,FBK@WLZ_#;X>(7EO3G?I%FFXX
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MC5JA>7PQPNI6 '?+' [IS=*8^:+.F0,](O$[D+,<CC\!/)50?U(VVD.(E5R
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M'*MA7K<R<G\T#0V.I)&+&0$G#:V%6L5$2BK+#HF8)V3ZJD"XL*E3=LG%]0=
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M=$*H$4E8MV^E6!$#D@JYU'()J%C\[J0EDG6F@'#([W34;2&WF=#"CCE98"A
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MP%?U)K,N5-8YPC" .["TR1<MU)(U6R/[JBM6U%?RQTJD.:43K3*68,20R1@
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MS*3+Y-=;0.V7+QF#@8:##=2L<5ZQPF9'G"]Y*LZ*)T2AI7H5)>M\E4))GO3
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M&;^29?.'G(G7&P\X$W] KU\&*4IIM4(76#RCJ?"WOS9P.*)?!D]EZ7R&9=J
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M*,!&HPEM;-*YI10M-H>X0WM!^A8/74AE6SJ60?.^Y*AQY(((A@Y#T R!!U)
M<"OR+XI@(W1$M$"@"> G.FBDH;/]P&5Q8">]820XLG'XQEZ@Y2R7:E8USW(
M8[R@5J1"8R>J\_+^)7<UPUBSQ1-W-2=%.B4T2TF>3:G%YGTKI". 90ITK:C-
MFQUY,*'1<""A1E#07)$VGG^'5O]3R[]89FFF\VZSS'9\B*)J57ZQ.=?Q=4V.
M90ZA-^CWL579JOH+O"4MI,L%+J\>0!O*LLUI212E"I?/:.^TI=2L.9!FN< 6
M-9;-7+Y9U;KL+VE:.XE^$J"%[G@. ==BED3F\$V_Q"HEB5+A=_$R=\SO4"::
MO'_BT/(_^6H<"?@_L'0@M!4R_*ZE@_Z+XO_%I3-BQ(@.#6O*3(L=WYS5+(_5
M[)'33%#*R:*6QXUL]HLL762;V7RQI.D]1^=+F@@Z^S4L87]/IL/D-2@IQ1:+
M(S7D/PWV?Y'!:LD.9/Q5@SV8 NQ\M(;Q3X/]TV#Q<WYGMG3XS*@C9THU'K#P
M^_:GVH*T)M$\W1SL4'*6+?R>!/CG3/^;.^@A_V\\F4(%Y,PO;*);N=R_L_>M
M==,LO>.1+;^PAV[+_UM[Z#:I8^O\%YZP\5N/USATRUV;=ZO7WY'[M.D[BXP#
M;OR\IX,N1K@BEQ394('.%[5RDLVG:FVASH<*_7J?7P/S[4^=?@GIIPX_A_'0
MU8[A!KDZ^^_O;FNZ:*VTF?382-@ PBC44:DU[AVN9[8-AC0/B( @;-K?,WO8
MGJ4\I[;Y)6VDQ?T=.V\=4LD=,N[#S*I#R8=[H(>9SORW*GS-W%H['&;C.4,'
M.,*.D1_4^.OT-CK'B;7]" <2[VOY+?(4VW8HV\Z;OT[7,<DVG\SFFSO>'4C<
MV?++Q.5&8 NJFD%EVO:%N6;#2 C>#W)PCU]&ZHA/4I%3V38;+1;_-8:?;O_&
MS+7LH5.^J8;HDB-5-7V0%/9W^)_>[#F<*?P?L **S91$NO#_>T/X@W;0N'NP
MI_B7VSG4L>QW.'Z15CN9',[K_%I,M]3H_&_98YN'[M@SHW^S7YSMR*]^LUMG
M*O4[=\]^<9+[)1"LT&HJ:R]()?EWRN#W/TJI-=/!IE.GUL9^5G.#?7,G_\;I
M@P,Z_3I.IYV#!Q(=UO+_ X$=3B;_M;3K@ \E#I^V'-"A\5BQ X=X0./^QWT%
M2\G#/R)L%/ KO7]U6HV[E-76UD,3ROY':!Y.'__]UY],_F3R)Y,_F?S)Y$\F
M?S+YOXI)CY\>PLWFF=&#*H/.;=N[I<G2U.4/OCI _BA&E[U/-_4\NNFYKN=U
MZ]*SJ6O/+MUZ=MG[?-,935V:NG;MIK4W[7\==73W([L=<4S7+CVT]@M.:NK2
MO:EKEZY'=.O6[>B>/8_N=D27KMVZ'ZGUZGGR*;UZ#SQFD+[/8+PO%!AB---*
MY=)IIYX&&RQ4,)0LWSSGX:7+EJ\8>A8:B:8*D]IOO&GZC,7/O/8&$B]>?M?Z
M#7]_?=-[&H<!&NLNW0\<0)/&X8@CC^I^]#%:,]VSJ4NW;AK+(X[L?N21QQUS
M?&=K4_>>1PX\^13]4;WP #U(F?;WWI?.>?B9UX[N,QAZKR]LI@I?#@F&DS<M
M/N;4H8@E,NG&&7>M?ST4+9;;IV_8N.G,LU"#E;"GU,ONGK=D[UM-QW739-"S
M6\^F<YM^_!&;]\L__/>C%[D>A,L3CE]UY8/ S/E7G+7XD94C]-T&+"K8>V6_
M>?#1I&/ZVDO.>Y&9=XM[VG5GP[XARF.M6\25X\Y\.+_LN8GJCA%_2R/I-=>?
M?8GS^B/_:CZYQU:%;5E^R;R5<^<,M:Q]?%PN<JPZ:]G."\>PRP=U_< ]8V>"
M?<CA/&5Z?D7_^/%+U]#>Q]]OW^)(O'[3K7<^6=_]^)HO^5VCWZV-/^O#D]^Y
M9]Z*8&3S>4^M'3;<L: /=]3T<Q%I:O6VA:%P<N)M[^YM:K_(?0?[W:-)W7.9
MP2^]OGSNDZO_.:8T["+N6-_5SM>/FKDH,:'XVOU[[A[S]4VK>C]&W;7CV/7;
MGKSAXT=7WW;]6Z^_=>6.$;DAU]\W0+?KG[>/]NQMRMY^WL4K9VS8V_0E]J.S
M=-1W0?+B]1,R/ZZ_8\WU-^UM&BS<\8\!E;U-;T8W7/C-CJ/[ORD-GW"C+K+1
M-^NI]>J''Y_NW+PQT.O:;@,?:-EVPKOCHR__O?]+6W9^]$#BF@_.^.O7YF?<
M\=;"A \FKAO28A?*P9T_WMURWYYG-UU\U^W-H?)I0WI,VS+_&KS'K+Z1+8.[
MFI8L.MV[>RVVXQSER9V#6^=O.6/$WP:.]C:=N7S<ZETWO+#H+N#4,[Y8.G/<
MYR_,F>6Y?,2LTS:?<_K"W+#UK;!KSJ.KF-V]]D!1T\+2G9;;=NW<=DM\0??3
M![UPX=9KOE>OFG_6_6],A%HJ1_2>%QCRS&T#G+,PY8A!K4\G##I;M7WZ0.:(
MA3VB&\?.VN-;]/W8#>O1:,;PV,1[-GPYX/K7'[@MYYE'+QE O=JW9_ZNC^J3
M_G'J#&Q:'_.M/3]HW? IM/.=Z[_/?3Q^^\W5L7N;2A->^>:T+\;_.'/7BS\4
M-UR\O??%=VZ]^//IC^]M6C9AQ8G?WMWMQUD?G_CCL'N^8]_I>_';XW;]L&K"
M&WN;YE\X\9$=3WUUS5.OYL_]QGGQ05T7;:^\;W^/N/2]Z)IWT-TGC+KE\OX_
M+((7@\CQ@RK+L13@6?%B9M>=%]H?.?V-.[)P[^AW[SZHDV+<BCXS7GAM^>J7
MNO@>'@G7SNHV><=QR/K*Z-!#(];>\=H-*[ OWVV?TOW,]P<O77';#:DG=LRV
MR"W+>\R8O[#<;^.J[8.O:&X?_'SIO&IXZZG3IIQ:[#:HZ_,CCY[<:\Z\ZY7)
MIU>WG'W$B:.\%P9QQ"=.<_6;W7_:(P^FIM]_S6/- \\;/F3XB*9YYTTZ>G#S
M)$/SE&?Z]3Q_^*;9]!NGU5:<5KNYSX:%K5<8/O$NO^NJ?LJR2Y9B5TR:/N>\
MX2.ZCVB:I)MU8V3'"\/W_8P8MN*+,^Z_ZZ&5]RUY8_+Q\T[8VK9BV<++^Q6]
M?RG1;UCVO&JZ^ODC'Y^Y=BF\:/5?O @.7ND>\MJ4?F\G/SCQ%M?*9W-YPXKU
M?;9>_GRB:V3>,;IKSIPW]::YTUL"H3.ZF%9[X1<^W?3&*9:=][WVWIHIF9J2
MV?SVZ].8A=]>!VZ?/,7V8?O$C^\9/W6#^$(F@&Q_>./C\]?DYW@7#@*!*+_K
MD=8W4 L^]\G73XS&YRWYY!_U&;?TGANYEG[+N+MVX:@^R,CN -=/JLV=?V1M
MT2</_&T^]3;ZZ?2[KSG_(=>-[R,;?-C?S6><'QH\67?L^[=\XG[QV.P]M[S;
M[P9#^_EFRX5Q^<[N/?D3KG_]YN&[/GNHY7KG]-RU]Y[I//NIWLJ$)V>L6/?H
M^/Y31IV[]:R*P_#F@\NOAIB1V>R@'LS*3X85)]Z^:8&_7]8SM=NFT5.=:TY;
M>\9)?SG-^?SIMIN'3!FP=B SI;GN6#B=2=H615>\,6QAEX$L=W3S28OO/-G\
M\*1>7K"@?_*[4Q_LOK)]]H4O\,A50X=ZAZS*W=SGV^#YQ.LSJ/:_!>D1([O>
M=O<5YY]WP?N/\O]\]LM=?9>\5OKZPW5O_N.?\Z[=*=WW\3^^65P"3E[77S=A
MV--'Z?135QRY^:VUYW^]?,_[P5,N\%B^6(+.4([)S;OKR.=6U[\7;ABX>9%C
M?)4E3C!LC4LG/=SOB?N&G_W0TI5S[</&3!87+#^?/?88Y</V)R?SGUZ\M-_&
M&6_?>\&;R6-';VIEGYYY3H![@!IWS?9O=\Q@L(WKOSS^VP7D$\8S^]OGHP,>
MF=1]G3L\^N0W1W^[ZZ)-VX [)@TZ>\'&>,NF\J6O12Y+E6/+$P]\"^V^+WG\
ML/*1&R]KV?KQP#U[!E\;</4Z:D"Y5+I(V3[EXT<&SKA$-SYZNG"T<ZM_S+HK
MQ[SOXJBI[>\=0[W>M5\7IT*:0W/FFA>?__D)PU>^=LGP*Y25W<F)2)_94_@5
MCZBWIIY"/_YT]44GC1GY\,GG7+_FUGD//7_F$,>T ?=,7'+.A?EU[2O(]M=?
MY8:-O*#7K0_4A0L6Z#YM-GVUJO]=[<AZ G:VGW;W7S9OCS-71O3]/W[GZK3E
MY'Z6!:,VO(QUL4Q9J'-.FGS,</^0_E.5ZU=B]S[R)M GOCBW8L+89[>T];M^
MV<C^FV]X<=J 55U=+Y7N\4]O7MIGTH?G_>U8,M+UTM;CKYHZ8&Q0N7?.TJ7K
MWXAO^V#1E9_#]6V+B7X?+EIT&CZ[Z^VKQ&MUZJ;$8S/[C;]AP<M])?JAV4/<
M+VU:<(T=[EW!LLJ',U:T+\<LEP:&7OXE]M 6,L=>?]2,KUXY]FC6V[)KZNKH
M9>/^>5&7^X<^M^R5:_ML&=3R'M3W&/?.T<@GM]WKW]BV;1"CCET[BQ%"R,R^
MDZ.&N^Q+E@=WSWJX1_N)$V<]WKKZ>]_8*5V_W;Q[QH+)718N6R/<.W'@+FK
MO/S$()!]X)*^8\\H+UJ_^SJ.Q1_H<_OBU2_=G[4T/3)GX6/7&<^PJH_>^=67
MSUZQ^/MX("<5KKDM=\R)5\X:<\WU\XY:?WD++PX=,>CYEWO>=V?B@W'C+UF]
M\.'0DQ?><K/+^F.?GNBUW,JAMYSRP9.?S8F>%KC 6./FO35VY@@D/7_ACN/F
M%%Z$A> ]O7[ZN>N'UX(;@QO/#>W^VO?9/?>/J-^SY[7@/P+5>[;LVC%NXG=#
M-]\>N*!+RVR.G:&S1[+?O![^YG5Z\<T/W?OLM'4/O_1*]HM7;ENRM/?.86^
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MK((.1["G-RIV7/NF6,@F/(,W]JK8C\9.1IQ>#7FW+GLS:7X9G=F&L5Z!R</
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M[.6V!-6+;9O:;N/#W/R<[>?,7WY)=HX%//WZ<'@H*==Y1JMPWRK#J'4,&VE
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M44<6W@)FC]3[; .E&SQLWT![$43[)-U)TJ#M28/4U&YMDWNZ\,.T-Z,E*W)
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M"Q7L\0EZ<_A\F6;XVGVUC\,L@N$R/_=+B$2 _J=;')RASL#N7B>9)=5:_5!
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M[F(Q8P7\J%LZ]3TX,TWE[!W'F?=PPM,X8*+Z^Y'B3-)9?P]I#6P-*2I9YYP
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MT5MVZI;PH:>/QN6NY6F'^*Y(2I+SC@!<%%)#TOJ,^HZR\V!#_,V#0?1=9\S
M(AZNH.3&Y/(<2K_X2CF*ZWX[,3JIHV:C@_^K^X7>WZG?)$YGEUY$+Y3L9$C;
MR.A5N^>*5,G0C['#*I98>(XE3<U3JCJDR$3&QIA-Q-7*+K8%K'FGNTWMV6'I
MNA@.>(6BSJ$5M2R#$C>.+.Y6%7 W%=;4E>1Q7OPP8PP7@::QK3#*R,@D\M N
M3R?I8K55N<[O@L+'&==D<MZ4R:%RT:F=#MJCX;\C7R-!;@(_]K!I).;MKDVS
M]@T#I;]%(@V9U[ J4%LVS1%J>W08'\U58]=EY;6)4W)$\ (*)YR_T"G#K2DO
MAV'MT@ZT,R<6@JI>S*,6:=+[HC6+XZ<F/1MHJ#P[XT<2<Z.)-XG[ UE(4<Y&
MB>&8&5V8BAP2%:XZZXPE]2E3'D2Y[]>NLN5GC\6'W[/\:<?;,-?*L/<T;- I
M@YX!VMKI  WM/.V.C$&#'%/^K,*[HA 3>$)F-O=D-"5V44D*6B>K*&B%Q1)>
MS?AB5[N.[T44.]],H.)(5#;VBRP[^NBG&6X#&OD1+;4%]".F_6A-;2DK@&EZ
ME5[ P(]'E_)6OO5'*VVE:AE(BU$T%I*I?;6);CU8VX<?RSMV:_6[ J=POLBI
MCV?#N)R -DP.W[+.9/' !S*]:2Q?!X"6F%#+^:D22LPI.3$XC+^>%SE7UJ7S
M6F<Z?Y=^;^52$T"5M8A35%IF\[??CN-E9U$$Y"?%T15$JBC\W>2=S=/)9%[-
M2M3WY<,=QN=KFV:^@<BF&&T!/W:VKFO&0?OU;+U/:(GI$"\WW$5]TD5$:B?.
MEE1.X5O=<@,=E&VT9LVT3=,>^<3XTTT:5?_?U5.8[A55UD-:PL.1<JU61,->
M;AO:D4/<R9[SR)NE&XM[YNXIZ5$M;=5T%+Y>#]"W !^!&&:_7]5C2!:\#AR$
M!+@B*:<1W/92X8-E/QER] 3#"[7=8C\OC@=:I!IGQC\3N;G]GKF82<'V4(LX
MZA@;G^FOO:&V/H!O4FHSP$K#>.-K.2*LH]SK'I2-G5=+0/$M:V065MGL,'6X
MV%6"D_7]@!]#NK!6GCGV@PWXT0L],?UY)2\5@[NTOB/Z-AO/K*M]*8OPSO Y
MG*"!38A#HFH3]QHF_&P QKPRRJ\1OG//]7)Q);TA)R3<_O#!PXL\Q;R35$MS
M;(%,O+L<_[7R _']0=WVJY>PB%P[*RMTG>H"Z=B>S_>B!9I:B=U1[<I7K,G4
M#.2E"&I12?/P2AN.^"CLX8[A/7(-7NC@$ZK<#CWH[R:@U%!)82E//=$B@B8E
M^VB&LO![ZY!-*M@?5@TWH\>OMF<VV])@+Z\*^E64TZB<W75;AH4_^A_;@3X#
M&Q%9EVE2^[99%\G)935%6B0F*G!MAH.J63%P2.-*L9>=RI:092AB.$1W[*/A
M*0P?9L=+#UB K25<92ZY/'/.BE^(QG80=7PN?Z&QHV+7.IZ(5G09TP/;$ZT5
M@646I#KZ2+3WX#[<<A/99/P'%[QY0^?>Z<\MF8/,VG>#OVOXL1Z]9OH#+(/@
M,\XT#8U/FBA9'A6@A4UM'>@QU$<SD4L/;*#\"0T7TFYZ9&(A%\'[S4G*F5X3
M[EO%IN74"(RQRQ/42X6QX%HJ)2YKH*:&=8Q8B9R0>,^5U=X;-MM*'PK<C:Y,
MK:-@H*D.'YJ4;23>O+9JPCJQQF/;&G-8][C69<$8)^9I1=I'$1"L_PEG=@$7
M[7W>>8Y=$1;6+ +"S;KU655_/L9^2VFL<Y2/?J!3?[=7O%YL@,1\A'[$-DS'
MQ-F9EU9UZ=DXX;SS.9=QB[LFM)=H0: H65K;^=U9Q^P?H14O-KL?7"W,3I]T
M#X=MY[DH6TV!,QR)E+0J<=RI'5];0O!/K>(%/BEH .]U(B" 5""3?P'Q/X30
MI6AB8@(2D]>R0YG<OT<S,^>9#.#FC9/$ZLOC>F ^?C"_!$/UOMP_!+F'H*>%
MXONKNA5K8/<M^Q(^%P.H-;4WQZP:#S 83^B6$H[H\4;A9&RA\7MKI7^J<O'#
M7R050$82QT^M/\KWO#SL[0Q"0O<E! D4^PNEQS@$(AC#"9$:!F9LIYRVW_K3
M:EHRJL^U<$<B4Z36.NV4&;O >#5/7UDE<DU%BRT/\*;L1;,$2I>RJO5V2#JK
MIP9!(6M?Q[2(T0DEO11XT60HW4C%L$>.Q!*55+Y2Z,O.FF3_WB!(.W[AQ3L$
M?L V+@&.IA.5RJ(KI3.H"_4[(+@UDR3VC7Q02\-<T+Q)ER3O5*RZZ&2=4N.4
M^MV\:!!0E>%%1A9(J6\Y[+@6.)BWVE,WP'H\.+TX90[B]E;UC51SG5Y6^5AK
M:3K]P@Z5CW\CFQC JZ:=L#@BEBGH3_'^,E%Q*'8(3) 83V!PW93ET5M[+_SC
M>GY,9P?@SK%F9@NVB\H*T1TU(MY!E(<ZRAD?#30IS+.D,JQ9;1K$T6:<V@=Z
M]6+!K0"PB?A5*R 0 =L^JRHOOH:L"OWYN<JLP$IW6Q=3*&T/NZ?>4IY"CP=U
MS[W=]*6U2/R7?E5U3E7K?B^=]L4(]*9^U,M:0^QY<6_<5,;8:-0HK56\.!&!
M$IGU3*F15L&&_>.9?.08HH$%FU-+O]/=N[)5-!FPN^Y9+#X(#L@:O9ZT6J*8
MDQ,#3XDU_GS/W6-8EGD>SUP45_4$@"I6&U(X6K#E/53QU\I[I.$1^;& H"6%
M:*S@2! X4:>41?$="Q(@60D!09D)L=(H.;32 :P9"JAT,$3[;Q^46HJ/"$Y$
M R0BO$^)OKEI91\^$UNR'I2YS(P955^]*B]X#O^<].G<BE)RY?O]L/MEM9G<
MX^!>(R&1'OU4 5&S[H@C,.:0V- LQ(GI]EOJ9+/"L<G'YUG.I@L<XU+97R9?
MUU<$EC+L99!U(E*0U\\JL6H8'!E^[PS$V_OVI+\A )O*[WM7]9V8G92FG\EE
M/RT+6I>4,<Q:\"V6SC4L1SX_&KGI S4J:^_'71#GF7P<HI?%N#:UOV3?'($N
M/'?30&)]5RA#^;0W@..7VO?]*X<.@$>3K@^U-I]VPYMP K<0=U=GA5EJ66B2
MII(*3>-US%_!)OKB=A_41%]C:NNVA)OVNWC*YOX^@V97$Y-ZB$L1PVC\V"FL
M_J0FJ_E0#058GTLV!Q3K=6-^ZAGL "E2Q27AZRX2]8'_Q%LQNQ%'-=JV)>*;
MPD5F-[<_JSAK.Q:V#/]#^$X2TG\+2[?RDV*<@SBDG7&W4'K-$Z4;WHWSFBQ8
MFMK62I]G^U?&T;0=S*UJ3E&Q@Y&Q+,?86C@,,ZL_&M7[--<*F?EDK^;YPKFQ
MY4-GUPY0S".,W'B-E;7T3"!R7,FI.SF=:2C)>!=?LKM[A>LL[>+'\AI7=DU:
MUEK/56I*?[:]L5=+U'ION8?_38P 8@J,)=E'N3KI#T.\_K+U (NAU;)UX[<X
MHY+]LOWUK,"Q!6]3/6F33L$+FW\(*!9ZO+KF3#"R$A-EO5[%6=(S1[>&-Z#X
MSQE90E<9.5?X3MV2S\P]QNS\[8@TON[+;%'-<)#B\R_"+Y,'GO=Y3H,(7*CD
M^K^Z,[ZDFL"\5;"JU:$+=4IS9XZ_<N?Q,KM7Z<N%#W[*-6X!8Z^(6+3./<RY
M8+7.0JM0WZI6BW\(2!KOFQXL34P7[NL_\RDV[LW=DUBH 46_$'3_&08(/>>X
M6<61)Q'),:\,9E8T$F#^Z;[J'(E;:<TR_[$7F<T%V!=DU3^[%K%2=!9)%7$L
M)4SDDB:=4N_YDK?1NU$@BKS!J6PG\P=LDEUV.^<T*6:) 3;NFNCFF8LF?6MF
M%[A&V[7[; "*J#$XLU&L]]#]N,YH$4&97$!4"#Z\X9<&@W6CEX3_(;PG6WU4
MQ/7N4>PQ)!9*FIT$I(#JH8K=:P.^9W+6;5>&]J)83&&MAC(0)[1K$"ZBPDL.
MUBA@/\64]E.]3YRB9V; / DD[.3*U;-7Y,@3^GI\O4G#%"]7R>9VI 0"AUZQ
MA]*RR$C)@)''QQ<._@<3HI=ONFP <0AB^.#=*V*R*;&*#I17U=MAN=4[L-U;
MP#&U8"M3-J-S/-UP':K6):2=3-]XDW+',<<O!KKP1:QJ)ZUCB7UMN1+8S<()
M9;>E@29P!6<1!A?5!.#SO=T#1)WZU(IV)\@'%)F,#NKHWS8]!>K08<)THH4?
ML 5BHN7X<=VIW4(M7VE#CNCA;3948_!S'L?FU.@=^CKO^-SR$=V!9FE-7B1M
MW(@D!ZX!61,,2T-L*%HQ:5,/4[')H2"NHJ]E;"J /FL+3SLT%, 4(VSXGL:2
ME>9;CBYB?R [JV:SB:H.G&%!F?@X+!2&ANIN6>7+.XXU(!M7!QIK,Y"-U"Y]
M9\=T_%*C@C]HVCC6R'(N$>%</SW/SWK1@S'R+!Y=&74MD(\HS/3L)XG:^YU\
M_U%BJ'V44=5M.'V% G:]E*YU)ASBYW#?G;9-T.=:@^CV39/=!^;C3"X^_3#2
M_<P(O)[R#QLBOTQJF#K?O:IDOL1RXQ\JR!-+9.OZDB^H%V!_=LOGM>A<G[4"
M&UY#H+VHHO(-RYLL3)2S @8RJ*'.D255S$RQ:_;HC=(;P5@.$^L^=*P2@_5P
M2TM9F=\#ZD,3?64B/QC\ ""ZVX\3CZ>6858L/LW21:%&6C7B/1C@KSNIPS]V
MK=D[*D&4()%6U1EETZ6AJ25)BP2V"0W)T33\?L76\YB&F16AW=6,:KAFO+L4
MN@2T+!?PC\S_$(0]E@KQL*<F>9>W>FDY&XJ652:9NPC+9(RE.4KI6;7-F*]"
MX^:U$U&,=8=KEB*/<]J)JU/08!US@OSBR-K*<+'G-@-[-X@R'J7?IW&U$6#E
MH./78JU?S2/Q^4/1[UK70)ERL.:IN47*3ZJ,N@8&G\\N3P8^JAR.C:&5HZO6
MQ58G9=O=Z-)JIP@G*C2%D1HD;- TI%:ZXX)A+:N$(81AM0L=H:4<1ZDZ>2I5
M;K2!2BI6%9@E;)8M]WXUG!P] RKL+=W$P#ZK,H! J_5P@G,<HG9=-T+).N[:
M<<>:4?A.S!CT=2AQ;![W.2NQLO5)]#$BN>EOJV'YKT4'2F-I3.3?8N<_?NMZ
MU9:2;@%=-%EPJ_XZ<(5ZNC<9,#AZR+([CCG+8G_[<8(&I-T-\3564<<& /\'
M;(+ZMT,[!%6()GJI;(5CFGC7ZD=RJJ!;BAT^Q+$7[316$ -,)Y\SS$,!AQB0
MRP=-EU1BTU1B@!+V VKD^L.M(!0U108;=39=%;?\.!1O=$J/Z1(4Y]P6K.<,
M\4J+52ABM\F"C8H/_"/?&(71:.^5(#FIN"=<<'=%%J88= ^:^'=I5I15NA;=
MA<.9)GDGZ98_282Q6+> '-Q.+*#!G_O$,EDAX)(*%0-5]S3 #9>TD$K/UDG-
M5J-+)S4>.*&'A..(LKS\6^)G=80US>/8@ D%)#,U)[>A'\+QWZXQV9M@1+5W
M$&?UT%_"3<7%'*4YE8<_L"M9C2!:NWUZ);2@=P8 1 <!XJ0%??8'+.$ J!R*
M\U=NQXS='#@W;4:]JC5M3B]E)8^!N3,/<6K;";X/_T)"N_\JV$V:5Q.1O*<R
M_ODKZ<*.05.\8W?9$'E,57,6/]2_QXC5@64ZIO&= QJ9E+72N.6.$UV@C&5Y
M3AZ+$G9+2FHUU-#XZUZD'O$LAEK-P4"Y*]BUMNJDQ;E$UJ<\S2&PV0S:1H*R
MMO.%.V=C%ICKN@,RZR3;H>4M&Y)V)IA*7JL,$E.M9./Y8%)K<N#J?=LJ9:RS
M+-4GU5+-%8"^%QY<W_!U$E\YG!'EF;/)P#K0^=94D9,GL44HM!96.L!LS283
MDEC@3U@)",') .A_8V6OX*&*$N"+=-^K@=&QEQDGT$80O$QVC5?*Q@$EF(W
MA;MLO6/5_PLB_?]4CRDY@^5>6FRR,%E-H(N]>()EDM9D@''T$O](5?2"O+R\
MCL[M/BXANLX[Y?>X4C0A7-(H%JC+WQN)6,#))96L+& EL$ZR3'*!.V$RE_1[
M1%1A%#?-H>HB-Q&&U$2S%$%SINH>?C W8L#2XZ0ATQV/X$55+=9/X?$'CZ7+
MT^IUOK@J%_Q5F8(NCW-%!#[E*QV/,\N9IAD)1GB,XF>2T\^R8 JU61Y7(48B
MDC[%$(;R^Y+G'FH$1WPQYDO71Z+<U8]KU>L,R!WK?'?U*S:';"S+7G&60;&N
M(O;@8R]SX<@X/6E]7UEQHT$]T;7?6<!QF75R!J>6B?VX_L:%T>1$ 5)0-,74
M4ZW0Q?+U6O?GWEG\/2NSG]^"VU8*>UMB&"9;ZYZ=M9BBI%^L%FV-J-ZG#.RW
M8;%]D&*V]>\*5O 9-E%O, ]8TTF2/GF\^BMEI7BFN0"Y?_*]0T@*/S,H=*=C
MFEC]?9O"'?0I-LVXHJ-ZVE;6%*@N,384;"D<HC$0_FFX$EQ=/;S4G7^BUY_^
MAF3'ZOJ^ZFYE8V=2X,_4*VNM!OS+G(J!L%@%=,V"D">G'"'67-24P0XYA])%
M;OI\,!#,X]"3<N[VKMF3P[ZXA%ITA<:< :%5<.$L5BTM->] 05ITWT'WEO8I
MMA9#1R]O6U._89<X)>Y/F14#FN8?%C9-7;V+[+/6Z]4Y^W/TRW*=:Q4+COHY
MGFEH:FW$ATNE\>XV[1ZDPQDL)?K(0OH2B8O-]PZ#%=/;G?7H5II)YA_BCVK&
MSC+^ZLC+YUEW1F?-HM);IM7H#]?2)KC#BFL2%(KAR$P*?J5L,0B &QG+=<<9
MS3J*U#H5"N^_[$@_B$.)DD*_Y^@SMMW[^4="="#Q.9T>U+)N!!AZ=D -_Z0)
M4W1C6XWUDKX%D!7U48X];T7TMV'Z_[)Z&<NZZ].AGT.X*NI'(_/I%-R#G.<J
M&/V@)X-YQ:IOQ=C5![JZ) _,><O_$+*B*_*ZYBGRL9QK2N<%DHO :;6&"+D1
MY%'*^O>1[^\&O?0Z2<[5V 7'9^ !^1B?=[VG)QR*"'T5= @^)_&CH=2CZ\@$
M^_"W].__0XBSXJ?$2<RENS7=>:W:,;K]A]!G66]T7W^?,V^JT7L\<ND6_"?C
M'\+-Y#^$U1I!4;9S\>((4>$E9<FGTF#Z$\VOX"]%#J'U+%VV6%7'KZ''<K=W
MNE8FA=&,IO"W?8=*:]/?&@I!"T0$%S'#@9&2+ZK!3X=3ZU5M4U8;%3VN6[8B
M^Y>Q]: M,H7@UC-"&O\7B.\B5N"/JR'=^X5[@PY;SAO#Z%^G#SQ*O3]I$RCS
MN@(O3,\@&)^..%<JNHI[Y?]X<OY#8$QK_UND:[@U,F7WF32M=!,6:U7UX-YL
M $Z*/;#O6C=C:$ ^BBU'\HA^-068VO?BX,U(R#KNIYRQ7WN-W2U8C?5.)-U3
M=CHMG4?:!J7OE>#7PX(FXOY&Y^3=#3:['7". ]V_/6]I2^&8-I?9/O'@B5=?
M])[MCJ0ZW]C-]]8D9P_K1*Z*4!6Q>7IBI1/T#"K7I\WXF52]MFQXS+^ITJ>O
MEM\CSVXUUF<DO %4\_ [PA.V\(.%8Y9G^:=NY71MJ]LIM$E>:GE&;MP&1>J#
MD>Q P7\_]:1)*MS+VVTZERT\_[SJ]9E;%/*WWW1;8+P,3G'-#\L-"<]61ANE
M84-L)OS+?J]H,Y9T+^GBO66=0 _E<7\+)O /0'S,?4BTM.@3$?]&)ZX+ >AO
MQ)B)[NI$Z[57/XS%V>:[:JI86'7_T::$\8V@_+1W<96\3K#L:["Y;R[CJ_)M
M68R?>389B&>LZXBR7_0/97=,-S!Y99V8&T5B,>E5&S+20Y^51B*1K1"C+SQ]
MOD7^SAM_BEZYOH)%(*A#F"[ 4U0-#;!\KQ DU4[T2Y_:TLX"DE=UK'7Z?*&W
M@<*&,*J-2R[$*JN,(Q$85(<(_2DN%%--7ZD\A(.[&-0Y-0\6'>P[]E\ KWU@
M%_6 /M,,*2.XRIFO/]B $09\9^AYOR*"_&/B4DX<]:0M<UB'\BVIBTI+FQKF
MR&[?J)&,A]#IDX*"J)C_C)^;.I0$"W9ZY\(@OGKSKJ?'PX]RL2*_Z0<1OJ[9
M+K0P0+:3V:(V^>/N;XG7KB=\JT:X:4/Z&9BJC&E!?MN!X)MJ!1^0-EA??&SA
M>/#__6SY_RTVG.#\HH4Y@R//^;LL= RW/,I2_A'9Y44##*:B'B1$#F'%/'X]
MV,@*O3O_N</:[WO8:!*^<06^82:RRA7#L(%7%'<NA+-IUQ\(A[ 8$84H@!6D
M:<Z4:I3_T&S0CL#7BQ3RD2$@&QWA6#@=7WC: CS3B]5I(/E=7[*K%/U[1-;O
MKQ^N;#?OJ)$"3#!RCKA8ZV;/H\=VWL8O]- ^86\B](<1Z1H(-0R^_]RS7&R)
M1Y;]>&[[R<QMHZBK (%CI-& VL\7 7'OUQKA7O0/4D@T>&$!Q.1_4-Y0-\$#
M8L=?5@:$%]N;:%&&VKI#,VRNP[,4_ 56\4-O05((Z,/P$\G^,Q23PVH.'^"L
M?H_FH21)Y35GHWQY\[=@KM;W1^PM+5'LX"(95Q[\?@N-*++ KO,'GN"T;E?N
MO[_71F[GLGR":XRJ4I;U;0S^(?QV2+Q[<UC(C[M\G#>)&7BL]_6BY$\P71IV
M-4>*I*$L7Z:2MV5QJ2EVYR$6<OK9L%]C+6$#^#XWHJS"NV]%#:C7ZPOS;J[3
M26,@@=*G <JSR08MHY]EPG%898F'-NT@V\#20LMG5D*7AE\3X!*@O[=J8AB#
M<:9_ G@B%@;81RD:[1*EW-]'A'C!R47= +?5UFL2K%Z7]K646TZ^![,/(7=_
MG6[]5ISXX0N$OF=MO;A%[ZN0>^Q7C5@/^8FU 1_-LQ[-PM"3_L0@RH]Q$F=[
M_;6H(VF-^V4_-M^N39EX,Z8=S>9F;Y0[!MV=U]G]I=?<D>K*?8?\]=RR16*<
M_=?QWU]WA'&TUD&+^?X;-C&.<93#'ZW9%?>0\1?+]G@2UVU [=RSY<*HCAT[
M)L2-QS@(G#CH\1)Q_8NS$P')>PY+?CTGZ_%"W^BWF&%Z7G<V.IG T!JSZ7Q#
MAAS<H@YEBN6EA4W]D_!T)$DY1?WTFVVOX<<IG.I9>/#]C/<_A*1_"+^\GB3\
MY&O.+[BX[RE?JT:WNW1?V7WTBO:;@^1CO\3ML7TOF?^VDLGV8A">L&CW%<>6
MG]0'S",@XFYB0NH<%P5H*OXX7&WWICDGN1^Y9>@;=.&B^P^A-08^]P]AU^L?
MPHGSRJ-4-8[\H]>C="X<\;IS*+XQ:Z@AG!BCKDII-E)8B[,#'V)8S+/8."!U
MJ_B3[UN/DI7"*$'&?7'RJ9&&6M.NL7P>GA&V]H1C5Z*B[(]K:&Q\0>H^Y=!N
MPP5U2;[S@Y [C?*YHFX17]G\Q#=T>V""T.P0\4R:DPV@8.T[BQN:+\- <EH8
M4G3[U=!(QDB1)7V\@(#07ES%D,(0'7^L)5GD8F.MG(/1O)P]W7_F88[P[BL7
M\@_LKW[Z>.#44A:0UO^PXTKQ=4H)DO\;_\/R&Q7->MXM^K]3SJK%TZ'=.WV1
MT^BXZ:?1EHU02<OXH[U=.%WK^J_O\*LY$*"Y]LU3SXPTJBG\2&CT YGQ_8 [
MN^/^_"Q%^\RKG4#R2T);%&W1;2'[EQ_LA8,0BI:N9+_(/5!QC="B%% BN30]
M6Q_@14[]^=RH<-5\O+'=31ZNP:G61N"CH[#?;VLJ=TZV?*()O"8AO7=Q2T??
M+^G8=2:V)8\C$LB<" (<PJG#?8< [K5K^9:4W@,"1IVBNC?G]"9>L]ZG5K.Z
MIZ*JU2X@G1"*2LX!K5K;_SP5@9?:RH ^[BEO666;,S6>@VD=+CR<<Q1%K2B0
MFG,49F7E&OL,.H=>UP%\:.BKU#(/Y$G03-9AGR-JBU 'ZZ@0)XIK2WNN0;ZR
MC9J^.J:NY>VI5XS0"+6D::/CW=Z(#W9Y7VQ@*YJ(,LS77WT("5U/0<E]/U>#
M'/5,AAU</_5OZPE8VGT%@,A>1#'61$4R&UO79C8@/V>(AF*8]PN%G4(UL"+F
M=8IN=CP6=_/[>,JFP:MZY<8FV?4.VK9K'(N/K8,_W-^(M[-3D[R"=M?7:N(H
MVL=:6C*N!INFVU8%V 5J7D?E,2<3Y^;VY1.0V9W+W7Q;O2=4CO;XD_4T'$)C
M2+A$4F#/3RWL,8K6OOB.+EZKW4(/J8;'+G434POC&2H=N[&L-28&*RH0U2MN
MB8E*-)_.[A_Z'Q59_#1Z/KT[Z,C[LW<I1NE4M!=M]R'/ CTUM.>CFQ/YJB2,
MF'U*BJ0:9"U(_%H]2P7CMFTN6B]=*_H9N%)@!-2#T_QJH]OZ$!-:LCY!BMDT
M7^[$L5$TV :+^(= J\8"'8:8.(XTI&B8^$N,F+'=^DV3VKFTG=<^/N0&ZZIU
MD:6S>EDON1W34#ZO_AK+_/%-@UXY?,/9Z0+XM[ZUM-)YA.V(]B<MB^PD4YR[
MS1BVO*S[=\=*; U?;'^&Y-2"*Q3A& _>)_N<"04ZZ69!2H%V7.-F8=H7I\$;
M8H8$9;L'FA,T;4<.M8Y&5N+XUK9=)_R66?R7&X(Q8XDC;*H;W3TQY>#\.3LO
M(@%HJNS=B#T0^R-%]SO9N_+K;"R9UL(E0>>/W_O.HLP;,[&R^+**F+XCF!-0
MNI(RMV [N'1=$[?.X0G9BQA^C@RWY5P^% YCX44UW*4'AB2F)H8^@E] 6M]<
M6R' Y%WYO,-BGVR)Y[?9 '5[EX6PB8E&=%2W5JHY.V,K8MPZM!B5"[$;4.(_
M!)Q/C\OZ>KOW0JM8FB0P^%L@L7TW!Z_F]R#LD-YJKK=/$9G5Q /EH_D"O?65
M6-8$=H31LZ/<U4[6GR@IO7046JHH_/!6@SAHERNM*89D3+#+"'T#04%L>D9@
MNM8Z4[8H=-:WHFGH=/0=CAV6??9"WHW$ AUF!MFWEYSX(P_('Q*7E*KZK/+.
M9GMO7FE!9*L3M!K2(5=[%2"/G- L52ZCCD/^'RBSU'AFR;)>=@$F4>6<KI[F
M9V8NJ.<'"Q$/?%VE>6'*39T5H")2*2^^=)"+@ZVJLJ))AZ.<5WU!^2\+_O*O
M*JS>,H0GVC].R.T6BUF*J=Y[T0*Y&=)($(%G.TO$K?,ZAY;(XVJPIG511_!6
M!Z]3\ZC%YLW;Q0J'SDM0WW^>L7!I^&D5NO_2'7TR1B?TM[6]< 2/;BAK354:
MM;L*[$S 8:A*$D4\GQ)6.&U_8U=:OMQT'2DRX>FA):TD:.G=,[K]N]O)065^
MPPAI]<%"T3M?-CHRLC\M#;K/<.5OM&>P[AAA')1G#T A!]&'3#OQ'(ZP^*S)
MY+E]SMI%RF_"2DSYL7-8>09Y<'"S%;CKV+)O#R+GF:C@W4SS!3.U\V\(EYR-
M?MGXB\&0;<Q<?RS$485V.9:WXH>>@M6SO=!,Q!GBV:P5E^YC3K9*Z[$ :U1&
M-I-NB7%%D3X0>7?0J03L O *Z&+3BP<(Z&@I!*;CFPSI[IAGZQ(1-9>M <-5
M2]V39_&Y1E2Z!B"DK40>R=NT:?R4Y1@L( W>#(PJ4"+YN(9SLY;X>,7<1.:O
M=:M1(WU/OS47CZ3ZNHXW((9#P^)JG9I&]SH-W<EI'0/7')J:E-VA-4=0X2E'
M9>UIU;2E>1F1"Z817T-RST.#V7C>IV(3IV9XJW%X>1"<R"6^#<[\G<_;F_B9
MAY(;MW63;-00@M*,C4]'2\,B;R8^!#XK&$N].4W<?<)13LRSR'&35Z]5\=R/
M-Y-&I>C5MF\7B58Y8>>9YZ]:VYBCP\YW/Z;,-BEB@%)HE 'U,.B[?T9JKCIE
M.W[^<SX9*M",YZY9R9;VE&WTO_]^2&VJ$RU_\W0^RZM5(SEW=-,$)._)6.>M
M&X=F50EUTKQ2.D1P+XJ>7+1_J3GC#WQ'9=CQ\W@($RD&BL>H$]_Y^F0[-S5;
M46_I@^*OV=W-LOO')$8H-VHF:'"%TK#N_#7!!7(_I/2WN&3CPS+2VKLM!9W+
M6I6&<^P?5Y:2\WM.B+GJ2!K+>KC*7M*YE431N<V]&<>QOG[^MD*W-8KF/N79
M]X8<BZ6GT2;@WX@G026/V1&/M:M^+WX[*(.L%\,3]S"3O(9P&]"92B\=&E,9
MS=5C=)1WVF]5$FM;J^] )_[K#%(JPW4KOSVJ;<&IA%)'_V#ZUZ5ZV&)_R$DV
M]D^)*C1M[@3XU0OL^0(N-^/2\=GX7?+]4/08>ZUC]RQVO?ND(X:QH810].&G
M2Q8;%_7S$SC(S#<?OI4?CKPI@>(&$33T$4P^]/8V@D.@2S:N:[E 8%QKUS\$
MJL[%8Z>:C>E-8B)L$P\"NXN"JQM1OYI-/P26!^]>'*+X>:]&RV,T7D/3;D''
M0J1@ZAJ_I(/>B&%QMCDJUJP?HOI0ZST/[-EI0=#C7S;>7^UU*L/R9X^]>#!6
M$-7OO]27XK]%X"M/;T&]7WA$;(-9]8*CM:/U=7[(-(3U&R"S]'<^37\4 _1=
M[CP59298O/5L>5^OU30]HU/9P1/]"^<9!JC]]5 ET;L&(O:$*&-?9C8H*<P'
M6[8?@# &V1-^PY?>.K>B(P2CZ,^?SSEAI*_/1CJC7.Z(>(<EBTVH /<@<0QH
MC>Q[;-O(6]1D.G[Z](._F'F\'39#-Y%&!7QA;B4[I4*SV#AXRDZPTJ:46+R?
M<\YIC<VU,#D;Z"K'5%L:K=+X;QO9J-V/>RI3?/"0N06FV*\^-%G1![]_M7LP
MNFY_>N]8W. )(S>O@S "5.B'DP:(O%70M0ZR##.)0A4P ,F@T 0Q#S6*O*RS
MQ5+8J&X'-6<@0-%.C$$*4,G \H&-YMU0,E'#EODG4?_HU[D^&4X2#I_FM"JK
M,+?W+" 0,>$.: W=: IHKG2_=/:B*);A'-JX9,'BHC3_]3B>HB(V-LM6$;-9
M/T_7L?GOV0J]TIBO/8B;UM)2&2P GZFH+E*:#E,7JIB;AJ;"B->\PO!#\5U#
MMCVO4A-L(TN(+ %(,"]4DVKW5<MNHPT>W%6D9/IQD'#\^Z]PS1ESL0*8M?&[
MP5#;4!8IFW;4/R>(.?7)8FCVO<%^A.P!Z<^ZQB=/NE^.W]B>/;",D TE+]L4
M%]3:<)XC+FN_U:TN3K_#F >:66(9HR)-6X $GJN;<"*!:).NUQ9?/8(5D11B
M/8+_Z(9@5_[]H [BPVSPR<1"FL1JT^@/HPXR"F[]XDL[8 I FI>4C*0.)OAE
MNP-)[.&67"#<B"&+>AX"TK7KORBSMSK)_3WIZUU7MX87).@[F_D+XN;\0QC3
M^9;P1O")?J.:R74P,>7-MOS;E0P=F^3-]]/:$E-*UX49)9/!R5&N!/)#.N5H
MY#;FG:BJ)^O,25*K: 'N.H_-TL8:"[:<BJB3O!01JL40C*F)P 1L@57IA]!6
M_3^N^@E,+2][[7B[:WM(;W1K4VWB8Y!1E]V9VB6&T!/E4&NH$9S_"YW2[VQ;
MM(;C;</=V\<X.VT",U'&.-VJPX$:3_O*)\A)SKVEW2F[,4L%)HNL*SRD)"<!
MUU3[&Y/D A)*&9M19O4=X"RB[CHQ90$O-<-N^$XI&@I*B8O4TE.\M"EE+HK_
MN$+(W<1<+.= 'Q47+\ O^;_0 UJ2(?]E_2L@<")^:F@)YOL2!(1K!+-W%[5>
M#O]5Q(NE0'MA,+2HE#FO% 1(UL@4KN]1TS8*-M],A_YPYELX)D_XM7<++VBU
M"53*L59C*8]>,3S)>]P0NBI>.<D[K((OB/N*(@96:E%+W;=>-M@QD@<E(W<J
MRWH4C=JS-RLT&=F?Z^D<H _5S58->4/F"<R1PMM*$TD^L[+;31"..K&!&%G+
M?DP5_AEY58Q8NP/7V#*F[O[_4YI)8$5':^5QIUDE.UJ%J&EQOQFE(V$,&@RV
M%I=&9;]?4.IR%#I5O)R/VCQ4FVAW$)NQGBRS*4WZXX8F2.ZK/=H/IA$;&"LZ
MNC%,_$NPN!&#/+_F3)2I,:%:J-MVG#@>V>+;YD-]38H:78_=8<!AGC)#TJ6W
M% +FNV]Z;-?_$"15*LL:IWX[R,'+8&32./4"C!/"N$IYT=%+02OT)+-*-G&&
M7#?\*=( ]Z'A5J7W9A=8[X9VJTM\TLGC:WYCE\X;DKJ 7.SOXR6-E3U$9+R>
M>N+9]#*KLN%5SQG V#2_44X(3_NB<U7*(<5A.B]U;*)0"$Y6Q'S.^?V[$U[]
MU*"<N%9J9]:I?DSZ?MR]00I<:7+:\(\&RX7AS*NQ\<S%%O^+/D$VQ%VQ"/L_
MJ'O+H+BB:$VT"80$=X([P0DAN$MP=VG<W25H@KL&=VNT&W=-</?NQ@G!W=TF
M4_.FYM[WYLV[?U]]=>K\/'5JU_[DK+7VP8%\_?IU1TFO?+W%#?H )@RF49-I
M**W^(IG90:Y-JKB6E6+KP%1CAY$P_2,>L+&11!<LS3K]I&:I\UNHKCWUA[K[
MEHN_3#R4ZL_SM8- @[S3%%A@T]0"QC.D$S)LJ^*@)"T]Y^P.A87Q\/#.D/3G
M5.#$??UJ'X C,C*&Z"+<6P.['P'Q_0>H'_?\7,KI7K9/PL*@EK3J,,DARO()
M37*OUY;\6QMP <NR\%8CRN*U&?;4Z0UN8GGYL:>SDL9\H6&<],TGDY,()SIY
M?([X$_[+<(&>AEMOZOC?77<YZ3=\/KHO:5J&12.+<=7[%O6&:]V@,B=?M:K#
MYGZA)%?%=$$M;W'<,>;04J568#;N'9QN^$&,U;SCQZI7DY$ZN[']YHE-(:,J
M^V#QJ*&7XH7( "OGT='LKZ'K$!LJ\QRA.N,;')DH4^&<*<O P.#Y&AU%F.Q2
M?N<%G?ZB.G C;1E3@:XF*NFSG!F1#4:DEWI**I/U>UO0SS8D_:8;X!4HO9$T
M6T7ED^T(W$;?L;%4U+N=1;'^>5.3^)"*+TQL;H+CR$-:0C$F]"[.X=^6AUO=
M*[P#[GG,1T$?V?C:W&/+.0^*X"14%L"@>2_#-1/:./?"FKJ;OI#"KN\3\G0N
M<CX$6IK*_CP?=35U.*]H!"X#)B5'+.4E<B0V0?3]8H8#<O(&GBQ+7YS\I*@^
MO,'&) 31OE.\,=@I:5FV>FG4@SBM;#9\SOA"LY87@+T.G?&0_-1ZQ.(1N6CX
ML/%6J*330)% (:TV=<A*:)P]9'2/0DE5+W;@Q]F:<^671A+!$D#6<GLL_*>A
MU.:I<^6\SE+]1<Y#7\=G8'+&^2I!<6CRFFD&&<T[1\F6PA3Z-$W$9*!MF<$&
MHVNS,[:C>U<HF"^,6OT58*+)T8V[049%[P-[&=4F3;F>W"4?^%VKV#K5(O&I
MY2-^1[J5?D<C.97@5F0X^B!=7:EX!W7$FR+0?+\C5*@E+^KG80^+Y!'<G*;@
M('[T3< "[L'E>A-WL46?8'4X>%@_LPYU2$K8QJL&57@"0*>A*>M74N]Z@!&4
ML@$:APYT?32-)PEC^RBO<.R>2"1?A"2CGR^_RJ001J,@Q]:LE7I^!I%5X?A[
MP#YJ-/?FHB.\:DZE:(":IRIBQBVW0VBPV$WI+PN/=_%R=O*5V -88]W)H7](
MWMP[T ]]W*^-5F7V'B2I^\YHOZJA17VWIB[3J6]:AXI#;V^[9.V:P=SYHNV
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M(; S")O4MR>2:8#4R"R\P?!S?(MT84TX'(;2= +A.+3C%_1 I'@%#%VN.YA
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MR:]>Y[_Z+D$*_>FD*!K@P<C1J*\>"/=M>0+RY<W%W1S.'#MO2THZG)MI[!D
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M*4S*I$?T7%:@%:@%B];9,G7A?5 H0]?'*7P%U#41SFE$*U=&)T&>Q[G%<JE
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M9'6U(B15W,*TGLE++]-FM+P:NI T[[:XK)E X&$FP(<T<\,'2YD[.1E!/ZK
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M--5W%[L[6Y0&O:TQH_=KC%N8BW]\XO8I0<*_7M<?G?=. DUP9VC[@!L*7?E
M@,,V/-H,NM&91'>[<.P00)H7J>/F2_G0<B*O*/D!YK<(@V]/_MWCSSZ0F%;
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M+2Y)G5+;Y]1!_>OODF4*;AG^[GME%XT)/[6CO#&*$3MGR?U0FD=>U=[P,.E
MLRE/+_(!YTS4)'H84>2B;8N%R%\)?4E_*>,9K<VSLMXL8\H*Z@6'3<)70 M[
M?YP#>&T^P^%LUE<^I3&*5LLD^ .SO\_<K%F9W1ASD1]M0M[AJI\HT "!VN6H
MCLQX)NU79RAB2J;;J K:7)[RJ-&>Z;O$H89QU[7LQ2EKGN.WCE2$N\:ES0F@
MZ@$D@C_GD:K!$:2$.Q_:<1J2R<C_RC0#'?/%VPIT9/]C5H=\(0@K_8U1@!LO
MN2:28%ZVG$D\-_!%I@6V*.?H^![E_68)P;HPUVRLX*PMS5V-3!)S)?/GA.[4
MMG/Y.<$/_#P=*-43D3M#IH[B%L**IU=7N/O%(G:2/Z%J.'^ 7XF3*BMIY!"U
M H<[*4^F\L.8,Z2ZX.N<=!4%[!FIV&]&05X!#VQBZ+6HB(7!-X)LA%CD/^LS
M)$R$[$*:;O7Y6.0!R[$#'N&]B">NY2\'7D,:?[S.Z#RF>J:UJK%%OSV)=IR!
M^5,OAD5.AHQ=056M%9-P9UOFXIKR(H%5@3M#6=[8<IAUS2E",'"4?'[1KVC=
M4+)@*HA1AT#6'>$A(X6"RLT]QS$6X$5+(6H,_?M%JRPT%F.HYA;]"K(34EU4
M'C3Z6,7\%T5ZU&1!3Z?:_L5V.(:Y<=QN_I!M4^>A9@A^P 73Z+@MI?@Z=B+?
M9UXQ(O*$U4!,H3>E7P"^<[P\U)/O[HBIVV@<(0[48A\#@[.]8Q9CC('\E]N"
MJ RCEE[U78GAA+&"2IAV*_;6-7/'8!U1<4^V#B[)*2>5+M.>+E,W!2M!]P(E
M!0D+!NWF5MC0EXX1TRM+1<58\@#TKMX#?N?.N?'VN4IQZ+5(:D)%5OA>VG'S
MOJ/&SMN!M&6_M"CQ0F:Z\LFS(DUB_\BQ@!^;F.[F,CY1Z$*CA+Q+>5UXU7_V
MQLUCX@]D'_$TOOO8_5%%7C_ [+^A/]?Y\@-$4<>=%M;M.UW*!8,.LAE(*O<H
M8)S_-:X^[%I9RRN-]9I/(XKYD#V)8S9@BBYCPO]K6D_2,8SOCVVW_:CK-A7;
M@+931FU+Z=$,1/:;O">FW$].&^N.S(;282^#-GGKK'L'OLM*#"YCO\1>_?AT
M-$=:W \V0Z2( PO%:J4P+RL4<7H<$8XJYT >IZ$_/=?6D[.K>K"DO9Y.[%D:
M[RJCSO.I<*&A\T<1?Q:3\EY*XDKR[OI92A!=K.8C_KKV]; G(@!)0.\][A:H
MK4U][.-:[B.1XD*?*I&FJ\#"+H8]=Q>0 O]QMJD_R<8*335;:H1GSC;P8BNL
M\Z 0B9^X^Y@T;8EV1*E-:3F5>L@2A[R@&8?\@ER&2\9J>N)!:>0QIEH/[OUA
M>,DG U+;R\X,Y%SEW/E@Z*4IZ24)]_AJF<%TJI*V56U@49'.>LIEM^_Q'^OS
MH /?0XSF'(DF_NBJ$/%H\;Y:JN\1%GSU7709C&!I#P8NXJVOR2Z!YML,?OKW
MA7Y94&F10,I4%K.RTO(IV#L%21UC!35C5+&WAJKF049DC-O>O43BYM'OB4_<
M\R#Q/$5=D[X/;:.5((O6_U#R\&^#>)?]NYJ&=QZ3/BQM/9/EE7?'J_RIN%7Y
MTZG>W0JRZ8I:\%FKFVR0*TF=P,\>/W'JU(TN1Z]BZ5):X.*FBN(^SN4&&EU,
M6FP-&R;6HAGQAT^PF!)*R2$RO"E(%(#SD2? T^IPA(TNB2W?YPM?NB.4%W-2
M=V<\I.GY]X?DTE(_^)WN97CW:S\5GU0"1?N 5+-6[P_>E\IDW,'UNLI@G^S:
M<N-"_#3$1)0,5@,#)I34Y 3#QBM!T67'"&Q$Z5A*KP +*_%=W4$W*8:FD"W;
MI!V>PQ[YWW)K ?)C.5!!/T1:0<_B/4,9%Y%\46Z$-.(J,D_3MKMCH.T9_4RR
M]$[<]7S?DSE:F'P2T4#TQ\G?Z^8M93W?O>:GIFK2NQM\UJ;Z]F51.]DP=%O2
MZ/9D:L87];2C0/R9V<M'UYF%,Q7U%$J^Y%FM_F]_XVU^*YSX\H+;)^12Z]^M
M<CN-[?L-CK#:!4UM 5A/'+'Z?^#13D\)AE<'-UT^FW,Q9Q=4L6PDW@ "Q$9.
MA336N/K:QJ..Y/*&5_[)/I9(/HF%3T)"NG&8A\E)-YA%4B:'U#V-*I>/,S-;
M (, '2J LM&IN-5X%3%DL;.T)N/4P_A02R2.GDGX@48Y'RV6\I-H0\VZ8D*^
M4;ZGB=Z6BM8@#JQYZ;W[_/44Q%3G@P4,2W^]:MHS/+Q=5Y:P?RH;.ZC#F^S3
M5.3BK]"_LA9;@U^D& >QTB=? 4Z#F92BVO]BWW"%K)*1[IT%%3D;0D@O3IJ&
M,OV$*_: H9$I]VX^76WR#0>5ROM?BDR3LL@<$M)9TDI(8/-WPW.TXS[79Y=@
MHF<0C+X[F=J/]+UBEAD]%B_1P]/3U/0'E,FJ#'UI&9-=_22";')#5@ U[J"[
M 6U6*+>Y-%;2<C64:_1&^Y.S=TGQB+'V7NE(GPK]R'PSP4V3BXHG6S^'3B%T
M(*6_'N<J[%F,*1N]EZZH*FF==":6,D'>YR%0[(6[Z^*?/U'S*BX1<':TIH?U
M5 D\RKESTJ@XNB<5B4QZV-'JAE*(?6(--5?#B>*:DF98C(RL&OYU08FJ3>34
M<'Y:ELV^A"ZC<=VKPWN;-<)XL0BJ<8C<J>2Y<!UP^4Y H \Q57MRWGD0#L"+
M1>@&7"^H-]9<V'QKN\8J_<[:YIQQ^R0:=7;\DG]R?77]T#(GDGKV"CCMX3_K
M$GEY!:CTD,E=XD-"E;/.?]93*X4Y STFQ^V]NSUGH%;UO(AZ\E6'K%/U +U"
MUC#WG@#:[61G[R49W[(BCI_3B->HFD'Q!]T-AXOOLU'@"^,^;QLV"+6=N=44
M]=3\DD9PZ %T2"JX_.4[ ZPU<961$+M/ (1IL]0>M_^CC_L?,,:*YA?NP>41
M7=CR$SZ6\:/(+\X^B#EV\WVIV/O'!W?_Z70'N^R./G>BN/BT1FU2\_PQX]4?
M9)#4<WQ++35K#"1PD+KW .OTYV3.MW>39FUUOL.0?V:QTSY7Q.9H8$O0$3DV
MQE%:/FU!0<.$LUB:HNBA.:5"O#P866=F' #C7(&+?B$P8+M'YAQ1@+A&'LPG
MIIQ;[#J3Q\N2"_MS>!WN9MOJT6&T/'5=6_"2,-7["(Z=?XW=%,-Z*8L0FB0S
M<QC+HJJBYDBKET%%FZ*SR@*:I?9&-F OE.C.Q#<K(PB[ZK!(MI<==6Z3AX,#
M>QOG#><0A'_S[7]I8WX*^V^U?7507-&SYA LD&!!@D.0$"Q <(]@@TV0P5T#
M@UO(P$#0$-P)!'<&&=PE@<!@@> .08(-SJ##P.;WMG;K;>V3WWM;6]^INE7W
MKW.[;G=_IZO/UZA703^^*NN0)Y<C2I,OK9(=WZC/+7:V7^&S#:2Q*0KJQ+II
M0LGXV[$@C=;Q_(<U["IVD^[%#NY-[K#W1#^Q?+Q-CN+6VH^0 IN)SQR\S\YJ
M.L!:72 O$KT;_)BT!$R7X?5-('UMU_)U8U7Q-B R.-SO:3E\_1<)\#T]5+36
M_GU>ULQCE'3:7G"(,2)CU]4#0[];6NPA^:M&PLU6\D1R--5G=*%#5=YO63YN
MU9#1<'/V3YE]@X?4)HY<6L!GU YS;*HA-_HM]N\_UMR&=RDO7M#U_BKA\=2C
MPLR/,/&+2VP#D)8#.OT]0V"[HR:%4W]6K#ON52QGV;DV/RK/!2FS(S^+KP]J
MM)8'+1OD^R6 Z5$N)-]7\IBS \/T0B9A@?*VJG[>2GM0YQ%=B&E+9QB\R\8+
ML7OP+24A_PY0XN6FC@9-&3.DR&L:RRIW'8EZ=/H9J<QII4*6^Z0TAU&@\#A/
M(\0E@Y0GUSDF178%[U7$4Q!H\Q5>;=M80HNV@S;QW S7KF_@[Z?4=X @5*_2
MWSP0B57CV0KX%-YU:\=B?LQ[^8_<$+EEB3MP:R\C< ?XEA)[!UCR.%:/$SJN
M<N%Q?'' \%65M*NI!BYFU/)V<=M^\67TY62R'E0U8XED4EMUX GUF9?M+'VJ
M<$W/9"&OHYJ)A';#2//(MWBRYBSL\AV M($P#VG"J"N=%%^Q8F'%6WJ &(Y2
M-^V?)_9SYC](??2L^^>"8<#8C?0"+_#CLP=CVT$91^^[)P+JF$R_#K'.ET09
MC1/<7_"WKE(B.UK9/8:3 [FDXW)R6BL#GY7_.YWD%:@7JZCR5Q42P>&A)&+R
M6E3!?$#VX3['G8:&]8'C_!0XM[)VK%#$=".8QC"1R#+=D!?7M6F?MI1=GCR
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MT@/C-PH?\D,1"372.[E#@NLM5C':$H]_UXI+QGJFL\ ;X*6?>Y5Q9%4PV#N
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M)W5ME$*W]FCY4KK#*_.)/[?VJ+\<9O\<UB$7=P0+%/]VRQC-2[LN<7(K.5^
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MX=:(:/^IX?<LE( @8_[Z0N =GNXX!16O!XV;"?9K1 -3DIZ2YF?<*C&KK]Z
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M]FE>X7 X(TS,@! ;%D^GTTMA"(1T=$2Z/^H-@)%TK[]%'.0S#MOB-R$..."
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M_X %+2U\/+-&Y'$P7 R_7(B+IW-./UI;1T)1BBLL]^/59#[.2PTH59BH7&X
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M"3@<FTQD?,;_!L8?^"C0',I1:@LL-^CWYY@M5C#H#GQ&^*KWCVMJ01PABQE
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ML,6;6OKM2^*RGC\G#L7CE3* &I0MYU/T2J5D$(B?07X_XL^12L,.Y'<$+#D
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MEN&]@VM^1'9F#>$QXP3+'\T;J3$V<-+E3W2-$G'%+6+7,+."?%%7U7EWT*K
M44S;#?ATIJA(/9_A7#LF(^8I<)81O&\1Y3[YV) R4J[IKGG9T\S]-:O@%I.#
M.=NY#FA)CHHNZ)8%R+=.Q>:8GYV$L0NF+2,A4$") '^W0M%6G$/[;P^Y,VX/
M'Y,390[MY#^TL2N=ES\PMM*V#\-[Q*6,645 EFE8HRU&D4LO&O/&E*<_OQ]
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M'%Y;\8XB\,$X$#\8.,<2U&";=F._UHPP*KX"QH];*9<2,J(5?)ET_GHS8+3
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M11F[0Z,)H^@$?%W/^1OP,Z+A3OSLVT415.>!3PQ\E8O*V[C0,I^=D9F(8.2
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M$S?Q6$0^A&B)>(<=M$@%>K_&0S2#>I\= (0$;Z53(FX+R>*WJ@0<NMT9PHK
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M\^V+#H$$@@9WM^ 0?+ 0W(,,+H'!W5V"!B<0=(#!G<&= ,'=80:'$-P"P8<
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M-QLK"2L=97[LK^>=U<+$9"!JNT2:[M(R?$M766,#VL/"4L^&23J'<7!,UI)
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M'RF"C%>6=3,=&02E 7RB%>0?U)<])Z)?JT4VMKVZK106 IWE;:G$(H:97F&
M@C[+2:N!4;QNO,ID_]F0/Q.,RM;!Q-TFT=I*R,H9(,+U;&(#J6FX*'TS4PC!
M4P\F\,HP^C"3"\K%R/ +1/V6:"*:R M2Z;#9:>FYM5>0?(66"0]T#\LHVTJ[
M_5CE%9M^;140ZDY994EYS"0$4@E5HBN//$EG^V?^A^>DGP&_?:7^9O;<4$Z;
M.X?7^?.,IX0,?'L&!/0LZ DS:_Z7&! )US?*.2)O?9(PHM&$#1(6K"/>%B?+
MD56MR%0.TZ5&)J5]BM+*8AHEI&7M=^B*]_C.<+W417A!Q4K4_RL G-*#"RM,
M5 C3'U[45D$U/9\Q-D0H4FVA"+WJ.PZ/F>ONQ!EX6^2ACQRCZ-"5N%T"']&E
ML+2OTN6F9X0=OW#$">70YNEB7EH)[Y1DN$@Y=:H/PH<.;AH +'^7<)1/5+9V
M8'I0L.>9*-0U%%9%#^L\C'XU'\Z954Q%0=>(JCP0F!^,55[FW;<0)/.1MW,]
MRBI,WLN]P_ZJHR-[CPI<LG-[79'O& 7]S0DV8Z0Y*+*XQTS\,L[I&Y$0]+H&
M$E=T=25(,'1+1ANNA#T_=(@*'#D\MBJ+%N_W(6FN": Z6%K$X)\=>MI7TBN=
MLW47JF74^SZWI@UP*A'QZV\QR3!9JC,!P[ G;&&43J;GOZI8_S$Q4H9IQH[:
MLPL(T.B8CW<.7K%)6!(W>WGR9^A9>*4178Q+B'NZ6Y -B#3:\][O%%5E:N#'
M?WA,*DS1).)&E@H["_X(^5!/?E1065%1E&W?B%\)P=A)?Z4U:A*K$-/BSY:G
MI,UC0OXI\H%6@2GL;0Z[_GHY?,3'[*.]&,D3Y!G YP:I9LFK#.A\3>1O'[49
M*MAJ$Q<=EE_$%ONFHQ/HFL%IY/RB/B)3,:(-_)&37NN5#\(S#@4V6%EQ5'[T
M]F>0Y.LY<;["AAR0[.%%NCDL](]V5XJ,H'B('!U4%'+3U2! 5N*\BC?_*U/0
ME%D31XYIH5Z2BI&Z?X6]@!@_JUYW1HBT&[W^0@55,GG;=M<!LM=55)7<J68X
M#SJXU,B%L1S!L8/+_TYJE >L.>NVH&1<./<T5"#'5/UMK)QH:#YC41CE2*S%
M-^-VLA&AK[^TQ_:RK.!'OYCQ?-602+HP-8:Y;+MU:*).+8.E[Q_[US0/721D
M3D3;/+5>14TS:B%9W'6FN6%!0?P#N= Z[;C,3$>E_J8FOVWE;DEX\;>9.5DX
MM+*1*!Q+($3UK# ,RD8/#7-G3@3R+K-:SD;G->WID)DIB,&</TJ?-*3=NPRV
M^--S]R^HJ&3^;7,N0D5D'31=2]L 3TK!)^<<J4*QA?K\A:M&:G8AQ;7S< .C
M7 >'F9]=@(&J<K#E N^L%_]B0REP7DV>C]XH\J=. BP*J,KV#!C?[WN*4K;%
M8C,0.(-6-K OE4*58Y#^N)%Z<,WZ!LU!17!Z26-#=;\RQZ I==1\D([FO'DM
MD=;/9X#\'3U7J6,CT#XV\Z@PW8\E8T8R]7#82_ 9X$9,1DZBYTUROPKL5/X(
M94G-Q*D)>U=Y[?R1+CZMJM%\#Y3\>I\>KZ.9VU::J6)5JN+*!R!"K:=(PUCP
M9KNM8. 3%,I/#5YFXL(+:[M6<T#&1#2\WQM_ZU<.51!B[>K=B G=ZAD]XBN+
M/AC03V=P*(1@C+/G+#/:>H*^5-F&@-XF7X@VB(M,\X^#/7*H0SR.2&?_@^QX
M2YQAZW4MCXRKJK[VHO?&A30XQ%(57TJTM'A]%1J=(Q.WHQ@\3VZZJ1P(K ZL
M,-7K<WC"^JL^6N_50$YXV?2VK:LU36+G/Q,N3'U-D)RSQ-Q_5[HBM2=.9'_/
M.M%W94L[&"D+V]U\Z@K-$F/"UR*0-!V@'U0V*19PU0LO5<#V4^5<.<#(&+.7
M^I*F(5+]=?M-%A]X+EUU)0.D@2/&]]TJ$T:5RM<U[40T6Q^6C>_$;Q';>J5\
M?D_OD+MW>451LH\?"*HGW39;(1E;"=<4^,A/,F@0/=>=D.21K<1!T?O2PVZ5
MRLNL5.%+-]V^KGZ2*F6"]W3(J]^UJ+#:CA,Z+WG;:UX;%HR<29X*.S%5:!<5
M>R9V'0*O:6I,:7#3EHNKJ-;WVF^Y-/Z5+)F))/7,A'(G_J!1S$_-06)Y#AS/
MM#18D:=+4=EAZ-!FY#L12J;FDP$VJGNFBBIHOJS!2\8<!@=P4E7!04F0E3?#
MF@QNXMNR@:*J(#5M.Q5:%71EZC@I'$?7&.9J)R_^7,8C=NM,62,<-@9><IH1
M+]J2;6!CO7LG&6,O!3$7NMT>=*G"BF([L59OQ1^V)YVE]144[WOTMDEUA(9Q
MC>H%O$^6N#93:>[5H_/+F>&MMF9<NMG(46I!;F%Y;[LX=K;\FJ'C>B"*[/DX
MK_8\*/8UF$6H@:2K+H-OE>.P+CA6[/5 ^;$A[R'Y2TDN96^[<=8P]@G#1OPB
MHB3L1EF!ZP^Q\@1##2SM]03#K^)K]N=;,N3\EI"5:H)TI B3]OFNKNC$&=2$
M"@I$);_HF-0 LOQ5JH5U;6>0].A-;/L,Y(:(K;Y%"TUS9Y7P(-?*1)W+2,U
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M.G'!RPBY2G+7R@ZF<V])K-6? 6W%Q64%)5&)*?0X@N(6(F [5BO8AO'VOL3
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M^,:RVA]$7\D:U[WI7?#[=+87PCI"<Z491 FK[['@-2HZXW D]S QUPLNREF
M<NX.C@B](.C=@@H+Q$9@_R@.#'U#WZ!$]5%=C,1<B$8RXC'YX\(5L8(.G-P9
M("QDK1>E%IG[]4.J0:2Z@)8&1QZGAJ*% =7OSV2';\RESP=Q,5Y%O<T2HI+$
M$<</$OZE=MY0RV S)Q/B:A25?,S9B"89P'+W=N^=G%N*MKQ7TV ^=ZZY_A9N
MO6$SPP"!_(-WGNKW>U>Y83]- PTU)R<-4V*U-"N[X6@KV[J7/(-O#!0=T8*@
M0@)UBOI/KQ=WA3XED/_!U2$8N'9!0[W9O>R/Y8HJ5Z%.!E*^=G%F!\!F5FW8
MJP[WWE@/I:)UMXTS,J<R,',V.C*P*.:G_7X! .,*$"NZN4_\]0LX\&-(WE$3
M[QC=:N0X'5Y869E+-C^WH(:_-K:L2W2LPQT9CDY!>Q"/XO4M),<R>)K$_LCI
MUJ*I_'_B38J>JJY-NI).-%09/G6FTS2/>D\[VG;TNZ!D?C>Y(E[TVU27+'K8
M,-'/ )KO>-DE2I6_M8W_L,DELB!KF''C37,7][F:R\;R'>GF ,Z &TB=]#SB
M0.S5L&#F]%6"'7"2U0T%(3.E8'["[TOR*_'JT>I(,#>3.R-H=JG+"Q:X-*9B
M6%GG@%RQ=QB_G<<'U;*R6NH65F>+C8XAUEPL4&8NQ&YMNO3ND_I"87!P0T>L
MB\IM.M.-W77%(G%3:U=K>9(VZ#XWJ:WYM?U)66GG^$H7C:J1^ U)7X\@9,V*
ML Z[LUK,1T\ELZXG-5OTN+3#TL5IQ_>2W+J%L+I+Y1;W@?*87Z_X>*+5#'T6
M\4KO6C^I92:O.=/'W^.XYC!"<G74:-^N;]J>76D3(6U/3'V=69\FF&XP(_Q'
MERMX(?\S5T\2CH\;K2@F'O51U?=W_J:Y_=XL?;6-N2M+&LHFV<1G8%KIK_.6
MBF>3)YG9$^K?Y=CG@=X>2NS*WJ^6,"=J(NNLO;>2P6!>L"&:&F+_<B_PUO3G
M4:T1<FII!LPG2,VGIK;$K'OL9=(9.W<C627J-Y<5:+ZN*CB(&U4K-Y>*N.D:
M^/'@'7L>R"D :G/ /OE@>_C@/RU5W;]BIRC7^O0$]/@SLD*H<:=2T5?5>_*@
M4I5_W T[H:)5NU7,C1"VZ*U"I9Q]O-5;2O;J+FL(MY9,:.^*$<LIY7_MD50F
MI9WW^6R\6DIBR3#*IK;_<YF-]T5 G!$?K.V>JDF_-9@0ZV>YF![(YM"HZ471
M84WULJ,8^LIZ_+=='U\SU<7N$A?>%2YR:GU:'=#\8_J09 VAXL8,O[84^#L)
MCT$CLRU)Z0?'2U*@[^J>H<M:"ZK4T<IC0)7HX7#(PO9N0"%R6-CQ[TU ':&-
MG-D"D*;[1$TUM^'A_B)+2PE6O'*=]EMS=6%0'I[4U#PZ,A[#[FF>.1=G%;S)
M$0!#_'=&MN/+#^GW$-ZH<4/-%_@ .*^LP"4B68 GD=#\\Y(BKIU<\B14)([&
MK3C0R?)\G! ZC.]''W/:HP6'Q/<8+".C^#!/?H.>"H%OU:[+C+P<67;=-Z 5
M#R1WO/7-/ZPY;#G%9.K-)\-%F1P <Q\1>XW9,G9_$@2+4EX;,7HXZ-MY5&SV
MT*^W<6\$+)250YX!1E[4M"[5?\N.H\5<^.9;_%/J?)756V?]KLSN[SJ4.\>"
MZ',C5=8S**V9%[G(T\J\_-H 5XO2Y*^^XG=/J& 1.B$0&HO.%^:K[L)L4=D+
M>+[6 7%M/%\VM):WZKH[@P21*A6',A=7%8)G4IW(VKG(YJ<\4=B+]U[Q:Q8\
M <=&RRW<DDXDWLX=O6LZ4F+Z5]Z5Y87]W'T!O9(MJ$VWG+ABY]&;Z @)#[>J
MHS\YUK<%79)G_BNK5C5"8?/M+8\K&JJ[^9\IJ9X!JOT+BUGB4$2;_7& ,K)'
M$W>30M -&0UDOOO6"+_YB'.I[3@5,/VY1^SL9*_ZE!9&,SUQX,(_<,4"G,F1
M?P94 <'>8Y(WG-\8SB2/WY C_Q1AXB2I@\3,$&>,FA'A)ET=>7AVD"B$\<<V
MH\T1+$7U-!(JC<^_-VNY[MU CIN1)#C,WIYGN0<X&3;C-85-W1.(+T('<5C-
MP]?"&C<V%GOR-<?0PE.5]T+D <Z7_5XY*)N(N3W:KNH3]B#O3BPA/G KV[+8
MG_/]@42JA0>E.VG%'PLG#[3U2*=[]<0Q[S*P%Z%W]8:*78N)L,F6<*<-?OYQ
M<5\$;B".4[=D;74#8V_G]YZF$YB)"6KY%HUA)V6#X^7$YX"D%ANUEX@"\J(:
MQ\NL!RYJ)C\83B2S)F)YQ''9!^?EZ"=IB1(F/;YH-.^+16JFK6$;,GK>FQ^1
M3=+9[!_Z*B?_@YN,=W!,J*D .S#%!W"HL%?RJD"(&.ALVB0!NKV_VB?M,+&U
ME8W!$I/Q,06)KXV7=@)27K?ZU?T^8[OL_:2>>,D)8IN>-SS@2&C"3)SKWK)G
MJ>S8L,:@_LJ_,+\XCH)*=4#@5NS9.T&T\T ?'YWOW[2AX5.G]7*RJ=V0.7E"
MR[;A_O'E 6=30W=)=7O>J9;Z>54/Q<O7%2 9PY1\(@'0*/"U@>9'WD^Q JHW
M?8T=!L47(T5.JIH:$CLINN^TL#88XZIM?4!H:JZ)&.#N"3=9>#T,E6,M;^&N
MF]'@BT5F%+4,7VEI_[%]^:^C+#)HV:%-X*N:[N*F!0OB:Q;)ELJ6!H,CYN0!
MTNB5(?X8T$6%/HFZB@/3"?(%N65?M'6JOU9'I]FG]MEK-M9=)H"<C0K_EW0.
M:R)!YHIEZ9(O0E<P=0VSMT5!9 'A)G'OT7K/D 58=6,5V"\J]_)YE0A;%#/L
MZD:0NNGST&HALD.&X74J^7)/[3<)"S6Q_)&C)J3*Y[%N,4H1)\\ SB"9"@=]
MFF$M()O#(=N%G_Y?S1Z=3O] *V)O=V1?O/R<$8J*[2<2.B5QC?CD4*@MQ)&6
M] 1^/3<RU# $A3.RPR(]"Y8Q%!M5"-OF?BQ9I.MC_<Q*[CI-3O)[5+-S)1!H
M:[!=DRN.^GA78L>97&-'KXTU>&S/QX[I?RC9D5+8DDX1:Q\EOW50DAOO%Z66
MV))8DN#F)>C$^+.J./6=OUUA6H+ONNI":P"9SD@MYOB\7J0RP,O@_'#E7IE5
M0L-=*8+0SL Z.0']EZX>BC$3XR#1!_$P)OH!.0QHI^I3 Q0]*@I=AK"% N @
M4^308LCU3>[D9>1GDM%@FX%"@;N$P%<*$^:PRNA1>NX4&:H_O*.,,9W0Q]PR
MRA1C)5;0VQ$#@S3J7=#$138XL].+">XV2/8,2"@( H%&= GBL,@!)2/$;>>Y
M&*>V8Y:$8P*N29S@P8Z?;%_^!Q8DTOX9\+.[[1F@IO(,0#X#?$: K:TGFN8/
M<L2+@ESV'#G'8CH.FL0@D!O%E:RL!N1_UZ>5M._AEFFZ> :H)&NUWS8H4R@Q
M>I@.+^AV)=D706Y$1(P1@J.[Q#5R<G(:*86%99QQQ%@0"/.?<NBQV$'VKJ;$
MW)/Z%LN=W8/EG9IG]\ C3U3L,X!F ;3C<H(64EQXYA"R79/]2-O^S\L0CLH%
M7=?^I2Y_!ER3UDG=E0Y'&!C[/$XK/67:AMRVG,>:_Q^O$C'<B+\8&@W#]4Z\
MR^FJT&LOY+9_WY@GX>GL_4!GU<54VBMV5#T^9N^YG*+Q<H98,D3.3X.SIJ99
MQ&^D"GNX=.-S'_R)XX?GM('7ULG;SC=[/RSX?1N/8)-CE!$I-Y!^82-#)[4K
MWW'4=X7K>E,27_T.-U7Y^/1XEMNT/8:'!8N;32$]Z+5%8Q!HXVD5=R-W3UUA
M@12;PH8H%%(]/42K]I*&TX38.H >?L=)')2&3=T@%*"WXN.9N+S9WU@R?>(-
MOZZ>@J-]4+HZ[9D4V"+Y?;T14' %_MU"[9+T0XEDX^@9  O@WLLC-]*6'$,4
MUPA0,[ID(3J4ORK-)46*<01]1FF)!W90Q/;4S:L(8H5[1DP$=8',8L>0W,.&
MEATA5?X])96K2_F-+1[W9Y6'2*4+711S&KIFB5 /M\C1Y*@"Y3XKBE;R@@5#
MT#C8G++2G0GBVHB%CS,YVK[F4O,,&,O[<F@S+Q$H:MY[=3MG(1TU2U@[)"NL
M9U%@K:T#KJ#131)?.C1,([64XL\*;/D4^&+C!.XUS@-A+WF3(:X1>X)RF#$?
MJ1M@DP([X,Y$Y5@:U,ONF7P-%RE_*S2HLS3J!A*J@0)U$;:T>BX"-\T]"0IL
M@ :H1X2B,L3 5"77V67HF,-G1H*T9/:PA8(;<C1^:HJ0#-8 %[?_V*W^+9@5
M9T@[:J3ZE#*Q4A'_O:QA_!FP,GM]XT' E[6C_($QI?Z-#O,T0:?&$;9CUX)4
M\!M1-&\,:F.SCPMI[*@WRO%>-=5<T#  "2]CXX-Z[%&>('/KRLG82X;Q^6#N
M%]\CFQ@F"@S%_Z]E4WU-S36?'3@)Y;!;6+>K&5JW+5LRMFRZ4^VZL488:OYN
M9M6VDG/0,3%8><?%G#(6T!"9/J6]XY="M$US2!1;]'T.*7&$DZA1SAUYF-B]
ML)J' ')"-9?9,?DLVJ)\@:WE7)]R_/5M#YT7<LZ#O."$)/HD'M,?7RDP7C 1
M*=^D[D^'4 LC]XK;JC-*)1*BNZLNUD,6(NRN%V ]+H%/+OQ-V>/*BN6?IDLB
M2S?@49W@-_U[[)'%_JN4F DRQH*."8EM^@7F_.3&-V;,6$5#2)Z>S56O%IOR
M#NM+/;>9=@N7/)DYG9NL.%H-"$@UD97?JZ=F:#J<E;80Z]7*WUH3VA*/,W[?
M(7+-'%:Q7#OI;WR_]O^,S1=?'1Y>\H>D+NX#.<K>"HHHEQ3V'[(!AXE!(0G%
MH#;W^5UGE.*P82G=FID#TA-B)@R>[-6T.U,GW+N=]FV]Q>FRX,^S>^%#MO["
M9;5NU\B QW)R%6CCX/)>W[+]"3=7,[#W[60)M-J).QTA$V*5WQ6A:VB<Y^=J
ME2R;;.WX+64_QBPW?*8+O"PJ4G>;5?=BK+.)5Z+73DW.3%N7)LX)(9$ .?5G
M;.)M:-$UX)WLEH^:>SQSM%ZO$\:PJR5+ :<6WLQG7I!(*O_Z/T'@/"[/ /_]
MGGG5O(>M8-#F[C-@3?)(OFOJBN/2ZQF /O<,*!5Y!CS1H:=+EY_25"GZ__KG
M:*;4%3_/TPXZ5$KIB2#C"4I[L]*C>O7M&: )?@;<5NL] W*!B8IQ]VX<?X.3
M=F\,I7PN@QF\>*PE#/8/?\M+).H^!M4X?/?5,<7UV8W5-LMX!B@-O!._&L_<
M)A4/V9F@? 8TME7!>BRO>HK>T_1)D\YM)4AKJ_D7N?M_$=6$.7N?&N_JR,HJ
MSX% H&#%Z#Q!T#U#X+U]WOGE,^#.ZAD@DZ$9'N86^!:@))*& ;!6$M341_F>
MUF*B'KMVK^;.+HI1_&_UXE0EY8B)2?=BX_[HF$%X)+3BV)4_>2%]I983?%\)
M2 _Q6>#T#AR/,'Z0K#2&@UF? ;@W&DA+TF< RO;]F(E%SO][ , 5\CRV?OW0
MS1577)=R[<SB+/\.5JG,W=<4]D((0Y$"E%ZJ59C9&U?#BYRGLQ_DB!#RP7Y?
MTO+"W(18,/?L2"(U_R"&?5^=^.7@+W;V<XF0:DZ.%V"9@\'OC<UL$5&SH]5T
MRT?'.1^3^;[P]NVQZP](;P57&8D1EDQS!>"UR(C\6ZF6UBK$@H$WSHUZ-NW:
M%6A;%TV-V[O)D8@A=LF&V0GS*XR\6$[Q-8;5IX4K@N46Z0+L# RZ<$X+/-KR
MCA_XXQR)JTD?G!P7U@SO#5>>5F\Y3-2G1J6)54W4EG B L)P8U<XSGI2_E!3
M/!PKU?VU$GI2LI0X=3@NC7P&D+&AV8-$%/0$"X4>6*.>])B")F$[1.@"OZ_O
M[Z;E](7=TBGK9,?6=SIK#LQ?/CB5R W*.[MM,Y.@VE<SQC'5LQ16$(@JB.-C
MUR6^*"8NU26F7=$![A?@MH_!*9_<NH-BG3':FF$UP3Z7NFJM[K\NF K,[>7&
MX Z>?*HF+I_ @HL$BX9&K+WO)DASCJ2:(D!AKP6CV7Y+8W"N"@+Q33A=>Q^!
M:\:_VYJO10^$5Q,>,M!EO/RWU:9'M9;LKHF!,7MTXUB4P/GWN=CU=>Q:$[GH
M&"EDG%(45O'FP4QYUB0BZ 96^D^,.Y2_NZ&!K0R0/_^244&2C$R^2A.NH-D[
M=@@2*MPH*CGNDO"''#JOC%N?<AQS![!7??>6A'#^ZC-2]=8]& $^W8HMK-*U
ML.QZBDS&:TW+XH#ZJT[." CJA-!<F(O=ZWR@@9+C(.X@0O]8?C]$,=Y]D3%4
M;P&ZWR[U5J'S@68)N];BZ0W-^O7+I2RMT>:C7*ZN2-/5^8U-_MAO/-%PK\_I
M%%K"5UTQ^6L6\T)HNZ145ZV?22Y)ST$U"N<6)_595)?\03:'Q\(U0]=)1EY=
MWVRYJ^VVSH#QZ!789>;.;%<=]MTM!*MB2AN/8M(>B!6WO=JY.EN!;S:_AV;W
MK1HL=X6G_['"_#?@Z)W-^AQW4@_NT_CK?!G<).$JA5>K1P&U7>*[1[?9C U/
M4.&@Y;+3%#?0O8K Y$*)E2X_96O5%!ZL: K+)@%PRBWV4HO['=^G>N9+:L2V
M4VU>0JAH56?-(T'N(K3 _)2*;KEZ0T=*,P-I?PZ8/=P1H55?H55(O:.4;"5I
MJM^OI>!PT?V@[R,X9?TB2\W&V7(]WBO&B!\37YDGK1WOC?N?47^Y__0!_+<<
M*#L%<Z22BZ-_KG"+T(H8SZ21?V=AX^GQ$4<SS+K':YYZ=JFK2U7WW'L_Q\_
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M-Y6HP0N6GHN/4V.A-67EAH(VYSD/)MM?$*J=3,1^VXB'2%A4) E[D&G+U?.
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M(],!L(7?4+ UUZ\P06XF_B^K+>A6L4TZT?7-TI*:#ED49H\N37()GZHV(+(
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M$9!P4G=WKG"L]1^G$"8N_4.C_Q!I<;SX@JH4[.8.==?/M_8@]V!,IQ&EJWO
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MR&0E@<\9%ED5*G:V'S/QS5Y)]#?Q!F*%\?+VXV8Z!ZKA\/T<PN9-[\!CU*O
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MAG8<)G(%*Y<9)>R,8*9L/\"E:IT"!<A'Q7BC20)".:'0Q& T<) N42)1"<O
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M/EY5VUV^0&3#:5I<E2=)* >AE,2Q6<!E@%[3M8OEE&B@*1XQLT*:H6O5;'F
M\_G!6+%=U3%%C!9Y$$TT?+Z4;5D!'P5YBN7S **T['8Q</P*6X%JJA,1&8HT
MVWB_TJPR@\*HY]4"8IBR"_$A3HS)$M<3N;A@XERJ4JSKPU*92!0\(*NU+"8E
M*H1D]>/)5M/J81&XAM?YBAYC8KE(I,=[5;4PB'((D4W;F4R.1WO>F,$*G6K?
MJ=!&G"EQM2)>;SBQ3UY\/=J#(W244YTAU"@*="FPK"ZKF58J"+CT0$A87F(@
M"KG(-&!;,_)Y!-=83>^U<Q$4BC6Y/)4TVK28;!(:*!04K,VP= G)=CG$[K,
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M*Q'I@EQST*;0%[11Q(E(K8AKVG!T3-HK9C16E S$K8/Y49VH:I ;YK"95(<
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MV<7S<G6D^&0_7K"X*-?A="S:S+,QN18Z8#],S$)Z)I;!7JO8I@(QC5!]&=*
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M93V!"_V5LWI<=206&U9*[52J(Q&@@A8*$1BHJ(ZMNOE*68YA8T!/[T<TOP+
M&)JG,E@B6FK4>2N,32E:0TNAQK.R'Z@NH44&_4#R._%Z-Q:;?L";ZX\R5*12
M;$:<8G9H8/[XH;\4"1,H.I-HU+1&A!!<T*[FVHEXU26E3SY5X. $*M ";,<E
M+RY)79(*:(/C*\5VRJO!(>.@2N,I3S=@ZJ,6R@.Q4='"$[8.BP.&J>/](B[6
M:H%+8B5-Q3F-MYRTF\V+4RF-KD?H4EVOTV@8">1ZOZ@BVIB*Y/0P'O5BO:&:
MUJM6AJ89QZ5\,.S2R+1TU*[E^A@#:LH Y"/Y: G&N2#>QEK5I&"[8>P+X[QG
MQIL9U4&4,3\4:0[I<HE&I(55>^E6(.)<+LSLB[U!C^ [/8H'!04/:,06 Q0G
M$F CVQ"YC@]'^!*LUW@-K Q1V\OY$!6,TUN1$8:@&I?(3%&J9ULI5ZYERDX1
M(M@,7K?S>BTDJDRT '6QIIQ*21#5%7D Z5;(LE0J6'!6*W*"Z_OMU63H)..#
M5ES*L_U(@V]%-0@J6-%_N!M$2W+E03[,?CO%8E0QPL >*6'1N$%X'*T4/"9:
MRH$X*O+@^%L$!#(BHDZ)-'M$4=;R><!,JTJYR:-V86@B<J_/&R&9&998FD:2
M,A;MMKD^SE,M Z=D6N&'1%&"DUK/I4EU_*"0J]2ZU*!3,H.68%53U6F/R'S*
M(ZIJ%IQ*'M*TZBIK9)-6A2N."2?60RP$(<%V>D@//;Y;TFLXX:E1GZS)5)RC
MA51;[0QS4E(RDE9:06UVU1.LO)$)QXOIT5%Z%$H@Y$[CF((X]JA>*I'=;,=J
M\FDBF99'\9XY*F=ILMI,2F YH?N=?*)N2(YH>$Q'ABI%1&@G\_802Z0Z649A
M,D3&".KC;%0N M%:,E,L*G4I3)O;I-*D:253H(<(WD_ ')+(P/&2.F3Z/"7T
MQ"Y-)LI O"+F1(09#5TBDQND2UT<&:+Y\<Y2?X@J"<JSP!)9:]-9@#?9JEY(
M96N]86U(4+5<MRS7M)(.-:M\LT=&,D C6H-9$60Z,!R7RLE:-DE&63--IL=;
M!-F>2'@]D<>C!NUX93. FCA8%.M=MPP0/*8 JE F4V1QU*PJM5;:"5S0@2"X
MF,:;>DX(G%8V&3-L+$SI.&C,8.T,BD11VD&BR! *O3">#9 .&_F"Y&#-%RLS
M_IY#*AH,9":*=IK12$UL.-TXQ[1&I4Q>L.5474L0>HOIUK68-"RW$[TRWXAK
MC=QP8'9T#:=1K^Y35<H#NM5@6!Z' +%2< VJ7^L6N ;MR0YK XFX(=>[6H9N
M1#7)8]*T'PLBOL;JIL! 85IH8>4..LQ2,,X$9++2UXL-A*?TE0];D59/-6W
MI4,HT U<U6E":<=+Q)UVBBY;R=P@F<WRJ4(QX#JF@>4BH!H3&<(2ZUHG*M5"
M$0%!C5/P-B:-+<6+&:52PVPA@A9OJ1&:,YB,&O(6*UG@W @Y*-AP/8_YU+#H
M]%.]&IWJ$JE:HEU(!^+ *H2T$:7[93T6J<LNOI+.52I2!^!C=9;K(;&!IR,Y
MMI/O%DO]=*>8]^->(<=5J$@C;8W2$&"K20;/@@&KR?V8F]2K(0>(EH08$(%Z
MXUV1;LVG/!M%-$WWR28**:3!9@./ZQ8T1^Y6$<?WQ.@@4Q(0!>/%T!Q]6AP9
M.=PFT1$V3'$-Q@ZZ%$XVNJTQ)19QEB'[HR2JMQQ(9Y.IC.)++$E-#<"OX2Q.
M.J$*N*Y6-C*U8LJR18%'A6A6'V'I$"?7[C3#/'\D,;@^EF';#KALG4,C#8WL
M9.6.K46=H9M#&452##M%:H+7@/ R5'"I6K\_ROE4N2<Z,!"KB9"2)E'"+1<4
MN:XW:7:\R@[?3;<]V1^I#A&&JLBP;8228JIIKA1*2H$38,ACFW435>NXIP%^
MQ]9] BYX)2V.-MA&FT,"39QZS-7*C_=ME!8LT#4!X_NV'Z1*X(CN=S)</N;:
M_5H8Z&0XTNC6):#(EPTRGW5*&FJ:R!"/U(E"*E]'RH1;#U/GFMF/CL93[H)I
MT&<!N-9LD( N\#%>:772C4@%KZ>Z:'8H=1FSH[H^TX\GXT&,@7@>#FN+4'48
MQN5<09%*V9"[Y+5(81Q3TJ&0ZA6/\K@ZUFFUC(S XR.9;&"BU!>#2L'OXT7)
M#SDYZV6KZ:)LV-6&T_-BH_B@J([:O9R7*+4%@2)SG7%<UGM5#-=3B%=AH )H
M25P]&$6-)*;YH1@Z:*F0$Q LI29EJY<(]=B&P% (F@NGAZ$0JFJN#B"0H$AJ
M&*_&N\28"G0Q+M2B02@)/!II!"#MEC#1MGRPS3?JL#N*&/6B%S);K%74DDF8
M,2(%R\F%T:^<+=M0EHHV^2XDPX7XF!(#H!&/^9F@H^D<C :.Q?JYK%,#&PUG
MF,&Y#%NL8VBC3ME#I,43IHH";LVP>9_JZ1+' (HHYVJ,*+*N,U8;-\R\U5*G
MJ[,=Q.#5,%(!#@$S="<W].AX:Y"0O4Z%(.(0C'?,"D8+/.:C/<#!U(@CM*0"
MB,1J;K*9E0(/'(< P97\JE,HE;/#?(P!84NRA\TPZ<CT(T.X#$":F8VS'4SN
MQ=QB)Q+'"Q4R%J+9*IQ@ZTG!'Y4!*TVQY79C;,N8 $2%R)!.$#&P8>757,R0
MK7!\%%BOB8D^DH@R39-&F'3'T,,ZN;(#(&'VY"N5HNWS?JM50H%,"R,Z=I 8
M[WW5@9YI@[R9C]3U $U0#NC&$ >TW1$E8Q9)\"HMVEQ'$W22B[A5K>>7!Y)G
MCL+X/.7=E:FON97;<"(NCK^SA+8EF"9$D$!1I*^F%2-GY[!T/QD7(KF"/9CZ
MLC"0FXH:W8IICO(MC!1YVB>+"A3Q&88D%5C5+2)::VOZ>%%J=(BC:S1;1WI1
M*22[IM*%M43,IG2EGB5].V:D"P(/-[(Y"LUF2IT4',D:4YK3G^(I'9GM=01!
MENJD.7YZZ].97)T*)+%J5UM""]&@?,0K<8I 102HUT):@,BY5+'&QHQ$2,1'
M,E83G-C('G]KKU N=3V/&?'8P$N/TXI1SBST()P7%,97^G+#BV$,IK5[G"]Z
M4*+?@E1=5-!N(E>H@P36+[*%N$L;75.NQ;VTUYG>Y6+B446TH^-=D0#P13[F
MA80,P]1VF-PD#*.KT+@N-RML-\L$5M#PAEX!R+=PGLS'P18E!G52 'TQ#Z!%
M;5"#LU+?]H!L?>5#_X"JUZ),OH7(W;CF=NP,*("Z(D =7<YDXVHA1OL@ZQ7T
M6GTP(+G2%,D?P2,\TLBY0@O5P1KCLE#@NTQY'.B+]1(@2J&<#*%09A@9T!$]
MV]5#OJB8"<*!<*X^C*$PZ+*5DMRW@1BO>263)!M(5F(ZN$^@8%\P:*Q:8\;N
M:TC&J9#19!%G!"=#VA<*7Q856#>;=;FA-8>A_L&-0@'@<(=O)-KE7J%/6?U1
M(3YD*@V5&;7]IEU/:D"$+X\WTT!T"-D,+PZ@!%]'8DJN I)I7$0+I8*G18NC
M4<7I&\4P&QFQKDR0K,ZQ"9+GTOFV:C0KW6)>3\?=:C^:))FQQV[D&RD^U'K-
ML!4VQL3Z?#_&8P8PC.A$J$V\ \5"GZ&8G-9KB&JIQ*:=D6/).L<5<8Y-9E,:
MF4UK!5C#XN.-H"8GCO).*HLDC;PE<'$Y597ZB11L=P<=NJ3Z$4:WHQJ# %%#
MK(V*CM;4K!Q9J_%4"HB 33,8T&IJ*)8@RQQ[[(@%=2MQ"AM%08IW6G'5+T:3
MY6&1I(J-N(>U@P)<-T)&;L"-DN?W6@Z;IWC6K8$B#[7-JNI7 4GU,G# E<?>
M1H';OD7$%+C+Y])D56.99,%Q+ OG:"]9XNK(ESS &><RV7P8/,;/ L"OS"S7
M=/&(^! ;/_YHQP=8UREQ#J!A D51V42^69,LI=0:=!$&SK)VI^J%%"Z.\DA"
M&/;S?#&1@SG,=Q,</2!CI2!=SE(UG1'!\4.N8B;&PP--1.Q:?1AURGV8[PE]
MO.6ID!9FMPJ4[N6[Z=[0@HL P&A>@\,4"W5:$!TGN$8'3?L^ZXM*CH&=E7L.
M=5;OX!)?MPH-FS,]M@38#;4/C5@ <NLZWQMVS+H&442T2'7S.8NALLTP30MS
MKECH*^5V*<68*W?NQX#_ 1$*?3M>Z=@#>!Q36#OT^% _KY;Q<D4P&:/@_U,K
M&XTV/SYL,CY)\ID#--'Q"9I/G;>)?O; S?CTSF=/Z/PG3V*52E]\I,HPUG@<
MR_-IY7/.SJYJZ4T=#(JN.A<45I^S9J!LW_\J0-F^8OIS/GW&JU2:S%A2SPC+
MB,S\\,8\694G4SB"H5 LF\32L6P&!)/I+)("4C$@FTTGT^CX/-$GFWX&EC ]
M7S E926L^A5@5VOZ&=BRJ[954]!7Z[K7"[$3F00*0)GXW$P6!N8B"30Y-Y$$
ML;D9$(;2 (Z "3"Y"G\-&)^5BN*J?47&7<OX)X]L[3>]MI/J&N:=_;)Y?Z;I
MFI#E-2S4/XDLKVFF'R-;_Y90/Q=C35VYBBFK4S:6U@7/FR\K+:&G^ZM /E7Z
M*9/^Y+)\=LWRJN=;[G -!_(8Q?G/',B;-KM)8?K(Z7Q/"(<R-?35[GU^HS4H
M!I[()*$8C">!SU^^3S7]?/Q!1S$_?:(Q/HF@JTXTKE;K\T&F#M\/!%=)ML,E
M_/)#GVMJ]/G@4D<PVXH\/[JJX:H;_YRK_W]CS;[<B?V;:[;Z*=3_[]=L?/>3
MYK?*EC]KKBOMF/X<'['&TO]T;)>E?T15N^?JTV_0D*6HHBM37LT+(ROXR9/2
MLC3IJ[ZNK,'M?-$YX+"W23T4Y?ZS@[DK9SA[_L=OQ)BHN(H7=BA,C?FK4)\U
M#&=JB/)G)?,O#-15;$%U9\_'55V9F'J5P>2G&K4AT(82\X3Q,W[64USSL[5<
M%X[%$NAXX[AH28(^45,_70L"YY8$5^K,G3*/B;$S0\?[ EFFMH8&GVH!@)/
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M.ZP-/#AWM\K+WW[%.O";KS[\DUB]]/W,97KS@>\M<#^BKUZ@+8\?<7SWHKG
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MMS*@(30$\L8]6#9D66M;I1G]UF2U0F$Y*BAM%5-14*O]1M=??.Y3U[5CJ1<
MM9Q0*)B*Z_A(VRTL%B.?VM!/\2/.@%.,8)NYXXKK:2I(REKI@&O<F*WC*G,S
M6QCP[6"I2X8Z05,-B*LNE,9XQ[,:L59\H1(1(5=V^@&G?28M@M8!(EZ_;/Z
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M8[B_^Q4BO[&9OZ1!#-*Q:KU>KW#K3Z+*1<KM^Z/(0[]^)X$AB+&(>P]R$.5
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MIM+^"E]U:THH:?XT)#)N3S<,E.3Y];>A+IJ(*N ^=5BCE'6;L;N6^F_#U5,
MQ[ZH[!K_AK+ETF)JA:0_R+G8H(B ])+TG_KPN?TZ I:0V%^8YOQ7@6OEO FF
M6UTBG@]/J9572C-6CU \E+^$R=;=$L@UUH[2^*K,,])7'!]9":26K'[I'1Q[
MJL>6KFHUB\,;YPI&6"RSC1[65M6AFR"KJ6.&%+M"XK)N^K5N7[). M'1H3';
M1?PW^=8AQ_KO4;B]"UO#FKFH=!A?G;X FQE.*=ZEN#_#NW8G\LWB'#3QSG1]
M5D!7!^NP6T\6U8O?9%P"]+@P;I!+.6K)TAC58H<)B#,Y:;$])SJNZ@EJB""L
M_3S*P81!9U?I^D!0T(;LK4S/3X]^YW/!17R&G[G3X@"[(L S6]NT PP(S"7:
M*3OKOE>(8MHCG$/WU]  A7Z"IGO@F-NO!+E*B>11,++4<+K*J861/D2=UMM/
MBKDOFV+#EV&O:\.LX&U?A=WS5MBG2!0=>PJDHK*.-%LD'7VC=CG?+5LCW"@J
M$?\3ZP?YTJ$ SJ<U.*@NV7_.SA2'5LQ<E[2<AL)H2)R5\U2EP"8]V7A'/.1"
MW.LD/ZNRTGR%FW"6I">7_8AGJ+>J?Z]D5*5KA?76E/H(HS0^--Z@M5[W(Z*E
M:D)5^^8;PY2TK [5VB(8*]T,ZL[-=QY2*"[(2Q:KPD%K@C6N51-#WA:2808(
M!(F3>=D]6GOJK/FTS=?BRY7%4A:=&>M=&LXC8USK]?S>)S8Y73TR_)4',J*=
M FITB(K5*Y.5M>)E&A%5ZPS!,5:3DM_FP:/G6IB-%*I^1B(]?N5 ,\XU?0/P
MPA\MH(0;R#:VHDE9IS$.+@F1<TQKU"*_VGZVKTS>>*L_6-J8 4\J+%6T'5=X
M9,"]\M8>/OQT;+ 2(.I681R##*9@-1UF42##4J+AC*R",9C\2T5;/21B:T7E
M\XT3>CA'PM(R6HO&G:;$VU&R*"(*R5:/J];*[MU5VJ<U>NL\8AEUO@ O/"\B
MU4:RI+V91%^ W]QK&5O+9YF,,9CU4V,(>+V(<T1_IGNKQV@8U\2#N-SO\?F+
MJY\2_;KI'H9+_TWQ,0]LZ"2G\@M@ C?QMCB]3A3W3E18>67&XZI:MV"#5#/@
MI;Y>X2RE]9'?\GTDD:(Q29L?J5CC"_#J1+#;[<Z@)U+;"V'U\UFX52-1X<UF
M+FKV<LR.CK:_^4&+E[#=&V2(GMO[^^!*,.TNAH=BZ9Y0];BK97%;8&<8!%XA
M1 &ZHB>>XOCJQ'/8KG<)-WF0/@,.'ZZHCPD7;O"@ 0-&MT2_LB.9/CC9N^")
M,1;S*4M\<3U+A-5M8.SNB=\,B2&GA>)&N.G$J>'-(%/6\0#_WTC^6O<T]&B:
M6?1 @K1*94C ;H(\1V]\Y^G^,.&V->>+N_+42N,221V/%"?6!Q#9957DVV9*
M?ZL=T[GJVMK)F]J:RNJ*6KI4_33VGIS* LDW9\JLQ7T //E4Z[PE%-%S=YU^
M 1ZOWB+/EGC9,>F'H[A5)"$;XT= 6\,IFS15HRA5>%=NCC FF<+WV"<9TDTQ
M!SD*>>[3EV9)H\P/+5.EI*21",+\(,@-5'1E$C0.E0QUAB =M$!3=](1K41\
M'Z?]&_U9PUTDD>/)\1RRH&09_NI#CR->AG#/NRR.#X\IMTVI,7_YJ%*^>6#4
MXR3?1]J%"=,1NVKZ7O4;/O14.BDO?8'KJ.(>AZ2#_X'D)&-YSX27V7B_W/T)
M4^4K!0AF2LL6+1.Y"#F'\C_B2(@S,4>IS$GZ0],H^]7Z?&(LX@K8L=O#L:)
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MEP/&3DYXB&+>[FO('A+2)0,R;-;<#?$SNR%DB8C8?3C#B>J*XW_S'Y6FLB^
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MB]EX'!H=%YP>/'Q*-IQ@KI":9+@G>D1BHI82@M?+2TI'?D&%I:'6:1&M(<_
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MK+I)]F'O_<:FK?V!&ITG^W&5#::YE!WZ95>"^3&YA90@Z@V]X %U+()EBWI
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MGB:-$2TL1TOKP+YEC@GLPL8<]VC1^$$8^=G HBJ-I+>),WZ<8K3%HSS+<KD
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M%S;KDVU&_]LDH$O'/VINOMP&RN6J#&"G9<M!&2T;VIT(J)?GP*+P*%8QTS)
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MKJ20LZ-2UP#"M$5@";+<QT?M-2-K@DUVRDGOM%N-$1GWEAY\XS7"<H=2+S3
M#SX4R:?MOP*QTKV&[/P0>>VY+U$]Z. G 3)Q05FP!3X*^/R:J6,[0+R<)Y0Z
M)M32'E!FDB.ZR+ANK_67P*):2 *]8%?3C-LX27T=JY1199FO6>RD;D\/+T(>
M-U+8<^S.]^QD?TQO:2JXI7$Z%0ZL[61$3F1&[P,XL0K:O"2D+D?NU+@_O1A4
MSN8UEE2DD$YY,H\B<441"^Z%TP(W[[=8Z+>73RS;^LA/OJ?-SH;Y^)3*38<=
MH^BXA6]*-'M?*T6X[4[I-96S'<=*KEJFE"Z7CEIX9#92+7?&X,2H;CX:6I4D
MCHX_N(.XV\-6CG%JZ@[XAJ-T=![;Z(DC'Q87@B_-18$U!6ML^G?&_7;9]$W7
MOP0V)0EOYX9G5;6Q2R_A LP>-_]&AEH>L-AM,*UVSJR-#";:*C%J-@#]G5I0
M%KAKE4.MW>KC'#\VPL _&BJK3-PA1(AN^/ZGWA1=#E\J$ MK/]O-I-3<N80Q
M#XCP/<JBP-HQ3A)*;-P<&D7?XWD_BS&KV?-+X!I):6B$RQ-*WG1'!P4=ES)W
M6^]T 2AQ&(^D&&VY\Z+-=]M1O14J$!NRT>%$*5H5H9R_YVB.'"5F%N%34R3_
MPCO8!?*.?]]\GXLSSZ:YZ[STM..R\42SE_JT569KUH^5*@G[2^#0+(G('S[F
M5B[:)@,<\YL]$,D;+U7J @D0]7HX!EAKMG=,P5CK<,"'L1I!=MK>X@M5EMQ$
MZ19F6>_],X<#^%<2ARD>.#C0].AN'-63K44,/L LD]%:M0X\ZKT.MR1]^M>T
M<B=)%V0!P,CSPP+ Y%T48%N5#>@VP*C=4:1#@OO4?1\JM5/#X5UP<0W)HZI-
MN*A:@'5O_OC E_<@O/L[$7'/22,^L:RYP^ZQT^/*-?5TG'B=\G0P%XEPD_T:
M>!HZ&F/B**'#O$E</Z $YP@WN^NH-=1Z9$L=C'Y"ZY-CB?:SYK 8 #]4[KZV
MM(8+EV )Y-<P\L=3_^_92"%S;0^M"V+WE29 _J=(O: @?4FXDG')54/BU-6/
MLJ4VCTMP?:HIBE]"\[6(H6&^3DYX'9!1UTT\H1C#S0B=(@(<1/A=$2^+?02R
MN-7I^Z/W32YS925^8_=X$VL%8\<,^[U:C=B.]!IEIEC,"$84V;IT?K=>9/,-
M#.#'L0^OD;(@'LY#JEYXYS^C_F$'@=K0W%7:T?M 6796MGP1N'3E(W03J?MR
MQ:7D-Q1OO'J0"0)6*ID;%$=? M6FJ=O@P ]M!,P0_9-I<VI&;6< $F%>LK&.
MSD6+W+G9SJY\S%@1*U09%W>)<#%5?J#V/;]Y\0=P7H$(,L\7>9X!;;JB&R2/
M<KG%%WN&\*)=U=!$<?)1X)*<+$"378GT-H,J$=Y'L5&M;B5;?)7(-MS>I_HE
M,"BRT4%"8TQC.W![Q\'C55\N1])C]O=%Z/LEB"WY D$/X#!&UX<91,!1/\_2
M^,-3;%*@BRUZ7DZ EJU7-R8;IB!WT> )&^>.CJ! ?REE5F:FFC?/1"]PQM84
M.KPFAJ26U-E."P)M9TT^L4R]WU<4OE%VI2;+VNLMWJ1.02=FA2*V2GMV0Q)8
MX%T;,$J<FMTA@>OX\$3%N.U&1?OUZ-Q4^T9&'8Y]W&;,_L)I:WZVQJU-0P()
M=\B^S(&36G(PZ0J"S/VLI$I<7<&',J_>+J"$T9Y_@DGX&;(!5@?9 :,^  $*
M<#;X9@[/>_YYSF:;VE(#7V1X(T!Y--8HO*GK\UA DXMSGH[5^!2P%E\(\L,"
M##W7^=#1;1(;AZR]]UYW=_:+L4?;!B6RT!SR-!&[>C<&Z3T[/@8'@:)O3I[J
M_H7LQF)Z'M2.:"=N+9_D$, L2]0FU4X<7]<KDXT:YJ@7M>I(V+&IL)4XX )*
M!_*&50+58@,H*:_7=EQ#40G(26? ./$J;LWXP=CIPH++0"J&L'!.LT;.J'@R
MP>D;!)X$-HZ9FUPUD'5YG6+J6 ?"A_/R:PK*!GFP>#;1'[X31>W3SZC/@F2+
M7RU!D;<#.H ]L"DL\&I',6W%VV(4XAEZS1,2AO%QN)O8GD_G12W[[@\78:_T
MZ3F"%*.R'<BP3_%+(*@)2F]9]%5XZ1!CH+<+]J:@T^#CH,HG0?GM>)6 R KA
M%[1$&<@HIJP#X]5(-'#P09\!12Z^>E&W]V=U3JH+G[E,'^[5<-FE'!(I):I
M!8@T<?D[E[M/%<RS4LUDQ$\1I5_W&9N>4+GX&3GRK]+I[Z^,Z)G=<?\$YY13
MY4B5'AQ9V)^8F*\X4/%>)S;?   )IX +K5?X'FY,+Q(X7N3;#2_2W6_:L#F&
M,L"EYI+PL'SXLM-DM6%N30K9^\2^Z/>=6]C17F6]X!FM@ C_+US?[J@WL<0N
ML1/)L/%TN!%3T!O'1T/-H%>L$0$ *S:P$4K::IZ19! ^:&=[U!*Z53IG!R8O
M',@2+@V =T1ST?!L7: ADMN5(<U:(5>$7,F/46JJZM9S-D]Q?UK[FY/R6P\+
MJ>L&;7J%\9M^"X=Z1.9O5-PHYJ&1HU;USQY=6V38EM<RI1^>XL+S;K>NP\F.
M<H]AB;C'V/BFP@IO-UQ7D-%+*V1.$'B/6;FMF[Q+=M_K;D)9%TGOXVP?I4:I
M+57A?- 71>,3YXTZ;2W[71#\8XN;VVX?M@PF0O<>"[TX=*^R"[?>DI .GXI[
M++4*<F\>,M^V+@B2_9Z.?JX^0\;S.SWV3MS >*[LU*(O<) /M0@/)2^[:LUD
M!MJ?1YY*+S%J#,?=IJQ5"X\67?!9]!N\C Z[&C90H!_RZ(B'EL(/)VI6.O-@
MW82(&R!'$($:7LT$%UQ%C>%@C4QM,UPOG80.J7?:OT&#WMYW1@'?MS!*3.RF
MZ9]"3THFK/>[<WCI5JO')<Y\;2IHEB%7B@VX3G37:13 7FD-?(^3/G6M=>DG
MN* * 9Y(("B-OZ?W1(@4^"7P36W#[J0P/ &@:/5WJ]FGA&/J=-E!U$PW5L1C
M!*P!V9E1][+N6!@#)0Y-R>)K._+W^K;J/0TQ89/2G^4^)Q$O$I#JH\NQ</ "
M!3P8F5:M#9</J1>U%5Z^4;3CN* +/CQV(YX+D-R<;(KLT7FU!7V?SX=>*S3Q
M64P;IY=%O"',#<^B*G [=**BT^\TOO(/DP3OXN+1_?4W98[:Q06$*<TB%Z9@
M"W"#B24:9M&]-(1HTXP_H7?P "MPZ;2+*D Y8[&B&6_?\(C""6O0FQ1Q0V0[
MZM!+WB;$#?[K?1X-D@PA7^:\B\HHGZY.,+\+!_UP/;RM(9O"1RU^:Z=+K:]
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M>.?;(BG-P;ADPR9S9@Y@Y,IA&HV)]>9GW:92MV7!_'&\,$4,J2\R([:!K_C
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M8;.MQM8)W#-ZBJ;<W.9- YL66"_DMR2OLNXVY]%,O#V2X]/%G/R^$1%$I?(
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MNNPC\'>'=_;NK'JQCIQ@DH!0R.]2L_.AK,<">A^DG$Y>#!&#A<T!O(*-^3X
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M9"$803;7% !09NPO_)(-IP^MR.R(=3&6PGG&%:[YZ9J8\B$0L;B[0JU67EJ
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M*PFSHUM2<.(P&9U@!T>@84 QEDRE0\@<&,7;#>/B&D8BN)+M9&@:2AE_L=Q
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M>D".V!4.MB0@4' @2!GNB#DR&(/H$4;P5F:L3DI'AA-CJ&1L$(\+%ME]YZ:
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M77Y9#V<GU,",]C8,A*]M/'0C8??,IV/G;K5]?#H=O>7==L6VX=?39TT)LEX
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MZ@%?GNE7LUCGB#+,H>Z*CR_!;)1L(1[,6_ $2MMS<V;MPO*S47(X9]7O/6N
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M! <O2EPD,F:XJ$"+F)T9&;"2S\QL1)9YG*0. 1EKO1H%)9<D!U6C*/W-=4Z
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MV6/UR70.!5&=0I!?!@6(;>1U)$R*_%A9O<MI/EE#J%=F*546CRQ:GV"S(*2
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M&=@4PZF(-DM6[J<PIO>0 <O!;@=L_(Q?6L"@G\B+VHD)2PB@\WH>E>YWRV8
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MH"% ]ERTC7O]>/PS@RBK0O65\25PVC]&6QD;6>#NH47QUZ@MG&=EVI^Z(K
M,8 C_]FMZPH/3Z&_UTVO)9W6AGGJA?=$)*647^ZE\XT?X7!7-M]EK%B*BU97
MF ]Z.18YB8U&;OH""VPTO=7E1T9\ ,_&F1DWG=6*DP@MDLU#FQW2LOAX<P;1
MTH/V[\5&:MY?P#]]H.?Z%\#./JTKOD97O>E<7,+_X!$NNFT=Q<S^=@X:H]Q2
MH!].^[E@-___\/&647%%S=I@)[@'=Y= X^X0W"&X!]?&W4EP&AIW=W=W=W>7
MX$Z".TSNK)F[UG?O._-__SFUJ^J14[4=\S48M[Y"&IY]O;IY_-?DIY/9Y-"(
ML>SP\]D:K.=#C:Y#=AI4-G!:$Q\A0;5QRXVQ4K0P37JXK($0DQ0F+2.F0I,0
M?LBO$@X7)]A9E1$&'6U-;2-*!%04$U/ 3ZRU!TLFE_^3:I>R=WE;7^:^R$+*
M\C%<?S?,>U"KFBEF(,%H2RNL5ITKE@;/F)(S]JX@-L7):/W$)</;^>WULT/'
MA=VS#., DB++Q_2)@['A,YJ^UTEA[[RMR[*"VT:4_X#@PV)3!OA0+</W00-K
MD!.]37)._;!AT):ZL B#J?;XE*62*+)(Q0Z&:+7 [Y-Z4#)M9B/04=!!EIM=
MN]08@0B*U% *P&C+R7=FS##OSQ]?4Q?G@\29J45L>RU%4ULZJHX&=&<X2"#1
MN*$3=&418&SG0Z]W4](C*CNHMP0%R7'-<E_$F9 Y'=316T?<ZK3-BG,P9&\N
M/7O<"7[3Z/T/&Q@MW$K@"M3O7"D1,>-X=Q[OM$^8H=DFU_[(76QIN;(L]I$V
MY?V44S2<*UPH\]KCUR/UYILPBP;B[@>M&/G$A9./,)(Z14GU^*%?PF\;8@F]
MY6P.%U7'W@BQ.19"/$X//&T<5?FT2>XY"_NKV]4+QAK?LLS7!,YT80F33EG
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M/<'&9#@NJ=G0V;'N!11"B.0)$ZDHX05>9 6S:7 E2,Q_TR*^BI4@Y<;,IR%
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MKL])3J@*%H?VNL#QXDBEFL?@-=@BXG!"MY'(*0!1'HY:XW?\8)CRTJ0F$W_
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MVG B'T_'J.V\28F-V:@H89^-##?A3X[Z:A#/=N*SU:+]YC#/J8=O?G]%JR7
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MCL^>A^JL8*@F>Z2+V71W?S3Z75%GL7MDQ%([;"/LF%N5=JT5Z3Q(XS)!6^5
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M%%\R)\C$X#)/"2<\=38GN+C-9?2D+^Y3=LUJ$<.()6L]:-A B FC)G''>!^
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MNX8!3^\%5!T>U9G6^:Y:3WFR;>E-!87269^S=*M(&I65)SO-*>1;+OS648S
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M%->36&[USFC37C,IRT]?*@<F]R+L83F2/H =(FTZ$4<M4DL>_HB=TZK2I[J
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M_#H<@"Q9%',?,=<H0O.HZ]W3>D=A<2G+24EB*P=CH9R(&\\(4?UZ_%Z3?-4
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M8"J;5KA]XT+5M,'U=?<>(A\NO)3YT)OY"6QX42Z^P[6ZMJ7$LVR"]&X?/K*
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MGI0IKI$PPP823@ZPJ&UU,H@6&QI5)QNI59!\40DU.,U#=+5-NE. KJJFZ^S
M)=KE% C50::)=7(9K(86D4@,&.3Y?#-4$[Q&L8NH' 5W]!K:2^7%JH/5(OUT
MNN RO HZ5"O*U")3@(K5@)4V5.CZ[%>Y%>.\%Y\"K.M>)-Q/IN$"!X)91';M
MF DG.F*AHVAR7BW$; %P*J#/%C0 'OIY 4X8()_,PU@6)M(5S.RWQ%*YPW9\
M AEI.0J6T[FFW&*%DAZ2*)$:%FVF6+'3C2CA4%P>3RO90/^1-FL[C,T560C'
M;%N4-5D..[)-YIUTQ4,&49ZSIP!Q(ZJ".<M&/0S&F40J9T3B=(5E*4[E<CJ:
MY08"$Z>5KL8VVDU<*=@N7:G3&@[R)HQDS5RHJMC-52MZ"C":8;I=C].K# B@
MH,<9>KP((HULOJ-0-)Q)#B/>H&&3;DDC49:S[2H/E,L.KT=1(M!8R,B@##EP
MRY;LH"/G -LBDLEKF*@K$*:J=@7+D!5;$SDSK%<M425"SH 3M799ADC3%2@B
MWF>[C38V%".8RC2PKE5W,:NI9D*Y]DC+FL9YCN,326! I3U_2*(FDT7K@I@4
M2+Q)!0ZFR3"M$%S+8%JB21*E=FW80S.@;><)2//=<A5AJO&^!K#U*4 +;0NA
M&%]2PH-6*L/E^Z%Z>=C,^*E$3PL%FB=<K"S#Q8H_D V<C7.4:3HMQ1;U4%K2
MP@-/L8VD$T:  21K4X!%$I&]2%&7Y01OX*Y:B]IIVLQ#"2*J6#6U0@XK<:6+
M.H"1^(QU3F>',:A9BW/=*4"I[,8+/:LNT'4(" 4>+A*5:@D8Y^A& V+(6#E?
M5S#*8^JVR@[-)N*DJHX9J"Y+.J$: 'OEFN*UU&*AV>F,HA[@=5";<')-(# $
M3DMPV8()#WIV3]?+PT18B]:0( 0:7ISP'#"J8Z1:'PR&M$]D>=L,<A$1#&7)
M4J^:82*C*7MAPC>ZG9P,#4Q$(3M<4G%Y!_>UM"V;6;5NLHE&(Y-I0FR89RLY
M/12*(9 *VK 6\KEX.\U$AU8HB@28*6"T]* X31<[V8%>T31;KC!"(F+[W?(P
M'Y*J0ZZOQEQ():K#2IYH,H$3$1W"=72M7Y"53,IP."\9B;#5<&"K-6,*<!#J
MQ:O"L&RILLXI>:%3K4=@NJHBO(#Z@P8G1IE.H XJ5K&85I)CZY^(=<&M'8E3
M;J,(T3X]4DJV&]%2=*4UF7SE8HF!VO$8%NUDN$)8;R;Y(=^P:#CI]5M@ ;<%
M.V)X:@HK<%K."W>*,F;4XS$V1;AL/3YR#C">-5 1JV 2!P01L6)6PY9+04P3
M;H<'U: Z9'VV-[00JC8D+8&KH96N5Q;M 4;#FLIFZ8J#*@,?1_.%+#L%2'LY
MA[8&1+MN>7VDA-6UBD9U.X-RCZ-D1E!2 Z$IUR)QMFL)@[C7,%.V-BP6RP77
MG5S!=L^FB4&[&JM0W"@_= "KG0A2M(&K@M54M!HS>F2FEQ2I(C+L*H#5B1=J
M %)BZHHJ1ZH=3HP7VR$JQH9R><ZO5<.)/"4W!C% K>FA*<"(RK,-BF[D^:0E
MM(9L"&LT$2\LL5&A#MEUN=X;], 4$PTS @2 *M3A%54II_IZ@>KE!06OYOM&
M)0:(Q$"(30%2 [(B"BP1SN?4#E,N2D@3S@SMF&[Z,""Y+0]F-2[C2%B;D&IU
MAN^&^R"4#2H#I_B)]6<,*R-_Z%DN7D]TT+@5KH7U4MMGR:D^2;)B&#EDP$L)
M2R>J?&V@,EPL\.0R.ZSH$2&.=K(&Q$)D4M$,N9 M<.%1*I+(DURXGPI!N48X
M3DF@8N/=, ZV);DA-&MZ+T[1'$P!&5.#"T4Q9-(UR!DRZ5BS3;5Z?<<+C"@%
MUH1FKLP1HV0I4H^JV9#I=.EAK%\>! &K'@-XS2(1*ZQC L4"0%6,1+1&F.6K
M'3]OY;/E=D3JBSJ0IWL($^(S(:O0,[((-P58@JI50*M0/<JWPI9&]0I\$DH[
M.;C!1XM=-HC/(;;4Y4HJ[UL2@G347A!S@"BJI0ATF(P([9PFEY!,0X>3(^=@
M5PHLCD9LDV^'JI!38P#>#]6-EJ>2 [-@%1K-:C='J; LJ4C%-$R+JI0R!=#W
M:F80-%B_CI;K$#DL!6O(FP(4 H'R2&"G'=_,-(;#!A3"E6XT'0HEF<::GC39
MS,L.U[70L)T9 'P/!6)NU\CF0S15R=1#Z4X%'!EV5M!QIXAV$D&2F$FZ-<8)
M)PB_1VB6Z44M7/<ZQ;QHB4J!+:K<,-6J\[XPA/S(0&QQHAC*I9L)/EIHY_CP
M:"V7P#*3MY!X"42C@,U5*D4,-S2^D*\G(KQ:MITLIR* P.M]",&ZA;3:#1>Z
M7;Z<4.,PTNJ150_QJH!:Y,L5?U169'H1/R94/;((-)*A:(.FS:)H>XJ&YC\G
MY\%[9!Q224V@W!C1+* >T@)&*Z6EL#T;0*MZB0C4H(D40)%V-!JMVT9WDK*=
MB==1NCFL>*F0$KCJO%,&0=!R0I5LAD)M6?&L888IITPS,G*PJH^V0+82ZR&2
MS",DT2LRLEC42Y&ND59@OB@E35LIZW@?C/B)(A74'&QR6&?*_1A;""H AZ])
M: V)&Z[0':T4#2Q$V@ VX.B8$0*0D >3U6Y-""?PO-)L9CBY;GY&CIPKE\FA
M[?!T5^/S>#W>&&F98P4>UI(1I5!JJX8F];,\2:6RJ!UA -$)UHCMR+5Z/ GT
M8@DX!=5R*$!&E4BZTLGX)3,LNUR06%G)$&"'1V$TVT\DS R30Q  R8-NT2)+
M;C04;<M\-@&[[4X$DY.]=@?.X8.N@K-.K *A:;7@6H%BRB6O# AU,)$/!\,$
M\J/\L%<)UTRYG8/*\7JXV N2L\C:<6C5C5%C,,7+4I%&>CI7RD+=8@/6I6'6
MIO1()]U>5=[:B1[F\?' I77C+3[4#BH32>GKW6BV2$<4NU6!.G#<I?MX0M0C
M!$V3@U(?<RII<L VFI/BK-<D'5;#9&EDAWRF/I0HKIH70UZ]AYI*0FMPK1YM
M,2FM2&F9)!@J:K%2P1T0;H7$ I.P*BIK2VC=]CFHGHN!0L@(LXK;J8VJ !Z6
M0* <J)-;QR2#FVL8;2_2R"-(1FDI3*]80##3+A3<(2&U$J5 E(JN!N6\X14[
MHSJE*G70#B)JJ2'4-JR<2'AXI#Z(E:U$N%?-<IU)1:;R'M=B6;)9#+4Q@.A:
ML*)YC=X0!=$A.>3R!ENIU_G1)@:+X2Z?9PI8.)VQC0Q'- V:#]4\HB,3@SZ-
M6@G-SQ9;7+]1KFIDMFY')+F2ZS-PJ)/!JU&NAX<TM"?!)$B6IP#%RJ!&4T$Z
MV:J#N6BW).,$5H?*N ]7;;H:8:Q*W:P/FZ&*EXZY/A0'&W"F'P.C-J2:@R&<
MLTPY$[BJ8@IS1SFV:(7P,!8IIP6GJ@0!!Z76[1*H;E2+RGA)Z^5%U<U$J"Q!
M%.)AN$,IVN2*PM'PR YSCA>B&H-"*$A(HFC#3O=R:E6$795)60FZV59;BJ0,
M8W1BF PJ#:5-#W+#%,]W)(Y@R)9*J#9,>J6^H?)Y>;1%T"NIOLD&E3(7+QG5
M7I";-R8MF\-AM:0/FKK0Z)%-SH9=LN5 (8.F!V&.RY-]P^[WVY%()>&4LF*0
M4&;A4;W,V ,[W>T-.@"'>B3EY>-5,!DA63GO= E2*%AI/(&92K^@L!&+L4TA
MPF9XUK:\2LP*U:12+%CCB%*##"XW"O39#(FY-*>I#:C1%N%"S NW.+-FMC P
M\(GQA%_YE'6RV5BOR V\O#.(:EP6] ">DQM#BAFE(LE!HQ--!!5%.M3(@S$X
M5Y4P#RJ#-29+(A(4=>-=!$ S9@=UQ!S7H,-V!P :; AON06\,M!*$4&+LV 0
MS\E11:^I %RU:HUTIV4DY,!WY6+2(+"R 4;"JI-MV3FVRMDNP>11;RB08EDH
M%CJU--]&\$J_:#ML1'7 !!DD,".ER&&#LEP6:<BUKI#1!=8, BLLZ$"U1W1B
M7 ''Z$&&U*,%+B8R;8-$G" <Y]4,TH3B'EI.5&6GH(AE%I&-X10@DA;E9B+&
MQ_G @*.(!4;I8FCHF@(6;G<;:;!&ASFEI2N-EM4S4=FT\KR1;T(2VNFGZO8@
MO*: 1U7 JM2[+0<9F,@-6[C62V5*@"7P:H<N5A0=S@%=3V3I,N.)79)J$;)2
MJ4E#@;""8-?00:X(-ML$[WO22,NJ;6C=&._V!(U))UG"Z57JEI %74%&=%?@
M 9Y4N12@</&,)B5\G6:B1*NLR*&"9:R*+L,>FPOWL<IHRGRE32CAJ!(L:*76
M@OT:60'ZA6Z!<?HPYZ5H+Q44K"2"0#$':@991<8.<WF!U6A$M/+]3J.5B@EM
MN0 @SFC_,!\$1,VIJAZ+47S&#NF\$VI 9HTS:HP$)T.M:#H3,5(B+>A(4QG$
M@SR^3Z9ZBE,BUHZ$HQ%R'F_Q*&M)PR;,#"J!)=3 1E"V-)1,5?-3.4E)N@1+
M)]"4HYNHGY=K3*SN"3R5M)!N.C-@L4(%B*7S'4\=95](B(*T)NCUW%:!SK(T
M2C;"#@O7?;DN<SJ'UG PQS2<;I9&*!K%(KELM@3S4!,LU>FJ3N5\'$M%Y((6
MK%)HM*E+Q_B@X@UU^9R55#"NEBR6B'S:K.11)N63>0PI%WFV2C6ABA]*5CI>
M+F:A38M!JY4A3$2I=B@'V@UKD,]71CN<FH:4V4',2+ VGVHJ209DZ6C,EZI@
MK1HO 4%^VS!:A@9BA8Q!1=F"'1/U81:E*3DPR*)2JJ"=>B[#^* P&&VF(1(H
M(VJ7I#VN6]/2_,#OD21:Q7(&6N?3)7SH$TZZF0))N5MPI5A?KI:+7*?/D; %
M&;8&A(+L9MBMI6II<U1)]7#?*Q+#7FY0S*D#(Z)4.:MN9(IE@BE]TFT[1272
M\B+YX$/ELEB&4W5=K1<4W+2'A&\F$JMVVM6@/%:&7C%5B]/=1K0[5$/V@*(&
M?LSI!IDK%.O0OJ]P8)++ 3I'!C7]()EB&Q5?R'!,.9NM%# V@>,1(#J:<L=.
M*6MXNQC:%:@@0%IN-"A[C:!&\;(=-\)Q,$>:09SC\#+H@'J.A."0P]H%L8O[
M]$"N#8H(JX\ C8[A]FHTT@2+6J/1L)(X!,K-_'#@^#6MYOAT#\J8)MVA)-*5
MR# Q"'G%+,Q!7CV.N2V5+V1J?+1+U01QE' &GQF._V1^Q*H 0*2+PRI=S*2R
M%D]3@PS+)FS:+_43/MN2?'D@\V7""9+>?K<C<S4"' H#;+128+4KM"L(Q7:*
ME-E'<*S,XF:"MUDUE:3UDH>"<A4F)'U0([UL(V$!H4&!1MNB[1.-8I94BAS$
M*EBCQS"CA!-"\B' I'0]5..'E!X&0E@6;N&JY\B%:)#7L #O-D(.F<M@3C'N
MJ(GJ $:C$7M0G)R-7XP-A%10>9)&VAX9=BQ& D4EF1<J-84 1*9E,KC0B3M1
MVAXV![;(5H>U)I'5T9Q P9S9K4=YNN+K=<RV:!(I]"*8VL@-S5*HX(Z< U@=
M&F99+X%>7<A6 C/A;+02\WJB#3!&=! +- LZL2K>;]30ELC%.T%RD5PSN6B0
M!=PTM(+;'WTG1?ML@JL#&;Y@POD@[:RD:WJ1S@)Z$":B;:%81>0\+<?"0)T1
M6_FP'&MZ;"[G!UF<UXOS(#R4:TT425ET>3 J'MU\6^R#&9N1X<"C4!I51ZP6
M7PCR6K391FV-'I;*58<KA;4>B(2YALH5*CI7L?RJ5,$'L*5HU6XF:OBE0KHZ
MVC]<LSZ,AN)>+4PVJT51R3M*%E196L55C2GG<"1.BV&8#J?B+2': DV08,SP
M,!>J<X$^P1XBA$:I2*]IAPPO[7I]A1)S-,OF-24U,(=6%E!P)!$">,S+!H8]
M'/0<5G,,I%7+VA#=]7H2GZR[]L#JJ[F0!K.L,$KG6JI4;N=S/44S]$+N7]^W
ME'D84?4VF/0(P"V*<-^S](*5C47:W0[:!.D2$B^&4+JF^S;"F9R)!V7&%&"3
M@$W4J<-2.R^1#F%V>(YFFFC9C%MYK)2/<W2Z-"12L4I;LG2$*:>+W4R!17-U
MM.=P#F]9DA-4NZ46Q2O%T929J!).A;FBSE,4[DIYIEP&>E7%+-B];*MLXP6Z
MT*,GMR%+?D<J!D58&T>D$(9KM-1F\$QVT"J4ZW63*A5&.YR3UN1286+(6L'D
ME+[1MH>]ID]AI. [.6- 5P6P0C$"&W'[69"67#95L!P>UHF&KM",3PZ5HIV-
MN&Q!U%9M594S2ED5V7H8,=QB80CH$#?T(M%&%BS3,M\/*I=V$0U*J%9"RC )
M)I:$?%;51X9M\E&P&@R>A]M=1QE5]%D.%=H"'DUD(#M)-7-26[&K?!2)Q'J\
M%)>\LL.HD FY19J&/+6E&Y48;W>G:JIPUVM@)0I-1*R$IX1&(Y3%,J$[H:H@
M\S30*V;Q2E"!@"&$2T68=(.G'!Y+1A"EZOEUOY#H^<VT[-8';FT@B!!1T>LM
MI::7J&HQYM1']7+1"YLJUX4(!6;#A-V'JT = QN9%,E7?)>+9TM$M]EF )+O
M\('<L(J+#R.-NJ6G>[;"%XOU>!X8E)D&&4Q@Y+&YL,[DBV*;0CN% I,4^M"@
MRBBQ3^89P[C'QOI4V"CH1@]%T5JYGFHIE.:(OIG/ICO=/(?UT-%.>T,"LG!:
M3OKT$(!BJ5*-X+5!A?89UDY44C4HZ5=\'DKD$+L6R222)FM44F&]V.T&UN&N
M\C@MJ-<TBJ-MECS088+\.",[93MK:D':!KLXU\5J];2:L%PYDQPD;*IF\EF5
MPFLUUBUE*TI>E56XUD<"YZ/%(DT]C/B@PF='_A 84 Z-N(+"<7%/*)1*3: M
M>%D@W]#X8(EIU9K*,$;#]*LX@DEV%(I6L;(=L4,J*,50E 6C784+-:/#X2@N
MIX/<$FPRC!LG.0KB_(()1GTC,JAI0[D" >Z@;:AY 8"T,&\FR+XKNK8#>UVE
M'VOFW!17HN!(UV#$<@T.C:)>3YZL7Y(Q3V[2) 5VO;[+XZ!G]D";YA(5U\2J
MKNWB>MG.XW9(R; 26!=!LF@D906MFI".4KS'H\T42HS6,ETF(D4B2N9QWHV6
MD(:>CP^5=O:?<94+-" @.-@95O,!%XQ+5U!)),MBOQ:X(;$:M7RAG<DB#3 Q
MRAP4."^35=!Q[6$GPY%-O2@..4/C^%"K%=3 =3AC2#[41UB5[,D4+2:8P*T7
M19Z-1*6X'<EGVT)#:?N#M)#HC38QI':,;H$Q-,0+-N UXD3,@,5^MPZJA#<4
M(:^'6?4$8.<T/11*YR _2&@;E*E*@V(+; XEF6O4>2EC@7ULE&.#H4*HJG8R
M57?(RS CR:&,XC>'1-B(<E(>,-"V-$0ENQK4XVTO*O- 7$ZU+)[CLA12%4)Z
MJ8[1)9ALI4+@*.K5!\ERWO,'2C'2EB$HSLAA58@/.DX982#9AC5#Y)TF&K;I
M_B &>U&4@PV%MUC%]LUZ)-*228RMA;(84[1&SJ$]#&7S E5.%^ ,B'2&,8A#
MI7J(*Y:0KD/W8UY1J,J*4FM:D-;+YMIJJF"3.)91,VF\ )*E<+",38HSJER*
M'SF'3,K2U2&DZT-?-'$3CT1KBMM'0*ZL=BA79N46V6QF&*\%"-5BAW(8OLFC
M1L-#B2989DR=*H)XA<+59FFTLZ0+[5XOAULYQ1,92VZ6FT8!CO6':#7<UE&0
M+Q7RN0PH!#EIAA[&O*C"FEPH74C2-3L;XS%21RV7P&,)K6F/-H*B$ESHQ*2P
M5-/U3 >)@CP"RA$ K0T,&^P"Z0(=@S)NX"Q"N&RAL)G&;" R(*HQKA^)!/4:
M8=5Y7Y$ZHL&/MJID6"[)8;0L.BB(0%VOX-4=I3J(VF)+U6G<R:J$Q7)EG_1;
MFBY$V&29;I-)AO4#3U;*86(;3R;,6K=2[K&C ER,(09=Q_-Y*=_CY(C>:0>9
M)4EQ(D8-ZKIF]0,/CB;B!:5+6$RWF&ZH2K^0+"&.%M($)W"0,4#/0EJV!<='
MF8,*^ID4#O!F&".A4*':P8"AH91:D:C>L@N1H5:CM%9?QNFB4E"J71Z1R)"%
M$IVV2JA\E^$)+]2/ERHA":/4D5+:3<7)(;T"(\(&G1I2^4+;\ ++<U+9M);"
M2ATCHL<%8!ACG&S/:H(^2TJU7B.:HX6@IH\VHI ,!M)0W,C(8P<S[E1<EP92
M.17)I9FDSR)=6#>&5 IQO+C8B9EHA\S;L@YY9EPUL<"[ZMU\MCXLI2D^2U%T
MK25;9I)VJR-O(R:]]J1\N&0_)"/Q/FJBD1@2UB- -60@&#>P4<JOTF@G*>EN
MIYVI][E(TL1@/P<F,AF:3F"B"CK59M-(C+XH[!J#&D]Q0!F$0"[6]@0L8_?I
M&I8G.0;MB%W;R?IUURV!A6BJF>$*(;XWZ,?ZJ!^JA]R:-,R(M:P*$VE1%491
M#_7I HU@E%_RX*+0[Z'U=EUK*EA,@T+%@I^.460T,\@CII'))CJ,"3>BT3!+
M4Y6FFBN+H7H> &D?+,?3ON^,@A3?JS?-P="(5X"$;??B-2Q:9O*Q&D3+721=
M]=-NHX$;63P:JY3[H6J1"K&PIO.05]3+E3#!$SY-\SR->+E1".AB/F/%&US$
MD,!(*)<)O&T-:E0B=BUEE$IH@FQUQ-HPVBL/J::>&@SM,&A4\V2I!:+8I//)
M2L5LA(? 0@H<Y8=#-MF3=*Y0=@9.OF]%A/I J;(9D8A0/:7CU](M :2B(:H'
MXZDAB31C*"02W1Z?L=*@XW@NIR=</"J#GI49:;D 6)H+=*.QX;#D-A-NB]4S
M";I2:) 6!77">BTDI+M:DVN$!VBW&/A[S(T/XT+'R^>Y#N?T<HVJKS0C/8BM
MC?QA!.M229*K0 U"I A?D?%:X+-"<CA?(O%8**PG94YD8CT5B^=PIM&6(#5?
M+,C%= 5F5,)NJ8+8#M>RA)-Q1M6H+Z:'V3Z/=E163L7Z93*MVU4H&>OPKM/W
M[8@ %@F<YL4V.ASF!2_N\<E\M@S9+5&DBK+=H/M@)QW-(B50&7F;J#^$PSDJ
M18?U'(((;-[) K$6VB[$&-XM<X9GIA&)"P,=+2]T"R4OT='LF-T1&FD/M9)^
M(DCR_ ;)@O&P#X_^3(LNQMR0U"1#IEQW.E6R$;-K)8W"%5DK=3 Y36!5? CG
MTTPUT59-MXFWVMU>%$]W?)9NU,U.-C"Q( EPNHG1#N>D<U6'0MY+!669;ONH
M&E<C  +0DW^L0[0C-D]@%:Y099*92K-5]BK1-IOB<T*HCK-@*EX,*M\^X,'Y
MO!4>_65:BU$\CI73588N6&RWIO!,"(_82A0KA:E\1QXDD9PNF2K3L@,I$WPK
MA@^[)I+U^+0J*HF48F= " 8A24B/@E19]"$G+U<&M>@@D=/X MTPP22%NJ%^
M#N(E/LH4["AG>I(:LHH6H3*5#(C%0S$+SWNLF&5QOZ\F&V NMWI#,FE6;,_%
MI6:5(UDYKK=50 _B$*"3A9"73:8S!E>-5+P47J*C:E3OU>MV6W>;9$%F8"\-
M)O,]HMT6.DTWHXRJ@/20X+*P17=:FHS;[7P"ADF1I4JM/AK.Y*2P%:PBFD)"
MK(ES2+M.9;(>5LUAO(<[/;IM#:P!2;!T".O'HJG1TL/<&!A/AMIL%X%)&W-H
MDN\)MEM(AUI:EI;H,-1MFYR081KU?JB1 66$CVEM@>[D\;CCRVZ?L=*N*!11
M8B3#6*6O\3W<D"@F&K%-61"J0TGL5_*(T*T+-%LM-)"&@8$.AO;M#)$98,G"
MH.M#$!<D/P,;'K)\2(S:&-2)C4HSF'0:=*S1D:IPLH$2=8[+U($XV8>C8,NO
M Y8?&H TP=;X84"8%YI5 + 1+]*( !H9)@O0D&ZR$(T7#+,WRKYJ()1R*X.L
M L"(4+!BR<H:)6ZH'B_'(%@9^CS5I#AZT*>+*3$7%46/::3ZA-B2>TFP*&IF
M%N+LT39+P6X$S/F.!#%:KP[C@1=A&N5:1.VVZPQ'$ZT6VQ$B-H%E+9\L!#$O
M:Q<*249O64R\JM@LQ[8=1N[!<5A<M>VL H-Z,5[U6C2MX1$0+ZB)HB_ELS9&
MPZ6VU:]E6-!K\ -#+\5[>4&K6FFOE\H)7+V8T?2*V\BG&*:F9A-F:?17!(6(
M;?7YFAWEBY;GB'"[QA0;42EJHXHT'*:+22M#\K*99X-X@J><@8DE")8)DVP;
M47M"O8+F):M!$YUB?O2E?Y2P<M$!:1<2G7 B"U  PB9K&L.6"E;;(4IF%66E
M/BKA+ALOI@<<X! ,5NJ;V3P6E(!H/+!!BPS2$<>$NJ.-H "J;+.QV!!ERS':
MXA4NPU*%&$?B2&68$BS%YE$V*?>A8;C&);OY?".?97,RE6:-<I)M]!T& Z()
MUJD&ECJ:,A"N]@@WJ%'1;E1'J#BN$; )M;3&P,C7D]F*I7!ZC.FDQ4%R&)3>
MH&75=+9,L,-F%55[:%ZN>\F ;0VOC)(E7*L60"R%*IEN(I-DHH9K6Q"GA.H4
MTI+#72?<MM JG/(Y@E'=EERB2WF<RJ-:HI=P\'"&HAW,J$JLR@5%Y.A[O36W
M6:T,XG5[1*!%JPU@R:#^JS(X'HUSF8IGPD60LV6-],+Q7H9-QINQX8#&-0]I
MJIB7'6:YT?<I?(D,&#9MO)-L,O4"#'%B(HCR$34POK97C?5#HIEM&6ZX&-.
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M4[ E1VDI!J^MP;K;#;#3R0B0BD9B<Y-P/#(W$D73<Y,0 ,X%XID,DHFG$R"
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M>%W1!JL1UB1>]>2+R$5Y8FVV4XV?3S<YR8F2%83]R=_6))YZ\MG$O5' HKW
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M9?*=BYYZC]KGJ?.VN?=X?\5!?_OHH,O#CX$OOGGG#][]]QS@Y,<!IT$__]Y
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MNFZKS!RN]]$OFDPL+7H3:8B5"Y&">\Q23K[C#TO'!6._ZETYK2,'/63(E,;
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M4L]REA'W?62\ \[W]Q+J<H,LA":^J&6#'(27</N?G97#ABB>S5ZDJKX*%$+
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M*(L;;72Z(G?(./\_<)HX_]"MW"(?N#+Z.2'Q2&C2/?'W@GNAM<28N/CFVU_
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M8'S""^>KTRWP91ZXB,]X*S\J^=$'PW+\$>% 7D0NP@B:Y-OBGRD^P2$3/$\
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M&W.&U7*MABZ%1 2G9.HR4;/ O>04JYAE%_EQ06V\1-A*<C[]RR"0/,A<]/L
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M%_ABA):O8G%J8X=8=XEC<5[<W]8KO![,<_ZOPFE]I;<!XU0/7P='<1P'Z /
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MW=)Q=W-1=W5XF;;QUH-4'RZ'T%%D142+2,H@MF \D+!Z-9L)9C>N8//[\GT
M0M+XKTI4:GAV0S29>=T5WF&.ZQP0&AK,'+GAG7==%Z^B\ EK,QUA]BK):,!Q
M2#'5"E/A<>4W31/^-IN^AK:=%_[ZWV-2V/%?V4K92^DI=6_PR.+ML]$PS ?V
MWD\RO_L_E:Y\&9?%%D5VR/8=\/%:IM5Y>VG %YK\17'<N!J1J3F?\I3Q:B1W
MI])O3EMG"X#ZPN$#G"]@XEPZ4C_,9NG-JY&$-Z4,6=:/T2$.>75$A/3T7"&(
MH"*9Z>'DS^A-TEM%*,9G9-<)RO-'JU;KN9X)TLX1,GO5HO#AK=H.\W_J"8=A
MQ2S_/AY<TS+#J*VFMOP/YKYJZ36/1:VNJOUV=UZ?,U<2)?*M>ZX6%Q&8V]7&
MLK]P+17UG%I:\F;<: <$!\Q7=!@ZK*1FQ\TLG)MN5* >S,98A07)F/&N!N%I
M9UM%<,_NC,=#<6I9#E7)!*;$M3D><*9/]7A[AWV/K[1@1"6[\51+^)'8D/X,
MUFHL.W*P)C8@M:9I2)$3S%E0$=!RKGI + XK;EGV.&+Y'B8^I]AK%136;UR*
M!MNOYH[V-BDMFZR6?FPM/YS;'0ERB)RL+1^@PV6ZF \9/T7MWM="5+;J9]21
M5EY^093>1"@KZ+53(]/E4A<,=?F\I2F==I9.+GH>H%ZZK '/&GX= ARG&3VA
MD$KD.V+B2HNH;C&QH#-*BR6S1OY+CT8_@[3Y3JT!QM"%:W:;IE#7Z5[1QK1V
M=3,O6&CBFD=JPN%TP7 RS.9E:EM7:\8?X#GNVP<FXGBAC('EAE9G-(J %S\Z
M=;75'W\LUM;Z6WM*72^2.Z15VI[SUW(_[132-T/PYU9#K=8D9NFP"4O6[DOT
M8@;6C,VBW+WEL J45XG4 G8MOC%T_IH0E'BR<R/\>=8\!B["N7 CGK"AEXP]
M7&*O&2.Q4<6[_#%*ROE89?4XJ0'6FK; 9'8B%V.K%FAE'+$%3DTXUE>\V55X
MSI$.:+'EEE@R;0L]K$& P1X*#-Q4?BI@A9:T1:M:%::1NP] TV:"U\G)_M%4
M!:G9(G^(MYR!]B4+9\T@99VK;HJG;:Q!!H!KH%FW$+%5- -]4(>89EE<L1F3
M;J*%(#:Y_W-I&7<1ONC-M50 T8PD!300!B^ O"C.C"@9X=C5\)4%0GR/G/\!
M&/^':*<([\<>QX#,+?^W1K>'7HQ@2*6I&#3%'K6M->2818_;5Y]E>1-LRCOD
MF-OB>#\-CW54\$-O5U)J^B(BKA].U3OS6\A"R$PR*=W)@VY#42'M$'N4Y7K5
M(<[;B88OW91SR,9PE;PW]0C=2<C4U@>@P.>4\*S5HUG30"%R"5IJY8>F*>/,
M]1MT348*OAMAHDE_A*H\)EMLV'(&IF#I?&[9^H5ST#]E:,]8:B&P-4XO,728
M5RX"O_S)20;@;>UI6Q$KXAFZW#V7@=3T,M\4H9(71 T[7]G>"(D$R>XS:VH-
M=H0G1WK?6*!((#(MKC2'MUD%4;.4\3T"W4=^NJ/;6C*U!=:6!![!;_:$BXC;
MZHY'3V17PP $NK@OE<I42^%R?[40]7;89N=U$.TM!E:GAE96,WQ&3FRW;;82
M\8,IA5@GU_=H6Z?!5><E0%?5[\SL\K+Y&/7B0Z'*PW=W]XTL 0!XGY:)QS([
M*_XCOXB@_Y'&D8DM_Z((BYN/N6+A KN,BW/NU^OY%XU9H0@O)GPH9AG/G<28
MP7S:$3T8?X('38BCU"F*\U)F>6CX[8FD+7NXAU^E61UX-.@$;]1B*])WIH#W
MDQ(J8R&E\#FJM ,MK5_"7.HQOD+&N I\@%72D#+^- 77>HZ39<SZO@+"K%W(
M!=9F@5U; Z\#O^5>!2[Y6J/I+URO;Q:H;6"VMM[7=UN?^_%(!9TT!S:C7U8X
M(,,8@EW[3((4:F>'2"(']A6>\RW$\^)#!B24TQKSF\;CEP<.0=Q'U*45$Q@P
MJ$"!>G<^#(/;7[?* H=5G1$WW'A5[R6&SIUW+MZ9=JNK(4(C17P;TLK6T>JU
MK82I)K\[7F'@&OC>A"V64(FJ80F<V*/IW/=ES=NJ)Q,R+ZA2FW07;&H913)D
M,/(IXCY[*;Q.IIPN;E;H7)K;:90S@RLQ516STSM$9Q^.*P$"@0TKS^?J:(YK
MIC+SNY26E63^T.2"LZ6E,G&C/_R2;%G)3=&6KN67UTZ;J2_R;>#C;#E(1%G(
M+'9ENO.JZ8_S0:>3NUW=I1"#^A6_M;OL+F^-)G[C&@*&G]KT^2=3<[0_XA;Z
MV8I'8W9;<%76W5U<6?B@(-?]!5)A(:LR>@,22+7:+RB2,B0 $/KG:IF&3J+_
M+7;CTL*/P^<'K5')JR5RFOQ; IF( WB_$X-*H"9=FD I)%<AY[C=%TIXC$YD
MX)"R:BNK\=,T2(U[3O&\?Q/2?3Y9Y(IH9!-T-AE$=O;MR*HI)&^91L,30&?0
M6'.^\H"A7G)JGU,QO];30EI2C1119 #;Q9M; 9S@C<.="]6QK>F0%J/"6I^9
M61WD!W,$:E%Q5#. S0FICZ4RC]]+*C7+VSOTU-T8VA_O;,9=)3"0XANT<VS9
MY+;'OPT)=8I( ,>=:%(HN]<816.)M_LB#QDI %@/EY*I/-TE7L YZ89BK/YE
MM6@E8(.-?K05O&SA@I0,JUGCLF4="X]C?6)4!Y5>ZT(2.?%%?DG\A:?XN&W8
M>?M+=$N[O%J5?Z'$V3_\* _KCVMBJ[Y.8\UH*4,'=EMF\0^H)E/-:$[?4+L&
M/$HP/;W*VO#RF7I98? 1W"Y>%<8$?)"QBHF*B2RZ@VZ0?BJLQE<>/+7P;^4M
M]82GLQZ4OR&D_JMH &LRL\Q,!9$,>MRS7%N;I@X:IJ([OCH,2[>3/BB8V@)Z
M9/8J%TS&^QM$?G'[A*!-'21#OR+?QF]EXY(1$%)6$^2P!<S7)1?% .K:GI+F
MY2H &3 D5A4/OE.EXZGVN-2;C\;%,W^I16IF_473U!9=A:$KL$.PZ3+I2C=G
M3$S O2'!+E:M+JHRJJJ/$(_1G0:-Q81,T(#@>Z*94OA5W(G 0[/7_"C%' E
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M%6C)J_('UDZ*K3^$>H=E:%,V4Z^HFDX1G5L-RAHF)E+%WN[%5;/F$@G%>[5
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M#B-S2; E07#%7%22RYE=R,GH,ITC])Q5_\%%-9*K&US[O%8"JVA,W:(\1'H
MTBV.2V@,"9C?[B+3GS8S&#7W+RP49IR.3G<JJ.LP^I+7VMUZ0T]^0#ED)Q=-
MX3*#4_<!L&[PS.INUL\XS^YH\2[ILF$<;N(*^G-_:E?:?<&'7+Y&^N6T(JRU
MN20913:)A6D,7J1>T+1 +.Q3X3\=][<A,YY7[4>Y&0FU48[<5F9;<H-*NPS
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M?(T;?1;MTCS>"P3,Y>QE$J?5BC=8RP3[4'IW5PD-_083YS@_A9\@S("\#+$
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MM4_YBV)6PI>WWPM7;\ZS&SNV#[>QD"@DK+&0YXK"<#!I#+H?'7W9GF7?S7;
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M-?XF*H %YX<=>HN,M0^J_#?N'(T+^'3L.:Y;[&5]Z-QPGY*]Q91:^<15[AC
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M9+ "Z"L.5= =F!Y[M#CQ$-/S_3@,9&3JLIE\L^&3M4HW4Y=N'Z]F"J$LR\S
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M&ER$^Q)*R3H#]D<21G'F) 9Z [!=&W4Z781: :SK%=]L@X-(R"?B0)R26"K
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MLZ1,E,I:3BN!D-89<=.Y :MYB1W2$: BO4:;4MG$Y$0@+E5+>@ZF 5KL0XM
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MK";M!@QEO061QL:P0G7-R:UF>C]KMHQ7*;M] VT['@(=;3E=>!14A.NT(Q(
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M\8V( 4GQ$W\I&%(^T&:3&M-:C?@W0+Q=GR9$!!(3!:JN<FCY)N(%\? 5=6^
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M#O,"?NV88H1C?J27F, :W2\_'[[((_"O6YMRD4=K$WVV54E&I3U>I:LN]\Z
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MT=\E"J7,HHP^Y)2[,RIF+X@!=Q;=:SD=NLN'E=B_%<48^VNVS*L]J<^<5BC
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M>DPU\7E]^2#(E>1Y9*[!=!,^\Y!F5LDP8#[KDAL[-EBH_/TG3.%_</:6097
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M) *=\8VHI #2WXIC&D96T^?U<!.Y."5@0M-8^J<VBS&]K=%2BF1Q$SNC1U4
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M@]KGG,24Q?JAIGFZA<?O]598JS23Y8)DQ?&=\N!TT>NJ;=W3YRGC+&U9EW$
M&Y(>2#"UJ?[=V5D]!@-7QP5#SY6!TC""A._N=C&C64@E C^LRW$06%-6;:MU
MU[^?P8BMM9'FVZGCJ9H2*3(><Z^OCZ7*R>GA,I*5FUIU<2.ZW4DV%9V1;?>;
MT"TB"WWF,+?.C?':@DWI^O [670/Z04L?]G@@?9PM6G]RP:\X9VS;U;D)%F(
M5G:L5/#/"KZ/DH.@-***BW!6'1_79P5\AD*]C\XWK^T%V):7_S:59U%S,&C:
MW\0+@EE>K&"!+A#;L!MO6H4U&R?4+6?(<]>2'X@1<\$.[SA4PHR6E&ZZ<$]?
M1CNZNII1A<OX\X@8B)C;[?P!X>LO( K,$TQL4EL4RI8S-"VF^B[(F)+G2IN*
M93%14*2+[3#J$%H-B70YL:0% P_V0^@;NL/M^E(&O/@JMH)4NUM'\..G7X70
M?_6D!+VE*EFK8(IG^(C59HB)F4A0I0:H_[&F VDF!UK<#AB13W;\\ !GJX[G
M):%@K*=\T2CI!UB.(5$^RR\O7S1P3L%C,X7_S5FJE*4G#>6296A@":Z/CHEQ
MSM;]1!6"23VX *?G_UNGL+B6!%,Z/,[]!7;U(N-BX$]I1)=,*\XW9;)<O9)Q
M$4E#/V! O_$4,\AIP<0(,Y46P#0QSG9F9I3<=.S WLW,*,1?P"D!^UV]'F[.
M_4AJR*18;$(T'F-!X<A\,]SK-)'1GV):93UD:797EQ( =['-6 Y=,L;&'#O6
M4).?:!V;JIVJA60]]QW$QS^):$R(C>DDO<)1SY5O4/@%MN06<I%I-]H4W/%-
MS9*^W6_"2F5 4B&W8%AS].!A<;=.<1B2,[KE"CC*0Q"^@MVE-3J*=SP*#B(V
MD/R;$+[@R*;U]L;PJJ!7T545[<>/XW0*E;IMF_E QC05'NQIDOH0!E^XGJ)Q
MG$/3JU?>_=B;#SQ2!EYW6H]M3(_$H$:('BA+R+\SWW$A.IS0I!7K%#'D@=T/
M_/!8BVP1U^?F8-"%*][?;^WFH<DO?6^2UVO6N21;% <>;,O'WQ.N[OU:8G^Y
MSJMXE9A[C#%<N8G-=62OL^U(DB?1UT=FP4AQ>]^T/HE@O+5JB\O?OMV/@9B+
M^24M0$ Z$G$.K&5.R6FMO#;I>C1D]I XJ0\A5V4\5U^^.>H>+SG9ANEJ!T.C
MJV1F^36NUJPMQ)XO=R3MLK9<IRPXJ<1\*$\_7E7Y8\B5,,XF0O)\8?;F_97N
MUMW3_@#U,.>4%A(P4U>>//]\*]D0*$?MNC1!F\R6\.,G3Y$N$"/YM^>X.AX#
M_?8.#L[9,K4N?ZK#FEA&)=X8*=E! T RA_;P?'OB<']*YR?C&$N@UF?EHSSE
MX5OTI-]JL <HH#1DS&?7$?8]IQ/!_.30/(U@NLH:XFH56VLI7NN=A\Q.B@Q]
M(:(HWBM G+!+M 02/38KU]_Y 5X@ZS/K[O&H)6JO#9&G\NXOMG9?]F2>>'X\
M.)HZI VL6&YK6K(#ODPC@^[D=R,\09(H.LT.^S%.U!M>"NUZ%^"?#3>V.ZLG
M.E^OQY=*T7\W9^EXO%.+E*YV*I 41FOX.,2W^PB$:DD.LL P)DAM9[=$9879
MS:9HD$@/HR@RKPEUGTYRR_0/KGE5K$G4$ =.93R_,[B6V& 5+^&HJV5<VL2$
M#OY-%F<K="!3'[H#=K"-]=EXVJ$ !><65RHZ!IMU.H((!0P4E#_SWE0;R^K5
M2A-SHDNP&'RQ#QQ3KH=  B%12SH,J.N6S"'3^[^1P2\Z5 F4G\.'\F(?,)NQ
MVTPK\91F5Q'5.T7:+/JHY32+T]-$=7 9_F#3]DK?=Z/MLGS88ENVG/8:_!G/
M6JWGN%LZ[\[P"?ZG<"H?R4.Q2%>%-P=(''%*?]L@(KKZ@3O67TS8JDO<Y ,P
MUZI:LM;+M)CL"1]H"")MCIZT<C_+J#*!BD)Q';6=$$E.,7(U!X:MZIZ3"&#+
M4!+N6I03G5;69D0/,+(4BDFEQ ^_=UYHUGD2Z.Z30 NO-(Y@/-V=E@T@8.(\
M)AC-D(N_X@D79E,,&V[2'*[S/X3)6*^5A&I/I3/L%:5/0<,H 2/_Z3BLXF[K
MCELC*ULF,5.)DJ*DQFM"AF97SI[V:_ZE.0:KTRAPZ?V@"'><23.#YJU!-NQZ
M3Q_7Z!R"T+2%5->9UT)K5^-2)P2,<N'40D:UC%C?4&VD2+B^>$YF8]'7&FQK
M&BLN[@>Q4%;\N?RP$&NF3@3I@.XBDT]=LKL!.CF6<K*82#^8_ T."_)"1DQR
M3)>E5M06X0'+^0E--LR\ROAKP^;T3-C['PU4*V-C? K#,X'>-=(43M-B668(
M.L0>\Z]7%B S #9Z[+IQDSZ ;8VCB;7#NY' 3/O)=!6?ZVC  MXC.IFPP,A;
MOQHZHU3Y$5'%M'3+S1QC01_3S%1WDFW\XC%J]1L">;2QO@]H5.KA%^C8+Y.4
M#5OYN>+WC=;Z0;VC@CW1Y4?L0YO3P+;,$LXOFLR0#H-R";U//K[8; 9YK)%#
MO9M'7AP6O%P:ZW%;LVTS/K^,NI/#"6D&NW%_IZM[QS'\*BQI#(\=[AVWQ[QV
M#YO&B]U64V^Y"P3RY,G]WH7NI.6^C>6<[EV2]KB+HQS\>)#/)NJZ7M+67Z<>
M/%Y7YHWE^=Y5IYLGS_'N19>#+.)0Z\K>PN9R8G-=K\=WDV2!54RDO'GW+)Q%
M_LM.$GI<%O.@]CU3*S%C2.1-5K13CI3E,5R5^H050G&H'>-'0U8T<SUDK367
MZ[U')MD/\6_G)N35]KC)-I@Y"9E2%+U8,EWIMY")!T>_;2-%Y/=#2WC*8HZJ
MYB:/L*-#HX$?P1;&*[':->X2&].GU?ZKA]$U=DCH,:6I?XOM3^2F^*VIM%MX
MA8T9I3GQU7B"\.VIRQY;"EW'IV;VF8SSFPF8IK?5])/@Z-@?=-V!Q>\/3EM_
MI"<'  ;(3R< )>Q<RW4F'(X<K+9U8CM.%L\VB^PA=%[&6OZ2*>+QBRH;[^#.
MCL10*]H#'P<KZCW*T<5<[?I#73:FF@O2W[];J<3D<*%_-6E%M&:BP#*R"@T@
MMQMHN6G$#\X%'BG6\^24[#\H% W]FM&^.")^8P[C@K&ZS%DV6VAJ8F];93SL
MY(]T_]W =OHS&ZCP^:P\OA:Q-ZC*H99!\D#8L'P8L3J_YE_H>/X=V6P],_$R
MV<D9,S'"$RT,/#"HU<QUJ S1^V%*KE]^17AG. M#NA"=2O(@FYV$ER6VP,MF
M1+R=[JG*N'/43BV-U$IDQ5:8SZY6&R_!Q&8^%\>#OX1>KE)=8A2/H4$KB&C:
MM-HU-FD$9%E$-=N>0QD"A"A1E+."YV$&5VL\= $9H[LA+KM3EC7P4'^K<'AA
M2&_]"",OO3A#$I71CLN5(WC>4"FIM-)XP*3>##E!(9Y"K0T<Z^^_T*&\3#:]
MZ6/J58Q!*[AH>W<6]Z2LYJ4:+$\(F%IE$Z9>LQ ?1VD))*!<3[[#C=9J_W>G
MQ;E+(ZO7:SK)5Q':2/SH'GX\9?M'7'":A'-4H^QZHJS8Z+)_3G'<N\R8;;;N
MF"P";W&11/\^5/O22W1W10LLI52N<2:-F2*Q:7Q"R9)#2;PGS9"?9U0,4SI2
MQ'H;^3&Z!73IOX9BJ7)71B^IIUAA9A-J3_=98P0/U4Q3_R48+6[-=G^>I]LS
MA[I"WS!DAQ; Y#0IXF1-A2CJ'1)+IZON468H:FPVB>5+;H*BR5*=:UE[M#X8
M;B=D?]'TK>BL6N20 Y,XN61O3FK@]CZNRV[Y,^;F#V/B>>9N9V&%U_]:\_[Z
M)[-67CYCYJCI6],A=[U'S8Q3W@H;RV]7=.?+B1X=![T%$"3(89G)Y NL1:UA
M1/FU)!Z$^UMM('5^^2'Z&7]_]/OID)OWNGG ,,$?N>+@ZG4(7%JV$QU+IR(-
MFQU[<>BA?5<7[/J+HNF">$[%-!X:N^:XX;.?9"5.,.3L<Z8NEU&_UAE=Y%+_
MEN?%MVL/943_20CYF^VX'!JC "UVMH1WSV!SC3?1A#QX:N(JZZ+K18\=,^;F
MONZ&K6C*OF\:1.I,6':CF9E)+7]<]^#--N>XT$Q0KXW):-;0T:O$N?C"[;P6
MZS5G7*.3NZ\: ^(=ZM$HA;;JKRTANUB;=&T?@C=+5M"&K]/W,-3Y=I$8S)0F
M35JV<,G0,]CC] 66XY8YB;Y^=.J2JD]@II5I_"W&O'FAD7 -<10^U3=W2%6^
M-2M+$2/@SP:O\V;W#$&4)+K$QC%][1MW\_JU#=[1ZH)V&HRS]%FG-NU:',3[
M,C9YI?%"DU9)6SW7*9^ :$J-%G&K1F3]KC=#YVJQAX^<0M73H.RW.3IQ,]"$
M2%EP#[3RAX#_ZMF6-"8IG)0K1F"BEF ^H621L\4I51%PSFR1Y,5Z+.T\CIKU
MKG[^(TV6D!))>STC27]9N 'VKFHDK;?[+X?[$N(P^Y2 WNR@%1P>P+WH^P1R
MXU;'9@1I_"@77>;@JV.:O)O^QDC>7-)\$NGJ4K?'VF,HKYI1(Z;SG=;E=XF]
M>O[,P:3Q':<4JD;BNJDU_BH*'-*X((5=VD-:SJ2#MAA)=UFS7RGBM.>9 VVQ
M<YQ%RX&VLL\%;,6UN<4_W.JV2JZ'M=A$2L&KIA8GP^O_1E:Q8&B[]ZRBX-;M
M.;WV"-(:+:G@+K);BD;V@ #^S.2'?II3JNJ@4H#;8N*0]CFS,45\'73.RHB[
M8[4*1[4+-#94GNF(&WVEJX)BDSPQ)-#%W^R1SK@"Y,22&:B[L_!8<ZJ+Q.<G
MG#086.VT2>>XX7T,IMEHOUY3MHR"#;H8FS)O3U:_B8R)*;I](4HEI:\/X'8P
MJ;8FKU_W<G)8=SP'N_;EXLL*OV\4URN;EF;#"3"_PFE_YQPC-5;N*:L[$UB
M5H86VB1'^F-T(3;!B'O%]=/"G8N25PY1(542:\HRD"NU#?JR^8R@]^$++"A*
M'9'(N/%]N*HJ;[%&$8D*7_:@*#:$7RUJ?AXD6WKX>5Q2/V73=BR9%!K"C2M
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M=]YU9[.(3FGE.+A>?D!G;5O0U1W^R[U6MOO@7-ECBK(6S?3T3T_E2CFZ/NW
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MH]H"1#Z@_T1^XF=H)0QE<"VHOV.P[,A>?)^1F*Y&U.$"6ODMBFV2S[N5P,,
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M7IZ$TUOWZ;%\@26F,YC5Q>,0S6BC;FA:6B24)B<AKTNX+&GH:+#L$-G'Z8"
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MAI&!O0-P%?0-1(V?>SX_MQ^'X3&S%QO'G".SX;@W)UGT?>R[OU"NCPATAIL
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M#CWR7L:#VY%KS(^A!5N>%+P.Q7=\GK:* K,Z=I&'6YPEEXASS.^],I1?/OW
M]:31JU+]\]A3\T[>KKQP5:.GB#[(H00F>.SB#2[A55QOYA4?FGS"HOCN9;-T
M=[W7,?R-V],#3$X>4GRXKH.O+?)59&XGJ3\3AV,O0&V0-&CWA)Q<ZA7@-.PX
MF3;.F*'F.6DK4R$"MK97,?18X4",2T\F.<36@,/"^U:#).E__FJ,+#W[(WL5
M^7?G9HL0+<5C)IK24>L._+7)ZJUG&<A*N]^XFE=5+/X58$\75S+MNG0Z@G6/
M"-V:IHT:W/V0:6B%3ZAOD"G6_9 Q1D@+98Q)KY;7;E8F]PR8;2@J$WRS36RJ
MH\MC8/SF;9,IY]4+JWCTC[0WOLWWRI;(U!1+19R4)=.!CDT#:NYCJF2LW94S
M$(Q6 [B6Q/W\'SYML^@)'+Q/8E_2B$-?[C;^[K?A;VYZ7V@VDCQFY/P\-I;K
M2N4E@7FQ;-2P;*5U=R2)D&ZF>&)'P3F6[@GS63>2=VH?-EIJ/:\W;I\E,O7T
M/=;N$51_NTM:JFU1C55!>PI:NJKQ6QZRM=024#<2#ZW&L(7@VRO[VICJMJRS
MC[XH4LV"14IL5TJ@I*!AQFG.T"1HSA?22B+>V_K$+]3!E/H8VF84K<!1;R\2
MU4<("9;').(9NIDXA<*:FPB.AMF5<?[BK>MIQ)>C@%*#=]$=WMZ^SIA+D\EL
M4BLDU4)+P!2@U]RHW(X4"@VETR5[\V[?>\O 1[.FRV<(=$5 ;7H?9V/6^HW7
M*R!]A-\>G:+#I%@.(TM9A4#+R7(.^B^D$A;WDD[/XU+AD*WA=#L81N*TN:MW
M@^YC,EJU%5,669PH /-=>OL%GI0]Q0E)9L_@;/<O3P-PYC%4\P@N6..I312;
MQOV _9,"Z.9* :0C7]13JZX%(U@F=4G,)32!ML)3V7C%PF:Z1Y1Z.J&PC7;P
M2Z]R8*])Z?75XNGC*P!R_0J 7[W<9TN<FJAZK]M\#Z;L,7G3VY_WB,,!A'J.
M)Y3\_[F5E-"R/_PR1;VKAT]6J>.MG8H#JH 9/_ZKA8P.]/)V+CPQ))^+[VM7
M&0YWSW,^._D1O_<F^R;4M.?SKI!#3EC36?1+=-W=Y:#$IO/F P(RSC5'Z!;^
MKYP'S-7*!C*[PD9T[JCE18L55S797<HE1*#X3XG0WQ-OB<I)5H>>W\*/OANY
M)?\^* X)\):M7^(JLRE?ER?Z04"FSB6$H570\]15+ .+ 36HS3CVX>%3E=VP
M:0A_4S%V_^WE)@W8D(UVVZJJ(7[*KAN>D7LQ?/8\DAC7LPRB$@^TYGZKK?8/
M=1Y'VD!IA]_'R9)1T5A0$<QH1[+\8"3ZHR*7FA0;2]\C!0IFL3M(M(J]VAQF
M$W&#G;#N;?:Z.G^/(2-[_O!&? I=\:W1H8JE=8_8DRQ'ID>9*/BJLHG5,L!)
MO2,;ENL]&T.LT?.X"%DT\GYQ\'MYI^#=FRDATW4+5>I8C'EJG,ZY5IGSLDQY
MSYD?UQ5)(2W(3:)8H<0-\Y# NK:8>>C3L*BL28#8T($"2X:-W*=%Z1X##J%U
M20:=TRE:?Y7VP!,(<NNE,'+Q.P%CZ0OS5M.\Z0):1I6??!Y=K/QK+13MEF2"
M+HVVE8T*9X4Y[A C]T+6Y"?"I]C@56*[5\#!SL@KX$D0K3S7?_L5X/_X^:X9
MAN/V8 :KEQ"I)&UK4-Z<&RO,*V38Z,OK-[8=I5Z(T)QQ@0I=TEST.K7;Z4(#
M5FKEN?W6LTU9X=JGQMW!C/[BOP3!H!_%JF%=.230;#MSK2+KQ8BF&=1Q;?X:
MGT?0^>8U5S82S::YN_86N(^"G\:4< 6MLC!:D"'O%6#,A'@Q;=P=E-T=U%L8
M:9,?0VUTGU49.>MA/98;:JS-[?66&SB$Y ,;8V. I'.F!TE?;B.9U7TFY35,
M+I/%HN"^OG='INR@4825.1'J@.J,WDF_T$<\93STX7N.Q3W5Z7Z]/LK7\S.8
M8E^.OM!)460P5'YGG1X2F]RAMD:*O8J;T$+^AWA"'=HZ2<&VPK&@)N$)%O>[
MOI9U[_UC,C+\W.!5]P(,^)=Q^UVBLS>^UB6_35[(H[MLHD[#0!K)U\FX O0G
MZ01]OHA1YWYAS4I5HO KS"A"46O@!(KN?*)R.[?@6^A]%J&.++OGN;R&S<BZ
M2?[/V\94"^[T)A;0*J7N[)/-&S2$C>!N475Y[P*%=5H="=W' CW+K6ZGQ>'B
M[MTP@XV6WMK>0%-"\[,6QPL#6#[U_>H<<Y!>M:YK3&LM4!?)K"\@?@_!7%I4
M"%*22C'Z."+JK;):L"CIC,$9;7===],.OOZAW?N?0@'ZOX5"O9+@SO>U=$PB
M>7W=?,[6K8,O[?%TNP6X%^D9.X^<7)<LPBX\?Q36?!13,B2?>CFB!.VDL=&X
MU4:@67HQ92QLCE[%.I5Z)4*^8?.\.AGR](6^T=II"N"1Z8$^784U]_W&)8J%
M=<&L0>OS[M\C6W4+HS.>E6>KH:V'$\NP'OVYEK,)\.>AWC YX>)FI[?SJL >
M%KCP8FF@'9'D228\F.;LM(2FWN[% B^M.B]9X'Q2UM"@9M="#U_-=1(L_30Y
M(HC@KQ!2:+I:OA2&3=[C :D1)%Z>2NTW_DX?7V'7W3'-&2Z=T'PFB%PL#/3&
MR-I/'NC#,.H9#@093>N^ C2?&^V?!5-F_>J$8T8W&\\%R%.#YY9LJ+8(:K)(
MZ?+>F^FR2XM]542.S%FFYW"U)8\#F?<2!L0ZOP(V.!<67ZB$+R1? 9B3\(#C
MYO%39VQ_%'++&5Y_R"SW*T">ZLJDA"V>X;<U2BA?[=3PD+)09F847O(@38+T
M.8IY_Q7W>#+6SF%GP&XH\'$.E.-:>[]'-M>4W='//CYKK:=>S;^,K%\8F^S-
M@'=OJ-HR-'MHTN#^VU:,@P( <K])_R:YH)UWS":O6F;GY2KAS)8THIPX :4L
MIRE\C-]T(*AJY#H&%SO::?5GXU-_:$VRW:6^G;)I<Y'\$0.-M$>[.ETD6/((
M?4:2-R]X(MQY_!E2WH3T58J>^4-V>.Z+F-ASI6%Y=.VT$,VI;6GX \U.]^VB
M./$[]04*R_<ZCAA@NT5@5]J %><KH-/&W-C<(RFMK9Y/]#QA&R/$AK9H+]<S
MJ^](V2!WVO:8_FJ?F2LAF]8 !?:EC0?8>')C5[\,?%N3U,3LD3>%^:Y#2(G.
MQ3_+^&2G-^Q1$-AYK#."<5"8^RQXE\"%=R_2J9-[^3(UJXY!#+R)-PR>/Z1*
MAE!?>U>/<BC;3Z^] J@VNB\!&U/"UR:UW:8R\FS+CJDNS&RG9G:1_FBJFYG?
M[G<U-7]_UU"1:L"S^[+52^.WM) )\!-5,7$.X(<&%O^=]W6@YR'S2V^.F0N^
M1Y<YDS*M>6,1^\.[<7B 7:G!ET)* &_1S<=$XQ6@F!716$.X@KD";7Z6IF*P
M/5(/+JT0)4\<R?8UJ$YK!D46?9XS<Q+)3.[ (]EX)-I*HJ(WVNL>C@X2?FXX
M*-@C]CQV=O!9R7?%BU!Y_^9KT>E#+</V_EH2K^77T*3<J..WM3<'FIG:V51)
M7.!$2;="&U'9(,VJY4GE3W&_7P%V\WQQMJZSMWQ['SZQ9A7=%3L$G_W+GO?>
MZ3QESUW8YM)K[,'7JIG'35HW\4Q-QR"1B1IE-5VCZ7F2-:#8[)1L/](-&9=&
M52>O&AK\,SB]:\VSPJ@^A2W"-(#UH8N/2->,[2+J<%S;@E-"ZUB%E/<-MMN0
M&H-LTCHRILSNT%>U\B'GD2!$;XM<6V.]5C6MJZQNU^*'C3TN!V</9?L]>Z4B
M^S7=?GIY?,0<Q!AY7/*$.9#69: :8O7O5?51+'-V,U^SJ&0E"L;^K@"7D;M,
MMI7)<7./6#SJ_@%!_8*H.\0E]<?*R5]T#4$&Z_,R7A7U9:6*E!4XOV9R%^9W
M,NY[#,:C$R/'HQ2$PB<[V/E";N.6V[2(L=\I>BY7YJ/_.8ASCUN(G;]<&OP,
M\V9*IB5WFC#B-W"F&S MK<?>M+7?M/6QMXC&W:E?#HJYB7J6>06H^%4U$'M)
MQ_;9VR6:<:>P'1IH?'.9N&$?(GKWW'AU\G)WKP?_(&##FRS K"QNOZB*D<L-
M<45_(M 5OZQ=N+6CO 6W]+1[;[X"*,5@>;T]'7 ?.TC0]3,_^'81_F@?[ S/
M/0QRJ54)>LMT^.P'6W4=O*V#Z+N>;VVC4O?T!D/.88."W9Y7#YYU=7-U=?<]
MG0^F8B_4JNMV7IMWA]=:&OZ:!+L-W9Z,Z7Y)?<T%+01)G."VRF$":IV/N_CS
M)I^W6QQ$V$A^BFGWQ >9U_9'TW1<\*?*>L=XE8XX1]DK(U?R,Q6_G&L_D_W5
M),R,L]_+;!Q8V54<'@7:6PA0,A3'A:_19[X)^N&%]:SDQ;8L:7EA\Z4G8R&S
M:GG4S8O?,:-\VZ(@,>@SK>)"!KO%=NI5X> P\M=E6ENN#[T_O&N9YT#?*X+M
M%M]=QS^B+LB>%(5+!Z4.6K3XJR,C(S )S0$-2(DE0@;-H/MO4^(+AR,,%0R>
M:Q:-@FO3/8 ;7,MV_B:-VL2Q*FTTL7H>G.Z%'\)#6>/CSU&(SXF^3R (0CON
MN(1<AOE3O7)OIH\Y1PR$G$\X?J8/<4]<*H*0?:UB5O0,&Y)=%/;/6]:8(\R\
MR-,QB#)D%8;]Y,8,YIGLTF=8(@C=B+^/(0E[ >,]A=0_+HZX!&L'DR2MC+I3
MJ4@N,JO^]B"L_"Q^N&IJ+:F_<W3&.>:U=P$YD5\L>*@@PG)=2?+'GH[,+0&1
M _O^IK"^2RW5'M-I'RM0/K#Y(2RGH_#'#+-#9#BX'%9^'<JG3-4[)OX)X7JY
M%OW@ZGGJ*-:W:1D<*DG[P'28UN%HK]?\"LA!A4PG67+&9M1X"]%K*$&=#V76
M/U5^/H,[<T901!TH?]<9)5MR6SGF"R/JO"_^]2=]G$5=7KS#R>L1WMM%/>VY
MHM0==V"SK">F8DD<TKRK>:)LS)< CK=P'.=T(N2Z7'VFF,4[ET=I>D,;N79:
M=(KHL9:(\I/N<Z:-?S%C0$PXONDI-77H(73"L;?7,5V6XYZJ_D?_)P7Z/S9]
MP\5SZ'^M>=P$^.Q8U]D_DHWI[RI+^E$T..@_2)*UE)Z81_$[''XT2T7(MNV?
MN;[:0M-P_!Q)?DYE&+^8]OBRZ[Y?3*IU[>QT$*WK>EALAJ\\TLV/?A'*<SD]
MR(6I5OVQN&TO32Q26$Z=IA!%:?H!+21?M%!--O=PHK7D+8-<;A&=A]",W%J/
M0;Q$4=UX?G_6T$[/>?=&TL7=I6>J_FCP1QF8*"U!:DY(Y =/TD:KF8/L2$VI
MDES)'PE)>E]IN/)5+>C-U'Q7^X!*?6Q#/&EO1W!S*]6EH-.E._LB 8*W]U26
M9M>0$=DX9Y5#<&(_/[M5E^2A#06>+ >[:%Q+LDYK69XS!A$UR5:EEZ*WBRB&
M>^4!@VR3HMOY8=.A9C0[TK,!-GL[FJV9X\CIHOG.WS#!LXOG6Q--YEW4F:DB
MW,RUUHPZS/!D'8^]V&J)#EI!3Z'@R5/H(^=&3+_Y([>D [$D4:*V7S2>7Y.6
M1CHMKUWG.S7YQ,#6M&33N7PCD+C(L=<EK&>M]9)MR_&",0"W.DX522>E(F6'
MT*2P%E2,I"O-&%;,XRRYF"+S?"7FQJ_Y\->>*"N+WIXBM&2B5&E\O[KO1U/.
M *Z3==:ES"ID&U7EQ^G986,."*9X]3;CNCM.3%!?477F]CBZ^RW G/B;3KC,
MV)*T.:Y\ZR?.8APCMEKS)%,-)".V-;6N2 1]S\8=$LD7&@OE\)U\M=XSL?N+
MNPNU<DD?(PLZ9B:[T,*-P>V6;F$><6X"G\Z1'4?CC>*.IR<R0^5-5H)R!BMT
M59GW QRP=D&WI)*=ZN340>,Z2B_T92N&)?_[_'@I'"[QVSWH^*27J<3_Z.RL
M@N( NFT-P4,(KL$9G"&X#NX0(+B[!8?!G01W&!P"@P].</?@)(0@@P\$M^!N
M-_^Y5??I5)U;YZ6K^K&KN_=>7\O:<J-N1[2L+ <_-,$55UK(U4EA*6+2HH$P
MUNLP*.]/V[0'P5I3,?&W_,C:Q 6=W.^WRD,_MFY()&?'[ 56%\HC+$X7CGM&
M=B<0ZXTO2 P/4+T-GP^VUA4;/Q1EV0FE,L-4C'M7O /,%3GZ:,988R.)M_DY
MNGEJ9S*_$0U&RK9P34S'?3DNH&L8\\-<GD>(]_0"$RVD_[_^V!U.!V.&>.O#
M0O+6;#Q"[I[;(:'-2E<6\-6%.6+=)6G*IC[KN>"XX#J\*)ZT!-2_BC'.#91]
MRQ;02GN,KM9=3-A2Y!'LY-:!A(K*KA\XRI Y%5'XOK84>?ML;2Q>3Q'R[OZ;
MH*L!6-*_<UNPNM,H$^A_F,"921,BH<DJ@5DD.N^LT,_6'F.FH,(>[<PG*3HZ
MNU?:Y(GJ_VH/D(>&W(5!&\+L.<D3_[,UL+R93-0HL'=C2I4O!QIW[2D7<^%[
MYY"7.[^F^^PX0_PC\ED 3TY+IH([5L$F\<\@63F;D  -BL:#91RVI*_.0H0#
M*$2)944KG.P4QJ&W3<^.'V[VP]'PJ?D_A=B>O>"@PR"O;H\ID?]<$^S7.)K!
M Q#7\[T]+T@M^)+/02$[O_$7.Y.X"2J4Y71:.$B]42I]TSX5</[]4GKI\$-3
M<8=C8X)F$QXY!I8WFICC,X.=>+93>U8N(62U?N+K/?CN9A=I';!I^.:4;WKK
M[EAOB(-Y+8D2HM/K).I1740,@3I"0AOM&. 87Y/GY#U9'X<4MHD:OGTTWY-\
M 3ESKKA731P.O\L^*SF]B[3'JV-7O #,9DS:P="&_R!')7NO*)M\%; ?E'(R
M[/)_*M^Z]]W@FP<?HZ^<E))L)D87(=@7\K7RM2T6?.==53[L4YRIZO7C%P(T
M#(B#\(QYF=0EPLE]WGJ?<I4.)[&(S7]W7U)N<7@J6F48=R$X;&"G"==O6O)X
M4V,)8]:E;!!&CY#7Y]!4 &924%$E?*9 0-M]=G RP;\^[=@[[M^T>6\3M:]=
MU5Q=K7V+)<7@.8]P9<?\B-H B?PA%NL9V,.W'?X%0"VS=X?B^W$-?;3XL>R,
M]%KEDI8>U;Z=+I#HF&63Y-WOKL:-GFLY:[=8%#:5'X)I5P[K]<J),PV/N^R1
MANIT[ 3QXV5$WW]HOV5\E2N!FAL58<&<X?P]2J.H[AVN;P,E9#\IB+FT-=P@
M3P^LW9IF8U#*;=/O_.D+>NP(29H>I""5[%ZA7^BQL* [$^GJ 8>0:'?O,[I9
MUN.@G,\4-FSX?KY%#K!!)&JK4AZUA>9WOYPZ7Y79$Z925%!Q5U]  70*51.2
M^KY.&VVA .K)?",/[&<L<<[F\E]%IO!:/G9#G*P)@Q]"L.Y#TN.TQ#^?=VV=
M'?"$MU7X.4%2*>>%&:H.E;H^+,8N:/NY6.&$I\8CTV\OH--1<>](-)$X?$')
MYW]B5>\'9ZY_BC7-5S>?"Q21,5\$WTZB8Q!25OC)#EL[.8&Y:4B2C,$5*,S8
M;9_X/-1$-?C^R;29\+:E2B:HF+/:[:ZU3AF-_ZVJBZ&_*;[+76N/&!$87R.I
MO5_-W.C/GU2%UV38R#4+$[F$#S;G2,, &'IH;(OW:2[S,*: RQ#_UYJ?FQ8]
M3VH/%X#+?X&M8$L8+.G][JW,*!@CV YFV@-Z-F*/@L1T/_%WG]P[WJSA:_ \
MU]QN0$5977(N)5)M$KLBG0<;!1@ZI9O8GVG>3OF:-KL=I<79IO_!_&MP7YPE
MORH,'KFRR>?$2"<Q:WYG(=]W&_#TW,YNI+>4G@Y'Q[#5:MP+@IHH^06L>'L@
M)\>FR_YTXXNK1Q4E"&2'A6&"1ZLPBO,NY\8[I"X4@#H(=GH895KU"Q)FEAQY
M4X<#QK42FW-"J1FH9;"PE;&*:08)>TJNL!!YBR9:FBGU.9%WOF]4BG)7C0P&
MEYI(9/[9,K;$?JV:!#EBN,ZS $(H(X><?"ESS,CW3P@42X+-J'D!2=[<+TCT
MT:=N9+\YE;'V_-1N*6XRCXV.BY_O;'M2W>=3%P7$O+=WJHJGG.?MAR6B409J
ML>C$RS*<^,G(;I61CXB%84,<_OUI0(KLKW'> J W[W&H]U$X(\>AG9P$(B(\
M!_H&R6C*WC>?)T)FX(-CRI#W:GY+%$R88$>?N61W;S<2GFB4[*X_8F]7&L15
M+E5Y.<FQV,]<J+B/#0!^#7'G&6TNIPME+@*IL&,-[5SJP ZO&\Y>T_*+%Z1M
M$I'21N-BC ^88>4+E0OISX5U @XV3*$";^<0//EQ3AV:"RD%K\_;/#%8G(L+
MWD1W)L?S 2P$'EZ0:#I&JSK?1OH:I]OIJ%;NPE!/=4TU\=%3Y$U2[+ZG%1%8
M_5:0>M6I$1RBS\MK[3NM]FMM)3D3%R#E7$=GVSB %RAUOGO'642SG\-C;?B.
MV.:3WI$3^;JMG55S;A4ZDKSO5=SI]Q)5@060K0:MBY8+4B2?34<?(MWZ]*,5
MJH$(>%(#+9?0:LO[8N&H048P#TAE6X\R_\.-*M6K5#4#K&Q/;0M]6_![O?EQ
M##8'IG2%I=AO041?@V82/+>LFVX5-YL@7 9A@J@+=\1D;Z[5\S^HC^L65Y=[
M5/!\7/C^ESZ)4%\"YQCSL5*"*[7!PXBC*?O]'S4*M#!%FA2?'H,$E^F<$\\[
M>0ZE#DO5I-WKY1LS PFCZ<WE+W+5HT1?=,V[F1A7 \C3I:T)HW=)NX;;(F7C
M1E%C4KN<0N7?'G_2L+(>20; D]$CB7 6TU21IBV=IUR3ED,6O8>9U^R[*N\:
MX== "Y%*^G$>H%!*/!3CK]A;#T)MXUM0?'@;7=D+T@!NL0HNEG#2.#X'<-V+
M/"8= X#XQ$,W)ASVZ^14/]TGT'<<EY2*I,[UM9"QET &93=ZN6$]K*I=DN^+
MKNU2=C9 4_*HGA1ENWBGQ*G"?C?1E('%F=Z=G;%8)&1^K/Y<W.R;9D' =6(R
MYH=3E> F-F+=VOQSU?@EH8W\G&^I@A&]!G(S#'#,\P'+XVJ-YW0$50-$2/9=
MK283#.C]L5[YG]S/8NPMU6M^DU.<#93L4-+0B Z'B'+0Z8IOE]2B#-92--(J
M/?K= '5R93I]6]?;=P-2D36<V?L%NM(NSA!PB84JG BL_]DF@\C8_2%6A>"#
M%XV-+%L%E'&A75>=OX;*L/_A=>9;3TDS[DB/CC-3:I!62S>MUM5SF]T MGO]
M7^_-_%_TTZTZKD76:SN7O44<[[%6:2FD#[ 5?J[I,7YX00K[&4$5.UJRN9T:
M=]08L]W=BE&K(J#+W?6E(W:*]EVT7"2VTY)^YSYJVOB/6''0W7-71Y XE4[-
MK6_1>T-JZ*4C^T]<0&17DU@(V/@TTUNE_'6KTQ*=.3.E;]KO0QMM*E%]U#P"
MMME4B5_K3YAOA&C/6/<PMZ]AFT0U[1LDJ<]ZH.,#]L;OXE65%%+] :_LG/ ^
MFN70G2K_[*I-^&B6KR93"SC/+JWW//*,&#W%/F#9L2)TIH2<V*PR_6;[UFA]
MR5$\$N(#AT=)$%3,P;80)BO/[=D3!.>7.^_?72K4!O-V:[(M92I7) U=;!&.
MN9_5 "MWW,+]1Y.IE3TF3G'Q8N+K4C(5 )3J^74K,3G.<8>0]'VX64MSW7\Y
M<L1ML.0H)]!"-J\-B,E%-BP,-QIR 5!%UMH%>\%8^IGNKMT UUHJMM3@7L)C
M$S5"A,FG. T$?OI0XT?DJTOYX?.NW4GWL9'ZVG=_2[#I_5184"I_SAGKX4=G
MN7NAI8@XH#8!XVT$RL*J9S\)*.(1A'M^]DP-F'@%[-T@A4)3W^,^^%]=P?*Z
M433B2H_:@#+>?F)';]\SB3&B<5:@#=;*ZS+.@-P698V&E:+3JBFHTVH6(.]M
M5[YOR* ,A;9['T%QU[K],;M1+(@"G,6YV.J^Q8W0OFNV_ES8P,M=.1,QR*\9
M!,!CG*;%1S55_,KW:NA[:*>NY7(OUW[Y/'N[ZO(("VV2PZF<5K  :)'Y@C3-
MHKZ*O^WR)(YCLO+NTB.EXMM&T4WSN/WW^4"QLB'O\CET6<ID>V3D930=JTDP
M$Q63@^<<GT^XW@QF!704 $KXO/DP3_ ZAF&O_4,#"GW"('L*\# =X<$+8ER/
MKNXF!K)R*+-(W *6A\%>V$Z_F2(!@JTIUR?8)=.5Q9/X.W%:C6R=T^&ACSR*
M^KZO-CTL[D143(2Z/X"-)KJ4+;G&_Z8VV).ZAT_5^#/51\IM:UI<"VD@8TF0
MSYK84*<^"1A#-5:EWCU)W5--^P/GGSONGP3K'EJ?P!I^?[+]IN8;H$:/F86[
M4\(Y%XH2.A_GJ.10+[53CF4I.A@XZZISJTNG+9*M]/1Y1(W=';WI'#H]S";G
MZKXJ_\X4GEXLZ',A<U2C#NY]OR'F_ZS3=OOEPN9DV]_PKOKOTI_F*B/05=XR
M3Y7EE;V"]9]'/0*>Z@#T(X%\[^)(_(@V^VM9,L(9 PHD3>='93YWTW096ISN
M8-.3I.T&8*-UT0RBS7%"%MHE+E9+43?JD:N3QR"<HPCL+"/[$T_4**0]7]CF
MD'7);3>3*T ERA4OKB6QXZ8HH_&VGP?5N'B=G1#"><03_BR^=F(B_CK[4>7V
M8IY/KX[18SD6DM%GOE1>IQB[E#/*_N67<H.4\.5AKC5:P!:,:X+:1"!9^_=Z
M*942TY +WO%6_$_D1!XBQ0"7/ 6C%%?>N3+8&0)D6':0 X25.M77_Q#Y_!N
M)1>6D#=^2S]R*5 RKDJ=F%A/1AOY*SG%[7A)+=66+BCF=Z0$;::UJ=?<.<XR
MT1D:*7'B[:NKK'L#W!#I;F=W2N SWN9V)(WT0_G[JH4AGT%UF62<-Y_5#49N
M4&HM:0$4@1=WOH,QAUQ[3GY%>&+^NZ=R!VXJ<-2(-_1[5NN)T"3;LU'+()ZC
MY/15056;2+PCQP:43O]^M7N'P\(3!,^^9]JR0N+')4<?EIZ_O8N'U_<O2)DA
M+;VU+TBN^W6/(67X?G[8.^],#R$/ HC+WI&I"@=R'0A/:MCLF;H Y5FCFH5G
M9I[K;5ZA(4Y4%QU8 I^M%>='[H6#OMH.UT9]B>79-NU9!%6'[5#['\^KPP/=
M_1Y19']-P>VV;U"=4Z7NG/"6\8\JK/3\O[7JKSQB+C_[Y^5ESLE#B"'7(FZ,
MR#<\[J_5I3JYBNX?YH(FAM+HN_1E!]C6DG(LRXVPE[]2B][/Q*VNWBV<-'E'
MA>!UG<^&C#N@/C1-J5V3:I ="C-+Z%P_@,4[X6K>O.'9;EJ]VZV($--M.CD'
M,D\!,\:OX>Z@CY?UTFQDRO\PJ!$3047$/.9C5B1=.B.3/-H*ZMHT;E#C0I)X
MM>!:R"#\B;UGT5.CM^9+I9BO)\R?0R5)^N?(I.+/XY@P/]^L(/_5]6EX?$CT
M4SJII-6I#6KUC[\+(TDCT6T.Q:<\0FUVV)[Z/)%2)*R(%6'<E>>N%R0U6<4+
M5RHX(?*O]7(",2H,5%C6;_=IF0[S;:9Z9(]*B)N$ Z=2,0Q;S*D;A*2^5I2K
MI(NKR%(9)/K8L)?&<G<3_L>I#.>H?*Z8.V8*51_"3@'P<**/B Q+575"R/R8
M%'![\ZUV(9=2JA5VA.GP9K4\M\D(C-3('*.8=7ZGF?<H[+E\_O1E:C^)7K8B
M0-[(+B$%+Q626F>)KZK$(H0 (S,>C_G:7V4T*@G5#^JMRT+,R7F-0ZW[/-"#
M:G,9!2[=] <E91&7#YY7CR>_]'IH/^LI2^N0 S/$-7'I*P%.(D%]SIYG/Y3,
M5-G[CE<O5\!&,V KIJU\PD>JLK*\@BB< *E>Q[(*+,3$R%\?_:>$LQO]A4;L
M2/"Y ;>Y[73*/*%D]<R"C\;]3R.3KV&C/R2B8[1]J(*S73*K'4=TVZ+JB)Z<
M)VT("JE'K-72A<<$MS XS::VVY=OL?_:KR]M%[P@C='1<8B>F<$C5MV00)YD
M?V,E%183!+:SAHL?5&$$I-XET=G!_@83Z=1@2#?(P >54I3IN>=K#XJ+R@[R
M!N8"9M7!JJB:]WE- #?,2;R04^&[UKYPGJ)I/OL84)DB3%IU!HOYW VL)O=<
M//6J(V,BP'SS_%&6_'NT$G-(]/W)P[E^RR-9&LW8]0M2_L&BBAZ$_"J(NE;F
M0XG3R'<U#XKH>$5*]_9%)T.0S5H)!RJ+5@O!\+3/8']^2#%]09>@ZJA/"0(J
MGGO2&M4+6:]ZI#]^/6#PKIGI;<XDHWO$'ZS,* IE0TD&=[WOYP]QJK&3V\G1
M-]Z,6=>N?'\5Q$'^Z "BO@[E,E.N?XM,*9E+.BA0$F.JCW,!,;*7NI4_:FKB
M3>@'&JT'7V^XKQ=@%EIZ2[L;J.ESN0!G[0\5S4_C9L^B)R1^^=RGCC;LA.@"
MGHVOL +H73=:W^/ZF*U DSHA6\5=$7:S0YN:K7H$@!(G@!;>W^QSU-?KQ4V3
M QO9QK_) EV;+#<P*9(G)CO"%485K9?WOQN"N)(D2;U]U'XH*2H"\GJ@=;5V
MQ]\"6?Z7KS!(+P[K:J^NX'##^9NZNI,:U\/+M:LGKYHGP<L7)+-_LOB_O,H&
M-@9P-'0F2B%.J]0"11.U,,RB3,H7I.:EV(H>W\V\D.".0T/X/QX5=HNR+ZK#
M9ORMQC^B.KNM)CAPKY7T7?W33<U3I6./Q-3P+<+,AV8'#C?KP?>P(,6.PEFB
M+XY2*5GL )TTZYFH$<AQ"L/AM;,ZJA<CE(=F\-J.^>;G-KE[)>U,)?X4K0@-
MO41M)>U[N%(YU/#^#$%U>#@5Z//S"B[FT7T!%X4;G_BOM88;_[=CU>;0\E0)
M6.^WF(Y+)%IB-"%+A*:DQ*XFLE<-R+$1FY&0UX-U(L5*9&0<S#5*%Y+4BQFV
M1IS:M6OPBF3*Q&7EQUA/[QYZI[;$02VP'>O@8<U=H#EGQ&58J%,-V[UQ6P>?
MT:\K1E^[Q3FRZRT6@2Z]D_9.U;8+1=S-875H2YOIY14O*D94L$T[6[R%.J>)
MP/)DPL\UT./-,NS7EU*RE1%$TNO8E.JFU5\L?](:)34(F\/90'FMY/GWK;^]
MCB)-'&K:P 31UI,T63)^U_",D8T#N',!S\!60/)W"IS@OY1]7WLE,OIHIMRG
MO/JU)L6&1/G5(]\SMC.<\?[N<'8LLF(MIG7+#A3Y4$I\0.YUI3<425.K@5$9
M2 7#N]"V9+<I?^6]#FELEPT6=9U<8?FUP$/5?KG=2^M#_<[C[" X3Z2:^:[3
M8X).5=(H2 E*>7%/,E():ZC8$G3S7=D"TIB]8E!JMS+)K-M7TJ:GMKU):<^5
M1U(W /$(_6.6712AIFJA#NYEU#,!:AKD*2B/SP7U.S\G*1,Y?,\ AR5,ZW#-
MR>0/20.%:^&0])B4L#XC >7U.%UJ=0GI7X2+54O41119 92E"79J#^RXF"P]
M&P R!;\\ )A>OP%UNW7F G2-J*/;;#GD9/5]D&8G_DJ1\*:W^K8RQ5%6S#38
M:&=X_?B\Y2*6B<O[E;B4X<AA%B2TH*CF^CST%1,$TXTE-\HE@)PM-3NIX)6F
M>>A;HX?6W0F7J!T?U#N/'1$LJY\^-(5.- K* SGLHH)F"HRM1_+6+$.&)((&
M@XLR*OT4<U-TURI"!?#S]FEIW#*I$NZ_903B1EB4&W>*LS;N V\F,+UOP=0!
M$/GGP"B)Y1'GK V__^4^_7]^[)I006+]BIL1P1+&T88LH.6L5U>&NU9*V 2L
MWJ.P++!@]8OZLN"7_#<EG]4,:GNQXOE6VHZ]YN';29MGXUTICG]&0]S]9.:&
M'E^0-ID2'/!2]7K)+S>-J&7>IIDR2LN?V$.;J!9MHHGJ :5F2CJQ1+: A=K7
MT.VN(#O,),^RSYT?O/.[_>]A=;#:$*\WI>? \T*3V:E=IBU:3IG4]X+^7'MT
M.*#3KQ(YM2J[N#9S^0X,3LD+=O+&2IWL.I-,>FF1(G>YOA?.<EKK9,&2K4&#
M;51BP5#8F)C_U7T5O^^RC]STJ<]QA=RJQ3S)HK9?QL@?$F)C:]1PZ\HV>2,T
M;>IM67KNT2ZJE2%(B4JH1-LGVVFXZG"CF2*M5+^ \R[\[ES=M.N1"&TO2=(X
M,FCJH_9WP%O+C[AL@?&Z%I4GC'IK(7[+9::!D;?/EFK<>TR\YF/\Z^'^JJP9
M>74#TL$[TSZ<(UBH&!D1H:G[8 Z1JKO@ZT^^Q#_V8H2U6J+RNHZ9SHFK+)_;
M=>8WG"SY@(>/RZ$K[I?+NL9 2AR&BC*4 @]!C?GP#Q,;)FAI V7GKZK<3IH8
MH)UU=="D0=>4#\K^5?,7,> USZN2#%:+$9>3I/:F9U7M/D=])>3FK;D7I*];
M I?I287#.>CAE3RT%H1(],1.SYR2::_59&GP[9&\+XIP:1J@$N]-@D+0.M43
MTD7U-J<&7[/#3<IA*5W'B*";[BM$T)66[ W<Q&O^/TWW2<!AP'^.U ,0)TE?
MV&O^6^"OVL\</1Q_?FI8Y^F00T\S,=B_YQW3C!LK+1_3VG3JE9PG!CV_\4S_
M*$W$VNB_ST#ZQI#$17IXG,/)JO8KM2[PVVB'3H7_QI; CB*SJQN )F9+;=G3
M9*\N_80J2_E]V<A19+B='5NAURUA.DX8A; 8MJ^\DW"ZDFA,?4H8\7T)15^"
M]C4KV1AT2*Z?F=M.4H.JG6&]/X;(#3HU,E%^>T'SL7%\<\MUO&7KW-%H_GQ1
M>UP/+0TSCMB*HF873 7Z6-K63/97EM<\%**AKVT[X;2NW6-]QL2]]XNO/8\P
M.!YKAERTR"V_JZ<X4ZO^YGS__'#,4K[[IIZZVW7G23M6.+0T8"BPQ>'/LZ@<
MP:#K6%U&W/V!.'ZSV2-+W0$7]2'R9"3^UQ<D:E[ ^">+;VF%KJ@M_D$8!["H
MC(>+93?0\(/7[<GEQ=:W5BA]PQ>?V8:TB+M3ZVC=7=(:?H,?UJ2\0A!>]K@I
MO"S0P2@N/VJSMP7%0<LZZ-N 5#7Z"$Q>L3TB9WO55Y@ B9A%M=VU-T74%^7B
M0-A%[ !0^*S^3IE_J^ ': JSR+PG=>/&7K%DOG%T%BVEU2=\H B=J9@+/=:4
MP1'2V$KN+%'M)V!:XFXQLH.O@UJ\G*IZ_S&BTW7VN#4J"P&5>!MLE:EC7RL!
MF>*9G@_/R<_R !-]'7K#%P^Q0RT"VI^6EGZOU'&5TL!O(*LVSA(\ER960;DP
MFTD.Z8[#($E.!A5DQ$\;3$O:@^X"1_=[EA\%MWJ$DL9"$K8:-KG)PIMFPA5T
M(!-'*^W=04S$J*ZHL?/-Z4/<$'R(.%%_I4KLEY4Y/TA0IWIBFA^/.7,$G&=R
MD*X4Q.S\]."\V2NQ\$2$K!+X38&8@2W6OY)C/B]W"+2*>V51P"U/L)]"UBSK
M4)=JG-JH55 <0>1#9J,Q_"M2VAJMP_<*2RZ/Q8HJOG'_S,*R1=-HRV?E2&PW
M*!)!W;/>PK@+E=/KR8T@RY\O'_^%B>X!K%5FX(HGB"64UD,/&<V6 603;!KY
MSUJX3F+OY1)3)IH\D(X*@%NWTPZQQU"]SO]-\/]:3OW?SE7-"Y*)8\CM\ZW<
MW<._+'A[\=1[</@0HG[\U-MZ;T%XM'L?U'$?LE%W>1_\@G3X$(SHP5>XKM$P
M6;U:Z2AK+BHN:YX]U;-@G-;L]!B]L)S5(>[XM-NBTNPS(F+0\?JTV Z3(R>&
M><G! RZR%O/MW #D+43!2H-!\FKJW'S3$OW5FQ\*;Z'>O_2]%1,IEUM+2#V?
M$(J\+A 38?_MP>:;G[-N'94WB"!\"ST<;GU$\^)!_EH,=ZX>. *%E3X6WSC,
M(M(3:7V1;'C+DWN3>*5!L>_S7V,NC:"&X)QWGYXP/F28=)28K#QW1BYQ&8C9
MB[Q.69 =)5R83"-5,\.5+: 'WCO<.B1&B%A*H5*VG)00+PLZSRV9> VG[>:W
MUJ2ZFNC!T</EV!6-E3N^H-J1A_<S6-"=8>X=LTX@<9>OSP\@1]F4INF8\%/P
M%]LZOR 1ZQ ] OP>Y41/#N='&ZK_VSI>WE;]XL8I)IKLYPJH8G1YRCMG#URG
MJ1D)U6H5#-9#['U>VB[]'O*=.14?ZOC1D!/1D.@_-.%K;@I;9J-S+F?L*ZRF
MG5&UG**XA 7%()RO$<Y/![P*?P:']OH2=$WZCYB38]XIGV+U1;Q_.&I%8[]/
M*9SG3Y#=7Q2E6W[>WR,T$'Z2<P2*[ #(I^TBR.,5.WJATT)))H^/&$E:9^+,
ME1GKSX "1SVP AX3B:SJU_Q^<CN1I+ N3O=IJ8:4:]OC&]"(Y0]8S.<D!0#O
M-E5:^F#X-T<B2!RM,I,Q;WG8+FT:'>!J>0_4<GX%K[RS[2&\,'Y>23'E(2NI
MBZ/X.+:+IO2YN4:_O-;:Y2!5V]+[XVB7K2T3'\D:L?JHBIXY,.65@3[^WG+:
M,EIRO4DN*4Y,^_X]KM@+$G_H1#!WH*LPG35^:I]M>$#S9H/^RE!9[4-W03/D
M*U*$' =#H1S/M^5O\9/564-^^$D+C?H7[@W9WSYOD2O&X2FKLD\/N%.;"%.-
MT)W<!(Q/Y-[23!D[P)RT.EOT"=+Y22%2]+Q3JO<\?ICR,JBI/MRA%,DRC-<Q
MY;-=X>A*+5N%5<KH)+^H(Q2,&C<S4GQGW %_0/<>*]0RP4%^Q[W\6>,@]]V8
MM,O27/HPH1 ^7O.6INB,'3TN^\&83G6)<5#72DL4K\B* RM,:;)$X_U,RJ>L
M-7C09%)+GI(A+^=G05'G7F#+G0ONSBNXD41$-%Y,:4Z)PW7^]_VJ#QR:.*SE
M_:W);<^,Y58H^^4-VEN3WW,&(;)J@UJU!_P%@Q^BJHM:])SL>/0NL"X7$8J'
M-B"CXXE_(&1J%U*Q<D49)5F3"7L6##S9KP56L.*7%I**51B/5GEQZF^T4R>&
M8=%5;1._*WQ$7K_ 0]U4*])LC<F)$7()#;-!']Y*Y(MO821,06%YR^!*MW&Q
MJF(J=F'5RZK5I5VU,'1D6ZZ\!:%[W?-'.?J36^-??+=P:J(E9Z'&71Q+9+CJ
MQ+SB)$=V?^]L'(F>G3!U%;*5#+P.X<GLT5L'51\S=/H?(Y;<R^+_ 5!+ P04
M    " #3-G96L^K0J__Z  !Z-P$ $0   &<T,# R,#9G,S5A,S4N:G!G[+T)
ML"Q9>A;V>GHT,QJ0T$@($ AXM$""2%[GGI7YU/U$5E;EGEE9N5=A',ZU*O<]
M*[/"#B"P6(2-;<)A<!!8++(P!,BLDFUP #8X! $(LX0P8I,LH["1$ 9C841X
MG/?6[>6]?J][1AK"$$Q%W^I[3Y[_.]N_?/^I4^=]]F]\]N\]^@J1%=A'K[WV
ML=?FU^9'CS[[_?E_>N[[^BD(EMV;7ECYT9M!58"35X/PFQ#XZ*UOFFHOR*+^
ML1^=DO+M-W[TC__)-QXGX=MO.+@"*343G1/^VD;&536#:Q90X1O?].S3;TU/
MIZ(NHMY[/!5YV3V=WG[C'OSI\OM=,?C&X_LJ??;V&_3=@\>NHCUFJC9ZO'H3
M>1) $/1X1;T)^P3NK:A?^AB!$ 2$"!!&G\"KIQCQ%,8>/[S>>/;IY?VM-HR?
MZAOVH;WEK[??>!C8Y7)Y\X*^6;4G$*8H"H00$$&>+#6>='/9>].3LONZ&\@[
M.)NH"]JD[I.J?'SWM^=70__V&V]\^O'[7K>&PN#==NJAS>];"0,PRJ,B*OMN
MF408?)G<,O9W!5\Z\Z\0XH3B].&")S I3J\25Y0/%RZ*ETIVO1[%'R[9F7,=
M@7K454,;1$OUKWLYT';L/Q^@[;A,XTNADCP?NK[U^JI].>#[*GS8C)K:1TQH
M#]8OG\^NWR3%YS*8I5I4=HLV=:^8%+;\G":%K5XQ%W>*\5%:\3*Y.GS%JBX/
M%C$4?-<N[DPC#)[&55MX_3.OKO,D\.X,!*RKKK^9RUO@>S6>%^N3/H^>/=>!
M>T.C\_[YTG<>Y,E=#Y_F7KDLSO0DC&)OR/LWGIU0W$/QM\!;G1<0P0]"WG?I
MQ=;O>A2^9^(_B7ZU4>TE[1O/V"2/'JM>$3U]0>C6WS>]Y.N_;J*_T>JBMOQ@
MK4V4]]Y]!;D*O/RQF;Q89?%7BM<&YR>+'T0?0\A3E'@*4?<B6\-\B<!C!'Z_
MQ.(SH7<EC/N!/[:C]DXEWY-#WB3NGPOOV<USE1#B3?Q-^+X*UWKU.0D>]XM6
MOJ]ANNTO59O=5[E_^X%?];L>K_#'?KZ$D,?MD$?=X^"\S%T4/NZKQ]48M76;
ME/V;STO */$@TD=3?R?1>D&_].2CA,US]#BN\KRZ).5I^6UQP(^]):34;=0M
M;N1Q4C[NERIA%0QWWOGIO=![W6>\//';Y.6E3]95'KZJJ:#*J_;S:FM]-[X7
M6U(.TGLM//F7^;IOX?,THY>;S%N+[WFJ+"$]]'IOX_71LSN->P*A3Q#$O&DJ
M3 $0_A2%W@(_4/=%G"I,XOES0GFOY@L83!LMI:_ (-^/\;Z:+\.H6K.J\F<W
M>O)^H[@SA,>_V$G*L+ITO^1]6 \2+X"9YZ'P2R_)N\_3T]S]K_;:+KIS_F^_
M\4Y(?.,# @\MW7&#IY<D[,_/$)RX[]?[BCY,Z!PEIW/_#%XA[TD]E'V8V(.O
M%[4M]Y[<!P+ !^62PCM%ST J!3&:WAO94=1/])H^;1F'%@\TO0%7>[JSN/,8
M<M35XZB+L%$&A::Q?9:K- #1]Z\UO=2_>VWI>WVF]W?"RVM/KT$ HS<9F_F(
MF-.<>1.(09\6EH>G_79-6]OUR6+7IXQ;[P\B<SEQZ]-)WM"5Q%RJFQUNUK2R
MH2]W/_L-C6E;FMQMUHK)KO?F=KKXW-0%_$3&[_Y<MOSZ$J@;&CHL+1RXLZ6S
M>G7_[![PN<J?YP](+@/=G^AV&2Y]V>JW(=."3N\5?1G:EO:$NT'R]-WH]EOZ
MO=>>I2\"MTP+S]#9,KSEV4G8O%CO80YI9AGM,B^!P.PK>7G,+ ULZ-.>6<J6
M&5F 2F59+$5?TS0KZ,*TM[?<%MDFP6%K*35W7D_.M$^T]2WF]?Q9F8X)R>CS
M:=SF^ZMN9HTT'U"-4:U]F1&[JWH.K2-O;J!!$,1*$9GSZ7@6EZEK#,CN55M:
MMS,&:MM[0'AG0D?787//@:?0S2GGB)QKK^@[W\'' ZK#81EBD5NO8AX&8G2W
M/1\\/A$**<%F-:T )L,-.Z^C0W&\!VS\4D2B$I?26G**FDCJIAFZUB/&2E_F
M=QF^L%GO%W79'[;,HA#^W9R=MYLULS44:\M:NGH63L?I=-S.]X"5SU]8A=<Q
M0V586TR"<7L5-_KF=/8,:W:2PTIFUJAFJ)&X/4VAE5U.]T,6TR/+)6$6LA9*
M-KOK93[5]X 0H%W/HI'UBFGAFIZ'!\>N?9>%(Q?6\V,15IY3MSX'#S[R4<._
M!P0VN>@X.9X<BWH(RB,19\TNJSVO;*2B:8BY;QM@!+U%T39W&K&]4[$-25,;
M(-+4%'!"I5_-._0TN.4]8+GE.7S 5IRJ$U96!_-\/G="8]7H9,N]0F)1Z#>Q
MB99DH]=U") 'T&#;1@F11C>2YAI8"2]*/MPFC7,/&)<V?MIEGGF0_>@@JAO8
M6^6*4YR,_>5B&'3E9$,MY@>&8Z4\7_-2KUY-UF$)% =@X@++UPWK$P12L1E^
M#SBA48DJ"M775.,/R#F/(E3A)48_U/R14UHZ&5B+#<%BC5=NT7$CRL,1 G3E
M7*O ZD",(M\8%UU8!=J-1@GU&C%*@<^1-FFA^%H"![[4YG$=>:F&VSU.,?T1
MJ\[QQKIT;:WMLJT/G"G'RYV,OY!@?9$H>K(1:9CL>\#[WWXB;[6*UU!IM*CI
M#BT!GX:C>@^H&@;>;P*84D4V51E*0V)^!52<-&H@K62Q6C1$SV\.*(O.':9J
M:<1,KE&O=I(<TG2.RK+472QU;P'P;<C-P+K-:M)GFM'98%-QM$:0S$!)&C:>
M7 SL5YL8!W;20.TT+#[SE_B <.@\V2<7)V.2SMK> B^, I3Q#1#F%OTH@9_H
MP-]Y8[S)?&##+BHIUPTQR@[K,.QTT2[G*U6,QNBS;@KBC'?VW%TURQ[:K<]<
MV4!1/A%CY)U%O[ZF5>M 9!!8+AUO;HL2E7O_8$<PQH9)V]F'-1#SX/TXL"L1
M@JCEQZP38\V*=0\O?<LSOC"-^NH#Q3W@$5 AVT$S#QFL]#!(K:%7EP(C?*PI
MHH\>JA#OD,'SZUVR"XU[P&1PNQ;KC_/LY ,%0?L\B3$T33?C!/!I5Z/"ZM"0
M!"BG-D5#IK723']C40<XE,_"BH'[(\6IU1(6<I&_!QP6#Z?8NE5%?DF89[L
M\13PPI#L"&6HB>,1Z;%FQQ:G0733/ ]16ZCDHZ4#07<^0&TG'=C#N8EQA,@/
M]X#S;/#&P?3<$ Z7KC/%<9+\X3H(OCVVBZNT4\^(_=0ZR2O,#@.PU-ILXV8B
MU""1O]<5L* 3;R_->[?J[@'!RT:7:BNG4$"KC7),&@[<K<@)%"D8MV%_GM:1
MH;8>&N9;/T!ZJ DP'UBC?*MNA3#?KT@*0-9N5RPS>@_XTJF6-&4L)%GW#0W"
MG#&T!F1Q0-Z1VXMRXN4>7:XD24O":]>L2M92Z^),H/QMR)[MNS#N*_E),,A
MV9SRRL)(78 F5J( #CPI]G%]IU#AA[Y9/N%%]X#,/(AM)%ROD[XC+5IE5DTM
MU2Y(,VF?M%>4[.+KFIR!8VCD'67TUC8<UZ(<H$I8!TB5%O*42%M@< #YEN!
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M\W#&VA%3>7R\A5'@T%QM<BA1Y40B<;G"L]UHBGB<)5Q1\_Q%8IW-;F_@N(&
M<MM#G)'GY6J<2&YE4]5UFBMZ@[E C5/M36W*U*+<T4<M)$(/Z,$QCA6&KW50
MWQMTD,+V2:>*7,>.9C8%%B"0J$MDI%-WY(HG=F2,=&=0*:_X<4FK;CN<R:!R
M\,*494.Z)JF'%<F2LFMV+NX984JK?53&XO&P)><EXI6])DIB.LI@ %:'M"D&
ME)VSH"A0LJR8Z48X,?R$&2X%LD==OTJ<7^R;H;:8X<(QD23N5HD'T68:@36O
M$C$^@)H/PU"SF2MJ%#JUTZ."2$Z#P?.T? L!F*%-A K7A:T)^U7J$DC$-?P.
M\!E00?$K<%B4LW- TRJ*67>,R67'@VGL)^[H%UB#)VG5[ X JX_]_A;U$%VI
MV>J*]TL&D=-\I.FK,VZ#NY$<;+(E=D,-'%<N)3)S?XZ 9L69\+0=FV#6!W37
M!R,OHHI<.910GDZW]%8HSF7J.&(35*BEU)675#O496:K]<UPU[LRTK<;>K5)
MEH3$9G2XMN_.'G-W>T%)65S)H1?)F4CY"+T=N41#!UV=?8,Z]4BZ#6%?5D3X
M7.#5BF;TJ&'-07=9V[]2N,V-D4DMKF4^G4"#JYRL4T=QR4NCALBDZXZ][<ZE
M\9@TOA.ER-:NUUNJ918^8CM":JW.^PTRV<;BM5<U4'E+!BDM]!:^;LG]L#H>
MX"+!DW*G%O:)XP_0]'!L%6KGO.;2R-'Q"+(=")D=%CO@?@ 5=KG>F.N9:V6+
M'/35$O8+ I2N9BM-9.O%E=UO^[$"VH46-]O^$MT^7X8(!BW3/ L!4<G24:K5
M<''5DUV@A *A8)Z=09QME_#EQM75C ''6+R->%_BR( WBD&Q+)LF#95S"U)L
MU[<5A:N!2W1T[>T,-!+W%9,ID;EIDU;2H&,]@K*X 6?9!0IIV.7$8;_W=_1I
MM>54C5AX#F]K,PP9YCW@5:]4ZD!H-;0K$ ]MO,6S;XVHZ:]KPO)RUDRPQK14
MY&)M ^&XQ&<KEO*S /5+8G[V#&4G:VM_/W5VZ]P8K-2H?;>GMXS "Z+OQ_D9
M<.$^E,,]L3ZVN_IP3CF.GTX->NGM\#+Q)BV<3\J6]FFVUEL--R-G23W\RJ9N
MWT*JBF(BM./%G;W<K]<\2V09=@;:\I30VD7Q*;-W_?:,[0N'6^.G6-RU)MF!
M,]CA&+[R9_ P7?<CT9D)>TM\&LS/.#;"_)@_,^O3=$*$! PJ3P=L#8\]/=Z[
M2$GLLB7F!^,^K,6:'D7F## ZZJ[D;:C0)SK9+31<31ZXC6%:=Q\8C+*-XU1'
M^: >#J&BV)/<*'JTYPS*,T1,7'.;J:);F+N@Z'K"Z/JR5P;AY%Q532KS4 1;
MYM9#[= &08*V#'+>D"FL";(S&+YG\ XXQXM+=2B]7-A6*"H]&I"QZ^WPH;+]
MTRGE5P/GJ&M2.OER9M)L]9#>!@$>Z&PNH: DZREP#.*"=K;"PFG3J[8FLE$@
MVJ631Q$TEWAZIA$4\< .(VF\ ^GS%-B;9 6MEM2PN6VS"+N>."&5E]?&C/K+
MFHN\JC%,$Q\!CC/4"'0*\;2YZAF$[([#?BTMB25$GA1BUBHV(Y,UNQF95C74
M?7,[PRDVIF[3Z 7B],M%[$[N*NM&<$:@U@(U".F\LH;+D-B%TJG#!'&[7OS@
M#B\6RV(EFMO9NC.(M!-)RMC<=D6DJ)Q57)*$U%O7UW:;Z#JY<MADFUI" A\-
M3ZIH3EV7EW30611WR X=-P1>LWD 9(P .CU6[P3-DF?KMB%)' Q68'3"QOE3
M%VM<3;3\$<F<S-V52%A[#NE)(V.@6;GX+H1E&D:T:Y.5Q?'.)DEZGO<@F<!@
MG32W,/K^#_#P$/"U B [BBO.0(^.N0<"'6CW[% 6757)\X$2W4Q>\!:#=P+M
M(C;K(>SLO99K5_7V/:EF&*_[%,*I@^G(ZCD8(^Y:G(K%,ZW7'-R M;XIUR)1
MHW*) 0Z\5Y,6!NDE18W,N)3Q'K[JH7$^=Z&900_^L,XHO+8"KS4H6-IA9V,'
M^UD;+;G7<4G?";A%+@WE)G*A,EB%6^P9XPK@[B3BN.D=4-'L@VJ3)**.MQYF
M[+0YND@VB<%4\/G!L<A+ J\Q>+_X/;[$SWS8D.80DM*X'^<.CJW0)FO0:1',
MHW1_)L^=3.PW>> $MYAR(1QR.M!KP/)2[*0"P]IQL89D!DVS$:0CFGYA7ODB
MB-2.7<;NMNL;N4!,F&<7@UA;ZWX5EY>S7;CC+:-?$]O<;="%2Y1-U$1Z+XV]
MD7L141@F:/"6!'7&==<I-4VS;F([K1GU =.5DTU2"ZF2+KW#=2A2SL#A-F2(
M'&<O/4QHU$VH.@:RAY )JC4E@626=QEED>7J5(KI'0"P;J?AP=+RL+1,<?#&
M3IQQ52 V7G/NZ7H[*U(FN$5;<JL/Q=H"!ORZ]I8PQ)%77;@FG&*'<R5BS0[7
M]H<&B%<Q.6D[I1X/L<+5;G1&?.*Z+2HWR_3^1I8.%],+J"OO"V1WP$XH<][I
MK"'%UX,=S6!.-;N6*'$>TBSU:+5-#A\O,QJ+L2F&^1IGH\EO3[9*F2%&W;YH
M,*"&?> -3L_+ +*9K;C)H-U,184TEHAV!6D)4\6T;Z]7.;C[2J#KH6/!H4,E
M%] @#])E"[<;#]7@B+LE/J-DSFEE6D&DMV=[!>/^T (K<B#LT$O&C24GUQ[W
M)V9DLNLD02>,:I0E'[+1PJ"&U69>-3EU%(D<]Y#;66*2ZGDSG_,T.6;L&FXN
MG#32.G <1JTB+6LQ0+;J IL*>$=H&PY/AG"?=M6Q-: T6X+\VIMWX(Z6J2JX
M>>R2:8DME'BK$BKF<MQB;M!M392Q,/+([=G)[/6.Z;VY,ST[!/IP7IQO$M8^
MLFVZ3)*DCNB(H<).(;R[G:H::4HG,2!4-9*6\S1"=Z/;M^NFKYNB]5A1)7SS
M>M5[9B@<)67$/9ZE8B:M]5F.$-:%-H?9W>:I/[L2>3O-<L8R[RA9V&"O#Y9V
M"ICF_2=M6C=),WJ;2!B_5^@8QAJD$6K1WC.>+; 2M! ']&XWRY.$Z1:7CWMC
M(+*TBGW6N3N;VESVEU.W3TZ+K_,1CHIYUL9HBU[^0VC>N/O"EGT0A/5<<]42
M9H&M#VJL?3G2:'TCG"=E[:9H?6NJ204JRQ*$/*>.@<E*)K/[(],S$U.N[!T@
M-8C4!/;DS[W068VA,BACVP?%BDX:VX2W<U_[$[236D3GK&8^YYJUM=>3/=[M
MG'9;17!/6TM8=&=OM61GNW<'E.VQUBT:D_=\MM[[*G;7P65^A/7#0;)AD[2Z
MSM!,)5BGU@J97:[8_N?^94<LQL_0QCIJU^TMZC6QT4K4@%/&:5A4G_#F/"D[
M)L^@P'=L /,DASN>+UMAC7H#+&'V/L_Q,PD2?A6F1Z2"$4(!,L_+2_EV<.)@
MY-AJUBP>&&4IUI<QGJLDGX9RNZ(">QEI7.B-6XBKZNJ5_A+N,+BOBKP#S4YV
M%RLN\E$C8D;W$^F!VXRIWV*4[3A>B&<DZ?6 532 )V^O<6W:-3J$0H\=)E7U
M';TPMHRDM.1"M?B<1M&=U*D.3JZ6;#+JRX==8AB;%XX,PX$S5+/37LRYY6MX
MD,,: QOKRL/\FDG/7+OEL\MDYV,..J,&@7B"N#D"#'7<'$_F=1T:^>U,NW[V
M9Z2YQ%;!:F=Z9*Y6[9PFF[B>/O^OH]ZV3#_X+345IRR@,4%WQ\,FA )=U)H0
M:&)E>6W[":,\K.F@D>+ "H%!/:[ "H4LH(X?OKRF54 Z\3507@#^/-53W9NL
M92:-NX^QF*0A*@3.E V:8Z7';L1O")A@'8J'I9B_M#,&+ZF,$MQVDV]'W3ZP
MS0R"R/[MM]^[R>%V3<,';J?X/&X->>7U%V_=WT7U5"B[WBN#2-@\6PK>3)+P
M*48@,>3AT1,(\X,G<8A!3_R0P)ZLX$4#8(S$4-2[!WY>_ /0FX>+5QZ@P\\3
M^GWB'X#>M<DI*;W\?76&8<''-PA$4@A&H8NMKV&8@C&:Q"EH@\(X1#+D.]@O
MD?] &WI4ALG=52M,[G7=LX<+D-Y!>.'I!P<?M<D8A6Q;%9_C+2)OW5_Q]31Y
M;T9O0T(H=-&L\ D<0-$3+/:Q)U[L>4\(+(PH+US!(8:]!7Y ]F70X0<7A PQ
M+R16T9,(CZ$G\ HCGO@0&C[Q28]:+2,F47_U#GKXLLEZ#[WZ":_)*^5?UDS[
MBF5YZ=,7+.'Y=?G@HO%)UU?M_))+8I94^@MS2<S]]6M/O>#^#I_.6[IRU_7W
ME;U:*/F@J2(Q!GM!'#XA S]Z$F 8_,3'??P)"JT0<A4BL$<0[^"_2CF>:^-R
MCLKG+NV!GV+D4^C=2WO>5^O5(%T5]Q>OC>C3LHR?P^T]+Y-Z-?K##53/P'<$
MWRGXW-SDOQH+][DYPI_,PKUP8].__@MW*WW>$-^QZ@\:[EOONWOPJ=%[;3_4
M6EO%21X]T^XN+7L+_) :K\!YN&+*&/R7WTOU/.8+M9_W-J9V>LI[G9UTB9]'
MNW>N4GMFMD-T/ZI75?@P&+/URF[1Z*@,YF>LEW<O@WJNT@?15&VA'-TS^%W)
MAX(/UE2\Z>Z1D5RCSSW$;9+BZ>79HDC0_>M.%6Y%+ZMX?@:OWH0(9+&*=RJ>
M7UIQ*)/^F98$7O=.O?N2%Q3EA4Z_9$AWUSN^[(ZPM7?Z0GD1MNR?WMV+=W=7
MX;.'F^WN.OU<^8>+LEZ1Y//+A!^>?)1X$#W3H].0>^WSPL%'M7PWQ&>[.BH?
MW_WV?N'[)Z\6'F^W&!K]HL.G9P]W&CXFWD30=T">K_%JI* JZJI+^N@=!7^Q
M^",&OYCW_10'M]E[L^_CYR;AG>?_LJ/)R_3@_H;#_Q^4X<5F_XW4!/\GJ0JW
MTN<]Q;MNYT7'\H[#T7*OOV_D95[G0TCG,V;VRH]2R6>*=Q>2O8^L=XCNKM'\
MR&KW-V9^GL'YE8-\9P:,B]<'9ZZMAOKSG(//_W;&IZ>[9N[7='/+&Q[?FG]\
MW_XM[WY?I0_'N5=TZ/U"KU3]^RK,W16EW@<"S$>/]R<U\!<ZT=V/]WYTSGDQ
MDH?NOZ_XHS&**EQ<EG*0'H3O__YHL;NK:I]I^H[9&L:#9/^*"7M!,EB4_1GT
M+F5XK^QSZ.O-!%Z4?J?XHP'F>]MX4?ZA]*/%[V_1?5'Z5OCJ97Z5(;Y7XPNJ
M" ]V_45%^%" +X@BP- 75!5>YG;?]_ CW,X7EM*\X#NYUIN[GXA'A?_U]:C,
MV]!C9?DY+#_2V_"[B_Q%HWH5P+\I1O6A_.@5%.BM>A'1VBH<@JA]V&S0-NSC
M.[;JM?-C>$FBE[SXN5J??G]SFQ>N"[^5ZAOVV:>7MM_Y]T$^=)J_8*\O-O+%
M1K[8R!<;^6(C7VSDBXW\*]7(I]_[%\:B,GS[C<L;W_3LL]_WB'GTVD_R=0?R
MD\5X[;-_ZM%G/O7:)U[[]:^_]IE''_O,:Z]_YK7/_IE'/^_1:X\^]K'7E^>/
MWGE]ZDL_\<F/?\FG7__8W?/-5SQZ[>.OO_;HM=<_]OKKG_K4EWS\]8]_[/4O
M^<1KG_S4HR_]S%=^U4__ZI_Q"Z:?27[7I]_X.IBR_[/O_%D_^Q<B[F_Y:]_[
M-=^ KO>_Z.M_,4XWOW-!^=H%_OE&'KUV!_/Q3WYJ>?K+/K.T<=? )S[^)1_[
MQ-+<79]>__AGON0K?\$GX*^B]Y_\Z6]XS1]"?O5_\H^^NOV=?_I__CK]4[]P
M[7____DS4,;X-;_Y?_@KG_V;CW[JTL./?>;USSSZID<_]CWPDY_[VF=^R3="
M^FN_X9M_T].C]KU?^0/?]^5/L9-,_IZO^"M?._!?&_^*04C^V'_S;;^;7/_T
MW__]U!O?_JW__,_\_"_[[*-_]CV__K./_MQ_\1]^]M'_\ME'7_TO5I]]]$?_
MP%_\GC^)_MVO^=N[[_I]/_OGK/^O?_$K?CS_N__6;XU_]SX[EM_R#_[(FW_*
M^=\*Y"_^,;#\WJ_XBM=_*?^S*.&G_='_?=_^\XWVOWH_\+>]7R?^E*]][1=]
MVVM_ZUN_XZM_[0]_\P\3?^R??O]?9-\F__MO_Y;?_LW'OU?\6OF[^V_X4?);
M -S^CF]VN#?_O6_YPW__LX^VO^&'?L$GKA;\*W_?7[@BS@_\I4__2>N'_O#O
M^<?"W_WO_M(_^,=_]K_\KM_][_[9[_R';_V<_PG][:#Q?3_;_FU_\/'PP\_^
M_.67?_>_#5Q_9?C+U+_U@]\#;[_SS_\@]U.I[S[\A?_1^?H_+/_G/^V[O^O'
MOS3\FW_U#_X'O^J'@D]^_,<>_<?U)[_U=WU_]M-^RX_\U[_B[_V_?_!'ONPW
M_N6_]75_33]F6O;;WLZT[A<2?^KW'L_?^/,#Z=?8O_;?_]MO?-_X9=^^^V>#
M_<>QGRI]\Y_^U3_K-__,GQ*'7WKZ5/$GOESYUJ_ZY;]N]0W_[>,?O/ZF3_Z8
M^_=_\/])?^3O?/DW?ML__8:C,_^#YA_^^1_[VO_CRW__7_[*ZV_^0^/W_O5/
M?OO__??_Q7?\$^'X-W_\JZG^C_Q<\*NEO_&=?_GKO^:W_/K?^AU_3C5_Q[?]
MHW_RN_Z<\JG_BOO1'_N>;_WAW_'OC)_Z[J]Y_$,?_T>KYE=]\O'/>^L_^NO*
MWTE_Y#M^X_?^W"=__4_\@7_\R>"O?-4GNQ]%_^J//_JR[_NVW_O_L>Z5T7$U
MR[4CRY8L!LMB!HN9F=D"RQ8S,VL$%MEBAA&SQ<S,S$RC$<.(F1G>=Y.;E=R7
MFZSW5O+G5/\[M;J[JO;>5:UN!73F2WX#K/DO8C3PV8S[73")_M ,":Y&(D/<
M.S(W3 9>DEV0/Y$W*&NQS*Q<RLM0$F)$./]>(5$45)]]K;+OG7SEI'L#/!BV
MOP%N&_O.UU]GRAO"74N/2Q3XC56HTC+SUP_KC^K%'&/',(I3VTM(>2$(9@&Q
MN+PPVK&A N+HO#V(QK2>*/'L:/FVE,6+ID+D[J%;U"&9_Q/#0&UJ\'R4]DI^
M>+RZ?25;;\27*,J#$.[QX"<,,[_.+OSUX]@#213MC/-SLJB5F_"=@*2*CBKC
M);Q,G?-NZ;+ W40\L3%V 79I>/G!JFUC=MY^%?#5^_=2 L'%)P+$'4-=OM(/
MW%](F&2LM=OL+_*">DLG='ZE]M&'AGR>_.L(KM5<9W2'J3MDB=L>G(]BHW/J
M6X6RP.K\>O5MF@<.-;>KP@9)]=:R"Q#'6BMLO,>R>7(C%6:*EE$/TL?R(*O/
MV_&+*#[Q=S^"IAZU/&HB,J5CSZZN=+P7X>MLEOS-U%T21G!T3PZ6)$$4VOH,
MRLW58K,53A@FX3"FL?Z/.Y@18D-\P_<HNT-$"[A2",A@8=)H=&,*P=K)Z1]H
M\ [F0\RXAR>%Y?C+S]_XO+?PSUSUP'I_UEP9:VOY5$99L3WYZ;,9N<H[#IFK
M:C .TL.RHH(0.RR.8W&>>9H:WI&JC)PZRQ+R=]I$P.S#\;R^>EW69PQNECH#
M+5<;:UOEG0]D3B;GGV=_[%IM$/:7G22<J%=N%KD=WH++UAG$]<M!B:O!UDX/
M"D5-5FB@< >^;<MSUBM>K/T5$70!;KLI!T(=)VG*#0]4'A(AN4-7[EYF<> *
MM?2JIWK.C:@@6HU'N(H3.*76PM;-.B3W2&LB=?E\^95ISP3NP)3+:MR\[41N
MFQ=<E9L1&!46_*.)I:+-7\2*\/=FGBWA.UGXYJ$!-C@I>+OG2V^L?>@:XWK\
M:<1:>^SB,H72<<9#$]"N9>JB_H1$OG;^1H'[A_5=GBF2(?):06$9>UQ2*V'T
M6=P^H_B ) ];;X3X1C+DHE]%:FH*%89R;RSK&*#S!DC$_XR%%C%QR8&O^Y7]
MPXX@Y#X_5">8,#;+*I2M8<WP5ER\K&7I(I!L )R0K=$#*C/'G0R9'%C?M5^A
MA>_27Y$.\\W+='@#P--V!-V2B-XJG^X=^AQJ__SQ/PR$?S'A(Y7CVT$Y"0\P
MVS_A1<5<N64/'IALEC_5$$;W6[7QUVPPP>B1XY6=%5O0]26X\ZL:&3 H?5/$
MP7;7=']W-'TYWO+#.;]?-E'CJAZR])$BR1B^D_#A]5[MVSE4=W=D-W4)ZBS,
M>;O'#I99S.TT++O#(AJ .S/*Z%<CJE.<E6[2M9ML5[43I)!N.Y<*FCR%)B[G
M%%O(E_AHO A7TU52QF841C\Z1@LK<3KHT?W=:[K+!YLW@!F)MZ_L<N^K6.J%
M9E9DY]AZD[;^K\ZF:*PW@*S YBOJ=V^48R'_X^S5R;F7N8;K(B4, 8F+3WW_
M(X.3)IRJS54R(\@Y(8C#>%E-<M'::%CW\@;0 DM6.FF^<'M XL,9<[CT!DIQ
M6:1!G1M?J'*R$U!P7$IE1&"MPNCLJDD9W@"GPA$U[)38079X[[>A1!>[0KZJ
M[$*$+9\S0V>UM?HFA]J2AEY)72W.FR&7.D4=2JZ_$^8-)UX_VA5MZVB5G73Z
M"?N\DCT1R<O%C-EAI4>FFV1O^/NMMKE.>$WR#JO#;.7\_6 KF1,G;PWO%JXS
MVH2W:2L_I]PO/X\_!=;?(SV%7"A=QTV0;.QP3ZWU[@N-$*V\**W*V\L%_$\W
MZ&_&H^F!G3^7U$>CZ=(Z7FE7D+DQ''IRA/UZ=8S'ZUKWVE_$6E4R,&0I@TZ>
MBP12',I+W5C&PJ1W0K^2 !\[A\2R+FVPL0XF2OW2.CZE8-QL'X2'G]P55@(U
MH**G'34OH8Q%=2T1_JX[.5Y>-BMF'+337BV4 K\!3&'L!K46[#UF.D-KO]2$
MVKZC0O["N(G55MZ_]Y&N%7!.R/,&*.V\A@WD?5;]NZNJ.Y>+KV-"CZ]QC<'/
M@9Q;M<($OBF=#@V=,+Z.Q+2O((_>9\*"1P*(-_RB>&M6\5.Q[8'R?QU+=-?3
M^!73344@;;C9:4%\K+8&\'ILYY\*&UR(!0VDI. 6<H/X;/+#&.@&(OV6<$]3
MA2>6 >S/\QVYJN"K+Y?0GHPU.XY+52AD=+5L#6@C7M@?$7?E)X F"%(@5#PR
M6TV5O %:L6FRV0Q[U.@=-CK,/ECVS#')^")Z+V#GQ*U?DLR]RQL,^W\X(FQA
M6U!"4(EF 6G. B_W)[U44%" /6KQ<*BRL2R=$"."*9V'? QC@80BOES&2.8
M@:+Z]6!(6_6I4-2>T&+$O+K/]3WL@^+BTT!A);EUG*EZ,_GMC5 GC2(KHT5
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MB*A<9UR4F@;-*0?(#6D&L(*D@:$Q!M97!8*A1D@F[G[#=?QF" 2AN-0\@UD
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MMT>.8)4KV4\G+I;\H%H);UBCUM<L!72)KV6KQ8=_+FU0#5*1DRG6V'TW%)"
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M61HYK_EHV4;K3M] '<R1>$Z(L.T*?U@Q^D\27/5_A_9+/J*] 6+6F=T\YM\
MRQ;K1"NS:)7DF'M7!CZ1Q^\"6E84$60>LWNM?V*'2H93T:OO8)1'/6+%;\3O
M4=F-$5?P/J?%KN_*OKRK?P-\_OZ/N5/\IIW?5O_1E6VQ$/BATK%KON[RYJ5
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M=/61R4V.UR?UZ#5T>OE[@5+]\%*QED\O'%=V\*H@K)JS=?]TI<4K8L)B=;7
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MEEX";J=P*SF.MC'9*:A1&Z+'D[#CS<>M=N18$2J6RA4Q-[H9B[<J,3Q_,QJ
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M;(?"%>?^97K G.E_?6>;>/W.\=^B W KBYH(:E ^K>^Y%P=8*3A2V!L_)."
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M)!DC2R^;[F342G4F41JN'][A:8F,:L%.)>)/CA"7S'9)[C,%-+7!$5_)\&&
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MD]&\2P:'DW[3&H-,3$Q$JSL^'M/[W7.B< <\''*KN,AY<JTTYR9%&M@D$L2
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M2.2WTH4IVIO]?IRAN(1AV6NVJ GMHL;4LOE5GR2<X<5'=O!<Y3J;BGL*F]$
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MQZD$$W^7L.]^,M.9YD 9.^1\?WFW?A@J)$-5D)*( '?H%=@G>8\(1/5&%$W
M%#O'&5O[4CKVW]ZX[$GES1XZEABB/$\%!#@0&ATI)5\Z*+US#31JJ#ZTXV="
MZ9X6VIXMY#CDG.U**;Y,X:[(_)GYAZ(5D7N[6=9L$SYZ!%/]:%A^51Z9/+_]
MPGXHT^THU>F>@_0OX$@ZHZLQU4?>!3]KS'#59, ].=P<=6F%@9Z-RXDHGBIB
M2IAG-XC,TAX'HY37!BBGC[X+!V3T;  P?KR>RX,C?XRW0>20@NIVE&+>F=JP
M:(WC$DYWJ9%RW05R/VMP+_]&]2TU^4"#LS> W/@O(.6/ALA!_17CCXK=HT^V
M]<MK>Q[&3V79??2=[H"LY7T:!O]/8U\5%%?313L);D%"<&> X.X6(+B[NS.X
M$RRX#>X>+(.[NSN#N[M#\.#W^_Y;MV[]#U=>>C_UJ=-K]]EG==7NM>@3V%"E
MUTN5,$.:.3H:8<T_LMIG%68_!7_*6R)?Z$B^F&\TH%<D&LB4?>&V7VWC=SG.
MAI"*-A*0JKL>JF12?ENPLAE,"U[!_HV5!A>++6HVM(V%9[YZ6K,1Z?<\TPI[
MA1NV&?<.2+)W>819RI3-")_V(2S=XDQ>V"X=.[%_KE60.B/;*(4.+QX4NMZ1
MBHMU-)PX&/_)YOOX_;2.I3;=Q[TH"&D0U3QA?(&W@-()"!,:P^(3(> K\4G(
MYKH3R4:G,V@,9]2BZA$YZQ$E-K"K=KRH?7/'J>S'KR$0QJFESG0^TV<-VN+2
M5;%M=K2FY_QO# 6Y+%;-D W&D"] Z(4.8?R2G\^KO[@'R7_<_@(-J3H\6/N(
MM%M^R%1H@5OU3RCG0"MO55S'<CVCFUR<.TV5)^G92M_A3>.4G1><#@Y",(ZN
MH9%@!DS@MZ\ILF;ETRW=)!O^(B-O =_?;,[MHQ;TV>?72JYA;&<:*7@?TFE?
M0TC;.28^[4H'*A3SLQO;IK41,TGT>"72/@G4\[<$"6%ZQF>%&3\,AZM%,,#S
M2EN1X1RFXFS%*7A25A/?/'X%7=/>^%]9MGOR5]5?E)_RO5:9V4+_[847M.YP
M:]G1^[<7'BM^ZDHJ,6<1T[&[?-;0.CB9E@)#;M]3&[9V [M=A =?>.KSYAZ;
MVIDWHDN&XPS24+]WS(2]M# 9<@AGUW5>BT/6HV+6;6/1(NYK44T#1/!XPLD\
M.SG\.[$0W;;"PEWK[>*1:71R:$*#6 0C@5(+%=N=V^=[HY])WR+M'@149;T)
M;>9C'?&N&*&4L0'K%96K6,+"YXY1!Y*F1<UO>4DM&0:Y$IW2\!LU=JO:!\#(
MF*PQYOHU__O]-H@P[]]0>),O30?>5G=O>B"+^R[AFVB.KE*Y BV[;%9\Q"/%
M=\!=,'7BZ K&&'!7>] Q=8>16(3EXZJ$2E!U@RGO@GR139-G4WDK8O8&&E^=
M<?<[P"&6_8 -_3#X9D\2);5EZD=G,^M<MFF%5N7+WPR-GTM/#G(NZ#O1%Q4,
M3X57;37F%1(6N]$M(_R2JO;"T6EXR6(;G<YXB_/+''DN21N\.][VL:\JG6>,
M\KBUC4)E&QZ/APGE_J_]03M2@F NB.JCMG6_:53AK7L@C7GFKP>[-A<A&I*]
MUG:%T+((@:QNC47)>_^9%51J-/;O52B(A&,Y!H]ZB/P'CBZHE\"/AEP/6!^8
MMF4K_-<,400:**(K!E=5"SN_/1?7;.8=G7S)>5YH FWT-6T2OA%]:NUW.\#J
M*-[*&W7L;V&GH!)TCH^W$RI=,ZZU^LA[/J$O%()S#E&H4/Z)WM:##7P'L$97
M,-&,)TC3%T=F*:&*&72X/Z;E1PH)F?_D>3/;VYWX@;2U@F[4>T09>=D1J[/L
MW66CPZ#9AD;2I!^ '%0$TICN[^:C:%5";=WO)<CG0S1:+BF@U@..P)@BI&2#
M =;+#B9U-;G!CCPC%W[^#$_,PKY%-_@3K90N(.%H@R_KK5&1]6_%=1]R D_X
M!IN<-Z7GKY*1XO>IZS<2%V]/HDOY#OUS!<-,F5*0>#Q.P1EJA7+!!;7T-=(#
M(I.SE\^OKVSA:WXT'Z7/V -=#J3/A$MX\&"2K8O? 5\EM]=I9=17&@ZQDR#X
M.@T*S[VI6:9XH_/!-JZ4R!K^.8[!5#Q0E_LBGB=3K+)MZ;?-D\WK+L.[X$[B
MKJLBO7? :/;S.Z!!B":$YMF_S'_4?P'KK_L[8##9Y1U YW'Y-O<W!SOW_*WB
M'4#[#M"2W5Y]!Q"H3[Z4;'8]J^YXJO@W/36]%%_.;S(;(A"'Y3$3G=>UI:79
MR#\^.:G,)/FZM.R<DV-*=BRX$Q%.2T"/5H&RVJ]O$)Q$#%OR<TR2_,$^.YYK
M4A!1#9MG8:C&18P&'W<355O:'YWME+CM.$6R0('(*QL=>5]#Q;:B$PS/6S>"
MNID6A,B_[3H+IJZJDCM]0!?)3NZ6MIWX6'OG18Z?ZDKJIOXCB96Z=%P1I'$3
M\YY8$/LRW7F%-C5;+(Y5L7GIOZ<8U1K-2U#!,"&9)FHU4PKY(11ZDJNKR@0*
M6=,;\_Y3BJGZ8@-@3/$:S.J5+/N*+B4Q85_:(]$0 NL_K C6Y:33%^*-<^]1
MI&NWXLLV"!VN$'GKA)3IAOQ9+^.D5Y;5V2@0]"K(J(C(]S:/V 6- '@^?AVS
MLU>PT3C<*+2A[[#KD')_V:C-**+UT^.:+R]JW(?*&K8.-TJDUWSBO\/:WB N
M6=!)$_O$'4$]97F@P$NL*]UZ+NJBDP6MA&4,KRF:6!JF, (D2*\VV4O3D.W[
MZ=VGG_6504[MS->%9WXT1.-P';O5+],MI/QX.U64G#UAXRERR3EL) 7TM4!=
MZO#7=IS5$UTNK:Y>%<,(%N_E]WNMEN1[+K?? 2%5!#3E>4W!7NZ^077 +4EO
M=^O!&(B.?')L*EBH7;O;0@"Q;L=H/T?,::",D/IVP)LZNXW />64(3+==4;$
MI..^$]'$^(I1(STF_@PSM,[;<2%TT'EAZ[5,^EZ[3 LRTQJ2C9 WD=$J+-?H
M8?/#ON:WFZ#T[2NS8I4)/T%G8O&@[21L\L:P>&1S#)>8]F.,0$:Q>X7V@/H0
MJWY07UI5A:<!1<#SGZ[5VJJNBQ=2C_4'?^&VT[NG=X!PU>):GZWBI9'GC>G&
MMZ'P%].!\^CUU/WPIZI2=)5:RKD?#R$O3C5__0<NS_Z\OG!;;'JNUCGT->$-
MX?6N/<N"0.?O@!KJ1C@XZ@9 QD9I6172<NIZ0/+87 /:)WB[^:4+S"_:1;3+
M+!$N]^7];YOPR29T7_M,^XE2!5?6W><RVD6QUOHHAVOX&Y"0$N;#+AZBR*_A
MF[,:R<0H$$P) (:B]V,NNL<3WE)Y1!H<=D\<"[DJ=MKKXI3KIL6<0UPC<P[?
MCW_F",;:B80?-WW9)32%'8>B/XHL$L'HKJJ53&2V6Z5X,PU^W(/A"'2[:TS3
MTYWC W.19/TZD\*G*#174Q.1*U6@&\)J" P(Z<4ZJHB/%9?)*)\KF_RM-V?=
MD<..8H/&>*OWO=+=HL"=Q9 6%H9!1?(/?!-_!O)9*_;SM[DG?HEY/G?[<I]S
M=PCL[#%7*^^3=(*@3 ]J2]X=8J#T6?C:^$J9 )HK-4_3WW@L^MIN.Y#KZCW\
MEML(OMNY8'J=.[6YOKM$YVV"O<<S50A"!P(QBQ3+)4X$;.>947 "CP)/7@8P
MF#LL=6N.8=6\19M]Y3B# JMY,:!H)MSTBD@'-B!D<LV=2[*A9661!Z (_7%3
M];0I=]*A$9P!=IS07=,VH77U_=QO7O![UO?7'_IUD/[EIU07?.<YI]Q WOWH
M"J\E=X,<4W?0A<-4KQS!"B];7ILU+3*#M,W85I/;:KE6AK0[X!PN%:2-B((\
MM@>',648PI@7F.TTPWHV[WMW6Y997L:H-_< SY?U:6G2V3JM949:Z(%/E!=C
M <UJ9:$=2U+]G,;PE'6Z@]5%W=SJ6-M24;I X95>VK,)^Y41+5K4(7+@I7W-
M$VIE+1_1'(-8!$[E5I=L='R(0@G4MK^Z> <@SRE!"I@7K8;6[506U?TH2&-S
M\6=T[*2>EZWOFI=.=<>,&4L>K@]RM,KX0BPZ4W(I?4]V@\QGBT>G+I'CUA9&
M]"= X=U.5G#='#QQ"[O[&JVQ*H(T^:U2]2"J5[&Y"HI#^=O]A7IQB&N)<73*
M;4DZ2M="HG<^B/@K(Q9N^"[JWC=,WN>)W?/6LY3Y3#)>)]NSU]"QJK*_?&5@
M/M4*[;AM!RH\L:\^R:W7\-8!<?4Q_&C<,0,_+ AX9^OSX:QAQ.HK.'L*-AF)
MR^%+4*V=7*)T8&37#N-;H-2MT"Z[#$/I=N7C6O.I\XZ>5_(99\ZB#ODYS(#/
MP&F]8?Q0!+QM6Z=636GV#/,4S4Y136^"2XFISUE%$NNK!(G.]6[U0A?QU!W"
MUEBWZCK"F876I[V-J@_.DWSM<MTUQ7S9-&I B:CPT%1DKZ;T5QC^D\0U2.%!
MN1OH> >AK:]":9:AV0UQM25Q)J7=#K3EW2[5_H$R:Z%KD)&-U3=,Y-2@;.HU
MI4MU]D0E3#$T:3;BY(AQQEJ\M*N<;NI/NH=(2]%BC+3KX[YK?29DB"$D?IG;
M' 0)<&#B>H1I=4;7.#J_G-)]SK_GRBT;W]B]X#C.SE";<VUE:'4QZ_ZV_S=]
M^6N:ZCRI55QPHG$+Q9]9(.RT&%?!$*;49.') [% _X!@[^C^1"#OV?!#H@!F
MPL)2#8,_C,%A8CT/9R',",+BV>PJ@H;-RF#AV(I^QP^^#(:4W9E;31OW!D*L
M;%5I2"NB&YK&A <B11/#=3;8VR1Z3VKAXE-R%WDN!Z.[W\*B,Y%VZU.L[-S1
MRK42X1JG(4C;[9N+AC6(PA"<X!8M7KL /!F,PI_690)=8=-]20D%7?'LU%TN
M<'I/+U8!,;5G-XX-%AL]MYD\46'M)B-99K.R./9BWG0O04*SK4WRT_7T&8R?
M\HY*#N?L%^M(&B#'!HQ+NQ4&4NLP!J_?/1U;H.A.=AX7GGB>>Z(];U+N=Y9J
MKAL1ZVT02WNKC80YC'J9=K_[34+G-RH_+=":M8JD&MFYX=#/+EXJ@A,1WZ9"
MN@ &M=V[!"HJQNHL'?N"4MTB-ZB+)2HZEM3U\#JJ'VP,-=?@H(-W%CR;'Y$E
M0NWB,__II)6@_(RO,6<+?#/=@ 4_ ;AN9I9ZVII??(Z*?3XT6PK88B*]:QDZ
M==^*-?$<OBUF$54)HD44C"7]H$YT I=1X8IY3?'=UB*\;&GG8$6;'JT116I)
M2^M50L(+\@Y WPS-$GV;-Q6!+'>>)O>[C!ZC7'VV2-#\?LS5UH?%W6]_@'N^
MQLU-2>EX(40[)2@V7^<6JR@.7U&FG_T4!/<CE9-^1JW.M"]Q?:MVA)$U)E0[
M")_,>VF]</_L172QS?L02W4/1L7FE1^Q-%IF$J;M8Z=TLCRRD3HI(5*9>__G
M7B:N/EY3' EBR:4>1A CFA]E*!BHQE=/=<"E8>\F=KP:JU6ADR4?P\VVD"SX
ME)@>4GJ.:@O.D2_W)B9W7_W0#UBOM'8B=3]1:+FOD_WM]N#F+],SNY.MHZHY
M=PO*:,P!-IX[2!?3BQ=;MP[D3S-Z<Q6Z4,Y1QI\'U]=:R:V:7#+>P=Z''F4;
MUU3QS^F#-. ZBM!I[=+SFFRB4+CD\>M_%0Q1-^@ZH[:D%E)]@OTZ".;'_#8N
M2,KBPM1$D&4Z4#CA/9B[?D<XD;K>#;K0FG-+2T,KK?#.E-#5-:0%=]2,I/PU
M'X#R<P<-/7/?1\RU-I:4=G,R*K3''>5['M9PJ]_]"F_3G:8;/JK'OP-]] +C
MF)NYXRVT5MYPQ#ZX0X<&1@>Z3#CEJSB@(\UL_&YI*2OX361_QN3RO[HV]GFJ
M$:2&KDJPK/CME_C;L]X9N+R\YC44'EUT&$-G2EJ@3;0NL>T7+F HU1 .8$0@
M"\"^'W+-Z*U6N%&TH/4#!#'0K;1A9.MLV*4<[F)A$X@6KV!V^ILE)N;Q.32@
MMY5Q_CK^]SWN8!8-^WR;GNQ^K:+*30?2NK3U8<;43(',PN^[%#,R\DN667DQ
MC'!<<FGK)CN.D=_F?;&J*G88V_:T^O7O@('^5&VF,I,)W &O6O6Z/&GUB? ^
MKJ7M>>L)K:&FGR-CJ#$ 3$HS\MT[^Z:J.W73><PN[1/^%5,.:*EW\2G)Q)T@
M=9MQD,S<?BC=NF[AY&\N1+RC75ONL>_7_0NM]/(UE-38FQJUDE/,?#,/]O6I
M,&I%=K[*MK70N2,=9ZQ9A ]Z2W=>$5X9:_7N'5$L2$O5,&1_$W0%S,BNEEY.
MAQ_=D ]<EXRYC4&$[C0\,@MC\"7E$P+F4\/K?R0ME6M@#NP]OE.%:D3 2!MW
M&WX\$JIH*;XS2!6_JQ)=I7BQT*?1/Y7]4>@URX3QRM58-$\0@E05^.'WF%IY
MOZVG5W@<:XKM>;3V2J:AHVVT=#4W*]_,93-70T:2V=M4![J0#VQC=PT.:O"U
M2<4EX&SYR(5:%KOO<J]ODZS)P.TP2P>B 5'@KS0MT<RJ18Z^:N#CN+!!1RM!
M$6FR&/^LR+ $X)V1VF$A8)D"7'O+SUO,M@[>T=W2>[)8OPHL^%_G9!Z_:A97
M7V3/Y/B##>==5U="HEJ<KJ*C5'G#7KEP!@=9&^V&#5G> <0OFT-?#YA"IFIU
M^9TT]A[BKE.E,^0ISAY#]!NI#L;TJ%8YN_//?@O!F@<RAB$S'B*9]R2%$JD0
M6&N?G,S,'D!D!X]+4[D6?W(Y2<K^Z4:UG\;S&Y*@Z+9"-15S?X$!,$_[LHRV
MQLK=UJ<*)HC/52:*SQBX%;O&1,5DKIU,M7%NU9D4SB_+O0/R\8FEM/&#PPFT
M\.1Y1#!Y(WVX/KLM,Q9\*3ZC2FD,[3<SH\&T?26PTB@_(O[].38?H\^.*HD;
MS!4Z S;FV:6ND%I/Y;-/DFZ@UG.MX&A/9!V+FE#9V5UK3MCQHA&H&OW1V677
M(5\J\?5V&O0/(?KD+WF;N4=F@U6/*_?Z959PS_G8X$'JT/S"RXG*[BUTXZFI
M_E*M PQ'URZ+;>!U6$'W5(2%5@@>.25VQ086;);S(0L:OQ6/5]Q)<@3JX-(_
M^^NIS!71E)SPIYK4Z+'>S(XK_J6HW2(AI \R$_H<Y+P-_:2' %M5]^QQ JV=
MN5LGH7O@[$Q"GSW/=9YM>,PD;MZ=*Q<W5$K\:W;52VI!S1&^M\[!@!8C%A]@
M0OIE\^N/JEW[MO:&]@0.1F/^C]LJ+8A4UQ,-UDPE% NIJ#=7TZUUN??]UJ85
MIKOH7\BIL-Q))'>ET-F2A"IB(BR5$X(,!MF6V65(J<J<.;>B RKP(YUU$ 2[
M\;>83I=Q.LY15([2&%5+#$L+W<M*)$W> <IW@DN,O:9??.BNTJULG&51= X%
M/K/#$%T3D@(S)E863E)>U[S'/+DQY9--[2\K#FL&XL*(2L*=@YK/VY+^*(B-
M:I<EMR%=D1;R)@TD<NL')+G"QA3DY0^/!;!.@G"9)8N7+-L5D4@^'>75, </
MX5$PH_88,:Y)(X!DZQ(^4/DPKU2IWT4SM2^"_(D6.%('UX$3OX\S+@HNL,]&
M\JUK=0+S8F3&?1BK']U'Z7O-)R./5@[C^/7'Y@F6.YUV[!09.T_8)ZW&[\'X
MK<Y=I4R.B1DBNC!^&A6.PPT&.$%Y7"BKJ #IC%#[<@SEVZ,T"XI"Y[WTL<DF
M7%H;OIA$R3[&6EF;T06L!:F>"RB6D'11ZJNF-&4/'AHCWE96\EU.R=%%YVF7
MA2^1E2RN$I_.*WOQ8NG# L2]7/YXC.6$J^JD->?W=,FD^UWX!B &MWL0'#&V
MER0_&7P9G\.V_];5:IM]TQJXZ)K.9->IW),=]_M,VR*\0>[LE4:0$./G:3)2
M.G:SG+B*SSA6]<QGZ1A51:S5/<39M\KL67LEMSI[<HSDZE#_DL\/./@>_K<;
M+Z8NWKN\NS7ZN-7^ENOZTRIW_*VI,@2><P73JW)13VZ3V'/NORT1UNR6_]RC
ML.P.+'<Y+;>!&I]R%!]%A3^=JBCES%2:RVA@9?F;Z]Z0ZI4)RYF>9JN"34^S
MW@%5O(/"+\_%AOD^M BOPG/^R2Y"#"#%81=H0(K LK8^,61O'QA%]HA/BV8I
MRW$#9=V/T_Z=)D<9C*VMV+R[A_4<(_ \IAM3(:N2G)"5J_J4G*%FI:;OAZE<
MSZ>OD$AD;5C)@1SM3-*(:?%&O?1J+-H'_QGVRU\"Z]PYOI7U%WFNS<U[<MH>
M">D+Y]K)_]@MLCPB[F%X=\7=/[!\<? WS*W^6)&KV8%.'.$V=Y&D&PQWG\=V
M:R"#I()YO@12WAT+G0[LE..EJ65%Q6C,%M&N7-ERRO+ZL6?T5/%YJ%VSDU;P
M2P<_;FVCW^\5_G> D\VK1W[!-D<1P9#BO.N$<E5.7"*9A7CKY-+99Y>F,J(8
MRW(MUNE=2E)BXP&./2\[\ >4@ ^_,#[0_.OL#C!"[RK-UCSW_CZ!<QRL?*)M
M8.,N0(E4(6:N;7AVX-NLP(*[2/?<F>LP^_CJEZMXN%-::O@SVM?@';#]98BT
MOS[<8>,=$':?>OH.\*F >:Y:?VVW8^Y[ZEH,>>IJN]T,N_)S./PKC+O\%GMV
M999*0EES?7Z+O-U5=X+['*_T#@C-Z[HU8  ]9ON*/5D>2T%VA>5>V3/&N9S
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MUOE?9$W,QOC./6NU-&DX@S.V<7BU3?!5,*:@M;TL"^RM#1XU\4*(9C%DA(3
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MO.GGIEI-82T\/CU30T#6")[8HUL[1]&^]5.\^PX.[0[8$1AC)<$R(I)&.9%
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MZP1A?5C Q@C45/Z"L_=)W"YU.R(:,+PHP<"Z80NAX1V!NN0*5';E>F7F/BJ
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MXB2J1BWCE)F4%?/?,RFK=O5%B*(J21"D0=:=D/O_<W'V?U_^'U!+ P04
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M8-7"<I/0.&15;JEB06BT%@J.KRYD5X.+,@B""UER-0QE)5G$W[$ @S $@#@
MH8L0L08FUD#0PH9KU=KMTO>#?45;TRE2&_I+OQVR:L/ IM/IZBFRVO&' $22
M) #"  POIBT6@\0.Q7C1#O:=@VS$*:J![.MNJ#OVPM)W47*B\)!5J[9;V.2:
M=^1NTM$+))A6I!)$@)<ABE^6*GY9LE1>FZ?:.%LO0U2N6L._3C@$=&OX<N2-
MQE\GMJS-4@9A1WT9V6RD#+J)JP(=-7 B7U;3YOMN'J@T"5\)4&FBVN%FH13Y
M.1PW\LUEG5!D0#55*R4)4BSHY:30;?T-&8: NWD1!F%1M_X>_M-FJAVD2A>\
MC!PH^^^2 ^6\S/"7=.%O*<+FZ'33C(+0%T/'WSSY)@WFBKCV>92#4YU>T_(=
M)9)5?VU#EWTG<+3P>^<NM)RIZK<<W5[ZHCG^PG.5"PB.'0R\@/"%@/&:!EMM
MO:\N2JKY/@R2<0W2Y$441Y!%%$&@12(+$8NPA! B2BJBK$'O*]FB9*K*VM"/
MU&7H?QSBU;+"JF%1#-6UJ5%#%D%D$0:[4'8-"*Z!X<$_R-I&R%?+6D,-1XZR
ME@U%6Q%]Y1_D9@/*JV6&$2UU;<&Q-5U)5Z<NF@L'3O44.0H7?#55-UU>LM#!
M0?\@E\OPKWHN]5"M*FL)#<_"60E9)%$\NX@2$KHH89*TJ$EX%L1!!804]!^=
MVGD/KY;1W+*P4B!8(5*72J"+A"(JBZB(:XLB*,N+64T"51R3,56&_T%6G^OC
MU3*;3GJ83GE>#X.UX#_(S*88F_"3VL U!5]=,E5=QS'7SJ./ZO,&; '&5J,+
M!_*ZK3C3)>5Z,<7FP-07+FBH"Q)K,'P-2F9 ; T";@*BOGB=+M4T'$77DK\'
M8Y.6+\9(PRI%#,6_"V73MB_"Z8XB2[)%W=Q4; L;(J.<&;ZP=&.%J2]'2J[H
M!^J2$SIDU49OO.HE!!MZ6@I+UDQU)1RMA3%\F;%-BOX:T4C5AZ-P+8$^3[2A
MZ*]1I1[&$L.UM5:I_#S=AL*_1J=;XE!="Y!C ,WEVJPQJ'6&N7QN6,JQN7PU
MERL"V78NZ)5'$Z5,SL0R.:T6&U$CET/;ALGD,F!N^<KGTO9+5REWP+YQ[IVY
M]A)Q>K5S>2"#YHH&94APS<R5NW,"#9!RU;1RV"[E<[U2?MBC\D.CG&_W:X7I
ML)P?#NO%G$,7I@Z]#%C,YQK%W'3IKUW,H:U2CF@6\XTNE6]W2_%4*L>!7(D)
M[;F_::F2G\I,,0?VTQ[ZY5&O0W6<Y;IEP!<T?H5_ )$.M#W,<>EP<]-29S[D
M7+63:S<ZZ=!*.7%Y])7<TNC:I=SS5YO*3:OE5"R50LY(AY?6#:O%%[?;(,-<
M(1UM*A>Y6F@[];2ZD'90S W;A;0LE4@*9#?2R6IT4OE3U4XU;G.E<@DNZ7*_
MU&NXY5$^YN.VWLHO _;"RJ@1#W2BT$F&DY+9GG6ZAD<G?:158'IMV\";,V:D
M] :5;A&,JM6:TZ@51L/!J):*SF-!+F0X.N\G*- J+0-"S2XX$'C*%'DH5@23
MY ?PR!6M,)!X;-)'.I!B*Z@JN%FM F4TI%D:]<6*7K5H'4V8L9,I&!C+F:[:
MMP;+@)YDUV#5QNBQ2_.6B^NNYT6!+^(3IY/*-QU^M9AOI^K2[I<*J4)(2S(;
ME8KY0HEM]$I4K\.,JL-!/!R4DF5 1ZI,J4:E@[),@>)JNCPIS6K%3G$X$ME>
MPNO];+V01UHLH]9*PUCI&=/A\I!KXP%5UA5#H7H(X35GTV3H+@."F=9L5&.-
ML-'M8:V.J?1YSI4$"E(%J&,.+,41>=>7RE DP7]K^,N F:)9XWD3TP>6&\GV
M -<,KVFXHFA[M.5Y>!+Z7F8"B*FB%9<THK2D8D4B1_90+TL)_8UO/)-1E@%)
M"D*X.@MV65<LE/L3&48@3YV2/:K,E3,!G$SH%FM4#;3G0 S!]3E@6"1F+5 ?
MH"%'%A" '48N![ ,"OC+@&V-'V!-P36;):XZZ*, VR-XE&M2@M_,/\_ 7W_C
M:ZK2J@-SQ:Z94!,(!B$=J<RD8.@,1<I1O0*ZUH -8Q[F ,'1 ]N=$+GB1(AC
MK@K4)D:6B!D&ZG9K80=B\@X9@*.(60:L9T*$@8%:ENOKL65QW6K9;B>C,MRU
MVDV8$MQ-^>S5/4\<9BQ!%.7$]8KMI"XVLWF*[WGM,36>&X=FOC,I,Q.R1S:X
M_JB*8 ;>&T[(-E2.[;"/2G291\A&(F.PP=*HHA9XMQWP];P^JX.]CA_7FUS'
MMK,SS2LO PZ%EAG-0+Q9X+/0C'.DO&'S@V%=&<ZZ3=M5RKV<% ;-D"[2&.L,
M:\6Z;(U@.HJYY]]J+88"I@5Q&5#BF]"8B/!!T:-BF6T8@3EKX:5&06<L#DE5
M(RCW\]I(H'IX.^#R<HYIR\-B+T?BY:%/PG2XI#V],3&#\>XRH,9%O#L3E1@#
MR5(RMH4Q1-:,S"R;:?9A9\K:'-L0@8H*#1H:!;G#IHN [<D@JF &XQ("I":#
M+(>*D5Z.S3F'$$=V(F[@0*H&#SB?-\N3.*[J.04?Q%2N:+DLP&?'?"\L8J0Q
MG@S<N&SZ%4KMQ G;@).AQ>H>VD0HKV@L Q9<=UKNLK-6XF(\,1,Y#R01CY^P
MXGB0M*TF'4L0S]6*M1G9->LUFE5;4S#;+P5!S-% 0RY/9KAJJ*-N#)/+@%F<
MJ*D\-_1T:I ;C(@>$R?U6B_7JV2"!L?RD$T0N*),;2Z;)%%=!:9YSM#UX5A7
M['%8J\)BC;(JD)QS>G,]5'N2 4QS,.U%848&/,&VVQ/:R'7\,==WLY9DC1N=
M8KZ;K>4YSB<$?M)UAQ/5"-QI&OGX ;?)VS+@AJ\5C9[8DS; 4)!7:AI1K4^V
MY*HT&F19;M">-1VE-+0LJU/$%:[AU1*J$'9T;X(EJ;KT- M 9SRR8>E1I1@=
M\7FU/V9\!&BV-=-G4:C("Z;6K8\Y*8Z[(I^5P+[):&2'KV0&)3H2HBZH!@.F
M^!R'7AN9*[:KBATL& 5UK9OMXWF<382FDR!Y7K(0+Q?'[5&1,VE'F;$C')J"
M^M2&\W1'%2=9"TGE.9A Q<:$E1.T&6++@/EFO0NH? 7H"61[5K9G=:N=,>BH
M,VC&7$'(^'C715S +9## .!\7(!TKAH)9;L^GE5]UO&-VJ :8T:^FJ\O \Y@
MB6TURCZ.,2IL:.:8XPP>-NP!"@AJPP+'@TJMB\*]Q.'U.A.-*C-*+SL:W;*;
M\,2P0(!MT41M;.O]"C@?,JQ2&EL/.)1@H*@U[JEY<BAS778:368CT[ -<PQ2
MJ"H;<G5D1&5.2\,J,40P((@F]) F0X(3BK,.9A/!7&T$A2=BP,K5.W4V&0[%
M)@*.:H/NS$N27LF..4,!.7:6[R"H[DYIVS;&LY%KVY5D)JK]L*%;H\ 'DP+=
MQ+AE0,JLN&Q80JI54 ?$-IBIN[JO64(& +M Z': :;%F"91@&BVK/-6 7"W)
M$8E(:DTBLE5>:88D%8ZDF)VQ\V")]WT@5QHZ@<P&X%A+(\!ILZ,W!RPO(S86
MJVV_#AH3">:A:%!%,2&L2>I@X)A62:KAGBQZ;)"$W:F/#FJ%N7$0\UB6\$2@
M891-86K;:@OB](9L2'*3;@DDZ@%!XHF*0G!=@.HYD]1!9#5>$KIUC?6]+"_3
M!(D/N7ZU#R\##LQ:/>*PQJ3L=A2\DKKMU& J56(J1(X8>Y0.&P+GBG ]+$5.
MEZ#&EL*VLJ%()"X7M46SZ<!-VH5TCQ7G7@\;3^HM/EMG?:&3C0 FH50UJQ=J
MTK3#5*NP@M7*O4;/3^@ZP36'*2VRM#+4KF9VL';@=X7)+)<J>,G0@W NPTEY
ME./S61%N-'KAK(CWVG2M''=1SZI9_$B0&8[BNAJO)1EPS$JLUD-]C[2B9M."
MISPK#6T7-D"Q(YLC?N[U;**&%(FA&M(HQTZ(H RJ)$$ 5@6;,C,I8>H>+;)F
M4LYQU; YXH3<P&RGTS]C6->AI8+KCQ6SIKHA4Y@/62X;G,#0-)N:Z*5]Y%HF
M6W.$X5!WD/R2#W*[/F*-6;*DPN,H9FHME1I)/!D6"&(\*CCRJ)=G*&QH4STX
M7@;DQ@J*:ZBA2T:S.J"M".DV\!R@4!#<!B;#I.M'C:G0=P<^;_/05&<C=CPR
MND;(3&=YL>SFLI@TGED5"\UH&R*'#)E:Z31(:HEP1^GW[&*ARO!^TQ4D$_1$
MK&LD&5\FX'ZCGTHS#'L@C)L-+E0ZW2C'=DKXA+6%;*TU-OISXZ"KG4$GZ;2J
ML!Y8L[8)N&4#'^-:ZC6=^@ST,B;9UUEAG+@)2DQ%SJ&Q M]L1/T\6VC'LQF5
MX6P#$3Q&F4^*/V5=*8'#24UB&0JGV;A6S&3'5'_88VMJ92KU$I$J3($:DM0'
M.)<94V%M4!^XFF!BLT2V3;0Y;JKY7M&HS0TLW,NIN5S,M2;UB=GM:/4D#5R$
M$L@*!N(GWHS"F;@ ]L+>2/% @I6YGM;R/,309CE?M>.F+?1;?J,T=O'Z7(;2
M0/>&*E8MTX$,U%OM.DL --(AF:@>^G 9,4F6SO(B; _&(N*:>JN)J-@0CW7/
MKP*5;*MJ<#&GR)F>4B&6 8,9'&9,1&F1(A0)/3]B45L"314=&6(_,RY54;6*
M<E2O5LYD*)X&C*R#6$5!JRHD-AI"93BH [D&*,X4<>[H24#B464L#L-<J=<L
MH:SJ^(V*V^/2X>E4O=X#M9FK"MU0S(@^EZ$4EVF,!QF&KG,95AI-BR1%*T1H
MCAOJ?)9%=%!-,*H+(=T6TS1A4,DJJE(76(G.HYD>&-KYTCAABCCM9&6C0KEP
M<:3UZT8YMC*V..[C9K\MD*-&& ^$94"VP"-V5Q$ZHUZCU4<I=L)).MH5ZDVF
M)O#,I)N*M]J#C"K3;B1$KRT/&"4U!K/1P#4&_6$ERI"M1EQAV!8[7WHZJ@GU
MA,$$D4G7O</7>CTC1^7DA C:C3ZC($B3&EE=TRBH0!8D9B49JC)2)%DM3E*J
MF- I<[3GEW*0O"&M:,P:I7:_/$7+CM4Q<ODNT&!F2-\C!"!=0X2+V)8]DS ]
M+!@,-"CTQ#'9B_K9"*9G2 .<!7X;5AQBFIHR8AX?FAC;AW->H5GP A-H2$2B
MT<H8:T%-C,+]A#<G(H)W2DW;<T"C%XAQ@'*\8@ZT81XK&F&;'E-\66UK]7YK
M/LO%!(0=/$_Y#.+U.,Q3TJQ:\*U&.RYG3+Y-$[U1/R#T?-MM=3P(MZM3*L_V
MNBV,!Q,@RGI8!%2AZ2"+LP(T7\MUGZ;4WIAEJNS$J^A>2$-T/12<1N!2@4?X
M8<V)7"1E,2,(H<\2DWRQ)2?BT(#Z&8FIR+0?J72)93H<M0S8)4*B$)"9"9_&
MCWP5[_F"-6F71RTAAJ<U5A#2.'-LZ93?I&661TL5F6Q-FP/5BF.CV)?K'%;K
M5!T7(M7 F]O#3- !77["J",FIT[&H57%/+X+PWKH&=*D:C/#;,.N-?-B<\1T
M^+"3>)TNAHE,IUH<R2I?R-OB ! DVB;GX5RE*Y&A!D]2)H&TM,H*L['7:PAF
M!E4+(N/F"*$DQ[PWJW:7;.W(R*/\I*X5 P*>D/U)+5V)'#R!0AY5YTZJBO'>
ML(AV4I/BI&Z>5JNVG"4Q13-BPRBEGX!^TB(B:50CQ30H*\8AGUG:PL@[<=<5
M&N-BN=J<&;C:D&!U&7 \,)K\\XE@G"6F6:C>2CB_!%H6X*H5/"#DC)6;>0/4
MS4^-KBEUA(8'=<91R6EB/:Y/!Q) TP0Q3\#A"B:)FI>NRU27+%OT6[.,4V#1
M".]VNP5HW$]8NM+RY%*F/HZSD#M)8U7 AC)]58<13!4"V!;:]J2?QI'L7+%'
M@EE)AY/F<+51)2F84<63(Q:JC(224\MAP0RHEV#5UDS$,3VAH"=AWQEHI$S3
M8,[GW:1<%LJ,Y5-6:;[T9*%#J4)=+].X37:FSD#14Y5(=0N6ZEP1',5,N1-3
MY4P?R]9\IHI5^U)0X&KY2L/VJF6]Q?!$+@ER'8L9SMVHW$%DOS?HYJ2JWU4Z
M(28U&T'2:7C#<D/+.918U(MPTN0K1=KB*[6X$^:%R.YT<;=(AXE:E*T^@9NM
M;K56F"\]6\H*X&!0[,D-M6S9-3=#]QDWQ$FGGZGX]?:0+LZ03+57B3F_EVGV
MA CCI)[)C5VC1P$UV2**;I2 &IK&^/,(=I!'D S0T%45A;HZ2J8./ )B;"F#
MYR4Q;'%L:@'D$53U&K%=9_4,F"!1J@BC=.C-86.(0;0>Q6T(SC?GX5RSU9K&
MGDTEN*2;BAO4LH-<B>1$GVAF<Y8W5L,N'_5CV:B#EF[XN.21N8):R\.MKHNB
MKBH!9JL/<.2 F ?M *]($E_'530?H3 8DTVNG"I-WU(&!<(3V*0YIOV117O#
MMM$K>)[=LL>)B0DF$2!&5^P,Y,%,;+, WJ+F7J_'"BQ5:DVSGMLW.["O#UT7
M:X=.'E/#ODN-3#'7R@GC0F!6W3+7+N1!JE'JBE5K.D);;2"NDFK++4U068%:
M\YVE@9U4LNZT:J1927,B*GVDK M06$M"%$,K(R:6>JS8:+KM5GGJQ@.5XUI2
MH]GH5D&,P K5P-&2T,F,>=Z:1PYTS/,\XU94EL\JKFLK2;EO(O742HV"YG2:
MNJA:&M"K[2XU@@.\,7!1K&^SC%#MF*(^+&4+]I@(HBD6YWISKU>!RKFD6J7%
M-LQ,*J5@T!D4G%P]7:Q,49@2<HR5$TSNM/LVEK54<!+29'&<Q_VN-ND51D-D
MFB;D!J6$4SF>Y\M=-2[JN)/DJ<88Y.F"P-9I;AKXDV)IQE)<K2ZWQ6RNV,>,
M?A;M2,OOFFQ.+$*4&%>&S7A2B%Q!H"1QGE9X]>JL@=NPF[C(E+7+> US[&8+
M-++FD!QC?6+&RX'LBRH!AC%7Q<%,4>^TT_B_VK*AZ728&U?&J-8(?,++S#FL
MS[IDM^PA_M1GIH-66T_MOR1.ZI*6HN66]E\JY:RO6&5V\/QF3: "C6:!UA+&
M][I=H5$JP#W0V)"-:JX:]5&P'NEJY,= V3.[/:4(502J5\SP1E-'6@:;L*"(
M3[)YUT_-A0>:H8*4 @^1QTR]QDAEMB"0Q'S(2=,O1[$O4%QKQF$,D29^3M"S
M=+@V;OJU!I?QXR*)@[U1/5LG';,S@>"X&N8IW1"P9A"FJ8L#E[AH4IY%<WOH
M&9[;RRNFT^4\*-_,]&$;CJHX%8=TOHR.C8+53). @9_M^3S=I#M9M<.9_% <
M*I2D:R.'P;/<K$KTDUI^KM@U6T=5NEU1)U!2Z6;3U!G'#+V3KU U>D"Q?GXX
MRM31#A\5Y$RY5J\WVM62;;*NJ^.:*BH24NATFD' 6@XW'W*K;$&= )'B>%37
M<_5Z)0VV4I<_*S(BG.;Y#$VP=3%)9C&2+_6=8M7,L>T.@F?+$3<8$ V'G'6M
M1$[_3;0-,@QBUBBI2-F>UC,ST@[A[$#%Z$J)&T*I491XVHOS4Y66W.HL-QZS
M(>U/#+6N6BUJPE8S+FR*F5&E5RI/\G.OY^G#5C=H& D[XP=U.C9!G,GR51A"
MY )DUCB5'J4Y?;Z2#R,Q Z=Q E&K6+Q=-]!N9<;0)J01.3,#1C-)F"\]9\H2
M&I<WN':Y9+;9(A!TA3+/5YE2X [Z,5,"?9S3\);J$)8U*:/"TO;I.-5MK5"@
M<V33*I?91M3I%FOE.6 5)@*@+@+E<::OS1BH28;U3K_.XVK6BJ2"AL>MIB&'
M(%D#><P:ZF:'0T>IL5&PO &+*NYF^IFAB/197)MOW<>(X%,*$ZF:8Z+3$&+*
MN#=K6\*0<SLZ2?EI ,L/\)+#)T:OK5-<)!FT4QB6"@-R2M62:KN4T_'VQ#+]
M#6Z4L\F24!++=LX(VFV'Z+!A(VRZIE D_7&Q6!HT!=S )CZ/1'4%M 7#R3.=
M=JE7Z:>AHM6WI@BV=-O$;6'UR3)@V)J051X+#;I;(B2WW*H9LA88J7#0I(4-
M,6468DS9\$<P5?%"@N@BU,15)DH[;XEPY+APA^UP?3QHB\K\CD\X,08%.-,/
MZ_Z$2$BFI)7CH2K*/A^X)5F$*C)0BAV-L''9MPVCV18#2VQCG2 80&6!TQI*
M4JP*DY$TLN>;ND@(%>12G6#[HRBUV8D\&I=<(6XT^B:=8;K23-&*K,,TAL8X
M3%.-?'G:(]RR(#/)((%H,*MYTQ)9A_M6&YO/,MYC,,4,.VDF2+N5.CZCP#*D
M]3+9J&'F<O+0+N>*026(!D6KN>E6<YKK5S"\4D\&OMP7.<$*)'WN4UKXI%3#
M$L*0JOIT:CH 9PS&G5(:XBL>ZL7=1,"&0\(#S)%+S3S(5V(B.\K*TY9K3MP2
M'C)R(K/0N(2.YH P+O,8*Z4&9^IR*9]*6"&F C3.]VLRX5<$.QC4*J/^-*Q)
MG58R&#@96:"&*$U8Q<ITZNF3&@+QLS0S)UU[?D\JZ")5BU1&,1IHO7J3170.
MRW&S D@69 =&RX;7P.)HI@#,@(;2^! ;^_5>K8]/AV-%YQ K1$=$DRR2AC_G
M4!I;A-OHRDP'Z-@D.N \HVV!<%9G"K7JH%3MYT<$6Y*&V4K#ZT<U.5NMZQVL
M,0#J/#&I*?5(:A)Z@XG[W<+\-AR(RFG22@EX-YR@:9+=[*!L$91;048>Y_2V
M$S-58#;&9$'(4E)GT&*C/J2*H)DM<&I5, -MU*)'B>K$<G\>$@>0:A,\(X]G
ME0D'U&"7%<>8%/A63QY$^;'%CZC*N.],$1\1:J*J43G*=ALC>YQO,>.)->9@
ML#6+^XCF>M7YSE($\[38"SP(39C$3P:=P$WCU8RHY<U\=HI:SDRE[#S.%IMF
MO^'TRT[5*Q+$S!ZX10P!,YE)6");7;P,Z-8\7U:AO NH;<BHI DSK 0QV2TE
MXW F"WP?8T<]S8MB@D$L7Q4F+4-S"RS8F^$VUW?*JE_#1<*S7)$11PDR#XG+
M85N&D"'6S%JX-%789A\Q21LO*VI[4D^#IR:)U#TR#25F;JEJCC7#(UBD6I)[
ME"@KL94&E U'B)LSL&G/;Q3VLXV9 F6:K)3A)S2<IHA^CR?MEHJDUK/)V!,)
MQB=TQBCD.%YE.U4<0DJBUY+Z S.:\JH\R3RWT=Z;1PX5G5(P*?)[,]$>Q(DQ
M:R/!C"EAK6H>QKA<WR!$([7]4Z<T\F*PT#9;=D=+APE;$5WVW6R[(%=I8YHP
MM3F'65]PVX6)5F1D6T,:4\X<M!/+"^CA."H:,(1E7=5&*N9D5NG/8DA:VI[H
M)S%.9X>5- %!1;-%:66+(ZIY=!DP\KO37$6O"-8LPH%)M@6,&UJFV["Z=9%/
M_?[21J3=,XJPZ/81&DCJ+!.&PS1!:ED3%#5R!,@."S1=)LS,?-M9RG9"+JK5
M=6C<*1;Z8-1W^0'O)=:P,TZ  6[TJV@:0,0C?5PQLH#)PV97'*G=KNI3N=D0
MGNJ*.J8+D.BP\YO^#(@D7-%*T$YJX"-;Y5KUC&WR898ITFZQ('9)%!THTVF=
M0VV <_6D*[WXOF.OZ/,CO.O/[Z<,E18D0N.)1-EC0X6M"LU8NLS69KULH\F.
M^]E*FB[Z;F3B U<Q*WU\L!3KFI0 ^CP\9LLUM4M9J#/D.MS<.+!*%-&NA)G
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ML9-!^DK#(RJUHEB#":0\=@.X):6)946INT0/A)*8B'&@6)-B&%0M)/V/9N:
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MU#@$Y5 0 XJ)'V?JYHCC@DEFI$U\RU)M8")EC'GTU5K2/PU,E0F:&9JG52!
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M(2B&AQ??_[M=\QT_NO"B0G#2IRYA/WGI]W[VYFY/.OJLKUSSTV?O6K']ENF
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M829E 4;R5'Q6+04?_'#G1D MH#L77'''*7&DOZH1?9_C^P$D15?EL"1KJ_2
MJF8IERX[MUK-V3/;-J*D;^0PK+7 EL>6QN25*.#=635)FD1#%BO#0<DR/779
MRRDJB<C2' 9-6#1'PT8G>2%5$Y;0\L)E'P/7LZ*YVOCTKB_CVH0M761L:/?+
MZ[2X%QT;578L.>*YTS.O0I%%]?</>-W>-PM5TUDKTGH$?7KI/A?Y>O7@![>[
M"Q7'Q36\.GP(>(3>];D>(67TZ,:GT&"B4JL3[@X?2H6+\W9R#6?Z>,*/B2YB
M"E;L87O9O]OM UETHD8Q8#"9+?PI99P9][1HYPJ]5(F/N2U5R25&W;;GH94)
M.:=G4+'DSHS*3T#9D\G.>/FBHY5?B-*>$3%AA<F5QV@7FAQ#_ V!VDXJY\"V
M>#I2GC0K=3-G4MNBE5B%@RUS(Y,,9BTOHV)<:'.4[XCF/,3":N?\7WU';HYU
M:%!V1?AJ_$8A9<:%06QB+QRBZGL47!K+CDQK:UH^_%:![S^)B'2PR'+.HIW<
MX.CHGT3/,.0"0[<O7MX])9P$/G[>K&WF)>ZVJQ<SBE.EO ]@L0@<EVG ;W-"
M(+/?H5>7E!WCH,V2D0'R:<L#\:DJ Q6]@=4)_2+Q^?]BLD'NE0T3\8N51.UX
MO*#T-'&^9D]/%FV5IM$82_X.$!-AGMKH<GG_^P)CM <=VP>Y=WG$]2A5=VKI
MD4]4;D=-/G_^=+\%6?&\*C1%.K]Z&T &D#)04"<Q'J])SU2Y=:VK=,K1"S&-
M+?OIA9>&?FEC+Y[WM!V,#FI_^![0MTY$1'/S'_*E.G-F[TS8-,ERB1J+QZ7)
M$:D>O^P+_#U!F31/OE\"D-0J+,$4:=UM<N<P]/O\2*UK2(IE$VH=%IWHB\V[
M1.N+W9OKE[[/A1DP_3J+<!?0JK,52<;8&2>7P@Z/6/IHWA0/MB$5435X87_<
MTL1I3)JV*=-4Q97NBTJBA:"9$='V_Q!1<PR.GS;6T]H#Z'?Y1YL>EI7W&VK<
MJW/35YV(%]?]O\!8,_<<2]99RX1]_5?QEN;C\'4>C'NW[KMY"7T&#QP55(>;
MLZ+Y@ G14.>9X\G^^0OXH*0RO_R-!7I#"X?84(1$A6[C$L<?']!%-)C06TR\
M(V(W%,:$]'DM)JYOW6=392:0-4N+=J==/AEYYA%.)E9':G_3R R6X"@PJ#(M
M;9T^3:ALG+:W2C0#D*RU?NG2=-?F;^:NTQ6;M%MT&QCG:JCQE<;EXFQ\ITB2
MJUG]J8F>9'$#"W-JBL"L8&03MKVY?23PYZI]U"FR32.0EQ6SB82ORX>_9]F7
M+%1I<_D7'SHNQ-6F%HE9+BSG"WPV)*=!Y_/[?#PY;$LR+*=5/FGX264/$JXQ
M+!>J,'0G]1<7GV>LY3X;_V '!OFO1@X)BRG)T[7:]\2A342(DN>H0S1-U:;?
ML"RC4>7BZ]UX/]B6)5K;+5<>[TE.]2@%HSJW,E#[(!;";1Q<=#M?.?<UY]"^
MQI6_M]VR\L7J>A$PCOCX/F"+,+P>9KFG$B,\H?3"5C/8;>GX6SMYB^I,B #1
M\==0S"ZWXCJ'-W>VN!/8?W^.!?(JG*Z[AT:8!1]=.$)G?\Q"HFA0QQMQD/(C
M+=.*9B2VEI12OC1G;ZD<PL3LYRL^\=T4ZKHF"5\EXKHF)9(*3?5<.>8F<OQO
M^WW#<U,U#\I#/JB$'N8I/';RLNEL8Z?^(LSNA'X8'9.QKLPC8DHR=;6"KZBC
M)X=OF<8B70G,J9DXAF \=2M*00-S%.V)'V0]*-KB1 DK;),R*OT^V E\QLT:
MA,D$\3U?C&0BK"W+$G>X\WN0)\(8FGS7AN6E_9$^HT]1H;)T.OG1=D8>*-D#
M#U&U@ QH P9YE4+*X @_.Z89"?3[ %*<,CDS/WW'P])((SRB(IILG"P7)'/%
M#5](>'O6C([. GFG6,V<*+&Y$DCF W[8F'F38M6P4H<DY0<P9<(?J>O)R1F=
M_-+_L XYK-GDH>0Y><^CPT2LWSW@ST'INE6+6CCLN^Z9'V@(?S=_N++BX*QV
ML6G99>>M7#?^="R_DR]>G7[*N7VJ0<J!%,OV2?Z&"#5Y3[W[@5JT8# ZG6L#
M.[[<,_U9:ID]6D)NMN*^5D74<V5)>SQ5Z+M4>T+)@]?)A-!K&3>8Q)/)6^30
M:;6-"-\QF08LU^6@*H353JJ#61U5T2M,FG+1M!B=Q/;5DP480<64>)JG[;;U
M(;YV.6';L"PG,MNE+(.@1CEVUF*)>ZAQ(HVGJ7E(2#(^DEX.%<72A\1.=,YU
MO,+AOG[8J%X%/1&\K,!X)SJO!%_2-,ITM*4IB0.V%)(DN>1W(]!2*J56X>8J
M&K+FB[)&=PA> F.Q_-&<3.,B(";S8YP(/.>?,7;>UG'NNOT093!0IX"H3Y?8
M&MD*SZ7;.'<O7.3#3LVMJ(>RG98=C@]I*J93*#V9M'685_%HTFT\)58>EP A
MQUSBE)_($OV %@)1:UWP\P"CK8=]IO]3Y=CEF2V;?3,<]6%PD5I$=P6==JR<
M.&MY&JX4HP'&$$<3LM8(E=:_/]HJ3#0=!1[;*GJR^R^T/J>E[R?=Z!4JSY^M
MID76@'*88_LJCL2(XCZH=S9WME-#1(QYDIPP!]<VA90@+;_O":J)>JE,3,:7
M ! $"YK[OP +9=^D9)B$^$M\[Q:%9T"VUR))I(!]TD6.\]EE!VB>U>X4[]H'
M'(K]#K&: Y[8/T6\4UQXG%K6EXS+F'T+[SYR;8!<1IVKT^U3G@Y[&HV[ES2;
MSFH%3I6Q P87OB?.>AROV"%/POBI#RQRHS-A*2,,@J!A>>V5GJH:]9 W.R60
MS!(TRQ#EZAMXA[@B!MVZWM7T[CD%U=6!5>R=.5S )NSS[Q8V/S;Q9U]68^6Q
M7ONS63LVGC06PPR';N0H'7_/6RHLP23[/4V=]CE8M?G/P90N :$;L$?G_M'=
MAT+VM=\:0P$N\ME@BY@E__N)DQ?KD=KH\[KH=X6XK%V=ZF/(R?ZK_&>VB,-!
MA7Y,I<RA]KZXVPKXN9B+0!/<X:/I!O+W'N: ;V^SXIM1D\%844E!*[(:-C"W
M?)K&!E]#XZ=:9[OFME<1*DQ0A\-*?0G'UTZ%FD]M"VFTZ9#YP3,/@ _>T\TF
M-N'KM[IOT A'O6:-M=$F?I(D\IW H-U[V.^ Q#64O$M?2]:<D8-O^N4)LE.Q
M=?%DUAW'K QLG!S@YSF2P/BV'^C^N82JSZ+9//3Z4D5E^E.XN;3:XV@?N7FO
M%PBA@_N[T$D/\;XM"I=/?5VN(OP7OG9M'@DP6SZY==L2P4KK&5\ZF+.\$JG9
MP>H\-[KHU.HI&7>.?*[Y3)#2]PSVH0[P)[R\OI\DSC<DAUG_=A.8&H*KNU$?
MEBZ&T(P0FTV<SBJ-R*8):MV25&D:$86,^1"'Z4Z2SNKR=JL4BJ9]1%H%]2 '
M3K/T@EGRPQ)4['6IH@JS=T?<X*]?MSA@W<,M%IL5TD.HK0V1@X7U;0K6^=#N
MI@9SMR%^N>16Q_!\G[E<!%/YL2KK/0VJQCT-?J^\Z&J;R&7"[YG9;+?/D8._
M+A66,P<M+K73U7J+O5/YYDOA?$TK9G6!X.LO@.<+R2(R@Z:V;W!^N)T>;.^G
M<F+JE!14M&1^PG.C3>0+CZ42DB/7TKA21.VWR;6)KT[4^02QQ[ ID,-'5U$3
M!KB9Q#A3:JILH"ZQ/=HQI9=+S]MYXPP,AJQ2JJ:@CO;9ZS.!9GCNC<<-S@I)
MFTDPVK?[NUW9-\>W]R\G!FM?N(H"Z/;L56B*VS89''_6W.OX#H GRK.M!ZG*
MT[=?/;]Y^9W975N,QP^F[Z,8_*$V]!7\"UB;)1+![OU)DK)__?Z&J+IP3>#8
M\T(FG^Q,/[M8(%C N><SJ%3J!QF6>:I8D$^6.9MPEHZ!8@*]Q$(2G,,??;J#
M=4WROIR3ZJL)$D(EHFG( U6:CJ$&54$K#7>BEZUN*X=:=LD1!R%]H^&A%QJE
M?0:_F%#(RPAR1&$_C2+>[P8O,W.9_%":/)<:)9)JBV:FZ0O$DS+A2^#)XV>9
M=MW,&O\3K:)ET)PS-D70G652 [RNA<$*]=%'''VBY?P&VVU'Q8Y!LC;(\$I.
MLC:=32TV&C[,)%6)84M)@N?-.E"(6>4,0[S2")KPY<@3=/EBB<Z/9@CE<TP?
M((_@MTX'>=F0>-=L $<9S5B5?I9\<[^EE\_E9/HEDXJK0Q/<S QY2W3]<@C(
MXUD+YR_U_H=%EK*"=4R"4%C0<&B\4PA^Z50BKB,<&L@;3GY1X<OZ_AP0>JZO
M#>4VX;^5VTMD>91AWMX][L\<W;VYVQYL'VS VCT#_QA*# F,%44^$+.27_U9
M!U?^.8H=]  /.O12P@$:&D!:2^8/E#B]CD?81\<_"C-^^YE3J?^G"N1Z34[[
M&^/ER;4=FK;2?,8^4W6N7 [[V>-<'O6/\,]LR.VX@'\@W+4!0Y*J]#4WZZ]-
M+N7Q11P<GN8338KQ.'"F9<49^\O>:\+AC\CO;Q["8!M_ 5$AD\W_97^0'+6N
M3GJA[@0^:== J8:9?SYW^R@/CA80Z.)0T2Z*JD+FZ%2Q8?1R1#%9"=3,RK+2
M43.R/R^5XGL*\DM/A:NRYNH9L/%PKUBY/+*%GB0R4L6=GTA@OE"7%Q>!(8<<
M6&9)UKOR+RL/*5117YS49A<.<(.I\'IZ>G5?^TR?>O-ASF4.%>,5IN43$4;L
M)=P6HT/5& =^@D%05'?6W:#.N7W^?@&"]&?-<HZ;N_MG][R]7AG9I?N.!9/E
M[UQCK[PN+;B7?\K;UIFL:=80+R7)3:[2[?-DRARYQS'SG2"IA$--'+5K44 T
MQ/=^NPD:+9)K2N(!SMFS7$(YHX03#YXL9>;G.S#'&!F6GKD%4%@<9<5 [B<X
MWBIJ*WT')'G6RJJJ)L4Z8]7W>OF-M8V47#%[W$HX%/X"/.F_78WZC5F\'5 <
MIV<7TU:8*P74%6)>8^@52(2Y7Y0%H.X=E/G^C_B_A&VJ[4U[+)JQ&/0E]-H9
M&%-YL\4ZBE(P?_W:FB1KAYQ+$7&ML(6XR.@:=XK04E+K-"Z]64[%Y"G98 CN
M!RVMT/06*E,XBO<(I-LM'P#MF/2Y+((UVBO463;C2KD2;%"6$C4LXI@+ON2O
M=NI?3'= .RYY:"I.T[W]CU8*!<S@:*0_E[-^!DF")B=YW?O-3WT/#T5@#%9M
M<I.L8__91;.U^\048+D--@[Z1):N9R,-.19\^T$#5UEHF47X+ \(7 -R+J U
M@WZ=DQ::X2/MQ]:@I$JKCF9/7CIQ7K=U6Q(ZR2GRZ@R3S@N ELR^',JE\A_:
M#W)P<XIPH@M 0GR)0(;[[&2UHLM.#N^$:M5H/S!4;[HH6?HH?<QGX6[$1-XT
M2O\=)K]F)47ZT1H?'6(OE,'M3_K)2,CF]Y,WF^B!]_%:^B)'Z<*9.LWX2$K>
M<Z#AB$[ZL6" -ZL6F,Y$:;$ MT3V2.&0-?;L0GXJRMM&_-\C?42T]0&NKR<8
MUB^FU1J[C3 )T29ET;0X^='I>J_-1[64!K:310M!/:#LX/]\8JL8Q(AGQQ^Y
MN:HW!P<:2EA\F+B 6>VT'AZW457A4Q-8WA3GM'OU7$A6FETX<+'"59QF<O/3
MMRL)_#",F'>TH=(M&X^?R&R?#-J$;5Q<W=S]QGP=N]O@;\VAS>@LP@%XZ97A
M/:OI?S'AI)I'1 #'I*,B[*M'XDK 0L!RNQWC<(/%04L1N#)<I<$6]J0V0F&3
M9R-M0#V@LGWWUYR#DH]W*N&?(0*QI[G@\X32#QYY+:,9V'^(4L[WVVA5\ZI)
M[>^3J_AX&_W/!@>RZ,5-* IKA5D(FJM/73HNNO*%N0A&NU6@,&W/!&(6*W'_
M:>=0:_ :B"$I+U.P6CL2 S>;[=AZ0H>+R 3A'1>B+"$V-3C'\6HS8];T-<F9
M6,PL@?W\M;8V7[8:WU\X^H\#I^4/[[14?B+^H9%L(0B?G]M.5_H1:7'";-H[
MN02@OA%/^GZK%L]\CJ!TL[)5S')8NZCV6#6K,K'_#]Y?TZ@=V68\E"D$"G(Q
MEXY  CPP)9,M(EF;#6(U0\H+$^F01[(D)!G%PN<;84N/&M'N\*KQ# O!:?$+
M0$:@NX6DN>%@C22BZ(D(B=5I,!FS"<QW1NM#F5,5X]%%;,T,FAOCP+%=4O]4
MV$HH9ES^59G5A@90<N<4$6/9M[%"XF88_OPD_W+;:=H4LUW-TR$2MIGDLN/S
MOJGHFN(\*7JZS.-*_']M71'N$PU]^X[<9#X(Y*>UM][T$80TC-MDTU)8\BQ^
MMD7#9&.?],YR+U/Q;L/=@R:0':^DMRS&J1!-_KLQU)EC>7KU;0;O+V"0(SL0
MX=E1Y0WZ_L\^YS>UU\\K$KNPX).\E3K/1^GW;YT?_P(2K?('KNY$@M<J_P+*
MGHX#19ZEDV 3_0^+_+.SHG;5_Y&>)4WZ@U"$R7<>U#8_,@KIK,25_*)TXE^T
M2[H/@5Q,$79+B]6O%+$?(UK:24PW25:\SKB@U52)AK/3INH;\V/=(3<=)-R%
MX4SH^!&)I96ZR\PJRN?2AC84]/(4S;3.>ZE4ER!Q!6]:0A*%LV?SSA7X:WH<
M47,NO] 4UE:SGZ:22:[,REFQ\S?)7)RIV1-!W\:$DJ>\A/^AJVV%.JEWPNU$
M_=@RI\O:QJTES!G[7XX3*IJZ/VHO#'\4Q1$XIWZ'>$'[O5W-:N&W2-1]C:=I
M*U[S9KO^5*N^B7#@.HLN$V69B@^R;!NJ\VH.[J_0[U_T/K4T54QPV+]#]GHN
MF\.NZ'<NAT^O1:9F**G'K]_ !=U"S)TSFLYPBU_M/N2XCVL;^^[;,N]7;C^A
MGW1];[.(% !=T[36N+6;$=%K9SC+&,6"?%B2)Y>/$9L1)B<,UH](Y'OM-*O5
M45I.[(=93HWUA##6/3?BAZM.]7B/&),_%XW3FK6NZ-N3F50N,@H]K4@?PFS!
M_\\'^>]K'-E<91FL^!17[VO\XK[WS+;AURZ' >AL<[,/E8^,GDJ*AE/-Y)7S
M!74X-'RD;Q7G_9X,)AGXCB$;+W?_IAG1,C(B;C^YKB35"%(<;[5G,TU,*%X
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MCFPWT+.E@:/3WIO%:XB-<L :T$3!OEVRVQ-"6/>G];9:5Z$,$Y5Z/]J_G<9
M1$1X.;LTL_&FZMJ_K+UA)1KVN]^P'7^T/ CMU6S!Q__W6=#NTG-ZB'^+8^/I
M\M9-( 6(]S785+?"IK9.?-1TU2;%O"LSW]T.L?;"M,;KIJP 54N*H9:BZB?Z
M?*6FQT0J@_3 *(**7H'B?&7,^3"O5OJF4>CG%:2#M?9# 6]([9C\@9-?IL^A
M.4*!/K*4,PSB)#]TU7$SJ\UJ"O/)2BCEC2O%@:!%>GM_D\MXI-YD9(. G[/
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M07_I,?JN-@Y;\9;^R\BNS1%S139U**Y^%V:\C2Q3FAK,:H5(-&_N<Z9#<W:
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MD*7)QJKH:9F9'[DY,87JS[]$XIR#UM0#[KER/X?46-CJSF$8 F="]#I_J$?
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MU^(P?.1IBO8_2!^-#"?<VSA?Z! ZZ58YH]13A\ISN&+@($.LG&B+L:TXC [
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M1K@P,AN"7@QGTKFG/JY9CZP%DU$=T*>(=MP]^7C=QSE#5%KLM)O4K9NPX@9
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M5N>/+7>W*,0P-MAD,U8NEM6QETH][2@7F+Q84-%>7N:)4E:FM)&$^V&L>G(
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MN%^F_26YTS*UH'C4&I)+, V29SN>$DC)F8TL?K+=G+Y;O &#X.8%**YZQ6K
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M'>%KC +YIF47F3(YDY"GDK8J,@9:E=<Y@S:?+^= MF&[7#;9'S4KH8"HL2\
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MI.'($VVFE0_L\'Z/C9;[]IRG9Z.@)_ADCL'Q!,P;/SQ+R[@%%7@F8TLS;J?
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MO$F;[OYCM??_JY?_6_D?4$L#!!0    ( -,V=E9')$0=85\! .N6 0 1
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MLRVZW*C7UG1GIC=[^B3X3/_[1#,X?722Q%5G3P]-W!BMTOG1B&&+HX$9T)@
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M(V$EX@$I/AJO5D4#B>O$)&"M$VBG0WTGIL1:EEEOUTNABHD"%)R$6OX2*O9
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MN7DZ!FE!SLK3/1[N,GB:I\FZU0]+,@)$N@@+D8+1TBDUC^J A[NTT,&"$B+
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M,M$^97CIDB75<+G8AU/5%$@A@I/ULL606*[K':O"2J@??G.6!->T#%$$<X&
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M#>PW*[H4=)D\:"7T@=C0);091(FV[2:!0-(/0O&NSD5TNPCC)3S230:J53>
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MY"2DZ527RWW,[C9_V/6:81J(HA7K*32>+,K#K:J2'%2BBE65L*KOU,A0V7)
MH!B3P&PNW0%[79SS\Y2R#H9H)>6[K+8>WTP:K%@#$(\5_9IZ2!H:IB) I0O8
MY3I(^O0 )Y0;8%/JPR#,V7E?V#Y]+[H%NA?9#BD9FH >/LJ$?+T#(Z!F@Q9<
MD<!0)-7R&;?0]\(?#.7#I&2H[Y.&<EM(AQGLQ%#48M(?\B1]*/3!+"?H<=/S
M$RTW#.7@=H5#( !IMJL!/VM/IWM ,60K5MJW8[13JS0[0TM1VTTI4!*4II8?
M^#E!F4D.PKZD"<EH@!+2;B+9@8"H,14J=\ATFDJT2D[,LG(-HA0/3SS.P,@
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ML\-6SM2=^@W5NSA QT_1[7+[?)?UX<G"R@;;C,<SH_QP'S9@L"%G$<B+&&
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M<K!13\"=?S?\X>GN;B[*LD#%,^>8@'+/3\7S;N2IZJ#@H-1/18VE2(M@RK)
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M*(?0/AP;Z]IE"B/QD8;,K84_J>T>>>Z.RQ2L3"NE.K' I'5*GG'!9NP)J=+
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ML;'+58SNB:?43.98:S=Z]?Y]%M6S_;.^BRN[T @-?'!F7WNGJ^>9]6Y5],(
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MZ]$D^&/2<JE52:J'=CO+]@^)*.T\9#2#H=B8K(EPU"&;J"3H4-NZ%CY&=!K
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M76)J*/B5@-N1\=)TN06M4ZF[]-V.4JLXYT:5>87PTE^Z.$/6X<YX<=BG&FI
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MT07J@ 1Q'/QW$BR+;7^)&;$"!S>MR!A)W^N!#JH=-9&OY))<DL$*N;['.B+
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M_21^\9F4UW8VW*0[\]#.5>K2J:<@P/V;>9<L12VZN>O;;6D)ZLFOB88%VF@
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M$ZS0X2Z<C4Q;-NI*#2EQY<&4%C6TRQA MQ_.RI-0J.O3:N9L&,O31F>;(RV
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MK]MPL-E:/)YBK23.GL_<AH=EZ_XY]#4\< 'OFVCO2&^5&>D5GJ_$9.^"%F\
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M8F"]8%7WW.A'7(UJV9M:N;MK%2TA]RK:_<T= W2$;'AK>-UW^XKY QZWI*&
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MUEQKUN3>^0__?..W>-T;VYNP-B8ERK[=^(^2*:8C'V/0M_3ZK+B+-O.&^1?
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M]<'CG4I1T-.;#UM3V7-92$71ZZ_BU9K+? /C+FXX/WM7G6(4+\ 4^S^O?&X
MWW\9LO<-E.F=KA78/$V/5BS1?GXO@QXA9_QI9I=T?1T^X)C/ML!WF*PI99'Q
M!Z#W!V"QEUO0T7]EL8A8N5BO.BA2]P?$FZQ1.CST'5!NU=1S>JRN4 53<?@Z
M9GNU._NTPJ'LA7Y_ "HNGJI]M2-4R^I-;3'4G]SS1@S3<J^5I(2O/*XN[\1[
M/ \G,J=#N'FGLQX0.UWC-J9LE#2KSL?%YD;:3K=LLR[CAIDQIV)4:+![VD"/
M PX.MJ&EBZIDR\.2SY.=4[,+[BR'K37M8^J7,8]%O9)!O5V\!?\P-Q[2_3_I
M!L?EXNTC9+9&O)J]Z94.C:U:_MHS1W&'BK8C<D"&FB^@HVB.3(9%H&#)]+O/
M*(R%C4Q:&HWP15X;:^+8!#08_R4;<[J6Z(NLKPY$*+2*RLHO0KMC[9&_YO"0
M)^9EJ99'+N%"K;"3I/OU4AH52\FY;\WHF6AMGDA>I'VG1R^Q<V9*10;SL,L=
M!:#CJC:#39+F[!9T'S WFYHDZJAR:7.LF2_/DEHRH*F_BPC&U)K@M7GD^6-6
M'J0C\XX5N675JP+?6("?L*S3;-#5!NML1T+5>TK7=WCP/O/%$G]-P%7N<A4<
M[/?XQ%WL,;AEO?*+Q5/'66<3_3L-*^>BI"<'-4:L;:H*: (RGHZG!AS$A5;6
MF:@,F_'5T-[".FWW3SJKTZ/U'D+#'YU$MIF$LN(#XT7G5-C%Q+#4>-^=8MB\
MY.'FBXZ<L>D*&2VL)^O".89'"=:=Z1S!68[5I6\@<&-L>15 Y-?+6&9VQ,^T
MBEZG1$O,+SB9"VN-;/HU:'"#)KKUV-R3I:9A]IC(H4NZR]"#N-;64Q=8QB<]
M;V\"3KB0BX.7=:R)JD+)K_LV98AP2 AV#IFP<-:7CSG=Q+416I%.GIM*0]Q)
M&!X]]Q2P:9L<7.? >&,B[,BO)4V%C@AE+\#H56%KLGN:HMJ+6/44_&;9F]'L
MK,R\#.@JV0W!3CI7P_:"',5[.UD)&6V%:3PZ;,:4 8P83H+M"L5_57_8#E:V
MT17R]R'T+&^^MK&"#)8&)!NA2N*ZN):S."#9S!PLUYB=KQ/EC&TV,3!&=>'S
M;&S$MG5/A.NX<4\*BXMDF E-P:"*X,! K S-)(IH72Q96("M(0\#'?=[- **
MIWCO(3AS0&Q\YDBZ*29S#G.J1\97+-8BJ$>V#/.V(K:RZ-=3NV?9/I"&NI%=
M%<FF&9@=?T:=]<Z/IJ8TUEV=HW9]&<M'[APO-"_WS%A!1,0Y;5ZU6;(Q.@-*
M_UU.(+,R0W".T-* -,YN*5&UI!4=.@(50Z[2%EZV[W(:?[%JJ97QEF&89EFB
M1<2[[WHG7=V:-6,%QFXT[HP_Y5>@08P,\8$ C9 AZ6OGN\NY+-0?1+G"EE^V
M)ZM43(+U'@7W?\)85V8B9!^RJBRL2/KXX52\L):.OBI=3<=FV/@6V&CE!N6#
M&R53' ;441-SGG[2&F;'UJC86FYCBJRJ:>E(/\!HW8D@&6R(X!231J_XH@/C
M-NN@T@2;"M+"' /6.$R2P.07*9]>D:IWBNTY"8SGXTI]RV<WM=>CS%(9/(X/
M^OZXH,)#C]R2U6:LK5UGL(CGW\"J6%J]TX]AR$]=.B5\P]CH.M"Q,R0^9?T.
M"1OS\07 <<6;MF2)=R[0_,8P, D 2K1GW@.TXR$!\+30AX4!Y+1\:;P1;4XN
M%&,D+,8ZG0=:^!D<:GL\!.JTO+2\@N3J%^F\!WBX*90H^?Z0?Y<JITO0N<JH
ME'15QJJ;\0G=>''EK*,&@M1L6<S UQP9\XPT<C3N2>U\Y;E?;K"Z3+6Y+H$[
M88S%.I5C<8+P3A=C_;2F]RV?1S'+R@20A\-)QO&QD7</C+YU%!O&?8Y#PFNT
MHZ0S?@36K&P9,B0&Y/E$UIML$SA;(R;JPO%R+-7\7\H0EKOPTM4;ZW-Z[^H_
MLU%F%[)^=#"OJ <N?9P==/+2CDD%&B[R<.].KN388/5]N:GKG;H4S3S\!JG.
M*#MV4?J)L%=ZR*]DUBG;95#W#,W*.\3W-,4]0.6P1M*S->Q%$\_H"]3H\1%]
M(W8^ -R8! ,F1%148F''M#IICN&,/!%*#IU94R3:'$8T:@:NO>XOXY)SU(_G
M?#TX4 U<\]XL;M0@'[WXY3/0H?:;F,8[RR^FY=WN[_<*P^+W5&#:Z-J+.PG?
MM8N/1.4UV,LKAEQUD?#^4+(WK:39VMF<=J:EN>I3S'LI+B(V9,L "Z_)0JPW
MD=%&*EZU0??2_A=(L46I,4G^*G?DOW]":GE/>]-_A-2G_ZS?]EX<.Y5:^0-(
MATM9=/<Z+UP_A4!M]]YR;3_WIO/LO;;),@/]--SY:7B]Z.^[:/8;+N'[U_D/
ML^OK3D1W%P+:\Z'M9[#WXN)I\OT]3Y'9(),%V^*;X*"B"P27.;GW16#_E\ZI
MVB]M\%/<"T1MS]\N&>S]$[*X2+6UD_S\G%Q)5;E=_/RCN)2^#N>A]-'NF:=3
MZ&ZFQC-G2S,N2.Z>]@]@.;?P+=JCR\8?P&SG'P ,(OE9.#@R>:W]60GJUR61
M7Q1'4M^*._]P=/Q_"X)/WSX&;&G"3QB>>=Q8J/:;4_\)@D<DX):'CM(3I;3J
M\#GIPS1_Z#IL!$MY5R\X5D=V>M.:H%7T?J!##J@9=R8&'I+=_:[]$AWO+NO]
MRN0#(TY2Y,D+!#BC9B$5I\2Y=[Z=OHHA:[)-$?,ZUKD+,_1-%B'9]SI3K:_U
M$&U@%I^BC#,0O@JS@36@.5L:ROXF@Z8PABE/UV'H+7GEJC 3E9NC^>N^Y_"O
M*9.ORFQ&]D.)6NAIG/"476.,7PG:&PT_L.W<.:D33>0$JD^,M9V5F3&..,!M
MJ!H1OX(#5BH3*\,CXQP;B?<-:%B/U5)_?190%&B$%_E8%W!R^AY-QHAXC8RV
M+;^T'6CMGH<Z,(A00TA\!",^CA7E2TJ:@>,=>;L(B>V.FAS&6/T<D>0Q% (M
M'%I7?7C T(]4NE$&9]T57TN7*+P^D(!76,AY[608R=,>38)P),GWYIT0F%JE
MT52?#2*:OCNTQ$S/BWKG*);Z!J#)J!I7-D0HE[/@&V\T)1-:6S-:>-_49O2)
MROL_T_Q<VA2#]#A*MW'V1J=%B4PZW.8+OBC:RVU,RVG>8).?D&4&5NM9*^#I
M_H<12%!(..X?P+71]M2=T+Z9]RVTU/?Y^>'_$0X7]U_=??D11"E!^)_UP?\]
M\F@ON SN-;Y>2@4=%U/^6D+505_,RA$05[_1=^[1I?ORJ-NG8(+N_50?K&+"
M\35$D45W33\[1'P1E6Z+JY[=-V;LVV&N'>B<;HS6/R#HV=STV=R""<I4#,DR
MSQ;IX= ?M[M7LAB[;' \E(4 ^2?S>A>C%[*!,DUNY<CW-5SVCO7O (*W\\'&
MQL>JKZ>,'Q>"["SC:Y7ALFPR$G49MY+FU9=[!SE_5\=F<YHG2WJ*J%3%'YBW
M6+2D2]23+$"!; ]* P]VW[',!,\EO\1$<'IQG/1L*[RL&?)</B*I 9GX9.HU
MKK$G"-)/F,*I)N&E)4R-6MD"$D]_K?>W+S,N=B1U#_8.BUGNQ+<>NI\D?1._
MU^VZR/[>&:RHJQ7/[CK.EQS1_A&SXC5%X\UZS)T_G,W!7P(]S)00:ZO/<@G*
MM]4F>=EH(7*WL*6^O8QA85^H.$V<N<-?V$C5W;TU(WXW<!]T%R!^%T W=^</
M$HR6*L\"43R/MGEVA/.)_0$D[]\H8&FSGJ/GOPXH$HHPWNV''6<VN]E-FG($
M]HJ:6CCDO] Y?BFA7X<0SJ\B?M'PBU.'YRP87[+ZLBC$<V%G/_E1O'+F3=#=
M8^[;Q=E[:T<]?7=]N7C>6<1RS5?$,)\#(V+3DRN)Y/>%Z5D+OZ]$:N:H;TK<
MH3?F[&\ASJH!)5M!$]D+)^&@S;K&,_^[>Y'[H">J/P"F[=R],;H9JAYW(:VX
M'BY!NU&:;\<^BU=5^57F8B^)>W')CG;Y*[O"1X@3CDQ84<?8B2P%06KO<$HM
MAAB[D#%5<%^1KAJL-L2= Q.3P^\DWB1+FMXIE2X>[!T\_2@H>%1MNE<R<QL\
MOY.1L=&>:_*;,LF;H@'BH!UV+:9QSS]ZL&3KT<"FP\%>SN\:Q2\X0+$:/8/W
M';%>V^":&P4G"A9C&\*Y\3'_*:DT:W_/8DW(S%A0L[WB4Y3%VMRSFB3OVK\H
MY ]3B_])(4-9_DXA^WP _YU"5A]9I]\MB,KOQ&Y9%GBTHU3C>6T7]KX\YSRS
M9[4,SK#5K@;&3;3-*\Y\VW$?@(9B6-,LVO5;:6 4)-_13S^]JK#L4FCY68A>
M<1IV@U@FYNS,F"^HAHW-6D_%[:RPT'?K&PPJ#_##<;+A34V0H]B3:C3]6&6(
M=37_D0#DO1RQI9.DLX9Y\$:8!T-K-SO1F$(MT*%]S9RY&72ZA03!RYSQ;B7%
ML_Y\;:-^:FSW$,C;YB2*5+K?J=F^TFA@O<#*!HPB[MP"*.HU./K0N^L]C.,Z
M!JS?]Y<8!9=.G]5ZNC4-FD4Z?6S]MI0%GR\,V71KO.X[0<GBM2Z83#*:Y;/Z
MS/L1[U/)1YDELNH?)HZ_6RNM(V43S8Q>WJS+./J7HW$C$7K0O-&^^6*UI4!1
M\+'4KUGGHDO/PLC&R]+A??<GW\:N9MO7Q@,7*@*4U;7&676F!8RHOXKN39E:
MZ_@-<9M#H$N#D,DNJRX8J-6I9$*_H6PLM%" JL8LJ:U<FY+XFP]7$!YVZR=E
M#H25N2Y;W$*UUA4,4M&3;7 NL')KA=FM8^+92QTM:&^^'-*#D<(;:9+#IP9P
MZ/#!23QT*8S=0IB9N9D86]5A-5'6'[(LHV<;IA1>I_MR9<OZ6B_K"UUHZ0U%
MY3@0KY<)TOBL=.6B%5OE=_KU2IPQQ\.N?B.%-'9SQB'O9"$)GC6R+!2X/!#5
M,G(TF=CBK%P<'G>5(=%M,GT;&6P[/C12_4I]H!97#LJ!QG) ER/^FJ'.K4Z<
MA(9P2/_,FOQH>GS_<-RN\?&>34'2O[@%T,L$H NI@6-#S-I2\0RG]^!FO3I7
M)W)P1*(<TY6)GW];KC,;@5'V*JW;I:.+0#>-$+GIL7%+GBH"0&24T>>&#_/3
M3;2-5H4N!*>>)U; D5W@G&L4LTNB%]"[9=.TG10L4[G0I2B-@[<0F36.; M!
MG9:XP0U2=S7!A0;>412/,K"<&(U1"CL>(_E$V:";Z3=818;=^%#T,3@O?UV
M_A!WC8S8@#KS9M#?]$"X1D=U(:_HHUE![)#H5+XJ5#\_E[@FT64\_/1W%NY7
M" Z5\PK =;[E2+05N6]1N5L>T?QM)8M;_89D$/\%<^32Z0*I84 &,2MR4I\R
MBD!4 ##?07J:X<T0!B&-50ACO>HV<J2LOW+Z0\R14<9G#JNU5A<B['E.^-F-
MF/0>?[%1MNKW.;T\A'$Z,&WEZVD[H=\" )QI&+W@O6\$K6VN<RGA8GQ!TO/M
M5CY;5Z9LDW$"E0<_LGY3!"K;WBWXF806\M1 7&ZFOCZ*0BBT3NWV$E'R*77M
M+)58OLY;6W @Y>?&_OMTQE1@]J?:"@="JI'( TL-U]<!EGW8BE_K\"(UR?EL
MH^HUIO5^H=WY&@2Z*"N\OQ\OE2]=R#:M]1H[T5>M2]JF3KN:S//R7ZSQ?S5O
M9=>H*R?IRGHP/ECW>BLLI_$@M\>G7%/?IW\000"S1#".=RM$ &F3(F$]B->F
M8V2#R?Z%,!ZG7=[72&,N%%%+VO1IWRA&L#AKBW&CC?"+6EG,\IYX4*A;24'!
M0^&4(Y_NQPBWB_XME;13N-UJ2'-6ND%@!0Y65,AGM&'.U"CB[RT>GU ,G^WK
M'R$!G'HW]8G[,]2:\++8!."" .3,,CPV[EGNJ'5=EP4#U</%!AZ0'9P_]+69
M<U$'2%:@6"$\E5@N(G0:S<4T-29APO&$,[U6),O"W*X9^$DKMZ*?_#5>ES4[
M;N<O>@T&O 8J:5;+K_CO;-4EC1:0T=+IU+]WO$'+]*V"UE00[#*X3%(%N'97
M:U7'P866$J/KVY.,+^]:U9P&] _C883U(KRX)_W81X;^&P]H/I^#B4-OG):!
MML0Z'L>9^:T<RU;0M)WQ[>U!AB]F5NKA:**LJ>SET2%AF+.C8F@4<,01U'J"
M 68-$[UF _"NTJC'JMDA")>A"R,4Z201%,*Q/>S\JW:+[<L.](98D"YN1EI\
M^P0_4U5_5NG)&QU<KN $:@FIXR*6_O!:6API:2PJK8U7VE;3A^EV/9@C;1BD
M5>KHV@QLH5%O[43C-_!O H/GBOGLC=2G)#U16KR=28\Z/PNGS!(2!&$+J@)?
M+^>\_4CW W$<<Q%F(3T@K\0\,@G:#:0PGO2)FXT]OL.1\.81$^"H:_Z-\6NN
M57)D";*M21/&,XKOO+)<%<$^ANT977T]NT&F:*W39((M<$)A5F'F05&3U.1C
MB&WFM_O2+I-5"2>,^Q0#VO/9EI1EQVN$WI@;Q*,4B]MT4'T @@$QQP6:!B;(
M@%T!OWRV0W?D7UI7O^1T1U5^\2O##/_!1+Q;U_&3P0'/IVZXIE*]H][)2:9S
M!>L1ZBOU*@/(!W[Z4VH,Q.N0IX_I8$[2 7G>B5FGJ^5(28$/UH>9M_Z9QYT3
MG9"^-@ZC,SB;&C&JW7CQILU&\N4@"BJ;R,<8="\9I0]Y^\_4)H>,+:QC&OIL
MP'SFYE5WG( #I:CBC]H;%,Y"W+2*H(C<U.)7HZU)91?OVFHC&Z(T\-I2>%86
MGI)( +Q&^OLY*4MS(J8]+<QSLIU4D#.(D.A(/,F@A?G8UW')V4=)LK!L&ZMR
M[TT5G,]Z43WS<>KD-A6F6<R3'O#1J0!#[@N^;#)ZNJY%7NUZ.8\\V1G6LA]=
M!YW<:,2_NCA-I,DQ]5[(?L)J ."E"%'==-(B.RUJLAF8.R;MWZ@VYZ._Y=^H
M6S#A#\2K!V8THI);NN9Q:U&#.@N?LBHE^SHB;MLV!3Q7B+5LT)C/_11%5U @
M(&"JE:,4/F< O)J!C >>XP2PPJLARD?1::S24;/PVH-TL2:T^O8[-;-)8+_W
M\Y,E<PE[K\Q:)4?FC,<X;F'NLD2J%IEP%.%UT]6<+$KY6^EV\M'&R^VR5&]'
M>.YOXI^8WAL[D/#_/[]'OX>I)+^YZZ[8#SZ;:R"Z0A(/X7\T=4D[WID3E/"O
M!5:*ES/HX :,@VXTS%CC/6T3K1>L"U?L\3M%L4JE"B)-)6W9Q00*H;+BZ\*1
MPE\G)H<IPC99 UWF:IG?4 HLO,LO.<XG8EM6/YDTI^T :CNG_UJLOYD<B_:M
M([OU:' A6CP!DV*;S3EH&TU  RI-0RZAB4ZKE +@EZ_JOI",K+P_^BF4##K6
MH60^FD<^ES%R9%K.&E^6%/H^.D-.HZB@WKG@1IX9J4W2=)M5K#N_<*0-:*YY
MJES ,1\B!2*S(X,#8H^,]BP+.PR"*@S8E(D/;K]J&](NI'SIRA8U7]WSJ:);
M=19\U#43W']D:UG>0"L5H$1EP-=RKC=!/E>2G]Q[41BOQ'_XIB>CZIHF8$&[
M=?A!S3A#3Y6VJ/\7X@0R]'KPY!H:N+NQ;/== ]7FM:]S7G-VYAV;$M!X@H*$
M3L)%J\Y>7]%_]H>KNFX@J@=UG?VQ3$6QH0G[>G7X\B:5\[/>>MC:K/>:D/EU
M 'SS\(3ZK]O3)SU10+!J(00.&N?/81ZB)@WZB^B_QPL:\D>L&G@&SS4*@_.]
M=N,=EACF/8Z7%[4Y@@WX6[N8] ]D]$HE5.""']&[N;V^18J/Z2YP]XJR[_ZS
MBB6H*/Q-YWW6G<#A$_3WOL6D-V7]HT30>>]%=%&0NUQQA;"-R=3->MD?P*+$
MU&,N4S$ _!=P)W61BC[8>^[X\CWH[?][WO>/R)G;M5MHW^\E$,]9ISC3POGB
M5$C<TDK,+QBF/.H(=$KDZ9]/>?.%0"YCAL$2_1:/'918< [*"-8D]0_ZDFN8
MY(E_,:'H&#WR5I4T/P\ZVD&%43I36NG8\=C">"?KE"4&[:N:]_Z>>D9@INOR
M>AUW"=X,BNIJ[VZS\5I&83_ZGC '*9!F<K;04TZI,)LCQ!\+VJ6[],QEWMG?
MVX_9N0LQ+.BFO%?QK>FZ&5OT,4LM=XPWN,.!'+QJJR)N\35CV.+,Z&1;]_QZ
MZ2A%Z!#A;>]![K1P76?F4GX"NJ*?[P(]<2S@9U/P;$7Q%=]:ORS>*3+=E/"4
M-#?]HJE^Y[F'/SX6="GP*'X1M]4M!/Q5N?Z[*(]_A7PB#<AO9ITHX6MEQ(PY
M@Z!#O-&V#)1(>FH+. 6/.MC=P #>_34I94T+D$^KRX8U/HI -!.>'<*QH*<0
M:$B(Q<+.4] 3#T\^O= 1[_-N\871><;_B<<X9+C'+]WQV'9^%7MOH#:"$NDJ
MA75_(K>--[N>PT#!>_"64],21-/JDWF&Z!^ L0GJC$V1+4;S=,@DN^?')WZ6
MR=*A82?5U5,3#2 1=#6H':;*U\%#-XD=9)Q&#\WE#?TXRJ&A\.-+S??TR+2Z
M5JM@,S#K_)&1L2R2JPA3(VU.J':Q8!!2V@YY6F#Z@$/5_<_*:RO;!J/&)M'8
M>4RU]A9R.^LCG'BM-]%F$7D$TRN&&;3E\>[-51Z_V.[+L9M$(C6L%]C1\TA-
M!OB<3D$[RTI6.AV6<"->W$(V/I=9P82L+,$9('20N88G;):$#(P4&QP5_FTN
MFCX0>BI(B26&33RRVF'.RHA9,[!6#J1\94(AV&</]\["XLT5X(JAZ)MCS2=S
M[J(0[2FK<XKR*F]PMU@BNG]*[&#UD;SI*&MTWA!%"Y?YCG>.D?:H45(L%M,D
MNH4=2\6*4.A6\)>Q9)@OOQZZ_%R"Y:W&J3J8 1,PSH]<\%A3&66_YPB%6CIK
M>JL7[IP],5+@$GO@;9:E&9%7K'L+CW >@ZL77E:4JX2&"?3IT]JJ+">M&N1,
M;0.SJIU6*GH<0BF%T21<GS1[E\CDK1^>O,T(=987P)U5MTQ&*0[LN%Q Z; ;
M^E:3O)UXY-=A+IF]_!T]@M\''TA)MF0P@5E>S/3O2G/=K*.T&\S@,B)L51^%
M4TVHE[Y1$^>%6OG<SVLKR&EUJ]2^]V[Y]7'6P,#\>KT>K^% +==QDRHV;+H!
MG=>2/Y[0?]KVWX3 FJ*D!LDP0[""#IRSE19RGVV]-J^I.<[^6?VP$FAWK4U"
M0U<OEOLQZR429I!<1 OOB-&9/24+;_(GS+B5'WE(&BGWU:1@%KBMT446M+^/
MD87%XQ,9LL?W:I)A9775K6+#,:>JP<O6#H5L@BK3IH[Z?5VV19NL=V1JMG!;
MO"\Y#.JI WT3PS+*71;R7#+P\@]*)6 [XGA5$/F2\T"R[2M;/+^T:3W#5Z,V
M3MATU')VK6;]M0B(['3==:4K^J#698-?^_:=H_--Q2F8T&F=.]BGB6@C(Y,&
M.1ZL[$OJJO)=(Z#L(8:W]II3+(*ZE,1NY\F0;>6W/N3]C)5:5MGG?J\8NT_"
M#^!JY+*>FS"B(W;PY]JBL#0'BF9&Z;-\$]\&+KTN@J=,0\6VD?&;EF]'DY\L
M,>IK,I^2*]FNI(_QFVIDR>L%7YO8-K.8>%2^(Z0-<>E4_J+@_//C&/9MT>]P
MB".3RJ1=5OE!#18=6]9K-6N$;2P6@72-#PL[CCLVPW"PAN1&V4=;8:?*>)A1
MGS<FSF0-C^V$M!.-@<!8C:!8YB^<-GRO47"N5JZ/<4-F>.B919!6!N*!PX&X
M"LS?_T9;VPC,CV6E0VY3(FZIJVVK^%V'F%[L54R=>>M*NP_KH+#MC7[_5&K(
M%*'*(4QPV1V7SPD<5R> T69JJ>TBS<;LM$DV<XMF;[I-)JTNDW(U<)7,!ZOJ
M3%+^6&B8K__.6PV5_C"1UW(LEQ=&Y%U+:DD-9\+TD_'V.&26^]_[J3B6":"&
MK-9Q"(U#NY9Q$'&G_ZN][XQJ:MW:C8H5%1%%5"04!16D"%*D9*M@D&)$D%Z4
M"$B33:])%*67"%*E1)$B4D(QM$ " H8>$2$4 0%#A("!A%!2R,6]S][[G#'V
M^<Z]XW[?_77'^R-9R5SS?=YGOG.M.59FYC2S;L#Z"Q3*=5X:D$T5XC^J'K(>
MW7=,:XKD><'HS$.;;=C849*US!/U^]X?%>JYA>V#/_(*;%+25N^\8Z"]\OG,
MCI89>#R/R;,/W%YWM4TFQW_"@WFUX;EV*>E\N\Q8]4WJ8>&W+^7,J!=5<UX\
MFW__RB2^Q]3IR0]!I.SN&]Y*<M_]-G;'L5*ZSY0WWD7>:K3[9'A5Y3;1[>1H
MN;>1,-%R:)&D@N[VMPFI.(B\IX3)C\7UM9VH,%$AO1J9IIY!3[L$5QRQ^#7Y
MQ?.T5V5D>^<# 3<$ZJIM\HH';ZAF6'C4NTJI1KS7Y:AT'4Q[7#\GX6-[J+;,
M5"'1L:MY?F5X5W&5< Y_7<#1?="(NZ\+%<CBX]Z-M^R"QY[NGI6+DGK0<B5Y
MNYG,SDQWPPQ)Y?W]]![?G5T/E#M\7A+5]>,:S\3)51#%V LI+3YI7^<?N;4\
MX;MXYA.43_N:5KYA"D$)I9[KK>.=_<3\AOL1GXL&]TKS#?;<?Y3OK/LZ^Q C
MYIN)5J&&4?#-VQO/Y?XNI7SVKZCRWZ64R_],*8\H67R"T6%K7F,L\@#_9245
M\#]54KD8@C)O/9%SG@?8E_A^4:_C-G]-EZ+NI906BS'635>F!_CJ:6C;U??;
MUP1=.M$PD5N9]_W6,_?;D@D!MS<E2]28.E+VCD?XAO<<S7I@''&>9E<H^*SN
M^+C24_C^XYW79"7[&E< E]:MO[G7ZIQTKG+N> R^F_%N(:_:[NKVO*]\']T6
M2@O;UD3JT[(5P6=N<()* R=ZI92C^%+]G]XLOJ11'I-L=25Z0-9'U+]2[_OE
M]D@-WVWH>@6+6!/PF9B-H_S!5W<^5!51FAZK7%2\FO"274-=0"<VM+_P2)7_
M=L[/P_UX0'[\I<-##1Z9X:8?[[0G^'W^+O#D$D-S("T\X<AYZT%JG*MU&?F:
ME?Z+Q03/JC>VA\]81D@VF@/4+ENJWC  Q\=I10\QQ^_YV297QF6;B\8&!*TR
M\J:5M5[56#]K1]4KWTJHTP@XK+A\69K?,3IRO<HQ%GI^-N]B<-_A+S;C[CG.
M"Z3T\Q\+P]0\T@^9G1T]^^/,ZJWA'U;W2U.FQ74+5","+9R@1._"Y+2H!['O
M)#]+8/8N3[/#1YX-+YR+[T)9%T1 W/+8>=_VY$3[OCWY0/7U/CZ*R5^/H;RR
M/CJ1[-SP9T*I:VL?86N;B.($&?2:/^EG W$=K8^<1J5R=L!OL2-H:K.;6>O*
M 4&RYBDMU?WJ?_8_^]\;QS<$HWQ:M&#P+\\ZHQPHQ/V55"X'JG,??L\]2SZ-
M/M:1X^L'B/"X/F:1M3US;YSZ:W<KC-4+';2:L%'E!XVI"][]>BI)@2FWJD2^
MAG871Z3OA\4TV\1FW3SV>57DXJA?OT&S/_CVN-4OR8?%PF908$M&]/R.P\AS
M1.#R;-Y$26S -R;0;;'[V+.^S.\J8Z[J^LY22;]T'B:FZSS??IR1:(6$3PA,
MY6V:"LQ17+.]+#GX!D2KQO?H$%HY*U<'^UO+OGQ".8N&1I-@@4/V6\?X45J\
M/[*;7<11;JR?BMW3@3&.MC:_5^60"<C*J/[&G]HN\U#L=HOT\57E2]<SWJUK
M=H^D[=7EU]%H4<EPNE=Z_)3<-J7P'=%*X8D8D4JG+D=HL8>@(DH_(V9_6]M-
MVX.IQ-O#5[2E1=_KN[QZ9'B7D6CZR5UR!_+*-OT>(Z,/?DVS(![ )(J#>LX#
M8 B;D))!.H*,Z&3"O"P60W"U)>GD)BA]<XX'V#]3)4$;I.;J<.U"&IC=2'AY
M$VQMGLI&EY'0.#;3G\U=FZ0M)U9N(/QX@$COQ:^;)Q3(BINY2D,@A1^H)4+M
MD_4'^)165A#A=U+$1L5X #=++ \P#>5J0=_*]/<AWFYQM?J1!^ '\@ ZH($/
M%F]!"OV@J>S0(%!DW(81J"B^Z!^,KO8C_A3*ACOD_=2G, 7E 2B$K1G4.7C=
M+1"!KX(>?,VN"&C[!5-XY5O'GIO)2@*+ 3X=NW$"3W-T(5<ZM:KX/P]3/A^^
MD9+$3(1QRJUDK42. VZ@2VI\E$Z?\CX$VZG4$Y(GR9]"4$\T)<H>S#B\Y]XO
M0*.,MI2]*[[?YY%7_!BYN=Y:]1LNX D)9B"I%CDX"0N<M!\ 6L"85&HYFTH.
M:8+Y3_Z6\46:7 \E;_QC2YQ*$H"M3?H2)F%K5!J.3,"Q:1SMM0E[''OFU!]\
MC[5P5!RZ[FV14PIW& =-(;UV+_4CSD6M_,FR=B.P58]3"!SX<)E Y@YLBJPN
M(0X<HV<@(")48/H:9!WZWZ%C:VDA3>_LT6/,4"-M^Y^-2[IF3EW['>1?EOE]
M"RO]9[O_X1]_+K1C<B]F$>D?7# CAB_8IFG:^J5A<VGURNMD?;/!-P%MJU$]
MQEG[?=HL0X^Z&$;FVB\G7H\_%H,,-C *6FMF2_TX3PUR<$ZKT&3O6WAM9SM3
MVM>\VG5=^U=,DB+N"M",WD<;ID+<7=HOD\ZY#).&[XP=G,M]9 >-1)H1\ZQ;
M=O*%.-_4JIXKB(>MZ"C!>8!;3"":@_]9YAV?JT>TH;PF):603D [/0?+REX;
MX()5#Y2/6)^-5T[<?30..H.2E].HII;JMT&B[Y=^668MBT@C%$2A::(,[K95
MN4G3:9W=_:G7]]H,4.==:^XX.MK9L58BG!3#M:8"GF&TG02EM.^+LA[E@51A
M&76A]UK%.K2N'1N"&@97U>,^?TG*T$OQF##/?:9CBWVW@,%D""WA=\DQA+<=
M<>\_%,@V;9W<R&_%\P"U.H\_.9SF"J%4YH%I.AE_,4X&;7V:Z$TG#/QEU)^_
M_N=Y]^E8LJ!_62*%\WSEI@:A&VCD(K:\&X'1TN8!EA5Y@/E__L8CH'JOX,=]
M'ZZ\NB\O7AF['1NK'-[<(O)5(NA>KOHS59E'>^M:%:P(_5<20)9L2ZGNDP?$
MWYN<>-HI<^'&H2N',V4=G>(R8YYIF%K72Y"U]RM2/ND)/1-KC[OB*7ZL_,C4
MCJ1CYT5JKXX(*NTZ]*VX8F=/:)P5?7Y;QORJD?;:9&DTEH8?8W9';3D-C<4#
M-##7NEF&Z2LNZ;.Y#N,9K#S8&>!-WY%#:Y/H^AD:?FE-6GMM4X '4%M7GT-Q
ME%>@;T'+X %ZB/)?^[\+?H,E\S,GHO"//?NOZ_W+=7Q0R? 8@OH&="[^S^V>
M:$J']*M3@'(PI90/M-0"OB=$E2#Q<+EOW7+DUO(&ZO[0[I]MZ;AV_B2[$':W
M@L76FRWL"CN3>NB))H(7=1WX?H'VZ<<&Z^J"-3(SZ=&9*[JSJAKNB4Y:L\[B
MOP0G94*>14>W)0E"4G1U>X@INL2T4(F0P_ZI>=4S1S^PG6RM$VM5/^HP'?B^
M5STJE96R2#(72CVM,17I_76(+Z<>*,KU69$5\<YZ0R:H0Y>0U:##)M/V&G5<
M=[T5_]3S<TGWM=[W#*15M:8K*?/58^Y]K4:&W]T.[3&01NC"PM5MH.]QA'>R
MBRG^-9KN:6LU;A<U+N;;/RVO$E$6%.\HML:*U*\;JAXZ<F5_V\,LU#EBU7]=
MCOAO2Q0W<GI77(,F9PGU[T;N?+E66Q:E#J@]N_JH(5*.36C,6U@J.#0)S;6\
MEU(Q#:G,:E3\\2!_0]N_4]N9XEKD@;7R9^ZO]U^-^PI4 'L[\563*5WZSM!L
M>@8E:>S"]>J'&=?[DN7E@E<"KX?&4>86W]VWQ,%QR=&9T9GQ0UX(EKJ8:N D
MO"S"GQFR6<M1P6W6L@QH>.;:)&** A;KR'8 ,@(0CDAL7^#$VA.<L\"H)VS5
MFRTJ<!+^K!P?F<JR$%O/=F!@057@\9D_)+BKFCQ ?_-R+7YLV +1VLV535EK
MG?Z^XID(VCP"F["88#_9='98%(:O 2OQR]5S^ZCKK@X%/K@_-9&U:4&:LW>Y
MA:1)Z.H60J[X..* [$JY]K(ZGA* N(_$$IIHN\-Z@._&V MPPHX/$WCW>W8A
M/,!& 3R5@),Y1BSRZ.0!UDW6@M::OFZ%[<]W+ZH6L<>S-PF[/]#R-6NGVN&I
M7:%3RX%]!&ZL#DV6!FOA 9055N- H<CAK^OC*U$!''7TI[HMV+0<)'L+M#:M
M#C3KM-GO0O/=D@@:6XD*Y&@1/ZW_K03J[W68_D40"/ID)O#3J;&E:;P!&;:L
MCJ7<WGR/'X?^O<3,I% <SE]A098[] <SDS^9T5&#28SC#_YD9FF] 3%;P(T(
MVB3_&R7D+1DL!;K9#@Q$ADX<W,@ N=:N#7,3!1(F]0.]6F.YLL@P'?F-81Z@
M\E]L^:] !.)P :"%WXFE93Y9S4+ _BUC_P[I_T?Q?X?B\I9WM6QY5UG:>VP(
MEC7.2E1 E[%Y (>\!AJ:P62RN#@<7FP]S(Y1R0,X_NXL8,Z6=LS:2+4#?],)
MN.KZ%<'9^?D>W[&38%'C"[TASR@1A&-6;'7&_; /BGWJ[&3[J=BK]&B$N\(U
MPD$-,BELB.!>.:;9YE%^><Q18Z]*?;0NG<*_[3$@ABRDN$.4,D"\K!U08E=L
M1!H:,-8S:GOV!BZ8XALMK5AH'"&H+"AMVJ7U.L7Y?3 P^7CDIMFZ1KY6C;VT
MY@&%7RWO,%$&G@;L#O O@2@[_\DJE;"OL@>QU/+*[A%!8:LI:JL\NY6=:^2J
M_L2_-8T3@'1RMW(&YV=:Y2@VQV0^\HG="]F3N?7:XQ@VK;'Q39H=N:)E8N#/
MN5)<4%/4IW_'T\[G=49TFD2K)&LA(SK&4:0Z(_&V;;5-<LA>?Q<?ER\V 6M/
M8>3TH'LCNDYT)1IN\R9(5I*^=9NR+V\*#IRPV^0!8&O,C4E"M5>5D2ZX=EFK
MR;><9,0#V*[;;N ;CU5"IGNXKN]0M%KE7&"I8:E.AH+#4R(+(DL;7WC.6.+:
M;06\LL@@H&,F#X!59A9^ C5,@"S3+6&*]OB]J)5<;793,AP.+,%,DGURE\3:
M@7%GF.4DSH3OY,LLRT!V:/C:^M9D^70<=Z(3!-H]V#!)KX<$"3A&;ZF38=:,
M(G"SEU>$W,7P[K_^KM!T$CLB0YEB8>TV+61I.Q9,UZL<K#U!O3/X*_(5-.I:
MW>_XQ'[3)S X2J/7K3U>/<NQ4B@+P,\NDUZF6_JS;>",S61I&O?;&@&_M6X>
M@$B87_1#^-N&-K./;,JE#V5!&,$$>+C=O4G.T@3^HVX38C/18FMFJ6YN@YC#
M)@K-Y0%ZJW!+]NV@N*U5#W FO%EM+UK1&U--FX(*")H4$DZ['\,#Y$8-LM8W
MY]>W()Q#L:M!UIY2[#(*Z \B#5G@<UM$)FT1Z7 5@6O\8#JQ>_CU\GT<9I0'
MR")0#U,%"OE)4\J;SPGXP"H(L949@.646TSP#Q<M.\/?C2+^K8SVUZ98A+ +
MU;AHH_$9IO:5$.$\)M4_?(E.J)(P,Y/>D[1QO^_UN:_$XY(]J0-"BGQDT0QF
MME7?Z2H]E,-YK8KN<NR\E.]"$2%K/@I\KTVU\+6C7L?;AI6(5IW;!\['&HH(
MB4Z;@\5-E/F4A9Y;*S@"H;FB#4V)Z(BYA&\I)^1LG'(>DY0H'1_5;)D7DLB2
M+;:*SN)/7S8R?/?>+BE_NU/RUDO;X@?]>PY= \?_BN139T8*3D5J;T50OP51
MS)"?37[A.#:%6#VG8?9_^-C@OVL<?^TEHRV^:1-4A@U[9_?PVDQ"JV%0YW2S
MO5US ]YZ=&\-['U.*/['*>\R3&.:,KK,K;A,2IMTCE(_KEE\ EE0-GRXO/K@
MO?:#1KA=TE+D3+(65Y!*^;ZAK9/HD'5Y++27J*\3&XCQ]R<?BS)6A8'?&R=0
M(GQ:+*[5%^2%=7_RN ZN7IGY'#E9&7:GM##-[>EGS^R3[6=/[#B %#83CXFW
M=2S*DW89[/-)$M2!A]4WLZ HE(XINTD4C[YP3"<-1BA>14=:TWZ-F/$]PW:K
M+_3*-<:_.>I>_+S4#6X],D/"74K0!;LV:%_*NJ,F*'IQ;+:J-^.QJ93UUT-)
MS0]W46S1$!TXR@%"GHM)Y@&*!K*TED]VC+D\&T1(BEFZWWBD!@EV_T9!IC('
MLV.B9 ;'@97'!TKB$Y/&SKU\_V%%T3$UORYY>]C-=+FOC[:%T$2/>VS !-DS
MN;\, <^&S=J\73WZ8F/:V/U#Y.<79+LM[S,WSX*\P*CJCN1< )X?-+RUWF1G
MBE/P<NN&+,@NU+_,)WVTO'MZ=&!LD4^RO*ZJ\?6@%@\@L^+2/T?1<<CJ<X;K
MH^1(N^VS@!(2I D53PMKA*G$VX53AC.K+=@]DHM%02?=K%3QR4@5,0*)9>@X
MT*D:55;VXL;55%)6JI?'T?L5?+-=PG5N389W\C4OI/N%;'&)2J''T*,SZ"B(
M&?$LZBQS@Z6LPA6'/QLG3D\0AOVY)N AX1.UB7!9<ZV6":"9V&+P\,-WFM?G
M/-_JO71[+ULF+%\RMLO!N&%XMGHDO%:VI]'=]7(9^,GVT?@5IPJM&2(JFTYG
M!OLRD)"U$ Y#2&$B$RG^8.\=CSR,=+9766,$E'Q N=WO]?% ![\26TXH8[=%
MT-.<-+:[K)"I1NGX%X\.A:@H,,0&:F9?:##D(2KL+!^)H,YU-T@1!WJ";T#2
MY6T+@\%D.EF4"WJNVCD%?(95#I6D;\?6'^D/'YE0#58*7>X:IEC%W;72;3"T
M+G:GLMPC_(\6-,4P?:0OE:6D2.MG6,EIA"^Z@^Y^>>ST9$_F?8*\0YK&QM:-
M 1'F[.&=\I_:N_U/CE[O10'^FH"/PV-I+/KB=$FVVL.72()A;$E1G$W-P$#9
M]BI":"6)R8T]Q*&4#5J)[3UY@C@FZV/@:5?B _GA(6DM'IM^H0C5#=3E 1+M
MA+K3B[J"-R *H/1^'F!,?!'QO:&!FJ)ILJ\7\]KSU$,[??LG6/RH=5P/K,F/
M!DYI>MN'N6!/JX:=&<+:"4>>[<N8E=QGXR=U/:P"\WP4LT<*[(-*T]FZ^,^W
MI>O8FY*U9M+/)B(4SHH@F=W].9K@O&J*MI<SZ8=QHWS(P2_E5)8=ICVNC29N
M:0V^5NYZJ=<%?<=4OE1;PF?4G_+@D(60;I7!R1=SOI95\MU:^2-92LXV*9S*
M%<CZ3$G_')VB1!&KIX!6PW@ -"/DHMXGL3T/R_96U)@/?(9?F4N]N4I.7'9K
M.@<R#T;Z#I4^M!BS5<6VESTLKF$9 >=9XYC>%*U"G5:;XF+__3Z5IGN?R:LO
M%07_IG[:65I2(P3$;>0!RD."B<P^@[$G! 7Y0,_+!L;5G8N*$0B/JP^5<RSR
M.(4#:GH+@-7AEHOL#\4K\::+X2VG=0]IE"QYC7ZX9BR^<.V\@KE(XZ8E2X8'
M*#G7)S4(,H*L)4+=('H%#75H8_/#GMJ'=N$_CN2K.<R'71+(-'5=*+V#G4G(
M2Z0%#)YF&<F\\NA]=/!#6!\MA^HH7CUJ955E.X4UWR6![BJFT G](*Z5E7S8
M!H/!9"0B9(J*LH/!"@H6:98;(:?E:Y+FZST%Q-]]F*HQ.U@'O8NQ6DE/X3<>
M=I?'QA,E8DEL'[S!2NS06RR_5=[( 3X89$A-]^;Y2\U7;0$&6+Y(D:J?9""H
MJ?/D[S%(*O!Y^B80HF!$.)?)6"';3NJJ>1!'"VLP05VCIQIQ',S\]1?'NJ$E
M1]4#"I9U!D;XYO>UB"5[?)R33C?.LK]6(:;Q^:5IEJ&'05G=;(+B+?\GOQF2
M!S"_C >5D,3>D(&K,!.MUZK\4VL)ONO5I>/N=-2@9Y0VWBJ /\Z13],8VGTG
M<BQ:"%>YH,9.#PL6A./L3R@)V_9B:G%34:XS!H].-S^-W=^!1J'9]8@AGY%<
M7ZYMDSVZ5Q"(O5@=7_B?_[_Z/S5"OFR<F@7EW\9_ Z<.+IZ(ZQ"=2^E5FOWH
MSR=LM_]M6Z9P[^!EQ9-HI%H"]")2Y-'QJJ;'?LU+KBW6G*CQ-D^!];NZ\RRY
M5^&"/1V*RH)]T$]:G)E^90J1."@&CR93LW';A\52A (^.8CIC]M8GD8WE@RE
M?A#3;YV>+6])/@6J"-M5_[ [>?!K>MF>(46)O(U=Q9ZJM>Y^!25^B]%V-QNU
MZQ07(GI%UD7KZ8DP9:UZ8N%!2>TP#F% S-[>NWL@R;R>4?OIQ@4O"ZF1E-[/
M!XFC@PYZH0VS^\*,*@3MCX0Z;U;<YK"<?(-V5=^S)CFMZ2:6*#/5(COV%:RL
M2X]N^)R-7:AS%>4!U%+@<'AC?O// H?N)"JY![9U;.]PFM'Q@H'ES-+-RJK1
MGBL0R84340<P4ZKOBTDU.LF+VK7VMIBM$)EA5E)G+J&:.F.?;7*BO:',,KUF
MD%..T^MV*-FVLVZQ-8.L;MN IW(1:!89FA(RPY(14@*=A2C8LERZ!RGSC/AZ
ME8G/C!+"3KC4^J2><+NIR6SB CTY!C+?4BX[KODQW1J8G^[UXP*V<N1"C<6O
M#\C"_4LUG5[^D..K!TT/3D0FL/2W[VNV*@"1?K8C8IGE21M TR4>KX1(7W:4
MU,)=)8LYR&T0Y'H0EX#![A:,5_&YZC(59B]Q5 &P?3$HP$+EXH%(-[Z3_+VG
M%LW'3U&<0F_Y;9O^R.S6LQ!*KM.Y_SG#,/*S91S8QZ3H8C]9J<NE2[PH'70N
M(YI,WD#(9).!OI:<J<80J4 A8=+X2GIGCE.3ZDZ7DZNU0Y)WU.1;!QN\>@K]
MF&J"WU//&P7=8Z ,)/;-OS?V-+,\57"WRNC-15DO >MVY).=WV,23<C*U"2*
M4I^TMI!6(U>L,?Q-O-:W@8EK/[1;7F=Y-L7IC>L$#)SWQ& 8A,$[J3;);TG]
M4*.J,OKAX?6$X-M8]Y'"L9#I! /5\YQ1ML.0YVZ=XN%#'[Y$'RYR@N]OT^W1
M;690B*AS5 5Y6PZG"%4>[&P>HK:*S-:YXDH45Z+;#\B6[/"\AOZUU-R!FO"X
M5.'%F(_UW-K4:IG$*W/0X3#+ J:]&<?MW=&N16\<O?J6RV.<VH56=VOZB\47
M&EO4!]AHY4'37Z-0Z.Q@N-56<#;;&U@@!*7U2DS+%ZE"5-[9YBJ'G LL?$1G
M.$7,$)-,K#$/Y^O?+MO82CT^\7"^Q-;+4+T4,]M6)2;]5KZG"Q:\P^5QH]7)
MI+[%=$9T<L9<K@=%L$];<' %G!T"0V2IG?J>!?50:'=,&U7YE*"E[?#0P[KI
MNELOV),: O]2)'O&RRW04_..EUS5R(L&?)AXY"G"342:]]T6TV-=TA*:'_53
MTX[)PTV)V?";WAO2T!2CV5[U[G^NJ_S_<BB+9 =93%^*P()I8>Z?RL8;'7VC
M#F10&SH]CF.<C0HK'+U-%?H<C53J9T\GGR&>DWYA^XTH5]6-8SL%$[M!1F1-
MYMYUZ*9LB,RRRYW-LAE1"AE5Z,UZRE'B 8XV":U7O]VZEB\G^M*) ^K<JW 1
M'B!V(H9C-8@H"2)H;+C,97]/^KK["?G$#LE&P^6%M/--U"F7I+?GJD_43K[Z
M[@MK+CY"5H=O[%)OML!V ANOD4QZZ4O4TG^<2X._ NU'M'OI;LK-XP<;?RME
MU0>ZA8H$3=?F(83]'>8GE/K@5BP7X!M(*W#9IA\4=QG-]!*A@.2XRLC/,E/(
M];+OJ/8<"U9M_,_:4)F$>:$E L=\!3+=5\*U^?"SOI;1M\$R?['R =<$M%L"
MPH2DGZF<U#E_[HV%!4EDU$1OUW7=Z)IM4QE?6OF4?*6T--//[@R7IV\(WB,9
M%6F@C!B=0O'0>!?>R/\"4$L#!!0    ( -,V=E83:]-BT+@! )/\ 0 1
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M";V9LNO28JG&8*D=SXRV(YK&)D$HT0!$'QY=NJ4_./KTH3G3DP/F]IC071#
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M+V+7O1L]/<16H!N"N;_SR_F9UG;,@6BZ.P3GW)JSR[Z-H[D&TF. !7>]WJ'
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M%#B>@?9)JH5IG=C?0 *+HQ5-.;"?4JB)=MG%FA'$&([(B)XU193M>O&26]H
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MR$$TAB@-H&&A+33;6C7.M+4(T_A$\<H^).OV/J>T"(J@[0D ][>PI8X=5'1
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MI@R\Y:K& 7;F:*MF@BWZL50Z+"KX>NHQVS)EO'3*)EU [P9[C$V;:W%$Y 9
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MBC& X^&48MF^0?=& 2 JLDW9H#A#AX">K]L."NF\M]TV4QZ#I_LQ;'/(&-8
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M[/%(3E'9 7+*07G.C"NAAA-[YX0^S@40+D---G58*IR%^UFF=ZBGK+>-S10
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M0O[?AS[_O>J;F[]ZYI]/_0]<_=9W/OX/;[GXHL=2UU,/OVDU?-_@:O.G;_R
M"17_^D4?^,^_=<.KYLVO^;?1U_S+OQM<_F]__#.;K^N_\<Q >NHC+MU<<NUC
M_W;\N3OQ.RZ?OOW##[[RJB><>*_^D=][OO@[__FK=X[?\<F_4-[\TCLGM__"
M[S_ZZ:_ZH5=LW_:&WW_XZV]X_(G-QVY[\A\^_/IK_O;K;WL2]0SRW;??=NS-
M_^]_^YEW/O03FUL^A"O_]<HG?ND$Y#ZO!G_NW_Q$^8*G_.AO_[ON,W_\5Y[\
MK*M?VGGL3?5+OQD<H[,/TL<_>[GQD ^^ZX\GS"/>;KTS#/[LCZ\]]M'?_JM/
M_> +_NYT^*1?^_E7O!I\Z\=^Y<8O8LP[O_CR9SSP'7>0JP==??L?W?#*2Z$_
M6K_WH<_O?_'.1[[C\9/7/?>63]PR_1=???ES+WW&#S^&?\NKC[[\8[??\;87
MAM1?6RIZ\FL?-JF7?OZ'_^7C?O7]?W+K3YVNGW[;@]K$\_4O_[L'O59YU7^[
M]/4T?>7%1^ K'_VBM_Z/%S[9?QS_NY]__:?OP-YXW5]V?JG[%P]XTL6/?M;@
M2]]\Y$\^\7=?]D/S1W[F@[]^XT4O_(4??]>O_.AUV=7'3EW^AI?<^=K/_\A+
MWOBP+[W>_)WJ59^_$;[AUB?\B"]\_-^^[:E_^YP7__&;5G_P*X^:7O9"[<&+
M%W!(/7S85W[CMA^1_JS_C9M>HE[YLN-OV#WI^M[7WOJG/_'JX[<]Q;[IRA>^
M;?DAYDGQFQ]G?% ]\@-OS/[HM5?-/O6Z3[_]13CWR5,??<8?O?,GMS^\>NOS
MGG'3+>__S9O_-GB3_IB_/'+U>U_\I)<I@^'_Q\Y;!L7A!(&>A #!W=T)&G8W
MN"3!/;CK HO+XI[@[KI!$MP66]C%27!;(,&=X,$M$#2Y_UU=O7KUZJ[J[NO5
MS:>IFNF>JJFN[E]WUTR7/AM;+BG_*KLF;?1KM(#24XV&V0>_#?[A,*"?2>+P
M*5%INS.-5?/S&\A)]:5FS:1B((;7!0QG5.'K!/BS=*;D7T^-O+7,9$*OBZ^<
M^H:V/"C_H9DV&0JG[#\WH]V7<U*.31!:1X@9;1Y=PKK:BKG=.^WV<&GTR4O\
M,<.[UF='QFOIBPMJKTQOHO4LECD%M!BKCK]DOCA.Y&=%=K;0EMGCM$3XD'OC
M<V#R"8RJDJ=Q"=)" \96<ZI+:3XVPV0*8X=VQ7+(_UK&*:8 :5WX_9AAIFAB
MXVEJ)]-$$*&-\0BI6MK/^/2D7#=)?SA$3% #_\^\-W_L8G L0V3/:-U<TI0^
M&-3:EX/;.![,M^.4K:7_I38)1_Z8*YI4+S="K/;3IS7,*N[V4M=KD^X)A',^
M;_!CT/67+YI*09FJG[G:]@DGH"-L-3FJY0.#'2IF".4N9EWCUV,5,/2C7V?P
M_B_1A]/_@G7VYIKT-=]M9JLJM?>UEPD75J'I89Q;XN\YB_UD7%+/13R^W=V%
M2X3^9Q*_=4WQY5F_%'G&,\J&D_&;9C9U-G#%<GO\0-N X++KF/-V@^B$_:Z6
MRG=?$X(6\A7/0T"%+RH=U=[.EYOH!D'IC./6#,$[\I 0TF\FSK+];T1'=B"X
M(O1]Y-Z4WY$PX'JJK("JZ ^AQF,G[V+I=BGHGK_(LY76BRPA<PV]T-4]T6Y:
MESI?9O::@]Z,N$,3DQW7-0P*G<:7QA'4@AJT<:CZ%TX[XSZVB#L^2E>JP]NG
M[NSF],OT]V4@?[,@0V*JM9K=K</MB9A608U10S8N9 U[GN 3=":7#%3IE+.!
M'[_G"X_#AO]1<H@A>-]XA"]2L@(@EGM'10F0^UR88N6 P_TS\&/O6V9C9AI<
M$\!TX#U#O^=V4;D[+P.P9BG-+<AXRR!? A\&+^0CR+.K(+/BJQHPZEM2,#;(
M%W06.%\H[YW9%15:&#-T\6LL5/&%$U XL&73&-0F=;9>T!%F6F>3Y%-[3A;L
M%CR941C,.7.).BO4(*- +Z0JBNNV:L0L?-V"NK6:2!9?D/"=4&GMY5!2.@Y=
MC^N6$^ONT+QI/$# FL<8Z"GP\.@%HR(#TT@9JPEW:@?,:/]L#.W^(NI*5@;7
MS"4Y?7LL!_\H=.W%D/K88$26_KR,6+1@"511_;'9#J.)8=--HSS$W>A%)I]Q
MY^B$6;N$_6A(MN&G!0\< 3!$:PZ]+AB9!G[VCNJ9O[F,+Q\@7/O&KT&F>G*@
MWH0'*\=4Q2;&REJ@W6M:!M%$7TC]NI+KV\?< G.Q[7&PYT;<<PYR>>  -0=5
M&(J3D-N]/JA62,\@>X& N/Z%O8LY2KM/)P]_>8DV!B^<=]T@*X_\V$AU6*M4
ML+>UWJTSH31TCLX^VV69M6H(2"ZJ+V0LG)?5._JR]\M.X!QS,_4\XGK*LC3,
M7:1DKN#[T[>-;M]L)LF;,Q'?H;5K3AU79Y\3(5.OKKI9SM>Y&<5"L@V$7R6_
M<DKPA%2K[?%VV=-M_5&.73'R#]<RHVUKY_AF=_![;E0HX"?$%0,MK22[:]C7
MIPS+,W\?ZO\@-7"RV[1(%CW^N@KO'8@LN&:/MVF*B\PDFL(X)>QD%F:P.Z"
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M%YNKU3@@7K99NYS*<HDW+RZ>).#8)"A3=_U&FDQG4K,JTJ=,![C;CBFP?_Y
MM@Q10-F.^<9TG6VJFT'7K+(E^O2V/S,Z^TVR@I:.+9D:),='3"D9YMN<JNQ4
MRJ+MWG*:DY"1VS).@2373E>W1==7T YZQH*M#-IPH6935;-4.(;",FO?LYTM
M-07\@!1VB2);=0*4* 91O/X"0PK, /-O;USHF" JUI77OH'LE1%M<XP+SF91
M[=S8LU<? ?OT-&QP:GHMTFG!&@U>*)3I)+F FF^>_:^MAYV'*:$ZGY)6C&X$
M[XIF<'W"W.F\O=E"NG/7LHBA)TUSNZ!7Q;-:!^-#9W?I.>D]*>SVBX!#AT\&
MTP-VC7?\- >R\S(4[O.RR_6V%S>\2PG6*P:+LM.)^/)#F@+FSW9D[RP467TK
M'#NQ+H%\2(E6HYB:6D^FUX/N%!,*)C7C"D<71HX$L$L;.<\U-^S!(3]7196L
M%0\4TO0O9+]WUO ^0=NR!^[8\<IVM>8//>=(G4^Z6[K25!:AXWR[R#JXXBW6
M"%KQUT:^4]R(*')!)N_8Q6O0$KJD(#F'35KOILU F2N!7^1-6=*J)+!@(N$U
MA)N'/C\*+9C;]YT0LU7-MJ8CW@)*_RK.+U\G8DSE>#9(*]2''0,?YW[K*9HD
M[^R60?C"I6:\KNT'E>B6]WBNJ*5[O15''$;5GFV!LSULU);?0#B?I,&\_,:]
MCM<WH[[/0K3%75DCGIO3P?#7V=-7[Q>)DX!<E]J7'YT/4_@%W1<9#1J<1Q2#
MLNC_E'Q9TNZXU]5WJ,&UX@#4A<TL=11ZV!R.J$O20Q!+0457(:0!;YOGY2O5
M(L7J:1L4:K_5?TG:2J]XUK*(3QI.B'7):PWAL5\4'DKOA_GX63SD)6V#Z[+W
M&I>.(4*#9B2U6G7ZIG5Y_*X=*U[9K O.V0J\<%39J-18N MCD3""X1\&D[Q$
M:Z;H8>NSHI5 UPF7[-K5;J^UA)QS&]6 W].Q'7TK[]G\^J<[W$,PV=94#?RO
M5:+%3LLI3.O,UI!5R7[K0)N:W_>+!#)(O<B4@9!,OAV^1CTL5F+*:NBRX.LL
ME?1H%6^R. EZ.?UE7]SE]OVU]I0$X?PLQH[Y.:\U/M):XJ-+':)N2(?I?A^Z
MMEK IDNYCMT6 .ILZKI9<Z8$VJ?G3H\NV'<(E:JS9>0:*+SX##9(K78:50RT
M)LKI=L;?TR;F^LS!.-KYU4@N7Y_E2@UWM".&PK;^$>/=T>M JN:I5DJNC)#E
M7XBT<","56]"$NF@M[WD:_(3S0#GE+\,J&YD/KA!:M&>+1EQ[_=4/VBJ1,,7
M5?C)V:*U.*>>E:-NSCD2+F!GETMJ,Q>XTNQ1WK;S6$P",:QSF>U.0(X?28H1
M&ND^Y"MU1^N5VD=CY.<2=T,H*0D@;^\_<'L0F6!N)U#6V@HN_@5AMAP*"VP7
MLYN,-0ZD^X*IAY0D])@<.0>J$EG,BMP!HSUW1&1?)-MUIC>#7<17?78QPS7?
M0-Q&8*$V")\T)9*N&JQ?/8>\7 @&J$$*XA&EVF+CP*%TNM954&:SE/&L^T3U
MB\[QS5C))34&G17S<=I"@3.0!$=([]U\WTK(7-^T[K>([+N2!>7_B2^<H_]\
MZ/2MKYW+H!5B76QE^D208E KU""D@$>$;AL2](L"MG1\1UG*Q]&_(8#H',#;
MF:*;B0%XWW=?$4F+=/9X:";*NLET:Z;3N"=YC@ND$"PZCBK$2\> S9<B\&M?
M@B)LJC5B0TPOP+&Q 6?VM3OK:S33BJE?]&8[$HOD@!*X=!'T/W6$HRX%VKZS
MXE$]_]208]:]M8(05*I?R!P00.43#DX*6.>OPV&O^&G52*,J<2&O52:XVKY_
M&72+TV9_C1:'+B:-:W*LTJ[:$\K0+Z[:ZT^7ZGBV&*G\_DCH#X/!,D3I-/+I
M^[A%HC1LTM,I_P;:7]X)G"JMF[V"+ER*F0DUV^_.0O26V=G9L5V,!P15C2,R
MFJBJGH$YF H.F#O%##_/K365Q^L)HHQ44[O0+1NB,F%Y]'=._2E ]8:@4Q@7
MB!BR;PZF'')@$EI5V$D7U_OJE9S!Q1?M+W2:/[:^R#12D(TO%[--HTP3VYK>
MG% ^0.X/L>)LM_#(=*>@5JNU-)&5,VXH^AER&+9LQ@H]/7^ GAAM(8Q&#\9;
M.?(FIP?GT':L<2R(QKP*>;=)PSC>DB._8NBKQHKAG!C#^,DEL7*]!LF]U3=6
M)Y)#DW%/U^WW>F9F+_)!T#)]MXF<V&Y?YA-"+>D M%Y9Z?,7.U(\GW4ZA6]O
M>D<@ZK)/!-1%"]V=7K^9<GK7^A  W;I1V)?EN8L[_ML[>=&>#V[&JK"BM]SF
MOQH-E/AUG;1]TFBRT"L/7QD0GH&<F_Y4A/?C0*'E/($,-],Q,!0FWMB]@6JU
M-X)3BJ,4V)C1-"3+9^6!G&^%0^9\:UM%#TZ^N0+82_A]PT6<=_BB98O?L[#:
M0^I,PX6@.$J$J:).P%?VTURX:;#7,-ZK<O6\PX+T&!VF&(@YSD9MZY&)FH!Y
MQ\,"7=J('9#XQ5HWM%8W_DRDCI<YJYC/=#K[)753''$U\"6#UZE+?M&:\E*=
M/(L9DZ(Q&@*BCFR09WHGX!W3[>GB*MWQV>;4Q55FTI9>CV<&XSEZ-O3#:O!B
M2;1S85C8,LI"'J0RD!+W$;LN0"TS8AXHI( #,)'K5A 1CGS5E>0@\/H4NCD>
M^+30ZM<1\GAJ6H[+EF%J[#7N'K<GH?BZ7U!2(H4SIX3L<P?;W!H2\4?IO.GX
MP9_ GXM=FRAH@:#<O#(^KCGPLL9W/_XPW"5J3/:G6K#S8D-5$(6.PW#S6E5-
M@A3+/XS@>5,UK.1$#_L-I/PH@X(O?EV&!^TDH^.76)M=DPMWKQ\YLW]>_.>M
M??;_83QD-S7(5G_HG' WC.%@EC\@UG02#QW(^A.O&.[ 7/O?*>GC_3*%J."S
M?QAD@+F3V <TSHSJ/A!L^5MV%6NAY&(+K#0(UI\*<!W6R*4*SO_RFV09^0_#
MP/W!TI;EXT2BKVO[,P22Y^"HV[BJ+(W.T5O\*DA+.>:K$/3ZOZ1[=V2EB'<W
MS,\L9-M376A7SVTS9D#YS7GR:E3%]!X[1"+2SIOEPD_0K'#FYSS#WF:7U/BI
MZ OKSH[F84.(;:N)]I#\ 8(@)4B%1OK](].PN:__$"Y\M\-(6S+<W)9%:8VM
MQLB&+VO[(%6[-N:%X+7M/PR*IKGMZT>6!MGMOKVO/>H#+*3N+/"$YB8="MF_
M9%1KSRG.*5*'&^(OX@UZW/G[7Q%6186.2KE/K)"QW,$URU2GIM])7O,O4P3X
M#P([GF;CX0XGB:]4E*#1//W]O&,ZUFZ!6A]8-F__85!#4PREN8=(/-?R[^R9
M8QBR?I:$ 4"ZMD7!]R[;QPNY1>BE,/J6-X^B;JQIC^:*/XK>"'6%/4Z86%\H
M]1^\,!T'[D_+(<_[)6M<\J;.$*L7Y.I=XS4/GJ?28WT]7\TOO]K"=[5N4\G_
M9'NEMB4UU^X;OL'--J;?DF>YO$F1<KK16VD-ACQR+>8HA9UZ(D_<YK.";WUM
M$6"]?QAB@?\P2 3(;GQ=&Y;+%_P;3-%O_F'XOI0P#G:/Q5:[&#*0*(F_6S=S
MVQ<?(\.NR&G9M+3GD36'%+U/;/,HH!'MN:QG+K8A_+9K1G: S_EA,Y']-\R)
M4@$-9?26A+_Y]OC;!Y5SMNB7>FIBV-?*30>216PVL? +*P7\U&4#,5Y)7]2S
M6<::PDNYC>_7FJ^'[8_.E]#5I+SVIL^:8A6&%^8!]<= >@X\M;[TF!+ES^*1
M1Y/:JP+[XWMMJ92.,T$'9XS<MA SF[?/O5[R!\0"/VPVY%9AY0Q K_*<=>6D
M,MDEMN8^OT"(?5]9H?"T_G/"1=@XDXAXW1QG#KVJLQ%JM*S.RSLPEIB4V,,V
MOZ!0G7S6J)\T_L*6&-P2HO<W:Y,[%DUL[I,5P$\T%BE2=<7>];G7D/Q(Q5(V
M87@EZ5*USKG\?A-2F/#'63K0(F'"(N$4[P1(I$._"%KG5JB064X0G.E,:EG.
M/5PN]FOZW8$L0R&SA(//!UK>U;X\ 6 !9#/I&Y<;$ XN% JQ7\4-?\@[Y0SG
MQHB:]1V#%/O "VFV<;ETXG1FBCYTB>F91Q6Y4HR*,>K))*_X-X\5W%]Q%"XA
M/7AO -H))B:\;GX2X'OG8.(D4R^7=D,]M;6:Q<-K#@[+IL4J,J%Z9BC09,5M
M[8\'\_*<MYX#6PP9Y9(NK>^9:$<DQ[%CZ*?3:ELVI4)X>6UF8C/4MQZ&+] \
M@MVW*9-H2^;1O>)Z?7_,EP:*C4LG,V->$50D%E6(KF'D;*6J8"O? >SHP]\E
M$^/8\Q[W1N)SF\1-J<=6VK(D%JNM#5DA#6OTP-MV<<?BF&Q),!L&3KN[CU>:
MR;_"KTR'?(7;-7;OVZ6'U-G4$IJ0@JO!1]IO/];7$.[I5U'%\>$_CW?(0O*@
M,R_URW_#?29=?6OFF@X_N*-8#(2<^*T"9WR\R8T'YR.%U%:HO8 A=34^V [$
MK)HI'"P/X7ZFA@91[&PX%22ZVPZ1&_G/R7J:IA-MJ1"^WWHTQ^#L5L;[L&A1
M*?6#QJ_K"^PI$CF<.8N1LZF;P_&!7XD139#T["[%'"Q[3[3=8+!+:KZ0QA3
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MP#EN*$'JC<HWCR;-YNJT\-?\+2J-M0->2[/>CB82]]6*CT5&LHGKU/QV.Y-
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M51VG7;4VB&RP _Y)D4[47L5V=7LLH@N,".,@BB>TR*/'^8=AIZ3[P#>+XG%
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M:Y0H7O\T4230W!O1Q@C/]#3F02"^J^R9U]?RNWEF&@L4X13SVJD<_6HEQA8
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MO><8\F";#N7[</J P@V-#SXF %LBQ;O^EH=>'61C+''*BFYZ83I#P[8T:?P
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M-LWMMK$XV:.">G?-O@4_!;(66!)!?L4(*5UE>*^[[J\<<:/XSQ8+>(&0U2B
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M PQ<2B3N5W*PGL![B!"+, D)B:#@P.FNV=J%P4R_QLQW3Y.F9'!NTU=3<HC
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M3S:0#6!7B!8:QCHJXZ>4E&)B0W#>2[NF:\WFT*"YX67U"% J[]Q(\D2>KI*
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MZU+H'P^@R[8OCF'?1AMB1*A3S/%-,#!1?:+UC0(DMWG$*S!R='@PO%[2)Q@
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M;._+.754;TP<GZ-N"_TX^MJNQ-\P=G(&XGB4G>*N9K"+CN2@2-W;&'$;Q$\
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MEALHKJ-89W-UPW518RU>ZC%QJ#DE^_7J/@K92I$);UAR)IO?:!EWS4^'2Y%
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MO2@S>H-]G1U"KHYS)L$ &9\M?=@X/:5A0:MSI/^&L-$G#<JO-A9SE>Q>U,,
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MS<G)R69*DB0R6L*XB.J%%ZQ? 1AIJR0\%4?O83V,])7-(ATOKN4X>_S1=&S
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MQ=0)[-6I4;O &RS@_"_H 2S(ZX]!&X63C.H EO>D9'!E6*9L8XZ(/QV*6\C
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MQQC=_IZRYTNVI(XQBMW+*E2"]3,HV%O_NYMXYYC/?TG(=X_Q[V$Z*YZ12'Y
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M+ZK\D Q%=UM@DY_D(PVZ-X.9V Z)"MM KY0 UZ9>0F(/>YK.H065_?(!NOF
MIJVA]Y 8Y\O]K;M#*SHDY'5X5A7LMXU[) Z^#IXMO:GPW&\W#,L#Y&F/Q93A
MP'S3F(DQ;%5S)&<'/!L4Q*9\:LM]]*F@YRVO[;;DY\7(-]RY39,^5GOZ%"?
MQ7ZV_&RKYL)'_(#(AA&=?2$=3X/U6\VP95:2.ATF!2*T@CV?$U!X:\*)(9\U
MUJ;:)S0HJ$D%S]IOT-+_4/TGL2&D;O.&TD6Q4=T%SA'X1@.%7B]B*(YR!84/
M;90 [WVV;E,%77$RL8ZPG[C0!J:\7QE"E\SWW<I- >HY?D!B88X0L7YVBZ\+
MRR<1UKIX74%(+4*9QD_;5RW<:#%$?QV]M9T3"CGN]>GM#S(JN/QA_P<HLG9G
M<A73.Y[:@A;<8&_&"E'_56]TZ=S#R>&*/K6"0<GE03L/H>R/"CAU9FQ>AG#O
MP9>0#OR0#<,#%1",+_XKN77S\77OPPF#;S'PWKL9VDV&"V'!_,A31=: RH&4
M_?Q--O$M1&ZM KG]5C<G(B3Y@HL);?"0PKCAO3UW0V!.BF19C@ QM#N36#H5
MJ9?+NIW?5HC4WKFXB^V'%0_$Y5=7H4B>,:?:.O1%?^J0]X#D8:PF8VPK&/W2
M.,OC;1EMAL#+RSQ2K!-6E$_O".?P[$/,*Z!NWV5%3S%3QHRQ=!HV[#CQ0<"0
MCI[D,+-IH?N-]L_Q@FE9<'.2VE#,QF$I&\2?,M;-5,WX[M!:2'YGV'Z&<QVA
ME^1<^Y0NQ)8CRDJQYJG.2 OB'&7ON<O%?V 4Z!WX*U&G1ZXBX#6M%3A5"O4V
M"0V0W=<_Z=3?O/=B-L:LWS35D1YQL__34DXF.44;[I['4!^UM:CG<%P(;:0,
M6"%BR(?GI)0/_%CA(Z;/AIFF\DJ>&A53T8Q*(FC/^*.X>=7 ()[?"2EPVV^*
M5E6T$DXF9!?MQ$*""'O&)X,M\D+&,6\#8H*4"6AK<[NN@U&Q'T^#"@>JX\>/
M@4.5WV1=R:?."<A.P3GK?R;LFUM=;( 4GT.BH"Y2+%_ELNR:SU#7->1,6RAJ
M'=SDPGW#HX]Y<+4F(7WG+@[^2R.K?HDCBVJ>\)N^7#GD-3!:0R\8Z<EN@C)(
M31_D"QK2\A_+FKQ+!W.N...3EUH667<Y5@PU<Q5U[I;8^D&IL11(OQ9&)DPT
M,CF6):U33#4Z)/@-7". -Y^1T"[R?.2KI-_K$9EO^G"JA>I1?^!FZ&G-?XHQ
M\1PFF-PUB:N28I:C_;&0J!.4R;."@ KH."*,<ED"\7N3A'V7C2N=!S^2:PD(
MGE;K-V+A4B2\I*?B$A7QB"D:OS^MHW9&%U95+JT#DE$.6G8;_2 =*%/Q5:Q%
M(YY']<0B"9\/2)*6C2A9#R3/&U.IVCH0-*ZTXG<]<-Y)??M0T_PF^%TV;$_^
M+P2$,!S:;KK@#\SDR(?KQ<T#SS;T,#OZ>K37I+MR3_KI#'#\/6-VP<#KKO/'
M6*S,*:+W52<G5I,V=0;AK>BIS#;?K^MM>J&S>R 3JO9:>#+<<P@H%N/Q$%\+
M[IDE!_M;+: :R/&PRZFXZ-6>5Z4&D?(/?@@F\L-1316V/<D<S4<V=>H)<>68
M?<JA.O3:.#0O$ M4&S7H3:US)_?&2PMM+T"8_S3O<G%LYH7ML]NXVJJIZYUG
M0^P;=GJ45Q?/C<;%_.)VTA I1UZ>T.95%=V+-N^ \:NZ-ZS[0L1B5-!OB]9$
M%CP6;";$V T(IT3-6?>H/OA2''[1%OL1+FNO\PDX54>A>8'/J5'' 4[IHTH\
M6WHQ[X#2!1MQS2@_N)4CB#&LER(]K^+C)!0\U[MS]U4T?22R#AT7.RP) /T.
MC=F2,ZIO8=\E$K)O'7HNR:.6[F5OB FM65*Q8=)U2+BBN,6TY4A@L0T1ZVU'
MON'U(FQV^V%%K>$AMF*]:8WCW/,3SGKSP7[ 8=H$-4$3SDK7:1SSO>F3(5N,
M7^;^OA]99),KW^BDJ&W60Q$E#Y.YZ6JX_)0=EWW.!]0#<!H1G&: /EO?FEW)
MFQLZAU='+"ZZ08JI5IO+MHM4W>:55Y"@?+*LW-CJ&6-!H:9&YGO,.=,:153G
M V?@"4A.M"!@9T_H8P$6_0<W:X*W[RN#E[$*>HZ@!W78(]4N0AA9J)+/CT+K
M!FLF-.K9</>0_1_$2Q>T'?-PB:*%P&C=97+1N="5K,^[0L,F;NOVJ,&";[:%
MMB,09*C3XLB,U<IY5N_JWE2HJ[88Y4F 6G7BN3HJK8QN_?1W+MT//=J: T+*
MV$]=UL.^UJ>V+-Q@ZM7+FU  ]>PX? _!R^B53A>;K 9K([3"B[/;CR[C,,O6
M>\P1;QS[JG^P,]=,YU+HQKT&GXY S#BRA5,]L*8S]1.4[!7 0[OTW)3@4-3)
MB=!E7]NVE??$7 ;?M)KL:7'+N1@0?&N@@5H>RFOO/A E%VK4TD>+TQL2U>AP
M90>[L4Z^Q_=JC)ZPUCS6U]F%?LZQP;9A<*>6[UM"69/;"#4QA),8$+2HGO1&
MCUID_79M;C?L,4.$; FM@/W#N3WLI(:3[)Z(?>V05)C2.WM('OQX[E6R+GSY
M1M'O*J\T9_9Y^L)XR^8_J4WN7U@PH3HOG3^KO?ET[3+6;Q[X?[9VZYQ%PF/V
M$1S)M+Z^RDKZM#TYB2M';+O9F@$F@>8>NHBHQSHO75C^H;S<;<M%X>>-.,G/
M)MXL7_NS]*5<SC0PA/3G-D@)==KS1R:XK6#%;GS\%-T=A1@-?69$L31F[SM>
M 9!:5LBX8!+T8P4U]DW.\4;G^'"[9W);[5EXMV?K;YLZEG+:G\W ] ,9.U[Y
MBG?YMK^#EC+#\Y. T84K W.0RN^_D!6UE6;JV@!M5;%\9B6M.IMT1+=4GGG-
MFAE#:))/8S@/6%4J?X,'K.NF9@8P;++4HG<;,C41+H6RSCV[=%J55BT'Z81Q
M*(%GGN287=8D=HM(HCGL*7)<F'IEUB:?IJH$-CR^UX\%,WS3UJ;%.Q*HD+>;
MQ[63T"0 ^;D;W$;10BV;Z%!XA\U/U.-,:Q*O30"S7F#<R:/B,-5+F1Q)3&%
M_*ALN6<,NYO1+0LBE;9'YO"YF\T+?,O&[F*(;L2T3W5EQ_+(O%K1C47+!XQ6
MSH(L>7Y:01FW90 2"9T&;?(Y'?U<2NMH. <%=MQVDK*63 NR1*[RRL-J]2$-
MW<I8.R ##1D:U3RL@,&3;2L[N7ANH,6V#>Z;1$R#MQLG7L^6]XH9LYL7LLW"
M;1U*C".X>%A#54H"/?!9H] 5ODO"WO1N3.*A^9@WSFI-6;\=6VO[B;8Z\\Q
M>4S#6="NH\B0](RA2O7L2,<S;20!O4AB_4(ZUE[-A\P!4\JODS,Z5B?6!CPH
MJQD,/Y57Y\ (,XXV@:8+.79MU.G&04[)\H^SY.&9Y;;9:0"UYF^G0KA?JWKC
M;+!2TTY,O\:!>TXN!C8'U86+V/LVIG9_':WS"]8B6.-7ZM+4L@JG:]W1:9'Z
MK *=6LJ8LW^\)[R:O,H:8=1 S1D&3;<XVUD&@0KAFSI+;J+C'2QQ;Y5R/]<C
M:="\P=>9YQN:[EACTEQ[Q((Z%ZQ0V4M]W+AB'[-[R-!$AI B)'T0[13C&3&6
M<B8-O+'Z2:KT3XI8=MK5O-%/P"34T]7B\E@P.U_+:"$Q1F9"VS*WOFM1+@]R
MY9CB)U49"A7-IQM,C9&M@8V-SH* -M]TB70NGVL*@UJ"1:M#G1GDIJ,J1AMP
M!0:5Z@@C[%'=KS)HKI/-."@)&B8/[U67[*.8=.!&Z+M*%O$;THUXBOP;1QDB
M06ZG05<G7L75F<]FD=3 V>0"^(6?AF;5H:0ZB,-:*6TG/90'9Q5:K</+;&8'
M+.R\"7[2#E3'E?B.OP*8):9TV+I9@9-6/ZUO[$B&4)!\.7G?'4R=OW\%W'K(
M*;/'IUA=;5),>C9 [D5.4);&U.KQNDUJ%WZB342#H=S9Z7$#7CT-@;^TH@<U
M<JGU D:SME-X;O;/]_,"R4$C^W]M7370OJM/+6N(>]2"A%H";T-^%#OL-?^=
ML#U?J9UC<& (JD215>#C[+A>MG#_,F/K?/NHZ6H3?Y.B)_OYW_>"<O,YWTG9
M2B5M<E6:&2/B:<)2E //7/M)A2>>I.]W9P)%-AQWUES_U LS6Y"?X_+\_+FR
M)OGR]NP-=RM1M_O?$?;\/"J1W2D+*%:E'D>_< V(FK1S.NS;&+#F=HXKD;52
M9/N%!W.KG'H%L-_%[0S(VQS"&Z95"J+^ RV++1B30$FQCW5:/XK:1R9/A)=:
M:()NL-PX.62,5"-U90=&_YUUYF_3=D)8B?!OO=:C]9#/YV),E MUY,'8&7>4
M%-YO=RZOA#\'I-YW/_,)/KP"+/_U#["KWKC W9).(TJ-,&.TY&3O[O#?IQ/\
MC4@1^5N+.F:@.5WDU%CCEAMM\MN'*/']M G1_"A25C].F:F$F(X:4%*2BF0\
MW=1?^.'NZ+U!;(IXB+C>GEH>BEM0T=/173@<CQJOMN<B\:0P\AI^]6X@H<5/
M,'1+$O@%$T_?8<> LMV8Y]XZ/E2G8;(3W?G+?++ ]U,.%ZV-H,._M8WE"_J%
M32X,)WZ*6#T=,Y+,DT)6XY-.''<-_%#MOXWXRCS9"AGK&@RLX^*\\_.Z?UVO
MI 66E6/F?5T&(S_'0PPX>(<,6;(<%]8IP@5!?I,=\OEU=4$C#>+SEUM?8Z:P
MWOWA'[4Z4\3@KRYJ,:[7H&Z\?@50Y_X*=O9L]+V^:1/TJ=RWSNNH+Q8LU6M>
M,:EQB=C-O5B4;]1G7+0P(@$9"\RB%V?KM8]-EQ,B.2 /0M]XK'W>E:#,FQ+Y
M.T.]?I[_5[+G6?2'5I<GZ ]!76-LL5\1;WU8L0N.>9,A70'Q9EGATE=*)4?$
M:B9J[8B^6:3R& G9&$7^L8T]24-"\Z>O_/5U!$<%WE*[#_<OFRY(0>25<EA1
MDIYJB?8><OK8/<CZ,,=XYB8)VW<&0+-/FLL>!]+H OCPJ[44^"H&IN($ R<]
M]DJIF$N;$9/@VJ_Y_!<I^E= 5"@UVG+5]BP'CD][9-<'O4&4B&TV<J*..%8R
MRU5!5@_S/I3&WIBD9>5QM!I7WTP#T6/6HO'3K\ZD+7%%]G)NLX9T4R(EPB\2
MKX CT15_(95K^PLV)SIW/K]4_ /!>OV?9N2<=:S-XE/:=<YE0QST'&7EMLF<
MNEV^/>$.>:7Y-M'3U&9=>CO+-Y0^<EULBB5,>0L$71+%R&Z?!': .B&QG^_1
MAON&1/6V\M\X5X0.#!HN7UM^B"C#4H\TS])/Q;$82@?PS/Z&D074'U:J4.)I
M&Y;,EYH'7\+/COI%\^"A'^;Y84G]&NE6M3TR#NCKR+81Y&!89MUJK(FK$*G6
M-RH7\Z=!N[>6T0V#;S5/TXROOG]2?.(%,78MT(S'S)?NWSUI4?:1;9_U6BS?
MUMFMC:CV+@& 8)-4O8VU/R(=Z8[D(:H?9>MPFWW(/ZH.\E2VFS">AD2M>3X4
M)3(S6PVLZX<8?L+=Y3\,#J4JF#4_EN TWLMG@/A'A$;1 E'71A9Y'$"$O7HH
M+HQG6//P3\\W"=?RTJ,=_2:FO*K/JIO0;>9RG3-BF_G!KQD\U5(&8=NIJ1-G
MJ6$=VD'OOT^1)2D?7_H-XB'/.$%3RC?C4=CDX]2?6[Z=;<8-?J,S>%<Q.C']
M#\-H?>2=845>"N^^#KA56\VM5DJ@^K\ @NWM/PI ]$7]ZUDN'?'@AVZ#D)>F
MWI4;.W(-!1HS&^-ESB6Z]G5DY?A$JH:I>LM_^((2*5A>58+KV'G\HC*)9GZJ
MFN49@^KVH;[@E2"<Y0FE9ZCNBI/7P%\6MXG5JPWLBA;:I:\.K$L8CE^A^DZC
MJY<G_JO9S'AG;8&/R&;,LYU'<GN]9'B@R:[Y_-.K+_"'QX<'^!SY=V-?#D8\
M$\ZEUNB4RDP*[ FO)&V2B8I_BVG$9BE#3Y'V/P5/W3\8I&S&&&7*O:DUJK/2
M0D(AAA07BU1+OFSU/)N79OYYH--.3VG3BM/_:!!5T*F+%KEA /RKU[DTCG[?
M4MTB2%JXJN(D/4W]-J@/09L&M3ML:9:''WZD;;?*QF)_W-="4W":N9$-4SQ]
MH3X V9C/L8E"(Q67=&LX,:M=NI+=DG7)$)TZFQ$FH-@8% HAAVD_V=7I$5)D
M/D[5O,>+ P[T,)7IGKVE*A <//C_-4G><)_Z)X-4>=4K(,8_]^05H-3X"C"3
MVL)N/GT%R$)> 6Y_SR;TZ#+4RYY#8B^WR)Z6_]\-%G/@[\S.5\E]JZH+>UC)
MPUFV>3[32HM.RC*;VT&K55"07@&JWWJ2;+_7^;S=Y,E64R6D8QV])S'WVB;O
M;?>_%*.6?P6,)8UCU:<V0UB;B582X-^_T-G/>L7>_TZX(J>SB YLY:'R\-SN
M_?<*L)5_'+/U[&>KP]9M3@_4\#5JZR8VR8!9@WY)LAO<>#:[T*>SB4.)\/A8
MA$L4;!Q @E(=O#?G&!1:@K'N/YW*(=^%\6)&?0+7>;IDV4A5M'1L8KZF=$<;
M_R*?HWF'NR9-FGF0FP!+(1_D>-:XGR</Y5^U3MNK_VU6H*+V@Z-.&:K6-B='
M5 17((&WN5XSM/PJ5-$TX-M3X1<7Z'V:*9Z$3X#3V*=4M;FYE&=M"W-/]W2"
M1N2'VV@+CIA21Q>/O4*^)P"]V>LE!(BN#;S*/L^GMR'BY/0EYC\0GG)8%8<<
M!)FEK[DZJ;E2%YZK><DL+5$U5 2I_?ZJU+;O)B_#K',WDWS=;FMS>H_C6 A+
MOA?UR&_,+EL['I']T2S%]%0.X$<#WL^;C&=E$5)D7<'-;D0W);RI9A)O'&%O
M#0XTCK"W[XF=>.^MEWY.A51?&)':AM<,6&\7$Z-\RWV#'Y3*45 "5ZQ?Y,@)
M^!Z3TH7]U;K_W6%M3S=[>*51UEVF]@EWDF)K$K9>GG81E6I:7E/%;IL53F"%
MW.!C$.F&F_KI"6'*8'&RMXN)>].6V<>6KX!F0ZZ6#FW?+ )DBJC>)&R']!V<
MZO]R8*"INA1EQBAG+5ZV,E!;8USXQD(T!S76>)VGMLU_3G\4%)6(4P_A?2LL
M!>5J&-AZ\+5MG%Z\-C;"H'RY;@7\;(JWZO(1/>P2>*M&8_ 5_3OBXL-[Y-,S
M0-3Z_J1"'F<K!T'^OW@R?2H[MM_-833ST/I-1(;37G. B1K(LIIV(C]A"K-T
M+"&I"L_P7Y@XL.439,J]JU,KM&E MN.TE>K#5L5I;\JPY(T#3VE5'>0KCW-Y
M)#3'VH'S;WKKV5A+GRJH1HWX$^2/((4XA^M7M&(D,\W-T^)1IKKK)9Z$4;$@
M=G>$F=\4T3]!&VP#ME]E%AMM5?D\^X*,],B4;UE@U<I,Q#H<"MITDOO!AMO!
MCK7#W]L]7@'K[+,%5G$3.9H<VN /')$\6@H'1,E!ML1%2_I$R&JV"O@_OLYK
MQ)*WN:GQ5LK2,NN.#>]/6[W!]?F[QLJ?US-F2T?\"Q* 78#?;7MH: +X;&4O
M<XA3*Y96/O!+5Q'=F_ZO!ORFS[O[%QLJL:UO P/CCR?TXVY"#*3F[&[V$5E2
M>D*?/UK5]WN/ T5V3P(J)G_=OE$R-[O3*@VG&(>IC=B>E;&)1O+ZHK:SZ0"5
MISN5[*R[7#M5!3Q"<>DI]4"[(\=->GO#SH9-S;GBS$]U.4/["+4*V^SX+J=R
MMPLW$SGR4[(E"STL33%0J/?'4!&Z9\E-:XPM6#*1>:MTF44VN(+DO7^%DNUF
M)^*G8>US&#9[(+WQB#X+LSO$())8[BOYW4?N\+O*-SGQV%,6N'[K\+VUH_6*
MC2I6/B3S:3Y&5!,J25?)3>B4L%J0H[4A:F ]>A(UR[AGU; ?[_,,II"9BXA/
M62_Y\9"] XI?K5TS.T8@[85]+ZM2XJ]'H7HPG 96Z>"I@--PU3!LPF: KJ E
M-/]6(=*M'CTD0P8\M%+"9NWR%7)(]HV5UIU'R?BC";T!2F;-H:OI"FHF"W[
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MWPBFK<?,%2JTN?N3TA7,[M&/2)F^H*'DT+_=[]6CLS1:;]G1[FTAY%K*%!C
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M@\V(P0DCE)&NW+R".M%F=-3TK B/B^\/[A[KH.#YZ$RAT('+;AY&!6(O7*6
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MRBA?3('#$K&>V.L^W=1(G/[GTND?ME( QQRYRQ*AR^85KYM6[FSF_H5BJ(J
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M@@/:EV1\-L02M9,?_\,XMHC[!SQ5NF%-Q]UB2WR5^X[K6@6XB[SJH._;$9L
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MN5#C&A4W=?]%9IM$#0?F7G!0I>$IXLB>)Y+:('5+/.R$]5FI@V:C6R9;=N\
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MNZ_[/<>3][F9&Q1>K$)*MI]S[AX>CS=<RO_G!M(@T0LJ\S/YIR>>]B[=!^7
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M+9TVINWO]?O>Y#D=;"C(TW1;QJ 1P V+)X_GBJNA-QE[+3BY^P6VO;.<989
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M*L?:.I<*!K)U-+N2Z08/C?RKYV7V ],8_)(.SU>/<O4ANIQCELS.%8:[78[
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MK)K1J*]\*:4HF$_Y(E?11WY?O7_6EUSFV.;:9^IK'EFL9BTDW_@YGW&/ZI3
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M@VX@H@B(J,FQ/3S\:UT5I<[^22?)-VJ*GMW"65^4>>1^'$GU.1&5?E+)#8Q
M*^G2R<:>G%P TTN,?3X46K%,,+5% :BSS@.3>G"O'B!! VK@!/:<TS]%W+)I
M!$7>/V$N49<>(?%WG@21MP;9MYX'M87^6,7N8W4**ESJOJ]U9^SZ4.@S?+@\
M$S"F72SD87=?DL$MY'>Y$*](!K(<-<X,#KME1JW!4E<D3H30];$?=(]98HQ
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M@B"%J1GN;1]UZ*ZCK3R&[Q!QU&"$3TR65++"#'T-9RU^VHJ,.FT]5&%?/C/
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MM,?/T:P 'A.IT8S,<],-O<D/0O_G$/_M4'#>"-,&/]T.:NX^P-WG O*@MQ\
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M\.0D.1UP ('!5S!@MQ]X10('3C(#AP5R \+V*Q<(.AV>0%A"),85EP/1?%=
M<#(!U+Y9SD6" 2(2+!-(L"Q%@[EB/-0N1X/E<C(<J"="[7IB$# <#*3"@?;
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MK&<=1+75<A0S@-T^;W1$K>C97-'=:+/YM?5O)N,S76 \F_#[7 H*R(YB'#$
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MA2MT.H4$AI,I3[.$^&DH24!L,QSQ95IM'^GR>'RLRCHY7T12$=I1\(<!RU2
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M1<,;G0Z>3H&6U:)8G0@#CD"@(.;*JDFIGC)#D*2>M%I9&I8,'U=J=:.-4LU
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M.(6^8TECP "G?UD/C]QA:"ME5R(K%)HV=>XX&L6D7VES>=_<[I(L-#+NZ1,
M=RY3DX:@=G8Z]=5$;[Z-<=1&>_;"&0J.$A>,KK37('F?_5LAT;XP/L]9S0V@
MD/6J.A]$5O];!E=1D?KE.!/O<_Y8^ A84&GJ%C36[J3^ESIZD.L;O$%*86VV
M5)<W"_$(=*2#H;' +\ T"QN+I^!;W$9-M/]C#"=@<:LZ, S[>4,&(LC$B-7
M/ -+@:T>\26HS Y;WP(H]#49<@7Z7KGI5KNFD[8ET'^_.X9VI4T3_]ZXB#9.
M'8LKXADF'CF(4O:Z;&CC^">"--ZBR*(CW[(%/FV%8I%R16*DXS!;CGDD;;RG
MJ_! (JQFL[W/_Z4>^TGK[3UC+US7_HI5OVWP 2S]:-G[(SO7(\]EU5_."Y.O
MMLC)/A/Q?.PS*%2X].H8EC]AA,P;P=S:B.5J4"!&D !#9L(<Z7[FLNP6B$5>
M$O\3P-&G>(DNS76'@$& !Z:.W.#$'O(=!O9-Z1@8=G KW9$K:,=(7*ASAV%-
M5;=E%X1 ,*%OQ96<F[NJ\VRAIIJL+@O/F39FLA3YSJ8M?R^8I.]^@>^^Y#OX
M_I*(5,MTP=F@H[@*#:TR,"L9'Y&U- ISH9\UJ['MGF//*#-MG.S'47"(L6B_
M>>7 R6(9I,'F)=B8$98F_CA1Y/(*2WVC(KTLDC]LBC)Q]FG1L]OC'<!Y?DUK
MZ^>Y^ MA+V!DEQ%JO*'WN?-RC.P-]0*GF/O+@I3JQW")[KL<6LP \!!J=913
M94S<G7_.MA?R!6E :+4S&@)DBQ&2(T3*P9]8S@ $8\"$)_TL?O2_OCB _@-]
MJNO6IS_^5FD_>N/BX"#1O3AS#&Q2O+LNY-=;R3F0-1'!B$TA[CFZ_W/7_OB9
MBLI!?%4M!HB3E+(!*,U00*?E^,?&> S5#JJ72Y)OR4PE 0SZD[*&"@!:CZ\O
M$#_YA!.1:KK9G\.\63YK$3B6@35KZ:2!?_3D]'9*G<GPR\Q<Y$Q#:-\-<@L\
M[[>D"4-28-.BW;BUTH8($=?%1!P#41DHJ.TO>W+V6_N8 O2I8!.8>!1 VS5/
MM2UQ4!AHRZ>OFA#N>)Y^&,3ADRU?EZOX!K:-5$IR<UQNKJZ-])C^H^F2C_TU
MME4E:,E+^AK%>E597A#A8Z*3Z4%[;YUG(IQ 76/7\KV5VE3+29&)].Q5I_([
M9TVU+\:0M4ZF-)3DN$AI4T;9ZWCSL==I3C<L//%%(#8"3L1%IL/0D;_S!FA3
M",N J?5Q \YNE06Y ?R%Q&&W1[*GWV#'O:>6;P#\6+;&2VIR"GVEL\C(3IHR
M<C"@RU.:E._!*&[A/@NCQ[6J69S**B1VFIQWR'&JN5G32KJ453M%D[HE0UN4
M-T2C*Z4I5F)6#L.+B,9XIZ)^\V-WYW!(R2!FHL"SN4G6B\1-<C&*,.28A-53
M>Z!Q Q3>X56]']+F22]^48%]3D:Y")EF@%4G,AME%P"X5\W!@H&4Z,C"<-;T
MUR<K]JBYV!IH:\W8755A/-SY$)5I;O;O3'0AUJ+S(SP6#KTLMZ3-%R>/,[UA
MWA!41):=B!XN5GEV29K'V=)@5;2I5J8KF!L+F8ZM,M!;IL["#AL:C[*U-:UR
M="AB7OW#_D(8ED[]%\#_@FB'#JP0SMZR4'KJP_$M@P"[9G'.Q87,33B<XWF=
M*2#SL8[Q/1&#J%^C(JMS;/8@L5B\2TIV.(SF16*/EP2V@*(8VK<TSGM_Y=@I
M5:WL,I:I\ZA,WKU=SKAR9(ZT)/8,3?S*+F4;S_I@%,I)E3!&YMYH?!%[1L<-
MS]GV 2HQ9T^4;>XT W72^=UL59TKFN17(_!28,QN%%6'#)5[,RZ@,XAZOW)>
M:!_&">-Z5$GGT)%Y[&&WG-H-L;\G-81<MOQ$&^PLLD).JFC3DI4;$M;QL);^
M+<,BG1T:DQ.5!6HZ9L,?V=>4D90TCV+G<=L9]O[H)9[,]Q@3>D.I,?--7 DZ
M3'HKW3C@KK5PH?4EY7ZHUIWEWH%9JN%DP@)GE@FIJN9?OOC6T7)%DK30\W&.
M4,M_"Y) LOL+H/^$ _3T>$#H1_'^T*_V963TWO)'O:X5L2OD(^S==1(4@;?&
M7';I<>5PN11N3L=CX)!U]^H_-M7SV<EI95_3:Q2&Y%YM2LIA%Q2WQJ//)/\L
M%HS<!U$J;W557)8I]*^]JD<P&CX@X0HF)J%E(#-E4+^1]KJ[!2#YU+K#HNL4
MTA3(WJ:;F/Z2NQ48@%J[WXEK7@P$IWX-;5]4D(2,DUL7)SE&Z!1N8FTEPK;B
MW5WC?+A]]5X>P3NVI BY4J0S[D,0W9^?22-:38RBTU<)+U_/ZMM[L ]J-+%B
MV2"/N.8A* 1"K[/,=_[Y:N(KT[-+9)'I_" QF$QICY4*PW"10_)Y:?T \V/?
M]MS=M*]8+!OK+OF,3SCG]K_4-#]G>-0T<;I-\:D^Z8@674*=$YEZA!/PQE7/
MUKOA8.<A]4&PN==2]SC =22Y94N,EYM?8WZNB81I[IO;N7Q_(0$\X;?U?CPN
M*7"L7GQ/O^]*0</K;I,2;5LMVTY@8OM%A\H?8E\MSH>&K9GN8VIA.[&-^:D*
MY'3$YY7EP0\*W&"VP\]'MR9Q7; _ID.SS+0&ZTS'!Q*Z6O]BI/?;^6#"+,KR
M35AK()A6? ;9<G-&[G6GK'Z\6 SM\_Y1R#4@K#K*?B"TYI-3E#W9!V:$-,&Q
M4!)[FY;?,S54>^+*7;MBV6V?BTQ'&3G:OH#Y][P_"6PA*8GXI8--$^G8,1P+
M]5-G6ME[H1^AT#UZ]>N2E"9$#Q3<Z6/BV+*N;<%@('&Y]DJBIT\>S6N)'VBP
M]^;CH;=FKU,DC*G8##)2VM-21.B>(0>^;+[K=C[O.5_6M_&C["SY]=59BK8N
M'$AX*E;GH438&S.9UH.1%S::=![ \/3S*]_4I,V0/%BI/:LV@^;/,5R_RRS&
M$6$CNX#,JF7XL:DENI&+!H]L+Q<,9*G;3X^A'Y-Z^R828]N+I_%3IK<F8US&
M[W\5@>.6!=%+\0:>G@W_]/"AF^W%7F@SQV.,;*$O&CV8Z6@T?=A%R+V@M810
MA#@(;5_NHA-V,PI>2AO*<F%-IN?@Y&/*'UUM0JVRQC)KU-X<76ACFT!O1Z.R
MCDA+)>@'YD59K=CZ>B5E( U:)I>J-<X:PH3816'Z6%Q;*PYN(*4YK#0,D5 6
MFRT)L)51H&O14K^J!J\A5:-!7U#&Z)%>CH<<\7S,GNE),-H=)8ZURY#_H'@A
M/9Z-IN));X"4!'/\-4VOE%]0L#(0SAEX3F9;&)8T4F=>&\O*<VH*HMSOG\KD
MS]VO;0>>XORCYDR:LS"SID6D<3SNDN[NDAHJY,V?V\4KO+0R4,,2,_M;EE,C
MRR\S9XV V2EC6W(($R'R4;C&^%9GXKP\LS =;S&Y2.-.5K;9IAU.XZZ-7*C;
MK5W9!'H$TE:D-?O?")S3.6)=[1#T#DZXI756T2@VZ*NAWIK,36/PQYC9>T>E
M'G'4RE;>W+T#$F<Z_?Q/O5NUW5X_?DQH^?KMN2KN-G;LE;3^F>(90NI^4OIL
MD-Q;O@\PR;G4T(VNT4OGJ1>1"N1>K9IM2-&K:;(8)0<J?X!W_#QSL&'FVQXL
MR2QLO&KT3I2TD+5]C:*R80K-#L!WV&@ZF@2^..Z7U?X%$(ZLB&[>$_Z2B^D*
MOE^EB&Z?9"EMRC06LKJ 337Y+JGZLI++V3-1#*2;.FA00D'I9OQ31H*\\X:H
M:Y>!+>$[7[0R_XGT9]S?9/4.WW%MN[-$1?T_U!?J7&[MGF,_4>_ICJF(J*,'
M_TU#*W%Y#3M4T3>LU\+ SOVAZT"27&XFG<ES%?S!*GJ#QQ]> 88OI#%"]8$
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M9SLVF CY#(/X':V1*H<3\8(1J;_T^EB+5U%Q!VRR8:90>ORW[PO$!&4\3>;
M8;6TR<$L=JN9SCD9KYAYCS$>\\<WI7'&TF%L1D&9:4GU)W,39(P0^Z!IR,Z9
M]PL:' ][:H]AJYV>>]A?G<YOM/9II#$2TGVQ[(+Q6(1)XM#6-:J<5$P#A2[C
M74B>J):$J49#_*FFH9'D3N=Q7"$<;#.2F<EV)S,/<_0+K7CF/ML9 IK-M5E+
MI]G#N+DKO.M3#'X>+T%L=% Q2;:P7?+*(S4'2+L(VK@K6R8KM0PW0&A-*>QQ
M;<&9),7U)#O5,WDV(^A9'H'(4<J%8T)V[Y\T3F"JPI/\1JV,N%W3VND)6D?G
M*;'.^D6QB9TUJV-8*G.(UW;E,:@OZA<'-L-K%#4_0=A!J$XZB$WKOEZ;]8.U
MJTT9X@<VC#SRA\4$[:-3[=Y$5]O5+=65T>9Y-6GHIY63-%"AE2O0M$.%E:RV
MN6&2U<L)L#-5YA2]?(O=\XXI?(7Q+HZ\&(\1H-]CY ;.?J=T'7<.?(,,WN\O
MBE-Q8Y::(9<R_/%H.?4J/'&'*J:2!WC!9&>NOQ8V4()=/J&-8SB\!];WZ_#U
MG+%OLJNC&54T$:5;?89,\,BI'5,UN)(QW+%TK,(&8CM9GS2PU_$G)]&[# :>
ML.%G?KJ[,L1TIV*OU'_>>D2"XD$JBYM#\84C4FY#<5XE$1!D5Z&-%)7842+9
M\/[OC/5/DQ-%]7ICI3-+[1?'8?3"XPO:U:0FILLNQ[V.NOJB;7S;CU1'Q5LC
MAYJ $[KO9W0CN^R^ T<.!UIZ$*6@FYX)5A?BH;<.CU#&XYD]SF^]5EU=83>]
M\)Z5'M$,"@)<Y>@1#6L5-C4.J9 6XFQ &$4DW$$B(=9I>'BZ'-Q5LBNL4O&1
M7$[V<(4-*L]81$R+DPLNDFN.R"+<VJ2EN1?XKGA./[:;G]ZS4J/*RH Z4AM;
M)#4@F0>09-T93"5SGM)!BE!0%@$P*,^HK->7K3T:F@!+R[^PP"Z#U9O^M->G
M:[!;^[!=3-E))]T0CKZ&V'Q295F'V/T0%8FA[X/FB$@OUB,20"3+F!@+UNNU
MUV+7%NTV\NUC]8QFZ[HP[X[&=<T^XV%^AI@TJ0?OK+22AR%L.%P,#N4!4SPW
MG@J*SVX/)EK >E^3$AYD,J3^G1G]O 59=)K-::5R%X=^B6+.T/#'MSX*8D!4
MV3V[2*2LJ+HK&!0*B"/9(@H.N^D4 JJ/)AC;][?3\42R?@@50OE&]C Q]0[H
MP:-7%LV(5&=)[U+C*-NV')(2?'GJ*BK3'CXZ.+J-7HYQS2H(),)LE'.ZX?%P
MS><>7<NT-569<6U8P:AX<N:H8YO%_FT86P80.D[*N$U[M\R]K8ZF595AFZC>
M.9LK]:/>B=02 4O?Q::VB#]-.7BR9XZN0XW#A6+N6VU3J%5S61 Z,>KRN=VU
M*S+0ZD"^7^QWOO#36P;E4&2]/*JU-:0!P;=?%;@%K:86I,0\^/8Q!D\:CHOR
M-7-JIK=T>@L$EDO;;B$P(;:1B:7G2#$P$4EI:*A@,MW=U-@7[)BIFY+LW&WH
M>ALMFIS75V]T/W<0:V/<T&5?!H^Q/X KO)T$6+C;4KK")@VKIZJI;1# ""F1
M,%'YD%#] G)QK8$9K6)W'(6<#NE>6!,1+EBR5F06%7K6X1B$6')).RKKC$'2
MBE.4 K4BQR2:2%C?K&TY"U:7C>ZX T>[A8M^2P4B%JNH-MS*1>&0=/N4@'SX
M-CD"N+HUN;\ P:>/%#'V4*OB"+?IPNQ*0>M4]RTO@XT4\,AHZD7*$,3L7E$Q
M/MH5&/O#\MA6^[Q2Z5H(->--"3N[O5IV!8]GJ!1$H/IYHJAITK[.B[IDM+0R
M)B*J!4L[-1EK!S!FHWZ!;+V8(:0#;DWKV RO2414@L#4AS+[0N=1@E0%!_^S
M*!DZB3(P^K@0P2&YT%QU@EJ3I9GSDJ989#XR27.RK([26Q#(\$/D]"$UUQM(
MS!X364Z?!))A:V3?U$4+?:$V_ */V\Z0U\40G@3-;L<R7/%2"ESYU"05FV.#
M<'3%"J?POBH,9GV,D#-/4)@S=RD2A6ZU^6/CI3=\;^SS]XW3VI:-GH2+IKF-
M?O%BLWMUN^"QXS/"WZ,PI6%JH,/*>("Y78+I!J/4G/A 0$*T66)A>Q@C$LB:
MY,,>W<%D"DRX^S4$T]28N#3T,[?<\ B32%EKC?4)XR-D(H35^6R_4K@J6#DS
M6+LE94B#;('3SM9N(_,3=*9=45YHXV+(JRT94\%W<H.'6_2<J!N8=C[G>4<_
M9V2,D0O,2X5C=][)YS#-M,V/8A'0VE=FS3&2:4Q9A*5,)U+M2 98G7\MIG6(
MC3%,0XWT=Y247(,"#S,SP.T4-6U6T[?!I>%?3MT49]?0B*0XZE#0.EJ[1*R0
M2 P9/9X-3KIH7(5=.ZLJ4LZ21OKT?CY>_P4<CNQJ?@G>[XW8##J#K2;U0 Z_
M90:^8N7OAS_;ZB_W[QFE?OTJA5_#7OW_OY6G]N5R ]F<'^I)J_J-*5BO^U)/
M%#UG>/HR,IM%HE0-S-B)B>V'?6;N 5QMRU-UK_P)ADN#R]Q@C%=>D?0^M0N6
M'GR<TMJ4VI,?8P?7F/Y(0ZO_\[WO-=+<Q)N97] WWY)-=K'1L19T5(9%2QU7
M" V)QU#MB1=O;_I1'[JMSDK>,J-B?GJ2Y=\:?8]-NE"AU;*VIX-'DN$SGST.
MC(M*_FN7K8$5IY-@4^<G!4>8!BA5SZ&UA RQ3"-JC"T;YT3Y,+";SG$-XY[*
M7H7,TG@S4JS;.9E-TLI+T\^FX\,W4+C+P?;H*2CTR^]CC+]^XA,RO;:LR2$\
M091T_C >OG-NRN5Q+T^=Z7REBE^]/SM.]P*5<IO&Y#N>TV\=^];%-;0R,H_1
M+_3<+N@Y3X%NTVI\%I#'_@(L_P*.ZK*^I.]97CB?Y0%M9!S8B0D#GI\NU%3*
M=@H]=?L6QY_FNNKB*+)EOV?4/1,L3WW )27V-]Q:N9H&;YY1$]&IW0M4 ;%0
MXJ>Q\;W!6CKOUSVM7)?.]ET#>X,KBWRS@G)U%889._R1B>?@<9YM*.[K,CYQ
MF@# L\207Z:H^+PFYW9DNCBHT'0Q7X)M5/S "+?=1\Q-1L B!">Q?F9S_"$Q
MC00<@+/[_K*E<CFU[,]X;-1<NG<D>+/Q+J0S]J963WQ.MJ69HS76-JS#5$H\
MX852]IBS WVIC:&HWMM "J&G!N<[Z076?8^";K1F/&R*3-2J[T*9E-9*;<?7
M%3;:"G-8?M,74"&!KYOJ.[!^MU/__9:Q?;^RK.*L5J1O?7//_+K'_TML%*F1
MTP25L9E=38WCT,Y&KJ0@N\.3@DP-_,/&O'TPFT"2C5N_>/*,6^]A1!70&GI!
M;V?G9QC3MV*ZO]/<>M+=NM]>Q:Z4R(:#VJ:+[%A+R;L2OW#(\N>ZNV3]5LL,
MGH=[X03_7+W@LWX>@#:I"'7/VY!?O2X[C%1$\[TBJ]T-)HK&X9JOY5K+@=X;
M^(3=]QWX&GXO*HLGLB!0-W'\7:W<X(J8-LC)1X<";5'YDVI+2=-+HO6Y8\W[
M=GC6O3@97_TJ0(M#4BN77AC30_&5]?PHMD!;=\"E.SJ##,:IHXE]=? :AVI.
MX8KSW+17S-5W&/E;AP6?I&UYZ:9EG+_"3 /9O(@1[PYUE'Y5]P_!-I)"URL*
M91G(#S1&#()[[E!_/H8XM @^_:TKN';J89.A2>VV>IQK;CV#YYOZ+\<;C91)
M&O9-WB5KFS]I):;1LL_=$.&[*AT&'3"1&98LY-QP*//#!]>L\ ,<1 0SJM/S
M$R2(=UV'&Q3.\O:>C"EG>L(=.)N_,!8T<.L87GI;@H!'$_EJEP8B=S_D[/X@
M:CHTK@*Y=.\9/>9T[ *[B'4=*"Q*GNH(V?FDFV#I*R5*7KH]V)GA4T@123^T
M:%JN,;T( #-/3^;VY=@D>;4,\S$VCDO3WVL4-<>_O"%2!XS9=MXJW8A&F<9F
M.#I^'GHZC*]YNY#S;7VDF%_+@!Z4VXDTXW4)2D\P2D5:U]X9M!3;4B_SP@E8
MJT_,#?'3E8K0C5Q?WR_;YGJ4P7J".)>$95H">]_U+FM&'M>US4NW5@W'3C_0
ME:><CJ'"3F=G]00R+[3<BC1&WN ZU<5+L^RQIB1@MIS@UNW;1:D+(!04SI6Y
MHB:I+J;)9\%DV3R)1AFHRJ%&UTB\KZ"V%:Y;1B*IY!Q+"Z^\Y#I@'>4!:\[M
MI0M9-GB^OSEWF7!2X].M__A!>=L:2H'U$.(E37'V%FW7(BK()0K.C#8OSVNU
M%/OP.#>ZZ=5D:MU!NN@[0_2N 6)N?6P_/6O->HYF1X"<ZQ^9EJ31E_$R5[U\
M;QQ4V7,)P>3**&SW"5;3A1D&^F#"_(T8)!FR.DRA24:0038=F%:C[7#D&NXD
M3LF( ]BHZLA%"@[N[?5OWJ.5<Z->>-V<T ?QHL$NT9)C 3->AI,,I,VOV;,<
M%?E%8_F\$L#;??PZSP("#0B_9!064>-W)<O S8<*YSC/EK@KN9',.']&0V0H
MPGQ_F9+6&VS>"[?VW1T/%=U=1U<RZS+9JUB4LLJAB_,Y8+OK^-")4UR_:3W#
M/61HP2V;QS^N.4J5K<)GJ4@0M2U$);&*<")'S-^CT6ERXY:@;S,Y60BKTG)\
M'!3&\7?W-NF1GSOV?!">6C#0<YILO,B]O*_2;\":+!T>,^CK:CC["$[N['^^
M*^!"$]G=PP&[C[ K0H?-V0@R&Y5TY>(&.:;]AKZNE\X>"C HG/BGVX,VP7=^
MH4KT=.[M5BINI,]!&B;S9Q]F,%'>K[!K)E/IWKS6CB:P+[ -^!RH53\;LI\8
M%[DV#CV%1 [@IDC=#3H-#;KWKVNOQ1D8S,Z1.6E&.ZDC'$/JW+3Y9TPR];[O
MZ0MHJ)5>[1#4QH2=(N_'.9S+*7>NI6\FQ*MHA0SH3/+4-+>F9-0?6/\IZIR8
MU+>N":)[C*=G,YYS;7[7B!TRN+0Z'%N<(.I,9([MU;BMO77H$0Q2UE7@@GQY
MO^)Z@@)*O^EW/3TWK&Q!ZT_':0JMG=OW]*8 <CUWWXD\>SWU\))U?.8#\6]T
M*0ZK?71N_\14'951W9U3_@@2_=EH?48CV*&Q)+JDM3^?O#:O,60PT9L3#&BY
M]7-@LI^H)[GBW')OF#DL]TC)6B8WEY\9\RA+8TI_]QTCS@M>.[LL3!KC[?.W
M(QW)R9G$NXB?M&@=6V/Q5#C*^&%**$U[8[H6^^*PC:I7FOX4?KO4\DGL7=6T
M*VUWW35"&,G0!T)VX3F9N+>[]8N;VG%YYJF5*A@A$D&QKV".O7R$'MA'RS*H
MH+XJ;K,?<%[J,NK.M_G4Z)(5<[^196'B(6?4:"#,\0B+[XSOS"$,:@?8+@XH
M^A0YCC_#T)C\?ELC58K/N_P+H,5.CAY]]5TG@$%#9"=1N0M6WIF\SE9.\UC)
MG(S&-1"+7R/E'=+OIO=D,-@(FTH@F"AP)E> <>+J\_NTOVC]<VK^%6K57FO\
MD!&_2"3";0% ?"0@V\_'H-A*%@.EJ*R1F9#\%&$UMBO\D%)'Q6$/[?+M&-<+
M4S-+A+2M5P##P[#A#B'L#:92"E\"/#>W9?,I, &B0+;22,FL1 N6S,DN.4"#
M8:O7V*N2D2J"L^W?7R)X!N,S'2H",Q3STP1CB3K/QU"#OSJ'0Z+7%4 #WR=:
MMVYH?@]":E_8YZ2F^]48E>[[0](ZLWG1&H$DGB?2TX=_)V4>72)PY;=TH$=J
M2](&CZ@WV*?X&T/FK@6+NUCXX&H;IU[@&QPZ\0JIM:23L0Y]0R'C EC$@%S&
M-QBOKA?FT%@Z]+Q'[9 +=I[&0M#@Q'E%6D/[""'7$-&[%1;R&) 6E:]U^/%<
MG.\VQBR"<B]FI1RNG=W,]K,P1Q7'!IHST%AW0DX=-T<B1I;8EF37V,=A36',
M,K,03) H"F<).DX2FIDRK>Z%04<3 1*NZ\^#(LEB6TA9#[VJ)Q$$TT[IZ7 .
M:VBIV_6<O\ /KGKB5V0>D24<?IS"[0CV>7;:[#%-[/GK]!^>?LHSG$,[KI"/
M7;\P)(3KVNA$N)=/O9L:_YE4J8;?0/\O3&S0ZY('P?92TWL%.4Z$?H.4CS<3
M*2H;Q';+\-\@BT/5ED+$<HHX'Z>\9F_\QK2$T:KE_2B1^K]R7@F#X]V-:[Q7
MTB/-245^%:S0_[F(97;$U.1 _DFY]"[D^$[+Z1DQ3<<E\7\RX2VA@RLZ4SG9
MZ9@K0>E@,H-INU]Z$*EZ@6LLE+V.^-,Z!C;A@YPDU/TQM3&@7*'V!04'X>3:
M28';<0&W?=6VW\\H^_Y&>KJAEQU&69%Y41-BH1#Z-PHC<UXRXPQ1&.Z>0WFQ
M&B,%2_:1+LP6XX5/4H@-U#0KF4DR!9SI$A^4M>@4GP(AKQJJT0SP?M7[.1RX
MR1@BLEBR* +1=N.S-(ED0OWR^TJ-Y$"Z?+$\]HD#.\+CY(X$'T^(O,T_6Z-5
M9;:FXKK7_^D 'I;GAO4SZ,)\Z?,!.]KO*WV&J.^FT_=;^Z_X'@2IHW3)#VG/
M&QUBU#9&LL.W_:C=?NV/;[)'L6<6;4L/>%[D5",6()8(<.U1.Z8YUI1(</HC
M=9%T"[('M+/VQ ['&,[+#LAKS#Q/O+K@FJLF\WLU?BE@O@PV9""#)Q =GXUC
M\+1+K*[R$DL!+]F"F:.,!9"Q1X>O!^;5E.E#KD_ _JUKXB%QX?=.$C;\,C;X
MH#RTD'PH3[5S*G/(!LC)BZL]Q@8E0<_!< ZQ+IJAF-% 3*'P6)=E H\CTLB$
M!>^\J-YTDW6=&UC/S)S!CF%7+U+^==FPLU.U4_-X@,,4=]1Y8XSMY?4=R1G\
MK=*FF:\9IG7SF<&RKR%[0G#8LN6#!<;&[RNS,&/LR[9L9+&EVGFM!N)^"!CP
M)K#78:_'N]WN)91?J.D#@?>!&:;EGB]+]I^9;\N)B;C-'&4=7'7I4W_S#,A
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MI^[PFPR5"F?UKUR\?:>U@#UYG(LS61-' '>BW^FS\*-%AP=C1+C]8AH"@VO
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M /2W: $3/D00_$S944[D,,U7[% K'D21- IG]\RC=N*-;MU$0.JQH@GEU:Q
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M#[,U=#0_+N6JPD^%M0C3(IFP=]WJL% H=-&B23"UJOZ9D8S,W@WKW=@X?'P
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M9O!#*&6H'$$!03E5F/@0H8GXX9CHRE=8M<'%B!NYH0-C62#X9^Q1<FL!5:>
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M_3<2)"A6 G=8/^J;>QKD!'YM'2U)U_2</%]_(;.YU8O\*%CP1$<NI&QV:SD
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MY=AGJ&2TC@5AU$S_JF&O79E'4T9S>!_*>\N5AJI,R[IA(*/;+Z#M9]'>\.F
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M$T?&0>W6;^'K4.TL3#1)E@3ENL!A[69@E3,SH,B^'S:S<_[%]7-N]S\<IDI
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MZ543S$4ZOLE&$AL[KJE17W9E$>W-M ]Z5E00J!NQ^9E[V?77UJZDG&F9&7Z
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M)#H:Z>@S!4?K1AE,;\W;0D8?)"CL4V;K>0W.[P;8]KUZ?+',G4Z>HK&ZD>]
MUN_HMZ)X)N?(Q&/\RDIE%(^*)_[9S?81E+ILH-9762!UTA'+X<G-(*?;/5K+
M[-3&F<V+09G]=#"R1^F8Q4:*V& %J>W%_3$YW)*H \?%<VT;O),_ECTF??6B
MBKLW>!7@S>!KPZ<J^[Z&0B2\Y/GQC&A>T9#(:H@=0O@+EM;',;OKB(*T3]1O
ML*\1D\]_S4A=$V+Q5@@%%6:=8FA@2T$!GNJD.,29U?<(;=<=ZGR515#,8<XD
M8-CSSYMAD\?G^A%VI\SM$["\F*<_^8VO-- GCS[$4.048KPZ.8C&%C[Z!%@&
M<I[5G;V/.L(T2M.L##U-C5X 6S_98Y<;RX+JQ+?EGQY9_SY "NCME'$*+6Z0
MF3F+L=1WUOZV^;900NI99[<"*]%)"VU\/K!V#M ITR/#MN&X2?8K#H,4I-T1
M;]9/&C1]]^8X3G<7XNP5O!X^\.(#,YM'_.@6P$V#R&(_IN%NU-ZW'E:;+])>
MJZ\:$*>TV="LW)LG@^A_(N#;DJ"IQ@-FD)U [$B,O6N.<D^3AN$BQY*><_JD
M(N&-KZ=F[?.PUW-TKKW[#&T&/^;L/*_;?GF[#0,/&PV;#='AC(MA,0O^[57X
MZN4)[=@K>+%]_CJ%"D?=X%K]5'+HC%;LN>W4#\@JEV!R@B$[FK7,FQF@#GF^
M^D1CVW9"0!QD8MYMOZ&D5/G((N!GOF. 5\KD"Z./]K.53 ]9^G>+#O7DF9'S
MU:';!19Y"\ZACL46EC(?H<I2>\[1S<YA]:U7-O.2-Z(T74@^R2OS;0OIK$L.
M+G<5'(E,]G!@'H-,S:EO.+=O,M>$T:1OC(I%\G/[(ZRAEIA=A&(N6RY_BIP?
M;Y1SR"S GYSC/06E51(A61T3^ ?26*J"*'9:3U4.;*%G<M<JQOLKO%5W#KF"
M/GUQ'@5]<,[\%]'>+?(?.5*PF5[BBI,$<*57KS#]INMY82N*T_#?E,A6>+K_
MMQ[%-E^%^]:E0UFN+:ZU^H+AV=R)?V^A-49J?-18FB*SMB"S]L(R+XR;#ECL
M- .W_D>/),[UAZPKSN'U7R<MQ:;-KCDLW+>OMQ9R9Q7//*D03W/>HH!93MJ=
M5ISLM_:!X1_.V%30@%'T]TR9YMOU.;Y0T.YF!I^#^MR[*&HNKH@/?Y#=89E:
M2,=H5+M)AH2^\1[-PZ7HRFDOUK4ZC?<NUI448'\RQ-7FI)*QH4_W5BV1?FH?
MX+^U=:C$CS2^D)B48!6"\KD;68^W*V!?Z=PN32P:L0*^X%Z1S917J^[+85EQ
M6A!&:-.AHTO\42LANT8V10;5@_@3'Q$BU+@[WV*7-JI/M>_^CP_R,^P+;HXA
M+UJJC[$Z4MU$&SD]79790LOSAE%7GQ'E\8-._MKK&P*P*(ANJMV(A (#%[^!
M6.P]UA2(-OI)L+8<E.2@ +'D1+@:F#WP5:,RH_WU_(=2K#SUUZRR8*0,FLUM
M\^7)H^,/UK-!RZY$1)TS[!\O$H8)A@Q3!)B$N+2MH9H^%"CY9*MZQWQK&R,R
M\S&JCROY0X/.P,%<A*NBC-@#_<ZOZ\:4&2'UR<DPD%;-DM;G*+(X?.'*'-Y1
M&7G(&K^"_3PH<L^?7@""<8R> _VQPM"Y"@77*_&RCB(>U572A]OB1]HG-PJL
M0C/E.SQ";2?O2OM%R'R+$V_B&0&WRD;U,GUE.NE"<.*D>XR+^ZQ1V*?IZET&
MD&FY3U^9+#>UJX%Z;^ 'V]5G 9/>2D'8)<[9%L40M._L. 5R9O XA2HJRFF.
MY8' 6NU LY*(NQ8J>&$#5G$7*WD L$-[+)!T/IDN69#UV =9AMOJJ_RILM+G
M7*1X#,M#:=-:>K_2(Q,;,[KOP!$9DD)#%UY&F'0AEPM=<6W2?)L&B"B D_$?
M#?H<%$II=SWWF%"_8!!HGYL(G+N].A55AF*[ #7?+)OFQJR(E=6-IWV*.BLC
MO[/GO -%ZV@KA$1%3K=3EX=.=1]\9T=JLW;?:TT%S@2@52(+*8B7VMLOIKWD
MIZUL9M. VS;<Y47R]#EY&'BF B"N=)3XR,S>%Z; _]I,A%R8F,N5@/J._"YD
M4R*PM15#<\=I/^*2OA[> @GS8$T6)5S]#:7\7PTM,#$,VDI_ZJK?23<^.F4^
M('B'0]F-\P\14/_@Z#H[LQ-QXLG(."MSS-T"0A[Q_6!!("?F-"2;5.XEH<>H
MN/JZ\QY]48X:?L)[UR+<%-=ZH+3X.%G9YN:7FV K>>U?1'=W9AI:^T+Z")N)
M2]G4C#;O9L.C3CWF%E=;5R].>@Z'R>*KU/8?=[VN]SST723<O%HYW[RCB<\[
M^[*L8BEWWG@8_*<R(>3D;8'[:(CA$2K.C]RC$:BKJ@Q:8W!/@DGM5.+3?'/H
MO:"BF4P_-5\)R.]GJ;Z<6C7I3S0=@%7? "1Q4W=7+NLF_L;2<)MN.(GV#D&<
M)Z^.W&]78/\_P)=;@0R9#_H1SA7<>MGQ4W9+I?C"\#]SXIKUFVO\1J@<MGC.
M><C=ERL1YB.C_YH6_B>+2)C:?LR&=M1@C'*4D5\2)1UXA0$A Q2H49MB2MBB
M>YA[VR)(:[UF3=53XU?F=9=_(JM"THRX\N#CWT/:]VK:_K>#&?\U2J+M,*V!
MND\*^$E4DMO#'B7B\\"54E@ZQ((<..@!Q2.*FQ(76NV*7(\%<?Y\WH3*A 3)
M,$(E6.%9&?;_7[\2))#-K.F=J;NR0QGD@K'[*\VO-;9Y-G[U('B$C#VI^[\O
M&U?%"8[-8H?\]?:)]HON#_>_MJ!49!XWG:[V(8#JE6Z]W8-W9$ZCJ\&OX"7J
MWZH2=!**:WFOR1VUZXRE<6;\^%3A6B^XY*<>7E2G2ZC,3-/YCLHC:7(7K'K'
M8$XOIN1 7]2-!H3SNTCIPZ@'G(HM61[8(UE,JO/9,!NC<)N&886U1GBY^>*]
MC\D0']EL V/>>0-#(.?&>#T"6>, 4::58@QD^8$0OT^. 85"=W=W!AS_1\D@
M_U'X)ZL*@$EK2!\$,X@I/LS% <,L*F>ER;F3!PO6!,:A^SF#2XR=J_"U:I@@
M\;3%G6E970V(7JW#7%M 2AE3_6+A\6.-\(23^ZN"$Z+WN_IZXE1=X=E(K4A>
M()4Y51@@13H55;*LS4%SEY=6C)%9I*:_H_)$\&.3M.N\G(IP4KN=B5YB1[K*
MV;A[:%]#NR/>J&V[E0_MR-BALV;4G^3T869J,&UX$Y5Z8%6%?JO7E^O)%?FJ
MU/3ROA\)F_'RFM@B)$'\XMX'E(9FP?D=$BXT#PN+6<&_1[G=?Z1S- "VKU[_
MPARS8G,BY%3DX!^;P$<7)H39PR?I#1(WF_'7AZ(8QH*OA)EDJF]BT>#9)&.M
M7K:'*+WPAO+;_=_BIH'D7QN&5'3=8TF>^\2AZ/O54,1GS)WGWU?ODH+NF3F
M>Q9X#A0%#047('X1:[QR585D=DG^KCFK<(?^"'JOOX@8EW?P>K]/=TLF2(^R
M3(>Y2S,O%TGA=)T_J80<XM0T6?#PS_'PA7(V;]Y7##Z58(-O/8+CRY=@Y^Z<
M&AXG<YX1.@^5_A\>312-?Q%Y>S?L6IL<3_ZBZ)&M;$_,:,E.U.$U\M$\#C;M
MLW9ZHFL*X7)J^FZ!Z*YI>J0&J>&SWP,>GQ-8',9_'&VG<=!>75]/G?Z77_',
ME%]M62)URY9I#DCZ[#'ZZG/3;M<U_@J%8QC@T)SJBPUVM7?^'9/RE#U?DD"T
M_BY^A3(N4WTMH?+B.9K%>4WC/3,9?M1-K.ZZ\]+R6TMZ&+Q;5^8GA60#]$U9
ME!^M/&GULWLVIN,P>J$'"&S!<7["G,-!1(N$ER;23IU?JJSBM+<SVO[#)LF1
M7E/8^?!=ANO]D@;#Z-9SRR+$3XIMCI%)C,M>3NZY$X1S^"MIO=OK24?5#^W-
M)4W6H",57V(>M3)U1G)6FE[-7ZOF/[0%F!.U&,@H5*E,A(NS_H6U#_]KYM\
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M9\[":E;+>LGD\_#F:[' OKK>0QTRRWFTLUY\8:E5\GQY.3? ,K&VG,MFC<Q
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MX(.R?1$;J[O,GKDESA(Q=$$GX"?#.2W3!<YQYX7;*.Q8+3,^/(^]90"[DUR
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MB%/LAA9<GL?:7$%W.33I4L>X2* $HS<"?C$V\HH:U[6=05G&2I+?*J9?Q@M
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MVH&OYD0L+"UBDO91MJ_.E6Z'R<H9_<K/O6L";CQ*P88E2^>ANAMV-AU*K=K
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MN Y)('. S08<3HB37KPUU@1#R5TN1V!63 B>'("O]=/(D6!-HP$%L0T7%6/
M7M<RDL&P9LM)8NFI(YV,6C"WQV7"++:6<\DQ>IX7TCK*ZZ42U< II6;/>R:/
MU1&/9.%4&#!.K\)]#39 I0/7U&R]L=N(A, %JAYF%^2/@(IV!Q W1_Q<#"7,
MS(KS0D"AR1'K5:7JVWP.M>?+U)C8,HME73O;GA<M,>/*#]ET*9S4Z0*O &B.
M'BUH[D]DN80'S[*  :L/M79 97G#D#N_PK6:WI2XUT(U-&)[WXA1_!!ZZVRH
MO.QR#?2!'9S\>EY#]E$!%Z:!N@NPVPD7/ST[R60Z9+?:JDL32]#9W4XD18R]
MU,VQRM?;C5<R%3V%^SUG<YU)7_-E>779AO8BBE4]/E<,)=KIVF]O-<7T&Q<J
ML4Z43Y<Y8UI:02NZ0(X?+76.[40D"J E,8Q0\!+$L[LHNFYBZ/M)V]NXX<[.
MB/6F\(#C!\^WE[JAB&DSH@M3-9:E$^LISQQ9<A.EM1VMD]T([$I0LFW>W1KL
M92VRLG=U7QP$G\Y )_%9D>4[J$E]93$5<V+-Y,N3QJX3.SOLJG6.$MF&#=UC
MM'/K9M-%-#^(!S$5SO!IS1!-GN?'ZR9&FBD[>./VYLP86:[(2SZ]BSC^A(+,
MYE&P"2,@C$05=T*;7(/,@F^VF2IU464I%X3*TVZF;M#U[FTO:.VRGHV0W-!5
MV]N\I 'F25GC>_>"QQ:6]>2<Y6A5IEGP9)ER('@;<@ZRL:"'0;_"(YBU;_.Z
MHFBON1ZP+^! GUBMK@YDX&UYL?9(Z&Q*D<4U%V/9U(1IR5$'JVXIK>>Q9]0
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M/?VT*[K>4#!<HJ393MGF<&ZH9'9_0U_</H V>\1X-BJ##"9)#5,5,!O7M9+
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M&W,4ZMA7S\O=IT5K+WW6 P%#TZ&::<>$UN0DW8AY'C1:5>0.FQ\6)%(^H?[
MWRS RM+B4;J2<5FRN,5X04AD<-2]&#@#K6G%M4RX,%J!3@;(%M])1#XMQ,]S
MHS_,_JG#SSJEY>EE$>#NN]J VPJVLQ$&%]!<4'PM \SZ8BB">S*'D(C5.[9_
MXM21]!@<QEL*]_O/;1BH,NO';+LQ8D*$77Z9CRNUFEU#G>_/(K%RQ(I#ME9Z
MEP(GE+H)L]1YM;2FL<(N2'-LR3T91^*KFAXK<4Y%][,ZAAB!0XR ?"SE44;*
M43J,PAQJ/[!-&4O]OBV@/:_V.+2[>XFRKO A1!79&#XPM%[>GO)C-VS[,&6=
MT(E\C))K.T4'^M(VH]20'L8?\EROH9]WIJMOI90(EFX,FJ[VWA$5WHDLDV]+
MVNK=':8$*1&R2/=_XYRJSCP5P%4E,E#0A">8RN5'[LW7Q>T$-*7:WO%U=A4B
MI2H-.))>HQN-(<!;XYM#YJ(:5 ;>,MFX<<9=JLK@3/&\71U\J+)ASOV!9?UM
M&_(],NN6 6_D6...8"*4_LQH=&T7UNJ>>HMK.UN9S3A"3 WYU9/-5-.Z*]2M
M0.%P#D\.7/$=^Y,=476"* 8P>*?RYWU3/LJQ6UUS>$%SN5WMT;>8E,SBW!6A
M&^FTD,[.%TM5P_(9H)(2&K$[B[/FS[[9B&\_2],Q/BS8;SU_( ]\SE..)6UP
MW9[A:!<SVOU"@MQSWR:;O1689F%_V-9#J4"TZ84<AEJ_S$Q\>@P,%*N<$&$O
M0-<%:[12^QF-6K;D@(VB0Q*69&<YGB/5K3/E8VDBMT*JDUXEY\2HF_=#?@U+
M!P8:Q.0R*]<N>62>XM&&L8;2#HPRG/K3)3VR1._&B5:1ET&3H('X%/;B58<N
M#9N\AP7 <X;9M8(JEN\-O2PSV4:Q0Z[U\9BX_ /K<O@"TWS.EPS3$&S5RMI5
M7,E/R;V*W/R$C_Z:SQ8(P &-M6';^P5#4G*\YG T/5L;T3%_[MX>^.-0!B.&
MDTZ^ [R)PS/U6"?U3BX."YV>:>@@#AQ!BE34IB].J/Z$Y(FKRH@!R3KEJ/$F
M@UJK%[27Y<!XR^,I(TVMSO-PM?KIV693PE&$0OZ$Y<@ITFIFO:E"!OA+H$;;
M@3C[)\-\BVH6+<VF ,<9=<>%27CV-H?+^>H*;A,BP).$MBQ]+U4?3 ]CSEW\
MH)>%:+^,JADL.UT!9VA#;Y+CSD6)\6V8%,"!U"QC#]R=5"V\X&Y7>2<#FJC&
M[7A-ZQ@/4/^A_]XHG_ZBIX6.R\4G(B(&L0B\GYELMG0=7A<R]<$R#6+118DT
MG0'ZN\Y>'1X',)(>_P/<_9J0+JCV[#AZ\NB:)FQSBA:Q<SF36[BVG7W:$)&9
M^ #V3-0S_P>HW%MR>0R]!<U]MMGC],&X6U9XIA:'('0&)*,W\GXE#+P=$_K;
MN5!WSG=+LS&Y#]Y=?X#:NF.-2_>3#9+%!91](Z^1KC170.7[&&&@O.I*3?HC
MCKTK0G*0OH056[ ;?9:1 7@RY;5=XJ:8.8+NHN5.-$$4>]] ]YFTB_C3C8A@
M$AL]*?SF1',X16A1\#X%HV'G6XUNG>KF]M_AO@:1@%O\%7L2(-GC7(LVKO33
M4Z?]U"4K#HMTN#2JOE2C+@L72Q0]<XQ <J9>*3Z',^N^$?[')PF#I9D5 1<X
M8QLXN;16S') 6>FUU?IZDX))5]$KL3M!'+QDE!*#_!T=C71<!]Y!G !,_(F2
MUF8*#?*B]Z;-UVGC%%0IGF)_(W8DH<NU#$U4'AC%[T6XVC12;=^:LO7U<73'
M DM<>0#UGDB6LP+[A9N8(OAC@%@?7CF;J@Z)2:FB,"ZH=;OMM;>[[?!1$>/$
M;;?18K V1UIK&\;,^5F:S#FDK6+EX^I3C;^X1K/9(D6/@"O,3RVVZ=EY".0\
MJ*1M\7B8M70W6<07ZUT*EKN>MFZ&Y,B<!BB_HI$-<A&5K[D*ZRZO_<V#0;-\
M.\"J\/8%-7^^^HTI$<XL=7-7/P<%M,L$-#D';;5LP,NWS-*0A@CX[#-CMA\Z
M!>H?V^J2NN(L;#$M/VX//UA/XTM@<+-WZ([<Q[V2KWCW]J<R+:\W=8DH3A10
MTE]2*MLX.%YW]GJV,_QI5AX ?LT;8#3UE<J\]D>KZTLB(N]-\0$)R DUD'4Z
MX6YGYJ_S!C@?7#SUZSK?%=1H\O)O5NO^T:,WPK<Q/)_D^DR=E<)QC,I% YS!
M+8.2)/"'#!/Q6[ D_P)6U+[1A^1"I=UYD0XI4XE#X<(SQ\$JJ3GENS[$#AF&
MC!^X\YYU]GH67$RL^I^(6M8OKX;GM'SLM.64^K== @M_,EHZ79<-EF'OID;K
MP;:G*DLY&.HD.0+$.@Y:;T/1EI9C8;Q+Z]56K"RM)NDS:;(I#Q G2,+<2D^/
M C_##,B6MAUU9T60B?\* ;UG#!VQXT&)N4/S'II"5HZ;?1R[D^=&6FZ0WA=;
M@4>R*>_K21H#;!?O:/%!]B-,,UF'-+8T^P"S+ (DF7JIQFTPW1(JGR)8<KY!
M^5RZ]9EM%+2+83GTK.0X6'4$S-Y:2/5$;K%;ZS"E8SE=6PS04J2# NXL9TIY
MOQP;B0P96RH(H[Q:4@?,R9\Z[A^[A29IFL&^#U<1!DEOOEB1KIVRRY1+1.K6
M@YLK,>7/B?;6UL7E!ABQ-XG' (/B-@N"G*^ -[BOV?T5-J$(9I</+%H*&T-\
MX\XJ1$>DZC\KCN@274*-U(OZ4X\2,FO_8&EAR<<1B4X;^+2(3JT*VN!QHI)>
M--'\L("NY4A'B7GD<:VTO]R- VF,9'6VZ1D4Y$RM%">DA9[8,%$FPV]OZ$+S
M\V= :/_=,->P%PU21?P#=  '?^G?>/Z1>%\??$WZNVRBAOX/$.C_-]WL-;)#
M,FF'\97YOWR/=%I=^=YB#5LHAU@,)7>5\PLU&1Y$Y>F%W>/T5.2(+D8E+>R\
MGGSKFKS/MZ.J];A_L&->$'.:JDS,':3:5&!!CI/KZ %3RD]Q&T5?7QM=Q_Z\
MV;6YA^+<S?M5/8=N6"^+YCEJ2)X*/4%ZQ5 I55%BCV>]_0J?<D=F+J%O[Z1)
MB9C?:CQO'/]<5A'\G]27O+)\5HN%;K!;/ER^F*YN1*S,??DXY+$J?]\2GI7_
M[:_S.%Z<U'\<PNEBAW]SO@7IQ#>MV<SLM+O=O'J6Q."H.LA-VKBSMZB!B:S(
MH*FG-53UBUP2V2ORFXCCK>MX0"-V*]7BF##EPE3K<CLEK<"S1\JA52=9V#[&
MWRRA(>J;SB(AO;7'PXREA+8-#-+FC0@*DJ_7DE\W,U-P&;A_H_U)HR7A9@Y;
M-C(L"+O Y2Y+B8Q:B1_$/-US10/J+U+_;TXCF02>NSQ$5BY2 M&N3T>&5$>_
M!NTWTQ@."?.V8N%1^-)1UV,M608DX7.3CS54PN#7KLD?4UK05!K4Z2I!U#N8
M]]<D/6J1=;LQGR!+AIO!<YT=KB&;V_E]AP-M422\ 7..0Q1;_9C:IQC_WDD_
M>T9UN 5T'EE"*2"PO E#EB!-[[@U5_#'XO1)T3JKM_-)- N*M$+.3HW-+J'"
M5X\AK/;4/X/Z:_]YWT+;!M)'!!UJ-VM6^DJA'.\A#UON::F4NOH1OX?#@WJ_
M "M),CJQ$70+]#%MY<0JCWSA_%-TID\*<-EXQ2FIQ*1#MX)3"R*M.HB6H ,%
M[6W2$#IFYPC$%\Q-P<5@+)':].T"T/*V(;C6=*Q%?[P@23VA"?V8OW&[\ZNW
M(V]+Q"B72Y_A!4$>I6Z4B0$.0[:&4TZQ>I[\= NE/ZZ^T68[_9@&_R0;BOH9
M[M1,M0)<00JIAD?]^DSBCQ>T0<+RA\I?ZVA97 T7%@F%7Q&<$^A23&5'/Y?&
MCAW#;5286<Y@\O.Z%Y=39V&98DB&*6%DCMV73RPF[G31(2_$'C7;#N<1@LO'
MLD@W2-(HP;LVXQUM=0(2B/ HU"$2R-3A:SARDB@W?(D2FCJA&*B(.!*(%#@2
MERAB*&(2#;X,I3VCLC)Z"$1-!44DZE^E&',X-9VR;4F6)0][!7_\=JF[,TS
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M7I7@,&YQ26(8%ZM.;2@C2Y]>,9LD#>N8QU:N7P!2Z8PA9^QXK!]@G9%F^05
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MT^")\_WD5J1=I/VE+(I8SQ?EC[((,+<H24-9X)J_?E \GK_*3)FL@>>"^0Z
M_A[]/0  0'/S,P7_6^]9EIH5IM[2P2E?W\C4M6Y [>F,+2_75\BR]U'R5$*V
MPX8&TK\NXZ<V )FK/P91#8F?T!F.U\\*4(O8JF(/GJ!U:@O1#?&%&>B+?2LJ
M8J]_9\7ZTS3<M0^.>)!,KY! '@H*WL$<1B:\(WJBR6UBER><"BO%>7@,0#J3
M^7UZ>H@,XOK_+#[]KU:1-A^SY[;O@F,K^0K2(4EV<?X74-#OD;>)?PK["YCY
M?!MUZ/OA<7G\NN"?D4 ]:M"&U*3FK26TW>MFYW_B9MEVA^[VEU=,>\_.BN/*
MZ[Q?C4Y1"Z\5B[ZH]/U)4206<4(K85DBKP;$^M9\@BM<426JWOKC5#6T56OK
M=2JP7D$S063@WD:GVKFKFMN0I!\I?'1V9SN[R4;1)"0K&*K>L-0Q-MWH??>M
MH[(CL[I]X1J2U30W';'FOWO8F#&:Z%ZA_VK8H=K%+ 6;:83/W*26Q/?WQA$D
M5EQ?MA(SGE"'S)Q%0E!HDS$"-7YQXOH)?ESCV#&:>5WN".MC*T?:*A9)N8EI
MFZX(^M-D''M&SN4P6,PC.?@K5^<;[Y[@YM/+"K#:85HW!PZLL*I@'2^4%-#/
M>BNL>3"6^M/G#_/G90-+"A[[U9(K,3'F/EZ' 8]]GWC6VN>#]@Q:4Y?4!8H\
M.4]X9,,0HHD6[6<!'TR$.G*.S^SA0(EO'F)(@>>AB=N<\@_U9\NI](2^RBU+
MUT\=8;'#.KZI$MEB+>DH%P[0<G/-(,J2]??"UTH2[\=_  EG0,^!^/X):R63
MC^%LNTVVG4=F3[5+=J)_ >8W'G9>.)RUKR6SE7XZG!9-/Z;;04Q#WH)&)$,8
M%=8C$V66&Y6;^'$H"=PBIV=5H;GKW#P37Z&VY;0 S>/37L=IY37!:$KDM)%C
M\34?0OWE<77!G(W_CDK; 77I_-#J22SU#-RAH76+U**\.F&^7\-0:C]*SCC?
M;<YOTC52@&4+"XXYIZ_]DG G_:7(3W3RCP'(<4TO]4#,UF%OQ]/^V\:?3UQ>
M4\:*EO:2C8M'7NG^1^VMTY7@9:VUA:^W<JPP[$"GG$*'9 AFJ@R^*T+<'!4Y
MK/W2>!X4115!U#NK2O#^* G;MMK?L_\+3=O'NJ./@&-V!ZZ2Y%):?Z'%I[Q:
MY.BR1+N0XDI#^2_\^?##1YI@V$%P4UB\%[@$O3226HL)D%KRNG9.Q7@ G2AC
MP=JEVH18CUO$R1!06#:FJ6 9@V_(</;HD'I\IBU&2].[F&/I,"D!7\N!1RL=
MR)-.9B_A:K^T4IDQKA9LFA>]1?ARSXWB. 4RRP]\JY-=@5!RG(0DOH:X#>P&
M*-/W[)^VEJ-Z2@"&7=#):9,?-=50XK;FYQR9JEM=X#=_ 4J*-J-VN!\:O>.&
M5AZ^U<-X%B -Q=Y!U9\K TQL0;NS_$?^0O4-$ Y["**P27(\BH31PU 1/3GE
M!2-U/>'[1:^#Z7GTU;N_ /P/YS?/2Q[[..L 1;6OR.H Y"7?6L!CO#'T@:#U
M=X-7R6S0B6M\.[R<V3_/^+LS3-GS(.WJ:)1F&!D.=D1[NT0R^A/A,S>!]N/.
MB;WBD$3_SA3T%1T!PN]P-NY$D%D'#A8FKDCXH;M*2'2B-/IX,I=6SBX>^C>-
MS#RGC^V:0&8_*Z,YI#<_,GYG=$0T>N=HKQ4ZK?^>NHX2426Y:-685Z2)-*Z@
M3KB25P.TS!>^#.$O"E$=ZN](*5^+CFU'&0"^D*#WQ_FZ>G?G=5H%B/P>$&PV
M^?0TZ\_\WEOCS*P.;TZHDM2"P]C'Y::A9;F*,'>\SG;-U)$WV[I/R?FGJ?PA
MZ7$D?K. *+H,GX'N=7 #AI0M"759_[>;H_*A'>4^_Q@K8G0[P%_ $M\:YL&:
MJ,]J>^LL_*@C;2JKIM(L5J-3IY$E<;4H",G@Y?6K"2DZ6N.=S[J+L&G @LVK
M=/SY/C+]>Z$OGVW=['#E2F%6X,*5Q.-[9_PW2W&-88&7/6GD:/XO1._NH 1N
MCQYGU1G>=:>!#BD^MHNMV:V(T8N@D([$0]WKY>^P3IS87Q"T8Q32)E.2D8\%
M*K#:8Y]#=5%/Y.J6T:OZ^(Z5OGCO!B$6]]G=A/)KY?WWE"M[I>]EMDHK2X]O
M?+#Z7[0SK@AVU-QVT(U5.@^#*N97KP^"KJ8I6O/F.1Z+WFAJ#Y%KOU[4\6>&
M&;0GUC69ST7&QXH4SJ:"8PV7T[Y5D9.KIIS*H.CZ%(ENO>N$ABB+U25_P7PR
M^P.2^=6:W6+/X=/YP?1A<8EU7,.9.NU:UZDP2Z65V0%C$<Q7CNM@V*2Q= 2Q
M$E\L6AD%+\"I[LQ&B^8TJXYY)\?U;/VK:J]1*]PEJ!)SJOFF"ZW"F%</F4_N
MYJ/\$UM<OC#JPQ6^G)B5[%?W7W=>-\^537[[=K+J57>S9U+HX'%]NKA6,O=T
MO#8\3>&P 6%A565CYJT-=GWK^M7MZT<]GQP]HE>BY>;?@.8QVULK&FP>'9'J
M+.Y'[;K(UB\PWD>962\N)=!O1:-*'T]C/4GF#\IZ<&65UIN>9<=ZV]=S9\:,
M*W,XH2S)"FVJ3%,SB&)Z&]<*DSW[?65MY,G@V=T6<9,S:]2_ L!@B-AK. ?$
MOU[!#)Q&4^%L1;PE22Z-VNG',+OUAZQGMFX+^NF^/\XM9J^;:GF?Q+',T5\_
M.79RY==2/_?9"),UG^<_:UGJL^8'E<D+CL>#3Q(P!\*F10C_\*"%T];K"*KW
M'AL/'W/_ @R,8:*51C8-A>49*MR9B@NIMK1GWT**)&U4XWK=/G>GTNI:%OHU
M0'>4+41^UT$M*3LD.QQ/66;JE>,F"^O"E,=ZFV)!\C3?G2E\^H/=)?9R+VU+
MF7)^9BEAH:8/<A:*6;Y21"9F,4E>.#1=[/702@I71>Q1FI[\1WZHE_U5[C#P
MRJS7UE&GUWB=[TA/4BU%[,V [:H&40L=GK0[CX4FUU!,^['[DH,.6%:7(J&/
M=\[GCU0OQ1VVZ>TJMDYN'Z@SE:!R>:4"&MH"3Q%_73:X/!*;B<E!R6!1F;49
M1+ QQE-W3"5?#';@KM["27H5=SB[ +!J1$84CS9 <5?*B:T [%$'^W/YM_'Y
M:6Q35F/3E%Y:A36L>OZ[_6_*#6U90?H[]P8F$ 3OD!N4KFE>UVN[6'@X*=?,
M _IX&_E4D*--ORD!4%H'W&6);PB96TJ$G">0W25QS2I+QCAPL^W&T3T/:[?%
M"V%=L$1B,K)[+7O0FD"WQ@19J_1\6)N@(P"T(LLD-W_; BYX7=%...-A 8>%
MF8G:-]=W*Y^V_@+V0C6K9-)#__&HX1\W/O\1/RF\?.RL#LZ2\";I\W.W/R=%
MG\VHL5+["[C9^F46P'5K?QE+E4UD1IWC$>=DG--5(N&;IQENXOL7X)/G993R
M65;C%P-=ZK%$><UA+7%*^8S^)DW+FR[Q3Z"I3#J\?!0$7_R;C;X!%0CY&.F.
M1_>[L73=YTEQ*2SN*4\.XP?M!-SKM%9/X#VWG=4,H_6XKUTA<]G!+]-7B4]I
M]UD^LK +DNA2&27V5D^#K.).\L-BVVBU,,.XX#1[/2LJ0<&Y*?^;_3]'XV96
MW9*T.)7P4QK7XX#V'3>5!$H&LK^ <8/>!@IN;D=(D%-?-L7+\"R(BKWUFH+'
MUJ8X>.=#M"^<L3'W@'^5\[W^]2JW.*':MS]"'@WMHQ,,E%M^H,4('(Z9K;<R
MYYJ)09CKD?3M\(9DT!Q]-Q.L,N.4*41ZWBNU59&Z.!-=C#&.I%5?3'TX9K>S
MZ48GS%U<ILNP&":'*5FZ#4/2I4T55]X3A:JK_!-G_^3()U.AE-$)9<94<8L7
M(AHJ=!BD+SO%.BVL:5&J ?'(]#1T8]>=V<:2MWJ2 ZVN#V;N</0<MXVJ.AH0
M0<G0IQ_)8]E')??UGP44F7XMPIZQ/I5?LL]],%K^H3P6]*M?U*4Z>W/PS\SV
M\J/ CY^:J9+R6<-'8CX'(N/+]WOJ-].?C*2RH-F?;1#W+)>E PU&@;;.3\PB
MCY^I#CI:7:*9KW2378[G_@+0)/5^DSAR59W\*MJ3<MG*$9I7O[!Z=G"'/&7]
M6B\=RJ,?M;[)05Y#]T[^>)0\''2PYXUJJ/]H /]Y\UOW/_UKG.<O4Z'>Y-_E
M@XA;Q\\A>:R?H@72Y[S/ICSR$!?_QB$B^#SJ<JZ[HYEH4_\PMOJ@X7'[+#(=
MZ/F+1'.W]']C_/\28PE_4/71$,M]&MT1CW HOE%&-"O([TV_;GF7B2Y+)MTQ
M?_$665=]/*=^C"7611]/G*PRPQ?JU<[3M>.%1Z'7^JP*F3O]5'Y]?G;E4!];
M.]0M";ZI>LW]!Q%Y_?]59?U_-</')?>8J(EEE'Z#T HKPJX%!8_U4C.@E><'
M>IZM>$&MZ;BV*LN_ )OIJ/,Q'JA'S;HPQ58T?YB64IQ1J<=Z)6[CE-6U,%JJ
MWN>53BM;@:[?*BU@9\QY\CB<VN5EV@N;YC9$],OY,!N/OP"'Y T022G%?J!I
MM?R @C8]&D4EA0I?/$Z!ZOOU$AF/^/4AL^Z,\V=\/ ?A$*^6>7CYQ*FR%_@N
MMMT-/H/$/U$#W85SK,V'7V/;HQC13C8.;.MPRT7;8B00KG$_?C.#FWMH@I?^
M\PT_^U6"4;-*_L/&Q^\KZ9?'OX96,?:'T<3<^]YS6K 0%C)+OI4*@?9]D@RR
M-C9<^S5$6]?0V@Z]D[5WX1@I/8Y[XR-5YXAWIU4[;2$D&GN3F^<L2G[F; $/
M?:N=YA.+?N*0OWO'4)$ W 7&_3ST$D^U)A]1S?A(>%YEVRUUY@H<C-Z(>6*]
M6?M0NO>[8:Q BAGJQ>JB\7H^)!&J7&HB<_\7H*&G.(YT#ISM']Z1'9SA=<^+
M]75J<O7SAU4-X'<H627QG#'6BJL;Z8V.EWGS17[\VNAU,J:2O'<KVMO7X>S^
M.L96Y*96,2&1 [I%-J:7;B23'&,[&N.A7G:^1V /:*HL<%AR?QEG?9KC R&4
M6(MID$NLE40S_+KN&%A\H8ES%/-:89.:5-\=D]#^H3AUY3M>J:>6VB4+#5T*
MX2::T:=IT -4Y_^IY2E.][*%;/",5+[S_J0P'W-OS98PI1_S%] M/%0'_7RS
M(VUX@]7CWRG%6M3Z,N00OZP6_92I/>CWZYN4MW"^N_N%OX =EZX@?:J!YSHI
MHC\'9XE21M*/NE*?8^.?07^8=S2L/AOF109YW@WD57U_*L_[T=?_%\ 6]/JR
ME%>J2K/GAVC MN:<5M#,^*^M?V9PZ@_,W[J9;^>8-S_D2%PR'[V3<K ]NZC[
M"QCZ%?JG?"3^Z/4%UUCN__GC>KN*-Y'WZ7N:GR(?AO"7,A__.'V^1&Q(L7HP
M//3\4;TJ[9![LD8_47MZ%I3Z#3[/2Q5)?/H8Q/A[^A=]4/W7VY*@OP#*MW]@
M]YI#T/\?H#!39N?P.Y<F4QG_P\,(W?L+0.2%5+U2J:6IQR"FFXQ[62[YO3.O
MF6*O6!G$7;2'I1'TR9:\SRWON7E'0#_HXM_<YFFG\MCLXL/6^RB0E:QY-BDD
MHLEC,T)ZO;&J+XS._B]@5/0/:3$7+O)>)$F)Z")FI\?7WP6#=H*?PS&Z&F!$
M@S[-[[HP@B"JQ:=_(<%HE$2K<K/ST[L=(+ M[L$\Y<RP\8S>)#Z0M",0ZYM_
M@%O$ZN<ZT/F <RY>ZGB]:V(DB&EA]#VEF$5%!\K(TD>44DK6I0.U[,;4X-GX
M%W'($V-)0]8_&N>7"4Q2!B8G:>HHGP'OD\U:__M=F.8H$P"Q+S0 @S/ZDG_/
MTM;+WK!@LO>+]=RAZ*_QI(G",%5L""XFZ/E+=]2S>566XRG8;;00'P+W");5
MBU6-:Z&VXDC4UZN:Q/!&WA4337I95()"5?ZI@9^6<>\F^)!(@HH*;!Y:@+I1
M2PNB 9%U>NH+@T$*_$XYF1/IPS$^ZERJLE?K,\02D/C88%5@ E&,*4X^%&>,
MM/24FUI \D,RP(G6$ ^&2=I,1LN1;Z3:-<D6VN%=%_W1C/'RJ9(JI*G<0)TE
M!]U?VN=<"0&^F]]TMG2F-=:5LHC;BNF^-0>7F79N[";_F;NM3J0C"XCLYG>\
M^)7RX83."SA](*DY:XZ0F1SL\=&J2AY3D!:U3MFW#&%_AHUNNP_3BJ@ZNE<R
M'&1M^;<Z,7 9NG@/$_=L/0N[PE)ZKG3;,D'ZA^ $Z;L5&U&^O%>%#2G<4VZA
M_$L$*:5OY>T?S+*+EF$EZ1:VI6!.'K34-M"D%4#H320!7X($LQ.2IJKGIB8-
MKFZI/W>:=6<X4P-718PYNYR6(+-1]QS:3G>T/H<+T+TQ9_T"**OAJS0U@XAN
MX0E><7*D9QF;V,^EE:S8][!AR<;"R+L2&MG(=$#_*J#P_*MVPC=@#=*I>LGV
MHJH*!:3#+8V>C^I)>\V07PZRLO;\6%7$^Z\V\*5T*3$$TH 0#-J8J 5\,PF@
M1-CDY7JLJ+_94CY_HQ!KC0\#O85A'<\Z=+/=)9!W%,NK9"IMLR^K8,/0A5SV
M(T&QQ8R?)JD?S88D4YP1#&(YX05"+;[-QE)\^>.?U75P:-F4:;B-[.$X-8I3
M_PDHOXW#N#SJ:V-DYS8S4^[)XDTUXC\QMDW;%.Y#?R(IV00CO?51+.-T/1RB
MN)LZ$[K]6A$!>D@4M;&>6=!FD:(BF-WH"+@=(%$=IR+#NTE+0S,\QL!C=MER
M>D60=M]R8#_3G[2Y-=#]F=?Q$YM/UT-ZEL )[Q+YJM%Q#9WZ+07TG:MU8VH*
M]5'J'GB Q#>:Q1/K**^Z^7,L>W._RM4OW,-YW>5\O1EVYB"SPB(3X8'P6]2/
M;8AN=\Z/7"[<((SMOONL@.OQN>3GF;M?N\A:HP#VM[A!^@U7N?DGZ6^).SSO
M#O)@S$_E9S_ZS>MO#24I_I3O2<@N<TJR?3HXFY8RUGS4_?4Y[J?U<>TG@=^Z
M8_[?FDP^@?[QA25!C7FWI1U_ =0APXOF]XZ7I= ;?*?F>]A5Z0^U)WNI$\W
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M-N 1':WT^T]49.NB-><V! -ZSO>Q=A!;"O9-RGGS!K;IUFS;.A7$L3*S)5M
MW8]%@DS08TN3%4\/AM1,1(S:F%TBWC785W@H[N#O<DF1MSAB22P9L$@Y'08P
M*J:\F?F!N65ECCC9>6@4+"NR(H !L:-<A67!ZG.2:MZX:HI%\L]+MUH%.$C%
M!CW.)759FRV(;46_5_-8M#$V$PZW'GMSPV<Q4XE(<S&SG+L?+;N?-RXT:LRL
MPR4W;>IZ;QM;([CD=.M64EDC5T1L+(4+= 23&V],$C(PW7IC/CTK'RH]$- 4
MV)'APHM_,-P6>NL 2JU;,N=G<" >J.R<;6T/60N3!:4D;7Z3;DX?S!C(0JP1
ME/HLKY>3,FRY-E;6%1@!C_<@;I'; MY.9"HRQPJ-UP._KNSDYR7O[A^\QKGM
M).R)%W-=Q<FX9MH&6=/$_JG&W:  *D1TGOK?9B[;AC[$'PJQL+:K=[N#<4[L
M_$BRZ]5KBO4(EHTUJ!RUJT3/#&_@Y"EE]CS*S*MTIC"E('L'4Q3\2CLS<YY-
MX"O)O8 OZ2;%0Q&+=RB&VY,A4L?5G#"]VZ/LJ0&,EHXMB96+"2<UI!.LP3M
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M!\G/%P[M-C/V7]A_S<BK@\JW Q[]7D7[=-U/_BT-<E/;GKXKZ;\I']*K7/\
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MXP]%)46QJ:0KP^E+9"/!D9QG&<9RQCZ,^"D\?Y8[=9_)YKLA YEFVF7D)/\
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M7:,\%'Q8C4"&L9<39BUA,MQO^@K&3G&@WL)&2[(5 @A!4B*,;/U,(H"^D6&
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M!C"J,,SCH.CL&#,/4S!V!/>0QSWFK?-E.X&1R&C2)O2/6.,H40]?U4,:%1W
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M<R\6I$L78PY& 9'&YX<W'(B)#L%=,EM%(Y=PY+*J.!)(J.JEB%=%8*XR[9#
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M2&O:UJZA?")NFT\>P'K,&S6ZSW:<'!P6FXHD%%-VXJ:->YP@]B,+#P79[C,
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M"#%MVYD>RO5:]36+AQ()L#H>JWNZI$@-2+&@V4A005[Z7@@YA 3?'/SSBXK
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M)K-^DQ79.3U)SCOUO/J+<!$=JM=%"Y]X4SY/WIC/UI??WJK#Z%:I:1^RM<2
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MND7!M<E8#\ \"#-H5\8>WT_T\,?=AYN5S]"Z%#\ 6TS_):/ GDS)Q,S78^2
MHY+A52K1QR:[UTR5,: 4P[)@C^FJ7!FC4G3-B(@*"_3WSL1VB7(VF*1DAT)
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MOKX&GC;&K;4@,N<(YOJ\_*3J\!_%V[A^GD)$U/7^!8RTVUOCO6,]!'EE@6P
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M<LS7P"D[>O/GT5SYW($*[SMI1QR8D]?$LNJ="TX]7@(=K2M)\Q^G%E 4:3#
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MR6:P-WQU<TNS 9V$KWCACE7'P:=!4)<U*J/.S2=I)^>=U5?21VH2%6?]E'F
MV7H#OBAZ'[W@1RY\*:JOO*AOD@EHW(4RSP58[9F&/JIY:#P''E2;E>$&?R#S
MKR;*[FO%ZC!O/NU]#/$R/GUI,PQ%>VZ:=T>;?%N],CK31I?5=*F#:@9L%Q?Y
M3=ANG^Y6MIZ&ZCJXIB]',IL6-//)\^\?P2>#Q</*SCSA=7.&G=EQ2M=+5":F
MH=V*<V\M=TT]/''#QDCC>A. !2U!754;-*,5&QH;;XIV<?D4'<*=W26:>9)4
MH"^]4[:W^E3:]O-/]+(I9;EPS+1@?3W5C&SPKX1E]CH*)D77\D=N-R9JZP(
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MB8#S"^@:4A9G7!1D1' RY"-\FR\EKT !TE&._^0\[:K)-3XR M'2TPPP7'P
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M'^MR3-=U91W]L>HD)_D'WNRH(AGCY3M]#JA>NDY7SB7&VC9#<XIC_RV$+R'
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MM&CMC[.VPL(PI9*\SE\+W7>%72)*8TYJ:QGZQ5ISI 6]WL7A_49-PZ(R@8O
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M8E']QF)2G8@P=M>:,*/03B(#FZ8^IYDK+Q^S$]VBV <H^E'<N:,9\HW]<,9
M.P9[NUFHOQN7_#*8^TJSXO CHM0G_Q5\"B&BSE!<.E%:[;JSLIP-JZC!C3M!
M8!>AT]%:C@#AU1Y: %B1A!HK^$E#!MA#\ZZWR^U;)2O&5BP,,?ISB&%-%%OD
M>9(/.%"A7)%KCS.DE*=/C?9JZNF^"@N9_ 4-_1'9J#^FNF8)>^%7?(1S AC]
M\B.8KOP:"0^Y)^S;N$N];ZTA&$N&?:EU6=*^7IMLRM&H:("- $S?SZECC48A
M2UC;W8P]HF$\FL,,>)M\%K\J&2;@9>M$6++C^"9)V 4VF/X1(=M]-//F%;H.
M/*YF2=7YX]8\JW R1N_>);S3X\R>V?L6<$4((2P#UTSSC377GSUD"@_?#$[]
MI-%)@C;5+XR5TP>DG./X86B:GG@.!$?6\7S3,E4KDC!PMX]+>3^4?0GG&=+P
M@6=@>^Y#S'97[>S)QQY!&<^Z=[G,I66\T FE!*V\E]S2OQNU7]1TN-:\E@ %
M!O"(<?_FR$6@0J#!4YOJ:*C6S'>(BC;S>[(55DL8..F%,],*@'P-SW7%(;['
M5JR%LJM/_'SP *=SR4XU_U-0:(Q!F;7#OH-$BM0W%YQ*4@?ASZ%HZ[V BEKV
M@0L]T8[6W(M8PS&^];F.9WR!%7NJ35!8UUUP*X@OD\8P!(RZRS>S>732'M=V
MKAZSVJ3I)^R1T'^CGP-X%10<_3!;>'HM39.5,-BW3KC)3WL[D;!$]@BQTFV)
M, T5Y*FCQ\ 'R TU@<)<DL[8(.P">?Q">S;[@BB[W9V N%]%AO4^P""L&A-C
M(2%I>G*K/&MM/RR+RE_THFRGW-NZ_R=-XMZ]-HH4BAEKK\<[\$37!]R*<5EG
M'U5]Y2(/0I$]W@I9M;![=6Z/MMF1/G%-4YLK/GO7OJAAZ+B7A"8*#.>T2(WX
M)=5JB;) QJM_#N;M!SZ<V,C(GZV(VQ\7\I%?\1X7W*TO#Q-:%3<*#ZQJ:DQY
ME2K#,"C(_..]/CI-M+,V^,>\\)%JDJN$W*RC81OD=7738N0_[&%HUMM-WRHJ
M,E$!!.1*GV^-\]!939 @]J(4O#@=-K\A53O[R^"0]DD2F+2HA*$Q_'5NM$)-
MS0RJ(:0(TKF?\_-66O63 K&#XKV%"F1?S@3M)V?RP5/+HX)@/!L'EZN_2R,L
M&'$&6,G8$+^6B'!.U'&_7BMW)U?Z=5?PN<2U^A!'8V+SYWZ2\-12<4SV-5LD
MBS]_]@KZA7Q;?CZCV1A__VUHT25I&,Z3WEHX WI0'F3?OS*2Y*R@'6M*D]HD
M;[5H.?VJX1%O?1LME%%S_J:LO'_YK*)SR[BB@XVF+QL8]>U5^*YQ_/5\[WZJ
M9#&J7*V"6"5R&I77U)@:Z,U?VC7MXQ'2X..>LH" 4^>I^"@E9QMWHMUP$Y:5
M9?6*-[6"W,6_1<X %O;[EJ7HVOJ'BNS,(8*(ZPJQKV3+-)CH=G4TR&C+^$0?
M>C9V^5Q,L?6:*YH%[_8FH_M]:Z\X_*G;8R,>2'2 /K@%UF2CD_/R\A-?.%7F
M&N,Y,$Q**><Z+\\75Q8FH% (G'(#OM')7_22-8<HVQN2>3\1430'V7J")8WS
MHK&>O:HC>,^+"@Y/XMRE% ;Z"D[.QTC)^]QZ,[,Z\\DX[LO YV0]QBO!(C/+
M?Q8^&6&$C6\O\W7IH(COQSZD.#FEPZF#1 MP.K3#G4J.:E[4+6[TD4[2,'_@
M4/NPGA%O52,PI-NW)9?F[=[KYOE>#V3WM%U;7=NRN[UVG:!FR#NBQC1\>4FG
MM5!=1X0=Q4?KRO]3,X(W<Y59;LSC3B?>O.Y6S<W90T+G?O,]3#+NP(G=)A.4
MZF_)^*KF\]HKCP^2+K'6'&EYB>:^VS:8XI,127$QZS'I'*F=8F1WA>OG 3'/
MK8(7/]Z1M)Q,-V5L_^&#ZR,A;J^\;V;#^I"._7W>9C[_=-FC'3S#8,@3^F8O
M9-,@]<"X"$@V%4_8NIB'U6+\N89G;&KMQ,2^1EI.5A3@46X-TKF,=*R,O^M=
M'[-5R-)W"VR?'K$0+7:[%;<[WG"# OS>T--O*@RO+ \ZLIAN"+]*=^RT;97Z
ML(7-1VER43?E"LF!R"*#%?[Z<38!7&_&C1O1N.N2U28ISA93\AF@QB%V\ZQ+
MYXU+J!P2KT&W)&]I-A4D1HF9O\RG: \&O;MC@=L1CXW7A4F:4DD8#MJFU?PC
MO-&<0XASEATR8"[@,X39EY&5[YVFV-S(V^"GZU3%)MS<*ME!1;NKI\W5%U.R
M?BQ38;L_36POND@@"4XSOF1J@7$.]*.X"T#<=IWE)@,5EF+Z-K;L\$]F\6IQ
M5Y+2$AA<[BO"8MH$+R>8/(HQP3&\#.';M+58C#.47CI8KI1S6WHWI%*_N8.\
MUYEI([]_%'&<(:<A%RB:#L4MXVR6L%]66WK&.N>'7"B!-)KT"R%)9YAX]>("
M3Y)N$VE@AV:'#$.;"=K9XA.I<N+T"R%UY:G4:;I(W0A<KQJ2Q66%] AED/A^
MK;-CC&+Q[R_\P4UD%E(_;HYW#M!Q'Y3A2_N3ZP?>P0L=U\[;TUX'*HR_G5 F
M0P<99.DO;$W)Y#X*=+&*?E&'S=LAEQ65<3U#(#-H_Y3E;F-)NG)R-O])A$0P
M^L=IC_:M<-^%2:K47UXI(/M.Q%OW;UQUCZ0"A-RM2S1D>.%;A7$]WG".1ZQ[
M>5UWM:I'9W$TNR[1UXV7*QE*_O#'L-K/6@289.LPK@(*V,[M1P[!.]%M_@C;
M--=M>\P-TPM=U=Z]]49S%^$UP6&3P_A\R7X\?G#80L3P!6O_-2)!(0EPYR,N
M60U?+M2,= X:9[I<*7,2_OP,D%?I%*8E-,YAGKD3,3O*1W5"0Z;TR11/BDUF
M:'F0Y(QLJ8ZL7:I$")>NQ,7P:SJ.XDL5AM;I*]I=\%M^MS]H"&4-=:.%;\[M
M]@YU8X9T%P=^X<QA=@2'-_PU$MP=G\"U \V63//K0M\X;2ZT0:F3N)?BI=8"
MCXO&0#5;/ ]<^&=7D$U^R@1M#X)7UD'S34R3KBO_4[6(B(>GHZM5?W^OMTX]
M \@$I-58#G:W>0<1_Q1ZS"J_"YV>WFKO0:#. (2'$]H?BR\K5(IGV3YB+F2[
M<U@FF17P-\/P7:]XR.//19?Y]8/_M!3/7MD+3Z,O3E >2Y'"3?]ZIKCG.:UH
MCP'3M38KWU,2__Y$R%%>'/9T&Z>)9PL11_(MQ4KVY@5:UK42;A[L%&%G!2TP
MO2F2H\;9QNQ5B+WH!67//O#WR+B($W&55H>Q</3ZF&?;33QWZ;&[Z5MZ^;0$
MVV"Z'_-5OHN)+#$6LR'[^A_?_I8IQ"9L^.,*,0:*FQ^@_'#\/XPTY4V=S__)
M1_^S3Y5"E6PT[C)HX*^D96;$Q8O]GN[*4MKJAE>[DTFQJB1@Y4G[XV/YD8M]
M2KOZV%2:'FHMQCE5Z&KSYR+%F9";EO;:1JJ;B"BMZG62B@07>:,_UN5\0+W@
MB +AO:67?0XG%G0[SI!MF"WSA'<8G$"UK&3IF;ZP0MK3*;?JF*K/?2A1VC1&
MS$=6T/$8V%>+6V5%=T23ECT;^;UH]MZ$^_ YB]7RQQ&KI@RS:FPC>*I06\$J
M6ZP4SA;EN]CM_$&SHE(LA!LNIWCULG]VQX$HDW]1]*"EX &TRPIC0JV]+<Y_
MDEG\8YZV[<%DJ&D$"@_54>VPKKEPO/W5D.&+X?EI>)]],_H%/;:H A J3]>X
M9+S?IF*AM]4'\Q5(7>%+?:++A"L)G;$"_?/IT'CM$N3V)4J-QH=9-B VP:7O
M8K1PKJ;L_,\=[5@&7B,8=J<I>96EF32SK)M=$&I6\!6\L4T>7+#MHB5 ($Z/
MA _NR;Z2UHSN6<)!S;7 1">YJ3?-3[XU*/!62SR!^$CY2KI=MZ52^T0&^G?N
M!6@QZY)4P%5,KSYSS+/X2E6=/*[&D-S42KM3S%]M#]KJS>@R1FLL:Y)9NZGF
MF9:<'KHY^4&HJ^.7^IV-'IY?V>]_()'X50>T0\DR$ON:&$.]Q#9./E9KKRS'
MRTC;>:O8UM6]EK%QFH(!QH03,^U_)=?ZO0!&-AV_#!7P89'VE^*PK:#<X&1'
MA,&KVXD3P0UZ(VW&$Q]?/].)4II;;#G]H=J2Y277L3EF<& 7L1GA3RF"%V &
MBKDKVK_,9$.0ENZ'R[J6@06K#PP#/TK9"%A8V A:&'.:*S^[P0RX& :X"&AP
M]*JWSUVXGYN#\W +L'GQ03@#"]LP"#L%39T!>,4=*65G .32;MG1[!F YWBC
MZ/$9P$RJ+S);_5_YUT(N\M A9=7P/_0_]'^C#Q?N2I#W24S,^J%N SY_<G5Y
M%>6_:?>-S4B3'4<][?<<VB =<<>GC@]J'%\.#3>PACNB_;T)V8T>X^1+H.NN
M2J*@WOJJ.%?T/=KDE+AORK"5$B(P^7E!R!>B\7_'=.[;6_SU4W?@<R%D\T((
M)[E5Q?2"G^);RGZ/D7NB=5W>VPU"Q#JAS8_B5'5323]6/=-E5W%==T#36(#D
MUG\38GQ2[710?C<@#+-= _"(F='<!(@=U@U+,C7X7'_*0&^>].G$\C]IR'$[
M?,0R*WDIU9K?SR3DVU@T4$.[9 @N'?=EL0#?_5KNQ,F*S1HSHK=>KGCU(K%\
ML [8DAIW[576RT8<ZO7:U*5O#!NES@62AIP>)0(SE>\?*T )W 9>JIFQ0&ES
M.X/(JV;"!WFII*,D"B2,AC+'^#U'#8IIW9%AQ39QZC!N[#QF]G92> *2?O2Y
MXG:4?@>BE1YI>V#!T_K;%,EF'Q_%(;V3*]J].K1?M&M.>%DBSZ[2#OY:92<1
M1J'O$([?"2 EY%C#MXW;+-]]DEUD) J::3'$4+E0I8'Q;5$?4YQ?/'F=5\1H
MU!LSDB&&+!SB/NUJ^M,H_?0!RO[&:1EF,"96P6*F=+ 5VRK;"$)GQ^0K'",W
M.?;I/DRO/@1RT*I,JW$VIJ/3:YSF\>4,A;+>T363/V5U[<U$#T]/SP!O:N@=
MDX4J36)9\ HGIZV0%4)23=1T42*_HL!A)8)<!S%>$]7,*.8Q82I1L$OY&/<\
MKI</9N22_I.R*'<'/7-.Z&B3 MK<7/]DPU*YURQ_VE3E;;D5E-^)%&Q6 2:5
M\F4U<0XOPW(J=+.SJECZ$_#WGW&'J8Y=N7K#K](.4ZWCCTQL^==@R[][VB@,
M4]W:C8T!4CL[Q5XX^9Z2R#,WV3[AK^#[F@7Q"E6Y(W7BZD'@=]*[K,Z2S:U*
M636@(.78_5P,YW9A:*!K\)51*\5,&./[IYH?.,2=XZ%V6\[93AJ"C1A^.<.9
M;RM3>[:\!M!!?Z*W'BVD'K4$OE"6;7]5;",EY?VL^ZUG"K4IY6N)FP.#^ECE
MX^4^<X/(NZ;:O5AZ<_WP="U>[V'+9F^_Y]WQISQ(TK3EU.<XU]:8K]S[A1PC
MWX'K:^D;Y,Z_NGA^R0['O?O]# #P)/!G?68C>P/3"W!!M[NO)D2V&#$BL:I'
MD(6J/FR'\"/F)#QB R:<X1L2;BU</&.OY6JR]@H)&)0T^"5!-1$5N_EWS8[S
M[Y:8'L5G4.9BT;2Q@@$7DD;#O7A2@=Z/GV> NMUC>G<D5;F_1,ZO@@I+K0'7
M,..+ PG)D+1(J7VKHI&3;,SUVP)?5<0$/T)?0HM ,J=Y2 [)B/G1\(VQ\B/N
M.Q-N\J>#=,MP7NYAR[6-"#=WO2&E<3E<LW['U2@ZP@%L 3E?II*UJJY/;+CP
M50]_!O#J,31WFSST&1X[>JY8&JY8.G$&2-#P!19QQC^3T^D I$.UT#Q&^]:3
MB^B(P$3"U5^,P&C]QK:IP-0NY@,YY)/A\!?6KBYRK?@^ECS$7TU>"W]K!$C6
MEEPYI_P(E*;^_@Q0#WDB2&TL:)_ONJ4MDKWO"2Q0V5XC"24AYI=-/K?LNH*E
M^I\B^N=M!"("+=H[7_"B+1'$A4$.RD45)48_7^.@W4)PD$.:N-4;OP: 7]J%
MQZZ+="!UV-,^TU')NQ"*6=,=B? CV>7,Q6UKZN VZ*8BVPUR/8@I1=F 9*Y7
M"3F:KC5A^O$NS6W\F %W/7]O4]D*"'(\H$+\_GC@[JJZZG(C6\A8D$;"ML+T
MTTSTO2\ HZ:FTYM"YZ?5%\UZ>B+;G^)W#"8^)9Q3'QPZ?.H4%C\O]A_U_X7Z
MVM%@XH@88W1A8T:CK&KQ/E08FCKEO;-ZJ&I<X,F7%P7[KN#W/W6H.I[-_1=0
M2P,$%     @ TS9V5IV&P_N;*0$  &D! !$   !G-# P,C V9S0R838T+FIP
M9^R]!YP3Y=8_OHB*%:Z5JPBLV(V[DTSZPBY.RJ3W9"8)ES*93)))9C(EDV02
M7+!<Q8)X%045 1M-D(XT@8L-*XAT$-"+2@?+LN@B\)_=T 6]^KZ_]W_?W\_Y
ML,EFGG/.\SSG?,]YSGDRSW)T_=$OJOYBAVUP5;MVY[4KM2M551W],K8M)0AL
M'0!D<[58G(D1M3A# R+& HI:.5#5J[?(8GB&$*IC1)+,UO?8OW!)CVHR7M\#
M5;OD+M9(I$AKF2<"97<0+V=P?;Q'[X9+>HEU(LW2A(!5BS25S=6)]3W:A-=)
MO[?>!GI4MY$(F?H>4&M#==CEK38R/%&MK977X'*YO%JKKP45VAB.:>ZJ!N6@
M I!K (6J1J&K W5U"D7UL:M'PR72:R\^GJCSF^!C_4F?ZGL<FUBQ6*PM*FL9
M/@DH]'H]( <!$*R1*&IRI:R B379W$T5(<?EF(@<SI.L0#+9ZM;/6(S)"_4]
M>EQ2?<I5Z2B.G^B'S?-46R]Q'" H@B:R0DY2H@(X&Y\T]Q.,9]7\.9@L-CKY
MZXQ)@*23YV)WN7Z=F:;/RID3_$3BUSESP1)+ 'XBQ^1YG)#(;SJ[('-!^#V"
MS 5)C6<515)4/B?PF,#P9Q=X"L&O:33H_0V%"@![=GWF!!-)_SN3D<B(;$Y"
M4^X<2H&S_Y928.8<NF@%QF^AXFQ\;/P<5I4:)#;EN9C$<W*)%;:&DWR]XGA=
M@N%I3&C 6)8B<:S5KP"6R0D5+^L%G*0XG4T@!8IH.&T(;?X)4<+I=X\W4&3K
M&.LH+"O95*R)$PDL3PD]&B!CL-K%Q(EJ)E$-X:W]]P(J]&=(!WXIOFUX9XZD
M=73QDU'BOS!&GF QDN_1 ),44>W&:*+N#*:D"L0TJEJ,O/4F$>H9RA%\]I=4
M/*]0*Q0Z11N-D\$QJCI(GDD%*FI<&(^G:J1HJJQ6R.N4RCJ5IHW%' B>A>$,
M#KFB3GZ"(] V]VJ$X%N!?9(/K*VTVTYZWVE$H+I655L9IX7'V!2)5PL2MD_I
M&.*%(L-GVDC:7OYU[\O22*J-KHBC.D9)JU$U$TL3N)"KQE.2%HEXM<!4)WFL
ME)/F3=2>SJA25Z<D!5-DEJCF\Q1Q&I.\5AK.2?IC VAE4RNK!4(46HEY#!>D
M"4AB"H3$)$BZ);.9:IPI$#R6E# EO5>#.GE%T)UWW@G;PM60VU3M-_M#[FJO
MWPP[;19KL#I@]-N\08G@9(_!%%&=8"B**9+9I/2;M&148](BR/)$3@I\4D?5
M@D029_!\ZWI2=^HPI<N<2/!8C8&AXN<2B3,4P_\NF:UJ/N.64G[F'?4O[MA<
M+BAH,P:J>2)^1I.AU68G!UCS?_)JZ^'_%U]2U<E5O\^73G#\#_K2GQ#_$^)_
M&.)J">6_#^(G./X'(2ZAKQ4@$A82%)E,M0*<D-8,4HK\#,U2A$#45GLI LL1
MU5)6EI=@0V/9O*2"-KH*D(Y3QJM9"?DLS^!$+E?[GX[KDRC\?< ^BS_\ NO_
M-^-:5Z?4_SY<G^#X$]?_RW%]BI7E_Z,1_'=6(&>O-GI)E5^=D2=:\15D&*JA
MLIER*NI:D59].TIFXTPQ=T<OX$R.LPDC3-)/0RO::^3*&E 1K'B)"I2U1G3Y
M*4(JE&?(D$HM,E'Z=V2<0GFF#$+ XIB _5M23J4]0TXPE:=C68RD<K^S2&M]
M8S$^1[26WO4]CF](]/@%P[&>6G=FZHID7$@U@&I-V\!.N?5K3"FBU9T;%'+5
M2:YC]WZ-[5C);/>:+2?Y?E%'_Y*/I*64K@'0IP$5!/D"F:C=GX0,4-(,!2"#
M#8),@-8'Y4*65"%NT9<QB[YH,[GR+@A2^3*4&Y+)H;;+ $GTK9<9:L,SY&ME
MEBX?9 !D*LB4@3,QT$Y!EF"%(0'$()O4F/29#5#(;$B&8$,R8S'X(G9C,6DQ
M))-.$\0XC$6FXK0F ^0R0<76'Y\)4GG-D,YC,KB"L,$7-(O%F$7,X591ESCQ
M4S1;#47<;8+D$:F'B"45\L-^IJVM3>!IQ+_S!]!)$_4E(4R:+E0T^RM3AFQ^
MR.?R2U,S0UC;[*U0Z^Q\9NCDY8.AHLTBJ<5JA#+2]*2VI,UT)MTQ'4)&:;:2
M7G";T<<XI6:CU($)2OJ,TCU)(Y*@K$LRELLOZ1^V^6VB#S%;S*"9Q"/FD(NU
MI PB*OI(KZ&R3@K6E$N,DCJCOY0LF"E?V1_,<(Y21.DUND.^;$;C*;M3\5#4
M&C3)\S:;G7'9C:ED-&675,<%Y(C@1AP&OJ0"O.8V@0I/4!X-HS"%H0HQ'J;T
M:!1,L1@MY&*HNA!1^A7Q;%Q%A%EMPJJ0)90><RJ"64D;[2!5)7>:D1DSZ@!"
ML42$CK8)Y&)9.TADU8XTZT!I5D.R')?/\9BFP/@E_4K3MYD,/@DNOHC9* $B
MUJJSE-ED,)H#KI 9#OG=*5LR*B:CYE*;0"9F+<(NJU\5<!MAQ$[B!7/9;O*;
MDBDL$"JA9$3K-!J4WH";L)N38CR4*2;;IFQ/1V$+&<_$X9!2QWG*Q5*2;1,H
MEWG+*7L@([B"(;773\4C*,+&PK""""O\5)2.,QC*\C&+(A\#?VOZ;0)E)LJ.
MHI2:C-)L'L]&-8D,Y\FP&);E'#3':4H"S\D* "8!S=2*"',KQ$PZ2.\@H@).
MR8.!;$$E>//N0+3B*7(AYB=P/N3/@M:"R.K*)%]6HH"7 M29G$UO!8J0AXC$
M70$=7'#;$VC.%PB8*94EX*;C%J:8H<*T(Q$UZ,44DJP(U*?UT9S?J4=T6G^^
MF.=#H,YD-J4-FC0C^L20*5 *.N (44Z4(UPI[RPI((0LV$1U,L\P6A1WFW54
M-)/PRXRBO$T@HM*K8QD;)%BL3EJ!R6'8& 91&C3C"45  X@.C3^ <OZP*2<'
MBTDRA\8M9H=0-(:+V80RI89,+,D5BP%-(J')M@G$ $9;CKMR2#:.Q6!O61]P
MQ&UQ?R"C@9P $31;290M!X0XK8ZP4:<ZH%-Y67?!&2W*PGJ<TL<+/$YI$RFU
MH^#TM@G4AU46G[TD,X0,WB+ \V1*XV0(1FEA-%$3$889?=KI+*G17(K3Z% '
MF2_I,403,3-:.!SAI)<LD"V77:D\ZX;;!&;EP1!/&\NT$"N&!89U>"($HBP:
MC (2EO&RM,W#FLPQQ *C#EI!916HK.!$E0JEPA17FEV!' %1(66)+X=H6V7*
M)!*CD'PF8>7!D -.P02FP+R>6+ ,FW!_"8L3M%VI=V:4+(L1V9"8,,9E(3(=
M4Z&:N")DC8@646%4%6!YN1S&*[FV2L13]J+=)O,56*,4,T,)&"%]@B-A3&D1
M$3&#0H;.>&-8&0/#M"O@+Y?E@MUA(LJH1V$ \B"74WA1Q@?YPI5D5R$B85(G
M+4 >(Z8L>%WE$I9P1D%68*,PPD;4,;F8 B-%,V4+>[4ERIOD1)[D4#3@<WK"
ML6#"G=/!RKC3%M%F7)7P!>5YB@C(,0]GRRH,<2X1S6B25CB<RU*QLC6.J4U.
MMYO-R&B1R9G\ .K095UR1RD'&3F@:%"6C5DEGPQD:4=>K. 0E'Y#T@FZ7$[C
MF %',R&4#(-\ LU+6DVX_( 9ECG5.)<%142=@B&=.2XX)8BI,P6[G45<-LK+
MY5(N;3CL;A,(HF:"YDL!V&+U0>F<RP%[K"5=1'"E"ED!<&5*Q7"&DG#G]I:C
M?H@,EP-PT)A0XB1(%HU9"0<@CH3TD ,5**)-(*H7F2S-A<(!-!CP*P/&I)NA
M,'_&Z<L!"IP, FA"M-H1.(R7"[R;3W@C1#3F"VM!!:C+LCI**'-NT>K1Y+W!
M2)O #%HPD2H-ES+J<TC0Z2NX]:(:IUTDYE2G%!$L98)AN]-I*J636#&G@(-^
MJ*33Z,(V4.T(!E@WXE30I7PPCN)P)<!&P)1+AP4(RF;DV7+(+4HKK0'&K! G
MD'P.B9,<J1=U]BAD3&I*'L*8\&%6/>)"?'*"M=LU2F,<-1N,A8#%!V!M MT&
MD5&*4#86L_EI>SCLSV5)R@QE.1*A*%6JQ&32-H.)1053(4PF5.:L7< XWE%*
M46X?CL3$BE$K+VT"*Q]Y*TWZ=&C$(+DJZBU!2A&)Z:-IG16 //Z8! \7$C_C
M<]CN-JN9=#+GX11*:]D:BG!M @NG]='Z@NDR>,00+R:]P8S/JU!Q.5D. B)^
MT)L2'0 )F*68H&"]>IU7KTGH%-(G3=GL%9!@!8=.KI36EAP1CN,DL"(VF]>7
M9BO:DUY"-$#D(V4@SNISA-T#6-4AC8JC['2:5N ^#1G)NW!WB"2R5H4EQK<)
MS*.A;%JE57%)+6$*J'@P4")IEX6*Y1@S:Z3QD!V)&I4.4F$P*AA7R@B1#E,T
M4RK1L4Q<'HTI]6Q$4Y31?DHT%-L$IFTF)(ID,I$4$I(03&KUR40V$Z0@JIA3
M:0A_2B0Y($3+"]H<'8I[]6 :!&A9!$#T%E0P\B?FTOI2<3V?0L_!0M2?8FF9
MO9#SI[7!D,Z0B9;-_CP8T>$LG=2 &5270B,!Q%\ S7;8I#)K+7E7U.C+V;*0
MZ(;-=@MI)"NK'FQ-&GR)5(8VAHBHUZVDM"6%P81CRC@04MG!J$T=M#HT"B0@
MJBWNL$IKTG.T(Y<0I-50ZRT5\]%L*JG(!0)^T5@I!15P(1[STSX_SLDH,,Z9
MXWZEQ@JC?LRD3NL*1)2'POE,V!%6\#J#.H4:#)DTBC@X%4+9 _Y@WAN3HEE$
MEK71NEB;0#P%V-1VF5HHZ_4X$F9M5EYA,FD#64Z"6MNB$>&$3"9-^EF[Q<@P
M7-D:,4G1$>;,<-$I>D,I(N,.>'PR.58)#J*L+"NHHQ97,EZD<9-9CL1MC-SN
MX/UI18P395&/NA2$@P5G29[C451;L*NTF#P9*@65YC)OM9#./!H';8C/:ZYL
MRW%4*)%-EQ"[*V=.T*9@.(N+*1M5L!G5+M8H)AU6CHBZ81T!.IAR,.&R)#5,
M($]C%*8L0ZZ $R,\D:3#9Y$5RQ4=&GTFDG-B!@=%\1:U)D>+WK+5!P1)/F73
M6#*"(\X:]%E-P@0CP=;IIZQ1/YM+"TX-E/%G]>%\EI.\01=P:"/VBL!BB<1L
M7K?-2:B#0=:9UFBMWK@_'/4S(.V3.SDFD$3]M$>F3&A<O%A423F2(,5:#T<:
MPC@/)F%6HU 2(.X0 VT"<W V#BM)DX-1:=-Q7U')4KPO);@%/9X2O&&'GXV)
M*3YE-C*0#^5U3BME,VE:%4M;+4%I\7&49!:#1EI<I9*@(C!JBH21@C<FVNPI
M3UG4<5H+IT4,-M#M\1E*:A'1DV6C4QYVHZ0,<B5 *D3Y$CHHA2-^RXF $J!H
M5:[B*9B)<@#^!!0'O0+)97%-(J9TF?Q!*",4-$DPXE8EU4;<8 NA92OE,D4B
M.HV4E^4 AQ!!I?H,, "0.9'+ I#)4ED"HN:<7Y>-)HOE=%FF<#->%Y%UF\-Y
M*YQ#K")>UGGE;CJ8+I/A FYULE&?4IVR^H(HI8WYRR(<9<(RNP6TZ;R,K;+0
M1W%5204J<EA2M/E +1**R9FXI(^DG^3QD,MELY%IU!W,^QAC6B=%?D')P^D8
ME"QH,DD@$L2! )$L<03F0@%KFT"6+6EB=J^50SFE7L>C9"H1](()$#8 2I6R
M $!.5(H0.74 Q$M$5BRF- 512_O%0LE@L,(*,$H()B#H4BA(;27[0NF(@XVF
M_3Y'1E84$9,2SEH)7XXJFL28UIB4.V2FA$8I4Z@4:8<MXW!ZK2[1G4IK14V*
M48BED(Z15 EHI5S'5#%*0B?29K_3DK"#2<KDM>0Y'$4E;RI!O*!Q%72\-::Q
ME.VI;-I9:E.B7QU+6<)Q'E-2K!L+AP)AF,=% ?8:;)5:KQ3PER"NY&)!1XYE
M_%0Y;;=Y2WH=:8Q'175"K@M*I0#O<&(VE]WLM8=YD2^%]"8I,3%C0;5'QVF\
M<8M67@C$T#:!I7S $BH5_8ZTV4,$%3:KU@\'I8"D=.LQL*2@,\9LKH"D=4FW
M+N6(I,LQ6X0-J VV&(#&:%E"PV.V(J)/,LJXJ*W4*9 .%^WJM!-SYEPHG8;P
M4$8EUWBT D]X/%H\X(HGBT!4!]NU$M9D:5?!8C04RKC)[;!3&B+@+L5"F3RC
M27!49:?3S*%"R:92>6!;P! JF.PE:R@A\$$MJA24)0ZW2]$^J;8X[>FT5>%7
MD2DW(:B$H"J!\E$MH4S[%7DIK1 ()XQ5*BG!@R1R>DPNEE1,24G)PP;.KM(S
M>"E/9@MQ%,6,GCB:SH'&',=$P$R$LZ2CBHR!$>*:.) OA5R9*$Y;PB8'C/O:
M!*H9.T4)6M'0NNLC%0R:#%*$([(4 I7-L,\(2FN'!$D^:HR3/J_.IA;RSI3+
M9"F@ 4>P'+ (K-U)ZX4DDF/SSC:!?E<QZ@OFHQ:CX.-,0CC&N82TS8Q:K=)Z
M9F]=1?)15(A!X4B0<F1%BTN+Z/T%,LP0ZF(.\0:%,*'-!XUR*"VK1)N\Q:3+
MIR V2!9T4E .(CRH1?68.XRY;44/%)+S(41M%9423-PQ(X9B99*B8&LDIN>T
M<H,L*RU1TB!%#F9+%8&<Z/7[55D8$018-&0BUJP]'R $3]'CX$"'X.)R+)*T
M("D_Y5'9O!%5QFY@225M+0'1("='\@F?(QEPR^1)CZR2.83T[@*4-!5+V2)D
MBH!X4L/YX8 2!?-)K!#QV:U8SH+$"\I0RL_IXT4E9-+J&(HLA2,X9TD8_7Z9
MW*%D"<PO%*E*<%#)6!@HAY,JO$!G23E Z=(REM?#&(#3&=:1+FCD@E]O-4D9
M$!J02@LY0+M<1!@TR40+6J!(>\"29X-.R7A(12 "R_QNPB\C:=0O9S046\)4
M0)$LB#*/WF.+2)=H-2;3Z3##D<FRW>PS^'!'*&T#B5A(60S15JT5%%6\4J:M
M9%^IB)1:<,%$P>XK:,UQ2TP9RWD9#2#EPE(F%&327"CN*[D<+A;V^;5)50;-
MF-.XW1N7H;%X"16B)DBI2\GL7D:;;A.H!9BR)<LF";1,J_1Q6R+D]-GDVK()
MRZ8AHPI0<1FK59MU)+@27\QEB&!"!5H27JU?QLEY3*]3)%@Q8,FJ#!A<R1RL
M13EDEY5@F4VKU^54:IT7!7"YU9I6R;(FK5P.%(UQ*F_0T[&TW,[EPBHSDRB6
M"GJML]":&HO6O$R/"(#37=)6BD<^C]L\&A&)IH$<#4$RE=KAH;VAG%VCL<DR
M";>']Q0%I]N8,T?0 DAK<LIR1*O.%$72:R_B-!HJYY$XA5".G*.RYT"F+$%,
MD7&Z?8S(:2PI+^D195DX++F7.F,%+4#!H))4"T@ 1F12OA>F"B4 \P4Q=9R-
MH7JM%"@A%U\B>)NFLH^?@CB'VNWSFD!MVL('3*@JPL83=$J&"+1/I:"#00 )
M9D*D$$M!&LF7H4#:YRX4LZT^EPU#MB2>*=%12RD6=%8*'U$MUZ4Q!5["# S(
M&F4$JB2BH50RB[J*=C&=22A*23+*E9QH.BX*A;3#35)IFVBS:5Q2CA=PN-!X
M+NV&+<%RM/(M%A;+9A"G$*)9#Q V6&RDPQ@MN]+1. =3;AS$,]$8K6:0H-81
M<YD"V02K+ 4-3KU-T)(6#48$7%P242$6!9K(%"K5J,\$0':[5.DX[:PU3^O1
M*!T1=#Y#1([F]3 <ERK M-_)J2BSW!#/JG!4[R])1;.4KMCM7K"UV>&'H(P-
MB%4R6)5,;;.H>9TL)2-:PT%;MI+SZN2:;!RDF3*J,_D<IIA%E\'B0-#D*&@+
M29;Q&9 $&=/3#.C&15R&BVY37JB49FA:'L(SA",,Z\.FG!. #&H37\AG42E/
MX^/.@AP55&HFXQ!S'KL[KA>U";%L2SM)R$NH+ &KP289 0O&["[KL=+LV/8+
MXH!2-M!')U-VE-48_/D"8)3BO3*6E&4LD5 <2$>L/")H$GZYB(1:9\'$P71>
MQ9H%/HFD$TFMGQ8J7\?!1L1K3B:U,BD :I(<8[!'DB&UE4O@$FN:9K&T*5J"
M4:=16F8T-M)M4R%A-9QWI-)R+TJY197:*)F&B,7(2CP,EL+%-*5.)@B:SH1]
M^0BIP[,\JD;"9(8O\24N(<1E8,!@@%,\96Y;%& 2+O!V6N_/V\-I35CK+1>9
MD!;T5+:=4[ MP_N=1E6\*#A<!9^.TR>-TDIOE[+(A"JJ H$LEY(E\91>8=++
M'%S>P;DH+HVP/H1' E#)4B!9(!6$D318V>&,X.%T"@\QQA (L8&LA>4%06%Q
M\)1@*#MSB,$+%H(A2:]\/@YJM%(I@R@01"KO(1-CD+?JDC.[.1MKB5A5E8H^
MAU@ U*>C^;!2$^%$EP'P0^%HWB8B'J\S;!&*"&P(>+6:0A@.@1IE&+"XO05U
M5F:5RH+P,8-:-+F80ZNJ;-VC/.%0Z5TZ!D#\896@XDL&!D\[(*H,YU31J$^6
MR825#C 0\9Q:I!O+ );U);0Y/RRC2B4$0$C.<>I&D"^GDJ.0BTL%G3(=02O0
M".+509)F$C!JQ4HQ4:O@2XZ0$;$2H-'E3:K<#G-8R1D-0%:@\V4SC0 &927[
MDI)#JX1 -1#)6BDVG$QB)34=\"@#WF0YI$[ )8,FH9'R #IGS*N+0BR4%A&_
MF\W&PS9!552'<L:BE%ED]<H"7:E35 '6EN7\+@HSB#XZ&U%QK55"7II-0J.3
MR@?1%>$X%7=\^_'8B^B012/:?,BJYZ))!Z&U2@J65Q).(@MI :G>E<? &,E(
MJ0!+<E$G4$#L &>7"3H$P4^6[*>]<' 6*(2]$:,YJS;Z,BJNDLYQ((\E6#>I
MUW/F H/F8C8^@*,)%6LU8R8R&4TC- 1:'+F(55T$*! U JR_6(8RCEA 9V!R
M"2XC=WF#J4*X(*^4%2J.3E#ELE8=T)6";@-#R9PE*=GU*\PX%T*L1E<@:@XE
M,*]<Q67=K!MV&DWFUK7<;$@%6:GR4+LC&<YGQ5(,9FD3F$1H#2#5)&:>=H>=
M9<'"YL,40+B+: $2='XV*%AUB*3+*"'#M#9W6:F4>7/Q<BI#F(UZ#O#+"C&M
M6913_EBA4MXZC0Q)HDZ%080@-1_F_%IS+*$HVZ01:7 O&K!S,D)KPTMA8XA/
M*KUPPF?,Z%(E=:*D:C46&Y8"IA/P^ATR:V6'4X<!_O )T)]\01V:8E:F=D1,
M$:/?%%0SK%<ES1HE&58N^(I\&0M26L!2!$(NR1LC/,ZD*[O$N"%C &@#@WB5
M#@P 51QYPJJ<46$-685P"C&K:1]% PK$I@[I 1(L\?:,"HOI/.:@X N&(RS+
M>#E-)?O28KX4FHG 0:0$%<R6;""OQTF7R@[C=%$3$@VJ?"1BD,6D=2>GTV)Q
MF TI*4*?E.<MOK I'"V .9650L*"',E4@*V/6B!?(!_,N36(AI36,KO)Q$EN
M5\Y@0I(2-?9"U)JWJ:4<66])A85PQ.US!],^6XHOH+S6+>01@B<0(:(3L<J4
MX7B!1U-9'YBB,0](8NIT'J72UH!/1C.(@Z05P23BT2$^K2V:X"&+&$T$0E*2
M'@QK00DUUH(KG,D"YE!!00G'-H+"029,IHVH/H4+,89%_5&C I;)482PJQ'0
M+CE.N)R@8G9[W">5S0B/)QC<J\241MAJI -,'/4G?9H2Y/(>VR*P6R.0 <$
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M[3K.3)X]KSB#F6;B1(/?8CC&U?;QM[DDW#:HCYU7;?OPVRQ)GI#2*(5&?\+
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MP#<YAK2-NX?6Y&Q'**<S3+&T1"T;A?:OLH_RZ?IJ3_)E/;;RA9]RW'VI6V1
M*XG'LQX)CJ!6F H32([NG<-)7/Q$OS^"/.ZATB;",D\0K=F$T41,F4JVL-E!
M=L)#QU!0XWYA!)=:_D!($$/CYR%;"644WA=_,8W\;5[[G Y/.I,@2GW('!$&
M;+%LTR@W[H>NWH[%QE6QC8\Q)TJ9$3XC3'&G,ZB?[4SQ7#0^*U:[<,ABQ=<.
MWY>S>WMWZ7_TQ##@T!)04FM=8;BV+,M.+:0@BKRB+1EOO;OFXU-CW1FB<<4N
M*J_PJOC@PG7\//I ]_8[5#.\N>/_/8MC<NT4D BL.98];CMI [,588P6K&%"
M*H'PZ0)UD0Z( ZS%,8Q^P'A,G 0!P4GK4N3&[M9E<HA9V'F5\\G.C) !X68
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MH:"Z0L4LAR:QM%F,N>J<L]H!MRH ^&2F@@Y4ZY?A&,Y7>OYQB&SU<7Q@)EL
MS^&$XCQF:@BF6:),Z*C+%K"XBJNZ(@8712%6P_]]*LD]B76($!ZKCLH</%P2
M:,CJ>H[[R]B)HH7Z&"KJD-YFE$53C(O*/N\F J%DDQ3,9,/Q&"VDNL?4$R5F
M@$\DNN=TH9I;^P=ZE0]/Z*Q<!/06->:?P-+V'+A?>;(6BLV=SIW,V,&1GS$@
M6=I1TE$YQL4UU>%.NU^L++S'@'%./VF'QO9^0_3_B[[F$:^N::RJB$A<PD>&
M9B@&NPF,'HU1:E=9YJ/U>R"F4G'Y4L)'&INKW@]@KY5E42W0#/3D>F:=GN#?
MI>G[]^<'_E@\C8*;B0*[XW1=P(AY/1<D"MHW*J#@G$[/9ZI7;Z*#-[\!YR"O
MKK]PBH\(Z=WXN:<^!A=,?O->?HJIAR$/;]VH0@I?;P4[WSIF!%-U7E@X-C?/
MQY:J7S;6G?EI'Y_^PI%)O%$?O11<W8#A_\C@,HW;OES+88K/INS_A2,(A;#S
M*9FF"]5LL_1%BAM\<D'.V4LR:.%L/,^A!)HPAQ_MVK!&N*(BB- F^!60,!*8
M?<GH+R<JN\5K&NXE6%!-H=M8;"Q2)ONO+OD_921H&[FG(TYNNC]R6ND+Q#RA
M:?DC_LB"4+!2@)<?&XM8Q /=BFHU8 J)^44*EHESD^('1Y;LA<0^EBZ?>=\E
MP]J\;BAL#ME!U9[8AI*]/' O;S1F/VP_EGGD=$OAD/V%LTY0N=<O>PYL/MXX
M 1<B?*0OIOC%_M _M(W(*UGC^!:2@M@YO& C\UF,W8)1F;83?U3Y 9'MP@'
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M \VY-4M"SA+I3;R4QA-!!%4F2_<5H&KK2MT%<7%5?4RO_[\8&J<YJ/5UM']
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M:*9.0Q(H]O&)D.2G!OD[UQ!I' 4@_=L7:JD:I&;FEG!P@VT@/7)RO,9ZY-"
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M5O*T/P[]3H-VZYQ^)I*1BJ"9RK0S'?@E.XYN[V?/S:]EG4]31BC*> G<7@C
M]"\9REG/UW?-?6:3Q?N9TEW4T/:H!GN3DXSG'Q=.,Z0V*U=V2.%%L;S*<8D:
MN(#)N -#X>BAY<'GN?Q2?AXA#"(J^V<_,B'R%*_D$M6WY/LIHOQ0Y3F<X<!J
MDN-63A\'W>G )2,(HCRR_"3_?=1E[VC^"'\R0>@ $]B8BRJ9'Z^A#9\$D-,N
ME]<04>B\E<E$T<PALB_U>_:=I7.XU7H>*6RBT#$5\Q!HRLF%=5P;P<?P]61A
MP5)TY<:M*C"E&*%M8?TK7R9?7B2'4:R+2CJ5<YH]=3MB&B,/HM>6&9\L %6
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MN&/"HW@BOJ]TX76LIG3(\*%TP&AX5:B;-%$%U1^?X<@<ZU3;[VF*RA8]=*M
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M&;EG(^ZU+#!1EGJ?(I V?59!R4P14)2BA24C;3I&#Y %7H]0%^-HU#Q?T*Z
M$NN\B#:KH3F:49_#:9,8K66-?$X,O'*;"&<RY3UTJ-<IN+^-X5QY[86,4<PE
MP'?)SEL?<Q65.U$"V0U_[X+BR.< ]@0N3JSG0PUAZ$,BPE,.FU@G)+05?1#+
ME,Z->1MO]B& 34[VL;.AUMP=D5.8L%M(20/W@-;2XV9H!^(8B1/' >(-:<V1
M#L')PRQTDK]N"Y5KE3H"N3%T6'>"K"W3ER+:,.W,94Z0U4@@(28:1DH1)2K
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MO].'L*;R7+TY!PS=['8MC,V^N^  #F_Z1MA*.,)O!FC6&O?41Q&"Y3:<BMK
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MUY"OQ/+>,T @KYO.RP'ZWHM..]1][V19!VHF#> _#Q8?8=<:C%&AW2UQ8]+
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MU@]WOO9O_,!^9^5(7/S+<&Q8WC!*0S<;1TAP1D=D-R,)%5**C.G4N&I$^]A
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MN/[ 0%OSFTX7OR@-P[9@],A!G>;>[\NQ/2&>P8F_(F/I.6X#S'IU_=%@O3S
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M;BRL*]/IQ)FV:.']O,=$OYW>8LXC>!OM8=4[_/C4[-4KW4#++R[9AMK')6V
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M;WZ@H%SW7M%==UG\,<%;K(!J1A@$K$!8JE_VR'VWS*8D"Q>P;]Q_,:1P24!
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M)4X-C0+A+WQFTXOQ9/IN:UGU<[4'='XMSM9E;='EE=**9S#MY&\OK)00>Z
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M-JO]?J+<S_&Q4^R\>Z<@P&.6BU/R0J.%WP1&WD?K#=+9$H9/T\"9F-BQ<E"
M)G3<OU!S9OX/[VWK4VL5170:I;UV5H4V9 W!*?=R\NMJP.)V/W,\O%2KI]Q
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M'PML?I5[9S%YX4#)ON0#:FUZXB!O@XS9X!2M]TJO)6C7G?7RY+9MAV._**;
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MI"2Z.0F;V4EZ6(R^(3J"K55_R.PCOQN$_/@[#+!!2&O?L-)Z.]O ZEMET:N
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M8SXXP'R2)7#D9)+X4J62+(D7\EQQNY:2&CTQ0!79^[NC("*LXP;\Z"4K3LN
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M9 VA(^&<UE&M:7@*[72BSI:1\;1V"O?(RQ)B$I25G?R5:*>F>J9PC.B-NVH
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M^T\Y9[@6([3\CORS\HM(I<>KB2(4:D51^FA6N(HD-4-W+93ZX9D 8>YK5?[
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M_QI8]O_Q0_T]3!CI3IJPFIL*@SG[3@E-A?N?+$DI.ZD?N"@C<-X$ESJIBD0
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M7#X2C#;=X:8A,( GF4EFB"(&A5I6H)U4$01!TVD21#K1PL#BAA5U\JEN AY
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M0A6E@I8.EH.RF"Y'HW:2"]FZJOF;9";-^MO=0!_&*8'$"@6@;-J$OQ$H9=P
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M_OU2N@ZZ0=#7W;<?5SA&[LF*6Y:R67R"T;E*[X"E]FQ@W]WM'^%,=BL"6T@
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MA6\NJ6'!A7KK#[[^0F-"3=G8QN]$1'VQ(\/J#!4TVL#N?P0X!!L+*KPLP]6
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M)W^W3DM*9.:I_^<]['^%WEO"67#_:B7E9G[N?&XKQ*4;Q;X0.*</5<] _>;
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MK^%;;KI^8H_F.OFB69+QY^\K1YGCG$ZCG6R)8JT\ECP6(=)AAF=\^?$V*1!
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MYB>WPF"//1/ZT<Z\H,5_"#HAU\9UF/KK<_7W\F<(1##4#];.ESH"F&FY6@2
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MP-JZ"5%[6/JW;NUM-=S(FR=[W3N0E*7WV\W4=525 N7!V@H9?AR6'?[MOC\
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M'A=$$4KH+7:P%,XP9^&@,>Q[1';-H.P-/:RYCLO(9:%JKG\76.YO##KJ= ,
M^_9>)77RFR:I:YI6.K7^'HPNOH<S2F%\\=/83#L(PT2D5 WPW7$?G[-%7P8I
MS41[Z.66^VTSP625V!E^UYB:RO)I D0DV,8.P53:="^V82QFT^944:F<*U]
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M2_A 7]5-;P_733(B-MD1VF[>0OD,G.*8Q*ZL+OELFD\M!/W4SPBD-NYHHP5
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MJ994Y*+VV,8WFR>N)YMPZG*\=+OSMNNPHY*C@DC&=?<J%['/]O_HZW?JI^1
M D8=JC\AJM,@TM$)D;=U-B%^0%@%$)1U*8B\"+VM$?EI#)_Y#$.;XC&'=.*4
MAA%S6KWQTU=+>+HN:>!<SC\D3-NRY->O>BZM!C6:K>.K/?!HV>]HTOSJBDPW
M"JS@>DV?#M)_,.U\O/R/KN(JKL!&<F?8&1'LJ3/DNK/NR#C92C%78$=@U*FV
M@:? HWZ9@'!M+7[)_1.MNR5X5R5@S=JG6VLTLSN"K?.-3P9J]YYMX4WJGX\F
M.WCUKGYE56_Z2;:IV,D-J:_LK]]&VF2KCU*...IO>\HNQT5O76;[\CY%<B$W
M)1$2&5?NF5E(R+"/ C#^YJ>V6TL*Z><P-5YF/RGYX^?6209_T0O&[A9O) 6A
MR@[_B7D1+@9/$R_V@35J-LDW.FA*DY.W@J[ZRRK2AT]-,0S 34^\G(^Y0L71
MR6L:E]Y"PF[*E"AY*;K-?XINEYC(@PM4#"J7-T@&%8W81$+H[\R3(\;)'/.D
M>N7H8NAPU6UE*JYL*F_O'E@.>;(F+W3<-R[?HU:GA,1(9D^V>.^-0D$;'SE5
MN[UBA\JOTGHL5E]GT]),4Q +&E@R]C6+8UH55Q$NM Z\X(4PR5LVA-#[5?*<
ML! YV[_;0/ 4!HX%1TN-E.R4NQ?,Y:B5#^7"B2-_<,+TO5$WS^DF@N2;:@WJ
MLXC/?JEV.?,;EQ9Y$VN=BD+J=86HF7>FK_[!66M/0Y><]0\4$M:>R5-$4[I=
MDDBZY'O6GM%JIU9T<$)A\>EU'*M,A$*1,1[I:VOS1D [3NLQ8.)E?&.J3<5T
MPA6CGURC\)W)]C8U'1TC+#&HWD7-N8:_ZCH@/2M.Y=3%<<SVBD8\+G"#NVLY
M.,O;5GN^;>828W2/T<7-,;VN<?W1*ENQN"T\61&#G$,+)FH!9_CG*S?7,R>J
M/2[[L $;[KFGD1&0,Z+HX/0R,1+W$4%WA<5NU\^@>ZU5] M=4H>OTI&FLL5Q
MGV2V9/X_N*\S0/;:7\,)0V?!J]VH/9NEQYM]T%U[KR,N_[I/_EG.,(-P=0,>
M:!_N9E>?=B*/UC)LM,$X3#BF=&>P+2F2KAAL-15WXS[:IBA;$:$[3 .!%#'9
M;5)C9S'U->5Q90-[$ADR-^/G'\*E/SHZ?3@>J%8+\*EY>YBU-I]XEWW6N]FS
M>//[_+A;TO<%<M?Y?5;O^[5@P9[">\J,K&ADOL=G"X&;YJY7!H-6:V_X*DL.
M&W1CK_*Z$O4QO"\?M(.BV^I7KIRD\40G#5 )=%'?TZ=%;%@U-G_,A[(IID_C
M:N 0.W;[=^9_]G&R; +3X%2G+G(2_&0[>A2HF2B#[,\Y[U.1R*M+5PQ;T2=H
M)V"R74<+#+#]T2ROMCO;QOT'9TQ!T<[1]=W#3FB=*4==Z"F6;DPA?:%1OJK'
M!>T;9]S/+F*G7QK\\)ZWRU*ROR7,67T_JD4V[&"M=L]'1VNDGJ"@MX,+AUIB
MNFJ6\6+6K)MMGL183_8-:9#/L:*V0'@*)&0.YL*]:3[)==//6\85NVO8 185
M3W&U#/7D?MW>V_'[[] B4VCH:@L_RA]IT309#J!KPV9<^DO\FBD8Y$H&<N3Z
M,D39HCO^6QNBHYE0"CI-YGX\JNX=E4+(:[2P:*_:\FYC*2OI4F;E*2.QMY=5
M&*).LGZFHS:,,##JH[Z/WLW[3;#$+()G[^P<LGB6GC<0R,3H&XLXLKJZE$Y_
MX1FSR>]V*OO!81R@XOA[6'ZZ%JXJ"<QW?*,@([5M!>+XTG\MHERX +82S26I
M<DHE@TN+,6"WQ3YI2>J>@!1> "/\LV@MWA8RB>A1%-OC"<ON=N@-@\*N_B8N
M!,U=1!LH/QE*QZ1/A-:AHVQ>A=1+)E;&.+TWND+62-(?)P/V0\;3&I#D\A]2
M7'C<&536>[6+15=<4AXGVI97(GA:'O.H;)H@:O<WN>&+O=1_J3?<'&:X'[UX
MN+V\,"QAXV9.*I:?WJ\#NP,9D1BM_,1?$B]P==A[!?"J$+SFV3K63I[S."S7
MZ3'J) UO><BA?Y1$:F:^K6%I7WGW:_7X,*/HW]=Y/NR+&T8#ZY8O34F$_R G
M=.O9_1T'B8C<Y8S93A8163'*I+A&Q.+>SRF)=!9 +8=4P<5H@T-S-%YAD]<I
MDUO1+")F=X8ECITR/V:$2B;!O<-;%,O4WWJ_1:K):=M[QMM\QWZYP'!0S9?.
MKT,)*(,U$B^Q?#AO<>@W:.\H7P</C=!JBVA:$2,F/B??#KX4<_[00QP*HL.)
M\_[EOGAF1:+BH_IW5NB73O:&/!-4 \=;3WY<_O.IU2]:FD(^,9O&)<&+SBB>
MJ(ER,V<(N^ %&86#B,JE.&;3.KQ!94$4D3626H;5#]]:NS#9*Y0\X\K*ZJ_^
MG@<?J.0F]M-$3#YN. HK+6P++G.?\6Z0M;3^+&6=M@[W]S<6!&Z*Y-A R5JV
M)=0<XRB+"LL-.02JUL3P]/40VD!G%X?Z0;H,]L=/A$$-/,7<S8<,#O>;@VTY
M3/Y_@H+)Q:3QQ10)4HR0 2-67A4,)5B_0]U+1 A>$C4(TNPB+*KW&']WUPS
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M$%S//[KWJ&.DLX<TL1SY%[?DR@'@R_6,U?)7)S.K)=9< UN^-,_;L:V1E#9
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M*V\\OC'CL:/-[B6ZH3[1G&LNDN$FNP7$+95N>E-DN(F2)-)T)(."@MG^(9.
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ME9UB#-?^"*6@A9ZS[CXG]8^P/WY)F4'MJ1;\C3_DF>2>O]>KV*2PD<CCTA&
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M0<=+)\U].7Y=B?BVX]/N9N>ZH=G3ZTCADDP]@1L72\BU$Z)WG<04KINV"=S
MW+!X%O&>U*BS9]B!;DQ;;AX!^VX@\X94H8%$5*73_N7-3=KMB5F34H6FC@?9
MEFR"?4[=\JYCJPP>J:WMPX=Q"5;*%L:($0(2-M !,#Y_R+WP!X4@2\)(%JJE
MCGX*KJ&-H;DD)N\#.UMKF5X#R,)B/"]EES&FF)H[$3EO^%%QYK\$\W\IYLO$
MJ<23=X]1 ,U<W,E_G\<$HM[77K_,;EBS.E\&^+)$R#\WJS%O"]<2TEC<*<'Z
M><M;V_-1 (6ZH4TX;)W+(><M%\W1DD,8?&8QM?T1S?3YRK;GD]@T3:QZRF74
MADU+9OP@2HQF$IPR;X J*(,V1#7]?K<BAF\,][CJQ7C4@6O)22/+K#Q(YN@"
M!5[U-#Y(BJ+A0./C\V?)&Z#+[4D&;67"M,GN+]7RQJSP\SDF5$7XVIR"588Y
MG*,O<R7%;__@GBF#%'LF78)-$G\'?S\4HTCSZ/'8ZZ7Y>+7@0L:Z 7/L\D/C
MX3=4XP$N14E3T7A*:P7F_.>6S^Y]LO,*.G#!MF[_&>:JM $A[AWT;F,>$NW=
M 7K9RSI2RX$(.HB,*43UI+?]U8!&216\4NZS$'NT*C^5VX=!/C>!YEB!ZMEH
M'5T>)=Y9-$OZ ]O*Y ^->>V)5+0C$HQE7SH=X_?,THR"F@FBBSM%ETV:,\X5
M;4'Z&(=NS(>NM'N;9E!_:S%2]SB,QA]#3IIU)1A<;NHW>#( XU5>SI]U1\S1
ML4^7."?12Z9O/DWMTX >K;4 N.&@,!;KRX^8(F9, 5'9C4H^HDVZ(NL[A=W$
M*(B>DR25R?:\"E^R2O741*G2*%QV6+#9\K%QE3# /&4XX<ANY/GFEE'TI3(@
MQ-/L9":64/.RVK,1P@\SZQ&)P4^T4O7IIDJGHP4Y^AAZ W&7O' 2%=+X\B3R
M^_*R*=*K.A@&!LS[!55RH0!'3AT DHFY[6]JF_6?\>ZN$W"W4C@D@GD2ZFFR
MTQ-2#G.5Y$ *@I4QNYDD?>=2/FB+1_#?)MK7M[0;G8M9N=;KN*6?,OJIA/?O
M$SO]JI!P2M?E=R\+Z5,!LKIC6#GKP/!859NR4!A#%YI'O@2+U[YG9+0O/L=0
MS.>L2C:\E67U@[;!O(7N]:2E)>JN-GP[J2XZG^/.$OHI%H?-Y!^H-S8X(BY]
MHO.H<\"6:FME,0JSW3KKCV15^W,I8Z?>*>;.*XW+X1^.E=C?F2YX-*<>U5)#
M!>H2&/%1;=7'+)V\R:Q%R]@7SWFP[R6HY:'),:,&$1B;EKB6L>QWK55#/ +P
MHU6#'8^=?M %ES7PKL/.CPLCH^SB2N_W$"8O<1L[I^YTK^0C\C5>9/_SCS,!
M5CEY#J!(R48\;8WU4//I*%Y6WF(%IQPHCL#C,<.R?$";! IM6O 2:"2GDT^4
M:#BM &$L \QET/#K:8\C)?^+L2A%NI_X*;0\/KNKE+6+^'%R EW)<+&,N99]
MA+Q6K:K5D(J0WZQR4%J>D--?4N,R=*;_"Z^A4XX,N@>>)L7QQ6*B1N5Q,>)!
M@T*B\''QA/0= U*J&6UUJ8M?(?]CK_"4574@I(E)KZCAT5,;3VZT;T/;O[M*
MJ?2J0@TOO#J]("F%PS#JXT<+23),3,Z08N\C+)6;M;$-RS3%ZIU:-'BA']6
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MTTSD9"9JX1<KTSE^=7[]P-[:%O^$X@ )?D+Q&KZH3)A?.FNL/?Q#E?F8C;I
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MK03L<>H=?*#).+Q6KK@I[ >W&G@%L$->^@,?1769=C1@:@A+S'K2P#TZ>P-
M)(^GM[J[4_Z[$;D;E>!AX-4 455#T5]D\*"3+]EKI>:'D 3*MBN7M2R+(]T
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MQA+(_;]K"WK=RU1HOBLZRC&!6;]+T/'NN[]\1Z=U9$R8375*[3J1LG!X0IX
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M$L;N2'!F>+/ >U,FHF!GT%#\,U#/D7E*MG*#G8C)( M; Q)+-3RZWALV61-
M+0UEB?;LKIKG('X.G(YI-0K\Q?R.HYP+F.",ZO4Y[AJTN"8GEDI=K?!=L=T
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MZZL>(9\*%+;DY>Q6X><Y6FYB!RK,0*+;>9S4UL;4=JW$\]C0R5O93TG>JM#
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MWB?C^<S:TF6AU84(A;9RE/"G&*](MNOA2)<[O.1@G'U Z\>Z3Z072:=K?5N
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M;0T=J?W#59&D7VM<ONZC25-=4=O7T"EIZ]2IT;'1\0A>,5(&VX0M"41?W\>
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M8L/#8QCQZ8,?45X."<QE!U&\4AR;WI^,^&E45]_'2Z[ 0X [^+V!^49YEQL
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MZ7=G*)S:^3Y+-J]R)Z@B->/94TQB?=*OCJ<Y1-E\HDC^,12O83=%1ER%UIO
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MLR[,:.:LI-?Z;R8YEEF]!Z4S]@'M;D!QB(*?F5RR&K.PN#8 -A>]1O+"?FT
M([5&=IJQY*D6B:0+AYV]P \)HDQ]7T6SS/C#(-[ONG4DB):1VL#ONX5T64V+
M-HD\^7_Z:B/C]224#Y=L=45JO:AZ7T0/N1O<7LKD$GS,295_+S?F]&<7QNLX
M(KFR0\DI/W^_8^]]IJ_=UBP':M8]_)K,8ZZ/L6)L?G#OQHDF#;D.<%XM,*^6
MDE6E%QA&(]!N&9*WNVW!UE)&HVN=K.4AY!&2J><\G!.[7W_O.:#-BPA13(W5
MDYI21D]QL]#A O\,C;]%W%@<G=[0WQ>6>W7NWF[;#>] &[RK9JN"34D'[[&V
M!(#!DLE^<S)=@JC:"<=5=3I%&<?>T :SWM2F!]Y/$NATA]"*SV0&%5U8QB-8
MDW5O,G]W#870)OHG])7X/&JQWJ */%_(3P@OEY'7_P(L2!7-UTD$=H+M6$38
MEL10; 29.FV[3DAM3H='AS%9/TSQ=0"!8@/,ZS8G/5[^QLKX:80*PK:.DO#>
MZ@'D(B)R;K0,K3E6R#RVDI%+*N+432?7YU?CEEXQ8!HNIF?PWUO9;QOM4FFX
MY:G.)3QQPT#WHYGF^W?2#W]V[MYS^2+_/WQ!O@>72YY^N9'4$EBC?W4U\F\\
M*OC?8UAEHH1Z/F_! 78#C>BE:M@Z&:5+*,WA0*<-6I.EH6BS9$;\U@>]7X9$
MV\)9UP8S.21IYS^F'(:80IOX^OQRS:FT@">MI3:F9@$C;Z,C&C<]4=&I5BYV
M%+M?B@@F^ZL M]U<.=JN5XJC&JJX PZM<?LUUQV+=];,>K[WL> 80X^^H)V1
MA1=OHIE1!/TWF<WG^YB9!S15?L^IZ@ 10_DQ69CN)!V"_?JOKM:CHSV0B]M,
MTR5RY\M"2U^9!B?>LN/Y%"#G2L%L]MS)-6A^L! ^3M,6KFVP/W=^U35FT2HP
MHJ]*_4?A&SG(S!V#MA>.YI[J\?9E42Y:[N]RH;PS4(:"36:HGFEL=4>0AJEA
M3MSCO;1R.6X627H4AJJT2D[W54)@$;@S['P#F+D<5+W780??"P@7=UYYM<-F
M0FO +&%96OG$XAP^,YOOJR4XAH1%;LAR2\0<%[..PX>:=+[7XMLU^]__J/0M
MA>;AAFIQ2=+%ZIQHYW<D78BZ;TC6%(^ALUK\:)X(VSRUO/=9A A^M:<BS/5!
MSK)-]=Y75)#&@D^  1X1>9+DVHZO?J_FV%5A&$P;] F^VPP::]0$-A$4 (O[
MK]\6VZ4N_(&S;&))9G2N-%.]4;PCX*7CD<G!%%!M6S+=$+B2CQGX.03O$ZU:
M$[7E':0X\]H@-IM/CA6]W*YO"KIA>JQ6N9]?C0ZC'5]O*/6<!I>:.H[> ,L\
M*K]5>=K^PM5^,.2IM]XS>^0SCG1)KEQG_F>4Z<4?V 7N 6Q"=T+"24?+GYZU
M,;6(684B]_&8A70A2>21\)4=:O/PXFRB:H.]_K]K]3E)%3WY^@[GPO!FY17'
MZ;%J\O1O_[%K,C_<-1FUW>['E^=-@3SQD.IUX0XI]YVNV"7W/6(;PK-]-0LD
MN-6A<JB56^>Y2D'9#'J.^V(R!M)CIA+K\2#W5O]J.%+U^!NEDTO?+Y_G#S-
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MA<IE/R Y5!I)3+EPZ/%-FK@UQ7ZFO<,$6GNF1TU?4GB@7Z<OU9BDO83A3E@
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M3?%1'>](0/G^@FT.9&9ZBTM=A3< )0.V)#XZ\GO57'1-^"]02P,$%     @
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MNA:\TS.6F(*J=#8<CHCE'BTS(7;-PP5:%X/JK\+FDU'&\()*$-<R*1?I%/N
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MES$$!._,.=%YH82:D ?>.1 Z,:.7&SI<=@(EG'B2NI;^T%U;&UI=7Y$6W*)
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M-H,KHQ2_07&)0.0*P_18^;($62[C8H&TO[E[>3CN/LNYV?S\NM'RNJ_A^$X
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M_-H\($J[KZ['BV -W,1N_IF1!/>J7IQ:LLSTQRL&4-ML*@ZZWHTP*JGWH[-
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MZV:J=ZU/3,U; P+SG0L^K08-7'G 1@\LJE+KD\DM8;Z[[G6A"+ZUW_.K\Y#
M@),M"B5.O[!'-@RF0AFRH&.L$IQX,RHND 'DY"0_$57(:'GF[O[&>J",W9H=
M8^[Z+B^W9526X:ZG9M:A!K+=8QA)&H#I.DO<T6?D,"V3TLEJ?2:1BL^N J]X
MF$88RM+J!+\]X$^9P:+*6(M723-/%HNH/;.EH/Z'HE#A#PR:5.;A-<D)V01
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ML56J%4)R9']R(C]2"H-,<;B5^0<4,'I9U+#C]$\,Q9](1'W&=NP8P7@-KJ\
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MCF)=D50+6O+@U-CIWBTRL#:/CJ/H!P8\E?YJ=9[^KGA'QDES#^$.CGBX'EA
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M=L)C9A^2WE_[Q5^"*HW]WJ\+LLK?6GK>3?3FW7O>\VR] G8M7@%P(CYWG*^
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M1RZ(3J4&J:0RCD<*T@V@??NH57.MLYXV,TKFFNRY-(,9"O\6GYYL3AN@P4)
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M ?)R-=F&P:J>J\4VN56L);5"UK T0M?+C3I2;_,UT*-TE7K1V-EYC^O!!*]
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M3HVX=E!B#?VJE$EED(D%"N-%%.O=O(T@C;F*8?>-)=S6JK2W[RS%U/XQ0J]
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M8]GF1K6DF1NF'P!:!9]?/E'QR12N :]1H=Z>!T[<;(OB<:AFQR1>OHZ-D'<
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MU@C.>TS=[5,YF)PU?V@T/8_&'2X8='#70_)SBJGM- HOA[EAR/*%]M.3=Y4
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MK:8_$G]HPWH[!(,V.6"(:L8BUPG/>'ZY&,42)O,O&B"==IV#Y=LG/]P#SDZ
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M[ A+W-L_35B/%7/) 5IT;34)9U3QM9J!/#6<?TGRWP:N#1<&,*V^7<1WS^R
M$NN ://J!RL"EL[!'FV+(Z8FB*6T^^IT.:;76=<M>MQX=![-H',-W%G,E4+0
MW,\5Z)D]N@(8U^9'^#GRN&IE5RZ?66SIWG-P_#\FC_^O,!W0M>Z*$QV6?_';
MH&-C@2C+^G$DT6_B9H(?%U&8__R&BG>94A9(2%.X7 )PQF@#K*-U5_65,,XK
M8[OY&U>5TL:7@MX._();AFL]'5R&:]0T0 >?[4M[\-0<R!KVEG9H?E#)V]>A
MH<,-]P&/AIL]%#J:<&H' *YW*I]P,F*B&3=XW$,*;5_]C/KF =;63'4DNK 1
M.#;D?=OG1-OG%+$^L9+]J4W:*%G@ZZG1KJ(--:H2611VL_C0?2D=_,6UFGGL
M:V9=*DU P=1U/: R@ZNO1[@=E84@XQ'$YPUP8S_[U9KL+CPM;Y5\[=D:+$XT
MYMUMJO";?K[S]-+<:Q*3W()* XVVMPPY3XVK61P5WI?PX_D34&C4'9'8AZ'R
M]]U7].W:N9=BM6+=8L327-.GK S&17J_EO:/FY\YE._G1!MWL,K/J$B^_CL3
M<5_ZXI5;<*S\<0KXP]SC&)11YP!:THG0.+/VG(D.\/5HCLW>!1(A:*E1LUL^
MW>&PQ&YST(^IT_''8F]QK.^\C\L(":V-'3Z21'U8:<_&.,QWTYP]>0G=1%<V
MFIDH\/7\+@85&&N^>?#)4)'V6W:15<8]1GY[E8:B;&$CGX^)OT9-/-E$$A>C
MG F'#6_2J(48-/2??#(1D- H[JW.U'#K7=P 2US[)J8\YV;7B%QYU$N 9@H:
MF5E$2C_'4P#(3J]PC'*?84?:FK9HS_Q.M^&UPB=^@ZTCO(J&7R8<5)AG978/
MO9Y';97O%^S)LKLYK*QHM ?0SZU<+L2X+-ML<%F@)SJ;>TH&$1OCAAIW]MY\
M$8N<&7JFVU;AV+MM6-3<P1]N97I06)ZU:_V2_YO$37^^]^5*>?Y\/Z:4"LN5
M* D)*5Y>WB5IIC_S;;LH'4R]T,</8,MFI%R=W-J3P$@=)5L/N,.&9?2'"B>3
MZHM&CK*L0/-8M_>OV2J,JSO<.0("+9B  RJ31$>(;JU,M;;OD@S>O.K'*N-W
MDQ)_UINP5> CW"LPW5/Q%U51=HS&1B=)_'(',H97U8/_CK&R8?*/A48;#1P<
M^@]DIKC*_#4^J!3J!/%??J^)9/@/E<=Q?E K$>&$LN: (V0YF'E[=>@;!=B4
MP@6TI1UF%N8TY)4_""6D?M"6?A>Y(KKDPYB^Z9NQ.UX@("SG4>VVT;V27Q+4
MX+00Q@SY7EC/JUR_:XU<_NZ3MZD2C.!+>&;-M^XVK[KR95\G\[-O:VG_ ;3!
MG$9%YJ[[4D"ZH"#5&T<VR5P%D6:SS_1<?(;:Q7<*Q*F!X9/5]&&NH'P%B?+:
M0BGM;N4S"#341G^*<C+<>!P:K)L$E_$Y_)FS$CA!Y]JM'^ 3E3?\!_DYZ;4)
M1VE22$F >9V>Q55T4%&93/+[NDK)BTV:M'^M.(>X *%YL6R7>$A^EWG+VS5+
M5E; ]*JYHZ+!XET5TLB9>*_*O=?CC%%NV963[+QR:+<JR2=;H! U^4*'GJ5[
M94L 0FR/TYLXK?4UJ"V'C]4Y<J[=T>]UF>A4K>&H^_N6J9IW0B'080)/D>;J
M["YC2K*D32<?-*[/@T.'^1%5<!@K!]?=BGP#OKL!#-/A.AILHHIS;L5NT)L]
MX];]!(ZG^WPT?-R=:O7R62$;!NVHJ"1EDH2&;.P>U:.HKG)1?<?RB0DYZ]82
M,3\_9$4ODMCI^$/L)A.+(V*2EK]"S-WKSP)N;C5Q)\:I=1$](MS7<Q004%"I
MU0OE9%L,49ZP+; +>.DS#\5%_Z5F]\?FG' ^ZS\S=W N?*4LCUBOK%4>5ZH,
M58VK]M-F;BAW^V]S;ZV$:AA! 82HIPWHI3Q1!AO%TC8^BZC_PGDWV$3KPNQ8
MU\;OMP^.<(ZP5.OKLO4X#=#/#^7*93]2F'TI%=#5-"^G)M' >>>S?GI%4UW?
M&ASPTD]A,K274^IZ?F43A>>@V*JLGW+@<7''R]U]X&-=;UYH4MD&T\TA(95=
MZ53W=Z"0!:M!VR3[,^2*\WRV:)181['<J^:V&E^W6>>\(/[WY5%U,(W=YI3N
M6 !R1;S@QNJ*Q0AM8-4BF.B3X<S.IN/(@Z69?O3V-]D(VF\FKKYNZFN+X,<J
M-AK>OLULD,&A+291GE7MTH:+K[;F.(UL=.Y"7_E8)*0D!2H+<.VK4=.)2;'S
M4WT=_=AL>#$%S-DG \9\AIHF.;"/V=B4G0R@;08UV&R>9'?%(!._ .GB[5P%
MB59@L8"3.W-'!WNSXK'+\IS>1]SRO$898#_4@:>F37-*?SP6W8L?CJNX#3H>
M#HQ[8H)H=:!>E6D2O\Z@S@G6,P3[&3S/7(<ZM%D4*QA^JX$?L6H0<QSP-9]9
ME)@MNRQ(1=K/RQ@[M$.=W[##7-$WBWJ\T-<1W+&V-IRTL^MS4Z*# V#??LD=
M#3@78.*!XMMEY@\T$BAG6?7.=0)TCBK7V>:#3*0L=]BO7Y.&-3=MM(L9<F4
MD CC6NHP5\]"&;G,FL O+NA-PQ==^T\ZB.U.,C\9!QF=[S(,CUATR?!9D!]*
M 'P86222I/UN\2GQ67@$9GJ8<.;Y"[?(KJ Z;*0MIOG^ZEIVF8;U"98STW=P
M0NJZWK8*K$6]TP_=M.C4\KIC3"='<)_ 7Q=S$-<B\L?/VHY/-+IXA>GW&]-4
M]\:BKH<[YA&W:NUI$IO7/ J6JN9+8V@G;28TP]B>$HL_2[J%V_U@]RL24JM!
MR24P]+89IF3;KR=0J[ZRFMW53Y>Y*>HO.GE+-<SLV_7"I^/VO@89S*6FV2P2
M8(=,_P=YX]!>H4R[S,H0AO]-66T4I;'_4Z_FCD 3EE/"KA)<^/%"<Y:F)/TD
MH+?PR] ,!FFSLW9+F8,8_YLB8N\D%OT5F%O=K$"RUV98'[E#MBQ:=1:*W"62
M)^+17KJOH65S&V;!0O&-U+;Y]E22,!!,;)JT\>.Z*"Q\"568]MP6V#U5EQB5
MD2DU5.FP<F3XE%OH][(R=C1:&)C^Z_L@S*F@TC-LPQ(B3"Z8-@U0\]0="1F,
M'7?>@;VQQ,?N"HH*E/URUX3^*6&2#FQR'RTFSM9]-'9SH$]C,"H;TJ]!;?E6
MLWN11S43^@^3ED<32M3#*.!_!+5Y_]O=&V]&<_MPZMPZE(G%WETKL?>P@!ZO
M@62$EM@'B37^,S\FG6H?>@N68NX@HKB[ ]!QNFA:+;6;.3X^88;7+%@^L%Z6
MU96RY:;AGEFND[_]GD=VMH?$9*5D-VDQN,7*7F[S-JB/QUC'XF[T1,#;%RIU
MY?K9TLW@^4H)^;+NB],%O5?YDRZK0JI#MFOQV'CHN:!N&1-P2QU2Z-J)KZ>:
MO;G\\RQ.?\#B]2',ZBY,,K7;)F]X3I;_<-+"%;9G)U-CS"=^KO3EJ67^CWC7
M^ 7D[*;VPR&Y<ZS].0W$>$6><I$DN.1(Q)@ESY>;6;&U? ]<:4[GXP]E?!.S
MWY;[(H5CFU6":]T+NWMHKJR8/*\LN;:'2NU:)N^LA[-<H%]*DC6;8EV>PLUA
MQU6ZX654'3>%D!JT_G8M!/(]@RS:,O3"?<V'^9F+@6QNCR;3-C]*Y5J\^\)9
MI^R/,(OD&(A ;JO_?(&G^W^9"/QG_7\!4$L#!!0    ( -,V=E9Y9S2&5!X!
M &%5 0 1    9S0P,#(P-F<T-7@V-"YJ<&?LO ?<V]3Y+YX!!$()A%$(!?J2
M$"B81))M>80D(,N69<E3TW8@(,FR+4NVAF5;,J.E[ TIA-(&6D;8 0*$%"@M
M.ZQ01B"0% HMHY  9;=0RE_OZP22D#!N^[O_>S^W^KRO;!^=YWO.><XSCW3T
M^7.?OS1J)P)+8:-&CQXSVAWMCAKU^<N'-^NV;<P @%9[NE#117FZI#<!1S
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M)@O>)(A21=9S7M8<2Q"]8*W70F@,@ZM9F&O:%595>%(0_$HCH_4-J!-U,#%
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M S.^=D$HYAJ]C)/3A58JCA-HT"#,1+C&\86&BD!)W M3P@V,A7UM&HBTP5;
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M+\G"9LOBUH ]X4WBRF$%:[FA'@HESSRW0&NS++93TD A[GH0F3>)_N:=6;,
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M^]G<_I:1EQ;W](N589^+)*5L9NN!IJ:^(\SZEW9X#6)U=>I8B,>MH27.77[
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M.NL*/9P5IS67L/7LB,6E2RA^A\;%USH4:E99)WVDFQUO?F:&]J*SB<=6_3R
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M3DALZ"ZW_P1L6>5SC5Q:CE+T2:/0G9Q5YFFJQ]+35?]IZP 5 _4W2D/01CW
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MQ["E7-)>4:5B-7.>K_W06"J<?2:@MDVNY4P,(V>6<0MK-P;-NT;0PH2;ZN(
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MBZ;YH;VFI3/^P88&408^O["-+]'3#S+>T<,-:F8("3=,8.=@&!VMR"AEVU\
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MR.8_ _#7\/ZM3" H;O=63DI)B1NV[(_S-E' J2*K1MD"*]6HGTS"2*MV5W&
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M.]*N/WOZOE 0.%ZXVJ4*(5\?_M .52'30"%N$)&@B[^L)3'W)I9<]MO135T
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M&<(;-2YAG:N)M"BTU,($:C4Y[)J(OMG?2,4C8]' !=P)GCEF ]E5;U!MP88
M4FQ'$ !RNED9';<H6L4:0?Z6^(?W8<]ZL;>.;@=WF&XFA29"/M:MWS\P4[U8
M_Y"@%7S96#T2U<QLIB#4!?A\^ ZQ;I)1WCV'EL,AHD8]U1,H?#OTU;3[B-7Y
M]H!74:BF\AF0"%J>.1C[:R4$&2^';)@)I1YG?'6O,TW^YJ9#G,I(N7+:(ZO"
M#Z;[FC$2BE&O2O_+4S(R]7.LR),AY?NQ9#[:HY3<3$JUJ#R[5CB;CY G?1=
MP< 0.(X]H3F6_&11X:)CNV46W:!-LX$6OL S2^S=5WZ-T2M;R4MH935U+;_>
MO-=S=7NZ%SH6]:?X:9:QX8A1:N6](<D(#^':OFSS(1CLW)'P8H^D'GQ=N+((
MNT?>6:^CBN#@@\J-S[[(=5T<RH34*_WJ;L&F)7F(EZ:+?08  NY'!?W78K+N
M[:Z.;'*LTY<^!==&UI:Y'-K3..CLH8=%22 ^".L65_UP,O,;'N;D<?7@_%,]
M;51]2E=E&M3@"T58;,;$X4L.(E7E:\J3NXKEY[ +GT%^G"P,59JD?2LCS[V6
M*=@KG_ 2^O%#9@9(Z;?16-4_F3P?69Z:28K'.:.[^L.:[RCL)@]1GLIJPE>R
M3YI59\/!E$Z"X>M*@:3)NU;\Q4APXI[KO>?>$;")^D?! <ZB8K3>SSC3S(\*
M&6$J942"X%YE&\'S+]ZJPO16M*88B3)^UX2_3UH&X]M2R%<ZWM!;49UOF_2'
M6B^UA[AOZSLN#: Y(A4^0"?VA^: 1+98MU=K%19MK!-Q:NA5"$/[3>;&3-#L
M+*00U!+6%%XLKEPH;\J5PBCP</;/=\AW\._68&8VKBEFHUB1^OH%TJYE+P.C
MJG)4^(=B,E/WXG<Y+(9U*:R"HX&GT:42R,5<YV$$JEOPE:$R\HKF- -5S:%F
M4XW]H1AZ127'T4_RJAYA.T2COLI8V4V?>$R.>19++X46R.5*WUPVA56*P5+3
M2,T*]4=%59K^=L7W/+R01=6U BA LTN$'3(TC\$I/8!5>L[UX; F;47O(CN
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M E*WR.*5HKF%0),@D8/*ZM@0!L:$I]^6S']_ZIFUI%%XA>E0;7H%FXS^%DG
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MP6V'I%O3]P+L]V0(,A79Z0,'^U&.B;EM4#:.3<4(Y7Q^U!#'OL83' Q.?%2
M/ /X!9X,*\4"=RC<P!NW. _G.="XL3[$^7\TJ+]"$5KSVSI)\%TA+Q!7GY>+
MU6^TZS!QD>HZ4C\_U;S(0:^7]^RU829:U[R?Q"="#D,W 5-FJC/&OU4-6$^>
MNH/GO0N? 29\T"?4\W^=PHF.8/L4.I9#TJ>Q0]15!]GP,O2(0QL+_^16$!A4
MY;$AWBJN_.@[57KS=D8YSOA!Z/9]<XTW'M%%ED4I)[B8I2]KQO[)6<1O[$_"
M0T?37WO1C,1+_,5=><Z,V14>E.&K45K&D4V+ Z6B!$6-4P(,_+%C%K_X*X=B
MOKJG[>FQ-AAK+IQ:90,K,*S4P 5'Q>MTJL^,LKC7$#8_TH\,K5/..]C;-?LZ
ME"XV4&OK,&G&+>BS6?>UY,C6"4C+E=R0.CA<1'BLV\9DX[J@O9WK7[68X8^0
MJ[L7K/-1<HWE8JEJU?.HFTF/_6-/G%<X_V98(D8XCS\*(?317;\[;\&I/H!<
M0]XL^.<12M7/A@ C%<?YC#>]G&&OG!6.O(0U;)+J/:)#\Z\E9P%3"\)T&'B?
M\ITQ4W71Z^P?U1789G?*UIM&+^L;3V5KZ=12[0Y_YID <?,?^,ABV;=-?L4"
M.>@+WW<E78SD5X-@T\/S5?>8-;4C!+ -Q^( L0DH!O[9T@)\6OOC@-@H)4X%
M6'I*C7N>U4*0ADMQ^;#1Y-O\=:J1]Y03+?!@UQF/YQ EJ\N/?5M."KF*T@XS
M7DMA441;AG2#NSI"</%'N/?T,T!>",Q%3>N57<K9)J\\D&@5<5'3YE:;-+DS
M-DRD*SWQ,BHM.C&!K:*6*B]*B*R;%F,($[;@06CS6*2_2^Q2-(\9EQ[B/UC*
M6'HOV=J1YU\>;G4UDX(G1%EG9[Z:459D\,8B@N@[&3&9DZ.4K-#.,R TNL&H
MG'%AI/+;8PP[CVMG-5]1-PHO)AN/=KPLY74H6WC\E%8OD6?M$.L?I8*$$PZW
MYF \;[4NCX<4^Q/TON2=6^>&)YB(WWG.7>Q83C%B;R?=K#UH1OS0IB?XZN5?
M1+B=['M<O+9^!CCQ#3V^MGL&!*<:E1/8<.'3L$]P8B<=FX-S2%&X=$+8G K2
MU#F0T_A(.A2^^4K7WI=YDXG47T1;,+NQ%^[P*VDW*I38;[9-3*@;&R,R,I0^
M!2*$Y(WI?,TC8'G+#AFNNZ$4ZW<D[GV)O^B0ZH6\X,*!.G5]]N7E58V\W?-E
MY;L6L)G!+G@:<<F/)A.:+YU;1R]2IB(Y*_TXF^%\2\;]4-S_Z=(FJ@92+-"W
ML['7!S60P:W@,46(BO)I4UI[6?L#FCWZ0\*2#A*XY7IZ$HW*P6 NQUN7".5F
M2]0BV2 %3K<!T>M928EW6/>8&^28?AY+"[OY%O$1]9-?/JL:HAVU[P#3 4V;
MOUU)EE5>3;?XF2C5ZS8Q;R:,%H> ((EY^OF,RS%3M8^ ])'?IM3@IGU][O"-
M=U+' &H<.A_'^E.W7/!M!(6>OCP1)Q)Q89N"=.(?<W5A)*Q!PH.QMG5#^WKF
M/OSD?,%>_#]D2$<3>'U/CKF4#Q,7_<=[XZ!6*S3X](*A?S#Z0'&?7=V%_K*_
MCYN>]58>^6&P+C5CU2_%D=%>:-F'!*[KN:72R>TB:\DG,R(^3W$M*QQF&BVK
MN*U&$^95)K? /<*]!5,C7CH;E>.9X5QSS]:>=]ZQ1R^\+SY[--:U'2E></76
MUZ0WOF\5F=)H<^"LZ2WR$=DZ^5YGI[_WYG3\\?SWT;A)4EGK%#1 6"4Z'M0Q
M;:=8(<)M-3)$2V[F3,C'7NJA&L]A*B-XB-H5L@2)M1IA^)C<$!HST--V ;T_
MV ':.V/8 1US'65=2>4!Q'19R/G?Z+)\DW9V076.^OP&]:FR/+@^P'F%[^/&
M2A ?V4ES7 4W*HQ$A<$_1#]\L"LZ$EKU2E#5JPI#-/OTO@70BL&(F-E^1MR_
MK*C?#Z>SU%S\KGC>B2$:MM5HI FM6_IY<5/S#&C9> 9LL:8MW_\5O/:'?POA
M10_7,38C&D9+7IO*Q:##EJK^P.*7VLP$,>;7#=)*[/0/) -@T< V&P-K=F!E
M9.)A<(\2![5\\$I7QI56GP[%,Z!>F\_5QX=D[EZTB[M-M3A D.P2'JJIJCNO
MYEWLE'?@7M@LVEM$S R*6* Q'[V@0.@ATI6^(0L(?1A'[61D;<O8WC) 9C,I
M5B/3Z=B'DR^K&W!4=T$TTZV[W&KZ.K%X5C075KLQ+&88.2Q2JZ&2GU@9)#8/
M_5ZV>!@N?W^X'F&E7"R)[GL&+*W@83T#WCT#['3W&YQ_:?STX]@KTZ&].&.^
MF,G3'_CI5SR1W/]0<:@6O+,Q"?X]YK$)[ H4O.Q#BPR.-GNQ>E\>>3I[V+<#
M*S53*PK>!_\<$T\5[W Y6OMP<A88<G_CZ&U[OLCSLWA*_$K:;$J\]7[[]+O/
M38>$V<QGI]]R32.UG<1621JJ O-G.CNLM%0R?(.&Q!K'(V.E+GS[IFXR@=,6
M/2T1I\)^MJR>)6/<.8E-3?_[4S_J"#_O4Q/63P^$VS\3ZKB&>?W-;RVL5UY(
M,7CW8]JK_%;6VY2R<_L&^>QJKV#OZSN@29G\!9 RWQL15I/2*2+J_Q 5<W&?
M)FEL[\[YVNL9H#PB/>=@CB&CK[05A.Z@,6?"2>U8KM#YX1-'RP8/$<FTG>'Q
M>T>F.:G]/_I]!]CCZ;V*(CN*OW>R._QMF[)M!4Z%MLRFRU?-^M,J2;S!XP2*
M#2NK&70$RTFY/3U@E;[R7A<#A3_Y[(:#"0R_M"[]?CEP2Z2G%JC:*"H0*F/\
M>BFGD&1: /$:$WF;LU^G&M_D4/<>C_>.H2%_:C-;W$M6?E S^PN]&GD9GQ,=
M9G( A44>\(FNX(R_Y(U:7V"HTD#X,(;[TK"=NV9A'Z(/,:$D]D\PH.Q-1:]Z
MJ0W]I:RQ-J]1A=(,P9B/&G_L/+6^J6M1^DH79"Q:#/1;LOS:57O-2E6]@/V%
MV%#;_&FU.2;HX)#\!\$[PRC^S]WS4MJ&2H8**X> @%@NA7AN3.K6GEW";PT-
MI,+88:8P.-1F^0@?I7K"S, Y58[OAQ*&<S%FHNE@2<^-5;#5;'OFKS;G36M'
M(,EL[XQH&!WA]&A?'N4+$9:3(K'92Z>KS278I9MYMZ)<WC8IXQT-6B4F.]F>
MY%9_ X1F-H]T4%WHM1;/U$S&7&@V\G$) 0>C;^(4J\)KUZPE6RH+D/>)-8];
MAN*&:ZA?;X--A9Z05(?4EU+'G [#PSK2Q1'X'K542Q9#1B^-UC&H&^OI)U[C
MPKKDS"L?G2HS_W'^OQ0_?:C\9$2^>, RPW-*KB.+7G*O7H@#)6->T*PDS,-T
MLA6-7O$E^Q/[6I76;'JW*F$OX]/1IE3Y"I;*DG@:)B_SQ7;]'IVA$]X'W,:7
M)/>-YK\X7A6S;?;\3A5UL6CIU9W0*9[,VV@ QG^>PS&H8?JQ505IO3UC%(O]
M+@0R.>0K0D1RKU%P[X\2)-L2G=VNZ?]5W#<NX&X0WX=;+%2J4ZK04A*@B2SJ
M5+:LT);[Z =_,O 5R<7XU8QCXL>G'W'-1M9/G4ZOG%E+.\0<]Y;O'8\I6Y/X
M-D:3FZ?5_%\+YO49$84_*([_)" *.!;9P<0;^Z[$T!WS@W.@WH=OR4CY]$ZB
M_AUL,@*F1;U20L >Q<^[8>CBZ&11251L/[/Z/M4DW&;\ZVJ#GORQ<V-S]L"#
M5H U57B*BUO2@HR^(Z-5S0!V_O6VK$$DNJ04!0?'CMR!EO/R)Y-]R4UB9U)?
M<(R)?M/X:]R7RF6OUYOGN4?F>&@-_<EINJIX/XR8;'F$C+&Q\,Q;8/W.43=3
M]8D+-MX8^[P>2% (_<TS[3IS73S<<L ,=B!O>[LBI^[546YEXL=M>?"D9CT@
M&D#T*$\L6,]JEOD&FR?!FS:K3HW+%]O=K5//7*&H6&#T;3#&AGAJ$WD/<&[/
M,<-;3*::=QJTUFR?!:)J1GLC8_G-4#&DXH2]G)8:7UI%8(<\U%AER'*N%_KB
M^T29M$3][RMF07L!TG).*PJ338^3L^,M1(3C'QT?%=+&$H:%5AG?O+GNG/@@
MFO1WU;*X(I,Q^B^9D&/.4'M425EI8PL(K[ERE>FL[D2'*W]F@% 8QH:"&I6,
M8'JL)EH.9+N@>!-B?*[F^P34CVP,K[PC_19/?"[(6O@($RZ&'GG#$8M2!]Y=
M.X[EUMJQ(:N8ZP+4&0:8(@'MZ1$2:FE"3&,.AO.TJ38?0MP73^JQ>=)-N*7B
M:@UD.9B4Z+CCP]3V[M6L49I2HU0JQ*53V_*:>F;2+W\EO'>D,+=^8/HF+V$[
M;/4%R=6VXYLB+?[T.G.6!G8$-;E4@5-5UI>8I93)1LSX_B61]A^OD]IX6(.*
M,4 BF%:C62%,W8R!6>7;SK\Q$R8QZ3Q#WWI<8=&U9NOBY3JV6((/6C5$OW_+
M, =5SD=>AB>^-VJ2163[F[0GJSQ1\CNR/<(::7CM>A>6JA<VO19Y6;UI]HY"
M*9!'S>GI6Q'. N:_7==ZK)*@XV=P^5$%4Q]CGJJ"-\$?G?R==Q+J]4/*C5$H
M"K.\7(I?ZO@#%)<XO0E),Q-ZN&66I.>F WKWMTM"Z/BMDZ.>>GX,ZNVIS?\N
M&KS8V$A ?-[J_LEH:F DLZ9#YD.<T9S.E&SBD[P-XVW%]+JF6>-#O>I-UF(Q
MZI3+(3U*/+<L3 RWVA*:PA!++C1@KMAB&0%D >@ND5B\;A]:@(EY*U3:MBT7
M7(0@-C4]Y=0B<^*D'WI-G=5*_'6LL9*_!G7S;:C3/*(@M?68IIKDI?UMPF06
M-.U4N"1NVSW8KA+(;J\E1>(W(K5BVV]N I.59WA-G.@I5(KX#2;Q9[SU9-K?
MQ'LN=Y2+5O[1-C%3^]JBH*R@,B*-8+8*(R-PIVDT+^V%.S0RK.2K#.M;KT=2
MXHABOLW.3Q\C%\SRTB/'8!=$:NWB/$IPJ%],:2%CH)O9+]W]M5W\]O-*<N-0
MG2'-2\L<X/>D[+I5QR\K-/E4M*05^TV&@59OL#W3A8GI]L!W@N(4Q @1_Q2>
M1MKI:_M)_>9#8G8OHDNK;LH J;%U7)6>5HIUU!M,ZL;!9![=NI,H;""^8G:7
MZR(6LZ^JL8ZI#3@H=DLE@IF410_XE2@/74%+*SHA\854BVN_ J<5#^>I'_4V
MNGU-#$%*4S]H[:<71D!4 ;:K]LYCP$/SJ6'7],)^ZOC4AY8A-SCW!S73Z\\[
M.H5WT<YB7,ME!8!9SM\@'*^#QHFN]M6B0N!O/7$KQC- IIL@2TV&%>G,AOJP
ME@B\K<E!-GT:N#6F;"NETN"U$E&GR6O$E3G;;RR0%82H=:7N<S#2S(\HF+%K
M=.1!?COXN4:77?OHDU]QMY.1S(&QP4F86=7+@\'[@7GUT0E:PW1J>,;IP]?I
M!RQ5H<WP)G^JKW$%6I^=OKDOOJHTPT11ZV.@\4W&Q*5E"G*@?QGRO=DV$2Q(
M2Q$?^DN6>:V:Z<9E0<*=HMWC3'=V,NZ+&-KTW GN)=,AE@-9>F1=@QXULZO<
MZ740<$[+07]C;3)C5!-J#0H85$Q<J!E1<]QC3]&=7*R:U#OL_8#'.W-]W^-M
M(.^)ZQ*J?=TD(#NR)R7/;N]B7[3'*EI7A^AT R]6>/K<10J1+Z O:AV?_?2V
MP5ZU-E_I*<81J>D<!0YQGV LDO!&J5^MX2@OX@GKBN.8HT\/+P\[)M!QDQ1+
M=ZY^,)/R]?M3?2'3%A$?2>&(>@II2-X@J,8Y?/!N"H]T.C:R5J8*X=,U=CDS
MHP!^&0N%.>9:.0%SJ-@"8TBKV)9=AURY,IT.#JIFL#J<4B@&M%N*[$U<"JH'
M+*U<(##GOIJTLS>TP 6+F TVX 5$V,3-@1VO,*PA1[;T&-V"T-]I>[UV$*5:
M:*LVTW[B(PQA 7KG6L!7>>N*E4/N\$-0)VVN7NY+[D+Y0(/$S(^U0>+YW=4?
ME>_)9-4X !@ONEO%R!<P"?X0?YP$RGCI#XD]H3L@"2W:&S@TO=.@U"N;8_Z#
M3FA3,=7P!RCR7@$^W-M(+12(DF?>68P<Y)XB!:Z0D/MF$DI-%<M(=(Y0%>G?
MRWF14G-D].?]N7753\RA9G&37MS\K\2(<*IW1;D_W_8](MAVZ7-K0[WE*<W[
MD.EA_>1JUFGQD=@%OYNQD.[*3_ZK'PTHQ98C1\XR@SV*-ZN7P55;$\+P<L83
MP%\)*Z1PFD8-X\/NG@ZZ8VE\==]%T4A1A_A]<'T&T9*5,\SO'S7U,&N=FB]*
MQ'.K\!(!IR3*KCHG LR(4)KBZI?LI\EJ*CWB_GPSY)@==\HR3C;KX?]6.1FU
M8&]O.+2E _@D30WG@Z4WO"1:V3ZQ+&*R+'7FSR^Q(!9<M='B>0;L3H'*%HY3
MJ3VC=2X4FPWD.XRJN#6UOQ1Q\X-".';>L]JTJ*#8H#2S)'1%,SAM5$_&_=*;
MYA2(L0M<PHQ)X*QNZ^ +(;E@+>+H%&30:S[V6^FG:XKWG"(B#:=S[5,A\YSL
ML/M((VA5EM%P_#^*N:^@)ASG0>#PI89>! *A=Q B73K2>Y J77H'::&#@O3>
M:Z@BO9?045KHH"080L> =# @"*)^[W</_YG_T]W<W<,][>L^[.SLSNY\0--\
MJZ;S4DB:LXQ[OLB>L0#$(WW,H$K;>!F3?M^K\WR6HFKA7I0.C-V/E+\;WW#;
M.%@AUD8"4N1 )NQ3[*E4#D8!OPC67>Y_*9\5Z_I\:3!M>-NN53PKAU1FE?6L
M*"T/8WB]#F4OS@B*6;+NRQS+[:.[2'CM4?HQULJ<R+/%"E#TY4E6^[OC(&.D
MT=K!>YYXKV(-T7S"9%Z=;)RQG*E?O_HR+Q:R5\FN.':A^,M]M&?<\^0WT5=)
M _T246+I.4ZYS1)VCW"G&'JS4[V/EYE6GW#DG=0J9K$MUD7>'!(?,1D5$@Y"
M>21"I X--Z>_*/R!)MH)%LRC7AM\XR'L3I*O7GK],U7\V3L^?O(?9UU]=]5'
MU2\*U&MKB*)I>1\6]6E%TW-#)+9MTG0_T[F*'Y[64]P+1Z\VN,+_UF6O&OAL
M)/!<3E>SE(RB:2E6+\4#3,8-&"=5PS,T"!VOP7B3G@CPL$=QDK".FS.-K@B0
MBW0I5<&'ZIW/Z<C54!?]T"Y^W\=I;\T/\B/VSB:Y5_GD1'63KA[CS0]4@Y7[
M<7/1R73+5<.SN3MAJ\U=;K:UB]3;LV(1=W^WMO!QLW;7(YH8"SWX27S9F<MD
M]<9KEZQ.XQ06;R.+IG"_/MUV2IOT)+HYPF^.PCOQX@):?LH8\F*,.6(>D_>J
MC IB$ES-?,V"K?QQ?T25JNDI:N>P*@8_&N*?AF&^86XI,[\OG,=SJ>9DL8\O
M^)D3'1&M$G:J2:D#J/'2@'AO89L^49:<<0J6PB1L07G?V90"K,H23/_WQTL&
M%IZ//E>N-H0R!Q0T@M>\V9)"BE7_:<;\4MP&>F+J7[5S1 6?J<M_+:$]%B*Q
M5/<#JL&XF^=,*Y5-T^^GT^\1DH<<+^NB_H;].CR^CPYZN-/\&6]6G$5 TF:*
M#TAY2NBG%"C+#&/O8 E?L0:X.7)P_2?C9>4U3)!(]:$=5'!\TZ1+\\6X &D-
MB9/H^W_,;'F3(*(C:;$Q\V;/KO#(Z]VKW^T#N"PGKSN9(M^8XL4 U9+# ]O'
M21\;N<JZZ>:K7-&GMN6!:0=1)W?S6-!:7:2J?\!V<*#LR% ))U-OZZSR=Y9R
MKP>SHP<@+T9OL3IV]5$5</2@D!1V"#-P''CQ\392,O'^M0L>+Z/<-&]DF5_@
M& _:AKD95:>I!RFR;]?W/F6E+\-+#E-@N*!K57+.;CL>4DW$(-HM7*B&_Z"-
M>P'"EL;]')? O)&#E.R$*5R2O,"SKQ#G@/1L51ZYE$M'*L3WB2PV_[.$\KI<
M70>77*2^SA5 :F6T_$I#5?FT7%_DNVSE-U">HI<T":>Z]41 N]:DRB_A(ONA
MB5N0?F:_Y:+CR#MND=5PX019@E 1ZQ'CY] TSCA#S"K/?]8WL0;2U)^[(Z4/
M7TBZ+A1>A 1*;@<S7\I^PB'E3B>:9G\TO(=<()1OCF]8_I&SR17J DL^(GC3
M:9+0:/;4I4 ^0OFE>.ZJYX XGS1BJ-@/8P#+:)SX%T_4 84Q:QUG5+/W:2_$
M6SY )AHAC9O6D-L??*W4_'N=F9?H8;_\6[#,2^*PN^4L.5S6O,H'1#CU/P&Y
M^)Q0)86NQHO+7Y[7QKXAT8UE"+H*N.;05^8I_M]I?_1%WZN$10J_F;A/FGQX
M(L1L=0_"C]Z!N<;4H'YU;4.95NT-%[+V9.TUQ?\Y_5E. QIIN^Q^119D,7WA
M9X  _@1N9B+#&%LMOVPG3/J=O9<3K0\!QYT^6\&OU',X-)7I4-I ^&[/3&1*
M%+E04W>W6%;T'6N.G[#8+^E(DLQTV35#YGV0G +6\%/.,<8/7O\\$_PC;_6)
MCG&#OHSLXQB.2TF/Z#VQJA70).2FAW7?$[MU.K';@>@9V.)R>&>#MK/,:ML%
M]ZIX1>30HA\35SJ!PC#V";_5+=(KX7.K>[S>5 LOQ)HS;(&=ONT -JV2-ET?
M?E85Z<# O;<[%2IU85BUK@^60J3M:V?TU!Z4ALV6$'AM@E7?IY[#*V,55]*-
M[?7)28T6U38E2<OT0'FJM"@.:YW1WP5BIP/JRY4\8E<K^,10@4_,UZ=?Q;<9
M.OM<>R]"&404F""O0F>+7%W%F<.)V]7EE8JFPD+C<B?C_ !$\'T7$E>4TY6F
MZS<2WZ[O\Q\L.J_3L.=N#Z]\[<=M+Z!4A3J[_1/:JKR<"'6L?]Y&&?77N47-
MR$;8VCI'DM1NU+<_TLV7&\'F9?B!0V8EWZ!**_(*&AU2B+L'.3NA=DIGOD(9
MN<2S7VR(Z5&>$"UPQ88!8L*S5"[!>YR<>9YS@'&@S/4BELN"T\X[LI".K62+
MO3$%QR=@FP5I?40J\)[+Q:B_EZ7.79VK'\-1A=Q5)?5A7]B>4S1EGV0)Z!<'
M/+K,I1YG/]R=N1O9F8@L2>*H^D]E<E%Q2MVG*IH.:["1#.Z,1SI$92=I_LZD
M&<'%*4T/% >F_[AG'V4(1CGUH1HQ*5(75+/D@E;0\J3N-Y\DQ2=\W^SS5-.Y
M\!62%2-6,QV/)05I-%8]P>!UQ9[GDHE-@O4*10Z(L!,IM)Q\L$"C_&E=F@ T
MSXG4;;SQ!=ZGMN<D92UGNCZ+3J'.2V7V@KW>H;7>FD_]FA =(AING-S0B8Q.
MKN2(J-LV0PD*0;*-_#=G+B3/%7L04FA[&$*A'^;J$Y0PZV27)?(]-<MU2U*R
MF]C+GAG' 2C5?3<-ZU(:GJWU)EQ+HO@M>Q*6SOJF3(TA7^*S;V03M*M"'=UN
MRU _:ECP1'5S$3$2HV6ZEAY0&ERK4? QD=UIF:F0OX"DY5#Y3UG(AWS^-4X&
MJ]VZK4#Q?,*H@&/]!9HC2=SWB\OC[9KM=]',K>O%'"VJZ#,#/TH!$@&\ Y#;
MJC":,HB6I_GQ<U#3R,MNS1P AS0;<$6$8)4ZUVU>*Z$Y@:WC?7E.,[!KMCS@
M/N9/.-;>"M4N\>0P940]C[Z98-4V94/Z^=<Z_"]#A)X!W.!7:\V%]8 ^"]ZB
MUL#4,S,?\')A!Z'9%#VW+65M)XOF+*-^%ED0,TOVZSI)9,K%M*+HVYWYCZL#
M(DH:V6L.RK2+NFCGDEC1%>Q?T 7-./:PUGDM3]53>W(R;$<P%Q8.SWZ<8A'%
M].1E$_S'V9A$@>#F$U,]+^-U>CD#0(MJW&-BP?%.3EE:W'Z-;LZ5&X=X'.]>
MC87_@90;4&_'FDZS]=>"J$OS%"('>HKGL)+2?EF<;-/"F'LFY0P4/]4);A@Q
M=O-2D?RV)7S+PA>AO/1CGV?OTR%^(#M["1&-BXQR0 !)+$\L)VXIJKN"UQL-
MD7T1G'(-)JGG?7G2XY^K[?TXWS<1J5(G0SFP6Y%:#9,*;U5#O__F1XO["U\E
M+EU:E-)?S05O\5DU+^Z]MW1UG:U[JUJA;3J1C.;$7<]BIYU9ML?D?-#Y^H:E
MHX:069=Z"_<6!F>@B--ID,GW:AV]C_GBYV+^^^HP==REA+-(_L;;1D*IC7YK
M.ML"XBENN8:H&B/;.9]J5OV[&!8QLI9<C#/WAR1[R\*!&=69B=8#I[WDFQ+.
MVY<3AJD]HN&(OIXK4_@;>+/K";R-)"3.FDPO4MIF;6GV846^%.=?[=,:&43C
M^Z0'\E,AH)-&;]$R\J7O DC=J#M(3.NNN<EM"-EY)6/A)YZW[N%=FZFE0'>Y
ML.;DX8;+EY4"Z>O+V2P 6[_\B%\JS30(6Z)D>VQ?;W%]S(>V#U$2+SC&,*NR
M M,'KQ?FM;7V]$*I>HHDOD4YAC!\J7Z5 6^-Z_=1$G!D3B0[-:]9.0;Q[' E
M841O5J4[1N6>EO-"?Z#JP=0>D:QHUK:ULK=MILJ'\. R5^N3%)"2K^C<9?!V
ME*^/6JB%[='QNP:7G-[87.3B<W)KX%>T6.\@NGGMQ_&&_,[=9?OUO"KW*^:Z
M0\XG-NOHLO<9"L2Z@=$^X'J%-[LM$#M03OF0CJ<61]'J 7@2_;%!%"/'AXVQ
M]@N$[BH/R&<00Y$0>7<3<\75(NNT9Z<;."7&)'?PD?-AMV[WBW9IKVC(LQ'E
MQK@3N@#)TK_\(V%O&G8%?_GT?%O,C.7&O[^;;L92"C=V: N'PQSPP@.FJ2D"
M9V39&%>ENHTICK<@*"+#]4?T$5]2D[TD<4N3*H:IADY/:&]>U%2&)6'9VP&)
M3K9944G;E$Z"H?90WT8O\,N*$4:#_S[4>3L/P6-2D0>>2;=%%CDN93D#%@Z[
M_)C5OG=6_'J>LJYDW < .E;1;%E9A]F\PI;H>VG.XK5#9L9!3PR- /1T_BP
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MW$I;KYN8FT5L/08I?(\V;3]HI<>2X*L5?Y@<M+O]>S#:8.9^6$>=Q<ZJ*!_
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M!K)P8.%<0<*ZK3SO_0G(Q*15R#TBNM?<W_\\@5+*3(<^QT126A_08<&O\6-
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M6"+YC>EQTY]Q^6-4!*&+=6:E^C>^QXU_QH=%D !:S):&V ( L$!AM\X: &1
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M%MN9?M)A3!M)'#=@JE@L8HVZ[#Q!'$URC!AIXH(@!*5QQO_:.+D@!5NY9F6
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M@-/EB6+67 @@Q-P,-QQ+(Y1>3VJX5BVBUG(28-0+.\-J.SLC#K$-;E@0-)"
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MZA68RN"6<_VP(*MBQJ.&&#=K84HL@=&ALHJEAHC,0H!)HPMR1")\MQZ/A'V
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M---ZD8 KTSO4K)##P7M<+\M"8;?3S^&P9$&[E\?*.JFD@/$(9H0=\0E-T;C
MD^(' S3ALGK5#K?&JA7P<3QHR= V+&H4HP[<QK$S<=[LRD6]"%L"X&(4L?ML
M3C@FH'RNI!,U69ER-RUQ^L.N@-HO-MB,'!$S;76$'5$)C5RUF/: /"ZDY',%
M@7"0EG-U$ 4H<][&24O)*(N6F)T>E<-:Y@Q"7'X6CT6"?(45P<1IJX4G3(@S
MS-R"M ",DTF0B[#5&14L#T02(*'1L+Q.7&ZWFG-EA9LI;5&Q(QM(J!QF#E\O
MXRG)N%OF,(>4#HHKLJO5.,QG&_F2)(RJ8*Y/9W;X@Q(YI D@4"04"F5DE">1
M5"IP)YWSV'Z C$6%<3:>U68(#44GM6*S44EJ-6Y,&L<R$*F2,\4Y%1"0).)F
MN=GAD-TM=G #7)T5Y8>L.H4[06%VVD 9 KEC9\":4'I06F:C, KTYHXN73[$
M'^$+U1%:E?!@+,;A"GP<2. 4, 6?RH&;B8@%C(%&9]ABA0@B!)%ALY!BX[F=
M8I(@%B2K B59F1:'=7[,E6$%5#(P !N2*3';S.R:)&$6AED0DR+J'6G:"%DI
MED3E\EA(09A4"=4)OB9N==#R5"[JR72R-!Q^O&?CJ"3+0GU*"9W 1%A<#&;D
MD%6@#6GC4%(;-[C1((.%^^Q.3)'PB11,8#")_!(@2C&AGRG6RP 36:F'%NH@
MJ0>$E$:O-N[-I P2S&K4*IU<M59EDSB9Z (9N78>6^A(LIR4@Q/GJ&F>-,6Q
M$P$6E38ZW(0%=@;BN2."6)H%6F&AWRW3DE:,A/E)H8B-"ST\CC*LXNO]?+N$
MM/AC+&Y(Z 0A2*=E:B>U$ K*@FXUGX?@/EH"HX&<;\]5]&%^))MU$G[<#R4Y
M!.DG_7 2AC12CDKO)12,5W'+6$8_,SU[@/%$,->/IS/N)(>4(3&9"!=QO)@%
M=/C"<CR2,VR;,Q)4 0;8%K6PS0RJT^=(T'I.1&SD^AQ>%YXP&;P!J\4AX CC
M,2?.,9J!0,BCLC,I, QA8@DM,G#%9E*$^&7&,D!*)LA8^4I2$I$Z&).S:K1L
M!91$(F#28(D*PT:"A5OX4:%?Y/$[C8DHDYJ)4]HXF(887ZU4V&/"$!R(L;(9
M/F47/#[N8\5$'F'<YM CW( $0YP^EM.220&J&![& FZ]R9<,Z@1Q94+GB2O2
M6LIJ36K),)-XLGP""B;4;#T%!1$9S.;GRELF4],$5%(#D;5&>18HS@6".A7,
MYZ5A1@PJ(45RFG:)"'U,%25X5$2E=KL$82DDC\%!31:@8).<2_#5,@?D(@.Y
M.@5)Z'D\3D22T*OUC',$53PF'JO(A(R6@!R]7Q0SVCAI6)CT\MF +BK).KA9
M'T*PG*JDET8(;XJ'.9E,5*<E=+F]C*GPD%#F-D8H 2 5N6 G$B4B"6O8D8CZ
M<2G!YR*<J!3AZ\)!MP-TI$$E@.(I;20,PGPRZ4G!D,-<>MZ@IOAT+K>1L9P^
MVH-P4:;6P[()8<*C\Y!\?U #:>U!".;B82_':$MR=68=;'(;Y0F]WVYR,,((
M0BB5\QV20)()'K&0U)/(_5W/JL>4 %/IVUD:W!Z0V)PT#$-FG++K:!N'[90)
M 5ILMDM5(.UFA5"=TJ&7!>QFPJMRZ>PXZK/"25\<=A-"%9>=.\2049&(C1^A
M$9LN)DE%0 LO3"9"02 FDJ0(#U/O&0  X1!T  Y'2C=\*,P7>E&K.Z3(<B .
M ;"-@):I<GEF52!W$$3KX RJXU',LMJ#;#U3QX52(&81*5Q60IE"C# M2*E<
M9E% JS(+I1+8J@H)S1*2I^1XI3BA(CQ92X(3MH>]()@K;Q,"P!VP&#$+LUG\
M3Q)"4AT0,85Z6N9U2D,RGXW'USHD<0Z2R,C2U@"A%0M(28K#EZ23&5:"&Z<T
ML%FOX.7*6\@%B;QA/*GF "JQ0:B4^ U6@Q_&0[A.$$.MC.A@6@>2ZB@[HF/9
M&5HNK8DI[4YN G&P0G%MC')A,.7P6JS9W.F<V! &338+Z4"B=B_&I-\*H:S4
M"3A8'A?A<W#\%CT$"FFW*YI0H_R @O*:@E&90I<A88,8H 7<%"A5/#ZN+P,4
M<H4QMC%D\<FY)C;M-T0BD)S/(=)FF3=E3T!6M=;,)RR8F</2)5VX2FZ#DP"<
MAC&O)NJ7A#PQMCUF!I$,SRMDY3*'M(P)L8(,9,W8(%,@I ]P;!Q>6.@SLI4<
M':Q!?"PO6VCE$0F?C:.!W'Z*LD))4&(D-)ZXQ.OU*@S.L#NL48>L^EQ,T023
M&,63RV%W3"O$>0ZK183%3%DYXQ.MTG0*3*9AO=F0P)T.4J0WNQQT5@I'<8/;
MX1$$:0U(Q0F!(63WP6 DF$N6-"J'.HU:S%EUT*JT9;D&D=7*BC"["I D W*N
M.^$W$01$0U8;;H\[=& \*TD@'M(192H'1!0E]2+*#V9ILS\1R/U=SQ!T9U)L
M'PF1 &@!]8P!&Y[^8^!??9"I5"H:@E4L=523"P$>+XJ;<:<*CM%ZNSP0# $
MP+/[ +[6E\AZV&85+/':O2Y"';"@\@#@ WU))KM[\N<?ET1I"+C,:DI&1Q0Y
M.U277H9A:UTD1X_P9*0V+.,;4:TH2DE98()%\G@"9A\;I93 FHS+DA* V0 P
M ,@L'L!%,G4?FV?IVO6W&R6YZR)_N"3#SMV2>>9.#?N/EVIR-W3^> OGOWG;
MRF#X\VM3D<ASKUS%:2OZ@LNP3SCCI9=_V$_N_C#D!<\'4B;IOP.D3*)1NN#9
M>UP&0Y$BYDU$F#ZMHIAIZ.3#?$6 3"%5<;A29E=(E HN5RI3" &QA"^3J$0
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M/L??_-D586:013BCPZXMTX6/W5_+XH! DN5S_TZ"]!SII2/R_5%__\&X*)1
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M@\1A+(YY<-1&(=$XDRNC46^F6(7@<?1?W"\@^C,TTY.(4FPK>^GU3PC^"&-
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M#;=P'C<B4R9)M];.=UO*VN'4RI1!]L&E]UULCL]$YPB@KT[08FN>=5$\Z70
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M*JMJ:U89[13B/K9=NUW604XNIOCU7GYMXZJ7W/-+T/'"/^.,-:)\'(]5(]W
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M:</C%+JHH'/0AQ)G=Z.I5,H2-<%:(%I6=@*2'SQ<(].73KQ-QE% *,S/S,%
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M%?YH^GT4'M]X =^DYDX%G&/TY GU8F'?LN1)8N?1(T/+6AV1I:DJAZ6M\>V
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M*"XEO>2O@.V6(4.9/MKX*H&6EIY3?!(.FT+'1T5@U,]!,ZO'6FS@\L^MUE<
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M&=.-5EYZ&-)@?MWNJ_DK_I:TO'L@Z_0??!NK!;W7E9CY:/NUBS2/B%A?XWT
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M4XJ8(?&.*ZOC#K1?=ND/%K)FLDXJ2Q#UZ2IT[\A56Y"BYY*G 5V*;VX6RAK
MA68 164A2BXL@"$V-PD /9? /^K%*R\]' 1'I/8+@3VDO_*9?N+S&'Y_U+#/
MV_XVB<[SX4G.FZ=>FU#._Y,CPI3Z]328K@]FFXUG09L1328R,]^=J%7B"#,+
MBT?G50M+HLI0UH0-H[0?Q6-")Y>L5QGDP.>?)&^W'9C48'*J]JI5)[I?#D\I
ML ?:$-H0L];ATBUJVU3781\7,+4LM/:-KRM(J08-I9NUJ+MH+ST F'07*]Q
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MQ$XBOJ%F]9U/2Y[_XN:UXQ]PEK)*$D*:>/M NGM((_RMTK2D1#0XEL= .6T
M2M =D?I!(Z0$I37NK6&3]]K)\S0L>WC#:9"ZV91!DSU%Y@.@"F-B(ZTTPM:
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M[(.8.\!BE/8(Q%1H,*Q?L"O/^C2\T,WWVK@.MSBW3XHS9FD7K]D,-1,D#Z#
M[U3M%H/D=QC[IW<WVQSKB]ZUHW#T]36)V6=9=:#BGH^L5$W,;H]BZQ_M8I<\
M+[T3N YK$,=%RMF:Q&UV-XV*(=^;$.A$JS#^42A:,H2[7L@)X=__%\#Q^<>E
M;URP?]VJI<NCJ^4:Z(M#^]4V$,YU+VGC_A9'>D>$@V2,?0JFT#'O0/3MLXI
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M*E<Y^\I"K?1NU.XU7\]*O=90-;!X:>VS[5!;T5)M]?6'<V?L4%+?S! S=9E
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MJH)9[FD%/E(H^<4F6$2M"MG1"UF[(ZB]7)30,28GAW6J$0'U>E0)T<UB$<!
MO) 9X$)K.(K+-;4CV%12(;,(U\)-7A%JUJ WD*!)+U/E-+_1-#J,E"]Y<+XF
M55LAVXM:5*' )AD0A1+50!L&Z66J- *T_.BP"=F]9B&,EC@Y"M!Q4,G29:CK
M=>IH,4%P0*W13#5=-^^G+%?V"$=TP\.6%_?*]7AE(-H=%RODLGG<G@)L1!(=
M M*@8H6+X2S63N:AL&L1H(5:;39<D2-"+&1W!DU(11K)G%R .PG!S/-,>9!
M-#O33\81#\&8>,()=Z< FVG;<\E &5J";4K#!EXA;#Z1\O&^Z^55H9<'<P2+
MILIN@ZW;*_@<*ZV!.IVO03@NPM%.IZUE1OGAT"64-L[ET4Y-C9?I?B@3#]@2
M-2,V7+4:(BU(<I]WA(8L1A(6W6H &84E,*NAUHI!'>,11F^2@0XBIXR1Q[8*
M#)(<8%5&;=J!2TI\-H,H6.NQ2*';L]IRO6.5^4Q7"XI UF=C':C3ZPV*'8 C
M>*:4[N5:(E.NI,I3@$0=S]M&H1'2!XU!WK)).D/D(I$"V@B0BVX6[ R 9I$U
MFQ')+IA%$N@Q]<(@"[7D:*V -2*6-;2:[4J\6B#54;(D1GT4+^6K'A@N\H.J
MQ,><0I,UZH6V5\?*O ET O\#TCTS(?7:%:(C65"S0$-H(5]3:A6V7"NQ@"=#
M(:L_4ALUXX)]A <R*F56JE9R&&N!,3"/-<PBCG*4,W"(1!$H#F0SG7<4MB[3
MF2)AT7;*B+=;9".)X7P,6\:F*< 1PU*@PC.8TZU6\7R@^G"393PAD2/4(@PP
M[9[#1G/5R?"2J:OA\H")*!0-8X(1M@OR$ LB<:Q?#4'RR/0$WP*3'HOGACZK
M=3L\&Z\DRP7?B.HM76T75:*4[22K"3Q63)A9/QHJ8$Q5CH):+3*,LD&PB;B!
MAP:#O)4;":4D4ZF ^V225= B2W-\HM_#,W0["GI IBX9_9B:)KAJ>X#6V&S4
MLL-Z$,@!0.=*!3"87=S4!AHH.#Y#^R/%-JP>4[,ZQ9&ZD"%3: NP:(*@58KX
M-. $TE%B#=1A.PKC02DK5:4H($LX@A,>Y@.1!]X_2#M*+2&N@%. 0I2+NW$-
MM^M5N-"P!MFDF:ST^;87375#8(-E$3)<"*1O%=UH019JJJ,AA(,,_'J?AFEJ
MR&+97-;N6UP,D:8 X7@0 ,U(6(T/?(.%#!(85HT\7@O6@@W[Z:H;-HI O5 M
M<93"4B1=#3RCQA%.%>SZ_+ J%I)-F 00K1X%1LZ!;!=ZP<R%B$!'TQ4_5B+C
M>H?O]RW5:4*\S.?M0:27[Q4<A<?T("$0Z52X&<LI6G&0DSJAB%\.$4X,L!DS
M/@JC4:4:L3G'U<OY+-M-MRV?&K2U&LIBN- LYE"KO"RZ0!4H V8CX7Z*C<IR
M@:"S1,2+=EIUM,+0')MOI4<>6^*-3C/:)QP]CF-R)$C%P Y?&4H=P"O9N: H
MX;%8P30@56A@U115#)*M5$(B&@S<8SV>% &6D9J5KI#P1'I45H#=;&K@^;5H
M7?/R*=R68CV@4\OX[1PNRID&#Z4T6A#KD@G'?! *-\"Z0N7J8LX(6=$&TFD,
M(V'0BRL4J.BC[,M,E<N&G==2B4(X0U,AL.H/\PD:3:*17 R)L_TA[B:%MA%I
M5RS$+<D<Z2!DAU)S6<Q0ZZDLGC:4A,"&\N51H$?(BC* ,V8#M]BV4J=C/;.:
M@EU1R T*!:S.IX.@#1(84,]'!+N$9UDJPP,A4E7S=E 4Z1#$9X=:--QUAN51
MD(I2D)$CXR$0@-$N%O,+^59[LOHP4YU428^%4<!1%2?;B&L=->&5J4HXUXP4
M&W(MPX>TDICF 5V&O939TM.I*4 LBB$XD:7S::7/T !E>=%XKLT39@PVFD:X
M-NRHN&/$!V$;U-/RD.SSC ;!3E\.<S$/*B@TF/95/Z1G:V%GE-L,6@V2 NV>
M6O0(*D=X<'L8 K4<D:WR78=C@VPB)V%&WLP$41'SR(8H50/SH"#.L+QX)4'H
M=K>4R]*E7L2= G2-:!X/['C0Y*HF4PFC:94U-%_BBVK@Q\QT!#130+60)H;=
MNFOV6#8E$%0_E@%-$+8LI.:S!2D3CH6##&WD'(K=<)"LLG+=C ?QH>:$"0!P
M6PDIGL2E:H2-9Q)Q.IOB\)A,%/!,+VO115 (UT-R-5NF.C[K*+Y$I,-:W+1'
ME@)Q645%M58%X)T4;>)HR&%R2*07K6-$34C72V8I(N45Q8D%/B[,Y6/Q<E2(
MH(V>+QA%U2@U4B:R++IF1QEL'QT$"4BX,!P6"#7F=CO (%ZK8FPCW4GYIM^L
M)7H.@"18N10B1=AW>F4>DOFRX4<+U2BO 1S2D7PMZT8K\5&0<IITAK<;KH;1
M@4IF UX46=D6;*B0 *+MGB_*HN@-.YYM%KH1*L-T,593I%@?(7W2S,)),J"R
MA#B8LDM3@/F$!>N&.S3:/;?9DUA=@,RR&B<2>+U4UCI62\VH5K@&-:-=""^P
M98P38A@=)K6ZF&6*J30B]JID7,S&M7QE-,,.QE;9$N,B9=<O%5,@C;&8.:AT
MR$S'U+KE7$;PNG9!B^6C5,6KM:%<(L*[B!WN=J-@F:W%::!'Y4R[,B!',\RQ
MH78C44WDF7 Z%BX4;;864S*ILB2Z<@XV137NP*Q6)P<J1A.M3B.3*V(#;BK!
M&*9)LQ")A2OV,$-G0A8W!>CI?8(@(S$-*CO<<)#(>.42BS.-;C(*B^F450;%
M:F5H-ZNU&%("@WHY#A94#>+:^:+F4 40IRE,Z)D-,I,01H$^["99SQ(JS4BT
M6R'C603$$+*MNS:8 @8=D*P7NH 4C@8>I=-4>OV.XG&Q#H7'6R"4K(7R(40O
M]4S7%7UJM&]#L2D*;=,^Y C(8)CHAG-Y6JN[W23=J1BR/N0="<+36<3/MCN9
MCI$56U5>R<*MAIN@BBU6'@ *+C(N6FM%1]6H)C;[R:093105C>* L(2GBY8C
M5S(:DRZ0*:VHXIEB-9/KJG"(1HIR7/-\"I+K AH'%,N@-+;9[(2 :IR!4\L4
M.UVJ6MU>/^_E-#A6MZU\Q.(&F7;-MD /-^K9)(DZR2PK":*B6S6]-*A48LU.
MX,[:J)L3-!/I%9J1A#MLC IP.Z,6\@"18$EWP&IJ'9;- =,1.HP=&7AEKDW6
MNRCN,HY4 92!E]/=O-82F&*B9U;Z';7804,FGF-9@?+RHUV14HN+LW LJ)EI
M#,NW4+%:XJ&T0<JQ?'B891V]6^DB=D1,P&&BU$MED%09U+O=6I]+J 8*A6NJ
MQG>5KNZ'NJ-Z6>Y&^90E1J-J.-&/=^%.3)8@41X@'%Q,,&Q'3#'](9WI6XZ9
M-!+%>JSME<-<-\E1H<#5TD2(XZI@/2E767FTS<)YL7@:8V0P$*UDRJ5D%HQF
MS4['2RE=BA$;E@U :*[?3U"6'>$T$;6QM$TT$W8^JX=-.IIIPF5+*B,%!![M
MP58X<X#(6@5I#\*12K.H]WM1'N.01 0+67:=[Q:'4VE4S0_5$0UK-C4(:KLX
MSY7J\6P=4V6.2&(-.Y&4N1&@VF%)L$S5VV[@M:,#783U--0-%PIT+.[';"%-
M137=%66$H[-\$!T*8*$Q((=) HA@61N,9#$^B-#P,%1W\"G '@C$29&&D"Q,
MB5DVW@GTM&[6M)J6HH("UHNK6BOIFR32MUVB5RDCPY)1['6S?<<F!WP%UUI=
M%6&S82IACJK14H95:5.%XJE:@JI*'<4F1%@&N9)AVIHHZ1A)]UF+A1739]-<
MV2)I&N.\6K\=,]/9.$IGD!*"P#K&IH>CK?M"L9<J>#$YTD;*503*TEE[J!BE
M5J,'A#%?5CD^"_+IOFPD\C4?&M*@R[IUW$ H *I+;(LK-^D.W!FJ"4L>[8H0
M':6-6''=: P2C"+9F1[=M."27$8SBIQK(WQ1XD2X'O:'8C7<2>>"D$%E!7#(
M5"=%)==";%4JA&1=I^KY*<"L4(H3@=TQ*%<B\[Z?3IJT7V\);(H)99!RES Q
MJ /H"=UT4V[-C@Y%F8S4>QU<: =1GM*TO)>$ [ET$6RT9=J-1M1012D-^8;5
M+69XU9'%'D'+?,&&ASD,:38!WHNWNTI0.N:"( :EHADG7@%9DNHQ0):O=1 >
M8>V!5)%'M9[-,:7.LAI3(%H(A90)CQ78*&X#=@0)[OB\-C#*)(;*2%JQY:GD
MLP,IB-0<QA,VG<),8VBRL18RVH,ETMFL&-,;;MYE^5HS99;#@[Z%E/N$YBG-
M!)H+!Y6]KP;NC:7\3-BV2!9)Z3X*0FPP&N-2:,G!RK!;2-GI46X3S(8DF[56
MS/*)R@"RD; 5YS,.PW4B2,=*(IEDK:##\1J8)%3&3@]CG1XCYSI:@RL7A9#E
MQZT*S&$9W:N+4X!F'W45(\+6ZQHCM:R!@R;C:!":N\KD)I]%R4W,R26Z HA9
M:<H6JISJ%'K%#DU9=98@.!8=9I+=9 1KL/(H2 E)P_7-ICY,]((DHRA%TT*(
MCRM1*?"-6"J>B"CUF*86BF2YDC>CIH\U""?<3[+A4G4P--L]T*O%^P-!:IA"
M= HP(W#QHC"@_;Z=3R-ZB]<YC4[)_3)(6E$Z7,EJH7K!IO "'?'B4KV@@_FL
M5Y,)FHCH@X'J#_)!;AL+&5C%'Q4^ F"5$H33\<!T-2IH6379:H>2%3<7@\K=
M)%-DZO5ZLU5G$!J,M:UP'*F*38R1&I0_$-JHJB1!),LD.#0?D4>*W:G%2+I,
MIX,PI"123,G4P[F26PD5B\TPFLS4 JX/);/K\8ZF(W3"MPW5RC*%#.KB@X1*
MTCV\U8Q**0(5M9&#+7=]P@VQE4*O&ZV*(2X&ZOS0"A(:BA5Y8&#0+%2NBVI@
M1GK0$<OU531<M\@@H^1$!0\/ZXFH;XDE)2_F$U. ,5-F@91#$ $;%;:E6'(;
MP6DA+ @:QM+B, FUW!J2I:#*8*CW$JC>+#J(4<M'J'JYY(=-E/ '103-IDO]
M45D!Q3,@1EO-;LP3>T,;DA7/Q54 K(DBT^VD2RE ;-3%9HM!2DJLA*5S:@M&
M$EHFGHL6\88?#R2>+A;"&HP3(RGG72$H:C-HV-']1-FCT'JF5T*20&^(VTS.
M%B@H$:8Q6PC\'\Z2JEO"Q;ALH"P!0%;?B/9 6[&!;K_MY0NC##;2\NK#1C3#
MT'BIH2:K>=A"AXG V^7D;I+HK;Q_+<MPKYEL#GL ,0S9*;)GEOJ0U^4864^(
MP"AS*.:XO.;AD7HVGZMV&) PE%A";W9+E4J:'_83)0,OJ-%BH]01[3S #%6?
M4#M8J$#E!10(=5 ;KQ3@@!7- CYZO@R87*(+T8,&607*833?B]4LDY9%!*UR
M!E(H&Q'#XUE%; S2(,D:DA^)E*20$1U$RJEZQT>S78_CBD$1473)9;E-$@+"
ML2$9>!8<*EIBIJI862 <B@5ZF!]6@]P'AQ(L59YT6YT<I$<EOQ[6$!L!17I
M\IF2GD\P3J%;ID:VS+!)ML_F0ZT.U,%XO:E&^1+G]4IAE0T4*HK4$UZU4I"K
M"D%S=:#NQJ Z"<0@C"T4LVB>2'A<!.-MP+.%PNAY2JZ !R4KT&@P@_ZPG'!J
MJ6'&PBBEZB"TBTJAP/QZ3;:$]^(Z%0$B<3?N807;%FD\'Q12G3+<K.%H.D].
M>L<IP"H=E&-YF F6YK?;X9A64&R7#'N9S]G 2GC8!XQ)<XP&YDA,;@5-LF48
M[G0C>CB;K825?.#&1[4>I'L]HFMQ0"8>8A$.M&2P)P[*49(:^"Z&IPNI!-#"
M:V*184RWY]?$G%KL#14R[WDD5.+*J)+F900'/$08I7/  .AQ+=7M>D8-ZKIF
MVU<[1:6M=#JAN@"4F9*=;18B;5ZMZ/% US6_1D<&49A#>FG);1@)!N9@@#%%
MHLR,<AN,3@W=7@2-6Z9H1;I-G0MU?1\6[6R7BEH\7ABXJ2!QKRF\1:L* 3;I
M6 N/@7A88"DV*$^[W=Q0,O)@E;%'(8 )EE-@>($5:_TB68\S):1+:8+B89Q2
M "P!(O!L/$MZ:BC1CQ95)AC.-H"@%*HTY&[<8%)<+)8)LMAA/C0*HVY8)+-#
M;*#!5B0D9ALH7<  M:FRX:(J&WP1BT.,&RRZ6R65P$^#6D?J$':HZS0L(S 8
MH)5*5TVD;XI9(3;:@_W\ 8G6[%9Y7,* *!S/F8AO59-]T[4IN:&E4C1809EH
M4&Y7"CE=X'F)\43<Q7IND4O2\" *U)7"Z$%A@VBF*-I$JJ%:$,BMMAQB@LZ]
M81F(#NEZ30.B5:G2=3-MJ +;=#3-UA*DP2NHA7"E9KI6LP9QC-'<--T?[<ZU
MP,!RH6BBTLX&Z9\D),P(+2"BH" N42(UCZSGW-IP8%B91KV:X/N8U&L&B1/<
M9#KM&.62L :6FVD-&EC,2"@0*O8HD>)YJB#EZGH=CP%X,\[WHWFN'6*)NI50
M;96.%[!<6TE*(:24:$5PS.*[53I<B'1Z5M;T8"X*=H7*:)=8*>7E*CW(!*(.
M.S'+@).A6D73>806^H GT ++R&2Y%J%25JJH=E0T&HIK<">4#2*ES^:#.*M$
M0VZ(*7% 9V1Z$85&>G8])DI01.UTT@Z!.D EWD?E"!'D#'98<R$7$+D>CH!%
MKSN(A+4XW03J$FU7*G"/('604\A^@\-&&6PO:]N!\+2(T=1L" >S7%SKE8HT
M1X<T3H9J3@R7\#QD*9UTAXVQA8;L(5*0IG!DB&D6/(676[;I=IT"&1U).>^X
MG$ &66U1XR2%JVE,%O)9-=,,YV@]'.OW@^PK8S98QH3TK@-(L8A2L?N=5I07
MZD66K5="92T9]MO=P*^,3$^Q\" =%U9(>OW)\-Y-A$O\0!3X$B@,^8SAB66:
MRW(9DLYH,8X(BDTL&\629!R,^";'"$UYV4X[T@[B>:X %"P<CWDDX?95INBR
M%1*H5#$N/@ 5+UZ6 0U*$;&.3%05VF[PC"5DI#09LQ*M1$)(AWBO%3:L47[(
ME.H@$0,%/^9'LMU^$,PJ>4X@.)QNLUJ;=K5$NIE"Z2# 8"FK G$"G Z".,_$
MFVP31S0!+^5,UB\TZ,%@M*F;DS$<QZ$"E1I2@#Z9''FMH/ACFTRSV%.%84\B
M@_RA*?O*L*WD0*D>5ZBNJO,@H[4(M1M+=J2JWTD:I03+C!0["!^0S 5Y> 6*
M>'R[Y22E7D8#BWZ7<2C8H1C589%2"Q!:J@0S/HN95E2U $<J 7(B$1GR;-QN
M(+K4YT>;&+0+.QT7RP8I?B_?]X>EM).M,$! Z$=Y36@.1=Q@*ET%P9 Z!S@N
M9$)>/=0K"178S[/53*:IZHT2[RI6;K29I@<:6S9\N&>Q+N1YD%L AH#FY4I@
M*9=+#PIH&>?R"(L':301SR@M.X@F94^F.E Q7-6BD-N#2L5>M*NX]LCTJM$4
MK08Q)(45FC*E*U2K%Y'@AM<.YD@+<8@ *\-JG=-,R-'HF-#OU.-<I"OES7S>
M,.N 9&HQHZ/A%6;Y8SB?-ZL84Q!#0B^?!**L)(K#MDP+U7HUA>KPL*PG^^U0
M8,:@CI#&D&"RH5@N4!B;$L(0Y70@L:TF(#[C&<)H0U*LQR5=TR31I(5,#ZW2
M6+V;R\7"CAKP$:9:; &1@0Y2@/F"&609HE?(!;8KPF"]!S.#D$8X&B:WC6RL
MP8WV' *SI--\DP!]0:C( [@LPN$>Q$%XK6=EG$RC0WM84\,3/$::>#DJIFQ,
M3,42(5Z"Z@4IQ+BL ];QC,<WV9$MLR!'MG,<.2QP3)M+$VX)"74)8X"T$SXI
M,X'^P/5F! GG&D5Q6(WWN K=Z;0[!;K2"'FI 8,S&!DX:%.QJJ/<)MSM#),-
MOFFF:8E2ZH97;#3T;BI"=*$\A&-LKJ[$609%FV[:]\FA/FB:.ABF2H&)0P+B
MUN/M9(/FTE'(,T9)^U!56UZ[V%!<K@?$S#J3KU%$G<H:FE@WT>0@'X%U.S0H
MII8_0ZR)5D_M#:MR-HP%GC*P]#+LJ9Y87_;M/KK&<AP>[:3!-)9210-+HB'"
MM'LLBPDL1('RT'$K':\D>P4OX0SLP7!8@ V9JJ5%D*&+<2*5PTL<C@?5:WO$
MPVR4=9L<787;DC!P,L5&K9APU*)@6%2B:]%5%S%B0:53KC(2!\!EN -:93E%
MDSVLD$RU&1LKRFA)ZO=CZ.BI67G(9C$FT%7!A0?#'$L4%<<(-RC \)G),@)"
M@T(WTA(Z$ASXL$I-"(N\9J8;V6R6CBAL$$X+@XS6C/08:%2GR&6?5RC09TMV
MKNK2;H^B$+((9.AVLUJD"1K#D@G29W.59#*?LGT+5L%\#54"?EL]%,623C*P
M1;!:C97HD2U'8&#R67X)2B4RG;Q<:-<Q0K4HH!R*$&8!"F)E>.!"+$W"50'P
M(*#3\6RXWL$K1%YC,:@HM9U6A)R,:&9XV1-PI->()%RWX=LE<6@ #:#82N?A
M<KE #/1:JP4$N23*AU&\EO"$EJ4@@ =ZY91A96DLQ7)%D"2$H(,;&/ R!QM$
M+SPH&J4AG^U$Z C$@W97\[1*E';D6LI&C&0G00:!L5,)!24_K_?$P 5VN8$K
MQJN%AHMJPPR043.5TB@E9KH8R+49O].22V3%B;-]JS.TPU 0X2TI:L7Y<C?B
MF8%W9;2H[& 9QVD I%S4!H3&*8;D>EHC9?*!O?;3(_<EU4)<D'\F;2)'EMC,
MH)=UF%9'SW!!!AI+=(,:V?3A=+Q$U%@2\Z6F:LHT''@:,Y4B^DY,D]-DJI=-
ML@H;'3VC[_039*)AU("Z!8KQI#TH$U9/*R1ZO7S(%'"[ J<#QY7GL2A1RR.B
M$JLT(@,B(*FIM5R7-,U!>5A(5"+4<AX.O<J 2S@T;F*]S)"$FV:LP8=TRT!2
MH6(K68? 7 Z!!C;5!AB-1,LM-@?S(3;4YOBN%0=#;$=N#+-2T8& 427E1X)$
MDN@S,,Y+F$F58*G!UK7/RD7&MD#7]B*::W?QNBW7:=6I=E2;B/C)I,_BM7 ^
MI\IE"8\AZ$@/$3PV''0T+J*D"9D4C#PW^7A8+^EU3M)$7(@T,I(K4JA23N&D
M0J0$@&51-%J>_';+2M_5@W!HM#'N(5RXJ+/91$^H(#4G7-#TAIMK"A:F4G5<
ME%MJIX*SK(?+NJD"9410<RU6UH62$='ADNF4=:&)P:R='(QR;)MQZ*'#2Y%:
MW!DZ?EV1S7*2[T:[T>'0SG6%<*])Y-304(99(TQ["*^H&0$?&+Y0YLRJ@II,
MHB53HD&1Y9$>UA&(2UAP!1(!OU"HVE)>(4VOSB23FHJ&\ A4C(L.#98IDXEA
MU2]\(XIU'*;A5'W:RBDC/60LN$BTM1J3SR,)M@;B(2X'R;U"FHAJH0'4#VI7
M*<^F-!R3LBR8ZWLI9Q@6DG 0]P9-#8'R6CW2!<I#K6"/*OIV1J4]@XYVD"S.
ML%8;HXL-$C.*+!^.I1-:DXV)(I*,5 PN5B,IN9WS21J'Q015%56]W^T25E!7
MI^S>((?4EPFEF:C 3:2F(U6PWK023;S'A8-Z4H_SS<GO"_0H*0]TL5B@:H9(
M!#RHY))91U !DU-:DL-2WF>"'KFOE86_XH?5*+DBZ1) D:9*Y; U=)0V'4^0
MO1+<%$3%P*J1+&$%(;)"(UF@1X^>WIJ&5'8!MU8/ZMQZWH#;%58K\;4"P*O2
M(.E.SK+^F9HWP_7/O]@_^M;^%\XJA$>'%58YVA#^XMF&T4&)+QZ&^'<>>BD6
MO_KT2K>[VI,OCDO)7W(F<3FE,WD&([S\"$;0?=[J@3(]]Y\!RO1DW9VWZG&:
M8G%1VFAXW>!>/CT1-"R4%&D1&DLC&  BD500R](@B"33$!I/1),)#$:!^.CL
MQLJD7X#-ZXXKZ UY&:SR3\"N0/H%V+*MM!1=T%88VO,";!C+8 B<R8R#:1@9
MCR&)Q'@B&D'&P024B"+Q5 I)))?CKP;C"^-0LBXID[J0T@3'F9#DIN!I[G*$
M5>Y^D:>RK?1D";.-[C]XMF:W*<U8I*R&:]&OX]H72%>'+*U&S/\@LK0Z/GV.
M;'PCD7PIQNJ&LK]$*JN]NXI#6%DL7Y193G%<PQZLYN04+5O_GI-34T:[2)@Z
M&SCA",%4)J>^0MN7$ZU&,1( #$1 - )^A?A6(?UR_'Y;UE<Z>@8NBL47Q2++
MCYZMT.O+01RCZ?8%6T9;@0B__G3>ZHB^'+S1%O26+$V$EQ,N;_C' L5_ALR^
MW@5^$YFM<ESP_WN9C5I7-K_EMKR*N?[;8KO4^"RJFIZM3;V90&J$94V>]$M.
M$%G!E0^E2HWE)Q$%T]24AC Y2M@T''<TYF[ASWNL3.8JKB:OQM]\U4G-8)*+
MM("'N\_UQY>YO[D3+0 0 .2?29!6,_KDC*0O\N]?F)<MFX)BSYW %$T>FSQ;
MOF@5HA84U0%HH3#ZRB[CR+;^Q5YI67-'VVX%HR%H8U5EU2Z1R'A1L!OM\4D;
M&!MI?W3TT#!#5U=#,!8!5Z28?-7 9Q3TU,+'6-EV@M5_3A=9"(]V>%>PB14[
M@?!"8.&H\LK:@ME6&F-NX%96&!BUW;ZQ;']NZN.%@R\<6Q[HQE*&%B 6#4D>
MZPO.F".[8ZXQ1F63"\84=ZP=-(FRK(\M,YS)>ZEBC5BX,EH\%O14;$W1Y3';
MTV1GQ?[ P@BT2O_8F*@)#?6+?8V>;)NVHKNK$$#QY22N[+N3%';@_@(V?!UQ
MM2V/-0U-,_J*W@K^"DQH+' <8Z8M.Y/+5_0Q-^BR/,58-$7T.>]2PN3K-Y15
M6E%;$;3QI*%)Q>KJ;JV^=:IMDFCU8XQ_=FLU$V],2NF?FGERDENKCA1([O,1
MQO]O7E,C_),>8?76/^D7&J,S]/]<;C1!"P%;=6&,;K3EX)_]SSCY+P[Z[ZS>
MJI6O>?F &S9;7U+ I97N/U)W!=UD?=)+.%]2OV'Z/U2_8<9DV?8E+U'XNC<H
MK%KN!>M>5*H$U;4S 4X%TA4:OM@S)SBLXBBB)E=M07>"E$G6&X.)ZM1[8[ZZ
MSU>!E9>[B2]#^KS#%V&*@C\Y75H9RO]X917(8E%_(AI?"$Q=D\G(J&EU'=L3
M8'0A! )@/+J\8WNU'3U=<2<J0<!WEO>;:EDE55EETJM9TJ2$5_?"AJ30^G>E
ML(&N+9KTO5,O>EGF(B<GO5+[5Y-B0E?1!B/B%4F7M7\=<4.>H.26IPGVRL2-
MKQMW<H$393,(@9-_K4@\=>?+B7NC($V[@2:U)I:%[+%)'5@.LG*/+T<*;"I(
MYQ17GL $S?EL#I\W?\WB@S1HBL'")._V!1>Z;G,E)BR__W^[D/FB%BR+H?_/
M56%RV/]=/8 6 O#_JAZ(TK[ ?X8F+,M__C4E6 WQ_V<> 5X8B?YO:4)CQ+W_
M,$T87]4\_Q^IP_^^5_@/T 7Q/T49IMS[@G]=%59/_P]IPY3L&%W5C;[^C64:
M60@"\*X5.O@CR/UV;1MNP]![8T&"O# .[-H55-EPFPL#WD<60@NAR1WJ_RT-
M* X"EDD5VQA?YA@7&M]($4:M*Z>1G^6DJV:=R[/1BB:X4X.L+B7]JFHO-1#T
MKU/(B:(PN6,H?&V_J>KYG]P4_-+9+U\:W1?<1CMK&Y[Y3R[NGW]!VJ+6Y#!3
MPDJ/MNG&1L./38T_>MBY0J>OQIE2?&!%HM6:PK_ L-7Q9/65]JB52F,3LP+J
MY6^07=W$__W7?P?Y[R#_'>2_@_QWD/\.\M]!_J,&F?7Y.^AE7=I];G_N'A.?
M/CTM-6WZ-[PF0;XIQO1/;YTV>^:T)]:HS)@^>]H:LZ?/F#W]TSNG;3MM^K0U
M9DQUF+;L6F?F6FNON^:,-:;/"NYC&TV;ON:,Z=.FKS%CQCKK35]GS1EKS5AS
M[76FKS%SVKH;;S)[T\TVWV*[N7 \T?=O^/8\L.;USKCVNAN?N&;['2((N_CZ
M+:-)$N4?#W"VF1Q@<J!IGUW3UUA[S;76F3$SN)N</6WZC#5FK#ESK>DSIZ\Y
M?:WI4[-:<_9:VX%K;XR2FPC6(2==<-5?UMET[FV_B6PV+TG95S__]N;;BX<^
M<N$.T9CCGOSI4]/6#V:YQNP9LZ?M,>W3:0=M.]<_^H6=CCKWB[]V^<DC!YZ&
MO2/4[SW^Q1U;L[;L=(4+U^;]EY+1V>+?;SKBQC-WVU1ZZ9?%.?HAM:W3P-P=
M[SKW.S^MOO,JR*W_"/UN8I?IBUI_^ONF>^S]R9GO?/)J[(![#WOY_*T?N/^Q
M-82#-US/VN'43:DG+OOYA0\>K[4SQD^?SO6\_F.;OGS R_G0TGFGG7W_O$.S
MFQRTI*J*<K_\R]\^]*2DNYO'?WWE^NN\]-;9?]J6O.ZFG^[X"'='^Z9+]V\^
M]9.E)Y3WWQS8>JZTPQ-7M8]^^2+KQ?N6/!+:;K]OW_/BDN,F%FYTSY6//7+
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MO3IR':FX0C(44ES)VEAV?49>PS%W70CO;11F<E3SH'5/.2#F-H6Q7K[@R#1
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M:RN?V'\;F-1 C? BQ?^VG=K119+;$1\9:*7G\F6OHS%L7O!/+=YXQ3Y ^MW
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MNO&<N:Z?H3+/H;/OU.A0;)%<);1CSGS4U5JTO&,V"[;"^C)7@=W'29AV2Y*
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M,0.'94-]1]8B1#XWEAATVF_+-BOU&5[(.?[/(<R1GHSBV=SIY(_WXI2)(T@
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MDVM7N4$GG1Y>/^ C,+O>O3T'D;H#MKA']?ODB9S#UYS $O(]4A/-:LQ\'H_
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MIF)'/-&H,<Q?+((F1<&A3P]M"$*]@_"T@5;OS:];M\!S*TE&P0JKNCAQI"L
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M]*C)$<D]J"7=;.2&D2[_YE%SOJQ8M)/? MS<3]XBE:^OL0-4$E8?L"[8^VT
MA\'T#X!U)V@Q+.+VZCF5"%5.;I8=CHXX*I6NAJAD?]>XB7]:/"[3K#U@51NM
MSO3,J2!/PS-8VVDX1N&@\1FT,C,#Z2UBEN5H&JL5(2L*VIR0,"ND@;V)B%Y1
M=>![OT']1$G#;2#IK'E.C^6D"\(+O7ZFJHRMW2 I0 _2)Z/<8=/V$D 61A5I
MVC<KFF J+L1G-*OVJQKP^U"F:TBHS$8Z4O(0>>Z7K79AJJUMF4&(-N^9GPS)
M-[](L3Y.F3Z1H#Q7Y;#5M!GN[+&2UMDY]2(K7J2XQY"3&#A]24VO7O<&961:
M9G%R(WIDRPY7PV>VY>&W'L(^W782GILBBNQ_,9<=FW83\Y4#$D]$A)7UVCA,
M*R#+FI,)3XY 3T]QK<]Y6J+(D(^O@[4P=XI^%6H.]&2'RTA+:)H"=?O%>4TI
M7C/")A%_ +OUBS9J.6V',3,.A+N\$'X/;W7@AJ.]&T#075@"BRTL'N?5_4"L
M9V/$F80)%D?+IU,LATYZ>GZ-G[LF)*?0=\^VP@4$^I2Z**F##A^Y@>,M+@?G
MS%^]K0P.3)F.SW!,.-+I"#&+ML$-ZND=Q!I,1BBGCY(IQ:1-D43YF36Y1%5B
MKZ_"XDVT/](6U&'<41?XIXB3]Y:;+?_X6.G954FN&8MI[F0@Y,7H26:;%I&R
MDHSL&5Y#F7*M89E\?M_&-($.J7^7VO^S1(=CK9#VNUGP9VF3SYUF>-S!K'EK
MQB=:PHOU;\'CGH-T%?2:4U2I<8G4]&UK9?G+5'%G;^MMY::5JJJ\@8V7[0D?
M</,/2.-^A9"K,27-; _0,U>#3?SN(5']>4<O>#['(CK4O HM $U\.O>,]: .
M3H%5\M&]RZ4!E,CF33LOE^Q75F3+L<%7BAOPY$KQK,//['&"7BG'ZVVS<!,H
M-E4-=G3><:B5Q=.@V]_=9X(UR?[T:'7%=-.^GGX-**NJ![^WD[/>KLIH8=D^
MD=JZ?1F)81*]S<'#;>'KJ:CX J#"=;BO;N(S[P\M( H;@<PP^1:YJJL],:N<
M_R"[^C]$\[^+\^Z*[/_N8>7\=P\K9]8TD90_ .+]OUM8B:1?[X]"_@".7Z=O
M?LF1#MSO.0V*JFR?6R:TX<\6[36G332EXGI.N;1$]CC_E2977[")=H*&@^_C
M5$%9]L6 "VZH=H045DHOZ0E2$ 0(8 H^$3E2B1C@[\19(+;_AZ#ZW\7/O\3M
M7^MG<>"4U\3VK"=7=@/]?^F5R\K7_+L IC],MF#KD!,FC&EV@'@X)CP;RC=$
MS?T!X+K1 _/4+TA/FK(,/1C6^'@WPOKU\!/:';G:AU)-V%E4%\-127-XNX'F
MXNOO. ;/,,[Q1NJ,JWV>333PTSPSO$ZNC:Z+T_'S7;5E.D%2X0-ZQZ01^OQ
M16^WI7!*9*7N421_Q/ZN.EXWSZ?!+N4^V &3^?L&#9R+[W92HX?5B>T#<?=M
MEO%O2?F:0LX;"\[?_#/^H=^V^DN\8CAO[/P)3O7Y3RM_RIHU??D_N>C_$9+_
MH/\-4$L#!!0    ( -,V=E;RFZTX(8X! $G" 0 1    9S0P,#(P-F<Y,F\W
M,2YJ<&>LNUG2[-AZ'4;Z44\>0L55A$(.N(@>B2R3I4#? XD>R!<%^K[O<S >
M@B?@!T=X%'ZT1^ AR#@GB^3EE43+I#/.GW$2R+VPFZ]9Z]L[_]/_\9_^S[_Z
M[V5>XO_JK__ZO_OKZZ^OO_JK__1_3?]SN:[C;R#8+W\3I4.<_4TR=. 9C2#\
M-Q#X5W_['\XQ2IIL_27.BJK_NS_]W__K__:G7ZKT[_[DXQJDC4Q65N)GSNR/
M[B2?)GFF?_H/O_^;OSU_.[NQR];HE[-K^^6W\^_^]!/\M_O_/RZ#?_KEYU?6
MYN_^1/VX\4N@O7YAACG[!?\;]-<$@N%?".)O8 PG"/A__ 6!8 2$[G_$KS#V
M&T[\ACQ^^>/UI]__S?W^MW.:_V:Q_!^/NS_]W9_^&-=Q'']SH'\SS 4(/Y_/
M'S (\NO]C5^7JU^C\]=^^;=?D+_'8;,EF:MQK8;^EQ^?HWC8UK_[TY_^S2]_
M]OH^:/RS!_V3";QOW!.(@O^ _ /\OOC;:Q[2+<GFW[4JF8=ER-?__7_YY34<
MV?P:JO['AWR8?_F'F[^@!/ZWX#]I^/==!?^BK_^*,9S_U4&<_\51G+]IMO3Z
MCVH49^U_Q.&$R.$\^14C4/17#$7A7\D'3/Z*Q"@98<\T2G+X/W)]%+=9^OLZ
M;]G/\?S+(?ZU7;&SE8W6['<$0M!?(?17!'+@QV\0]!N"O/^%7?M[R']MU[1L
M+8?T=WN-^C2:TW]A;_Y ^==V1H^Z['=FZ/,JS?JUBMI?_OU1W<C;^LN<+>M<
M)3^L:_D?_H6]_ G_KU[+:LVD]'<R)Q[((T9_?6+$XU>,C+%?8SR.?\UCX@$1
M4 K!*?8O7=KO$_ZU':5^3M8-A*1D$A$D]BN91NFO6$3DOT90DOSZR&,H(_ $
MSQ+D7]C5?WC&O[:S]Z*O]Y+3U;K\#OT+._/G&/]_1ZP[<?R7 ];?IZW_2B-!
MZHI_OF$!5EWQ3\/=W>XW9LZB=9B=86A__Z8KJ6VWVP=^7/V%L8E?_KU?]>EP
M_/"&OVSP7\+*_FD$@AWH^1N,_(8_ 0C_#87^#"3[R\#RXXXVI%5^_;=@_-DW
M_Q+C3L-IM$;_32A__MV_P''*K8O[J&J7W__)K/]<5*I=_^G5O[_15C\7>8SF
M)7.N,?N[/UG9,FQSDOWI/VOPQY-^K-YO1Y6NY>\(3OSLV)]=^N<:E5E5E.OO
M,([\8ZL_KOUSS>Y$W$7K[_*+$_ZQW1\7_[EV51<5V>_@LP8QBC+MYBU;!453
M!4?9%"U1% L^3&IQA7)/A><G$IZ'Q&J;1E&8V;0Z!4#4SQ=-W=__\>*H?_=O
M3^I_HLP?C>^72=$@@%%LPS<Q(K>4X'P;Y&!,2??-PN1HRN7HPN7IHA%H,Y29
MHQ#HHE!9:E"88U!^ K(TI;'4\>//9"GLQ5&DP=*:P].FPYU'+)Q+(IYD_@]_
M!R?21Z*S%!3>3PB%TK5X:_AY[R?@/_GR_\<_D+P':A94=P^7.CCK.V1*LBA3
ML^ZA<53T<_0B]6-T)D?]X\ODJ4,2[FD1&:JYAW??*R3V+[_WQQQ2S#W:>UX2
MB3$'];[-W ]@J<)D[FOWC-Q O78OEF;=\\]+EG2:'B=P"%<E(>=JHU#2IW^:
MU8O^">BN8JF=[XIDK*O8N=;\6$XS*5>(OAC=-?N&,#YZF;IOT6&A39+D09.9
MLGB7\CUUDPUYJ^XI]'QAX(O["0@;#O0.?+Z-?/A,@_;IOY%RC+IUB7U\#U$+
M3OL4RX+QD8LPD*,&5X:16$F=4F&77@\ T^"VUXY9V+U_ DYQ+R-9CROUJ/C=
M2%3C-&W+'!'[8-WS>P]?8FGS-A<SY)C;(.(?<U9R+,UPMN9RO&OII52\S^+-
M73\!AU@\>$VT,%MG>$^NDIW[R*S%%F5DNY=?A0^5H=&7K6<R5YRIVQS%SR'+
M]9L7JK1)>1<E)^-S7,7X$Q "7I]2MIM5<US\9;5IZ'MC'/!P%L!6^^[2(?+'
M.1;@+4;^WX;_$Q!@6]GW6[QZ=^.6]&\B;R:C&:.HGY1NFHAKG2=@!Z/;T-@?
M%L'],#&6I)XN-K5HIT#[XV/.! P!WA=012(>6O'A[MT[D!"I838/2%\;@4V'
MX[S4%W[Y[6C4!,A\"B5TU2J:\XTB9CGQR::"K+=9ACM)\>;"_@3<2V]^LGD/
M2?+^_"#]*]%&[LU%2K6\WZ_*%9#P8<WBR7*/=H*18:K7A-SSSGV/3PMR7&Q(
MG791%1'"OW.(WZDV'1X=F:HIW)2N,5249&^?E'%<I>7A-]ACJ0M,_C8@Q*'&
MRB.83^0LM(=-=EZ.FBWB8!8IQGG^]65F4K9<V?'&V#K+)JKG1Z;%K"+Z6_>]
M-#WWH<GJ?%D:.6T=196;E5DP]H#W[V$R.3Y84=%^XFB8+%G["?C963D/-&(7
M'G 9U+)XBG#TPEAP?SP<UU F3FQ9$O76F#%R;PAL^*:8 E[9SYUO^@Q[!D\,
MPMW]4[^^0^89HV5NJYTZ'AQV_#H1KV1'?T&4G1XACC_>QUO(GM8AO[NFJ9KW
M$9X/#R6$\E#FZ#WN^,'Z<Q0]X>QKV+DMX;W^B0?NW==:12F,FC*&EAL%[N&I
M+R''!.,>N6=Y+'Z2>/;C)?#[91N6=WL_@66R"-&7LFYTZ0LXG1>G"H5GH7KB
MO<'"0Y3M_,LW')>'%SX>T2</A#ZJ.=7&MQ$WUT_R4O9!4WPRLJYO/+0KL? G
ME V+]&,64UM"'Y"2+WI]JKN,Z^$R;T_KO4_KRC443EEN.5XK=GZT$A?F)"K2
MJ>;=D]PC%HB_T6:<R12>_,5O@/:#QC;ZW*)="NGXM"QI?XR<U49ZA8XE]<EY
MNQQX[]GB&:B' 8_G*+ @)(RM=>(#[?$-#BA#QYT#50NT1,<T4UK=9H%:C91^
M6^V$)EGP^NA:VD^</QVUC\V"(CP<>+R#1Z"@C&"=,>F7HH'B\T_ Z_EZU] #
MFP8?J,&^&M/QF2P!35A3$TITFS12/B&?K%I"=[VH=R>S\6T2FMC.'S2-O+=Z
MBQ4F\*34+'\"]AO[_MA^(Z_<((?MDY:"N-\BVP/"TZN?\#OO'Q%R-+$;JE?Z
MJ!C-1")_/PX-^CB7]L9"L.(EU^[#IOD)Z*&GU[P:T,X_\IK&S0;J_FP&ZT"R
MQWGXJ&#H;UH1+-!YWG,P^7R6F\R:, OR#V8PIG@-;8$'_A%MILCC7T^OA1FH
M7\-'7W^>^CAT-4M&=ZIH)VBN9E;]D/,SW'5.Z-'MCFA)%:B?4Y\2K46%HEVY
M(L:"GX =SF/X09(6GE/^0"E4Z=G[ZSI(S"9*6F5Q%&:,LVHV"EZOSMUI;<"L
MA;!';T#Q).!O+TL797)SW,M^ L;83.!-0>)HH]=J(N#% FG7+)@+[D55& O1
M6Q9%"] %^O2X" 9\84>-\;:9T=C5D5O/B4$7^!$?QOH3\*&SI!?;6.][N5LZ
M+? (ZO4I*!/_!#RTCR*$XV<<W>=P<+4$R_ HJ)KYRKHS2]NW+0;-Z6[92VP/
MY/PNBD#L0/#JN@>$?%95_:09XBYZK\>H?LEJV;==EQCOJ<NF-CWZH'@MCY2:
M@@ML6YRLEMN >H;8'H0?2=_PU4496561A YMYUGBRW^!%/>VA-?=ZQ!22,10
MQAZ70'7_B'@"PS- DA#J3XC;[K*HCN142MTFR[FK_P0\3:'75\ 1LY$@(Y;W
M,VQZ\$'XEV_GXU/B]S)G]N$CL. X3A2(TW69+=QDVN2F?%/_!,QT2/8JI<#N
ML ,>[/4@'X&&](Z5)8^)G@W5@;:-:AF4:SM&1M^T>HAPN:(B!Q/B6$U\#2K[
M9^3:0OK:X<L?R#L^(MV&1#:6PZ#E9L/(-5#/OV7FP5NK>;/HJIH4$/?>TY(-
MZ(J_(R)]M=O8WZX#EYF!]7779_9/0#-(BE:<ML8MJS(J,)=U$8KV5'R_&A)W
M(HN-[2Q]P*M5-.J=0/Q>G68Y'3 W6TFU)Y!6?JV4[(R%]YU#'E3S8-2U777<
M-3=FT/?7._P!@W4YR&S[Y#)?JLR0X\SK AFU_# HR22,IT>!Y+22CV0N6Y)
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MP[[[P-XJ_%JA.\SN@?M<$]L1)&MJ>)2. H42+-YXF%4T/GI8Z\6N85.\CK^
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M:U6*AVL^6!=V]<<IEK2::/ACAVL 3;F#^YC\.G'=:9T*R\<55$MZE'0!T6;
M]R:IYI#!7LJX_R:I.V=+H-. G/U66<#7[F0)M:I9E73MPB** =):[F#K\_,I
MZ0 ^F]Y3CVY_WQ_WK;$95\!+Y^/MPH+W+9GF"%C0M'C-)>E1NBX#GMXT<N4#
M6<DKG<:!!\LM.>\_D?.^50DTL%]5;U=L3"8YYYPJGE_;@C+W7'YW*RYJ0"6Q
M4)K[Z<6M9Y7> MOT/8 :2LY:Y$T#2CW$7#QYK#7!MG_#+^&A%#!.6?6. G"-
MW3RY!:\)^7P/\-Q^!Y6J1_%NPH^F,!#-/92^1L:W"GA\*[^(<\>-#'PP3W;'
ML/RF  KP(BD%@6JO#5R9FM,<C4#XR+Z&75?! ;9U="H6T+P[&:45=7VPR$E:
MVH@8CI[,H?%'O*DH4(L,*T16G8+MAT\\K55_2KX7;XJP3]\ZMJ4\H5JIP%O*
MEPPJWQZO3-R.;YG'0?X!I[D7(3_TTOJFT75.-H>3M]P@NJ+R,EI$>I9[W!8T
MS<0,?#?]@8)(Z0F"&OX@B)?1\"?IK3S1:\L^F0+6E;YEJ;S,GS3>PLHTGA[W
MHVW0U'8:!M9JP98:NY\8#-AO/-1%Q5XH^MVGK3D,GNE'(^+R]:)@TWCE78DK
MM2[L<F5S6FA?>Z"5R3EQ%7;T<$#WIE9Y[SOBT-4T_W%L-7RUN.Y!@1.^7S.W
M[>:<^EQUF99R!RG%=C<Y?(NX!WRX>04;;$)U(.Q;10"RL]G&,I6U.(?.*(CI
M\<MM4BBT%JE:"FOHV*64_ X7;G7\ 0V57!^H\^C=V/'I5^27H7/)=-(4DW5A
M(Q'HA$<#G!C?*G/Z\>NOX.MZ0&"??GK*4S\BW; R78^JEDW*7:].@TO;1.)P
M)MYXYEY7$X&#^N=*>57EF1@A,H$AMO?+7N9&X1;H"[AER62-%B SKZ"P&<-7
MQC8#.Q$WEE7>]6!;+5]UGB\N#IJ'=8$T,7<ZCY6&E7>C2+&-@9V>&9#02_Y2
MD79^1N6.;M)DK0"VQM.;<"PATX!>Y#ZW4*T-?5^J39FT'E_!]B%FR-JJTU%O
M*N$-JO:B$ZE9*I=-Y*\ KQG.TPTO\I YX+T&Q'_L,^7^LWB"252K]/M$R!2Y
MA4N?G87EV((B]>W-E)O0LUZKMI]4DI*>A73WJ+[Q,( -HBD7>8PK18&:O=_Y
MHN.W<-A$%<(%SU)R=$!JW"6$$CD]-F*!*&C9#Z6N3[[;5 1=5?4IO5+U:X>.
M=:SBIZD5A9S.PJ8'AU3=&?CX=>*YN@XD8M,A2SEY>"; T 'T@M\6VYG,B=V0
MX0]NL6[#)-#H@VF_FPN>Z_=XE_D!A/HQ3J?]D\[69[;FTW)TRO&Q37ZXQ:JM
M!&6<.N3KD7-%H<P\J->7 ,$PI9LML"#>T7[%8WH+7H/DH 1JDCN-68+8\5S"
MU1IL**5S2>>/7^=\8%#E544A*MAZ%*B^OU+?V\4(E=K^%B7@E'5+$WUURBQ<
M-ZF@)0,X3^^E.R0 !*G>+4,\SJ6L(H814@A$,((0:FZ&JT-1@!L""'8-,M8Y
ML=44^"_\S-M/_BUB0"D<1<L[CBQ9I@W5?W#1S'_P;#@KJ@:W#BL)?H.CFO=L
ME?R Z@G3:N0Z8_PY]U>,AFO\*98D\7;I_.[>%B27PPFT0=+L12ZNS1I_>LVS
MG/AQXJ<5?5_9'&^!)RO:(-?) !LF/5XN],JG6^];PI__?//+OKX?:Z['X\SM
M61:*5UY=R.@D[@3ZH[,)7##.)+EYET46Z<71H-_!Y>;B)]DN]0FZ>%,DL+Z*
MWY,8:)-0(@MUGN1VOLYE+RRP/&;3._KT/GF;X_Q3R0S1H:/JX35[L,IS!3?;
MG6H_S(W4U%FB^7KNJFGRQ['51W^5N+\_B/<[]K%;Q?,QJBD7VO"CSE!F95L#
MX<.G97J2%!6(<:^=O;RD_C;/_7C.<3MOUU.^DPCQ';*<FY*BU8R,^[ZV$PI?
M\71>&5[B66^R ?SZ=B'0\VDH,Q3AL-XX;%H(3M^!G,+\&$)<[:;1FQK7.?_=
MH]?'OF'-A^.^5Z?W'KLKQU-&U%W3=(I5I;C_- Q^%"J3?B-LXE$)R!VS74W-
MCN>9A8?PPE+/S].\^?V7M+_ON-9G2+UA%G=9)-Y'O%";">\7?NL-M]_?W/K"
MR-$'!P%='Y7@H^$N)A8*$PVN&F2=X&W'S27:AM\ABV&Y/2/V-C,,5-&K-G*T
M;3 P>45BF01:KC#6F\_TC:O(5NKS\$F(TRWLX1D7[WPN>JIQAY?PZ<&,\QTR
MWI5:N_PH3,SGTC1.98D.! .Z3\LH,CN\*TXO/ 0"]1SL':[XW:LSH./13,"V
M$!MDB;-M[!DZGFM_?Z\7XQPT[=8=WU]B$UQ7[3]\DH,'>+ECNSZFZ$W6-7#:
MYNSNS\?I-RZ:ZN4V1+8&*68G.ZO,]#6E!_C]90XC._' 6P*28Q,S_?/ZV!9N
M76]8"I^?:M+7E[2W'=QMX_#(/'0/9=7'N2><.A/DHB)L\FV;>EII\HC[W6SM
M#%R6;[:@M[A*#@1/9X$6V7<GVUEF\P_*/U);@NCW&$3O$0]HA>RD)L9:.BHI
M^?3D]19#4E<3,QM]R\[1*]L'';P-'<-18+,^=L<@S7J/C,$6O'V'T\+,KN2/
MK.)X7A-ESDKQ?8+,ARZU#U:-T;JSS?O_I_H][?S2W>G 6OR-1A-T=Z.@AJE=
MT'L=O-W<]ZEQ%_V16=>D3CZVQ3.$R\-<:9<JOA3B[IWXU#[L\-'\U_E- =@T
M$ [@=_WI!R.!IJ@QH?5Y(22);3,@&#;2XCGQDFKT1Q%O)NK$TB606S+=*#S'
M?I)UYL]$!'>[^@T./M:LDKLV6@LGBRQAQ6$ZQ>5NS#Z]K'%S;I8:)-BTU&0!
M^.$C/!B#"),0\B,;W$<9]J4M/)K'1U?Z/WZYL)[8HJ0;H@SI?J'D8D71LQ])
MUI^!,CG,2]<31[W9_M;N,G'I*@"Z,R_<+-T@RK4#5-X%H=D9= WZ>LH'(E!P
M4Q7!0*M;S?NR68!4./VC(/C/W\(8GW]LR*POS1_LH/TD$A,2/O'=>:3DE_W_
ML/<>4$UMZ_YH$!11D:YTD"J=T#O2>^^=D(2:!)+0JX TZ2!($5#I'41 I$KO
MJ B$(DA5NH#T]E#//F>?O=WGW/._]XWWQGMW,0:#,==7YOSF_-K*XA>X@JF>
M%D3/V%C V8M?U18H8&,HSV&J[>4- VH;"?,;BFJ[J^MYN GSVPNAT3!'(1$7
M-3XG40<!J*ZI@)*IOCR81TZ;S\C@YWNPNB):L@9N-B).FFJ"QAH710):R=E8
M%:$*5%+CE^.7<P7K&>MK";E[JPI"81"4HO%%YP%QM;,Q5.8PUO9"HD65+P*P
M,5K0!BGD^K."53?B5]!TLKFH6"Z*7QTWE8O$"-+3TN0Q4-94A,FJRFJK&/+)
MN4!<$(*J(%L02ED9K&^DX60BJNCB*.O""W$3UK;QU-?5Y371<__YXH2!@M=%
MTVOJIF>HKH PX4,9NG#HPIW !A?UO;J6D*&JB8NBJX"P@JZ1T$52-?&R5X'#
M8 *N8-V+R*L&M'70<$0XZ[G(.3MZ"7/\_"A32$@3"74Q1H+@%\ZNILOK?'$<
ME/A,E9V=- S4]+2]X$X.%Q6J'%2. RZOZZ!DBI17-'#G18DXF-C(>=NC$>XV
M2H*N*@((.P7PS[R,<%<S48 :&1DX>$%!PC"H_,4^".B)./!HZLBZ.B!5M 75
M5961<OR:*"B?AH:!X44]IZN+T'?3-W" .\&,@=H7;866GJDA3,/@Y\<?CKJ\
MNFH&>L[R,D@'?0Y]45=M04,'7CD1-Y0IKYV3NZFSL3W:6UG!"<8O)P*V03IZ
MZWEIB*A[09V5H88(=7EAG8M,AI1QX_%2_MMS;&-#>PB?J+ \B _$)\H/TN5S
M@ESXMI$HORI86T@.ILKK**JJC5+A4/!T AJ;(.5T'9 @#F,>+WX>'0YW?D]7
M/151-4U7+2!,2>%G&E51<+,1$H"I@U6<!16=E(%0/B,E9:2S&J\ KY":H1Z2
MCT=%T 2EI\7'HV>(4E(1UA-P-8"Y7I3(%UN-<'!3L5=6X+\X['8N$/#/ZDO%
MVPND"Y37$ 4)*.I[Z[E[>7,X0VW4;8UY4&B%B\"F(JKDJF9L+.REI7?1][K9
M&FHK*4!1WJ+:O#RNAIH040>4LJJVEZ*"$Q#Q\YTE#B=A+24C;P>$G:*G#0@L
MHB#B[*:B+R>"%G:!B)B:"FH9FKI<-/M"\@X*_$A%7=A%N^MD:ZJO#N8318'Y
MP)KV8)V+<&SHKFJB^'.770V=-!PUU/7TM 3L00KZ2@8H,!@BJ,"'=+GP>T,]
M((\JE-?5!N2M)P?RT(,"W83U!!4\T::F;AJ&""4T2,>#QTC=S=2>UP1I^O/1
MO9.<"-+.4$9+S5U/Y!>A@$=&F\?T'VA+/Z&4_H0@Q?,30NH/@%,\?T:<^@E?
M]6>(JO])*#(-C7^-*0:'_Q*/#.VJ"_T+\,C?.-'?D;%X?@/&NB!G_+4@!7?7
M_T20@CL4X<KX1Y S#0TQ>6>P&_SBGHJ\U,4 -\0!(L8OJ* H*R(L*BHC)ZP@
M#P2*B B*R(N*R@G*R0D("O'+_##P/[/^2:P* NT*0H"A?Q/K\!^(_1WKG\1J
MH1SL'! @V.]4N[E=R!;A5> %*B@J</$*BP*Y!/@4%;ED! 7YN&1X@4**,J+"
M,O(*?Y?_"QE_M@H4Y> .A2BBG.'_1<PRB1][*^;PYW4+B )%!7CY>$5%_FK=
M?V+]E63(GS?JORH9\JN5_D.R\W_+J'\IXU>J4% $Q.&[C\G!0&BT% 1J"W*#
MN?XFY ]W_^#2_[PM?]XS90>TJS/*ZQ>(='I0Y/\,(MT/MQ,#_<!<E$*#+J;R
M?>J_&_MKIE\=#)%_OWU_8/UK^1[V4,2?(?WX_@[I]SNJOQ;R'7W6 X2"RMA=
M;.&_1SW\%=-?"P?;@Q!V4(@4SV^,OPW\UT+]_SOV[-\'L?_VG@G^?V?/?H[^
ML_O]YLM_=M>_^;'N7\2(7][]G\[M$/#?LZJ+&PKV T(: N:!PJ#?HQKZ(K,"
M_QDJ% (6<W5PA4%_$7;^%1#FA38QV(4I)1D\N?ZV0@:I?T!"TVNCH.@+A:#O
M<_Y/2I]?3.?[%"%_MLS_P4114!>0 XI!2M$!!J7_CN4K]@<F7EX^;M#/SSL-
MT% 4XL\DNKI H+"@\,]"4]T9#(+1ZSO\D8H/R*4!0H'MN;[[!OW?O.+G1X *
M>OJ_8*#GX_T]!Q^_F,#?.?1^+)S>$(I"7ZS^'WQ\W$(_Z_'?^<KOB8!"W+S<
M/_^I20D%<K%W -.[7H2;WRF60;EZ.*-^OK#]XQ<[.[N^/93>!06UA7U'&J4'
MVT/!3O0.:/J+PLP%!G6%<M-KPZ @-)0>BD"[H:#T<!#"[<($/^C0]!<.^7=*
M"+T+%'4ARAD,1:.Y+R3_0\UW';;.,)BSQT7-?_'7Q;G\P>KR\\S0.R#H72](
M?LOZ8C^8_C%M.1#,P0;E\.M1+EEG&.2O5(&=8<ZH_TB7+ P$_IV!N/[OO'YH
M^ ]]Y==^\=UCP#_1?/^S:D)*#W1A0P2(7N_[CMI#4?])6/RETN]3^1O\+,C%
M!>8 _A$1>%R<T:X_9_Z#[Y\!:O\G&QU][7^#GNS*XV+W%[V.O /\O]*B7)!=
M>,-W6/&_:'44$?^E5D?1^7N'\Q<HT/\. OJ/G='%NL4T0)[:%ZVHGH,W]+_>
M!%RL1LQ#2E!4D)M/6)!?%/@]<?X<^Q6EO92( )!;1)17B$_P-TK[7U*Z(1Q<
MI7[D!O1OA#^&_I!8_S#O7ZQ*\_L]M!3P[^1_&_@SI3((;>B =K"!0?51( 3Z
M8OE0!-A+2A$$0T/_SOT71/]*FI8[%.5RX2:N4OH_OAG@7Q#\6<SW7?X5ZK0L
MR.Y_JEZ\.&]BWZ/J3S#\GW'QN\W_:?Q?LRJ"X XPKU\Q_^W.OV,'0Z5TH79N
M,!#JGYG!_T[S]R5*:;E $?3?__H]\X\[?\WL_C/WZ;E>&-Y.ZF^9D%Z06XCO
M-R'_3/'7DKZG,&>T@ROTMZ/RQ^%_L_B+ZN+WIK?BY79UM?TG,_Q&\7]WY_"K
MD_ C0_X_<!S^J/;_EV>!_KL5_IO'X>?H/\>+OP>A/X:7W\*.-@SD^D/)KV+/
MOZH(Y+Q ?U' _XY( _2]#P/]6SH3Z/=2[-^2_:BZ_L..["\7^9L%]#Q KF![
M)92SF\M_:(/_'/5?S.Z[FA][*O^S.:+_J9[^A_Z?SXI_1_2OY?PX[+R_9_KE
M\?\_,-BO;/+KZNOGJ*Z\HM2U"^[?OBGI5Q/_G[_^5\G_*OE?)?^KY'^5_*^2
M_U7R_RHEU_[Q78M0!$22P8-!6NI\$B 'P/IO7M^%_'=E8)VW (BN CYB>6)C
M$0$N$6%A$V&=MP-H 0 L'.R+VX"_7SB7K^!B7\6[A'7MXKX@(>#2WRXL;&SL
M"])+V%C?*8BN$@-(2.^0,>#=8@3>9N)CEM$AYQ>0I9 #Z5ZP45\(Q/ZA]N]B
ML;!Q+EWP7;VX*WTQ :Q+ER_AX.!<OAB]D(AUB0C[#@"'&"BC [I,PH#D"XS_
M>N59Y1M21MEWL[BZ6V3\-BBYUJ#GMY@$@L\G #>PL2Z6@$T$D :<GOB"@N=O
M.$@?7IT\Y%?<"H!C#F(3*ZG5ZMYAOETI=QBXG/9H8[7[H\MC81I!<9M7,X]7
MD(-&OA]6;5U/;C,LOAI#=#JF-@Q*[2"?V3A^+&H/3U\/>-^%K&R:GZ'^-.LL
M(C$[ON_GK*;8J**V,+#:3N.C,GH2,4>3?;VG =XI43B[T=?W)+!;(CMI/GDY
M;;3G!6N"JWIF?M(-1'W^I]5-=[0(9%Y@"@U,.[L<06]5D!KL_)#3N6L-&6EQ
M#F ^@SOK:)$5?+6BS)9^L?9:$[B';O :^-+NHND$>7_R:KRFB601(@R,JJQ#
ME5-I 9 #41L!!O5%JV-&O9@3:+2/Y8V8_ H[\GNQ#BGTYX":^6G-4^%IQO'F
M[?K%C>RNHSUGQZU]2Z[/ULT=QPA6\Y%77?&HE!LU8=U/F%LEFA^]Y5X39V5V
M*!\]I%/QN OS'FF,)'FXP!G:,B#,EMSE$FWNCHU$-+4O6^V[35]IOZ^D#7;N
MGW>5*!@_;(N6J'GOGF'W^'#<G#]ZBZ OEEZ8EN6#0.EUY##?Y%B,"1VUWM,5
M^Z(8GOH>$[K=#9YX4?QQ26'\;@&AZ#;&F)QH8;;[9V*]4^U7W[NG BR_NFD!
M6QK,*-TBS@'L4N8+(I->"X8NS=3O6[:TB Z%>^IO.DOG(U*4%Q21M@'R(P>/
MB;+G!<]T%_#5+MOYUO5X1G7429G,N-1Q6I8F&Q+8%NM9WSC+:5->$098MMHN
M=!$-9XZ9% 4DTO%[3)T#;G])F[F-Q'\RQ. H#OTZN3)+*4*"&>MK6._H&RE^
M5SZ4#K3Q4@MUD8!WG43V-<@$UO:+VDTO*'X1JIH*T"*(7<!/B@A$BR.';D^"
MA83FQCKB++4/55YZ#ISQ"1>E/IR\S8^6JNWUL=V-&G6;:J:;%^5)/3@'M#;Y
M+W I!0O1."Z^:7X(W] =736=JDBBBRQ]A/$<8BF!4BO60;X66-^['*;U!%_V
M.)/@<]/=?J7$]/5&K4Z\<=^%[5J23NJ0;)1ES\*,2"S@2\I 5V1#:JN]N5;\
M>PF/3C#%W)NYET]N^;!6H@8[SJ)[5HZEQL19:69%OKE7YPM,T;;,U,[X,OK@
MO<2;HFA86<,=(DIK<K_8QT]2VFTHA)9@KI>HC\DY@'K< +2=1N+Z91[.G^32
MP!&[/1QOX)A/C$)(ZTM:NI?62]9.]"Y+/)(0C'^2J>EJ7L.C655>&7$'XKJ[
MTZ"9,=?)&+'/2"*I-CC$PR]1/2<UD2FQ??WZO.6SL-E,\>TX](1_\2L.X=K#
MNZ>;>NT(GYM?3'FH-H4>=Z9>\1SI3KFQE]K^>H]1,!O5].5,8;3:+*5HN:#=
M@?89 T+AR,HID %"PH=#TK_SX*1_&ZVZE3ATTZ".JBMA[!4Z\V#S<JM)R2#)
M[:I/Y<B:W:!9:L69"O ^/CKRQ."FVK,.DXRL>%'^!-Z;\V? \N>L% '1TF/Y
M4:T!Q5O],I<FN:(V7R4BF:9;W*9Y1Y+/ 6R9EI\T$\"=&4JN:@WP*=$@_M>&
M_'$[QN9AS*O&5O3<JT^$=3=RT7XM@SW=1S.4*]3ST8KU+S<Z2NW5I@XVK&H0
M%(/ "7=#IH+5?LM.L6E.(<G-#[B]T@L^_;XA1](M2#JR34K+NLJ%U+2%$Z'@
M?@R7QQ//<P#=@G1L@T!C<,@6!?69[O33/N,RNXEML ^DS_E@9D$D4AH5M)VV
M8>X\:WP?U[A6@AB/V-O8SSMR=KNK)Y:I@A:$[B+ ]&XK9K0Y?8+7TCVU?;4O
M56K\,HU@2SKU4!JT;0>VR+S:+RY<YBB17C3_ZJ.9H7CW.M%KS9-,B2Z#^;7-
MHT0QKR4F+,"$[7L";0:[ST1(R4K,!O9DS46D"GIEYCOUI9/?Y>.K]!CW]7*J
MJR?&76OU+%FA_9_M.Q!A6W-YNNLY?K39NWX!5CJK8YVB0DRNK+>&.AEQ.\FE
M>-]LA1)$\?Z(TW3DU@=M_Q@$'O9;I63"ORY5+66>EJWXY,>9UQ=Y1?=/:-UR
MN?4Q8G&MX+.($M& E,SH&%7^+.\)SU,G2F*W,K810:Y)J_$MW_Q!P4-QE3'$
MK$GT2&UTLP[5#7< TTT&S5:AJ6GG-Y.1-N_. 8<W=L"VBQ_;HCPG'[J8F!.M
M-\CD.IQDO_8L'DASKP^JKCW$[?*5KH./F]]%+]G=:7)8?N_A8_ZFI&_SZZ!I
M4^'#4@]^@X,;134"0$)..W\FS:Z*R/"E@V)4P,+\$)Q'8_Z8NKCKA*=K_$RK
M[ZLL4ES-UWX;;-/B='UA\,[.F-/DKH\$/&C11WQTIWKEV"C<F]:VC5>TA&%W
M@#7EL1:T37:+3'@JG9A,O3V%2CEQ1:?A'JY!B?LF8-AWY1QPYVBI/Q3R"I<M
MIG)@:C@8\^(@TVSX4$V\> N6%7X.F$\4]>G2H&-^.&"=^DS1RG=1BP$QY]YW
M\'$NP4-*8NHNJPSF15BU^)7VN$HP$_;@65Y=K08O%Q^WZ 0=5T/]#H?>9V[U
M3QMD;Y$&E>$?-N9?]H=DXB^>#MOWO.\[F.GUC05WPX190>Y3=&2Z(Z_&D@6C
MC1YR;]F:X=K9CN]QAN-;-!,%2!?/HCA1@ BI+<8"HM'3 '/>#2D-+[6Y+*R
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M(E1<<8/P<3A:H>[^VZ^O5IL4D:%">VA0/X]A$16+T$ATO!;UDC2@_<WQX3D
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MKQ43*U5^//264/K._C1O\9T%*[[WWC02T0%;DC*0@DYKS*B(]:>%AT#:I_Q
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MXQ[[LI&[X3#.)1D&G$3Z*9K[5#-$:H+:^H5J \BDLMXDG5:@0!LYL7RA'*=
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M]QF_U^>6>D8Y?PE2C1.5)L^(\7^QCT>>E?#,O)1-+/H^/1:X./^VT-%Z9%P
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M@3@W4KOW='"T&6F\]W<ZO<SBZS(ZA@*:@F&^ =5=ATL*-<VUZCYZI?I-;>I
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M;?J;P?<:R..^2NEP%]<&-[?JD1C<!.8;UV12:50W\-4N>(_[ W58(Q^JG #
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M@Y6'3/?ZUOUN;GYQ30IQ3Y=YC]GQ&JC>+)9;P,H#7'7.8,?6"%&,<M1V?DS
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M,$@[M\(D/7G_&UT.S&\!63A5 *I&$0)2VP+V?;].LEX<AT$!!:[S%OM44&O
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M#0V.I4V$U_(JY*DM#9'HO]U10<X\!:QTT>!>^YND4F4Y5,)O^%OWZ0?80<O
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MR(!NMI\.:29/89^D"3(;?_%)VH#G0JL, *SH=WK9K*+=>]H;6P'L&4X3R]J
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M+.W/@*HA',,).1\Y1^$=\/C1#=]PHIDDG9'TWPN9X/0#_G%LV.@7K4LP-UV
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MO',T1$BE7@S*K5.VGT4R<J8Y?@>-\-]D&E_?X%\BJ 6;+K46IKD<-=?]#T5
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MQOV;,9F[+BN7+MGZC56]/> "1-ON(SW$S[ 77M!D41'OUU/M/4VL%9B$F"(
M[F+1 !^H^>V.N+C8F8.VPYWVD7O!^4<9E$7;-QM9)/R"2!$*EOHTUD).%@Q$
M^DQ[Q,Q'[GJ)B9CJ8^=>6Z@:XT+,D3(F(YCOTWVPD0#-P( V[7/2.X^I)PBP
MS;DY$V6Z)P2 ]IKL@9[_ .0]^YB)B5Q)%[1_X=C,1UU\ZJ* @*FTC> 8Z^]Q
MQ?>8(Q:;BYB0!]_I$]L3O'R#@Z&Q]?M/?L\I;""B8@8F0"3$C'J1+^PS'Z.
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M,CR3Z[$H7[,=]("3!&G#,+P(C:;]>W2U\>G^&1X?4SF:RV8RYS#-EJ]2@O\
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M;2,5$RUQ/$7[P+7]XB<4!4B@="Z=4OHO5VD4ID!ACTA[#]H3ZS+.IE13V/\
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M;]^O&/SS,>+U4_$GB.?_  DV?R.4%4Y[*T@XH')TWT?R_0P5U4Z3,>85;UJ
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M.P.4R%^Y?I4\:TJM1]SV*S*_Q*:S&6JKQ9%KC< 1)."M!L)RS_O,G"?E[U]
M4@EI@6D<3,6M^FV*?+IO3JU*^9_AJ-=]:IH6H:K#:001 ),201:VYPVEC47+
M#L[3AR2"J!/E9 U2K-DOIGV8]<N954^?M]1A;ON7V1%U,1UKVU2':\7:8!VB
M1MUM86Q=_$C^'7(U&-5#61EK%54H"5 5PI,@@ $(2L&]IB=:PN&?CKV(VVJ"
M*GNBQ+:]$BLK^J9%'O7,K176R]8?7/N2PAY=S'M--9V@>6H,D F1*DG;U$1
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M+%'(U;: LU;]=X&JU5MTV"P'UCK&ZLQ5A9*,&$HX@#]9FHE-@T$E;@21,<<
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MKSLTK;34US#L5@9!.E4L+H/7_:@@8#9_4G##B.X@H]9AYCM3TE53TZ0#!8
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M)4K9BNF:6O)152?13="^H:;A-4@ @"2MK"<9OQ5F/%O"_P +?AK\*YK\-'P
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M2]8B9G]=M453=9D;@&Y$WM'TYQ(;3WF)CCY6F-SUM><2#$B8C8*G82=U'HN
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MG'WO7;GC+D/1]C62WA!U")W*$\-VBJK2)18L15B#DYA<3)"OYVM>HQTOEM0
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M]EA<I#JIG%IZOT"LH>*+\ F8.Y6[WDLFXK/G\>.'][&',Y(B;7GQ$^'IQ-K
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MG0?AI$VG/<1$,D,I$ND)GQI_['Z8]-GK7;!L.Q.;FG&R+35^ @;/W!M&AS?
MGHL*-@DC(,/#_IU')EPG\ZV:)QV7\T;E<7*0E- 48WZJ"/!KB&H57'EQ%+WV
M$BR9U& H;>;D H4:79J6;;T*EQ+W]^]#G$')LAWP5+>]@%WQ'_@RAB06)?5*
M;F"ZL;#"/U@)&8!5N\DSKBI4]5^+[(Y0^5VJ?8B29W2_XUS;>P6BDE%CG-E
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M+7Z!TBX2MH/(!HI*T[.S.#'YNO\G0%?0;9[@VG-IK U$\1)LW*^8&-$@NZ)
M$9R);=Y.)P]-D7#/07N*]5J0NZA#BQQ!8_3++U:I.T4()CY]DG_;R<[!*3 W
M)?*]V#=>?OQ4IU@GHG?U)6=5 1^*,5FO[H"#3H-=' #''/^2%0^&TTO1&03
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M=E@$[I>M=YOKZ['POYHT*V?A>@8MP</J6,VI_R50:6N+0^ V-.."/ABS_0Z
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MG8T,)*>-@V) ^%]$OG>[!PYV<JPQ+C2M(S$HW?D:9H' =3KIN8UM&_CJ%M#
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M!R@G^M2[.OV.9:+^*AP:P06.P];64>ZS?(.7FZST_;;TZ*[*J+=T=I_N/TV
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M_6-T%D?_EY?%TQ])N-TB,G1S#^_^[BVQ?_N[WWU(,_=H;[^D$F,-ZOTU<]^
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M]1C<FAI6G20W(22!7H\MN\7@%VT&G&GC-]MCV%.J7[S*FA+:/Q_BY?4=\ZB
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M;PD@$M7,EDI/&4-#74<AY9*2^RA.TM1W%B(K](%?8P2I434V(^*:_0_2Q_6
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M.DD*"%9U&4<Y 4(_,YO6":OWCZ<<TAZXZ95E6X^;KWXH>8A>ZE<%5"K9Q]E
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M<!R+Z?PI-^-T^.010::CY$ZYU%ATJPW&3$ AP+P+IOUN2,0%0E8HFGT(5]#
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M!7QQE E8DDH]*/?J8T4<1PC"GG%D95I?.J),1Y(@BQ24'C#B$1QEY*#@4WA
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M,)FMLO)9!#F%6>+RT&@1EDA]B$VE+;C_[CDY-PXQ\:J!\L"X$H64+AV)H:Z
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M'/<X:#ON92-%12(G,J,T%.<(5JXG@Z&2#,EG4_F<,1/.P^5A%AHQ9AF[RVS
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MSH6%0(@K%="BUV1U:^PT'*&]AB!"^"7AB#/+DMH(@3.LA$$AQA$FPM)(T4A
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M9N][@K'ADA7\W,\TC2W&/CNG0<"*;2T^BNXX%NWA69@[O;LI>]S7=86WY^W
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M=9Y_")!45DH<*5@*"B2E2D* "B,%!(KC<H^6&DYS1LGK[3&W"9Z;BMI5:\[
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MLCU;;PTE62WL,MI$**\X1X:ULA*E)<(.W*DE!(P#S9)&0!WKC,@>&I1)04J
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M( [G']OPSYU:[TJFLO?ZF"VVBH0';Z)J,F7%2<YR;-JI+X+272B(B=#K#,F
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MQZBTYJ^SW75E_L:K5:KG$N##UK=D>]75<1WQFD-L+0$0SXJ6B^HNNCPPZ$)
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MYEH#6L%/IM=D@,[<L]P03$EU@VH!/:&OD9$,MUZQ."V3#DRN585+G?C&P_\
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MW]#?NI3QNRJSP^A !LK>8NWC(4)2"T5 )<;R5Z(.:/?XNNY+LG*] UY.,Y
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MZON=[Z@&%!U93Q0L"<@T58HUD]0W701^@L*^C\2G$+%YL$'?WTF+8B(= 8I
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MLVIEY!O$$O'B='FQ:3'!SV ;UAOJ]Y$'8!OPAG/?HX%/ DXZF\86 ,LM_OM
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M1@[[$;>B-N0@W!UZ.2>:^ 7Y]3#@<E ;=97!]N.!\891US.*&[S7!>EH#9O
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M)G]HQ6=^;P:(*076PB3"# H< :DIJ:L+(6AW6"@_!>&@5ZG(G&\#D*/Z"@A
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MHROJH^@M\,-W$)#6UJ*GANP1T"/7/-;6XD7A,:$(3R/>8?#9T=>3MY0=Q?B
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MO6L:69!]F]%5W>S]LLZ\ *RS2=A%P,E8]H]$%(M^%-&-.8!^)X'*).K3F,I
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MF#ODPZ#NJW4SR[:D:[O%?"N2:YB'CBCFWNA4QX*!!7E4%Z1QN?_1*[^[0Q'
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M-,@:[HZ48F'!9_X+?0=R^0O0WPR(RD 94(#WI^13X2BFN#8";N,.AB"D-1S
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MVQ(FOIV"^[I:3S'57-])0ERSY=DTJU97>44[5]&47,X4MFI#J;O&7HSY>O5
MX,LVCH KD?O$R@.4$ >I!RPCT>'<$&D_-XNO*0.</JUXNF@73&_L>_FIRV:\
M< -**\GATEN*,O?4Z+ZQZU27N.XK]>4IE5;_GN4D X:>*;ZQ$*2DYA45VTPZ
M5?S+'"'UVG=KF[G/7X;<(V 0EN2/CC?A5DSA^?:H\*HHO6+7$&UIV0,X+^ C
MR3\V--,W;M-)O#)[.$1N&[I21%QD:Q5^"%V8]J$\EXI\Z?41KRIKARYZ$D%)
M7_UPVJ'W*C*)M$:0KH!FIHHO,I_+T=)O>>ZF#CY^.^OXOB^&U%ZP:"GH(5N\
M '9UK/8$^SB?C4<I^CJ[H,&G*YRA P8:S:.\&7:W2C.XZ](6:(.,GESZM#+J
MKM73ZHW/A)][ K!PJDY9/QA,3E9RODSMJ:'_17O,:LISR<(A(C;F,4NE>*WA
M2 A/:G9,UB171^BJ2H1=-!U)#T/4K5\[&KN@A6Y6L_@J.?VL80F!ZU9%]AJ_
MD8J)>4@]O*! ></M(%"=[;7/C74(^.N5V)(8GDG<E#?!'SY6"[YF?L#@PM+&
M:74%WBJ\R/#V^')'E8#NNK^0[(A!A@^#.Y:>&=Z<?N[@$M,0+DWM;(TG(T>"
MW590 </7PDA&*<;%M ]T0LC.]HW#XY?.\]DBU5R,E*P5G%.$1+DJDQW)RGLM
M:0P\<%9+/8SW,)_L?(L;5QWLWC-2-.GPZ7)TFI%;5SS4C8=67&O6S:6-5;UV
MK^T3-,MH']D7;0M^^4;$ U'ZS;)=1%;6B59^H0.SRQ<1U?"A81L\<&4M0V$I
MF?^PQ*^&\8MAR7U?2ELIFL@GB&B!@]756'^9EY6:8ELOY!LLS<$.\\*!UF,7
M8C%I)TCL9#-DU10V^-LM6P4L9>BW/Q<Z]#-K=C?AB-/FJ.8P#Z8Q#TP+1SS8
MO<ZQ%>B%\_LMY@E(/G?L5N=+R=?+ZB5 @MFLBB((I ?_Y?OAS,N5")TGT1R4
MRN]JN!I:R([Z2:92ODF\D+G-2^=W DB^SE5Q FAW!XM&[23*/:N.5)%%7F9'
M9 L\;,8MUBY8#Z/FP))^A>?6I6:SS=3+T9$2&^:$1B=D'YA\LT+*6C$UUG4/
M;=M-N3U1+ICU*9Q-^$/2@B9=_@%_WM-&C9O<PAZY6<&IPJFB]]M4-S+> Y.!
M1O8E;ZH)62^]+J :[UI,N9+UJHA)Z@3 - G_"*H*B!:IAF>0,=CXL/@Q>D:X
M28%M@5.^+P=NDFN^*+:APC*P:HV_/3[;.<=8MB;6_LG5B)80!HQH6Y@<"QFD
M\4][:EGX&]N$,FSW#OBFQY9]T/86M:QW=E-6!!C"IM 1=Q=. )TO F\(NC_
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M?I!H'!E]ULY*<JP[C@*DYI*ILN]X6 GD \PN:DUK/1LVJ5HN*/BQU2F(-C8
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M++\5MQE-V%2^)%-RB\?;, Y>JM9?$R%Y6>2W0@IF%VO7'< %%Q8JF&IW%^]
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M3L%RH)-5;Y7HO7P^Q=<?U^ZQY3SG,!0GFRM!\^!S2B3@<3N.S+PG]GLQTEC
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M'MRGP,H7]BUX!<SE8L:<;UX[Q%OYR7*=_33>FNO!'B)CUY,CI7'HN- ;'FX
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MPF6D\N>!A4?K(OK(7+M=W+A$LZ-5"N[7\+0CV8G)Z%[T)Y^C!B$KA>]'6WW
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MGIB8GY#HIRO:R-U)2'[$F8?]$ *%T!%E =ZKII,@L?(<&G45@LWL&UAW<MX
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MPX>(@GF!1+_-5?G5H'DYVWK$1LX25-\[.J%ZX2:[N#Z8]7M8U22?M1&R4=T
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M\O-JAQIUI'N[M4OPF!X7DT+/;6*QDZ7*ZS/FS<?D3@@!$:"Y?%K<3&&GX49
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MAS[JX9,@,H^ZO=Z+[U4O[9BX8\1N8WEF%%LJ."\\HT-K%D>Y3I7[+J4F-\N
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MY1^4%YW \O7?@(\\=E6"E5)-]@&9WBPS&BH"Z\6-VW"STFF?$:?M&$"-C<*
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M;HO!5]P#>&,;C *^2SP&B[>V_JP4TS]+-WCB 2.&NM^=NOERA5=*-;U47O6
MKWY[+9W6ME,UJ^PEU"QF>1("W]B*,R;:;U!9?IUM@CI090&@\DTBH(4J.3DU
M)$@/+'<,A_< 0&+)/X8L[6U3EK]D*HQPM39U%L.&;SIB":N<C]UKR)JJU*XA
MC(X1;4U/SVZ9#UEUJB114V?G+#5_]:Q[I2M?=9>4]96\+>DYK5$*S=$7Y&-Y
MU^;37+09M_S!?VL0,SSQ58>61)/OJ@1_=&GV@&'_FN60[C1A/2/O<,P<X#!
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M3U#?#W?Y[X!_9*(68H(E.JYSR\.Y1VJ8>]C-OE$%?M[08/ZP\=!JIJU9#\K
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MV3>#V6U*]).K3;:Q2KD\SJFV?/\\I84Q)^ .N*O_5T< U]@MQF)'Y!_//9]
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M@RE>,7?0_IVR3AX@T'5^-L[^<I:Q'^3@<**Y@N[;^# UO4SVE_:K*FA'?X=
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MEAG*SY*#_I6WGRBC[X.YN$ORL:4Q[0T</&UDD6+4><G]X/KSB_=;9&.@<X:
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MF6L.8E/*\5B47!74A,4\F[W;C>M7GW< 0K^K41@'Y)-+ AL+TGX,S]/8H7%
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M>'-D[7UM;^,XMN;W!?8_:+/ WAZ@4TFJNGNF^D[/A9-*JG,GB8,D53V#Q6+
M2)3-*5ET4W(2SV+_^QZ2>K5$O5 TY0O[2U4LB><\YX44>71X^.?_>%L$S@MF
M$:'A+T=G[TZ/'!RZU"/A[)>C5>P?_^GH/_[RW__;G__'\?%G'&*&8NPYSVOG
MT]7UG?.W\X<;YSJ,8A2ZV/E$W=4"A[%S[,SC>/GSR<GKZ^L[SR=A1(-5# RB
M=RY=G,#]KY*A\_#AW2G\A+_>OS^^1<R='[\_??_!^=^G?_SY_<>?/_ST?YS_
M.[G]?\?''$+DSO$".3%B,QS?H06.ELC%OQPES,@B?A/T@<+[L_<?SD"2 '-
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MM&,HHR]"4WJ"$0<ZG<O))(5(O17GQ=^YTCOM:*,+#F.#@LQACOA91E+)#["
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M-1B&"@6DN)[N.4[BXFQ>\_1*1Q2S ZJA@E_RY)H112SQ'RK,TRL.7L;TRS*
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M%SE=51>5%4WX*1_W@)/)@*\M:8=AW*Y.SC'\A7=<*34@-0*A(CY%7@H^!Y.
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MG^=\$-N4HIQN2%BC[M)230>;%PS"""CF.4[W-T/(UR&!^E[HQZ&<)%YQ6 7
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M?"?44SQNS$<1V3(ZLVV0T4G*3,%IZ-GZ>*/1_.<3YNH2(B;/)_%J<+9/G#[
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MQ;(Z[Y8LS5*WL)C.%%<LY73I!2S6F+E$0A-'SD9**SI*\=#9+2XVNL' ;E;
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M%)+QU$W5 7JB7A&._]O_ 5!+ P04    " #3-G96HCN^5CER  !]1P< %0
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MLJT X>W\54_O;0'HZ5<P'_,A_4#B1<Z,*V\Q3U6A<3:4-17GW:ZIR[5(%$+
M?!&S%/=,![F</V4S!?<WV@ABO=\X'=DNAZ#@-^;+=B7__8.GQZ14:HV:S<0Z
MW35_ B4*!>,Q7[;5MK<.%=?L-K*F@O1=TYMJD2B$@.]?7IU:U7\8CGV;)T*]
M/0>Q[_V-UDJ-K8.CD F^%;NBYH+^.,P?LU?5W5316@#83><.-1B%-'I[27-[
MTS"_R[.7)(WU%CAY%P%EUQP]K! IA(/O@[Z:+\(.:+5.1%-!^J[=6+5(%$+
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M>./Y-H@S#;KS!"*OH&&^7&[2?$\H(Z,T^1>GU6ZA6PPA#B//.BT@*;O !<]
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MPA2*-1#*=.$[Q:=TF;B:+G8@.6=WBZ#O5)M.DE(B\)4&LP\+4R-3'TL8X9P
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M!?X*?Y_V[W/;+5REV4\@]VP(;25,&U!AV[K7BD'-G<?>$F(8A/,$J6Y!F/=
M5\:$G>=(@\)B!S#V%EQ VM3;&$ILI:82OSWBL-,;]2/W@"YZ?4\ TRT.(C/2
M'3VE^"UT585#;R%1-!<$>SZK[=>5Q"9B H:8[VA5],1. O+6@D[/F8XZ"<"
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MD"B//*%[R.SKDN0/_UPD3Q?9_#E*EX: #UVGBGPOIUO+A2,YYRPA*B032A&
MZMQ@^1-_CYAN8;88D=%-NCI$5FE#EN?1+$IC,BC/R21)TR2=#,=W)$\R?4T7
M@/'YJ77LST\9-), "F,4T;^AZ'^:D$R9?23M!51_QD^<.: #JI!I*/H>D3^F
M*BQ4D)'@1L'RK@Z?6!K687Z]F(V3V0ICL<$CO7-MM[$%"_W4SL2;*U!,4<RK
M4)1.@SG+O%L(;P$59+I;+O*<55WJ/M?@OR=8[>?MCCC_$!FEF),02C+)%EO1
M_2]Y-3IC)^&7??A!SB('N HI06C2S&F^5*(R]ZP ?)#UZ(I9(32(A"1W64F_
ME42S9G0>_8\N@9BI'X=^XB=1*XJ\K $KA 61NN3[,T7)O\@^3)<W25[4&Z"\
MM=BO/Y!@## 5XH (<&K.!/%MW:I1]Q (_:7P 1>+!52%:"#T78,9;TU''HXW
M)\AC]AKEH^*B,FT\,M/&VG#(RE%P*]079H5221%D\,I1Y -)')@MBMD1BLZ-
M9W>F?*+DW>440(6>79OO">-^DD[N2,ZSF;*\ST^S9,*9HW_*M!^VLLA]D)T=
ME"&*?&X0B6'>)WTV7HA)_RPF?2DFO=2&:MY97$:K@/I+PH>XE;3C@T+@((E7
M3:35_1A:R[D^2 7K@^C..\!72#44K9>$-0XZ+&/OB@]A5$X'-Z'8X%;('R0+
M[3H!^?JZ6I6$EY\MIK=7V_$JD^,'$3(,)Q1BAU!9K1\I]V2RF+%N2WH?O<^6
M]&196CZS7<:H0'V@2W\[] J1@BBTI+/J8C%GU%$J-E\FQH7<<C@!=?^#7,9!
M&*&0.81>;(6J^58PF0::[2MB/]!%VHQ4(18(_5B%X-T,<;G(Z6OM<4J$ZX-T
M2AEL!&Z#53 _T-6Y(QL4TE[=-]!*P S+*<DOF%DQK5NH'A;S>90OAV/%WQ%*
MP(@AF9/.9E$>!06W+A5AVHXM!!Y*4&Q%Z&/T5B\W)7ZI=_G1=!00P[C7=A:3
MZBUCQ0"\FC =,%H7"VHSKH".X\MC5SL(6N*@7 &L+ 21XJ=.LVI&U-L(2UL8
M3QH,.4NQ M3#0=S!%7"UF[>BCS!KAW$C1MNW3=@!"O-@>MO%<;Z(9AMU &V.
M:TT_,<\_N-1M\ -4 NK[IN9^11.%PS^ZN W0 0H.X4OZ+L]>$A:S5%QG^=7\
M>98M"3DG*968H::VS0!BUOL)(>Y[&M@Q0E\"J>_7<E]54D-](I^!I*4.^95T
MAA1/A_]*XK)!>B5QKOBJOXJXJ9]G>9Z])NFD.-<%L.L[".:'5$^BFY@5V[86
M.L!CN$<Q6^1?D7<1>/U7E]#*PE: #4AA/ZBA1>@[L!U3EGW4L_V6I3<LU)L4
MY3F)F %D'6FK#VDW=A0@/&>9,ZP5R3%KCROL%^T[\E7%$\M%MFHN<.Z^-E)V
MG[*!K7_&HKU8'J913FZ3HJ1$7;T],^<]5KIQ&J43<I->1TG^6S1;4)[\'N7,
MJ<_#JT9"HM/+1=>?LO_DP,V5 7$1W8Q8I-(X81<K$>4YB/^Y2'(RJK.]*!9S
MN=]+JX$X"T["4!Y8B4JUN%J!QC/J#4;_L:C2]+*$H]O(U"Z(AHZ"^#!"*MM(
MS UDV&^$*SK#RN7J""^&XVK.&1)0JWHQU(>!G(*=%J,98=@/AV\+QJ7A^"8M
MRGS!Y^DP7\.YH;L(&=%?T/^J5$LMA_JQO__Y\/0D#,^G3E.@+>ZPC7;721JE
MK*BUK>5&UH&!/?M\$(9732<AZ]&%_6:YB\3E]HZ( T@KQF9CSIE @O8Z25 )
M+&S#6AW_^:*@<(OB(IL_T?G('9R5*G^W$3@WD&HHVBGW.PG7#2.@JCX4GT@9
M:+.Z7M%)L!LG]XR=RKZM8%7Z"!-0N7#;USX%OGQO%G60H7&O!J,>17 %2<7H
MHL8W24UY*7=&*I=_**'\?N0?D V@KXE@+#L-$I&?+R.]$>"]A:#+3Y;!#LM)
MI@C9QJ3@<2C6;^YV1XKJ9G(1/2<4O_%,5?82AQ2._M'+H6I&JA!P*#HM*0"+
MC5333T#W5=C:139.4FV 4\@U%)T6GES#.1(Q!6P\!4/140WS$=VR\B5'8G,%
MDG40H/VHJ)Q6G4J@6E *"8:BFEKC7NO7:EI4^[-6U5NP <?,X/?,-2)6"#X4
MM986B,M>K>XO[IE(FLLV9[%19JVDW@"KD'LH>JK^Y![@6=W#!#">W1#)*RL?
M&4/]L<U6@CX_YKY6"TGRAE4@4G :HB3MZHO"BL@S8]R1O/JMB?'23I7],8S$
MXFV]*BP1*EPJ0JE8\H7RJKC-^(Q,90;&0;EV3'N<YMEB,KW+LW%2#G/62[M/
M=AR[XF$8Y2TZ68; &*&83"MM58B>B^OL)1?1+.9ID%CJV\<ID8S98YA65T?'
M-N-R_]-3B/ L5'^WX[.S,-9<)Q[+U+_6X,,.B?+G+\69&X8G#>3DZ,J.L-TF
MN[K>4(QA.$FBB%P)&,!G4IGRC<ZN)"[)Z"(JIN]9R@8%/QBY]V;!N7P9E<JM
MW&V4Z@X1ANLY],;>EA5A>S]N![^\UZ$:K+Q\]?.D[5@5B\)P>T=9]JT9$K:;
M97^>>L=G2"^S;F'XG2:%&W9 #[[@-.)@[@:4X3[#[MN*UL5NN8$T; ]-'*LT
M1>X_WMXLFG;&: $N;-],/+$&:,! D*_)8!&*#R:4KP'%'(H11+/F''T-!"@(
MG\F=]C6@;-@IIWG+ ]>(>%<<.5%MSI05_EWF[676S=0LP.Z*?R>ZW ,\JGN8
M $9? PB%74M? TJ?9Z]YEX5DXVL@$ 7ND0D=AD9/J)WRF->?J$:@@7MK]A^'
M1-GBWYG>*#:5O-V1!NZUZ6<"A'.Z]C83C$<KB">#6R :I<NSE[S[>I)Y(FQC
MZL%5$M"!CSM*A)$W!=J8: <<PM]RIU(E4=AA^&NB6'[,R /WX_25SHXRQT\>
MT%ZF12MF>'72/(\*NFE5]27?*\=Q:HHO; NK]K31=WIP3<YG4?S'0SRE_;E/
M7)339P3]WGS 2TQ?9.D+R6F7:H"O41E/:;>',HO_J'XW2$=?F0GT(LIGF?@=
M^P!M]34;D9FK3V=/QO%'DL\9Z12AR*RYTD4_U1@X8'O^A-MU;W7.H;!?X.[$
M9Z$HL+I <O,V:#4Z9Q:2QEONB8 D;!N?A&X<\E4<0%6#>!:E*K5,_>^4_M/C
M?1Q%6@<-3$=9;-\[M_#B5:]CG](_NMY;"'*0_ ;-"A I9Q3<:Q",Y\#9@G_>
M]0>M&=E'JGK9O4+/8'4/3C:6&<SB4BJ9B1(V6] ?MJ?A(_VJ8<LS:]UM!Q'[
MYL<^ ]HS)6R?0BT."TVM17_!"6]G5'O)J:: "^:P/0[[D[[W$];G-# =TA!J
MY/<:%%R/4'Q/Z="/K]GC-%L443JB&^'C*Z5LR7_8_C7]G?GB!/H1=I2>?O:3
M-[C56I:9"E 8 N#GJ)@E6RHCK;CEK3F92+E?^Y*; 1EB;L<[DG,5:!H+;:"5
M(+2=Q+3Q4_H62AYV  /W(KQZHU?5I"!<@\L9LJG9/=C;/],>IS8#")649\^E
M?I1K3NP(W-/PDA1QGG#RAN/[I/CC.B=D9=&ZCTH9/KUNML6 /WC%$<\[=T^*
MV2[L"3Q[)3.4L7#:R^0E&1%ZFRCH]AE3]D03YVGD.)9@D>?:@GWM/NTX$[C_
MY<;"6&'\+6.I7UBIQ4[;D-5PG%%[GOV$/&Q";LP)W,_S=Y),II3> ;U%K]9#
MZVN/ZV""27Z2)?0\@UJS)G WT8V5(6#<)N-NER#M,&)[]OQ(\K#KV#'%X$+J
MPRGF:OX\RY9D@^P_O57:3);#@U#N'HW=;.-]5P&J)#U<E$494;#IY";5(74]
M7*"^*1C[46XQ?(I8GD'@' P[G9L]^FI3[6V^6G^/<_K0LZ(]M+GJSKVP\\C9
M([_.\C%)^IRI#E\4W/XH]S2@N=J&?V$7%;;'7OV)^6;T-E^=OBDX_E%48D S
MMAT'P\[XMTH_*L%I6IG:>=EAW!_[AX>G>TCE2P*;?"!L"MMKSV5]/;,XEQYW
M1,OO"58?_[D==F5?V&Z#J\58>_'5\5KM=XJ^G.V^W1GZW=),G C;B;"Q#.X)
MXS&%0OE5YE%<+E@QA3%1PG3=IEI]@/N0K+T!/O2L F47GL/BN^[W(INSR$\>
M%7J^W-()UYC0@+8N;:%+GH[U+<&BC^),(9M1Z)P+.Y^C\VNGU_N8]1?%E>)/
ME0H  P-/7RE_(5G</%L\3RU&%7P[^;=X"@ P*7#G5AE"2[VD\_2R'%?<C_]M
MYY<KEP+WD-7H=\QJQ+8*-O/(G'V^JU)ZU[ Y\"EPY]D=R)AQ>+#;&3.TDPR.
M0Y 9,R#"Y%DEFN&8VY5UF3,:S?AC:"^X N0=1;/]D%3!AG!T-0M$'UZUU5"\
M4+T5!M?Q2\_:!OD07J!8S/4>$0S$Y5X2<5;>*L/T?RQ2(@LDU<O LKM Y$=3
MH)_($GFX8D),X;DFY2M%.Y71,DR)I83,0_ GXX$G779[,;D 0ZR7OJ;G@3R7
M_+/=Y&4WC(#FR:K57F:NX )/P]E[5IS#@X^3%4=VL6O/%$,:3M\S10L$+C'*
MX<%NI<7AHE/- 1?,"O&'HHOJ3_S>;\$^YX'IZGP D0X0.GO=Z9%GC;/+.I,<
M[A;H%-* 4)(@I3_Q'4_<429V !5B@5"5[&CV**SCLR>QXS!$,4T@E#Y@Z:,^
M[T;Z*)7@#,@4$@C%84]FY[$*AW*VLEF-*@R4']F1"I!'BJFU.OYZC-1^W[QJ
M11W^C-!N,6=.#T]#>?>&;QT]/3S",9;U9!T5PL:TC@H.!59/@!-^3Q)Z;A8E
MH^ AGE*2=(9231>.$JG6F ?=6B6Q[7N&#0OP"A$HOJZ_]&D[":*1PM7L[*HV
M++671 ,67E$#-%EX5T A"V47"R0<GOI)UF _T9WU2AP20/0E0+F:PV,<[H9T
M<&SA!0@G!"JW<GB,9+EV+U?#.:/@7H-@@! \./X%L6>W8F0?F?"_9J-DG,3\
M/3H<BU)Y3<W:(TFW=&H/"7T.D]0L#[ /"*;XT6$JYKEL8P>'BY???I/6AL[4
M7;:: 1B8HT-_3CAM9&<#!S'UO8Z8EHO/8L8='?JKC-M=2&I($/%"JL>&^6W>
MN)]_&#<7]5-\&S%$0(U6 H;7W=;%W&L=0 F#E&QL$ T1,@++R"!N6*TY:G1)
MAGCT;CT4'741=8I/_#UW9?/11M70(#_P?-U]>SZ>'B-YR81R)+1G2N"9N?MQ
M?:.LV"G/1R$ZU1QPP0P1)/(AQ._]B/4Y#XPG-(0B!,I;Y^34S_G<:GU)SFX#
M,L1@$QQOQY.#G2CVII2''<# 8TGN&6#CE6G=2EP4<>06W)UH&W7@X1Z<8)OC
MK=Y0@/-FS-!P6RN7)O6!AV)T$4TX5XQ.,H(-DT"4U7E6EME\..88+$0F:2\@
M>W8&E:X3E<!T(" "*3"U MFSO;":C05(S[$P3I)2(D ,K+B(2C+)Z@6-E'H6
M37-A/<"YA8=R>["!CQG:L/UIPWM)U4%0BQ209*>+-_'1CO4-.!!1#7TQW_O)
MCR0%XU4 Q($B2B.Q8,6WC;YLTN9B=_7GR&:>T#)3K &+@NL0NH)!7"8OQ'+^
M2QL+8'Z*0;3FN!Z)PJ$6PAOAD1Y+\51KY:XUX6J)PX]OYI9!5@@!PM.@^IQ^
MLF\T$E1YM73+>*1F98-L!3,AG 9:,S.(T[(#5TVGXB&$)T'UX<?7S(K!ZW8_
M3D_VSCR53%=/0S5GMPE7,!7"B6#U3=K(;M[66@KZ_'E/.C-60KJ"M1 OS^JK
MQDQ6S78"B3^/#%>V;A.N8&HH%O;S19&DI"@NLOE3DG*O/[/OA:J3L&)][( &
M>R8H)!^*<?TJ+9-R63QF932[SG(9' M%G/4H@BU(NE0' X51;"IYNR-53 "G
M5_&'FP#>KW?]SP3CC1#BQ=X^X?/)P<?VCM/!5H1A0CSIN^4D/L$JY]XZX?.)
MHBB3FGP%<R&>ZIV9ZWT; N*R,:(8XBWO,4WMH<<WE7IF2P34&IQ";A!: CN:
M((3VSI_3O0\EL 8PA; @M _]954_.?1G"&DG(DM,"NG F,Z+Z>K>P8).5^4#
MZ>]4F88LNHED!)[31:(F$W)A@D)\H:A*5)4D!W0F1XQ]#"";WY*$:MHG5)>!
M!?,^2-DQ?3HJ$#8IYAA([@3ZVJ$44-*&8S[E\RPF9$3?B>?D?!VN)9\++OT%
M%C^6U?XV#6=N*"0;BK9EE:GP,:.<&J;G9!K-QC7CM':','7F3#CS<ZKWO M8
MLT(Q'R!T+5=OK/@PN:9,>)R2S8CY]]R4(CF%:K6[C"$P?9"BN<H5WXHCBBQ.
MH01FU#!=_7/!M(:D+&=DM,4L9C\JHICS\B;]?9K$TR]9-BJ&^0/)7Y*8%/<D
M)LD+&5TFHV]9^3\7T2P9+Z^SG/X^FU3SH1@4] /ZO<0/24)@?C*4]+Q#>6:P
M8D6$$MUB7Q7;*A<Q8!ESZ^\Q5G_&2AP6UES&Y)YBHH82ZW-)BCA/GL7Y\S5Z
M2^:+.6/T<+R)F"['UFG*@;XA6.HY+K:GG,3 '%-,0@CMJU!U_49?*4DZH?AK
MJ2CUU@II%TXQEOT\"!G;,D ALE#BF&H:3CU#]#N#[2B<+1_Z;="!)XJI J$0
M_DKY3/>>KU'^!RDOHN>DI)>S?_'GBFIU:[H(%?9'5N/9,D ALE"4P.&5*Z&W
M_G^+D[\[CQ13*Q2'O,9=6YA(V$5;@MCUV6,<C&^9GNR"?M\T]JQ1S!^(*+=W
M_=9%-F?J [XIGB^W*MW4$*OL(2OSFNH8POB6N)Q]=$,F*N<4LVNEK^ZQF-+#
M8CZ/ZI%S]V1&KUXC.?Q*W>5:;$GU:*K)4 S)MO=U2:?!4[8HM73<ZJHEP7Z!
MWUG.()9_9YJ4Y8[@1A=H<1Z@\G)'2-*2/3MA.118N:.;E"YV\E#2-<RWNDQ8
M571NPIHN J5/EV$,B6W/"1L6X)4[4GQ=[P.F[22(Q@D:MO0JMF&IO20:L/#*
M':')(@@G9$2A]%'NZ)X4A$*>TKO>)7DAL^R9D5,M<KV(++H*(/X\6NVFOD0\
M+MCP*B%](2F]]<XH$8/1G+*N*/.(9UBP$8]59^&9B[2K80K(#1U Q:1^O!RT
M1N[?DW)JY_#4:D3!+8^^S>AW52#^Z.M'X;XTI]F,?JT0GA&7=-PX*7>I>N_%
M+"J*=8;F2HFM?72V&(9*ZOCT#,(IE5O0;HIB04:7BSQ))W<D3[(15T%\(Z_\
M+^K"*C:=?[!JT"&YHUJR5J;?<<(+\&!#]3<U:P.5C1F3SCSMI( R->,#>, A
MRE!,Q0JM5H ;+06Z@$S"':4G!P?PWNO+3E@,%V511NF(;BGV=L!Z+\&CG=]D
M'8 "O!A[$Z^8H Z2%1U^[!\>T?\%Y$@(*M4F2,1G9IX5Q2I A-V)^:<I'22F
MQWB9J&\XYIX5_0$Y7K6_W[B@#?O%R:%SZBO;U$56Z%TLI#TJN 'YW71<@0:4
M (6#L:\[P[%X&IJO.ZN6%3P_.B"T^\XV.H BQ3[?R$H3I>,0G'U(&:WE=D@,
M&3MB!;0H.@7 H=9GR//LE5[YBO/EMTA=X57;@3/H!&<R=,A?9"-1Q<30HH2H
MA]RC2*VJ;LBZ",!(SQV79'$Z8=A*L $)HE3R#LG0NXT349C&PGD0G@!WR3.Y
M3M(HC2D5>HN9I"E7EWSVK LRK C)2T6'!+% \]4+T:?/6S?X<7K"3OC=/WCD
MJ!!+-?./76YLO5(NBR:<(JS,!G9>*]O<4;&P03)$&69()GK?BCMPT[C50I3=
MN2<46916(2DFYY'MMH)6/YNM:A)*N*LE':(DL,[)_3;AL7V5 5NWURJ:,TH_
M(U4Z['WG-6%$+,@K^;1^0U%V$-1Z2^ULPT<[UC?@(-;B!6=^$'L[@A2,-:8@
M4O4.\F7TE>03DAL*'37:"1K]5=,P3V$)QY4@(,KB*CUH>;(N[79?;U,I/7'\
M+GO?Y.7(($K=&MAM\E"NMZH(0PHEM?4/ES%*P]$FZ1 E:1%X&L3FW)&YQHT8
MXFWX\/+T;HN\36(]L^6M*X+]Q"+J)J?L]#,@0*P%.YCDA%L1='OR1J.*K ^B
M\U! 0RSJNOZB_J;7:"9(._:J 5'P2L?5)O&(]5J[\36(O;DS@WLIQ3HH65Y&
MGKQC38;APJSL41'N+W!#.5-E3+>  5&,%=&LPZ(-LI1%=Z\<"XSV5GF7"O$'
MN)I; X6H^XH9?<-)MBG55&M8H?-VW;=FODIH<C 0U6%#%97WDPI%9L;B6$$Z
MXUN(4-*^PNPY38I\Y:ADIH4!4>$6VTOT+B?S9#&WD-AV\PJI9[][-X'I4$ 4
MS\6\I,C.</,]1=5+.!@$5]RNRTW%"!6BAF_?$K98FII^ KJWO!8.LG&2:@-<
MX&6$\>0:T*T'4<#&6U H/OK#?)2D42Y2GMG4AY5U$*#]9-5P6G4J@6I!!5[V
M]R&9I+RR1EH*337/^7:3/BR>BF241'E"S!7 ;0?A3#G%V9S]','.R"%J_O97
M!;H.P[WZ\W9OP09OM6S;BTWYAK5&#%%;>.<%'\[QW?L,,&:_"D4K5>U_]X2^
M,T45/?,!H.@CGIHG.-8J3V\N$U*(PLO]2M?F8J[J5>%&<G)U>6^9Y.(@T"8T
MB)K,NR?2</9J/-D:-V68G(23I"A)S@IWY20NA^,QR8W1._I>%0#/R2(LUH[$
M?FJ+#*)^<T_J9&M%LLA7L_/I(_38("HWZSREA1&")^FWRFXO:5_-LIU/]6"'
MT5#F&"W%W[<LO<C2DOY,6TYN4K;H"[IY0R3X4V:XJW)O%K>FU.^2IBR;VUXP
M)4"Z)FT[V?-4!<[$7=5NHL00>'*]/'O.<D;<<#Q\34E>3)/G]6S_E<Q&YTNZ
M%&+)4M"+M/VX@G/^O%Y;21\ +EX*]LUL5E=O\935]!AM:@Q46XU59P'"GP^<
M@\S<,>'E8U>DZ11D#6)Z-2U$R1?U.6 Y@ #C+_VWHX#<<>'E9>\G\>R>)]\,
M..$H,.$ER[M)XYRP=-%$_/=QFF>+R522CEHE'?L1.!RLR%!X$;4 !I F3R&G
MVZPHAJG\^%-)1M='D.PO.-U1%E90 /+9&5\5VM)*C68"$,X;4UTCR7DCDM,,
MF&,L%%OW!44ZR=BU9#BN$B+2%T=I8^'6=Q5,\YEW3"M)I7;4"E/8>>,:YK=-
M'.Z62UE_P0G_Z<<LY65IJ-0B#3RS7']"#\D(TI/TC;EU(%( ?!T-4E;XPY17
MI]E.W(@]ER)P64F2$U>)"2)M'&8NP$5!+Q1%02_ 3TG*[[_F@U/528#&N7_B
M'9E&-!#9Z/K;.&5PW+=/]2B"+4A&2I?$G2:Q6>Z:%D@A4N5]N D0SBG:VTPP
MGJ(0RIM[^OK-DY@58V;JI)I.SS(BVWH @<JSW=I]-4I.7W?(B"D&1?8E<Y*I
M=WH\6ZQ!1"#!A)AG4*7&X^:*XL91I]9N-*&B\E>+$$CS:0G2D*80S=W@CE^J
M4S*KU++OI>NW_A*.MT$P.2&&Y929W;.\I.*<K\I$GI.4RL9@J-9WY3 /P[-K
M'FP_SUP1X55I[Z!Q/L"Q4+IKG"4,UM$,J'&&29NGK(2M.1PTQ;/IE/'I":]E
MO?0,,&+9L2+KE&AOCNJV++671 ,6GNT>31;>GX7(0C&] 8&>@+@%[RD0/U[F
M]E-?_LJSQH9GM.^EX#T%X<^EHK6 W-"%7:FN>3W4.,R8^@C$X7DQZ>[*)BAA
M.P7\'M$G+9V&#]%,Z<*I;"PP>DSYW4)<2@QA&_J5CS&;U6;J+'@0GF>G3H[6
MF$(WY@MR60%:[IKZQ!1/=]&2L>,QC](BBKE>\?>DG*Z@ZE=IJQ$%N\+SF-?N
MO)V &LS[:&HZ<6=XC-[6ZKE+,B9Y3D;T=X.B(&4PZKGCLR,(54(-WVT2/24S
MGN%[.!X_$*6B6=?GQ^G)_MYI:(ZT@EF2NYX5E+!#?+9FJ'8#VFK-U]Q>:/I_
MJ< L0 #HW/H156VVV<JKUD7@]??X[2@T&1(\A=W6;*'+N[#:W>K-^6Z 5, 7
M=V.3HL",IVEI'C@^^XSSNG0U#RB9JJ(9T#P02@H!,6GH6ZRV5HT>=:I.@J<X
MEX(N%H9*>HH-RX@&0#O7LP0M'*C4W01N)(V"@\N<42XN FU "UN;AR52[]:.
M'F1KLGA U!VY2<LHG21T<Q'DF.Q0LM:"7,\I1RU6BM3PI 4$H,0SW/#NR0M)
M%P;CA;2Q(-)SOOMV7-?C@="P&;C.R?Y&RM*8.$K=@]/KR0L-B/\:4(C1*O)7
MU7TRF9;#\?="K$0[J5@,P1&=[N3FU 8E1-2+D]Q6OUWY K81G'P,CNG,3\X=
M%,D98$)$NQA$MR)FZ;3WR7L)NG?Z_#$ "SSZA'M5FFYMZM8\H=GGSSNWOFP0
M(4:);)R=]R3.)FE2D)'#+:+9B0/UE @'\B*AQ(48\G'+'.K7RU@O!%E;0:.?
MQ!T=>:^%@Q@!TN[ EYQY6*&,_4QY!2!#M$8WYT2^OMC0PS&[660LQ>5%E.<)
M&5UG^6N4&[8A^Q'X5GITM).OFS8H%6*#>.E_R]*\3M&VF2-])//G+(_RY67"
MLO>2-#8MJTZ#5K!W<M<# JXPNH;BQ2.!\#VE-(_6TYGR;?V;"XH_L:@KT'K4
MBF\X^S6>-00 KV*>A.)(T0JAQ6.AP[@5[Y#<:1QL+@#2!YU83?8HIE8HCA\!
M3ZUP;#]ASS%CX7H<5Q7I 6SONB+M7D$*+>S5P9?% $LAH96N"=]]-/ T\FZ6
M!TR#]O/S+(G9_8,R[9X2J[=C-UL+,*&YP0G^*@W52A!X$=L76<Y62TG6$U3%
M:W5K069HCKU27EN "-M/E%)[1;<U5G]F?4#I[P&2#@)K> % NL6AQ8'G(7I'
MWTR4T&A"AG3_GR<EWZ_I*2-H8-J.Y5CH.HK!N"3Y79YDN4B+K5I%7<84D$,[
MGY5K#00JGD.J"WGGA/Y$@,6[-:@ '5Y,%X!\U5CQ LW%EI&\U/9Z$F=IG,P2
M3BDE9!ZE+,B:-^3Q2+=)P8R4A@3RW4?^<7IR?!+<55LI:D# 87O'7BSHBR(M
MV8$CZ!: M:>LHH^PE!Z&5\](=](:L>!EK*]M)^-JFDVC\B)*S\EW]@#/'@@K
MO+=A;%A6I@:+[=AYS,K2'5[! ?-VW $KGA=LG;Z[G#YZWZI4#(NG_Z![QF.V
MWEMLI*D?H<*S$T_ MLCP_&8[9/+:P_%5<L_DI6"TBF; 4)U@PM1#,W!17G\^
M""_:IYH X/:M%5P(+]_09@FR#8*SSG]$47?98Q@>5LP)//=^N//J(YBV\">8
M,1TX3-+$BOMD\UHZMO&TLNHLT/AY:(,N=\EEQHT!$)[6"C$^OM(#=?F0O/V#
M1'D+2=KV%U@\>_$B"=.9!Q#^UYC9KY))FHR3.$K+F_2%%"6_=&W66C5>-FT'
MJ?03(=8STUTNW>%!N'GW5ZRCCL/B:#?VKOC@O["9N^!44\ !,X2_^>[+/IS;
MFX=)8+R4@82KSYEC2ER<)UE)XFF:S;()I>3+_&EJN)"9.E;*J["*H>F6G.S2
M90\2PN%]8\&.H^*)8R_RDJ_53V16%NQ?7(Q<A/0?[^?0%Y)-\NAY2B?I3''8
M:MM76'9#:6.)!-PMW5HJ0IE8I^QRXZ1I2D75OL+B2T%BR6>)<,R P'W!O0G'
M]SF%)R6CRVM[%51!XK],LI=/<;9(RUS<1U;_>)=7]8L?EU<2X;S_L:+7R]O?
M<KIO<E]&.J)7\2/M,1P/1F)TY6-,T51LPCA7<? 7EPF#P3,8D,L&18BL,:7R
M[ !+ZV%7!T3'.S.K&S 4S(9P^0%CMN_=&YKKQCT[% U"Y9$K_(A8FFA1PNTF
MM?$$-W46H0"?0\O6:71^M02E$&TH"H*&EI0^O7ZGA^+T6]8,Y'A/<J"5=HOQ
M*EZ%5ZU"-P$ZX53,"?3*AM=)&J5Q$LWND^*/KU$:33CL(?=G25ZXDOPNFR5Q
M4BMZ*+S/XB7K<_7VG!6+G "%QUPF!7/>H /*/W-K"IJQ'H#+\Q0B\8;IDUKO
M'*O.@E:<&[+:9\>=E9+3S@T?I'\/^EMT^)J2O)@FSQJ5S48; 1/'T]3^+NXH
MD:V'IQP2=$B.LQ"T:H!&*T$UTOW"2C$C9Z*&V0W" :)I>F>W[\MZ=[Z;KN<@
M11$KQ?6W%SLM_JJ=(-'+E4DW436J^2W*P\ZISMYMQ7#,MDH+]\M&8X[QS'>5
MUBY;OP6VL&-&ZF3;.+!M-1<XO15Z-?/?1F -*&%G3(<2F>^3!T-VH!G1T4.U
MQ#YC(</MY@*OYP1YFB6DDIP&2> %$7MU">,\\6VYACD8G3$''IF"[2K$V> _
M?L!9;"KYVR,./-BD'\&'<RKW/@.,#F(02>I7[RQ[C[":=Q2GT[,_OOUZTKPR
M)9@@(B4P;TQ1P<K+L_]<_7.1O$0S-AOUMR9I%P'87Z**S@ID6WR!9Z=?&UDL
M*GPVV@J(_I(3P(E0!0PQ/_W7Z"V9+^:<5A997P>@V@IU?03-_JR2( 89*X"&
M^(6PS)$/[*"G?Z5GQ8"2NRP2^E*CYP6AIWH='8*)4O)I^N&K*)X*+X^O4?X'
M*=G'G0R7+89EHMO?"V7'^RV:+<B@5"TT63L.X,#/,Q^2_ZK]3P8U[-+4%Y0=
M23JI5M+56\P=6HS>/>IN K>_8M78(K9 #F F5<;HQCDK@W%)Q']O4EX4YB*;
M/^=DRM"NTD(-T_.([Y&_)A/:XC9[)3G_S5V6*"Z:H!\07B^'_C+V(,T#)";A
M)4[<)O8NS\9)R1R81":XQ^@-;+:XCRU6S;_)/.G 'CQC=#L.6#L\.0XI&(JC
M*[9S@P*>!1"\"*)Z.:K+U#Y2&MQVYH'6<MH0OQHHM!$=W;-G'RO5;3M'*LY$
M#;,;A$,;P/M@MV_%>7>^]U+.NX,CU;Z?]+ZZB:I1<6]1CIASL-K]"-O[(J%J
M6>E8=)%IIGYBF\392'SN\V[@$<M]ZVA0;D&6/07]7B/?K%GL*)X&0,12X#T(
MR/>YT9^D>K&O7BWR['<2_4&).E_N#R;T\T7YO;C,9K,H-P0UVO056#Q&P=FO
M"XFLG! BYJYC=#R4E.A).6TG)W-O@<-CN%IG23E@1$Q0MS%GCCJL*$5?<4'R
MIX &7%$FA(AFU<9\:2$G<V^!PV-2=\@59<*(6!1\<Q?>ZW)(*3H+%!Y3N .>
M4B:(B*7$FYMP"U%9=!=(/)8! SVH3" ADJ]])#_K_?V08D^!'MCM.0&>]VWG
MG'#W]WW%P'80FTK^]H@#KWC>C^"]*P/\S0!CEAT(?<Y*.?N=(HGM--"UII7Y
MWW/4D_V2TFBGI:@@4M(AN;WO[_MYR,-R78+)D*-N-YTZ[R)6"&U*2IZW[\-[
M>!Y E_BZ)U%!Y\/3;'F7%45"+UKO+BD2=JNP=1B2X_)8OPU*+)+%",$5O+K2
M>NI6'DJ TT [I "\V\ZAK::!'5?P'$<#]/$ZP'FGXOIX*80/P0M 'R\(DPJ>
M$\#)'E81H/YT% ?;+Q0G\'C>G+@F9D8^4J :E ] Q>&6EN4*(%XE[![DX_W5
MWYN@3(]\*.M*'TI["@BKF@Z0TKY:&UV4]A5(O,K5^/X:C MA^VOHY62-$,]K
MLQ]W#0;CHRPH T8\7U!\;PVV)81M6;9<3R:$B(Z?_7AK,!QAFY6M%Y0)(Z(/
M:!_>&@P%4LZEGL\H$T3PRLNX44Y'(64'A7GXJH&"I^#!C[LY\I7Y4\U%#;<;
MA(-GR.F#W[X?J]T9;_1#AU ;= IT.O)RO])-58U1<XORP.OL]N_A=112)DT@
M[6E[3OR;E^+E;-BM_)I<;"KYVR,.W/.S'\'[/CX]S@#CN0NA_^CL:'2T"_DU
M^7K2G,D23!#^E9A>=<$7MK9@NQ25M[*\!NMOLPD'B"0&W^]=*4Z\"KS5UZH2
MO-6_:C5XJ]_\&,QF%65TFBG?8KKF HS/1["4M9L2L ( 4:PW$&GX/N/AQ&)T
MREY=9,/R4[U-_KF@NW<)F6%44GU2:?B7%ZK</X:PQ36J-IMI>-\;C_LN5JAC
MA.085=$<1 %"Z#2>$:M'.APW,C ;%0^ZCH)A 985%U)4/!^L$$%7,D3-)6[Q
M7)3VX&A/D"["#KH!*XFHQ*E'!ETB,60Y^KX&]"#0/FHO/DRSO"Q)/K\DSQE]
M#Q@LKHKF@F#/H5OZM2$[$0U@\-P>Y<4=]*S7]?EQ>G)\<NPGH*0]_ZT0X;DR
MGF?IR,#S6I,?^X>')Z>^%2G./)8BV)T2B*VJCNZ?^#8)N=[2E"C"+G18)]OB
M.-]N+G#ZM]<H^6\CL :4L"L=0HDLG.L7G.R,)I10TB5L:& LI"AI+R![ML9H
M5I%*>#HH@9<8;)S=OY+9Z#K+N=8M22<;P%Q>1;IQ!&O\E4-S4%%U@F?P>PQ"
M?SH8C1)!X$TZSG)FT\K2<-2GIZ$4G:]7ZV)U:+.+G%#.&9>%IA\#>. S":*&
MYZIE8 ,'+U"^@Q[\%$<-X*X'EW!71S.@'CP4S>D]*\9D?$*M6_%YM8=S&^_V
M=N+R42R4;?+#5H-R>FWNWO6& INOJA,Z9FO%TJ0>0(\9J&3">0]U$I'I"13*
M)>$Q>Z;O!D:_S2.VT5A@]5-A5K\^E$]6%0+HTCFP4CK/RC*;VPM*TEX@]1-A
MW$Y6.A"^2N^T<58[P[G'05\$E+1#JTY]>3R=(069MO,_.]L2@!4 :*6H/V'X
M/NCAI(*H[G06S]7W>YTXZ)\%T5[">*UFN(+]=<K!]9/.;/[^<*EC,_VS(-:+
M7K@+F^N4@P=!AV;>/,6Y#N$]T94HP&.B0S26G2*E7>EJWSS5*.$U4,#CJL.4
MF>]S'D-XL+'9F Z\M7R@%D+<;BY>7)X=TC2+2"4Z#9+  [_?S1,V FLT%F>W
M9]^J-N)2X0@\#/M[FCT5)'^)>#+>YX6%:[R\RX_]_<]')]ZK5;M>2$Q@ @^F
MWB;?8LVI.E6H_=L63$*Q%V836.!E;U#$&<[]!4NNQO"Y4-RU?DT*^CE6K>&W
M;!:5R2PIERP*>AKE3*L<,?L^V[PX2 O1MQBOXID?3R"'E:J:"YT@(Y:\J?+7
M7[W%4Z;NOZ?'D,&E7-U#$'S@^=+J+"-;4. !X<"VJD61I*0H+K+Y4Y)RYRSS
MI4C5J4(=8K"@[EIDA@,>1PXKQ$:>"1D>]VPSZE$$7[!B0ARN3F;!J43> JLA
M6/W?= Z$<]_J<3(8KV 0P7*#?!GIS]3W%A5AGN\Y+1:5Y%"5H5*P.1@ET%8H
M[$U:E/F"GT$MHN\;O04?D"HFX1VK#K@4\@U%;Z1%8J/W,_>O>.$KZ4XKJ;42
M?!.N0O2AZ)QZ%'TX1VF_<\!XFD*D\/L]RO/(&&R^V:HBT$^V^W:K27*>JC I
MW,5#T1Y](=DDCYZG3/DQ8&7SC.>HM =/F8>5!Q_O[#1@4<@NE)"_+>HM-DI%
MGPJS?S6]02+6@FS"4H@R%/T0@BC#.>=P9&HZSPZ=U$:J6IX:Q_+ZWRNB/+\,
MC:M <FYM(U"P$R(?4'B%D@_V/=87<PLMA$"JD&THGCE?6/V9VXQ?Q-;Z_LMD
M/"8,"OOE([UD%3.NY;@G<39)DX*,;M*[/!LGY3!G??6;)L07.#L/_%78;A/Q
M"PM<,8]"T12M2D#7%D64Y+]%LP6IF?,N%^0QTZVD+6N5BB_G9$P7W6/T=IM$
M3\Q\F!#]- R!0/%&V?-89:S%- Z+<8IE$(I"C:[H$:'(2,*!&IS!&XVK"\%N
MY350@U"(*A@%F#1;G5[G)>TBCGH_9OZV4C,@48@N% >K83DE>2.OC%9PL@X"
MK,<Z@BW$IL6A",:'J%FAOPBO3@C 5X1V2('83[PW^"O"#JE"MJ'HQ6PA;ET"
M;&]O$!_@EXCCLYV8-TC %=,H%)V<[7L;:1K9?:"ZB^[6+0T6N&(:A>(UUNG%
MHEE28;Q%@0BLI+E;U]:P&*=8!M!J6_E=G>51O$DOLWD2)^J$;J[C5*^WG9@5
MW? IA ?AX,9S=%-*>#[ZQUH^>I64E!TJ<G="860)1,'WE1X3/[5GS<E@70+I
M(LKS99).!O-LP3Q!TM%Z7RF&XR]YMG@N9 .XIOM$//3JI>!DI-[J$HFZCT)G
MP?&)6XDFC^"522_=1N"@D>H3R_-A=A",Z@QU0_H1JTG1+6V2L5J5+0I*Z?L*
MMOGTR6DK9J6>T YOV'E3&Y17H);N%8LV>PKT_CUX;(6D$K(=R+"SL.**.!S/
MGCYD#5JGJC^9#TIZ?<M+]HJ[R(JR_130#L1OLH=GGOV.[):LY22PQ!MV!EFL
M&I&4DS[3<T&?YS9@PTY""U=VD*+UG\K+2B*6"[F!+.RR8+!R#.B$QA*HZ5@.
MY3'>] BQR=HF[2*>LGXL])9+S-8KI@$(('VN0O?(/02$";G\EE7&Y-*TQ.QZ
M"O(]UYARDH<C+HB\N:J@YSCFJL6[:,DFA"'^6=984!G6O=/,?3T4B RZV(5P
M*:6>4[@X,]T$!B*CKL7^4S.:V6\]6YT$U9ZK.W3:==20(/+EPE7#/3G:M=U%
MB@ BH6U?=9ZY6<QW7E-GMMM!@LA)JY!#;45=9[E="+2N3T6TYX!H9SG800H\
MT>PM\\FP.BH,72K$._E>,"$*//^L5"M=@]/.KM88H-)$XMP$PK&N*5$'GL16
M!J"-#E[9O>($4O1H5WN;4FQ&58\%X, 3WO8F^H"T?#W/@9U)CBME1KEVIWJ<
MYMEB,JT[67:<*2Z#5]Q$TOH[7Q$L5K[+S&G'"8ALNKW/I\Z67MO1JBN8YU(&
M>#/&"GK@J7YKKM_&BV:C;8411Z?MY4ZI!!AXJM_!9)*3"9V HQH"BQ6MZ5=A
M1U)J.5P8E3)1"=$*5.!Y>Q$%&LXU$$.RL$EX45_]=:]YFYR1D@X5:L_Z?:L%
MIW[&ZV %GN*W=FFT69S-UA5.SP6=.XE/@RGP]+TN*1"VLP8<GQQ[?@C!!36H
MT 6>A%=V)W=^OW"P)YY?* BBE$%$3*3;=-=*1[;2L>]=[2Q^\IC!R:H-8$-6
M7C]Q?]](>4\*>M>ZIFR2M3Q?U@Z4=YV?:]R?*M=E31!B2!: /,[R.<\)-WC*
M%F5;$F]U\7Z]?5S(W\U&H6 6I65-@2!*A6R[946&G^/. [,EZU7'%(!X/0\S
M7!G4V<N'*^[A;.7R8- P)E*/G 4,/@U%5XD9?"KXAN-,9)\1OL_YX6)7ES'J
MWS.F4<!'<G8"C%M=B\GRU:>"N5-1C-!2#D=7VH^X3=K34)2GX=O)/WM*L>BZ
MO%%-Y)_5V1=#T>#Z"X/^["E]*O@,<0*\4V&5\%N*^[@5Z\(*'.L\5]K@#SMP
M,PA7&]\US5$.'2O4^J!03XG1>-$*>F%[G-;=TVO/MG0RB,OD1;@DL=#G9)R0
MT:#@P2'C,6%_)(-TQ$(OZ[_J484*!R+-TIC^BJQ^!:)D[8$\,<G<[)9!,KRS
MS@^9M(K1.#J8;EK!7J=92[UA;]+YB&GMMO).. 7@F'I7O,/1&L%J%_N;12K]
MHSTSP]96R^AO>?6KWW8.D)Z-G=+N*$7D<M5KHMP1!3.T> -2.O8A9]"$>;V&
M/!^$\BC7K"')7<(.6-@*8."XYX-0WLWVDK3&!:!_-:^J09X4]&*@NB74;P86
MZ\UAM JGOZJHN_!ZZ,I: *5MURGT30"'FT7- 2NT87LY[<Q$4G-7K\5%4]1=
M9/-Y4G+]'$N^0I^NE%Y"J28U?1W];1[%Y2*:#9]FR83S'<-=4?XA)WV880CN
M?.I6<E"5M:?ZT#TI")W.TV$^B=+D7V).3G(B"ERH2+;KS:D-9 ^W9:QD=3B"
MQ7,<K&%@Z_X=ATE,6QT$L6%LB@"24>,#4"6T7OC6>EE-=X'>I^JT@WA<,0(J
M($/1)GR-RD6>E$MS#':MH6!(2%I%*^DI'C)29&&[G[V'SCU2)IU'VJR!YEX"
MM7_]GE02*K&9T82M2L"183A*/%!AFI1UH;AUW5((^2-]+3W23Y%_T.M8P<WH
MY?H/U_15PG]OHSIR'4UP*YBP;-7"5*J46N,-V[VKF_"EF(.)W6XM8Q6LL-VM
MZI-QF'( %K)4]A*H/>OSVPO3C L@:7X?"[,BOK';O&]#+NO5;BS!(<_Z?X!E
M[(@6,5N_] TP'#?M%!:Z"%UW\7+WXT*-HYFP0HN8])]G7><?KH%024G:6%#I
M9Q<%E(D>FR'_OP\-]F T2@0]-8,!D-Y:4L18-2>D]8Y/CD_.(-1HW].<Q(S9
M[]#7M0&6*HJTG01M_K3..G9)9J4=%CRE\CNY6GUEHYD@K.] ;T?6JFCV%4*M
M*H.SLB&HE(1;C002WPI")7NW)2&G'D!U:V+IY8923,E4T4P0YDU/IV:4CJ,-
MTO&<K3KQU+O>#("YH%&TRDOVC#(TRQO&14,U%5TG0;R_RYMJHDHOS38X]!I*
MM'O:/9FQA]Q=E)?+]PMIW<M@_DQG(:?].J.O-/*PH#OI2U)D^?(\B_*1Z\T-
M\6%>OU&+#(W%31JSRDRC\^45O8:42XKA+L\H^?SA\G>R_!JET81+Y([D19:F
M9/; \,6DX U'K.\#>8ZH_,A[8SZ:*?=2$(2QI\#1"<2)+B>J/D,>\^B%S.A(
MDZLW]DOUN[G-6!S)D>?*/4&(4K++=&(HWCW<3-;#-,K)><0C)M]_6Y'8?OIH
MAQ7 /2M0=W<FV?$6[VEAIK##OE.M"L\ZUMV='._\PWL(64S1QBVE_K<.FXIF
M5 [;MQ5U=Z>-%6OQGH%F N^B)8?]EI0#%H0BFK:?2_+Q?IR>[AV=>K;3[NXL
M,C U;-\>#VQ7*D>]$\7G 5(Y9KDJ-NCI'XX\ -7,H?A?U=/5U10BKM4LM[L*
MIOG4: <T;Q03VI*#8?MJ"086CUD9S2@;-W%8N(%8]!><0'JSMDSEJ9&72MPN
M2,-VZNI/YM[-#/T+WV25@ @6NYHE64G)*$JB<<>3MQ3GM.?J#BYK27*=UJ!"
M=+BZHV*]H"2:>-YL)Y!X?E]WY+@2$Z*CU*\DXAY"7R-Z@NM9+FDJ*/3\'NW(
M=1TL@W]4)\OR*)H_E%FJ*;8E:28H\URMJ2/#59 4S(;0"-X1NJ@NIM'\*3?P
M>[NEV/4\VY6Z[BQJ5 JN0VC-?J4W_]GHNBBS^ _#UK+54M#G.:MPUYU%C4K!
M=1!OBFF>T$\^3W\E99G$4X,;A;2UH--S);&.W#<@4T@ (I?,5_JUB,R^#"BA
M!O9+F@I,G@U,'7FO@Z5@/$0&EF]1&B]_BV8D+0W;_'9+43?;MVZ](]]UL!1\
MAZC(=4V??*.<RORW+#W/IO3SW]/1K]'L*3)M/^:>',#1Y]T^?UU@*N2$GO[9
MY.LUY"057UB&-3)ZS+A&+TDGETE.8CI3!NFH9J5;_=8YY4Q/%I1'"J.(8@[I
MG)2OA*2;0KUU=MVR'Y)-E>.]4#15EZ2(\^19!.M\)>4T&PW'#_30%,I[.MVY
M1\<3\^BH+&@&$R?0T)Q-^P'5,VTA8:6A!H8S86<BOJ2L&8[YCD'!M9Y$MJ,(
MK@144Q5ROC@S(>R$PM\6C)'#<:W60'6RW*2M9TK;007/<*S)OB=.9YZ$G6OH
MZHWD<5*0.WJ[(AS/YCWE8&__3#MG; 80O C(M1AP?CCAQ_.P$OO;U=MSPNZ:
M$CI4+PAC1T;\Z5Y WKS=A>>&>W?<FHR<<7-(LAN.O]M.^XSJ1+\KM.?!G^X[
MCO9LKP&I(!)73")+['\ZWG!.^,]S9RDOY37  >F?CC>"$SOE> ,C_#X<;[J[
M)!SO>7[+N:PF>Y<$#@O1]Z:[W>IX;T<LM@K&ZV A.N%T<7HZ]OVTZ<AR)29$
MWYNNKGW'>SMBGE7P7(,*T0GGURA_S@DI'Y)T8MA>)$T%GMV>ZSI8B'XXG;V?
MSG9[NFM0(?KA='#P.]L1/U8%OU60$%UNNGM^(.7UZHOG.EB('C?(GA^')T>^
M"]-UE(L+3$0/G4?:8SC^C10LV9XNY=I60Z$HPKG6>]-RZ9$:/'# Y*#/*29I
M*BA$.HSM<K6IN69B<0."PCP-\8X%8;)WY0X@MTU:FP.@0DTOA+[C1I49RI2^
M3=9:[*1^3F+3A)5PW !"P6R(%^P=R7ERW#06F7:L>*[M)'#ZN7BV8+T=%H4$
M(%ZS5:BS%>-E;06-_C+V.O);"T'!9HBWZ]>HC*>4P@<61&'%;'4/0:^_ G".
M++< HF \3%+.S;UM:'K(*CO\.#W9.SS8V4U]&X>"ZQ#OV,UE9N2YHKF@U%\]
M@4Y[RS8*!;\AWJ^;GWY\S5SXO6XNGG"?_>6;[<1P"0P%QR%>HHUOLYH>3CQ_
M[U"%MNS,?FX!1,%WB)?GYM>OLX7!\J%J7ZF5_'CE=^:Z#(?"P=7I)=I7>$9=
M[?%[4D[K03MZOSC;480ER'.$>1]!%U9,4,R-U66F[V LD.(HH3ASWF)'6)T&
MLX1#\'$]/L*Y$.+YN#+Y*9=R>QX ^KB&$FAUOB@HYXKB(IL_):E(M&OT;E5U
MXHQ"2E[4B\9?2%DQ<8RHPXZ;:IBC9&C<?1S5HPBN($6^.'BW&J6F$K<[TL#C
MG;S(W[LQI/^)8+*9@%07RI>1P3MDW4*0%99[I<5JDKS())CP:@MU,WP?(^5A
M\78,ZI$"!/*@F62/L9+[=;![<Z;96V*/U;G\('29(#SVOM,#,MNTA<.K,]N9
M 8\]95 T354',^"Q.EMB*'6Y'Y))FHR3.$K+F_2% N:Q\#?IP^*I2$9)E-M$
M!-H.(DXV'(. _S>4,Q<@@E;ZNU378;A?IK=["S9X.[[:B\WR+JU!#!$TL_."
M]WZF^IL!IB,8))SG9LX4X7'Q9?YD<#K>;BGH#"OKGV8]28YD#2:(8)Z-U3>.
MBB<.M<A+OO ^D5E9L']QL7"1T'_\&+ZF)"^FR;/B0-UJ(ZQQ^SOL9BPY,#4H
M(:)]NDE&^4"0M*KH]N5XK.&CAN%-TB%"??IGN>^S X+WQD, 0L.P3C@Y2$=7
M;R1>E,D+7<#TL*,DZ4\%BZX5%"]F<>VLEAP(3G @8H-V-7G+,5*-5_\/-$OL
M$ %'NY_)XQBKFBMH]A8N,,OKN!8I1'33AQ"Z[Z/5@_2-@4"A:&3DY>6&8P%U
MF%-P] \6T\%E(,&DW8B]YDM9-2%:@48,#;N;1>FW:$YT]K=Z&T$3SJ/<J^E-
M"A(S3*SZGMX:M-E*T(5TT[4SMDG9I&%G@W#$J*\.#/5^W'3FK/'T@/")>'RE
M6]-2_/]-&M/_T-<+(T?_AC-T$S8J/UG!-#-59LZT!((8^D5/#/9=>GX,QSSX
MC)D'R6CX0O+'*:%_35BR>N9*_P\2Y8]TZO$0S,J(^!!/R6@A=V&%&UTXB'IV
MAX'U;45@#D2D6@])X(>+LBBC=,0@U!(9:R]VAKZ"!9[S%B'Y/MM"1XR;J_+%
M#\?T!\J3V6/T1B%.R=7\>98M"5%?\TP=.?5GGO,W(BQL:]R(L7>KB;,.<:V'
M%M^DC!S^0E )S[:_P.+9J 8O0V?XB.%\*UHD0>(.@M3W9CA.]G:WGHI!C);@
M P\/7*&IGP#763XF"4PME1;C5M:%W2W<9'/X=N*+(:S0]YP:S+-%6A84 5-H
MU&,1ZXS43A^[(:H@W ]UVK=F@6)2K)B#&&OZ0M(%N::<N: WD^@IR[DK_V"2
M$SYOWVL FINZ!J,JK;GO(C%_]%872=IA.%&4$<@\[4*!,@:TY5 5$!QSISP
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M0V%2%H/2SUER3LL@IP@6+RNCME8!,QXI!R--0VI('"\@' &/8<"1[F(S_W1
M#@W"WBE(Q2M&OZ'5.1^,D3/AI!6HFKF=;990QU/-DNAB\WQSA/D>F9*/>?92
M'E0FG-/#ZLSS1LV!0-T<T/9^@$$H^3$JA&)?,#2]2M-SD%"/51*5[C>U') >
MC),;BZ;MJGV$ZR@T2[BL #1+LHN9A+NTA#BE/'Z&'X(RJ/8L0IO ZV+5*'#'
MS;$*G?8X)A74>TRW9D$L_;%=$(M^ 9#<A;M\=8YB1&=5EK"@^5&"7 11!TL
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M#]J#]T&U>2AAJ^^B$-%346UI%\OIV>80Y^7E"3_ZI*YKC$XN](TU=K$@:0]
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M>R0##/AA@*^S0N*_]QNZ,+_U&'G6-\1_7PJY&RT;S!OJT 3[ 6$6!K@VN >
M64E?08(WSM@9P7OI6S2P0<P3_?,ER*/K+"4GR=P$STFD[*5_3>%SG$5#J1 '
ME,1W 9[)QJUN'-0=I864H2+FX)1S"98G<FLQ%6PRG ?Y8&ZQK)@4Y@^F9YB@
MG]+<G!&:2,R6&9K*ZW#26CJOPA0MQ;;OYF@6M'L&R3VNE4R2#_CV*5[?S=W;
MP/Q8K%+,=T1R;(NJ9,DV0'P^!!<LW16^R[,G[_%JE^J:_@%G9;QFR$1\B:+$
MA&D.>T.Z*?/REE ')TH>!"U]+^M=S06.N!;67-2\8@WC/E%IDOJKT2VU%PDG
M*U;I[L5*\V QJU(]I,SPI!_0O/&JM_?_;LO?[8QH5 , _0M\63FK:LX26,_E
M&DIKYL2(*S-W6]B<'&XY7SH]KBLJCP4WFB)7-9+5I??WXI#>BZYXF_["JUDV
M[Y4O]DY>.A-^_4A;9_6O5T*OQ\,8Z9=9+V.D7*X+6GZ%>8BV^*3V!1GX^D38
M^(C+6<#H^^_>_RBT-&H$[):Y5.-I5/&RZD:K>KRI[OEGM"O8T[X.ZT.:X,J5
MY9HX^*<RCW^%57VB. 4_/7UP7-Q20UT8=2XU=,6UBP*+,(_)Z-:[Q[CX]3:'
ML#ZV?PQ*UO#%'LDD@G8=D&D\C\YR4$^P0UW;ESARU-F605'U)4PSFS,J;5A>
M]F=@EK'*SP"L\T7]!'&5B0_Q<QS!-%H5#\CPX+W47EMOM6E97NIU.1VOCY0"
MB"H2N!3'J2'BF=;.Y[?N"2XQ3$9\V%Y-)^&4M;!. JE/:VS-PL]9$I3DM:99
M*ZPB.7?KJRJ_7'U];CIZIJ-&V&S;>[2F:F%4LJ)J =2QHOX"X_T!#6>%-FNU
M19F\8=8G9E5))_ ZJI)9D0 !I5&II]5MM:*N&N#VIS2">4(*SW?X=!<G6'@"
MVV=:)%-HUTY-5=&QE9JJGSXY$W24]_%NWC9=0L:=\R#C;Y1K3AJ !'7P+J[W
M_Y7W[;UQY$B>7X7 XO9F +MW&H-=8&^! \J2[-:.[/)9<C<&_<<@5<52Y715
MIC8S2W;-IS\^\EE\9#"3R:!Z@+V;MHJ,C,<O@L%7<)9@#^E1U!].\RWYPYDF
M1?G'B/(%$ Q'\@00!N>4160S^?5.T+/MVBO-@I4J5/A39G2L!2\>)]I@;^8;
MU#DL ;B@+F'%_& Z92/=4T^GW@IQ=E^W'T?0-$1 G7%[_0)WV*<4C&HU80_K
MS )8MRW^O-5WE%%SG?WW*:,/W_*'?7XJDVR[RK8/WQC;(P^7@[L'J\ (ED>I
M[29[\B)!O"]AG4G3F[#N1/8WHGKA^8E?X?@;$?C^Z0B^8>U"!.3!BA'.-A)+
M2__.C50Q!%8- OG_JX8(]!X#/C+C[74LKS,*C ,0$L%C 4@NB\N(_L: P(A$
M$13\2,G@\6-$D0$.27UT"(Q'MP@QRV(L2AR%Q4QA(L_\58%N.+YGAA.,S8L2
M4#+!(P58/HL?M32BCQA^I8TL<KA!51\]$'#J%D%F6Y!%D;*UH"621'EH^F)=
M=G"6JCYS62\.K;OWD&\SVV%,U[T:?]_$W-+QJ+G1C0,Z.'VH[AWTGZY.L[$C
MQM[#IUPYO<D Q7BB4>(;TOL 22IR33?"6__U7W[\CS_]UY]_?+.0FNZKI*A>
MLZ+^.\E.27&6>E+5A+IAY3N<C>YK^8YEKV9TJ ?#8".#P_<B'15<-#9[1*CW
MXS!&@VEG!A92W/WJRW*;DXZ/7P>26.! FGN3'WDU,/D TF/]PCDQWSVZ0%7[
MH'64AQ-\!J<Y<=XY,KV:&/\^+W8T#1GEG;X8:9QWT]KL2+]K/O>[B/7SE">B
M?:N0UQ*M)KC9G'@UP<=>3<2J?^(U*(+%+,=O1AJU7#4W.V[1[H._B\@U5X$B
M=O64\EJBUR27FQ._)OD;]H,,)[ZTI)5C+ Y;H]0LNF&?=IBE >7]!T'-&%2B
M3H;\:J(?-K!3'@\HUSPV,1_BKRA]>4Z+@-,MA^]%F[; ->8A91$?BSBVA%%<
M'7,$@=>3ICBZUKP4Q=&O(DE/>EL6?7% *8BQ+TJ:898$FDI$L:<*W"ST)O6;
M@=CCFWTAMXZ7$W+YK5_'U- K>N/("4="BSGO&XDK<>5V7^@Q23/&:E,0_)0<
M^*4KHQBNR=S$#V!F;U-U,IJN%0WAMEXZHRQN)W)_Z/OXP#<BR<T"JD7J)(J+
MC3[]931#F^4L,X[^"I+O>*IPU=N ?7?N_JYF@Q>L=V\)TT)T,YT/7N9;H0X1
M+Z0I_9ZXH$?Z'R+OSJ3_6_TQTOL::?VK_M[@R7,V](K^P>\]!U2>$F!Z#T_S
M.(M:@B(XB*8=K.B_U=T<JD [[KUD>!J<"8\^-H$.CK\">'VSN&B+M]=Y"AVX
MU.M_/_>5+XNZ:,W77N[O9FETCO)BVI!9U,T\[.&^PB52YV7>"?NW(*H1[-["
MI(?OW<:^N^)3"_'LH<Q&-G3/U@'6$3H[\-B<L[N#Z:([/%P#4)=_#6=7_6K"
M?D)U_H3&[49"_%;&#X6.?@\+AHY.'V$X!)_"FWI^#4(9/22Z:,'Q#%OD!V-]
M:R.NXZ]>$.]TE@T.]PB# >@*E',@ %)%#P)0Z:$!(/Z[FSZUL.@-37#Y6*\2
MS5C)O<3 ]E3PG=QJW]2GC2\N.CD_+"8Z>?[<C=HO-,U>:%EQFO>;/:-MJV!K
M[1)TV]3(MQZ/_>9$ML>N<@M0O[J?%$#W\&TA1QL4?1N4?1OXJCIFX,I>8VRD
M$S*JC?68++C&KJ@%,@,$VUC5LJ;90HMOSY4W/^;;=)=N!/?KW>I;4FQ+\7A$
MKYS7 \U$1:]^?:_[]'M%:3;^?+7'#X3R')\ZN;1LGS:O4RVI$T%^6*V/?:&N
MV'=1PJ_^#+&^PQW@H,CO04W!0IAW/QN$NSB=#!0:@Z&(30P3B:*30-&@U&#%
M@"++#5[4'RQK%#W/>K8=%'PO"BBZ!U<K 9S@:9=IS.O5ZJ71A;W0 B(%+  V
M+0$I%# G!)P9]N.OTBOE2C%"Q<1<+-)\:WZR\$HR)BQ!HP@A4_*:R'.7^?E)
MV.P#L#J'L1AG7?>)8Z%M9%T-<QD-K#V_*!I9$<-9 !M98XEE<6MT+0MWZ<I)
MBXLMO#HNN:(OMKHLLR)F)(OPC;<N[+(B',U:L,LJL&\_NTHJ^I07Y_7NYOA\
MR,^4EK:$P-@\E)^9^;U47M.2Y\EM6^S,843= \"&T#4(L--T3B]TOB!B[6.#
MI0,B:HU.;\ M=J@=5?L8=K'"[23=YP/\^E[*2;)$GKF0A$?P:VP>;'G&R*\R
MGVU;DKHIZFK+$GR'6SRQHV2X3!( (K %D2DJ/UZHW)>?K395^D*!HX2A<2@?
M,_%ZJ3;9#C P!/ O[SP'\RTK,@:>M3PL0'[EJ.KEQJZKI-PW9P?Y9FIS Y_]
MC1^Y-N=@(]W"96)C_*LY0;GO*IGP/EV=$E)W0[IX-$.@]K"L$*A[F>19+U#
M-!.$KXMD,QRX@"GG$C:)N.!$6Y!CQ<;]I#P58F#GS\5KCB'K8H0GPICE(UQU
MX%(7*.%)4DN3;!G1-_I;#MA7(#TKY?V@-E)9Y9O?2/+\7-!-*C?-"OXYI08=
M:EF(2<XP6OUADB?,&.A9S-KP./=$USL1SXI\0^FV?,C?T7?M\J7>F]WZAQKZ
M'22ZA&'7E:_*R(R@[DT><O*.\O_K*"#DXGZ$8SZV$2-1(UR5D\=N!1JIM,(4
M. X2!!0L@C*%0&:+*76H$R,FXBK;KK-W=)\<=KW%.6MZ,-XY: H D$4Q6]V%
MVXB?\.#WV$2WP9HCUDW$"0(-4E<F5#?WE,.UO)PG3][BCM-0Y*EC,11V,\;;
MF^_\8B-]S_A^V-/AP:*N-)X\'FT:<]UHA!IW'26[Q%?=G?#^A!$@EX?@Y$Q<
M5AQ=:6$68/R=*:3QCBN5=$MRU!YE1QN/I\!U,":C814T+GO"+%>:N&Q\:;W^
MO65IR9B&Z)[T-_]S2JMS2:OJ0+?*]>$'-MTHDXV8>MQFO^S3S?Y#GF_+=7%/
MBY=T0\LO=$/3%[J]3K>?\NK_G9)#NCN_SPOV]_Q)SBM7Y:ID'[ /_%@L!4TG
MT/1NQ2\5K+RM>='64*AZ_/ Z"]\X1^2)LT3R@I0U4RPCE5R1;;HE65Z1_Y&,
M\9I&_,>&-9*4[/\X<UB)4#2F6&W_?JK/_O",<;L5'9(#TWTJ:EILDN>T8O_>
MGBAO<1EIG@OZDN:G\G FC06E0:-(R7 CC9KHX889Y+!_3<M-D3[+4>YC\CT]
MGHX/M#BN=\/5)2;$Y,(TWKX1-##[T\RE>_<H<V\]2MJ$1:FCIAJ\B).1%K%9
M3D=S"L TBI1S4<.3)6%CGF<W4X.89Q^;,:GER]/KW<^TK-+LB67.W B61]!&
MNX2:LMKY5GR8M>83T;J]F),*N*U17LB9* !SDI=:@"C\!8B?P:0R%'A <TB_
M-HAI?B@E$U&DG@Y/2@7@5,(.]@[2F:PHQNMVHA]PL 97:)LCY9P!66J&[V"C
M)2HS)/]@Y#YP#N'J@9HLP=7]YIQX3C.>A'Q,BM]H=24GK.D_M-&S/?YJZQ+L
MY+.5;^5(JVQ-9',R;(]Q_GD2]T?)_<;*?;A3T./(&9Z$#@0;V&EH?P;P=7Z3
MKUML]M9+WX,FH3QMR->E:NI?L6]O:90W -]2F@.!S46#GM%D/UE_T2@PHHQ'
MI5N-8!]&URI1ARNLP^>NFO2,KH=O.0A@O7:!,=;GT*0<7JH%\:Z&)TY#.X5B
M>YU?*(;W@#G6"!;6!BU#XV[ I=&>O%4,V// ;7#\J3C0(E %P7P,KC,8 GOM
M N.OSZ')GJQ-!-B;RVEHW"FVUZ%N&<.[I 2N:O65&=0;&.OLGNE3D+XHX_>-
M"7"V>X\;C5">Y2B9=GV*;IG224M 4V12$,%TRR7$9##Y$[X#3X'FP+G1< ER
M?$^&RS-2MH93BV@.\>DK:ERGY>:0\ZLSZ]TUK9+TP-_$V.7%48B\>LQ/57>X
MK_\Z=7TL9/585D6RT6YK>/Y L)U.CSI1-D-:VGQ+M*%.>N2)H#\XP=O_!&G.
MH?W:? 7/K[V#9[AQ&25R8-N<81"4[\BV05#:0U B$%2:=J2H@J!HHLF#[<*\
M+^JO)HX\&&Y&>PPBXA.O.((\&&_ 1XB6,+$#@)JY@4.B)IJH<9=F])8E3N8#
M5!Z_\&JB1U\K"T80_ADBOH,Q:?H=:.GU!%O%S_P&W&6<+$S0!<)H;N#MP2BF
MPV^]*P+66P&_I-4>=JEY(D6LJTE.4EMO%HU>)?K&J.%?BO8E^WU/7!WD\0X#
M8DF(=MG(W7.M=X7<W1;[!&]O#+@Z\*MV97T(L#ZF9)R<.I,(>W87*I=]W-K(
MKMU-W>:2W:^5=@X9*A(AB1?X;*L3-C4'6YV &;LC6N=[D\C$Y9#P9-*,V@//
M%%.,:5DT<D;FHN;9TPS(SGE.A%^EN2W+$]U>BR?@/XO7WT5!M4_TF_C%_ H2
MK'.PIT: LBC)F;A.)#L2V9/(KD3T):RS_-E_ICV6B<Z7*Y5R;:5<SZ+K&UDZ
M\ W)F&3I,I(!GEC!D"O<$RPNGC5\D"6X6\&>9PEAKI@6-#Z=^"Y['7O+]:DJ
MJR3;,O:M&8>E5] $P\;]I8EDVW9@94-LUQPK<5B*_[ )P2B&U/%_%$!1N84,
M" X>T71 =(:6YU$<R:CEWP5RGL8MQ75,B!_"8PSL0VS,.@>9EV53,Y0O1 G*
M[#-TPP:@*C7GM)">X<X\ J103Y*Q3ET57E$=4/03Y1?:GBAG&\.)$_!8(Q1I
M%X<9@\(,>(1QLGW: KMB^T)$31&/VIXQY76U6+*.E77DNF@9=,BZY/)2\;>-
MDF75,JPT;2:;8<<FK>7504EK]KEOMLJQ[7.1;FCS[(5Q7<78/NBKK7J.]34O
MZM43T5B\T"'^C/5NJW_.P[[<:L&*^G3KTD"!O]WJHO9Z/>"Y5;O(77V=)KMY
MX:4Z+'?Y>PV"E7ON\:3L_K^(-VQQ;_$K2AO6);[4V%SS7.?')#66.1DT"6JB
MEB^#D>3OR&8:*D\UU%!S,TSUA3(FDZRNMF&_.:9O&\IX!DXOK3ALAG\ORJ;@
M@5UMVIV;G-REHKA:<_' $CB-S8.F)EI^]0/-03;M77A #;(CZE:']X5U#1_=
MI^O<TZ"NX<(^AE@Z(*+5.+X8\(H]WHRJ?0RSWL:B57%./M+BB18C3]8J[8*]
M5JMRJ-0M__+7%9%MEKMH#-E6]L1K,!R:K#]\EG9)T\->I 6J]2C:^)KPW,H'
MK:Q#][!-*)>XX$Q9'ZI_QAZ7=0H<(&LQ[8%0!=4B_]TWINS!]K)5:%P9O:Q#
M%G;DTBM2BRZLJ 77IFSA"V/W+X_=]L)=NK%CS=0Z6#9GXE9)Y5X>>YM3A#7%
M+"JR!-OATD\K0H:YY_+P@$V77/1=#O7MU[U6%7^E2]1-73T55)0M'LF=+3V"
M9=$VKI5DJI*/W\GBL&U[3'];E/]P^?8H=H:9=QC@P')P1P.(E^BD 9+6 ,=I
MGKC@QG5]_OL+WTJ5SUR7IGQ_O$_0S6PSY^JKJ?),?]%K2GY-T.8&4.6KN\@C
MFH\/2^:! =(+&T]&_]8CZH@87>%& *'*VU; %_J4LAR_X&^S%713K7<[RH]K
MC^WZV'N%V_\9X5[="6HZ$-F#-%TPDX<08@3<W((@ZF*;*QB<0+G$''MLI3WR
MNDM,N<3G(G_."_D4VOI;QF"Y3Y]O,\YW694_T</VW?D3LW">54Q7C*>G]D?K
M"#&+;M@WZF=I0'F^OJ4FGB=LZ)&TZ4/VC")_""C+L[<]HET+M+?MO2IB[4/T
ML,.P!U]0!VH/CC!C*!^>J[_YOMGS5XNVM]G]Z;%,MVE26,[  SN'&MBALHS>
MYJ!-5_X\<-GKC##,AQ<JV*#OA+W!V!\>>* 48'E;>5M.U]_1E(RO-FS.4*;6
M5T8=""!?Z];*Y'"U6_8G?0+QW(%V$$Y_L58"[@U)+.)A7X4VHQ)R'7IA2,ZY
M$CT3FF]J;+X9@--7B+C+RW*=Z3,/4U2P]PD5"$8XOU0P;\[KJ6>##FW.B>#L
MTP7H9\W_^B\__L>?_LLD1C"GAN!HX,?!0 1R73^V:-$4T]3^*JGH4\[3BO7N
M"SVP?VT_)P7?803L%MB[!E[D'9%#7>EM.O"<JY!=R+/L$\DF L0TNE5?B%VP
M"X!F55J=RP=^N?U]7@SY!&PN@/J'+>X)DDBY)R)Z_>^2B&O^9)<7*A8-VP^A
MEGRF"?:> 7!;I)L]>6&A\%V^/]",G+(M^2DY/":;/7(52SC\-#4KX=B;\]PS
M?PF&66CL(HW:+MC#SBJ'RG.\UZ1I@[E/XHG38/F2R?;#5YH-AI^UJ5=6S&<9
MFL6,HS>E )X(<B 0;JL/+I.Z/=/T)7(*UNL=Q_$A1.D";@PZHO)BC] 1DM@9
M>5/&L2EW_(YF=)=6)>#]K E$PF;I<-F4?+TKZ-G4,B>/=>_N_E-B>N(J5+*$
M)V'@R8DC2C73%$>((KOENMKS,@5Y43$D'"]YMCKC6->@+C@JA[)'RSN0DO=X
MR[NHX,3RM8FBC/(?UI-@P%+]!X8J[&F^WK?M4WM3G[#3>2/GRA3>%*RQ2@'"
M61=36.29N!TAFMFW'1[(@/\E>:(EFY?=)P?CL0E+XZ 0U_!Z"1#11#PG6]:-
ML(*]%V;#0MN$!173)B @@]DXND#"^'CGH& 'R*+66##G/-@Q?H(X(MB3/,8<
M" HTU7.@*,/VI'R3)H?ZHM_YBF\*IH\GX^D:6+^P_F.50'$=T;JYKW@FFWY[
MK"%D01$"N\LXFC2>,@ZE&*;8C1]#AAA]A_#3:97GD9GG8H.'P\1YG&DY5!S3
M<D,/[ >:G]IA+X8YLP$IAIFR 2;8-RORLI*HX.O0]=C5E$)B_YWQMT,[3_W,
MS#!RI6(2P;!W*:;)K%RB8&3>=G2:3*9!Z!NRE;0&@9L\<VIHER>BDSSPW8D9
M:-=<FI@!]3GU2.M \A--#M7^-BM/1<+DO\K-1R*M78+5*[7R;5S4DLU)VK0G
MO /"1N=$]O>7[&\T[(<KQSJ.G6%YUD#  9V"]&F!F(Y ?DS^GA?\A>X\XS>D
MU[N'Y'L=1FZS37Z$[;@Z4 DZVKI(IYR)X7W%&\2R,]^:9"IO-R/_D H*?XQ@
MWQ59S+#CJ#-BU<'3&:XS1DQ.>K<3UZ$_T^*8\"]>I_R>,V4"&Z\7C78+-7*.
M\Z\LM3'TR"[\Y9FV$^GU0AA"W>4 <1YL] 3B:#""A@01:!2=!B8JP<0"TW-K
MDFW7*Z;AM!60OPIT):XPWF;LCU^2RKZ:8^\8=- <D<%B(?&FD;RXR>]M\F&D
M8)W\>?M_2ADR^L0/'8\/C(ZB=%#LLX\\;X1 2AWB('C"/NMW*IBNJ\NQU^HF
MQCYA3_(9.5>.M<F6VHP*[90>F'O^NS@AR]BGXE:79#UX%>Z%-1_X]* =]YK#
M@G;0^TE./^3,"!D?P3^PF2K?0J3'9V9['C\>N/D!F2J !D+:"I',DL.RM*.C
M0"0)TM"0SRP**K@Y[10A>V(]2;%H(Y88R2N=6!@)+QB;INPW+#!=4^&I .WR
MXB>():/,D]>[.J9]RJMKNCUMJO3QP +<->7G&M(LS9Y8VX3][7.1[U(>!/D-
M8U@N/9DX3KX]71=V=#3#7Y:S>5-+EZ>XVXXRQP@GS5\HY?LI?^ #YX&1]YBG
M3$[?_6GF4YZ][70@*P1PT=_&L;?KRR\L$X*93H$?..K-KE61EHQ7'B0_%_0E
MS4_EX?PU*^@F?\K2DFYKQMG_7!5TFU;KXH'%Q+Q(BG,WT5OO/A=I7LAZ(E]Y
MK_P+5PI5DJZQD(/&5NA@A:=_79AK]G\3R8X<[YY;ALBIQQ%I8MH;\5\;P1;)
M"U(UC/76E<1Z$^>M+A5$3H)"3@K!']FH$PRL&5U41OE:I8?FS4"AP@M3%-N>
M(=BL<I,4_+8\O_W_+2FVZ/$7.;QH(S=R;)E37C'/ODCV9('':\JX* 2GM%QG
M-</B_+>&57/AQ;ED@Y5DG"V_)H,A14>2^]BV)MJMT_3\BU\)T,4WE%J.2VCC
M;4\;,J'+=_)__>@E7#E(/[XR+!09D:/ 2DB^!HC$-)7N*6C%N*ZX9N[2Y)&-
MPJ+L$>3\!IA&T%P3+IFRD=.S*DE$7V',0]<[FO,,CO93\P-'XR'#5<OB6+4U
M<Z>@@+3PKKR58P(=?FFU,0NH"!M3?X20 E11LW5#AY7Y$28#L*)XIF7<$C!P
M>:OI=,NRC>R)+W#)SXR]T*EO'>ZE3@.WZAN334-2XP&Q"M,4KA,[U\%2;CL^
M+AX>M8%C!D:;\?L+?:'9:>0164/C4 @U\6I,P.J&F/ATYKD8X3D8.JW(&(#3
M"@L/V!20_T2K:O21*UN/T"C5<FTTNVA-ZN:X+\X["3#&<7"XFL&BQ:P9*1Z
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M?!:"-9,'!P.:JS_/ %SGV/PTY>'29+Z\7;PT*UCK9>HFWS8T#OJNL897_5/
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M,OR#Y!@-BQ8<#(!H <$,%'Y*LLWYY^1 LVHD+]2U#(5!+9?*PSV\$:E;+0=
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MC%H#2NY8@/M-_HO]![]P^7__/U!+ P04    " #3-G96M(D!DFZ5   $\ D
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MJ2M/) V3R7W,-CMW9$P6KR0]/6;?T*%O]=--:0EG<4C'<Q#GV][]QW(R8]-
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M,^A6/DO92E%(Y-N;R($L3V_Z;K(57Y<$:M#M>98"%D.02+?3'H! C,&V"EA
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MW9')DOG-,B#RN&UF-;]?75Y<G/FXJ:DA:DO(C:/ >;R]+ESTA]-J[/CR'DY
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MRZ&<Q#GM'OW>;/U8V634*VL"<^@^>U;CWPP0<AQA% /.(UT&'^C?U*=U@_K
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M+'N>VKC![<IM&@B$UZ9U1LE32O^9++-H!1=H@GS6^&E[N7?2U9DOP[L'=T_
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M5T>4AD1(-*6YERURZI1-[L"[ L6&IV)S10F25.U3@I4C3PZ.1<(?:\\D:36
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M='-).V;BF5&6.* T&1,RH9/Q#;G9.,]LXQ()[FN-Z@,;G0X88Z04UGQ(M.-
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MLG@-8RXO_8PNJP1L8;[QLYW+M4@<Q6_R>!8746 _E\M; 2K138U:21O.Y09
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M-*;)59B]PZ9!;M5;]HG+>$YRGF3FS^PZNTE8V3/7V1,L:V9],3@[_>RRT*F
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ML5PJ3?,'V.FU)>M+\!JNUJNKUV>1'6H<;]UXM<NDII]X!#SVXZZS3R*T0MH
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MUU,B)W][</YV'9!A95!%Y70XF0CG@H?@+==#0T(T56.)KW^KKAX,5F+2UC[
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M$+3O-MHN-:[F%MP948?X"+$7M.Z4VLK4NY =96I=KS0(?*JP%^0A/U:X!7_
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MV#2X2,,Q ,*NN:I.DW"R^!%'HWBQ9-'W:/HY6#X%DX6>0'-/$;9[^K'OC+H
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M &0T,# R,#9D97@Q,C$N:'1M4$L! A0#%     @ TS9V5L;/G)-;!P  @AD
M !$              ( ![V8% &0T,# R,#9D97@Q,C(N:'1M4$L! A0#%
M  @ TS9V5KYA"&I6!   KPX  !$              ( !>6X% &0T,# R,#9D
M97@Q,S$N:'1M4$L! A0#%     @ TS9V5B%O[IY'!   CPX  !$
M     ( !_G(% &0T,# R,#9D97@Q,S(N:'1M4$L! A0#%     @ TS9V5JVB
M\OM> P  @@L  !$              ( !='<% &0T,# R,#9D97@Q-3$N:'1M
M4$L! A0#%     @ TS9V5OQ7Y)KSG@$ OA8- !$              ( ! 7L%
M &0T,# R,#9D97@T,3<N:'1M4$L! A0#%     @ TS9V5O/VIHM1! $ Z40!
M !$              ( !(QH' &<T,# R,#9G,#)D,#,N:G!G4$L! A0#%
M  @ TS9V5O*:XY9$  , 7WP# !$              ( !HQX( &<T,# R,#9G
M,#=K,CDN:G!G4$L! A0#%     @ TS9V5C;\F>L<-@$ SWP! !$
M     ( !%A\+ &<T,# R,#9G,3%A,#$N:G!G4$L! A0#%     @ TS9V5L9_
MFT2D+@$ E&8! !$              ( !854, &<T,# R,#9G,3)P,3,N:G!G
M4$L! A0#%     @ TS9V5FCBH:U[J0  P=,  !$              ( !-(0-
M &<T,# R,#9G,C%P,C<N:G!G4$L! A0#%     @ TS9V5J<KCU(TK@  K]<
M !$              ( !WBT. &<T,# R,#9G,C%P,C@N:G!G4$L! A0#%
M  @ TS9V5JS\E:8SJP  )=D  !$              ( !0=P. &<T,# R,#9G
M,C%P,CDN:G!G4$L! A0#%     @ TS9V5E[S?[@"6 $ K9@! !$
M     ( !HX</ &<T,# R,#9G,C%P,S N:G!G4$L! A0#%     @ TS9V5I70
M)D/)$0$ $T,! !$              ( !U-\0 &<T,# R,#9G,C%P,S$N:G!G
M4$L! A0#%     @ TS9V5N"JRY8F( $ +%,! !$              ( !S/$1
M &<T,# R,#9G,S!F,#$N:G!G4$L! A0#%     @ TS9V5K/JT*O_^@  >C<!
M !$              ( !(1(3 &<T,# R,#9G,S5A,S4N:G!G4$L! A0#%
M  @ TS9V5F=:ZVY(-0$ JVL! !$              ( !3PT4 &<T,# R,#9G
M,S5A,S<N:G!G4$L! A0#%     @ TS9V5D<D1!UA7P$ ZY8! !$
M     ( !QD(5 &<T,# R,#9G,S9A-3@N:G!G4$L! A0#%     @ TS9V5A-K
MTV+0N $ D_P! !$              ( !5J(6 &<T,# R,#9G,S=A,S<N:G!G
M4$L! A0#%     @ TS9V5NI-O2#5UP  ^@P! !$              ( !55L8
M &<T,# R,#9G,SAA-C N:G!G4$L! A0#%     @ TS9V5MJ<3T?RD $ K=T!
M !$              ( !63,9 &<T,# R,#9G-#%A-C,N:G!G4$L! A0#%
M  @ TS9V5IV&P_N;*0$  &D! !$              ( !>L0: &<T,# R,#9G
M-#)A-C0N:G!G4$L! A0#%     @ TS9V5D$#*73R5P$ SIH! !$
M     ( !1.X; &<T,# R,#9G-#-A-C0N:G!G4$L! A0#%     @ TS9V5M.\
M3+T%*0$ ^%X! !$              ( !948= &<T,# R,#9G-#5X-C,N:G!G
M4$L! A0#%     @ TS9V5GEG-(94'@$ 854! !$              ( !F6\>
M &<T,# R,#9G-#5X-C0N:G!G4$L! A0#%     @ TS9V5@X"_$ U" $ #30!
M !$              ( !'(X? &<T,# R,#9G-#AZ,S$N:G!G4$L! A0#%
M  @ TS9V5NA*_T2*( $ \U8! !$              ( !@)8@ &<T,# R,#9G
M-3-N,#4N:G!G4$L! A0#%     @ TS9V5O*;K3@AC@$ 2<(! !$
M     ( !.;<A &<T,# R,#9G.3)O-S$N:G!G4$L! A0#%     @ TS9V5D+)
M *=]#0$ 0DH! !$              ( !B44C &<T,# R,#9G.35R,3,N:G!G
M4$L! A0#%     @ TS9V5C+^]ZFY>0$ Z=4! !$              ( !-5,D
M &<T,# R,#9G.3AM,S,N:G!G4$L! A0#%     @ TS9V5D8N^5;Z*@  <R("
M !$              ( !'<TE &EM='@M,C R,C$R,S$N>'-D4$L! A0#%
M  @ TS9V5HP[''8@#0  !<$  !4              ( !1O@E &EM='@M,C R
M,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -,V=E:B.[Y6.7(  'U'!P 5
M          "  9D%)@!I;71X+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4
M" #3-G96FQF>= NX  ![X@H %0              @ $%>"8 :6UT>"TR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ TS9V5K2) 9)NE0  !/ ) !4
M         ( !0S G &EM='@M,C R,C$R,S%?<')E+GAM;%!+!08     )0 E
+ "D)  #DQ2<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
